No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
nutritional	nutritional	JJ	B-NP	O	O
supplement	supplement	NN	I-NP	O	O
,	,	,	O	O	O
food	food	NN	B-NP	O	O
or	or	CC	I-NP	O	O
herb	herb	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
yet	yet	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Plenaxis	Plenaxis	NN	B-NP	O	S-brand
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Plenaxis	Plenaxis	NN	B-NP	O	S-brand
.	.	.	O	O	O

Plenaxis	Plenaxis	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
(	(	(	O	O	O
96	96	CD	B-NP	O	O
to	to	TO	O	O	O
99	99	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Laboratory	Laboratory	NNP	B-NP	O	O
Tests	Test	NNPS	I-NP	O	O
Response	Response	NNP	I-NP	O	O
to	to	TO	B-PP	O	O
Plenaxis	Plenaxis	NNP	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
measuring	measure	VBG	B-VP	O	O
serum	serum	NN	B-NP	O	O
total	total	JJ	I-NP	O	O
testosterone	testosterone	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
just	just	RB	B-ADVP	O	O
prior	prior	RB	I-ADVP	O	O
to	to	TO	B-PP	O	O
administration	administration	NN	B-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
29	29	CD	I-NP	O	O
and	and	CC	O	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
thereafter	thereafter	RB	B-ADVP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	B-protein	O
transaminase	transaminase	NN	I-NP	I-protein	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
obtained	obtain	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Plenaxis	Plenaxis	NN	B-NP	O	S-brand
and	and	CC	O	O	O
periodically	periodically	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Periodic	Periodic	JJ	B-NP	O	O
measurement	measurement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
PSA	PSA	NN	I-NP	B-protein	O
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Formal	Formal	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ORENCIA	ORENCIA	NN	B-NP	O	S-brand
.	.	.	O	O	O

Population	Population	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
analyses	analysis	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
MTX	MTX	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
TNF	TNF	NN	B-NP	B-protein	B-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
abatacept	abatacept	JJ	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
majority	majority	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
RA	RA	NN	B-NP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
ORENCIA	ORENCIA	NNP	B-NP	O	S-brand
:	:	:	O	O	O
MTX	MTX	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
TNF	TNF	NN	B-NP	B-protein	B-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug
,	,	,	O	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug
,	,	,	O	O	O
gold	gold	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydroxychloroquine	hydroxychloroquine	NN	B-NP	O	S-drug
,	,	,	O	O	O
leflunomide	leflunomide	NN	B-NP	O	S-drug
,	,	,	O	O	O
sulfasalazine	sulfasalazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
anakinra	anakinra	NN	B-NP	O	S-drug
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
TNF	TNF	NN	I-NP	B-protein	B-group-EF-1
antagonist	antagonist	NN	I-NP	O	E-group-EF-1
with	with	IN	B-PP	O	O
ORENCIA	ORENCIA	NNP	B-NP	O	S-brand-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
infections	infection	NNS	I-NP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
additional	additional	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
over	over	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TNF	TNF	NN	I-NP	O	B-group
antagonists	antagonist	NNS	I-NP	O	E-group
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ORENCIA	ORENCIA	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
TNF	TNF	NN	I-NP	B-protein	B-group-AD-2
antagonists	antagonist	NNS	I-NP	O	E-group-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
insufficient	insufficient	JJ	B-NP	O	O
experience	experience	NN	I-NP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ORENCIA	ORENCIA	NNP	B-NP	O	S-brand-AD-1
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
anakinra	anakinra	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Formal	Formal	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Abciximab	Abciximab	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Abciximab	Abciximab	NNP	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ischemic	ischemic	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
broad	broad	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angina	angina	NN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
infarction	infarction	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
included	include	VBN	I-VP	O	O
heparin	heparin	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
receptor	receptor	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
,	,	,	O	O	O
angiotensin	angiotensin	NN	B-NP	O	B-group
converting	convert	VBG	B-VP	O	I-group
enzyme	enzyme	NN	B-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
oral	oral	JJ	I-NP	O	O
nitrates	nitrate	NNS	I-NP	O	S-group
,	,	,	O	O	O
ticlopidine	ticlopidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
.	.	.	O	O	O

Heparin	Heparin	NN	B-NP	O	S-drug
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
,	,	,	O	O	O
thrombolytics	thrombolytic	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
anti	anti	JJ	B-NP	O	B-group
platelet	platelet	NN	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bleeding	bleed	VBG	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
HACA	HACA	NN	B-NP	O	O
titers	titer	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
allergic	allergic	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	S-group
or	or	CC	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	B-group
monoclonal	monoclonal	JJ	I-NP	B-protein	I-group
antibodies	antibody	NNS	I-NP	I-protein	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Acamprosate	Acamprosate	NN	I-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
acamprosate	acamprosate	NN	I-NP	O	S-drug
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
acamprosate	acamprosate	NN	B-NP	O	S-drug
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
naltrexone	naltrexone	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
Acamprosate	Acamprosate	NN	B-NP	O	S-drug-ME-2
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
33	33	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acamprosate	acamprosate	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
naltrexone	naltrexone	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
major	major	JJ	I-NP	B-protein	O
metabolite	metabolite	NN	I-NP	I-protein	O
6	6	CD	I-NP	I-protein	B-drug_n
-	-	HYPH	B-NP	I-protein	I-drug_n
beta	beta	SYM	I-NP	I-protein	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
naltrexol	naltrexol	NN	B-NP	O	E-drug_n
were	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
following	follow	VBG	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Acamprosate	Acamprosate	NN	B-NP	O	S-drug
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Acamprosate	Acamprosate	NN	B-NP	O	S-drug
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
anxiolytics	anxiolytic	NNS	B-NP	O	S-group
,	,	,	I-NP	O	O
hypnotics	hypnotic	NNS	I-NP	O	S-group
and	and	CC	I-NP	O	O
sedatives	sedative	NNS	I-NP	O	S-group
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
non	non	AFX	O	O	B-group
-	-	HYPH	O	O	I-group
opioid	opioid	JJ	B-NP	O	I-group
analgesics	analgesic	NNS	I-NP	O	E-group
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
placebo	placebo	NN	B-NP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
Acamprosate	Acamprosate	NN	B-NP	O	S-drug-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	S-group-EF-2
more	more	RBR	B-VP	O	O
commonly	commonly	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
both	both	CC	O	O	O
weight	weight	NN	B-NP	O	O
gain	gain	NN	I-NP	O	O
and	and	CC	O	O	O
weight	weight	NN	B-NP	O	O
loss	loss	NN	I-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
either	either	CC	O	O	O
medication	medication	NN	B-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
tend	tend	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
thyroid	thyroid	NN	B-NP	B-protein	B-group
products	product	NNS	I-NP	I-protein	E-group
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
nicotinic	nicotinic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
sympathomimetics	sympathomimetic	NNS	B-NP	O	S-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	B-protein	B-group
channel	channel	NN	I-NP	I-protein	I-group
-	-	HYPH	O	O	I-group
blocking	block	VBG	B-VP	O	I-group
drugs	drug	NNS	B-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
Acarbose	Acarbose	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
Acarbose	Acarbose	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
sulfonylureas	sulfonylureas	NN	B-NP	O	S-group
or	or	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
any	any	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

Intestinal	Intestinal	JJ	B-NP	O	B-group-ME-1
adsorbents	adsorbent	NNS	I-NP	O	E-group-ME-1
(	(	(	O	O	O
e.	e.	FW	B-NP	O	O
g.	g.	NN	I-NP	O	O
,	,	,	O	O	O
charcoal	charcoal	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
and	and	CC	O	O	O
digestive	digestive	JJ	B-NP	O	B-group
enzyme	enzyme	NN	I-NP	O	I-group
preparations	preparation	NNS	I-NP	O	E-group
containing	contain	VBG	B-VP	O	O
carbohydrate	carbohydrate	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
splitting	split	VBG	B-VP	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
(	(	(	O	O	O
e.	e.	FW	B-NP	O	O
g.	g.	NN	I-NP	O	O
,	,	,	O	O	O
amylase	amylase	NN	B-NP	B-protein	S-drug-ME-1
,	,	,	O	O	O
pancreatin	pancreatin	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Acarbose	Acarbose	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Acarbose	Acarbose	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailabillty	bioavailabillty	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-2
when	when	WRB	B-ADVP	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
Acarbose	Acarbose	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Acarbose	Acarbose	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
or	or	CC	I-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sulfonylurea	sulfonylurea	NN	I-NP	O	S-drug
glyburide	glyburide	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Acarbose	Acarbose	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
bioavailabillty	bioavailabillty	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
dose	dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
:	:	:	O	O	O
8	8	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
23	23	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
decrease	decrease	VB	B-VP	O	O
mean	mean	JJ	B-NP	O	O
C	C	NN	I-NP	O	O
max	max	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
by	by	IN	B-PP	O	O
26	26	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
:	:	:	O	O	O
16	16	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
34	34	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
mean	mean	JJ	B-NP	O	O
trough	trough	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
9	9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
limit	limit	NN	I-NP	O	O
:	:	:	O	O	O
19	19	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
to	to	TO	B-PP	O	O
2	2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metformin	metformin	NN	B-NP	O	S-drug
absorbed	absorb	VBN	B-VP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
Acarbose	Acarbose	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
bioequivalent	bioequivalent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
absorbed	absorb	VBN	B-VP	O	O
when	when	WRB	B-ADVP	O	O
taking	take	VBG	B-VP	O	O
placebo	placebo	NN	B-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
indicated	indicate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metformin	metformin	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
taking	take	VBG	B-VP	O	O
Acarbose	Acarbose	NN	B-NP	O	S-drug-ME-M
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
delay	delay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metformin	metformin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
little	little	JJ	B-NP	O	O
if	if	IN	B-SBAR	O	O
any	any	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
Acarbose	Acarbose	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Catecholamine	Catecholamine	NN	B-NP	O	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
depleting	deplete	VBG	B-VP	O	I-group-EF-1
drugs	drug	NNS	B-NP	O	E-group-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	B-PP	O	I-group-EF-2
blocking	block	VBG	B-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
acebutolol	acebutolol	NN	B-NP	O	S-drug-AD-1
plus	plus	CC	I-NP	O	O
catecholamine	catecholamine	NN	I-NP	B-protein	B-group-AD-2
depletors	depletor	NNS	I-NP	I-protein	E-group-AD-2
should	should	MD	B-VP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
be	be	VB	B-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
marked	marked	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
or	or	CC	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
present	present	VB	I-VP	O	O
as	as	IN	B-PP	O	O
vertigo	vertigo	NN	B-NP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
presyncope	presyncope	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
orthostatic	orthostatic	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
without	without	IN	B-PP	O	O
compensatory	compensatory	JJ	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
.	.	.	O	O	O

Exaggerated	Exaggerate	VBN	B-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
adrenergic	adrenergic	JJ	I-NP	O	I-group-EF-1
antagonists	antagonist	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
alpha	alpha	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-2
stimulants	stimulant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
those	those	DT	B-NP	O	O
contained	contain	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
proprietary	proprietary	JJ	B-NP	O	O
cold	cold	JJ	I-NP	O	O
remedies	remedy	NNS	I-NP	O	O
and	and	CC	O	O	O
vasoconstrictive	vasoconstrictive	JJ	B-NP	O	O
nasal	nasal	JJ	I-NP	O	O
drops	drop	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	B-protein	O
receiving	receive	VBG	B-VP	I-protein	O
beta	beta	SYM	B-NP	I-protein	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warned	warn	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
hazard	hazard	NN	I-NP	O	O
.	.	.	O	O	O

Blunting	Blunting	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
adrenoceptor	adrenoceptor	NN	I-NP	O	I-group-EF-1
blocking	block	VBG	B-VP	O	I-group-EF-1
agents	agent	NNS	B-NP	O	E-group-EF-1
by	by	IN	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-EF-2
anti	anti	AFX	I-NP	O	I-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydralazine	hydralazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
sulfinpyrazone	sulfinpyrazone	NN	B-NP	O	S-drug
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
,	,	,	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

DIAMOX	DIAMOX	NN	B-NP	O	S-brand-ME-1
modifies	modify	VBZ	B-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
osteomalacia	osteomalacia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
chronic	chronic	JJ	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
chronic	chronic	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
decreasing	decrease	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
primidone	primidone	NN	B-NP	O	S-drug
,	,	,	O	O	O
DIAMOX	DIAMOX	NN	B-NP	O	S-brand-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
primidone	primidone	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
consequent	consequent	JJ	I-NP	O	O
possible	possible	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
beginning	begin	VBG	B-VP	O	O
,	,	,	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
changing	change	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DIAMOX	DIAMOX	NN	B-NP	O	S-brand-AD-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
primidone	primidone	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
possible	possible	JJ	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
carbonic	carbonic	JJ	I-NP	O	B-group
anhydrase	anhydrase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
advisable	advisable	JJ	B-ADJP	O	O
.	.	.	O	O	O

Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
folic	folic	JJ	I-NP	O	B-group-EF-2
acid	acid	NN	I-NP	O	I-group-EF-2
antagonists	antagonist	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Consideration	Consideration	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
antidiabetic	antidiabetic	JJ	B-NP	O	S-drug
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug-ME-1
decreases	decrease	VBZ	B-VP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
and	and	CC	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug-ME-1
reduces	reduce	VBZ	B-VP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
antiseptic	antiseptic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methenamine	methenamine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-2
excretion	excretion	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
sodium	sodium	NN	I-NP	O	B-drug-EF-2
bicarbonate	bicarbonate	NN	I-NP	O	E-drug-EF-2
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
calculus	calculus	NN	I-NP	O	O
formation	formation	NN	I-NP	O	O
.	.	.	O	O	O

Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
elevate	elevate	VB	I-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
iron	iron	NN	B-NP	O	B-group
supplements	supplement	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
iron	iron	NN	B-NP	O	S-drug
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
acyclovir	acyclovir	NN	B-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	O	O	O
time	time	NN	B-NP	O	O
curve	curve	NN	I-NP	O	O
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
correspondingly	correspondingly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Ethanol	Ethanol	NN	B-NP	O	S-drug
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
etretinate	etretinate	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
formed	form	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
ingestion	ingestion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acitretin	acitretin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Glibenclamide	Glibenclamide	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
7	7	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
acitretin	acitretin	NN	B-NP	O	S-drug-EF-1
treatment	treatment	NN	I-NP	O	O
potentiated	potentiate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
lowering	lower	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
glibenclamide	glibenclamide	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
a	a	DT	B-NP	O	O
sulfonylurea	sulfonylurea	NN	I-NP	O	S-group
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
chlorpropamide	chlorpropamide	NN	B-NP	O	S-drug
)	)	)	O	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
7	7	CD	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Repeating	Repeat	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
6	6	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glibenclamide	glibenclamide	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
detect	detect	VB	I-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acitretin	acitretin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
supervision	supervision	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Soriatane	Soriatane	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Hormonal	Hormonal	JJ	B-NP	O	B-group
Contraceptives	Contraceptive	NNS	I-NP	O	E-group
:	:	:	O	O	O
It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
acitretin	acitretin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
combined	combined	JJ	B-NP	O	B-group
oral	oral	JJ	I-NP	O	I-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
acitretin	acitretin	NN	B-NP	O	S-drug-EF-1
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
microdosed	microdose	VBN	B-NP	O	O
progestin	progestin	NN	I-NP	O	S-drug-EF-2
minipill	minipill	NN	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
.	.	.	O	O	O

Microdosed	Microdose	VBN	B-NP	O	O
minipill	minipill	NN	I-NP	O	O
progestin	progestin	NN	I-NP	O	S-drug-AD-1
preparations	preparation	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Soriatane	Soriatane	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
other	other	JJ	B-NP	O	O
progestational	progestational	JJ	I-NP	O	B-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
implants	implant	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
injectables	injectable	NNS	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
adequate	adequate	JJ	B-NP	O	O
methods	method	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
during	during	IN	B-PP	O	O
acitretin	acitretin	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
An	An	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatitis	hepatitis	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
etretinate	etretinate	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
acitretin	acitretin	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
If	If	IN	B-SBAR	O	O
acitretin	acitretin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Tetracyclines	Tetracycline	NNS	B-NP	O	S-group
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
both	both	CC	O	O	O
acitretin	acitretin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
tetracyclines	tetracycline	NNS	I-NP	O	S-group-EF-2
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
intracranial	intracranial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
their	their	PRP$	B-NP	O	O
combined	combine	VBN	I-NP	O	O
use	use	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Vitamin	Vitamin	NN	B-NP	O	B-group
A	A	NN	I-NP	O	E-group
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
retinoids	retinoid	NNS	I-NP	O	S-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-AD-1
A	A	NN	I-NP	O	E-group-AD-1
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
retinoids	retinoid	NNS	I-NP	O	S-group-AD-1
with	with	IN	B-PP	O	O
acitretin	acitretin	NN	B-NP	O	S-drug-AD-2
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
because	because	RB	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypervitaminosis	hypervitaminosis	NN	B-NP	O	O
A	A	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-ADJP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
no	no	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
acitretin	acitretin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Investigations	Investigation	NNS	B-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acitretin	acitretin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	B-group
of	of	IN	B-PP	O	I-group
the	the	DT	B-NP	O	I-group
coumarin	coumarin	NN	I-NP	O	I-group
type	type	NN	I-NP	O	E-group
(	(	(	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
)	)	)	O	O	O
revealed	reveal	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Laboratory	Laboratory	NN	B-NP	O	O
Tests	Test	NNS	I-NP	O	O
If	If	IN	B-SBAR	O	O
significant	significant	JJ	B-NP	O	O
abnormal	abnormal	JJ	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
,	,	,	O	O	O
either	either	CC	O	O	O
dosage	dosage	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
or	or	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
,	,	,	O	O	O
depending	depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
judgement	judgement	NN	I-NP	O	O
.	.	.	O	O	O

Blood	Blood	NNP	B-NP	O	O
Sugar	Sugar	NNP	I-NP	O	O
:	:	:	O	O	O
Some	Some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
retinoids	retinoid	NNS	B-NP	O	S-group
have	have	VBP	B-VP	O	O
experienced	experience	VBN	I-VP	O	O
problems	problem	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
sugar	sugar	NN	I-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
new	new	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diabetes	diabete	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
retinoid	retinoid	NN	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
ketoacidosis	ketoacidosis	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
diabetics	diabetic	NNS	B-NP	O	O
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
sugar	sugar	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
very	very	RB	B-ADVP	O	O
carefully	carefully	RB	I-ADVP	O	O
.	.	.	O	O	O

Lipids	Lipid	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertriglyceridemia	hypertriglyceridemia	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
66	66	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
33	33	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
HDL	HDL	NN	I-NP	B-protein	O
was	be	VBD	B-VP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Pretreatment	Pretreatment	NN	B-NP	O	O
and	and	CC	O	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
measurements	measurement	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
obtained	obtain	VBN	I-VP	O	O
under	under	IN	B-PP	O	O
fasting	fast	VBG	B-VP	O	O
conditions	condition	NNS	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
tests	test	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
performed	perform	VBN	I-VP	O	O
weekly	weekly	RB	B-ADVP	O	O
or	or	CC	O	O	O
every	every	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
week	week	NN	I-NP	O	O
until	until	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
Soriatane	Soriatane	NNP	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
.	.	.	O	O	O

Liver	Liver	NN	B-NP	O	O
Function	Function	NNP	I-NP	O	O
Tests	Test	NNPS	I-NP	O	O
:	:	:	O	O	O
Elevations	Elevation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
AST	AST	NN	B-NP	O	O
(	(	(	O	O	O
SGOT	SGOT	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
ALT	ALT	NN	B-NP	B-protein	O
(	(	(	O	O	O
SGPT	SGPT	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
LDH	LDH	NN	B-NP	B-protein	O
were	be	VBD	B-VP	O	O
experienced	experience	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
1	1	CD	I-NP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Soriatane	Soriatane	NN	B-NP	O	S-brand
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
tests	test	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
performed	perform	VBN	I-VP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Soriatane	Soriatane	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
until	until	IN	B-PP	O	O
stable	stable	JJ	B-ADJP	O	O
and	and	CC	O	O	O
thereafter	thereafter	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
intervals	interval	NNS	B-NP	O	O
as	as	IN	B-SBAR	O	O
clinically	clinically	RB	B-ADVP	O	O
indicated	indicate	VBN	B-VP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
HUMIRA	HUMIRA	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
MTX	MTX	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
suggest	suggest	VB	I-VP	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
HUMIRA	HUMIRA	NN	B-NP	B-protein	S-brand
or	or	CC	I-NP	O	O
MTX	MTX	NN	I-NP	B-protein	S-drug
.	.	.	O	O	O

Anakinra	Anakinra	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anakinra	anakinra	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
an	an	DT	B-NP	O	O
interleukin	interleukin	NN	I-NP	B-protein	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
1	1	CD	I-NP	O	I-group-EF-1
antagonist	antagonist	NN	I-NP	O	E-group-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
another	another	DT	B-NP	O	O
TNF	TNF	NN	I-NP	B-protein	B-group-EF-2
-	-	HYPH	B-ADJP	O	I-group-EF-2
blocking	block	VBG	B-VP	O	I-group-EF-2
agent	agent	NN	B-NP	O	E-group-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
infections	infection	NNS	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neutropenia	neutropenia	NN	B-NP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
benefit	benefit	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
these	these	DT	B-NP	O	O
medicinal	medicinal	JJ	I-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anakinra	anakinra	NN	B-NP	O	S-drug
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
HUMIRA	HUMIRA	NN	B-NP	B-protein	S-brand
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-NP	O	O
the	the	DT	I-NP	O	O
,	,	,	O	O	O
combination	combination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anakinra	anakinra	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
TNF	TNF	NN	I-NP	B-protein	B-group-EF-2
-	-	HYPH	B-VP	O	I-group-EF-2
blocking	block	VBG	B-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
HUMIRA	HUMIRA	NNP	B-NP	O	S-brand-EF-2
,	,	,	O	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
result	result	VB	I-VP	O	O
i	i	NN	B-NP	O	O
n	n	NN	I-NP	O	O
similar	similar	JJ	I-NP	O	O
toxicities	toxicity	NNS	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
DIFFERIN	DIFFERIN	NN	B-NP	O	S-brand
Gel	Gel	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
produce	produce	VB	I-VP	O	O
local	local	JJ	B-NP	O	O
irritation	irritation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
irritating	irritate	VBG	I-VP	O	O
topical	topical	JJ	B-NP	O	O
products	product	NNS	I-NP	O	O
(	(	(	O	O	O
medicated	medicate	VBN	B-NP	O	O
or	or	CC	I-NP	O	O
abrasive	abrasive	JJ	I-NP	O	O
soaps	soap	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
cleansers	cleanser	NNS	I-NP	O	O
,	,	,	I-NP	O	O
soaps	soap	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
cosmetics	cosmetic	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
drying	drying	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
products	product	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	O
,	,	,	O	O	O
astringents	astringent	NNS	B-NP	O	O
,	,	,	O	O	O
spices	spice	NNS	B-NP	O	O
or	or	CC	O	O	O
lime	lime	NN	B-NP	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Particular	Particular	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
sulfur	sulfur	NN	B-NP	O	S-drug
,	,	,	O	O	O
resorcinol	resorcinol	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
salicylic	salicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
DIFFERIN	DIFFERIN	NN	B-NP	O	S-brand
Gel	Gel	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
not	not	RB	O	O	O
to	to	TO	B-VP	O	O
start	start	VB	I-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
DIFFERIN	DIFFERIN	NN	B-NP	O	S-brand
Gel	Gel	NN	I-NP	O	O
until	until	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
skin	skin	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
subsided	subside	VBN	I-VP	O	O
.	.	.	O	O	O

Before	Before	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
,	,	,	O	O	O
tell	tell	VB	B-VP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacist	pharmacist	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
prescription	prescription	NN	I-NP	O	O
and	and	CC	I-NP	O	O
nonprescription	nonprescription	NN	I-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
you	you	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
use	use	VB	I-VP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
:	:	:	O	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
amikacin	amikacin	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
non	non	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	B-DNA	I-group
steroidal	steroidal	JJ	B-NP	I-DNA	I-group
anti	anti	AFX	I-NP	I-DNA	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	E-group
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Do	Do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
start	start	VB	I-VP	O	O
or	or	CC	I-VP	O	O
stop	stop	VB	I-VP	O	O
any	any	DT	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
without	without	IN	B-PP	O	O
doctor	doctor	NN	B-NP	O	O
or	or	CC	I-NP	O	O
pharmacist	pharmacist	NN	I-NP	O	O
approval	approval	NN	I-NP	O	O
.	.	.	O	O	O

Intravenous	Intravenous	JJ	B-NP	O	O
Adenocard	Adenocard	NN	I-NP	O	S-brand
(	(	(	O	O	O
adenosine	adenosine	NN	B-NP	O	S-drug
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
effectively	effectively	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cardioactive	cardioactive	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	O	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blocking	block	VBG	B-VP	O	I-group
agents	agent	NNS	B-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
angiotensin	angiotensin	NN	B-NP	O	B-group
converting	convert	VBG	B-VP	O	I-group
enzyme	enzyme	NN	B-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
without	without	IN	B-PP	O	O
any	any	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug-EF-1
use	use	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
rarely	rarely	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	O
fibrillation	fibrillation	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Adenocard	Adenocard	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SA	SA	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AV	AV	NN	I-NP	O	O
nodes	node	NNS	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
Adenocard	Adenocard	NNP	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Adenocard	Adenocard	NN	B-NP	O	S-brand-EF-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
rarely	rarely	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	O
fibrillation	fibrillation	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	O	S-drug-EF-1
are	be	VBP	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
methylxanthines	methylxanthine	NNS	B-NP	O	S-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
methylxanthines	methylxanthine	NNS	I-NP	O	S-group-AD-1
,	,	,	O	O	O
larger	large	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	O	S-drug-AD-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
or	or	CC	O	O	O
adenosine	adenosine	NN	B-NP	O	S-drug-AD-2
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
effective	effective	JJ	B-ADJP	O	O
.	.	.	O	O	O

Adenosine	Adenosine	NN	B-NP	O	S-drug-EF-1
effects	effect	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
smaller	small	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
block	block	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
conduction	conduction	NN	B-NP	O	O
through	through	IN	B-PP	O	O
the	the	DT	B-NP	O	O
A	A	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
V	V	NN	I-NP	O	O
node	node	NN	I-NP	O	O
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
block	block	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
produced	produce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antifungal	antifungal	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Nafazodone	Nafazodone	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-AD-1
(	(	(	O	O	O
consider	consider	NN	B-NP	O	O
Xanax	Xanax	NN	I-NP	O	S-brand-AD-2
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Fluoxetine	Fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
OCs	OC	NNS	B-NP	B-cell_type	S-group
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
,	,	,	O	O	O
macrolide	macrolide	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
(	(	(	O	O	O
exercise	exercise	NN	B-NP	O	O
caution	caution	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Dexamethasone	Dexamethasone	NN	B-NP	O	S-drug
:	:	:	O	O	O
Steady	Steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
albendazole	albendazole	NN	B-NP	O	B-drug
sulfoxide	sulfoxide	NN	I-NP	O	E-drug
were	be	VBD	B-VP	O	O
about	about	RB	B-NP	O	O
56	56	CD	I-NP	O	O
%	%	NN	I-NP	O	O
higher	high	JJR	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
8	8	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
each	each	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
albendazole	albendazole	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
neurocysticercosis	neurocysticercosis	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Praziquantel	Praziquantel	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fed	feed	VBN	I-NP	O	O
state	state	NN	I-NP	O	O
,	,	,	O	O	O
praziquantel	praziquantel	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
mean	mean	JJ	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
of	of	IN	B-PP	O	O
albendazole	albendazole	NN	B-NP	O	B-drug-ME-2
sulfoxide	sulfoxide	NN	I-NP	O	E-drug-ME-2
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
separate	separate	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
given	give	VBN	B-NP	O	O
albendazole	albendazole	NN	I-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
T	T	NN	I-NP	O	O
max	max	NN	I-NP	O	O
and	and	CC	O	O	O
mean	mean	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
albendazole	albendazole	NN	B-NP	O	B-drug
sulfoxide	sulfoxide	NN	I-NP	O	E-drug
were	be	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
praziquantel	praziquantel	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
following	follow	VBG	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
albendazole	albendazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Albendazole	Albendazole	NN	B-NP	O	B-drug-ME-1
sulfoxide	sulfoxide	NN	I-NP	O	E-drug-ME-1
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
bile	bile	NN	B-NP	O	O
and	and	CC	O	O	O
cystic	cystic	JJ	B-NP	O	O
fluid	fluid	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
hydatid	hydatid	JJ	B-NP	O	O
cyst	cyst	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
7	7	CD	B-NP	O	O
)	)	)	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
albendazole	albendazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
alone	alone	RB	B-ADVP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Albendazole	Albendazole	NN	B-NP	O	B-drug
sulfoxide	sulfoxide	NN	I-NP	O	E-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
4	4	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
(	(	(	O	O	O
aminophylline	aminophylline	NN	B-NP	O	S-drug
5.8	5.8	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
infused	infuse	VBN	B-VP	O	O
over	over	IN	B-PP	O	O
20	20	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
albendazole	albendazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
6	6	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
information	information	NN	I-NP	O	O
provided	provide	VBD	B-VP	O	O

PROLEUKIN	PROLEUKIN	NN	B-NP	B-protein	S-brand
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
central	central	JJ	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
interactions	interaction	NNS	B-NP	O	O
could	could	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
psychotropic	psychotropic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
analgesics	analgesic	NNS	B-NP	O	S-group
,	,	,	O	O	O
antiemetics	antiemetic	NNS	B-NP	O	S-group
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
possessing	possess	VBG	B-VP	O	O
nephrotoxic	nephrotoxic	JJ	B-ADJP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
,	,	,	O	O	O
myelotoxic	myelotoxic	JJ	B-ADJP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cytotoxic	cytotoxic	JJ	B-NP	O	S-group-EF-1
chemotherapy	chemotherapy	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
cardiotoxic	cardiotoxic	JJ	B-ADJP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
or	or	CC	O	O	O
hepatotoxic	hepatotoxic	JJ	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
asparaginase	asparaginase	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
effects	effect	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
PROLEUKIN	PROLEUKIN	NN	B-NP	B-protein	S-brand-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
organ	organ	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PROLEUKIN	PROLEUKIN	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
antineoplastic	antineoplastic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
reduced	reduce	VBD	B-VP	O	O
kidney	kidney	NN	B-NP	O	O
and	and	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
PROLEUKIN	PROLEUKIN	NN	B-NP	O	S-brand
treatment	treatment	NN	I-NP	O	O
may	may	MD	B-VP	O	O
delay	delay	VB	I-VP	O	O
elimination	elimination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
those	those	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Hypersensitivity	Hypersensitivity	NN	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
combination	combination	NN	B-NP	O	O
regimens	regimen	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
sequential	sequential	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
PROLEUKIN	PROLEUKIN	NN	I-NP	O	S-brand-EF-1
and	and	CC	O	O	O
antineoplastic	antineoplastic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
specifically	specifically	RB	B-ADVP	O	O
,	,	,	O	O	O
dacarbazine	dacarbazine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
cis	cis	NN	B-NP	B-protein	B-drug-EF-2
-	-	HYPH	B-NP	O	I-drug-EF-2
platinum	platinum	NN	I-NP	O	E-drug-EF-2
,	,	,	I-NP	O	O
tamoxifen	tamoxifen	NN	I-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
interferon	interferon	NN	I-NP	B-protein	B-drug-EF-2
-	-	HYPH	B-NP	O	I-drug-EF-2
alfa	alfa	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
consisted	consist	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
erythema	erythema	NN	B-NP	O	O
,	,	,	O	O	O
pruritus	pruritus	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	O	O	O
occurred	occur	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
hours	hour	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
events	event	NNS	I-NP	O	O
required	require	VBD	B-VP	O	O
medical	medical	JJ	B-NP	O	O
intervention	intervention	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Myocardial	Myocardial	JJ	B-NP	O	O
injury	injury	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	O
infarction	infarction	NN	I-NP	O	O
,	,	,	O	O	O
myocarditis	myocarditis	NN	B-NP	O	O
,	,	,	O	O	O
ventricular	ventricular	JJ	B-NP	O	O
hypokinesia	hypokinesia	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
severe	severe	JJ	B-NP	O	O
rhabdomyolysis	rhabdomyolysis	NN	I-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
PROLEUKIN	PROLEUKIN	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	I-NP	O	O
interferon	interferon	NN	I-NP	B-protein	B-drug-EF-2
-	-	HYPH	B-NP	O	I-drug-EF-2
alfa	alfa	NN	I-NP	O	E-drug-EF-2
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Exacerbation	Exacerbation	NN	B-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
presentation	presentation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
autoimmune	autoimmune	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
disorders	disorder	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interferon	interferon	NN	B-NP	B-protein	B-drug-EF-1
-	-	HYPH	B-NP	O	I-drug-EF-1
alfa	alfa	NN	I-NP	O	E-drug-EF-1
and	and	CC	I-NP	O	O
PROLEUKIN	PROLEUKIN	NN	I-NP	B-protein	S-brand-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
crescentic	crescentic	JJ	B-NP	O	O
IgA	IgA	NN	I-NP	O	O
glomerulonephritis	glomerulonephritis	NN	I-NP	O	O
,	,	,	O	O	O
oculo	oculo	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
bulbar	bulbar	NN	I-NP	O	O
myasthenia	myasthenia	NN	I-NP	O	O
gravis	gravis	NN	I-NP	O	O
,	,	,	O	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
,	,	,	O	O	O
thyroiditis	thyroiditis	NN	B-NP	O	O
,	,	,	O	O	O
bullous	bullous	JJ	B-NP	O	O
pemphigoid	pemphigoid	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Stevens	Stevens	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Johnson	Johnson	NNP	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
glucocorticoids	glucocorticoid	NNS	B-NP	O	S-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
PROLEUKIN	PROLEUKIN	NN	B-NP	B-protein	S-brand-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
fever	fever	NN	B-NP	O	O
,	,	,	O	O	O
renal	renal	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
,	,	,	O	O	O
hyperbilirubinemia	hyperbilirubinemia	NN	B-NP	O	O
,	,	,	O	O	O
confusion	confusion	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
dyspnea	dyspnea	NN	B-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
PROLEUKIN	PROLEUKIN	NN	B-NP	B-protein	S-brand
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antitumor	antitumor	JJ	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PROLEUKIN	PROLEUKIN	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
thus	thus	RB	B-VP	O	O
should	should	MD	I-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O
12	12	CD	B-NP	B-protein	O
Beta	Beta	NNP	I-NP	I-protein	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
antihypertensives	antihypertensive	NNS	I-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
seen	see	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
PROLEUKIN	PROLEUKIN	NN	B-NP	B-protein	S-brand-EF-2
.	.	.	O	O	O

Delayed	Delay	VBN	B-NP	O	O
Adverse	Adverse	JJ	I-NP	O	O
Reactions	Reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
Iodinated	Iodinated	NNP	B-NP	O	B-group
Contrast	Contrast	NNP	I-NP	O	I-group
Media	Media	NNP	I-NP	O	E-group
:	:	:	O	O	O
A	A	DT	B-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
12.6	12.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
11	11	CD	I-NP	O	O
-	-	HYPH	O	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
501	501	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
interleukin	interleukin	NN	I-NP	B-protein	B-drug-EF-1
-	-	HYPH	B-NP	I-protein	I-drug-EF-1
2	2	CD	I-NP	I-protein	E-drug-EF-1
containing	contain	VBG	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
subsequently	subsequently	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
radiographic	radiographic	JJ	B-NP	O	B-group-EF-2
iodinated	iodinate	VBN	I-NP	O	I-group-EF-2
contrast	contrast	NN	I-NP	O	I-group-EF-2
media	medium	NNS	I-NP	O	E-group-EF-2
experienced	experience	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	O
,	,	,	I-NP	O	O
atypical	atypical	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
usually	usually	RB	B-ADVP	O	O
occurred	occur	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
hours	hour	NNS	B-NP	O	O
(	(	(	O	O	O
most	most	RBS	B-NP	O	O
commonly	commonly	RB	I-NP	O	O
1	1	CD	I-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
)	)	)	O	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
media	medium	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
fever	fever	NN	B-NP	O	O
,	,	,	O	O	O
chills	chill	NNS	B-NP	O	O
,	,	,	O	O	O
nausea	nausea	NN	B-NP	O	O
,	,	,	O	O	O
vomiting	vomiting	NN	B-NP	O	O
,	,	,	O	O	O
pruritus	pruritus	NN	B-NP	O	O
,	,	,	O	O	O
rash	rash	NN	B-NP	O	O
,	,	,	O	O	O
diarrhea	diarrhea	NN	B-NP	O	O
,	,	,	O	O	O
hypotension	hypotension	NN	B-NP	O	O
,	,	,	O	O	O
edema	edema	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
oliguria	oliguria	NN	B-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
clinicians	clinician	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
noted	note	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
resemble	resemble	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
immediate	immediate	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
interleukin	interleukin	NN	B-NP	B-protein	B-drug
-	-	HYPH	O	O	I-drug
2	2	CD	B-NP	O	E-drug
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
interleukin	interleukin	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
2	2	CD	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Most	Most	JJS	B-NP	O	O
events	event	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
contrast	contrast	NN	B-NP	O	O
media	medium	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interleukin	interleukin	NN	B-NP	B-protein	B-drug
-	-	HYPH	B-NP	I-protein	I-drug
2	2	CD	I-NP	I-protein	E-drug
.	.	.	O	O	O

These	These	DT	B-NP	O	O
events	event	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
contrast	contrast	NN	B-NP	O	O
media	medium	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
several	several	JJ	B-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
interleukin	interleukin	NN	B-NP	B-protein	B-drug
-	-	HYPH	O	O	I-drug
2	2	CD	B-NP	O	E-drug
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
period	period	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
before	before	IN	B-SBAR	O	O
one	one	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
consider	consider	VB	I-VP	O	O
starting	start	VBG	I-VP	O	O
other	other	JJ	B-NP	O	O
immunosuppressive	immunosuppressive	JJ	I-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Carcinogenesis	Carcinogenesis	NN	B-NP	O	O
,	,	,	O	O	O
Mutagenesis	Mutagenesis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Fertility	Fertility	NN	B-NP	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
chronic	chronic	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
cynomolgus	cynomolgus	NN	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
dosed	dose	VBN	I-VP	O	O
weekly	weekly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
52	52	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
alefacept	alefacept	NN	I-NP	O	S-drug
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dose	dose	NN	I-NP	O	O
or	or	CC	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
animal	animal	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
group	group	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
B	B	NN	I-NP	B-cell_type	O
-	-	HYPH	B-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
lymphoma	lymphoma	NN	I-NP	I-cell_type	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
28	28	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
B	B	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
cell	cell	NN	I-NP	O	O
hyperplasia	hyperplasia	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
spleen	spleen	NN	I-NP	O	O
and	and	CC	I-NP	O	O
lymph	lymph	NN	I-NP	O	O
nodes	node	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
positive	positive	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
endemic	endemic	JJ	I-NP	O	O
primate	primate	JJ	I-NP	O	O
gammaherpes	gammaherpes	NN	I-NP	O	O
virus	virus	NN	I-NP	O	O
also	also	RB	B-VP	O	O
known	know	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
lymphocryptovirus	lymphocryptovirus	NN	B-NP	O	O
(	(	(	O	O	O
LCV	LCV	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Latent	Latent	JJ	B-NP	O	O
LCV	LCV	NN	I-NP	O	O
infection	infection	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
generally	generally	RB	B-ADVP	O	O
asymptomatic	asymptomatic	JJ	B-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
can	can	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
B	B	NN	B-NP	B-cell_type	O
-	-	HYPH	B-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
lymphomas	lymphoma	NNS	I-NP	I-cell_type	O
when	when	WRB	B-ADVP	O	O
animals	animal	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
immune	immune	JJ	B-ADJP	O	O
suppressed	suppress	VBN	B-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
separate	separate	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
baboons	baboon	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
3	3	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alefacept	alefacept	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
centroblast	centroblast	NN	B-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
B	B	NN	B-NP	B-cell_type	O
-	-	HYPH	B-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
dependent	dependent	JJ	I-NP	O	O
areas	area	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
germinal	germinal	JJ	I-NP	O	O
centers	center	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
spleen	spleen	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
116	116	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
washout	washout	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lymphoid	lymphoid	JJ	I-NP	O	O
malignancy	malignancy	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
hyperplasia	hyperplasia	NN	I-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
human	human	JJ	I-NP	O	O
primates	primate	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
humans	human	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Immunodeficiency	Immunodeficiency	NN	B-NP	O	O
-	-	HYPH	B-PP	O	O
associated	associate	VBN	B-NP	O	O
lymphocyte	lymphocyte	NN	I-NP	O	O
disorders	disorder	NNS	I-NP	O	O
(	(	(	O	O	O
plasmacytic	plasmacytic	JJ	B-NP	O	O
hyperplasia	hyperplasia	NN	I-NP	O	O
,	,	,	O	O	O
polymorphic	polymorphic	JJ	B-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
B	B	NN	B-NP	B-cell_type	O
-	-	HYPH	B-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
lymphomas	lymphoma	NNS	I-NP	I-cell_type	O
)	)	)	O	O	O
occur	occur	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
congenital	congenital	JJ	I-VP	O	O
or	or	CC	I-VP	O	O
acquired	acquire	VBN	I-VP	O	O
immunodeficiencies	immunodeficiency	NNS	B-NP	O	O
including	include	VBG	B-PP	O	O
those	those	DT	B-NP	O	O
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
immunosuppressive	immunosuppressive	JJ	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
carcinogenicity	carcinogenicity	NN	I-NP	O	O
or	or	CC	I-NP	O	O
fertility	fertility	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Mutagenicity	Mutagenicity	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
;	;	:	O	O	O

no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mutagenicity	mutagenicity	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Pregnancy	Pregnancy	NN	B-NP	O	O
(	(	(	O	O	O
Category	Category	NN	B-NP	B-protein	O
B	B	NN	I-NP	I-protein	O
)	)	)	O	O	O

Women	Woman	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
childbearing	childbeare	VBG	B-VP	O	O
potential	potential	JJ	B-NP	O	O
make	make	VB	B-VP	O	O
up	up	RP	B-PRT	O	O
a	a	DT	B-NP	O	O
considerable	considerable	JJ	I-NP	O	O
segment	segment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
population	population	NN	I-NP	O	O
affected	affect	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
psoriasis	psoriasis	NN	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
and	and	CC	O	O	O
fetal	fetal	JJ	B-NP	O	O
development	development	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
immune	immune	JJ	B-NP	O	O
system	system	NN	I-NP	O	O
development	development	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
,	,	,	O	O	O
health	health	NN	B-NP	O	O
care	care	NN	I-NP	O	O
providers	provider	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
encouraged	encourage	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
enroll	enroll	VB	I-VP	O	O
patients	patient	NNS	B-NP	O	O
currently	currently	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
who	who	WP	B-NP	O	O
become	become	VBP	B-VP	O	O
pregnant	pregnant	JJ	B-ADJP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Biogen	Biogen	NNP	I-NP	O	O
Pregnancy	Pregnancy	NNP	I-NP	O	O
Registry	Registry	NNP	I-NP	O	O
by	by	IN	B-PP	O	O
calling	call	VBG	B-VP	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
866	866	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
AMEVIVE	AMEVIVE	NN	I-NP	O	S-brand
(	(	(	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	O	O	O
866	866	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
263	263	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
8483	8483	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Reproductive	Reproductive	JJ	B-NP	O	O
toxicology	toxicology	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cynomolgus	cynomolgus	NN	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
week	week	NN	I-NP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
62	62	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
revealed	reveal	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
fertility	fertility	NN	I-NP	O	O
or	or	CC	I-NP	O	O
harm	harm	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
fetus	fetus	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
.	.	.	O	O	O

No	No	DT	B-NP	O	O
abortifacient	abortifacient	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
teratogenic	teratogenic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cynomolgus	cynomolgus	NN	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
bolus	bolus	NN	I-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
administered	administer	VBN	B-VP	O	O
weekly	weekly	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
organogenesis	organogenesis	NN	B-NP	O	O
to	to	TO	B-PP	O	O
gestation	gestation	NN	B-NP	O	O
.	.	.	O	O	O

AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
underwent	undergo	VBD	B-VP	O	O
trans	trans	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
placental	placental	JJ	B-NP	O	O
passage	passage	NN	I-NP	O	O
and	and	CC	O	O	O
produced	produce	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
utero	utero	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
developing	develop	VBG	I-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
utero	utero	NN	B-NP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
maternal	maternal	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fetal	fetal	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
immune	immune	JJ	B-NP	O	O
system	system	NN	I-NP	O	O
development	development	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

Animal	Animal	JJ	B-NP	O	O
reproduction	reproduction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
always	always	RB	B-ADVP	O	O
predictive	predictive	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
and	and	CC	O	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
adequate	adequate	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fetal	fetal	JJ	I-NP	O	O
immune	immune	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
and	and	CC	O	O	O
postnatal	postnatal	JJ	B-NP	O	O
immune	immune	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
,	,	,	O	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
only	only	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
clearly	clearly	RB	B-ADVP	O	O
needed	need	VBN	B-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
pregnancy	pregnancy	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
,	,	,	O	O	O
continued	continue	VBN	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
assessed	assess	VBN	I-VP	O	O
.	.	.	O	O	O

Nursing	Nurse	VBG	B-VP	O	O
Mothers	Mother	NNS	B-NP	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
milk	milk	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
many	many	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
milk	milk	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
because	because	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
exists	exist	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
nursing	nurse	VBG	B-VP	O	O
infants	infant	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decision	decision	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
to	to	TO	B-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
nursing	nursing	NN	B-NP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
or	or	CC	O	O	O
to	to	TO	B-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
taking	take	VBG	B-VP	O	O
into	into	IN	B-PP	O	O
account	account	NN	B-NP	O	O
the	the	DT	B-NP	O	O
importance	importance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
mother	mother	NN	I-NP	O	O
.	.	.	O	O	O

Geriatric	Geriatric	NNP	B-NP	O	O
Use	Use	NNP	I-NP	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1357	1357	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O

65	65	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
and	and	CC	O	O	O
13	13	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O

75	75	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
safety	safety	NN	B-NP	O	O
or	or	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
and	and	CC	I-NP	O	O
younger	young	JJR	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
sufficient	sufficient	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
exclude	exclude	VB	I-VP	O	O
important	important	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
infections	infection	NNS	B-NP	O	O
and	and	CC	O	O	O
certain	certain	JJ	B-NP	O	O
malignancies	malignancy	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	B-cell_type	O
population	population	NN	I-NP	I-cell_type	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
general	general	JJ	B-ADJP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
treating	treat	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
.	.	.	O	O	O

Pediatric	Pediatric	NNP	B-NP	O	O
Use	Use	NNP	I-NP	O	O

The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

AMEVIVE	AMEVIVE	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
indicated	indicate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Campath	Campath	NN	B-NP	O	S-brand
.	.	.	O	O	O

An	An	DT	B-NP	O	O
immune	immune	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
Campath	Campath	NNP	B-NP	O	S-brand
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
utilize	utilize	VBP	B-VP	O	O
antibodies	antibody	NNS	B-NP	B-protein	S-group

Intravenous	Intravenous	JJ	B-NP	O	O
ranitidine	ranitidine	NN	I-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
double	double	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
alendronate	alendronate	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
and	and	CC	O	O	O
whether	whether	IN	B-SBAR	O	O
similar	similar	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
oral	oral	JJ	B-NP	O	O
H2	H2	NN	I-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
;	;	:	O	O	O

no	no	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
specific	specific	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Products	Product	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
multivalent	multivalent	JJ	I-NP	O	B-drug-ME-1
cations	cation	NNS	I-NP	O	E-drug-ME-1
likely	likely	RB	B-ADVP	O	O
will	will	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
alendronate	alendronate	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Both	Both	CC	O	O	O
the	the	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
and	and	CC	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
and	and	CC	O	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ALFENTA	ALFENTA	NN	B-NP	B-protein	S-brand-EF-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
opioids	opioid	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
inhalation	inhalation	NN	B-NP	O	O
general	general	JJ	I-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Postoperative	Postoperative	JJ	B-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
depression	depression	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
combined	combined	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Limited	Limit	VBN	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
experience	experience	NN	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
requirements	requirement	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
volatile	volatile	JJ	B-NP	O	B-group-ME-1
inhalation	inhalation	NN	I-NP	O	I-group-ME-1
anesthetics	anesthetic	NNS	I-NP	O	E-group-ME-1
are	be	VBP	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
30	30	CD	B-NP	O	O
to	to	TO	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
sixty	sixty	CD	I-NP	O	O
(	(	(	O	O	O
60	60	CD	B-NP	O	O
)	)	)	O	O	O
minutes	minute	NNS	B-NP	O	O
following	follow	VBG	B-PP	O	O
ALFENTA	ALFENTA	NN	B-NP	O	S-brand-ME-2
induction	induction	NN	I-NP	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
ALFENTA	ALFENTA	NN	B-NP	B-protein	S-brand-ME-2
can	can	MD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
ALFENTA	ALFENTA	NN	B-NP	O	S-brand
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
delayed	delay	VBN	I-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ALFENTA	ALFENTA	NN	B-NP	B-protein	S-brand-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-NP	O	O
smaller	small	JJR	I-NP	O	O
ALFENTA	ALFENTA	NN	I-NP	O	S-brand
doses	dose	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
prolonged	prolong	VBN	B-NP	O	O
administration	administration	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ALFENTA	ALFENTA	NN	B-NP	B-protein	S-brand
my	my	PRP$	B-NP	O	O
be	be	VB	B-VP	O	O
extended	extend	VBN	I-VP	O	O
.	.	.	O	O	O

Perioperative	Perioperative	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
affecting	affect	VBG	B-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
or	or	CC	O	O	O
enzyme	enzyme	NN	B-NP	O	O
function	function	NN	I-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
prolong	prolong	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
UROXATRAL	UROXATRAL	NN	B-NP	O	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
alpha	alpha	SYM	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
interactions	interaction	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
UROXATRAL	UROXATRAL	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
NOT	NOT	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
alpha	alpha	SYM	I-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
blockers	blocker	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
Aliskiren	Aliskiren	NNP	B-NP	O	S-drug
Based	Based	NNP	I-NP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-PP	O	O
-	-	HYPH	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
aliskiren	aliskiren	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
atenolol	atenolol	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
furosemide	furosemide	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
celecoxib	celecoxib	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
ramipril	ramipril	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
valsartan	valsartan	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
amlodipine	amlodipine	NN	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
aliskiren	aliskiren	JJ	B-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
irbesartan	irbesartan	NN	B-NP	O	S-drug-ME-1
reduced	reduce	VBD	B-VP	O	O
aliskiren	aliskiren	JJ	B-NP	O	S-drug-ME-2
Cmax	Cmax	NN	I-NP	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
after	after	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-ME-1
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
about	about	RB	B-NP	O	O
a	a	DT	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
aliskiren	aliskiren	JJ	B-NP	O	S-drug-ME-2
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
after	after	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-NP	O	O
-	-	HYPH	I-NP	O	O
daily	daily	JJ	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
aliskiren	aliskiren	NN	B-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aliskiren	aliskiren	NNS	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
-	-	HYPH	I-ADVP	O	O
daily	daily	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
but	but	CC	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
aliskiren	aliskiren	JJ	B-NP	O	S-drug
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
further	further	RBR	B-ADVP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Aliskiren	Aliskiren	NNP	B-NP	O	S-drug
on	on	IN	B-PP	O	O
Other	Other	NNP	B-NP	O	O
Drugs	Drugs	NNP	I-NP	O	O
Aliskiren	Aliskiren	NNP	I-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CYP450	CYP450	NN	I-NP	B-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
(	(	(	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C8	2C8	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
2D6	2D6	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
2E1	2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A	3A	NN	I-NP	I-protein	O
)	)	)	O	O	O
or	or	CC	O	O	O
induce	induce	VB	B-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aliskiren	aliskiren	NNS	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
valsartan	valsartan	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
amlodipine	amlodipine	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
celecoxib	celecoxib	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
atenolol	atenolol	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
atorvastatin	atorvastatin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
ramipril	ramipril	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	O	S-drug
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aliskiren	aliskiren	NNS	B-NP	O	S-drug
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
aliskiren	aliskiren	NNS	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
applying	apply	VBG	I-VP	O	O
Panretin	Panretin	NN	B-NP	O	S-brand-AD-1
gel	gel	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
concurrently	concurrently	RB	I-VP	O	O
use	use	VB	I-VP	O	O
products	product	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
contain	contain	VBP	B-VP	O	O
DEET	DEET	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
N	N	NN	B-NP	O	O
,	,	,	O	O	O
N	N	NN	B-NP	O	B-drug-AD-2
-	-	HYPH	B-NP	O	I-drug-AD-2
diethyl	diethyl	NN	I-NP	O	I-drug-AD-2
-	-	HYPH	B-NP	O	I-drug-AD-2
m	m	NN	I-NP	O	I-drug-AD-2
-	-	HYPH	B-NP	O	I-drug-AD-2
toluamide	toluamide	NN	I-NP	O	E-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
component	component	NN	I-NP	O	O
of	of	IN	B-PP	O	O
insect	insect	NN	B-NP	B-protein	O
repellent	repellent	JJ	I-NP	I-protein	O
products	product	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Animal	Animal	JJ	B-NP	O	O
toxicology	toxicology	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
increased	increase	VBN	B-NP	O	O
DEET	DEET	NN	I-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
DEET	DEET	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
proof	proof	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
formulation	formulation	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
controlled	control	VBN	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
antiretroviral	antiretroviral	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
protease	protease	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
macrolide	macrolide	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
azole	azole	NN	B-NP	O	B-group
antifungals	antifungal	NNS	I-NP	O	E-group
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Panretin	Panretin	NN	B-NP	O	S-brand
gel	gel	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Panretin	Panretin	NN	B-NP	O	S-brand
gel	gel	NN	I-NP	O	O
and	and	CC	O	O	O
systemic	systemic	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
KS	KS	NN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
allopurinol	allopurinol	NN	I-NP	O	S-drug
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
use	use	NN	B-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
allopurinol	allopurinol	NN	I-NP	O	S-drug
includes	include	VBZ	B-VP	O	O
longer	long	JJR	B-NP	O	O
term	term	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
gout	gout	NN	B-NP	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
calculi	calculus	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
experience	experience	NN	I-NP	O	O
gained	gain	VBN	B-VP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
relevant	relevant	JJ	B-ADJP	O	O
.	.	.	O	O	O

Mercaptopurine	Mercaptopurine	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Azathioprine	Azathioprine	NN	I-NP	O	S-drug
:	:	:	O	O	O
Allopurinol	Allopurinol	NN	B-NP	O	S-drug-ME-1
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
enzymatic	enzymatic	JJ	I-NP	O	O
oxidation	oxidation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mercaptopurine	mercaptopurine	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
azathioprine	azathioprine	NN	I-NP	O	S-drug-ME-2
to	to	TO	B-PP	O	O
6	6	CD	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
thiouric	thiouric	JJ	I-NP	O	I-drug
acid	acid	NN	I-NP	O	E-drug
.	.	.	O	O	O

This	This	DT	B-NP	O	O
oxidation	oxidation	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
catalyzed	catalyze	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
xanthine	xanthine	NN	B-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
,	,	,	O	O	O
inactivates	inactivate	VBZ	B-VP	O	O
mercaptopurine	mercaptopurine	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
mercaptopurine	mercaptopurine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Purinethol	Purinethol	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Imuran	Imuran	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
300	300	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
600	600	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-AD-1
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
will	will	MD	B-VP	O	O
require	require	VB	I-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
to	to	TO	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
third	third	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
fourth	fourth	JJ	I-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mercaptopurine	mercaptopurine	NN	B-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
azathioprine	azathioprine	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Subsequent	Subsequent	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
mercaptopurine	mercaptopurine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
azathioprine	azathioprine	NN	I-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxic	toxic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Dicumarol	Dicumarol	NN	B-NP	O	S-drug
:	:	:	O	O	O
It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-ME-1
prolongs	prolong	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group
,	,	,	O	O	O
dicumarol	dicumarol	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
but	but	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
noted	note	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
already	already	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
dicumarol	dicumarol	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reassessed	reassess	VBN	I-VP	O	O
periodically	periodically	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Uricosuric	Uricosuric	NNP	B-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxipurinol	oxipurinol	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
urate	urate	NN	B-NP	O	O
,	,	,	O	O	O
uricosuric	uricosuric	JJ	B-NP	O	B-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
urate	urate	NN	B-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
also	also	RB	B-ADVP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxipurinol	oxipurinol	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
thus	thus	RB	O	O	O
lower	low	JJR	O	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
xanthine	xanthine	NN	B-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
uricosuric	uricosuric	JJ	B-NP	O	B-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
and	and	CC	O	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxypurines	oxypurine	NNS	B-NP	O	O
(	(	(	O	O	O
hypoxanthine	hypoxanthine	NN	B-NP	O	O
and	and	CC	O	O	O
xanthine	xanthine	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
uric	uric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
clinical	clinical	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
to	to	TO	B-PP	O	O
date	date	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
renal	renal	JJ	B-NP	O	O
precipitation	precipitation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxypurines	oxypurine	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
either	either	CC	B-PP	O	O
on	on	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
uricosuric	uricosuric	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
kept	keep	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mind	mind	NN	B-NP	O	O
.	.	.	O	O	O

Thiazide	Thiazide	NN	B-NP	O	B-group
Diuretics	Diuretic	NNS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reviewed	review	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
attempt	attempt	NN	I-NP	O	O
to	to	TO	B-VP	O	O
establish	establish	VB	I-VP	O	O
a	a	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
-	-	HYPH	I-NP	O	O
effect	effect	NN	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
causation	causation	NN	B-NP	O	O
.	.	.	O	O	O

Review	Review	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
case	case	NN	I-NP	O	O
reports	report	NNS	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
mainly	mainly	RB	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
for	for	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
tests	test	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
rule	rule	VB	I-VP	O	O
out	out	RP	B-PRT	O	O
decreased	decrease	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
often	often	RB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
those	those	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
renal	renal	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
documented	document	VBN	I-VP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
recommendation	recommendation	NN	I-NP	O	O
to	to	TO	B-VP	O	O
lower	lower	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
causal	causal	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
-	-	HYPH	I-NP	O	O
effect	effect	NN	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
,	,	,	O	O	O
current	current	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-AD-1
diuretics	diuretic	NNS	I-NP	O	E-group-AD-1
and	and	CC	O	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-AD-2
even	even	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
failure	failure	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
dosage	dosage	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
even	even	RB	B-ADJP	O	O
more	more	RBR	B-VP	O	O
conservatively	conservatively	RB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
combined	combined	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
diminished	diminish	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
detected..	detected..	NN	B-NP	O	O

Ampicillin	Ampicillin	NN	B-NP	B-protein	S-drug
/	/	SYM	I-NP	O	O
Amoxicillin	Amoxicillin	NN	I-NP	O	S-drug
:	:	:	O	O	O
An	An	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
skin	skin	NN	B-NP	O	O
rash	rash	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
among	among	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
amoxicillin	amoxicillin	NN	I-NP	O	S-drug-EF-1
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-EF-2
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
association	association	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Cytotoxic	Cytotoxic	JJ	B-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Enhanced	Enhance	VBN	B-NP	O	O
bone	bone	NN	I-NP	O	O
marrow	marrow	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
by	by	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
among	among	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
neoplastic	neoplastic	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
,	,	,	O	O	O
except	except	IN	B-PP	O	O
leukemia	leukemia	NN	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
lymphoma	lymphoma	NN	B-NP	O	O
on	on	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
bleomycin	bleomycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
procarbazine	procarbazine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
mechlorethamine	mechlorethamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Chlorpropamide	Chlorpropamide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Chlorpropamides	Chlorpropamide	NNS	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	O	O	O
life	life	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
chlorpropamide	chlorpropamide	NN	I-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
compete	compete	VB	I-VP	O	O
for	for	IN	B-PP	O	O
excretion	excretion	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
tubule	tubule	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
chlorpropamide	chlorpropamide	NN	I-NP	O	S-drug-EF-2
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
.	.	.	O	O	O

Cyclosporin	Cyclosporin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Reports	Report	NNS	B-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-1
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	B-drug-ME-2
sodium	sodium	NN	I-NP	O	E-drug-ME-2
for	for	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
.	.	.	O	O	O

Monitoring	Monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

Tolbutamides	Tolbutamide	NNS	B-NP	O	O
conversion	conversion	NN	I-NP	O	O
to	to	TO	B-PP	O	O
inactive	inactive	JJ	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
catalyzed	catalyze	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
xanthine	xanthine	NN	B-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
from	from	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
any	any	DT	B-NP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
observations	observation	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Ergot	Ergot	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
Containing	Contain	VBG	B-VP	O	I-group
Drugs	Drug	NNS	B-NP	O	E-group
:	:	:	O	O	O
These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
prolonged	prolonged	JJ	B-NP	O	O
vasospastic	vasospastic	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
theoretical	theoretical	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
,	,	,	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug-AD-1
-	-	HYPH	B-VP	O	O
containing	contain	VBG	I-VP	O	O
or	or	CC	O	O	O
ergot	ergot	NN	B-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
type	type	NN	I-NP	O	I-group-AD-1
medications	medication	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
like	like	IN	B-PP	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	S-drug-AD-1
or	or	CC	O	O	O
methysergide	methysergide	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
and	and	CC	O	O	O
AXERT	AXERT	NN	B-NP	B-protein	S-brand-AD-2
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Monoamine	Monoamine	NN	B-NP	O	B-group
Oxidase	Oxidase	NN	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
moclobemide	moclobemide	NN	B-NP	O	S-drug-ME-1
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
27	27	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
almotriptan	almotriptan	NN	B-NP	O	S-drug-ME-2
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
6	6	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
5	5	CD	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
HT1B	HT1B	NN	I-NP	B-protein	I-group
/	/	SYM	B-NP	O	I-group
1D	1D	NN	I-NP	O	I-group
Agonists	Agonist	VBZ	B-VP	O	E-group
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
5	5	CD	I-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
HT1B	HT1B	NN	I-NP	B-protein	I-group-AD-1
/	/	SYM	B-NP	O	I-group-AD-1
1D	1D	NN	B-NP	O	I-group-AD-1
agonists	agonist	NNS	I-NP	O	E-group-AD-1
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
AXERT	AXERT	NN	B-NP	B-protein	S-brand-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Propanolol	Propanolol	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
almotriptan	almotriptan	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Selective	Selective	JJ	B-NP	O	B-group
Serotonin	Serotonin	NN	I-NP	O	I-group
Reuptake	Reuptake	NN	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	O	S-group
)	)	)	O	O	O
:	:	:	O	O	O
SSRIs	SSRI	NNS	B-NP	O	S-group-EF-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rarely	rarely	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
weakness	weakness	NN	B-NP	O	O
,	,	,	O	O	O
hyperreflexia	hyperreflexia	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
incoordination	incoordination	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
HT1	HT1	NN	I-NP	O	I-group-EF-2
agonists	agonist	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
AXERT	AXERT	NN	B-NP	B-protein	S-brand-AD-1
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	B-protein	S-group-AD-2
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
,	,	,	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
.	.	.	O	O	O

Verapamil	Verapamil	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
almotriptan	almotriptan	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
24	24	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
almotriptan	almotriptan	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
almotriptan	almotriptan	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-2
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
q.d	q.d	NN	I-NP	O	O
.	.	.	O	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
approximately	approximately	RB	I-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
time	time	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
and	and	CC	O	O	O
maximal	maximal	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
almotriptan	almotriptan	NN	B-NP	O	S-drug
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
almotriptan	almotriptan	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
and	and	CC	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
exposures	exposure	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
almotriptan	almotriptan	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
almotriptan	almotriptan	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

AXERT	AXERT	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
commonly	commonly	RB	B-NP	O	O
employed	employ	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
CYP	CYP	NN	I-NP	I-protein	O
drug	drug	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
metabolizing	metabolize	VBG	B-VP	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
,	,	,	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
may	may	MD	B-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
.	.	.	O	O	O

Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
strong	strong	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
and	and	CC	O	O	O
also	also	RB	B-VP	O	O
inhibits	inhibit	VBZ	I-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
40	40	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
female	female	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
escalating	escalate	VBG	B-VP	O	O
doses	dose	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
50	50	CD	B-NP	O	O
to	to	TO	I-NP	O	O
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
for	for	IN	B-PP	O	O
16	16	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
mean	mean	JJ	B-NP	O	O
alosetron	alosetron	NN	I-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
approximately	approximately	RB	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
and	and	CC	O	O	O
prolonged	prolong	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	B-VP	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
fluvoxamine	fluvoxamine	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
moderate	moderate	JJ	B-NP	O	O
CYP1A2	CYP1A2	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
quinolone	quinolone	NN	B-NP	O	B-group-AD-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-AD-2
and	and	CC	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
unless	unless	IN	B-SBAR	O	O
clinically	clinically	RB	B-ADJP	O	O
necessary	necessary	JJ	I-ADJP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
similar	similar	JJ	B-NP	O	O
potential	potential	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
strong	strong	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
38	38	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
female	female	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
mean	mean	JJ	B-NP	O	O
alosetron	alosetron	NN	I-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
29	29	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
strong	strong	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
telithromycin	telithromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
protease	protease	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
voriconazole	voriconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-2
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
but	but	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
similar	similar	JJ	B-NP	O	O
potential	potential	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
or	or	CC	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
human	human	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
microsome	microsome	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
probe	probe	NN	I-NP	O	O
study	study	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
2D6	2D6	NN	I-NP	B-protein	O
,	,	,	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C9	2C9	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
or	or	CC	O	O	O
2C19	2C19	NN	B-NP	O	O
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
27	27	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
peak	peak	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
observed	observe	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
,	,	,	O	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
inhibited	inhibit	VBD	B-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
1A2	1A2	NN	I-NP	B-protein	O
(	(	(	O	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
2E1	2E1	NN	B-NP	B-protein	O
(	(	(	O	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
probe	probe	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
produce	produce	VB	I-VP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
N	N	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
acetyltransferase	acetyltransferase	NN	I-NP	I-protein	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
not	not	RB	O	O	O
studied	study	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
N	N	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
acetyltransferase	acetyltransferase	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
consequences	consequence	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
hydralazine	hydralazine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
explored	explore	VBN	I-VP	O	O
further	further	RBR	B-ADVP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Another	Another	DT	B-NP	O	O
study	study	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
ethinyl	ethinyl	NN	I-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	O	O	O
levonorgestrel	levonorgestrel	NN	B-NP	O	S-drug
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
substrates	substrate	NNS	I-NP	I-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
or	or	CC	O	O	O
QT	QT	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	B-protein	O
oxidases	oxidas	NNS	I-NP	I-protein	O
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
first	first	JJ	I-NP	O	O
pass	pass	NN	I-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
high	high	JJ	B-NP	O	O
intraluminal	intraluminal	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
examined	examine	VBN	I-VP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
above	above	JJ	I-NP	O	O
data	data	NN	I-NP	O	O
from	from	IN	B-PP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
will	will	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
CYP	CYP	NN	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
3A4	3A4	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
2D6	2D6	NN	I-NP	B-protein	O
,	,	,	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
2E1	2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
1A2	1A2	NN	B-NP	B-protein	O
.	.	.	O	O	O

Alosetron	Alosetron	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
)	)	)	O	O	O
drug	drug	NN	B-NP	O	O
metabolizing	metabolize	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	B-protein	O
3A	3A	NN	I-NP	I-protein	O
.	.	.	O	O	O

Alosetron	Alosetron	NN	B-NP	O	S-drug
also	also	RB	B-ADVP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
2E1	2E1	NN	I-NP	B-protein	O
or	or	CC	I-NP	O	O
2C19	2C19	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
alosetron	alosetron	NN	B-NP	O	S-drug
might	might	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
other	other	JJ	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-EF-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
produce	produce	VBP	B-VP	O	O
additive	additive	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
psychotropic	psychotropic	JJ	I-NP	O	B-group-EF-2
medications	medication	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
anticonvulsants	anticonvulsant	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
antihistaminics	antihistaminic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
themselves	themselves	PRP	B-NP	O	O
produce	produce	VBP	B-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
imipramine	imipramine	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
desipramine	desipramine	NN	I-NP	O	S-drug-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
average	average	NN	I-NP	O	O
of	of	IN	B-PP	O	O
31	31	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-2
tablets	tablet	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Drugs	Drugs	NNP	B-NP	O	O
That	That	NNP	I-NP	O	O
Inhibit	Inhibit	NNP	I-NP	O	O
Alprazolam	Alprazolam	NNP	I-NP	O	S-drug
Metabolism	Metabolism	NNP	I-NP	O	O
Via	Via	NNP	I-NP	O	O
Cytochrome	Cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A	3A	NN	I-NP	I-protein	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
step	step	NN	I-NP	O	O
in	in	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
hydroxylation	hydroxylation	NN	B-NP	O	O
catalyzed	catalyze	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A	3A	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A	3A	NN	I-NP	I-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
this	this	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
profound	profound	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Demonstrated	Demonstrate	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A	3A	NN	I-NP	I-protein	O
Inhibitors	Inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Possible	Possible	JJ	B-NP	O	O
Clinical	Clinical	JJ	I-NP	O	O
Significance	Significance	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Basis	Basis	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Clinical	Clinical	NNP	B-NP	O	O
Studies	Studies	NNP	I-NP	O	O
Involving	Involving	NNP	I-NP	O	O
Alprazolam	Alprazolam	NNP	I-NP	O	S-drug
(	(	(	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-2
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
46	46	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
clearance	clearance	NN	B-NP	O	O
by	by	IN	B-PP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
half	half	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
life	life	NN	B-NP	O	O
by	by	IN	B-PP	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
measured	measure	VBN	B-NP	O	O
psychomotor	psychomotor	NN	I-NP	O	O
performance	performance	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
propoxyphene	propoxyphene	NN	B-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
6	6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
clearance	clearance	NN	B-NP	O	O
by	by	IN	B-PP	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
half	half	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
life	life	NN	B-NP	O	O
by	by	IN	B-PP	O	O
58	58	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-ME-1
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
clearance	clearance	NN	B-NP	O	O
by	by	IN	B-PP	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
half	half	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
life	life	NN	B-NP	O	O
by	by	IN	B-PP	O	O
29	29	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
substances	substance	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A	3A	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
involving	involve	VBG	B-VP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
metabolized	metabolize	VBN	B-VP	O	O
similarly	similarly	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
or	or	CC	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group
(	(	(	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Available	Available	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
suggest	suggest	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-IN-1
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
macrolide	macrolide	NN	B-NP	O	B-group-IN-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-IN-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-IN-2
and	and	CC	I-NP	O	O
clarithromycin	clarithromycin	NN	I-NP	O	S-drug-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
.	.	.	O	O	O

Data	Data	NN	B-NP	O	O
from	from	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
suggest	suggest	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-IN-1
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug-IN-2
and	and	CC	I-NP	O	O
paroxetine	paroxetine	NN	I-NP	O	S-drug-IN-2
.	.	.	O	O	O

Data	Data	NN	B-NP	O	O
from	from	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-IN-1
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-IN-1
suggest	suggest	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
nicardipine	nicardipine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug-IN-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
Prostin	Prostin	NNP	B-NP	O	B-brand
VR	VR	NNP	I-NP	O	I-brand
Pediatric	Pediatric	NNP	I-NP	O	E-brand
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
standard	standard	NN	I-NP	O	O
in	in	IN	B-PP	O	O
neonates	neonate	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
restricted	restricted	JJ	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
systemic	systemic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
.	.	.	O	O	O

Standard	Standard	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
includes	include	VBZ	B-VP	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
penicillin	penicillin	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
gentamicin	gentamicin	NN	I-NP	O	S-drug
;	;	:	O	O	O

vasopressors	vasopressor	NNS	B-NP	O	S-group
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
dopamine	dopamine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
isoproterenol	isoproterenol	NN	I-NP	O	S-drug
;	;	:	O	O	O

cardiac	cardiac	JJ	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
;	;	:	O	O	O

and	and	CC	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Caverject	Caverject	NN	B-NP	O	S-brand
:	:	:	O	O	O
The	The	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
alprostadil	alprostadil	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
formally	formally	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Activase	Activase	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cardioactive	cardioactive	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
cerebroactive	cerebroactive	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
bleeding	bleeding	NN	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group-EF-1
K	K	NN	I-NP	O	I-group-EF-1
antagonists	antagonist	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
alter	alter	VBP	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug-IN-1
acid	acid	NN	I-NP	O	E-drug-IN-1
,	,	,	O	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
Abciximab	Abciximab	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
if	if	IN	B-SBAR	O	O
administered	administer	VBN	B-VP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
after	after	IN	B-SBAR	O	O
Activase	Activase	NN	B-NP	O	S-brand-MU-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Antithrombotics	Antithrombotic	NNS	B-NP	B-protein	S-group
Aspirin	Aspirin	NN	I-NP	I-protein	S-brand
and	and	CC	I-NP	O	O
heparin	heparin	NN	I-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
and	and	CC	O	O	O
following	follow	VBG	B-VP	O	O
infusions	infusion	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Activase	Activase	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
infarction	infarction	NN	I-NP	O	O
or	or	CC	O	O	O
pulmonary	pulmonary	JJ	B-NP	O	O
embolism	embolism	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
heparin	heparin	NN	B-NP	O	S-drug
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
or	or	CC	O	O	O
Activase	Activase	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
bleeding	bleeding	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
for	for	IN	B-PP	O	O
bleeding	bleeding	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	B-DNA	O
puncture	puncture	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
24	24	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
symptom	symptom	NN	B-NP	O	O
onset	onset	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
prohibited	prohibit	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
The	The	DT	B-NP	O	O
NINDS	NINDS	NN	I-NP	O	O
t	t	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
PA	PA	NN	I-NP	O	O
Stroke	Stroke	NNP	I-NP	O	O
Trial	Trial	NNP	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Activase	Activase	NN	B-NP	O	S-brand
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
ischemic	ischemic	JJ	I-NP	O	O
stroke	stroke	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HEXALEN	HEXALEN	NN	B-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	B-group-EF-2
of	of	IN	B-PP	O	I-group-EF-2
the	the	DT	B-NP	O	I-group-EF-2
MAO	MAO	NN	I-NP	O	I-group-EF-2
inhibitor	inhibitor	NN	I-NP	O	I-group-EF-2
class	class	NN	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
orthostatic	orthostatic	JJ	I-NP	O	O
hypotension.Cimetidine	hypotension.Cimetidine	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
microsomal	microsomal	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
altretamines	altretamine	NNS	B-NP	O	O
half	half	RB	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
life	life	NN	I-NP	O	O
and	and	CC	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
model	model	NN	I-NP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HEXALEN	HEXALEN	NN	B-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	O	S-drug-EF-2
plus	plus	CC	B-NP	O	O
or	or	CC	O	O	O
minus	minus	CC	O	O	O
pyridoxine	pyridoxine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
ovarian	ovarian	JJ	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
pyridoxine	pyridoxine	NN	B-NP	O	S-drug
significantly	significantly	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
neurotoxicity	neurotoxicity	NN	B-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
adversely	adversely	RB	B-VP	O	O
affected	affect	VBD	I-VP	O	O
response	response	NN	B-NP	O	O
duration	duration	NN	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
pyridoxine	pyridoxine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
HEXALEN	HEXALEN	NN	B-NP	O	S-brand-AD-2
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
cisplatin.1	cisplatin.1	NN	B-NP	O	O

Careful	Careful	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
amantadine	amantadine	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
central	central	JJ	B-NP	O	B-group-AD-2
nervous	nervous	JJ	I-NP	O	I-group-AD-2
system	system	NN	I-NP	O	I-group-AD-2
stimulants	stimulant	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
thioridazine	thioridazine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
worsen	worsen	VB	I-VP	O	O
the	the	DT	B-NP	O	O
tremor	tremor	NN	I-NP	O	O
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Parkinsons	Parkinson	NNS	B-NP	O	O
disease	disease	NN	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
other	other	JJ	B-NP	O	O
phenothiazines	phenothiazine	NNS	I-NP	O	S-group
produce	produce	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Special	Special	JJ	B-NP	O	O
consideration	consideration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ETHYOL	ETHYOL	NN	B-NP	B-protein	S-brand-AD-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group-AD-2
medications	medication	NNS	I-NP	O	E-group-AD-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
or	or	CC	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
hypotension	hypotension	NN	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
amiloride	amiloride	NN	B-NP	O	S-drug-EF-1
HCl	HCl	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
angiotensin	angiotensin	NN	I-NP	O	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
converting	convert	VBG	B-VP	O	I-group-EF-2
enzyme	enzyme	NN	B-NP	O	I-group-EF-2
inhibitor	inhibitor	NN	I-NP	O	E-group-EF-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
demonstrated	demonstrate	VBN	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
frequent	frequent	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug-AD-1
generally	generally	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-AD-2
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
reduce	reduce	VBP	B-VP	O	O
its	its	PRP$	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
add	add	VB	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Read	Read	JJ	B-NP	O	O
circulars	circular	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
preparations	preparation	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	B-DNA	B-group-EF-1
-	-	HYPH	I-NP	B-DNA	I-group-EF-1
steroidal	steroidal	JJ	I-NP	I-DNA	I-group-EF-1
anti	anti	AFX	I-NP	I-DNA	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
agent	agent	NN	I-NP	O	E-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
loop	loop	NN	B-NP	O	S-group-EF-2
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	B-group-EF-2
-	-	HYPH	B-VP	O	I-group-EF-2
sparing	spar	VBG	B-NP	O	E-group-EF-2
and	and	CC	I-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
MIDAMOR	MIDAMOR	NN	B-NP	O	S-brand-AD-1
and	and	CC	O	O	O
non	non	AFX	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	B-DNA	I-group-AD-2
steroidal	steroidal	JJ	B-NP	I-DNA	I-group-AD-2
anti	anti	AFX	I-NP	I-DNA	I-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
potassium	potassium	NN	I-NP	O	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
sparing	spar	VBG	B-VP	O	I-group-EF-2
diuretics	diuretic	NNS	B-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
MIDAMOR	MIDAMOR	NN	B-NP	O	S-brand-EF-2
,	,	,	O	O	O
may	may	MD	B-VP	O	O
each	each	DT	B-NP	O	O
be	be	VB	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	O
kinetics	kinetic	NNS	I-NP	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Laboratory	Laboratory	NNP	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
:	:	:	O	O	O
Prolongation	Prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
template	template	NN	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
time	time	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
continuous	continuous	JJ	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AMICAR	AMICAR	NN	B-NP	B-protein	S-brand
at	at	IN	B-PP	O	O
dosages	dosage	NNS	B-NP	O	O
exceeding	exceed	VBG	B-VP	O	O
24	24	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Platelet	Platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
any	any	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
platelet	platelet	NN	I-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
7.4	7.4	CD	B-NP	O	O
mMol	mMol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	B-NP	O	O
or	or	CC	O	O	O
0.97	0.97	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
and	and	CC	O	O	O
greater	great	JJR	B-ADJP	O	O
)	)	)	O	O	O
EACA	EACA	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
ADP	ADP	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
collagen	collagen	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
platelet	platelet	NN	I-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ATP	ATP	NN	B-NP	O	O
and	and	CC	I-NP	O	O
serotonin	serotonin	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fibrinogen	fibrinogen	NN	B-NP	B-protein	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
platelets	platelet	NNS	I-NP	B-cell_type	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
response	response	NN	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

Following	Follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
g	g	NN	I-NP	O	O
bolus	bolus	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AMICAR	AMICAR	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
transient	transient	JJ	B-NP	O	O
peak	peak	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
4.6	4.6	CD	B-NP	O	O
mMol	mMol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	B-NP	O	O
or	or	CC	O	O	O
0.60	0.60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AMICAR	AMICAR	NN	B-NP	O	S-brand
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fibrinolysis	fibrinolysis	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
0.99	0.99	CD	B-NP	O	O
mMol	mMol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	B-NP	O	O
or	or	CC	O	O	O
0.13	0.13	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
5	5	CD	I-NP	O	O
g	g	NN	I-NP	O	O
bolus	bolus	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
1	1	CD	B-NP	O	O
to	to	TO	B-PP	O	O
1.25	1.25	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
hr	hr	NN	I-NP	O	O
should	should	MD	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
and	and	CC	O	O	O
sustain	sustain	VB	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
0.13	0.13	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
concentrations	concentration	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
obtained	obtain	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
clinically	clinically	RB	I-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
considerably	considerably	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
found	find	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
abnormalities	abnormality	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
AMICAR	AMICAR	NN	B-NP	B-protein	S-brand
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
.	.	.	O	O	O

Cytadren	Cytadren	NN	B-NP	O	S-brand-ME-1
accelerates	accelerate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	S-group
replacement	replacement	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
,	,	,	O	O	O
hydrocortisone	hydrocortisone	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
.	.	.	O	O	O

Aminoglutethimide	Aminoglutethimide	NN	B-NP	O	S-drug-EF-1
diminishes	diminish	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	S-group-EF-2
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
measurements	measurement	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PAH	PAH	NN	B-NP	B-protein	S-drug-EF-1
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
accuracy	accuracy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
procaine	procaine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
thiazolesulfone	thiazolesulfone	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
chemical	chemical	JJ	B-NP	O	O
color	color	NN	I-NP	O	O
development	development	NN	I-NP	O	O
essential	essential	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
analytical	analytical	JJ	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug-ME-1
depresses	depress	VBZ	B-VP	O	O
tubular	tubular	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
weak	weak	JJ	I-NP	O	O
acids	acid	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
PAH	PAH	NN	B-NP	B-protein	S-drug-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-EF-1
will	will	MD	B-VP	O	O
have	have	VB	I-VP	O	O
erroneously	erroneously	RB	B-NP	O	O
low	low	JJ	I-NP	O	O
ERPF	ERPF	NN	I-NP	B-protein	O
and	and	CC	I-NP	O	O
Tm	Tm	NN	I-NP	O	O
PAH	PAH	NN	I-NP	O	S-drug-EF-2
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LEVULAN	LEVULAN	NN	B-NP	B-protein	B-brand
KERASTICK	KERASTICK	NN	I-NP	I-protein	E-brand
for	for	IN	B-PP	O	O
Topical	Topical	JJ	B-NP	O	O
Solution	Solution	NN	I-NP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
controlled	control	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
possible	possible	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
known	know	VBN	I-NP	O	O
photosensitizing	photosensitize	VBG	I-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
griseofulvin	griseofulvin	NN	B-NP	B-protein	S-drug-EF-1
,	,	,	O	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-1
diuretics	diuretic	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
sulfonylureas	sulfonylurea	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
tetracyclines	tetracycline	NNS	I-NP	O	S-group-EF-1
might	might	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
photosensitivity	photosensitivity	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
actinic	actinic	JJ	B-NP	O	O
keratoses	keratos	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
LEVULAN	LEVULAN	NNP	I-NP	O	B-brand-EF-2
KERASTICK	KERASTICK	NNP	I-NP	O	E-brand-EF-2
for	for	IN	B-PP	O	O
Topical	Topical	NNP	B-NP	O	O
Solution	Solution	NNP	I-NP	O	O
.	.	.	O	O	O

Aminosalicylic	Aminosalicylic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
Lanoxin	Lanoxin	NN	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
Lanoxicaps	Lanoxicaps	NNP	B-NP	O	S-drug
)	)	)	O	O	O
that	that	WDT	B-NP	O	O
gets	get	VBZ	B-VP	O	O
absorbed	absorb	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
your	your	PRP$	B-NP	O	O
body	body	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-AD-1
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
aminosalicylic	aminosalicylic	JJ	B-NP	O	B-drug-AD-2
acid	acid	NN	I-NP	O	E-drug-AD-2
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

Aminosalicylic	Aminosalicylic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B-protein	B-drug-ME-2
B12	B12	NN	I-NP	I-protein	E-drug-ME-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
you	you	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
take	take	VB	I-VP	O	O
a	a	DT	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-drug-AD-1
B12	B12	NN	I-NP	O	E-drug-AD-1
supplement	supplement	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
aminosalicylic	aminosalicylic	JJ	B-NP	O	B-drug-AD-2
acid	acid	NN	I-NP	O	E-drug-AD-2
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
desethylamiodarone	desethylamiodarone	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	I-protein	O
CYP450	CYP450	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
enzyme	enzyme	NN	B-NP	I-protein	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
specifically	specifically	RB	B-NP	O	O
cytochromes	cytochrome	NNS	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
)	)	)	O	O	O
and	and	CC	O	O	O
CYP2C8	CYP2C8	NN	B-NP	B-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	I-NP	O	O
intestines	intestine	NNS	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
substances	substance	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
substrates	substrate	NNS	B-NP	O	O
,	,	,	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
or	or	CC	O	O	O
inducers	inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
only	only	RB	B-NP	O	O
a	a	DT	I-NP	O	O
limited	limit	VBN	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
chiefly	chiefly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
especially	especially	RB	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
other	other	JJ	B-NP	O	O
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	S-group
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
,	,	,	O	O	O
their	their	PRP$	B-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reassessed	reassess	VBN	I-VP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
where	where	WRB	B-ADVP	O	O
appropriate	appropriate	JJ	B-ADJP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
measured	measure	VBN	B-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
view	view	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
variable	variable	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
,	,	,	O	O	O
potential	potential	NN	B-NP	O	O
for	for	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
not	not	RB	B-CONJP	O	O
only	only	RB	I-CONJP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
but	but	CC	B-CONJP	O	O
also	also	RB	I-CONJP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
administered	administer	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2C8	CYP2C8	NN	I-NP	B-protein	O
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
/	/	SYM	B-VP	O	O
substances	substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
these	these	DT	B-NP	O	O
isoenzymes	isoenzyme	NNS	I-NP	B-protein	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
serum	serum	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Reported	Report	VBN	B-NP	O	O
examples	example	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
Protease	Protease	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Protease	Protease	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
to	to	TO	B-PP	O	O
varying	vary	VBG	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
taking	take	VBG	B-VP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-ME-1
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-ME-2
800	800	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
0.9	0.9	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1.3	1.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
.	.	.	O	O	O

DEA	DEA	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
.	.	.	O	O	O

Monitoring	Monitor	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
and	and	CC	O	O	O
serial	serial	JJ	B-NP	O	O
measurement	measurement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-AD-1
serum	serum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
protease	protease	NN	I-NP	O	B-group-AD-2
inhibitor	inhibitor	NN	I-NP	O	E-group-AD-2
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Histamine	Histamine	NN	B-NP	O	B-group-ME-1
H2	H2	NN	I-NP	O	I-group-ME-1
antagonists	antagonist	NNS	I-NP	O	E-group-ME-1
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-2
inhibits	inhibit	VBZ	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	O	O	O
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
substances	substance	NNS	I-NP	O	O
:	:	:	O	O	O
Grapefruit	Grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
given	give	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
by	by	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
by	by	IN	B-PP	O	O
84	84	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Grapefruit	Grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
information	information	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
changing	change	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
suppress	suppress	VB	I-VP	O	O
certain	certain	JJ	B-NP	O	O
CYP450	CYP450	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

This	This	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
unexpectedly	unexpectedly	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	S-drug
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
those	those	DT	B-NP	O	O
CYP450	CYP450	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Reported	Report	VBN	B-NP	O	O
examples	example	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
include	include	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
Immunosuppressives	Immunosuppressive	NNS	B-NP	O	O
:	:	:	O	O	O
Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
administered	administer	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
persistently	persistently	RB	B-NP	O	O
elevated	elevate	VBN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
,	,	,	O	O	O
despite	despite	IN	B-PP	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
.	.	.	O	O	O

HMG	HMG	NN	B-NP	B-protein	B-drug
-	-	HYPH	I-NP	O	I-drug
CoA	CoA	NN	I-NP	O	I-drug
Reductase	Reductase	NN	I-NP	O	I-drug
Inhibitors	Inhibitor	NNS	I-NP	O	E-drug
:	:	:	O	O	O
Simvastatin	Simvastatin	NN	B-NP	O	S-drug
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
rhabdomyolysis	rhabdomyolysis	NN	I-NP	O	O
.	.	.	O	O	O

Cardiovasculars	Cardiovascular	NNS	B-NP	O	O
:	:	:	O	O	O
Cardiac	Cardiac	JJ	B-NP	O	B-drug
glycosides	glycoside	NNS	I-NP	O	E-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
regularly	regularly	RB	B-ADVP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
reach	reach	VB	I-VP	O	O
toxic	toxic	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
resultant	resultant	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
taken	take	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
by	by	IN	B-PP	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
after	after	IN	B-PP	O	O
one	one	CD	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug-AD-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-AD-2
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reviewed	review	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
reduced	reduce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
or	or	CC	O	O	O
discontinued	discontinue	VBN	B-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
digitalis	digitalis	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
continued	continue	VBN	I-VP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
observed	observe	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
precautions	precaution	NNS	I-NP	O	O
probably	probably	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
apply	apply	VB	I-VP	O	O
to	to	TO	B-PP	O	O
digitoxin	digitoxin	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
as	as	RB	B-ADVP	O	O
well	well	RB	I-ADVP	O	O
.	.	.	O	O	O

Antiarrhythmics	Antiarrhythmic	NNS	B-NP	O	S-drug
:	:	:	O	O	O
Other	Other	JJ	B-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	S-drug
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
case	case	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
decreases	decrease	VBZ	B-VP	O	O
serum	serum	NN	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
taken	take	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
increases	increase	VBZ	B-VP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
serum	serum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
by	by	IN	B-PP	O	O
33	33	CD	B-NP	O	O
%	%	NN	I-NP	O	O
after	after	IN	B-PP	O	O
two	two	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
taken	take	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
procainamide	procainamide	NN	B-NP	O	S-drug
for	for	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
seven	seven	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
procainamide	procainamide	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
n	n	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
acetyl	acetyl	NN	I-NP	O	O
procainamide	procainamide	NN	I-NP	O	S-drug
by	by	IN	B-PP	O	O
55	55	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
33	33	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Quinidine	Quinidine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
procainamide	procainamide	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
third	third	JJ	I-NP	O	O
when	when	WRB	B-ADVP	O	O
either	either	CC	O	O	O
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
;	;	:	O	O	O

because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
this	this	DT	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	S-drug
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
general	general	JJ	B-ADJP	O	O
,	,	,	O	O	O
any	any	DT	B-NP	O	O
added	add	VBN	I-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	B-drug
drug	drug	NN	I-NP	O	E-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
initiated	initiate	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
than	than	IN	B-PP	O	O
usual	usual	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
with	with	IN	B-PP	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
.	.	.	O	O	O

Combination	Combination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reserved	reserve	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
incompletely	incompletely	RB	B-ADJP	O	O
responsive	responsive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
or	or	CC	O	O	O
incompletely	incompletely	RB	B-ADJP	O	O
responsive	responsive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
.	.	.	O	O	O

During	During	IN	B-PP	O	O
transfer	transfer	NN	B-NP	O	O
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
previously	previously	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
30	30	CD	B-NP	O	O
to	to	TO	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
several	several	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
continued	continued	JJ	I-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	S-drug
agent	agent	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reviewed	review	VBN	I-VP	O	O
after	after	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
discontinuation	discontinuation	NN	B-NP	O	O
ordinarily	ordinarily	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
attempted	attempt	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
continued	continue	VBN	I-VP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
particularly	particularly	RB	B-ADJP	O	O
carefully	carefully	RB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
conduction	conduction	NN	B-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
and	and	CC	O	O	O
exacerbation	exacerbation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tachyarrhythmias	tachyarrhythmia	NNS	B-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
continued	continue	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
require	require	VBP	B-VP	O	O
additional	additional	JJ	B-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approximately	approximately	RB	B-NP	O	O
half	half	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
recommended	recommended	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Antihypertensives	Antihypertensive	NNS	B-NP	O	S-drug
:	:	:	O	O	O
Amiodarone	Amiodarone	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
-	-	HYPH	B-NP	O	O
receptor	receptor	NN	I-NP	O	S-drug
blocking	block	VBG	B-VP	O	O
agents	agent	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	S-drug
inhibitor	inhibitor	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
calcium	calcium	NN	B-NP	O	B-drug
channel	channel	NN	I-NP	O	E-drug
antagonists	antagonist	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	S-drug
substrate	substrate	NN	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	S-drug
inhibitor	inhibitor	NN	I-NP	O	O
)	)	)	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bradycardia	bradycardia	NN	B-NP	O	O
,	,	,	O	O	O
sinus	sinus	NN	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
AV	AV	NN	B-NP	O	O
block	block	NN	I-NP	O	O
;	;	:	O	O	O

if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
,	,	,	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
continue	continue	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
insertion	insertion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pacemaker	pacemaker	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
or	or	CC	I-NP	O	O
sinus	sinus	NN	I-NP	O	O
arrest	arrest	NN	I-NP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-drug
:	:	:	O	O	O
Potentiation	Potentiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
type	type	NN	B-NP	O	O
(	(	(	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	S-drug
and	and	CC	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
substrate	substrate	NN	I-NP	O	O
)	)	)	O	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-drug
response	response	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
almost	almost	RB	I-VP	O	O
always	always	RB	I-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
and	and	CC	O	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
by	by	IN	B-PP	O	O
100	100	CD	B-NP	O	O
%	%	NN	I-NP	O	O
after	after	IN	B-PP	O	O
3	3	CD	B-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
third	third	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
half	half	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
substances	substance	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
accelerate	accelerate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
stimulating	stimulate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
(	(	(	O	O	O
enzyme	enzyme	NN	B-NP	O	O
induction	induction	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
low	low	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
potential	potential	JJ	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
.	.	.	O	O	O

Reported	Report	VBN	B-NP	O	O
examples	example	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
include	include	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
Antibiotics	Antibiotic	NNS	B-NP	O	S-drug
:	:	:	O	O	O
Rifampin	Rifampin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
decreases	decrease	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
desethylamiodarone	desethylamiodarone	NN	I-NP	O	S-drug
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
substances	substance	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
herbal	herbal	JJ	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
:	:	:	O	O	O
St.	St.	NNP	B-NP	O	O
John	John	NNP	I-NP	O	O
s	s	NNS	I-NP	O	O
Wort	Wort	NNP	I-NP	O	O
(	(	(	O	O	O
Hypericum	Hypericum	NNP	B-NP	O	O
perforatum	perforatum	NNP	I-NP	O	O
)	)	)	O	O	O
induces	induce	VBZ	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
St.	St.	NNP	B-NP	O	O
John	John	NNP	I-NP	O	O
s	s	VBZ	B-VP	O	O
Wort	Wort	NNP	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
could	could	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
reported	report	VBN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
:	:	:	O	O	O
Fentanyl	Fentanyl	NN	B-NP	O	S-drug
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypotension	hypotension	NN	B-NP	O	O
,	,	,	O	O	O
bradycardia	bradycardia	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
.	.	.	O	O	O

Sinus	Sinus	NN	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
given	give	VBN	B-PP	O	O
for	for	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	S-drug
.	.	.	O	O	O

Seizure	Seizure	NN	B-NP	O	O
,	,	,	O	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
lidocaine	lidocaine	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
.	.	.	O	O	O

Dextromethorphan	Dextromethorphan	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
both	both	CC	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	S-drug
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
increases	increase	VBZ	B-VP	O	O
enterohepatic	enterohepatic	JJ	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
t1	t1	NN	B-NP	B-protein	S-drug
/	/	SYM	O	I-protein	O
2	2	CD	B-NP	I-protein	O
.	.	.	O	O	O

Disopyramide	Disopyramide	NN	B-NP	O	S-drug
increases	increase	VBZ	B-VP	O	O
QT	QT	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
arrhythmia	arrhythmia	NN	B-NP	O	O
.	.	.	O	O	O

Fluoroquinolones	Fluoroquinolone	NNS	B-NP	O	S-drug
,	,	,	O	O	O
macrolide	macrolide	NN	B-NP	O	B-drug
antibiotics	antibiotic	NNS	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
azoles	azole	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
QTc	QTc	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
QTc	QTc	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
TdP	TdP	NN	B-NP	B-protein	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
fluoroquinolones	fluoroquinolone	NNS	B-NP	O	S-drug
,	,	,	O	O	O
macrolide	macrolide	NN	B-NP	O	B-drug
antibiotics	antibiotic	NNS	I-NP	O	E-drug
,	,	,	O	O	O
or	or	CC	O	O	O
azoles	azole	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Hemodynamic	Hemodynamic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
electrophysiologic	electrophysiologic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
.	.	.	O	O	O

Volatile	Volatile	NNP	B-NP	O	O
Anesthetic	Anesthetic	NNP	I-NP	O	S-drug
Agents	Agent	NNPS	I-NP	O	O
:	:	:	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
noted	note	VBD	B-VP	O	O
above	above	RB	B-ADVP	O	O
,	,	,	O	O	O
chronic	chronic	JJ	B-ADJP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
)	)	)	O	O	O
oral	oral	JJ	B-NP	O	O
Cordarone	Cordarone	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
impairs	impair	VBZ	B-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
dextromethorphan	dextromethorphan	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

Electrolyte	Electrolyte	NNP	B-NP	O	O
Disturbances	Disturbances	NNP	I-NP	O	O
Patients	Patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
or	or	CC	I-NP	O	O
hypomagnesemia	hypomagnesemia	NN	I-NP	O	O
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
the	the	DT	B-NP	O	O
condition	condition	NN	I-NP	O	O
corrected	correct	VBN	B-VP	O	O
whenever	whenever	WRB	B-ADVP	O	O
possible	possible	JJ	B-ADJP	O	O
before	before	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Cordarone	Cordarone	NN	B-NP	O	B-drug
I.V	I.V	NN	I-NP	O	I-drug
.	.	NN	I-NP	O	E-drug
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
disorders	disorder	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
exaggerate	exaggerate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
QTc	QTc	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
TdP	TdP	NN	B-NP	B-protein	O
.	.	.	O	O	O

Special	Special	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
electrolyte	electrolyte	NN	B-NP	O	O
and	and	CC	I-NP	O	O
acid	acid	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
base	base	NN	I-NP	O	O
balance	balance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
experiencing	experience	VBG	B-VP	O	O
severe	severe	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-drug
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
-	-	HYPH	O	O	O
The	The	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
metabolizing	metabolize	VBG	B-VP	O	O
isozyme	isozyme	NN	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
debrisoquin	debrisoquin	NN	B-NP	B-protein	O
hydroxylase	hydroxylase	NN	I-NP	I-protein	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
caucasian	caucasian	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
7	7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caucasians	caucasian	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
so	so	RB	I-VP	O	O
called	call	VBN	I-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

reliable	reliable	JJ	B-NP	O	O
estimates	estimate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
P450	P450	NN	I-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
among	among	IN	B-PP	O	O
Asian	Asian	JJ	B-NP	O	O
,	,	,	I-NP	O	O
African	African	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
populations	population	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
yet	yet	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
.	.	.	O	O	O

Poor	Poor	NN	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
expected	expect	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
(	(	(	O	O	O
TCAs	TCA	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
usual	usual	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Depending	Depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-ADJP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
quite	quite	RB	B-ADJP	O	O
large	large	JJ	I-ADJP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
and	and	CC	O	O	O
make	make	VB	B-VP	O	O
normal	normal	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
resemble	resemble	VBP	B-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
individual	individual	NN	I-NP	O	O
who	who	WP	B-NP	O	O
is	be	VBZ	B-VP	O	O
stable	stable	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
given	give	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TCA	TCA	NN	B-NP	B-protein	S-group
may	may	MD	B-VP	O	O
become	become	VB	I-VP	O	O
abruptly	abruptly	RB	B-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
inhibiting	inhibit	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
include	include	VBP	B-VP	O	O
some	some	DT	O	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
(	(	(	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
;	;	:	O	O	O

cimetidine	cimetidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
many	many	JJ	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
many	many	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Type	Type	NN	I-NP	O	B-group
1C	1C	NN	I-NP	O	I-group
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	E-group
propafenone	propafenone	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
flecainide	flecainide	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
selective	selective	JJ	I-NP	O	O
serotonin	serotonin	NN	I-NP	O	B-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
inhibit	inhibit	VBP	B-VP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
vary	vary	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
to	to	TO	B-PP	O	O
which	which	WDT	B-NP	O	O
SSRI	SSRI	NN	I-NP	B-protein	S-group-EF-1
-	-	HYPH	I-NP	O	O
TCA	TCA	NN	I-NP	O	S-group-EF-2
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
pose	pose	VB	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
problems	problem	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
depend	depend	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	O	S-group
involved	involve	VBN	B-VP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TCAs	TCA	NNS	B-NP	B-protein	S-group-AD-1
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRIs	SSRI	NNS	I-NP	O	S-group-AD-2
and	and	CC	O	O	O
also	also	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
switching	switch	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
one	one	CD	B-NP	O	O
class	class	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
importance	importance	NN	I-NP	O	O
,	,	,	O	O	O
sufficient	sufficient	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
must	must	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
before	before	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
TCA	TCA	NN	B-NP	B-protein	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
being	be	VBG	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
parent	parent	NN	I-NP	O	O
and	and	CC	O	O	O
active	active	JJ	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
(	(	(	O	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
5	5	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
than	than	IN	B-SBAR	O	O
usually	usually	RB	B-ADVP	O	O
prescribed	prescribe	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
whenever	whenever	WRB	B-ADVP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-drug
antidepressant	antidepressant	NN	I-NP	O	E-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
desirable	desirable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
TCA	TCA	NN	B-NP	O	S-group
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
whenever	whenever	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group
is	be	VBZ	B-VP	O	O
going	go	VBG	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
.	.	.	O	O	O

Monoamine	Monoamine	NN	B-NP	O	B-drug
Oxidase	Oxidase	NN	I-NP	O	I-drug
Inhibitors	Inhibitor	NNS	I-NP	O	E-drug
:	:	:	O	O	O
Guanethidine	Guanethidine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
similarly	similarly	RB	B-ADVP	O	O
acting	act	VBG	B-VP	O	O
compounds	compound	NNS	B-NP	O	O
;	;	:	O	O	O

thyroid	thyroid	JJ	B-NP	O	S-drug
medication	medication	NN	I-NP	O	O
;	;	:	O	O	O

alcohol	alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-drug
depressants	depressant	NNS	I-NP	O	E-drug
;	;	:	O	O	O

and	and	CC	O	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug
When	When	WRB	B-ADVP	O	O
amitriptyline	amitriptyline	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	S-drug
agents	agent	NNS	I-NP	O	O
or	or	CC	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	S-drug
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-drug
,	,	,	O	O	O
close	close	JJ	B-NP	O	O
supervision	supervision	NN	I-NP	O	O
and	and	CC	O	O	O
careful	careful	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dosages	dosage	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Hyperpyrexia	Hyperpyrexia	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
amitriptyline	amitriptyline	NN	B-NP	O	B-drug-EF-1
HCl	HCl	NN	I-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	S-drug-EF-2
agents	agent	NNS	I-NP	O	O
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	S-drug
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
hot	hot	JJ	B-NP	O	O
weather	weather	NN	I-NP	O	O
.	.	.	O	O	O

Paralytic	Paralytic	JJ	B-NP	O	O
ileus	ileus	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-drug-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-drug-EF-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	S-drug-EF-2
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-drug-ME-2
antidepressants	antidepressant	NNS	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
thereby	thereby	RB	B-VP	O	O
delaying	delay	VBG	I-VP	O	O
elimination	elimination	NN	B-NP	O	O
and	and	CC	O	O	O
increasing	increase	VBG	B-VP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	S-drug
.	.	.	O	O	O

Clinically	Clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-drug-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-drug-EF-1
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Increases	Increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-drug-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADJP	O	O
anticholinergic	anticholinergic	JJ	I-ADJP	O	S-drug
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	S-drug
regimen	regimen	NN	I-NP	O	O
.	.	.	O	O	O

Discontinuation	Discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
well	well	RB	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
controlled	control	VBN	B-VP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-drug-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-drug-ME-1
and	and	CC	I-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
efficacy	efficacy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-drug
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
receive	receive	VBP	B-VP	O	O
large	large	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ethchlorvynol	ethchlorvynol	NN	B-NP	O	S-drug
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Transient	Transient	JJ	B-NP	O	O
delirium	delirium	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
one	one	CD	B-NP	O	O
gram	gram	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethchlorvynol	ethchlorvynol	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
75	75	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
150	150	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amitriptyline	amitriptyline	NN	B-NP	O	B-drug-EF-2
HCl	HCl	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-EF-1
B	B	NN	I-NP	O	E-drug-EF-1
:	:	:	O	O	O
Antineoplastic	Antineoplastic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
:	:	:	O	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	I-NP	O	O
bronchospasm	bronchospasm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

Antineoplastic	Antineoplastic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.	e.	FW	B-NP	O	O
g.	g.	NN	I-NP	O	O
,	,	,	O	O	O
nitrogen	nitrogen	NN	B-NP	O	B-drug
mustard	mustard	NN	I-NP	O	E-drug
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
only	only	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
great	great	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
Corticotropin	Corticotropin	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
ACTH	ACTH	NN	B-NP	O	S-group-EF-1
)	)	)	O	O	O
:	:	:	O	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-EF-2
B	B	NN	I-NP	O	E-drug-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
predispose	predispose	VB	I-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
to	to	TO	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
.	.	.	O	O	O

Avoid	Avoid	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
unless	unless	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
side	side	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
used	use	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
closely	closely	RB	B-NP	O	O
monitor	monitor	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
electrolytes	electrolyte	NNS	I-NP	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
:	:	:	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-EF-1
B	B	NN	I-NP	O	E-drug-EF-1
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-2
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
any	any	DT	B-NP	O	O
deficit	deficit	NN	I-NP	O	O
promptly	promptly	RB	B-VP	O	O
corrected	correct	VBN	I-VP	O	O
.	.	.	O	O	O

Flucytosine	Flucytosine	NN	B-NP	O	S-drug
:	:	:	O	O	O
while	while	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
with	with	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-EF-1
B	B	NN	I-NP	O	E-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flucytosine	flucytosine	NN	B-NP	O	S-drug-EF-2
by	by	IN	B-PP	O	O
possibly	possibly	RB	B-ADVP	O	O
increasing	increase	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
cellular	cellular	JJ	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
impairing	impair	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
.	.	.	O	O	O

Imidazoles	Imidazole	NNS	B-NP	O	S-group
(	(	(	O	O	O
e.	e.	FW	B-NP	O	O
g.	g.	FW	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
miconazole	miconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
clotrimazole	clotrimazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
:	:	:	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
animal	animal	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
and	and	CC	O	O	O
imidazoles	imidazole	NNS	B-NP	O	S-group
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
imidazoles	imidazole	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
fungal	fungal	JJ	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-EF-2
B	B	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Combination	Combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
immunocompromised	immunocompromised	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
nephrotoxic	nephrotoxic	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
:	:	:	O	O	O
agents	agent	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
pentamidine	pentamidine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
renal	renal	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
only	only	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
great	great	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
.	.	.	O	O	O

Intensive	Intensive	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
requiring	require	VBG	B-VP	O	O
any	any	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxic	nephrotoxic	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

Skeletal	Skeletal	JJ	B-NP	O	B-group
muscle	muscle	NN	I-NP	O	I-group
relaxants	relaxant	NNS	I-NP	O	E-group
:	:	:	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-EF-1
B	B	NN	I-NP	O	E-drug-EF-1
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
curariform	curariform	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
skeletal	skeletal	JJ	B-NP	O	B-group-EF-2
muscle	muscle	NN	I-NP	O	I-group-EF-2
relaxants	relaxant	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
tubocurarine	tubocurarine	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
deficiencies	deficiency	NNS	B-NP	O	O
corrected	correct	VBN	B-VP	O	O
.	.	.	O	O	O

Leukocyte	Leukocyte	NN	B-NP	O	B-drug_n
transfusions	transfusion	NNS	I-NP	O	E-drug_n
:	:	:	O	O	O
acute	acute	JJ	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
intravenous	intravenous	JJ	B-NP	O	O
amphotericin	amphotericin	NN	I-NP	O	B-drug-EF-1
B	B	NN	I-NP	O	E-drug-EF-1
and	and	CC	O	O	O
leukocyte	leukocyte	NN	B-NP	O	B-drug_n-EF-2
transfusions	transfusion	NNS	I-NP	O	E-drug_n-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
ampicillin	ampicillin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

Allopurinol	Allopurinol	NN	B-NP	O	S-drug
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
skin	skin	NN	B-NP	O	O
rash	rash	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
hyperuricemic	hyperuricemic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Bacteriostatic	Bacteriostatic	JJ	B-NP	O	B-group
Antibiotics	Antibiotic	NNS	I-NP	O	E-group
:	:	:	O	O	O
Chloramphenicol	Chloramphenicol	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
erythromycins	erythromycin	NNS	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
or	or	CC	O	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bactericidal	bactericidal	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
penicillins	penicillin	NNS	B-NP	B-protein	S-group-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
view	view	NN	B-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
well	well	RB	I-VP	O	O
documented	document	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
May	May	MD	B-VP	O	O
be	be	VB	I-VP	O	O
less	less	RBR	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
breakthrough	breakthrough	NN	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Probenecid	Probenecid	NNP	B-NP	O	S-drug-ME-1
:	:	:	O	O	O
May	May	NNP	B-NP	O	O
decrease	decrease	VBP	B-VP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug-ME-2
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interaction	Interaction	NN	I-NP	O	O
After	After	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
copper	copper	NN	B-NP	O	B-drug_n
sulfate	sulfate	NN	I-NP	O	E-drug_n
tests	test	NNS	I-NP	O	O
(	(	(	O	O	O
Benedicts	Benedict	NNS	B-NP	O	O
solution	solution	NN	I-NP	O	O
,	,	,	O	O	O
Fehlings	Fehling	NNS	B-NP	O	O
solution	solution	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
Clinitest	Clinit	JJS	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
)	)	)	O	O	O
but	but	CC	B-PP	O	O
not	not	RB	I-PP	O	O
with	with	IN	B-PP	O	O
enzyme	enzyme	NN	B-NP	O	O
based	based	JJ	I-NP	O	O
tests	test	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Clinistix	Clinistix	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
Glucose	Glucose	NNP	I-NP	O	O
Enzymatic	Enzymatic	NNP	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Strip	Strip	NNP	I-NP	O	O
USP	USP	NNP	I-NP	O	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministering	coadministere	VBG	B-VP	O	O
medications	medication	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
,	,	,	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
inducers	inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
potentially	potentially	RB	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
uridine	uridine	NN	B-NP	O	O
glucuronosyltransferase	glucuronosyltransferase	NN	I-NP	O	O
(	(	(	O	O	O
UDPGT	UDPGT	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

HIV	HIV	NN	B-NP	O	B-group
Protease	Protease	NN	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
HIV	HIV	NN	I-NP	O	B-group
protease	protease	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
comparisons	comparison	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
historical	historical	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
.	.	.	O	O	O

Indinavir	Indinavir	NN	B-NP	O	S-drug-ME-1
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	I-NP	O	O
A.C.	A.C.	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmin	Cmin	NN	I-NP	B-protein	O
were	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
27	27	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
amprenavir	amprenavir	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Similar	Similar	JJ	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Saquinavir	Saquinavir	NN	B-NP	O	S-drug-ME-1
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	I-NP	O	O
A.C.	A.C.	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmin	Cmin	NN	I-NP	B-protein	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
19	19	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
48	48	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
amprenavir	amprenavir	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Nelfinavir	Nelfinavir	NN	B-NP	O	S-drug-ME-1
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	I-NP	O	O
A.C.	A.C.	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmin	Cmin	NN	I-NP	B-protein	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
amprenavir	amprenavir	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Methadone	Methadone	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
methadone	methadone	NN	I-NP	O	S-drug-EF-2
can	can	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methadone	methadone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
methadone	methadone	NN	I-NP	O	S-drug-ME-2
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
matched	match	VBN	I-NP	O	O
historicalcontrol	historicalcontrol	NN	I-NP	O	O
group	group	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
27	27	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
amprenavir	amprenavir	NN	I-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
,	,	,	O	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
,	,	,	O	O	O
andCmin	andCmin	NN	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
C.P.A	C.P.A	NN	I-NP	I-protein	O
.	.	.	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-VP	O	O
should	should	MD	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
narrow	narrow	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
windows	window	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Laboratory	Laboratory	NNP	B-NP	O	O
Tests	Test	NNPS	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Amprenavir	Amprenavir	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
low	low	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
elevations	elevation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cholesterol	cholesterol	NN	B-NP	O	O
and	and	CC	I-NP	O	O
triglycerides	triglyceride	NNS	I-NP	O	O
,	,	,	O	O	O
SGOT	SGOT	NN	B-NP	B-protein	O
(	(	(	O	O	O
AST	AST	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
SGPT	SGPT	NN	B-NP	B-protein	O
(	(	(	O	O	O
ALT	ALT	NN	B-NP	B-protein	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Appropriate	Appropriate	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
testing	testing	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Amprenavir	Amprenavir	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug-AD-2
and	and	CC	B-PP	O	O
at	at	IN	B-PP	O	O
periodic	periodic	JJ	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
or	or	CC	O	O	O
if	if	IN	B-SBAR	O	O
any	any	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
signs	sign	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O	O
or	or	CC	O	O	O
elevated	elevated	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
occur	occur	VBP	B-VP	O	O
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
comprehensive	comprehensive	JJ	B-NP	O	O
information	information	NN	I-NP	O	O
concerning	concern	VBG	B-VP	O	O
laboratory	laboratory	NN	B-NP	O	O
test	test	NN	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
refer	refer	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
complete	complete	JJ	I-NP	O	O
prescribing	prescribe	VBG	I-NP	O	O
information	information	NN	I-NP	O	O
for	for	IN	B-PP	O	O
NORVIR	NORVIR	NN	B-NP	O	S-brand
(	(	(	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Taking	Take	VBG	B-VP	O	O
amyl	amyl	NN	B-NP	O	B-drug-EF-1
nitrite	nitrite	NN	I-NP	O	E-drug-EF-1
after	after	IN	B-PP	O	O
drinking	drink	VBG	B-VP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
worsen	worsen	VB	I-VP	O	O
side	side	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
and	and	CC	O	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
collapse	collapse	NN	I-NP	O	O
.	.	.	O	O	O

Limited	Limit	VBN	B-NP	O	O
PK	PK	NN	I-NP	B-protein	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
PD	PD	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
investigating	investigate	VBG	B-VP	O	O
possible	possible	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
medicinal	medicinal	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
PK	PK	NN	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug
,	,	,	O	O	O
nor	nor	CC	O	O	O
does	do	VBZ	O	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug
affect	affect	VB	B-VP	O	O
the	the	DT	B-NP	O	O
PK	PK	NN	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
additional	additional	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
used	use	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
,	,	,	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
,	,	,	O	O	O
iron	iron	NN	B-NP	O	S-drug
,	,	,	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydroxyurea	hydroxyurea	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
to	to	TO	B-VP	O	O
suggest	suggest	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug
interacts	interact	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
1mg	1mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
900	900	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
generally	generally	RB	B-ADVP	O	O
well	well	RB	B-ADJP	O	O
tolerated	tolerate	VBN	I-ADJP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
time	time	NN	B-NP	O	O
,	,	,	O	O	O
PT	PT	NN	B-NP	O	O
or	or	CC	I-NP	O	O
aPTT	aPTT	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug
and	and	CC	O	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
that	that	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
alone	alone	RB	B-ADVP	O	O
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
in	in	IN	B-PP	O	O
platelet	platelet	NN	B-NP	B-cell_type	O
aggregation	aggregation	NN	I-NP	O	O
ex	ex	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

Anagrelide	Anagrelide	NN	B-NP	O	S-drug-EF-1
alone	alone	RB	B-ADVP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
platelet	platelet	NN	B-NP	B-cell_type	O
aggregation	aggregation	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
slightly	slightly	RB	I-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
by	by	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

Anagrelide	Anagrelide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
by	by	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
medicinal	medicinal	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
such	such	JJ	B-NP	O	O
medicinal	medicinal	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
theoretically	theoretically	RB	I-VP	O	O
adversely	adversely	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Anagrelide	Anagrelide	NN	B-NP	O	S-drug
demonstrates	demonstrate	VBZ	B-VP	O	O
some	some	DT	B-NP	O	O
limited	limited	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
towards	towards	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
present	present	VB	I-VP	O	O
a	a	DT	B-NP	O	O
theoretical	theoretical	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
coadministered	coadministere	VBN	I-NP	O	O
medicinal	medicinal	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
sharing	share	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
clearance	clearance	NN	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
e.g	e.g	NN	I-NP	O	O
.	.	.	O	O	O

Anagrelide	Anagrelide	NN	B-NP	O	S-drug-ME-1
demonstrates	demonstrate	VBZ	B-VP	O	O
some	some	DT	B-NP	O	O
limited	limited	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
towards	towards	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
present	present	VB	I-VP	O	O
a	a	DT	B-NP	O	O
theoretical	theoretical	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
coadministered	coadministere	VBN	I-NP	O	O
medicinal	medicinal	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
sharing	share	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
clearance	clearance	NN	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
e.g	e.g	NN	I-NP	O	O
.	.	.	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Anagrelide	Anagrelide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclic	cyclic	JJ	B-NP	B-protein	O
AMP	AMP	NN	I-NP	I-protein	O
PDE	PDE	NN	I-NP	I-protein	O
III	III	CD	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
medicinal	medicinal	JJ	B-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
with	with	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
inotropes	inotrope	NNS	B-NP	O	O
milrinone	milrinone	NN	I-NP	O	S-drug-EF-1
,	,	,	O	O	O
enoximone	enoximone	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
amrinone	amrinone	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
olprinone	olprinone	NN	B-NP	O	S-drug_n-EF-1
and	and	CC	I-NP	O	O
cilostazol	cilostazol	NN	I-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exacerbated	exacerbate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug-ME-2
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Food	Food	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
no	no	RB	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anagrelide	anagrelide	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Toxicologic	Toxicologic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
toxicokinetic	toxicokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
demonstrate	demonstrate	VB	I-VP	O	O
any	any	DT	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
or	or	CC	I-NP	O	O
toxicologic	toxicologic	JJ	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
Kineret	Kineret	NN	I-NP	O	S-brand
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
agents	agent	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
RA	RA	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
24	24	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
Kineret	Kineret	NN	I-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
etanercept	etanercept	NN	I-NP	O	S-drug-EF-2
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
7	7	CD	I-NP	O	O
%	%	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
infections	infection	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
etanercept	etanercept	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
percent	percent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Kineret	Kineret	NN	B-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
etanercept	etanercept	NN	I-NP	O	S-drug-EF-2
developed	develop	VBD	B-VP	O	O
neutropenia	neutropenia	NN	B-NP	O	O
(	(	(	O	O	O
ANC	ANC	NN	B-NP	B-protein	O
1	1	CD	I-NP	I-protein	O
x	x	SYM	B-NP	O	O
109	109	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Anastrozole	Anastrozole	NN	B-NP	O	S-drug
inhibited	inhibit	VBD	B-VP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
catalyzed	catalyze	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cytochromes	cytochrome	NNS	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
1A2	1A2	NN	I-NP	I-protein	O
,	,	,	O	O	O
2C8	2C8	NN	B-NP	B-protein	O
/	/	SYM	B-VP	O	O
9	9	CD	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
but	but	CC	O	O	O
only	only	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
relatively	relatively	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Anastrozole	Anastrozole	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
P450	P450	NN	B-NP	B-protein	O
2A6	2A6	NN	I-NP	I-protein	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
polymorphic	polymorphic	JJ	I-NP	O	O
P450	P450	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

Anastrozole	Anastrozole	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
these	these	DT	B-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ARIMIDEX	ARIMIDEX	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
-	-	HYPH	B-VP	I-protein	O
mediated	mediate	VBN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anastrozole	anastrozole	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
or	or	CC	O	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
a	a	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
follow	follow	VB	I-NP	O	O
-	-	HYPH	B-VP	O	O
up	up	RP	B-PRT	O	O
of	of	IN	B-PP	O	O
33	33	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ARIMIDEX	ARIMIDEX	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
tamoxifen	tamoxifen	NN	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
demonstrate	demonstrate	VB	I-VP	O	O
any	any	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
benefit	benefit	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
tamoxifen	tamoxifen	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hormone	hormone	NN	I-NP	B-protein	O
receptor	receptor	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
subpopulation	subpopulation	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
arm	arm	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ATAC	ATAC	NN	I-NP	O	O
trial	trial	NN	I-NP	O	O
,	,	,	O	O	O
tamoxifen	tamoxifen	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
anastrozole	anastrozole	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
see	see	VB	B-VP	O	O
CLINICAL	CLINICAL	NNP	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NNP	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
and	and	CC	O	O	O
CLINICAL	CLINICAL	NN	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
-	-	HYPH	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
Studies	Study	NNS	I-NP	O	O
-	-	HYPH	B-NP	O	O
Adjuvant	Adjuvant	JJ	I-NP	O	O
Treatment	Treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Breast	Breast	NN	B-NP	O	O
Cancer	Cancer	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Postmenopausal	Postmenopausal	JJ	B-NP	O	O
Women	Woman	NNS	I-NP	O	O
subsections	subsection	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anastrozole	anastrozole	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
tamoxifen	tamoxifen	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anastrozole	anastrozole	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
27	27	CD	B-NP	O	O
%	%	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
achieved	achieve	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
anastrozole	anastrozole	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Estrogen	Estrogen	NN	B-NP	O	S-group-AD-1
-	-	HYPH	B-PP	O	O
containing	contain	VBG	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ARIMIDEX	ARIMIDEX	NN	B-NP	O	S-brand-AD-2
as	as	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O

No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
anidulafungin	anidulafungin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
anileridine	anileridine	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
opioids	opioid	NNS	I-NP	O	S-group-AD-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
respiratory	respiratory	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
circulatory	circulatory	JJ	I-NP	O	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

Addition	Addition	NN	B-NP	O	O
or	or	CC	I-NP	O	O
deletion	deletion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
patient	patient	NN	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group
.	.	.	O	O	O

Frequent	Frequent	JJ	B-NP	O	O
determination	determination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
and	and	CC	O	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
ascertain	ascertain	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
adjustment	adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anticoagulant	anticoagulant	NN	B-NP	O	S-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
variability	variability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
response	response	NN	I-NP	O	O
,	,	,	O	O	O
multiple	multiple	JJ	B-NP	O	O
interacting	interact	VBG	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dependency	dependency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
and	and	CC	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
interacting	interact	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
difficult	difficult	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
predict	predict	VB	I-VP	O	O
the	the	DT	B-NP	O	O
direction	direction	NN	I-NP	O	O
and	and	CC	I-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ultimate	ultimate	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-group
response	response	NN	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
example	example	NN	B-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-ME-2
and	and	CC	O	O	O
vitamin	vitamin	NN	B-NP	O	B-group-ME-2
K	K	NN	I-NP	O	E-group-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
net	net	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unpredictable	unpredictable	JJ	B-ADJP	O	O
.	.	.	O	O	O

Chloral	Chloral	JJ	B-NP	O	B-drug-ME-1
hydrate	hydrate	NN	I-NP	O	E-drug-ME-1
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
response	response	NN	I-NP	O	O
by	by	IN	B-PP	O	O
displacing	displace	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group-ME-2
from	from	IN	B-PP	O	O
protein	protein	NN	B-NP	B-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
diminished	diminished	JJ	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
response	response	NN	I-NP	O	O
through	through	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
unbound	unbound	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
by	by	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
induction	induction	NN	I-NP	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
inter	inter	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
patient	patient	NN	I-NP	O	O
variation	variation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
ultimate	ultimate	JJ	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
interacting	interact	VBG	I-NP	O	O
drug	drug	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
leads	lead	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
necessitating	necessitate	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
an	an	DT	B-NP	O	O
adequate	adequate	JJ	I-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
may	may	MD	B-VP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
abruptly	abruptly	RB	B-ADVP	O	O
discontinued	discontinue	VBN	B-VP	O	O
,	,	,	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
diminish	diminish	VB	I-VP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group-EF-1
response	response	NN	I-NP	O	O
,	,	,	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBN	B-NP	O	O
prothrom	prothrom	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
bin	bin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
response	response	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
adrenocortical	adrenocortical	JJ	B-NP	O	B-group-EF-2
steroids	steroid	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O

alcohol	alcohol	NN	B-NP	O	S-drug
*	*	SYM	B-NP	O	O
;	;	:	O	O	O

antacids	antacid	NNS	B-NP	O	S-group
;	;	:	O	O	O

antihistamines	antihistamine	NNS	B-NP	O	S-group
;	;	:	O	O	O

barbiturates	barbiturate	NNS	B-NP	O	S-group
;	;	:	O	O	O

carbamazepine	carbamazepine	NN	B-NP	O	S-drug
;	;	:	O	O	O

chloral	chloral	JJ	B-NP	O	B-drug
hydrate	hydrate	NN	I-NP	O	E-drug
*	*	SYM	B-NP	O	O
;	;	:	O	O	O

chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug
;	;	:	O	O	O

cholestyramine	cholestyramine	NN	B-NP	O	S-drug
;	;	:	O	O	O

diet	diet	NN	B-NP	O	O
high	high	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
K	K	NN	I-NP	O	E-group
;	;	:	O	O	O

diuretics	diuretic	NNS	B-NP	O	S-group
*	*	SYM	B-NP	O	O
;	;	:	O	O	O

ethchlorvynol	ethchlorvynol	NN	B-NP	O	S-drug
;	;	:	O	O	O

glutethimide	glutethimide	NN	B-NP	O	S-drug
;	;	:	O	O	O

griseofulvin	griseofulvin	NN	B-NP	O	S-drug
;	;	:	O	O	O

haloperidol	haloperidol	NN	B-NP	O	S-drug
;	;	:	O	O	O

meprobamate	meprobamate	NN	B-NP	O	S-drug
;	;	:	O	O	O

oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
;	;	:	O	O	O

paraldehyde	paraldehyde	NN	B-NP	O	S-drug
;	;	:	O	O	O

primidone	primidone	NN	B-NP	O	S-drug
;	;	:	O	O	O

ranitidine	ranitidine	NN	B-NP	O	S-drug
*	*	SYM	B-NP	O	O
;	;	:	O	O	O

rifampin	rifampin	NN	B-NP	O	S-drug
;	;	:	O	O	O

unreliable	unreliable	JJ	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
;	;	:	O	O	O

vitamin	vitamin	NN	B-NP	O	B-drug
C	C	NN	I-NP	O	E-drug
;	;	:	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
diminish	diminish	VB	I-VP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group-EF-1
response	response	NN	I-NP	O	O
,	,	,	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBN	B-NP	O	O
prothrom	prothrom	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
bin	bin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
response	response	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
adrenocortical	adrenocortical	JJ	B-NP	O	B-group-EF-2
steroids	steroid	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
*	*	SYM	B-NP	O	O
;	;	:	O	O	O
antacids	antacid	NNS	B-NP	O	S-group-EF-2
;	;	:	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
;	;	:	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
;	;	:	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
chloral	chloral	JJ	B-NP	O	B-drug-EF-2
hydrate	hydrate	NN	I-NP	O	E-drug-EF-2
*	*	SYM	B-NP	O	O
;	;	:	O	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
diet	diet	NN	B-NP	O	O
high	high	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-EF-2
K	K	NN	I-NP	O	E-group-EF-2
;	;	:	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-2
*	*	SYM	B-NP	O	O
;	;	:	O	O	O
ethchlorvynol	ethchlorvynol	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
glutethimide	glutethimide	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
griseofulvin	griseofulvin	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
meprobamate	meprobamate	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
;	;	:	O	O	O
paraldehyde	paraldehyde	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
primidone	primidone	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug-EF-2
*	*	SYM	B-NP	O	O
;	;	:	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
unreliable	unreliable	JJ	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
;	;	:	O	O	O
vitamin	vitamin	NN	B-NP	O	B-drug-EF-2
C	C	NN	I-NP	O	E-drug-EF-2
;	;	:	O	O	O
warfarin	warfarin	NN	B-NP	O	B-drug-EF-2
sodium	sodium	NN	I-NP	O	E-drug-EF-2
under	under	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
reportedly	reportedly	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group-EF-1
response	response	NN	I-NP	O	O
,	,	,	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
response	response	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
*	*	SYM	B-NP	O	O
;	;	:	O	O	O

allopurinol	allopurinol	NN	B-NP	O	S-drug
;	;	:	O	O	O

aminosalicylic	aminosalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
;	;	:	O	O	O

amiodarone	amiodarone	NN	B-NP	O	S-drug
;	;	:	O	O	O

anabolic	anabolic	JJ	B-NP	O	B-group
steroids	steroid	NNS	I-NP	O	E-group
;	;	:	O	O	O

antibiotics	antibiotic	NNS	B-NP	O	S-group
;	;	:	O	O	O

bromelains	bromelain	NNS	B-NP	O	S-drug
;	;	:	O	O	O

chloral	chloral	JJ	B-NP	O	B-drug
hydrate	hydrate	NN	I-NP	O	E-drug
*	*	SYM	B-NP	O	O
;	;	:	O	O	O

chlorpropamide	chlorpropamide	NN	B-NP	O	S-drug
;	;	:	O	O	O

chymotrypsin	chymotrypsin	NN	B-NP	B-protein	S-drug
;	;	:	O	O	O

cimetidine	cimetidine	NN	B-NP	O	S-drug
;	;	:	O	O	O

cinchophen	cinchophen	NN	B-NP	O	S-drug
;	;	:	O	O	O

clofibrate	clofibrate	NN	B-NP	O	S-drug
;	;	:	O	O	O

dextran	dextran	NN	B-NP	O	S-drug
;	;	:	O	O	O

dextrothyroxine	dextrothyroxine	NN	B-NP	O	S-drug
;	;	:	O	O	O

diazoxide	diazoxide	NN	B-NP	O	S-drug
;	;	:	O	O	O

dietary	dietary	JJ	B-NP	O	O
deficiencies	deficiency	NNS	I-NP	O	O
;	;	:	O	O	O

diflunisal	diflunisal	JJ	B-NP	O	S-drug
;	;	:	O	O	O

diuretics	diuretic	NNS	B-NP	O	S-group
*	*	SYM	B-NP	O	O
;	;	:	O	O	O

disulfiram	disulfiram	NN	B-NP	O	S-drug
;	;	:	O	O	O

drugs	drug	NNS	B-NP	O	O
affecting	affect	VBG	B-VP	O	O
blood	blood	NN	B-NP	B-DNA	O
elements	element	NNS	I-NP	I-DNA	O
;	;	:	O	O	O

ethacrynic	ethacrynic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
;	;	:	O	O	O

fenoprofen	fenoprofen	NN	B-NP	O	S-drug
;	;	:	O	O	O

glucagon	glucagon	NN	B-NP	O	S-drug
;	;	:	O	O	O

hepatotoxic	hepatotoxic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
;	;	:	O	O	O

ibuprofen	ibuprofen	NN	B-NP	O	S-drug
;	;	:	O	O	O

indomethacin	indomethacin	NN	B-NP	O	S-drug
;	;	:	O	O	O

influenza	influenza	NN	B-NP	O	B-group
virus	virus	NN	I-NP	O	I-group
vaccine	vaccine	NN	I-NP	O	E-group
;	;	:	O	O	O

inhalation	inhalation	NN	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
;	;	:	O	O	O

mefenamic	mefenamic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
;	;	:	O	O	O

methyldopa	methyldopa	NN	B-NP	O	S-drug
;	;	:	O	O	O

methylphenidate	methylphenidate	NN	B-NP	O	S-drug
;	;	:	O	O	O

metronidazole	metronidazole	NN	B-NP	O	S-drug
;	;	:	O	O	O

miconazole	miconazole	NN	B-NP	O	S-drug
;	;	:	O	O	O

monoamine	monoamine	NN	B-NP	O	B-group
oxidase	oxidase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
;	;	:	O	O	O

nalidixic	nalidixic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
;	;	:	O	O	O

naproxen	naproxen	NN	B-NP	O	S-drug
;	;	:	O	O	O

oxolinic	oxolinic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
;	;	:	O	O	O

oxyphenbutazone	oxyphenbutazone	NN	B-NP	O	S-drug
;	;	:	O	O	O

pentoxifylline	pentoxifylline	NN	B-NP	O	S-drug
;	;	:	O	O	O

phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug
;	;	:	O	O	O

phenyramidol	phenyramidol	NN	B-NP	O	S-drug_n
;	;	:	O	O	O

phenytoin	phenytoin	NN	B-NP	O	S-drug
;	;	:	O	O	O

prolonged	prolonged	JJ	B-NP	O	O
hot	hot	JJ	I-NP	O	O
weather	weather	NN	I-NP	O	O
;	;	:	O	O	O

prolonged	prolonged	JJ	B-NP	O	B-group
narcotics	narcotic	NNS	I-NP	O	E-group
;	;	:	O	O	O

pyrazolones	pyrazolone	NNS	B-NP	O	S-group
;	;	:	O	O	O

quinidine	quinidine	NN	B-NP	O	S-drug
;	;	:	O	O	O

quinine	quinine	NN	B-NP	O	S-drug
;	;	:	O	O	O

ranitidine	ranitidine	NN	B-NP	O	S-drug
*	*	SYM	B-NP	O	O
;	;	:	O	O	O

salicylates	salicylate	NNS	B-NP	O	S-group
;	;	:	O	O	O
sulfinpyrazone	sulfinpyrazone	NN	B-NP	O	S-drug
;	;	:	O	O	O

sulfonamides	sulfonamide	NNS	B-NP	O	S-group
,	,	,	O	O	O
long	long	JJ	B-ADJP	O	O
acting	act	VBG	B-VP	O	O
;	;	:	O	O	O

sulindac	sulindac	NN	B-NP	O	S-drug
;	;	:	O	O	O

thyroid	thyroid	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
;	;	:	O	O	O

tolbutamide	tolbutamide	NN	B-NP	O	S-drug
;	;	:	O	O	O

triclofos	triclofos	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
;	;	:	O	O	O

trimethoprim	trimethoprim	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
sulfamethoxazole	sulfamethoxazole	NN	I-NP	O	S-drug
;	;	:	O	O	O

unreliable	unreliable	JJ	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
;	;	:	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
reportedly	reportedly	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group-EF-1
response	response	NN	I-NP	O	O
,	,	,	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
response	response	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
*	*	SYM	B-NP	O	O
;	;	:	O	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
aminosalicylic	aminosalicylic	JJ	B-NP	O	B-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
;	;	:	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
anabolic	anabolic	JJ	B-NP	O	B-group-EF-2
steroids	steroid	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group-EF-2
;	;	:	O	O	O
bromelains	bromelain	NNS	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
chloral	chloral	JJ	B-NP	O	B-drug-EF-2
hydrate	hydrate	NN	I-NP	O	E-drug-EF-2
*	*	SYM	B-NP	O	O
;	;	:	O	O	O
chlorpropamide	chlorpropamide	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
chymotrypsin	chymotrypsin	NN	B-NP	B-protein	S-drug-EF-2
;	;	:	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
cinchophen	cinchophen	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
clofibrate	clofibrate	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
dextran	dextran	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
dextrothyroxine	dextrothyroxine	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
diazoxide	diazoxide	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
dietary	dietary	JJ	B-NP	O	O
deficiencies	deficiency	NNS	I-NP	O	O
;	;	:	O	O	O
diflunisal	diflunisal	JJ	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
drugs	drug	NNS	B-NP	B-DNA	O
affecting	affect	VBG	B-VP	I-DNA	O
blood	blood	NN	B-NP	I-DNA	O
elements	element	NNS	I-NP	I-DNA	O
;	;	:	O	O	O
ethacrynic	ethacrynic	JJ	B-NP	O	B-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
;	;	:	O	O	O
fenoprofen	fenoprofen	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
glucagon	glucagon	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
hepatotoxic	hepatotoxic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
;	;	:	O	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
influenza	influenza	NN	B-NP	O	B-group-EF-2
virus	virus	NN	I-NP	O	I-group-EF-2
vaccine	vaccine	NN	I-NP	O	E-group-EF-2
;	;	:	O	O	O
inhalation	inhalation	NN	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-2
;	;	:	O	O	O
mefenamic	mefenamic	JJ	B-NP	O	B-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
;	;	:	O	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
methylphenidate	methylphenidate	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
metronidazole	metronidazole	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
miconazole	miconazole	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O
nalidixic	nalidixic	JJ	B-NP	O	B-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
;	;	:	O	O	O
naproxen	naproxen	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
oxolinic	oxolinic	JJ	B-NP	O	B-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
;	;	:	O	O	O
oxyphenbutazone	oxyphenbutazone	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
pentoxifylline	pentoxifylline	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
phenyramidol	phenyramidol	NN	B-NP	O	S-drug_n-EF-2
;	;	:	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
prolonged	prolonged	JJ	B-NP	O	O
hot	hot	JJ	I-NP	O	O
weather	weather	NN	I-NP	O	O
;	;	:	O	O	O
prolonged	prolonged	JJ	B-NP	O	B-group-EF-2
narcotics	narcotic	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O
pyrazolones	pyrazolone	NNS	B-NP	O	S-group-EF-2
;	;	:	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
quinine	quinine	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug-EF-2
*	*	SYM	B-NP	O	O
;	;	:	O	O	O
salicylates	salicylate	NNS	B-NP	O	S-group-EF-2
;	;	:	O	O	O
sulfinpyrazone	sulfinpyrazone	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
long	long	JJ	B-ADJP	O	O
acting	act	VBG	B-VP	O	O
;	;	:	O	O	O
sulindac	sulindac	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
thyroid	thyroid	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
triclofos	triclofos	NN	B-NP	O	B-drug-EF-2
sodium	sodium	NN	I-NP	O	E-drug-EF-2
;	;	:	O	O	O
trimethoprim	trimethoprim	NN	B-NP	O	S-drug-EF-2
/	/	SYM	I-NP	O	O
sulfamethoxazole	sulfamethoxazole	NN	I-NP	O	S-drug-EF-2
;	;	:	O	O	O
unreliable	unreliable	JJ	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
;	;	:	O	O	O
warfarin	warfarin	NN	B-NP	O	B-drug-EF-2
sodium	sodium	NN	I-NP	O	E-drug-EF-2
overdosage	overdosage	NN	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycemic	hypoglycemic	JJ	B-NP	O	B-group-ME-2
agents	agent	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	I-NP	O	O
tolbutamide	tolbutamide	NN	I-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
chlorpropamide	chlorpropamide	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
by	by	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
their	their	PRP$	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
toxic	toxic	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticonvulsant	anticonvulsant	NN	I-NP	O	S-group
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group-ME-1
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
reduce	reduce	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	B-cell_type	O
platelets	platelet	NNS	I-NP	I-cell_type	O
by	by	IN	B-PP	O	O
causing	cause	VBG	B-VP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
depression	depression	NN	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
antineoplastic	antineoplastic	JJ	B-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
)	)	)	O	O	O
or	or	CC	O	O	O
drugs	drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
non	non	AFX	I-NP	O	B-group-EF-1
-	-	HYPH	I-NP	B-DNA	I-group-EF-1
steroidal	steroidal	JJ	I-NP	I-DNA	I-group-EF-1
anti	anti	AFX	I-NP	I-DNA	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
hydrochloroquine	hydrochloroquine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
clofibrate	clofibrate	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
dextran	dextran	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bleeding	bleeding	JJ	I-NP	O	O
tendency	tendency	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	B-protein	S-group-EF-2
without	without	IN	B-PP	I-protein	O
altering	alter	VBG	B-VP	I-protein	O
prothrombin	prothrombin	NN	B-NP	I-protein	O
time	time	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
beneficial	beneficial	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
thrombus	thrombus	NN	I-NP	O	O
formation	formation	NN	I-NP	O	O
from	from	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antiplatelet	antiplatelet	JJ	B-NP	O	S-group-AD-1
and	and	CC	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	B-group-AD-2
medication	medication	NN	I-NP	O	E-group-AD-2
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
weighed	weigh	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inducing	induce	VBG	B-VP	O	O
hemorrhage	hemorrhage	NN	B-NP	O	O
.	.	.	O	O	O

*	*	SYM	O	O	O
Increased	Increase	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
decreased	decrease	VBN	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
responses	response	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interferences	Interference	NNS	I-NP	O	O
:	:	:	O	O	O
Dicumarol	Dicumarol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
indanedione	indanedione	NN	I-NP	O	B-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
anisindione	anisindione	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
their	their	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
color	color	VB	I-VP	O	O
alkaline	alkaline	NN	B-NP	O	O
urine	urine	NN	I-NP	O	O
red	red	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
orange	orange	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
spectrophotometrically	spectrophotometrically	RB	B-NP	O	O
determined	determine	VBN	I-NP	O	O
urinary	urinary	JJ	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
color	color	NN	I-NP	O	O
reverses	reverse	VBZ	B-VP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
test	test	NN	I-NP	O	O
sample	sample	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
acidified	acidify	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
pH	pH	NN	I-NP	B-protein	O
below	below	IN	B-PP	I-protein	O
4	4	CD	B-NP	I-protein	O
.	.	.	O	O	O

5HT3	5HT3	NN	B-NP	O	B-group
Antagonists	Antagonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
Based	Base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
profound	profound	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
and	and	CC	I-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
consciousness	consciousness	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
5HT3	5HT3	NN	I-NP	O	B-group-AD-2
antagonist	antagonist	NN	I-NP	O	I-group-AD-2
class	class	NN	I-NP	O	E-group-AD-2
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
example	example	NN	B-NP	O	O
,	,	,	O	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
granisetron	granisetron	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
dolasetron	dolasetron	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
palonosetron	palonosetron	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
alosetron	alosetron	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Antihypertensive	Antihypertensive	JJ	B-NP	O	B-group
Medications	Medication	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
Vasodilators	Vasodilator	NNS	I-NP	O	S-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
experienced	experience	VBN	I-VP	O	O
more	more	RBR	B-ADVP	O	O
commonly	commonly	RB	I-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-EF-1
medications	medication	NNS	I-NP	O	E-group-EF-1
or	or	CC	I-NP	O	O
vasodilators	vasodilator	NNS	I-NP	O	S-group-EF-2
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
94	94	CD	B-NP	O	O
)	)	)	O	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
not	not	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
these	these	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
456	456	CD	B-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
hypotension	hypotension	NN	B-NP	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	CC	O	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
myocardial	myocardial	JJ	B-NP	O	O
infarction	infarction	NN	I-NP	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
serious	serious	JJ	B-NP	O	O
pneumonia	pneumonia	NN	I-NP	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
serious	serious	JJ	B-NP	O	O
falls	fall	VBZ	B-VP	O	O
9	9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
bone	bone	NN	B-NP	O	O
and	and	CC	I-NP	O	O
joint	joint	NN	I-NP	O	O
injuries	injury	NNS	I-NP	O	O
6	6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
2	2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
many	many	JJ	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
events	event	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
may	may	MD	B-VP	O	O
represent	represent	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

Dopamine	Dopamine	NN	B-NP	O	B-group
Antagonists	Antagonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
dopamine	dopamine	NN	I-NP	O	B-group
agonist	agonist	NN	I-NP	O	E-group
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
dopamine	dopamine	NN	B-NP	O	B-group-EF-1
antagonists	antagonist	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
neuroleptics	neuroleptic	NNS	I-NP	O	S-group
(	(	(	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
butyrophenones	butyrophenone	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
thioxanthenes	thioxanthene	NNS	B-NP	O	S-group-EF-1
)	)	)	O	O	O
or	or	CC	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-EF-M
,	,	,	O	O	O
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
APOKYN	APOKYN	NN	B-NP	B-protein	S-brand-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
psychotic	psychotic	JJ	I-NP	O	O
disorders	disorder	NNS	I-NP	O	O
,	,	,	O	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
neuroleptics	neuroleptic	NNS	B-NP	O	S-group-AD-1
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	B-group-AD-2
agonists	agonist	NNS	I-NP	O	E-group-AD-2
only	only	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
benefits	benefit	NNS	I-NP	O	O
outweigh	outweigh	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Prolonging	Prolong	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
Interval	Interval	NN	I-NP	O	O
Caution	Caution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
prescribing	prescribe	VBG	B-VP	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
prolong	prolong	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
APOKYN	APOKYN	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Apraclonidine	Apraclonidine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
MAO	MAO	NN	B-NP	B-protein	B-group-AD-2
inhibitors..	inhibitors..	.	O	O	O

Although	Although	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
topical	topical	JJ	B-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	O	O	O
systemic	systemic	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
IOPIDINE	IOPIDINE	NN	B-NP	O	S-brand-AD-1
0.5	0.5	CD	I-NP	O	O
%	%	NN	I-NP	O	O
Ophthalmic	Ophthalmic	JJ	I-NP	O	O
Solution	Solution	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
potentiating	potentiate	VBG	I-NP	O	O
effect	effect	NN	I-NP	O	O
with	with	IN	B-PP	O	O
CNS	CNS	NN	B-NP	O	B-group-AD-2
depressants	depressant	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
opiates	opiate	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-AD-2
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Tricyclic	Tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
blunt	blunt	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
clonidine	clonidine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
apraclonidine	apraclonidine	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
IOP	IOP	NN	B-NP	O	O
lowering	lowering	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
circulating	circulate	VBG	B-VP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
after	after	IN	B-PP	O	O
apraclonidine	apraclonidine	NN	B-NP	O	S-drug
withdrawal	withdrawal	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
circulating	circulate	VBG	B-VP	O	O
amines	amine	NNS	B-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
clonidine	clonidine	NN	I-NP	O	S-drug-EF-1
and	and	CC	O	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	S-group-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
clonidine	clonidine	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
production	production	NN	I-NP	O	O
of	of	IN	B-PP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
and	and	CC	O	O	O
mask	mask	VB	B-VP	O	O
the	the	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
apraclonidine	apraclonidine	NN	B-NP	O	S-drug-AD-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
pulse	pulse	NN	B-NP	O	O
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
beta	beta	SYM	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
blockers	blocker	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
ophthalmic	ophthalmic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
systemic	systemic	JJ	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
antihypertensives	antihypertensive	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	B-group-AD-2
glycosides	glycoside	NNS	I-NP	O	E-group-AD-2
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
IOPIDINE	IOPIDINE	NN	B-NP	O	S-brand
0.5	0.5	CD	I-NP	O	O
%	%	NN	I-NP	O	O
Ophthalmic	Ophthalmic	JJ	I-NP	O	O
Solution	Solution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
pulse	pulse	NN	B-NP	O	O
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressures	pressure	NNS	I-NP	O	O
frequently	frequently	RB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
similar	similar	JJ	I-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O

Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
also	also	RB	B-ADVP	O	O
an	an	DT	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	JJ	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O

As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
aprepitant	aprepitant	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
coadministered	coadministere	VBN	B-NP	O	O
medicinal	medicinal	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Aprepitant	Aprepitant	JJ	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
S	S	NN	B-NP	B-protein	B-drug-ME-2
(	(	(	O	I-protein	I-drug-ME-2
-	-	SYM	O	I-protein	I-drug-ME-2
)	)	)	O	I-protein	I-drug-ME-2
warfarin	warfarin	NN	B-NP	I-protein	E-drug-ME-2
and	and	CC	I-NP	O	O
tolbutamide	tolbutamide	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	O	O	O
glycoprotein	glycoprotein	NN	B-NP	B-protein	O
transporter	transporter	NN	I-NP	I-protein	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
demonstrated	demonstrate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

5	5	CD	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
HT3	HT3	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
aprepitant	aprepitant	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
granisetron	granisetron	NN	I-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
dolasetron	dolasetron	NN	B-NP	O	S-drug
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
:	:	:	O	O	O
Dexamethasone	Dexamethasone	NN	B-NP	O	S-drug
:	:	:	O	O	O
Aprepitant	Aprepitant	JJ	B-ADJP	O	S-drug-ME-1
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
125mg	125mg	NN	B-NP	O	O
with	with	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-ME-2
coadministered	coadministere	VBN	B-VP	O	O
orally	orally	RB	B-ADVP	O	O
as	as	IN	B-PP	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Aprepitant	Aprepitant	JJ	B-ADJP	O	S-drug-ME-1
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
80	80	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
with	with	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-ME-2
coadministered	coadministere	VBN	B-VP	O	O
orally	orally	RB	B-ADVP	O	O
as	as	IN	B-SBAR	O	O
8	8	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
2	2	CD	B-NP	O	O
through	through	IN	B-PP	O	O
5	5	CD	B-NP	O	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
by	by	IN	B-PP	O	O
2.2	2.2	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
fold	fold	RB	B-ADVP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
5	5	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	O	S-drug-AD-1
doses	dose	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-ADJP	O	S-drug-AD-2
,	,	,	O	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
exposures	exposure	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
obtained	obtain	VBN	B-VP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
without	without	IN	B-PP	O	O
Aprepitant	Aprepitant	NNP	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-ME-1
administered	administer	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug-ME-2
reflects	reflect	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Aprepitant	Aprepitant	JJ	B-ADJP	O	S-drug-ME-1
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
125	125	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
80	80	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
2	2	CD	I-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
1.34	1.34	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	O	O	O
by	by	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
as	as	IN	B-PP	O	O
125	125	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	O	O	O
orally	orally	RB	B-ADVP	O	O
as	as	IN	B-SBAR	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
2	2	CD	I-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
IV	IV	CD	I-NP	O	O
methylprednisolone	methylprednisolone	NN	I-NP	O	S-drug-AD-1
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
methylprednisolone	methylprednisolone	NN	I-NP	O	S-drug-AD-1
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-ADJP	O	S-drug-AD-2
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
exposures	exposure	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
obtained	obtain	VBN	B-VP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
without	without	IN	B-PP	O	O
Aprepitant	Aprepitant	NNP	B-NP	O	S-drug
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
125	125	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
80	80	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
2	2	CD	I-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
R	R	NN	B-NP	O	B-drug
(	(	(	O	O	I-drug
+	+	SYM	B-NP	O	I-drug
)	)	)	O	O	E-drug
or	or	CC	O	O	O
S	S	NN	B-NP	B-protein	B-drug
(	(	(	O	I-protein	I-drug
-	-	SYM	O	I-protein	I-drug
)	)	)	O	I-protein	I-drug
warfarin	warfarin	NN	B-NP	I-protein	E-drug
determined	determine	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
34	34	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
S	S	NN	B-NP	O	B-drug-ME-1
(	(	(	O	O	I-drug-ME-1
-	-	SYM	O	O	I-drug-ME-1
)	)	)	O	O	I-drug-ME-1
warfarin	warfarin	NN	B-NP	O	E-drug-ME-1
(	(	(	O	O	O
a	a	DT	B-NP	O	O
CYP2C9	CYP2C9	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
trough	trough	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
accompanied	accompany	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
14	14	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
reported	report	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
International	International	NNP	B-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
or	or	CC	O	O	O
INR	INR	NN	B-NP	O	O
)	)	)	O	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
completion	completion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Aprepitant	Aprepitant	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-AD-1
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
INR	INR	NN	B-NP	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
7	7	CD	B-NP	O	O
to	to	TO	I-NP	O	O
10	10	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
following	follow	VBG	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug-AD-2
with	with	IN	B-PP	O	O
each	each	DT	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
.	.	.	O	O	O

Tolbutamide	Tolbutamide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Aprepitant	Aprepitant	JJ	B-ADJP	O	S-drug
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
125	125	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
80	80	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
2	2	CD	I-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
(	(	(	O	O	O
a	a	DT	B-NP	O	O
CYP2C9	CYP2C9	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
4	4	CD	I-NP	O	O
,	,	,	O	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
8	8	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NNP	B-NP	O	O
15	15	CD	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-ME-1
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
admini	admini	NNS	B-NP	O	O
,	,	,	O	O	O
stered	stere	VBD	B-VP	O	O
orally	orally	RB	B-ADJP	O	O
prior	prior	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	NN	B-NP	O	S-drug-ME-2
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
4,8	4,8	CD	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
15	15	CD	B-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
Aprepitant	Aprepitant	JJ	B-ADJP	O	S-drug-ME-1
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
100	100	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
capsule	capsule	NN	I-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group
containing	contain	VBG	B-VP	O	O
35	35	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug-ME-2
estradiol	estradiol	NN	I-NP	O	E-drug-ME-2
and	and	CC	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
by	by	IN	B-PP	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
8	8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-1
during	during	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	NNP	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug-AD-1
given	give	VBN	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-AD-2
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
,	,	,	O	O	O
alternative	alternative	JJ	B-VP	O	O
or	or	CC	O	O	O
back	back	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
methods	method	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

Midazolam	Midazolam	NN	B-NP	O	S-drug
:	:	:	O	O	O
Aprepitant	Aprepitant	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
2.3	2.3	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
3.3	3.3	CD	I-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
Day	Day	NNP	B-NP	O	O
5	5	CD	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
Day	Day	NN	I-NP	O	O
5	5	CD	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
125	125	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
80	80	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
2	2	CD	B-NP	O	O
through	through	IN	B-PP	O	O
5	5	CD	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-AD-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-AD-1
metabolized	metabolize	VBN	B-VP	O	O
via	via	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministering	coadministere	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Aprepitant	Aprepitant	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
another	another	DT	B-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
,	,	,	O	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
125	125	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
80	80	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
2	2	CD	I-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
IV	IV	CD	B-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	NN	B-NP	O	S-drug
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
4	4	CD	I-NP	O	O
,	,	,	I-NP	O	O
8	8	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
15	15	CD	B-NP	O	O
.	.	.	O	O	O

Aprepitant	Aprepitant	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
4	4	CD	I-NP	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
19	19	CD	B-NP	O	O
%	%	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
8	8	CD	I-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
1	1	CD	B-NP	O	O
through	through	IN	B-PP	O	O
3	3	CD	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
Day	Day	NNP	B-NP	O	O
15	15	CD	I-NP	O	O
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinefics	pharmacokinefic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	JJ	B-NP	O	S-drug

Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	NN	B-NP	O	S-drug
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
strong	strong	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
moderate	moderate	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
result	result	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	JJ	B-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
strongly	strongly	RB	B-VP	O	O
induce	induce	VBP	I-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	NN	B-NP	O	S-drug-ME-2
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	NNP	B-NP	O	S-drug
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
125	125	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
Day5	Day5	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
125	125	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
Day5	Day5	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
terminal	terminal	JJ	I-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	B-VP	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
with	with	IN	B-PP	O	O
strong	strong	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
375	375	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
Day9	Day9	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
14	14	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducer	inducer	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	NN	B-NP	O	S-drug
decreased	decrease	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
11	11	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
terminal	terminal	JJ	I-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	JJ	B-NP	O	S-drug
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
efficacy	efficacy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Aprepitant	Aprepitant	NNP	B-NP	O	S-drug
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O

Diltiazem	Diltiazem	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
mild	mild	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	JJ	B-NP	O	S-drug-ME-1
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tablet	tablet	NN	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
230	230	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
capsule	capsule	NN	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	B-protein	S-drug-ME-2
120	120	CD	I-NP	I-protein	O
mg	mg	NN	I-NP	I-protein	O
3	3	CD	B-NP	I-protein	O
times	time	NNS	I-NP	I-protein	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	JJ	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
simultaneous	simultaneous	JJ	I-NP	O	O
1.7	1.7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
meaningful	meaningful	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
ECG	ECG	NN	B-NP	O	O
,	,	,	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
or	or	CC	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
beyond	beyond	IN	B-PP	O	O
those	those	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Paroxetine	Paroxetine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
once	once	RB	B-NP	O	O
daily	daily	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aprepitant	aprepitant	JJ	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tablet	tablet	NN	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
85	85	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
or	or	CC	O	O	O
170	170	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
capsule	capsule	NN	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-ME-2
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	B-protein	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	B-NP	O	O
aprepitant	aprepitant	JJ	I-NP	O	S-drug
and	and	CC	I-NP	O	O
paroxetine	paroxetine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group
-	-	HYPH	O	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
may	may	MD	B-VP	O	O
blunt	blunt	VB	I-VP	O	O
the	the	DT	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
arbutamine	arbutamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group-AD-1
-	-	HYPH	O	O	I-group-AD-1
adrenergic	adrenergic	JJ	B-NP	O	I-group-AD-1
blocking	block	VBG	I-NP	O	I-group-AD-1
agents	agent	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
48	48	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
conducting	conduct	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
arbutamine	arbutamine	NN	I-NP	O	S-drug-AD-2
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
stress	stress	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Antiarrhythmic	Antiarrhythmic	JJ	B-NP	O	B-drug
agents	agent	NNS	I-NP	O	I-drug
,	,	,	O	O	I-drug
class	class	NN	B-NP	O	I-drug
I	I	CD	I-NP	O	E-drug
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
flecainide	flecainide	NN	B-NP	O	S-drug
,	,	,	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
arbutamine	arbutamine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
proarrhythmic	proarrhythmic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Antidepressants	Antidepressant	NNS	B-NP	O	S-group
(	(	(	O	O	O
tricyclic	tricyclic	JJ	B-ADVP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
atropine	atropine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
or	or	CC	O	O	O
digitalis	digitalis	NN	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
:	:	:	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
arbutamine	arbutamine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
inotropic	inotropic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
/	/	SYM	I-NP	O	O
or	or	CC	O	O	O
chronotropic	chronotropic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group-EF-1
including	include	VBG	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
,	,	,	O	O	O
indandione	indandione	NN	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
platelet	platelet	NN	B-NP	B-cell_type	B-group-EF-1
aggregation	aggregation	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-ADJP	O	B-group-EF-1
anti	anti	AFX	B-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ardeparin	ardeparin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
additional	additional	JJ	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	B-group-AD-1
drugs	drug	NNS	I-NP	O	E-group-AD-1
are	be	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
any	any	DT	B-NP	O	O
route	route	NN	I-NP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pharmacologically	pharmacologically	RB	I-NP	O	O
predictable	predictable	JJ	I-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
BROVANA	BROVANA	NN	B-NP	O	S-brand-AD-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
BROVANA	BROVANA	NN	B-NP	O	S-brand
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
,	,	,	O	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
either	either	CC	O	O	O
drug	drug	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
BROVANA	BROVANA	NN	B-NP	O	S-brand
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
methylxanthines	methylxanthine	NNS	B-NP	O	S-group-EF-1
(	(	(	O	O	O
aminophylline	aminophylline	NN	B-NP	O	S-drug-EF-1
,	,	,	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-EF-1
)	)	)	O	O	O
,	,	,	O	O	O
steroids	steroid	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
or	or	CC	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
any	any	DT	B-NP	O	O
hypokalemic	hypokalemic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adrenergic	adrenergic	JJ	B-NP	O	B-group-EF-2
agonists	agonist	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ECG	ECG	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
non	non	AFX	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
potassium	potassium	NN	I-NP	O	I-group-EF-1
sparing	spar	VBG	B-VP	O	I-group-EF-1
diuretics	diuretic	NNS	B-NP	O	E-group-EF-1
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
loop	loop	NN	B-NP	O	S-group-EF-1
or	or	CC	I-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group-EF-1
diuretics	diuretic	NNS	I-NP	O	E-group-EF-1
)	)	)	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
acutely	acutely	RB	I-VP	O	O
worsened	worsen	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
agonists	agonist	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
agonist	agonist	NN	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
exceeded	exceed	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-AD-1
-	-	HYPH	O	O	I-group-AD-1
agonists	agonist	NNS	B-NP	O	E-group-AD-1
with	with	IN	B-PP	O	O
non	non	AFX	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
potassium	potassium	NN	I-NP	O	I-group-AD-2
sparing	spar	VBG	B-VP	O	I-group-AD-2
diuretics	diuretic	NNS	B-NP	O	E-group-AD-2
.	.	.	O	O	O

BROVANA	BROVANA	NN	B-NP	O	S-brand-AD-1
,	,	,	O	O	O
as	as	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
beta2	beta2	NN	I-NP	B-protein	B-group-AD-1
-	-	HYPH	B-NP	O	I-group-AD-1
agonists	agonist	NNS	I-NP	O	E-group-AD-1
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
extreme	extreme	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-MU-M
oxidase	oxidase	NN	I-NP	O	I-group-MU-M
inhibitors	inhibitor	NNS	I-NP	O	E-group-MU-M
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-MU-M
antidepressants	antidepressant	NNS	I-NP	O	E-group-MU-M
,	,	,	O	O	O
or	or	CC	O	O	O
drugs	drug	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adrenergic	adrenergic	JJ	B-NP	O	B-group-EF-2
agonists	agonist	NNS	I-NP	O	E-group-EF-2
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
or	or	CC	I-ADVP	O	O
orally	orally	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
methylxanthines	methylxanthine	NNS	I-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
aminophylline	aminophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
)	)	)	O	O	O
by	by	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
BROVANA	BROVANA	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
completely	completely	RB	B-ADJP	O	O
evaluated	evaluate	VBN	I-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
two	two	CD	B-NP	O	O
combined	combine	VBN	I-NP	O	O
12	12	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
controlled	controlled	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
included	include	VBD	B-VP	O	O
BROVANA	BROVANA	NN	B-NP	O	S-brand
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
,	,	,	O	O	O
25	25	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
50	50	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
,	,	,	O	O	O
54	54	CD	B-NP	O	O
of	of	IN	B-PP	O	O
873	873	CD	B-NP	O	O
BROVANA	BROVANA	NN	I-NP	O	S-brand
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
at	at	IN	B-PP	O	O
study	study	NN	B-NP	O	O
entry	entry	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
12	12	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
month	month	NN	I-NP	O	O
controlled	control	VBN	I-NP	O	O
trial	trial	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
included	include	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
mcg	mcg	NN	I-NP	O	O
once	once	RB	B-NP	O	O
daily	daily	JJ	I-NP	O	O
BROVANA	BROVANA	NN	I-NP	O	S-brand
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
30	30	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
528	528	CD	I-NP	O	O
BROVANA	BROVANA	NN	I-NP	O	S-brand
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
at	at	IN	B-PP	O	O
study	study	NN	B-NP	O	O
entry	entry	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	O	O	O
systolic	systolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
3	3	CD	I-NP	O	O
bpm	bpm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
higher	high	JJR	B-ADJP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
adrenergic	adrenergic	JJ	I-NP	O	I-group-EF-1
receptor	receptor	NN	I-NP	O	I-group-EF-1
antagonists	antagonist	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
beta	beta	SYM	B-NP	O	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
BROVANA	BROVANA	NN	B-NP	O	S-brand-EF-2
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
blockers	blocker	NNS	B-NP	O	E-group-EF-1
not	not	RB	B-CONJP	O	O
only	only	RB	B-VP	O	O
block	block	VB	I-VP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	B-NP	O	I-group-EF-2
agonists	agonist	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
but	but	CC	O	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
bronchospasm	bronchospasm	NN	I-NP	O	O
in	in	IN	B-PP	O	O
COPD	COPD	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
COPD	COPD	NN	B-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
normally	normally	RB	I-VP	O	O
be	be	VB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
under	under	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
circumstances	circumstance	NNS	I-NP	O	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
prophylaxis	prophylaxis	NN	B-NP	O	O
after	after	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	O
infarction	infarction	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
no	no	DT	B-NP	O	O
acceptable	acceptable	JJ	I-NP	O	O
alternatives	alternative	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
COPD	COPD	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
setting	setting	NN	I-NP	O	O
,	,	,	O	O	O
cardioselective	cardioselective	JJ	B-NP	B-protein	B-group
beta	beta	SYM	I-NP	I-protein	I-group
-	-	HYPH	I-NP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Heparin	Heparin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
heparin	heparin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Argatroban	Argatroban	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
heparin	heparin	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
indication	indication	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
Argatroban	Argatroban	NNP	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
initiated	initiate	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
cessation	cessation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
allow	allow	VBP	B-VP	O	O
sufficient	sufficient	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
for	for	IN	B-PP	O	O
heparins	heparin	NNS	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
aPTT	aPTT	NN	I-NP	O	O
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Argatroban	Argatroban	JJ	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
/	/	SYM	I-NP	O	O
Acetaminophen	Acetaminophen	NN	I-NP	O	S-drug
:	:	:	O	O	O
Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
Argatroban	Argatroban	NNP	B-NP	O	S-drug
and	and	CC	O	O	O
concomitantly	concomitantly	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand
(	(	(	O	O	O
162.5	162.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
orally	orally	RB	B-VP	O	O
given	give	VBN	I-VP	O	O
26	26	CD	B-NP	O	O
and	and	CC	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Argatroban	Argatroban	NNP	B-NP	O	S-drug
1	1	CD	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O
over	over	IN	B-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
(	(	(	O	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
orally	orally	RB	B-VP	O	O
given	give	VBN	I-VP	O	O
12	12	CD	B-NP	O	O
,	,	,	I-NP	O	O
6	6	CD	I-NP	O	O
and	and	CC	I-NP	O	O
0	0	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
6	6	CD	B-NP	O	O
and	and	CC	I-NP	O	O
12	12	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
subsequent	subsequent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
,	,	,	O	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Argatroban	Argatroban	NNP	B-NP	O	S-drug
1.5	1.5	CD	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O
over	over	IN	B-NP	O	O
18	18	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
Argatroban	Argatroban	NN	B-NP	O	S-drug
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
7.5	7.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
single	single	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Argatroban	Argatroban	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
(	(	(	O	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
7.5	7.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
initial	initial	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
orally	orally	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
10	10	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
PT	PT	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
International	International	NNP	B-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
(	(	(	O	O	O
INR	INR	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Thrombolytic	Thrombolytic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Argatroban	Argatroban	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
thrombolytic	thrombolytic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Argatroban	Argatroban	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
antiplatelet	antiplatelet	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
thrombolytics	thrombolytic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
Argatroban	Argatroban	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Given	Given	IN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ABILIFY	ABILIFY	NNP	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
taken	take	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
centrally	centrally	RB	I-NP	O	B-group-AD-2
acting	act	VBG	I-NP	O	I-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
and	and	CC	I-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
its	its	PRP$	B-NP	O	O

1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonism	antagonism	NN	I-NP	O	O
,	,	,	O	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
Affect	Affect	VB	I-VP	O	O
ABILIFY	ABILIFY	NN	B-NP	O	S-brand
Aripiprazole	Aripiprazole	NN	I-NP	O	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP1A1	CYP1A1	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2A6	CYP2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2B6	CYP2B6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C8	CYP2C8	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Aripiprazole	Aripiprazole	NN	B-NP	O	S-drug
also	also	RB	B-ADVP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
undergo	undergo	VB	I-VP	O	O
direct	direct	JJ	B-NP	O	O
glucuronidation	glucuronidation	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
,	,	,	O	O	O
like	like	IN	B-PP	O	O
smoking	smoking	NN	B-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	B-protein	O
are	be	VBP	B-VP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
could	could	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-ME-2
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
lower	low	JJR	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
or	or	CC	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
or	or	CC	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-ME-2
elimination	elimination	NN	I-NP	O	O
and	and	CC	O	O	O
cause	cause	VBP	B-VP	O	O
increased	increase	VBN	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
15	15	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-ME-2
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
by	by	IN	B-PP	O	O
63	63	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
77	77	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-AD-2
occurs	occur	VBZ	B-VP	O	O
,	,	,	O	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
half	half	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
normal	normal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
strong	strong	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
)	)	)	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
similar	similar	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
need	need	VB	B-VP	O	O
similar	similar	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
reductions	reduction	NNS	I-NP	O	O
;	;	:	O	O	O

weaker	weak	JJR	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
then	then	RB	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Quinidine	Quinidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
166	166	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
13	13	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
112	112	CD	B-NP	O	O
%	%	NN	I-NP	O	O
but	but	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
dehydroaripiprazole	dehydroaripiprazole	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
by	by	IN	B-PP	O	O
35	35	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Aripiprazole	Aripiprazole	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
half	half	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
normal	normal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-AD-2
occurs	occur	VBZ	B-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
significant	significant	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
paroxetine	paroxetine	NN	I-NP	O	S-drug
,	,	,	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
similar	similar	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
reductions	reduction	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
then	then	RB	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducer	inducer	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
70	70	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
dehydro	dehydro	AFX	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
aripiprazole	aripiprazole	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
doubled	double	VBN	I-VP	O	O
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
increases	increase	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug-AD-2
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
then	then	RB	I-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
famotidine	famotidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
valproate	valproate	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
lithium	lithium	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
see	see	VB	B-VP	O	O
CLINICAL	CLINICAL	NN	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
:	:	:	O	O	O
Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
ABILIFY	ABILIFY	NNP	B-NP	O	S-brand
to	to	TO	B-PP	O	O
Affect	Affect	NNP	B-NP	O	O
Other	Other	NNP	I-NP	O	O
Drugs	Drugs	NNP	I-NP	O	O
Aripiprazole	Aripiprazole	NNP	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
10	10	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
30	30	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
by	by	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
(	(	(	O	O	O
dextromethorphan	dextromethorphan	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
(	(	(	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
(	(	(	O	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
dextromethorphan	dextromethorphan	NN	B-NP	O	S-drug
)	)	)	O	O	O
substrates	substrate	NNS	B-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
and	and	CC	O	O	O
dehydroaripiprazole	dehydroaripiprazole	NN	B-NP	O	S-drug_n
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
show	show	VB	I-VP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
altering	alter	VBG	B-VP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
:	:	:	O	O	O
There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
between	between	IN	B-PP	O	O
aripiprazole	aripiprazole	NN	B-NP	O	S-drug
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
performance	performance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
gross	gross	JJ	B-NP	O	O
motor	motor	NN	I-NP	O	O
skills	skill	NNS	I-NP	O	O
or	or	CC	O	O	O
stimulus	stimulus	NN	B-NP	O	O
response	response	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
psychoactive	psychoactive	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-AD-1
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
ABILIFY	ABILIFY	NN	B-NP	O	S-brand-AD-2

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
assessments	assessment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
TRISENOX	TRISENOX	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
TRISENOX	TRISENOX	NN	B-NP	B-protein	S-brand-AD-1
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O
certain	certain	JJ	B-NP	O	O
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	S-group-AD-2
or	or	CC	O	O	O
thioridazine	thioridazine	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
or	or	CC	O	O	O
lead	lead	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
electrolyte	electrolyte	VB	I-VP	O	O
abnormalities	abnormality	NNS	B-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-AD-2
or	or	CC	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-AD-2
B	B	NN	I-NP	O	E-drug-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

Tissue	Tissue	NN	B-NP	O	O
culture	culture	NN	I-NP	O	O
and	and	CC	I-NP	O	O
animal	animal	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ELSPAR	ELSPAR	NN	B-NP	B-protein	S-brand-EF-1
can	can	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
or	or	CC	I-VP	O	O
abolish	abolish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-EF-2
on	on	IN	B-PP	O	O
malignant	malignant	JJ	B-NP	O	O
cells.14	cells.14	NNS	I-NP	O	O
This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
activity	activity	NN	I-NP	O	O
persists	persist	VBZ	B-VP	O	O
as	as	RB	B-ADVP	O	O
long	long	RB	I-ADVP	O	O
as	as	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
asparagine	asparagine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
suppressed	suppress	VBN	I-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
would	would	MD	B-VP	O	O
seem	seem	VB	I-VP	O	O
to	to	TO	I-VP	O	O
dictate	dictate	VB	I-VP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
ELSPAR	ELSPAR	NN	B-NP	B-protein	S-brand-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
period	period	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
ELSPAR	ELSPAR	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
plasma	plasma	NN	B-NP	O	O
asparagine	asparagine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
below	below	IN	B-PP	O	O
normal	normal	JJ	B-ADJP	O	O
.	.	.	O	O	O

Uricosuric	Uricosuric	NNP	B-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Aspirin	Aspirin	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
sulfinpyrazone	sulfinpyrazone	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug-EF-1
:	:	:	O	O	O
Has	Have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-2
in	in	IN	B-PP	O	O
causing	cause	VBG	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group-EF-1
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
ulceration	ulceration	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Pyrazolone	Pyrazolone	NN	B-NP	O	B-group-EF-1
Derivatives	Derivative	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
oxyphenbutazone	oxyphenbutazone	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
possibly	possibly	RB	B-ADVP	O	O
dipyrone	dipyrone	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
ulceration	ulceration	NN	I-NP	O	O
.	.	.	O	O	O

Nonsteroidal	Nonsteroidal	JJ	B-NP	O	B-drug
Antiinflammatory	Antiinflammatory	JJ	I-NP	O	E-drug
Agents	Agent	NNPS	I-NP	O	O
:	:	:	O	O	O
Aspirin	Aspirin	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
hypersensitive	hypersensitive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-drug-AD-2
anti	anti	AFX	I-NP	O	I-drug-AD-2
-	-	HYPH	I-NP	O	I-drug-AD-2
inflammatory	inflammatory	JJ	I-NP	O	E-drug-AD-2
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	O
Alkalinizers	Alkalinizer	NNS	I-NP	O	O
:	:	:	O	O	O
Decrease	Decrease	VB	B-VP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
effectiveness	effectiveness	NN	I-NP	O	O
by	by	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylate	salicylate	NN	B-NP	O	S-group
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug-ME-1
:	:	:	O	O	O
Decreases	Decrease	VBZ	B-VP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-2
effectiveness	effectiveness	NN	I-NP	O	O
by	by	IN	B-PP	O	O
enzyme	enzyme	NN	B-NP	B-protein	O
induction	induction	NN	I-NP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Serum	Serum	NN	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-EF-1
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

Propranolol	Propranolol	NN	B-NP	O	S-drug-EF-1
:	:	:	O	O	O
May	May	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
aspirins	aspirin	NNS	B-NP	O	S-brand-EF-2
anti	anti	AFX	O	O	O
-	-	HYPH	O	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
by	by	IN	B-PP	O	O
competing	compete	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
Enteric	Enteric	JJ	B-NP	O	O
Coated	Coated	JJ	I-NP	O	O
Aspirin	Aspirin	NN	I-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pH	pH	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stomach	stomach	NN	I-NP	O	O
may	may	MD	B-VP	O	O
effect	effect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
enteric	enteric	JJ	I-NP	O	O
coating	coating	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Itraconazole	Itraconazole	NN	I-NP	O	S-drug
,	,	,	O	O	O
Macrolides	Macrolides	NNP	B-NP	O	S-group
,	,	,	O	O	O
Including	Include	VBG	B-VP	O	O
Erythromycin	Erythromycin	NN	B-NP	O	S-drug

Catecholamine	Catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	I-NP	O	O
reserpine	reserpine	NN	I-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	B-PP	O	I-group-EF-2
blocking	block	VBG	B-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
TENORMIN	TENORMIN	NN	B-NP	B-protein	S-brand
plus	plus	CC	O	O	O
a	a	DT	B-NP	O	O
catecholamine	catecholamine	NN	I-NP	O	O
depletor	depletor	NN	I-NP	O	O
should	should	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
marked	marked	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
vertigo	vertigo	RB	B-ADVP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
postural	postural	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	B-group-EF-1
channel	channel	NN	I-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
TENORMIN	TENORMIN	NN	B-NP	B-protein	S-brand-EF-2
.	.	.	O	O	O

Beta	Beta	NN	B-NP	O	B-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
exacerbate	exacerbate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
rebound	rebound	NN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
follow	follow	VB	I-VP	O	O
the	the	DT	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
beta	beta	NN	I-NP	O	B-group-AD-1
blocker	blocker	NN	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
several	several	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gradual	gradual	JJ	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
replacing	replace	VBG	B-VP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
blocker	blocker	NN	I-NP	O	E-group
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
introduction	introduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	NN	B-NP	O	B-group-AD-1
blockers	blocker	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
delayed	delay	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-AD-2
administration	administration	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
stopped	stop	VBN	I-VP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	B-protein	O
synthase	synthase	NN	I-NP	I-protein	O
inhibiting	inhibit	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
,	,	,	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	NN	B-NP	O	B-group-EF-2
blockers	blocker	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Information	Information	NN	B-NP	O	O
on	on	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
usage	usage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atenolol	atenolol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand
is	be	VBZ	B-VP	O	O
limited	limit	VBN	B-ADJP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
TIMI	TIMI	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
II	II	CD	B-NP	O	O
,	,	,	O	O	O
ISIS	ISIS	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
2	2	CD	B-NP	I-protein	O
,	,	,	O	O	O
currently	currently	RB	B-ADVP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
suggest	suggest	VB	I-VP	O	O
any	any	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
infarction	infarction	NN	I-NP	O	O
setting	setting	NN	I-NP	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anaphylactic	anaphylactic	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allergens	allergen	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
severe	severe	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
on	on	IN	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
,	,	,	O	O	O
either	either	CC	O	O	O
accidental	accidental	JJ	B-ADJP	O	O
,	,	,	I-ADJP	O	O
diagnostic	diagnostic	JJ	I-ADJP	O	O
or	or	CC	I-ADJP	O	O
therapeutic	therapeutic	JJ	I-ADJP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
unresponsive	unresponsive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
the	the	DT	B-NP	O	O
allergic	allergic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Albuterol	Albuterol	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
STRATTERA	STRATTERA	NN	I-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
systemically	systemically	RB	B-NP	O	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	B-VP	O	O
(	(	(	O	O	O
oral	oral	JJ	B-NP	O	O
or	or	CC	O	O	O
intravenous	intravenous	JJ	B-ADJP	O	O
)	)	)	O	O	O
albuterol	albuterol	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
beta2	beta2	NN	I-NP	O	B-group
agonists	agonist	NNS	I-NP	O	E-group
)	)	)	O	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
albuterol	albuterol	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

CYP2D6	CYP2D6	NN	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
-	-	:	O	O	O
Atomoxetine	Atomoxetine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	B-protein	O
pathway	pathway	NN	I-NP	O	O
to	to	TO	B-PP	O	O
4	4	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
hydroxyatomoxetine	hydroxyatomoxetine	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

In	In	IN	B-PP	O	O
EMs	EM	NNS	B-NP	O	O
,	,	,	O	O	O
selective	selective	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	O	O
increase	increase	NN	I-NP	O	O
atomoxetine	atomoxetine	NN	I-NP	O	S-drug
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
exposures	exposure	NNS	B-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
PMs	PM	NNS	B-NP	B-cell_type	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STRATTERA	STRATTERA	NN	B-NP	O	S-brand-AD-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	I-protein	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
EM	EM	NN	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-ME-1
or	or	CC	I-NP	O	O
fluoxetine	fluoxetine	NN	I-NP	O	S-drug-ME-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atomoxetine	atomoxetine	NN	B-NP	O	S-drug-ME-2
is	be	VBZ	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
to	to	TO	B-PP	O	O
8	8	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
and	and	CC	O	O	O
Css	Css	NN	B-NP	B-protein	O
,	,	,	O	O	O
max	max	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
about	about	RB	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
4	4	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
fold	fold	RB	I-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
atomoxetine	atomoxetine	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	I-protein	O
to	to	TO	B-PP	O	O
PMs	PM	NNS	B-NP	B-cell_type	O
will	will	MD	B-VP	O	O
not	not	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atomoxetine	atomoxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Pressor	Pressor	NN	B-NP	O	O
agents	agent	NNS	I-NP	O	O
-	-	:	O	O	O
Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
possible	possible	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
STRATTERA	STRATTERA	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
pressor	pressor	NN	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
class	class	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
fibric	fibric	JJ	B-NP	O	B-group
acid	acid	NN	I-NP	O	I-group
derivatives	derivative	NNS	I-NP	O	E-group
,	,	,	O	O	O
niacin	niacin	NN	B-NP	O	S-drug
(	(	(	O	O	O
nicotinic	nicotinic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
)	)	)	O	O	O
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
azole	azole	NN	B-NP	O	B-group
antifungals	antifungal	NNS	I-NP	O	E-group
.	.	.	O	O	O

Antacid	Antacid	NN	B-NP	O	S-group
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
Maalox	Maalox	NN	I-NP	O	B-brand-ME-2
TC	TC	NN	I-NP	O	E-brand-ME-2
suspension	suspension	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug
decreased	decrease	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
35	35	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
LDL	LDL	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
C	C	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

Antipyrine	Antipyrine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Because	Because	IN	B-SBAR	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	S-drug
metabolized	metabolize	VBN	B-VP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

Colestipol	Colestipol	NN	B-NP	O	S-drug
:	:	:	O	O	O
Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug
decreased	decrease	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
colestipol	colestipol	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
atorvastatin	atorvastatin	NN	I-NP	O	S-drug-ME-2
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
LDL	LDL	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
C	C	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
colestipol	colestipol	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
than	than	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
either	either	CC	O	O	O
drug	drug	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Atorvastatin	Atorvastatin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
LDL	LDL	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
C	C	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-2
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
,	,	,	O	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
appropriately	appropriately	RB	B-ADVP	O	O
.	.	.	O	O	O

Erythromycin	Erythromycin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group-ME-2
increased	increase	VBD	B-VP	O	O
AUC	AUC	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug-ME-2
estradiol	estradiol	NN	I-NP	O	E-drug-ME-2
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
increases	increase	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
selecting	select	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group-AD-1
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
woman	woman	NN	I-NP	B-protein	O
taking	take	VBG	B-VP	I-protein	O
atorvastatin	atorvastatin	NN	B-NP	I-protein	S-drug-AD-2
.	.	.	O	O	O

Warfarin	Warfarin	NNP	B-NP	O	S-drug
:	:	:	O	O	O
Atorvastatin	Atorvastatin	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
chronic	chronic	JJ	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Endocrine	Endocrine	JJ	B-NP	O	O
Function	Function	NN	I-NP	O	O
HMG	HMG	NN	I-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
CoA	CoA	NN	I-NP	O	I-group
reductase	reductase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
cholesterol	cholesterol	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
and	and	CC	O	O	O
theoretically	theoretically	RB	B-VP	O	O
might	might	MD	I-VP	O	O
blunt	blunt	VB	I-VP	O	O
adrenal	adrenal	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
gonadal	gonadal	JJ	B-NP	O	O
steroid	steroid	NN	I-NP	O	O
production	production	NN	I-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
basal	basal	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
cortisol	cortisol	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
or	or	CC	O	O	O
impair	impair	NN	B-NP	O	O
adrenal	adrenal	JJ	I-NP	O	O
reserve	reserve	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	B-NP	O	I-group
CoA	CoA	NN	I-NP	O	I-group
reductase	reductase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
on	on	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
fertility	fertility	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
numbers	number	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
if	if	IN	B-PP	O	O
any	any	DT	B-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pituitary	pituitary	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
gonadal	gonadal	JJ	I-NP	O	O
axis	axis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
premenopausal	premenopausal	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
HMG	HMG	NN	I-NP	B-protein	B-group-AD-1
-	-	HYPH	B-NP	O	I-group-AD-1
CoA	CoA	NN	I-NP	B-protein	I-group-AD-1
reductase	reductase	NN	I-NP	I-protein	I-group-AD-1
inhibitor	inhibitor	NN	I-NP	O	E-group-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
endogenous	endogenous	JJ	B-NP	O	O
steroid	steroid	NN	I-NP	O	O
hormones	hormone	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

CNS	CNS	NNP	B-NP	O	O
Toxicity	Toxicity	NNP	I-NP	O	O
Brain	Brain	NNP	I-NP	O	O
hemorrhage	hemorrhage	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
female	female	JJ	I-NP	O	O
dog	dog	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
120	120	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Brain	Brain	NN	B-NP	O	O
hemorrhage	hemorrhage	NN	I-NP	O	O
and	and	CC	O	O	O
optic	optic	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
vacuolation	vacuolation	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
another	another	DT	B-NP	O	O
female	female	JJ	I-NP	O	O
dog	dog	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
sacrificed	sacrifice	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
moribund	moribund	NN	B-NP	O	O
condition	condition	NN	I-NP	O	O
after	after	IN	B-PP	O	O
11	11	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
escalating	escalate	VBG	B-VP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
280	280	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
approximately	approximately	RB	B-NP	O	O
16	16	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
area	area	NN	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
under	under	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
the	the	DT	B-NP	O	O
-	-	HYPH	I-NP	O	O
curve	curve	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
,	,	,	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
24	24	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
)	)	)	O	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
80	80	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
tonic	tonic	JJ	I-NP	O	O
convulsion	convulsion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
male	male	JJ	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
(	(	(	O	O	O
one	one	CD	B-NP	O	O
treated	treat	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
at	at	IN	B-PP	O	O
120	120	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
lesions	lesion	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
after	after	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
2	2	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
6	6	CD	B-NP	O	O
to	to	TO	B-PP	O	O
11	11	CD	B-NP	O	O
times	time	NNS	B-NP	O	O
(	(	(	O	O	O
mouse	mouse	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
8	8	CD	B-NP	O	O
to	to	TO	I-NP	O	O
16	16	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
(	(	(	O	O	O
rat	rat	NN	B-NP	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
24	24	CD	I-NP	O	O
)	)	)	O	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
80	80	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

CNS	CNS	NN	B-NP	B-protein	O
vascular	vascular	JJ	I-NP	O	O
lesions	lesion	NNS	I-NP	O	O
,	,	,	O	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
perivascular	perivascular	JJ	B-NP	B-cell_type	O
hemorrhages	hemorrhage	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
edema	edema	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
mononuclear	mononuclear	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
infiltration	infiltration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
perivascular	perivascular	JJ	B-NP	O	O
spaces	space	NNS	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
members	member	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
class	class	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
chemically	chemically	RB	I-NP	O	O
similar	similar	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
class	class	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
optic	optic	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
degeneration	degeneration	NN	I-NP	O	O
(	(	(	O	O	O
Wallerian	Wallerian	JJ	B-NP	O	O
degeneration	degeneration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
retinogeniculate	retinogeniculate	NN	B-NP	O	O
fibers	fiber	NNS	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
normal	normal	JJ	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
fashion	fashion	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
produced	produce	VBD	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
about	about	IN	B-NP	O	O
30	30	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
level	level	NN	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
recommended	recommended	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Atovaquone	Atovaquone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
(	(	(	O	O	O
99.9	99.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
MEPRON	MEPRON	NN	B-NP	O	S-brand
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
highly	highly	RB	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
narrow	narrow	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
indices	index	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
competition	competition	NN	B-NP	O	O
for	for	IN	B-PP	O	O
binding	bind	VBG	B-NP	B-DNA	O
sites	site	NNS	I-NP	I-DNA	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atovaquone	atovaquone	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
plasma	plasma	NN	I-NP	I-cell_type	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
(	(	(	O	O	O
15	15	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
nor	nor	CC	O	O	O
is	be	VBZ	O	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
affected	affect	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atovaquone	atovaquone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
MEPRON	MEPRON	NN	I-NP	O	S-brand-ME-2
Suspension	Suspension	NN	I-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
average	average	JJ	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
atovaquone	atovaquone	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Alternatives	Alternative	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PCP	PCP	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
MEPRON	MEPRON	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

Rifabutin	Rifabutin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
another	another	DT	B-NP	O	O
rifamycin	rifamycin	NN	I-NP	O	S-drug
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
structurally	structurally	RB	B-ADJP	O	O
similar	similar	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
possibly	possibly	RB	I-VP	O	O
have	have	VB	I-VP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
trials	trial	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
MEPRON	MEPRON	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
MEPRON	MEPRON	NN	B-NP	B-DNA	S-brand
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
or	or	CC	I-NP	O	O
assay	assay	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TRACRIUM	TRACRIUM	NN	B-NP	O	S-brand-EF-1
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
enflurane	enflurane	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O

isoflurane	isoflurane	NN	B-NP	O	S-drug
;	;	:	O	O	O

halothane	halothane	NN	B-NP	O	S-drug
;	;	:	O	O	O

certain	certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
aminoglycosides	aminoglycoside	NNS	I-NP	O	S-group
and	and	CC	I-NP	O	O
polymyxins	polymyxin	NNS	I-NP	O	S-group
;	;	:	O	O	O

lithium	lithium	NN	B-NP	O	S-drug
;	;	:	O	O	O

magnesium	magnesium	NN	B-NP	O	S-drug
salts	salt	NNS	I-NP	O	O
;	;	:	O	O	O

procainamide	procainamide	NN	B-NP	O	S-drug
;	;	:	O	O	O

Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TRACRIUM	TRACRIUM	NN	B-NP	O	S-brand-EF-1
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
enflurane	enflurane	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
isoflurane	isoflurane	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
halothane	halothane	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
certain	certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
aminoglycosides	aminoglycoside	NNS	I-NP	O	S-group-EF-2
and	and	CC	I-NP	O	O
polymyxins	polymyxin	NNS	I-NP	O	S-group-EF-2
;	;	:	O	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-EF-2
salts	salt	NNS	I-NP	O	O
;	;	:	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O
and	and	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
other	other	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
prior	prior	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-1
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
quickens	quicken	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
depth	depth	NN	I-NP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	B-protein	O
block	block	NN	I-NP	I-protein	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
TRACRIUM	TRACRIUM	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

TRACRIUM	TRACRIUM	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
until	until	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
recovered	recover	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-AD-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
block	block	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
atropine	atropine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
pralidoxime	pralidoxime	NN	I-NP	O	S-drug-EF-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atropinization	atropinization	NN	B-NP	O	O
(	(	(	O	O	O
flushing	flushing	NN	B-NP	O	O
,	,	,	O	O	O
mydriasis	mydriasis	NN	B-NP	O	O
,	,	,	O	O	O
tachycardia	tachycardia	NN	B-NP	O	O
,	,	,	O	O	O
dryness	dryness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mouth	mouth	NN	I-NP	O	O
and	and	CC	I-NP	O	O
nose	nose	NN	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
earlier	earlier	RBR	B-ADVP	O	O
than	than	IN	B-SBAR	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
than	than	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
atropine	atropine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
because	because	IN	B-SBAR	O	O
pralidoxime	pralidoxime	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atropine	atropine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
precautions	precaution	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
kept	keep	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mind	mind	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinesterase	anticholinesterase	NN	B-NP	B-protein	O
poisoning	poison	VBG	B-VP	O	O
although	although	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
bear	bear	VB	I-VP	O	O
directly	directly	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atropine	atropine	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
pralidoxime	pralidoxime	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-AD-1
are	be	VBP	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticholinesterases	anticholinesteras	NNS	I-NP	B-protein	S-group-AD-2
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	O
.	.	.	O	O	O

Auranofin	Auranofin	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
any	any	DT	B-NP	O	O
gold	gold	JJ	I-NP	O	B-group-AD-2
medication	medication	NN	I-NP	O	E-group-AD-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
Solganal	Solganal	JJ	B-NP	O	S-brand-AD-2
and	and	CC	I-NP	O	O
Myochrysine	Myochrysine	NN	I-NP	O	S-brand-AD-2
.	.	.	O	O	O

Auranofin	Auranofin	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
penicillamine	penicillamine	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
Depen	Depen	NN	B-NP	O	S-brand-AD-2
,	,	,	O	O	O
Cuprimine	Cuprimine	NN	B-NP	O	S-brand-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
another	another	DT	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
medication	medication	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
,	,	,	O	O	O
liver	liver	NN	B-NP	O	O
or	or	CC	O	O	O
kidney	kidney	NN	B-NP	O	O
diseases	disease	NNS	I-NP	O	O
,	,	,	O	O	O
recent	recent	JJ	B-NP	O	O
radiation	radiation	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
uncontrolled	uncontrolled	JJ	B-NP	O	O
diabetes	diabete	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
report	report	VB	I-VP	O	O
to	to	TO	B-PP	O	O
their	their	PRP$	B-NP	O	O
practitioners	practitioner	NNS	I-NP	O	O
any	any	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
rashes	rash	NNS	I-NP	O	O
,	,	,	O	O	O
itching	itch	VBG	B-VP	O	O
,	,	,	O	O	O
mouth	mouth	JJ	B-NP	O	O
sores	sore	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
unusual	unusual	JJ	B-NP	O	O
taste	taste	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
auranofin	auranofin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Gold	Gold	NNP	B-NP	O	S-group
is	be	VBZ	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
slowly	slowly	RB	B-ADVP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
.	.	.	O	O	O

Safety	Safety	NN	B-NP	O	O
and	and	CC	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
assessments	assessment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
Vidaza	Vidaza	NNP	B-NP	O	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O

MAO	MAO	NN	B-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
prolong	prolong	VB	B-VP	O	O
and	and	CC	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
central	central	JJ	I-NP	O	B-group-EF-2
nervous	nervous	JJ	I-NP	O	I-group-EF-2
system	system	NN	I-NP	O	I-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
crises	crisis	NNS	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
mecamylamine	mecamylamine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
veratrum	veratrum	NN	B-NP	O	B-drug-EF-1
alkaloids	alkaloid	NNS	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
sympathomimetics	sympathomimetic	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group-IN-1
-	-	HYPH	O	O	I-group-IN-1
adrenergic	adrenergic	JJ	B-NP	O	I-group-IN-1
blocking	block	VBG	I-NP	O	I-group-IN-1
agents	agent	NNS	I-NP	O	E-group-IN-1
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
sympathomimetics	sympathomimetic	NNS	B-NP	O	S-group-IN-2
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
ectopic	ectopic	JJ	I-NP	O	O
pacemaker	pacemaker	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
pseudoephedrine	pseudoephedrine	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group-ME-1
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pseudoephedrine	pseudoephedrine	NN	B-NP	O	S-drug-ME-M
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
kaolin	kaolin	NN	B-NP	O	S-drug-ME-2
decreases	decrease	VBZ	B-VP	O	O
it	it	PRP	B-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Allopurinol	Allopurinol	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
principal	principal	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
for	for	IN	B-PP	O	O
detoxification	detoxification	NN	B-NP	O	O
of	of	IN	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
allopurinol	allopurinol	NN	I-NP	O	S-drug-AD-2
concomitantly	concomitantly	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug
,	,	,	O	O	O
to	to	TO	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
3	3	CD	I-NP	O	O
to	to	TO	I-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
4	4	CD	I-NP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Agents	Agent	NNPS	I-NP	O	O
Affecting	Affect	VBG	I-NP	O	O
Myelopoesis	Myelopoesis	NN	I-NP	O	O
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
leukocyte	leukocyte	NN	B-NP	O	O
production	production	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
co	co	AFX	B-NP	O	B-brand
-	-	HYPH	I-NP	O	I-brand
trimoxazole	trimoxazole	NN	B-NP	O	E-brand
,	,	,	O	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
exaggerated	exaggerated	JJ	B-NP	O	O
leukopenia	leukopenia	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
recipients	recipient	NNS	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Angiotensln	Angiotensln	NN	B-NP	O	B-group
Converting	Convert	VBG	B-VP	O	I-group
Enzyme	Enzyme	NN	B-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	O	B-group-EF-1
converting	convert	VBG	B-VP	O	I-group-EF-1
enzyme	enzyme	NN	B-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
hypertension	hypertension	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
leukopenia	leukopenia	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
information	information	NN	I-NP	O	O
provided	provide	VBD	B-VP	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-EF-1
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
2	2	CD	B-NP	O	O
x	x	SYM	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
)	)	)	O	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
azithromycin	azithromycin	NN	I-NP	O	S-drug
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
for	for	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
liver	liver	NN	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
and	and	CC	O	O	O
hearing	hear	VBG	B-VP	O	O
impairment	impairment	NN	B-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
.	.	.	O	O	O

Azithromycin	Azithromycin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
prudent	prudent	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
practice	practice	NN	I-NP	O	O
dictates	dictate	VBZ	B-VP	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-AD-2
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
macrolides	macrolide	NNS	B-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
practice	practice	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug-ME-1
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
modest	modest	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
cetirizine	cetirizine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
didanosine	didanosine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug-ME-2
,	,	,	O	O	O
sildenafil	sildenafil	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
intravenous	intravenous	JJ	B-ADJP	O	O
and	and	CC	O	O	O
oral	oral	JJ	B-ADJP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
trimethoprim	trimethoprim	NN	B-NP	O	S-drug-ME-2
/	/	SYM	B-VP	O	O
sulfamethoxazole	sulfamethoxazole	NN	B-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug-ME-1
or	or	CC	I-NP	O	O
fluconazole	fluconazole	NN	I-NP	O	S-drug-ME-1
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
modest	modest	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
co	co	NN	B-NP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
above	above	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
listed	list	VBN	B-VP	O	O
below	below	IN	B-ADVP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
potential	potential	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Nonetheless	Nonetheless	RB	B-ADVP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
macrolide	macrolide	NN	B-NP	B-protein	B-group
products	product	NNS	I-NP	I-protein	E-group
.	.	.	O	O	O

Until	Until	IN	B-PP	O	O
further	further	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
developed	develop	VBN	I-VP	O	O
regarding	regard	VBG	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
:	:	:	O	O	O
Digoxin	Digoxin	NN	B-NP	O	S-drug
elevated	elevate	VBD	B-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Ergotamine	Ergotamine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
dihydroergotamine	dihydroergotamine	NN	I-NP	O	S-drug
acute	acute	JJ	I-NP	O	O
ergot	ergot	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
vasospasm	vasospasm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
dysesthesia	dysesthesia	NN	I-NP	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
hexobarbital	hexobarbital	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Laboratory	Laboratory	NNP	B-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Repeat	Repeat	NN	B-NP	O	O
Treatment	Treatment	NN	I-NP	O	O
Studies	Study	NNS	I-NP	O	O
evaluating	evaluate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
courses	course	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Zmax	Zmax	NN	B-NP	B-protein	S-brand
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Azlocillin	Azlocillin	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
amikacin	amikacin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
netilmicin	netilmicin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
tobramycin	tobramycin	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Injection	Injection	NN	B-NP	O	O
There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
inadequate	inadequate	JJ	B-NP	O	O
systematic	systematic	JJ	I-NP	O	O
experience	experience	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
baclofen	baclofen	NN	B-NP	O	S-drug
injection	injection	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
predict	predict	VB	I-VP	O	O
specific	specific	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
attributed	attribute	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
combined	combine	VBN	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
baclofen	baclofen	NN	B-NP	O	S-drug-EF-1
injection	injection	NN	I-NP	O	O
and	and	CC	O	O	O
epidural	epidural	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug-EF-2
include	include	VBP	B-VP	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	I-NP	O	O
dyspnea	dyspnea	NN	I-NP	O	O
.	.	.	O	O	O

SIDE	SIDE	NN	B-NP	O	O
EFFECTS	EFFECTS	NNS	I-NP	O	O
(	(	(	O	O	O
KEMSTRO	KEMSTRO	NN	B-NP	O	S-brand
)	)	)	O	O	O
The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
baclofen	baclofen	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
transient	transient	JJ	B-NP	O	O
drowsiness	drowsiness	NN	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
63	63	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
controlled	control	VBN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
175	175	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
transient	transient	JJ	B-NP	O	O
drowsiness	drowsiness	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
63	63	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
those	those	DT	B-NP	O	O
receiving	receive	VBG	I-NP	O	O
baclofen	baclofen	NN	I-NP	O	S-drug
tablets	tablet	NNS	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
36	36	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
common	common	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
dizziness	dizziness	NN	B-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
15	15	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
weakness	weakness	NN	B-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
15	15	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
fatigue	fatigue	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Others	Other	NNS	B-NP	O	O
reported	report	VBD	B-VP	O	O
:	:	:	O	O	O
Neuropsychiatric	Neuropsychiatric	JJ	B-ADJP	O	O
:	:	:	O	O	O
Confusion	Confusion	NN	B-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
11	11	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
headache	headache	NN	B-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
insomnia	insomnia	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
7	7	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
,	,	,	O	O	O
rarely	rarely	RB	B-ADVP	O	O
,	,	,	O	O	O
euphoria	euphoria	NN	B-NP	O	O
,	,	,	O	O	O
excitement	excitement	NN	B-NP	O	O
,	,	,	O	O	O
depression	depression	NN	B-NP	O	O
,	,	,	O	O	O
hallucinations	hallucination	NNS	B-NP	O	O
,	,	,	O	O	O
paresthesia	paresthesia	NN	B-NP	O	O
,	,	,	O	O	O
muscle	muscle	NN	B-NP	O	O
pain	pain	NN	I-NP	O	O
,	,	,	O	O	O
tinnitus	tinnitus	NN	B-NP	O	O
,	,	,	O	O	O
slurred	slur	VBD	B-VP	O	O
speech	speech	NN	B-NP	O	O
,	,	,	O	O	O
coordination	coordination	NN	B-NP	O	O
disorder	disorder	NN	I-NP	O	O
,	,	,	O	O	O
tremor	tremor	NN	B-NP	O	O
,	,	,	O	O	O
rigidity	rigidity	NN	B-NP	O	O
,	,	,	O	O	O
dystonia	dystonia	NN	B-NP	O	O
,	,	,	O	O	O
ataxia	ataxia	NN	B-NP	O	O
,	,	,	O	O	O
blurred	blur	VBD	B-VP	O	O
vision	vision	NN	B-NP	O	O
,	,	,	O	O	O
nystagmus	nystagmus	NN	B-NP	O	O
,	,	,	O	O	O
strabismus	strabismus	NN	B-NP	O	O
,	,	,	O	O	O
miosis	miosis	NN	B-NP	O	O
,	,	,	O	O	O
mydriasis	mydriasis	NN	B-NP	O	O
,	,	,	O	O	O
diplopia	diplopia	NN	B-NP	O	O
,	,	,	O	O	O
dysarthria	dysarthria	NN	B-NP	O	O
,	,	,	O	O	O
epileptic	epileptic	JJ	B-NP	O	O
seizure	seizure	NN	I-NP	O	O
.	.	.	O	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O	O
:	:	:	O	O	O
Hypotension	Hypotension	NN	B-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
9	9	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Rare	Rare	NN	B-NP	O	O
instances	instance	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dyspnea	dyspnea	NN	B-NP	O	O
,	,	,	O	O	O
palpitation	palpitation	NN	B-NP	O	O
,	,	,	O	O	O
chest	chest	NN	B-NP	O	O
pain	pain	NN	I-NP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
.	.	.	O	O	O

Gastrointestinal	Gastrointestinal	NNP	B-NP	O	O
:	:	:	O	O	O
Nausea	Nausea	NNP	B-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
12	12	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
constipation	constipation	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
,	,	,	O	O	O
rarely	rarely	RB	B-ADVP	O	O
,	,	,	O	O	O
dry	dry	JJ	B-NP	O	O
mouth	mouth	NN	I-NP	O	O
,	,	,	O	O	O
anorexia	anorexia	NN	B-NP	O	O
,	,	,	O	O	O
taste	taste	NN	B-NP	O	O
disorder	disorder	NN	I-NP	O	O
,	,	,	O	O	O
abdominal	abdominal	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	O
,	,	,	O	O	O
vomiting	vomiting	NN	B-NP	O	O
,	,	,	O	O	O
diarrhea	diarrhea	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
positive	positive	JJ	B-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
occult	occult	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
in	in	IN	B-PP	O	O
stool	stool	NN	B-NP	O	O
.	.	.	O	O	O

Genitourinary	Genitourinary	JJ	B-ADJP	O	O
:	:	:	O	O	O
Urinary	Urinary	JJ	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
,	,	,	O	O	O
rarely	rarely	RB	B-ADVP	O	O
,	,	,	O	O	O
enuresis	enuresis	NN	B-NP	O	O
,	,	,	O	O	O
urinary	urinary	JJ	B-NP	O	O
retention	retention	NN	I-NP	O	O
,	,	,	O	O	O
dysuria	dysuria	NN	B-NP	O	O
,	,	,	O	O	O
impotence	impotence	NN	B-NP	O	O
,	,	,	O	O	O
inability	inability	NN	B-NP	O	O
to	to	TO	B-VP	O	O
ejaculate	ejaculate	VB	I-VP	O	O
,	,	,	O	O	O
nocturia	nocturia	NN	B-NP	O	O
,	,	,	O	O	O
hematuria	hematuria	NN	B-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-ADJP	O	O
:	:	:	O	O	O
Instances	Instance	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
rash	rash	NN	B-NP	O	O
,	,	,	O	O	O
pruritus	pruritus	NN	B-NP	O	O
,	,	,	O	O	O
ankle	ankle	NN	B-NP	O	O
edema	edema	NN	I-NP	O	O
,	,	,	O	O	O
excessive	excessive	JJ	B-NP	O	O
perspiration	perspiration	NN	I-NP	O	O
,	,	,	O	O	O
weight	weight	NN	B-NP	O	O
gain	gain	NN	I-NP	O	O
,	,	,	O	O	O
nasal	nasal	JJ	B-NP	O	O
congestion	congestion	NN	I-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
and	and	CC	O	O	O
genitourinary	genitourinary	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
underlying	underlie	VBG	I-NP	O	O
disease	disease	NN	I-NP	O	O
rather	rather	RB	B-CONJP	O	O
than	than	IN	I-CONJP	O	O
to	to	TO	B-PP	O	O
drug	drug	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
abnormal	abnormal	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
baclofen	baclofen	NN	B-NP	O	S-drug
:	:	:	O	O	O
increased	increase	VBN	B-NP	O	O
SGOT	SGOT	NN	I-NP	O	O
,	,	,	O	O	O
elevated	elevated	JJ	B-NP	O	O
alkaline	alkaline	NN	I-NP	B-protein	O
phosphatase	phosphatase	NN	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
elevation	elevation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
sugar	sugar	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
experience	experience	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
seen	see	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
KEMSTROTM	KEMSTROTM	NN	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
seen	see	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
baclofen	baclofen	NN	B-NP	O	S-drug
tablets	tablet	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
COLAZAL	COLAZAL	NN	B-NP	O	S-brand
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
orally	orally	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
could	could	MD	B-VP	O	O
,	,	,	O	O	O
theoretically	theoretically	RB	B-ADVP	O	O
,	,	,	O	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mesalamine	mesalamine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
colon	colon	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
Simulect	Simulect	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
triple	triple	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
immunosuppression	immunosuppression	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
either	either	CC	O	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
mycophenolate	mycophenolate	NN	B-NP	O	B-drug
mofetil	mofetil	NN	I-NP	O	E-drug
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
Simulect	Simulect	NN	B-NP	O	S-brand
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
triple	triple	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
.	.	.	O	O	O

Pharmacokinetics	Pharmacokinetic	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Total	Total	JJ	B-NP	O	O
body	body	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Simulect	Simulect	NN	B-NP	O	S-brand-ME-1
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
22	22	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
51	51	CD	B-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
mycophenolate	mycophenolate	NN	I-NP	O	B-drug-ME-2
mofetil	mofetil	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
consisting	consist	VBG	B-VP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
USP	USP	NN	B-NP	B-protein	O
(	(	(	O	O	O
MODIFIED	MODIFIED	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
.	.	.	O	O	O

Nonetheless	Nonetheless	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
Simulect	Simulect	NN	I-NP	O	S-brand
clearance	clearance	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug
(	(	(	O	O	O
12	12	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
57	57	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
h	h	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
mycophenolate	mycophenolate	NN	B-NP	O	B-drug
mofetil	mofetil	NN	I-NP	O	E-drug
(	(	(	O	O	O
7	7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
54	54	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
extend	extend	VB	I-VP	O	O
outside	outside	IN	B-PP	O	O
the	the	DT	B-NP	O	O
range	range	NN	I-NP	O	O
observed	observe	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
dual	dual	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
78	78	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
medications	medication	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Simulect	Simulect	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
:	:	:	O	O	O
ATG	ATG	NN	B-NP	O	O
/	/	SYM	O	O	O
ALG	ALG	NN	B-NP	O	O
,	,	,	O	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
mycophenolate	mycophenolate	NN	B-NP	O	B-drug
mofetil	mofetil	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
muromonab	muromonab	NN	B-NP	B-protein	B-drug
-	-	HYPH	B-NP	O	I-drug
CD3	CD3	NN	I-NP	B-protein	E-drug
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
REGRANEX	REGRANEX	NN	B-NP	O	S-brand
Gel	Gel	NN	I-NP	O	O
interacts	interact	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
topical	topical	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
applied	apply	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
ulcer	ulcer	NN	I-NP	B-DNA	O
site	site	NN	I-NP	I-DNA	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
REGRANEX	REGRANEX	NN	B-NP	O	S-brand
Gel	Gel	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
topical	topical	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Albuterol	Albuterol	NNP	B-NP	O	S-drug
,	,	,	O	O	O
Antihistamines	Antihistamines	NNP	B-NP	O	S-group
,	,	,	O	O	O
antidiabetic	antidiabetic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
digitalis	digitalis	NN	B-NP	O	S-group
.	.	.	O	O	O

Diuretics	Diuretic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
diuretic	diuretic	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
recently	recently	RB	I-VP	O	O
instituted	institute	VBN	I-VP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
experience	experience	VB	I-VP	O	O
an	an	DT	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Lotensin	Lotensin	NN	B-NP	B-protein	S-brand-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotensive	hypotensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Lotensin	Lotensin	NN	B-NP	B-protein	S-brand
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
either	either	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-AD-1
or	or	CC	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
salt	salt	NN	I-NP	O	O
intake	intake	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Lotensin	Lotensin	NN	B-NP	B-protein	S-brand-AD-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
possible	possible	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
starting	start	VBG	I-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Potassium	Potassium	NN	B-NP	O	S-drug
Supplements	Supplement	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
Potassium	Potassium	NN	I-NP	O	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
Sparing	Spar	VBG	B-VP	B-protein	I-group-EF-1
Diuretics	Diuretics	NNP	B-NP	I-protein	E-group-EF-1
Lotensin	Lotensin	NNP	I-NP	I-protein	O
can	can	MD	B-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
potassium	potassium	NN	B-NP	O	O
loss	loss	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Potassium	Potassium	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
(	(	(	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug
,	,	,	O	O	O
amiloride	amiloride	NN	B-NP	O	S-drug
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
others	other	NNS	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
potassium	potassium	NN	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
frequently	frequently	RB	B-ADVP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Anticoagulants	Anticoagulant	NNS	I-NP	O	S-group
Interaction	Interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
acenocoumarol	acenocoumarol	NN	I-NP	O	S-drug
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
identify	identify	VB	I-VP	O	O
any	any	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
or	or	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ACE	ACE	NN	B-NP	O	B-group-ME-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-ME-1
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
frequent	frequent	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-EF-1
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
toxicity	toxicity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
No	No	NNP	I-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
when	when	WRB	B-ADVP	O	O
Lotensin	Lotensin	NN	B-NP	B-protein	S-brand
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	O	O	O
chlorthalidone	chlorthalidone	NN	B-NP	O	S-drug
,	,	,	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
atenolol	atenolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Lotensin	Lotensin	NNP	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	B-protein	B-group
-	-	HYPH	B-NP	I-protein	I-group
channel	channel	NN	I-NP	I-protein	I-group
-	-	HYPH	B-VP	O	I-group
blocking	block	VBG	B-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
hydralazine	hydralazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Benazepril	Benazepril	NNP	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
like	like	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
ACE	ACE	NN	I-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
had	have	VBN	I-VP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	B-NP	O	I-group-EF-2
adrenergic	adrenergic	JJ	I-NP	O	I-group-EF-2
blockers	blocker	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
presumably	presumably	RB	B-ADVP	O	O
because	because	IN	B-SBAR	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
lower	low	JJR	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
by	by	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
parts	part	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renin	renin	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
angiotensin	angiotensin	NN	I-NP	O	O
system	system	NN	I-NP	O	O

May	May	MD	O	O	O
interact	interact	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
colestipol	colestipol	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
use	use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
from	from	IN	B-PP	O	O
working	work	VBG	B-VP	O	O
properly	properly	RB	B-ADVP	O	O
;	;	:	O	O	O

Bentiromide	Bentiromide	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Tylenol	Tylenol	NN	B-NP	O	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
chloramphenicol	chloramphenicol	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Chloromycetin	Chloromycetin	NN	B-NP	B-protein	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
benzocaine	benzocaine	NN	B-NP	O	S-drug-IN-2
and	and	CC	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
para	para	AFX	O	O	B-drug_n-IN-2
-	-	HYPH	O	O	I-drug_n-IN-2
aminobenzoic	aminobenzoic	JJ	B-NP	O	I-drug_n-IN-2
acid	acid	NN	I-NP	O	E-drug_n-IN-2
(	(	(	O	O	O
PABA	PABA	NN	B-NP	O	S-drug_n-IN-2
)	)	)	O	O	O
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
sunscreens	sunscreen	NNS	B-NP	O	O
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
multivitamins	multivitamin	NNS	I-NP	O	S-group-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Pronestyl	Pronestyl	NN	B-NP	O	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group-IN-2
(	(	(	O	O	O
sulfa	sulfa	NN	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
thiazide	thiazide	NN	B-NP	O	B-group-IN-2
diuretics	diuretic	NNS	I-NP	O	E-group-IN-2
(	(	(	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
test	test	NN	I-NP	O	O
period	period	NN	I-NP	O	O
will	will	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
test	test	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
pancreatic	pancreatic	JJ	B-NP	O	O
supplements	supplement	NNS	I-NP	O	O
(	(	(	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pancreatic	pancreatic	JJ	B-NP	O	O
supplements	supplement	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
give	give	VB	I-VP	O	O
false	false	JJ	B-NP	O	O
test	test	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

May	May	MD	B-VP	O	O
interact	interact	VBP	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
creams	cream	NNS	I-NP	O	O
,	,	,	O	O	O
lotions	lotion	NNS	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
skin	skin	NN	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
placed	place	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
areas	area	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
your	your	PRP$	B-NP	O	O
skin	skin	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
using	use	VBG	I-VP	O	O
bentoquatam	bentoquatam	NN	B-NP	O	S-drug_n
.	.	.	O	O	O

No	No	DT	B-NP	O	O
information	information	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

Hypertensive	Hypertensive	JJ	B-NP	O	O
crises	crisis	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
resulted	result	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-1
amines	amine	NNS	I-NP	O	E-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
within14	within14	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
following	follow	VBG	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group-EF-2
oxidase	oxidase	NN	I-NP	I-protein	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

DIDREX	DIDREX	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-AD-2
stimulants	stimulant	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihypertensives	antihypertensive	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	O
alkalinizing	alkalinize	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
increase	increase	VBP	B-VP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
excretion	excretion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	B-drug-ME-1
acidifying	acidify	VBG	I-NP	O	E-drug-ME-1
agents	agent	NNS	I-NP	O	O
decrease	decrease	VBP	B-VP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
increase	increase	VBP	B-VP	O	O
excretion	excretion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-ME-2
.	.	.	O	O	O

Benzthiazide	Benzthiazide	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
blood	blood	NN	B-NP	O	B-group-IN-2
thinners	thinner	NNS	I-NP	O	O
,	,	,	O	O	O
decongestant	decongestant	JJ	B-NP	O	B-group-IN-2
drugs	drug	NNS	I-NP	O	E-group-IN-2
(	(	(	O	O	O
allergy	allergy	NN	B-NP	O	O
,	,	,	O	O	O
cold	cold	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sinus	sinus	NN	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
diabetic	diabetic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-IN-2
like	like	IN	B-PP	O	O
Aleve	Aleve	NNP	B-NP	O	S-brand-IN-2
or	or	CC	I-NP	O	O
Ibuprofen	Ibuprofen	NNP	I-NP	O	S-drug-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
high	high	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

Antipsychotic	Antipsychotic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
or	or	CC	O	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
;	;	:	O	O	O

tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
.	.	.	O	O	O

Nitrates	Nitrate	NNS	B-NP	O	S-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Bepridil	Bepridil	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
short	short	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
acting	act	VBG	I-NP	O	O
nitrates	nitrate	NNS	I-NP	O	S-group
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
safely	safely	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
angina	angina	NN	I-NP	O	O
pectoris	pectoris	NN	I-NP	O	O
.	.	.	O	O	O

Sublingual	Sublingual	JJ	B-NP	O	O
nitroglycerin	nitroglycerin	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
angina	angina	NN	I-NP	O	O
attacks	attack	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
Bepridil	Bepridil	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group
-	-	HYPH	O	O	I-group
blocking	block	VBG	B-VP	O	I-group
Agents	Agent	NNPS	B-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Bepridil	Bepridil	NN	B-NP	O	S-drug
and	and	CC	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	O	O	I-group
blocking	block	VBG	B-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
angina	angina	NN	I-NP	O	O
.	.	.	O	O	O

Available	Available	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
predict	predict	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
on	on	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
or	or	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
controlled	controlled	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
bepridil	bepridil	NN	B-NP	O	B-drug-ME-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-1
either	either	CC	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
(	(	(	O	O	O
one	one	CD	B-NP	O	O
study	study	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
modest	modest	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
,	,	,	O	O	O
about	about	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
two	two	CD	B-NP	O	O
studies	study	NNS	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Limited	Limit	VBN	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
angina	angina	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
bepridil	bepridil	NN	I-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
and	and	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
discernible	discernible	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Available	Available	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
neither	neither	DT	B-NP	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
rule	rule	VB	I-VP	O	O
out	out	RP	B-PRT	O	O
possible	possible	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
nor	nor	CC	O	O	O
other	other	JJ	B-NP	O	O
possible	possible	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
(	(	(	O	O	O
Also	Also	RB	B-VP	O	O
see	see	VB	I-VP	O	O
WARNINGS	WARNINGS	NNP	B-NP	O	O
Congestive	Congestive	NNP	I-NP	O	O
Heart	Heart	NNP	I-NP	O	O
Failure	Failure	NNP	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Hypoglycemics	Hypoglycemic	NNS	I-NP	O	S-group
:	:	:	O	O	O
Bepridil	Bepridil	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
safely	safely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
significantly	significantly	RB	B-VP	O	O
lowering	lower	VBG	I-VP	O	O
their	their	PRP$	B-NP	O	O
blood	blood	NN	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
or	or	CC	O	O	O
altering	alter	VBG	B-VP	O	O
their	their	PRP$	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

General	General	NNP	B-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
Certain	Certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potentially	potentially	RB	B-NP	O	O
serious	serious	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
bepridil	bepridil	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
general	general	JJ	B-ADJP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
are	be	VBP	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
activities	activity	NNS	I-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
bepridil	bepridil	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
anti	anti	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
arrhythmic	arrhythmic	JJ	B-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
procainamide	procainamide	NN	I-NP	O	S-drug
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
and	and	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
depressants	depressant	NNS	I-NP	O	E-group
.	.	.	O	O	O

Anti	Anti	AFX	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
arrhythmics	arrhythmic	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
anti	anti	AFX	I-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
depressants	depressant	NNS	B-NP	O	E-group-EF-1
could	could	MD	B-VP	O	O
exaggerate	exaggerate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
observed	observe	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
bepridil	bepridil	NN	B-NP	O	B-drug-EF-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	B-group-EF-1
glycosides	glycoside	NNS	I-NP	O	E-group-EF-1
could	could	MD	B-VP	O	O
exaggerate	exaggerate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
depression	depression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AV	AV	NN	B-NP	O	O
nodal	nodal	JJ	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
observed	observe	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
bepridil	bepridil	NN	B-NP	O	B-drug-EF-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

APRD00513_IN	APRD00513_IN	NN	B-NP	B-protein	O
,	,	,	O	O	O
txt	txt	NN	B-NP	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Kerlone	Kerlone	NNP	B-NP	O	S-brand
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
its	its	PRP$	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
:	:	:	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
chlorthalidone	chlorthalidone	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Kerlone	Kerlone	NNP	B-NP	O	S-brand
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
warfarin	warfarin	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
not	not	RB	O	O	O
to	to	TO	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Catecholamine	Catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-drug-EF-2
-	-	HYPH	B-PP	O	I-drug-EF-2
blocking	block	VBG	B-NP	O	E-drug-EF-2
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
receptor	receptor	NN	I-NP	O	I-group
blocking	block	VBG	B-VP	O	I-group
agent	agent	NN	B-NP	O	E-group
plus	plus	CC	O	O	O
a	a	DT	B-NP	O	O
catecholamine	catecholamine	NN	I-NP	O	O
depletor	depletor	NN	I-NP	O	O
should	should	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
or	or	CC	O	O	O
marked	marked	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
vertigo	vertigo	RB	B-ADVP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
postural	postural	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

Should	Should	MD	O	O	O
it	it	PRP	B-NP	O	O
be	be	VB	B-VP	O	O
decided	decide	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
therapy	therapy	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
beta	beta	SYM	B-NP	O	B-group-AD-1
-	-	HYPH	B-NP	O	I-group-AD-1
blockers	blocker	NNS	I-NP	O	E-group-AD-1
and	and	CC	O	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-AD-2
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
blocker	blocker	NN	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
slowly	slowly	RB	B-ADVP	O	O
over	over	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gradual	gradual	JJ	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Literature	Literature	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group-AD-1
antagonists	antagonist	NNS	I-NP	O	E-group-AD-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-AD-2
-	-	HYPH	B-PP	O	I-group-AD-2
adrenergic	adrenergic	JJ	B-NP	O	I-group-AD-2
blocking	block	VBG	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
when	when	WRB	B-ADVP	O	O
heart	heart	NN	B-NP	O	O
function	function	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Hypotension	Hypotension	NN	B-NP	O	O
,	,	,	O	O	O
AV	AV	NN	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
failure	failure	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-1
-	-	HYPH	B-PP	O	I-group-EF-1
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-1
blocking	block	VBG	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
when	when	WRB	B-ADVP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
calcium	calcium	NN	I-NP	O	B-group-EF-2
antagonist	antagonist	NN	I-NP	O	E-group-EF-2
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
.	.	.	O	O	O

Hypotension	Hypotension	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
likely	likely	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
occur	occur	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group
antagonist	antagonist	NN	I-NP	O	E-group
were	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
dihydropyridine	dihydropyridine	NN	I-NP	O	B-group
derivative	derivative	NN	I-NP	O	E-group
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
and	and	CC	O	O	O
AV	AV	NN	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
complete	complete	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
block	block	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
likely	likely	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug
.	.	.	O	O	O

Risk	Risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Anaphylactic	Anaphylactic	NNP	B-NP	O	O
Reaction	Reaction	NNP	I-NP	O	O
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
beta	beta	SYM	O	O	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
blockers	blocker	NNS	B-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
refractory	refractory	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anaphylactic	anaphylactic	JJ	B-NP	O	O
shock	shock	NN	I-NP	O	O
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
can	can	MD	B-VP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
modulation	modulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allergic	allergic	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
and	and	CC	O	O	O
lead	lead	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
severity	severity	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
frequency	frequency	NN	B-NP	O	O
of	of	IN	B-PP	O	O
attacks	attack	NNS	B-NP	O	O
.	.	.	O	O	O

Severe	Severe	JJ	B-NP	O	O
allergic	allergic	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
anaphylaxis	anaphylaxis	NN	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allergens	allergen	NNS	B-NP	O	O
either	either	CC	B-PP	O	O
by	by	IN	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
accidental	accidental	JJ	B-NP	O	O
contact	contact	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
with	with	IN	B-PP	O	O
diagnostic	diagnostic	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
while	while	IN	B-SBAR	O	O
receiving	receive	VBG	B-VP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
unresponsive	unresponsive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
allergic	allergic	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

Special	Special	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ganglion	ganglion	NN	B-NP	O	B-group
blocking	block	VBG	B-VP	O	I-group
compounds	compound	NNS	B-NP	O	E-group
because	because	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
critical	critical	JJ	I-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Usually	Usually	RB	B-ADVP	O	O
,	,	,	O	O	O
severe	severe	JJ	B-NP	O	O
abdominal	abdominal	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
appear	appear	VBP	B-VP	O	O
before	before	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
such	such	PDT	B-NP	O	O
a	a	DT	I-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
neoplastic	neoplastic	JJ	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
Study	Study	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
colorectal	colorectal	JJ	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
irinotecan	irinotecan	NN	B-NP	O	S-drug
/	/	SYM	O	O	O
5	5	CD	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
FU	FU	NN	I-NP	O	E-drug
/	/	SYM	O	O	O
leucovorin	leucovorin	NN	B-NP	O	S-drug
(	(	(	O	O	O
bolus	bolus	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
IFL	IFL	NN	I-NP	B-protein	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
or	or	CC	I-PP	O	O
without	without	IN	I-PP	O	O
AVASTIN	AVASTIN	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Irinotecan	Irinotecan	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
bolus	bolus	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
IFL	IFL	NN	I-NP	B-protein	O
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
AVASTIN	AVASTIN	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
SN38	SN38	NN	B-NP	B-protein	S-drug_n
,	,	,	O	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
irinotecan	irinotecan	NN	B-NP	O	S-drug
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
average	average	JJ	B-NP	O	O
33	33	CD	I-NP	O	O
%	%	NN	I-NP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
bolus	bolus	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
IFL	IFL	NN	I-NP	B-protein	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
AVASTIN	AVASTIN	NN	B-NP	B-protein	S-brand
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
bolus	bolus	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
IFL	IFL	NN	I-NP	B-protein	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
Study	Study	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
bolus	bolus	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
IFL	IFL	NN	I-NP	B-protein	O
plus	plus	CC	O	I-protein	O
AVASTIN	AVASTIN	NN	B-NP	I-protein	S-brand
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Grade	Grade	NN	B-NP	B-protein	O
3	3	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
and	and	CC	I-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
high	high	JJ	B-NP	O	O
inter	inter	NN	I-NP	O	O
-	-	HYPH	O	O	O
patient	patient	NN	B-NP	O	O
variability	variability	NN	I-NP	O	O
and	and	CC	O	O	O
limited	limited	JJ	B-NP	O	O
sampling	sampling	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
SN38	SN38	NN	B-NP	B-protein	S-drug_n
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
irinotecan	irinotecan	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
AVASTIN	AVASTIN	NN	I-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
uncertain	uncertain	JJ	B-ADJP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
bexarotene	bexarotene	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Bexarotene	Bexarotene	NN	B-NP	O	S-drug
oxidative	oxidative	JJ	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
formed	form	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bexarotene	bexarotene	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
gemfibrozil	gemfibrozil	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
bexarotene	bexarotene	NN	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
bexarotene	bexarotene	NN	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Targretin	Targretin	NN	B-NP	O	S-brand-ME-1
capsules	capsule	NNS	I-NP	O	O
and	and	CC	O	O	O
gemfibrozil	gemfibrozil	NN	B-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
substantial	substantial	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bexarotene	bexarotene	NN	B-NP	O	S-drug
,	,	,	O	O	O
probably	probably	RB	B-ADVP	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
partially	partially	RB	B-ADJP	O	O
related	related	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibition	inhibition	NN	I-NP	O	O
by	by	IN	B-PP	O	O
gemfibrozil	gemfibrozil	NN	B-NP	O	S-drug
.	.	.	O	O	O

Under	Under	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
,	,	,	O	O	O
bexarotene	bexarotene	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
atorvastatin	atorvastatin	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gemfibrozil	gemfibrozil	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
Targretin	Targretin	NN	B-NP	O	S-brand-AD-2
capsules	capsule	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
Bezalip	Bezalip	NNP	B-NP	O	S-brand
or	or	CC	I-NP	O	O
Bezalip	Bezalip	NNP	I-NP	O	B-brand
retard	retard	NN	I-NP	O	E-brand
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
other	other	JJ	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
or	or	CC	O	O	O
substances	substance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
account	account	NN	B-NP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
Bezalip	Bezalip	NNP	I-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
Bezalip	Bezalip	NNP	I-NP	O	B-brand-EF-1
retard	retard	NN	I-NP	O	E-brand-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	B-group-EF-2
of	of	IN	B-PP	O	I-group-EF-2
the	the	DT	B-NP	O	I-group-EF-2
coumarin	coumarin	NN	I-NP	O	I-group-EF-2
type	type	NN	I-NP	O	E-group-EF-2
.	.	.	O	O	O

For	For	IN	B-PP	O	O
this	this	DT	B-NP	O	O
reason	reason	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
30	30	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
start	start	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Bezalip	Bezalip	NNP	B-NP	O	S-brand-AD-2
or	or	CC	I-NP	O	O
Bezalip	Bezalip	NNP	I-NP	O	S-brand-AD-2
retard	retard	NN	I-NP	O	O
and	and	CC	O	O	O
then	then	RB	B-VP	O	O
titrated	titrate	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
clotting	clotting	NN	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O

-	-	HYPH	O	O	O
The	The	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sulphonylureas	sulphonylureas	NN	B-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
Bezalip	Bezalip	NNP	B-NP	O	S-brand-EF-2
or	or	CC	I-NP	O	O
Bezalip	Bezalip	NNP	I-NP	O	B-brand-EF-2
retard	retard	NN	I-NP	O	E-brand-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
improved	improve	VBN	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
utilization	utilization	NN	I-NP	O	O
with	with	IN	B-PP	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
insulin	insulin	NN	B-NP	O	S-drug
requirement	requirement	NN	I-NP	O	O

-	-	HYPH	O	O	O
In	In	IN	B-PP	O	O
isolated	isolate	VBN	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
pronounced	pronounced	JJ	I-NP	O	O
though	though	IN	B-PP	O	O
reversible	reversible	JJ	B-ADJP	O	O
,	,	,	O	O	O
impairment	impairment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
accompanied	accompany	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
corresponding	corresponding	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
level	level	NN	I-NP	O	O
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
organ	organ	NN	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
immuno	immuno	AFX	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
suppressant	suppressant	NN	I-NP	O	E-group-EF-1
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
bezafibrate	bezafibrate	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Accordingly	Accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
event	event	NN	I-NP	O	O
of	of	IN	B-PP	O	O
relevant	relevant	JJ	B-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
laboratory	laboratory	NN	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
,	,	,	O	O	O
bezafibrate	bezafibrate	NN	B-NP	O	S-drug
should	should	MD	O	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
,	,	,	O	O	O
be	be	VB	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O

-	-	HYPH	O	O	O
When	When	WRB	B-ADVP	O	O
Bezalip	Bezalip	NNP	B-NP	O	S-brand-AD-1
or	or	CC	I-NP	O	O
Bezalip	Bezalip	NNP	I-NP	O	B-brand-AD-1
retard	retard	NN	I-NP	O	E-brand-AD-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
anion	anion	NN	B-NP	O	B-group-AD-2
-	-	HYPH	B-NP	O	I-group-AD-2
exchange	exchange	NN	I-NP	O	I-group-AD-2
resins	resin	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	I-NP	O	O
cholestryramine	cholestryramine	NN	I-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
maintained	maintain	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
medicines	medicine	NNS	I-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Bezalip	Bezalip	NNP	B-NP	O	S-brand
or	or	CC	I-NP	O	O
Bezalip	Bezalip	NNP	I-NP	O	B-brand
retard	retard	NN	I-NP	O	E-brand
is	be	VBZ	B-VP	O	O
impaired	impair	VBN	I-VP	O	O

-	-	HYPH	B-NP	O	O
Perhexiline	Perhexiline	NN	I-NP	O	B-drug-AD-1
hydrogen	hydrogen	NN	I-NP	O	I-drug-AD-1
maleate	maleate	NN	I-NP	O	E-drug-AD-1
or	or	CC	I-NP	O	O
MAO	MAO	NN	I-NP	B-protein	B-group-AD-1
-	-	HYPH	B-NP	O	I-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
with	with	IN	B-PP	O	O
hepatotoxic	hepatotoxic	JJ	B-NP	O	O
potential	potential	NN	I-NP	O	O
)	)	)	O	O	O
must	must	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Bezalip	Bezalip	NNP	B-NP	O	S-brand-AD-2
or	or	CC	I-NP	O	O
Bezalip	Bezalip	NNP	I-NP	O	B-brand-AD-2
retard	retard	NN	I-NP	O	E-brand-AD-2
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
CASODEX	CASODEX	NN	B-NP	O	S-brand-ME-1
can	can	MD	B-VP	O	O
displace	displace	VB	I-VP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-ME-2
anticoagulants	anticoagulant	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
from	from	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
protein	protein	NN	I-NP	B-DNA	O
-	-	HYPH	B-VP	I-DNA	O
binding	bind	VBG	B-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
if	if	IN	B-SBAR	O	O
CASODEX	CASODEX	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
started	start	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
already	already	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-AD-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
adjustment	adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group-AD-2
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
Information	Information	NN	I-NP	O	O
Provided	Provide	VBN	B-VP	O	O

Drug	Drug	NNP	B-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	S-group-EF-1
syndrome	syndrome	NN	I-NP	O	O
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
AKINETON	AKINETON	NN	B-NP	O	S-brand-EF-1
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
secondary	secondary	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
narcotic	narcotic	JJ	I-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
meperidine	meperidine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
phenothiazines	phenothiazine	NNS	I-NP	O	S-group-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
antipsychotics	antipsychotic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	S-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
quinidine	quinidine	NN	I-NP	O	S-drug-EF-2
salts	salt	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

ZEBETA	ZEBETA	NN	B-NP	B-protein	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
blocking	block	VBG	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
catecholamine	catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
guanethidine	guanethidine	NN	I-NP	O	S-drug-EF-1
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
added	add	VBN	I-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZEBETA	ZEBETA	NN	B-NP	B-protein	S-brand-EF-2
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
excessive	excessive	JJ	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sympathetic	sympathetic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
therapy	therapy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
ZEBETA	ZEBETA	NN	B-NP	B-protein	S-brand-AD-1
be	be	VB	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

ZEBETA	ZEBETA	NN	B-NP	B-protein	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
care	care	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
myocardial	myocardial	JJ	B-NP	O	B-group-AD-2
depressants	depressant	NNS	I-NP	O	E-group-AD-2
or	or	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
AV	AV	NN	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
certain	certain	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group-AD-2
antagonists	antagonist	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
particularly	particularly	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
phenylalkylamine	phenylalkylamine	NN	I-NP	O	S-group-AD-2
[	[	(	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-AD-2
]	]	)	O	O	O
and	and	CC	O	O	O
benzothiazepine	benzothiazepine	NN	B-NP	O	S-group-AD-2
[	[	(	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug-AD-2
]	]	)	I-NP	O	O
classes	class	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
antiarrhythmic	antiarrhythmic	JJ	B-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZEBETA	ZEBETA	NN	B-NP	B-protein	S-brand-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
shortened	shorten	VBN	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZEBETA	ZEBETA	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
initial	initial	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
modification	modification	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
generally	generally	RB	B-ADVP	O	O
not	not	RB	O	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
document	document	VBP	B-VP	O	O
no	no	RB	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZEBETA	ZEBETA	NN	B-NP	B-protein	S-brand
on	on	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Risk	Risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Anaphylactic	Anaphylactic	NNP	B-NP	O	O
Reaction	Reaction	NNP	I-NP	O	O
:	:	:	O	O	O
While	While	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
anaphylactic	anaphylactic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allergens	allergen	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
reactive	reactive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
,	,	,	O	O	O
either	either	CC	O	O	O
accidental	accidental	JJ	B-NP	O	O
,	,	,	I-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
or	or	CC	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
unresponsive	unresponsive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
allergic	allergic	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
an	an	DT	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	O	O	O
heart	heart	NN	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
using	use	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
steroid	steroid	NN	I-NP	O	S-group-AD-1
inhaler	inhaler	NN	I-NP	O	O
,	,	,	O	O	O
take	take	VBP	B-VP	O	O
bitolterol	bitolterol	NN	B-NP	O	S-drug-AD-M
first	first	RB	B-ADVP	O	O
and	and	CC	O	O	O
then	then	RB	O	O	O
wait	wait	VB	B-VP	O	O
about	about	IN	B-NP	O	O
15	15	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
steroid	steroid	NN	I-NP	O	S-group-AD-2
inhaler	inhaler	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
allows	allow	VBZ	B-VP	O	O
bitolterol	bitolterol	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-VP	O	O
open	open	VB	I-VP	O	O
air	air	NN	B-NP	O	O
passages	passage	NNS	I-NP	O	O
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steroid	steroid	NN	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Angiomax	Angiomax	NN	B-NP	O	S-brand
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
binding	bind	VBG	I-VP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
(	(	(	O	O	O
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
thrombin	thrombin	NN	B-NP	B-protein	O
)	)	)	O	O	O
or	or	CC	O	O	O
red	red	JJ	B-NP	B-cell_type	O
blood	blood	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
PTCA	PTCA	NN	B-NP	B-protein	O
/	/	SYM	B-NP	O	O
PCI	PCI	NN	I-NP	B-protein	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Angiomax	Angiomax	NN	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
thrombolytics	thrombolytic	NNS	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
glycoprotein	glycoprotein	NN	B-NP	B-protein	O
IIb	IIb	NN	I-NP	I-protein	O
/	/	SYM	B-NP	O	O
IIIa	IIIa	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
bleeding	bleed	VBG	I-NP	O	O
events	event	NNS	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
not	not	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
these	these	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
experience	experience	NN	I-NP	O	O
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Angiomax	Angiomax	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
expanders	expander	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
dextran	dextran	NN	B-NP	O	S-drug
.	.	.	O	O	O

Angiomax	Angiomax	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
disease	disease	NN	B-NP	O	O
states	state	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-NP	O	O
.	.	.	O	O	O

Immunogenicity	Immunogenicity	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Re	Re	NN	I-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
Angiomax	Angiomax	NN	B-NP	O	S-brand
exhibited	exhibit	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
platelet	platelet	NN	I-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
response	response	NN	I-NP	O	O
against	against	IN	B-PP	O	O
sera	serum	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	B-protein	O
/	/	SYM	B-NP	O	O
HITTS	HITTS	NN	I-NP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
494	494	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
Angiomax	Angiomax	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
antibodies	antibody	NNS	B-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
emergent	emergent	JJ	I-NP	O	O
positive	positive	JJ	I-NP	O	O
bivalirudin	bivalirudin	NN	I-NP	O	S-drug
antibody	antibody	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Neither	Neither	DT	B-NP	O	O
subject	subject	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allergic	allergic	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
anaphylactic	anaphylactic	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
and	and	CC	O	O	O
repeat	repeat	NN	B-NP	O	O
testing	testing	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Nine	Nine	CD	B-NP	O	O
additional	additional	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
initial	initial	JJ	B-NP	O	O
positive	positive	JJ	I-NP	O	O
tests	test	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
negative	negative	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
repeat	repeat	NN	B-NP	O	O
testing	testing	NN	I-NP	O	O
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
antibiotic	antibiotic	NN	I-NP	O	S-group
,	,	,	O	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
diuretic	diuretic	JJ	B-NP	O	S-group
,	,	,	I-NP	O	O
foscarnet	foscarnet	JJ	I-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
vaccines	vaccine	NNS	B-NP	O	S-group
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
VELCADE	VELCADE	NN	B-NP	O	S-brand
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
bortezomib	bortezomib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
1A2	1A2	NN	B-NP	B-protein	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
concomitantly	concomitantly	RB	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
VELCADE	VELCADE	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
either	either	CC	O	O	O
toxicities	toxicity	NNS	B-NP	O	O
or	or	CC	O	O	O
reduced	reduce	VBN	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
and	and	CC	I-NP	O	O
hyperglycemia	hyperglycemia	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemics	hypoglycemic	NNS	I-NP	O	S-group
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group-AD-1
agents	agent	NNS	I-NP	O	E-group-AD-1
receiving	receive	VBG	B-VP	O	O
VELCADE	VELCADE	NN	B-NP	O	S-brand-AD-2
treatment	treatment	NN	I-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
blood	blood	NN	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
adjustment	adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group
medication	medication	NN	I-NP	O	E-group
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Laboratory	Laboratory	NNP	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
None	None	NNP	I-NP	O	O
known	know	VBN	B-VP	O	O
.	.	.	O	O	O

Bosentan	Bosentan	NNP	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
isoenzymes	isoenzyme	NNS	I-NP	B-protein	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
.	.	.	O	O	O

Bosentan	Bosentan	NNP	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2C9	CYP2C9	NN	I-NP	B-protein	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
isoenzymes	isoenzyme	NNS	I-NP	B-protein	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
TRACLEER	TRACLEER	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

Bosentan	Bosentan	NNP	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
any	any	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
tested	test	VBN	B-VP	O	O
(	(	(	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
TRACLEER	TRACLEER	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
.	.	.	O	O	O

Hormonal	Hormonal	JJ	B-NP	O	B-group
Contraceptives	Contraceptive	NNS	I-NP	O	E-group
,	,	,	O	O	O
Including	Include	VBG	B-VP	O	O
Oral	Oral	NNP	B-NP	O	O
,	,	,	O	O	O
Injectable	Injectable	NNP	B-NP	O	O
,	,	,	O	O	O
Transdermal	Transdermal	NNP	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Implantable	Implantable	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
An	An	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group
contraceptive	contraceptive	JJ	I-NP	O	E-group
Ortho	Ortho	NNP	I-NP	O	B-brand-ME-2
-	-	HYPH	I-NP	O	I-brand-ME-2
Novum	Novum	NNP	I-NP	O	E-brand-ME-2
produced	produce	VBD	B-VP	O	O
average	average	JJ	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
31	31	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
decreases	decrease	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
as	as	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
as	as	IN	I-NP	O	O
56	56	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
66	66	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
hormonal	hormonal	JJ	B-NP	O	B-group-EF-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
oral	oral	JJ	B-NP	O	O
,	,	,	I-NP	O	O
injectable	injectable	JJ	I-NP	O	O
,	,	,	I-NP	O	O
transdermal	transdermal	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
implantable	implantable	JJ	B-NP	O	O
forms	form	NNS	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
reliable	reliable	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
TRACLEER	TRACLEER	NN	B-NP	B-protein	S-brand-EF-2
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

Women	Woman	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
practice	practice	VB	I-VP	O	O
additional	additional	JJ	B-NP	O	O
methods	method	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
and	and	CC	O	O	O
not	not	RB	B-VP	O	O
rely	rely	VB	I-VP	O	O
on	on	IN	B-PP	O	O
hormonal	hormonal	JJ	B-NP	O	O
contraception	contraception	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
taking	take	VBG	B-VP	O	O
TRACLEER	TRACLEER	NN	B-NP	O	S-brand
.	.	.	O	O	O

Specific	Specific	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
Cyclosporine	Cyclosporine	NN	B-NP	O	B-drug
A	A	NN	I-NP	O	E-drug
:	:	:	O	O	O
During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
trough	trough	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
30	30	CD	I-NP	O	O
-	-	HYPH	B-VP	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

Steady	Steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
bosentan	bosentan	NN	I-NP	O	S-drug-ME-1
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
4	4	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	B-drug-ME-2
A	A	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	B-drug-AD-2
A	A	NN	I-NP	O	E-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	B-drug-ME-2
A	A	NN	I-NP	O	E-drug-ME-2
(	(	(	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Tacrolimus	Tacrolimus	NN	B-NP	O	S-drug
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
bosentan	bosentan	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
bosentan	bosentan	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
markedly	markedly	RB	B-NP	O	O
increased	increase	VBN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
bosentan	bosentan	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
.	.	.	O	O	O

Glyburide	Glyburide	NN	B-NP	O	S-drug
:	:	:	O	O	O
An	An	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
aminotransferases	aminotransferas	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TRACLEER	TRACLEER	NN	B-NP	B-protein	S-brand-AD-1
and	and	CC	I-NP	O	O
glyburide	glyburide	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
alternative	alternative	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Bosentan	Bosentan	NNP	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-ME-2
agents	agent	NNS	I-NP	O	E-group-ME-2
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
predominantly	predominantly	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
or	or	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
worsened	worsen	VBN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
control	control	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug-ME-1
125	125	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O
and	and	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
increased	increase	VBN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Simvastatin	Simvastatin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Other	Other	JJ	I-NP	O	O
Statins	Statin	NNPS	I-NP	B-protein	S-group
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
hydroxy	hydroxy	NN	I-NP	O	O
acid	acid	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

Bosentan	Bosentan	NNP	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
statins	statin	NNS	I-NP	O	S-group-ME-2
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
significant	significant	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
atorvastatin	atorvastatin	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
statin	statin	NN	I-NP	O	S-group
efficacy	efficacy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
metabolized	metabolize	VBD	B-VP	O	O
statins	statin	NNS	B-NP	O	S-group-AD-1
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
cholesterol	cholesterol	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
monitored	monitor	VBN	B-VP	O	O
after	after	IN	B-SBAR	O	O
TRACLEER	TRACLEER	NN	B-NP	B-protein	S-brand-AD-2
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
see	see	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
statin	statin	NN	I-NP	O	S-group
dose	dose	NN	I-NP	O	O
needs	need	VBZ	B-VP	O	O
adjustment	adjustment	NN	B-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NNP	B-NP	O	S-drug
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug-ME-1
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
S	S	NN	B-NP	O	B-drug-ME-2
-	-	HYPH	B-NP	O	I-drug-ME-2
warfarin	warfarin	NN	I-NP	O	E-drug-ME-2
(	(	(	O	O	O
a	a	DT	B-NP	O	O
CYP2C9	CYP2C9	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
and	and	CC	O	O	O
R	R	NN	B-NP	B-protein	B-drug-ME-2
-	-	HYPH	B-NP	O	I-drug-ME-2
warfarin	warfarin	NN	I-NP	O	E-drug-ME-2
(	(	(	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
29	29	CD	B-NP	O	O
and	and	CC	I-NP	O	O
38	38	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
experience	experience	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
pulmonary	pulmonary	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
show	show	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
or	or	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
baseline	baseline	NN	B-NP	O	O
vs.	vs.	CC	O	O	O
end	end	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
to	to	TO	B-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
trials	trial	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
or	or	CC	O	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
among	among	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	O	O	O
treated	treat	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NNP	B-NP	O	S-drug
,	,	,	I-NP	O	O
Nimodipine	Nimodipine	NNP	I-NP	O	S-drug
and	and	CC	I-NP	O	O
Losartan	Losartan	NNP	I-NP	O	S-drug
:	:	:	O	O	O
Bosentan	Bosentan	NNP	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
nimodipine	nimodipine	NN	I-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
losartan	losartan	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bosentan	bosentan	NN	B-NP	O	S-drug
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
BOTOX	BOTOX	NN	B-NP	B-protein	S-brand-AD-1
and	and	CC	I-NP	O	O
aminoglycosides	aminoglycoside	NNS	I-NP	O	S-group-AD-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
interfering	interfere	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
transmission	transmission	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
curare	curare	NN	B-NP	O	B-group-AD-2
-	-	HYPH	B-NP	O	I-group-AD-2
like	like	JJ	I-NP	O	I-group-AD-2
compounds	compound	NNS	I-NP	O	E-group-AD-2
)	)	)	O	O	O
should	should	MD	B-VP	O	O
only	only	RB	I-VP	O	O
be	be	VB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxin	toxin	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
administering	administer	VBG	B-VP	O	O
different	different	JJ	B-NP	O	O
botulinum	botulinum	NN	I-NP	O	B-group
neurotoxin	neurotoxin	NN	I-NP	O	E-group
serotypes	serotype	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	B-PP	O	O
within	within	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Excessive	Excessive	JJ	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
weakness	weakness	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exacerbated	exacerbate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
another	another	DT	B-NP	O	O
botulinum	botulinum	NN	I-NP	O	B-group-EF-1
toxin	toxin	NN	I-NP	O	E-group-EF-1
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
resolution	resolution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
previously	previously	RB	I-NP	O	O
administered	administer	VBN	I-NP	O	O
botulinum	botulinum	NN	I-NP	O	B-group-EF-2
toxin	toxin	NN	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MYOBLOC	MYOBLOC	NN	B-NP	B-protein	S-brand-AD-1
and	and	CC	I-NP	O	O
aminoglycosides	aminoglycoside	NNS	I-NP	O	S-group-AD-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
interfering	interfere	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
transmission	transmission	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
curare	curare	NN	B-NP	O	B-group-AD-2
-	-	HYPH	B-NP	O	I-group-AD-2
like	like	JJ	I-NP	O	I-group-AD-2
compounds	compound	NNS	I-NP	O	E-group-AD-2
)	)	)	O	O	O
should	should	MD	B-VP	O	O
only	only	RB	I-VP	O	O
be	be	VB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxin	toxin	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
administering	administer	VBG	B-VP	O	O
different	different	JJ	B-NP	O	O
botulinum	botulinum	NN	I-NP	O	B-group
neurotoxin	neurotoxin	NN	I-NP	O	E-group
serotypes	serotype	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
within	within	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
4	4	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
paralysis	paralysis	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
or	or	CC	O	O	O
overlapping	overlap	VBG	B-VP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
botulinum	botulinum	NN	I-NP	O	B-group
toxin	toxin	NN	I-NP	O	E-group
serotypes	serotype	NNS	I-NP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	S-group-EF-1
toxicity	toxicity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aggravated	aggravate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Bretylium	Bretylium	NNP	B-NP	O	B-drug-EF-2
Tosylate	Tosylate	NNP	I-NP	O	E-drug-EF-2
Injection	Injection	NNP	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
catecholamines	catecholamine	NNS	B-NP	O	S-group-EF-1
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
dopamine	dopamine	NN	B-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	S-drug-EF-1
are	be	VBP	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
Bretylium	Bretylium	NNP	B-NP	O	B-drug-EF-2
Tosylate	Tosylate	NNP	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
catecholamines	catecholamine	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
,	,	,	O	O	O
dilute	dilute	JJ	B-NP	O	O
solutions	solution	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
and	and	CC	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
little	little	JJ	B-NP	O	O
published	publish	VBN	I-NP	O	O
information	information	NN	I-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
Bretylium	Bretylium	NNP	B-NP	O	B-drug
Tosylate	Tosylate	NNP	I-NP	O	E-drug
,	,	,	O	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
often	often	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
without	without	IN	B-PP	O	O
any	any	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
or	or	CC	O	O	O
diminished	diminish	VBN	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
specific	specific	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ALPHAGAN	ALPHAGAN	NN	B-NP	B-protein	B-brand-AD-1
P	P	NN	I-NP	I-protein	E-brand-AD-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
potentiating	potentiate	VBG	I-NP	O	O
effect	effect	NN	I-NP	O	O
with	with	IN	B-PP	O	O
CNS	CNS	NN	B-NP	O	B-group-AD-2
depressants	depressant	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
opiates	opiate	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-AD-2
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Alpha	Alpha	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
agonists	agonist	NNS	I-NP	O	E-group
,	,	,	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
class	class	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
pulse	pulse	NN	B-NP	O	O
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
(	(	(	O	O	O
ophthalmic	ophthalmic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
systemic	systemic	JJ	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
anti	anti	AFX	O	O	B-group
-	-	HYPH	O	O	I-group
hypertensives	hypertensive	NNS	B-NP	O	E-group
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
.	.	.	O	O	O

Tricyclic	Tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
blunt	blunt	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
clonidine.It	clonidine.It	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
ALPHAGAN	ALPHAGAN	NN	B-NP	B-protein	B-brand
P	P	NN	I-NP	I-protein	E-brand
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
can	can	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
resulting	result	VBG	B-VP	O	O
interference	interference	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
IOP	IOP	NN	I-NP	O	O
lowering	lowering	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
circulating	circulate	VBG	B-VP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
after	after	IN	B-PP	O	O
ALPHAGAN	ALPHAGAN	NN	B-NP	O	B-brand
P	P	NN	I-NP	O	E-brand
administration	administration	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
circulating	circulate	VBG	B-VP	O	O
amines	amine	NNS	B-NP	O	O
.	.	.	O	O	O

AZOPT	AZOPT	NN	B-NP	O	S-brand
(	(	(	O	O	O
brinzolamide	brinzolamide	NN	B-NP	O	S-drug
ophthalmic	ophthalmic	JJ	I-NP	O	O
suspension	suspension	NN	I-NP	O	O
)	)	)	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
contains	contain	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
carbonic	carbonic	JJ	I-NP	O	B-group
anhydrase	anhydrase	NN	I-NP	O	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
.	.	.	O	O	O

Acid	Acid	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
base	base	NN	I-NP	O	O
and	and	CC	I-NP	O	O
electrolyte	electrolyte	NN	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
brinzolamide	brinzolamide	NN	B-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
carbonic	carbonic	JJ	I-NP	O	B-group-IN-1
anhydrase	anhydrase	NN	I-NP	O	I-group-IN-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-IN-1
,	,	,	O	O	O
rare	rare	JJ	B-NP	O	O
instances	instance	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-drug-IN-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
AZOPT	AZOPT	NN	B-NP	O	S-brand
(	(	(	O	O	O
brinzolamide	brinzolamide	NN	B-NP	O	S-drug
ophthalmic	ophthalmic	JJ	I-NP	O	O
suspension	suspension	NN	I-NP	O	O
)	)	)	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
bromocriptine	bromocriptine	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bromocriptine	bromocriptine	NN	B-NP	O	B-drug-EF-2
mesylate	mesylate	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Bromocriptine	Bromocriptine	NN	B-NP	O	B-drug-IN-1
mesylate	mesylate	NN	I-NP	O	E-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	B-group-IN-2
antagonists	antagonist	NNS	I-NP	O	E-group-IN-2
,	,	,	O	O	O
butyrophenones	butyrophenone	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
certain	certain	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Compounds	Compound	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
categories	category	NNS	I-NP	O	O
result	result	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bromocriptine	bromocriptine	NN	B-NP	O	B-drug-EF-1
mesylate	mesylate	NN	I-NP	O	E-drug-EF-1
:	:	:	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
pimozide	pimozide	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bromocriptine	bromocriptine	NN	B-NP	O	B-drug-AD-1
mesylate	mesylate	NN	I-NP	O	E-drug-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
ergot	ergot	NN	I-NP	O	B-group-AD-2
alkaloids	alkaloid	NNS	I-NP	O	E-group-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Dexbrompheniramine	Dexbrompheniramine	NN	B-NP	O	S-drug-EF-1
can	can	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
these	these	DT	I-NP	O	O
medications	medication	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
antihistamines	antihistamine	NNS	I-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
anticholinergics	anticholinergic	NNS	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group-EF-2
oxidase	oxidase	NN	I-NP	I-protein	I-group-EF-2
(	(	(	O	O	I-group-EF-2
MAO	MAO	NN	B-NP	O	I-group-EF-2
)	)	)	O	O	I-group-EF-2
inhibitors	inhibitor	NNS	B-NP	O	E-group-EF-2
(	(	(	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
and	and	CC	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group
depressants	depressant	NNS	I-NP	O	E-group
(	(	(	O	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
these	these	DT	I-NP	O	O
medications	medication	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
antihistamines	antihistamine	NNS	I-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
anticholinergics	anticholinergic	NNS	B-NP	O	S-group
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group
oxidase	oxidase	NN	I-NP	I-protein	I-group
(	(	(	O	O	I-group
MAO	MAO	NN	B-NP	O	I-group
)	)	)	O	O	I-group
inhibitors	inhibitor	NNS	B-NP	O	E-group
(	(	(	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
and	and	CC	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
a	a	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
mucosa	mucosa	NN	I-NP	O	O
)	)	)	O	O	O
caused	cause	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
eight	eight	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
budesonide	budesonide	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
intraconazole	intraconazole	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
,	,	,	O	O	O
reduction	reduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
budesonide	budesonide	NN	I-NP	O	S-drug-AD-2
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
extensive	extensive	JJ	B-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
(	(	(	O	O	O
which	which	WDT	B-NP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
predominantly	predominantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
mucosa	mucosa	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
budesonide	budesonide	NN	I-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
about	about	RB	B-NP	O	O
two	two	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
primarily	primarily	RB	B-VP	O	O
being	be	VBG	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
ingestion	ingestion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
grapefruit	grapefruit	NN	B-NP	O	O
or	or	CC	I-NP	O	O
grapefruit	grapefruit	NN	I-NP	O	O
juice	juice	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
connection	connection	NN	B-NP	O	O
with	with	IN	B-PP	O	O
budesonide	budesonide	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
ototoxic	ototoxic	JJ	B-NP	O	O
potential	potential	NN	I-NP	O	O
:	:	:	O	O	O
Especially	Especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
parenterally	parenterally	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
bumetanide	bumetanide	NN	I-NP	O	S-drug-AD-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
whom	whom	WP	B-NP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-group-AD-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-AD-2
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
being	be	VBG	I-VP	O	O
given	give	VBN	I-VP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
,	,	,	O	O	O
except	except	IN	B-PP	O	O
in	in	IN	B-PP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
conditions	condition	NNS	B-NP	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
nephrotoxic	nephrotoxic	JJ	B-NP	O	O
potential	potential	NN	I-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
experience	experience	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
nephrotoxic	nephrotoxic	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
simultaneous	simultaneous	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Lithium	Lithium	NN	I-NP	O	S-drug
:	:	:	O	O	O
Lithium	Lithium	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
generally	generally	RB	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-AD-2
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
reduce	reduce	VBP	B-VP	O	O
its	its	PRP$	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
add	add	VB	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Probenecid	Probenecid	NN	I-NP	O	S-drug
:	:	:	O	O	O
Pretreatment	Pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-EF-1
reduces	reduce	VBZ	B-VP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
natriuresis	natriuresis	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hyperreninemia	hyperreninemia	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
antagonistic	antagonistic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
on	on	IN	B-PP	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug-ME-2
natriuresis	natriuresis	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
on	on	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
but	but	CC	O	O	O
is	be	VBZ	B-VP	O	O
probably	probably	RB	B-ADVP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Indomethacin	Indomethacin	NN	I-NP	O	S-drug
:	:	:	O	O	O
Indomethacin	Indomethacin	NN	B-NP	O	S-drug-MU-1
blunts	blunt	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
volume	volume	NN	I-NP	O	O
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
seen	see	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug-ME-2
treatment	treatment	NN	I-NP	O	O
and	and	CC	O	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
bumetanide	bumetanide	NN	I-NP	O	S-drug-EF-2
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
renin	renin	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
thus	thus	RB	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Antihypertensives	Antihypertensive	NNS	I-NP	O	S-group
:	:	:	O	O	O
Bumetanide	Bumetanide	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
necessitating	necessitate	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Digoxin	Digoxin	NN	I-NP	O	S-drug
:	:	:	O	O	O
Interaction	Interaction	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Anticoagulants	Anticoagulant	NNS	I-NP	O	S-group
:	:	:	O	O	O
Interaction	Interaction	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
or	or	CC	B-PP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
prothrombin	prothrombin	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	B-group
solutions	solution	NNS	I-NP	O	E-group
containing	contain	VBG	B-VP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-1
or	or	CC	O	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
or	or	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
,	,	,	I-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
generally	generally	RB	I-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
situations	situation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
concurrent	concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-NP	O	O
,	,	,	I-NP	O	O
careful	careful	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasopressor	vasopressor	NN	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
ergot	ergot	NN	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
type	type	NN	I-NP	O	I-group
oxytocic	oxytocic	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
,	,	,	I-NP	O	O
persistent	persistent	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
or	or	CC	O	O	O
cerebrovascular	cerebrovascular	JJ	B-NP	O	O
accidents	accident	NNS	I-NP	O	O
.	.	.	O	O	O

Phenothiazines	Phenothiazine	NNS	B-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
butyrophenones	butyrophenone	NNS	I-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
or	or	CC	I-VP	O	O
reverse	reverse	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Buprenorphine	Buprenorphine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
norbuprenorphine	norbuprenorphine	NN	B-NP	O	S-drug_n
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
CYP	CYP	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
buprenorphine	buprenorphine	NN	B-NP	O	S-drug
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
already	already	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
azole	azole	NN	B-NP	O	B-group
antifungals	antifungal	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O

ketoconazole	ketoconazole	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
macrolide	macrolide	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	B-protein	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
HIV	HIV	NN	B-NP	B-protein	B-group
protease	protease	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	I-protein	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
and	and	CC	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
)	)	)	O	O	O
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SUBUTEX	SUBUTEX	NN	B-NP	O	S-brand
or	or	CC	I-NP	O	O
SUBOXONE	SUBOXONE	NN	I-NP	O	S-brand
adjusted	adjust	VBN	B-VP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
anecdotal	anecdotal	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
buprenorphine	buprenorphine	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-IN-2
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reports	report	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
marketing	marketing	NN	I-NP	O	O
experience	experience	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coma	coma	NN	B-NP	O	O
and	and	CC	I-NP	O	O
death	death	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
misuse	misuse	NN	I-NP	O	O
of	of	IN	B-PP	O	O
buprenorphine	buprenorphine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-drug-EF-2
by	by	IN	B-PP	O	O
addicts	addict	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
buprenorphine	buprenorphine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
misused	misuse	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
self	self	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
crushed	crushed	JJ	B-NP	O	O
SUBUTEX	SUBUTEX	NN	I-NP	O	S-brand
tablets	tablet	NNS	I-NP	O	O
.	.	.	O	O	O

SUBUTEX	SUBUTEX	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
SUBOXONE	SUBOXONE	NN	I-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-AD-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
act	act	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
regardless	regardless	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
whether	whether	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
taken	take	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
advice	advice	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
or	or	CC	O	O	O
are	be	VBP	B-VP	O	O
taken	take	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
abuse	abuse	NN	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warned	warn	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
danger	danger	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
self	self	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-AD-1
while	while	IN	B-SBAR	O	O
under	under	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
SUBOXONE	SUBOXONE	NN	B-NP	O	S-brand-AD-2
or	or	CC	I-NP	O	O
SUBUTEX	SUBUTEX	NN	I-NP	O	S-brand-AD-2
.	.	.	O	O	O

Few	Few	JJ	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
collected	collect	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
WELLBUTRIN	WELLBUTRIN	NN	B-NP	O	S-brand
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	O	O	O
,	,	,	O	O	O
alternatively	alternatively	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
WELLBUTRIN	WELLBUTRIN	NN	B-NP	B-protein	S-brand
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
extensively	extensively	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
hydroxybupropion	hydroxybupropion	NN	B-NP	O	S-drug_n
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP2B6	CYP2B6	NN	I-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
WELLBUTRIN	WELLBUTRIN	NN	B-NP	O	S-brand-IN-1
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
affect	affect	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
CYP2B6	CYP2B6	NN	I-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
orphenadrine	orphenadrine	NN	B-NP	O	S-drug-IN-2
and	and	CC	O	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug-IN-2
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
threohydrobupropion	threohydrobupropion	NN	I-NP	O	S-drug_n
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
produced	produce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
24	24	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
young	young	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

Following	Follow	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
150	150	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
sustained	sustain	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
release	release	NN	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
and	and	CC	B-NP	O	O
without	without	IN	I-NP	O	O
800	800	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
hydroxybupropion	hydroxybupropion	NN	I-NP	O	S-drug_n
were	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
32	32	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combined	combine	VBN	I-NP	O	O
moieties	moiety	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
threohydrobupropion	threohydrobupropion	NN	B-NP	O	S-drug_n
and	and	CC	I-NP	O	O
erythrohydrobupropion	erythrohydrobupropion	NN	I-NP	O	S-drug_n
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
not	not	RB	B-VP	O	O
systematically	systematically	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Animal	Animal	NN	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
metabolizing	metabolize	VBG	B-VP	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
following	follow	VBG	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
,	,	,	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
3	3	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
8	8	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
own	own	JJ	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
coadministered	coadministere	VBN	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450IID6	P450IID6	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
)	)	)	O	O	O
:	:	:	O	O	O
Many	Many	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
most	most	JJS	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	O	O
,	,	,	O	O	O
many	many	JJ	B-NP	O	O
tricyclics	tricyclic	NNS	I-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
,	,	,	O	O	O
antiarrhythmics	antiarrhythmic	NNS	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
antipsychotics	antipsychotic	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	O	O
,	,	,	O	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
hydroxybupropion	hydroxybupropion	NN	I-NP	O	S-drug_n
are	be	VBP	B-VP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
male	male	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
(	(	(	O	O	O
ages	age	NNS	B-NP	O	O
19	19	CD	B-NP	O	O
to	to	TO	I-NP	O	O
35	35	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
extensive	extensive	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
,	,	,	O	O	O
daily	daily	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug-ME-1
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-VP	O	O
daily	daily	RB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
desipramine	desipramine	NN	I-NP	O	S-drug-ME-2
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	O	O	O
AUC	AUC	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
t1	t1	NN	B-NP	O	O
/	/	SYM	O	O	O
2	2	CD	B-NP	O	O
of	of	IN	B-PP	O	O
desipramine	desipramine	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
average	average	NN	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
,	,	,	O	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
present	present	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
7	7	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
formally	formally	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
including	include	VBG	B-PP	O	O
certain	certain	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group-AD-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
nortriptyline	nortriptyline	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
imipramine	imipramine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
desipramine	desipramine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
antipsychotics	antipsychotic	NNS	B-NP	O	S-group-AD-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
risperidone	risperidone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
thioridazine	thioridazine	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
beta	beta	SYM	O	O	B-group-AD-2
-	-	HYPH	O	O	I-group-AD-2
blockers	blocker	NNS	B-NP	O	E-group-AD-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
metoprolol	metoprolol	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Type	Type	NN	B-NP	O	B-group-AD-2
1C	1C	NN	I-NP	O	I-group-AD-2
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
propafenone	propafenone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
flecainide	flecainide	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
initiated	initiate	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
bupropion	bupropion	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
already	already	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
original	original	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
those	those	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
narrow	narrow	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
index	index	NN	I-NP	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Studies	Study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
MAO	MAO	NN	I-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
phenelzine	phenelzine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Levodopa	Levodopa	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Amantadine	Amantadine	NN	I-NP	O	S-drug
:	:	:	O	O	O
Limited	Limit	VBN	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
experiences	experience	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
bupropion	bupropion	NN	B-NP	O	S-drug-EF-1
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
levodopa	levodopa	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
amantadine	amantadine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
WELLBUTRIN	WELLBUTRIN	NN	B-NP	O	S-brand-AD-1
Tablets	Tablet	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
either	either	CC	O	O	O
levodopa	levodopa	NN	B-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
amantadine	amantadine	NN	I-NP	O	S-drug-AD-2
concurrently	concurrently	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
small	small	JJ	B-NP	O	O
initial	initial	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
and	and	CC	O	O	O
small	small	JJ	B-NP	O	O
gradual	gradual	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
increases	increase	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	IN	B-SBAR	O	O
Lower	Lower	NNP	B-NP	O	O
Seizure	Seizure	NNP	I-NP	O	O
Threshold	Threshold	NNP	I-NP	O	O
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
WELLBUTRIN	WELLBUTRIN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
antipsychotics	antipsychotic	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group-AD-2
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
systemic	systemic	JJ	B-NP	O	O
steroids	steroid	NNS	I-NP	O	S-group-AD-2
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
that	that	WDT	B-NP	O	O
lower	low	JJR	B-NP	O	O
seizure	seizure	NN	I-NP	O	O
threshold	threshold	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
extreme	extreme	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
.	.	.	O	O	O

Low	Low	JJ	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
and	and	CC	O	O	O
small	small	JJ	B-NP	O	O
gradual	gradual	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
increases	increase	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
employed	employ	VBN	I-VP	O	O
.	.	.	O	O	O

Nicotine	Nicotine	NNP	B-NP	O	S-drug
Transdermal	Transdermal	NNP	I-NP	O	O
System	System	NNP	I-NP	O	O
:	:	:	O	O	O
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
marketing	marketing	NN	I-NP	O	O
experience	experience	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rare	rare	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
neuropsychiatric	neuropsychiatric	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
or	or	CC	O	O	O
reduced	reduce	VBN	B-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug
tolerance	tolerance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
drinking	drink	VBG	I-VP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-1
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
WELLBUTRIN	WELLBUTRIN	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
consumption	consumption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-AD-1
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
WELLBUTRIN	WELLBUTRIN	NN	B-NP	O	S-brand-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
(	(	(	O	O	O
also	also	RB	B-ADVP	O	O
see	see	VB	B-VP	O	O
a	a	DT	B-NP	O	O
href	href	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
bupropz_od.htm	bupropz_od.htm	NN	B-NP	O	O
#	#	#	B-NP	O	O
CI	CI	NN	I-NP	O	O
CONTRAINDICATIONS	CONTRAINDICATIONS	NNS	I-NP	O	O
)	)	)	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
buspirone	buspirone	NN	B-NP	O	B-drug-AD-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-AD-1
not	not	RB	O	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
Because	Because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
buspirone	buspirone	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
with	with	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
other	other	JJ	I-NP	O	O
psychotropic	psychotropic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
buspirone	buspirone	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
active	active	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
one	one	CD	B-NP	O	O
report	report	NN	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
trazodone	trazodone	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
(	(	(	O	O	O
Desyrel	Desyrel	NN	B-NP	O	S-brand-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
buspirone	buspirone	NN	B-NP	O	B-drug-EF-2
HCl	HCl	NN	I-NP	O	E-drug-EF-2
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
caused	cause	VBN	I-VP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
elevations	elevation	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
SGPT	SGPT	NN	B-NP	O	O
(	(	(	O	O	O
ALT	ALT	NN	B-NP	B-protein	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
attempting	attempt	VBG	B-VP	O	O
to	to	TO	I-VP	O	O
replicate	replicate	VB	I-VP	O	O
this	this	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
interactive	interactive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
transaminases	transaminase	NNS	I-NP	I-protein	O
was	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
buspirone	buspirone	NN	B-NP	O	B-drug-ME-1
HCl	HCl	NN	I-NP	O	E-drug-ME-1
and	and	CC	I-NP	O	O
haloperidol	haloperidol	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
haloperidol	haloperidol	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
clear	clear	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
buspirone	buspirone	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
displace	displace	VB	I-VP	O	O
tightly	tightly	RB	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
like	like	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
from	from	IN	B-PP	O	O
serum	serum	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
one	one	CD	B-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
buspirone	buspirone	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
chronically	chronically	RB	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
levothyroxine	levothyroxine	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
buspirone	buspirone	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
displace	displace	VB	I-VP	O	O
less	less	RBR	B-ADVP	O	O
firmly	firmly	RB	I-ADVP	O	O
bound	bind	VBN	I-ADJP	O	O
drugs	drug	NNS	B-NP	O	O
like	like	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
property	property	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Itraconazole	Itraconazole	NN	B-NP	O	S-drug-ME-1
decreases	decrease	VBZ	B-VP	O	O
busulfan	busulfan	NN	B-NP	O	S-drug-ME-2
clearance	clearance	NN	I-NP	O	O
by	by	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
AUCs	AUC	NNS	B-NP	O	O
1500	1500	CD	B-NP	O	O
M	M	NN	I-NP	O	O
min	min	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Fluconazole	Fluconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
5	5	CD	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
HT3	HT3	NN	I-NP	O	I-group
antiemetics	antiemetic	NNS	I-NP	O	E-group
ondansetron	ondansetron	NN	I-NP	O	S-drug
(	(	(	O	O	O
Zofran	Zofran	NN	B-NP	O	S-brand
)	)	)	O	O	O
and	and	CC	O	O	O
granisetron	granisetron	NN	B-NP	O	S-drug
(	(	(	O	O	O
Kytril	Kytril	NN	B-NP	O	S-brand
)	)	)	O	O	O
have	have	VBP	O	O	O
all	all	DT	O	O	O
been	be	VBN	B-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
BUSULFEX	BUSULFEX	NN	B-NP	O	S-brand
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
busulfan	busulfan	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glutathione	glutathione	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
S	S	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	I-protein	O
transferase	transferase	NN	I-NP	I-protein	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
BUSULFEX	BUSULFEX	NN	B-NP	O	S-brand-ME-1
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
BUSULFEX	BUSULFEX	NN	B-NP	O	S-brand
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
lower	low	JJR	B-ADJP	O	O
and	and	CC	O	O	O
exposure	exposure	NN	B-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
not	not	RB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
busulfan	busulfan	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
via	via	IN	B-PP	O	O
conjugation	conjugation	NN	B-NP	O	O
with	with	IN	B-PP	O	O
glutathione	glutathione	NN	B-NP	O	O
,	,	,	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-ME-1
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
(	(	(	O	O	O
72	72	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
concurrent	concurrent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
BUSULFEX	BUSULFEX	NN	B-NP	O	S-brand-ME-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
busulfan	busulfan	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
based	base	VBN	B-VP	O	O
upon	upon	IN	B-PP	O	O
the	the	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
property	property	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
glutathione	glutathione	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
adrenocorticoids	adrenocorticoid	NNS	B-NP	O	O
(	(	(	O	O	O
cortisone	cortisone	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
medicine	medicine	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
(	(	(	O	O	O
blood	blood	NN	B-NP	O	B-group
thinners	thinner	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
corticotropin	corticotropin	NN	B-NP	O	S-drug
(	(	(	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
central	central	JJ	B-NP	O	B-group
nervous	nervous	JJ	I-NP	O	I-group
system	system	NN	I-NP	O	I-group
(	(	(	O	O	I-group
CNS	CNS	NN	B-NP	B-protein	I-group
)	)	)	O	O	I-group
depressants	depressant	NNS	B-NP	O	E-group
(	(	(	O	O	O
using	use	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
divalproex	divalproex	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
,	,	,	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
(	(	(	O	O	O
using	use	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
medicine	medicine	NN	B-NP	O	O
that	that	IN	B-NP	O	O
you	you	PRP	B-NP	O	O
need	need	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
take	take	VB	I-VP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
containing	contain	VBG	B-VP	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
(	(	(	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
you	you	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
change	change	VB	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
different	different	JJ	I-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
birth	birth	NN	B-NP	O	O
control	control	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
butalbital	butalbital	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group-EF-2
oxidase	oxidase	NN	I-NP	I-protein	I-group-EF-2
(	(	(	O	O	I-group-EF-2
MAO	MAO	NN	B-NP	O	I-group-EF-2
)	)	)	O	O	I-group-EF-2
inhibitors	inhibitor	NNS	B-NP	O	E-group-EF-2
.	.	.	O	O	O

Butalbital	Butalbital	NN	B-NP	O	S-drug-EF-1
,	,	,	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
caffeine	caffeine	NN	I-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
:	:	:	O	O	O
other	other	JJ	B-NP	O	O
narcotic	narcotic	JJ	I-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	O
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
sedative	sedative	JJ	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
hypnotics	hypnotic	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
causing	cause	VBG	B-VP	O	O
increased	increase	VBN	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Acetaminophen	Acetaminophen	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
false	false	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hydroxyindoleacetic	hydroxyindoleacetic	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
Mentax	Mentax	NN	B-NP	O	S-brand
(	(	(	O	O	O
butenafine	butenafine	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
cream	cream	NN	I-NP	O	O
)	)	)	O	O	O
Cream	Cream	NNP	B-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
central	central	JJ	B-NP	O	B-group-EF-2
nervous	nervous	JJ	I-NP	O	I-group-EF-2
system	system	NN	I-NP	O	I-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
)	)	)	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
central	central	JJ	I-NP	O	B-group
nervous	nervous	JJ	I-NP	O	I-group
system	system	NN	I-NP	O	I-group
depressant	depressant	NN	I-NP	O	E-group
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
smallest	small	JJS	I-NP	O	O
effective	effective	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
reduced	reduce	VBD	B-VP	O	O
as	as	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
as	as	IN	B-PP	O	O
possible	possible	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
potentiate	potentiate	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
opioids	opioid	NNS	B-NP	O	S-group
.	.	.	O	O	O

In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
STADOL	STADOL	NN	B-NP	O	B-brand
NS	NS	NN	I-NP	O	E-brand
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
subcutaneous	subcutaneous	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
another	another	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
(	(	(	O	O	O
29	29	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
and	and	CC	O	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STADOL	STADOL	NN	B-NP	O	B-brand-ME-1
NS	NS	NN	I-NP	O	E-brand-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
1	1	CD	B-NP	O	O
minute	minute	NN	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
20	20	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug-ME-2
nasal	nasal	JJ	I-NP	O	O
spray	spray	NN	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
The	The	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
opposite	opposite	JJ	B-NP	B-cell_type	O
nostrils	nostril	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O
)	)	)	O	O	O

When	When	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
STADOL	STADOL	NN	I-NP	O	B-brand-ME-1
NS	NS	NN	I-NP	O	E-brand-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
30	30	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sumatriptan	sumatriptan	NN	I-NP	O	S-drug-ME-2
nasal	nasal	JJ	I-NP	O	O
spray	spray	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
neither	neither	DT	B-NP	O	O
case	case	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug
affected	affect	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
STADOL	STADOL	NN	B-NP	O	B-brand
NS	NS	NN	I-NP	O	E-brand
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STADOL	STADOL	NN	B-NP	O	B-brand-EF-1
NS	NS	NN	I-NP	O	E-brand-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
diminished	diminish	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
shortly	shortly	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug-EF-2
nasal	nasal	JJ	I-NP	O	O
spray	spray	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
by	by	IN	B-PP	O	O
30	30	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
any	any	DT	B-NP	O	O
such	such	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
effect	effect	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimal	minimal	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
STADOL	STADOL	NN	B-NP	O	B-brand
NS	NS	NN	I-NP	O	E-brand
and	and	CC	O	O	O
IMITREX	IMITREX	NN	B-NP	O	S-brand
(	(	(	O	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug
)	)	)	O	O	O
Nasal	Nasal	JJ	B-NP	O	O
Spray	Spray	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
episode	episode	NN	I-NP	O	O
of	of	IN	B-PP	O	O
migraine	migraine	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
noted	note	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
both	both	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
producing	produce	VBG	B-VP	O	O
transient	transient	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
STADOL	STADOL	NN	B-NP	O	B-brand
NS	NS	NN	I-NP	O	E-brand
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
(	(	(	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QID	QID	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Conversely	Conversely	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STADOL	STADOL	NN	B-NP	O	B-brand
NS	NS	NN	I-NP	O	E-brand
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
butorphanol	butorphanol	NN	I-NP	O	S-drug
QID	QID	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
300	300	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug-AD-1
are	be	VBP	B-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
affect	affect	VBP	B-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
(	(	(	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
alert	alert	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
smaller	small	JJR	I-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	O	O	O
longer	long	JJR	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STADOL	STADOL	NN	B-NP	O	B-brand
NS	NS	NN	I-NP	O	E-brand
absorbed	absorb	VBN	B-VP	O	O
is	be	VBZ	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nasal	nasal	JJ	I-NP	O	B-group
vasoconstrictor	vasoconstrictor	NN	I-NP	O	E-group
(	(	(	O	O	O
oxymetazoline	oxymetazoline	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
slower	slow	JJR	I-NP	O	O
onset	onset	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
STADOL	STADOL	NN	B-NP	O	B-brand-EF-1
NS	NS	NN	I-NP	O	E-brand-EF-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
immediately	immediately	RB	B-VP	O	O
following	follow	VBG	I-VP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
nasal	nasal	JJ	I-NP	B-protein	B-group-EF-2
vasoconstrictor	vasoconstrictor	NN	I-NP	I-protein	E-group-EF-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
information	information	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
available	available	JJ	B-ADJP	O	O
about	about	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

DOSTINEX	DOSTINEX	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
D2	D2	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
butyrophenones	butyrophenone	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
thioxanthines	thioxanthine	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
1A2	1A2	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
inhibit	inhibit	VBP	B-VP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
induce	induce	VB	B-VP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
.	.	.	O	O	O

Few	Few	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
exist	exist	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
preterm	preterm	JJ	B-NP	O	O
neonates	neonate	NNS	I-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-AD-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
needed	need	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
elimination	elimination	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-AD-2
and	and	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
and	and	CC	O	O	O
higher	high	JJR	B-NP	O	O
caffeine	caffeine	NN	I-NP	O	S-drug-AD-1
doses	dose	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
needed	need	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
increase	increase	VBP	B-VP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
elimination	elimination	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-AD-2
and	and	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	O	S-drug-EF-1
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug-EF-2
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
volume	volume	NN	I-NP	O	O
in	in	IN	B-PP	O	O
4	4	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
preterm	preterm	JJ	B-NP	O	O
neonates	neonate	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Interconversion	Interconversion	NN	B-NP	O	O
between	between	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
preterm	preterm	JJ	B-NP	O	O
neonates	neonate	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	I-group
analogues	analogue	NNS	I-NP	O	E-group
(	(	(	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug
D2	D2	NN	I-NP	O	E-drug
,	,	,	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug
D3	D3	NN	I-NP	O	E-drug
,	,	,	O	O	O
Calcitriol	Calcitriol	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
Calcidiol	Calcidiol	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fat	fat	JJ	B-NP	O	B-group-ME-2
soluble	soluble	JJ	I-NP	O	I-group-ME-2
vitamins	vitamin	NNS	I-NP	O	E-group-ME-2
;	;	:	O	O	O

as	as	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
it	it	PRP	I-NP	O	O
may	may	MD	B-VP	O	O
impair	impair	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Phenobarbital	Phenobarbital	NN	I-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
or	or	CC	I-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug-ME-1
will	will	MD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
,	,	,	O	O	O
but	but	CC	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
endogenous	endogenous	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcitriol	calcitriol	NN	B-NP	O	S-drug-ME-2
/	/	SYM	B-NP	O	O
ergocalcitriol	ergocalcitriol	NN	I-NP	O	O
by	by	IN	B-PP	O	O
accelerating	accelerate	VBG	B-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
blood	blood	NN	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcitriol	calcitriol	NN	B-NP	O	S-drug
/	/	SYM	B-NP	O	O
ergocalcitriol	ergocalcitriol	NN	I-NP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Rocaltrol	Rocaltrol	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
if	if	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

Thiazides	Thiazide	NNS	B-NP	O	S-group
:	:	:	O	O	O
Thiazides	Thiazide	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thiazides	thiazide	NNS	B-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-EF-2
D	D	NN	I-NP	O	E-group-EF-2
causes	cause	VBZ	B-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
precaution	precaution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministration	coadministration	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	S-group
:	:	:	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-group-AD-1
D	D	NN	I-NP	O	E-group-AD-1
dosage	dosage	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
care	care	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-AD-2
,	,	,	O	O	O
as	as	IN	B-PP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
precipitate	precipitate	VB	I-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
both	both	CC	O	O	O
synthetic	synthetic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
catabolic	catabolic	JJ	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-ME-2
D	D	NN	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Reductions	Reduction	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
endogenous	endogenous	JJ	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	O
D	D	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1200	1200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
week	week	NN	I-NP	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
men	man	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
:	:	:	O	O	O
A	A	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
of	of	IN	B-PP	O	O
functional	functional	JJ	B-NP	O	O
antagonism	antagonism	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
between	between	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-ME-1
D	D	NN	I-NP	O	I-group-ME-1
analogues	analogue	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
promote	promote	VBP	B-VP	O	O
calcium	calcium	NN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
calcium	calcium	NN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Phosphate	Phosphate	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Binding	Binding	NNP	I-NP	O	O
Agents	Agent	NNPS	I-NP	O	O
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
also	also	RB	B-ADVP	O	O
has	have	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
phosphate	phosphate	NN	B-NP	O	O
transport	transport	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intestine	intestine	NN	I-NP	O	O
,	,	,	O	O	O
kidneys	kidney	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
bones	bone	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phosphate	phosphate	NN	B-NP	O	O
-	-	HYPH	O	O	O
binding	bind	VBG	B-NP	O	O
agents	agent	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
accordance	accordance	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
phosphate	phosphate	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

Vitamin	Vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group
D	D	NN	I-NP	O	I-group
analogues	analogue	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
as	as	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
could	could	MD	B-VP	O	O
create	create	VB	I-VP	O	O
possible	possible	JJ	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
hypercalcemia	hypercalcemia	NN	I-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	S-drug
Supplements	Supplement	NNS	I-NP	O	O
:	:	:	O	O	O
Uncontrolled	Uncontrolled	JJ	B-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
additional	additional	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Magnesium	Magnesium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Magnesium	Magnesium	NN	B-NP	O	S-drug-AD-1
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypermagnesemia	hypermagnesemia	NN	B-NP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-AD-2
D	D	NN	I-NP	O	E-group-AD-2
by	by	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	I-group
analogues	analogue	NNS	I-NP	O	E-group
(	(	(	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug
D2	D2	NN	I-NP	O	E-drug
,	,	,	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug
D3	D3	NN	I-NP	O	E-drug
,	,	,	O	O	O
Calcitriol	Calcitriol	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
Calcidiol	Calcidiol	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fat	fat	JJ	B-NP	O	B-group-ME-2
soluble	soluble	JJ	I-NP	O	I-group-ME-2
vitamins	vitamin	NNS	I-NP	O	E-group-ME-2
;	;	:	O	O	O

as	as	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
it	it	PRP	I-NP	O	O
may	may	MD	B-VP	O	O
impair	impair	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Phenobarbital	Phenobarbital	NN	I-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
or	or	CC	I-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug-ME-1
will	will	MD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
,	,	,	O	O	O
but	but	CC	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
endogenous	endogenous	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcitriol	calcitriol	NN	B-NP	O	S-drug-ME-2
/	/	SYM	B-NP	O	O
ergocalcitriol	ergocalcitriol	NN	I-NP	O	O
by	by	IN	B-PP	O	O
accelerating	accelerate	VBG	B-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
blood	blood	NN	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcitriol	calcitriol	NN	B-NP	O	S-drug
/	/	SYM	B-NP	O	O
ergocalcitriol	ergocalcitriol	NN	I-NP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Rocaltrol	Rocaltrol	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
if	if	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

Thiazides	Thiazide	NNS	B-NP	O	S-group
:	:	:	O	O	O
Thiazides	Thiazide	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	S-drug
excretion	excretion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thiazides	thiazide	NNS	B-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-EF-2
D	D	NN	I-NP	O	E-group-EF-2
causes	cause	VBZ	B-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
precaution	precaution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministration	coadministration	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	S-group
:	:	:	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-group-AD-1
D	D	NN	I-NP	O	E-group-AD-1
dosage	dosage	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
care	care	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-AD-2
,	,	,	O	O	O
as	as	IN	B-PP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
precipitate	precipitate	VB	I-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
both	both	CC	O	O	O
synthetic	synthetic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
catabolic	catabolic	JJ	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-ME-2
D	D	NN	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Reductions	Reduction	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
endogenous	endogenous	JJ	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	O
D	D	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1200	1200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
week	week	NN	I-NP	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
men	man	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
:	:	:	O	O	O
A	A	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
of	of	IN	B-PP	O	O
functional	functional	JJ	B-NP	O	O
antagonism	antagonism	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
between	between	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-ME-1
D	D	NN	I-NP	O	I-group-ME-1
analogues	analogue	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
promote	promote	VBP	B-VP	O	O
calcium	calcium	NN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
calcium	calcium	NN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Phosphate	Phosphate	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Binding	Binding	NNP	I-NP	O	O
Agents	Agent	NNPS	I-NP	O	O
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
also	also	RB	B-ADVP	O	O
has	have	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
phosphate	phosphate	NN	B-NP	O	O
transport	transport	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intestine	intestine	NN	I-NP	O	O
,	,	,	O	O	O
kidneys	kidney	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
bones	bone	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phosphate	phosphate	NN	B-NP	O	O
-	-	HYPH	O	O	O
binding	bind	VBG	B-NP	O	O
agents	agent	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
accordance	accordance	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
phosphate	phosphate	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

Vitamin	Vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group
D	D	NN	I-NP	O	I-group
analogues	analogue	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
as	as	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
could	could	MD	B-VP	O	O
create	create	VB	I-VP	O	O
possible	possible	JJ	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
hypercalcemia	hypercalcemia	NN	I-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	S-drug
Supplements	Supplement	NNS	I-NP	O	O
:	:	:	O	O	O
Uncontrolled	Uncontrolled	JJ	B-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
additional	additional	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Magnesium	Magnesium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Magnesium	Magnesium	NN	B-NP	O	S-drug-AD-1
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypermagnesemia	hypermagnesemia	NN	B-NP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-AD-2
D	D	NN	I-NP	O	E-group-AD-2
by	by	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
containing	contain	VBG	B-VP	O	O
medicines	medicine	NNS	B-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
)	)	)	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
too	too	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
calcium	calcium	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
or	or	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Using	Use	VBG	B-VP	O	O
calcium	calcium	NN	B-NP	O	B-drug-EF-1
acetate	acetate	NN	I-NP	O	E-drug-EF-1
with	with	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	B-group-EF-2
glycosides	glycoside	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
heart	heart	NN	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
(	(	(	O	O	O
too	too	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
calcium	calcium	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
irregular	irregular	JJ	I-NP	O	O
heartbeat	heartbeat	NN	I-NP	O	O
.	.	.	O	O	O

May	May	MD	O	O	O
interact	interact	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
cefamandole	cefamandole	NN	B-NP	O	B-drug
naftate	naftate	NN	I-NP	O	E-drug
,	,	,	O	O	O
cephalothin	cephalothin	JJ	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
,	,	,	O	O	O
magnesium	magnesium	NN	B-NP	O	B-drug
sulfate	sulfate	NN	I-NP	O	E-drug
,	,	,	O	O	O
prednisolone	prednisolone	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	I-drug
succinate	succinate	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
prochlorperazine	prochlorperazine	NN	B-NP	O	B-drug
edisylate	edisylate	NN	I-NP	O	E-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
candesartan	candesartan	NN	B-NP	O	B-drug
cilexetil	cilexetil	NN	I-NP	O	E-drug
given	give	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
given	give	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
enalapril	enalapril	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
(	(	(	O	O	O
NYHA	NYHA	NN	B-NP	O	O
class	class	NN	I-NP	O	O
II	II	CD	I-NP	O	O
and	and	CC	I-NP	O	O
III	III	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
candesartan	candesartan	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
and	and	CC	B-PP	O	O
at	at	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
or	or	CC	O	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
those	those	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
Reversible	Reversible	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
toxicity	toxicity	NN	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-ME-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
angiotensin	angiotensin	NN	I-NP	O	B-group-ME-2
II	II	CD	I-NP	O	I-group-ME-2
receptor	receptor	NN	I-NP	O	I-group-ME-2
antagonists	antagonist	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

An	An	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
ATACAND	ATACAND	NN	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
so	so	RB	B-NP	O	O
careful	careful	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Antacid	Antacid	NN	B-NP	O	S-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
aluminum	aluminum	NN	I-NP	O	B-drug
hydroxide	hydroxide	NN	I-NP	O	E-drug
-	-	HYPH	O	O	O
and	and	CC	O	O	O
magnesium	magnesium	NN	B-NP	O	B-drug
hydroxide	hydroxide	NN	I-NP	O	E-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacid	antacid	NN	B-NP	O	S-group
(	(	(	O	O	O
Maalox	Maalox	NN	B-NP	O	S-brand
)	)	)	O	O	O
*	*	SYM	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
capecitabine	capecitabine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
capecitabine	capecitabine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
DFCR	DFCR	NN	I-NP	O	E-drug_n
)	)	)	O	O	O
;	;	:	O	O	O

there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
3	3	CD	I-NP	O	O
major	major	JJ	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
DFUR	DFUR	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
5	5	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
FU	FU	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
FBAL	FBAL	NN	I-NP	B-protein	S-drug_n
)	)	)	O	O	O
.	.	.	O	O	O

Coumarin	Coumarin	NN	B-NP	O	B-group
Anticoagulants	Anticoagulant	NNS	I-NP	O	E-group
Altered	Alter	VBD	B-VP	O	O
coagulation	coagulation	NN	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
bleeding	bleed	VBG	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
capecitabine	capecitabine	NN	B-NP	O	S-drug-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
derivative	derivative	JJ	I-NP	O	I-group-EF-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
phenprocoumon	phenprocoumon	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-AD-1
-	-	HYPH	B-NP	O	I-group-AD-1
derivative	derivative	JJ	I-NP	O	I-group-AD-1
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-AD-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
capecitabine	capecitabine	NN	B-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
regularly	regularly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
(	(	(	O	O	O
PT	PT	NN	B-NP	O	O
or	or	CC	O	O	O
INR	INR	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Leucovorin	Leucovorin	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	B-drug-ME-1
-	-	HYPH	I-NP	O	I-drug-ME-1
fluorouracil	fluorouracil	NN	I-NP	O	E-drug-ME-1
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
leucovorin	leucovorin	NN	B-NP	B-protein	S-drug-ME-2
.	.	.	O	O	O

Deaths	Death	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
enterocolitis	enterocolitis	NN	I-NP	O	O
,	,	,	O	O	O
diarrhea	diarrhea	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
dehydration	dehydration	NN	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
weekly	weekly	JJ	B-NP	O	O
leucovorin	leucovorin	NN	I-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
fluorouracil	fluorouracil	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Hypotension	Hypotension	NN	B-NP	O	O
Patients	Patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
Diuretic	Diuretic	JJ	B-NP	O	S-group
Therapy	Therapy	NN	I-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
especially	especially	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
diuretic	diuretic	JJ	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
recently	recently	RB	I-VP	O	O
instituted	institute	VBN	I-VP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
those	those	DT	B-NP	O	O
on	on	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
dietary	dietary	JJ	I-NP	O	O
salt	salt	NN	I-NP	O	O
restriction	restriction	NN	I-NP	O	O
or	or	CC	I-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
experience	experience	VB	I-VP	O	O
a	a	DT	B-NP	O	O
precipitous	precipitous	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
usually	usually	RB	B-ADVP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
hour	hour	NN	I-NP	O	O
after	after	IN	B-PP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
captopril	captopril	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotensive	hypotensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
captopril	captopril	NN	B-NP	O	S-drug-EF-1
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
either	either	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-EF-2
or	or	CC	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
salt	salt	NN	I-NP	O	O
intake	intake	NN	I-NP	O	O
approximately	approximately	RB	B-NP	O	O
one	one	CD	I-NP	O	O
week	week	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
captopril	captopril	NN	B-NP	O	S-drug
(	(	(	O	O	O
captopril	captopril	NN	B-NP	O	S-drug
tablets	tablet	NNS	I-NP	O	O
,	,	,	O	O	O
USP	USP	NN	B-NP	B-protein	O
)	)	)	O	O	O
or	or	CC	O	O	O
initiating	initiate	VBG	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
small	small	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
(	(	(	O	O	O
6.25	6.25	CD	B-NP	O	O
or	or	CC	I-NP	O	O
12.5	12.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Alternatively	Alternatively	RB	B-ADVP	O	O
,	,	,	O	O	O
provide	provide	VB	B-VP	O	O
medical	medical	JJ	B-NP	O	O
supervision	supervision	NN	I-NP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
one	one	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
hypotension	hypotension	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
placed	place	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
supine	supine	NN	I-NP	O	O
position	position	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
,	,	,	O	O	O
receive	receive	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
saline	saline	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
transient	transient	JJ	I-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
contraindication	contraindication	NN	I-NP	O	O
to	to	TO	B-PP	O	O
further	further	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
without	without	IN	B-PP	O	O
difficulty	difficulty	NN	B-NP	O	O
once	once	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
volume	volume	NN	B-NP	O	O
expansion	expansion	NN	I-NP	O	O
.	.	.	O	O	O

Agents	Agent	NNPS	B-NP	O	O
Having	Having	NNP	I-NP	O	O
Vasodilator	Vasodilator	NNP	I-NP	O	O
Activity	Activity	NNP	I-NP	O	O
:	:	:	O	O	O
Data	Data	NNP	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
vasodilators	vasodilator	NNS	I-NP	O	S-group
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
captopril	captopril	NN	B-NP	O	S-drug
for	for	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
available	available	JJ	B-ADJP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
nitroglycerin	nitroglycerin	NN	B-NP	O	S-drug-AD-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
nitrates	nitrate	NNS	I-NP	O	S-group-AD-1
(	(	(	O	O	O
as	as	IN	B-SBAR	O	O
used	use	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
management	management	NN	B-NP	O	O
of	of	IN	B-PP	O	O
angina	angina	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
having	have	VBG	B-VP	O	O
vasodilator	vasodilator	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
should	should	MD	B-VP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
possible	possible	JJ	B-ADJP	O	O
,	,	,	O	O	O
be	be	VB	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
captopril	captopril	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
resumed	resume	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
captopril	captopril	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
perhaps	perhaps	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Agents	Agent	NNPS	B-NP	O	O
Causing	Causing	NNP	I-NP	O	O
Renin	Renin	NNP	I-NP	B-protein	O
Release	Release	NNP	I-NP	O	O
Captopril	Captopril	NNP	I-NP	O	S-drug-EF-1
's	's	POS	B-NP	O	O
effect	effect	NN	I-NP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
augmented	augment	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
that	that	WDT	B-NP	O	O
cause	cause	VBP	B-VP	O	O
renin	renin	NN	B-NP	B-protein	O
release	release	NN	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
example	example	NN	B-NP	O	O
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
thiazides	thiazide	NNS	B-NP	O	S-group
)	)	)	O	O	O
may	may	MD	B-VP	O	O
activate	activate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
renin	renin	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
angiotensin	angiotensin	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
aldosterone	aldosterone	NN	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
Affecting	Affect	VBG	B-VP	O	O
Sympathetic	Sympathetic	JJ	B-NP	O	O
Activity	Activity	NN	I-NP	O	O
The	The	DT	B-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
especially	especially	RB	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
supporting	support	VBG	B-VP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
captopril	captopril	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
agents	agent	NNS	B-NP	O	O
affecting	affect	VBG	B-VP	O	O
sympathetic	sympathetic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ganglionic	ganglionic	JJ	B-NP	O	B-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
or	or	CC	O	O	O
adrenergic	adrenergic	JJ	B-NP	O	B-group
neuron	neuron	NN	I-NP	O	I-group
blocking	block	VBG	B-VP	O	I-group
agents	agent	NNS	B-NP	O	E-group
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-1
blocking	block	VBG	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
add	add	VBP	B-VP	O	O
some	some	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
to	to	TO	B-VP	O	O
captopril	captopril	VB	I-VP	O	S-drug-EF-2
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
additive	additive	JJ	B-ADJP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
Increasing	Increase	VBG	B-VP	O	O
Serum	Serum	NN	B-NP	O	O
Potassium	Potassium	NN	I-NP	O	O
Since	Since	IN	B-SBAR	O	O
captopril	captopril	NN	B-NP	O	S-drug
decreases	decrease	VBZ	B-VP	O	O
aldosterone	aldosterone	NN	B-NP	O	O
production	production	NN	I-NP	O	O
,	,	,	O	O	O
elevation	elevation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Potassium	Potassium	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
amiloride	amiloride	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
potassium	potassium	NN	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
documented	document	VBN	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
.	.	.	O	O	O

Salt	Salt	NNP	B-NP	O	O
substitutes	substitute	VBZ	B-VP	O	O
containing	contain	VBG	I-VP	O	O
potassium	potassium	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
Of	Of	IN	B-PP	O	O
Endogenous	Endogenous	JJ	B-NP	O	O
Prostaglandin	Prostaglandin	NN	I-NP	O	O
Synthesis	Synthesis	NN	I-NP	O	O
It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
captopril	captopril	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
renin	renin	NN	I-NP	B-protein	O
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
)	)	)	O	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
have	have	VB	I-VP	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
ACE	ACE	NN	I-NP	O	B-group-EF-2
inhibitor	inhibitor	NN	I-NP	O	E-group-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
coad	coad	NN	B-NP	O	O
-	-	HYPH	O	O	O
ministered	minister	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	O	O	O
frequent	frequent	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-EF-1
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	B-group
Glycosides	Glycoside	NNS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
young	young	JJ	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
captopril	captopril	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
interaction	interaction	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

Loop	Loop	NNP	B-NP	O	B-group
Diuretics	Diuretics	NNP	I-NP	O	E-group
:	:	:	O	O	O
Furosemide	Furosemide	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
captopril	captopril	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
captopril	captopril	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
renally	renally	RB	B-NP	O	O
impaired	impaired	JJ	I-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Allopurinol	Allopurinol	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
when	when	WRB	B-ADVP	O	O
captopril	captopril	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
allopurinol	allopurinol	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
/	/	NNP	I-NP	O	O
Laboratory	Laboratory	NNP	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Captopril	Captopril	NNP	I-NP	O	S-drug
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
urine	urine	NN	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
acetone	acetone	NN	B-NP	O	O
.	.	.	O	O	O

Clinically	Clinically	RB	B-NP	O	O
meaningful	meaningful	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
and	and	CC	O	O	O
include	include	VBP	B-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
limited	limit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
Agents	Agent	NNS	B-NP	O	O
Highly	Highly	RB	B-ADVP	O	O
Bound	Bind	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
Plasma	Plasma	NN	B-NP	O	O
Protein	Protein	NN	I-NP	O	O
Carbamazepine	Carbamazepine	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
highly	highly	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
taking	take	VBG	B-VP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-NP	O	O
protein	protein	NN	I-NP	O	O
bound	bind	VBD	B-VP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
free	free	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
Inhibit	Inhibit	VBP	B-VP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
Isoenzymes	Isoenzyme	NNS	I-NP	I-protein	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
Epoxide	Epoxide	NN	B-NP	B-protein	O
Hydrolase	Hydrolase	NN	I-NP	I-protein	O
Carbamazepine	Carbamazepine	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
mainly	mainly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	I-protein	O
CYP	CYP	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
3A4	3A4	NN	B-NP	I-protein	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	B-drug
10,11	10,11	CD	I-NP	O	I-drug
-	-	HYPH	I-NP	O	I-drug
epoxide	epoxide	NN	I-NP	O	E-drug
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
further	further	RBR	B-ADJP	O	O
metabolized	metabolize	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
trans	trans	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
diol	diol	NN	I-NP	O	O
by	by	IN	B-PP	O	O
epoxide	epoxide	NN	B-NP	B-protein	O
hydrolase	hydrolase	NN	I-NP	I-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
any	any	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
epoxide	epoxide	NN	B-NP	B-protein	O
hydrolase	hydrolase	NN	I-NP	I-protein	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
are	be	VBP	B-VP	O	O
expected	expect	VBN	I-VP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand-ME-1
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
azole	azole	NN	B-NP	O	B-group-ME-2
antifungals	antifungal	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
1	1	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
dalfopristin	dalfopristin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
danazol	danazol	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
delavirdine	delavirdine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
1	1	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
,	,	,	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
loratadine	loratadine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
niacinamide	niacinamide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nicotinamide	nicotinamide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
protease	protease	NN	B-NP	O	B-group-ME-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
propoxyphene	propoxyphene	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
quinine	quinine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
quinupristin	quinupristin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
valproate	valproate	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
1	1	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
zileuton	zileuton	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	B-VP	O	O
begins	begin	VBZ	I-VP	O	O
a	a	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
or	or	CC	I-NP	O	O
epoxide	epoxide	NN	I-NP	B-protein	O
hydrolase	hydrolase	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
reasonable	reasonable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
expect	expect	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
Induce	Induce	VBP	B-VP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
Isoenzymes	Isoenzyme	NNS	I-NP	I-protein	O
Carbamazepine	Carbamazepine	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
any	any	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
induces	induce	VBZ	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
CYP	CYP	NN	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
are	be	VBP	B-VP	O	O
expected	expect	VBN	I-VP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand-ME-1
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
Cisplatin	Cisplatin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
doxorubicin	doxorubicin	NN	B-NP	O	B-drug-ME-2
HCL	HCL	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
felbamate	felbamate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
primidone	primidone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
methsuximide	methsuximide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
Thus	Thus	RB	O	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
on	on	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NNP	B-NP	O	S-brand
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	B-VP	O	O
begins	begin	VBZ	I-VP	O	O
a	a	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducers	inducer	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
reasonable	reasonable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
expect	expect	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
for	for	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Decreased	Decrease	VBN	B-NP	O	O
Levels	Level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Presence	Presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
Induction	Induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
Enzymes	Enzyme	NNS	I-NP	I-protein	O
Carbamazepine	Carbamazepine	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
any	any	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
one	one	CD	B-NP	O	O
(	(	(	O	O	O
or	or	CC	O	O	O
more	more	JJR	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
are	be	VBP	B-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand-ME-1
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
Acetaminophen	Acetaminophen	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
amitriptyline	amitriptyline	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
bupropion	bupropion	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
buspirone	buspirone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
citalopram	citalopram	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clobazam	clobazam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clozapine	clozapine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
cyclosporin	cyclosporin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
delavirdine	delavirdine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
desipramine	desipramine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
dicumarol	dicumarol	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
doxycycline	doxycycline	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
ethosuximide	ethosuximide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
felbamate	felbamate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
felodipine	felodipine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
glucocorticoids	glucocorticoid	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
lamotrigine	lamotrigine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
levothyroxine	levothyroxine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
lorazepam	lorazepam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
methadone	methadone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
mirtazapine	mirtazapine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nortriptyline	nortriptyline	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-ME-2
(	(	(	O	O	O
3	3	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
oxcarbazepine	oxcarbazepine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
4	4	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
praziquantel	praziquantel	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
protease	protease	NN	B-NP	O	B-group-ME-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
quetiapine	quetiapine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
risperidone	risperidone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
topiramate	topiramate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
tramadol	tramadol	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
valproate	valproate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
5	5	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
ziprasidone	ziprasidone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
zonisamide	zonisamide	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
on	on	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
category	category	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	B-VP	O	O
begins	begin	VBZ	I-VP	O	O
a	a	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
reasonable	reasonable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
expect	expect	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Increased	Increase	VBN	B-NP	O	O
Levels	Level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Presence	Presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
:	:	:	O	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
:	:	:	O	O	O
Clomipramine	Clomipramine	NN	B-NP	O	B-drug-ME-2
HCl	HCl	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
primidone	primidone	NN	B-NP	O	S-drug-ME-2
Thus	Thus	RB	O	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
on	on	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
category	category	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	B-VP	O	O
begins	begin	VBZ	I-VP	O	O
a	a	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
reasonable	reasonable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
expect	expect	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Pharmacological	Pharmacological	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
Pharmacodynamic	Pharmacodynamic	JJ	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
Concomitant	Concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurotoxic	neurotoxic	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
thyroid	thyroid	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticonvulsants	anticonvulsant	NNS	I-NP	O	S-group
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
anti	anti	AFX	O	O	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
malarial	malarial	JJ	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
mefloquine	mefloquine	NN	I-NP	O	S-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
on	on	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
category	category	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	B-VP	O	O
begins	begin	VBZ	I-VP	O	O
a	a	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
reasonable	reasonable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
expect	expect	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
primary	primary	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
EQUETROTM	EQUETROTM	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
centrally	centrally	RB	I-NP	O	B-group-AD-2
acting	act	VBG	I-NP	O	I-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
and	and	CC	I-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Geocillin	Geocillin	NN	B-NP	B-protein	S-brand-ME-1
(	(	(	O	O	O
carbenicillin	carbenicillin	NN	B-NP	O	B-drug-ME-1
indanyl	indanyl	NN	I-NP	O	I-drug-ME-1
sodium	sodium	NN	I-NP	O	E-drug-ME-1
)	)	)	O	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
and	and	CC	O	O	O
prolonged	prolong	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
LODOSYN	LODOSYN	NN	B-NP	O	S-brand
(	(	(	O	O	O
Carbidopa	Carbidopa	NN	B-NP	O	S-drug
)	)	)	O	O	O
given	give	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
carbidopa	carbidopa	NN	I-NP	B-protein	S-drug
-	-	HYPH	B-NP	I-protein	O
levodopa	levodopa	NN	I-NP	I-protein	S-drug
combination	combination	NN	I-NP	I-protein	O
products	product	NNS	I-NP	I-protein	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
monoamine	monoamine	NN	B-NP	O	B-group
oxidase	oxidase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
see	see	VB	B-VP	O	O
CONTRAINDICATIONS	CONTRAINDICATIONS	NNS	B-NP	O	O
.	.	.	O	O	O

Dopamine	Dopamine	NN	B-NP	O	B-group-EF-1
D2	D2	NN	I-NP	O	I-group-EF-1
receptor	receptor	NN	I-NP	O	I-group-EF-1
antagonists	antagonist	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
butyrophenones	butyrophenone	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
risperidone	risperidone	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
beneficial	beneficial	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	O	S-drug-EF-1
in	in	IN	B-PP	O	O
Parkinsons	Parkinsons	NNP	B-NP	O	O
disease	disease	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
reversed	reverse	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
papaverine	papaverine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
LODOSYN	LODOSYN	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
levodopa	levodopa	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
carbidopa	carbidopa	NN	I-NP	B-protein	S-drug
-	-	HYPH	B-NP	I-protein	O
levodopa	levodopa	NN	I-NP	I-protein	S-drug
combination	combination	NN	I-NP	I-protein	O
products	product	NNS	I-NP	I-protein	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Iron	Iron	NN	B-NP	O	S-drug-ME-1
salts	salt	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbidopa	carbidopa	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
levodopa	levodopa	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
gastric	gastric	JJ	B-NP	O	O
emptying	emptying	NN	I-NP	O	O
,	,	,	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
adversely	adversely	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
disease	disease	NN	B-NP	O	O
control	control	NN	I-NP	O	O
by	by	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
dopamine	dopamine	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonistic	antagonistic	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
.	.	.	O	O	O

Iodine	Iodine	NN	B-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
iodine	iodine	NN	I-NP	O	S-drug
excess	excess	NN	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Carbimazole	Carbimazole	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
iodine	iodine	NN	I-NP	O	S-drug-EF-1
deficiency	deficiency	NN	I-NP	O	O
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Carbimazole	Carbimazole	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
digitoxin	digitoxin	NN	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
patients	patient	NNS	B-NP	O	O
take	take	VBP	B-VP	O	O
antithyroid	antithyroid	JJ	B-NP	O	B-group-ME-2
agents	agent	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

A	A	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
patient	patient	NN	B-NP	O	O
becomes	become	VBZ	B-VP	O	O
euthyroid	euthyroid	JJ	B-ADJP	O	O
.	.	.	O	O	O

Antithyroid	Antithyroid	JJ	B-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
thyroidal	thyroidal	JJ	B-NP	O	O
uptake	uptake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B-protein	B-drug-EF-2
iodide	iodide	NN	I-NP	I-protein	I-drug-EF-2
I131	I131	NN	I-NP	I-protein	E-drug-EF-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
rebound	rebound	NN	I-NP	O	O
in	in	IN	B-PP	O	O
uptake	uptake	NN	B-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
sudden	sudden	JJ	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Carbimazole	Carbimazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
/	/	SYM	I-NP	O	O
her	her	PRP$	I-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
and	and	CC	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
status	status	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O

Antihistamines	Antihistamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
prolong	prolong	VB	B-VP	O	O
and	and	CC	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Sympathomimetic	Sympathomimetic	JJ	B-NP	O	B-group-EF-1
amines	amine	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
veratrum	veratrum	NN	B-NP	O	B-group-EF-2
alkaloids	alkaloid	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
mecamylamine	mecamylamine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
sympathomimetics	sympathomimetic	NNS	B-NP	O	S-group-EF-1
are	be	VBP	B-VP	O	O
increased	increase	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	B-group-EF-2
adrenergic	adrenergic	JJ	I-NP	O	I-group-EF-2
blockers	blocker	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxic	nephrotoxic	JJ	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
Carboplatin	Carboplatin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

HEMABATE	HEMABATE	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
augment	augment	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
oxytocic	oxytocic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
oxytocic	oxytocic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O

Ocupress	Ocupress	NNP	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
adrenergic	adrenergic	JJ	I-NP	O	I-group-AD-2
blocking	block	VBG	I-NP	O	I-group-AD-2
agent	agent	NN	I-NP	O	E-group-AD-2
orally	orally	RB	B-ADVP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
.	.	.	O	O	O

Close	Close	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
blocker	blocker	NN	I-NP	O	E-group-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
catecholamine	catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
possible	possible	JJ	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
production	production	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
marked	marked	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
vertigo	vertigo	RB	B-ADVP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
postural	postural	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
;	;	:	O	O	O

poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
debrisoquin	debrisoquin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Interactions	Interaction	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
carvedilol	carvedilol	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
strong	strong	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
propafenone	propafenone	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
R	R	NN	I-NP	O	O
(	(	(	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
enantiomer	enantiomer	NN	B-NP	O	O
of	of	IN	B-PP	O	O
carvedilol	carvedilol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Retrospective	Retrospective	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
poor	poor	JJ	B-NP	O	O
2D6	2D6	NN	I-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dizziness	dizziness	NN	B-NP	O	O
during	during	IN	B-PP	O	O
up	up	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
titration	titration	NN	B-NP	O	O
,	,	,	O	O	O
presumably	presumably	RB	B-ADVP	O	O
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
vasodilating	vasodilate	VBG	B-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
a	a	NN	I-NP	O	O
-	-	:	O	O	O
blocking	block	VBG	B-VP	O	O
R	R	NN	B-NP	O	O
(	(	(	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
enantiomer	enantiomer	NN	B-NP	O	O
.	.	.	O	O	O

Catecholamine	Catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
Agents	Agent	NNPS	B-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	B-group-EF-1
with	with	IN	B-PP	O	I-group-EF-1
b	b	NN	B-NP	O	I-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
blocking	block	VBG	B-VP	O	I-group-EF-1
properties	property	NNS	B-NP	O	E-group-EF-1
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
deplete	deplete	VB	I-VP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
severe	severe	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
.	.	.	O	O	O

Clonidine	Clonidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	B-group-EF-2
with	with	IN	B-PP	O	I-group-EF-2
b	b	NN	B-NP	O	I-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
blocking	block	VBG	B-NP	O	I-group-EF-2
properties	property	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
heart	heart	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
rate	rate	NN	I-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-VP	O	O
effects	effect	NNS	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	B-group-AD-1
with	with	IN	B-PP	O	I-group-AD-1
b	b	NN	B-NP	O	I-group-AD-1
-	-	HYPH	O	O	I-group-AD-1
blocking	block	VBG	B-VP	O	I-group-AD-1
properties	property	NNS	B-NP	O	E-group-AD-1
and	and	CC	O	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
terminated	terminate	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
b	b	NN	I-NP	O	B-group
-	-	HYPH	O	O	I-group
blocking	block	VBG	B-VP	O	I-group
agent	agent	NN	B-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
first	first	RB	B-ADVP	O	O
.	.	.	O	O	O

Clonidine	Clonidine	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
can	can	MD	B-VP	O	O
then	then	RB	I-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
several	several	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
gradually	gradually	RB	B-VP	O	O
decreasing	decrease	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Modest	Modest	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
trough	trough	JJ	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug-ME-1
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
carvedilol	carvedilol	NN	B-NP	O	S-drug-ME-2
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
21	21	CD	B-NP	O	O
renal	renal	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
suffering	suffer	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
rejection	rejection	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
about	about	IN	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
remainder	remainder	NN	I-NP	O	O
no	no	DT	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
average	average	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
about	about	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
wide	wide	JJ	B-NP	O	O
interindividual	interindividual	JJ	I-NP	O	O
variability	variability	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
required	require	VBD	B-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-AD-1
concentrations	concentration	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
carvedilol	carvedilol	NN	B-NP	O	S-drug-AD-M
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-AD-2
be	be	VB	B-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
appropriate	appropriate	JJ	B-ADJP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Digoxin	Digoxin	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
15	15	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
carvedilol	carvedilol	NN	I-NP	O	S-drug-ME-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
COREG	COREG	NN	I-NP	O	S-brand-EF-2
slow	slow	JJ	I-NP	O	O
AV	AV	NN	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
,	,	,	O	O	O
adjusting	adjust	VBG	B-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
COREG	COREG	NN	B-NP	B-protein	S-brand-AD-2
.	.	.	O	O	O

Inducers	Inducer	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
Inhibitors	Inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Hepatic	Hepatic	JJ	B-NP	O	O
Metabolism	Metabolism	NN	I-NP	O	O
:	:	:	O	O	O
Rifampin	Rifampin	NN	B-NP	O	S-drug-ME-1
reduced	reduce	VBD	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
carvedilol	carvedilol	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
70	70	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
AUC	AUC	NN	B-NP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
but	but	CC	O	O	O
caused	cause	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NNP	B-NP	O	B-group
Channel	Channel	NNP	I-NP	O	I-group
Blockers	Blocker	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Isolated	Isolate	VBN	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
conduction	conduction	NN	B-NP	O	O
disturbance	disturbance	NN	I-NP	O	O
(	(	(	O	O	O
rarely	rarely	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
hemodynamic	hemodynamic	JJ	B-NP	O	O
compromise	compromise	NN	I-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
COREG	COREG	NN	B-NP	B-protein	S-brand-EF-1
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	B-group
with	with	IN	B-PP	O	I-group
b	b	NN	B-NP	O	I-group
-	-	HYPH	O	O	I-group
blocking	block	VBG	B-VP	O	I-group
properties	property	NNS	B-NP	O	E-group
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
COREG	COREG	NN	B-NP	B-protein	S-brand-AD-1
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
orally	orally	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug-AD-2
type	type	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
ECG	ECG	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Insulin	Insulin	NN	B-NP	B-protein	S-drug
or	or	CC	O	O	O
Oral	Oral	JJ	B-NP	O	O
Hypoglycemics	Hypoglycemic	NNS	I-NP	O	S-group
:	:	:	O	O	O
Agents	Agent	NNS	B-NP	O	B-group-EF-1
with	with	IN	B-PP	O	I-group-EF-1
b	b	NN	B-NP	O	I-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
blocking	block	VBG	B-NP	O	I-group-EF-1
properties	property	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
sugar	sugar	NN	I-NP	O	O
-	-	HYPH	O	O	O
reducing	reduce	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug-EF-2
and	and	CC	I-NP	O	O
oral	oral	JJ	I-NP	O	O
hypoglycemics	hypoglycemic	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemics	hypoglycemic	NNS	I-NP	O	S-group
,	,	,	O	O	O
regular	regular	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
caspofungin	caspofungin	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
)	)	)	O	O	O
system	system	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
caspofungin	caspofungin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Caspofungin	Caspofungin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
poor	poor	JJ	I-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CANCIDAS	CANCIDAS	NN	B-NP	B-protein	S-brand
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
,	,	,	O	O	O
mycophenolate	mycophenolate	NN	B-NP	O	S-drug
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
.	.	.	O	O	O

CANCIDAS	CANCIDAS	NN	B-NP	B-protein	S-brand
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
,	,	,	O	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mycophenolate	mycophenolate	NN	B-NP	O	O
.	.	.	O	O	O

CANCIDAS	CANCIDAS	NN	B-NP	O	S-brand-ME-1
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
AUC0	AUC0	NN	I-NP	O	O
-	-	HYPH	O	O	O
12	12	CD	B-NP	O	O
of	of	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
peak	peak	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
(	(	(	O	O	O
Cmax	Cmax	NN	B-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
12	12	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
blood	blood	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
(	(	(	O	O	O
C12hr	C12hr	NN	B-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
26	26	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
(	(	(	O	O	O
2	2	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
0.1	0.1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
12	12	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
apart	apart	RB	B-ADVP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
10th	10th	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CANCIDAS	CANCIDAS	NN	B-NP	O	S-brand
70	70	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
results	result	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
control	control	NN	I-NP	O	O
period	period	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
,	,	,	O	O	O
standard	standard	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
blood	blood	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
two	two	CD	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
one	one	CD	B-NP	O	O
4	4	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
dose	dose	NN	I-NP	O	O
or	or	CC	O	O	O
two	two	CD	B-NP	O	O
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caspofungin	caspofungin	NN	B-NP	B-protein	S-drug-ME-2
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
35	35	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

CANCIDAS	CANCIDAS	NN	B-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
transient	transient	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
ALT	ALT	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AST	AST	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
CANCIDAS	CANCIDAS	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	B-NP	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
caspofungin	caspofungin	NN	B-NP	O	S-drug-ME-2
trough	trough	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
receive	receive	VB	I-VP	O	O
70	70	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CANCIDAS	CANCIDAS	NN	B-NP	B-protein	S-brand-AD-2
daily	daily	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
results	result	VBZ	B-VP	O	O
from	from	IN	B-PP	O	O
regression	regression	NN	B-NP	O	O
analyses	analysis	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
(	(	(	O	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
or	or	CC	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
with	with	IN	B-PP	O	O
CANCIDAS	CANCIDAS	NN	B-NP	B-protein	S-brand-ME-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
meaningful	meaningful	JJ	I-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
caspofungin	caspofungin	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
which	which	WDT	B-NP	O	O
drug	drug	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
caspofungin	caspofungin	NN	B-NP	O	S-drug
disposition	disposition	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
inducible	inducible	JJ	B-ADJP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
CANCIDAS	CANCIDAS	NN	B-NP	B-protein	S-brand-AD-1
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
inducers	inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
70	70	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CANCIDAS	CANCIDAS	NN	B-NP	B-protein	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Positive	Positive	JJ	B-NP	O	O
direct	direct	JJ	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
tests	test	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cephalosporin	cephalosporin	NN	I-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
.	.	.	O	O	O

In	In	IN	B-PP	O	O
hematologic	hematologic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
transfusion	transfusion	NN	B-NP	B-cell_line	O
cross	cross	AFX	O	I-cell_line	O
-	-	HYPH	O	I-cell_line	O
matching	match	VBG	B-VP	I-cell_line	O
procedures	procedure	NNS	B-NP	I-cell_line	O
when	when	WRB	B-ADVP	I-cell_line	O
anti	anti	AFX	B-NP	I-cell_line	O
-	-	HYPH	I-NP	O	O
globulin	globulin	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
performed	perform	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
minor	minor	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
Coombs	Coombs	NNP	B-NP	O	O
testing	testing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
newborns	newborn	NNS	B-NP	O	O
whose	whose	WP$	B-NP	O	O
mothers	mother	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
received	receive	VBN	I-VP	O	O
cephalosporin	cephalosporin	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
before	before	IN	B-PP	O	O
parturition	parturition	NN	B-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
recognized	recognize	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cephalosporins	cephalosporin	NNS	B-NP	O	S-group-ME-2
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
more	more	RBR	I-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
cephalosporin	cephalosporin	NN	I-NP	O	S-group
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
A	A	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
Benedicts	Benedict	NNS	B-NP	O	O
solution	solution	NN	I-NP	O	O
,	,	,	O	O	O
Fehlings	Fehling	NNS	B-NP	O	O
solution	solution	NN	I-NP	O	O
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
CLINITEST	CLINITEST	NN	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
with	with	IN	B-PP	O	O
enzyme	enzyme	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
tests	test	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
CLINISTIX	CLINISTIX	NN	B-NP	B-protein	O
.	.	.	O	O	O

Positive	Positive	JJ	B-NP	O	O
direct	direct	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
indirect	indirect	JJ	I-NP	O	O
antiglobulin	antiglobulin	NN	I-NP	O	O
(	(	(	O	O	O
Coombs	Coomb	NNS	B-NP	O	O
)	)	)	O	O	O
tests	test	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
;	;	:	O	O	O

these	these	DT	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
neonates	neonate	NNS	B-NP	O	O
whose	whose	WP$	B-NP	O	O
mothers	mother	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
cephalosporins	cephalosporin	NNS	B-NP	O	S-group
before	before	IN	B-PP	O	O
delivery	delivery	NN	B-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
(	(	(	O	O	O
aluminum	aluminum	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
or	or	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
300	300	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
cefdinir	cefdinir	NN	I-NP	O	S-drug-ME-1
capsules	capsule	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
30	30	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
Maalox	Maalox	NN	I-NP	O	B-brand-ME-2
TC	TC	NN	I-NP	O	E-brand-ME-2
suspension	suspension	NN	I-NP	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
)	)	)	O	O	O
and	and	CC	O	O	O
extent	extent	NN	B-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Time	Time	NN	B-NP	O	O
to	to	TO	B-VP	O	O
reach	reach	VB	I-VP	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
1	1	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cefdinir	cefdinir	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
antacid	antacid	NN	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	B-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
cefdinir	cefdinir	NN	B-NP	O	S-drug
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
antacids	antacid	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
required	require	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
OMNICEF	OMNICEF	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
OMNICEF	OMNICEF	NN	B-NP	B-protein	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	I-PP	O	O
after	after	IN	I-PP	O	O
the	the	DT	B-NP	O	O
antacid	antacid	NN	I-NP	O	S-group-AD-2
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
b	b	NN	I-NP	O	B-group-ME-1
-	-	HYPH	B-NP	O	I-group-ME-1
lactam	lactam	NN	I-NP	O	I-group-ME-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cefdinir	cefdinir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
doubling	doubling	NN	I-NP	O	O
in	in	IN	B-PP	O	O
A.C.	A.C.	NNP	B-NP	O	O
a	a	DT	B-NP	O	O
54	54	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
peak	peak	NN	B-NP	O	O
cefdinir	cefdinir	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
.	.	.	O	O	O

Iron	Iron	NNP	B-NP	O	B-group
Supplements	Supplements	NNP	I-NP	O	E-group
and	and	CC	O	O	O
Foods	Foods	NNP	B-NP	O	O
Fortified	Fortified	NNP	I-NP	O	O
With	With	IN	B-PP	O	O
Iron	Iron	NNP	B-NP	O	S-drug
Concomitant	Concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cefdinir	cefdinir	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
iron	iron	NN	I-NP	O	B-group
supplement	supplement	NN	I-NP	O	E-group
containing	contain	VBG	B-VP	O	O
60	60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
elemental	elemental	JJ	B-NP	O	O
iron	iron	NN	I-NP	O	S-drug-ME-2
(	(	(	O	O	O
as	as	IN	B-PP	O	O
FeSO4	FeSO4	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
vitamins	vitamin	NNS	B-NP	O	S-group
supplemented	supplement	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
elemental	elemental	JJ	B-NP	O	O
iron	iron	NN	I-NP	O	S-drug-ME-2
reduced	reduce	VBD	B-VP	O	O
extent	extent	NN	B-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
by	by	IN	B-PP	O	O
80	80	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
31	31	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
iron	iron	NN	B-NP	O	B-group-AD-1
supplements	supplement	NNS	I-NP	O	E-group-AD-1
are	be	VBP	B-VP	O	O
required	require	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
OMNICEF	OMNICEF	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
OMNICEF	OMNICEF	NN	B-NP	B-protein	S-brand-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	I-PP	O	O
after	after	IN	I-PP	O	O
the	the	DT	B-NP	O	O
supplement	supplement	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
foods	food	NNS	B-NP	O	O
highly	highly	RB	B-VP	O	O
fortified	fortify	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
elemental	elemental	JJ	B-NP	O	O
iron	iron	NN	I-NP	O	S-drug_n
(	(	(	O	O	O
primarily	primarily	RB	B-NP	O	O
iron	iron	NN	I-NP	O	S-drug_n
-	-	HYPH	O	O	O
fortified	fortify	VBN	B-NP	O	O
breakfast	breakfast	NN	I-NP	O	O
cereals	cereal	NNS	I-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
cefdinir	cefdinir	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Concomitantly	Concomitantly	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
iron	iron	NN	I-NP	O	S-drug_n
-	-	HYPH	B-VP	O	O
fortified	fortify	VBN	B-NP	O	O
infant	infant	NN	I-NP	O	O
formula	formula	NN	I-NP	O	O
(	(	(	O	O	O
2.2	2.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
elemental	elemental	JJ	I-NP	O	O
iron	iron	NN	I-NP	O	S-drug_n
/	/	SYM	O	O	O
6	6	CD	B-NP	O	O
oz	oz	NN	I-NP	O	O
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
cefdinir	cefdinir	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
OMNICEF	OMNICEF	NN	B-NP	B-protein	S-brand
for	for	IN	B-PP	O	O
Oral	Oral	JJ	B-NP	O	O
Suspension	Suspension	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
iron	iron	NN	B-NP	O	S-drug_n
-	-	HYPH	B-NP	O	O
fortified	fortify	VBN	I-NP	O	O
infant	infant	NN	I-NP	O	O
formula	formula	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rare	rare	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
reddish	reddish	JJ	B-NP	O	O
stools	stool	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
received	receive	VBN	I-VP	O	O
cefdinir	cefdinir	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
Japan	Japan	NNP	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reddish	reddish	JJ	I-NP	O	O
color	color	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
formation	formation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonabsorbable	nonabsorbable	JJ	I-NP	B-protein	O
complex	complex	NN	I-NP	I-protein	O
between	between	IN	B-PP	O	O
cefdinir	cefdinir	NN	B-NP	O	S-drug-ME-1
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
breakdown	breakdown	NN	I-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
and	and	CC	I-NP	O	O
iron	iron	NN	I-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
A	A	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ketones	ketone	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
tests	test	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
nitroprusside	nitroprusside	NN	B-NP	O	S-drug
,	,	,	O	O	O
but	but	CC	B-PP	O	O
not	not	RB	I-PP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
using	use	VBG	I-NP	O	O
nitroferricyanide	nitroferricyanide	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cefdinir	cefdinir	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
using	use	VBG	B-VP	O	O
Clinitest	Clinitest	NNP	B-NP	O	O
,	,	,	O	O	O
Benedict	Benedict	NNP	B-NP	O	O
s	s	VBZ	B-VP	O	O
solution	solution	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
Fehlings	Fehling	NNS	B-NP	O	O
solution	solution	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
glucose	glucose	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
enzymatic	enzymatic	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
oxidase	oxidase	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Clinistix	Clinistix	NNP	B-NP	O	O
or	or	CC	I-NP	O	O
Tes	Tes	NNP	I-NP	O	O
-	-	HYPH	B-NP	O	O
Tape	Tape	NNP	I-NP	O	O
)	)	)	O	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

Cephalosporins	Cephalosporin	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
direct	direct	JJ	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
Multiple	Multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cefditoren	cefditoren	NN	B-NP	O	B-drug
pivoxil	pivoxil	NN	I-NP	O	E-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
estrogenic	estrogenic	JJ	I-NP	O	O
component	component	NN	I-NP	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
cefditoren	cefditoren	NN	B-NP	O	B-drug-AD-1
pivoxil	pivoxil	NN	I-NP	O	E-drug-AD-1
be	be	VB	B-VP	O	O
taken	take	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-2
.	.	.	O	O	O

H2	H2	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
Receptor	Receptor	NN	I-NP	O	I-group
Antagonists	Antagonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
Co	Co	AFX	O	B-DNA	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intravenously	intravenously	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
famotidine	famotidine	NN	I-NP	O	S-drug-ME-1
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cefditoren	cefditoren	NN	B-NP	O	B-drug-ME-2
pivoxil	pivoxil	NN	I-NP	O	E-drug-ME-2
administered	administer	VBN	B-VP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
meal	meal	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
evidenced	evidence	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
27	27	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
22	22	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
cefditoren	cefditoren	NN	B-NP	O	B-drug
pivoxil	pivoxil	NN	I-NP	O	E-drug
be	be	VB	B-VP	O	O
taken	take	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
H2	H2	NN	B-NP	B-protein	B-group
receptor	receptor	NN	I-NP	I-protein	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
b	b	NN	I-NP	O	B-group-ME-1
-	-	HYPH	B-NP	O	I-group-ME-1
lactam	lactam	NN	I-NP	O	I-group-ME-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
cefditoren	cefditoren	NN	B-NP	O	B-drug-ME-2
pivoxil	pivoxil	NN	I-NP	O	E-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cefditoren	cefditoren	NNS	B-NP	O	S-drug
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
49	49	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
122	122	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
53	53	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
half	half	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Cephalosporins	Cephalosporin	NNS	I-NP	O	S-group
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
direct	direct	JJ	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
copper	copper	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
(	(	(	O	O	O
Benedicts	Benedict	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
Fehlings	Fehling	NNS	I-NP	O	O
solution	solution	NN	I-NP	O	O
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
CLINITEST	CLINITEST	NN	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	B-PP	O	O
not	not	RB	I-PP	O	O
with	with	IN	B-PP	O	O
enzyme	enzyme	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
tests	test	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
glycosuria	glycosuria	NN	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
CLINISTIX	CLINISTIX	NN	B-NP	O	O
,	,	,	O	O	O
TES	TES	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
TAPE	TAPE	NN	I-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
negative	negative	JJ	I-NP	O	O
result	result	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ferricyanide	ferricyanide	NN	I-NP	O	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
glucose	glucose	NN	I-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
or	or	CC	O	O	O
hexokinase	hexokinase	NN	B-NP	O	O
method	method	NN	I-NP	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
cefditoren	cefditoren	NNS	B-NP	O	B-drug
pivoxil	pivoxil	NN	I-NP	O	E-drug
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group-AD-1
are	be	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
MAXIPIME	MAXIPIME	NN	B-NP	O	S-brand-AD-2
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	O
and	and	CC	I-NP	O	O
ototoxicity	ototoxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
.	.	.	O	O	O

Nephrotoxicity	Nephrotoxicity	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cephalosporins	cephalosporin	NNS	I-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cefepime	cefepime	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
Clinitest	Clinitest	NN	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
glucose	glucose	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
enzymatic	enzymatic	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
oxidase	oxidase	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Clinistix	Clinistix	NNP	B-NP	O	O
or	or	CC	I-NP	O	O
Tes	Tes	NNP	I-NP	O	O
-	-	HYPH	B-NP	O	O
Tape	Tape	NNP	I-NP	O	O
)	)	)	O	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NNP	B-NP	O	S-drug
:	:	:	O	O	O
Elevated	Elevate	VBN	B-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-ME-1
levels	level	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
postmarketing	postmarkete	VBG	B-VP	O	O
experience	experience	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
SUPRAX	SUPRAX	NN	B-NP	O	S-brand-ME-2
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
assistance	assistance	NN	B-NP	O	O
in	in	IN	B-PP	O	O
detecting	detect	VBG	B-VP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NNP	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
Anticoagulants	Anticoagulant	NNPS	I-NP	O	S-group-EF-1
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
cefixime	cefixime	NN	B-NP	O	S-drug-EF-2
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
A	A	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ketones	ketone	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
tests	test	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
nitroprusside	nitroprusside	NN	B-NP	O	S-drug
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
with	with	IN	I-PP	O	O
those	those	DT	B-NP	O	O
using	use	VBG	I-NP	O	O
nitroferricyanide	nitroferricyanide	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SUPRAX	SUPRAX	NN	B-NP	B-protein	S-brand
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
Clinitest	Clinitest	NN	B-NP	O	O
*	*	SYM	B-VP	O	O
*	*	SYM	B-NP	O	O
,	,	,	O	O	O
Benedict	Benedict	NNP	B-NP	O	O
s	s	VBZ	B-VP	O	O
solution	solution	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
Fehling	Fehling	NN	B-NP	O	O
s	s	NN	I-NP	O	O
solution	solution	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
glucose	glucose	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
enzymatic	enzymatic	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
oxidase	oxidase	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Clinistix	Clinistix	NN	B-NP	O	O
*	*	SYM	B-NP	O	O
*	*	SYM	B-VP	O	O
or	or	CC	O	O	O
Tes	Te	NNPS	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
Tape	Tape	NN	I-NP	B-DNA	O
*	*	SYM	O	I-DNA	O
*	*	SYM	O	O	O
)	)	)	O	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
direct	direct	JJ	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cephalosporin	cephalosporin	NN	I-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
recognized	recognize	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cephalosporins	cephalosporin	NNS	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-group-EF-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Cephalosporins	Cephalosporin	NNS	I-NP	O	S-group
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
cefotaxime	cefotaxime	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
direct	direct	JJ	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Increases	Increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
CEFOTAN	CEFOTAN	NN	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
CEFOTAN	CEFOTAN	NN	B-NP	O	S-brand-EF-1
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
aminoglycoside	aminoglycoside	NN	I-NP	O	S-group-EF-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CEFOTAN	CEFOTAN	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
Clinitest	Clinitest	NNP	B-NP	O	O
,	,	,	O	O	O
Benedicts	Benedicts	NNP	B-NP	O	O
solution	solution	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
Fehlings	Fehling	NNS	B-NP	O	O
solution	solution	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
glucose	glucose	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
enzymatic	enzymatic	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cephalosporins	cephalosporin	NNS	I-NP	O	S-group
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cefotetan	cefotetan	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
Jaffe	Jaffe	NN	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
and	and	CC	O	O	O
produce	produce	VBP	B-VP	O	O
false	false	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	O	O
reported	report	VBD	B-VP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cephalosporins	cephalosporin	NNS	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-group-EF-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
As	As	IN	B-ADVP	O	O
with	with	IN	B-PP	O	O
cephalothin	cephalothin	JJ	B-NP	O	S-drug
,	,	,	I-NP	O	O
high	high	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cefoxitin	cefoxitin	NN	B-NP	O	S-drug
(	(	(	O	O	O
100	100	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Jaff	Jaff	NNP	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
produce	produce	VB	B-VP	O	O
false	false	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
modest	modest	JJ	B-NP	O	O
degree	degree	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	O	O
reported	report	VBD	B-VP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
cefoxitin	cefoxitin	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	O	O
if	if	IN	B-SBAR	O	O
withdrawn	withdraw	VBN	B-VP	O	O
within	within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cefoxitin	cefoxitin	NN	B-NP	B-protein	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
17	17	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hydroxy	hydroxy	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Porter	Porter	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Silber	Silber	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
produce	produce	VB	B-VP	O	O
false	false	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
modest	modest	JJ	B-NP	O	O
degree	degree	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
reported	report	VBD	B-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CLINITEST	CLINITEST	NN	B-NP	O	O
reagent	reagent	NN	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O

Registered	Register	VBN	B-NP	O	O
trademark	trademark	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ames	Ames	NNP	B-NP	O	O
Company	Company	NNP	I-NP	O	O
,	,	,	O	O	O
Division	Division	NNP	B-NP	O	O
of	of	IN	B-PP	O	O
Miles	Miles	NNP	B-NP	O	O
Laboratories	Laboratories	NNP	I-NP	O	O
,	,	,	O	O	O
Inc	Inc	NNP	B-NP	O	O
.	.	.	O	O	O

Nephrotoxicity	Nephrotoxicity	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-group-EF-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
cephalosporin	cephalosporin	NN	B-NP	O	B-group-EF-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
doubled	double	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
for	for	IN	B-PP	O	O
cefprozil	cefprozil	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
capsule	capsule	NN	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cefprozil	cefprozil	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
5	5	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
an	an	DT	B-NP	O	O
antacid	antacid	NN	I-NP	O	S-group
.	.	.	O	O	O

Nephrotoxicity	Nephrotoxicity	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cephalosporins	cephalosporin	NNS	B-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-group-EF-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-2
or	or	CC	O	O	O
potent	potent	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
higher	high	JJR	B-NP	O	O
dosages	dosage	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
aminoglycosides	aminoglycoside	NNS	I-NP	O	S-group
are	be	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
or	or	CC	O	O	O
if	if	IN	B-SBAR	O	O
therapy	therapy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
ototoxicity	ototoxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycosidic	aminoglycosidic	JJ	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
.	.	.	O	O	O

Nephrotoxicity	Nephrotoxicity	NN	B-NP	O	O
and	and	CC	I-NP	O	O
ototoxicity	ototoxicity	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
noted	note	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ceftazidime	ceftazidime	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Chloramphenicol	Chloramphenicol	NN	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
antagonistic	antagonistic	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	B-NP	O	I-group-EF-2
lactam	lactam	NN	I-NP	O	I-group-EF-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ceftazidime	ceftazidime	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
and	and	CC	O	O	O
time	time	NN	B-NP	O	O
kill	kill	NN	I-NP	O	O
curves	curve	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
enteric	enteric	JJ	B-NP	O	O
gram	gram	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
negative	negative	JJ	I-NP	O	O
bacilli	bacilli	NNS	I-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antagonism	antagonism	NN	B-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
bactericidal	bactericidal	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
desired	desire	VBN	I-VP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
combination	combination	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ceftazidime	ceftazidime	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
CLINITEST	CLINITEST	NN	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
,	,	,	O	O	O
Benedicts	Benedict	VBZ	B-VP	O	O
solution	solution	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
Fehlings	Fehling	NNS	B-NP	O	O
solution	solution	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
glucose	glucose	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
enzymatic	enzymatic	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
oxidase	oxidase	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
CLINISTIX	CLINISTIX	NN	B-NP	O	O
or	or	CC	I-NP	O	O
TES	TES	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
TAPE	TAPE	NN	I-NP	O	O
)	)	)	O	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Twelve	Twelve	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
one	one	CD	B-NP	O	O
200	200	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
ceftibuten	ceftibuten	JJ	I-NP	O	S-drug
capsule	capsule	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
the	the	DT	B-NP	O	O
morning	morning	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ceftibuten	ceftibuten	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
6	6	CD	I-NP	O	O
,	,	,	O	O	O
each	each	DT	B-NP	O	O
volunteer	volunteer	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ceftibuten	ceftibuten	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
orally	orally	RB	B-ADVP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
or	or	CC	O	O	O
H	H	NN	B-NP	B-DNA	B-group
2	2	CD	I-NP	I-DNA	I-group
-	-	HYPH	I-NP	O	I-group
receptor	receptor	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
gastric	gastric	JJ	I-NP	O	O
pH	pH	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ceftibuten	ceftibuten	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
18	18	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
adult	adult	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
volunteer	volunteer	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
one	one	CD	B-NP	O	O
400	400	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
mg	mg	NN	I-NP	O	O
ceftibuten	ceftibuten	JJ	I-NP	O	S-drug
capsule	capsule	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
liquid	liquid	JJ	B-NP	O	O
antacid	antacid	NN	I-NP	O	S-group
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
C	C	NN	I-NP	O	O
max	max	NN	I-NP	O	O
or	or	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ceftibuten	ceftibuten	NNS	B-NP	O	S-drug
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ranitidine	ranitidine	NN	B-NP	B-protein	S-drug-ME-1
q12h	q12h	NN	I-NP	I-protein	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
ceftibuten	ceftibuten	JJ	I-NP	O	S-drug-ME-2
C	C	NN	I-NP	O	O
max	max	NN	I-NP	O	O
by	by	IN	B-PP	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
ceftibuten	ceftibuten	JJ	I-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
by	by	IN	B-PP	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
increases	increase	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
chemical	chemical	NN	I-NP	O	O
or	or	CC	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
ceftibuten	ceftibuten	NN	B-NP	O	S-drug
noted	note	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
date	date	NN	B-NP	O	O
.	.	.	O	O	O

False	False	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
direct	direct	JJ	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
tests	test	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cephalosporins	cephalosporin	NNS	I-NP	O	S-group
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
recognized	recognize	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
assays	assay	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
red	red	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
from	from	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
ceftibuten	ceftibuten	NN	B-NP	O	S-drug
would	would	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
direct	direct	JJ	B-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
at	at	IN	B-PP	O	O
ceftibuten	ceftibuten	JJ	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
as	as	RB	B-ADJP	O	O
high	high	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
40	40	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Cefizox	Cefizox	NN	B-NP	O	S-brand
,	,	,	O	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cephalosporins	cephalosporin	NNS	I-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
aminoglycosides	aminoglycoside	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
copper	copper	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
(	(	(	O	O	O
Benedict	Benedict	NNP	B-NP	O	O
s	s	NNS	I-NP	O	O
or	or	CC	O	O	O
Fehling	Fehle	VBG	B-VP	O	O
s	s	NNS	B-NP	O	O
solution	solution	NN	I-NP	O	O
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
Clinitest	Clinitest	NNP	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
)	)	)	O	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
with	with	IN	I-PP	O	O
enzyme	enzyme	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
tests	test	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
glycosuria	glycosuria	NN	B-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
negative	negative	JJ	I-NP	O	O
result	result	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ferricyanide	ferricyanide	NN	I-NP	O	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
glucose	glucose	NN	I-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
or	or	CC	O	O	O
hexokinase	hexokinase	NN	B-NP	O	O
method	method	NN	I-NP	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
cefuroxime	cefuroxime	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cefuroxime	Cefuroxime	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
assay	assay	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alkaline	alkaline	NN	I-NP	O	O
picrate	picrate	NN	I-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

General	General	JJ	B-ADJP	O	O
:	:	:	O	O	O
Significant	Significant	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
P450	P450	NN	B-NP	B-protein	O
2C9	2C9	NN	I-NP	I-protein	O
.	.	.	O	O	O

Celecoxib	Celecoxib	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
predominantly	predominantly	RB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2C9	2C9	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
2C9	2C9	NN	B-NP	B-protein	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
done	do	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2C9	2C9	NN	I-NP	I-protein	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	O	O
or	or	CC	I-NP	O	O
3A4	3A4	NN	I-NP	B-protein	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug-IN-1
have	have	VBP	B-VP	O	O
identified	identify	VBN	I-VP	O	O
potentially	potentially	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-IN-2
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-IN-2
.	.	.	O	O	O

Experience	Experience	NN	B-NP	O	O
with	with	IN	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-IN-1
anti	anti	AFX	I-NP	O	I-group-IN-1
-	-	HYPH	I-NP	O	I-group-IN-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-IN-1
drugs	drug	NNS	I-NP	O	E-group-IN-1
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-IN-1
)	)	)	O	O	O
suggests	suggest	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-IN-2
and	and	CC	I-NP	O	O
ACE	ACE	NN	I-NP	O	B-group-IN-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-IN-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
celecoxib	celecoxib	VBP	B-VP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
pharmacodynamics	pharmacodynamic	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
and	and	CC	O	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Reports	Report	NNS	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Angiotensin	Angiotensin	NNP	B-NP	O	B-group-EF-2
Converting	Convert	VBG	B-VP	O	I-group-EF-2
Enzyme	Enzyme	NN	B-NP	B-protein	I-group-EF-2
(	(	(	O	O	I-group-EF-2
ACE	ACE	NN	B-NP	O	I-group-EF-2
)	)	)	O	O	I-group-EF-2
inhibitors	inhibitor	NNS	B-NP	O	E-group-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
consideration	consideration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
CELEBREX	CELEBREX	NN	B-NP	O	S-brand-AD-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
post	post	NN	B-NP	O	O
marketing	marketing	NN	I-NP	O	O
observations	observation	NNS	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group-EF-2
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
response	response	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
CELEBREX	CELEBREX	NN	B-NP	O	S-brand-AD-1
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-2
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
CELEBREX	CELEBREX	NN	B-NP	O	S-brand-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GI	GI	NN	B-NP	O	O
ulceration	ulceration	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CELEBREX	CELEBREX	NN	B-NP	B-protein	S-brand
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
CELEBREX	CELEBREX	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substitute	substitute	NN	I-NP	O	O
for	for	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
for	for	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
.	.	.	O	O	O

Fluconazole	Fluconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
two	two	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug-ME-1
metabolism	metabolism	NN	I-NP	O	O
via	via	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2C9	2C9	NN	I-NP	I-protein	O
by	by	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
see	see	VB	B-VP	O	O
CLINICAL	CLINICAL	NN	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Pharmacokinetics	Pharmacokinetics	NN	I-NP	O	O
:	:	:	O	O	O
Metabolism	Metabolism	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CELEBREX	CELEBREX	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
introduced	introduce	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lowest	low	JJS	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
conducted	conduct	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
17	17	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-1
450	450	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
with	with	IN	B-PP	O	O
CELEBREX	CELEBREX	NN	B-NP	O	S-brand-ME-2
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-1
treatment	treatment	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
CELEBREX	CELEBREX	NN	B-NP	B-protein	S-brand-AD-2
is	be	VBZ	B-VP	O	O
introduced	introduce	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
,	,	,	O	O	O
CELEBREX	CELEBREX	NN	B-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
coagulant	coagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
daily	daily	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
as	as	IN	B-SBAR	O	O
determined	determine	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
CELEBREX	CELEBREX	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
since	since	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
complications	complication	NNS	B-NP	O	O
.	.	.	O	O	O

Metformin	Metformin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
given	give	VBN	B-VP	O	O
single	single	JJ	B-NP	O	O
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cephalexin	cephalexin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug
mean	mean	NN	I-NP	O	O
cmax	cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
average	average	NN	I-NP	O	O
of	of	IN	B-PP	O	O
34	34	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
metformin	metformin	NN	B-NP	O	S-drug
mean	mean	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
information	information	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
available	available	JJ	B-ADJP	O	O
about	about	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cephalexin	cephalexin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug
following	follow	VBG	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
not	not	RB	O	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
arise	arise	VB	I-VP	O	O
from	from	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cephalexin	cephalexin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
via	via	IN	B-PP	O	O
organic	organic	JJ	B-NP	O	O
cationic	cationic	JJ	I-NP	O	O
transporter	transporter	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
.	.	.	O	O	O

Accordingly	Accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
and	and	CC	I-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metformin	metformin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
cephalexin	cephalexin	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
b	b	NN	I-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
lactams	lactam	NNS	I-NP	O	E-group
,	,	,	O	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cephalexin	cephalexin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Keflex	Keflex	NNP	B-NP	O	S-brand
,	,	,	O	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Benedict	Benedict	NNP	B-NP	O	O
s	s	NNS	I-NP	O	O
and	and	CC	O	O	O
Fehling	Fehle	VBG	B-VP	O	O
s	s	NNS	B-NP	O	O
solutions	solution	NNS	I-NP	O	O
and	and	CC	O	O	O
also	also	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Clinitest	Clinitest	NN	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
.	.	.	O	O	O

Immunosuppressive	Immunosuppressive	JJ	B-NP	O	B-group
Drugs	Drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
Fibric	Fibric	NNP	B-NP	O	B-group
Acid	Acid	NNP	I-NP	O	I-group
Derivatives	Derivatives	NNP	I-NP	O	E-group
,	,	,	O	O	O
Niacin	Niacin	NN	B-NP	O	S-drug
(	(	(	O	O	O
Nicotinic	Nicotinic	NNP	B-NP	O	B-drug
Acid	Acid	NNP	I-NP	O	E-drug
,	,	,	O	O	O
Erythromycin	Erythromycin	NNP	B-NP	O	S-drug
,	,	,	O	O	O
Azole	Azole	NNP	B-NP	O	B-group
Antifungals	Antifungal	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Skeletal	Skeletal	JJ	B-NP	O	O
Muscle	Muscle	NN	I-NP	O	O
.	.	.	O	O	O

ANTACID	ANTACID	NN	B-NP	O	S-group
(	(	(	O	O	O
Magnesium	Magnesium	NN	B-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
Aluminum	Aluminum	NN	I-NP	O	I-drug
Hydroxide	Hydroxide	NN	I-NP	O	E-drug
)	)	)	O	O	O
:	:	:	O	O	O
Cerivastatin	Cerivastatin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacid	antacid	NN	B-NP	O	S-group
.	.	.	O	O	O

CIMETlDINE	CIMETlDINE	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cerivastatin	Cerivastatin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

CHOLESTYRAMINE	CHOLESTYRAMINE	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bile	bile	NN	I-NP	O	O
-	-	HYPH	O	O	O
acidsequestering	acidsequestere	VBG	B-VP	O	O
agent	agent	NN	B-NP	O	O
cholestyramine	cholestyramine	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetits	pharmacokinetit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cerivastatin	cerivastatin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
males	male	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
separate	separate	JJ	I-NP	O	O
randomized	randomize	VBN	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.2	0.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	B-drug-ME-1
sodium	sodium	NN	I-NP	O	E-drug-ME-1
and	and	CC	O	O	O
12	12	CD	B-NP	O	O
g	g	NN	I-NP	O	O
cholestyramine	cholestyramine	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
decreases	decrease	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
22	22	CD	I-NP	O	O
%	%	NN	I-NP	O	O
for	for	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
and	and	CC	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
g	g	NN	I-NP	O	O
cholestyramine	cholestyramine	NN	I-NP	O	S-drug-ME-1
1	1	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
evening	evening	NN	I-NP	O	O
meal	meal	NN	I-NP	O	O
and	and	CC	O	O	O
0.3	0.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	B-drug-ME-2
sodium	sodium	NN	I-NP	O	E-drug-ME-2
approximately	approximately	RB	B-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
evening	evening	NN	I-NP	O	O
meal	meal	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
8	8	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
of	of	IN	B-PP	O	O
about	about	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cerivastatin	cerivastatin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
given	give	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
bedtime	bedtime	NN	B-NP	O	O
and	and	CC	I-NP	O	O
cholestyramine	cholestyramine	NN	I-NP	O	S-drug
given	give	VBN	B-PP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
evening	evening	NN	I-NP	O	O
meal	meal	NN	I-NP	O	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cerivastatin	cerivastatin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

DIGOXIN	DIGOXIN	NN	B-NP	O	S-drug
:	:	:	O	O	O
Plasma	Plasma	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.2	0.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

Cerivastatin	Cerivastatin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

WARFARIN	WARFARIN	NN	B-NP	O	S-drug
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	S-drug
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
clotting	clot	VBG	B-VP	O	O
factor	factor	NN	B-NP	O	O
VII	VII	CD	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
the	the	DT	O	O	O
(	(	(	O	O	O
R	R	NN	B-NP	B-protein	O
)	)	)	O	O	O
and	and	CC	O	O	O
(	(	(	O	O	O
S	S	NN	B-NP	O	O
)	)	)	O	O	O
isomers	isomer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.3	0.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cerivastatin	cerivastatin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

ERYTHROMYCIN	ERYTHROMYCIN	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
hypercholesterolemic	hypercholesterolemic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
cerivastatin	cerivastatin	NN	I-NP	O	S-drug-ME-1
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
respectively	respectively	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

OTHER	OTHER	NN	B-NP	O	O
CONCOMITANT	CONCOMITANT	NN	I-NP	O	O
THERAPY	THERAPY	NN	I-NP	O	O
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
specific	specific	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
cerivastatin	cerivastatin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B-protein	B-group
-	-	HYPH	O	I-protein	I-group
converting	convert	VBG	B-VP	I-protein	I-group
enzyme	enzyme	NN	B-NP	I-protein	I-group
(	(	(	O	O	I-group
ACE	ACE	NN	B-NP	O	I-group
)	)	)	O	O	I-group
inhibitors	inhibitor	NNS	B-NP	O	E-group
,	,	,	O	O	O
betablockers	betablocker	NNS	B-NP	O	S-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
)	)	)	O	O	O
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cetirizine	cetirizine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
pseudoephedrine	pseudoephedrine	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
antipyrine	antipyrine	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
azithromycin	azithromycin	NN	I-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
cetirizine	cetirizine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
16	16	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cetirizine	cetirizine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
cetirizine	cetirizine	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
pseudoephedrine	pseudoephedrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cetirizine	cetirizine	NN	B-NP	O	S-drug-ME-1
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
400	400	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
larger	large	JJR	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Cetrotide	Cetrotide	NN	B-NP	O	S-brand
.	.	.	O	O	O

A	A	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
ERBITUX	ERBITUX	NN	B-NP	B-protein	S-brand
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
irinotecan	irinotecan	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
ERBITUX	ERBITUX	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
irinotecan	irinotecan	NN	I-NP	O	S-drug
.	.	.	O	O	O

Cevimeline	Cevimeline	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
beta	beta	NN	B-NP	O	B-group-AD-2
adrenergic	adrenergic	JJ	I-NP	O	I-group-AD-2
antagonists	antagonist	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
conduction	conduction	NN	B-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
parasympathomimetic	parasympathomimetic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
cevimeline	cevimeline	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Cevimeline	Cevimeline	NN	B-NP	O	S-drug
might	might	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
desirable	desirable	JJ	B-NP	O	O
antimuscarinic	antimuscarinic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP3A3	CYP3A3	NN	I-NP	B-protein	O
/	/	SYM	O	O	O
4	4	CD	B-NP	O	O
also	also	RB	B-ADVP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cevimeline	cevimeline	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cevimeline	Cevimeline	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
individuals	individual	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
or	or	CC	O	O	O
suspected	suspect	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
deficient	deficient	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
experience	experience	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
1A2	1A2	NN	I-NP	I-protein	O
,	,	,	O	O	O
2A6	2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
2D6	2D6	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
2E1	2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
cevimeline	cevimeline	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
chlorambucil	chlorambucil	NN	B-NP	O	S-drug
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
established	establish	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
and	and	CC	I-NP	O	O
effect	effect	NN	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
variable	variable	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
an	an	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
very	very	RB	B-ADVP	O	O
rarely	rarely	RB	I-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
chlordiazepoxide	chlordiazepoxide	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
central	central	JJ	I-NP	O	B-group
nervous	nervous	JJ	I-NP	O	I-group
system	system	NN	I-NP	O	I-group
depressants	depressant	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	B-group-EF-1
solutions	solution	NNS	I-NP	O	E-group-EF-1
containing	contain	VBG	B-VP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-1
or	or	CC	O	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
or	or	CC	I-NP	O	O
phenothiazines	phenothiazine	NNS	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
,	,	,	I-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
or	or	CC	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
generally	generally	RB	I-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
situations	situation	NNS	B-NP	O	O
when	when	WRB	B-ADVP	O	O
concurrent	concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-NP	O	O
,	,	,	I-NP	O	O
careful	careful	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasopressor	vasopressor	NN	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
obstetric	obstetric	JJ	B-NP	O	O
blocks	block	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ergot	ergot	NN	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
type	type	NN	I-NP	O	I-group-EF-2
oxytocic	oxytocic	JJ	I-NP	O	I-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
,	,	,	I-NP	O	O
persistent	persistent	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
or	or	CC	O	O	O
cerebrovascular	cerebrovascular	JJ	B-NP	O	O
accidents	accident	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
para	para	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
aminobenzoic	aminobenzoic	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chloroprocaine	chloroprocaine	NN	B-NP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
chloroprocaine	chloroprocaine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
condition	condition	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
a	a	DT	B-NP	O	O
sulfonamide	sulfonamide	NN	I-NP	O	B-group-AD-2
drug	drug	NN	I-NP	O	E-group-AD-2
is	be	VBZ	B-VP	O	O
being	be	VBG	I-VP	O	O
employed	employ	VBN	I-VP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
and	and	CC	I-NP	O	O
kaolin	kaolin	NN	I-NP	O	S-drug
:	:	:	O	O	O
Antacids	Antacid	NNS	B-NP	O	S-group-ME-1
and	and	CC	I-NP	O	O
kaolin	kaolin	NN	I-NP	O	S-drug-ME-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

an	an	DT	B-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
intake	intake	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
level	level	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Ampicillin	Ampicillin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug-ME-1
significantly	significantly	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ampicillin	ampicillin	NN	B-NP	B-protein	S-drug-ME-2
.	.	.	O	O	O

An	An	DT	B-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
two	two	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
intake	intake	NN	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
and	and	CC	I-NP	O	O
chloroquine	chloroquine	NN	I-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Cyclosporin	Cyclosporin	NN	B-NP	O	S-drug
:	:	:	O	O	O
After	After	IN	B-PP	O	O
introduction	introduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
oral	oral	JJ	B-NP	O	O
form	form	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
sudden	sudden	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
cyclosporin	cyclosporin	NN	I-NP	O	S-drug-ME-2
level	level	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
cyclosporin	cyclosporin	NN	I-NP	O	S-drug
level	level	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
,	,	,	O	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Alcohol	Alcohol	NN	I-NP	O	S-drug
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
or	or	CC	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Potentiation	Potentiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
otthostatic	otthostatic	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O

-	-	HYPH	B-NP	O	O
Antidiabetic	Antidiabetic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
(	(	(	O	O	O
Oral	Oral	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
Dosage	Dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O

-	-	HYPH	B-NP	O	O
Other	Other	JJ	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
Additive	Additive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
or	or	CC	I-NP	O	O
potentiation	potentiation	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Cholestyramine	Cholestyramine	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
colestipol	colestipol	NN	I-NP	O	S-drug
resins	resin	NNS	I-NP	O	S-group
:	:	:	O	O	O
Cholestytamine	Cholestytamine	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
colestipol	colestipol	NN	I-NP	B-protein	S-drug-ME-1
resins	resin	NNS	I-NP	I-protein	S-group
have	have	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
binding	binding	NN	B-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group-ME-2
diuretics	diuretic	NNS	I-NP	O	E-group-ME-2
and	and	CC	O	O	O
reducing	reduce	VBG	B-VP	O	O
diuretic	diuretic	JJ	B-NP	O	S-group
absorption	absorption	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Corticosteroids	Corticosteroid	NNS	I-NP	O	S-group
,	,	,	O	O	O
ACTH	ACTH	NN	B-NP	O	S-drug
:	:	:	O	O	O
Intensified	Intensify	VBN	B-NP	O	O
electrolyte	electrolyte	NN	I-NP	O	O
depletion	depletion	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O

-	-	HYPH	B-NP	O	O
Pressor	Pressor	NN	I-NP	O	O
amines	amine	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Possible	Possible	JJ	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
pressor	pressor	NN	B-NP	O	O
amines	amine	NNS	I-NP	O	O
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
preclude	preclude	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Skeletal	Skeletal	JJ	I-NP	O	B-group
muscle	muscle	NN	I-NP	O	I-group
relaxants	relaxant	NNS	I-NP	O	E-group
,	,	,	O	O	O
nondepolarizing	nondepolarize	VBG	B-VP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
tubocurarine	tubocurarine	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Possible	Possible	JJ	B-NP	O	O
increased	increase	VBN	I-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	B-group
relaxant	relaxant	NN	I-NP	O	E-group

-	-	HYPH	B-NP	O	O
Lithium	Lithium	NN	I-NP	O	S-drug-AD-1
:	:	:	O	O	O
Generally	Generally	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-AD-2
.	.	.	O	O	O

Diuretic	Diuretic	JJ	B-NP	O	B-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
reduce	reduce	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
add	add	VB	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-2
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Refer	Refer	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
package	package	NN	I-NP	O	O
insert	insert	NN	I-NP	O	O
for	for	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-1
preparations	preparation	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
chlorothiazide	chlorothiazide	NN	B-NP	O	S-drug-AD-2

-	-	HYPH	B-NP	O	O
Non	Non	AFX	I-NP	B-protein	B-group
-	-	HYPH	I-NP	B-protein	I-group
steroidal	steroidal	JJ	B-NP	I-protein	I-group
Anti	Anti	AFX	I-NP	I-protein	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
Drugs	Drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	B-DNA	B-group-EF-1
-	-	HYPH	I-NP	B-DNA	I-group-EF-1
steroidal	steroidal	JJ	I-NP	I-DNA	I-group-EF-1
anti	anti	AFX	I-NP	I-DNA	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
agent	agent	NN	I-NP	O	E-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
loop	loop	NN	B-NP	O	S-group-EF-2
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	B-group-EF-2
-	-	HYPH	B-VP	O	I-group-EF-2
sparing	spar	VBG	B-NP	O	E-group-EF-2
and	and	CC	I-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-drug-EF-2
diuretics	diuretic	NNS	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
chlorothiazide	chlorothiazide	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
non	non	AFX	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	B-DNA	I-group-AD-2
steroidal	steroidal	JJ	B-NP	I-DNA	I-group-AD-2
anti	anti	AFX	I-NP	I-DNA	I-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O

-	-	HYPH	B-NP	O	O
Drug	Drug	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
Thiazides	Thiazide	NNS	B-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
carrying	carry	VBG	B-VP	O	O
out	out	RP	B-PRT	O	O
tests	test	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
parathyroid	parathyroid	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Chlorotrianisene	Chlorotrianisene	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
bromocriptine	bromocriptine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	S-drug-IN-2
supplements	supplement	NNS	I-NP	O	O
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
corticotropin	corticotropin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
dantrolene	dantrolene	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
nicotine	nicotine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
somatropin	somatropin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
tamoxifen	tamoxifen	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-IN-2
.	.	.	O	O	O

May	May	MD	O	O	O
interact	interact	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
skin	skin	NN	B-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
or	or	CC	I-NP	O	O
shampoos	shampoo	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
dandruff	dandruff	NN	B-NP	O	O
or	or	CC	I-NP	O	O
psoriasis	psoriasis	NN	I-NP	O	O
.	.	.	O	O	O

Substrate	Substrate	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
(	(	(	O	O	O
minor	minor	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
major	major	JJ	B-ADJP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

Inhibits	Inhibit	VBZ	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
(	(	(	O	O	O
weak	weak	JJ	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
(	(	(	O	O	O
CNS	CNS	NN	B-NP	O	O
depression	depression	NN	I-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
CNS	CNS	NN	B-NP	O	B-group
depressants	depressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
.	.	.	O	O	O

CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
:	:	:	O	O	O
May	May	MD	B-VP	O	O
increase	increase	VBP	I-VP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
/	/	SYM	B-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
chlorpheniramine	chlorpheniramine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Example	Example	NN	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
azole	azole	NN	B-NP	O	B-group
antifungals	antifungal	NNS	I-NP	O	E-group
,	,	,	O	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug
,	,	,	O	O	O
doxycycline	doxycycline	NN	B-NP	O	S-drug
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
imatinib	imatinib	NN	B-NP	O	S-drug
,	,	,	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
,	,	,	O	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug
,	,	,	O	O	O
nicardipine	nicardipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
propofol	propofol	NN	B-NP	O	S-drug
,	,	,	O	O	O
protease	protease	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
-	-	HYPH	O	O	O
-	-	HYPH	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
an	an	DT	B-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	B-group-EF-1
drug	drug	NN	I-NP	O	E-group-EF-1
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
chlorpromazine	chlorpromazine	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
antiparkinsonian	antiparkinsonian	JJ	I-NP	O	B-group-EF-M
drug	drug	NN	I-NP	O	E-group-EF-M
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
trihexyphenidyl	trihexyphenidyl	NN	B-NP	O	S-drug-EF-M
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-EF-2
antidepressant	antidepressant	NN	I-NP	O	E-group-EF-2
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	I-NP	O	O
amitriptyline	amitriptyline	NN	I-NP	O	S-drug-EF-2
)	)	)	O	O	O
-	-	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
commonly	commonly	RB	B-ADVP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
excessive	excessive	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
dry	dry	JJ	B-NP	O	O
mouth	mouth	NN	I-NP	O	O
and	and	CC	O	O	O
associated	associate	VBN	B-VP	O	O
dental	dental	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
,	,	,	O	O	O
blurred	blur	VBD	B-VP	O	O
vision	vision	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
high	high	JJ	B-NP	O	O
temperature	temperature	NN	I-NP	O	O
and	and	CC	I-NP	O	O
humidity	humidity	NN	I-NP	O	O
,	,	,	O	O	O
hyperpyrexia	hyperpyrexia	NN	B-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
anti	anti	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
depressants	depressant	NNS	I-NP	O	E-group
/	/	SYM	O	O	O
anti	anti	AFX	O	O	B-group
-	-	HYPH	B-NP	O	I-group
anxiety	anxiety	NN	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
an	an	DT	B-NP	O	O
overactive	overactive	JJ	I-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
,	,	,	O	O	O
beta	beta	SYM	O	O	B-group
-	-	HYPH	O	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
sparfloxacin	sparfloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
guanadrel	guanadrel	NN	B-NP	O	S-drug
,	,	,	O	O	O
metrizamide	metrizamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
cabergoline	cabergoline	NN	B-NP	O	S-drug
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug
,	,	,	O	O	O
narcotic	narcotic	JJ	B-NP	O	S-group
pain	pain	NN	I-NP	O	O
medication	medication	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
codeine	codeine	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
aid	aid	VB	I-VP	O	O
sleep	sleep	NN	B-NP	O	O
,	,	,	O	O	O
drowsiness	drowsiness	NN	B-NP	O	O
-	-	HYPH	O	O	O
causing	cause	VBG	B-VP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
diphenhydramine	diphenhydramine	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
make	make	VB	I-VP	O	O
you	you	PRP	B-NP	O	O
drowsy	drowsy	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sulfonylurea	sulfonylurea	NN	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-EF-2
anti	anti	AFX	I-NP	O	I-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
highly	highly	RB	B-ADVP	O	O
protein	protein	NN	B-NP	O	O
bound	bind	VBD	B-VP	O	O
,	,	,	O	O	O
salicylates	salicylate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
chloramphenicol	chloramphenicol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
coumarins	coumarin	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	B-group-EF-2
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
DIABINESE	DIABINESE	NN	B-NP	O	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
DIABINESE	DIABINESE	NN	B-NP	O	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
tend	tend	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
thyroid	thyroid	NN	B-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
nicotinic	nicotinic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
sympathomimetics	sympathomimetic	NNS	B-NP	O	S-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blocking	block	VBG	B-VP	O	I-group
drugs	drug	NNS	B-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
DIABINESE	DIABINESE	NN	B-NP	O	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
DIABINESE	DIABINESE	NN	B-NP	O	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
animal	animal	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
chlorpropamide	chlorpropamide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
employed	employ	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
disulfiram	disulfiram	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
produced	produce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ingestion	ingestion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
miconazole	miconazole	NN	I-NP	O	S-drug-EF-1
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Whether	Whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
occurs	occur	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
,	,	,	I-NP	O	O
topical	topical	JJ	I-NP	O	O
,	,	,	I-NP	O	O
or	or	CC	I-NP	O	O
vaginal	vaginal	JJ	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
miconazole	miconazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Chlorprothixene	Chlorprothixene	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitantly	concomitantly	RB	B-NP	O	O
given	give	VBN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug
intoxication	intoxication	NN	I-NP	O	O
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
chlorprothixene	chlorprothixene	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
opioids	opioid	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
opioid	opioid	JJ	I-NP	O	S-group
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
(	(	(	O	O	O
by	by	IN	B-PP	O	O
approx	approx	NN	B-NP	O	O
.	.	.	O	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
chlorprothixene	chlorprothixene	NN	B-NP	O	S-drug-EF-1
amplifies	amplify	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
side	side	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
opioids	opioid	NNS	B-NP	O	S-group-EF-2
massively	massively	RB	B-ADVP	O	O
.	.	.	O	O	O

Avoid	Avoid	VB	B-VP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chlorprothixene	chlorprothixene	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
tramadol	tramadol	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
Ultram	Ultram	NN	B-NP	O	S-brand-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

Massive	Massive	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
encountered	encounter	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Consider	Consider	VB	B-VP	O	O
additive	additive	JJ	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
confusional	confusional	JJ	B-NP	O	O
states	state	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
emerge	emerge	VB	I-VP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
chlorprothixene	chlorprothixene	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-EF-2
or	or	CC	I-NP	O	O
barbituates	barbituate	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Choose	Choose	VB	B-VP	O	O
particular	particular	JJ	B-NP	O	O
low	low	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Exert	Exert	JJ	B-NP	O	O
particular	particular	JJ	I-NP	O	O
caution	caution	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combining	combine	VBG	B-VP	O	O
chlorprothixene	chlorprothixene	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-2
and	and	CC	O	O	O
antiparkinsonian	antiparkinsonian	JJ	B-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
)	)	)	O	O	O
:	:	:	O	O	O
Particularly	Particularly	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
delirium	delirium	NN	B-NP	O	O
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
fever	fever	NN	I-NP	O	O
,	,	,	O	O	O
severe	severe	JJ	B-NP	O	O
obstipation	obstipation	NN	I-NP	O	O
,	,	,	O	O	O
even	even	RB	B-NP	O	O
ileus	ileus	NN	I-NP	O	O
and	and	CC	I-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	O
.	.	.	O	O	O

Chlorthalidone	Chlorthalidone	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
add	add	VB	I-VP	O	O
to	to	TO	B-PP	O	O
or	or	CC	O	O	O
potentiate	potentiate	VB	B-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Potentiation	Potentiation	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
ganglionic	ganglionic	JJ	B-NP	O	B-group
peripheral	peripheral	JJ	I-NP	O	I-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
blocking	blocking	NN	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

Medication	Medication	NN	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
electrolytes	electrolyte	NNS	I-NP	O	O
.	.	.	O	O	O

Warning	Warning	NN	B-NP	O	O
signs	sign	NNS	I-NP	O	O
,	,	,	O	O	O
irrespective	irrespective	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
cause	cause	NN	B-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
:	:	:	O	O	O
dryness	dryness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
mouth	mouth	NN	B-NP	O	O
,	,	,	O	O	O
thirst	thirst	RB	B-ADVP	O	O
,	,	,	O	O	O
weakness	weakness	NN	B-NP	O	O
,	,	,	O	O	O
lethargy	lethargy	NN	B-NP	O	O
,	,	,	O	O	O
drowsiness	drowsiness	NN	B-NP	O	O
,	,	,	O	O	O
restlessness	restlessness	NN	B-NP	O	O
,	,	,	O	O	O
muscle	muscle	NN	B-NP	O	O
pains	pain	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
cramps	cramp	NNS	I-NP	O	O
,	,	,	O	O	O
muscular	muscular	JJ	B-NP	O	O
fatigue	fatigue	NN	I-NP	O	O
,	,	,	O	O	O
hypotension	hypotension	NN	B-NP	O	O
,	,	,	O	O	O
oliguria	oliguria	NN	B-NP	O	O
,	,	,	O	O	O
tachycardia	tachycardia	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
nausea	nausea	NN	B-NP	O	O
and	and	CC	I-NP	O	O
vomiting	vomiting	NN	I-NP	O	O
.	.	.	O	O	O

Insulin	Insulin	NN	B-NP	O	S-drug
requirements	requirement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
decreased	decrease	VBN	B-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

Higher	High	JJR	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Latent	Latent	JJ	B-NP	O	O
diabetes	diabetes	NN	I-NP	O	O
mellitus	mellitus	NN	I-NP	O	O
may	may	MD	B-VP	O	O
become	become	VB	I-VP	O	O
manifest	manif	JJS	B-ADJP	O	O
during	during	IN	B-PP	O	O
chlorthalidone	chlorthalidone	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Chlorthalidone	Chlorthalidone	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
related	related	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
tubocurarine	tubocurarine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Chlorthalidone	Chlorthalidone	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
related	related	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
arterial	arterial	JJ	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
diminution	diminution	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
preclude	preclude	VB	I-VP	O	O
effectiveness	effectiveness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
central	central	JJ	I-NP	O	B-group
nervous	nervous	JJ	I-NP	O	I-group
system	system	NN	I-NP	O	I-group
depressants	depressant	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
analogues	analogue	NNS	I-NP	O	O
(	(	(	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug
D2	D2	NN	I-NP	O	E-drug
,	,	,	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug
D3	D3	NN	I-NP	O	E-drug
,	,	,	O	O	O
Calcitriol	Calcitriol	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
Calcidiol	Calcidiol	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fat	fat	JJ	B-NP	O	B-group-ME-2
soluble	soluble	JJ	I-NP	O	I-group-ME-2
vitamins	vitamin	NNS	I-NP	O	E-group-ME-2
;	;	:	O	O	O

as	as	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
it	it	PRP	I-NP	O	O
may	may	MD	B-VP	O	O
impair	impair	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Phenobarbital	Phenobarbital	NN	I-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug
will	will	MD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
,	,	,	O	O	O
but	but	CC	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
endogenous	endogenous	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcitriol	calcitriol	NN	B-NP	O	S-drug
/	/	SYM	B-NP	O	O
ergocalcitriol	ergocalcitriol	NN	I-NP	O	O
by	by	IN	B-PP	O	O
accelerating	accelerate	VBG	B-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
blood	blood	NN	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcitriol	calcitriol	NN	B-NP	O	S-drug
/	/	SYM	B-NP	O	O
ergocalcitriol	ergocalcitriol	NN	I-NP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Rocaltrol	Rocaltrol	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
if	if	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

Thiazides	Thiazide	NNS	B-NP	O	S-group
:	:	:	O	O	O
Thiazides	Thiazide	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thiazides	thiazide	NNS	B-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-EF-2
D	D	NN	I-NP	O	E-group-EF-2
causes	cause	VBZ	B-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
precaution	precaution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministration	coadministration	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	S-group
:	:	:	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-group-AD-1
D	D	NN	I-NP	O	E-group-AD-1
dosage	dosage	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
care	care	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-AD-2
,	,	,	O	O	O
as	as	IN	B-PP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
precipitate	precipitate	VB	I-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
both	both	CC	O	O	O
synthetic	synthetic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
catabolic	catabolic	JJ	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-ME-2
D	D	NN	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Reductions	Reduction	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
endogenous	endogenous	JJ	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	O
D	D	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1200	1200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
week	week	NN	I-NP	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
men	man	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
:	:	:	O	O	O
A	A	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
of	of	IN	B-PP	O	O
functional	functional	JJ	B-NP	O	O
antagonism	antagonism	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
between	between	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-EF-1
D	D	NN	I-NP	O	E-group-EF-1
analogues	analogue	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
promote	promote	VBP	B-VP	O	O
calcium	calcium	NN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
calcium	calcium	NN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Phosphate	Phosphate	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Binding	Binding	NNP	I-NP	O	O
Agents	Agent	NNPS	I-NP	O	O
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
also	also	RB	B-ADVP	O	O
has	have	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
phosphate	phosphate	NN	B-NP	O	O
transport	transport	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intestine	intestine	NN	I-NP	O	O
,	,	,	O	O	O
kidneys	kidney	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
bones	bone	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phosphate	phosphate	NN	B-NP	O	O
-	-	HYPH	O	O	O
binding	bind	VBG	B-NP	O	O
agents	agent	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
accordance	accordance	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
phosphate	phosphate	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

Vitamin	Vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group
D	D	NN	I-NP	O	E-group
analogues	analogue	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
as	as	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
could	could	MD	B-VP	O	O
create	create	VB	I-VP	O	O
possible	possible	JJ	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
hypercalcemia	hypercalcemia	NN	I-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	S-drug
Supplements	Supplement	NNS	I-NP	O	O
:	:	:	O	O	O
Uncontrolled	Uncontrolled	JJ	B-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
additional	additional	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Magnesium	Magnesium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Magnesium	Magnesium	NN	B-NP	O	S-drug-EF-1
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
antacids	antacid	NNS	B-NP	O	S-group-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypermagnesemia	hypermagnesemia	NN	B-NP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-EF-2
D	D	NN	I-NP	O	E-group-EF-2
by	by	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	B-protein	S-drug-ME-1
resin	resin	NN	I-NP	I-protein	S-group
may	may	MD	B-VP	O	O
delay	delay	VB	I-VP	O	O
or	or	CC	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-group-ME-2
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
thiazide	thiazide	NN	B-NP	O	B-group-ME-2
diuretics	diuretic	NNS	I-NP	O	E-group-ME-2
(	(	(	O	O	O
acidic	acidic	JJ	B-ADJP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
basic	basic	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
tetracycline	tetracycline	NN	B-NP	O	S-drug-ME-2
penicillin	penicillin	NN	I-NP	O	B-drug-ME-2
G	G	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
thyroid	thyroid	NN	B-NP	O	O
and	and	CC	I-NP	O	O
thyroxine	thyroxine	NN	I-NP	O	S-drug-ME-2
preparations	preparation	NNS	I-NP	O	O
,	,	,	I-NP	O	O
estrogens	estrogen	NNS	I-NP	O	S-group-ME-2
and	and	CC	I-NP	O	O
progestins	progestin	NNS	I-NP	O	S-group-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
digitalis	digitalis	NN	B-NP	O	S-group-ME-2
.	.	.	O	O	O

Interference	Interference	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
phosphate	phosphate	NN	I-NP	O	S-drug_n
supplements	supplement	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
another	another	DT	B-NP	O	O
positively	positively	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
charged	charge	VBN	I-NP	O	O
bile	bile	NN	I-NP	O	O
acid	acid	NN	I-NP	O	O
sequestrant	sequestrant	NN	I-NP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	B-protein	S-drug
resin	resin	NN	I-NP	I-protein	S-group
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
undergo	undergo	VBP	B-VP	O	O
enterohepatic	enterohepatic	JJ	B-NP	O	O
circulation	circulation	NN	I-NP	O	O
,	,	,	O	O	O
The	The	DT	B-NP	O	O
discontinuance	discontinuance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cholestyramine	cholestyramine	NN	B-NP	B-protein	S-drug-ME-1
resin	resin	NN	I-NP	I-protein	S-group
could	could	MD	B-VP	O	O
pose	pose	VB	I-VP	O	O
a	a	DT	B-NP	O	O
hazard	hazard	NN	I-NP	O	O
to	to	TO	B-PP	O	O
health	health	NN	B-NP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
filtrated	filtrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
level	level	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
taking	take	VBG	I-VP	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug
resin	resin	NN	I-NP	O	S-group
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug
binds	bind	VBZ	B-VP	O	O
bile	bile	NN	B-NP	O	O
acids	acid	NNS	I-NP	O	O
,	,	,	O	O	O
cholestyramine	cholestyramine	NN	B-NP	B-protein	S-drug
resin	resin	NN	I-NP	I-protein	S-group
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
fat	fat	JJ	I-NP	O	O
digestion	digestion	NN	I-NP	O	O
and	and	CC	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
and	and	CC	O	O	O
thus	thus	RB	O	O	O
may	may	MD	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fat	fat	JJ	B-NP	O	B-group
soluble	soluble	JJ	I-NP	O	I-group
vitamins	vitamin	NNS	I-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
A	A	NN	B-NP	O	O
,	,	,	O	O	O
D	D	NN	B-NP	O	O
,	,	,	O	O	O
E	E	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
K	K	NN	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
cholestyramine	cholestyramine	NN	B-NP	B-protein	S-drug
resin	resin	NN	I-NP	I-protein	S-group
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
periods	period	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
time	time	NN	B-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
supplementation	supplementation	NN	I-NP	O	O
with	with	IN	B-PP	O	O
water	water	NN	B-NP	O	O
-	-	HYPH	O	O	O
miscible	miscible	JJ	B-ADJP	O	O
(	(	(	O	O	O
or	or	CC	O	O	O
parenteral	parenteral	JJ	B-ADJP	O	O
)	)	)	O	O	O
forms	form	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
fat	fat	NN	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
soluble	soluble	JJ	I-NP	O	I-group
vitamins	vitamin	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

SINCE	SINCE	NNP	B-NP	O	O
CHOLESTYRAMINE	CHOLESTYRAMINE	NNP	I-NP	O	S-drug
RESIN	RESIN	NNP	I-NP	O	S-group
MAY	MAY	NNP	I-NP	O	O
BIND	BIND	NNP	I-NP	O	O
OTHER	OTHER	NNP	I-NP	O	O
DRUGS	DRUGS	NNP	I-NP	O	O
GIVEN	GIVEN	NNP	I-NP	O	O
CONCURRENTLY	CONCURRENTLY	NNP	I-NP	O	O
,	,	,	O	O	O
IT	IT	NNP	B-NP	O	O
IS	IS	NNP	I-NP	O	O
RECOMMENDED	RECOMMENDED	NNP	I-NP	O	O
THAT	THAT	NN	I-NP	O	O
PATIENTS	PATIENTS	NNS	I-NP	O	O
TAKE	TAKE	NN	I-NP	O	O
OTHER	OTHER	NN	I-NP	O	O
DRUGS	DRUGS	NN	I-NP	O	O
AT	AT	NN	I-NP	O	O
LEAST	LEAST	NN	I-NP	O	O
1	1	CD	I-NP	O	O
HOUR	HOUR	NN	I-NP	O	O
BEFORE	BEFORE	NN	I-NP	O	O
OR	OR	NN	I-NP	O	O
4	4	CD	I-NP	O	O
TO	TO	NN	I-NP	O	O
6	6	CD	B-NP	O	O
HOURS	HOURS	NN	I-NP	O	O
AFTER	AFTER	NN	I-NP	O	O
CHOLESTYRAMINE	CHOLESTYRAMINE	NN	I-NP	O	S-drug
RESIN	RESIN	NN	I-NP	O	S-group
(	(	(	O	O	O
OR	OR	NNP	B-NP	O	O
AT	AT	NNP	I-NP	O	O
AS	AS	NNP	I-NP	O	O
GREAT	GREAT	NNP	I-NP	O	O
AN	AN	NNP	I-NP	O	O
INTERVAL	INTERVAL	NNP	I-NP	O	O
AS	AS	NNP	I-NP	O	O
POSSIBLE	POSSIBLE	NNP	I-NP	O	O
)	)	)	O	O	O
TO	TO	TO	B-PP	O	O
AVOID	AVOID	NNP	B-NP	O	O
IMPEDING	IMPEDING	NNP	I-NP	O	O
THEIR	THEIR	NNP	I-NP	O	O
ABSORPTION	ABSORPTION	NNP	I-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
des	de	VBZ	B-VP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
ciclesonide	ciclesonide	NN	I-NP	O	E-drug
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
no	no	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
induction	induction	NN	I-NP	O	O
potential	potential	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
450	450	CD	B-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciclesonide	ciclesonide	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
CYP450	CYP450	NN	B-NP	B-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
des	de	NNS	B-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
ciclesonide	ciclesonide	NN	I-NP	O	E-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
or	or	CC	O	O	O
salicylic	salicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
no	no	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
based	base	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
orally	orally	RB	B-NP	O	O
inhaled	inhale	VBN	I-NP	O	O
ciclesonide	ciclesonide	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
oral	oral	JJ	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
des	des	AFX	O	O	B-drug
-	-	HYPH	O	O	I-drug
ciclesonide	ciclesonide	NN	B-NP	O	E-drug
or	or	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
orally	orally	RB	B-NP	O	O
inhaled	inhale	VBN	I-NP	O	O
ciclesonide	ciclesonide	NN	I-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
oral	oral	JJ	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
des	de	NNS	B-NP	O	B-drug
-	-	HYPH	O	O	I-drug
ciclesonide	ciclesonide	NN	B-NP	O	E-drug
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
3.6	3.6	CD	I-NP	O	O
-	-	HYPH	B-VP	O	O
fold	fold	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
ciclesonide	ciclesonide	NN	B-NP	O	S-drug
remained	remain	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
with	with	IN	B-PP	O	O
intranasal	intranasal	JJ	B-NP	O	O
ciclesonide	ciclesonide	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
Probenecid	Probenecid	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
or	or	CC	I-NP	O	O
renal	renal	JJ	I-NP	O	O
tubular	tubular	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
acyclovir	acyclovir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
angiotensin	angiotensin	NN	B-NP	B-protein	B-group-ME-2
-	-	HYPH	O	O	I-group-ME-2
converting	convert	VBG	B-VP	O	I-group-ME-2
enzyme	enzyme	NN	B-NP	O	I-group-ME-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
aminosalicylic	aminosalicylic	JJ	B-NP	O	B-drug-ME-2
acid	acid	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
bumetanide	bumetanide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clofibrate	clofibrate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
famotidine	famotidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-ME-2
anti	anti	AFX	I-NP	O	I-group-ME-2
-	-	HYPH	I-NP	O	I-group-ME-2
inflammatory	inflammatory	JJ	I-NP	O	E-group-ME-2
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
assessed	assess	VBN	I-VP	O	O
.	.	.	O	O	O

Zidovudine	Zidovudine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
either	either	RB	I-VP	O	O
be	be	VB	I-VP	O	O
temporarily	temporarily	RB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-AD-2
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VISTIDE	VISTIDE	NN	B-NP	O	S-brand
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

Nephrotoxic	Nephrotoxic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VISTIDE	VISTIDE	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
agents	agent	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
nephrotoxic	nephrotoxic	JJ	B-NP	O	O
potential	potential	NN	I-NP	O	O
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
aminoglycosides	aminoglycoside	NNS	I-NP	O	S-group-AD-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
tobramycin	tobramycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
amikacin	amikacin	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-AD-2
B	B	NN	I-NP	O	E-drug-AD-2
,	,	,	O	O	O
foscarnet	foscarnet	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
pentamidine	pentamidine	NN	I-NP	O	S-drug-AD-2
,	,	,	O	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
non	non	AFX	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	B-DNA	I-group-AD-2
steroidal	steroidal	JJ	B-NP	I-DNA	I-group-AD-2
anti	anti	AFX	I-NP	I-DNA	I-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
]	]	)	O	O	O
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
seven	seven	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
starting	start	VBG	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
VISTIDE	VISTIDE	NN	B-NP	O	S-brand
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
PLETAL	PLETAL	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
extensively	extensively	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
PLETAL	PLETAL	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
C.P.A	C.P.A	NN	B-NP	B-protein	O
.	.	.	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
and	and	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-ME-1
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cilostazol	cilostazol	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
major	major	JJ	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
.	.	.	O	O	O

Population	Population	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
higher	high	JJR	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cilostazol	cilostazol	NN	B-NP	O	S-drug-ME-1
among	among	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concurrently	concurrently	RB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
C.P.A..	C.P.A..	NN	B-NP	B-protein	O

Pletal	Pletal	NNP	B-NP	O	S-brand
does	do	VBZ	B-VP	O	O
not	not	RB	O	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
with	with	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
very	very	RB	B-ADJP	O	O
sensitive	sensitive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
C.P.A	C.P.A	NN	B-NP	B-protein	O
.	.	.	O	O	O
inhibition	inhibition	NN	B-NP	O	O
.	.	.	O	O	O

Tagamet	Tagamet	NN	B-NP	O	S-brand-ME-1
,	,	,	O	O	O
apparently	apparently	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
microsomal	microsomal	JJ	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	B-group-ME-2
-	-	HYPH	B-NP	O	I-group-ME-2
type	type	NN	I-NP	O	I-group-ME-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-ME-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
metronidazole	metronidazole	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
thereby	thereby	RB	B-VP	O	O
delaying	delay	VBG	I-VP	O	O
elimination	elimination	NN	B-NP	O	O
and	and	CC	O	O	O
increasing	increase	VBG	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Clinically	Clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	B-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
adjustment	adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group-AD-1
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
Tagamet	Tagamet	NNP	B-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
lidocaine	lidocaine	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
produce	produce	VB	I-VP	O	O
adverse	adverse	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
either	either	CC	O	O	O
Tagamet	Tagamet	NN	B-NP	O	S-brand-ME-1
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
q.i.d	q.i.d	NN	I-NP	O	O
.	.	.	O	O	O
or	or	CC	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
h.s	h.	NNS	I-NP	O	O
.	.	.	O	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
Theo	Theo	NNP	B-NP	O	B-brand-ME-2
-	-	HYPH	O	O	I-brand-ME-2
Dur	Dur	NNP	B-NP	O	E-brand-ME-2
,	,	,	O	O	O
Key	Key	NNP	B-NP	O	O
Pharmaceuticals	Pharmaceutical	NNPS	I-NP	O	O
,	,	,	O	O	O
Inc.	Inc.	NNP	B-NP	O	O
)	)	)	O	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
less	less	JJR	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
peak	peak	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
800	800	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
h.s	h.	NNS	I-NP	O	O
.	.	.	O	O	O
regimen	regimen	NN	B-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
aged	age	VBN	B-VP	O	O
54	54	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
and	and	CC	O	O	O
older	old	JJR	B-NP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
beyond	beyond	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
Note	Note	NN	B-NP	O	O
:	:	:	O	O	O
All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
appropriately	appropriately	RB	B-ADVP	O	O
,	,	,	O	O	O
regardless	regardless	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Dosage	Dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
mentioned	mention	VBN	B-VP	O	O
above	above	IN	B-PP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
similarly	similarly	RB	I-NP	O	O
metabolized	metabolize	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	O	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
hepatic	hepatic	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
adjustment	adjustment	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
starting	start	VBG	B-VP	O	O
or	or	CC	I-VP	O	O
stopping	stop	VBG	I-VP	O	O
concomitantly	concomitantly	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
Tagamet	Tagamet	NNP	I-NP	O	S-brand
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
optimum	optimum	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Alteration	Alteration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pH	pH	NN	B-NP	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
experience	experience	NN	I-NP	O	O
may	may	MD	B-VP	O	O
reveal	reveal	VB	I-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
affected	affect	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Tagamet	Tagamet	NNP	B-NP	O	S-brand
.	.	.	O	O	O

and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
Drug	Drug	NNP	B-NP	O	O
/	/	NNP	I-NP	O	O
Laboratory	Laboratory	NNP	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
See	See	NNP	I-NP	O	O
CLINICAL	CLINICAL	NNP	I-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NNP	I-NP	O	O
,	,	,	O	O	O
Pharmacokinetics	Pharmacokinetics	NNP	B-NP	O	O
and	and	CC	O	O	O
Drug	Drug	NNP	B-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Sensipar	Sensipar	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
)	)	)	O	O	O
:	:	:	O	O	O
Sensipar	Sensipar	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
dose	dose	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
predominantly	predominantly	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
narrow	narrow	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
index	index	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
flecainide	flecainide	NN	B-NP	O	S-drug
,	,	,	O	O	O
vinblastine	vinblastine	NN	B-NP	O	S-drug
,	,	,	O	O	O
thioridazine	thioridazine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
most	most	RBS	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
)	)	)	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Amitriptyline	Amitriptyline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
or	or	CC	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
cinacalcet	cinacalcet	NN	I-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
amitriptyline	amitriptyline	NN	I-NP	O	S-drug-ME-2
increased	increase	VBD	B-VP	O	O
amitriptyline	amitriptyline	NN	B-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
and	and	CC	O	O	O
nortriptyline	nortriptyline	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
active	active	JJ	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
)	)	)	O	O	O
exposure	exposure	NN	B-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	O	O
extensive	extensive	JJ	I-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
Sensipar	Sensipar	NNP	B-NP	O	S-brand
:	:	:	O	O	O
Sensipar	Sensipar	NNP	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
primarily	primarily	RB	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Sensipar	Sensipar	NNP	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
cinacalcet	cinacalcet	NN	B-NP	O	S-drug-ME-2
exposure	exposure	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
90	90	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Sensipar	Sensipar	NNP	B-NP	O	S-brand
by	by	IN	B-PP	O	O
2.3	2.3	CD	B-NP	O	O
fold	fold	RB	I-NP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Sensipar	Sensipar	NNP	B-NP	O	S-brand-AD-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
and	and	CC	O	O	O
PTH	PTH	NN	B-NP	O	O
and	and	CC	I-NP	O	O
serum	serum	NN	I-NP	O	O
calcium	calcium	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
initiates	initiate	VBZ	B-VP	O	O
or	or	CC	I-VP	O	O
discontinues	discontinue	VBZ	I-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-2
;	;	:	O	O	O

see	see	VB	B-VP	O	O
DOSAGE	DOSAGE	NN	B-NP	O	O
AND	AND	CC	O	O	O
ADMINISTRATION	ADMINISTRATION	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Elevated	Elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-2
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
side	side	NN	I-NP	O	O
-	-	HYPH	O	O	O
effects	effect	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-EF-1
-	-	HYPH	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	S-group-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
monitoring	monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
and	and	CC	O	O	O
dosage	dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
adjusted	adjust	VBN	B-VP	O	O
as	as	IN	B-SBAR	O	O
required	require	VBN	B-VP	O	O
.	.	.	O	O	O

Quinolones	Quinolone	NNS	B-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cinoxacin	cinoxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
cinoxacin	cinoxacin	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-AD-2
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
products	product	NNS	B-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group-ME-1
or	or	CC	O	O	O
sucralfate	sucralfate	VB	B-VP	O	S-drug-ME-1
substantially	substantially	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
urine	urine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group-ME-1
with	with	IN	B-PP	O	O
products	product	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
multivitamins	multivitamin	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
zinc	zinc	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
Videx	Videx	NN	B-NP	O	S-brand-ME-2
(	(	(	I-NP	O	O
didanosine	didanosine	NN	I-NP	O	S-drug-ME-2
)	)	)	I-NP	O	O
chewable	chewable	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
buffered	buffered	JJ	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
powder	powder	NN	I-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
solution	solution	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
urine	urine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Quinolones	Quinolone	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
cinoxacin	cinoxacin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Seizures	Seizure	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
another	another	DT	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	B-group-EF-1
class	class	NN	I-NP	O	I-group-EF-1
antimicrobial	antimicrobial	JJ	B-ADJP	O	E-group-EF-1
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-EF-2
anti	anti	AFX	I-NP	O	I-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-2
drug	drug	NN	I-NP	O	E-group-EF-2
fenbufen	fenbufen	NN	I-NP	O	S-drug-EF-2
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Animal	Animal	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
suggest	suggest	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
2	2	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Fenbufen	Fenbufen	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
approved	approve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
States	States	NNP	I-NP	O	O
at	at	IN	B-PP	O	O
this	this	DT	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Physicians	Physician	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
provided	provide	VBN	I-VP	O	O
this	this	DT	B-NP	O	O
information	information	NN	I-NP	O	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
awareness	awareness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
cinoxacin	cinoxacin	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
certain	certain	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-AD-2
anti	anti	AFX	I-NP	O	I-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Elevated	Elevated	JJ	B-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group-ME-1
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
serum	serum	NN	I-NP	B-protein	O
half	half	NN	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-EF-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
transient	transient	JJ	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-EF-2
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Glyburide	Glyburide	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sulfonylurea	sulfonylurea	NN	I-NP	O	S-group-EF-2
glyburide	glyburide	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
rare	rare	JJ	B-NP	O	O
occasions	occasion	NNS	I-NP	O	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
.	.	.	O	O	O

Histamine	Histamine	NN	B-NP	O	B-group
H2	H2	NN	I-NP	O	I-group
-	-	HYPH	B-NP	O	I-group
receptor	receptor	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
Histamine	Histamine	NN	B-NP	O	B-group
H2	H2	NN	I-NP	O	I-group
-	-	HYPH	B-NP	O	I-group
receptor	receptor	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
Renal	Renal	JJ	I-NP	O	O
tubular	tubular	JJ	I-NP	O	O
transport	transport	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
potentially	potentially	RB	B-VP	O	O
leading	lead	VBG	I-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

This	This	DT	B-NP	O	O
might	might	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
toxic	toxic	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
under	under	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-AD-1
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
concomitant	concomitant	JJ	B-NP	O	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
.	.	.	O	O	O

Multivalent	Multivalent	JJ	B-NP	O	O
Cation	Cation	NN	I-NP	O	O
-	-	HYPH	O	O	O
Containing	Contain	VBG	B-VP	O	O
Products	Product	NNS	B-NP	O	O
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	S-group-ME-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
with	with	IN	B-PP	O	O
multivalent	multivalent	JJ	B-NP	O	O
cation	cation	NN	I-NP	O	O
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
products	product	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug-ME-2
antacids	antacid	NNS	I-NP	O	S-group-ME-2
,	,	,	O	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand-ME-2
chewable	chewable	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
buffered	buffered	JJ	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
powder	powder	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
products	product	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
zinc	zinc	NN	B-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
substantially	substantially	RB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
considerably	considerably	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
than	than	IN	B-SBAR	O	O
desired	desire	VBN	B-VP	O	O
.	.	.	O	O	O

Proquin	Proquin	NN	B-NP	B-protein	B-brand
XR	XR	NN	I-NP	I-protein	E-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	B-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
time	time	NN	I-NP	O	O
window	window	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
different	different	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
formulations	formulation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
usually	usually	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	B-NP	O	O
6	6	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-2
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-group
-	-	HYPH	I-NP	B-DNA	I-group
steroidal	steroidal	JJ	I-NP	I-DNA	I-group
anti	anti	AFX	I-NP	I-DNA	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
)	)	)	O	O	O
:	:	:	O	O	O
These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
very	very	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
provoke	provoke	VB	I-VP	O	O
convulsions	convulsion	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
pre	pre	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Omeprazole	Omeprazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
bioequivalent	bioequivalent	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
Proquin	Proquin	NN	B-NP	B-protein	B-brand
XR	XR	NN	I-NP	I-protein	E-brand
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
when	when	WRB	B-ADVP	O	O
Proquin	Proquin	NN	B-NP	B-protein	B-brand
XR	XR	NN	I-NP	I-protein	E-brand
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
maximally	maximally	RB	B-VP	O	O
suppresses	suppress	VBZ	I-VP	O	O
gastric	gastric	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

Omeprazole	Omeprazole	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
as	as	RB	O	O	O
directed	direct	VBN	B-VP	O	O
and	and	CC	O	O	O
Proquin	Proquin	NN	B-NP	B-protein	B-brand
XR	XR	NN	I-NP	I-protein	E-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
meal	meal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
preferably	preferably	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
evening	evening	NN	I-NP	O	O
meal..	meal..	NN	I-NP	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Altered	Alter	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
increased	increase	VBN	B-VP	O	O
and	and	CC	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
Probenecid	Probenecid	NN	B-NP	O	S-drug-ME-1
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
produces	produce	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
As	As	IN	B-SBAR	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-1
,	,	,	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
elimination	elimination	NN	I-NP	B-protein	O
half	half	NN	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
dosage	dosage	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
made	make	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
appropriate	appropriate	JJ	B-ADJP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Quinolones	Quinolone	NNS	B-NP	O	S-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Cisapride	Cisapride	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
mainly	mainly	RB	B-ADVP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
where	where	WRB	B-ADVP	O	O
serious	serious	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
,	,	,	O	O	O
QT	QT	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
torsades	torsade	NNS	B-NP	O	O
de	de	FW	I-NP	O	O
pointes	pointes	FW	I-NP	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	I-protein	O
,	,	,	O	O	O
elevated	elevated	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
.	.	.	O	O	O

Antibiotics	Antibiotic	NNS	B-NP	O	S-group
:	:	:	O	O	O
In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-ME-1
markedly	markedly	RB	B-ADVP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	B-protein	O
.	.	.	O	O	O

Anticholinergics	Anticholinergic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group-EF-1
compounds	compound	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
belladonna	belladonna	NN	B-NP	O	B-group-EF-1
alkaloids	alkaloid	NNS	I-NP	O	E-group-EF-1
and	and	CC	I-NP	O	O
dicyclomine	dicyclomine	NN	I-NP	O	S-drug-EF-1
,	,	,	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
compromise	compromise	VB	I-VP	O	O
the	the	DT	B-NP	O	O
beneficial	beneficial	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
(	(	(	O	O	O
Oral	Oral	NNP	B-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
,	,	,	O	O	O
the	the	DT	B-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
times	time	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
check	check	VB	I-VP	O	O
coagulation	coagulation	NN	B-NP	B-protein	O
time	time	NN	I-NP	I-protein	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
few	few	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
start	start	NN	I-NP	O	O
and	and	CC	I-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-AD-1
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group-AD-2
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Antidepressants	Antidepressant	NNS	B-NP	O	S-group
:	:	:	O	O	O
In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug-ME-1
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	B-protein	O
.	.	.	O	O	O

Antifungals	Antifungal	NNS	B-NP	O	S-group
:	:	:	O	O	O
In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
markedly	markedly	RB	B-ADVP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	B-protein	O
.	.	.	O	O	O

Human	Human	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
markedly	markedly	RB	B-ADVP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
eight	eight	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
14	14	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
female	female	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-EF-2
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	B-protein	O
.	.	.	O	O	O

H2	H2	NN	B-NP	B-protein	B-group
Receptor	Receptor	NN	I-NP	I-protein	I-group
Antagonists	Antagonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
coadministration	coadministration	NN	I-NP	O	O
leads	lead	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
peak	peak	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
ranitidine	ranitidine	NN	I-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
accelerated	accelerate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Protease	Protease	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug-ME-1
markedly	markedly	RB	B-ADVP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	B-protein	O
.	.	.	O	O	O

Other	Other	JJ	B-ADJP	O	O
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
with	with	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
and	and	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Cisapride	Cisapride	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
:	:	:	O	O	O
certain	certain	JJ	B-NP	O	O
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	S-group-AD-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
Class	Class	NNP	B-NP	O	O
IA	IA	NNP	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-AD-2
and	and	CC	I-NP	O	O
procainamide	procainamide	NN	I-NP	O	S-drug-AD-2
)	)	)	O	O	O
and	and	CC	O	O	O
Class	Class	NN	B-NP	B-protein	O
III	III	CD	I-NP	I-protein	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
sotalol	sotalol	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
;	;	:	O	O	O

tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
amitriptyline	amitriptyline	NN	B-NP	O	S-drug
)	)	)	O	O	O
;	;	:	O	O	O

certain	certain	JJ	B-NP	O	O
tetracyclic	tetracyclic	JJ	I-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
maprotiline	maprotiline	NN	B-NP	O	S-drug
)	)	)	O	O	O
;	;	:	O	O	O

certain	certain	JJ	B-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	B-group
medications	medication	NNS	I-NP	O	E-group
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
sertindole	sertindole	NN	B-NP	O	S-drug
)	)	)	O	O	O
;	;	:	O	O	O

astemizole	astemizole	NN	B-NP	O	S-drug
,	,	,	O	O	O
bepridil	bepridil	NN	B-NP	O	S-drug
,	,	,	O	O	O
sparfloxacin	sparfloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
terodiline	terodiline	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
preceding	precede	VBG	I-NP	O	O
lists	list	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
comprehensive	comprehensive	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
acceleration	acceleration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastric	gastric	JJ	B-NP	O	O
emptying	emptying	NN	I-NP	O	O
by	by	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
could	could	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
narrow	narrow	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
require	require	VBP	B-VP	O	O
careful	careful	JJ	B-NP	O	O
titration	titration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
;	;	:	O	O	O

if	if	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
being	be	VBG	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reassessed	reassess	VBN	I-VP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
0.1	0.1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
x	x	SYM	I-NP	O	O
ED95	ED95	NN	I-NP	O	O
)	)	)	O	O	O
NIMBEX	NIMBEX	NN	B-NP	O	S-brand-EF-1
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
or	or	CC	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
an	an	DT	B-NP	O	O
intubating	intubate	VBG	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
produced	produce	VBD	B-VP	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
block	block	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
onset	onset	NN	B-NP	O	O
of	of	IN	B-PP	O	O
maximum	maximum	NN	B-NP	O	O
block	block	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand-EF-1
is	be	VBZ	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
2	2	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
faster	faster	RBR	B-ADVP	O	O
with	with	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Prior	Prior	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
block	block	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
initial	initial	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
bolus	bolus	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Infusion	Infusion	NN	B-NP	O	O
requirements	requirement	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
administered	administer	VBN	B-VP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-1
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
infusions	infusion	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand-EF-2
were	be	VBD	B-VP	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
or	or	CC	O	O	O
slightly	slightly	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand
before	before	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
not	not	RB	O	O	O
studied	study	VBN	B-VP	O	O
systematically	systematically	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
vecuronium	vecuronium	NN	B-NP	O	S-drug
,	,	,	O	O	O
pancuronium	pancuronium	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
atracurium	atracurium	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
varying	vary	VBG	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
from	from	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
infusions	infusion	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Isoflurane	Isoflurane	NN	B-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
enflurane	enflurane	NN	I-NP	O	S-drug-EF-1
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nitrous	nitrous	JJ	B-NP	O	B-drug-EF-1
oxide	oxide	NN	I-NP	O	E-drug-EF-1
/	/	SYM	B-NP	O	O
oxygen	oxygen	NN	I-NP	O	S-drug
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
1.25	1.25	CD	B-NP	O	O
MAC	MAC	NNP	I-NP	O	O
[	[	(	O	O	O
Minimum	Minimum	NNP	B-NP	O	O
Alveolar	Alveolar	NNP	I-NP	O	O
Concentration	Concentration	NNP	I-NP	O	O
]	]	)	O	O	O
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
effective	effective	JJ	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand-EF-2
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
the	the	DT	B-NP	O	O
required	required	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
depend	depend	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
volatile	volatile	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Fifteen	Fifteen	CD	B-NP	O	O
to	to	TO	I-NP	O	O
30	30	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
1.25	1.25	CD	B-NP	O	O
MAC	MAC	NN	I-NP	O	O
isoflurane	isoflurane	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
enflurane	enflurane	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
minimal	minimal	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
shortly	shortly	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
volatile	volatile	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
surgical	surgical	JJ	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
enflurane	enflurane	NN	B-NP	O	S-drug-AD-1
or	or	CC	I-NP	O	O
isoflurane	isoflurane	NN	I-NP	O	S-drug-AD-1
anesthesia	anesthesia	NN	I-NP	O	O
,	,	,	O	O	O
less	less	RBR	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
,	,	,	O	O	O
lower	low	JJR	B-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
reduced	reduce	VBN	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand-AD-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
requirement	requirement	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
as	as	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
as	as	IN	I-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
propofol	propofol	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
or	or	CC	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
requirements	requirement	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nondepolarizing	nondepolarize	VBG	B-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand-EF-M
include	include	VBP	B-VP	O	O
certain	certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-EF-2
(	(	(	O	O	O
e.	e.	FW	B-NP	O	O
g.	g.	FW	I-NP	O	O
,	,	,	O	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
bacitracin	bacitracin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
polymyxins	polymyxin	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
lincomycin	lincomycin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
colistin	colistin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-EF-2
colistemethate	colistemethate	NN	I-NP	O	E-drug-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
magnesium	magnesium	NN	B-NP	O	S-group-EF-2
salts	salt	NNS	I-NP	O	O
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Resistance	Resistance	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nondepolarizing	nondepolarize	VBG	B-VP	O	B-group-EF-1
neuromuscular	neuromuscular	JJ	B-NP	O	I-group-EF-1
blocking	block	VBG	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
chronically	chronically	RB	B-VP	O	O
administered	administer	VBN	I-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-EF-1
therapy	therapy	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NIMBEX	NIMBEX	NN	B-NP	B-protein	S-brand-EF-2
are	be	VBP	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
,	,	,	O	O	O
slightly	slightly	RB	B-NP	O	O
shorter	short	JJR	I-NP	O	O
durations	duration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
block	block	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
and	and	CC	O	O	O
infusion	infusion	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
requirements	requirement	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
higher	high	JJR	B-ADJP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
None	None	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	B-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
become	become	VB	I-VP	O	O
subtherapeutic	subtherapeutic	JJ	B-ADJP	O	O
during	during	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug-ME-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Central	Central	JJ	B-NP	O	B-group
nervous	nervous	JJ	I-NP	O	I-group
system	system	NN	I-NP	O	I-group
depressant	depressant	NN	I-NP	O	E-group
(	(	(	O	O	O
CNS	CNS	NN	B-NP	B-protein	O
)	)	)	O	O	O
drugs	drug	NNS	B-NP	O	O
including	include	VBG	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
antidepressants	antidepressant	NNS	B-NP	O	S-group
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
,	,	,	O	O	O
antipsychotics	antipsychotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
(	(	(	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug
,	,	,	O	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
)	)	)	O	O	O
,	,	,	O	O	O
motion	motion	NN	B-NP	O	O
sickness	sickness	NN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
muscle	muscle	NN	B-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group
,	,	,	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group
,	,	,	O	O	O
sleeping	sleep	VBG	B-VP	O	O
pills	pill	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
tranquilizers	tranquilizer	NNS	I-NP	O	S-group

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
LEUSTATIN	LEUSTATIN	NN	B-NP	O	S-brand
Injection	Injection	NN	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
LEUSTATIN	LEUSTATIN	NN	B-NP	O	S-brand
Injection	Injection	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
before	before	RB	B-ADVP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
immunosuppression	immunosuppression	NN	B-NP	O	O
or	or	CC	I-NP	O	O
myelosuppression	myelosuppression	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
ampicillin	ampicillin	NN	I-NP	B-protein	S-drug-EF-2
increases	increase	VBZ	B-VP	O	O
substantially	substantially	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rashes	rash	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug-EF-1
rashes	rash	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
hyperuricemia	hyperuricemia	NN	I-NP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
controlled	control	VBN	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
AUGMENTIN	AUGMENTIN	NN	B-NP	O	B-brand
XR	XR	NN	I-NP	O	E-brand
,	,	,	O	O	O
22	22	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
allopurinol	allopurinol	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
AUGMENTIN	AUGMENTIN	NN	I-NP	O	B-brand
XR	XR	NN	I-NP	O	E-brand
.	.	.	O	O	O

No	No	DT	B-NP	O	O
rashes	rash	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
sample	sample	NN	I-NP	O	O
size	size	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
too	too	RB	B-ADJP	O	O
small	small	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
allow	allow	VB	I-VP	O	O
for	for	IN	B-PP	O	O
any	any	DT	B-NP	O	O
conclusions	conclusion	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
drawn	draw	VBN	I-VP	O	O
regarding	regard	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rashes	rash	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
AUGMENTIN	AUGMENTIN	NN	I-NP	O	B-brand
XR	XR	NN	I-NP	O	E-brand
and	and	CC	O	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug
use	use	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
common	common	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
broad	broad	JJ	I-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
spectrum	spectrum	NN	I-NP	O	I-group-EF-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
AUGMENTIN	AUGMENTIN	NN	B-NP	O	B-brand-EF-1
XR	XR	NN	I-NP	O	E-brand-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2

Additive	Additive	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depression	depression	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-1
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
including	include	VBG	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	B-group-AD-2
depressant	depressant	NN	I-NP	O	I-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Monoamine	Monoamine	NN	B-NP	B-protein	B-group-EF-1
oxidase	oxidase	NN	I-NP	I-protein	I-group-EF-1
(	(	(	O	O	I-group-EF-1
MAO	MAO	NN	B-NP	O	I-group-EF-1
)	)	)	O	O	I-group-EF-1
inhibitors	inhibitor	NNS	B-NP	O	E-group-EF-1
prolong	prolong	VB	B-VP	O	O
and	and	CC	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Amantadine	Amantadine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
MAOIs	MAOI	NNS	B-NP	B-protein	S-group-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clidinium	clidinium	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Clidinium	Clidinium	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
levodopa	levodopa	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Clindamycin	Clindamycin	NN	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
blocking	block	VBG	I-NP	O	O
properties	property	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	B-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
such	such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Antagonism	Antagonism	NNP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-EF-2
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
possible	possible	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
(	(	(	O	O	O
increases	increase	VBZ	B-VP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
by	by	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
valproates	valproate	NNS	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
separate	separate	JJ	I-NP	O	O
information	information	NN	I-NP	O	O
available	available	JJ	B-ADJP	O	O

Although	Although	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
date	date	NN	B-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
p450	p450	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clofarabine	clofarabine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clofarabine	clofarabine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
p450	p450	NN	I-NP	I-protein	O
substrates	substrate	NNS	I-NP	I-protein	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Tests	Test	VBZ	B-VP	O	O
Interactions	Interaction	NNS	B-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CLOLAR	CLOLAR	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
or	or	CC	O	O	O
laboratory	laboratory	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CLOLAR	CLOLAR	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Preliminary	Preliminary	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
dapsone	dapsone	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Lamprene	Lamprene	NN	B-NP	O	S-brand-EF-2
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
leprosy	leprosy	NN	B-NP	O	O
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
develop	develop	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
dapsone	dapsone	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
clofazimine	clofazimine	NN	I-NP	O	S-drug-AD-2
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
still	still	RB	B-ADVP	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
continue	continue	VB	I-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-AD-1
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Atromid	Atromid	NN	B-NP	O	B-brand-AD-2
-	-	HYPH	B-NP	O	I-brand-AD-2
S	S	NN	I-NP	O	E-brand-AD-2
.	.	.	O	O	O

Usually	Usually	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
half	half	NN	I-NP	O	O
(	(	(	O	O	O
depending	depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
individual	individual	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
level	level	NN	I-NP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
bleeding	bleeding	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
.	.	.	O	O	O

Frequent	Frequent	JJ	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
until	until	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
determined	determine	VBN	I-VP	O	O
definitely	definitely	RB	B-ADVP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	B-protein	O
level	level	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
.	.	.	O	O	O

Atromid	Atromid	JJ	B-NP	O	B-brand-ME-1
-	-	HYPH	I-NP	O	I-brand-ME-1
S	S	NN	I-NP	O	E-brand-ME-1
may	may	MD	B-VP	O	O
displace	displace	VB	I-VP	O	O
acidic	acidic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
tolbutamide	tolbutamide	NN	I-NP	O	S-drug-ME-2
from	from	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
binding	bind	VBG	I-NP	B-DNA	O
sites	site	NNS	I-NP	I-DNA	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
treating	treat	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
either	either	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
highly	highly	RB	I-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
Atromid	Atromid	NN	I-NP	O	B-brand
-	-	HYPH	B-NP	O	I-brand
S	S	NN	I-NP	O	E-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Atromid	Atromid	JJ	B-NP	O	B-brand-EF-2
-	-	HYPH	I-NP	O	I-brand-EF-2
S	S	NN	I-NP	O	E-brand-EF-2
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Fulminant	Fulminant	JJ	B-NP	O	O
rhabdomyolysis	rhabdomyolysis	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
seen	see	VBN	I-VP	O	O
as	as	RB	B-ADVP	O	O
early	early	RB	I-ADVP	O	O
as	as	IN	B-PP	O	O
three	three	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
another	another	DT	B-NP	O	O
fibrate	fibrate	NN	I-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
lovastatin	lovastatin	NN	I-NP	O	S-drug-EF-2
but	but	CC	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
seen	see	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
these	these	DT	B-NP	O	O
reasons	reason	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
felt	feel	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
had	have	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
unsatisfactory	unsatisfactory	JJ	I-NP	O	O
lipid	lipid	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
either	either	CC	O	O	O
drug	drug	NN	B-NP	O	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
benefits	benefit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
combined	combined	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
fibrate	fibrate	NN	I-NP	O	S-group-EF-2
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
outweigh	outweigh	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
myopathy	myopathy	NN	I-NP	O	O
,	,	,	O	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
acute	acute	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
occurs	occur	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
fibrates	fibrate	NNS	B-NP	O	S-group
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
gemfibrozil	gemfibrozil	NN	B-NP	O	S-drug
,	,	,	O	O	O
myopathy	myopathy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
rhabdomyolysis	rhabdomyolysis	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fibrates	fibrate	NNS	B-NP	O	S-group
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
clofibrate	clofibrate	NN	B-NP	O	S-drug
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
fibrates	fibrate	NNS	B-NP	O	S-group-AD-2
should	should	MD	B-VP	O	O
generally	generally	RB	I-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
clomiphene	clomiphene	NN	B-NP	O	B-drug
citrate	citrate	NN	I-NP	O	E-drug
tablets	tablet	NNS	I-NP	O	O
USP	USP	NNP	B-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
documented	document	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
Anafranil	Anafranil	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Anafranil	Anafranil	NN	B-NP	O	S-brand
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
it	it	PRP	B-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
active	active	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Anafranil	Anafranil	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Close	Close	JJ	B-NP	O	O
supervision	supervision	NN	I-NP	O	O
and	and	CC	O	O	O
careful	careful	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
required	require	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Anafranil	Anafranil	NNP	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	S-group-AD-2
or	or	CC	I-NP	O	O
sympathomimetic	sympathomimetic	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
block	block	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
similar	similar	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
such	such	PDT	B-NP	O	O
an	an	DT	I-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CMI	CMI	NN	B-NP	B-protein	S-drug-EF-2
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
structural	structural	JJ	I-NP	O	O
similarity	similarity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
other	other	JJ	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CMI	CMI	NN	B-NP	B-protein	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
closely	closely	RB	I-NP	O	O
related	related	JJ	I-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylphenidate	methylphenidate	NN	B-NP	O	S-drug-ME-M
or	or	CC	O	O	O
hepatic	hepatic	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-M
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-ME-M
)	)	)	O	O	O
and	and	CC	O	O	O
decreased	decrease	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
inducers	inducer	NNS	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-ME-M
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-M
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
such	such	PDT	B-NP	O	O
an	an	DT	I-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CMI	CMI	NN	B-NP	B-protein	S-drug-ME-2
as	as	RB	B-ADVP	O	O
well	well	RB	I-ADVP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CMI	CMI	NN	B-NP	B-protein	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
metabolizing	metabolize	VBG	B-VP	O	O
isozyme	isozyme	NN	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
debrisoquin	debrisoquin	NN	B-NP	B-protein	O
hydroxylase	hydroxylase	NN	I-NP	I-protein	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
aucasian	aucasian	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
7	7	CD	I-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Caucasians	Caucasian	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
so	so	RB	B-ADJP	O	O
-	-	HYPH	I-ADJP	O	O
called	call	VBN	B-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

reliable	reliable	JJ	B-NP	O	O
estimates	estimate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
P450	P450	NN	I-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
among	among	IN	B-PP	O	O
Asian	Asian	JJ	B-NP	O	O
,	,	,	I-NP	O	O
African	African	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
populations	population	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
yet	yet	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
.	.	.	O	O	O

Poor	Poor	NN	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
expected	expect	VBN	B-NP	O	O
lasma	lasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
(	(	(	O	O	O
TCAs	TCA	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
usual	usual	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Depending	Depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-ADJP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
quite	quite	RB	B-ADJP	O	O
large	large	JJ	I-ADJP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
and	and	CC	O	O	O
make	make	VB	B-VP	O	O
normal	normal	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
resemble	resemble	VBP	B-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
individual	individual	NN	I-NP	O	O
who	who	WP	B-NP	O	O
is	be	VBZ	B-VP	O	O
stable	stable	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
given	give	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TCAmay	TCAmay	NN	B-NP	O	O
become	become	VBP	B-VP	O	O
abruptly	abruptly	RB	B-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
inhibiting	inhibit	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
include	include	VBP	B-VP	O	O
some	some	DT	O	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
(	(	(	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
;	;	:	O	O	O

cimetidine	cimetidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
many	many	JJ	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
many	many	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Type	Type	NN	I-NP	O	B-group
1C	1C	NN	I-NP	O	I-group
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	E-group
propafenone	propafenone	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
flecainide	flecainide	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
selective	selective	JJ	I-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
inhibit	inhibit	VBP	B-VP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
vary	vary	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
.	.	.	O	O	O

Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
P450	P450	NN	B-NP	B-protein	O
1A2	1A2	NN	I-NP	I-protein	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
isoform	isoform	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
TCAmetabolism	TCAmetabolism	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
to	to	TO	B-PP	O	O
which	which	WDT	B-NP	O	O
SSRI	SSRI	NN	B-NP	B-protein	S-group-IN-1
-	-	HYPH	I-NP	O	O
TCAinteractions	TCAinteraction	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
pose	pose	VB	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
problems	problem	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
depend	depend	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	O	S-group
involved	involve	VBN	B-VP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TCAs	TCA	NNS	B-NP	B-protein	S-group-AD-1
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRIs	SSRI	NNS	I-NP	O	S-group-AD-2
and	and	CC	O	O	O
also	also	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
switching	switch	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
one	one	CD	B-NP	O	O
class	class	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
importance	importance	NN	I-NP	O	O
,	,	,	O	O	O
sufficient	sufficient	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
must	must	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
before	before	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
TCAtreatment	TCAtreatment	NN	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
being	be	VBG	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
parent	parent	NN	I-NP	O	O
and	and	CC	O	O	O
active	active	JJ	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
(	(	(	O	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
5	5	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	I-group
class	class	NN	I-NP	O	E-group
(	(	(	O	O	O
which	which	WDT	B-NP	O	O
includes	include	VBZ	B-VP	O	O
Anafranil	Anafranil	NN	B-NP	O	S-brand
)	)	)	O	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
than	than	IN	B-SBAR	O	O
usually	usually	RB	B-ADVP	O	O
prescribed	prescribe	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	I-group
agent	agent	NN	I-NP	O	E-group
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
whenever	whenever	WRB	B-ADVP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	I-group
agent	agent	NN	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
desirable	desirable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
TCAplasma	TCAplasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
whenever	whenever	WRB	B-ADVP	O	O
an	an	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	I-group
class	class	NN	I-NP	O	E-group
including	include	VBG	B-PP	O	O
Anafranil	Anafranil	NNP	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
going	go	VBG	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
(	(	(	O	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
P450	P450	NN	B-NP	B-protein	O
1A2	1A2	NN	I-NP	I-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
Anafranil	Anafranil	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
serum	serum	NN	B-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Anafranil	Anafranil	NN	B-NP	O	S-brand-ME-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
highly	highly	RB	I-VP	O	O
bound	bind	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
protein	protein	NN	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
potentially	potentially	RB	B-VP	O	O
resulting	result	VBG	I-VP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Conversely	Conversely	RB	B-ADVP	O	O
,	,	,	O	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
displacement	displacement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
-	-	HYPH	O	O	O
bound	bind	VBN	B-VP	O	O
Anafranil	Anafranil	NN	B-NP	O	S-brand
by	by	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
highly	highly	RB	I-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Clonazepam	Clonazepam	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Pharmacokinetics	Pharmacokinetics	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
Clonazepam	Clonazepam	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Pharmacokinetics	Pharmacokinetics	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Clonazepam	Clonazepam	NN	B-NP	O	S-drug
:	:	:	O	O	O
Literature	Literature	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
an	an	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
decreases	decrease	VBZ	B-VP	O	O
stomach	stomach	NN	B-NP	O	O
acidity	acidity	NN	I-NP	O	O
,	,	,	O	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
greatly	greatly	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
clonazepam	clonazepam	NN	I-NP	O	S-drug-ME-1
orally	orally	RB	B-VP	O	O
disintegrating	disintegrate	VBG	I-VP	O	O
tablet	tablet	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
and	and	CC	I-PP	O	O
without	without	IN	I-PP	O	O
propantheline	propantheline	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
an	an	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group
agent	agent	NN	I-NP	O	E-group
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
GI	GI	NN	I-NP	O	O
tract	tract	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-ADVP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
orally	orally	RB	I-NP	O	O
disintegrating	disintegrate	VBG	I-NP	O	O
tablet	tablet	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
propantheline	propantheline	NN	B-NP	O	S-drug-ME-2
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Fluoxetine	Fluoxetine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	O	O
450	450	CD	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug-ME-1
,	,	,	O	O	O
induce	induce	VBP	B-VP	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
causing	cause	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
approximately	approximately	RB	I-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
clonazepam	clonazepam	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	I-protein	O
450	450	CD	I-NP	I-protein	O
3A	3A	NN	I-NP	I-protein	O
family	family	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
notably	notably	RB	B-NP	O	O
oral	oral	JJ	I-NP	O	O
antifungal	antifungal	JJ	I-NP	O	B-group-AD-1
agents	agent	NNS	I-NP	O	E-group-AD-1
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Pharmacodynamic	Pharmacodynamic	JJ	B-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
depressant	depressant	NN	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
benzodiazepine	benzodiazepine	NN	I-NP	O	B-group-EF-1
class	class	NN	I-NP	O	E-group-EF-1
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
nonbarbiturate	nonbarbiturate	JJ	B-NP	O	B-group-EF-2
hypnotics	hypnotic	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
antianxiety	antianxiety	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
phenothiazines	phenothiazine	NNS	I-NP	O	S-group-EF-2
,	,	,	I-NP	O	O
thioxanthene	thioxanthene	NN	I-NP	O	S-group-EF-2
and	and	CC	I-NP	O	O
butyrophenone	butyrophenone	NN	I-NP	O	B-group-EF-2
classes	class	NNS	I-NP	O	I-group-EF-2
of	of	IN	B-PP	O	I-group-EF-2
antipsychotic	antipsychotic	JJ	B-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
by	by	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Tablet	Tablet	NN	B-NP	O	O
If	If	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
clonidine	clonidine	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
taking	take	VBG	I-VP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
necessitating	necessitate	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
.	.	.	O	O	O

Clonidine	Clonidine	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
depressive	depressive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
sedatives	sedative	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Amitriptyline	Amitriptyline	NN	B-NP	O	S-drug-EF-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-EF-2
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
manifestation	manifestation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corneal	corneal	JJ	B-NP	O	O
lesions	lesion	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
Epidural	Epidural	JJ	B-NP	O	O
Injection	Injection	NN	I-NP	O	O
Clonidine	Clonidine	NN	I-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
depressive	depressive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
sedating	sedate	VBG	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Narcotic	Narcotic	JJ	B-NP	O	B-group-EF-1
analgesics	analgesic	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Tricyclic	Tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
on	on	IN	B-PP	O	O
clonidines	clonidine	NNS	B-NP	O	O
analgesic	analgesic	JJ	B-NP	O	O
actions	action	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Beta	Beta	NN	B-NP	O	B-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
exacerbate	exacerbate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
seen	see	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-EF-2
withdrawl	withdrawl	NN	I-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
due	due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
bradycardia	bradycardia	NN	B-NP	O	O
and	and	CC	I-NP	O	O
AV	AV	NN	I-NP	O	O
block	block	NN	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
affect	affect	VB	I-VP	O	O
sinus	sinus	NN	B-NP	O	O
node	node	NN	I-NP	O	O
function	function	NN	I-NP	O	O
or	or	CC	O	O	O
AV	AV	NN	B-NP	O	O
nodal	nodal	JJ	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
digitalis	digitalis	NN	B-NP	O	S-group-AD-2
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group-AD-2
channel	channel	NN	I-NP	O	I-group-AD-2
blockers	blocker	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
beta	beta	SYM	B-NP	O	B-group-AD-2
-	-	HYPH	B-VP	O	I-group-AD-2
blockers	blocker	NNS	B-NP	O	E-group-AD-2
.	.	.	O	O	O
)	)	)	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
one	one	CD	B-NP	O	O
reported	report	VBN	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
delirium	delirium	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
simultaneous	simultaneous	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluphenazine	fluphenazine	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
clonidine	clonidine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Symptoms	Symptom	NNS	B-NP	O	O
resolved	resolve	VBD	B-VP	O	O
when	when	WRB	B-ADVP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
and	and	CC	O	O	O
recurred	recur	VBN	B-VP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
rechallenged	rechallenge	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Epidural	Epidural	JJ	B-NP	O	O
clonidine	clonidine	NN	I-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pharmacologic	pharmacologic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epidural	epidural	JJ	B-NP	O	O
local	local	JJ	I-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
both	both	CC	O	O	O
sensory	sensory	NN	B-NP	O	O
and	and	CC	O	O	O
motor	motor	NN	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
heparin	heparin	NN	B-NP	O	S-drug
,	,	,	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group

If	If	IN	B-SBAR	O	O
TRANXENE	TRANXENE	NN	B-NP	B-DNA	S-brand
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
acting	act	VBG	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
consideration	consideration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
employed	employ	VBN	I-VP	O	O
.	.	.	O	O	O

Animal	Animal	NN	B-NP	O	O
experience	experience	NN	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
clorazepate	clorazepate	NN	B-NP	O	B-drug-EF-1
dipotassium	dipotassium	NN	I-NP	O	E-drug-EF-1
prolongs	prolong	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
sleeping	sleeping	NN	I-NP	O	O
time	time	NN	I-NP	O	O
after	after	IN	B-PP	O	O
hexobarbital	hexobarbital	NN	B-NP	O	S-drug-EF-2
or	or	CC	B-PP	O	O
after	after	IN	B-PP	O	O
ethyl	ethyl	NN	B-NP	O	B-drug-EF-2
alcohol	alcohol	NN	I-NP	O	E-drug-EF-2
,	,	,	O	O	O
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chlorpromazine	chlorpromazine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
but	but	CC	O	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
monoamine	monoamine	NN	B-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
inhibition	inhibition	NN	I-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
increased	increase	VBN	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
hypnotic	hypnotic	JJ	I-NP	O	B-group
medications	medication	NNS	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
TRANXENE	TRANXENE	NN	B-NP	O	S-brand
tablets	tablet	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
anxiety	anxiety	NN	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
somatic	somatic	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
states	state	NNS	I-NP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
paid	pay	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
possible	possible	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
at	at	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TRANXENE	TRANXENE	NN	B-NP	B-protein	S-brand
tablets	tablet	NNS	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Pharmacodynamic	Pharmacodynamic	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
related	relate	VBN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug
induced	induced	JJ	I-NP	O	O
agranulocytosis	agranulocytosis	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
;	;	:	O	O	O

nonetheless	nonetheless	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
causative	causative	JJ	B-NP	B-protein	O
factors	factor	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
synergistically	synergistically	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
severity	severity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
warrants	warrant	NNS	I-NP	O	O
consideration	consideration	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
having	have	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
known	know	VBN	I-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
suppress	suppress	VB	I-VP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
it	it	PRP	B-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
active	active	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Orthostatic	Orthostatic	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
rare	rare	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
1	1	CD	I-NP	O	O
case	case	NN	I-NP	O	O
per	per	IN	B-PP	O	O
3,000	3,000	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
be	be	VB	B-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
profound	profound	JJ	B-NP	O	O
collapse	collapse	NN	I-NP	O	O
and	and	CC	I-NP	O	O
respiratory	respiratory	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
collapse	collapse	NN	B-NP	O	O
/	/	SYM	O	O	O
respiratory	respiratory	NN	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
during	during	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
being	be	VBG	I-VP	O	O
administered	administer	VBN	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group
;	;	:	O	O	O

similar	similar	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
psychotropic	psychotropic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
or	or	CC	B-NP	O	O
even	even	RB	I-NP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
itself	itself	PRP	B-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
psychotropics	psychotropic	NNS	I-NP	O	S-group
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
benzodiazepine	benzodiazepine	NN	I-NP	O	S-group-AD-2
or	or	CC	O	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
psychotropic	psychotropic	JJ	I-NP	O	B-group-AD-2
drug	drug	NN	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Clozapine	Clozapine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atropine	atropine	NN	B-NP	O	S-drug-EF-2
-	-	HYPH	B-NP	O	O
type	type	NN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
induced	induce	VBD	B-VP	O	O
hypotension	hypotension	NN	B-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
reverse	reverse	JJ	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	O	S-drug
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
related	related	JJ	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
450	450	CD	B-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
1A2	1A2	NN	I-NP	B-protein	O
,	,	,	O	O	O
2D6	2D6	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
and	and	CC	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
individual	individual	JJ	I-NP	O	O
isoform	isoform	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
either	either	CC	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
nicotine	nicotine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
effectiveness	effectiveness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
previously	previously	RB	I-NP	O	O
effective	effective	JJ	I-NP	O	O
Clozapine	Clozapine	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
potentially	potentially	RB	B-VP	O	O
resulting	result	VBG	I-VP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
noted	note	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-ME-1
administration	administration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenic	schizophrenic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
under	under	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
paroxetine	paroxetine	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
16	16	CD	B-NP	O	O
and	and	CC	I-NP	O	O
14	14	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
trough	trough	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
,	,	,	O	O	O
N	N	NN	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
desmethylclozapine	desmethylclozapine	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
clozapine	clozapine	NN	I-NP	O	B-drug_n
N	N	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
oxide	oxide	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
elevated	elevate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
three	three	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-VP	O	O
compared	compare	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Paroxetine	Paroxetine	NN	B-NP	O	S-drug-ME-1
produced	produce	VBD	B-VP	O	O
only	only	RB	B-NP	O	O
minor	minor	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
published	publish	VBN	I-NP	O	O
reports	report	NNS	I-NP	O	O
describe	describe	VBP	B-VP	O	O
modest	modest	JJ	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
(	(	(	O	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
two	two	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
such	such	JJ	B-NP	O	O
combined	combined	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
Clozapine	Clozapine	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

A	A	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
Clozapine	Clozapine	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
population	population	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
activity	activity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
drug	drug	NN	I-NP	B-protein	O
metabolizing	metabolize	VBG	B-VP	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
referred	refer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
as	as	IN	B-PP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
debrisoquin	debrisoquin	NN	B-NP	O	S-drug
,	,	,	O	O	O
dextromethorphan	dextromethorphan	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
.	.	.	O	O	O

These	These	DT	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-SBAR	O	O
expected	expect	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
usual	usual	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
many	many	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
(	(	(	O	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
,	,	,	O	O	O
selective	selective	JJ	B-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
others	other	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
thus	thus	RB	B-VP	O	O
may	may	MD	I-VP	O	O
make	make	VB	I-VP	O	O
normal	normal	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
resemble	resemble	VBP	B-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
regard	regard	NN	B-NP	O	O
to	to	TO	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
drug	drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
than	than	IN	B-SBAR	O	O
usually	usually	RB	B-ADVP	O	O
prescribed	prescribe	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
either	either	CC	O	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
Type	Type	NN	B-NP	O	B-group-AD-2
1C	1C	NN	I-NP	O	I-group-AD-2
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
propafenone	propafenone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
flecainide	flecainide	NN	B-NP	O	S-drug-AD-2
and	and	CC	O	O	O
encainide	encainide	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
NovoSeven	NovoSeven	CD	B-NP	O	S-brand
and	and	CC	O	O	O
coagulation	coagulation	NN	B-NP	B-protein	B-group
factor	factor	NN	I-NP	I-protein	E-group
concentrates	concentrate	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
adequately	adequately	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
preclinical	preclinical	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Simultaneous	Simultaneous	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
activated	activate	VBN	B-NP	O	B-group
prothrombin	prothrombin	NN	I-NP	O	I-group
complex	complex	NN	I-NP	O	I-group
concentrates	concentrate	NNS	I-NP	O	E-group
or	or	CC	O	O	O
prothrombin	prothrombin	NN	B-NP	O	B-group
complex	complex	NN	I-NP	O	I-group
concentrates	concentrate	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
50	50	CD	I-NP	O	O
episodes	episode	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antifibrinolytic	antifibrinolytic	JJ	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
tranexamic	tranexamic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
aminocaproic	aminocaproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
)	)	)	O	O	O
and	and	CC	O	O	O
NovoSeven	NovoSeven	CD	B-NP	O	S-brand
.	.	.	O	O	O

NovoSeven	NovoSeven	RB	B-ADVP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
mixed	mix	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
infusion	infusion	NN	B-NP	O	O
solutions	solution	NNS	I-NP	O	O
until	until	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
direct	direct	VB	I-VP	O	O
this	this	DT	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Codeine	Codeine	NN	B-NP	O	S-drug-EF-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
narcotic	narcotic	JJ	I-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
sedative	sedative	JJ	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
hypnotics	hypnotic	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
additive	additive	JJ	B-NP	O	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
s.c	s.c	NN	B-NP	O	O
.	.	.	O	O	O

combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
contemplated	contemplate	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Colchicine	Colchicine	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
acidifying	acidify	VBG	B-NP	O	B-group-ME-2
agents	agent	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
colchicine	colchicine	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
alkalinizing	alkalinize	VBG	B-NP	O	B-group-ME-2
agents	agent	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Colchicine	Colchicine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
sensitivity	sensitivity	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Response	Response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
colchicine	colchicine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

WelChol	WelChol	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
human	human	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
meal	meal	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
test	test	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

WelChol	WelChol	NN	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
metoprolol	metoprolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

WelChol	WelChol	NN	B-NP	O	S-brand-ME-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sustained	sustained	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
release	release	NN	I-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug-ME-2
(	(	(	O	O	O
Calan	Calan	NN	B-NP	B-protein	B-brand-ME-2
SR	SR	NN	I-NP	I-protein	E-brand-ME-2
)	)	)	O	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
31	31	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
variability	variability	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
WelChol	WelChol	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-VP	O	O
activity	activity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
HMG	HMG	NN	I-NP	B-protein	B-group
-	-	HYPH	B-NP	I-protein	I-group
CoA	CoA	NN	I-NP	I-protein	I-group
reductase	reductase	NN	I-NP	I-protein	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
safety	safety	NN	B-NP	O	O
or	or	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
consider	consider	VB	I-VP	O	O
monitoring	monitor	VBG	I-VP	O	O
drug	drug	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
or	or	CC	O	O	O
effects	effect	NNS	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
colestipol	colestipol	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
anion	anion	NN	I-NP	O	B-group
exchange	exchange	NN	I-NP	O	I-group
resin	resin	NN	I-NP	O	E-group
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
affinity	affinity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
anions	anion	NNS	B-NP	O	O
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bile	bile	NN	I-NP	O	O
acids	acid	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
colestipol	colestipol	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
binds	bind	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
COLESTlD	COLESTlD	NN	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
delay	delay	VB	I-VP	O	O
or	or	CC	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interval	interval	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
COLESTID	COLESTID	NN	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
and	and	CC	O	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
as	as	RB	B-ADVP	O	O
long	long	RB	I-ADVP	O	O
as	as	IN	B-PP	O	O
possible	possible	JJ	B-ADJP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
take	take	VB	I-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
one	one	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	B-NP	O	O
four	four	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
COLESTID	COLESTID	NN	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
impeding	impede	VBG	I-VP	O	O
their	their	PRP$	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Repeated	Repeat	VBN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
colestipol	colestipol	NN	B-NP	O	B-drug-ME-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-1
given	give	VBN	B-VP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
follow	follow	VB	I-NP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
study	study	NN	B-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
single	single	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
colestipol	colestipol	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
and	and	CC	O	O	O
twice	twice	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
a	a	DT	B-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
yet	yet	CC	I-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
;	;	:	O	O	O

the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-VP	O	O
reach	reach	VB	I-VP	O	O
maximum	maximum	JJ	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
delayed	delay	VBN	I-VP	O	O
approximately	approximately	RB	B-NP	O	O
30	30	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
COLESTID	COLESTID	NN	B-NP	O	S-brand-AD-2
Tablets	Tablet	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
either	either	RB	I-VP	O	O
added	add	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
deleted	delete	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chlorothiazide	chlorothiazide	NN	B-NP	O	S-drug-ME-1
as	as	IN	B-SBAR	O	O
reflected	reflect	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
markedly	markedly	RB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
even	even	RB	B-ADVP	O	O
when	when	WRB	I-ADVP	O	O
administered	administer	VBN	B-VP	O	O
one	one	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
colestipol	colestipol	NN	B-NP	O	B-drug-ME-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
penicillin	penicillin	NN	B-NP	O	B-drug-ME-1
G	G	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
gemfibrozil	gemfibrozil	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
colestipol	colestipol	NN	B-NP	O	B-drug-ME-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-2
;	;	:	O	O	O

these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
tested	test	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
one	one	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
colestipol	colestipol	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
depressant	depressant	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
colestipol	colestipol	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
:	:	:	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
clindamycin	clindamycin	NN	B-NP	O	S-brand
,	,	,	O	O	O
clofibrate	clofibrate	NN	B-NP	O	S-drug
,	,	,	O	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug
,	,	,	O	O	O
nicotinic	nicotinic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
(	(	(	O	O	O
niacin	niacin	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Particular	Particular	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	B-group-EF-1
preparations	preparation	NNS	I-NP	O	E-group-EF-1
since	since	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
conflicting	conflict	VBG	I-VP	O	O
results	result	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
colestipol	colestipol	NN	B-NP	O	B-drug-MU-M
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-MU-M
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
availability	availability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
digitoxin	digitoxin	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
binding	binding	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
if	if	IN	B-SBAR	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
is	be	VBZ	B-VP	O	O
present	present	JJ	B-ADJP	O	O
.	.	.	O	O	O

Discontinuing	Discontinue	VBG	B-VP	O	O
colestipol	colestipol	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
could	could	MD	B-VP	O	O
pose	pose	VB	I-VP	O	O
a	a	DT	B-NP	O	O
hazard	hazard	NN	I-NP	O	O
to	to	TO	B-PP	O	O
health	health	NN	B-NP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
bound	bind	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
resin	resin	NN	I-NP	O	S-group
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
level	level	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
taking	take	VBG	I-VP	O	O
colestipol	colestipol	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
.	.	.	O	O	O

Bile	Bile	NN	B-NP	B-protein	B-group-ME-1
acid	acid	NN	I-NP	I-protein	I-group-ME-1
binding	binding	NN	I-NP	I-protein	I-group-ME-1
resins	resin	NNS	I-NP	I-protein	E-group-ME-1
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
phosphate	phosphate	NN	I-NP	O	S-drug-ME-2
supplements	supplement	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
hydrocortisone	hydrocortisone	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
(	(	(	O	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group
and	and	CC	O	O	O
polymyxin	polymyxin	NN	B-NP	O	S-group
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
transmission	transmission	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
junction	junction	NN	I-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
this	this	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Coly	Coly	NNP	B-NP	O	B-brand
-	-	HYPH	I-NP	O	I-brand
Mycin	Mycin	NN	I-NP	O	I-brand
M	M	NN	I-NP	O	E-brand
Parenteral	Parenteral	NNP	I-NP	O	O
except	except	IN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
greatest	great	JJS	I-NP	O	O
caution	caution	NN	I-NP	O	O
.	.	.	O	O	O

Curariform	Curariform	JJ	B-NP	O	B-brand-EF-1
muscle	muscle	NN	I-NP	O	I-brand-EF-1
relaxants	relaxant	NNS	I-NP	O	E-brand-EF-1
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	I-NP	O	O
tubocurarine	tubocurarine	NN	I-NP	O	S-drug-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ether	ether	NN	B-NP	O	O
,	,	,	O	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
gallamine	gallamine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
decamethonium	decamethonium	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-EF-1
citrate	citrate	NN	I-NP	O	E-drug-EF-1
,	,	,	O	O	O
potentiate	potentiate	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	blocking	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
extreme	extreme	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Coly	Coly	NNP	B-NP	O	B-brand-EF-2
-	-	HYPH	B-NP	O	I-brand-EF-2
Mycin	Mycin	NNP	I-NP	O	I-brand-EF-2
M	M	NNP	I-NP	O	E-brand-EF-2
Parenteral	Parenteral	NNP	I-NP	O	O
.	.	.	O	O	O

Sodium	Sodium	NN	B-NP	B-protein	B-drug-EF-1
cephalothin	cephalothin	NN	I-NP	I-protein	E-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Coly	Coly	NNP	B-NP	O	B-brand-EF-2
-	-	HYPH	B-NP	O	I-brand-EF-2
Mycin	Mycin	NNP	I-NP	O	I-brand-EF-2
M	M	NNP	I-NP	O	E-brand-EF-2
Parenteral	Parenteral	NNP	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug-AD-1
cephalothin	cephalothin	NN	I-NP	O	E-drug-AD-1
and	and	CC	O	O	O
Coly	Coly	NNP	B-NP	O	B-brand-AD-2
-	-	HYPH	O	O	I-brand-AD-2
Mycin	Mycin	NNP	B-NP	O	I-brand-AD-2
M	M	NNP	I-NP	O	E-brand-AD-2
Parenteral	Parenteral	NNP	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	O	O	O
glycoprotein	glycoprotein	NN	B-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
conivaptan	conivaptan	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clearance	clearance	NN	B-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
VAPRISOL	VAPRISOL	NN	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clinician	clinician	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
alert	alert	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

DRUG	DRUG	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
LABORATORY	LABORATORY	NN	I-NP	B-protein	O
TEST	TEST	NN	I-NP	I-protein	O
INTERACTIONS	INTERACTIONS	NN	I-NP	I-protein	O
1	1	CD	I-NP	I-protein	O
.	.	.	O	O	O

Accelerated	Accelerate	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
partial	partial	JJ	B-NP	O	O
thromboplastin	thromboplastin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
platelet	platelet	NN	B-NP	B-cell_type	O
aggregation	aggregation	NN	I-NP	O	O
time	time	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
platelet	platelet	NN	I-NP	O	O
count	count	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
II	II	CD	B-NP	O	O
,	,	,	O	O	O
VII	VII	CD	B-NP	B-protein	O
antigen	antigen	NN	I-NP	I-protein	O
,	,	,	O	O	O
VIII	VIII	CD	B-NP	B-protein	O
antigen	antigen	NN	I-NP	I-protein	O
,	,	,	O	O	O
VIII	VIII	CD	B-NP	O	O
coagulant	coagulant	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
IX	IX	NN	B-NP	O	O
,	,	,	O	O	O
X	X	NN	B-NP	B-DNA	O
,	,	,	O	O	O
XII	XII	NN	B-NP	B-DNA	O
,	,	,	O	O	O
VII	VII	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
X	X	NN	I-NP	B-protein	O
complex	complex	NN	I-NP	I-protein	O
,	,	,	O	O	O
II	II	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
VII	VII	CD	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
X	X	NN	I-NP	B-protein	O
complex	complex	NN	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
beta	beta	SYM	O	O	O
-	-	HYPH	O	O	O
thromboglobulin	thromboglobulin	NN	B-NP	B-protein	O
;	;	:	O	O	O

decreased	decrease	VBN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
factor	factor	NN	I-NP	O	O
Xa	Xa	NN	I-NP	O	O
and	and	CC	O	O	O
antithrombin	antithrombin	NN	B-NP	B-protein	B-drug
III	III	CD	I-NP	I-protein	E-drug
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
antithrombin	antithrombin	NN	B-NP	B-protein	B-drug
III	III	CD	I-NP	I-protein	E-drug
activity	activity	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fibrinogen	fibrinogen	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
fibrinogen	fibrinogen	NN	I-NP	B-protein	S-drug
activity	activity	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
plasminogen	plasminogen	NN	I-NP	B-protein	O
antigen	antigen	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

2	2	LS	B-LST	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
thyroid	thyroid	NN	I-NP	B-protein	O
-	-	HYPH	B-VP	I-protein	O
binding	bind	VBG	I-VP	I-protein	O
globulin	globulin	NN	B-NP	I-protein	O
(	(	(	O	O	O
TBG	TBG	NN	B-NP	O	O
)	)	)	O	O	O
levels	level	NNS	B-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
circulating	circulate	VBG	I-NP	O	O
total	total	JJ	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
-	-	HYPH	O	O	O
bound	bind	VBN	B-VP	O	O
iodine	iodine	NN	B-NP	O	S-drug
(	(	(	O	O	O
PBI	PBI	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
T4	T4	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
by	by	IN	B-PP	O	O
column	column	NN	B-NP	O	O
or	or	CC	B-PP	O	O
by	by	IN	B-PP	O	O
radioimmunoassay	radioimmunoassay	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
T3	T3	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
radioimmunoassay	radioimmunoassay	NN	B-NP	O	O
.	.	.	O	O	O

T3	T3	NN	B-NP	O	O
resin	resin	NN	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
,	,	,	O	O	O
reflecting	reflect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
TBG	TBG	NN	I-NP	O	O
.	.	.	O	O	O

Free	Free	JJ	B-NP	O	O
T4	T4	NN	I-NP	O	O
and	and	CC	O	O	O
free	free	JJ	B-NP	O	O
T3	T3	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unaltered	unaltered	JJ	B-ADJP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	B-group
hormone	hormone	NN	I-NP	O	E-group
.	.	.	O	O	O

3	3	LS	B-LST	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
binding	binding	NN	I-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
elevated	elevate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
,	,	,	O	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	I-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	B-protein	O
binding	binding	NN	I-NP	I-protein	O
globulin	globulin	NN	I-NP	I-protein	O
(	(	(	O	O	O
CBG	CBG	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
sex	sex	NN	B-NP	B-protein	O
hormone	hormone	NN	I-NP	I-protein	O
binding	binding	NN	I-NP	I-protein	O
globulin	globulin	NN	I-NP	I-protein	O
(	(	(	O	O	O
SHBG	SHBG	NN	B-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
total	total	JJ	I-NP	O	O
circulating	circulate	VBG	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group
and	and	CC	O	O	O
sex	sex	NN	B-NP	O	B-group
steroids	steroid	NNS	I-NP	O	E-group
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Free	Free	JJ	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
(	(	(	O	O	O
angiotensinogen	angiotensinogen	NN	B-NP	O	O
/	/	SYM	O	O	O
renin	renin	NN	B-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
,	,	,	O	O	O
alpha	alpha	SYM	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
1	1	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
antitrypsin	antitrypsin	NN	I-NP	B-protein	O
,	,	,	I-NP	O	O
ceruloplasmin	ceruloplasmin	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

4	4	LS	B-LST	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
HDL	HDL	NN	I-NP	O	O
and	and	CC	O	O	O
HDL2	HDL2	NN	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	O	O
subfraction	subfraction	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
reduced	reduce	VBD	B-VP	O	O
LDL	LDL	NN	B-NP	B-protein	O
cholesterol	cholesterol	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
triglyceride	triglyceride	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

5	5	LS	B-LST	O	O
.	.	.	O	O	O

Impaired	Impaired	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
.	.	.	O	O	O

6	6	CD	B-NP	O	O
.	.	.	O	O	O

Reduced	Reduce	VBN	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
metyrapone	metyrapone	NN	B-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Corticotropin	Corticotropin	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
accentuate	accentuate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
electrolyte	electrolyte	NN	I-NP	O	O
loss	loss	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
diuretic	diuretic	JJ	B-NP	O	S-drug-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
listed	list	VBN	B-VP	O	O
below	below	IN	B-PP	O	O
are	be	VBP	B-VP	O	O
potentially	potentially	RB	B-ADJP	O	O
clinically	clinically	RB	I-ADJP	O	O
important	important	JJ	I-ADJP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-MU-1
,	,	,	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-MU-1
and	and	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-MU-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group-AD-2
dose	dose	NN	I-NP	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
and	and	CC	O	O	O
thus	thus	RB	B-ADVP	O	O
decrease	decrease	VB	B-VP	O	O
their	their	PRP$	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
steroid	steroid	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
could	could	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
or	or	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylate	salicylate	NN	B-NP	O	S-group-EF-1
toxicity	toxicity	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-drug-EF-2
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cortico	cortico	AFX	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
steroids	steroid	NNS	B-NP	O	E-group-AD-2
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
suffering	suffer	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
hypopro	hypopro	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
thrombinemia	thrombinemia	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-1
on	on	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-2
is	be	VBZ	B-VP	O	O
variable	variable	JJ	B-ADJP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
enhanced	enhance	VBN	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
diminished	diminish	VBN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-1
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
coagulation	coagulation	NN	B-NP	O	O
indices	index	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Corticotropin	Corticotropin	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
accentuate	accentuate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
electrolyte	electrolyte	NN	I-NP	O	O
loss	loss	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
diuretic	diuretic	JJ	B-NP	O	S-group-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
During	During	NNP	I-NP	O	O
Pregnancy	Pregnancy	NNP	I-NP	O	O
:	:	:	O	O	O
Cromolyn	Cromolyn	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
and	and	CC	O	O	O
isoproterenol	isoproterenol	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
subcutaneous	subcutaneous	JJ	B-NP	O	O
injections	injection	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Cromolyn	Cromolyn	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
alone	alone	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
540	540	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
340	340	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
maximum	maximum	NN	I-NP	O	O
recommended	recommend	VBD	B-VP	O	O
daily	daily	JJ	B-NP	O	O
inhalation	inhalation	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
m2	m2	NN	B-NP	O	O
basis	basis	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
resorptions	resorption	NNS	B-NP	O	O
or	or	CC	O	O	O
major	major	JJ	B-NP	O	O
malformations	malformation	NNS	I-NP	O	O
.	.	.	O	O	O

Isoproterenol	Isoproterenol	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2.7	2.7	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
7	7	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
maximum	maximum	NN	I-NP	O	O
recommended	recommend	VBD	B-VP	O	O
daily	daily	JJ	B-NP	O	O
inhalation	inhalation	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
m2	m2	NN	B-NP	O	O
basis	basis	NN	I-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
both	both	CC	O	O	O
resorptions	resorption	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
malformations	malformation	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
540	540	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cromolyn	cromolyn	NN	B-NP	O	B-drug-EF-1
sodium	sodium	NN	I-NP	O	E-drug-EF-1
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
340	340	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
maximum	maximum	NN	I-NP	O	O
recommended	recommend	VBD	B-VP	O	O
daily	daily	JJ	B-NP	O	O
inhalation	inhalation	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
m2	m2	NN	B-NP	O	O
basis	basis	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
2.7	2.7	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
7	7	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
maximum	maximum	NN	I-NP	O	O
recommended	recommend	VBD	B-VP	O	O
daily	daily	JJ	B-NP	O	O
inhalation	inhalation	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
m2	m2	NN	B-NP	O	O
basis	basis	NN	I-NP	O	O
)	)	)	O	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
resorptions	resorption	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
malformations	malformation	NNS	I-NP	O	O
.	.	.	O	O	O

None	None	NN	B-NP	O	O
known	know	VBN	B-VP	O	O
.	.	.	O	O	O

Persons	Person	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
most	most	JJS	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
,	,	,	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
pyrimethamine	pyrimethamine	NN	I-NP	O	S-drug
invalidate	invalidate	NN	I-NP	O	O
folic	folic	JJ	I-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-drug
B12	B12	NN	I-NP	O	E-drug
diagnostic	diagnostic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
assays	assay	NNS	I-NP	O	O
.	.	.	O	O	O

Colchicine	Colchicine	NN	B-NP	O	S-drug-ME-1
para	para	AFX	O	O	B-drug-ME-1
-	-	HYPH	O	O	I-drug-ME-1
aminosalicylic	aminosalicylic	JJ	B-NP	O	I-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
and	and	CC	O	O	O
heavy	heavy	JJ	B-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug-ME-1
intake	intake	NN	I-NP	O	O
for	for	IN	B-PP	O	O
longer	long	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
2	2	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
malabsorption	malabsorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B-protein	B-drug-ME-2
B12	B12	NN	I-NP	I-protein	E-drug-ME-2
.	.	.	O	O	O

FLEXERIL	FLEXERIL	NN	B-NP	B-protein	S-brand-IN-1
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group-IN-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-IN-2
.	.	.	O	O	O

FLEXERIL	FLEXERIL	NN	B-NP	B-protein	S-brand-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Tricyclic	Tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
block	block	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
similarly	similarly	RB	B-VP	O	O
acting	act	VBG	I-VP	O	O
compounds	compound	NNS	B-NP	O	O
.	.	.	O	O	O

Tricyclic	Tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
seizure	seizure	NN	I-NP	O	O
risk	risk	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
tramadol	tramadol	NN	B-NP	O	S-drug-EF-2

Cyclopentolate	Cyclopentolate	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbachol	carbachol	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	O	S-drug-EF-2
;	;	:	O	O	O

also	also	RB	B-ADVP	O	O
,	,	,	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
may	may	MD	B-VP	O	O
antagonise	antagonise	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	O
and	and	CC	I-NP	O	O
miotic	miotic	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ophthalmic	ophthalmic	JJ	B-NP	O	O
cholinesterase	cholinesterase	NN	I-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
leukopenic	leukopenic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug-ME-1
reportedly	reportedly	RB	B-ADVP	O	O
are	be	VBP	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
alert	alert	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
combined	combine	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
actions	action	NNS	I-NP	O	O
,	,	,	O	O	O
desirable	desirable	JJ	B-ADJP	O	O
or	or	CC	I-ADJP	O	O
undesirable	undesirable	JJ	I-ADJP	O	O
,	,	,	O	O	O
involving	involve	VBG	B-VP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug
even	even	RB	B-SBAR	O	O
though	though	IN	I-SBAR	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
successfully	successfully	RB	B-ADVP	O	O
concurrently	concurrently	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
other	other	JJ	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Cyclophosphamide	Cyclophosphamide	NN	B-NP	O	S-drug-EF-1
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
persistent	persistent	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cholinesterase	cholinesterase	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
potentiates	potentiate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	B-drug-EF-2
chloride	chloride	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug
within	within	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
anesthesiologist	anesthesiologist	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
alerted	alert	VBN	I-VP	O	O
.	.	.	O	O	O

May	May	MD	O	O	O
interact	interact	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
wthionamide	wthionamide	NN	B-NP	O	O
(	(	(	O	O	O
Trecator	Trecator	NN	B-NP	O	B-brand
-	-	HYPH	B-NP	O	I-brand
SC	SC	NN	I-NP	O	E-brand
)	)	)	O	O	O
and	and	CC	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
(	(	(	O	O	O
Nydrazid	Nydrazid	NN	B-NP	O	S-brand
)	)	)	O	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
prolong	prolong	VB	B-VP	O	O
and	and	CC	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Antihistamines	Antihistamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
hypnotics	hypnotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
antianxiety	antianxiety	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Steady	Steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
digitoxin	digitoxin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
change	change	VB	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
monitoring	monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
indicated	indicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
similar	similar	JJ	B-NP	O	O
combination	combination	NN	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
utilization	utilization	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digitoxin	digitoxin	NN	B-NP	O	S-drug
for	for	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
alternative	alternative	NN	I-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-NP	O	O
flucytosine	flucytosine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
LaboratoryTest	LaboratoryTest	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Dactinomycin	Dactinomycin	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
bioassay	bioassay	NN	B-NP	O	O
procedures	procedure	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
determination	determination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antibacterial	antibacterial	JJ	B-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Dantrium	Dantrium	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
theoretically	theoretically	RB	B-ADJP	O	O
possible	possible	JJ	I-ADJP	O	O
that	that	IN	B-SBAR	O	O
its	its	PRP$	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
microsomal	microsomal	JJ	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
neither	neither	CC	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
nor	nor	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	O	S-drug
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
Dantrium	Dantrium	NN	B-NP	O	S-brand
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Binding	Binding	NN	B-NP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
diphenylhydantoin	diphenylhydantoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Binding	Binding	NN	B-NP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
clotibrate	clotibrate	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O	O
collapse	collapse	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
varapamil	varapamil	NN	B-NP	O	O
and	and	CC	I-NP	O	O
dantrolene	dantrolene	NN	I-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
rare	rare	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
dantrolene	dantrolene	NN	I-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug
a	a	DT	B-NP	O	O
-	-	:	I-NP	O	O
chloralose	chloralose	NN	I-NP	O	O
anesthetized	anesthetize	VBN	I-NP	O	O
swine	swine	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
resulted	result	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	O
fibrillation	fibrillation	NN	I-NP	O	O
and	and	CC	O	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
collapse	collapse	NN	I-NP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
marked	marked	JJ	B-NP	O	O
hyperkalemia	hyperkalemia	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
dantrolene	dantrolene	NN	I-NP	O	B-drug-AD-1
sodium	sodium	NN	I-NP	O	E-drug-AD-1
and	and	CC	O	O	O
calcium	calcium	NN	B-NP	O	B-group-AD-2
channel	channel	NN	I-NP	O	I-group-AD-2
blockers	blocker	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
not	not	RB	O	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
malignant	malignant	JJ	B-NP	B-cell_type	O
hyperthermia	hyperthermia	NN	I-NP	I-cell_type	O
crisis	crisis	NN	I-NP	I-cell_type	O
until	until	IN	B-SBAR	I-cell_type	O
the	the	DT	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
humans	human	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dantrolene	dantrolene	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
vecuronium	vecuronium	NN	B-NP	O	S-drug-EF-2
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
block	block	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACZONE	ACZONE	NN	B-NP	O	S-brand
Gel	Gel	NN	I-NP	O	O
,	,	,	O	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
double	double	JJ	B-NP	O	O
strength	strength	NN	I-NP	O	O
(	(	(	O	O	O
160	160	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
800	800	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
trimethoprim	trimethoprim	NN	B-NP	O	S-drug
/	/	SYM	O	O	O
sulfamethoxazole	sulfamethoxazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
TMP	TMP	NN	B-NP	O	S-drug
/	/	SYM	O	O	O
SMX	SMX	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
systemic	systemic	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TMP	TMP	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
SMX	SMX	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
essentially	essentially	RB	B-ADJP	O	O
unchanged	unchanged	JJ	I-ADJP	O	O
.	.	.	O	O	O

Notably	Notably	RB	B-ADVP	O	O
,	,	,	O	O	O
systemic	systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
(	(	(	O	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
12	12	CD	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
dapsone	dapsone	NN	B-NP	O	B-drug_n
hydroxylamine	hydroxylamine	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
DHA	DHA	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
more	more	JJR	B-VP	O	O
than	than	IN	I-VP	O	O
doubled	double	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TMP	TMP	NN	B-NP	B-protein	S-drug
/	/	SYM	B-NP	O	O
SMX	SMX	NN	I-NP	O	S-drug
.	.	.	O	O	O

Exposure	Exposure	NN	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
proposed	propose	VBN	I-NP	O	O
topical	topical	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
about	about	IN	B-NP	O	O
1	1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
that	that	DT	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
even	even	RB	B-ADVP	O	O
when	when	WRB	I-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
TMP	TMP	NN	B-NP	B-protein	S-drug
/	/	SYM	I-NP	O	O
SMX	SMX	NN	I-NP	O	S-drug
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
,	,	,	O	O	O
anticonvulsants	anticonvulsant	NNS	B-NP	O	S-group
,	,	,	O	O	O
St	St	NNP	B-NP	O	O
.	.	.	O	O	O

John	John	NNP	B-NP	O	O
s	s	VBZ	B-VP	O	O
wort	wort	NN	B-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
formation	formation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dapsone	dapsone	NN	B-NP	O	B-drug_n
hydroxylamine	hydroxylamine	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
a	a	DT	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dapsone	dapsone	NN	B-NP	O	S-drug
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
hemolysis	hemolysis	NN	B-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
dapsone	dapsone	NN	I-NP	O	S-drug-EF-1
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
folic	folic	JJ	B-NP	O	B-group-EF-2
acid	acid	NN	I-NP	O	I-group-EF-2
antagonists	antagonist	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
pyrimethamine	pyrimethamine	NN	B-NP	O	S-drug-EF-2
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
noted	note	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
possibly	possibly	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hematologic	hematologic	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
daptomycin	daptomycin	NN	B-NP	O	S-drug
(	(	(	O	O	O
6	6	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
every	every	DT	B-NP	O	O
24	24	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
single	single	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
INR	INR	NN	I-NP	B-protein	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	O	I-group
Reductase	Reductase	NN	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Inhibitors	Inhibitor	NNS	B-NP	O	B-group
of	of	IN	B-PP	O	I-group
HMG	HMG	NN	B-NP	B-protein	I-group
-	-	HYPH	B-NP	I-protein	I-group
CoA	CoA	NN	I-NP	I-protein	I-group
reductase	reductase	NN	I-NP	I-protein	E-group
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
myopathy	myopathy	NN	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
manifested	manifest	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	O
pain	pain	NN	I-NP	O	O
or	or	CC	I-NP	O	O
weakness	weakness	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CPK	CPK	NN	B-NP	B-protein	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
skeletal	skeletal	JJ	B-NP	O	O
myopathy	myopathy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-VP	O	O
Phase	Phase	NN	B-NP	O	O
I	I	CD	I-NP	O	O
trial	trial	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
10	10	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
simvastatin	simvastatin	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
daptomycin	daptomycin	NN	B-NP	O	S-drug
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
every	every	DT	B-NP	O	O
24	24	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Experience	Experience	NN	B-NP	O	O
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	B-NP	O	I-group
CoA	CoA	NN	I-NP	B-protein	I-group
reductase	reductase	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
and	and	CC	O	O	O
Fentanyl	Fentanyl	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
limited	limited	JJ	B-ADJP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
consideration	consideration	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
temporarily	temporarily	RB	B-VP	O	O
suspending	suspend	VBG	I-VP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
HMG	HMG	NN	B-NP	B-protein	B-group-AD-1
-	-	HYPH	B-NP	O	I-group-AD-1
CoA	CoA	NN	I-NP	O	I-group-AD-1
reductase	reductase	NN	I-NP	O	I-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
Fentanyl	Fentanyl	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Aranesp	Aranesp	NN	B-NP	O	S-brand
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ENABLEX	ENABLEX	NNP	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
exceed	exceed	VB	I-VP	O	O
7.5	7.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-AD-2
and	and	CC	O	O	O
nefazadone	nefazadone	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ENABLEX	ENABLEX	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
predominantly	predominantly	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
and	and	CC	O	O	O
which	which	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
narrow	narrow	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
window	window	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
flecainide	flecainide	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
thioridazine	thioridazine	NN	B-NP	O	S-drug-AD-2
and	and	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
see	see	VB	B-VP	O	O
CLINICAL	CLINICAL	NN	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ENABLEX	ENABLEX	NN	B-NP	B-protein	S-brand-EF-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
severity	severity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dry	dry	JJ	B-NP	O	O
mouth	mouth	NN	I-NP	O	O
,	,	,	O	O	O
constipation	constipation	NN	B-NP	O	O
,	,	,	O	O	O
blurred	blur	VBD	B-VP	O	O
vision	vision	NN	B-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
concomitantly	concomitantly	RB	I-NP	O	O
administered	administer	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
effects	effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Laboratory	Laboratory	NNP	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
darifenacin	darifenacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
Inhibitors	Inhibitor	NNS	I-NP	O	O
:	:	:	O	O	O
Dasatinib	Dasatinib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand-ME-1
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
atazanavir	atazanavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
telithromycin	telithromycin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand
,	,	,	O	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
for	for	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
SPRYCEL	SPRYCEL	NN	I-NP	O	S-brand
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
systemic	systemic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
Inducers	Inducer	NNS	I-NP	O	O
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inducers	inducer	NNS	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
rifampicin	rifampicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
,	,	,	O	O	O
alternative	alternative	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
induction	induction	NN	I-NP	O	O
potential	potential	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducer	inducer	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

St.	St.	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
wort	wort	NN	I-NP	O	O
(	(	(	O	O	O
Hypericum	Hypericum	NNP	B-NP	O	O
perforatum	perforatum	NNP	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
unpredictably	unpredictably	RB	B-ADVP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
take	take	VB	I-VP	O	O
St.	St.	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
wort	wort	NN	I-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
Nonclinical	Nonclinical	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
solubility	solubility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
pH	pH	NN	B-NP	O	O
dependent	dependent	JJ	B-ADJP	O	O
.	.	.	O	O	O

Simultaneous	Simultaneous	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
antacid	antacid	NN	B-NP	O	S-group-AD-1
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
antacid	antacid	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
or	or	CC	O	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

H2	H2	NN	B-NP	O	B-group
Blockers	Blocker	NNS	I-NP	O	E-group
/	/	SYM	O	O	O
Proton	Proton	NN	B-NP	O	B-group
Pump	Pump	NN	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Long	Long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastric	gastric	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
by	by	IN	B-PP	O	O
H2	H2	NN	B-NP	O	B-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
or	or	CC	O	O	O
proton	proton	NN	B-NP	O	B-group-EF-1
pump	pump	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
famotidine	famotidine	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug-EF-2
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
H2	H2	NN	B-NP	O	B-group-AD-1
blockers	blocker	NNS	I-NP	O	E-group-AD-1
or	or	CC	O	O	O
proton	proton	NN	B-NP	O	B-group-AD-1
pump	pump	NN	I-NP	O	I-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
with	with	IN	B-PP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
place	place	NN	B-NP	O	O
of	of	IN	B-PP	O	O
H2	H2	NN	B-NP	O	B-group-AD-1
blockers	blocker	NNS	I-NP	O	E-group-AD-1
or	or	CC	O	O	O
proton	proton	NN	B-NP	O	B-group-AD-1
pump	pump	NN	I-NP	O	I-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand-AD-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
altered	alter	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
CYP3A4	CYP3A4	NN	I-NP	O	O
Substrates	Substrate	NNS	I-NP	O	O
:	:	:	O	O	O
Dasatinib	Dasatinib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
time	time	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
substrates	substrate	NNS	I-NP	I-protein	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
narrow	narrow	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
index	index	NN	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
alfentanil	alfentanil	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
fentanyl	fentanyl	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
pimozide	pimozide	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
or	or	CC	O	O	O
ergot	ergot	NN	B-NP	O	B-group-AD-1
alkaloids	alkaloid	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug-AD-1
,	,	,	I-NP	O	O
dihydroergotamine	dihydroergotamine	NN	I-NP	O	S-drug-AD-1
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

Hepatic	Hepatic	JJ	B-NP	O	O
Impairment	Impairment	NN	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
currently	currently	RB	B-ADVP	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
excluded	exclude	VBN	I-VP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ALT	ALT	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
AST	AST	NN	B-NP	O	O
2.5	2.5	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
upper	upper	JJ	I-NP	O	O
limit	limit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
total	total	JJ	B-NP	O	O
bilirubin	bilirubin	NN	I-NP	O	O
2	2	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
upper	upper	JJ	I-NP	O	O
limit	limit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Metabolism	Metabolism	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
mainly	mainly	RB	B-ADJP	O	O
hepatic	hepatic	JJ	I-ADJP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	O
Impairment	Impairment	NN	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
currently	currently	RB	B-ADVP	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
SPRYCEL	SPRYCEL	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
excluded	exclude	VBN	I-VP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
1.5	1.5	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
upper	upper	JJ	I-NP	O	O
limit	limit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Dasatinib	Dasatinib	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
minimally	minimally	RB	I-VP	O	O
excreted	excrete	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
unchanged	unchanged	JJ	B-NP	O	O
dasatinib	dasatinib	NN	I-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
body	body	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Cerubidine	Cerubidine	NN	B-NP	O	S-brand-EF-1
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
has	have	VBZ	B-VP	O	O
previously	previously	RB	I-VP	O	O
received	receive	VBN	I-VP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug-EF-2
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	O
.	.	.	O	O	O

Cerubidine	Cerubidine	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
previously	previously	RB	I-VP	O	O
received	receive	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
maximum	maximum	NN	I-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
Cerubidine	Cerubidine	NN	I-NP	O	S-brand
.	.	.	O	O	O

Cyclophosphamide	Cyclophosphamide	NN	B-NP	O	S-drug-EF-1
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Cerubidine	Cerubidine	NN	B-NP	O	S-brand-EF-2
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Cerubidine	Cerubidine	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
myelosuppressive	myelosuppressive	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Hepatotoxic	Hepatotoxic	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug
,	,	,	O	O	O
may	may	MD	B-VP	O	O
impair	impair	VB	I-VP	O	O
liver	liver	NN	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
.	.	.	O	O	O

Potentially	Potentially	RB	B-NP	O	O
fatal	fatal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
and	and	CC	I-NP	O	O
bradyarrhythmias	bradyarrhythmia	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Anticholinesterases	Anticholinesteras	NNS	B-NP	B-protein	S-group
(	(	(	O	O	O
neostgmine	neostgmine	NN	B-NP	O	O
,	,	,	I-NP	O	O
physostigmine	physostigmine	NN	I-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
lignocaine	lignocaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
quinine	quinine	NN	B-NP	O	S-drug
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
and	and	CC	O	O	O
cause	cause	VBP	B-VP	O	O
cardio	cardio	NN	B-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
blocking	blocking	NN	I-NP	O	O
action	action	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
,	,	,	O	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
like	like	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
procaine	procaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
,	,	,	O	O	O
metaclopramide	metaclopramide	NN	B-NP	O	S-drug
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	B-drug
carbonate	carbonate	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
terbutaline	terbutaline	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
decitabine	decitabine	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
decitabine	decitabine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
or	or	CC	I-VP	O	O
induce	induce	VB	I-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
decitabine	decitabine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	B-protein	O
liver	liver	NN	I-NP	I-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
decitabine	decitabine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
negligible	negligible	JJ	B-ADJP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
interactions	interaction	NNS	B-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
displacement	displacement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
more	more	RBR	B-NP	O	O
highly	highly	RB	I-NP	O	O
protein	protein	NN	I-NP	O	O
bound	bind	VBD	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Exjade	Exjade	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacid	antacid	NN	B-NP	O	B-group
preparations	preparation	NNS	I-NP	O	E-group
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
formally	formally	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
deferasirox	deferasirox	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
affinity	affinity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug
than	than	IN	B-PP	O	O
for	for	IN	B-PP	O	O
iron	iron	NN	B-NP	O	S-drug
,	,	,	O	O	O
Exjade	Exjade	NNP	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-AD-2
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacid	antacid	NN	B-NP	O	B-group
preparations	preparation	NNS	I-NP	O	E-group
.	.	.	O	O	O

In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
Exjade	Exjade	NNP	B-NP	O	S-brand
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
Exjade	Exjade	NNP	B-NP	O	S-brand
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Exjade	Exjade	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-drug
C	C	NN	I-NP	O	E-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
formally	formally	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Doses	Dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-drug
C	C	NN	I-NP	O	E-drug
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
allowed	allow	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
negative	negative	JJ	B-NP	O	O
consequences	consequence	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Exjade	Exjade	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
hydroxyurea	hydroxyurea	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
formally	formally	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
deferasirox	deferasirox	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
by	by	IN	B-PP	O	O
hydroxyurea	hydroxyurea	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Exjade	Exjade	NNP	B-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
iron	iron	NN	I-NP	O	O
chelator	chelator	NN	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
safety	safety	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Food	Food	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
The	The	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
deferasirox	deferasirox	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
variably	variably	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
meal	meal	NN	I-NP	O	O
.	.	.	O	O	O

Deferasirox	Deferasirox	NNP	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
empty	empty	JJ	I-NP	O	O
stomach	stomach	NN	I-NP	O	O
30	30	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
eating	eat	VBG	B-VP	O	O
.	.	.	O	O	O

Exjade	Exjade	NN	B-NP	O	S-brand
tablets	tablet	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
suspension	suspension	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
dispersed	disperse	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
water	water	NN	B-NP	O	O
,	,	,	O	O	O
orange	orange	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
apple	apple	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
.	.	.	O	O	O

Antiacid	Antiacid	NN	B-NP	O	O
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
Didanosine	Didanosine	NN	B-NP	O	S-drug
,	,	,	O	O	O
Fluconazole	Fluconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
Fluoxetine	Fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
Indanavir	Indanavir	NN	B-NP	O	O
,	,	,	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
Phenobarbitol	Phenobarbitol	NN	B-NP	O	O
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
Rifabutin	Rifabutin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
Rifampin	Rifampin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
Ritanovir	Ritanovir	NN	B-NP	O	O
,	,	,	O	O	O
Saquinavir	Saquinavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

Possible	Possible	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
HUMORSOL	HUMORSOL	NN	B-NP	O	S-brand-IN-1
with	with	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-IN-2
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinesterase	anticholinesterase	NN	I-NP	O	B-group-IN-2
agents	agent	NNS	I-NP	O	E-group-IN-2
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
tetracyclines	tetracycline	NNS	I-NP	O	S-group-AD-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
depress	depress	VB	I-VP	O	O
plasma	plasma	NN	B-NP	B-protein	O
prothrombin	prothrombin	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-group-AD-2
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
downward	downward	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
bacteriostatic	bacteriostatic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
tetracycline	tetracycline	NN	I-NP	O	B-group-EF-1
class	class	NN	I-NP	O	E-group-EF-1
of	of	IN	B-PP	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bactericidal	bactericidal	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
penicillins	penicillin	NNS	B-NP	B-protein	S-group-EF-2
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
administer	administer	VB	I-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
render	render	VB	I-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
less	less	RBR	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
.	.	.	O	O	O

Breakthrough	Breakthrough	IN	B-PP	O	O
bleeding	bleeding	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O

No	No	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
rodent	rodent	NN	I-NP	O	O
study	study	NN	I-NP	O	O
denileukin	denileukin	NN	I-NP	O	B-drug
diftitox	diftitox	NN	I-NP	O	E-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Taking	Take	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
rauwolfia	rauwolfia	NN	I-NP	O	B-group-EF-1
alkaloid	alkaloid	JJ	B-ADJP	O	E-group-EF-1
while	while	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
or	or	CC	O	O	O
within	within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
taking	take	VBG	B-VP	O	O
MAO	MAO	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
depression	depression	NN	I-NP	O	O
or	or	CC	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
severe	severe	JJ	I-NP	O	O
high	high	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
commonly	commonly	RB	B-NP	O	O
used	use	VBN	I-NP	O	O
preanesthetic	preanesthetic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
drugs	drug	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
(	(	(	O	O	O
muscle	muscle	NN	B-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group
,	,	,	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
local	local	JJ	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
desflurane	desflurane	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

Like	Like	IN	B-PP	O	O
isoflurane	isoflurane	NN	B-NP	O	S-drug
,	,	,	O	O	O
desflurane	desflurane	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
predispose	predispose	VB	I-VP	O	O
to	to	TO	B-PP	O	O
premature	premature	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
exogenously	exogenously	RB	B-NP	O	O
infused	infuse	VBN	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
swine	swine	NN	B-NP	O	O
.	.	.	O	O	O

1	1	LS	B-LST	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
metabolizing	metabolize	VBG	B-VP	O	O
isozyme	isozyme	NN	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
debrisoquin	debrisoquin	NN	B-NP	B-protein	O
hydroxylase	hydroxylase	NN	I-NP	I-protein	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
caucasian	caucasian	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
7	7	CD	I-NP	O	O
to	to	TO	I-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caucasians	caucasian	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
so	so	RB	I-VP	O	O
called	call	VBN	I-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

reliable	reliable	JJ	B-NP	O	O
estimates	estimate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
P450	P450	NN	I-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
among	among	IN	B-PP	O	O
Asian	Asian	JJ	B-NP	O	O
,	,	,	I-NP	O	O
African	African	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
populations	population	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
yet	yet	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
.	.	.	O	O	O

Poor	Poor	NN	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
expected	expect	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
(	(	(	O	O	O
TCAs	TCA	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
usual	usual	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Depending	Depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
traction	traction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-ADJP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
quite	quite	RB	B-ADJP	O	O
large	large	JJ	I-ADJP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
and	and	CC	O	O	O
make	make	VB	B-VP	O	O
normal	normal	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
resemble	resemble	VBP	B-VP	O	O
p.o	p.o	NN	B-NP	O	O
.	.	.	O	O	O

metabolizers	metabolizer	NNS	B-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
individual	individual	NN	I-NP	O	O
who	who	WP	B-NP	O	O
is	be	VBZ	B-VP	O	O
stable	stable	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
given	give	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TCA	TCA	NN	B-NP	B-protein	S-group
may	may	MD	B-VP	O	O
become	become	VB	I-VP	O	O
abruptly	abruptly	RB	B-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
inhibiting	inhibit	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
include	include	VBP	B-VP	O	O
some	some	DT	O	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
(	(	(	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
;	;	:	O	O	O

cimetidine	cimetidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
many	many	JJ	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
many	many	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Type	Type	NN	I-NP	O	O
1C	1C	NN	I-NP	O	O
antiarrhythrnics	antiarrhythrnic	NNS	I-NP	O	O
propatenone	propatenone	NN	I-NP	O	O
and	and	CC	I-NP	O	O
flecainide	flecainide	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
selective	selective	JJ	I-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
seriraline	seriraline	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
inhibit	inhibit	VBP	B-VP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
vary	vary	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
to	to	TO	B-PP	O	O
which	which	WDT	B-NP	O	O
SSRI	SSRI	NN	I-NP	B-protein	S-group-IN-1
-	-	HYPH	I-NP	O	O
TCA	TCA	NN	I-NP	O	S-group-IN-2
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
pose	pose	VB	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
problems	problem	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
depend	depend	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	O	S-group
involved	involve	VBN	B-VP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
T.A	T.A	NN	B-NP	B-protein	B-group-AD-1
.	.	.	O	O	E-group-AD-1
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRIs	SSRI	NNS	I-NP	O	S-group-AD-2
and	and	CC	O	O	O
also	also	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
switching	switch	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
one	one	CD	B-NP	O	O
class	class	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
importance	importance	NN	I-NP	O	O
,	,	,	O	O	O
sufficient	sufficient	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
must	must	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
before	before	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
TCA	TCA	NN	B-NP	B-protein	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
being	be	VBG	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
parent	parent	NN	I-NP	O	O
and	and	CC	O	O	O
active	active	JJ	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
(	(	(	O	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
5	5	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
than	than	IN	B-SBAR	O	O
usually	usually	RB	B-ADVP	O	O
prescribed	prescribe	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
whenever	whenever	WRB	B-ADVP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
desirable	desirable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
TCA	TCA	NN	B-NP	O	S-group
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
whenever	whenever	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group
is	be	VBZ	B-VP	O	O
going	go	VBG	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
.	.	.	O	O	O

2	2	LS	B-LST	O	O
.	.	.	O	O	O

Close	Close	JJ	B-NP	O	O
supervision	supervision	NN	I-NP	O	O
and	and	CC	O	O	O
careful	careful	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
required	require	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	S-group
or	or	CC	I-NP	O	O
sympathomimetic	sympathomimetic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

3	3	LS	B-LST	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
experience	experience	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ECT	ECT	NN	B-NP	O	O
and	and	CC	O	O	O
antidepressant	antidepressant	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
limited	limit	VBN	B-ADJP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
benefits	benefit	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

4	4	LS	B-LST	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
desipramine	desipramine	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
psychotropic	psychotropic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
sedative	sedative	JJ	B-NP	O	S-group-EF-2
/	/	SYM	I-NP	O	O
hypnotics	hypnotic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
consideration	consideration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
employed	employ	VBN	B-VP	O	O
since	since	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
desipramine	desipramine	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
additive	additive	JJ	B-ADJP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
the	the	DT	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	B-group-EF-1
tranquilizers	tranquilizer	NNS	I-NP	O	E-group-EF-1
are	be	VBP	B-VP	O	O
also	also	RB	B-ADVP	O	O
additive	additive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
desipramine	desipramine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

5	5	LS	B-LST	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-ME-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-2
can	can	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
.	.	.	O	O	O

Conversely	Conversely	RB	B-ADVP	O	O
,	,	,	O	O	O
decreases	decrease	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
upon	upon	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	B-DNA	B-group
antidepressant	antidepressant	NN	I-NP	I-DNA	E-group
6	6	CD	I-NP	I-DNA	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
two	two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
previously	previously	RB	B-NP	O	O
stable	stable	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-1
when	when	WRB	B-ADVP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
two	two	CD	B-NP	O	O
controlled	controlled	JJ	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
male	male	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
study	study	NN	I-NP	O	O
)	)	)	O	O	O
a	a	DT	B-NP	O	O
nd	nd	NN	I-NP	O	O
female	female	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
study	study	NN	I-NP	O	O
)	)	)	O	O	O
volunteers	volunteer	NNS	B-NP	O	O
,	,	,	O	O	O
desloratadine	desloratadine	NN	B-NP	O	S-drug
7.5	7.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	B-protein	S-drug
500	500	CD	I-NP	I-protein	O
mg	mg	NN	I-NP	I-protein	O
every	every	DT	B-NP	I-protein	O
8	8	CD	I-NP	I-protein	O
hours	hour	NNS	I-NP	I-protein	O
or	or	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
12	12	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
three	three	CD	B-NP	O	O
separate	separate	JJ	I-NP	O	O
controlled	controlled	JJ	I-NP	O	O
,	,	,	I-NP	O	O
parallel	parallel	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
desloratadine	desloratadine	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
18	18	CD	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
with	with	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
23	23	CD	I-NP	O	O
day	day	NN	I-NP	O	O
pretreatment	pretreatment	NN	I-NP	O	O
period	period	NN	I-NP	O	O
with	with	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
18	18	CD	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	B-protein	S-drug
600	600	CD	I-NP	I-protein	O
mg	mg	NN	I-NP	I-protein	O
every	every	DT	B-NP	I-protein	O
12	12	CD	I-NP	I-protein	O
hours	hour	NNS	I-NP	I-protein	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
18	18	CD	B-NP	O	O
)	)	)	O	O	O
under	under	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
female	female	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
C	C	NN	B-NP	O	O
max	max	NN	I-NP	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	B-protein	O
0	0	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
24	24	CD	I-NP	O	O
hrs	hr	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
desloratadine	desloratadine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
3	3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
hydroxydesloratadine	hydroxydesloratadine	NN	I-NP	O	E-drug_n
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
desloratadine	desloratadine	NN	B-NP	O	S-drug
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
electrocardiographic	electrocardiographic	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
corrected	correct	VBN	I-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
clinical	clinical	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
,	,	,	O	O	O
vital	vital	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

Table	Table	JJ	B-NP	O	O
1	1	CD	I-NP	O	O
Changes	Change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Desloratadine	Desloratadine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
3	3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
Hydroxydesloratadine	Hydroxydesloratadine	NN	I-NP	O	E-drug_n
Pharmacokinetics	Pharmacokinetics	NNP	I-NP	O	O
in	in	IN	B-PP	O	O
Healthy	Healthy	NNP	B-NP	O	O
Male	Male	NNP	I-NP	O	O
and	and	CC	O	O	O
Female	Female	NNP	B-NP	O	O
Volunteers	Volunteer	NNPS	I-NP	O	O

Desloratadine	Desloratadine	NN	B-NP	O	S-drug
3	3	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
Hydroxydesloratadine	Hydroxydesloratadine	NN	I-NP	O	E-drug_n

C	C	NN	B-NP	B-protein	O
max	max	NN	I-NP	I-protein	O
AUC	AUC	NN	I-NP	I-protein	O
0	0	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	I-protein	O
24	24	CD	I-NP	I-protein	O
hrs	hr	NNS	I-NP	I-protein	O
C	C	NN	I-NP	I-protein	O
max	max	NN	I-NP	I-protein	O
AUC	AUC	NN	I-NP	I-protein	O
0	0	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
24	24	CD	I-NP	O	O
hrs	hr	NNS	I-NP	O	O

(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Q8h	Q8h	NN	I-NP	O	O
)	)	)	O	O	O

+	+	SYM	O	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O

(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Q12h	Q12h	NN	I-NP	O	O
)	)	)	O	O	O

+	+	SYM	O	O	O
45	45	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
39	39	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
72	72	CD	B-NP	O	O
%	%	NN	I-NP	O	O

(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
day	day	NN	I-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
250	250	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O

+	+	SYM	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	O	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	O	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O

(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O

+	+	SYM	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
13	13	CD	B-NP	O	O
%	%	NN	I-NP	O	O

(	(	(	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Q12h	Q12h	NN	I-NP	O	O
)	)	)	O	O	O

+	+	SYM	O	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
19	19	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Desmopressin	Desmopressin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
very	very	RB	B-ADJP	O	O
low	low	JJ	I-ADJP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
antidiuretic	antidiuretic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
large	large	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Desmopressin	Desmopressin	NNP	B-NP	O	S-drug
Tablets	Tablet	NNPS	I-NP	B-cell_type	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
only	only	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
careful	careful	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
.	.	.	O	O	O

Reduced	Reduce	VBN	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
breakthrough	breakthrough	NN	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
and	and	CC	O	O	O
menstrual	menstrual	JJ	B-NP	O	O
irregularities	irregularity	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
association	association	NN	I-NP	O	O
,	,	,	O	O	O
though	though	IN	B-SBAR	O	O
less	less	RBR	B-ADJP	O	O
marked	marked	JJ	I-ADJP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
phenyl	phenyl	NN	B-NP	O	O
-	-	HYPH	O	O	O
butazone	butazone	NN	B-NP	O	O
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
possibly	possibly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
griseofulvin	griseofulvin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group
(	(	(	O	O	O
72	72	CD	B-NP	O	O
)	)	)	O	O	O

No	No	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
information	information	NN	I-NP	O	O
available	available	JJ	B-ADJP	O	O

Aminoglutethimide	Aminoglutethimide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Aminoglutethimide	Aminoglutethimide	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
adrenal	adrenal	JJ	B-NP	O	O
suppression	suppression	NN	I-NP	O	O
by	by	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Amphotericin	Amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
injection	injection	NN	I-NP	O	O
and	and	CC	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
agents	agent	NNS	B-NP	O	O
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-AD-1
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
agents	agent	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-AD-2
B	B	NN	I-NP	O	E-drug-AD-2
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
development	development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
cases	case	NNS	B-NP	O	O
reported	report	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-EF-1
B	B	NN	I-NP	O	E-drug-EF-1
and	and	CC	O	O	O
hydrocortisone	hydrocortisone	NN	B-NP	O	S-drug-EF-2
was	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
enlargement	enlargement	NN	I-NP	O	O
and	and	CC	O	O	O
congestive	congestive	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
failure	failure	NN	I-NP	O	O
.	.	.	O	O	O

Antibiotics	Antibiotic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Macrolide	Macrolide	NN	B-NP	O	B-group-ME-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group-ME-2
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

Anticholinesterases	Anticholinesteras	NNS	B-NP	B-protein	S-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinesterase	anticholinesterase	NN	B-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
and	and	CC	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
weakness	weakness	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
myasthenia	myasthenia	NN	B-NP	O	O
gravis	gravis	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
possible	possible	JJ	B-ADJP	O	O
,	,	,	O	O	O
anticholinesterase	anticholinesterase	NN	B-NP	O	B-group-AD-1
agents	agent	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
24	24	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group-AD-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-ADJP	O	O
:	:	:	O	O	O
Co	Co	AFX	O	B-DNA	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
usually	usually	RB	B-ADVP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
some	some	DT	B-NP	O	O
conflicting	conflict	VBG	I-NP	O	O
reports	report	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
coagulation	coagulation	NN	B-NP	O	O
indices	index	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
frequently	frequently	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Antidiabetics	Antidiabetic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Because	Because	IN	B-SBAR	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
dosage	dosage	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antidiabetic	antidiabetic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Antitubercular	Antitubercular	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
:	:	:	O	O	O
Serum	Serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Convulsions	Convulsion	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Dexamethasone	Dexamethasone	NN	B-NP	O	O
suppression	suppression	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
DST	DST	NN	B-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
False	False	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
negative	negative	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
DST	DST	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
results	result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DST	DST	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
interpreted	interpret	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
at	at	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
.	.	.	O	O	O

Ephedrine	Ephedrine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ephedrine	Ephedrine	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
lessened	lessen	VBD	B-VP	O	O
physiologic	physiologic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
requiring	require	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Estrogens	Estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
Estrogens	Estrogen	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group-ME-2
,	,	,	O	O	O
thereby	thereby	RB	B-VP	O	O
increasing	increase	VBG	I-VP	O	O
their	their	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Hepatic	Hepatic	JJ	B-NP	O	O
Enzyme	Enzyme	NN	I-NP	O	O
Inducers	Inducer	NNS	I-NP	O	O
,	,	,	I-NP	O	O
Inhibitors	Inhibitor	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
Substrates	Substrate	NNS	I-NP	O	O
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
)	)	)	O	O	O
enzyme	enzyme	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-ME-1
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
and	and	CC	O	O	O
require	require	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	S-group
be	be	VB	B-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
macrolide	macrolide	NN	B-NP	O	B-group-ME-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-1
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
.	.	.	O	O	O

Dexamethasone	Dexamethasone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group-ME-2
by	by	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-EF-1
alone	alone	RB	B-ADVP	O	O
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
adrenal	adrenal	JJ	B-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	S-drug-EF-2
synthesis	synthesis	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
adrenal	adrenal	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
during	during	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
.	.	.	O	O	O

Nonsteroidal	Nonsteroidal	JJ	B-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
NSAIDS	NSAIDS	NN	B-NP	O	S-group
)	)	)	O	O	O
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-1
(	(	(	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-EF-1
antiinflammatory	antiinflammatory	JJ	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-AD-2
in	in	IN	B-PP	O	O
hypoprothrombinemia	hypoprothrombinemia	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylates	salicylate	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
marketing	marketing	NN	I-NP	O	O
experience	experience	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
increases	increase	NNS	B-NP	O	O
and	and	CC	O	O	O
decreases	decrease	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
levels	level	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-ME-2
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

Skin	Skin	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
:	:	:	O	O	O
Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
suppress	suppress	VB	I-VP	O	O
reactions	reaction	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
skin	skin	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Thalidomide	Thalidomide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
employed	employ	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
toxic	toxic	JJ	B-NP	O	O
epidermal	epidermal	JJ	I-NP	O	O
necrolysis	necrolysis	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Vaccines	Vaccine	NNS	B-NP	O	S-group
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group-EF-1
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
a	a	DT	B-NP	O	O
diminished	diminished	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
toxoids	toxoid	NNS	B-NP	O	O
and	and	CC	O	O	O
live	live	JJ	B-NP	O	S-group-EF-2
or	or	CC	I-NP	O	O
inactivated	inactivate	VBN	I-NP	O	B-group-EF-2
vaccines	vaccine	NNS	I-NP	O	E-group-EF-2
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
antibody	antibody	NN	B-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
replication	replication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
organisms	organism	NNS	I-NP	O	O
contained	contain	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
live	live	JJ	B-NP	O	B-group-EF-2
attenuated	attenuate	VBN	I-NP	O	I-group-EF-2
vaccines	vaccine	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Routine	Routine	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vaccines	vaccine	NNS	B-NP	O	S-group-AD-1
or	or	CC	I-NP	O	O
toxoids	toxoid	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
deferred	defer	VBN	I-VP	O	O
until	until	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group-AD-2
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
possible	possible	JJ	B-ADJP	O	O
.	.	.	O	O	O

Dexbrompheniramine	Dexbrompheniramine	NN	B-NP	O	S-drug-IN-1
can	can	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-IN-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-IN-2
depressants	depressant	NNS	I-NP	O	E-group-IN-2
(	(	(	O	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
these	these	DT	I-NP	O	O
medications	medication	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
antihistamines	antihistamine	NNS	I-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
anticholinergics	anticholinergic	NNS	B-NP	O	S-group-IN-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group-IN-2
oxidase	oxidase	NN	I-NP	I-protein	I-group-IN-2
(	(	(	O	O	I-group-IN-2
MAO	MAO	NN	B-NP	O	I-group-IN-2
)	)	)	O	O	I-group-IN-2
inhibitors	inhibitor	NNS	B-NP	O	E-group-IN-2
(	(	(	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
and	and	CC	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
nonselective	nonselective	JJ	B-NP	O	O
monoamine	monoamine	NN	I-NP	O	B-group-EF-1
oxidase	oxidase	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
MAOIs	MAOI	NNS	B-NP	O	S-group-EF-1
)	)	)	O	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
selegiline	selegiline	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
)	)	)	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
serotoninergic	serotoninergic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
venlafaxine	venlafaxine	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
,	,	,	I-NP	O	O
sometimes	sometimes	RB	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
,	,	,	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
dexfenfluramine	dexfenfluramine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
serotonin	serotonin	NN	I-NP	O	O
releaser	releaser	NN	I-NP	O	O
and	and	CC	O	O	O
reuptake	reuptake	NN	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
dexfenfluramine	dexfenfluramine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
MAO	MAO	NN	I-NP	O	B-group-AD-2
inhibitor	inhibitor	NN	I-NP	O	E-group-AD-2
.	.	.	O	O	O

At	At	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
14	14	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
between	between	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
MAO	MAO	NN	I-NP	O	B-group-AD-1
inhibitor	inhibitor	NN	I-NP	O	E-group-AD-1
and	and	CC	O	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
dexfenfluramine	dexfenfluramine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

At	At	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
3	3	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
between	between	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dexfenfluramine	dexfenfluramine	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
MAO	MAO	NN	I-NP	O	B-group-AD-2
inhibitor	inhibitor	NN	I-NP	O	E-group-AD-2
.	.	.	O	O	O

A	A	DT	B-NP	O	O
rare	rare	JJ	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
serious	serious	JJ	B-ADJP	O	O
,	,	,	O	O	O
constellation	constellation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
,	,	,	O	O	O
termed	term	VBN	B-NP	O	O
serotonin	serotonin	NN	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
selective	selective	JJ	B-NP	O	B-group-EF-1
serotonin	serotonin	NN	I-NP	O	I-group-EF-1
reuptake	reuptake	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
agents	agent	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
migraine	migraine	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Imitrex	Imitrex	NN	B-NP	O	S-brand-EF-2
(	(	(	O	O	O
sumatriptan	sumatriptan	NN	B-NP	O	B-drug-EF-2
succinate	succinate	NN	I-NP	O	E-drug-EF-2
)	)	)	O	O	O
and	and	CC	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
requires	require	VBZ	B-VP	O	O
immediate	immediate	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
attention	attention	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
include	include	VB	I-VP	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
:	:	:	O	O	O
excitement	excitement	NN	B-NP	O	O
,	,	,	O	O	O
hypomania	hypomania	NN	B-NP	O	O
,	,	,	O	O	O
restlessness	restlessness	NN	B-NP	O	O
,	,	,	O	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
consciousness	consciousness	NN	B-NP	O	O
,	,	,	O	O	O
confusion	confusion	NN	B-NP	O	O
,	,	,	O	O	O
disorientation	disorientation	NN	B-NP	O	O
,	,	,	O	O	O
anxiety	anxiety	NN	B-NP	O	O
,	,	,	O	O	O
agitation	agitation	NN	B-NP	O	O
,	,	,	O	O	O
motor	motor	NN	B-NP	O	O
weakness	weakness	NN	I-NP	O	O
,	,	,	O	O	O
myoclonus	myoclonus	NN	B-NP	O	O
,	,	,	O	O	O
tremor	tremor	NN	B-NP	O	O
,	,	,	O	O	O
hemiballismus	hemiballismus	NN	B-NP	O	O
,	,	,	O	O	O
hyperreflexia	hyperreflexia	NN	B-NP	O	O
,	,	,	O	O	O
ataxia	ataxia	NN	B-NP	O	O
,	,	,	O	O	O
dysarthria	dysarthria	NN	B-NP	O	O
,	,	,	O	O	O
incoordination	incoordination	NN	B-NP	O	O
,	,	,	O	O	O
hyperthermia	hyperthermia	NN	B-NP	O	O
,	,	,	O	O	O
shivering	shiver	VBG	B-VP	O	O
,	,	,	O	O	O
pupillary	pupillary	JJ	B-NP	O	O
dilation	dilation	NN	I-NP	O	O
,	,	,	O	O	O
diaphoresis	diaphoresis	NN	B-NP	O	O
,	,	,	O	O	O
emesis	emesis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
tachycardia	tachycardia	NN	B-NP	O	O
.	.	.	O	O	O

Dexfenfluramine	Dexfenfluramine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
serotoninergic	serotoninergic	JJ	I-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
interval	interval	NN	I-NP	O	O
between	between	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
dexfenfluramine	dexfenfluramine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexfenfluramine	dexfenfluramine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
active	active	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
;	;	:	O	O	O

consequently	consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
dexfenfluramine	dexfenfluramine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

General	General	JJ	B-NP	O	O
In	In	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
demonstrated	demonstrate	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
-	-	HYPH	B-VP	I-protein	O
mediated	mediate	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
.	.	.	O	O	O

Anesthetics	Anesthetic	NNPS	B-NP	O	S-group
/	/	SYM	I-NP	B-cell_type	O
Sedatives	Sedative	NNPS	I-NP	I-cell_type	S-group
/	/	SYM	I-NP	I-cell_type	O
Hypnotics	Hypnotic	NNPS	I-NP	O	S-group
/	/	SYM	I-NP	O	O
Opioids	Opioid	NNPS	I-NP	O	S-group
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PRECEDEX	PRECEDEX	NN	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
hypnotics	hypnotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
opioids	opioid	NNS	B-NP	O	S-group-EF-2
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
effects	effect	NNS	B-NP	O	O
.	.	.	O	O	O

Specific	Specific	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
sevoflurane	sevoflurane	NN	B-NP	O	S-drug
,	,	,	O	O	O
isoflurane	isoflurane	NN	B-NP	O	S-drug
,	,	,	O	O	O
propofol	propofol	NN	B-NP	O	S-drug
,	,	,	O	O	O
alfentanil	alfentanil	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
isoflurane	isoflurane	NN	I-NP	O	S-drug
,	,	,	O	O	O
propofol	propofol	NN	B-NP	O	S-drug
,	,	,	O	O	O
alfentanil	alfentanil	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
possible	possible	JJ	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
PRECEDEX	PRECEDEX	NN	B-NP	O	S-brand
,	,	,	O	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PRECEDEX	PRECEDEX	NN	B-NP	O	S-brand-AD-1
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	S-group-AD-2
,	,	,	I-NP	O	O
sedative	sedative	JJ	I-NP	O	S-group-AD-2
,	,	,	I-NP	O	O
hypnotic	hypnotic	JJ	I-NP	O	S-group-AD-2
or	or	CC	I-NP	O	O
opioid	opioid	JJ	I-NP	O	S-group-AD-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Neuromuscular	Neuromuscular	JJ	B-NP	O	B-group
Blockers	Blocker	NNS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PRECEDEX	PRECEDEX	NN	B-NP	O	S-brand
for	for	IN	B-PP	O	O
45	45	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
(	(	(	O	O	O
one	one	CD	B-NP	O	O
)	)	)	O	O	O
ng	ng	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
meaningful	meaningful	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
or	or	CC	O	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
rocuronium	rocuronium	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

ZINECARD	ZINECARD	NN	B-NP	O	S-brand
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Carcinogenesis	Carcinogenesis	NN	B-NP	O	O
,	,	,	O	O	O
Mutagenesis	Mutagenesis	NN	B-NP	O	O
,	,	,	O	O	O
Impairment	Impairment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Fertility	Fertility	NN	B-NP	O	O
No	No	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
carcinogenicity	carcinogenicity	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
with	with	IN	B-PP	O	O
dexrazoxane	dexrazoxane	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
.	.	.	O	O	O

Dexrazoxane	Dexrazoxane	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
mutagenic	mutagenic	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Ames	Ames	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
but	but	CC	O	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
clastogenic	clastogenic	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
lymphocytes	lymphocyte	NNS	I-NP	I-cell_type	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	B-PP	O	O
to	to	TO	B-PP	O	O
mouse	mouse	NN	B-NP	B-cell_type	O
bone	bone	NN	I-NP	I-cell_type	O
marrow	marrow	NN	I-NP	I-cell_type	O
erythrocytes	erythrocyte	NNS	I-NP	I-cell_type	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
(	(	(	O	O	O
micronucleus	micronucleus	NN	B-NP	O	O
test	test	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ZINECARD	ZINECARD	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fertility	fertility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
and	and	CC	O	O	O
experimental	experimental	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
male	male	JJ	B-ADJP	O	O
or	or	CC	I-ADJP	O	O
female	female	JJ	I-ADJP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
adequately	adequately	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Testicular	Testicular	JJ	B-NP	O	O
atrophy	atrophy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
dexrazoxane	dexrazoxane	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
as	as	RB	B-ADJP	O	O
low	low	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
weekly	weekly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
3	3	CD	I-NP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
m	m	NN	B-NP	O	O
2	2	CD	I-NP	O	O
basis	basis	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
as	as	RB	B-ADJP	O	O
low	low	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
weekly	weekly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
13	13	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-ADJP	O	O
equal	equal	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
m	m	NN	B-NP	O	O
2	2	CD	I-NP	O	O
basis	basis	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Acidifying	Acidify	VBG	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
Gastrointestinal	Gastrointestinal	JJ	B-NP	O	B-group-ME-1
acidifying	acidify	VBG	I-NP	O	I-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
(	(	(	O	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
glutamic	glutamic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	I-drug-ME-1
HCl	HCl	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
ascorbic	ascorbic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
fruit	fruit	NN	B-NP	O	O
juices	juice	NNS	I-NP	O	O
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
lower	low	JJR	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-ME-2
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	B-group-ME-1
acidifying	acidify	VBG	I-NP	O	I-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
(	(	(	O	O	O
ammonium	ammonium	NN	B-NP	O	B-drug-ME-1
chloride	chloride	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	I-drug-ME-1
phosphate	phosphate	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ionized	ionize	VBN	I-NP	O	O
species	specie	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	B-protein	S-drug-ME-2
molecule	molecule	NN	I-NP	I-protein	O
,	,	,	O	O	O
thereby	thereby	RB	B-ADVP	O	O
increasing	increase	VBG	B-VP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
lower	low	JJR	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
efficacy	efficacy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group
.	.	.	O	O	O

Adrenergic	Adrenergic	JJ	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
:	:	:	O	O	O
Adrenergic	Adrenergic	JJ	B-NP	O	B-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
are	be	VBP	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Alkalinizing	Alkalinize	VBG	B-NP	O	O
agents	agent	NNS	I-NP	O	O
:	:	:	O	O	O
Gastrointestinal	Gastrointestinal	JJ	B-NP	O	O
alkalinizing	alkalinize	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-ME-1
bicarbonate	bicarbonate	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
increase	increase	VBP	B-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	O
alkalinizing	alkalinize	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
acetazolamide	acetazolamide	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
some	some	DT	B-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group-ME-1
)	)	)	O	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
ionized	ionize	VBN	I-NP	O	O
species	specie	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	B-protein	S-drug-ME-2
molecule	molecule	NN	I-NP	I-protein	O
,	,	,	O	O	O
thereby	thereby	RB	B-VP	O	O
decreasing	decrease	VBG	I-VP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
increase	increase	VBP	B-VP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
potentiate	potentiate	VB	B-VP	O	O
the	the	DT	B-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group
.	.	.	O	O	O

Antidepressants	Antidepressant	NNS	B-NP	O	S-group
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-ADJP	O	S-group
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	S-group-EF-2
or	or	CC	I-NP	O	O
sympathomimetic	sympathomimetic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O

d	d	LS	B-LST	O	B-drug-ME-1
-	-	:	O	O	I-drug-ME-1
amphetamine	amphetamine	NN	B-NP	O	E-drug-ME-1
with	with	IN	B-PP	O	O
desipramine	desipramine	NN	B-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
protriptyline	protriptyline	NN	I-NP	O	S-drug-ME-2
and	and	CC	O	O	O
possibly	possibly	RB	B-ADVP	O	O
other	other	JJ	B-NP	O	O
tricyclics	tricyclic	NNS	I-NP	O	S-group-ME-2
cause	cause	VBP	B-VP	O	O
striking	striking	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
sustained	sustained	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d	d	NN	B-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
amphetamine	amphetamine	NN	I-NP	O	E-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
;	;	:	O	O	O

cardiovascular	cardiovascular	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
MAOI	MAOI	NN	B-NP	O	B-group-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
a	a	DT	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furazolidone	furazolidone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
slow	slow	JJ	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	O	S-group-ME-2
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
slowing	slow	VBG	B-VP	O	O
potentiates	potentiate	VBZ	B-VP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
their	their	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
monoamines	monoamine	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
adrenergic	adrenergic	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
endings	ending	NNS	I-NP	O	O
;	;	:	O	O	O

this	this	DT	B-NP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
headaches	headache	NNS	B-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
crisis	crisis	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurological	neurological	JJ	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
malignant	malignant	JJ	B-NP	O	O
hyperpyrexia	hyperpyrexia	NN	I-NP	O	O
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
,	,	,	O	O	O
sometimes	sometimes	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
.	.	.	O	O	O

Antihistamines	Antihistamine	NNS	B-NP	O	S-group
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
counteract	counteract	VB	I-VP	O	O
the	the	DT	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Antihypertensives	Antihypertensive	NNS	B-NP	O	S-group
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihypertensives	antihypertensive	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Chlorpromazine	Chlorpromazine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Chlorpromazine	Chlorpromazine	NN	B-NP	O	S-drug-EF-1
blocks	block	VBZ	B-VP	O	O
dopamine	dopamine	NN	B-NP	O	O
and	and	CC	I-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	O
reuptake	reuptake	NN	I-NP	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
stimulant	stimulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-group
poisoning	poisoning	NN	I-NP	O	O
.	.	.	O	O	O

Ethosuximide	Ethosuximide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
delay	delay	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethosuximide	ethosuximide	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Haloperidol	Haloperidol	NN	B-NP	O	S-drug
:	:	:	O	O	O
Haloperidol	Haloperidol	NN	B-NP	O	S-drug-EF-1
blocks	block	VBZ	B-VP	O	O
dopamine	dopamine	NN	B-NP	O	O
and	and	CC	I-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	O
reuptake	reuptake	NN	I-NP	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
stimulant	stimulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	B-drug
carbonate	carbonate	NN	I-NP	O	E-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
stimulatory	stimulatory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	B-drug-EF-2
carbonate	carbonate	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Meperidine	Meperidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
potentiate	potentiate	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meperidine	meperidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Methenamine	Methenamine	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
:	:	:	O	O	O
Urinary	Urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-ME-1
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
efficacy	efficacy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
acidifying	acidify	VBG	B-VP	O	B-group-ME-2
agents	agent	NNS	B-NP	O	E-group-ME-2
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
methenamine	methenamine	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Norepinephrine	Norepinephrine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
enhance	enhance	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
delay	delay	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
delay	delay	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
.	.	.	O	O	O

Propoxyphene	Propoxyphene	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
propoxyphene	propoxyphene	NN	B-NP	O	S-drug-EF-1
overdosage	overdosage	NN	I-NP	O	O
,	,	,	O	O	O
amphetamine	amphetamine	NN	B-NP	O	S-group-EF-2
CNS	CNS	NN	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
potentiated	potentiated	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
convulsions	convulsion	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Veratrum	Veratrum	NN	B-NP	O	B-group
alkaloids	alkaloid	NNS	I-NP	O	E-group
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
veratrum	veratrum	NN	B-NP	O	B-group-EF-2
alkaloids	alkaloid	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	S-group-EF-2
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
greatest	great	JJS	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
evening	evening	NN	I-NP	O	O
.	.	.	O	O	O

Amphetamines	Amphetamine	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
steroid	steroid	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
.	.	.	O	O	O

Additive	Additive	JJ	B-NP	O	O
depressant	depressant	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group
,	,	,	O	O	O
antianxiety	antianxiety	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
hypnotics	hypnotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
opiate	opiate	JJ	I-NP	O	B-group
analgesics	analgesic	NNS	I-NP	O	E-group
.	.	.	O	O	O

May	May	MD	B-VP	O	O
interact	interact	VBP	I-VP	O	O
with	with	IN	B-PP	O	O
thyroid	thyroid	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
levothyroxine	levothyroxine	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
iodine	iodine	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
products	product	NNS	B-NP	O	O
,	,	,	O	O	O
antacids	antacid	NNS	B-NP	O	S-group
,	,	,	O	O	O
H2	H2	NN	B-NP	B-protein	B-group
-	-	HYPH	O	O	I-group
antagonists	antagonist	NNS	B-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
famotidine	famotidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
proton	proton	NN	B-NP	O	B-group
pump	pump	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
lansoprazole	lansoprazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
product	product	NN	I-NP	O	O
can	can	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
lab	lab	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-1
and	and	CC	O	O	O
carbonic	carbonic	JJ	B-NP	O	B-group-AD-2
anhydrase	anhydrase	NN	I-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
as	as	IN	B-PP	O	O
anorexia	anorexia	NN	B-NP	O	O
,	,	,	O	O	O
tachypnea	tachypnea	NN	B-NP	O	O
,	,	,	O	O	O
lethargy	lethargy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
coma	coma	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rarely	rarely	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
displaced	displace	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
binding	bind	VBG	I-NP	O	O
sites	site	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
peak	peak	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
:	:	:	O	O	O
While	While	IN	B-SBAR	O	O
studies	study	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-AD-1
to	to	TO	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	B-group
of	of	IN	B-PP	O	I-group
the	the	DT	B-NP	O	I-group
warfarin	warfarin	NN	I-NP	O	I-group
type	type	NN	I-NP	O	E-group
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
,	,	,	O	O	O
nonetheless	nonetheless	RB	B-ADVP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
interactions	interaction	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
seen	see	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-AD-2
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
prostaglandins	prostaglandin	NNS	B-NP	O	O
play	play	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hemostasis	hemostasis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
affect	affect	VBP	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
as	as	RB	B-ADVP	O	O
well	well	RB	I-ADVP	O	O
,	,	,	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
all	all	DT	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-AD-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
requires	require	VBZ	B-VP	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
certain	certain	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
Methotrexate	Methotrexate	NN	B-NP	O	S-drug
,	,	,	O	O	O
Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Diclofenac	Diclofenac	NN	B-NP	O	S-drug
,	,	,	O	O	O
like	like	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group
,	,	,	O	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandins	prostaglandin	NNS	I-NP	O	O
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Ingestion	Ingestion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-MU-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug-ME-2
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-EF-2
s	s	NN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
begin	begin	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-EF-1
or	or	CC	O	O	O
who	who	WP	B-NP	O	O
increase	increase	VBP	B-VP	O	O
their	their	PRP$	B-NP	O	O
diclofenac	diclofenac	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
or	or	CC	O	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
NSAID	NSAID	NN	I-NP	O	S-group-EF-1
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
impaired	impaired	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Diclofenac	Diclofenac	NN	B-NP	O	S-drug-ME-1
decreases	decrease	VBZ	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-2
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
increases	increase	VBZ	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-EF-2
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Hypoglycemics	Hypoglycemic	NNS	I-NP	O	S-group
:	:	:	O	O	O
Diclofenac	Diclofenac	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
glucose	glucose	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
nor	nor	CC	O	O	O
does	do	VBZ	O	O	O
it	it	PRP	B-NP	O	O
alter	alter	VB	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
rare	rare	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
marketing	marketing	NN	B-NP	O	O
experiences	experience	NNS	I-NP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug-EF-1
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-EF-2
that	that	WDT	B-NP	O	O
necessitated	necessitate	VBD	B-VP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
hypo	hypo	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
hyperglycemic	hyperglycemic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
causal	causal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
consider	consider	VB	I-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
a	a	DT	B-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
s	s	VBZ	B-VP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug-EF-2
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Diuretics	Diuretic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Diclofenac	Diclofenac	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
small	small	JJ	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
7	7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
10	10	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug
,	,	,	O	O	O
gold	gold	NN	B-NP	O	S-group
,	,	,	O	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug
,	,	,	O	O	O
D	D	NN	B-NP	O	B-drug
-	-	HYPH	O	O	I-drug
penicillamine	penicillamine	NN	B-NP	O	E-drug
,	,	,	O	O	O
prednisolone	prednisolone	NN	B-NP	O	S-drug
,	,	,	O	O	O
doxycycline	doxycycline	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
digitoxin	digitoxin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
occurred	occur	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug-EF-1
treatment	treatment	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Protein	Protein	NN	B-NP	O	O
Binding	Binding	NN	I-NP	O	O
In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug-ME-1
interferes	interfere	VBZ	B-VP	O	O
minimally	minimally	RB	B-ADVP	O	O
or	or	CC	O	O	O
not	not	RB	O	O	O
at	at	IN	B-ADVP	O	O
all	all	DT	I-ADVP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylic	salicylic	JJ	B-NP	O	B-drug-ME-2
acid	acid	NN	I-NP	O	E-drug-ME-2
(	(	(	O	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
binding	binding	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
prednisolone	prednisolone	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
binding	binding	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Benzylpenicillin	Benzylpenicillin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
,	,	,	O	O	O
oxacillin	oxacillin	NN	B-NP	O	S-drug
,	,	,	O	O	O
chlortetracycline	chlortetracycline	NN	B-NP	O	S-drug
,	,	,	O	O	O
doxycycline	doxycycline	NN	B-NP	O	S-drug
,	,	,	O	O	O
cephalothin	cephalothin	NN	B-NP	O	S-drug
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
sulfamethoxazole	sulfamethoxazole	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Effect	Effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Blood	Blood	NNP	B-NP	O	O
Coagulation	Coagulation	NNP	I-NP	O	O
:	:	:	O	O	O
Diclofenac	Diclofenac	NN	B-NP	O	S-drug
increases	increase	VBZ	B-VP	O	O
platelet	platelet	NN	B-NP	B-cell_type	O
aggregation	aggregation	NN	I-NP	O	O
time	time	NN	I-NP	O	O
but	but	CC	O	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
bleeding	bleed	VBG	I-VP	O	O
time	time	NN	B-NP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
thrombin	thrombin	NN	I-NP	O	O
clotting	clotting	NN	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	B-protein	O
fibrinogen	fibrinogen	NN	I-NP	I-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
factors	factor	NNS	B-NP	O	O
V	V	CD	B-NP	O	O
and	and	CC	O	O	O
VII	VII	CD	B-NP	O	O
to	to	TO	B-PP	O	O
XII	XII	CD	B-NP	B-DNA	O
.	.	.	O	O	O

Statistically	Statistically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	B-protein	O
and	and	CC	O	O	O
partial	partial	JJ	B-NP	O	O
thromboplastin	thromboplastin	NN	I-NP	O	O
times	time	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
1	1	CD	I-NP	O	O
second	second	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
instances	instance	NNS	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
are	be	VBP	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
.	.	.	O	O	O

Diclofenac	Diclofenac	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthetase	synthetase	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
all	all	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
prostaglandin	prostaglandin	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
interfere	interfere	NN	I-NP	O	O
with	with	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
to	to	TO	B-PP	O	O
some	some	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adversely	adversely	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
an	an	DT	I-NP	O	O
action	action	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Tetracycline	Tetracycline	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
bacteriostatic	bacteriostatic	JJ	I-NP	O	B-group
antibiotic	antibiotic	NN	I-NP	O	E-group
,	,	,	O	O	O
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bactercidal	bactercidal	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
penicillin	penicillin	NN	B-NP	B-protein	S-drug-EF-2
and	and	CC	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
certain	certain	JJ	B-NP	O	O
actions	action	NNS	I-NP	O	O
or	or	CC	O	O	O
side	side	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O
amantadine	amantadine	NN	B-NP	O	S-drug
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
of	of	IN	B-PP	O	O
class	class	NN	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	I-NP	O	O
quinidine	quinidine	NN	I-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
antihistamines	antihistamine	VBZ	B-VP	O	S-group
antipsychotic	antipsychotic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	I-NP	O	O
phenothiazines	phenothiazine	NNS	I-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
narcotic	narcotic	JJ	B-NP	O	B-group
analgesics	analgesic	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
meperidine	meperidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
nitrates	nitrate	NNS	B-NP	O	S-group
and	and	CC	I-NP	O	O
nitrites	nitrite	NNS	I-NP	O	S-group
,	,	,	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
having	have	VBG	B-VP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Anticholinergics	Anticholinergic	NNS	B-NP	O	S-group
antagonize	antagonize	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antiglaucoma	antiglaucoma	NN	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
intraocular	intraocular	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
hazardous	hazardous	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
corti	corti	NN	B-NP	O	O
costeroids..	costeroids..	NN	I-NP	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
slowly	slowly	RB	B-VP	O	O
dissolving	dissolve	VBG	I-VP	O	O
dosage	dosage	NN	B-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
.	.	.	O	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group-ME-1
drugs	drug	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
alter	alter	VBP	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
antacids	antacid	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group-ME-2
agents	agent	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
inhibiting	inhibit	VBG	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
on	on	IN	B-PP	O	O
gastric	gastric	JJ	B-NP	O	O
hydrochloric	hydrochloric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
achlorhydria	achlorhydria	NN	B-NP	O	O
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
test	test	VB	I-VP	O	O
gastric	gastric	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
pancreatitis	pancreatitis	NN	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
(	(	(	O	O	O
see	see	VB	B-VP	O	O
WARNINGS	WARNINGS	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
done	do	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
extreme	extreme	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
,	,	,	O	O	O
only	only	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
other	other	JJ	B-NP	O	O
alternatives	alternative	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
available	available	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
only	only	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
clearly	clearly	RB	B-ADVP	O	O
indicated	indicate	VBN	B-VP	O	O
.	.	.	O	O	O

Neuropathy	Neuropathy	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
more	more	RBR	B-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuropathy	neuropathy	NN	B-NP	O	O
or	or	CC	O	O	O
neurotoxic	neurotoxic	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
stavudine	stavudine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
at	at	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuropathy	neuropathy	NN	B-NP	O	O
during	during	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
see	see	VB	B-VP	O	O
ADVERSE	ADVERSE	NN	B-NP	O	O
REACTIONS	REACTIONS	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Allopurinol	Allopurinol	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
about	about	RB	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
fold	fold	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
200	200	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VIDEX	VIDEX	CD	B-NP	O	S-brand-ME-2
to	to	TO	B-PP	O	O
two	two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
(	(	(	O	O	O
CLcr	CLcr	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
15	15	CD	B-NP	O	O
and	and	CC	I-NP	O	O
18	18	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group-EF-1
containing	contain	VBG	B-VP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand-EF-2
Chewable	Chewable	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
Dispersible	Dispersible	JJ	I-NP	O	O
Buffered	Buffer	VBN	I-NP	O	O
Tablets	Tablet	NNPS	I-NP	O	O
or	or	CC	O	O	O
Pediatric	Pediatric	NNP	B-NP	O	O
Powder	Powder	NNP	I-NP	O	O
for	for	IN	B-PP	O	O
Oral	Oral	NNP	B-NP	O	O
Solution	Solution	NNP	I-NP	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antacid	antacid	NN	I-NP	B-protein	S-group
components	component	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Whose	Whose	DT	B-NP	O	O
Absorption	Absorption	NN	I-NP	O	O
Can	Can	MD	B-VP	O	O
Be	Be	VB	I-VP	O	O
Affected	Affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Level	Level	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Acidity	Acidity	NNP	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Stomach	Stomach	NN	I-NP	O	O
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
with	with	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand-AD-2
.	.	.	O	O	O

Ganciclovir	Ganciclovir	NN	B-NP	O	S-drug
:	:	:	O	O	O
Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	O	S-brand-ME-1
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
or	or	CC	O	O	O
concurrent	concurrent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
ganciclovir	ganciclovir	NN	I-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
111	111	CD	I-NP	O	O
(	(	(	O	O	O
114	114	CD	B-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
21	21	CD	I-NP	O	O
(	(	(	O	O	O
17	17	CD	B-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ganciclovir	ganciclovir	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
ganciclovir	ganciclovir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Quinolone	Quinolone	NNP	B-NP	O	B-group
Antibiotics	Antibiotic	NNPS	I-NP	O	O
:	:	:	O	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
or	or	CC	O	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-AD-2
because	because	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-1
are	be	VBP	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
HIV	HIV	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
infected	infect	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
average	average	NN	I-NP	O	O
of	of	IN	B-PP	O	O
26	26	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
37	37	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
marketed	market	VBN	I-NP	O	O
chewable	chewable	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
dispersible	dispersible	JJ	I-NP	O	O
tablet	tablet	NN	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
average	average	NN	I-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
given	give	VBN	B-VP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
didanosine	didanosine	NN	I-NP	O	S-drug-ME-2
-	-	HYPH	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
subject	subject	NN	I-NP	O	O
given	give	VBN	B-VP	O	O
one	one	CD	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug-ME-1
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug-ME-2
-	-	HYPH	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
than	than	IN	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
quinolone	quinolone	NN	B-NP	O	B-group-ME-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-1
are	be	VBP	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
optimal	optimal	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
for	for	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
consulting	consult	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
quinolone	quinolone	NN	I-NP	O	S-group
package	package	NN	I-NP	O	O
insert	insert	NN	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Antiretroviral	Antiretroviral	JJ	I-NP	O	B-group
Drugs	Drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
Significant	Significant	JJ	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
delavirdine	delavirdine	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
84	84	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
occurred	occur	VBD	B-VP	O	O
following	follow	VBG	I-VP	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand-ME-2
.	.	.	O	O	O

To	To	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
,	,	,	O	O	O
delavirdine	delavirdine	NN	B-NP	O	S-drug-AD-1
or	or	CC	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
1	1	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
with	with	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
degree	degree	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
light	light	JJ	I-NP	O	O
meal	meal	NN	I-NP	O	O
1	1	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
after	after	IN	B-PP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Certain	Certain	JJ	B-NP	O	O
endocrine	endocrine	NN	I-NP	O	O
and	and	CC	O	O	O
liver	liver	NN	B-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	O	S-group
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
similar	similar	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
larger	large	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	O	S-group
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
Increased	Increase	VBN	I-NP	O	O
sulfobromophthalein	sulfobromophthalein	NN	I-NP	O	O
retention	retention	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Increased	Increase	VBN	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	B-protein	O
and	and	CC	I-NP	O	O
factors	factor	NNS	I-NP	O	O
VII	VII	CD	B-NP	O	O
,	,	,	I-NP	O	O
VIII	VIII	CD	I-NP	B-protein	O
,	,	,	I-NP	O	O
IX	IX	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
X	X	NN	B-NP	O	O
;	;	:	O	O	O

decreased	decrease	VBN	B-NP	O	O
antithrombin	antithrombin	NN	I-NP	B-protein	B-drug
3	3	CD	I-NP	I-protein	E-drug
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
platelet	platelet	NN	I-NP	O	O
aggregability	aggregability	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Increased	Increase	VBN	I-NP	O	O
thyroid	thyroid	NN	I-NP	B-protein	O
-	-	HYPH	B-VP	I-protein	O
binding	bind	VBG	I-VP	I-protein	O
globulin	globulin	NN	B-NP	I-protein	O
(	(	(	O	O	O
TBG	TBG	NN	B-NP	O	O
)	)	)	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
in	in	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
creased	crease	VBN	B-VP	O	O
circulating	circulate	VBG	B-VP	O	O
total	total	JJ	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
;	;	:	O	O	O

as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
PBI	PBI	NN	B-NP	B-protein	O
,	,	,	O	O	O
T4	T4	NN	B-NP	O	O
by	by	IN	B-PP	O	O
column	column	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
T4	T4	NN	B-NP	O	O
by	by	IN	B-PP	O	O
radioimmunoassay	radioimmunoassay	NN	B-NP	O	O
.	.	.	O	O	O

Free	Free	JJ	B-NP	O	O
T3	T3	NN	I-NP	O	O
resin	resin	NN	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
,	,	,	O	O	O
reflecting	reflect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
TBG	TBG	NNP	I-NP	O	O
;	;	:	O	O	O

free	free	JJ	B-NP	O	O
T4	T4	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unaltered	unaltered	JJ	B-ADJP	O	O

-	-	HYPH	B-NP	O	O
Impaired	Impaired	JJ	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
tolerance	tolerance	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Decreased	Decrease	VBN	I-NP	O	O
pregnanediol	pregnanediol	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Reduced	Reduce	VBN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
metyrapone	metyrapone	NN	B-NP	O	O
test	test	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Reduced	Reduce	VBN	I-NP	O	O
serum	serum	NN	I-NP	O	O
folate	folate	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Increased	Increase	VBN	I-NP	O	O
serum	serum	NN	I-NP	O	O
triglyceride	triglyceride	NN	I-NP	O	O
and	and	CC	O	O	O
phospholipid	phospholipid	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

Antidiabetic	Antidiabetic	JJ	B-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
requirements	requirement	NNS	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
)	)	)	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diethylpropion	diethylpropion	NN	B-NP	O	S-drug
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
;	;	:	O	O	O

conversely	conversely	RB	B-ADVP	O	O
,	,	,	O	O	O
diethylpropion	diethylpropion	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group-IN-2
drugs	drug	NNS	I-NP	O	E-group-IN-2
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
a	a	DT	B-NP	O	B-drug-IN-2
-	-	HYPH	I-NP	O	I-drug-IN-2
methyldopa	methyldopa	NN	I-NP	O	E-drug-IN-2
)	)	)	O	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anorectic	anorectic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diethylpropion	diethylpropion	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

May	May	MD	O	O	O
interact	interact	VBP	O	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
(	(	(	O	O	O
altered	alter	VBN	B-VP	O	O
hypo	hypo	AFX	O	O	O
-	-	HYPH	O	O	O
prothrombinemic	prothrombinemic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
microsomal	microsomal	JJ	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
oxidation	oxidation	NN	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
decreased	decrease	VBN	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diethylstilbestrol	diethylstilbestrol	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
(	(	(	O	O	O
increased	increase	VBN	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Anticoagulants	Anticoagulant	NNS	I-NP	O	S-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
,	,	,	O	O	O
acenocoumarol	acenocoumarol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
phenprocoumon	phenprocoumon	NN	B-NP	O	S-drug-EF-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
because	because	IN	B-SBAR	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-ME-1
competitively	competitively	RB	B-ADVP	O	O
displaces	displace	VBZ	B-VP	O	O
coumarins	coumarin	NNS	B-NP	O	S-group-ME-2
from	from	IN	B-PP	O	O
protein	protein	NN	B-NP	B-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
.	.	.	O	O	O

Accordingly	Accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-AD-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
and	and	CC	I-PP	O	O
for	for	IN	I-PP	O	O
several	several	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Adjustment	Adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Tolbutamide	Tolbutamide	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
diflunisal	diflunisal	JJ	B-NP	O	S-drug
and	and	CC	I-NP	O	O
tolbutamide	tolbutamide	NN	I-NP	O	S-drug
,	,	,	O	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
or	or	CC	O	O	O
fasting	fast	VBG	B-VP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
.	.	.	O	O	O

Hydrochlorothiazide	Hydrochlorothiazide	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
significantly	significantly	RB	B-NP	O	O
increased	increase	VBN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Diflunisal	Diflunisal	NNP	B-NP	O	S-drug-EF-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
hyperuricemic	hyperuricemic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
furosemide	furosemide	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Diflunisal	Diflunisal	NNP	B-NP	O	S-drug-EF-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
hyperuricemic	hyperuricemic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
small	small	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
occasional	occasional	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
,	,	,	O	O	O
but	but	CC	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
antacids	antacid	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
continuous	continuous	JJ	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
.	.	.	O	O	O

Acetaminophen	Acetaminophen	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
.	.	.	O	O	O

Acetaminophen	Acetaminophen	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug
.	.	.	O	O	O

Since	Since	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
hepatotoxicity	hepatotoxicity	NN	B-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
,	,	,	B-PP	O	O
but	but	CC	I-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
2	2	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
maximum	maximum	NN	I-NP	O	O
human	human	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
(	(	(	O	O	O
40	40	CD	B-NP	O	O
to	to	TO	I-NP	O	O
52	52	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug
/	/	SYM	B-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
greater	great	JJR	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
than	than	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
either	either	CC	O	O	O
drug	drug	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Nonsteroidal	Nonsteroidal	JJ	B-NP	O	B-group-ME-1
anti	anti	AFX	I-NP	O	I-group-ME-1
-	-	HYPH	I-NP	O	I-group-ME-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-ME-1
drugs	drug	NNS	I-NP	O	E-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nonsteroial	nonsteroial	JJ	B-NP	O	B-group-ME-1
anti	anti	AFX	I-NP	O	I-group-ME-1
-	-	HYPH	I-NP	O	I-group-ME-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-ME-1
drugs	drug	NNS	I-NP	O	E-group-ME-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADJP	O	O
due	due	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	B-protein	O
prostacyclin	prostacyclin	NN	I-NP	I-protein	O
.	.	.	O	O	O

NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Nonsteroidal	Nonsteroidal	JJ	B-NP	O	B-group
Anti	Anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
Inflammatory	Inflammatory	JJ	I-NP	O	I-group
Drugs	Drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	JJ	B-ADVP	O	S-drug-ME-1
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-ME-2
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
significantly	significantly	RB	B-VP	O	O
increased	increase	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
diflunisal	diflunisal	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
hemorrhage	hemorrhage	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
diflunisal	diflunisal	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	JJ	B-NP	O	S-drug-EF-1
tablets	tablet	NNS	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-EF-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
little	little	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
no	no	DT	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
information	information	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diflunisal	diflunisal	JJ	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-ME-2
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Sulindac	Sulindac	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
sulindac	sulindac	NN	I-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
lowering	lower	VBG	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
sulindac	sulindac	NN	I-NP	O	O
sulfide	sulfide	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
third	third	JJ	I-NP	O	O
.	.	.	O	O	O

Naproxen	Naproxen	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
naproxen	naproxen	NN	I-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
,	,	,	O	O	O
but	but	CC	O	O	O
significantly	significantly	RB	B-VP	O	O
decreased	decrease	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
glucuronide	glucuronide	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
.	.	.	O	O	O

Naproxen	Naproxen	NNP	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
Serum	Serum	NNP	I-NP	O	O
Salicylate	Salicylate	NNP	I-NP	O	O
Assays	Assay	NNPS	I-NP	O	O
:	:	:	O	O	O
Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
interpreting	interpret	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	O
assays	assay	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
present	present	JJ	B-ADJP	O	O
.	.	.	O	O	O

Salicylate	Salicylate	NN	B-NP	O	S-group
levels	level	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
falsely	falsely	RB	B-ADJP	O	O
elevated	elevated	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
assay	assay	NN	I-NP	O	O
methods	method	NNS	I-NP	O	O
.	.	.	O	O	O

Potassium	Potassium	NN	B-NP	O	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
depleting	deplete	VBG	B-VP	O	I-group-EF-1
diuretics	diuretic	NNS	B-NP	O	E-group-EF-1
are	be	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	B-protein	O
contributing	contribute	VBG	I-NP	I-protein	O
factor	factor	NN	I-NP	I-protein	O
to	to	TO	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-2
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	S-drug
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
administered	administer	VBN	B-VP	O	O
rapidly	rapidly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
serious	serious	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
digitalized	digitalized	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Quinidine	Quinidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
propafenone	propafenone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug-ME-1
raise	raise	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-2
concentration	concentration	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clearance	clearance	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
volume	volume	NN	B-NP	O	O
of	of	IN	B-PP	O	O
distribution	distribution	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
implication	implication	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
digitalis	digitali	VBZ	B-VP	O	S-group
intoxication	intoxication	NN	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
.	.	.	O	O	O

Erythromycin	Erythromycin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
clarithromycin	clarithromycin	NN	I-NP	O	S-drug-ME-1
(	(	(	O	O	O
and	and	CC	O	O	O
possibly	possibly	RB	B-ADVP	O	O
other	other	JJ	B-NP	O	O
macrolide	macrolide	NN	I-NP	O	B-group-ME-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-1
)	)	)	O	O	O
and	and	CC	O	O	O
tetracycline	tetracycline	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
absorption	absorption	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
inactivate	inactivate	VBP	B-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
bacterial	bacterial	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
intestine	intestine	NN	I-NP	O	O
,	,	,	O	O	O
so	so	IN	B-SBAR	O	O
that	that	IN	I-SBAR	O	O
digitalis	digitalis	NN	B-NP	O	S-group
intoxication	intoxication	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
capsules	capsule	NNS	B-NP	O	O
.	.	.	O	O	O

Propantheline	Propantheline	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
diphenoxylate	diphenoxylate	NN	I-NP	O	S-drug-ME-1
,	,	,	O	O	O
by	by	IN	B-PP	O	O
decreasing	decrease	VBG	B-VP	O	O
gut	gut	NN	B-NP	O	O
motility	motility	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group-ME-1
,	,	,	O	O	O
kaolin	kaolin	NN	B-NP	B-protein	S-drug-ME-1
-	-	HYPH	O	I-protein	O
pectin	pectin	NN	B-NP	I-protein	O
,	,	,	O	O	O
sulfasalazine	sulfasalazine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
neomycin	neomycin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
anticancer	anticancer	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-2
absorption	absorption	NN	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
unexpectedly	unexpectedly	RB	B-NP	O	O
low	low	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-2
concentration	concentration	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
inconsistent	inconsistent	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
quinine	quinine	NN	B-NP	O	S-drug
,	,	,	O	O	O
penicillamine	penicillamine	NN	B-NP	O	S-drug
)	)	)	O	O	O
on	on	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

Thyroid	Thyroid	JJ	B-NP	O	S-group-AD-1
administration	administration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
digitalized	digitalized	JJ	I-NP	O	O
,	,	,	I-NP	O	O
hypothyroid	hypothyroid	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
requirement	requirement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
sympathomimetics	sympathomimetic	NNS	I-NP	O	S-group-EF-2
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Succinylcholine	Succinylcholine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
sudden	sudden	JJ	I-NP	O	O
extrusion	extrusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	O
from	from	IN	B-PP	O	O
muscle	muscle	NN	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
thereby	thereby	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
digitalized	digitalized	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
beta	beta	SYM	B-NP	O	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
or	or	CC	O	O	O
calcium	calcium	NN	B-NP	O	B-group-EF-1
channel	channel	NN	I-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
atrial	atrial	JJ	B-NP	O	O
fibrillation	fibrillation	NN	I-NP	O	O
,	,	,	O	O	O
their	their	PRP$	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
AV	AV	NN	B-NP	O	O
node	node	NN	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
advanced	advance	VBN	B-NP	O	O
or	or	CC	I-NP	O	O
complete	complete	JJ	I-NP	O	O
heart	heart	NN	I-NP	O	O
block	block	NN	I-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
the	the	DT	B-NP	O	O
considerable	considerable	JJ	I-NP	O	O
variability	variability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
individualized	individualize	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
patients	patient	NNS	B-NP	O	O
receive	receive	VBP	B-VP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
combining	combine	VBG	B-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
decline	decline	NN	I-NP	O	O
in	in	IN	B-PP	O	O
glomerular	glomerular	JJ	B-NP	O	O
filtration	filtration	NN	I-NP	O	O
or	or	CC	O	O	O
tubular	tubular	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
may	may	MD	B-VP	O	O
impair	impair	VB	I-VP	O	O
the	the	DT	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Vasoconstrictors	Vasoconstrictor	NNS	B-NP	O	S-group
:	:	:	O	O	O
D.H.E	D.H.E	NNP	B-NP	O	B-brand-EF-1
.	.	.	O	O	I-brand-EF-1
45	45	CD	B-NP	O	E-brand-EF-1
(	(	(	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	B-drug-EF-1
mesylate	mesylate	NN	I-NP	O	E-drug-EF-1
)	)	)	O	O	O
Injection	Injection	NN	B-NP	O	O
,	,	,	O	O	O
USP	USP	NNP	B-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	B-group-EF-2
vasoconstrictors	vasoconstrictor	NNS	I-NP	O	E-group-EF-2
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
synergistic	synergistic	JJ	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Sumatriptan	Sumatriptan	NNP	B-NP	O	S-drug
:	:	:	O	O	O
Sumatriptan	Sumatriptan	NNP	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
vasospasm	vasospasm	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
D.H.E	D.H.E	NNP	B-NP	O	B-brand-EF-2
.	.	.	O	O	I-brand-EF-2
45	45	CD	B-NP	O	E-brand-EF-2
(	(	(	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	B-drug-EF-2
mesylate	mesylate	NN	I-NP	O	E-drug-EF-2
)	)	)	O	O	O
Injection	Injection	NNP	B-NP	O	O
,	,	,	O	O	O
USP	USP	NNP	B-NP	O	O
.	.	.	O	O	O

Sumatriptan	Sumatriptan	NNP	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
D.H.E	D.H.E	NNP	I-NP	O	B-brand-AD-2
.	.	.	I-NP	O	I-brand-AD-2
45	45	CD	I-NP	O	E-brand-AD-2
(	(	(	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	B-drug-AD-2
mesylate	mesylate	NN	I-NP	O	E-drug-AD-2
)	)	)	O	O	O
Injection	Injection	NN	B-NP	O	O
,	,	,	O	O	O
USP	USP	NNP	B-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other..	other..	NN	I-NP	O	O

Beta	Beta	NNP	B-NP	O	B-group
Blockers	Blocker	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
indicate	indicate	VB	I-VP	O	O
a	a	DT	B-NP	O	O
safe	safe	JJ	I-NP	O	O
problem	problem	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
D.H.E	D.H.E	NNP	B-NP	O	B-brand
.	.	.	O	O	I-brand
45	45	CD	B-NP	O	E-brand
(	(	(	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
)	)	)	O	O	O
Injection	Injection	NN	B-NP	O	O
,	,	,	O	O	O
USP	USP	NNP	B-NP	O	O
to	to	TO	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
already	already	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
that	that	IN	B-SBAR	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
vasoconstrictive	vasoconstrictive	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug-EF-2
by	by	IN	B-PP	O	O
blocking	block	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
vasodilating	vasodilate	VBG	I-NP	O	O
property	property	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	O
.	.	.	O	O	O

Nicotine	Nicotine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Nicotine	Nicotine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
provoke	provoke	VB	I-VP	O	O
vasoconstriction	vasoconstriction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
predisposing	predispose	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
ischemic	ischemic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-VP	O	O
ergot	ergot	VB	I-VP	O	S-drug-EF-2
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

Macrolide	Macrolide	NN	B-NP	O	B-group
Antibiotics	Antibiotic	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.	e.	FW	B-NP	O	O
g.	g.	FW	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
troleandomycin	troleandomycin	NN	I-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Agents	Agent	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ergot	ergot	NN	I-NP	O	B-group-ME-1
alkaloid	alkaloid	JJ	I-NP	O	I-group-ME-1
class	class	NN	I-NP	O	E-group-ME-1
,	,	,	O	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
D.H.E	D.H.E	NNP	B-NP	O	B-brand-ME-1
.	.	.	I-NP	O	I-brand-ME-1
45	45	CD	I-NP	O	E-brand-ME-1
(	(	(	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	B-drug-ME-1
mesylate	mesylate	NN	I-NP	O	E-drug-ME-1
)	)	)	O	O	O
Injection	Injection	NN	B-NP	O	O
,	,	,	O	O	O
USP	USP	NNP	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
member	member	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
macrolide	macrolide	NN	I-NP	O	B-group-ME-2
class	class	NN	I-NP	O	E-group-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
unchanged	unchanged	JJ	B-NP	O	O
alkaloids	alkaloid	NNS	I-NP	O	O
and	and	CC	O	O	O
peripheral	peripheral	JJ	B-NP	O	O
vasoconstriction	vasoconstriction	NN	I-NP	O	O
.	.	.	O	O	O

Vasospastic	Vasospastic	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug-EF-1
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

SSRIs	SSRI	NNS	B-NP	O	S-group
:	:	:	O	O	O
Weakness	Weakness	NN	B-NP	O	O
hyperreflexia	hyperreflexia	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
incoordination	incoordination	NN	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
rarely	rarely	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
5	5	CD	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
HT1	HT1	NN	I-NP	O	I-group-EF-1
agonists	agonist	NNS	I-NP	O	E-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group-EF-2
(	(	(	O	O	O
e.	e.	FW	B-NP	O	O
g	g	NN	I-NP	O	O
.	.	.	O	O	O

fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
fluvoxamine	fluvoxamine	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
paroxetine	paroxetine	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
sertraline	sertraline	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
cases	case	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group
and	and	CC	O	O	O
D.H.E	D.H.E	NNP	B-NP	O	B-brand
.	.	.	I-NP	O	I-brand
45	45	CD	I-NP	O	E-brand
(	(	(	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
)	)	)	O	O	O
Injection	Injection	NNP	B-NP	O	O
,	,	,	O	O	O
USP	USP	NNP	B-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
D.H.E	D.H.E	NNP	B-NP	O	B-brand
.	.	.	I-NP	O	I-brand
45	45	CD	I-NP	O	E-brand
(	(	(	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
)	)	)	O	O	O
Injection	Injection	NN	B-NP	O	O
,	,	,	O	O	O
USP	USP	NNP	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-1
diuretics	diuretic	NNS	I-NP	O	E-group-EF-1
to	to	TO	B-PP	O	O
hypoparathyroid	hypoparathyroid	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
concurrently	concurrently	RB	I-VP	O	O
being	be	VBG	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
dihydrotachysterol	dihydrotachysterol	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	O	O	O
careful	careful	JJ	B-NP	O	O
titration	titration	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
diltiazem	diltiazem	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
affect	affect	VB	I-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
contractility	contractility	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
conduction	conduction	NN	B-NP	O	O
.	.	.	O	O	O

Pharmacologic	Pharmacologic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
prolonging	prolong	VBG	B-VP	O	O
AV	AV	NN	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
or	or	CC	O	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Tiazac	Tiazac	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
all	all	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
care	care	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
treating	treat	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

Diltiazem	Diltiazem	NNP	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
both	both	DT	B-NP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	I-protein	O
450	450	CD	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
specific	specific	JJ	B-NP	O	O
substrates	substrate	NNS	I-NP	O	O
,	,	,	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
inducers	inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
impact	impact	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP450	CYP450	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	O	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
hepatic	hepatic	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
starting	start	VBG	B-VP	O	O
or	or	CC	I-VP	O	O
stopping	stop	VBG	I-VP	O	O
concomitantly	concomitantly	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
optimum	optimum	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Beta	Beta	NN	B-NP	O	B-group
Blockers	Blocker	NNS	I-NP	O	E-group

Controlled	Controlled	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
uncontrolled	uncontrolled	JJ	I-NP	O	O
domestic	domestic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
and	and	CC	O	O	O
beta	beta	SYM	O	O	B-group
-	-	HYPH	O	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
is	be	VBZ	B-VP	O	O
usually	usually	RB	B-ADVP	O	O
well	well	RB	B-ADJP	O	O
tolerated	tolerate	VBN	I-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
available	available	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
predict	predict	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
or	or	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	B-drug-ME-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
five	five	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-ME-1
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
displaced	displace	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
binding	bind	VBG	I-NP	O	O
sites	site	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
an	an	DT	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
six	six	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
peak	peak	NN	B-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
58	58	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
53	53	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
1200	1200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
60mg	60mg	NN	I-NP	O	O
.	.	.	O	O	O

Ranitidine	Ranitidine	NN	B-NP	O	S-drug
produced	produce	VBD	B-VP	O	O
smaller	small	JJR	B-NP	O	O
,	,	,	I-NP	O	O
nonsignificant	nonsignificant	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cimetidines	cimetidine	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
system	system	NN	I-NP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
pass	pass	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
currently	currently	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-AD-1
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pharmacological	pharmacological	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
and	and	CC	I-VP	O	O
discontinuing	discontinue	VBG	I-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

An	An	DT	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	B-drug-ME-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-1
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
24	24	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Another	Another	DT	B-NP	O	O
investigator	investigator	NN	I-NP	O	O
found	find	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conflicting	conflict	VBG	I-VP	O	O
results	result	NNS	B-NP	O	O
regarding	regard	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-AD-1
levels	level	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
,	,	,	O	O	O
adjusting	adjust	VBG	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
diltiazem	diltiazem	NN	B-NP	O	B-drug-AD-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-AD-2
therapy	therapy	NN	I-NP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
possible	possible	JJ	B-ADJP	O	O
over	over	AFX	B-PRT	O	O
-	-	HYPH	B-VP	O	O
or	or	CC	O	O	O
under	under	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
digitalization	digitalization	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
depression	depression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
contractility	contractility	NN	I-NP	O	O
,	,	,	O	O	O
conductivity	conductivity	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
automaticity	automaticity	NN	B-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
dilation	dilation	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	B-group-EF-2
channel	channel	NN	I-NP	O	I-group-EF-2
blockers	blocker	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-AD-1
and	and	CC	O	O	O
calcium	calcium	NN	B-NP	O	B-group-AD-2
channel	channel	NN	I-NP	O	I-group-AD-2
blockers	blocker	NNS	I-NP	O	E-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug-IN-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
involving	involve	VBG	B-VP	O	O
renal	renal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
recipients	recipient	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-1
dose	dose	NN	I-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
48	48	CD	I-NP	O	O
%	%	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
trough	trough	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
seen	see	VBN	B-VP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-AD-1
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
,	,	,	B-NP	O	O
adjusted	adjust	VBN	I-NP	O	O
,	,	,	I-NP	O	O
or	or	CC	I-NP	O	O
discontinued	discontinue	VBN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
(	(	(	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
72	72	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
triazolam	triazolam	NN	I-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
by	by	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
fold	fold	RB	B-ADVP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
triazolam	triazolam	NN	I-NP	O	S-drug-ME-1
also	also	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2.5	2.5	CD	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
)	)	)	O	O	O
during	during	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
seen	see	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-EF-1
coadministration	coadministration	NN	I-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
prolonged	prolonged	JJ	B-NP	O	O
sodation	sodation	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
triazolam	triazolam	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
ten	ten	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
subject	subject	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
120	120	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
bid	bid	RB	B-ADVP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
increase	increase	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
lovastatin	lovastatin	NN	I-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
Cmax	Cmax	NN	B-NP	O	O
vs.	vs.	CC	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
alone	alone	RB	I-NP	O	O
;	;	:	O	O	O

no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pravastatin	pravastatin	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
coadministration	coadministration	NN	I-NP	O	O
.	.	.	O	O	O

Diltiazem	Diltiazem	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
pravastatin	pravastatin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
lowered	lower	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
undetectable	undetectable	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
any	any	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducer	inducer	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
possible	possible	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
alternative	alternative	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
considered	consider	VBN	B-VP	O	O
.	.	.	O	O	O

Dimenhydrinate	Dimenhydrinate	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
emetic	emetic	JJ	B-NP	O	S-group
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Oxytocin	Oxytocin	NN	B-NP	O	S-drug-EF-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
oxytocics	oxytocic	NNS	I-NP	O	S-group-EF-1
(	(	(	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
dinoprost	dinoprost	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
uterine	uterine	JJ	B-NP	O	O
hypertonus	hypertonus	NN	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
causing	cause	VBG	B-VP	O	O
uterine	uterine	JJ	B-NP	O	O
rupture	rupture	NN	I-NP	O	O
or	or	CC	O	O	O
cervical	cervical	JJ	B-NP	O	O
laceration	laceration	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
cervical	cervical	JJ	I-NP	O	O
dilatation	dilatation	NN	I-NP	O	O
;	;	:	O	O	O

although	although	IN	B-SBAR	O	O
combinations	combination	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
sometimes	sometimes	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
advantage	advantage	NN	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
patient	patient	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

PROSTIN	PROSTIN	NN	B-NP	B-protein	B-brand-EF-1
E2	E2	NN	I-NP	I-protein	E-brand-EF-1
may	may	MD	B-VP	O	O
augment	augment	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
oxytocic	oxytocic	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
oxytocic	oxytocic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Diphenhydramine	Diphenhydramine	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
has	have	VBZ	B-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
hypnotics	hypnotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
prolong	prolong	VB	B-VP	O	O
and	and	CC	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
(	(	(	O	O	O
drying	drying	JJ	B-ADJP	O	O
)	)	)	O	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

CNS	CNS	NN	B-NP	O	O
depression	depression	NN	I-NP	O	O
producing	produce	VBG	B-VP	O	O
medications	medication	NNS	B-NP	O	O
-	-	HYPH	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
these	these	DT	I-NP	O	O
medications	medication	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
diphenidol	diphenidol	NN	I-NP	O	S-drug
;	;	:	O	O	O

anticholinergics	anticholinergic	NNS	B-NP	O	S-group
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
diphenidol	diphenidol	NN	B-NP	O	S-drug
;	;	:	O	O	O

apomorphine	apomorphine	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
prior	prior	JJ	I-NP	O	O
ingestion	ingestion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diphenidol	diphenidol	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
emetic	emetic	JJ	I-NP	O	S-group
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
poisoning	poisoning	NN	B-NP	O	O
.	.	.	O	O	O

Known	Know	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Diphenoxylate	Diphenoxylate	NN	B-NP	O	B-drug-IN-1
HCl	HCl	NN	I-NP	O	E-drug-IN-1
and	and	CC	O	O	O
atropine	atropine	NN	B-NP	O	B-drug-IN-1
sulfate	sulfate	NN	I-NP	O	E-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group-IN-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-IN-2
In	In	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
diphenoxylate	diphenoxylate	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	B-protein	O
microsomal	microsomal	JJ	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
diphenoxylate	diphenoxylate	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
biological	biological	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
lives	life	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
elimination	elimination	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
dependent	dependent	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
microsomal	microsomal	JJ	I-NP	B-protein	O
drug	drug	NN	I-NP	I-protein	O
metabolizing	metabolize	VBG	B-VP	I-protein	O
enzyme	enzyme	NN	B-NP	I-protein	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group
depressants	depressant	NNS	I-NP	O	E-group
(	(	(	O	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
these	these	DT	I-NP	O	O
medications	medication	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
antihistamines	antihistamine	NNS	I-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
anticholinergics	anticholinergic	NNS	B-NP	O	S-group
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group
oxidase	oxidase	NN	I-NP	I-protein	I-group
(	(	(	O	O	I-group
MAO	MAO	NN	B-NP	O	I-group
)	)	)	O	O	I-group
inhibitors	inhibitor	NNS	B-NP	O	E-group
(	(	(	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-drug
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
and	and	CC	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
PERSANTINE	PERSANTINE	NN	B-NP	O	S-brand
(	(	(	O	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug
USP	USP	NN	I-NP	O	O
)	)	)	O	O	O
Tablets	Tablet	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
information	information	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

Adenosine	Adenosine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Dipyridamole	Dipyridamole	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Adjustment	Adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Cholinesterase	Cholinesterase	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Dipyridamole	Dipyridamole	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
counteract	counteract	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinesterase	anticholinesterase	NN	I-NP	B-protein	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cholinesterase	cholinesterase	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
thereby	thereby	RB	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
aggravating	aggravate	VBG	I-VP	O	O
myasthenia	myasthenia	NN	B-NP	O	O
gravis	gravis	NN	I-NP	O	O
.	.	.	O	O	O

Terfenadine	Terfenadine	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
six	six	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
dirithromycin	dirithromycin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
.	.	.	O	O	O

These	These	DT	B-NP	O	O
six	six	CD	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
(	(	(	O	O	O
60	60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
dirithromycin	dirithromycin	NN	B-NP	O	S-drug
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
Both	Both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
thus	thus	RB	I-VP	O	O
dosed	dose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
acid	acid	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
electrocardiographic	electrocardiographic	JJ	I-NP	O	O
QT	QT	NN	I-NP	O	O
c	c	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
both	both	DT	B-NP	O	O
periods	period	NNS	I-NP	O	O
:	:	:	O	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
plus	plus	CC	I-NP	O	O
dirithromycin	dirithromycin	NN	I-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
five	five	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
,	,	,	O	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
undetectable	undetectable	JJ	B-ADJP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
throughout	throughout	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
;	;	:	O	O	O

in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
man	man	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
C	C	NN	I-NP	O	O
max	max	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
8.1	8.1	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	O	O	O
mL	mL	NN	B-NP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
7.2	7.2	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	O	O	O
mL	mL	NN	B-NP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-ME-1
plus	plus	CC	I-NP	O	O
dirithromycin	dirithromycin	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
C	C	NN	I-NP	O	O
max	max	NN	I-NP	O	O
,	,	,	O	O	O
T	T	NN	B-NP	B-protein	O
max	max	NN	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acid	acid	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
changed	change	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
QT	QT	NN	I-NP	O	O
c	c	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
(	(	(	O	O	O
msec	msec	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
369	369	CD	B-NP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
367	367	CD	B-NP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-EF-1
plus	plus	CC	I-NP	O	O
dirithromycin	dirithromycin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
dirithromycin	dirithromycin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
observed	observe	VBN	B-VP	O	O
between	between	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug-IN-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
dirithromycin	dirithromycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Serious	Serious	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
dysrhythmias	dysrhythmia	NNS	I-NP	O	O
,	,	,	O	O	O
some	some	DT	B-NP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
death	death	NN	B-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
macrolide	macrolide	NN	I-NP	O	B-group-EF-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
most	most	JJS	B-NP	O	O
macrolides	macrolide	NNS	I-NP	O	S-group-AD-1
are	be	VBP	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
pre	pre	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
existing	exist	VBG	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
(	(	(	O	O	O
arrhythmia	arrhythmia	NN	B-NP	O	O
,	,	,	O	O	O
bradycardia	bradycardia	NN	B-NP	O	O
,	,	,	O	O	O
QT	QT	NN	B-NP	O	O
c	c	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
,	,	,	O	O	O
ischemic	ischemic	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
,	,	,	O	O	O
congestive	congestive	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
failure	failure	NN	I-NP	O	O
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
electrolyte	electrolyte	NN	B-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Following	Follow	VBG	B-VP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
250	250	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dirithromycin	dirithromycin	NN	I-NP	O	S-drug
tablets	tablet	NNS	I-NP	O	O
administered	administer	VBN	B-VP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
200	200	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
tablets	tablet	NNS	I-NP	O	O
administered	administer	VBN	B-VP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
14	14	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
general	general	JJ	B-ADJP	O	O
,	,	,	O	O	O
most	most	JJS	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
dirithromycin	dirithromycin	NN	B-NP	O	S-drug
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
require	require	VB	I-VP	O	O
empiric	empiric	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
or	or	CC	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
as	as	IN	B-PP	O	O
appropriate	appropriate	JJ	B-ADJP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
whose	whose	WP$	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
requires	require	VBZ	B-VP	O	O
maintaining	maintain	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
given	give	VBN	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
for	for	IN	B-PP	O	O
optimal	optimal	JJ	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
or	or	CC	O	O	O
H	H	NN	B-NP	B-protein	B-group
2	2	CD	I-NP	I-protein	I-group
receptor	receptor	NN	I-NP	I-protein	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
dirithromycin	dirithromycin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
immediately	immediately	RB	B-ADVP	O	O
following	follow	VBG	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group-ME-2
or	or	CC	O	O	O
H	H	NN	B-NP	B-DNA	B-group-ME-2
2	2	CD	I-NP	I-DNA	I-group-ME-2
-	-	HYPH	I-NP	O	I-group-ME-2
receptor	receptor	NN	I-NP	O	I-group-ME-2
antagonists	antagonist	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dirithromycin	dirithromycin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
slightly	slightly	RB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	B-protein	S-drug
products	product	NNS	I-NP	I-protein	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
presently	presently	RB	I-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
occur	occur	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
dirithromycin	dirithromycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Until	Until	IN	B-PP	O	O
further	further	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
regarding	regard	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dirithromycin	dirithromycin	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
.	.	.	O	O	O

Triazolam	Triazolam	NN	B-NP	O	S-drug
:	:	:	O	O	O
Erythromycin	Erythromycin	NN	B-NP	O	S-drug-MU-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triazolam	triazolam	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triazolam	triazolam	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
:	:	:	O	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-2
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounce	VBN	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
.	.	.	O	O	O

Ergotamine	Ergotamine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
ergotamine	ergotamine	NN	I-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
dihydroergotamine	dihydroergotamine	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
ergot	ergot	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
vasospasm	vasospasm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
dysesthesia	dysesthesia	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
Drug	Drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-IN-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
hexobarbital	hexobarbital	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
alfentanil	alfentanil	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
bromocriptine	bromocriptine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
valproate	valproate	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-IN-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
taken	take	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Norpace	Norpace	NNP	B-NP	O	S-brand-ME-2
or	or	CC	O	O	O
Norpace	Norpace	NNP	B-NP	O	B-brand-ME-2
CR	CR	NNP	I-NP	O	E-brand-ME-2
,	,	,	O	O	O
lower	low	JJR	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Monitoring	Monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
ineffective	ineffective	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Norpace	Norpace	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Excessive	Excessive	JJ	B-NP	O	O
widening	widening	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QRS	QRS	NN	I-NP	B-protein	O
complex	complex	NN	I-NP	I-protein	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Q	Q	NN	I-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
T	T	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
situations	situation	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Norpace	Norpace	NNP	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	O	S-drug
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Norpace	Norpace	NN	B-NP	O	S-brand-ME-1
and	and	CC	I-NP	O	O
quinidine	quinidine	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
slight	slight	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
disopyramide	disopyramide	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
slight	slight	JJ	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
quinidine	quinidine	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Norpace	Norpace	NNP	B-NP	O	S-brand
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
disopyramide	disopyramide	NN	B-NP	O	B-drug-ME-1
phosphate	phosphate	NN	I-NP	O	E-drug-ME-1
and	and	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-ME-2
concomitantly	concomitantly	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
excessive	excessive	JJ	B-NP	O	O
widening	widening	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QRS	QRS	NN	I-NP	B-protein	O
complex	complex	NN	I-NP	I-protein	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Q	Q	NN	I-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
T	T	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
disopyramide	disopyramide	NN	B-NP	O	B-drug
phosphate	phosphate	NN	I-NP	O	E-drug
and	and	CC	O	O	O
hepatic	hepatic	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Until	Until	IN	B-PP	O	O
data	datum	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
disopyramide	disopyramide	NN	I-NP	O	B-drug
phosphate	phosphate	NN	I-NP	O	E-drug
are	be	VBP	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
,	,	,	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
48	48	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	O	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-AD-2
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Disulfiram	Disulfiram	NN	B-NP	O	S-drug
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
at	at	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-VP	O	O
may	may	MD	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

DISULFIRAM	DISULFIRAM	NN	B-NP	O	S-drug-AD-1
SHOULD	SHOULD	NN	I-NP	O	O
BE	BE	NN	I-NP	O	O
USED	USED	VBD	B-VP	O	O
WITH	WITH	NN	B-NP	O	O
CAUTION	CAUTION	NN	I-NP	O	O
IN	IN	IN	B-PP	O	O
THOSE	THOSE	NN	B-NP	O	O
PATIENTS	PATIENTS	NNS	I-NP	O	O
REVEIVING	REVEIVING	VBG	B-VP	O	O
PHENYTOIN	PHENYTOIN	NN	B-NP	B-protein	S-drug-AD-2
AND	AND	CC	I-NP	O	O
ITS	ITS	NNS	I-NP	O	O
CONGENERS	CONGENERS	NNS	I-NP	O	O
.	.	.	O	O	O

SINCE	SINCE	VB	B-VP	O	O
THE	THE	DT	B-NP	O	O
CONCOMITANT	CONCOMITANT	JJ	I-NP	O	O
ADMINISTRATION	ADMINISTRATION	NN	I-NP	O	O
OF	OF	IN	B-PP	O	O
THESE	THESE	NNP	B-NP	O	O
TWO	TWO	NNP	I-NP	O	O
DRUGS	DRUGS	NNP	I-NP	O	O
CAN	CAN	NNP	I-NP	O	O
LEAD	LEAD	NNP	I-NP	O	O
TO	TO	NNP	I-NP	O	O
PHENYTOIN	PHENYTOIN	NNP	I-NP	O	S-drug
INTOXICATION	INTOXICATION	NNP	I-NP	O	O
,	,	,	O	O	O
PRIOR	PRIOR	NNP	B-NP	O	O
TO	TO	NNP	I-NP	O	O
ADMINISTERING	ADMINISTERING	NNP	I-NP	O	O
DISULFIRAM	DISULFIRAM	NNP	I-NP	O	S-drug-EF-1
TO	TO	NNP	I-NP	O	O
A	A	NNP	I-NP	O	O
PATIENT	PATIENT	NNP	I-NP	O	O
ON	ON	NNP	I-NP	O	O
PHENYTOIN	PHENYTOIN	NNP	I-NP	O	S-drug-EF-2
THERAPY	THERAPY	NNP	I-NP	O	O
,	,	,	O	O	O
A	A	DT	B-NP	O	O
BASELINE	BASELINE	NNP	I-NP	O	O
PHENYTOIN	PHENYTOIN	NNP	I-NP	O	S-drug
SERUM	SERUM	NNP	I-NP	O	O
LEVEL	LEVEL	NNP	I-NP	O	O
SHOULD	SHOULD	NNP	I-NP	O	O
BE	BE	NNP	I-NP	O	O
OBTAINED	OBTAINED	NNP	I-NP	O	O
.	.	.	O	O	O

SUBSEQUENT	SUBSEQUENT	NN	B-NP	O	O
TO	TO	TO	B-VP	O	O
INITIATION	INITIATION	NN	I-VP	O	O
OF	OF	IN	B-PP	O	O
DISULFIRAM	DISULFIRAM	JJ	B-NP	O	S-drug
THERAPY	THERAPY	NN	I-NP	O	O
.	.	.	O	O	O

SERUM	SERUM	NN	B-NP	O	O
LEVELS	LEVELS	NN	I-NP	O	O
OF	OF	IN	B-PP	O	O
PHENYTOIN	PHENYTOIN	NNP	B-NP	O	S-drug
SHOULD	SHOULD	NNP	I-NP	O	O
BE	BE	NNP	I-NP	O	O
DETERMINED	DETERMINED	NNP	I-NP	O	O
ON	ON	NNP	I-NP	O	O
DIFFERENT	DIFFERENT	NNP	I-NP	O	O
DAYS	DAYS	NNP	I-NP	O	O
FOR	FOR	NN	I-NP	O	O
EVIDENCE	EVIDENCE	NN	I-NP	O	O
OF	OF	IN	B-PP	O	O
AN	AN	NN	B-NP	O	O
INCREASE	INCREASE	NN	I-NP	O	O
OR	OR	NN	I-NP	O	O
FOR	FOR	NN	I-NP	O	O
A	A	NN	I-NP	O	O
CONTINUING	CONTINUING	NN	I-NP	O	O
RISE	RISE	NN	I-NP	O	O
IN	IN	IN	B-PP	O	O
LEVELS	LEVELS	NN	B-NP	O	O
.	.	.	O	O	O

INCREASED	INCREASED	NNP	B-NP	O	O
PHENYTOIN	PHENYTOIN	NNP	I-NP	O	S-drug
LEVELS	LEVELS	NNP	I-NP	O	O
SHOULD	SHOULD	NNP	I-NP	O	O
BE	BE	NNP	I-NP	O	O
TREATED	TREATED	NNP	I-NP	O	O
WITH	WITH	NNP	I-NP	O	O
APPROPRIATE	APPROPRIATE	NNP	I-NP	O	O
DOSAGE	DOSAGE	NNP	I-NP	O	O
ADJUSTMENT	ADJUSTMENT	NNP	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
adjust	adjust	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-AD-1
upon	upon	IN	B-PP	O	O
beginning	begin	VBG	B-VP	O	O
or	or	CC	I-VP	O	O
stopping	stop	VBG	I-VP	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O
since	since	IN	B-SBAR	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-AD-1
when	when	WRB	B-ADVP	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
unsteady	unsteady	JJ	B-NP	O	O
gait	gait	NN	I-NP	O	O
or	or	CC	O	O	O
marked	marked	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mental	mental	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
;	;	:	O	O	O

the	the	DT	B-NP	O	O
disulfiram	disulfiram	NN	I-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
appear	appear	VBP	B-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
ingestion	ingestion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
nitrite	nitrite	NN	I-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diet	diet	NN	I-NP	O	O
for	for	IN	B-PP	O	O
78	78	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
tumors	tumor	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
react	react	VB	I-VP	O	O
with	with	IN	B-PP	O	O
nitrites	nitrite	NNS	B-NP	O	S-group-EF-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
stomach	stomach	NN	I-NP	O	O
to	to	TO	B-VP	O	O
form	form	VB	I-VP	O	O
a	a	DT	B-NP	O	O
nitrosamine	nitrosamine	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
tumorigenic	tumorigenic	JJ	B-ADJP	O	O
.	.	.	O	O	O

Disulfiram	Disulfiram	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
s	s	NN	I-NP	O	O
diet	diet	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
such	such	JJ	B-NP	O	O
tumors	tumor	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
to	to	TO	B-PP	O	O
humans	human	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
this	this	DT	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Animal	Animal	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
dobutamine	dobutamine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
ineffective	ineffective	JJ	B-ADJP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
recently	recently	RB	I-VP	O	O
received	receive	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
b	b	NN	I-NP	O	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
blocking	block	VBG	B-VP	O	I-group-EF-2
drug	drug	NN	B-NP	O	E-group-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
such	such	PDT	B-NP	O	O
a	a	DT	I-NP	O	O
case	case	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
vascular	vascular	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
.	.	.	O	O	O

Preliminary	Preliminary	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dobutamine	dobutamine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
nitroprusside	nitroprusside	NN	I-NP	O	S-drug-EF-2
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
output	output	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
usually	usually	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
wedge	wedge	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
than	than	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
either	either	CC	O	O	O
drug	drug	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
dobutamine	dobutamine	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	B-group
preparations	preparation	NNS	I-NP	O	E-group
,	,	,	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
,	,	,	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug
,	,	,	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
glyceryl	glyceryl	NN	B-NP	O	B-drug
trinitrate	trinitrate	NN	I-NP	O	E-drug
,	,	,	O	O	O
isosorbide	isosorbide	NN	B-NP	O	B-drug
dinitrate	dinitrate	NN	I-NP	O	E-drug
,	,	,	O	O	O
morphine	morphine	NN	B-NP	O	S-drug
,	,	,	O	O	O
atropine	atropine	NN	B-NP	O	S-drug
,	,	,	O	O	O
heparin	heparin	NN	B-NP	O	S-drug
,	,	,	O	O	O
protamine	protamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	B-drug
chloride	chloride	NN	I-NP	O	E-drug
,	,	,	O	O	O
folic	folic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOTERE	TAXOTERE	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
docetaxel	docetaxel	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
modified	modify	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
,	,	,	O	O	O
inhibit	inhibit	VBP	B-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
treating	treat	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
TAXOTERE	TAXOTERE	NN	B-NP	O	S-brand
as	as	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
None	None	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Cimetidine	Cimetidine	NN	I-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
(	(	(	O	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
prescription	prescription	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	O	S-brand-ME-2
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
58	58	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
(	(	(	O	O	O
OTC	OTC	NNP	B-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
13	13	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
intermediate	intermediate	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
requires	require	VBZ	B-VP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	O	S-brand-AD-1
and	and	CC	O	O	O
anti	anti	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
ulcer	ulcer	NN	I-NP	O	E-group
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
antacids	antacid	NNS	B-NP	O	S-group
(	(	(	O	O	O
aluminum	aluminum	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	B-drug
hydroxides	hydroxide	NNS	I-NP	O	O
)	)	)	O	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-SBAR	O	O
alternatives	alternative	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Verapamil	Verapamil	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	B-protein	S-brand-ME-1
with	with	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
peak	peak	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
42	42	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
overall	overall	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
significantly	significantly	RB	B-ADJP	O	O
increased	increase	VBN	I-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
supraventricular	supraventricular	JJ	I-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	O
and	and	CC	I-NP	O	O
DIAMOND	DIAMOND	NN	I-NP	O	O
patient	patient	NN	I-NP	O	O
populations	population	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug-EF-2
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
torsade	torsade	FW	B-NP	O	O
de	de	FW	I-NP	O	O
pointes	pointes	FW	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
(	(	(	O	O	O
the	the	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
approved	approve	VBD	B-VP	O	O
prescription	prescription	NN	B-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	O	S-brand-ME-2
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
Cmax	Cmax	NN	I-NP	O	O
by	by	IN	B-PP	O	O
53	53	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
males	male	NNS	B-NP	O	O
and	and	CC	O	O	O
97	97	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
females	female	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
by	by	IN	B-PP	O	O
41	41	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
males	male	NNS	B-NP	O	O
and	and	CC	O	O	O
69	69	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
females	female	NNS	B-NP	O	O
.	.	.	O	O	O

Trimethoprim	Trimethoprim	NN	B-NP	O	S-drug
Alone	Alone	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
Combination	Combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Sulfamethoxazole	Sulfamethoxazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
trimethoprim	trimethoprim	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
sulfamethoxazole	sulfamethoxazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Hydrochlorothiazide	Hydrochlorothiazide	NN	B-NP	O	S-drug
(	(	(	O	O	O
HCTZ	HCTZ	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
Alone	Alone	NN	B-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
Combination	Combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Triamterene	Triamterene	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HCTZ	HCTZ	NN	B-NP	B-protein	S-drug
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
triamterene	triamterene	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

HCTZ	HCTZ	NN	B-NP	O	S-drug
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
or	or	CC	I-NP	O	O
HCTZ	HCTZ	NN	I-NP	B-protein	S-drug
/	/	SYM	B-NP	O	O
triamterene	triamterene	NN	B-NP	B-protein	S-drug
50	50	CD	I-NP	I-protein	O
/	/	SYM	I-NP	I-protein	O
100	100	CD	I-NP	I-protein	O
mg	mg	NN	I-NP	I-protein	O
QD	QD	NN	I-NP	I-protein	O
was	be	VBD	B-VP	I-protein	O
co	co	AFX	B-ADJP	I-protein	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	O	S-brand
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
following	follow	VBG	B-PP	O	O
2	2	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diuretic	diuretic	JJ	B-NP	O	S-group
use	use	NN	I-NP	O	O
at	at	IN	B-PP	O	O
half	half	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
HCTZ	HCTZ	NN	B-NP	B-protein	S-drug-ME-1
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
27	27	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
Cmax	Cmax	NN	B-NP	O	O
by	by	IN	B-PP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
197	197	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
QTc	QTc	NN	B-NP	O	O
increase	increase	NN	I-NP	O	O
over	over	IN	B-PP	O	O
time	time	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
by	by	IN	B-PP	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
maximum	maximum	JJ	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
190	190	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
QTc	QTc	NN	B-NP	O	O
increase	increase	NN	I-NP	O	O
over	over	IN	B-PP	O	O
time	time	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
by	by	IN	B-PP	O	O
84	84	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
Maximum	Maximum	JJ	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
explained	explain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DIAMOND	DIAMOND	NN	I-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
1252	1252	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group
concomitantly	concomitantly	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
493	493	CD	B-NP	O	O
died	die	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
508	508	CD	B-NP	O	O
deaths	death	NNS	I-NP	O	O
among	among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1248	1248	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
placebo	placebo	NN	B-NP	O	O
and	and	CC	I-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
229	229	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
potassium	potassium	NN	B-NP	O	B-group
depleting	depleting	NN	I-NP	O	I-group
diuretics	diuretic	NNS	I-NP	O	E-group
added	add	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
their	their	PRP$	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DIAMOND	DIAMOND	NN	I-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	O	S-brand
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
significantly	significantly	RB	I-NP	O	O
reduced	reduce	VBN	I-NP	O	O
relative	relative	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
death	death	NN	B-NP	O	O
of	of	IN	B-PP	O	O
0.68	0.68	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
0.376	0.376	CD	I-NP	O	O
,	,	,	I-NP	O	O
1.230	1.230	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Potential	Potential	NNP	B-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
Dofetilide	Dofetilide	NNP	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
by	by	IN	B-PP	O	O
cationic	cationic	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
cationic	cationic	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
actively	actively	RB	I-VP	O	O
secreted	secrete	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
this	this	DT	B-NP	O	O
route	route	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
metformin	metformin	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
amiloride	amiloride	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	I-ADJP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
care	care	NN	B-NP	O	O
as	as	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
might	might	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug-AD-2
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Dofetilide	Dofetilide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
extent	extent	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
could	could	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
systemic	systemic	JJ	B-NP	O	O
dofetilide	dofetilide	NN	I-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	B-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
macrolide	macrolide	NN	B-NP	O	B-group-AD-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-AD-1
,	,	,	O	O	O
azole	azole	NN	B-NP	O	B-group-AD-1
antifungal	antifungal	JJ	I-NP	O	I-group-AD-1
agents	agent	NNS	I-NP	O	E-group-AD-1
,	,	,	O	O	O
protease	protease	NN	B-NP	O	B-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
,	,	,	O	O	O
serotonin	serotonin	NN	B-NP	O	B-group-AD-1
reuptake	reuptake	NN	I-NP	O	I-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
,	,	,	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
cannabinoids	cannabinoid	NNS	B-NP	O	S-group-AD-1
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
,	,	,	O	O	O
nefazadone	nefazadone	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
quinine	quinine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
zafirlukast	zafirlukast	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
cautiously	cautiously	RB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	O	S-brand-AD-2
as	as	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
can	can	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Dofetilide	Dofetilide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
nor	nor	CC	B-PP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
)	)	)	O	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Information	Information	NNP	I-NP	O	O
Digoxin	Digoxin	NNP	I-NP	O	S-drug
:	:	:	O	O	O
Studies	Study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
TIKOSYN	TIKOSYN	NN	B-NP	B-protein	S-brand
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug-EF-2
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
torsade	torsade	FW	B-NP	O	O
de	de	FW	I-NP	O	O
pointes	pointes	FW	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
clear	clear	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
represents	represent	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	B-protein	S-brand
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
more	more	RBR	B-NP	O	O
severe	severe	JJ	I-NP	O	O
structural	structural	JJ	I-NP	O	O
heart	heart	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
;	;	:	O	O	O

structural	structural	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
arrhythmia	arrhythmia	NN	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mortality	mortality	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
as	as	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
amlodipine	amlodipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
,	,	,	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
hormone	hormone	NN	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
conjugated	conjugate	VBN	B-NP	O	O
estrogens	estrogen	NNS	I-NP	O	S-group
and	and	CC	O	O	O
medroxyprogesterone	medroxyprogesterone	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
antacid	antacid	NN	B-NP	O	S-group
(	(	(	O	O	O
aluminum	aluminum	NN	B-NP	O	S-drug
and	and	CC	O	O	O
magnesium	magnesium	NN	B-NP	O	B-drug
hydroxides	hydroxide	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TIKOSYN	TIKOSYN	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
studies	study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
TIKOSYN	TIKOSYN	NN	B-NP	B-protein	S-brand
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
.	.	.	O	O	O

Population	Population	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
analyses	analysis	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
1445	1445	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
clearance	clearance	NN	B-NP	O	O
or	or	CC	I-NP	O	O
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
distribution	distribution	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
grouped	group	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
,	,	,	O	O	O
inducers	inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
substrates	substrate	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
substrates	substrate	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
,	,	,	O	O	O
nitrates	nitrate	NNS	B-NP	O	S-group
,	,	,	O	O	O
sulphonylureas	sulphonylureas	NN	B-NP	O	S-group
,	,	,	O	O	O
loop	loop	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	B-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
,	,	,	O	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
,	,	,	O	O	O
substrates	substrate	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
organic	organic	JJ	I-NP	O	O
cation	cation	NN	I-NP	O	O
transport	transport	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
QTc	QTc	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
prolonging	prolong	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

Differences	Difference	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
clearance	clearance	NN	B-NP	O	O
between	between	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
(	(	(	O	O	O
at	at	IN	B-PP	O	O
any	any	DT	B-NP	O	O
occasion	occasion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
off	off	RP	B-PRT	O	O
medications	medication	NNS	B-NP	O	O
varied	vary	VBD	B-VP	O	O
between	between	IN	B-PP	O	O
-	-	SYM	B-NP	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
+	+	SYM	B-NP	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
clearances	clearance	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug-ME-1
were	be	VBD	B-VP	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-ME-2
diuretics	diuretic	NNS	I-NP	O	E-group-ME-2
and	and	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
organic	organic	JJ	I-NP	O	O
cation	cation	NN	I-NP	O	O
transport	transport	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
posed	pose	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
dolasetron	dolasetron	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
hydrodolasetron	hydrodolasetron	NN	I-NP	O	S-drug_n
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
low	low	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
commonly	commonly	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
or	or	CC	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
hydrodolasetron	hydrodolasetron	NN	B-NP	O	S-drug_n
is	be	VBZ	B-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
routes	route	NNS	I-NP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hydrodolasetron	hydrodolasetron	NN	B-NP	O	S-drug_n
increased	increase	VBD	B-VP	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
dolasetron	dolasetron	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
nonselective	nonselective	JJ	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
450	450	CD	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
potent	potent	JJ	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
450	450	CD	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Dolasetron	Dolasetron	NNP	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
safely	safely	RB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
prolong	prolong	VBP	B-VP	O	O
ECG	ECG	NN	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
prolong	prolong	VBP	B-VP	O	O
ECG	ECG	NN	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
QTc	QTc	NNP	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
,	,	,	O	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
,	,	,	O	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
various	various	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hydrodolasetron	hydrodolasetron	NN	B-NP	O	S-drug_n
.	.	.	O	O	O

Clearance	Clearance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hydrodolasetron	hydrodolasetron	NN	B-NP	O	S-drug_n
decreased	decrease	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
27	27	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
dolasetron	dolasetron	NN	B-NP	O	B-drug-ME-1
mesylate	mesylate	NN	I-NP	O	E-drug-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
concomitantly	concomitantly	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
atenolol	atenolol	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Dolasetron	Dolasetron	NNP	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Dolasetron	Dolasetron	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antitumor	antitumor	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
four	four	CD	B-NP	O	O
chemotherapeutic	chemotherapeutic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
5	5	CD	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
fluorouracil	fluorouracil	NN	I-NP	O	E-drug
,	,	,	O	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug
)	)	)	O	O	O
in	in	IN	B-PP	O	O
four	four	CD	B-NP	O	O
murine	murine	JJ	I-NP	O	O
models	model	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
or	or	CC	I-VP	O	O
Induce	Induce	VBP	I-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
and	and	CC	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Aricept	Aricept	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
dopamine	dopamine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
(	(	(	O	O	O
MAO	MAO	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
prolongs	prolong	VBZ	B-VP	O	O
and	and	CC	I-VP	O	O
potentiates	potentiate	VBZ	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
within	within	IN	B-PP	O	O
two	two	CD	B-NP	O	O
to	to	TO	I-NP	O	O
three	three	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	B-drug-AD-2
HCl	HCl	NN	I-NP	O	E-drug-AD-2
should	should	MD	B-VP	O	O
receive	receive	VB	I-VP	O	O
initial	initial	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
no	no	RB	B-ADVP	O	O
greater	great	JJR	I-ADVP	O	O
than	than	IN	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
tenth	tenth	NN	I-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
/	/	SYM	O	O	O
10	10	CD	O	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
dopamine	dopamine	NN	I-NP	O	B-drug-EF-1
HCl	HCl	NN	I-NP	O	E-drug-EF-1
and	and	CC	O	O	O
diuretic	diuretic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
potentiating	potentiate	VBG	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
flow	flow	NN	I-NP	O	O
.	.	.	O	O	O

Tricyclic	Tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adreneric	adreneric	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	S-drug-EF-1
are	be	VBP	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	B-PP	O	I-group-EF-2
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
metoprolol	metoprolol	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
vasoconstriction	vasoconstriction	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	B-drug-EF-1
HCl	HCl	NN	I-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
alpha	alpha	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	B-PP	O	I-group-EF-2
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Dopamine	Dopamine	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
renal	renal	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
mesenteric	mesenteric	JJ	I-NP	O	O
vasodilation	vasodilation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
either	either	CC	O	O	O
alpha	alpha	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	E-group
or	or	CC	O	O	O
beta	beta	SYM	B-NP	O	B-drug
-	-	HYPH	O	O	I-drug
adrenergic	adrenergic	JJ	B-NP	O	I-drug
blocking	block	VBG	I-NP	O	I-drug
agents	agent	NNS	I-NP	O	E-drug
.	.	.	O	O	O

Butyrophenones	Butyrophenone	NNS	B-NP	O	S-group-EF-1
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
suppress	suppress	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
mesenteric	mesenteric	JJ	I-NP	O	O
vasodilation	vasodilation	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
dopamine	dopamine	NN	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

Cyclopropane	Cyclopropane	NN	B-NP	O	S-drug-EF-1
or	or	CC	O	O	O
halogenated	halogenate	VBN	B-NP	O	B-group-EF-1
hydrocarbon	hydrocarbon	NN	I-NP	O	I-group-EF-1
anesthetics	anesthetic	NNS	I-NP	O	E-group-EF-1
increase	increase	VBP	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
autonomic	autonomic	JJ	I-NP	O	O
irritability	irritability	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
sensitize	sensitize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
intravenously	intravenously	RB	I-NP	O	O
administered	administer	VBN	I-NP	O	O
catecholamines	catecholamine	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
dopamine	dopamine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
related	relate	VBN	I-VP	O	O
both	both	CC	B-PP	O	O
to	to	TO	I-PP	O	O
pressor	pressor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	B-PP	O	O
to	to	TO	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	O	O	O
adrenergic	adrenergic	JJ	B-NP	O	O
stimulating	stimulate	VBG	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
catecholamines	catecholamine	NNS	I-NP	O	S-group
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
EXTREME	EXTREME	NN	B-NP	O	O
CAUTION	CAUTION	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
dopamine	dopamine	NN	B-NP	O	B-drug-AD-1
HCl	HCl	NN	I-NP	O	E-drug-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
cyclopropane	cyclopropane	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
halogenated	halogenate	VBN	B-NP	O	B-group-AD-2
hydrocarbon	hydrocarbon	NN	I-NP	O	I-group-AD-2
anesthetics	anesthetic	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
results	result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
dopamine	dopamine	NN	B-NP	O	S-drug-EF-1
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reversed	reverse	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasopressors	vasopressor	NNS	B-NP	O	O
,	,	,	O	O	O
vasoconstricting	vasoconstricte	VBG	B-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ergonovine	ergonovine	JJ	B-ADJP	O	S-drug-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
oxytocic	oxytocic	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
dopamine	dopamine	NN	B-NP	O	B-drug-EF-2
HCl	HCl	NN	I-NP	O	E-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
dopamine	dopamine	NN	B-NP	O	B-drug-AD-1
HCl	HCl	NN	I-NP	O	E-drug-AD-1
,	,	,	O	O	O
alternatives	alternative	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
Pulmozyme	Pulmozyme	NN	B-NP	B-protein	S-brand
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
effectively	effectively	RB	B-VP	O	O
and	and	CC	I-VP	O	O
safely	safely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
standard	standard	JJ	B-NP	O	O
cystic	cystic	JJ	I-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
oral	oral	JJ	B-NP	O	O
,	,	,	O	O	O
inhaled	inhale	VBN	B-VP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
parenteral	parenteral	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
,	,	,	O	O	O
bronchodilators	bronchodilator	NNS	B-NP	O	S-group
,	,	,	O	O	O
enzyme	enzyme	NN	B-NP	O	O
supplements	supplement	NNS	I-NP	O	O
,	,	,	O	O	O
vitamins	vitamin	NNS	B-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
inhaled	inhaled	JJ	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
analgesics	analgesic	NNS	B-NP	O	S-group
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
acid	acid	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
base	base	NN	I-NP	O	O
and	and	CC	I-NP	O	O
electrolyte	electrolyte	NN	I-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
dorzolamide	dorzolamide	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
these	these	DT	B-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
carbonic	carbonic	JJ	I-NP	O	B-group-EF-2
anhydrase	anhydrase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
instances	instance	NNS	I-NP	O	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
toxicity	toxicity	NN	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
dorzolamide	dorzolamide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Prior	Prior	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NUROMAX	NUROMAX	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NUROMAX	NUROMAX	NN	B-NP	B-protein	S-brand
before	before	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NUROMAX	NUROMAX	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
nondepolarizing	nondepolarize	VBG	I-NP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	B-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

Isoflurane	Isoflurane	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
enflurane	enflurane	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
halothane	halothane	NN	B-NP	O	S-drug-ME-1
decrease	decrease	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
ED50	ED50	NN	I-NP	B-protein	O
of	of	IN	B-PP	O	O
NUROMAX	NUROMAX	NN	B-NP	B-protein	S-brand-ME-2
by	by	IN	B-PP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
45	45	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
effective	effective	JJ	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
by	by	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nondepolarizing	nondepolarize	VBG	B-NP	O	O
agents	agent	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
NUROMAX	NUROMAX	NN	B-NP	B-protein	S-brand-EF-1
include	include	VBP	B-VP	O	O
certain	certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-EF-2
(	(	(	O	O	O
e.	e.	FW	B-NP	O	O
g.	g.	FW	I-NP	O	O
,	,	,	O	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
bacitracin	bacitracin	NN	B-NP	O	S-group-EF-2
,	,	,	O	O	O
polymyxins	polymyxin	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
lincomycin	lincomycin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
colistin	colistin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-EF-2
colistimethate	colistimethate	NN	I-NP	O	E-drug-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-EF-2
salts	salt	NNS	I-NP	O	O
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
nondepolarizing	nondepolarizing	JJ	I-NP	O	B-group-EF-1
neuromuscular	neuromuscular	JJ	I-NP	O	I-group-EF-1
blocking	block	VBG	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
onset	onset	NN	B-NP	O	O
of	of	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	B-protein	O
block	block	NN	I-NP	I-protein	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
NUROMAX	NUROMAX	NN	B-NP	B-protein	S-brand-EF-1
is	be	VBZ	B-VP	O	O
lengthened	lengthen	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
block	block	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
shortened	shorten	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
doxapram	doxapram	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	S-group-EF-2
or	or	CC	I-NP	O	O
monoamine	monoamine	NN	I-NP	B-protein	B-group-EF-2
oxidase	oxidase	NN	I-NP	I-protein	I-group-EF-2
inhibiting	inhibit	VBG	B-VP	O	I-group-EF-2
drugs	drug	NNS	B-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
received	receive	VBN	I-VP	O	O
muscle	muscle	NN	B-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group
,	,	,	O	O	O
doxapram	doxapram	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
temporarily	temporarily	RB	I-VP	O	O
mask	mask	VB	I-VP	O	O
the	the	DT	B-NP	O	O
residual	residual	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	B-group-EF-2
relaxant	relaxant	JJ	I-NP	O	I-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
received	receive	VBN	I-VP	O	O
general	general	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
utilizing	utilize	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
volatile	volatile	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
sensitize	sensitize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
to	to	TO	B-PP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
doxapram	doxapram	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
delayed	delay	VBN	I-VP	O	O
until	until	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
volatile	volatile	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
excreted	excrete	VBN	I-VP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
lessen	lessen	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
and	and	CC	O	O	O
ventricular	ventricular	JJ	B-NP	O	O
fibrillation	fibrillation	NN	I-NP	O	O
.	.	.	O	O	O

Most	Most	JJS	B-NP	O	O
(	(	(	O	O	O
98	98	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
doxazosin	doxazosin	NN	I-NP	I-protein	S-drug
is	be	VBZ	B-VP	O	O
protein	protein	NN	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
plasma	plasma	NN	I-NP	I-cell_type	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
doxazosin	doxazosin	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
indomethacin	indomethacin	NN	I-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
information	information	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
highly	highly	RB	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
bound	bind	VBD	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
doxazosin	doxazosin	NN	B-NP	O	S-drug
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

Doxazosin	Doxazosin	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
without	without	IN	B-PP	O	O
any	any	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blocking	block	VBG	B-NP	O	I-group
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-NP	O	O
trial	trial	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxazosin	doxazosin	NN	B-NP	O	S-drug-ME-1
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
four	four	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug-ME-2
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxazosin	doxazosin	NN	B-NP	O	S-drug
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.006	0.006	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
but	but	CC	B-ADJP	O	O
not	not	RB	I-ADJP	O	O
statistically	statistically	RB	B-ADVP	O	O
significant	significant	JJ	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	O	O	O
mean	mean	VB	B-VP	O	O
half	half	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxazosin	doxazosin	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
doxazosin	doxazosin	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
doxazosin	doxazosin	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
tablets	tablet	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
;	;	:	O	O	O

while	while	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Doxazosin	Doxazosin	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
tablets	tablet	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	O	O	O
drug	drug	NN	B-NP	O	O
classes	class	NNS	I-NP	O	O
:	:	:	O	O	O
1	1	LS	B-LST	O	O
.	.	.	O	O	O

Analgesic	Analgesic	JJ	O	O	S-group
/	/	SYM	O	O	O
anti	anti	AFX	O	O	B-group
-	-	HYPH	O	O	I-group
inflammatory	inflammatory	JJ	O	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
codeine	codeine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
codeine	codeine	NN	I-NP	O	S-drug
combinations	combination	NNS	I-NP	O	O
,	,	,	O	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

2	2	LS	B-LST	O	O
.	.	.	O	O	O

Antibiotics	Antibiotic	NNS	B-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
trimethoprim	trimethoprim	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
sulfamethoxazole	sulfamethoxazole	NN	I-NP	O	S-drug
,	,	,	O	O	O
amoxicillin	amoxicillin	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

3	3	LS	B-LST	O	O
.	.	.	O	O	O

Antihistamines	Antihistamine	NNS	B-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
chlorpheniramine	chlorpheniramine	NN	B-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

4	4	LS	B-LST	O	O
.	.	.	O	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
atenolol	atenolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

5	5	LS	B-LST	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
.	.	.	O	O	O

6	6	CD	B-NP	O	O
.	.	.	O	O	O

Gastrointestinal	Gastrointestinal	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
antacids	antacid	NNS	B-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

7	7	CD	B-NP	O	O
.	.	.	O	O	O

Hypoglycemics	Hypoglycemic	NNS	B-NP	O	S-group
and	and	CC	O	O	O
endocrine	endocrine	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

8	8	CD	B-NP	O	O
.	.	.	O	O	O

Sedatives	Sedative	NNS	B-NP	O	S-group
and	and	CC	I-NP	O	O
tranquilizers	tranquilizer	NNS	I-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

9	9	CD	B-NP	O	O
.	.	.	O	O	O

Cold	Cold	NN	B-NP	O	O
and	and	CC	I-NP	O	O
flu	flu	NN	I-NP	O	O
remedies	remedy	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
metabolizing	metabolize	VBG	B-VP	O	O
isozyme	isozyme	NN	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
debrisoquin	debrisoquin	NN	B-NP	B-protein	O
hydroxylase	hydroxylase	NN	I-NP	I-protein	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Caucasian	Caucasian	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
7	7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Caucasians	Caucasian	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
so	so	RB	B-ADJP	O	O
-	-	HYPH	I-ADJP	O	O
called	call	VBN	B-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

reliable	reliable	JJ	B-NP	O	O
estimates	estimate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
P450	P450	NN	I-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
among	among	IN	B-PP	O	O
Asian	Asian	JJ	B-NP	O	O
,	,	,	I-NP	O	O
African	African	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
populations	population	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
yet	yet	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
.	.	.	O	O	O

Poor	Poor	NN	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
expected	expect	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
(	(	(	O	O	O
TCAs	TCA	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
usual	usual	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Depending	Depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-ADJP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
quite	quite	RB	B-ADJP	O	O
large	large	JJ	I-ADJP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
and	and	CC	O	O	O
make	make	VB	B-VP	O	O
normal	normal	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
resemble	resemble	VBP	B-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
individual	individual	NN	I-NP	O	O
who	who	WP	B-NP	O	O
is	be	VBZ	B-VP	O	O
stable	stable	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
given	give	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TCA	TCA	NN	B-NP	B-protein	S-group
may	may	MD	B-VP	O	O
become	become	VB	I-VP	O	O
abruptly	abruptly	RB	B-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
inhibiting	inhibit	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
include	include	VBP	B-VP	O	O
some	some	DT	O	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
(	(	(	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
;	;	:	O	O	O

cimetidine	cimetidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
many	many	JJ	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
many	many	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Type	Type	NN	I-NP	O	B-group
1C	1C	NN	I-NP	O	I-group
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	E-group
propafenone	propafenone	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
flecainide	flecainide	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
selective	selective	JJ	I-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
citalopram	citalopram	NN	B-NP	O	S-drug
,	,	,	O	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
inhibit	inhibit	VBP	B-VP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
vary	vary	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
to	to	TO	B-PP	O	O
which	which	WDT	B-NP	O	O
SSRI	SSRI	NN	I-NP	B-protein	S-group-IN-1
-	-	HYPH	I-NP	O	O
TCA	TCA	NN	I-NP	O	S-group-IN-2
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
pose	pose	VB	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
problems	problem	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
depend	depend	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	O	S-group
involved	involve	VBN	B-VP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TCAs	TCA	NNS	B-NP	B-protein	S-group-AD-1
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRIs	SSRI	NNS	I-NP	O	S-group-AD-2
and	and	CC	O	O	O
also	also	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
switching	switch	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
one	one	CD	B-NP	O	O
class	class	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
importance	importance	NN	I-NP	O	O
,	,	,	O	O	O
sufficient	sufficient	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
must	must	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
before	before	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
TCA	TCA	NN	B-NP	B-protein	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
being	be	VBG	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
parent	parent	NN	I-NP	O	O
and	and	CC	O	O	O
active	active	JJ	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
(	(	(	O	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
5	5	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
than	than	IN	B-SBAR	O	O
usually	usually	RB	B-ADVP	O	O
prescribed	prescribe	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
whenever	whenever	WRB	B-ADVP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
desirable	desirable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
TCA	TCA	NN	B-NP	O	S-group
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
whenever	whenever	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group
is	be	VBZ	B-VP	O	O
going	go	VBG	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
.	.	.	O	O	O

Doxepin	Doxepin	NNP	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
(	(	(	O	O	O
with	with	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
as	as	IN	B-PP	O	O
minor	minor	JJ	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
substrates	substrate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
selective	selective	JJ	B-NP	O	B-group-ME-1
serotonin	serotonin	NN	I-NP	O	I-group-ME-1
reuptake	reuptake	NN	I-NP	O	I-group-ME-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-ME-1
[	[	(	O	O	O
SSRIs	SSRI	NNS	B-NP	O	S-group-ME-1
]	]	)	O	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxepin	doxepin	NN	B-NP	O	S-drug-ME-2
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
depends	depend	VBZ	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
variability	variability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
effect	effect	NN	B-NP	O	O
on	on	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
doxepin	doxepin	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Serious	Serious	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
even	even	RB	B-ADVP	O	O
death	death	NN	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
MAO	MAO	NN	B-NP	O	B-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
two	two	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
cautious	cautious	JJ	I-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
SINEQUAN	SINEQUAN	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
exact	exact	JJ	I-NP	O	O
length	length	NN	I-NP	O	O
of	of	IN	B-PP	O	O
time	time	NN	B-NP	O	O
may	may	MD	B-VP	O	O
vary	vary	VB	I-VP	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
dependent	dependent	JJ	B-ADJP	O	O
upon	upon	IN	B-PP	O	O
the	the	DT	B-NP	O	O
particular	particular	JJ	I-NP	O	O
MAO	MAO	NN	I-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
being	be	VBG	B-VP	O	O
used	use	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
length	length	NN	I-NP	O	O
of	of	IN	B-PP	O	O
time	time	NN	B-NP	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
involved	involve	VBN	B-VP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
fluctuations	fluctuation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-ME-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Serious	Serious	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
severe	severe	JJ	B-NP	O	O
dry	dry	JJ	I-NP	O	O
mouth	mouth	NN	I-NP	O	O
,	,	,	O	O	O
urinary	urinary	JJ	B-NP	O	O
retention	retention	NN	I-NP	O	O
and	and	CC	O	O	O
blurred	blur	VBD	B-VP	O	O
vision	vision	NN	B-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
elevations	elevation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressant	antidepressant	NN	I-NP	O	E-group-EF-1
when	when	WRB	B-ADVP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-EF-2
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
expected	expect	VBN	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-ME-1
antidepressant	antidepressant	JJ	I-NP	O	E-group-ME-1
levels	level	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
begun	begin	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
already	already	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
well	well	RB	I-VP	O	O
controlled	control	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
receiving	receive	VBG	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
established	establish	VBN	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-ME-2
antidepressant	antidepressant	NN	I-NP	O	E-group-ME-2
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
compromise	compromise	VB	B-VP	O	O
their	their	PRP$	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
:	:	:	O	O	O
It	It	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
borne	bear	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mind	mind	NN	B-NP	O	O
that	that	IN	B-SBAR	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-ME-1
ingestion	ingestion	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
danger	danger	NN	I-NP	O	O
inherent	inherent	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
intentional	intentional	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
unintentional	unintentional	JJ	I-NP	O	O
SINEQUAN	SINEQUAN	NN	I-NP	O	S-brand-ME-2
overdosage	overdosage	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
especially	especially	RB	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
may	may	MD	B-VP	O	O
use	use	VB	I-VP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
excessively	excessively	RB	B-ADVP	O	O
.	.	.	O	O	O

Tolazamide	Tolazamide	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
type	type	NN	I-NP	O	O
II	II	CD	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
maintained	maintain	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
tolazamide	tolazamide	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
1	1	CD	B-NP	O	O
gm	gm	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
11	11	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxepin	doxepin	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
DOXIL	DOXIL	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Until	Until	IN	B-PP	O	O
specific	specific	JJ	B-NP	O	O
compatibility	compatibility	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
DOXIL	DOXIL	NN	B-NP	B-protein	S-brand
be	be	VB	B-VP	O	O
mixed	mix	VBN	B-ADJP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

DOXIL	DOXIL	NN	B-NP	B-protein	S-brand
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
conventional	conventional	JJ	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-AD-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
depress	depress	VB	I-VP	O	O
plasma	plasma	NN	B-NP	B-protein	O
prothrombin	prothrombin	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-group-AD-2
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
downward	downward	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
bacteriostatic	bacteriostatic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bactericidal	bactericidal	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
penicillin	penicillin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
giving	give	VBG	I-VP	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-AD-1
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
penicillin	penicillin	NN	B-NP	B-protein	S-group-AD-2
.	.	.	O	O	O

Absorption	Absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-ME-1
is	be	VBZ	B-VP	O	O
impaired	impair	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
.	.	.	O	O	O

Absorption	Absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
impaired	impair	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
bismuth	bismuth	JJ	B-NP	O	B-drug-ME-2
subsalicylate	subsalicylate	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

Barbiturates	Barbiturate	NNS	B-NP	O	S-group-ME-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
decrease	decrease	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxycycline	doxycycline	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
Penthrane	Penthrane	NN	B-NP	O	S-brand-EF-2
(	(	(	O	O	O
methoxyflurane	methoxyflurane	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
render	render	VB	I-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
less	less	RBR	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
False	False	VBP	B-VP	O	O
elevations	elevation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
catecholamine	catecholamine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
interference	interference	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fluorescence	fluorescence	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
doxylamine	doxylamine	NN	B-NP	O	S-drug
include	include	VBP	B-VP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
doxylamine	doxylamine	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	B-group-EF-2
depressant	depressant	NN	I-NP	O	I-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Antihistamines	Antihistamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
partially	partially	RB	I-VP	O	O
counteract	counteract	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Doxylamine	Doxylamine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Androgens	Androgen	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
sensitivity	sensitivity	NN	B-NP	O	O
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulahts	anticoagulaht	NNS	I-NP	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
satisfactory	satisfactory	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
hypoprothrombinemia	hypoprothrombinemia	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxyphenbutazone	oxyphenbutazone	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
androgens	androgen	NNS	I-NP	O	S-group-ME-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oxyphenbutazone	oxyphenbutazone	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
androgens	androgen	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
insulin	insulin	NN	B-NP	O	S-drug-EF-2
requirements	requirement	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	B-group-EF-1
depressant	depressant	NN	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	I-NP	O	O
barbiturates	barbiturate	NNS	I-NP	O	S-group-EF-1
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
opioids	opioid	NNS	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-1
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
additive	additive	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
potentiating	potentiating	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
INAPSINE	INAPSINE	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
patients	patient	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
received	receive	VBN	I-VP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INAPSINE	INAPSINE	NN	B-NP	O	S-brand
required	require	VBN	B-VP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
usual	usual	JJ	B-ADJP	O	O
.	.	.	O	O	O

Following	Follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INAPSINE	INAPSINE	NN	B-NP	O	S-brand-AD-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	B-group-AD-2
depressant	depressant	NN	I-NP	O	I-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Xigris	Xigris	NNP	B-NP	O	S-brand
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
sepsis	sepsis	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
Xigris	Xigris	NN	B-NP	B-DNA	S-brand
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
employed	employ	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Xigris	Xigris	NNP	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
affect	affect	VBP	B-VP	O	O
hemostasis	hemostasis	NN	B-NP	O	O
.	.	.	O	O	O

Approximately	Approximately	RB	B-NP	O	O
2	2	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
3	3	CD	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Phase	Phase	NN	I-NP	O	O
3	3	CD	I-NP	O	O
study	study	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
either	either	CC	O	O	O
prophylactic	prophylactic	JJ	B-NP	O	O
low	low	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
heparin	heparin	NN	I-NP	O	S-drug
(	(	(	O	O	O
unfractionated	unfractionated	JJ	B-NP	O	B-drug
heparin	heparin	NN	I-NP	O	E-drug
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
15,000	15,000	CD	I-NP	B-DNA	O
units	unit	NNS	I-NP	I-DNA	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
prophylactic	prophylactic	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	B-group
molecular	molecular	JJ	I-NP	O	I-group
weight	weight	NN	I-NP	O	I-group
heparins	heparin	NNS	I-NP	O	E-group
as	as	IN	B-SBAR	O	O
indicated	indicate	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prescribing	prescribe	VBG	I-NP	O	O
information	information	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prophylactic	prophylactic	JJ	B-NP	O	O
low	low	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
heparin	heparin	NN	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
safety	safety	NN	B-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Xigris	Xigris	NNP	B-NP	O	S-brand
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adequate	adequate	JJ	I-NP	O	O
and	and	CC	O	O	O
well	well	RB	B-VP	O	O
-	-	HYPH	I-VP	O	O
controlled	control	VBN	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interaction	Interaction	NN	I-NP	O	O
Because	Because	IN	B-SBAR	O	O
Xigris	Xigris	NNP	B-NP	O	S-brand
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
APTT	APTT	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
,	,	,	O	O	O
Xigris	Xigris	NNP	B-NP	O	S-brand
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
stage	stage	NN	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
assays	assay	NNS	I-NP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
APTT	APTT	NN	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
factor	factor	NN	B-NP	O	O
VIII	VIII	CD	I-NP	O	O
,	,	,	I-NP	O	O
IX	IX	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
XI	XI	NN	B-NP	O	O
assays	assay	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interference	interference	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
factor	factor	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
true	true	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

Xigris	Xigris	NN	B-NP	O	S-brand
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
stage	stage	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
assays	assay	NNS	I-NP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PT	PT	NN	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
factor	factor	NN	B-NP	B-DNA	O
II	II	CD	I-NP	I-DNA	O
,	,	,	I-NP	O	O
V	V	CD	I-NP	O	O
,	,	,	I-NP	O	O
VII	VII	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
X	X	NN	B-NP	O	O
assays	assay	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
Affect	Affect	VB	I-VP	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Both	Both	CC	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	B-protein	O
are	be	VBP	B-VP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
a	a	DT	I-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
and	and	CC	B-PP	O	O
about	about	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2.5	2.5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
of	of	IN	B-PP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
similar	similar	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
:	:	:	O	O	O
Because	Because	IN	B-SBAR	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Paroxetine	Paroxetine	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
greater	great	JJR	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
expected	expect	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Similar	Similar	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
Affect	Affect	VB	I-VP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
:	:	:	O	O	O
In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
substrates	substrate	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
:	:	:	O	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
(	(	(	O	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
60	60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
50	50	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
desipramine	desipramine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
desipramine	desipramine	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
extensively	extensively	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
and	and	CC	O	O	O
which	which	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
narrow	narrow	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
index	index	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
certain	certain	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group-AD-2
(	(	(	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-2
[	[	(	O	O	O
TCAs	TCA	NNS	B-NP	O	S-group-AD-2
]	]	)	O	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
nortriptyline	nortriptyline	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
amitriptyline	amitriptyline	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
imipramine	imipramine	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-AD-2
and	and	CC	O	O	O
Type	Type	NN	B-NP	O	B-group-AD-2
1C	1C	NN	I-NP	O	I-group-AD-2
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
propafenone	propafenone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
flecainide	flecainide	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
TCA	TCA	NN	I-NP	O	S-group
concentrations	concentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group-AD-1
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
and	and	CC	O	O	O
sudden	sudden	JJ	B-NP	O	O
death	death	NN	I-NP	O	O
potentially	potentially	RB	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
thioridazine	thioridazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
thioridazine	thioridazine	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	I-ADJP	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
:	:	:	O	O	O
Results	Result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
or	or	CC	I-VP	O	O
induce	induce	VB	I-VP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Duloxetine	Duloxetine	NNP	B-NP	O	S-drug
May	May	NNP	I-NP	O	O
Have	Have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
Clinically	Clinically	RB	I-NP	O	O
Important	Important	JJ	I-NP	O	O
Interaction	Interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Following	Follow	VBG	I-NP	O	O
Other	Other	JJ	I-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
Alcohol	Alcohol	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
several	several	JJ	B-NP	O	O
hours	hour	NNS	I-NP	O	O
apart	apart	RB	B-ADVP	O	O
so	so	IN	B-SBAR	O	O
that	that	IN	I-SBAR	O	O
peak	peak	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
would	would	MD	B-VP	O	O
coincide	coincide	VB	I-VP	O	O
,	,	,	O	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mental	mental	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
motor	motor	NN	I-NP	O	O
skills	skill	NNS	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Duloxetine	Duloxetine	NN	I-NP	O	S-drug
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
database	database	NN	I-NP	O	O
,	,	,	O	O	O
three	three	CD	B-NP	O	O
Duloxetine	Duloxetine	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
liver	liver	NN	B-NP	O	O
injury	injury	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
manifested	manifest	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ALT	ALT	NN	B-NP	B-protein	O
and	and	CC	O	O	O
total	total	JJ	B-NP	O	O
bilirubin	bilirubin	NN	I-NP	O	O
elevations	elevation	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
obstruction	obstruction	NN	B-NP	O	O
.	.	.	O	O	O

Substantial	Substantial	JJ	B-NP	O	O
intercurrent	intercurrent	JJ	I-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug
use	use	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
contributed	contribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
seen	see	VBN	B-VP	O	O
.	.	.	O	O	O

CNS	CNS	NNP	B-NP	O	O
Acting	Acting	NNP	I-NP	O	O
Drugs	Drugs	NNP	I-NP	O	O
:	:	:	O	O	O
Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
taken	take	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
or	or	CC	O	O	O
substituted	substitute	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-ADJP	O	O
centrally	centrally	RB	B-ADVP	O	O
acting	act	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Drugs	Drugs	NNP	B-NP	O	O
that	that	IN	B-SBAR	O	O
Affect	Affect	NNP	B-NP	O	O
Gastric	Gastric	NNP	I-NP	O	O
Acidity	Acidity	NNP	I-NP	O	O
:	:	:	O	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
enteric	enteric	JJ	I-NP	O	O
coating	coating	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
resists	resist	VBZ	B-VP	O	O
dissolution	dissolution	NN	B-NP	O	O
until	until	IN	B-PP	O	O
reaching	reach	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
segment	segment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
where	where	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
pH	pH	NN	I-NP	O	O
exceeds	exceed	VBZ	B-VP	O	O
5.5	5.5	CD	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
extremely	extremely	RB	B-NP	O	O
acidic	acidic	JJ	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
,	,	,	O	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
unprotected	unprotected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enteric	enteric	JJ	I-NP	O	O
coating	coating	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
undergo	undergo	VB	I-VP	O	O
hydrolysis	hydrolysis	NN	B-NP	O	O
to	to	TO	B-VP	O	O
form	form	VB	I-VP	O	O
naphthol	naphthol	NN	B-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
conditions	condition	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
slow	slow	VB	I-VP	O	O
gastric	gastric	JJ	B-NP	O	O
emptying	emptying	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
some	some	DT	B-NP	O	O
diabetics	diabetic	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
raise	raise	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
pH	pH	NN	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
earlier	early	JJR	I-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacids	antacid	NNS	B-NP	O	S-group
(	(	(	O	O	O
51	51	CD	B-NP	O	O
mEq	mEq	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
Duloxetine	Duloxetine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
famotidine	famotidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
or	or	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
40	40	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
proton	proton	NN	B-NP	O	B-group
pump	pump	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
affects	affect	VBZ	B-VP	O	O
duloxetine	duloxetine	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Synergism	Synergism	NN	B-NP	O	O
between	between	IN	B-PP	O	O
xanthine	xanthine	NN	B-NP	B-protein	B-group-EF-1
bronchodilators	bronchodilator	NNS	I-NP	I-protein	E-group-EF-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
,	,	,	O	O	O
ephedrine	ephedrine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
sympathomimetic	sympathomimetic	JJ	I-NP	O	B-group-EF-2
bronchodilators	bronchodilator	NNS	I-NP	O	E-group-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
whenever	whenever	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dyphylline	dyphylline	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
probenecid	probenecid	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
competes	compete	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dyphylline	dyphylline	NN	B-NP	O	S-drug
.	.	.	O	O	O

Phospholine	Phospholine	NN	B-NP	O	B-drug-EF-1
Iodide	Iodide	NN	I-NP	O	E-drug-EF-1
potentiates	potentiate	VBZ	B-VP	O	O
other	other	JJ	B-NP	O	O
cholinesterase	cholinesterase	NN	I-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
organophosphate	organophosphate	NN	I-NP	O	S-drug_n-EF-2
and	and	CC	I-NP	O	O
carbamate	carbamate	NN	I-NP	O	B-drug_n-EF-2
insecticides	insecticide	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
systemic	systemic	JJ	B-NP	O	O
anticholinesterase	anticholinesterase	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warned	warn	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Phospholine	Phospholine	NN	B-NP	O	B-drug
Iodide	Iodide	NN	I-NP	O	E-drug
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Soliris	Soliris	NNP	B-NP	O	S-brand
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
interference	interference	NN	I-NP	O	O
with	with	IN	B-PP	O	O
standard	standard	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Steroids	Steroid	NNS	B-NP	O	S-group-EF-1
enhance	enhance	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
edetate	edetate	NN	B-NP	O	B-drug-EF-2
calcium	calcium	NN	I-NP	O	I-drug-EF-2
disodium	disodium	NN	I-NP	O	E-drug-EF-2
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
.	.	.	O	O	O
7	7	CD	B-NP	O	O
Edetate	Edetate	NNP	I-NP	O	B-drug-ME-1
calcium	calcium	NN	I-NP	O	I-drug-ME-1
disodium	disodium	NN	I-NP	O	E-drug-ME-1
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zinc	zinc	NN	B-NP	O	B-drug-ME-2
insulin	insulin	NN	I-NP	O	E-drug-ME-2
preparations	preparation	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
chelating	chelate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
zinc	zinc	NN	I-NP	O	S-drug
.	.	.	O	O	O
7	7	CD	B-NP	O	O

Care	Care	NNP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
myasthenic	myasthenic	JJ	B-NP	O	O
weakness	weakness	NN	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
anticholinesterase	anticholinesterase	NN	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
anticholinesterase	anticholinesterase	NN	B-NP	B-protein	O
overdose	overdose	NN	I-NP	O	O
(	(	(	O	O	O
cholinergic	cholinergic	JJ	B-NP	O	O
crisis	crisis	NN	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
mimic	mimic	VB	I-VP	O	O
underdosage	underdosage	NN	B-NP	O	O
(	(	(	O	O	O
myasthenic	myasthenic	JJ	B-NP	O	O
weakness	weakness	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
their	their	PRP$	B-NP	O	O
condition	condition	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
worsened	worsen	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
RAPTIVA	RAPTIVA	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

RAPTIVA	RAPTIVA	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
immunosuppressive	immunosuppressive	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Acellular	Acellular	JJ	B-NP	O	S-group-AD-1
,	,	,	I-NP	O	O
live	live	JJ	I-NP	O	S-group-AD-1
and	and	CC	I-NP	O	O
live	live	JJ	I-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
attenuated	attenuate	VBN	I-NP	O	I-group-AD-1
vaccines	vaccine	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
RAPTIVA	RAPTIVA	NN	B-NP	O	S-brand-AD-2
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Increases	Increase	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
lymphocyte	lymphocyte	NN	B-NP	O	O
counts	count	NNS	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
frequently	frequently	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
RAPTIVA	RAPTIVA	NN	B-NP	O	S-brand
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Efavirenz	Efavirenz	NNP	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
(	(	(	O	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
2C9	2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
observed	observe	VBN	B-NP	O	O
efavirenz	efavirenz	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
primarily	primarily	RB	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
isozymes	isozyme	NNS	I-NP	B-protein	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
altered	alter	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministered	coadministere	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
rifabutin	rifabutin	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug-ME-2
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
lowered	lower	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
are	be	VBP	B-VP	O	O
summarized	summarize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Table	Table	JJ	B-NP	B-protein	O
5	5	CD	I-NP	I-protein	O
.	.	.	O	O	O

Table	Table	JJ	B-NP	B-protein	O
5a	5a	NNS	I-NP	I-protein	O
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
That	That	IN	B-NP	O	O
Should	Should	MD	B-VP	O	O
Not	Not	RB	I-VP	O	O
Be	Be	VB	I-VP	O	O
Coadministered	Coadministere	VBN	I-VP	O	O
With	With	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand

Drug	Drug	NNP	B-NP	O	O
Class	Class	NNP	I-NP	O	O

Drugs	Drug	NNS	B-NP	O	O
Within	Within	IN	B-PP	O	O
Class	Class	NNP	B-NP	O	O
Not	Not	NNP	I-NP	O	O
To	To	TO	B-VP	O	O
Be	Be	VB	I-VP	O	O
Coadministered	Coadministere	VBN	I-VP	O	O
With	With	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand

Antihistamines	Antihistamine	NNS	B-NP	O	S-group
:	:	:	O	O	O
Benzodiazepines	Benzodiazepines	NNP	B-NP	O	S-group
GI	GI	NNP	I-NP	O	O
Motility	Motility	NNP	I-NP	O	O
Agents	Agent	NNPS	I-NP	O	O
Anti	Anti	NNP	I-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
Migraine	Migraine	NNP	I-NP	O	E-group
Antifungal	Antifungal	NNP	I-NP	O	S-group

astemizole	astemizole	NN	B-NP	O	S-drug
midazolam	midazolam	NN	I-NP	O	S-drug
,	,	,	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug
cisapride	cisapride	NN	I-NP	O	S-drug
ergot	ergot	NN	I-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
voriconazole	voriconazole	NN	I-NP	O	S-drug

Established	Established	NNP	B-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O

Drug	Drug	NNP	B-NP	O	O
Name	Name	NNP	I-NP	O	O

Clinical	Clinical	NNP	B-NP	O	O
Comment	Comment	NNP	I-NP	O	O

When	When	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
naive	naive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atazanavir	atazanavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
SUSTIVA	SUSTIVA	NN	I-NP	O	S-brand
600	600	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
all	all	DT	B-ADVP	O	O
once	once	RB	I-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Dosing	Dose	VBG	B-VP	O	O
recommendations	recommendation	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
atazanavir	atazanavir	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
experienced	experience	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Established	Established	NNP	B-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
(	(	(	O	O	O
continued	continue	VBN	B-VP	O	O
)	)	)	O	O	O

Drug	Drug	NNP	B-NP	O	O
Name	Name	NNP	I-NP	O	O

Clinical	Clinical	NNP	B-NP	O	O
Comment	Comment	NNP	I-NP	O	O

clarithromycin	clarithromycin	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
decreased	decrease	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
;	;	:	O	O	O

clinical	clinical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
uninfected	uninfected	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
46	46	CD	B-NP	O	O
%	%	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
rash	rash	NN	B-NP	O	O
while	while	IN	B-SBAR	O	O
receiving	receive	VBG	B-VP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
clarithromycin	clarithromycin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Alternatives	Alternative	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
macrolide	macrolide	NN	I-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
.	.	.	O	O	O

14	14	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
OH	OH	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

The	The	DT	B-NP	O	O
optimal	optimal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Increasing	Increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
compensate	compensate	VB	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-ME-1
metabolism	metabolism	NN	I-NP	O	O
due	due	IN	B-PP	O	O
to	to	TO	I-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand-ME-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand-ME-2
(	(	(	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmin	Cmin	NN	I-NP	B-protein	O
were	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
average	average	NN	B-NP	O	O
by	by	IN	B-PP	O	O
33	33	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
46	46	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
39	39	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
57	57	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
when	when	WRB	B-ADVP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
(	(	(	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Lopinavir	Lopinavir	NN	B-NP	O	S-drug
/	/	SYM	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug

lopinavir	lopinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

A	A	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lopinavir	lopinavir	NN	B-NP	O	S-drug-AD-1
/	/	SYM	B-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug-AD-1
to	to	TO	B-PP	O	O
533	533	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
133	133	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
capsules	capsule	NNS	I-NP	O	O
or	or	CC	O	O	O
6.5	6.5	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
twice	twice	RB	B-VP	O	O
daily	daily	RB	I-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
food	food	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

methadone	methadone	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Coadministration	Coadministration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	O	O	O
infected	infect	VBN	B-VP	O	O
individuals	individual	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
use	use	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methadone	methadone	NN	B-NP	O	S-drug
and	and	CC	O	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
opiate	opiate	NN	B-NP	O	S-group
withdrawal	withdrawal	NN	I-NP	O	O
.	.	.	O	O	O

Methadone	Methadone	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	NN	I-NP	O	O
of	of	IN	B-PP	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-VP	O	O
alleviate	alleviate	VB	I-VP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
methadone	methadone	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
as	as	IN	B-SBAR	O	O
required	require	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
alleviate	alleviate	VB	I-VP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

Ethinyl	Ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug

ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
concentration	concentration	NN	I-NP	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
increased	increase	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
(	(	(	O	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
)	)	)	O	O	O
;	;	:	O	O	O

clinical	clinical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-AD-2
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
fully	fully	RB	I-VP	O	O
characterized	characterize	VBN	I-VP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
reliable	reliable	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
of	of	IN	B-PP	O	O
barrier	barrier	NN	B-NP	O	O
contraception	contraception	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
.	.	.	O	O	O

rifabutin	rifabutin	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Increase	Increase	NN	B-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug
by	by	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Consider	Consider	VB	B-VP	O	O
doubling	double	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
regimens	regimen	NNS	B-NP	O	O
where	where	WRB	B-ADVP	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
or	or	CC	I-NP	O	O
3	3	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
week	week	NN	I-NP	O	O
.	.	.	O	O	O

efavirenz	efavirenz	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Clinical	Clinical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
efavirenz	efavirenz	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

ritonavir	ritonavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Combination	Combination	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
experiences	experience	NNS	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
dizziness	dizziness	NN	B-NP	O	O
,	,	,	O	O	O
nausea	nausea	NN	B-NP	O	O
,	,	,	O	O	O
paresthesia	paresthesia	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
laboratory	laboratory	NN	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
(	(	(	O	O	O
elevated	elevate	VBN	B-NP	O	O
liver	liver	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Monitoring	Monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
liver	liver	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

efavirenz	efavirenz	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

saquinavir	saquinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Should	Should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
sole	sole	JJ	B-NP	O	O
protease	protease	NN	I-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
.	.	.	O	O	O

sertraline	sertraline	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Increases	Increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
guided	guide	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Potentially	Potentially	RB	I-NP	O	O
Clinically	Clinically	RB	I-NP	O	O
Significant	Significant	JJ	I-NP	O	O
Drug	Drug	NN	I-NP	O	O
or	or	CC	O	O	O
Herbal	Herbal	JJ	B-NP	O	O
Product	Product	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
With	With	IN	B-PP	O	O
SUSTIVAb	SUSTIVAb	NN	B-NP	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
:	:	:	O	O	O
Warfarin	Warfarin	NN	B-NP	O	S-drug

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
effects	effect	NNS	I-NP	O	O
potentially	potentially	RB	B-VP	O	O
increased	increase	VBN	I-VP	O	O
or	or	CC	O	O	O
decreased	decrease	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
.	.	.	O	O	O

Anticonvulsants	Anticonvulsant	NNS	B-NP	O	S-group
:	:	:	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug
Phenobarbital	Phenobarbital	NN	I-NP	O	S-drug
Carbamazepine	Carbamazepine	NN	I-NP	O	S-drug

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
anticonvulsant	anticonvulsant	NN	B-NP	O	S-group-ME-1
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
;	;	:	O	O	O

periodic	periodic	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	S-group
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Antifungals	Antifungal	NNS	B-NP	O	S-group
:	:	:	O	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug
Ketoconazole	Ketoconazole	NN	I-NP	O	S-drug

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
imidazole	imidazole	NN	I-NP	O	S-group
and	and	CC	I-NP	O	O
triazole	triazole	NN	I-NP	O	B-group
antifungals	antifungal	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand-ME-1
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Anti	Anti	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	B-protein	I-group
HIV	HIV	NN	I-NP	I-protein	I-group
protease	protease	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Saquinavir	Saquinavir	NN	B-NP	O	S-drug
/	/	SYM	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
combination	combination	NN	I-NP	O	O

No	No	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

SUSTIVAhas	SUSTIVAha	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-group
-	-	HYPH	I-NP	B-protein	I-group
nucleoside	nucleoside	NN	I-NP	I-protein	I-group
reverse	reverse	JJ	I-NP	I-protein	I-group
transcriptase	transcriptase	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group

No	No	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NNRTIs	NNRTI	NNS	I-NP	O	S-group
.	.	.	O	O	O

St.	St.	NNP	B-NP	O	O
John	John	NNP	I-NP	O	O
s	s	NN	I-NP	O	O
wort	wort	NN	I-NP	O	O
(	(	(	O	O	O
Hypericum	Hypericum	NNP	B-NP	O	O
perforatum	perforatum	NNP	I-NP	O	O
)	)	)	O	O	O

Expected	Expect	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
substantially	substantially	RB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
;	;	:	O	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
.	.	.	O	O	O

a	a	DT	B-NP	O	O
See	See	NNP	I-NP	O	O
Tables	Tables	NNP	I-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
2	2	CD	I-NP	O	O
.	.	.	O	O	O

b	b	VB	B-VP	O	O
This	This	DT	B-NP	O	O
table	table	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
all	all	RB	B-ADJP	O	O
-	-	HYPH	I-ADJP	O	O
inclusive	inclusive	JJ	I-ADJP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
Based	Base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
(	(	(	O	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
aluminum	aluminum	NN	B-NP	O	B-group
/	/	SYM	I-NP	O	I-group
magnesium	magnesium	NN	I-NP	O	I-group
hydroxide	hydroxide	NN	I-NP	O	I-group
antacids	antacid	NNS	I-NP	O	E-group
,	,	,	O	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
cetirizine	cetirizine	NN	B-NP	O	S-drug
,	,	,	O	O	O
famotidine	famotidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
,	,	,	O	O	O
lorazepam	lorazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Specific	Specific	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
SUSTIVA	SUSTIVA	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
NRTIs	NRTI	NNS	I-NP	O	S-group
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Clinically	Clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
since	since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
NRTIs	NRTI	NNS	I-NP	B-DNA	S-group
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
a	a	DT	B-NP	O	O
different	different	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
than	than	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
and	and	CC	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
compete	compete	VB	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
and	and	CC	O	O	O
elimination	elimination	NN	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
EMTRIVA	EMTRIVA	NN	B-NP	B-protein	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
stavudine	stavudine	NN	B-NP	O	S-drug
,	,	,	O	O	O
famciclovir	famciclovir	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
tenofovir	tenofovir	NN	B-NP	O	B-drug
disoproxil	disoproxil	NN	I-NP	O	I-drug
fumarate	fumarate	NN	I-NP	O	E-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O

Hypotension	Hypotension	NN	B-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
Diuretic	Diuretic	JJ	B-NP	O	O
Therapy	Therapy	NN	I-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
especially	especially	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
diuretic	diuretic	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
recently	recently	RB	I-VP	O	O
instituted	institute	VBN	I-VP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
experience	experience	VB	I-VP	O	O
an	an	DT	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
enalapril	enalapril	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
enalaprilat	enalaprilat	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotensive	hypotensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
enalapril	enalapril	NN	B-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
enalaprilat	enalaprilat	NN	I-NP	O	S-drug-EF-1
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
either	either	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-drug-EF-2
or	or	CC	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
salt	salt	NN	I-NP	O	O
intake	intake	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
enalapril	enalapril	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
enalaprilat	enalaprilat	NN	I-NP	O	S-drug
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
continue	continue	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
,	,	,	O	O	O
provide	provide	VBP	B-VP	O	O
close	close	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
supervision	supervision	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
two	two	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
until	until	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
an	an	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
hour..	hour..	NN	I-NP	O	O

Agents	Agent	NNS	B-NP	O	O
Causing	Cause	VBG	B-VP	O	O
Renin	Renin	NN	B-NP	B-protein	O
Release	Release	NN	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enalapril	enalapril	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
enalapril	enalapril	NN	I-NP	O	S-drug-EF-1
IV	IV	CD	I-NP	O	O
is	be	VBZ	B-VP	O	O
augmented	augment	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
that	that	WDT	B-NP	O	O
cause	cause	VBP	B-VP	O	O
renin	renin	NN	B-NP	B-protein	O
release	release	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-group
-	-	HYPH	I-NP	B-protein	I-group
steroidal	steroidal	JJ	I-NP	I-protein	I-group
Anti	Anti	AFX	I-NP	I-protein	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
compromised	compromise	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
being	be	VBG	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-EF-1
anti	anti	AFX	I-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enalapril	enalapril	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
usually	usually	RB	B-ADVP	O	O
reversible	reversible	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
sulindac	sulindac	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	B-cell_type	O
patients	patient	NNS	I-NP	I-cell_type	O
receiving	receive	VBG	B-VP	I-cell_type	O
VASOTEC	VASOTEC	NNP	B-NP	I-cell_type	S-brand
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
blunting	blunting	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VASOTEC	VASOTEC	NNP	B-NP	O	S-brand
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
reports	report	NNS	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
consideration	consideration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Cardiovascular	Cardiovascular	NNP	I-NP	O	O
Agents	Agent	NNPS	I-NP	O	O
:	:	:	O	O	O
Enalapril	Enalapril	NNP	B-NP	O	S-drug
and	and	CC	O	O	O
enalapril	enalapril	NN	B-NP	O	S-drug
IV	IV	CD	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
beta	beta	NN	B-NP	O	B-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug
,	,	,	O	O	O
nitrates	nitrate	NNS	B-NP	O	S-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blocking	block	VBG	B-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
hydralazine	hydralazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
prazosin	prazosin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Enalapril	Enalapril	NNP	B-NP	O	S-drug
IV	IV	NNP	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Agents	Agent	NNPS	B-NP	O	O
Increasing	Increasing	NNP	I-NP	O	O
Serum	Serum	NNP	I-NP	O	O
Potassium	Potassium	NNP	I-NP	O	O
:	:	:	O	O	O
Enalapril	Enalapril	NNP	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
enalapril	enalapril	VB	B-VP	O	S-drug-EF-1
IV	IV	CD	B-NP	O	O
attenuate	attenuate	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
loss	loss	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
type	type	NN	I-NP	O	I-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Potassium	Potassium	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
amiloride	amiloride	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
potassium	potassium	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
salt	salt	NN	B-NP	O	O
substitutes	substitute	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
demonstrated	demonstrate	VBN	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
frequent	frequent	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
.	.	.	O	O	O

Potassium	Potassium	NN	B-NP	O	O
sparing	spar	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
generally	generally	RB	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
enalapril	enalapril	NN	B-NP	O	S-drug
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Lithium	Lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
cause	cause	VBP	B-VP	O	O
elimination	elimination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
frequently	frequently	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
enalapril	enalapril	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nondepolarizing	nondepolarize	VBG	B-NP	O	O
relaxants	relaxant	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
augmented	augment	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
Enflurane	Enflurane	NN	B-NP	O	S-drug
.	.	.	O	O	O

Less	Less	RBR	B-ADVP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
amounts	amount	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
amounts	amount	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nondepolarizing	nondepolarizing	JJ	B-NP	O	O
relaxants	relaxant	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
for	for	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
from	from	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
longer	longer	RBR	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Enflurane	Enflurane	NN	B-NP	O	S-drug
than	than	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
halothane	halothane	NN	B-NP	O	S-drug
or	or	CC	O	O	O
nitrous	nitrous	JJ	B-NP	O	B-drug
oxide	oxide	NN	I-NP	O	E-drug
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
balanced	balanced	JJ	I-NP	O	O
technique	technique	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

CYP450	CYP450	NN	B-NP	B-protein	O
Metabolized	Metabolize	VBD	B-VP	O	O
Drugs	Drugs	NNP	B-NP	O	O
Results	Result	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
enfuvirtide	enfuvirtide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
significant	significant	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
concomitantly	concomitantly	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP450	CYP450	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Antiretroviral	Antiretroviral	JJ	B-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antiretroviral	antiretroviral	JJ	I-NP	O	B-group
medications	medication	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
identified	identify	VBN	I-VP	O	O
that	that	WDT	B-NP	O	O
would	would	MD	B-VP	O	O
warrant	warrant	VB	I-VP	O	O
alteration	alteration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
enfuvirtide	enfuvirtide	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
antiretroviral	antiretroviral	JJ	I-NP	O	B-group
medication	medication	NN	I-NP	O	E-group
.	.	.	O	O	O

Bismuth	Bismuth	NNP	B-NP	O	S-drug
:	:	:	O	O	O
Bismuth	Bismuth	NNP	B-NP	O	B-drug-ME-1
subsalicylate	subsalicylate	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug-ME-2
or	or	CC	O	O	O
60	60	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug
bioavailability	bioavailability	NN	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
bismuth	bismuth	JJ	B-NP	O	B-drug-AD-2
subsalicylate	subsalicylate	NN	I-NP	O	E-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Enoxacin	Enoxacin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylxanthines	methylxanthine	NNS	B-NP	O	S-group-ME-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug-ME-1
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
thereby	thereby	RB	B-VP	O	O
decreasing	decrease	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
five	five	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Trough	Trough	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
enoxacin	enoxacin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
higher	high	JJR	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
enoxacin	enoxacin	NN	I-NP	O	S-drug-ME-2
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
consuming	consume	VBG	B-VP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-EF-1
while	while	IN	B-SBAR	O	O
on	on	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Elevated	Elevate	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
members	member	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	B-group-ME-2
class	class	NN	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Enoxacin	Enoxacin	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
raise	raise	VB	I-VP	O	O
serum	serum	NN	B-NP	B-protein	O
digoxin	digoxin	NN	I-NP	I-protein	S-drug-ME-2
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
signs	sign	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
suggestive	suggestive	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
occur	occur	VBP	B-VP	O	O
when	when	WRB	B-ADVP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-EF-2
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
advised	advise	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
obtain	obtain	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
adjust	adjust	JJ	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
doses	dose	VBZ	B-VP	O	O
appropriately	appropriately	RB	B-ADVP	O	O
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-group
-	-	HYPH	I-NP	B-DNA	I-group
steroidal	steroidal	JJ	I-NP	I-DNA	I-group
anti	anti	AFX	I-NP	I-DNA	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
Seizures	Seizure	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drug	drug	NN	I-NP	O	E-group
fenbufen	fenbufen	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Animal	Animal	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
suggest	suggest	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Fenbufen	Fenbufen	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
approved	approve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
States	States	NNP	I-NP	O	O
at	at	IN	B-PP	O	O
this	this	DT	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Sucralfate	Sucralfate	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
antacids	antacid	NNS	I-NP	O	S-group
:	:	:	O	O	O
Quinolones	Quinolone	NNS	B-NP	O	S-group
form	form	VBP	B-VP	O	O
chelates	chelate	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
metal	metal	NN	B-NP	O	O
cations	cation	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group
with	with	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
calcium	calcium	NN	B-NP	O	S-drug
,	,	,	O	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
aluminum	aluminum	NN	B-NP	O	S-drug
;	;	:	O	O	O

with	with	IN	B-PP	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug
;	;	:	O	O	O

with	with	IN	B-PP	O	O
divalent	divalent	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
trivalent	trivalent	JJ	I-NP	O	O
cations	cation	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
iron	iron	NN	B-NP	O	S-drug
;	;	:	O	O	O

or	or	CC	O	O	O
with	with	IN	B-PP	O	O
multivitamins	multivitamin	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
zinc	zinc	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
substantially	substantially	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
and	and	CC	O	O	O
result	result	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
insufficient	insufficient	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
quinolone	quinolone	NN	I-NP	O	S-group-ME-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
aluminum	aluminum	NN	B-NP	O	B-drug-ME-1
hydroxide	hydroxide	NN	I-NP	O	E-drug-ME-1
and	and	CC	O	O	O
magnesium	magnesium	NN	B-NP	O	B-drug-ME-1
hydroxide	hydroxide	NN	I-NP	O	E-drug-ME-1
reduce	reduce	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	I-PP	O	O
for	for	IN	I-PP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Enoxacin	Enoxacin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylxanthines	methylxanthine	NNS	B-NP	O	S-group-ME-2
.	.	.	O	O	O

Enoxacin	Enoxacin	NN	B-NP	O	S-drug-ME-1
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
42	42	CD	I-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
74	74	CD	I-NP	O	O
%	%	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
subsequent	subsequent	JJ	I-NP	O	O
260	260	CD	I-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
350	350	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
when	when	WRB	B-ADVP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
enoxacin	enoxacin	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Quinolones	Quinolone	NNS	B-NP	O	S-group-ME-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
decrease	decrease	VB	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
R	R	NN	B-NP	B-protein	B-drug-ME-2
-	-	HYPH	B-NP	I-protein	I-drug-ME-2
warfarin	warfarin	NN	I-NP	I-protein	E-drug-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
less	less	RBR	I-NP	O	O
active	active	JJ	I-NP	O	O
isomer	isomer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	B-protein	O
warfarin	warfarin	NN	I-NP	I-protein	S-drug
.	.	.	O	O	O

Enoxacin	Enoxacin	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
S	S	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
isomer	isomer	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
clotting	clotting	NN	B-NP	O	O
time	time	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
test	test	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-1
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
enoxacin	enoxacin	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Unless	Unless	IN	B-SBAR	O	O
really	really	RB	B-ADVP	O	O
needed	need	VBN	B-VP	O	O
,	,	,	O	O	O
agents	agent	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hemorrhage	hemorrhage	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Lovenox	Lovenox	NN	B-NP	O	S-brand
Injection	Injection	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
medications	medication	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
:	:	:	O	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
,	,	,	O	O	O
platelet	platelet	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
including	include	VBG	B-PP	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
sali	sali	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
cylates	cylate	NNS	B-NP	O	O
,	,	,	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
ketorolac	ketorolac	NN	B-NP	O	B-drug
tromethamine	tromethamine	NN	I-NP	O	E-drug
)	)	)	O	O	O
,	,	,	O	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
sulfinpyrazone	sulfinpyrazone	NN	B-NP	O	S-drug
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
,	,	,	O	O	O
conduct	conduct	NN	B-NP	O	O
close	close	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	B-protein	O
CYP	CYP	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
entacapone	entacapone	NN	B-NP	O	S-drug
inhibited	inhibit	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
1A2	1A2	NN	I-NP	B-protein	O
,	,	,	O	O	O
2A6	2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
2D6	2D6	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
2E1	2E1	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
3A	3A	NN	I-NP	O	O
only	only	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
very	very	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
IC50	IC50	NN	B-NP	O	O
from	from	IN	B-PP	O	O
200	200	CD	B-NP	O	O
to	to	TO	B-PP	O	O
over	over	IN	B-NP	O	O
1000	1000	CD	I-NP	O	O
uM	uM	NN	I-NP	O	O
;	;	:	O	O	O

an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
achieves	achieve	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
5	5	CD	I-NP	O	O
uM	uM	NN	I-NP	O	O
in	in	IN	B-PP	O	O
people	people	NNS	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
would	would	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Protein	Protein	NN	B-NP	O	O
Binding	Binding	NN	I-NP	O	O
:	:	:	O	O	O
Entacapone	Entacapone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-ADVP	O	O
protein	protein	NN	B-NP	O	O
bound	bind	VBD	B-VP	O	O
(	(	(	O	O	O
98	98	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
displacement	displacement	NN	I-NP	O	O
between	between	IN	B-PP	O	O
entacapone	entacapone	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
highly	highly	RB	I-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
salicylic	salicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Catechol	Catechol	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
O	O	NN	I-NP	I-protein	O
-	-	HYPH	O	O	O
methyltransferase	methyltransferase	NN	B-NP	O	O
(	(	(	O	O	O
COMT	COMT	NN	B-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
Hormone	Hormone	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
:	:	:	O	O	O
Levodopa	Levodopa	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
depress	depress	VB	I-VP	O	O
prolactin	prolactin	NN	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
growth	growth	NN	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
entacapone	entacapone	NN	B-NP	O	S-drug
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B-protein	S-drug
/	/	SYM	I-NP	I-protein	O
dopa	dopa	NN	I-NP	I-protein	B-group
decarboxylase	decarboxylase	NN	I-NP	I-protein	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
MAO	MAO	NN	I-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
B	B	NN	I-NP	O	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
selegiline	selegiline	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
entacapone	entacapone	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
levodopa	levodopa	NN	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
dopa	dopa	NN	I-NP	O	B-group
decarboxylase	decarboxylase	NN	I-NP	O	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
29	29	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

More	More	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
600	600	CD	I-NP	O	O
Parkinsons	Parkinson	NNPS	I-NP	O	O
disease	disease	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
selegiline	selegiline	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
entacapone	entacapone	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
levodopa	levodopa	NN	I-NP	B-protein	S-drug
/	/	SYM	B-NP	I-protein	O
dopa	dopa	NN	I-NP	I-protein	B-group
decarboxylase	decarboxylase	NN	I-NP	I-protein	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
most	most	JJS	B-NP	O	O
entacapone	entacapone	NN	I-NP	O	S-drug
excretion	excretion	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bile	bile	NN	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
drugs	drug	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
biliary	biliary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
,	,	,	O	O	O
glucuronidation	glucuronidation	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
intestinal	intestinal	JJ	B-NP	B-protein	O
beta	beta	SYM	I-NP	I-protein	O
-	-	HYPH	I-NP	I-protein	O
glucuronidase	glucuronidase	NN	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
entacapone	entacapone	NN	B-NP	O	S-drug
.	.	.	O	O	O

These	These	DT	B-NP	O	O
include	include	VBP	B-VP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
,	,	,	O	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
rifamipicin	rifamipicin	NN	B-NP	O	O
,	,	,	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
chloramphenicol	chloramphenicol	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
imipramine	imipramine	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
entacapone	entacapone	NN	B-NP	O	S-drug
without	without	IN	B-PP	O	O
coadministered	coadministere	VBN	B-NP	O	O
levodopa	levodopa	NN	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
dopa	dopa	NN	I-NP	B-protein	B-group
-	-	HYPH	B-NP	I-protein	I-group
decarboxylase	decarboxylase	NN	I-NP	I-protein	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
entecavir	entecavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
BARACLUDE	BARACLUDE	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
reduce	reduce	VBP	B-VP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
or	or	CC	I-NP	O	O
compete	compete	NN	I-NP	O	O
for	for	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
entecavir	entecavir	NN	B-NP	O	S-drug
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
coadministered	coadministere	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
entecavir	entecavir	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
,	,	,	O	O	O
adefovir	adefovir	NN	B-NP	O	B-drug
dipivoxil	dipivoxil	NN	I-NP	O	E-drug
,	,	,	O	O	O
or	or	CC	O	O	O
tenofovir	tenofovir	NN	B-NP	O	B-drug
disoproxil	disoproxil	NN	I-NP	O	I-drug
fumarate	fumarate	NN	I-NP	O	E-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
BARACLUDE	BARACLUDE	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
renally	renally	RB	I-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
or	or	CC	O	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
BARACLUDE	BARACLUDE	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

None	None	NN	B-NP	O	O
Reported	Report	VBD	B-VP	O	O

Epinephrine	Epinephrine	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hyperthyroidism	hyperthyroidism	NN	B-NP	O	O
,	,	,	O	O	O
hypertension	hypertension	NN	B-NP	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
vasopressors	vasopressor	NNS	I-NP	O	S-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group-AD-2
oxidase	oxidase	NN	I-NP	I-protein	I-group-AD-2
(	(	(	O	O	I-group-AD-2
MAO	MAO	NN	B-NP	O	I-group-AD-2
)	)	)	O	O	I-group-AD-2
inhibitors	inhibitor	NNS	B-NP	O	E-group-AD-2
.	.	.	O	O	O

Epinephrine	Epinephrine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
sympathomimetic	sympathomimetic	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
possible	possible	JJ	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Combined	Combine	VBN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
serious	serious	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
alternately	alternately	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
preceding	precede	VBG	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
such	such	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
subsided	subside	VBN	I-VP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
cyclopropane	cyclopropane	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
halogenated	halogenate	VBN	B-NP	O	B-group-EF-2
hydrocarbon	hydrocarbon	NN	I-NP	O	I-group-EF-2
general	general	JJ	I-NP	O	I-group-EF-2
anesthetics	anesthetic	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug-EF-2
which	which	WDT	B-NP	O	O
sensitize	sensitize	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmia..	arrhythmia..	NN	I-NP	O	O

When	When	WRB	B-ADVP	O	O
encountered	encounter	VBN	B-VP	O	O
,	,	,	O	O	O
such	such	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
respond	respond	VB	I-VP	O	O
to	to	TO	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
drug	drug	NN	I-NP	O	E-group
.	.	.	O	O	O

Epinephrine	Epinephrine	NN	B-NP	O	S-drug-AD-1
also	also	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
digitalis	digitalis	NN	B-NP	O	S-group-AD-2
,	,	,	O	O	O
glycosides	glycoside	NNS	B-NP	O	S-group-AD-2
)	)	)	O	O	O
that	that	WDT	B-NP	O	O
sensitize	sensitize	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

Diuretic	Diuretic	JJ	B-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
vascular	vascular	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
pressor	pressor	NN	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Epinephrine	Epinephrine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neuron	neuron	NN	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-EF-2
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
and	and	CC	O	O	O
requiring	require	VBG	B-VP	O	O
increased	increase	VBN	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
.	.	.	O	O	O

ELLENCE	ELLENCE	NN	B-NP	O	S-brand
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
show	show	VB	I-VP	O	O
on	on	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
additive	additive	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-NP	O	O
hematologic	hematologic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ELLENCE	ELLENCE	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cardioactive	cardioactive	JJ	I-NP	O	O
compounds	compound	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
heart	heart	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group-AD-2
channel	channel	NN	I-NP	O	I-group-AD-2
blockers	blocker	NNS	I-NP	O	E-group-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
requires	require	VBZ	B-VP	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
throughout	throughout	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
few	few	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
radiation	radiation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
epirubicin	epirubicin	NN	I-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
adjuvant	adjuvant	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epirubicin	epirubicin	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
CEF	CEF	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
120	120	CD	B-NP	O	O
or	or	CC	O	O	O
FEC	FEC	NNP	B-NP	O	O
-	-	HYPH	O	O	O
100	100	CD	B-NP	O	O
chemotherapies	chemotherapy	NNS	I-NP	O	O
,	,	,	O	O	O
breast	breast	NN	B-NP	O	O
irradiation	irradiation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
delayed	delay	VBN	I-VP	O	O
until	until	IN	B-PP	O	O
after	after	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
completed	complete	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
practice	practice	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
no	no	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
breast	breast	NN	I-NP	O	O
cancer	cancer	NN	I-NP	O	O
recurrence	recurrence	NN	I-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
published	publish	VBN	B-NP	O	O
accounts	account	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
epirubicin	epirubicin	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
based	base	VBN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
radiation	radiation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
but	but	CC	O	O	O
had	have	VBD	B-VP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
interrupted	interrupt	VBD	B-VP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
potential	potential	JJ	B-NP	O	O
overlapping	overlap	VBG	I-NP	O	O
toxicities	toxicity	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
epirubicin	epirubicin	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
radiotherapy	radiotherapy	NN	B-NP	O	O
may	may	MD	B-VP	O	O
sensitize	sensitize	VB	I-VP	O	O
tissues	tissue	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
irradiation	irradiation	NN	B-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ELLENCE	ELLENCE	NN	B-NP	O	S-brand
after	after	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
radiation	radiation	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
recall	recall	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
site	site	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
irradiation	irradiation	NN	I-NP	O	O
.	.	.	O	O	O

Epirubicin	Epirubicin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
extensively	extensively	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

Changes	Change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
epirubicin	epirubicin	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
,	,	,	O	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
toxicity	toxicity	NN	B-NP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epirubicin	epirubicin	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug-AD-1
treatment	treatment	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
stopped	stop	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ELLENCE	ELLENCE	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
ELLENCE	ELLENCE	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
Eplerenone	Eplerenone	NN	I-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
predominantly	predominantly	RB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
evaluating	evaluate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INSPRA	INSPRA	NN	B-NP	O	S-brand-ME-1
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
pathway	pathway	NN	I-NP	O	O
,	,	,	O	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
1.7	1.7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
of	of	IN	B-PP	O	O
eplerenone	eplerenone	NN	B-NP	O	S-drug
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
5.4	5.4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
of	of	IN	B-PP	O	O
eplerenone	eplerenone	NN	B-NP	O	S-drug
.	.	.	O	O	O

INSPRA	INSPRA	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
described	describe	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
strong	strong	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
labeling	labeling	NN	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
eplerenone	eplerenone	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-2
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-ME-2
240	240	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
,	,	,	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug-ME-2
1200	1200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
TID	TID	NN	I-NP	O	O
,	,	,	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-2
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
of	of	IN	B-PP	O	O
eplerenone	eplerenone	NN	B-NP	O	S-drug
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
1.4	1.4	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
1.6	1.6	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
from	from	IN	B-PP	O	O
2.0	2.0	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
2.9	2.9	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

ACE	ACE	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
and	and	CC	O	O	O
Angiotensin	Angiotensin	NN	B-NP	O	B-group
II	II	CD	I-NP	O	I-group
Receptor	Receptor	NN	I-NP	O	I-group
Antagonists	Antagonist	NNS	I-NP	O	E-group
(	(	(	O	O	O
Congestive	Congestive	JJ	B-NP	O	O
Heart	Heart	NNP	I-NP	O	O
Failure	Failure	NNP	I-NP	O	O
Post	Post	NNP	I-NP	O	O
-	-	HYPH	B-NP	O	O
Myocardial	Myocardial	NNP	I-NP	O	O
Infarction	Infarction	NN	I-NP	O	O
)	)	)	O	O	O
-	-	:	O	O	O
In	In	IN	B-PP	O	O
EPHESUS	EPHESUS	NNP	B-NP	O	O
,	,	,	O	O	O
3020	3020	CD	B-NP	O	O
(	(	(	O	O	O
91	91	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
INSPRA	INSPRA	NN	B-NP	O	S-brand
25	25	CD	I-NP	O	O
to	to	TO	I-NP	O	O
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
received	receive	VBD	B-VP	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
or	or	CC	O	O	O
angiotensin	angiotensin	NN	B-NP	O	B-group
II	II	CD	I-NP	O	I-group
receptor	receptor	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
(	(	(	O	O	O
ACEI	ACEI	NN	B-NP	O	S-group
/	/	SYM	O	O	O
ARB	ARB	NN	B-NP	B-protein	S-group
)	)	)	O	O	O
.	.	.	O	O	O

Rates	Rate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
maximum	maximum	JJ	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
5.5	5.5	CD	B-NP	O	O
mEq	mEq	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
regardless	regardless	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACEI	ACEI	NN	B-NP	B-protein	S-group
/	/	SYM	B-NP	O	O
ARB	ARB	NN	I-NP	B-protein	S-group
.	.	.	O	O	O

ACE	ACE	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
and	and	CC	O	O	O
Angiotensin	Angiotensin	NN	B-NP	O	B-group
II	II	CD	I-NP	O	I-group
Receptor	Receptor	NN	I-NP	O	I-group
Antagonists	Antagonist	NNS	I-NP	O	E-group
(	(	(	O	O	O
Hypertension	Hypertension	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	O	O	O
In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INSPRA	INSPRA	NN	B-NP	O	S-brand-EF-1
50	50	CD	I-NP	O	O
to	to	TO	I-NP	O	O
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
to	to	TO	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
angiotensin	angiotensin	NN	B-NP	O	B-group-EF-2
II	II	CD	I-NP	O	I-group-EF-2
receptor	receptor	NN	I-NP	O	I-group-EF-2
antagonists	antagonist	NNS	I-NP	O	E-group-EF-2
increased	increase	VBD	B-VP	O	O
mean	mean	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
slightly	slightly	RB	B-ADVP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
0.09	0.09	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
0.13	0.13	CD	I-NP	O	O
mEq	mEq	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diabetics	diabetic	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
microalbuminuria	microalbuminuria	NN	B-NP	O	O
INSPRA	INSPRA	NN	I-NP	O	S-brand-EF-1
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ACE	ACE	NN	I-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
enalapril	enalapril	NN	I-NP	O	S-drug-EF-2
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	O
(	(	(	O	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
5.5	5.5	CD	B-NP	O	O
mEq	mEq	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
on	on	IN	B-PP	O	O
enalapril	enalapril	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
A	A	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
eplerenone	eplerenone	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
frequently	frequently	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
INSPRA	INSPRA	NN	B-NP	B-protein	S-brand-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Nonsteroidal	Nonsteroidal	JJ	B-NP	O	B-group
Anti	Anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
Inflammatory	Inflammatory	JJ	I-NP	O	I-group
Drugs	Drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
A	A	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
eplerenone	eplerenone	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
NSAID	NSAID	NN	I-NP	O	S-group
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
potassium	potassium	NN	I-NP	O	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
sparing	spar	VBG	B-VP	O	I-group-EF-1
antihypertensives	antihypertensive	NNS	B-NP	O	E-group-EF-1
with	with	IN	B-PP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
result	result	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hyperkalemia	hyperkalemia	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
INSPRA	INSPRA	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-AD-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PROCRIT	PROCRIT	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
FLOLAN	FLOLAN	NN	B-NP	O	S-brand-EF-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
vasodilators	vasodilator	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
other	other	JJ	B-NP	O	O
antiplatelet	antiplatelet	JJ	I-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
or	or	CC	I-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-1
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
FLOLAN	FLOLAN	NN	B-NP	O	S-brand-EF-2
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
infusions	infusion	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
FLOLAN	FLOLAN	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
FLOLAN	FLOLAN	NN	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
vasodilators	vasodilator	NNS	I-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
supplemental	supplemental	JJ	B-NP	O	O
oxygen.In	oxygen.In	NN	I-NP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
substudy	substudy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
congestive	congestive	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
failure	failure	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-ME-1
or	or	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-1
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
FLOLAN	FLOLAN	NN	B-NP	O	S-brand-ME-2
was	be	VBD	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
,	,	,	O	O	O
apparent	apparent	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
23	23	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
30	30	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
13	13	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
returned	return	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
day	day	NN	B-NP	O	O
87	87	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
value	value	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
show	show	VB	I-VP	O	O
elevations	elevation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
FLOLAN	FLOLAN	NN	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
prone	prone	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Eprosartan	Eprosartan	NNP	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
glyburide	glyburide	NN	I-NP	O	S-drug
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
no	no	DT	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
eprosartan	eprosartan	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP450	CYP450	NN	B-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
fluconazole	fluconazole	NN	I-NP	O	S-drug
,	,	,	O	O	O
potent	potent	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
2C9	2C9	NN	I-NP	B-protein	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
eprosartan	eprosartan	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Ranitidine	Ranitidine	NN	B-NP	O	S-drug
also	also	RB	B-ADVP	O	O
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
eprosartan	eprosartan	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Eprosartan	Eprosartan	NN	B-NP	O	S-drug
(	(	(	O	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O
or	or	CC	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
q.d	q.d	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
doses	dose	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
safely	safely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group
diuretic	diuretic	JJ	I-NP	O	E-group
(	(	(	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Eprosartan	Eprosartan	NN	B-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
safely	safely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
sustained	sustained	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
release	release	NN	I-NP	O	O
calcium	calcium	NN	I-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
(	(	(	O	O	O
sustained	sustain	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
release	release	NN	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug
)	)	)	O	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Enoxaparin	Enoxaparin	NN	B-NP	O	S-drug
dosed	dose	VBD	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1.0	1.0	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
subcutaneous	subcutaneous	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
q12h	q12h	NN	I-NP	O	O
for	for	IN	B-PP	O	O
four	four	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
eptifibatide	eptifibatide	NN	B-NP	O	S-drug
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
adults	adult	NNS	I-NP	O	O
.	.	.	O	O	O

Mineral	Mineral	JJ	B-NP	O	B-drug-ME-1
oil	oil	NN	I-NP	O	E-drug-ME-1
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fat	fat	NN	B-NP	O	B-group-ME-2
-	-	HYPH	B-NP	O	I-group-ME-2
soluble	soluble	JJ	I-NP	O	I-group-ME-2
vitamins	vitamin	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-ME-2
D	D	NN	I-NP	O	I-group-ME-2
preparations	preparation	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-1
diuretics	diuretic	NNS	I-NP	O	E-group-EF-1
to	to	TO	B-PP	O	O
hypoparathyroid	hypoparathyroid	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
concurrently	concurrently	RB	I-VP	O	O
being	be	VBG	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ergocalciferol	ergocalciferol	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
reported	report	VBD	B-VP	O	O
interactions	interaction	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ERGOMAR	ERGOMAR	NN	B-NP	B-protein	S-brand-ME-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
triacetyloleandomycin	triacetyloleandomycin	NN	B-NP	O	S-drug-ME-M
which	which	WDT	B-NP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ERGOMAR	ERGOMAR	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
vasoconstrictor	vasoconstrictor	NN	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
can	can	MD	B-VP	O	O
combine	combine	VB	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
dangerous	dangerous	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
erlotinib	erlotinib	NN	B-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
by	by	IN	B-PP	O	O
2	2	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
3	3	CD	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
or	or	CC	I-VP	O	O
taking	take	VBG	I-VP	O	O
TARCEVA	TARCEVA	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
strong	strong	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	B-VP	O	O
limited	limit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
,	,	,	O	O	O
atazanavir	atazanavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
telithromycin	telithromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
TAO	TAO	NN	B-NP	B-protein	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
voriconazole	voriconazole	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Pre	Pre	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducer	inducer	NN	I-NP	O	O
rifampicin	rifampicin	NN	I-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
erlotinib	erlotinib	NN	B-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
2	2	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
3	3	CD	I-NP	O	O
.	.	.	O	O	O

Alternate	Alternate	JJ	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
lacking	lack	VBG	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inducing	induce	VBG	B-VP	O	O
activity	activity	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
alternative	alternative	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unavailable	unavailable	JJ	B-ADJP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
TARCEVA	TARCEVA	NN	I-NP	O	S-brand
dose	dose	NN	I-NP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
NSCLC	NSCLC	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
greater	great	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
considered	consider	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
pancreatic	pancreatic	JJ	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
TARCEVA	TARCEVA	NN	I-NP	O	S-brand-AD-1
dose	dose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
upward	upward	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
will	will	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
upon	upon	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducers	inducer	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
limited	limit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
,	,	,	O	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
rifapentine	rifapentine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
and	and	CC	O	O	O
St.	St.	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
Wort	Wort	NNP	I-NP	O	O
.	.	.	O	O	O

Hepatotoxicity	Hepatotoxicity	NN	B-NP	O	O
Asymptomatic	Asymptomatic	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	B-protein	O
transaminases	transaminase	NNS	I-NP	I-protein	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
TARCEVA	TARCEVA	NN	B-NP	O	S-brand
treated	treat	VBN	B-VP	O	O
patients	patient	NNS	B-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
periodic	periodic	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
testing	testing	NN	I-NP	O	O
(	(	(	O	O	O
transaminases	transaminase	NNS	B-NP	B-protein	O
,	,	,	O	O	O
bilirubin	bilirubin	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
alkaline	alkaline	NN	B-NP	B-protein	O
phosphatase	phosphatase	NN	I-NP	I-protein	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
or	or	CC	I-NP	O	O
interruption	interruption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TARCEVA	TARCEVA	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
function	function	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
severe	severe	JJ	B-ADJP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Hepatic	Hepatic	JJ	B-NP	O	O
Impairment	Impairment	NN	I-NP	O	O
In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
erlotinib	erlotinib	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
cleared	clear	VBN	I-VP	O	O
primarily	primarily	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
erlotinib	erlotinib	NN	B-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
.	.	.	O	O	O

Elevated	Elevated	NNP	B-NP	O	O
International	International	NNP	I-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
and	and	CC	O	O	O
Potential	Potential	NNP	B-NP	O	O
Bleeding	Bleeding	NNP	I-NP	O	O
International	International	NNP	I-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
(	(	(	O	O	O
INR	INR	NN	B-NP	O	O
)	)	)	O	O	O
elevations	elevation	NNS	B-NP	O	O
and	and	CC	O	O	O
infrequent	infrequent	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
events	event	NNS	B-NP	O	O
including	include	VBG	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
bleedings	bleeding	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
some	some	DT	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
coumarin	coumarin	NN	I-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
derivative	derivative	JJ	I-NP	O	I-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
regularly	regularly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
INR	INR	NN	B-NP	B-protein	O

When	When	WRB	B-ADVP	O	O
ertapenem	ertapenem	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
p.o	p.o	NN	I-NP	O	O
.	.	.	O	O	O
every	every	DT	B-NP	O	O
6	6	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
competes	compete	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
and	and	CC	O	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ertapenem	ertapenem	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
ertapenem	ertapenem	NN	I-NP	O	S-drug-ME-1
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-2
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
by	by	IN	B-PP	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
clearances	clearance	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
35	35	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
4.0	4.0	CD	B-NP	O	O
to	to	TO	I-NP	O	O
4.8	4.8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
half	half	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-AD-1
to	to	TO	B-VP	O	O
extend	extend	VB	I-VP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ertapenem	ertapenem	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ertapenem	ertapenem	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
transport	transport	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
vinblastine	vinblastine	NN	I-NP	O	S-drug
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
ertapenem	ertapenem	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
mediated	mediate	VBN	I-NP	O	O
transport	transport	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ertapenem	ertapenem	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
mediated	mediate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
six	six	CD	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
p450	p450	NN	I-NP	I-protein	O
(	(	(	O	I-protein	O
CYP	CYP	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
isoforms	isoform	NNS	B-NP	I-protein	O
:	:	:	O	O	O
1A2	1A2	NN	B-NP	B-protein	O
,	,	,	I-NP	O	O
2C9	2C9	NN	I-NP	B-protein	O
,	,	,	I-NP	O	O
2C19	2C19	NN	I-NP	B-protein	O
,	,	,	I-NP	O	O
2D6	2D6	NN	I-NP	B-cell_line	O
,	,	,	I-NP	O	O
2E1	2E1	NN	I-NP	B-protein	O
and	and	CC	I-NP	O	O
3A4	3A4	NN	I-NP	B-protein	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
or	or	CC	I-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
listed	list	VBN	I-NP	B-protein	O
isoforms	isoform	NNS	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
,	,	,	O	O	O
no	no	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O

Erythromycin	Erythromycin	NN	B-NP	O	S-drug-EF-1
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
potential	potential	JJ	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
case	case	NN	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
elevated	elevate	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-2
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
anticoagulents	anticoagulent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounce	VBN	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
ergotamine	ergotamine	NN	I-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
dihydroergotamine	dihydroergotamine	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
ergot	ergot	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
vasospasm	vasospasm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
dysesthesia	dysesthesia	NN	I-NP	O	O
.	.	.	O	O	O

Erythromycin	Erythromycin	NN	B-NP	O	S-drug-MU-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triazolam	triazolam	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
midazolam	midazolam	NN	I-NP	O	S-drug-ME-2
and	and	CC	O	O	O
thus	thus	RB	B-VP	O	O
may	may	MD	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concurrently	concurrently	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
elevations	elevation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-IN-1
with	with	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
hexobarbital	hexobarbital	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
alfentanil	alfentanil	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
bromocriptine	bromocriptine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
valproate	valproate	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-IN-2
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concurrently	concurrently	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Erythromycin	Erythromycin	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nonsedating	nonsedating	JJ	B-NP	O	O
antihistamines	antihistamine	NNS	I-NP	O	S-group
terfenadine	terfenadine	NN	I-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
astemizole	astemizole	NN	I-NP	O	S-drug-ME-2
when	when	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Rare	Rare	NN	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
electrocardiographic	electrocardiographic	JJ	B-NP	O	O
QT	QT	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
,	,	,	O	O	O
torsades	torsades	FW	B-NP	O	O
de	de	FW	I-NP	O	O
pointes	pointes	FW	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
deaths	death	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
rarely	rarely	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
postmarketing	postmarketing	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
QT	QT	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrythmias	arrythmia	NNS	I-NP	O	O
,	,	,	O	O	O
ventricular	ventricular	JJ	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
,	,	,	O	O	O
ventricular	ventricular	JJ	B-NP	O	O
fibrulation	fibrulation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
torsades	torsade	NNS	B-NP	O	O
de	de	FW	I-NP	O	O
pointes	pointes	FW	I-NP	O	O
,	,	,	O	O	O
most	most	RBS	B-ADVP	O	O
like	like	IN	B-PP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-1
by	by	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Fatalities	Fatality	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
lovastatin	lovastatin	NN	I-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
;	;	:	O	O	O

cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
seriously	seriously	RB	B-NP	O	O
ill	ill	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

CNS	CNS	NN	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
-	-	HYPH	B-VP	O	O
Given	Give	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
taken	take	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-ADJP	O	O
centrally	centrally	RB	B-ADVP	O	O
acting	act	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
-	-	:	O	O	O
Although	Although	IN	B-SBAR	O	O
LEXAPRO	LEXAPRO	NN	B-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
motor	motor	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
psychotropic	psychotropic	JJ	I-NP	O	B-group-AD-1
medications	medication	NNS	I-NP	O	E-group-AD-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-AD-1
by	by	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
LEXAPRO	LEXAPRO	NN	B-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Monoamine	Monoamine	NN	B-NP	O	B-group
Oxidase	Oxidase	NN	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
MAOIs	MAOI	NNS	B-NP	O	S-group
)	)	)	O	O	O

Drugs	Drugs	NNP	B-NP	O	O
That	That	DT	I-NP	O	O
Interfere	Interfere	NNP	I-NP	O	O
With	With	IN	B-PP	O	O
Hemostasis	Hemostasis	NNP	B-NP	O	O
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
,	,	,	O	O	O
Aspirin	Aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
Warfarin	Warfarin	NNP	B-NP	O	S-drug
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Serotonin	Serotonin	NN	B-NP	O	O
release	release	NN	I-NP	O	O
by	by	IN	B-PP	O	O
platelets	platelet	NNS	B-NP	B-cell_type	O
plays	play	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hemostasis	hemostasis	NN	B-NP	O	O
.	.	.	O	O	O

Epidemiological	Epidemiological	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
and	and	CC	O	O	O
cohort	cohort	JJ	B-NP	O	O
design	design	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
psychotropic	psychotropic	JJ	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
that	that	WDT	B-NP	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	O	O
reuptake	reuptake	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
upper	upper	JJ	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
NSAID	NSAID	NN	I-NP	O	S-group-EF-2
or	or	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-EF-2
potentiated	potentiate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
cautioned	caution	VBN	I-VP	O	O
about	about	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
LEXAPRO	LEXAPRO	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
-	-	HYPH	B-ADJP	O	O
In	In	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
racemic	racemic	JJ	I-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug-ME-1
,	,	,	O	O	O
combined	combined	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug-ME-2
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
citalopram	citalopram	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
39	39	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
-	-	HYPH	B-ADJP	O	O
In	In	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
racemic	racemic	JJ	I-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug
,	,	,	O	O	O
combined	combined	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
citalopram	citalopram	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
(	(	(	O	O	O
single	single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
citalopram	citalopram	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
Coadministration	Coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
lithium	lithium	NN	B-NP	O	S-drug
(	(	(	O	O	O
30	30	CD	B-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
citalopram	citalopram	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
appropriate	appropriate	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
accordance	accordance	NN	B-NP	O	O
with	with	IN	B-PP	O	O
standard	standard	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
practice	practice	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
LEXAPRO	LEXAPRO	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Pimozide	Pimozide	NNP	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Celexa	Celexa	NNP	I-NP	O	S-brand
-	-	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
controlled	controlled	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pimozide	pimozide	NN	B-NP	B-protein	S-drug-EF-1
2	2	CD	I-NP	I-protein	O
mg	mg	NN	I-NP	I-protein	O
co	co	AFX	O	I-protein	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug-EF-2
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
given	give	VBN	B-VP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
11	11	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
QTc	QTc	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
10	10	CD	I-NP	O	O
msec	msec	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
pimozide	pimozide	VB	I-VP	O	S-drug
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Racemic	Racemic	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
or	or	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pimozide	pimozide	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Sumatriptan	Sumatriptan	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rare	rare	JJ	B-NP	O	O
postmarketing	postmarketing	JJ	I-NP	O	O
reports	report	NNS	I-NP	O	O
describing	describe	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
weakness	weakness	NN	B-NP	O	O
,	,	,	O	O	O
hyperreflexia	hyperreflexia	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
incoordination	incoordination	NN	B-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	B-group-EF-1
serotonin	serotonin	NN	I-NP	O	I-group-EF-1
reuptake	reuptake	NN	I-NP	O	I-group-EF-1
inhibitor	inhibitor	NN	I-NP	O	E-group-EF-1
(	(	(	O	O	O
SSRI	SSRI	NN	B-NP	B-protein	S-group-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	O	S-group-AD-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
citalopram	citalopram	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
,	,	,	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
-	-	HYPH	B-PP	O	O
Combined	Combine	VBN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
CYP1A2	CYP1A2	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
(	(	(	O	O	O
single	single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
citalopram	citalopram	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
Administration	Administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
racemic	racemic	JJ	I-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug
for	for	IN	B-PP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
.	.	.	O	O	O

Prothrombin	Prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
-	-	HYPH	B-PP	O	O
Combined	Combine	VBN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
(	(	(	O	O	O
titrated	titrate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
35	35	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
trough	trough	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
inducing	induce	VBG	B-VP	O	O
properties	property	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
might	might	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug-ME-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Triazolam	Triazolam	NN	B-NP	O	S-drug
-	-	HYPH	B-PP	O	O
Combined	Combine	VBN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug
(	(	(	O	O	O
titrated	titrate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
28	28	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	O	O
triazolam	triazolam	NN	I-NP	O	S-drug
(	(	(	O	O	O
single	single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
citalopram	citalopram	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
triazolam	triazolam	NN	I-NP	O	S-drug
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
-	-	HYPH	B-PP	O	O
Combined	Combine	VBN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug-ME-1
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
citalopram	citalopram	NN	B-NP	O	S-drug
.	.	.	O	O	O

Ritonavir	Ritonavir	NN	B-NP	O	S-drug
-	-	HYPH	B-PP	O	O
Combined	Combine	VBN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
(	(	(	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
both	both	CC	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
escitalopram	escitalopram	NN	I-NP	O	S-drug
.	.	.	O	O	O

CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	O	O	O
-	-	HYPH	B-NP	O	O
2C19	2C19	NN	I-NP	B-protein	O
Inhibitors	Inhibitors	FW	B-NP	O	O
-	-	HYPH	B-VP	O	O
In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	O	O	O
-	-	HYPH	B-NP	O	O
2C19	2C19	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
(	(	(	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
,	,	,	O	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
appreciably	appreciably	RB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P4502D6	P4502D6	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
In	In	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reveal	reveal	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	B-ADJP	O	O
significantly	significantly	RB	I-ADJP	O	O
different	different	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
and	and	CC	O	O	O
extensive	extensive	JJ	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
citalopram	citalopram	NN	B-NP	O	S-drug
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
coadministration	coadministration	NN	B-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
,	,	,	O	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
limited	limited	JJ	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
modest	modest	JJ	I-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
for	for	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
,	,	,	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
desipramine	desipramine	NN	I-NP	O	S-drug-ME-2
(	(	(	O	O	O
single	single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
100	100	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
of	of	IN	B-PP	O	O
desipramine	desipramine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
.	.	.	O	O	O

Metoprolol	Metoprolol	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
Administration	Administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
LEXAPRO	LEXAPRO	NN	I-NP	O	S-brand-ME-1
for	for	IN	B-PP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
and	and	CC	O	O	O
82	82	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
blocker	blocker	NN	I-NP	O	E-group
metoprolol	metoprolol	NN	I-NP	O	S-drug-ME-2
(	(	(	O	O	O
given	give	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
metoprolol	metoprolol	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
cardioselectivity	cardioselectivity	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
LEXAPRO	LEXAPRO	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
metoprolol	metoprolol	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
or	or	CC	I-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

Electroconvulsive	Electroconvulsive	JJ	B-NP	O	O
Therapy	Therapy	NN	I-NP	O	O
(	(	(	O	O	O
ECT	ECT	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	O	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ECT	ECT	NN	B-NP	O	O
and	and	CC	I-NP	O	O
escitalopram	escitalopram	NN	I-NP	O	S-drug
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
Administration	Administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Racemic	Racemic	NNP	B-NP	O	O
Citalopram	Citalopram	NNP	I-NP	O	S-drug
Citalopram	Citalopram	NNP	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
Since	Since	NNP	I-NP	O	O
escitalopram	escitalopram	NN	I-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
isomer	isomer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	O	O
citalopram	citalopram	NN	I-NP	O	S-drug-AD-2
(	(	(	O	O	O
Celexa	Celexa	NN	B-NP	O	S-brand-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Catecholamine	Catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand
(	(	(	O	O	O
esmolol	esmolol	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
)	)	)	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
catecholamine	catecholamine	NN	I-NP	O	O
depletor	depletor	NN	I-NP	O	O
should	should	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
or	or	CC	O	O	O
marked	marked	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
vertigo	vertigo	NN	B-NP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
postural	postural	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand-ME-1
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
equivocally	equivocally	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
but	but	CC	O	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
BREVIBLOC	BREVIBLOC	NN	I-NP	O	S-brand-ME-2
were	be	VBD	B-VP	O	O
concomitantly	concomitantly	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
some	some	DT	B-NP	O	O
time	time	NN	I-NP	O	O
points	point	NNS	I-NP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
intravenous	intravenous	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
BREVIBLOC	BREVIBLOC	NN	I-NP	O	S-brand
were	be	VBD	B-VP	O	O
concomitantly	concomitantly	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand-ME-1
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
46	46	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
changed	change	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
surgery	surgery	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
by	by	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand-EF-2
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
5	5	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
to	to	TO	O	O	O
8	8	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
importance	importance	NN	I-NP	O	O
,	,	,	O	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
succinylcholine	succinylcholine	NN	I-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
anaphylactic	anaphylactic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allergens	allergen	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
reactive	reactive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
,	,	,	O	O	O
either	either	CC	O	O	O
accidental	accidental	JJ	B-NP	O	O
,	,	,	I-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
or	or	CC	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
unresponsive	unresponsive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
allergic	allergic	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
considering	consider	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug-AD-2
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
depressed	depressed	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Fatal	Fatal	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
arrests	arrest	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
BREVIBLOC	BREVIBLOC	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
supraventricular	supraventricular	JJ	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
vasoconstrictive	vasoconstrictive	JJ	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
inotropic	inotropic	JJ	I-ADJP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
dopamine	dopamine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-AD-2
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
danger	danger	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blocking	block	VBG	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
contractility	contractility	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
systemic	systemic	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
high	high	JJ	B-ADJP	O	O
.	.	.	O	O	O

Esomeprazole	Esomeprazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
extensively	extensively	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
by	by	IN	B-PP	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
esomeprazole	esomeprazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
CYPs	CYP	NNS	B-NP	B-protein	O
1A2	1A2	NN	I-NP	I-protein	O
,	,	,	O	O	O
2A6	2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
2D6	2D6	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
2E1	2E1	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
3A4	3A4	NN	I-NP	B-protein	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
esomeprazole	esomeprazole	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
any	any	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
quinidine	quinidine	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
clarithromycin	clarithromycin	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
amoxicillin	amoxicillin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Post	Post	AFX	O	O	O
-	-	HYPH	O	O	O
marketing	market	VBG	B-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
measures	measure	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
received	receive	VBN	I-VP	O	O
among	among	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
esomeprazole	esomeprazole	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Increases	Increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
and	and	CC	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
and	and	CC	O	O	O
even	even	RB	B-ADVP	O	O
death	death	NN	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
proton	proton	NN	B-NP	O	B-group-EF-1
pump	pump	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
concomitantly	concomitantly	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
and	and	CC	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Esomeprazole	Esomeprazole	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	B-protein	O
esomeprazole	esomeprazole	NN	I-NP	I-protein	S-drug
metabolizing	metabolize	VBG	B-VP	I-protein	O
enzyme	enzyme	NN	B-NP	I-protein	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
esomeprazole	esomeprazole	NN	B-NP	O	S-drug-ME-1
30	30	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP2C19	CYP2C19	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
45	45	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clearance	clearance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
12	12	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
and	and	CC	I-NP	O	O
onwards	onward	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
that	that	DT	B-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
below	below	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
interval	interval	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
thus	thus	RB	O	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
.	.	.	O	O	O

Esomeprazole	Esomeprazole	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
gastric	gastric	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
esomeprazole	esomeprazole	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
where	where	WRB	B-ADVP	O	O
gastric	gastric	JJ	B-NP	O	O
pH	pH	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
determinant	determinant	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
salts	salt	NNS	I-NP	O	O
and	and	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
seem	seem	VB	I-VP	O	O
to	to	TO	I-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
esomeprazole	esomeprazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
pimozide	pimozide	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
ProSom	ProSom	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
acting	act	VBG	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
consideration	consideration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
anticonvulsants	anticonvulsant	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
psychotropic	psychotropic	JJ	B-NP	O	B-group-EF-2
medications	medication	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
produce	produce	VBP	B-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

Smokers	Smoker	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
nonsmokers	nonsmoker	NNS	B-NP	O	O
;	;	:	O	O	O

this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
estazolam	estazolam	NN	B-NP	O	S-drug
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
estazolam	estazolam	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
,	,	,	O	O	O
compounds	compound	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
potent	potent	JJ	B-NP	O	O
CYP3A	CYP3A	NN	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-ME-2
)	)	)	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
estazolam	estazolam	NN	B-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Estazolam	Estazolam	NN	B-NP	O	S-drug
:	:	:	O	O	O
Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
Inhibit	Inhibit	VBP	B-VP	O	O
Metabolism	Metabolism	NN	B-NP	O	O
via	via	IN	B-PP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A	3A	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
)	)	)	O	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
estazolam	estazolam	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
circulating	circulate	VBG	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
4	4	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
hydroxy	hydroxy	NN	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
estazolam	estazolam	NN	I-NP	O	E-drug_n
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
triazolobenzodiazepines	triazolobenzodiazepine	NNS	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
catalyzed	catalyze	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
estazolam	estazolam	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
and	and	CC	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug-AD-2
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
very	very	RB	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
lesser	less	JJR	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
still	still	RB	B-ADVP	O	O
significant	significant	JJ	B-NP	O	O
degree	degree	NN	I-NP	O	O
,	,	,	O	O	O
estazolam	estazolam	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	I-NP	O	O
consideration	consideration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
appropriate	appropriate	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
are	be	VBP	B-VP	O	O
examples	example	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
related	related	JJ	I-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-ME-1
,	,	,	O	O	O
presumably	presumably	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
:	:	:	O	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
isoniazide	isoniazide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
macrolide	macrolide	NN	I-NP	O	B-group-ME-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
Interaction	Interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Fluoxetine	Fluoxetine	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
estazolam	estazolam	NN	B-NP	O	S-drug
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
QHS	QHS	NN	I-NP	O	O
after	after	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
estazolam	estazolam	NN	B-NP	O	S-drug
(	(	(	O	O	O
Cmax	Cmax	NN	B-NP	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
fluoxetine	fluoxetine	NN	I-NP	O	S-drug
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
no	no	RB	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Estazolam	Estazolam	NN	B-NP	O	S-drug
:	:	:	O	O	O
Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
Metabolized	Metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
)	)	)	O	O	O
:	:	:	O	O	O
At	At	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
estazolam	estazolam	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.6	0.6	CD	B-NP	O	O
M	M	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
inhibitory	inhibitory	JJ	B-ADJP	O	O
towards	towards	IN	B-PP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
isoforms	isoform	NNS	I-NP	O	O
CYP1A2	CYP1A2	NN	I-NP	B-protein	O
,	,	,	O	O	O
CYP2A6	CYP2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
these	these	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
estazolam	estazolam	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
very	very	RB	B-ADJP	O	O
unlikely	unlikely	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
biotransformation	biotransformation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
isoforms	isoform	NNS	I-NP	I-protein	O

D	D	NN	B-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
and	and	CC	O	O	O
Laboratory	Laboratory	NNP	B-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
1	1	CD	I-NP	O	O
.	.	.	O	O	O

Accelerated	Accelerate	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
partial	partial	JJ	B-NP	O	O
thromboplastin	thromboplastin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
platelet	platelet	NN	B-NP	B-cell_type	O
aggregation	aggregation	NN	I-NP	O	O
time	time	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
platelet	platelet	NN	I-NP	O	O
count	count	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
II	II	CD	B-NP	O	O
,	,	,	O	O	O
VII	VII	CD	B-NP	B-protein	O
antigen	antigen	NN	I-NP	I-protein	O
,	,	,	O	O	O
VIII	VIII	CD	B-NP	B-protein	O
antigen	antigen	NN	I-NP	I-protein	O
,	,	,	O	O	O
VIII	VIII	CD	B-NP	O	O
coagulant	coagulant	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
IX	IX	NN	B-NP	O	O
,	,	,	O	O	O
X	X	NN	B-NP	B-DNA	O
,	,	,	O	O	O
XII	XII	NN	B-NP	B-DNA	O
,	,	,	O	O	O
VII	VII	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
X	X	NN	I-NP	B-protein	O
complex	complex	NN	I-NP	I-protein	O
,	,	,	O	O	O
II	II	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
VII	VII	CD	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
X	X	NN	I-NP	B-protein	O
complex	complex	NN	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
beta	beta	SYM	O	O	O
-	-	HYPH	O	O	O
thromboglobulin	thromboglobulin	NN	B-NP	B-protein	O
;	;	:	O	O	O

decreased	decrease	VBN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
factor	factor	NN	I-NP	O	O
Xa	Xa	NN	I-NP	O	O
and	and	CC	O	O	O
antithrombin	antithrombin	NN	B-NP	B-protein	O
III	III	CD	I-NP	I-protein	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
antithrombin	antithrombin	NN	B-NP	B-protein	O
III	III	CD	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fibrinogen	fibrinogen	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
fibrinogen	fibrinogen	NN	I-NP	B-protein	O
activity	activity	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
plasminogen	plasminogen	NN	I-NP	B-protein	O
antigen	antigen	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

2	2	LS	B-LST	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
thyroid	thyroid	NN	I-NP	B-protein	O
-	-	HYPH	B-VP	I-protein	O
binding	bind	VBG	I-VP	I-protein	O
globulin	globulin	NN	B-NP	I-protein	O
(	(	(	O	O	O
TBG	TBG	NN	B-NP	O	O
)	)	)	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
circulating	circulate	VBG	I-NP	O	O
total	total	JJ	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
-	-	HYPH	O	O	O
bound	bind	VBN	B-VP	O	O
iodine	iodine	NN	B-NP	O	O
(	(	(	O	O	O
PBI	PBI	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
T4	T4	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
by	by	IN	B-PP	O	O
column	column	NN	B-NP	O	O
or	or	CC	B-PP	O	O
by	by	IN	B-PP	O	O
radioimmunoassay	radioimmunoassay	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
T3	T3	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
radioimmunoassay	radioimmunoassay	NN	B-NP	O	O
.	.	.	O	O	O

T3	T3	NN	B-NP	O	O
resin	resin	NN	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
,	,	,	O	O	O
reflecting	reflect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
TBG	TBG	NN	I-NP	O	O
.	.	.	O	O	O

Free	Free	JJ	B-NP	O	O
T4	T4	NN	I-NP	O	O
and	and	CC	I-NP	O	O
T3	T3	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unaltered	unaltered	JJ	B-ADJP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	B-group
hormone	hormone	NN	I-NP	O	E-group
.	.	.	O	O	O

3	3	LS	B-LST	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
binding	binding	NN	I-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
elevated	elevate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
,	,	,	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
corticosteroid	corticosteroid	NN	B-NP	B-protein	O
binding	binding	NN	I-NP	I-protein	O
globulin	globulin	NN	I-NP	I-protein	O
(	(	(	O	O	O
CBG	CBG	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
sex	sex	NN	B-NP	B-protein	O
hormone	hormone	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
binding	bind	VBG	B-VP	I-protein	O
globulin	globulin	NN	B-NP	I-protein	O
(	(	(	O	O	O
SHBG	SHBG	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
total	total	JJ	I-NP	O	O
circulating	circulate	VBG	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group
and	and	CC	O	O	O
sex	sex	NN	B-NP	O	B-group
steroids	steroid	NNS	I-NP	O	E-group
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Free	Free	JJ	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
(	(	(	O	O	O
angiotensinogen	angiotensinogen	NN	B-NP	O	O
/	/	SYM	O	O	O
renin	renin	NN	B-NP	B-protein	O
substrate	substrate	NN	I-NP	I-protein	O
,	,	,	O	O	O
alpha	alpha	SYM	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
1	1	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
antitrypsin	antitrypsin	NN	I-NP	B-protein	O
,	,	,	I-NP	O	O
ceruloplasmin	ceruloplasmin	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

4	4	LS	B-LST	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
HDL	HDL	NN	I-NP	O	O
and	and	CC	O	O	O
HDL2	HDL2	NN	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	O	O
subfraction	subfraction	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
reduced	reduce	VBD	B-VP	O	O
LDL	LDL	NN	B-NP	B-protein	O
cholesterol	cholesterol	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
triglyceride	triglyceride	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

5	5	LS	B-LST	O	O
.	.	.	O	O	O

Impaired	Impaired	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
.	.	.	O	O	O

6	6	CD	B-NP	O	O
.	.	.	O	O	O

Reduced	Reduce	VBN	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
metyrapone	metyrapone	NN	B-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Milk	Milk	NN	B-NP	B-protein	O
,	,	,	O	O	O
milk	milk	NN	B-NP	O	O
products	product	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-1
-	-	HYPH	B-NP	O	O
rich	rich	JJ	I-NP	O	O
foods	food	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
impair	impair	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EMCYT	EMCYT	NN	B-NP	B-protein	S-brand-ME-2
.	.	.	O	O	O

CNS	CNS	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
Active	Active	JJ	I-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
Ethanol	Ethanol	NN	I-NP	O	S-drug
An	An	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
psychomotor	psychomotor	NN	B-NP	O	O
performance	performance	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug-EF-2
0.70	0.70	CD	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Paroxetine	Paroxetine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
paroxetine	paroxetine	NN	I-NP	O	S-drug
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
produced	produce	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Lorazepam	Lorazepam	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
lorazepam	lorazepam	NN	I-NP	O	S-drug
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Olanzapine	Olanzapine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug-EF-1
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
olanzapine	olanzapine	NN	I-NP	O	S-drug-EF-2
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
DSST	DSST	NN	B-NP	B-DNA	O
scores	score	NNS	I-NP	I-DNA	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
pharmacodynamic	pharmacodynamic	JJ	B-ADJP	O	O
;	;	:	O	O	O

there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
That	That	DT	B-NP	O	O
Inhibit	Inhibit	NN	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
(	(	(	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
)	)	)	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
for	for	IN	B-PP	O	O
elimination	elimination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
2.2	2.2	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Cmax	Cmax	NN	B-NP	O	O
and	and	CC	I-NP	O	O
t1	t1	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
1.4	1.4	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
and	and	CC	O	O	O
1.3	1.3	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
strong	strong	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug
,	,	,	O	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
)	)	)	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
behave	behave	VB	I-VP	O	O
similarly	similarly	RB	B-ADVP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
That	That	DT	B-NP	O	O
Induce	Induce	NNP	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
(	(	(	O	O	O
Rifampicin	Rifampicin	NN	B-NP	O	S-drug
)	)	)	O	O	O
Racemic	Racemic	JJ	B-NP	O	O
zopiclone	zopiclone	NN	I-NP	O	S-drug-ME-1
exposure	exposure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
80	80	CD	B-NP	O	O
%	%	NN	I-NP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
useof	useof	NN	I-NP	O	O
rifampicin	rifampicin	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drugs	Drugs	NNP	B-NP	O	O
Highly	Highly	NNP	I-NP	O	O
Bound	Bound	NNP	I-NP	O	O
To	To	TO	B-PP	O	O
Plasma	Plasma	NNP	B-NP	O	O
Protein	Protein	NNP	I-NP	O	O
Eszopiclone	Eszopiclone	NNP	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
highly	highly	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
(	(	(	O	O	O
52	52	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
59	59	CD	I-NP	O	O
%	%	NN	I-NP	O	O
bound	bind	VBN	B-VP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
sensitive	sensitive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
taking	take	VBG	B-VP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-NP	O	O
protein	protein	NN	I-NP	O	O
-	-	HYPH	O	O	O
bound	bind	VBN	B-VP	O	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
an	an	DT	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
free	free	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
With	With	IN	B-PP	O	O
A	A	NNP	B-NP	O	O
Narrow	Narrow	NNP	I-NP	O	O
Therapeutic	Therapeutic	NNP	I-NP	O	O
Index	Index	NNP	I-NP	O	O
Digoxin	Digoxin	NNP	I-NP	O	S-drug
A	A	NNP	I-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
eszopiclone	eszopiclone	NN	B-NP	O	S-drug
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
measured	measure	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
of	of	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
one	one	CD	B-NP	O	O
day	day	NN	I-NP	O	O
and	and	CC	O	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
next	next	JJ	I-NP	O	O
6	6	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NNP	B-NP	O	S-drug
:	:	:	O	O	O
Eszopiclone	Eszopiclone	NN	B-NP	O	S-drug
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
administered	administer	VBN	B-VP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	O	B-drug
R	R	NN	B-NP	O	I-drug
)	)	)	O	O	I-drug
-	-	HYPH	O	O	E-drug
or	or	CC	O	O	O
(	(	(	O	O	B-drug
S	S	NN	B-NP	O	I-drug
)	)	)	O	O	I-drug
-	-	HYPH	B-NP	O	I-drug
warfarin	warfarin	NN	I-NP	O	E-drug
,	,	,	O	O	O
nor	nor	CC	O	O	O
were	be	VBD	B-VP	O	O
there	there	RB	B-ADVP	O	O
any	any	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
profile	profile	NN	I-NP	O	O
(	(	(	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
)	)	)	O	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug

Specific	Specific	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ENBREL	ENBREL	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ENBREL	ENBREL	NN	B-NP	B-protein	S-brand
was	be	VBD	B-VP	O	O
unaltered	unaltered	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
RA	RA	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
24	24	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
ENBREL	ENBREL	NN	I-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
anakinra	anakinra	NN	I-NP	O	S-drug-EF-2
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
7	7	CD	I-NP	O	O
%	%	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
infections	infection	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ENBREL	ENBREL	NN	B-NP	O	S-brand
alone	alone	RB	B-ADVP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
percent	percent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ENBREL	ENBREL	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	I-NP	O	O
anakinra	anakinra	NN	I-NP	O	S-drug-EF-2
developed	develop	VBD	B-VP	O	O
neutropenia	neutropenia	NN	B-NP	O	O
(	(	(	O	O	O
ANC	ANC	NN	B-NP	B-protein	O
1	1	CD	I-NP	I-protein	O
x	x	SYM	B-NP	O	O
109	109	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
established	established	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
sulfasalazine	sulfasalazine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
to	to	TO	B-PP	O	O
which	which	WDT	B-NP	O	O
ENBREL	ENBREL	NN	I-NP	O	S-brand-EF-2
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
develop	develop	VB	I-VP	O	O
a	a	DT	B-NP	O	O
mild	mild	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
neutrophil	neutrophil	NN	I-NP	O	O
counts	count	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
to	to	TO	B-PP	O	O
groups	group	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
ENBREL	ENBREL	NN	B-NP	O	S-brand
CI	CI	NN	I-NP	O	O
or	or	CC	I-NP	O	O
sulfasalazine	sulfasalazine	NN	I-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
observation	observation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug-ME-1
generally	generally	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-ME-2
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
reduce	reduce	VBP	B-VP	O	O
its	its	PRP$	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
add	add	VB	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Read	Read	JJ	B-NP	O	O
circulars	circular	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
preparations	preparation	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

EDECRIN	EDECRIN	NN	B-NP	B-protein	S-brand-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
ototoxic	ototoxic	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	S-group-EF-2
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
cephalosporin	cephalosporin	NN	I-NP	O	B-group-EF-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Their	Their	PRP$	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ethacrynic	ethacrynic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
displace	displace	VB	I-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
from	from	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
;	;	:	O	O	O

a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	B-DNA	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
steroidal	steroidal	JJ	I-NP	O	I-group-EF-1
antiinflammatory	antiinflammatory	JJ	I-NP	O	I-group-EF-1
agent	agent	NN	I-NP	O	E-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
loop	loop	NN	B-NP	O	S-group-EF-2
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	B-group-EF-2
-	-	HYPH	B-VP	O	I-group-EF-2
sparing	spar	VBG	B-NP	O	E-group-EF-2
and	and	CC	I-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
EDECRIN	EDECRIN	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	O	O	O
non	non	AFX	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	B-DNA	I-group-EF-2
steroidal	steroidal	JJ	B-NP	I-DNA	I-group-EF-2
anti	anti	AFX	I-NP	I-DNA	I-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
aluminum	aluminum	NN	I-NP	O	B-drug-ME-2
hydroxide	hydroxide	NN	I-NP	O	E-drug-ME-2
containing	contain	VBG	B-VP	O	O
antacid	antacid	NN	B-NP	O	S-group
to	to	TO	B-PP	O	O
13	13	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
tuberculosis	tuberculosis	NN	B-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	O	S-drug
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
13	13	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
antacid	antacid	NN	I-NP	B-protein	B-group
products	product	NNS	I-NP	I-protein	E-group
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
avoid	avoid	VB	I-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
aluminum	aluminum	NN	B-NP	O	B-drug-AD-2
hydroxide	hydroxide	NN	I-NP	O	E-drug-AD-2
containing	contain	VBG	B-VP	O	O
antacids	antacid	NNS	B-NP	O	S-group
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Dicumarol	Dicumarol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
hypoprothrombinemic	hypoprothrombinemic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
depressasnts	depressasnt	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
MAOIs	MAOI	NNS	B-NP	B-protein	S-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
depression	depression	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ethchlorvynol	ethchlorvynol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

May	May	MD	B-VP	O	O
interact	interact	VBP	I-VP	O	O
with	with	IN	B-PP	O	O
addictive	addictive	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-NP	O	O
central	central	JJ	I-NP	O	B-group
nervous	nervous	JJ	I-NP	O	I-group
system	system	NN	I-NP	O	I-group
(	(	(	O	O	I-group
CNS	CNS	NN	B-NP	B-protein	I-group
)	)	)	O	O	I-group
depressants	depressant	NNS	B-NP	O	E-group
with	with	IN	B-PP	O	O
habituating	habituate	VBG	B-VP	O	O
potential	potential	JJ	O	O	O
(	(	(	O	O	O
prolonged	prolonged	JJ	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
habituation	habituation	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
or	or	CC	O	O	O
CNS	CNS	NN	B-NP	B-protein	O
depression	depression	NN	I-NP	O	O
producing	produce	VBG	B-VP	O	O
medications	medication	NNS	B-NP	O	O
(	(	(	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
these	these	DT	I-NP	O	O
medications	medication	NNS	I-NP	O	O
or	or	CC	O	O	O
ethinamate	ethinamate	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
endocrine	endocrine	NN	I-NP	O	O
and	and	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	O	S-group
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
similar	similar	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
larger	large	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	O	S-group
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
sulfobromophthalein	sulfobromophthalein	NN	I-NP	O	O
retention	retention	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	B-protein	O
and	and	CC	I-NP	O	O
factors	factor	NNS	I-NP	O	O
VII	VII	CD	B-NP	O	O
,	,	,	I-NP	O	O
VIII	VIII	CD	I-NP	B-protein	O
,	,	,	I-NP	O	O
IX	IX	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
X	X	NN	B-NP	O	O
;	;	:	O	O	O

decreased	decrease	VBN	B-NP	O	O
antithrombin	antithrombin	NN	I-NP	B-protein	O
3	3	CD	I-NP	I-protein	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
platel	platel	NN	I-NP	O	O
et	et	NN	I-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
thyroid	thyroid	NN	I-NP	B-protein	O
binding	binding	NN	I-NP	I-protein	O
globulin	globulin	NN	I-NP	I-protein	O
(	(	(	O	O	O
TBG	TBG	NN	B-NP	O	O
)	)	)	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
circulating	circulate	VBG	I-NP	O	O
total	total	JJ	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
PBI	PBI	NN	B-NP	B-protein	O
,	,	,	O	O	O
T4	T4	NN	B-NP	O	O
by	by	IN	B-PP	O	O
column	column	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
T4	T4	NN	B-NP	O	O
by	by	IN	B-PP	O	O
radioimmunoassay	radioimmunoassay	NN	B-NP	O	O
.	.	.	O	O	O

Free	Free	JJ	B-NP	O	O
T3	T3	NN	I-NP	O	O
resin	resin	NN	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
,	,	,	O	O	O
reflecting	reflect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
TBG	TBG	NNP	I-NP	O	O
;	;	:	O	O	O

free	free	JJ	B-NP	O	O
T4	T4	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unaltered	unaltered	JJ	B-ADJP	O	O
:	:	:	O	O	O
impaired	impaired	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
;	;	:	O	O	O

decreased	decrease	VBN	B-NP	O	O
pregnanediol	pregnanediol	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
;	;	:	O	O	O

reduced	reduce	VBN	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
metyrapone	metyrapone	NN	B-NP	O	O
test	test	NN	I-NP	O	O
;	;	:	O	O	O

reduced	reduce	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
folate	folate	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
triglyceride	triglyceride	NN	I-NP	O	O
and	and	CC	O	O	O
phospholipid	phospholipid	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

Trecator	Trecator	NN	B-NP	O	S-brand-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
temporarily	temporarily	RB	I-VP	O	O
raise	raise	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Trecator	Trecator	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antituberculous	antituberculous	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
,	,	,	O	O	O
convulsions	convulsion	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ethionamide	ethionamide	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cycloserine	cycloserine	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
special	special	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
includes	include	VBZ	B-VP	O	O
both	both	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Excessive	Excessive	JJ	B-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug
ingestion	ingestion	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
psychotic	psychotic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Ethopropazine	Ethopropazine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
causing	cause	VBG	B-VP	O	O
increased	increase	VBD	B-VP	O	O
sedative	sedative	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
amantadine	amantadine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
or	or	CC	I-NP	O	O
MAOIs	MAOI	NNS	I-NP	B-protein	S-group
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
.	.	.	O	O	O

Ethopropazine	Ethopropazine	NN	B-NP	O	S-drug-ME-1
can	can	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
chlorpromazine	chlorpromazine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chlorpromazine	chlorpromazine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
Zarontin	Zarontin	NN	B-NP	B-protein	S-brand-IN-1
(	(	(	O	O	O
ethosuximide	ethosuximide	NN	B-NP	O	S-drug-IN-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
concurrently	concurrently	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
antiepileptic	antiepileptic	JJ	I-NP	O	B-group-IN-2
drugs	drug	NNS	I-NP	O	E-group-IN-2
,	,	,	O	O	O
periodic	periodic	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
level	level	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
(	(	(	O	O	O
eg	eg	FW	O	O	O
,	,	,	O	O	O
ethosuximide	ethosuximide	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
elevate	elevate	VB	I-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
both	both	CC	I-VP	O	O
increase	increase	VB	I-VP	O	O
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
ethosuximide	ethosuximide	NN	B-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

PEGANONE	PEGANONE	NN	B-NP	O	S-brand
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
adversely	adversely	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hematopoietic	hematopoietic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
possible	possible	JJ	B-ADJP	O	O
.	.	.	O	O	O

Considerable	Considerable	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
PEGANONE	PEGANONE	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Phenurone	Phenurone	NN	B-NP	O	S-brand-AD-2
(	(	(	O	O	O
phenacemide	phenacemide	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
since	since	IN	B-PP	O	O
paranoid	paranoid	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
two	two	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
way	way	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hydantoin	hydantoin	NN	I-NP	O	B-group-IN-1
antiepileptic	antiepileptic	JJ	B-ADJP	O	E-group-IN-1
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
coumarin	coumarin	NN	I-NP	O	B-group-IN-2
anticoagulants	anticoagulant	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
.	.	.	O	O	O

Presumably	Presumably	RB	B-ADVP	O	O
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
acts	act	VBZ	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
stimulator	stimulator	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	S-group-ME-2
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
decreased	decrease	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coumarin	coumarin	NN	I-NP	O	B-group-ME-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-ME-2
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
proconvertin	proconvertin	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Conversely	Conversely	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
coumarin	coumarin	NN	I-NP	O	B-group-ME-1
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
prolong	prolong	VB	B-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
documentation	documentation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
ethotoin	ethotoin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
coumarin	coumarin	NN	I-NP	O	B-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
PEGANONE	PEGANONE	NN	B-NP	O	S-brand-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-AD-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Ethoxzolamide	Ethoxzolamide	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclics	tricyclic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
excretion	excretion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
ASA	ASA	NN	B-NP	O	S-drug
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylates	salicylate	NNS	B-NP	O	S-group
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ethoxzolamide	ethoxzolamide	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-EF-2
B	B	NN	I-NP	O	E-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
.	.	.	O	O	O

Ethinyl	Ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
:	:	:	O	O	O
Substrate	Substrate	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
major	major	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
3A5	3A5	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
7	7	CD	I-NP	O	O
(	(	(	O	O	O
minor	minor	NN	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

Inhibits	Inhibit	VBZ	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
(	(	(	O	O	O
weak	weak	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
2B6	2B6	NN	B-NP	B-protein	O
(	(	(	O	O	O
weak	weak	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	O	O
(	(	(	O	O	O
weak	weak	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
weak	weak	JJ	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Acetaminophen	Acetaminophen	NN	B-NP	O	S-drug-ME-1
:	:	:	O	O	O
May	May	MD	B-VP	O	O
increase	increase	VBP	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
synthetic	synthetic	JJ	B-NP	O	B-group-ME-2
estrogens	estrogen	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
conjugation	conjugation	NN	B-NP	O	O
.	.	.	O	O	O

Combination	Combination	NN	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group-ME-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Acitretin	Acitretin	NN	B-NP	O	S-drug-EF-1
:	:	:	O	O	O
Interferes	Interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
microdosed	microdose	VBN	B-NP	O	O
progestin	progestin	NN	I-NP	O	S-group-EF-2
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
minipill	minipill	NN	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
progestational	progestational	JJ	I-NP	O	B-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
implants	implant	NNS	B-NP	O	O
,	,	,	O	O	O
injectables	injectable	NNS	B-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Aminoglutethimide	Aminoglutethimide	NN	B-NP	O	S-drug-ME-1
:	:	:	O	O	O
May	May	MD	B-VP	O	O
increase	increase	VBP	I-VP	O	O
CYP	CYP	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
progestins	progestin	NNS	B-NP	O	S-group-ME-2
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
possible	possible	JJ	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
contraceptive	contraceptive	JJ	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonhormonal	nonhormonal	JJ	I-NP	B-protein	B-group
contraceptive	contraceptive	JJ	I-NP	I-protein	I-group
product	product	NN	I-NP	I-protein	E-group
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Antibiotics	Antibiotic	NNS	B-NP	O	S-group
(	(	(	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
tetracycline	tetracycline	NN	I-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Pregnancy	Pregnancy	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
consistent	consistent	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
synthetic	synthetic	JJ	B-NP	O	B-group
steroids	steroid	NNS	I-NP	O	E-group
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonhormonal	nonhormonal	JJ	I-NP	B-protein	B-group
contraceptive	contraceptive	JJ	I-NP	I-protein	I-group
product	product	NN	I-NP	I-protein	E-group
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
:	:	:	O	O	O
Combination	Combination	NN	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group-EF-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-EF-2
derivatives	derivative	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Combination	Combination	NN	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
risk	risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
thromboembolic	thromboembolic	JJ	B-NP	O	O
disorders	disorder	NNS	I-NP	O	O
.	.	.	O	O	O

Anticonvulsants	Anticonvulsant	NNS	B-NP	O	S-group-ME-1
(	(	(	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
felbamate	felbamate	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
topiramate	topiramate	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
:	:	:	O	O	O
Increase	Increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug-ME-2
estradiol	estradiol	NN	I-NP	O	E-drug-ME-2
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
some	some	DT	B-NP	O	O
progestins	progestin	NNS	I-NP	O	S-group-ME-2
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
possible	possible	JJ	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
contraceptive	contraceptive	JJ	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonhormonal	nonhormonal	JJ	I-NP	B-protein	B-group
contraceptive	contraceptive	JJ	I-NP	I-protein	I-group
product	product	NN	I-NP	I-protein	E-group
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Ascorbic	Ascorbic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
:	:	:	O	O	O
Doses	Dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
ascorbic	ascorbic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
(	(	(	O	O	O
vitamin	vitamin	NN	B-NP	O	B-drug-ME-1
C	C	NN	I-NP	O	E-drug-ME-1
)	)	)	O	O	O
1	1	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
synthetic	synthetic	JJ	B-NP	O	B-group-ME-2
estrogens	estrogen	NNS	I-NP	O	E-group-ME-2
by	by	IN	B-PP	O	O
~	~	NN	B-NP	O	O
47	47	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
conjugation	conjugation	NN	B-NP	O	O
;	;	:	O	O	O

clinical	clinical	JJ	B-NP	O	O
implications	implication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
.	.	.	O	O	O

Atorvastatin	Atorvastatin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Atorvastatin	Atorvastatin	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
for	for	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug-ME-2
estradiol	estradiol	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

Benzodiazepines	Benzodiazepine	NNS	B-NP	O	S-group
:	:	:	O	O	O
Combination	Combination	NN	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group-ME-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-ME-2
(	(	(	O	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
and	and	CC	O	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
others	other	NNS	B-NP	O	O
(	(	(	O	O	O
lorazepam	lorazepam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
oxazepam	oxazepam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
temazepam	temazepam	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Clofibric	Clofibric	JJ	B-NP	O	B-drug_n
acid	acid	NN	I-NP	O	E-drug_n
:	:	:	O	O	O
Combination	Combination	NN	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group-ME-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clofibric	clofibric	JJ	B-NP	O	B-drug_n-ME-2
acid	acid	NN	I-NP	O	E-drug_n-ME-2
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Combination	Combination	NN	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group-ME-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
;	;	:	O	O	O

monitor	monitor	NN	B-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inducers	inducer	NNS	I-NP	O	O
:	:	:	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inducers	inducer	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
/	/	SYM	B-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
.	.	.	O	O	O

Example	Example	NN	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
aminoglutethimide	aminoglutethimide	NN	B-NP	O	S-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
nafcillin	nafcillin	NN	B-NP	O	S-drug
,	,	,	O	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
rifamycins	rifamycin	NNS	B-NP	O	S-group
.	.	.	O	O	O

Griseofulvin	Griseofulvin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Griseofulvin	Griseofulvin	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
combination	combination	NN	B-NP	O	B-group-ME-2
hormonal	hormonal	JJ	I-NP	O	I-group-ME-2
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-2
causing	cause	VBG	B-VP	O	O
menstrual	menstrual	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
;	;	:	O	O	O

pregnancies	pregnancy	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
barrier	barrier	NN	B-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
while	while	IN	B-SBAR	O	O
on	on	IN	B-PP	O	O
griseofulvin	griseofulvin	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Morphine	Morphine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Combination	Combination	NN	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group-ME-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-group
-	-	HYPH	I-NP	B-protein	I-group
nucleoside	nucleoside	NN	I-NP	I-protein	I-group
reverse	reverse	JJ	I-NP	I-protein	I-group
transcriptase	transcriptase	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
NNRTIs	NNRTI	NNS	B-NP	O	S-group
)	)	)	O	O	O
:	:	:	O	O	O
Nevirapine	Nevirapine	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
combination	combination	NN	B-NP	O	B-group-ME-2
hormonal	hormonal	JJ	I-NP	O	I-group-ME-2
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-2
;	;	:	O	O	O

use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonhormonal	nonhormonal	JJ	I-NP	B-protein	B-group
contraceptive	contraceptive	JJ	I-NP	I-protein	I-group
product	product	NN	I-NP	I-protein	E-group
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
delavirdine	delavirdine	NN	B-NP	O	S-drug
;	;	:	O	O	O

incomplete	incomplete	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
.	.	.	O	O	O

Prednisolone	Prednisolone	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ethinyl	Ethinyl	NN	B-NP	O	B-drug-ME-1
estradiol	estradiol	NN	I-NP	O	E-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prednisolone	prednisolone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Protease	Protease	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Amprenavir	Amprenavir	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
lopinavir	lopinavir	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
combination	combination	NN	B-NP	O	B-group-ME-2
hormonal	hormonal	JJ	I-NP	O	I-group-ME-2
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-2
;	;	:	O	O	O

use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonhormonal	nonhormonal	JJ	I-NP	B-protein	B-group
contraceptive	contraceptive	JJ	I-NP	I-protein	I-group
product	product	NN	I-NP	I-protein	E-group
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Indinavir	Indinavir	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
combination	combination	NN	B-NP	O	B-group-ME-2
hormonal	hormonal	JJ	I-NP	O	I-group-ME-2
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Rifampin	Rifampin	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug-ME-2
estradiol	estradiol	NN	I-NP	O	E-drug-ME-2
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
progestins	progestin	NNS	I-NP	O	S-group-ME-2
(	(	(	O	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
menstrual	menstrual	JJ	B-NP	O	O
irregularities	irregularity	NNS	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonhormonal	nonhormonal	JJ	I-NP	B-protein	B-group
contraceptive	contraceptive	JJ	I-NP	I-protein	I-group
product	product	NN	I-NP	I-protein	E-group
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Salicylic	Salicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
:	:	:	O	O	O
Combination	Combination	NN	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group-ME-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylic	salicylic	JJ	B-NP	O	B-drug-ME-2
acid	acid	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

Selegiline	Selegiline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Combination	Combination	NN	B-NP	O	B-group-ME-1
hormonal	hormonal	JJ	I-NP	O	I-group-ME-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
selegiline	selegiline	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ethinyl	Ethinyl	NN	B-NP	O	B-drug-ME-1
estradiol	estradiol	NN	I-NP	O	E-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Tricyclic	Tricyclic	JJ	B-NP	O	B-group-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-1
(	(	(	O	O	O
amitriptyline	amitriptyline	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
imipramine	imipramine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
nortriptyline	nortriptyline	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
:	:	:	O	O	O
Metabolism	Metabolism	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
combination	combination	NN	B-NP	O	B-group-ME-2
hormonal	hormonal	JJ	I-NP	O	I-group-ME-2
contraceptives	contraceptive	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antidepressant	antidepressant	NN	B-NP	O	S-group
;	;	:	O	O	O

use	use	NN	B-NP	O	O
caution	caution	NN	I-NP	O	O
.	.	.	O	O	O

ETHANOL	ETHANOL	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
NUTRITION	NUTRITION	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
HERB	HERB	NN	I-NP	B-protein	O
INTERACTIONS	INTERACTIONS	NNS	I-NP	O	O
:	:	:	O	O	O
Food	Food	NN	B-NP	O	O
:	:	:	O	O	O
CNS	CNS	NN	B-NP	B-protein	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
combination	combination	NN	B-NP	O	B-group-EF-1
hormonal	hormonal	JJ	I-NP	O	I-group-EF-1
contraceptives	contraceptive	NNS	I-NP	O	E-group-EF-1
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Grapefruit	Grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
progesterone	progesterone	NN	B-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
as	as	RB	B-ADVP	O	O
well	well	RB	I-ADVP	O	O
;	;	:	O	O	O

clinical	clinical	JJ	B-NP	O	O
implications	implication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
.	.	.	O	O	O

Herb	Herb	NN	B-NP	B-protein	O
/	/	SYM	I-NP	O	O
Nutraceutical	Nutraceutical	NN	I-NP	O	O
:	:	:	O	O	O
St	St	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
wort	wort	NN	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
combination	combination	NN	B-NP	O	B-group
hormonal	hormonal	JJ	I-NP	O	I-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
by	by	IN	B-PP	O	O
inducing	induce	VBG	B-VP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Avoid	Avoid	JJ	B-NP	O	O
dong	dong	NN	I-NP	O	O
quai	quai	NN	I-NP	O	O
and	and	CC	O	O	O
black	black	JJ	B-NP	O	O
cohosh	cohosh	NN	I-NP	O	O
(	(	(	O	O	O
have	have	VBP	B-VP	O	O
estrogen	estrogen	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Avoid	Avoid	NNP	B-NP	O	O
saw	see	VBD	B-VP	O	O
palmetto	palmetto	JJ	B-NP	O	O
,	,	,	I-NP	O	O
red	red	JJ	I-NP	O	O
clover	clover	NN	I-NP	O	O
,	,	,	O	O	O
ginseng	ginseng	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
isolated	isolate	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
experiencing	experience	VBG	B-VP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
times	time	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
etidronate	etidronate	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
majority	majority	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
concerned	concern	VBD	B-VP	O	O
variable	variable	JJ	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
sequelae	sequela	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
and	and	CC	O	O	O
any	any	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coagulation	coagulation	NN	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
monitored	monitor	VBN	B-VP	O	O
.	.	.	O	O	O

ACE	ACE	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
Reports	Report	NNS	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
consideration	consideration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Lodine	Lodine	NN	B-NP	O	S-brand
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
antacids	antacid	NNS	B-NP	O	S-group
can	can	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
reached	reach	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
but	but	CC	O	O	O
have	have	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
detectable	detectable	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
-	-	HYPH	B-NP	O	O
peak	peak	NN	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
Lodine	Lodine	NN	B-NP	O	S-brand-ME-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
etodolac	etodolac	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Lodine	Lodine	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
generally	generally	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	O
,	,	,	O	O	O
Digoxin	Digoxin	NN	B-NP	O	O
,	,	,	O	O	O
Methotrexate	Methotrexate	NNP	B-NP	O	O
Lodine	Lodine	NNP	I-NP	O	S-brand-ME-1
,	,	,	O	O	O
like	like	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-ME-1
,	,	,	O	O	O
through	through	IN	B-PP	O	O
effects	effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandins	prostaglandin	NNS	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Nephrotoxicity	Nephrotoxicity	NN	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
Lodine	Lodine	NN	B-NP	O	S-brand
,	,	,	O	O	O
or	or	CC	O	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
NSAID	NSAID	NN	I-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
particularly	particularly	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
altered	alter	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
toxicities	toxicity	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Diuretics	Diuretic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Etodolac	Etodolac	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	O	S-drug
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
postmarketing	postmarketing	JJ	B-NP	O	O
observations	observation	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
Lodine	Lodine	NN	B-NP	O	S-brand-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group-EF-2
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
response	response	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
failure	failure	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
to	to	TO	B-VP	O	O
assure	assure	VB	I-VP	O	O
diuretic	diuretic	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
.	.	.	O	O	O

Glyburide	Glyburide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Etodolac	Etodolac	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
produced	produce	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
minimum	minimum	JJ	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
NSAID	NSAID	NN	I-NP	O	S-group
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-EF-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
subjects	subject	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Phenylbutazone	Phenylbutazone	NN	B-NP	O	S-drug
:	:	:	O	O	O
Phenylbutazone	Phenylbutazone	NN	B-NP	O	S-drug-ME-1
causes	cause	VBZ	B-VP	O	O
increase	increase	NN	B-NP	O	O
(	(	(	O	O	O
by	by	IN	B-PP	O	O
about	about	IN	B-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
free	free	JJ	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
etodolac	etodolac	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
done	do	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
see	see	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
etodolac	etodolac	NN	B-NP	O	S-drug-AD-1
clearance	clearance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
changed	change	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
be	be	VB	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Etodolac	Etodolac	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-EF-2
on	on	IN	B-PP	O	O
GI	GI	NN	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
synergistic	synergistic	JJ	B-ADJP	O	O
,	,	,	O	O	O
such	such	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
together	together	RB	B-ADVP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
GI	GI	NN	I-NP	O	O
bleeding	bleed	VBG	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Short	Short	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
Lodine	Lodine	NN	B-NP	O	S-brand-ME-2
(	(	(	O	O	O
etodolac	etodolac	NN	B-NP	O	S-drug-ME-2
capsules	capsule	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
)	)	)	O	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
but	but	CC	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Lodine	Lodine	NN	B-NP	O	S-brand
as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Lodine	Lodine	NN	I-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
require	require	VB	I-VP	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
spontaneous	spontaneous	JJ	I-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
prolonged	prolong	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
times	time	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
bleeding	bleeding	NN	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
etodolac	etodolac	NN	B-NP	O	S-drug-EF-1
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
The	The	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
take	take	VBP	B-VP	O	O
Lodine	Lodine	NN	B-NP	O	S-brand
can	can	MD	B-VP	O	O
give	give	VB	I-VP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
bilirubin	bilirubin	NN	I-NP	O	O
(	(	(	O	O	O
urobilin	urobilin	NN	B-NP	O	O
)	)	)	O	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenolic	phenolic	JJ	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
etodolac	etodolac	NN	B-NP	O	S-drug
.	.	.	O	O	O

Diagnostic	Diagnostic	JJ	B-NP	O	O
dip	dip	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
stick	stick	NN	I-NP	O	O
methodology	methodology	NN	I-NP	O	O
,	,	,	O	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
detect	detect	VB	I-VP	O	O
ketone	ketone	NN	B-NP	O	O
bodies	body	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
resulted	result	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
false	false	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Lodine	Lodine	NN	B-NP	O	S-brand
.	.	.	O	O	O

Generally	Generally	RB	B-ADVP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Lodine	Lodine	NN	B-NP	O	S-brand
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
uric	uric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
arthritic	arthritic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
etodolac	etodolac	NN	B-NP	O	S-drug
(	(	(	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
then	then	RB	B-ADVP	O	O
remained	remain	VBD	B-VP	O	O
stable	stable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
1	1	CD	I-NP	O	O
year	year	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Effect	Effect	NNP	I-NP	O	O

Probenecid	Probenecid	JJ	B-NP	O	S-drug
Prolonged	Prolonged	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	O	S-drug

Diazoxide	Diazoxide	NN	B-NP	O	S-drug
Hypotension	Hypotension	NN	I-NP	O	O

Zimelidine	Zimelidine	NN	B-NP	O	S-drug_n
etomidate	etomidate	NN	I-NP	O	S-drug
antagonism	antagonism	NN	I-NP	O	O

Opioid	Opioid	JJ	B-NP	O	B-group
analgesics	analgesic	NNS	I-NP	O	E-group
Decreased	Decrease	VBD	B-VP	O	O
antinociceptive	antinociceptive	JJ	B-NP	O	O
action	action	NN	I-NP	O	O

Aminophylline	Aminophylline	NN	B-NP	O	S-drug
Etomidate	Etomidate	NN	I-NP	O	S-drug
antagonism	antagonism	NN	I-NP	O	O

Midazolam	Midazolam	NNP	B-NP	O	S-drug
Synergism	Synergism	NNP	I-NP	O	O

Etonogestrel	Etonogestrel	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
medications	medication	NNS	I-NP	O	O
:	:	:	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
Tylenol	Tylenol	NN	B-NP	O	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group-IN-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug-IN-2
and	and	CC	I-NP	O	O
tetracycline	tetracycline	NN	I-NP	O	S-drug-IN-2
,	,	,	O	O	O
anticonvulsants	anticonvulsant	NNS	B-NP	O	S-group-IN-2
(	(	(	O	O	O
Dilantin	Dilantin	NN	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
Tegretol	Tegretol	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Trileptal	Trileptal	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Topamax	Topamax	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Felbatol	Felbatol	NNP	B-NP	O	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
antifungals	antifungal	NNS	B-NP	O	S-group-IN-2
(	(	(	O	O	O
Gris	Gris	NNP	B-NP	O	B-brand-IN-2
-	-	HYPH	O	O	I-brand-IN-2
PEG	PEG	NNP	B-NP	O	E-brand-IN-2
,	,	,	O	O	O
Nizoral	Nizoral	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Sporanox	Sporanox	NNP	B-NP	O	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
Lipitor	Lipitor	NN	B-NP	O	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
clofibrate	clofibrate	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
Atromid	Atromid	NN	B-NP	O	B-brand-IN-2
-	-	HYPH	B-NP	O	I-brand-IN-2
S	S	NN	I-NP	O	E-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
Neoral	Neoral	JJ	B-ADJP	O	S-brand-IN-2
,	,	,	O	O	O
Sandimmune	Sandimmune	JJ	B-ADVP	O	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
HIV	HIV	NN	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
classified	classify	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
protease	protease	NN	B-NP	O	B-group-IN-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-IN-2
(	(	(	O	O	O
Agenerase	Agenerase	NN	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Crixivan	Crixivan	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Fortovase	Fortovase	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Invirase	Invirase	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Kaletra	Kaletra	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Norvir	Norvir	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Viracept	Viracept	NNP	B-NP	O	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
morphine	morphine	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
Astramorph	Astramorph	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
Kadian	Kadian	NNP	B-NP	O	S-brand-IN-2
,	,	,	O	O	O
MS	MS	NNP	B-NP	B-protein	B-brand-IN-2
Contin	Contin	NNP	I-NP	I-protein	E-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
prednisolone	prednisolone	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
Prelone	Prelone	NN	B-NP	O	S-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
rifadin	rifadin	NN	B-NP	O	S-brand-IN-2
(	(	(	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
St.	St.	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
wort	wort	NN	I-NP	O	O
,	,	,	O	O	O
temazepam	temazepam	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
Theo	Theo	NNP	B-NP	O	B-brand-IN-2
-	-	HYPH	O	O	I-brand-IN-2
Dur	Dur	NNP	B-NP	O	E-brand-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
vitamin	vitamin	NN	B-NP	O	B-drug-IN-2
C	C	NN	I-NP	O	E-drug-IN-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
ETOPOPHOS	ETOPOPHOS	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
phosphatase	phosphatase	NN	B-NP	B-protein	O
activities	activity	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
levamisole	levamisole	NN	B-NP	O	B-drug-AD-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
cyclosporin	cyclosporin	NN	I-NP	O	B-drug-ME-1
A	A	NN	I-NP	O	E-drug-ME-1
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
above	above	IN	B-PP	O	O
2000	2000	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
etoposide	etoposide	NN	I-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
led	lead	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
etoposide	etoposide	NN	B-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
38	38	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
body	body	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
etoposide	etoposide	NN	B-NP	O	S-drug
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
etoposide	etoposide	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Exemestane	Exemestane	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
extensively	extensively	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
but	but	CC	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
exemestane	exemestane	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Significant	Significant	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
mediated	mediate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
therefore	therefore	RB	B-ADVP	O	O
appear	appear	VBP	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
medications	medication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
rifampicin	rifampicin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
or	or	CC	O	O	O
St.	St.	NNP	B-NP	O	O
John	John	NNP	I-NP	O	O
s	s	VBZ	B-VP	O	O
wort	wort	NN	B-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
exemestane	exemestane	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
modification	modification	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inducer	inducer	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Tests	Test	VBZ	B-VP	O	O
Interactions	Interaction	NNS	B-NP	O	O
No	No	RB	B-ADJP	O	O
clinically	clinically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
significantly	significantly	RB	B-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
penciclovir	penciclovir	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
conversion	conversion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
deoxy	deoxy	NN	I-NP	O	I-drug_n
penciclovir	penciclovir	NN	I-NP	O	E-drug_n
to	to	TO	B-PP	O	O
penciclovir	penciclovir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
catalyzed	catalyze	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
aldehyde	aldehyde	NN	B-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
could	could	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
famotidine	famotidine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
animal	animal	NN	B-NP	O	O
models	model	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interference	interference	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	B-protein	O
microsomal	microsomal	JJ	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Compounds	Compound	NNS	B-NP	O	O
tested	test	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
include	include	VBP	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
diazepam	diazepam	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
aminopyrine	aminopyrine	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
antipyrine	antipyrine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Indocyanine	Indocyanine	NN	B-NP	O	B-drug_n
green	green	JJ	B-ADJP	O	E-drug_n
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
index	index	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
extraction	extraction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
tested	test	VBN	I-VP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
described	describe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
section	section	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
controlled	control	VBN	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
studies	study	NNS	I-NP	O	O
involving	involve	VBG	B-VP	O	O
otherwise	otherwise	RB	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
adults	adult	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
in	in	IN	B-PP	O	O
Conjunction	Conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Antiepileptic	Antiepileptic	JJ	I-NP	O	B-group
Drugs	Drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand-ME-1
to	to	TO	B-PP	O	O
antiepileptic	antiepileptic	JJ	B-NP	O	B-group-ME-2
drugs	drug	NNS	I-NP	O	E-group-ME-2
(	(	(	O	O	O
AEDs	AED	NNS	B-NP	O	S-group-ME-2
)	)	)	O	O	O
affects	affect	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
AEDs	AED	NNS	B-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
net	net	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
summarized	summarize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
table	table	NN	I-NP	O	O
:	:	:	O	O	O
AED	AED	NNP	B-NP	O	S-group
AED	AED	NNP	I-NP	O	S-group
Felbatol	Felbatol	NNP	I-NP	O	S-brand

Coadministered	Coadministere	VBN	B-NP	O	O
Concentration	Concentration	NN	I-NP	O	O
Concentration	Concentration	NN	I-NP	O	O

Valproate	Valproate	NN	B-NP	O	S-drug
*	*	SYM	B-NP	O	O
*	*	SYM	B-NP	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
(	(	(	O	O	O
CBZ	CBZ	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O

*	*	SYM	O	O	O
CBZ	CBZ	NN	B-NP	O	O
epoxide	epoxide	NN	I-NP	O	O

*	*	SYM	O	O	O
Not	Not	RB	O	O	O
administered	administer	VBN	B-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
an	an	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
.	.	.	O	O	O

*	*	SYM	O	O	O
*	*	SYM	O	O	O
No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Specific	Specific	JJ	B-NP	O	O
Effects	Effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
Other	Other	NNP	B-NP	O	O
Antiepileptic	Antiepileptic	NNP	I-NP	O	B-group
Drugs	Drugs	NNP	I-NP	O	E-group
Phenytoin	Phenytoin	NNP	I-NP	O	S-drug
:	:	:	O	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand-ME-1
causes	cause	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
10	10	CD	B-NP	O	O
otherwise	otherwise	RB	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	B-protein	O
ingesting	ingest	VBG	B-VP	I-protein	O
phenytoin	phenytoin	NN	B-NP	I-protein	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
steadystate	steadystate	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
(	(	(	O	O	O
Cmin	Cmin	NN	B-NP	O	O
)	)	)	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
17	17	CD	B-NP	O	O
5	5	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	B-protein	O
Cmin	Cmin	NN	I-NP	I-protein	O
increased	increase	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
21	21	CD	B-NP	O	O
5	5	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
1200	1200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Increasing	Increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
felbamate	felbamate	NN	I-NP	O	S-drug-ME-1
dose	dose	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1800	1800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
in	in	IN	B-PP	O	O
six	six	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-2
Cmin	Cmin	NN	I-NP	O	O
to	to	TO	B-PP	O	O
25	25	CD	B-NP	O	O
7	7	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
limit	limit	VBP	B-VP	O	O
adverse	adverse	JJ	B-NP	O	O
experiences	experience	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
achieve	achieve	VB	B-VP	O	O
the	the	DT	B-NP	O	O
felbamate	felbamate	NN	I-NP	O	S-drug-AD-1
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
3600	3600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-AD-2
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
10	10	CD	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
controlled	controlled	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand-ME-1
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	B-drug_n
epoxide	epoxide	NN	I-NP	O	E-drug_n
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
nine	nine	CD	B-NP	O	O
otherwise	otherwise	RB	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
ingesting	ingest	VBG	B-VP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
(	(	(	O	O	O
Cmin	Cmin	NN	B-NP	O	O
)	)	)	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
8	8	CD	B-NP	O	O
2	2	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-ME-1
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	B-protein	O
Cmin	Cmin	NN	I-NP	I-protein	O
decreased	decrease	VBD	B-VP	O	O
31	31	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
5	5	CD	B-NP	O	O
1	1	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
3000	3000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
divided	divide	VBN	B-VP	O	O
into	into	IN	B-PP	O	O
three	three	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	B-drug_n
epoxide	epoxide	NN	I-NP	O	E-drug_n
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
Cmin	Cmin	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
57	57	CD	B-NP	O	O
%	%	NN	I-NP	O	O
from	from	IN	B-PP	O	O
1.0	1.0	CD	B-NP	O	O
0.3	0.3	CD	I-NP	O	O
to	to	TO	B-PP	O	O
1.6	1.6	CD	B-NP	O	O
0.4	0.4	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
similar	similar	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	B-drug_n
epoxide	epoxide	NN	I-NP	O	E-drug_n
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	O	S-drug
:	:	:	O	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand-ME-1
causes	cause	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
four	four	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
ingesting	ingest	VBG	B-VP	O	O
valproate	valproate	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
(	(	(	O	O	O
Cmin	Cmin	NN	B-NP	O	O
)	)	)	O	O	O
valproate	valproate	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
63	63	CD	B-NP	O	O
16	16	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	B-protein	O
Cmin	Cmin	NN	I-NP	I-protein	O
increased	increase	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
78	78	CD	B-NP	O	O
14	14	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
1200	1200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Increasing	Increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
felbamate	felbamate	NN	I-NP	O	S-drug-ME-1
dose	dose	NN	I-NP	O	O
to	to	TO	B-PP	O	O
2400	2400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
steadystate	steadystate	NN	I-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug-ME-2
Cmin	Cmin	NN	I-NP	O	O
to	to	TO	B-PP	O	O
96	96	CD	B-NP	O	O
25	25	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

Corresponding	Correspond	VBG	B-VP	O	O
values	value	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug
Cmin	Cmin	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
7	7	CD	B-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
9	9	CD	B-NP	O	O
4	4	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
11	11	CD	B-NP	O	O
6	6	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
for	for	IN	B-PP	O	O
0	0	CD	B-NP	O	O
,	,	,	I-NP	O	O
1200	1200	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
2400	2400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
Felbatol	Felbatol	NN	I-NP	O	S-brand
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ratios	ratio	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUCs	AUC	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
unbound	unbound	JJ	B-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
AUCs	AUC	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
11.1	11.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
13.0	13.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
11.5	11.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
0	0	CD	B-NP	O	O
,	,	,	I-NP	O	O
1200	1200	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
2400	2400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
causes	cause	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
In	In	IN	B-PP	O	O
12	12	CD	B-NP	O	O
otherwise	otherwise	RB	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
ingesting	ingest	VBG	B-VP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
(	(	(	O	O	O
Cmin	Cmin	NN	B-NP	O	O
)	)	)	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
14.2	14.2	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
Cmin	Cmin	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
17.8	17.8	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
2400	2400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
one	one	CD	B-NP	O	O
week	week	NN	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Antiepileptic	Antiepileptic	JJ	I-NP	O	B-group
Drugs	Drug	NNS	I-NP	O	E-group
on	on	IN	B-PP	O	O
Felbatol	Felbatol	NNP	B-NP	O	S-brand
Phenytoin	Phenytoin	NNP	I-NP	O	S-drug
:	:	:	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug-ME-1
causes	cause	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
doubling	doubling	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand-ME-2
(	(	(	O	O	O
felbamate	felbamate	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
causes	cause	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
45	45	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand-ME-2
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
monotherapy	monotherapy	NN	B-NP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug-ME-1
causes	cause	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand-ME-2
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand-ME-2
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
monotherapy	monotherapy	NN	B-NP	O	O
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	O	S-drug
:	:	:	O	O	O
Available	Available	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valproate	valproate	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
,	,	,	O	O	O
Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valproate	valproate	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
(	(	(	O	O	O
felbamate	felbamate	NN	B-NP	O	S-drug
)	)	)	O	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
:	:	:	O	O	O
It	It	PRP	B-NP	O	O
appears	appear	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
felbamate	felbamate	NN	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Steady	Steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
felbamate	felbamate	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
29	29	CD	B-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
newly	newly	RB	B-NP	O	O
diagnosed	diagnose	VBN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
also	also	RB	B-ADVP	O	O
receiving	receive	VBG	B-VP	O	O
2400	2400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Antacids	Antacid	NNS	B-NP	O	S-group
on	on	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
The	The	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2400	2400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
as	as	IN	B-PP	O	O
monotherapy	monotherapy	NN	B-NP	O	O
given	give	VBN	B-VP	O	O
as	as	IN	B-SBAR	O	O
tablets	tablet	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Erythromycin	Erythromycin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
(	(	(	O	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
,	,	,	O	O	O
Cmin	Cmin	NN	B-NP	B-protein	O
,	,	,	O	O	O
AUC	AUC	NN	B-NP	O	O
,	,	,	O	O	O
CI	CI	NN	B-NP	B-protein	O
/	/	SYM	B-VP	O	O
kg	kg	NN	B-NP	O	O
or	or	CC	I-NP	O	O
tmax	tmax	NN	I-NP	O	O
at	at	IN	B-PP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug
daily	daily	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
3000	3000	CD	B-NP	O	O
or	or	CC	I-NP	O	O
3600	3600	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
in	in	IN	B-PP	O	O
10	10	CD	B-NP	O	O
otherwise	otherwise	RB	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Felbatol	Felbatol	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
Low	Low	NNP	B-NP	O	O
-	-	HYPH	B-NP	O	O
Dose	Dose	NNP	I-NP	O	O
Combination	Combination	NNP	I-NP	O	B-group
Oral	Oral	NNP	I-NP	O	I-group
Contraceptives	Contraceptive	NNPS	I-NP	O	E-group
A	A	NNP	I-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
24	24	CD	B-NP	O	O
nonsmoking	nonsmoking	JJ	I-NP	O	O
,	,	,	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
white	white	JJ	I-NP	O	O
female	female	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
established	establish	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	S-group
regimen	regimen	NN	I-NP	O	O
containing	contain	VBG	B-VP	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
gestodene	gestodene	NN	I-NP	O	S-drug
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
3	3	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
2400	2400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug
from	from	IN	B-PP	O	O
midcycle	midcycle	NN	B-NP	O	O
(	(	(	O	O	O
day	day	NN	B-NP	O	O
15	15	CD	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
midcycle	midcycle	NN	B-NP	O	O
(	(	(	O	O	O
day	day	NN	B-NP	O	O
14	14	CD	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	S-group
cycles	cycle	NNS	I-NP	O	O
.	.	.	O	O	O

Felbamate	Felbamate	NN	B-NP	O	S-drug-ME-1
treatment	treatment	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
42	42	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gestodene	gestodene	NN	I-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
0	0	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
24	24	CD	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
volunteer	volunteer	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
hormonal	hormonal	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ovulation	ovulation	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
one	one	CD	B-NP	O	O
volunteer	volunteer	NN	I-NP	O	O
reported	report	VBD	B-VP	O	O
intermenstrual	intermenstrual	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
during	during	IN	B-PP	O	O
felbamate	felbamate	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
Inhibitors	Inhibitor	NNS	I-NP	O	O
Felodipine	Felodipine	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
with	with	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
several	several	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
either	either	CC	B-PP	O	O
due	due	IN	I-PP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
or	or	CC	O	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
concentration	concentration	NN	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
(	(	(	O	O	O
lower	low	JJR	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	S-drug
inhibitor	inhibitor	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	S-drug
inhibitors	inhibitor	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
conservative	conservative	JJ	I-NP	O	O
approach	approach	NN	I-NP	O	O
to	to	TO	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
felodipine	felodipine	NN	I-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
specific	specific	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
:	:	:	O	O	O
Itraconazole	Itraconazole	NN	B-NP	O	O
Co	Co	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
another	another	DT	B-NP	O	O
extended	extend	VBN	I-NP	O	O
release	release	NN	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
,	,	,	O	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Erythromycin	Erythromycin	NN	B-NP	B-protein	O
Co	Co	AFX	O	I-protein	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
(	(	(	O	O	O
PLENDIL	PLENDIL	NN	B-NP	O	S-drug
)	)	)	O	O	O
with	with	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
2.5	2.5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
about	about	RB	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Grapefruit	Grapefruit	NN	B-NP	B-protein	O
juice	juice	NN	I-NP	I-protein	O
Co	Co	AFX	O	I-protein	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	B-protein	O
Co	Co	AFX	O	I-protein	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
(	(	(	O	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
specific	specific	JJ	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
450	450	CD	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Beta	Beta	NNP	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
Blocking	Blocking	NNP	I-NP	O	O
Agents	Agent	NNPS	I-NP	O	O
A	A	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
metoprolol	metoprolol	NN	B-NP	O	S-drug
demonstrated	demonstrate	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metoprolol	metoprolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
approximately	approximately	RB	B-NP	O	O
31	31	CD	I-NP	O	O
and	and	CC	I-NP	O	O
38	38	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
controlled	control	VBN	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
beta	beta	NN	B-NP	O	B-drug
blockers	blocker	NNS	I-NP	O	E-drug
including	include	VBG	B-PP	O	O
metoprolol	metoprolol	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
concurrently	concurrently	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	O
When	When	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
PLENDIL	PLENDIL	NN	B-NP	O	S-drug
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

Anticonvulsants	Anticonvulsant	NNS	B-NP	O	S-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
maximum	maximum	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug-ME-1
were	be	VBD	B-VP	O	O
considerably	considerably	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
epileptic	epileptic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	S-group-ME-2
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
felodipine	felodipine	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
time	time	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
6	6	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
that	that	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
,	,	,	O	O	O
alternative	alternative	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Tacrolimus	Tacrolimus	NN	B-NP	O	O
Felodipine	Felodipine	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug
blood	blood	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Concomitant	Concomitant	JJ	I-NP	O	O
Therapy	Therapy	NN	I-NP	O	O
In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
spironolactone	spironolactone	NN	I-NP	O	S-drug
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Food	Food	NNP	B-NP	O	O
See	See	NNP	I-NP	O	O
CLINICAL	CLINICAL	NNP	I-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NNP	I-NP	O	O
,	,	,	O	O	O
Pharmacokinetics	Pharmacokinetics	NNP	B-NP	O	O
and	and	CC	O	O	O
Metabolism	Metabolism	NN	B-NP	O	O
.	.	.	O	O	O

Fenfluramine	Fenfluramine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
slightly	slightly	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	B-group-AD-1
depressant	depressant	NN	I-NP	O	I-group-AD-1
drugs	drug	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
fenfluramine	fenfluramine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Anticoagulants	Anticoagulant	NNS	I-NP	O	S-group
CAUTION	CAUTION	NN	I-NP	O	O
SHOULD	SHOULD	NN	I-NP	O	O
BE	BE	NN	I-NP	O	O
EXERCISED	EXERCISED	VBD	B-VP	O	O
WHEN	WHEN	JJ	B-NP	O	O
COUMARIN	COUMARIN	NN	I-NP	O	B-group-AD-1
ANTICOAGULANTS	ANTICOAGULANTS	NNS	I-NP	O	E-group-AD-1
ARE	ARE	VBP	B-VP	O	O
GIVEN	GIVEN	NN	B-NP	O	O
IN	IN	NN	I-NP	O	O
CONJUNCTION	CONJUNCTION	NN	I-NP	O	O
WITH	WITH	NN	I-NP	O	O
TRICOR	TRICOR	NN	I-NP	O	S-brand-AD-2
.	.	.	O	O	O

THE	THE	DT	B-NP	O	O
DOSAGE	DOSAGE	NN	I-NP	O	O
OF	OF	IN	B-PP	O	O
THE	THE	DT	B-NP	O	O
ANTICOAGULANTS	ANTICOAGULANTS	NNS	I-NP	O	S-group
SHOULD	SHOULD	NN	I-NP	O	O
BE	BE	NN	I-NP	O	O
REDUCED	REDUCED	VBD	B-VP	O	O
TO	TO	TO	B-VP	B-cell_type	O
MAINTAIN	MAINTAIN	NNP	I-VP	O	O
THE	THE	DT	B-NP	O	O
PROTHROMBIN	PROTHROMBIN	NN	I-NP	B-protein	O
TIME	TIME	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
INR	INR	NN	I-NP	B-protein	O
AT	AT	IN	B-PP	O	O
THE	THE	DT	B-NP	O	O
DESIRED	DESIRED	NNP	I-NP	O	O
LEVEL	LEVEL	NNP	I-NP	O	O
TO	TO	TO	B-PP	O	O
PREVENT	PREVENT	NN	B-NP	O	O
BLEEDING	BLEEDING	NN	I-NP	O	O
COMPLICATIONS	COMPLICATIONS	NNS	I-NP	O	O
.	.	.	O	O	O

FREQUENT	FREQUENT	NN	B-NP	O	O
PROTHROMBIN	PROTHROMBIN	NN	I-NP	O	O
TIME	TIME	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
INR	INR	NN	I-NP	O	O
DETERMINATIONS	DETERMINATIONS	NN	I-NP	O	O
ARE	ARE	NNP	I-NP	O	O
ADVISABLE	ADVISABLE	NNP	I-NP	O	O
UNTIL	UNTIL	NNP	I-NP	O	O
IT	IT	NNP	I-NP	O	O
HAS	HAS	NNP	I-NP	O	O
BEEN	BEEN	NNP	I-NP	O	O
DEFINITELY	DEFINITELY	NNP	I-NP	O	O
DETERMINED	DETERMINED	NNP	I-NP	O	O
THAT	THAT	NNP	I-NP	O	O
THE	THE	DT	B-NP	O	O
PROTHROMBIN	PROTHROMBIN	NN	I-NP	B-protein	O
TIME	TIME	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
INR	INR	NN	I-NP	B-protein	O
HAS	HAS	VBZ	B-VP	O	O
STABILIZED	STABILIZED	VBN	I-VP	O	O
.	.	.	O	O	O

HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	B-protein	I-group
reductase	reductase	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TRICOR	TRICOR	NN	B-NP	B-protein	S-brand-AD-1
and	and	CC	I-NP	O	O
HMG	HMG	NN	I-NP	B-protein	B-group-AD-2
-	-	HYPH	B-NP	O	I-group-AD-2
CoA	CoA	NN	I-NP	O	I-group-AD-2
reductase	reductase	NN	I-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
unless	unless	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
benefit	benefit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
further	further	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
outweigh	outweigh	VB	I-VP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Resins	Resin	NNS	B-NP	O	S-group
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
bile	bile	NN	B-NP	O	B-group
acid	acid	NN	I-NP	O	I-group
sequestrants	sequestrant	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
bind	bind	VB	I-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
take	take	VB	I-VP	O	O
TRICOR	TRICOR	NN	B-NP	B-protein	S-brand-ME-1
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
1	1	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
bile	bile	NN	I-NP	O	B-group-ME-2
acid	acid	NN	I-NP	O	I-group-ME-2
binding	binding	NN	I-NP	O	I-group-ME-2
resin	resin	NN	I-NP	O	E-group-ME-2
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
impeding	impede	VBG	I-VP	O	O
its	its	PRP$	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Because	Because	IN	B-SBAR	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-EF-1
can	can	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	O
with	with	IN	B-PP	O	O
decreases	decrease	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
rises	rise	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
because	because	IN	B-SBAR	O	O
renal	renal	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
route	route	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fibrate	fibrate	NN	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
including	include	VBG	B-PP	O	O
TRICOR	TRICOR	NN	B-NP	B-protein	S-brand-EF-2
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
that	that	IN	B-NP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
will	will	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
deterioration	deterioration	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
benefits	benefit	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
TRICOR	TRICOR	NN	B-NP	B-protein	S-brand-AD-1
with	with	IN	B-PP	O	O
immunosuppressants	immunosuppressant	NNS	B-NP	O	S-group-AD-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
nephrotoxic	nephrotoxic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
lowest	low	JJS	I-NP	O	O
effective	effective	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
employed	employ	VBN	B-VP	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
human	human	JJ	B-NP	B-DNA	O
liver	liver	NN	I-NP	I-DNA	O
microsomes	microsome	NNS	I-NP	I-DNA	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
fenofibrate	fenofibrate	NN	B-NP	O	S-drug
and	and	CC	O	O	O
fenofibric	fenofibric	JJ	B-NP	O	B-drug_n
acid	acid	NN	I-NP	O	E-drug_n
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
(	(	(	O	I-protein	O
CYP	CYP	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
P450	P450	NN	B-NP	I-protein	O
isoforms	isoform	NNS	I-NP	I-protein	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
weak	weak	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2A6	CYP2A6	NN	I-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
mild	mild	JJ	B-ADJP	O	O
-	-	HYPH	O	O	O
to	to	TO	B-PP	O	O
-	-	HYPH	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
at	at	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Potentiation	Potentiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
type	type	NN	I-NP	O	I-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
INR	INR	NN	I-NP	B-protein	O
.	.	.	O	O	O

Bile	Bile	NN	B-NP	O	B-group
acid	acid	NN	I-NP	O	I-group
sequestrants	sequestrant	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
bind	bind	VB	I-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
fenofibrate	fenofibrate	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
1	1	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
bile	bile	NN	I-NP	O	B-group-AD-2
acid	acid	NN	I-NP	O	I-group-AD-2
binding	binding	NN	I-NP	O	I-group-AD-2
resin	resin	NN	I-NP	O	E-group-AD-2
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
impeding	impede	VBG	I-VP	O	O
its	its	PRP$	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fenofibrate	fenofibrate	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
equivalent	equivalent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
145mg	145mg	NN	B-NP	O	O
TRICOR	TRICOR	NN	I-NP	O	S-brand-ME-1
)	)	)	O	O	O
with	with	IN	B-PP	O	O
pravastatin	pravastatin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
pravastatin	pravastatin	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
36	36	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
from	from	IN	B-PP	O	O
69	69	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
to	to	TO	B-PP	O	O
321	321	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
from	from	IN	B-PP	O	O
54	54	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
to	to	TO	B-PP	O	O
128	128	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hydroxy	hydroxy	NN	I-NP	O	O
-	-	HYPH	O	O	O
iso	iso	AFX	O	O	O
-	-	HYPH	O	O	O
pravastatin	pravastatin	NN	B-NP	O	O
by	by	IN	B-PP	O	O
55	55	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
from	from	IN	B-PP	O	O
32	32	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
to	to	TO	B-PP	O	O
314	314	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
39	39	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
from	from	IN	B-PP	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
to	to	TO	B-PP	O	O
261	261	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
23	23	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
adults	adult	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pravastatin	pravastatin	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fenofibric	fenofibric	JJ	B-NP	O	B-drug_n
acid	acid	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fenofibrate	fenofibrate	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
equivalent	equivalent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
145	145	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
TRICOR	TRICOR	NN	I-NP	O	S-brand-ME-1
)	)	)	O	O	O
with	with	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
17	17	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
from	from	IN	B-PP	O	O
67	67	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
to	to	TO	B-PP	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
22	22	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
males	male	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
atorvastatin	atorvastatin	NN	I-NP	O	S-drug
Cmax	Cmax	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
fenofibrate	fenofibrate	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fenofibric	fenofibric	JJ	B-NP	O	B-drug_n
acid	acid	NN	I-NP	O	E-drug_n
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug

Drug	Drug	NN	B-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Beta	Beta	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
Blockers	Blocker	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fenoldopam	fenoldopam	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-AD-2
-	-	HYPH	B-VP	O	I-group-AD-2
blockers	blocker	NNS	B-NP	O	E-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
unexpected	unexpected	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
could	could	MD	B-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
blocker	blocker	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
reflex	reflex	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
fenoldopam	fenoldopam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
,	,	,	O	O	O
General	General	NNP	B-NP	O	O
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
fenoldopam	fenoldopam	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
safely	safely	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group
and	and	CC	O	O	O
sublingual	sublingual	JJ	B-NP	O	O
nitroglycerin	nitroglycerin	NN	I-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
limited	limited	JJ	B-NP	O	O
experience	experience	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
alpha	alpha	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	B-protein	B-group
channel	channel	NN	I-NP	I-protein	I-group
-	-	HYPH	B-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
(	(	(	O	O	O
both	both	CC	O	O	O
thiazide	thiazide	NN	B-NP	O	S-group
-	-	HYPH	O	O	O
like	like	JJ	O	O	O
and	and	CC	O	O	O
loop	loop	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-1
decreases	decrease	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
biologic	biologic	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fenoprofen	fenoprofen	NN	B-NP	O	S-drug-ME-2
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hydroxylated	hydroxylate	VBN	B-NP	O	B-drug_n
fenoprofen	fenoprofen	NN	I-NP	O	E-drug_n
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
fenoprofen	fenoprofen	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-ME-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
totally	totally	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
,	,	,	O	O	O
enzyme	enzyme	NN	B-NP	B-protein	O
induction	induction	NN	I-NP	O	O
and	and	CC	O	O	O
displacement	displacement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fenoprofen	fenoprofen	NN	B-NP	O	S-drug
from	from	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-DNA	O
albumin	albumin	NN	I-NP	I-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
are	be	VBP	B-VP	O	O
possibilities	possibility	NNS	B-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
Nalfon	Nalfon	NNP	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
any	any	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
beyond	beyond	IN	B-PP	O	O
that	that	DT	B-NP	O	O
obtained	obtain	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
because	because	IN	B-SBAR	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
excretion	excretion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Nalfon	Nalfon	NNP	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Nalfon	Nalfon	NNP	B-NP	O	S-brand-AD-1
and	and	CC	O	O	O
salicylates	salicylate	VBZ	B-NP	O	S-group-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inducer	inducer	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fenoprofen	fenoprofen	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
or	or	CC	O	O	O
withdrawn	withdraw	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Nalfon	Nalfon	NNP	B-NP	O	S-brand-AD-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
fenoprofen	fenoprofen	NN	B-NP	O	S-drug
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
affinity	affinity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
albumin	albumin	NN	B-NP	B-protein	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
displace	displace	VB	I-VP	O	O
from	from	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
binding	bind	VBG	I-NP	O	O
sites	site	NNS	I-NP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	B-ADVP	O	O
albumin	albumin	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
drug	drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Theoretically	Theoretically	RB	B-ADVP	O	O
,	,	,	O	O	O
fenoprofen	fenoprofen	NN	B-NP	O	S-drug
could	could	MD	B-VP	O	O
likewise	likewise	RB	I-VP	O	O
be	be	VB	I-VP	O	O
displaced	displace	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
hydantoins	hydantoin	NNS	B-NP	O	S-group
,	,	,	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group
,	,	,	O	O	O
or	or	CC	O	O	O
sulfonylureas	sulfonylurea	NNS	B-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
from	from	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
type	type	NN	I-NP	O	I-group-EF-1
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Nalfon	Nalfon	NN	B-NP	O	S-brand-EF-2
to	to	TO	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
could	could	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
under	under	IN	B-PP	O	O
careful	careful	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Nalfon	Nalfon	NNP	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
resistant	resistant	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
loop	loop	NN	B-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
Nalfon	Nalfon	NNP	B-NP	O	S-brand-AD-1
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
steroid	steroid	NN	I-NP	O	S-group-AD-2
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
any	any	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
steroid	steroid	NN	B-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
gradual	gradual	JJ	B-ADJP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sudden	sudden	JJ	B-NP	O	O
steroid	steroid	NN	I-NP	O	S-group
withdrawal	withdrawal	NN	I-NP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
Affecting	Affect	VBG	B-VP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
Isoenzyme	Isoenzyme	NN	I-NP	I-protein	O
System	System	NN	I-NP	O	O
Fentanyl	Fentanyl	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
mainly	mainly	RB	B-ADVP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	B-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
potential	potential	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
DURAGESIC	DURAGESIC	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
affect	affect	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Coadminstration	Coadminstration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
3A4	3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DURAGESIC	DURAGESIC	NN	B-NP	O	S-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
transdermal	transdermal	JJ	B-NP	O	O
fentanyl	fentanyl	NN	I-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-ME-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
potent	potent	JJ	I-NP	O	O
3A4	3A4	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
nefazadone	nefazadone	NN	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
fentanyl	fentanyl	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
transdermal	transdermal	JJ	B-NP	O	O
fentanyl	fentanyl	NN	I-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
fentanyl	fentanyl	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
adverse	adverse	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
serious	serious	JJ	B-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
situation	situation	NN	I-NP	O	O
,	,	,	O	O	O
special	special	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
care	care	NN	I-NP	O	O
and	and	CC	I-NP	O	O
observation	observation	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
appropriate	appropriate	JJ	B-ADJP	O	O
.	.	.	O	O	O

Central	Central	NNP	B-NP	O	B-group
Nervous	Nervous	NNP	I-NP	O	I-group
System	System	NNP	I-NP	O	I-group
Depressants	Depressant	NNPS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DURAGESIC	DURAGESIC	NN	B-NP	O	S-brand-EF-1
(	(	(	O	O	O
fentanyl	fentanyl	NN	B-NP	O	S-drug-EF-1
transdermal	transdermal	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
central	central	JJ	I-NP	O	B-group-EF-2
nervous	nervous	JJ	I-NP	O	I-group-EF-2
system	system	NN	I-NP	O	I-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
but	but	CC	O	O	O
not	not	RB	B-VP	O	O
limited	limit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
other	other	JJ	B-NP	O	O
opioids	opioid	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
hypnotics	hypnotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
skeletal	skeletal	JJ	B-NP	O	B-group-EF-2
muscle	muscle	NN	I-NP	O	I-group-EF-2
relaxants	relaxant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
respiratory	respiratory	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
,	,	,	O	O	O
hypotension	hypotension	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
profound	profound	JJ	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
potentially	potentially	RB	B-VP	O	O
result	result	VBP	I-VP	O	O
in	in	IN	B-PP	O	O
coma	coma	NN	B-NP	O	O
or	or	CC	I-NP	O	O
death	death	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
combined	combine	VBN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
contemplated	contemplate	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
DURAGESIC	DURAGESIC	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
received	receive	VBN	I-VP	O	O
MAOI	MAOI	NN	B-NP	O	S-group-AD-2
within	within	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
because	because	IN	B-SBAR	O	O
severe	severe	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
unpredictable	unpredictable	JJ	I-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
by	by	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
opioid	opioid	JJ	B-NP	O	B-group-AD-2
analgesics	analgesic	NNS	I-NP	O	E-group-AD-2

Drug	Drug	NN	B-NP	O	O
Interaction	Interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Erythromycin	Erythromycin	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
Ketoconazole	Ketoconazole	NN	I-NP	O	S-drug
Fexofenadine	Fexofenadine	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
minimal	minimal	JJ	B-NP	O	O
(	(	(	O	O	O
ca	ca	NN	B-NP	O	O
.	.	.	O	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
metabolism	metabolism	NN	B-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
co	co	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	B-drug-ME-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-1
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-ME-2
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Fexofenadine	Fexofenadine	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
2	2	CD	B-NP	O	O
separate	separate	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
fexofenadine	fexofenadine	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	O	O	O
(	(	(	O	O	O
240	240	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
total	total	JJ	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
erythromycin	erythromycin	NN	B-NP	B-protein	S-drug
500	500	CD	I-NP	I-protein	O
mg	mg	NN	I-NP	I-protein	O
every	every	DT	B-NP	I-protein	O
8	8	CD	I-NP	I-protein	O
hours	hour	NNS	I-NP	I-protein	O
or	or	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
under	under	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
24	24	CD	B-NP	O	O
,	,	,	O	O	O
each	each	DT	B-NP	O	O
study	study	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
or	or	CC	O	O	O
QTc	QTc	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
subjects	subject	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
summarized	summarize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
table	table	NN	I-NP	O	O
:	:	:	O	O	O
Effects	Effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
fexofenadine	fexofenadine	NN	I-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
12	12	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
(	(	(	O	O	O
two	two	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	O	O	O
recommended	recommend	VBD	B-VP	O	O
twice	twice	RB	B-NP	O	O
daily	daily	RB	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
24	24	CD	B-NP	O	O
)	)	)	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
Drug	Drug	NN	I-NP	O	O

cmaxSS	cmaxSS	NN	B-NP	O	O
(	(	(	O	O	O
Peak	Peak	NN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
)	)	)	O	O	O

AUCss	AUCss	NN	B-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
12h	12h	NN	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
Extent	Extent	NN	B-NP	O	O
of	of	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
)	)	)	O	O	O

Erythromycin	Erythromycin	NN	B-NP	O	S-drug
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
hrs	hr	NNS	I-NP	O	O
)	)	)	O	O	O

+	+	SYM	O	O	O
82	82	CD	B-NP	O	O
%	%	NN	I-NP	O	O

+	+	SYM	O	O	O
109	109	CD	B-NP	O	O
%	%	NN	I-NP	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O

+	+	SYM	O	O	O
135	135	CD	B-NP	O	O
%	%	NN	I-NP	O	O

+	+	SYM	O	O	O
164	164	CD	B-NP	O	O
%	%	NN	I-NP	O	O

The	The	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
achieved	achieve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
adequate	adequate	JJ	B-ADJP	O	O
and	and	CC	O	O	O
well	well	RB	B-VP	O	O
-	-	HYPH	I-VP	O	O
controlled	control	VBN	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
in	in	FW	B-ADVP	O	O
situ	situ	FW	I-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
animal	animal	NN	I-NP	O	O
models	model	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
or	or	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	B-protein	S-drug-ME-1
co	co	AFX	O	I-protein	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
enhances	enhance	VBZ	B-VP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	S-drug-ME-2
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
observed	observe	VBN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
transport	transport	NN	B-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
p	p	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
.	.	.	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
animal	animal	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
enhancing	enhance	VBG	B-VP	O	O
absorption	absorption	NN	B-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
decreases	decrease	VBZ	B-VP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	S-drug-ME-2
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
biliary	biliary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Antacids	Antacid	NNS	B-NP	O	S-group
Administration	Administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
120	120	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	B-drug-ME-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-1
(	(	(	O	O	O
2	2	CD	B-NP	O	O
x	x	SYM	O	O	O
60	60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
capsule	capsule	NN	I-NP	O	O
)	)	)	O	O	O
within	within	IN	B-PP	O	O
15	15	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug-ME-2
containing	contain	VBG	B-VP	O	O
antacid	antacid	NN	B-NP	O	S-group-ME-2
(	(	(	O	O	O
Maalox	Maalox	NN	B-NP	O	S-brand-ME-2
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
by	by	IN	B-PP	O	O
41	41	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
cmax	cmax	NN	B-NP	O	O
by	by	IN	B-PP	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

ALLEGRA	ALLEGRA	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
time	time	NN	B-NP	O	O
with	with	IN	B-PP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-AD-2
and	and	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug-AD-2
containing	contain	VBG	B-VP	O	O
antacids	antacid	NNS	B-NP	O	S-group
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Fruit	Fruit	NNP	B-NP	O	O
Juices	Juice	NNPS	I-NP	O	O
Fruit	Fruit	NNP	I-NP	O	O
juices	juice	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
grapefruit	grapefruit	NN	B-NP	O	O
,	,	,	I-NP	O	O
orange	orange	NN	I-NP	O	O
and	and	CC	I-NP	O	O
apple	apple	NN	I-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
and	and	CC	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	S-drug
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
3	3	CD	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
histamine	histamine	NN	B-NP	O	S-drug
induced	induce	VBD	B-VP	O	O
skin	skin	NN	B-NP	O	O
wheals	wheal	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
flares	flare	NNS	I-NP	O	O
coupled	couple	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
population	population	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
size	size	NN	I-NP	O	O
of	of	IN	B-PP	O	O
wheal	wheal	NN	B-NP	O	O
and	and	CC	I-NP	O	O
flare	flare	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
larger	large	JJR	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
grapefruit	grapefruit	NN	B-NP	O	O
or	or	CC	I-NP	O	O
orange	orange	NN	I-NP	O	O
juices	juice	NNS	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
water	water	NN	B-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
reports	report	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
extrapolated	extrapolate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
other	other	JJ	B-NP	O	O
fruit	fruit	NN	I-NP	O	O
juices	juice	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
apple	apple	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
observations	observation	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
population	population	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combined	combine	VBN	I-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
grapefruit	grapefruit	NN	B-NP	O	O
and	and	CC	I-NP	O	O
orange	orange	NN	I-NP	O	O
juices	juice	NNS	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
bioequivalence	bioequivalence	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
36	36	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
maximize	maximize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fexofenadine	fexofenadine	NN	B-NP	O	S-drug
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
ALLEGRA	ALLEGRA	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
water	water	NN	B-NP	O	O

Drug	Drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
NEUPOGEN	NEUPOGEN	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
fully	fully	RB	B-ADJP	O	O
evaluated	evaluate	VBN	I-ADJP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neutrophils	neutrophil	NNS	B-NP	B-cell_type	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
importance	importance	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

Finasteride	Finasteride	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
-	-	HYPH	B-VP	O	O
linked	link	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	O	O	O
metabolizing	metabolize	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Compounds	Compound	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
tested	test	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
include	include	VBP	B-VP	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
meaningful	meaningful	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
Although	Although	IN	B-SBAR	O	O
specific	specific	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
finasteride	finasteride	NN	B-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
were	be	VBD	B-VP	O	O
concomitantly	concomitantly	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
,	,	,	O	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
-	-	HYPH	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
,	,	,	O	O	O
analgesics	analgesic	NNS	B-NP	O	S-group
,	,	,	O	O	O
angiotensin	angiotensin	NN	B-NP	B-protein	B-group
-	-	HYPH	O	I-protein	I-group
converting	convert	VBG	B-VP	I-protein	I-group
enzyme	enzyme	NN	B-NP	I-protein	I-group
(	(	(	O	O	I-group
ACE	ACE	NN	B-NP	O	I-group
)	)	)	O	O	I-group
inhibitors	inhibitor	NNS	B-NP	O	E-group
,	,	,	O	O	O
anticonvulsants	anticonvulsant	NNS	B-NP	O	S-group
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
,	,	,	O	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
nitrates	nitrate	NNS	I-NP	O	S-group
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
H2	H2	NN	B-NP	O	B-group
antagonists	antagonist	NNS	I-NP	O	E-group
,	,	,	O	O	O
HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	O	I-group
reductase	reductase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
prostaglandin	prostaglandin	NN	B-NP	O	B-group
synthetase	synthetase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
also	also	RB	B-VP	O	O
referred	refer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
as	as	IN	B-PP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
quinolone	quinolone	NN	B-NP	O	B-group
anti	anti	AFX	O	O	I-group
-	-	HYPH	O	O	I-group
infectives	infective	NNS	B-NP	O	E-group
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Finasteride	Finasteride	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
circulating	circulate	VBG	B-VP	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cortisol	cortisol	NN	B-NP	O	O
,	,	,	O	O	O
thyroid	thyroid	NN	B-NP	O	O
-	-	HYPH	O	O	O
stimulating	stimulate	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
thyroxine	thyroxine	NN	B-NP	O	O
,	,	,	O	O	O
nor	nor	CC	O	O	O
did	do	VBD	O	O	O
it	it	PRP	B-NP	O	O
affect	affect	VB	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
lipid	lipid	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
total	total	JJ	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	O	O
,	,	,	O	O	O
low	low	JJ	B-NP	B-protein	O
-	-	HYPH	I-NP	I-protein	O
density	density	NN	I-NP	I-protein	O
lipoproteins	lipoprotein	NNS	I-NP	I-protein	O
,	,	,	O	O	O
high	high	JJ	B-NP	B-protein	O
-	-	HYPH	I-NP	I-protein	O
density	density	NN	I-NP	I-protein	O
lipoproteins	lipoprotein	NNS	I-NP	I-protein	O
and	and	CC	I-NP	O	O
triglycerides	triglyceride	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
bone	bone	NN	B-NP	O	O
mineral	mineral	NN	I-NP	O	O
density	density	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
finasteride	finasteride	NN	B-NP	O	S-drug
,	,	,	O	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
meaningful	meaningful	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
luteinizing	luteinize	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
(	(	(	O	O	O
LH	LH	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
follicle	follicle	NN	B-NP	O	O
-	-	HYPH	O	O	O
stimulating	stimulate	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
(	(	(	O	O	O
FSH	FSH	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
prolactin	prolactin	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
finasteride	finasteride	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
response	response	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LH	LH	NN	B-NP	O	O
and	and	CC	I-NP	O	O
FSH	FSH	NN	I-NP	O	O
to	to	TO	B-PP	O	O
gonadotropin	gonadotropin	NN	B-NP	O	O
-	-	HYPH	O	O	O
releasing	release	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
hypothalamic	hypothalamic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
pituitary	pituitary	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
testicular	testicular	JJ	I-NP	O	O
axis	axis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
PROPECIA	PROPECIA	NN	B-NP	O	S-brand
(	(	(	O	O	O
finasteride	finasteride	NN	B-NP	O	S-drug
,	,	,	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
men	man	NNS	B-NP	O	O
18	18	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
41	41	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	B-protein	O
prostate	prostate	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	I-protein	O
specific	specific	JJ	I-NP	I-protein	O
antigen	antigen	NN	I-NP	I-protein	O
(	(	(	O	O	O
PSA	PSA	NN	B-NP	B-protein	O
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
0.7	0.7	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
to	to	TO	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
at	at	IN	B-PP	O	O
Month	Month	NNP	B-NP	O	O
12	12	CD	I-NP	O	O
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
PROSCAR	PROSCAR	NN	B-NP	O	S-brand
(	(	(	O	O	O
finasteride	finasteride	NN	B-NP	O	S-drug
,	,	,	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
men	man	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
benign	benign	JJ	B-NP	O	O
prostatic	prostatic	JJ	I-NP	O	O
hyperplasia	hyperplasia	NN	I-NP	O	O
(	(	(	O	O	O
BPH	BPH	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
PSA	PSA	NN	B-NP	B-protein	O
levels	level	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
account	account	NN	B-NP	O	O
for	for	IN	B-PP	O	O
proper	proper	JJ	B-NP	O	O
interpretation	interpretation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
PSA	PSA	NN	I-NP	B-protein	O
when	when	WRB	B-ADVP	O	O
evaluating	evaluate	VBG	B-VP	O	O
men	man	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
finasteride	finasteride	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
.	.	.	O	O	O

TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
digitalis	digitalis	NN	B-NP	O	B-group
preparations	preparation	NNS	I-NP	O	E-group
or	or	CC	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	O	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
without	without	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand-ME-1
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
stabilized	stabilize	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
13	13	CD	I-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
19	19	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
at	at	IN	B-PP	O	O
six	six	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
postdose	postdose	VBP	B-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand-ME-1
and	and	CC	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug-ME-2
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
flecainide	flecainide	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
about	about	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
about	about	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
control	control	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
each	each	DT	B-NP	O	O
found	find	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
negative	negative	JJ	B-NP	O	O
inotropic	inotropic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
;	;	:	O	O	O

when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
additive	additive	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug-EF-2
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PR	PR	NN	I-NP	B-protein	O
interval	interval	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
additive	additive	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
concurrently	concurrently	RB	B-ADVP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
experience	experience	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
negative	negative	JJ	I-NP	O	O
inotropic	inotropic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	NN	B-NP	O	B-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
flecainide	flecainide	NN	B-NP	O	S-drug-EF-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
recognized	recognize	VBN	I-VP	O	O
.	.	.	O	O	O

Flecainide	Flecainide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
extensively	extensively	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	O	S-drug
binding	binding	NN	I-NP	O	O
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	B-protein	O
plasma	plasma	NN	I-NP	I-protein	O
proteins	protein	NNS	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
either	either	CC	O	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
or	or	CC	O	O	O
only	only	RB	B-ADJP	O	O
slightly	slightly	RB	I-ADJP	O	O
less	less	JJR	I-ADJP	O	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
highly	highly	RB	B-ADVP	O	O
protein	protein	NN	B-NP	O	O
bound	bind	VBD	B-VP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
)	)	)	O	O	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
without	without	IN	B-PP	O	O
apparent	apparent	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Limited	Limited	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
known	know	VBN	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
(	(	(	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
indicate	indicate	VBP	B-VP	O	O
only	only	RB	B-NP	O	O
a	a	DT	I-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	O	S-drug-ME-2
elimination	elimination	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
1	1	CD	B-NP	O	O
gm	gm	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
one	one	CD	B-NP	O	O
week	week	NN	I-NP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
flecainide	flecainide	NN	I-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
increased	increase	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
flecainide	flecainide	VB	I-VP	O	S-drug-ME-2
therapy	therapy	NN	B-NP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
flecainide	flecainide	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
two	two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	I-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
flecainide	flecainide	NN	B-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450IID6	P450IID6	NN	I-NP	I-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
might	might	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
flecainide	flecainide	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
;	;	:	O	O	O

especially	especially	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
extensive	extensive	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
little	little	JJ	B-NP	O	O
experience	experience	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand
and	and	CC	O	O	O
either	either	CC	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
both	both	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
negative	negative	JJ	B-NP	O	O
inotropic	inotropic	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand
are	be	VBP	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
,	,	,	O	O	O
neither	neither	CC	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug-AD-1
nor	nor	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
TAMBOCOR	TAMBOCOR	NN	B-NP	O	S-brand-AD-2
unless	unless	IN	B-SBAR	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
judgment	judgment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
benefits	benefit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
outweigh	outweigh	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
too	too	RB	B-NP	O	O
little	little	JJ	I-NP	O	O
experience	experience	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TAMBOCOR	TAMBOCOR	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug
to	to	TO	B-VP	O	O
recommend	recommend	VB	I-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Combination	Combination	NN	B-NP	O	O
Therapy	Therapy	NN	I-NP	O	O
:	:	:	O	O	O
Any	Any	DT	B-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
which	which	WDT	B-NP	O	O
adds	add	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
stress	stress	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
nutrition	nutrition	NN	B-NP	O	O
or	or	CC	O	O	O
depresses	depress	VBZ	B-VP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
function	function	NN	I-NP	O	O
will	will	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Floxuridine	Floxuridine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cytosine	Cytosine	NN	B-NP	O	B-drug-EF-1
arabinoside	arabinoside	NN	I-NP	O	E-drug-EF-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
cytostatic	cytostatic	JJ	I-NP	O	B-group
agent	agent	NN	I-NP	O	E-group
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inactivate	inactivate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antifungal	antifungal	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flucytosine	flucytosine	NN	B-NP	O	S-drug-EF-2
by	by	IN	B-PP	O	O
competitive	competitive	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
impair	impair	VBP	B-VP	O	O
glomerular	glomerular	JJ	B-NP	O	O
filtration	filtration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
biological	biological	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flucytosine	flucytosine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
Measurement	Measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Jaffe	Jaffe	NNP	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
Ancobon	Ancobon	NNP	B-NP	O	S-brand
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
determination	determination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

Most	Most	JJS	B-NP	O	O
automated	automate	VBN	I-NP	O	O
equipment	equipment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	O	O
makes	make	VBZ	B-VP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Jaffe	Jaffe	NNP	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
FLUDARA	FLUDARA	NN	B-NP	O	S-brand-AD-1
FOR	FOR	NN	I-NP	O	O
INJECTION	INJECTION	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
pentostatin	pentostatin	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
adrenal	adrenal	JJ	B-NP	O	B-group
corticosteroids	corticosteroid	NNS	I-NP	O	E-group
.	.	.	O	O	O

Amphotericin	Amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
or	or	CC	I-NP	O	O
potassium	potassium	NN	I-NP	O	B-group
-	-	HYPH	O	O	I-group
depleting	deplete	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
(	(	(	O	O	O
benzothiadiazines	benzothiadiazine	NNS	B-NP	O	S-group
and	and	CC	O	O	O
related	related	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
ethacrynic	ethacrynic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
and	and	CC	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
)	)	)	O	O	O
enhanced	enhance	VBD	B-VP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
.	.	.	O	O	O

Check	Check	NN	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
frequent	frequent	JJ	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
;	;	:	O	O	O

use	use	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
enhanced	enhance	VBD	B-VP	O	O
possibility	possibility	NN	B-NP	O	O
of	of	IN	B-PP	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	O
or	or	CC	O	O	O
digitalis	digitalis	NN	B-NP	O	S-group
toxicity	toxicity	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
.	.	.	O	O	O

Monitor	Monitor	NN	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
;	;	:	O	O	O

use	use	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
decreased	decrease	VBD	B-VP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Monitor	Monitor	NN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
adjust	adjust	JJ	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
.	.	.	O	O	O

Antidiabetic	Antidiabetic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
oral	oral	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
diminished	diminish	VBD	B-VP	O	O
antidiabetic	antidiabetic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Monitor	Monitor	NN	B-NP	O	O
for	for	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
;	;	:	O	O	O

adjust	adjust	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antidiabetic	antidiabetic	JJ	B-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
upward	upward	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
increased	increase	VBD	B-VP	O	O
ulcerogenic	ulcerogenic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
;	;	:	O	O	O

decreased	decrease	VBN	B-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
.	.	.	O	O	O

Rarely	Rarely	RB	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group
toxicity	toxicity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
discontinue	discontinue	VBP	B-VP	O	O
steroids	steroid	NNS	B-NP	O	S-group-EF-1
after	after	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Monitor	Monitor	NN	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group
levels	level	NNS	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
for	for	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
;	;	:	O	O	O

adjust	adjust	JJ	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
effect	effect	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

Barbiturates	Barbiturate	NNS	B-NP	O	S-group-ME-1
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
or	or	CC	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
metabolic	metabolic	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fludrocortisone	fludrocortisone	NN	B-NP	O	B-drug-ME-2
acetate	acetate	NN	I-NP	O	E-drug-ME-2
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Observe	Observe	VB	B-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
for	for	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
diminished	diminish	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
steroid	steroid	NN	B-NP	O	S-group
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
steroid	steroid	NN	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
.	.	.	O	O	O

Anabolic	Anabolic	JJ	B-NP	O	B-group
steroids	steroid	NNS	I-NP	O	E-group
(	(	(	O	O	O
particularly	particularly	RB	B-NP	O	O
C	C	NN	I-NP	O	O
-	-	HYPH	O	O	O
17	17	CD	B-NP	O	O
alkylated	alkylate	VBN	I-NP	O	O
androgens	androgen	NNS	I-NP	O	S-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
oxymetholone	oxymetholone	NN	B-NP	O	S-drug
,	,	,	O	O	O
methandrostenolone	methandrostenolone	NN	B-NP	O	S-drug
,	,	,	O	O	O
norethandrolone	norethandrolone	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
similar	similar	JJ	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
)	)	)	O	O	O
enhanced	enhance	VBD	B-VP	O	O
tendency	tendency	NN	B-NP	O	O
toward	toward	IN	B-PP	O	O
edema	edema	NN	B-NP	O	O
.	.	.	O	O	O

Use	Use	NNP	B-NP	O	O
caution	caution	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
giving	give	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
together	together	RB	B-ADVP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Vaccines	Vaccine	NNS	B-NP	O	S-group
neurological	neurological	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
and	and	CC	O	O	O
lack	lack	NN	B-NP	O	O
of	of	IN	B-PP	O	O
antibody	antibody	NN	B-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Estrogen	Estrogen	NN	B-NP	O	S-group
increased	increase	VBD	B-VP	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
binding	bind	VBG	B-NP	I-protein	O
globulin	globulin	NN	I-NP	I-protein	O
,	,	,	O	O	O
thereby	thereby	RB	B-ADVP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
bound	bind	VBN	I-NP	O	O
(	(	(	O	O	O
inactive	inactive	JJ	O	O	O
)	)	)	O	O	O
fraction	fraction	NN	B-NP	O	O
;	;	:	O	O	O

this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
at	at	IN	B-VP	O	O
least	least	JJS	I-VP	O	O
balanced	balance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
estrogen	estrogen	NN	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
amounts	amount	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
estrogen	estrogen	NN	B-NP	O	S-group
is	be	VBZ	B-VP	O	O
terminated	terminate	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Corticosteroids	Corticosteroid	NNS	I-NP	O	S-group
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
nitrobluetetrazolium	nitrobluetetrazolium	NN	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
bacterial	bacterial	JJ	B-NP	O	O
infection	infection	NN	I-NP	O	O
and	and	CC	O	O	O
produce	produce	VBP	B-VP	O	O
false	false	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
negative	negative	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O

Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
central	central	JJ	B-NP	O	B-group
nervous	nervous	JJ	I-NP	O	I-group
system	system	NN	I-NP	O	I-group
depressants	depressant	NNS	I-NP	O	E-group
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
specifically	specifically	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
deleterious	deleterious	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ROMAZICON	ROMAZICON	NN	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
narcotics	narcotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
inhalational	inhalational	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
,	,	,	O	O	O
muscle	muscle	NN	B-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group
and	and	CC	O	O	O
muscle	muscle	NN	B-NP	O	O
relaxant	relaxant	JJ	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
administered	administer	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
sedation	sedation	NN	B-NP	O	O
or	or	CC	I-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
.	.	.	O	O	O

Particular	Particular	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
ROMAZICON	ROMAZICON	NN	B-NP	O	S-brand-EF-1
in	in	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
mixed	mix	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
overdosage	overdosage	NN	I-NP	O	O
since	since	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
convulsions	convulsion	NNS	B-NP	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
dysrhythmias	dysrhythmia	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
taken	take	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
overdose	overdose	NN	B-NP	O	O
(	(	(	O	O	O
especially	especially	RB	B-NP	O	O
cyclic	cyclic	JJ	I-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
)	)	)	O	O	O
may	may	MD	B-VP	O	O
emerge	emerge	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reversal	reversal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
benzodiazepine	benzodiazepine	NN	I-NP	O	S-group
effect	effect	NN	I-NP	O	O
by	by	IN	B-PP	O	O
flumazenil	flumazenil	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ROMAZICON	ROMAZICON	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
epileptic	epileptic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
benzodiazepine	benzodiazepine	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
ROMAZICON	ROMAZICON	NN	B-NP	O	S-brand-EF-1
exerts	exert	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
intrinsic	intrinsic	JJ	I-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
abrupt	abrupt	JJ	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
benzodiazepine	benzodiazepine	NN	I-NP	O	S-group-EF-2
agonist	agonist	NN	I-NP	O	O
can	can	MD	B-VP	O	O
give	give	VB	I-VP	O	O
rise	rise	NN	B-NP	O	O
to	to	TO	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
epileptic	epileptic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

ROMAZICON	ROMAZICON	NN	B-NP	O	S-brand-EF-1
blocks	block	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-EF-2
by	by	IN	B-PP	O	O
competitive	competitive	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
level	level	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nonbenzodiazepine	nonbenzodiazepine	JJ	B-NP	O	O
agonists	agonist	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
benzodiazepine	benzodiazepine	NN	B-NP	B-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
zopiclone	zopiclone	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
triazolopyridazines	triazolopyridazine	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
others	other	NNS	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
blocked	block	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ROMAZICON	ROMAZICON	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
unaltered	unaltered	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
flumazenil	flumazenil	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
vice	vice	NN	I-NP	O	O
versa	versa	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
flumazenil	flumazenil	NN	I-NP	O	S-drug
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
in	in	IN	B-PP	O	O
Ambulatory	Ambulatory	JJ	B-NP	O	O
Patients	Patient	NNS	I-NP	O	O
The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ROMAZICON	ROMAZICON	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
wear	wear	VB	I-VP	O	O
off	off	RP	B-PRT	O	O
before	before	IN	B-PP	O	O
a	a	DT	B-NP	O	O
long	long	JJ	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
acting	act	VBG	I-NP	O	I-group
benzodiazepine	benzodiazepine	NN	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
completely	completely	RB	I-VP	O	O
cleared	clear	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
general	general	JJ	O	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
shows	show	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sedation	sedation	NN	B-NP	O	O
within	within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flumazenil	flumazenil	NN	B-NP	O	S-drug
,	,	,	O	O	O
serious	serious	JJ	B-NP	O	O
resedation	resedation	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
later	later	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
adequate	adequate	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
observation	observation	NN	B-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
provided	provide	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
any	any	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
either	either	CC	O	O	O
long	long	RB	B-VP	O	B-group
-	-	HYPH	I-VP	O	I-group
acting	act	VBG	I-VP	O	I-group
benzodiazepines	benzodiazepine	NNS	B-NP	O	E-group
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
)	)	)	O	O	O
or	or	CC	O	O	O
large	large	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
short	short	JJ	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
acting	act	VBG	I-NP	O	I-group
benzodiazepines	benzodiazepine	NNS	I-NP	O	E-group
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
taking	take	VBG	I-VP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
regular	regular	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
particularly	particularly	RB	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
that	that	IN	B-SBAR	O	O
physicians	physician	NNS	B-NP	O	O
query	query	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
or	or	CC	O	O	O
their	their	PRP$	B-NP	O	O
guardians	guardian	NNS	I-NP	O	O
carefully	carefully	RB	B-ADVP	O	O
about	about	IN	B-PP	O	O
benzodiazepine	benzodiazepine	NN	B-NP	O	S-group
,	,	,	I-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
sedative	sedative	JJ	I-NP	O	S-group
use	use	NN	I-NP	O	O
as	as	IN	B-PP	O	O
part	part	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
history	history	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
any	any	DT	B-NP	O	O
procedure	procedure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ROMAZICON	ROMAZICON	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
planned	plan	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
information	information	NN	I-NP	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

Do	Do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
take	take	VB	I-VP	O	O
this	this	DT	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
with	with	IN	B-PP	O	O
thioridizine	thioridizine	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
within	within	IN	B-PP	O	O
5	5	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
taking	take	VBG	B-VP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Talk	Talk	NN	B-NP	O	O
to	to	TO	B-PP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
certain	certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
clarithromycin	clarithromycin	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
azithromycin	azithromycin	NN	I-NP	O	S-drug
.	.	.	O	O	O

This	This	DT	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
taking	take	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
certain	certain	JJ	I-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

This	This	DT	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
think	think	VBP	B-VP	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
an	an	DT	B-NP	O	O
MAO	MAO	NN	I-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
talk	talk	NN	I-NP	O	O
to	to	TO	B-PP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacist	pharmacist	NN	I-NP	O	O
.	.	.	O	O	O

Do	Do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
take	take	VB	I-VP	O	O
this	this	DT	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
with	with	IN	B-PP	O	O
St.	St.	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
Wort	Wort	NNP	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sertonin	sertonin	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

Your	Your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacist	pharmacist	NN	I-NP	O	O
can	can	MD	B-VP	O	O
give	give	VB	I-VP	O	O
you	you	PRP	B-NP	O	O
more	more	JJR	B-NP	O	O
information	information	NN	I-NP	O	O
on	on	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

Wait	Wait	VB	B-VP	O	O
5	5	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
stopping	stop	VBG	B-VP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug-AD-1
before	before	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
selective	selective	JJ	I-NP	O	I-group-AD-2
MAO	MAO	NN	I-NP	O	I-group-AD-2
inhibitor	inhibitor	NN	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Wait	Wait	VB	B-VP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
stopping	stop	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
MAO	MAO	NN	I-NP	O	B-group-AD-1
inhibitor	inhibitor	NN	I-NP	O	E-group-AD-1
before	before	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
escitalopram	escitalopram	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
medications	medication	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
migraines	migraine	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Imitrex	Imitrex	NNP	B-NP	O	S-brand
,	,	,	O	O	O
talk	talk	NN	B-NP	O	O
to	to	TO	B-PP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
before	before	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
,	,	,	O	O	O
talk	talk	NN	B-NP	O	O
to	to	TO	B-PP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
before	before	IN	B-PP	O	O
taking	take	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
.	.	.	O	O	O

St.	St.	NNP	B-NP	O	O
John	John	NNP	I-NP	O	O
s	s	VBZ	B-VP	O	O
Wort	Wort	NNP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	O	O
.	.	.	O	O	O

Tell	Tell	VB	B-VP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
:	:	:	O	O	O
blood	blood	NN	B-NP	O	B-group
thinners	thinner	NNS	I-NP	O	O
(	(	(	O	O	O
Coumadin	Coumadin	NN	B-NP	O	S-brand
)	)	)	O	O	O
other	other	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
metoprolol	metoprolol	NN	I-NP	O	S-drug
antihistamines	antihistamine	NNS	I-NP	O	S-group
carbamazepine	carbamazepine	NN	I-NP	O	S-drug
(	(	(	O	O	O
Tegretol	Tegretol	NN	B-NP	O	S-brand
)	)	)	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Tagamet	Tagamet	NN	B-NP	O	S-brand
)	)	)	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
fluoxetine	fluoxetine	NN	I-NP	O	S-drug
(	(	(	O	O	O
Prozac	Prozac	NN	B-NP	O	S-brand
)	)	)	O	O	O
intraconazole	intraconazole	NN	B-NP	O	O
(	(	(	O	O	O
Sporanox	Sporanox	NN	B-NP	O	S-brand
)	)	)	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
Nizoral	Nizoral	JJ	O	O	S-brand
)	)	)	O	O	O
levodopa	levodopa	NN	B-NP	O	S-drug
lithium	lithium	NN	I-NP	O	S-drug
muscle	muscle	NN	I-NP	O	B-group
relaxants	relaxant	VBZ	B-VP	O	E-group
birth	birth	NN	B-NP	O	O
control	control	NN	I-NP	O	O
pills	pill	NNS	I-NP	O	O
sleeping	sleep	VBG	B-VP	O	O
pills	pill	NNS	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
medications	medication	NNS	I-NP	O	O

Androgens	Androgen	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
sensitivity	sensitivity	NN	B-NP	O	O
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulahts	anticoagulaht	NNS	I-NP	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
satisfactory	satisfactory	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
hypoprothrombinemia	hypoprothrombinemia	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxyphenbutazone	oxyphenbutazone	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
androgens	androgen	NNS	I-NP	O	S-group-ME-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oxyphenbutazone	oxyphenbutazone	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
androgens	androgen	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
insulin	insulin	NN	B-NP	O	S-drug-EF-2
requirements	requirement	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
Flupenthixol	Flupenthixol	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
like	like	IN	B-PP	O	O
Monoamine	Monoamine	NN	B-NP	O	B-group-IN-2
oxidase	oxidase	NN	I-NP	O	I-group-IN-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-IN-2
(	(	(	O	O	O
MAOI	MAOI	NN	B-NP	O	S-group-IN-2
)	)	)	O	O	O
:	:	:	O	O	O
MAOI	MAOI	NN	B-NP	O	S-group-EF-1
could	could	MD	B-VP	O	O
theoretically	theoretically	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
flupenthixol	flupenthixol	NN	B-NP	O	S-drug-EF-2
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
-	-	HYPH	B-NP	O	O
Arecoline	Arecoline	NN	I-NP	O	S-drug_n
-	-	HYPH	B-NP	O	O
Eproxindine	Eproxindine	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Ethanol	Ethanol	NN	I-NP	O	S-drug
:	:	:	O	O	O
Flupenthixol	Flupenthixol	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
Ethanol	Ethanol	NN	I-NP	O	S-drug-EF-2
cause	cause	VBP	B-VP	O	O
additive	additive	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depression	depression	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Tricyclic	Tricyclic	JJ	I-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
:	:	:	O	O	O
Flupenthixol	Flupenthixol	NN	B-NP	O	S-drug-EF-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Tricyclic	Tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
volunteers	volunteer	NNS	B-NP	O	O
under	under	IN	B-PP	O	O
fasting	fast	VBG	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
with	with	IN	B-PP	O	O
antacid	antacid	NN	B-NP	O	S-group
suspension	suspension	NN	I-NP	O	O
yielded	yield	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
flurbiprofen	flurbiprofen	NN	I-NP	O	S-drug
time	time	NN	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
young	young	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
geriatric	geriatric	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
7	7	CD	B-NP	O	O
)	)	)	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
:	:	:	O	O	O
Flurbiprofen	Flurbiprofen	NN	B-NP	O	S-drug-EF-1
like	like	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-EF-1
anti	anti	AFX	B-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
bleeding	bleeding	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
anti	anti	AFX	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
coagulants	coagulant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
serious	serious	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
cautious	cautious	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-AD-2
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-1
and	and	CC	I-NP	O	O
flurbiprofen	flurbiprofen	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-NP	O	O
serum	serum	NN	I-NP	O	O
flurbiprofen	flurbiprofen	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
(	(	(	O	O	O
which	which	WDT	B-NP	O	O
also	also	RB	B-ADVP	O	O
lowers	lower	VBZ	B-VP	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
given	give	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
it	it	PRP	B-NP	O	O
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
15	15	CD	B-NP	O	O
)	)	)	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
16	16	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group
-	-	HYPH	O	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
Blocking	Blocking	NNPS	I-NP	O	I-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
atenolol	atenolol	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
men	man	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
mild	mild	JJ	B-NP	O	O
uncomplicated	uncomplicated	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Flurbiprofen	Flurbiprofen	NN	B-NP	O	S-drug-EF-1
pretreatment	pretreatment	NN	I-NP	O	O
attenuated	attenuate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-EF-2
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
atenolol	atenolol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Flurbiprofen	Flurbiprofen	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

Flurbiprofen	Flurbiprofen	NN	B-NP	O	S-drug-IN-1
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
under	under	IN	B-PP	O	O
lying	lie	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
interference	interference	NN	I-NP	O	O
with	with	IN	B-PP	O	O
propranolols	propranolol	NNS	B-NP	O	O
hypotensive	hypotensive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
both	both	CC	O	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
blocker	blocker	NN	I-NP	O	E-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
ensure	ensure	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
satisfactory	satisfactory	JJ	I-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
Ranitidine	Ranitidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
9	9	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
ranitidine	ranitidine	NN	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
except	except	IN	B-PP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
(	(	(	O	O	O
13	13	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
but	but	CC	O	O	O
statistically	statistically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug-ME-1
resulted	result	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Studies	Study	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
men	man	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
14	14	CD	B-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
show	show	VB	I-VP	O	O
a	a	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Diuretics	Diuretic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Studies	Study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug-EF-1
like	like	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-EF-1
anti	anti	AFX	B-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
can	can	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
results	result	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
varied	vary	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
study	study	NN	B-NP	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
,	,	,	O	O	O
effects	effect	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
stimulated	stimulate	VBN	I-NP	O	O
diuresis	diuresis	NN	I-NP	O	O
,	,	,	O	O	O
natriuresis	natriuresis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
kaliuresis	kaliuresis	NN	B-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-EF-1
anti	anti	AFX	I-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
prostaglandin	prostaglandin	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
sparing	spar	VBG	B-VP	O	I-group-EF-2
diuretics	diuretic	NNS	B-NP	O	E-group-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
furosemide	furosemide	NN	I-NP	O	S-drug-AD-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	NNP	B-NP	O	O
Hypoglycemic	Hypoglycemic	NNP	I-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
adult	adult	JJ	B-NP	O	O
diabetics	diabetic	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
already	already	RB	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
4	4	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
metformin	metformin	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
chlorpropamide	chlorpropamide	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
phenformin	phenformin	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
3	3	CD	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
phenformin	phenformin	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
sugar	sugar	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flurbiprofen	flurbiprofen	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
hypoglycemic	hypoglycemic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

Increases	Increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
noted	note	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-1
therapy	therapy	NN	I-NP	O	O
after	after	IN	B-PP	O	O
flutamide	flutamide	NN	B-NP	O	S-drug-EF-2
was	be	VBD	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
and	and	CC	O	O	O
adjustment	adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
EULEXIN	EULEXIN	NN	B-NP	O	S-brand-AD-1
Capsules	Capsule	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Monoamine	Monoamine	NN	B-NP	B-protein	B-group
Oxidase	Oxidase	NN	I-NP	I-protein	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
another	another	DT	B-NP	O	O
serotonin	serotonin	NN	I-NP	O	B-group-EF-1
reuptake	reuptake	NN	I-NP	O	I-group-EF-1
inhibitor	inhibitor	NN	I-NP	O	I-group-EF-1
drug	drug	NN	I-NP	O	E-group-EF-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
MAOI	MAOI	NN	B-NP	B-protein	S-group-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
,	,	,	I-NP	O	O
sometimes	sometimes	RB	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
,	,	,	O	O	O
reactions	reaction	NNS	B-NP	O	O
including	include	VBG	B-PP	O	O
hyperthermia	hyperthermia	NN	B-NP	O	O
,	,	,	O	O	O
rigidity	rigidity	NN	B-NP	O	O
,	,	,	O	O	O
myoclonus	myoclonus	NN	B-NP	O	O
,	,	,	O	O	O
autonomic	autonomic	JJ	B-NP	O	O
instability	instability	NN	I-NP	O	O
with	with	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
fluctuations	fluctuation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
vital	vital	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
mental	mental	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
include	include	VBP	B-VP	O	O
extreme	extreme	JJ	B-NP	O	O
agitation	agitation	NN	I-NP	O	O
progressing	progress	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
delirium	delirium	NN	B-NP	O	O
and	and	CC	I-NP	O	O
coma	coma	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
drug	drug	NN	B-NP	O	O
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
started	start	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
MAOI	MAOI	NN	I-NP	B-protein	S-group
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
presented	present	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
features	feature	NNS	B-NP	O	O
resembling	resemble	VBG	B-VP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	O
malignant	malignant	JJ	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug-AD-1
Tablets	Tablet	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
MAOIs	MAOI	NNS	B-NP	B-protein	S-group-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
within	within	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
discontinuing	discontinue	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
MAOI	MAOI	NN	I-NP	B-protein	S-group-AD-2
.	.	.	O	O	O

After	After	IN	B-PP	O	O
stopping	stop	VBG	B-VP	O	O
Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug-AD-1
Tablets	Tablet	NNS	I-NP	O	O
,	,	,	O	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
allowed	allow	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
MAOI	MAOI	NN	I-NP	B-protein	S-group-AD-2
.	.	.	O	O	O

Potential	Potential	JJ	B-NP	O	O
Terfenadine	Terfenadine	NN	I-NP	O	S-drug
,	,	,	O	O	O
Astemizole	Astemizole	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
Cisapride	Cisapride	NN	B-NP	O	S-drug
Interactions	Interaction	NNS	I-NP	O	O

Terfenadine	Terfenadine	NN	B-NP	O	S-drug-ME-1
,	,	,	I-NP	O	O
astemizole	astemizole	NN	I-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug-ME-1
are	be	VBP	B-VP	O	O
all	all	DT	O	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450IIIA4	P450IIIA4	NN	I-NP	I-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
IIIA4	IIIA4	CD	B-NP	B-protein	O
,	,	,	O	O	O
blocks	block	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
parent	parent	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
,	,	,	O	O	O
astemizole	astemizole	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
cause	cause	VBP	B-VP	O	O
QT	QT	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
torsades	torsade	NNS	B-NP	O	O
de	de	IN	B-PP	O	O
pointes	pointe	NNS	B-NP	O	O
-	-	HYPH	B-NP	O	O
type	type	NN	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
,	,	,	O	O	O
sometimes	sometimes	RB	B-ADJP	O	O
fatal	fatal	JJ	I-ADJP	O	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
noted	note	VBN	B-VP	O	O
below	below	IN	B-PP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
sub	sub	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
for	for	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
IIIA4	IIIA4	CD	I-NP	B-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
definitively	definitively	RB	B-ADVP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
IIIA4	IIIA4	CD	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
substantial	substantial	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-IN-1
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-IN-2
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-AD-1
not	not	RB	O	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
terbinafine	terbinafine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Potentially	Potentially	NNP	I-NP	O	O
Important	Important	NNP	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
Benzodiazepines	Benzodiazepine	NNS	B-NP	O	S-group
:	:	:	O	O	O
Benzodiazepines	Benzodiazepine	NNS	B-NP	O	S-group-ME-1
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
oxidation	oxidation	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug-ME-1
elc	elc	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
glucuronidation	glucuronidation	NN	B-NP	O	O
(	(	(	O	O	O
e.	e.	FW	B-NP	O	O
g.	g.	NN	I-NP	O	O
,	,	,	O	O	O
lorazepam	lorazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
oxazepam	oxazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
temazepam	temazepam	NN	B-NP	O	S-drug
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Alprazolam	Alprazolam	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	B-drug-ME-1
maleate	maleate	NN	I-NP	O	E-drug-ME-1
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
qd	qd	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
q.d	q.d	NN	I-NP	O	O
.	.	.	O	O	O
were	be	VBD	B-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
,	,	,	O	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
,	,	,	O	O	O
T1	T1	NN	B-NP	B-protein	O
/	/	SYM	B-VP	O	O
2	2	CD	B-NP	O	O
,	,	,	O	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
twice	twice	RB	I-NP	O	O
those	those	DT	I-NP	O	O
observed	observe	VBN	B-VP	O	O
when	when	WRB	B-ADVP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
;	;	:	O	O	O

oral	oral	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
alprazolam	alprazolam	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
psychomotor	psychomotor	NN	I-NP	O	O
performance	performance	NN	I-NP	O	O
and	and	CC	I-NP	O	O
memory	memory	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
since	since	IN	B-SBAR	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
exhibits	exhibit	VBZ	B-VP	O	O
non	non	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
linear	linear	JJ	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
range	range	NN	I-NP	O	O
100	100	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
.	.	.	O	O	O
If	If	IN	B-SBAR	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug-AD-2
Tablets	Tablet	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
alprazolam	alprazolam	NN	I-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
at	at	IN	B-ADJP	O	O
least	least	JJS	B-VP	O	O
halved	halve	VBN	I-VP	O	O
and	and	CC	O	O	O
titration	titration	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
lowest	low	JJS	I-NP	O	O
effective	effective	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug
Tablets	Tablet	NNS	I-NP	O	O
.	.	.	O	O	O

Diazepam	Diazepam	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug-AD-1
Tablets	Tablet	NNS	I-NP	O	O
and	and	CC	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
generally	generally	RB	B-ADVP	O	O
not	not	RB	O	O	O
advisable	advisable	JJ	B-ADJP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-ME-1
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
N	N	NN	B-NP	O	B-drug_n-ME-2
-	-	HYPH	B-NP	O	I-drug_n-ME-2
desmethyldiazepam	desmethyldiazepam	NN	I-NP	O	E-drug_n-ME-2
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
of	of	IN	B-PP	O	O
substantial	substantial	JJ	B-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
species	specie	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Evidence	Evidence	NN	B-NP	O	O
supporting	support	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
conclusion	conclusion	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
inadvisable	inadvisable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administer	administer	NN	I-NP	O	O
fluvoxamine	fluvoxamine	NN	I-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
derived	derive	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
B	B	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
65	65	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
N	N	NN	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
desmethyldiazepam	desmethyldiazepam	NN	I-NP	O	E-drug_n
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
level	level	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
too	too	RB	B-ADJP	O	O
low	low	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
measure	measure	VB	I-VP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
2	2	CD	I-NP	O	O
week	week	NN	I-NP	O	O
long	long	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
experience	experience	NN	B-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
underestimates	underestimate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
accumulation	accumulation	NN	B-NP	O	O
that	that	WDT	B-NP	O	O
might	might	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
repealed	repeal	VBN	B-NP	O	O
diazepam	diazepam	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
noted	note	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
even	even	RB	I-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Accordingly	Accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
fluvoxamine	fluvoxamine	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
ordinarily	ordinarily	RB	I-VP	O	O
be	be	VB	I-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
fluvoxamine	fluvoxamine	NN	I-NP	O	S-drug
l50	l50	NN	I-NP	O	O
mg	mg	NN	I-NP	O	O
bid	bid	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Theophylline	Theophylline	NN	B-NP	O	S-drug
(	(	(	O	O	O
375	375	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
as	as	IN	B-PP	O	O
442	442	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
aminophylline	aminophylline	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
smoking	smoking	NN	I-NP	O	O
,	,	,	O	O	O
male	male	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
approximately	approximately	RB	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	B-drug-AD-2
maleate	maleate	NN	I-NP	O	E-drug-AD-2
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
third	third	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
daily	daily	JJ	I-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	O	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
to	to	TO	I-VP	O	O
monitored	monitored	VB	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug
Tablets	Tablet	NNS	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NNP	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	B-drug-ME-1
maleate	maleate	NN	I-NP	O	E-drug-ME-1
(	(	(	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
tid	tid	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
for	for	IN	B-PP	O	O
two	two	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
increased	increase	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
98	98	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
times	time	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-AD-1
and	and	CC	O	O	O
Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug-AD-2
Tablets	Tablet	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
monitored	monitor	VBN	B-VP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
dose	dose	NN	I-NP	O	O
adjusted	adjust	VBN	B-VP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug
Tablets	Tablet	NNS	I-NP	O	O
.	.	.	O	O	O

Medications	Medication	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
your	your	PRP$	B-NP	O	O
bodys	body	NNS	I-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
use	use	VB	I-VP	O	O
folate	folate	NN	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	S-group
.	.	.	O	O	O

Medications	Medication	NNS	B-NP	O	O
can	can	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
folate	folate	JJ	B-NP	O	O
utilization	utilization	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
:	:	:	O	O	O
anticonvulsant	anticonvulsant	NN	B-NP	O	B-group
medications	medication	NNS	I-NP	O	E-group
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
primidone	primidone	NN	B-NP	O	S-drug
)	)	)	O	O	O
metformin	metformin	NN	B-NP	O	S-drug
(	(	(	O	O	O
sometimes	sometimes	RB	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
control	control	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
sugar	sugar	NN	I-NP	O	O
in	in	IN	B-PP	O	O
type	type	NN	B-NP	O	O
2	2	CD	I-NP	O	O
diabetes	diabetes	NN	I-NP	O	O
)	)	)	O	O	O
sulfasalazine	sulfasalazine	NN	B-NP	O	S-drug
(	(	(	O	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
inflammation	inflammation	NN	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Crohns	Crohn	NNS	B-NP	O	O
disease	disease	NN	I-NP	O	O
and	and	CC	O	O	O
ulcerative	ulcerative	JJ	B-NP	O	O
colitis	colitis	NN	I-NP	O	O
)	)	)	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug
(	(	(	O	O	O
a	a	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
)	)	)	O	O	O
Methotrexate	Methotrexate	NNP	B-NP	O	S-drug
There	There	EX	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
concern	concern	NN	B-NP	O	O
about	about	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B-protein	B-drug-IN-1
B12	B12	NN	I-NP	I-protein	E-drug-IN-1
and	and	CC	O	O	O
folic	folic	JJ	B-NP	O	B-drug-IN-2
acid	acid	NN	I-NP	O	E-drug-IN-2
.	.	.	O	O	O

Folic	Folic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
supplements	supplement	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
correct	correct	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anemia	anemia	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	O
B12	B12	NN	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
.	.	.	O	O	O

Unfortunately	Unfortunately	RB	B-ADVP	O	O
,	,	,	O	O	O
folic	folic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
will	will	MD	B-VP	O	O
not	not	RB	I-VP	O	O
correct	correct	VB	I-VP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
result	result	VBP	B-VP	O	O
from	from	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	O
B12	B12	NN	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
.	.	.	O	O	O

Permanent	Permanent	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
damage	damage	NN	I-NP	O	O
could	could	MD	B-VP	O	O
theoretically	theoretically	RB	I-VP	O	O
occur	occur	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
vitamin	vitamin	NN	B-NP	O	O
B12	B12	NN	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
intake	intake	NN	B-NP	O	O
of	of	IN	B-PP	O	O
supplemental	supplemental	JJ	B-NP	O	O
folic	folic	JJ	I-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
exceed	exceed	VB	I-VP	O	O
1000	1000	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
(	(	(	O	O	O
g	g	NN	B-NP	O	O
,	,	,	O	O	O
sometimes	sometimes	RB	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
)	)	)	O	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
folic	folic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
from	from	IN	B-PP	O	O
masking	mask	VBG	B-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	O
B12	B12	NN	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
important	important	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
adults	adult	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
folic	folic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-drug
B12	B12	NN	I-NP	O	E-drug
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
greater	great	JJR	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
having	have	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	O
B12	B12	NN	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
50	50	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
or	or	CC	O	O	O
older	old	JJR	B-ADJP	O	O
,	,	,	O	O	O
ask	ask	VB	B-VP	O	O
your	your	PRP$	B-NP	O	O
physician	physician	NN	I-NP	O	O
to	to	TO	B-VP	O	O
check	check	VB	I-VP	O	O
your	your	PRP$	B-NP	O	O
B12	B12	NN	I-NP	B-protein	O
status	status	NN	I-NP	O	O
before	before	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
take	take	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
supplement	supplement	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
contains	contain	VBZ	B-VP	O	O
folic	folic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Antizol	Antizol	NN	B-NP	O	S-brand-ME-1
(	(	(	O	O	O
10	10	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
via	via	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	B-protein	O
dehydrogenase	dehydrogenase	NN	I-NP	I-protein	O
inhibition	inhibition	NN	I-NP	O	O
,	,	,	O	O	O
significantly	significantly	RB	B-VP	O	O
reduced	reduce	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
elimination	elimination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
given	give	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
elimination	elimination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Antizol	Antizol	NN	B-NP	O	S-brand-ME-2
(	(	(	O	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
.	.	.	O	O	O

Reciprocal	Reciprocal	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Antizol	Antizol	NN	B-NP	O	S-brand-ME-1
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
increase	increase	VBP	B-VP	O	O
or	or	CC	I-VP	O	O
inhibit	inhibit	VBP	I-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
,	,	,	O	O	O
though	though	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
performed	perform	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Fondaparinux	Fondaparinux	NNP	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
(	(	(	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
platelet	platelet	NN	B-NP	B-protein	B-group
inhibitors	inhibitor	NNS	I-NP	I-protein	E-group
(	(	(	O	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
)	)	)	O	O	O
,	,	,	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
(	(	(	O	O	O
piroxicam	piroxicam	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
/	/	SYM	B-VP	O	O
pharmacodynamics	pharmacodynamic	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
fondaparinux	fondaparinux	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
Fondaparinux	Fondaparinux	NNP	B-NP	O	S-drug
neither	neither	CC	O	O	O
influenced	influence	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
piroxicam	piroxicam	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
nor	nor	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hemorrhage	hemorrhage	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Fondaparinux	Fondaparinux	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-NP	O	O
,	,	,	I-NP	O	O
close	close	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
appropriate	appropriate	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2A6	CYP2A6	NN	B-NP	B-protein	O
hydroxylation	hydroxylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	S-group-ME-1
by	by	IN	B-PP	O	O
fondaparinux	fondaparinux	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
200	200	CD	B-NP	O	O
m	m	NN	I-NP	O	O
m	m	NN	I-NP	O	O
M	M	NN	I-NP	O	O
i.e	i.e	JJ	I-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
350	350	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
17	17	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
28	28	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
isozymes	isozyme	NNS	I-NP	B-protein	O
evaluated	evaluate	VBN	B-VP	O	O
(	(	(	O	O	O
CYPs	CYP	NNS	B-NP	B-protein	O
2A1	2A1	NN	I-NP	I-protein	O
,	,	,	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
2D6	2D6	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
3E1	3E1	NN	B-NP	B-protein	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
16	16	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
fondaparinux	fondaparinux	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
markedly	markedly	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
CYP450s	CYP450	NNS	B-NP	B-protein	O
(	(	(	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2A6	CYP2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
)	)	)	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
fondaparinux	fondaparinux	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
by	by	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
mediated	mediate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
isozymes	isozyme	NNS	I-NP	B-protein	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
fondaparinux	fondaparinux	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
bind	bind	VB	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
ATIII	ATIII	NN	B-NP	B-protein	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
-	-	HYPH	B-PP	O	O
binding	bind	VBG	B-NP	O	O
displacement	displacement	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

Short	Short	JJ	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
Acting	Act	VBG	I-NP	B-protein	I-group
beta2	beta2	NN	I-NP	I-protein	I-group
-	-	HYPH	I-NP	O	I-group
agonists	agonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
Aerosol	Aerosol	NN	B-NP	O	O
bronchodilators	bronchodilator	NNS	I-NP	O	S-group
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
acting	act	VBG	B-VP	O	O
adrenergic	adrenergic	JJ	B-NP	O	O
stimulant	stimulant	NN	I-NP	O	O
type	type	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
relief	relief	NN	B-NP	O	O
of	of	IN	B-PP	O	O
breakthrough	breakthrough	NN	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
while	while	IN	B-SBAR	O	O
using	use	VBG	B-VP	O	O
formoterol	formoterol	NN	B-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
control	control	NN	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
deterioration	deterioration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
asthma	asthma	NN	B-NP	O	O
control	control	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
to	to	TO	B-VP	O	O
reassess	reassess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
s	s	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
sympathomimetic	sympathomimetic	JJ	I-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
undesirable	undesirable	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
FORADIL	FORADIL	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

Monoamine	Monoamine	NN	B-NP	B-protein	B-group
Oxidase	Oxidase	NN	I-NP	I-protein	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
and	and	CC	O	O	O
Tricyclic	Tricyclic	JJ	B-NP	O	B-group
Antidepressants	Antidepressant	NNS	I-NP	O	E-group
:	:	:	O	O	O
FORADIL	FORADIL	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
extreme	extreme	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-AD-2
oxidase	oxidase	NN	I-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
or	or	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-2
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
formoterol	formoterol	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
,	,	,	I-NP	O	O
Methylxanthines	Methylxanthine	NNS	I-NP	O	S-group
and	and	CC	I-NP	O	O
Diuretics	Diuretic	NNS	I-NP	O	S-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
xanthine	xanthine	NN	B-NP	O	B-group-EF-1
derivatives	derivative	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
steroids	steroid	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
or	or	CC	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
hypokalemic	hypokalemic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta2	beta2	NN	B-NP	B-protein	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
agonists	agonist	NNS	I-NP	O	I-group-EF-2
.	.	.	O	O	E-group-EF-2

Hypokalemia	Hypokalemia	NN	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
susceptibility	susceptibility	NN	B-NP	O	O
to	to	TO	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
Blockers	Blocker	NNS	I-NP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
weaken	weaken	VB	I-VP	O	O
or	or	CC	I-VP	O	O
antagonise	antagonise	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
FORADIL	FORADIL	NN	B-NP	O	S-brand
.	.	.	O	O	O

Therefore	Therefore	RB	B-NP	O	O
FORADIL	FORADIL	NN	I-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
eye	eye	NN	B-NP	O	O
drops	drop	NNS	I-NP	O	O
)	)	)	O	O	O
unless	unless	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
compelling	compel	VBG	I-VP	O	O
reasons	reason	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
QT	QT	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
interval	interval	NN	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	O
.	.	.	O	O	O

INFORMATION	INFORMATION	NN	B-NP	O	O
TO	TO	TO	B-VP	O	O
BE	BE	NN	I-VP	O	O
PROVIDED	PROVIDED	VBN	B-VP	O	O
TO	TO	TO	B-PP	O	O
THE	THE	DT	B-NP	O	O
PATIENT	PATIENT	JJ	I-NP	O	O
OR	OR	NN	I-NP	O	O
GUARDIAN	GUARDIAN	NN	I-NP	O	O
See	See	NN	I-NP	O	O
illustrated	illustrated	JJ	I-NP	O	O
Information	Information	NN	I-NP	O	O
For	For	IN	B-PP	O	O
The	The	DT	B-NP	O	O
Patient	Patient	NN	I-NP	O	O
or	or	CC	O	O	O
Guardian	Guardian	JJ	B-NP	O	O
section	section	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
important	important	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
understand	understand	VBP	B-VP	O	O
how	how	WRB	B-ADVP	O	O
to	to	TO	B-VP	O	O
use	use	VB	I-VP	O	O
FORADIL	FORADIL	NN	B-NP	O	S-brand
(	(	(	O	O	O
formoterol	formoterol	NN	B-NP	O	B-drug
fumarate	fumarate	NN	I-NP	O	E-drug
)	)	)	O	O	O
capsules	capsule	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
supplied	supply	VBN	I-NP	O	O
AerolizerTM	AerolizerTM	NN	I-NP	O	O
inhalation	inhalation	NN	I-NP	O	O
device	device	NN	I-NP	O	O
and	and	CC	O	O	O
how	how	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
relation	relation	NN	B-NP	O	O
to	to	TO	B-PP	O	O
other	other	JJ	B-NP	O	O
asthma	asthma	NN	I-NP	O	O
or	or	CC	I-NP	O	O
COPD	COPD	NN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNPS	B-NP	O	O
/	/	SYM	I-NP	O	O
Guardians	Guardian	NNPS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
information	information	NN	I-NP	O	O
:	:	:	O	O	O
i	i	LS	B-LST	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
(	(	(	O	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
two	two	CD	I-NP	O	O
capsules	capsule	NNS	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
,	,	,	O	O	O
morning	morning	NN	B-NP	O	O
and	and	CC	O	O	O
evening	evening	NN	B-NP	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
exceeded	exceed	VBN	I-VP	O	O
.	.	.	O	O	O

ii	ii	LS	B-LST	O	O
.	.	.	O	O	O

FORADIL	FORADIL	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
meant	mean	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
relieve	relieve	VB	I-VP	O	O
acute	acute	JJ	B-NP	O	O
asthma	asthma	NN	I-NP	O	O
or	or	CC	I-NP	O	O
COPD	COPD	NN	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
and	and	CC	O	O	O
extra	extra	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
that	that	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
acting	act	VBG	B-VP	O	O
,	,	,	O	O	O
inhaled	inhale	VBN	B-NP	B-protein	O
beta2	beta2	NN	I-NP	I-protein	B-group
-	-	HYPH	B-NP	O	I-group
agonist	agonist	NN	I-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
salbutamol	salbutamol	NN	B-NP	O	S-drug
(	(	(	O	O	O
the	the	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
should	should	MD	B-VP	O	O
provide	provide	VB	I-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
and	and	CC	O	O	O
instruct	instruct	VB	B-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
in	in	IN	B-PP	O	O
how	how	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

iii	iii	LS	B-LST	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
notified	notify	VBN	I-VP	O	O
immediately	immediately	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
situations	situation	NNS	I-NP	O	O
occur	occur	VBP	B-VP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
sign	sign	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seriously	seriously	RB	B-NP	O	O
worsening	worsen	VBG	I-NP	O	O
asthma	asthma	NN	I-NP	O	O
:	:	:	O	O	O
Decreased	Decrease	VBN	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
short	short	JJ	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
acting	act	VBG	B-VP	O	I-group
,	,	,	O	O	I-group
inhaled	inhale	VBN	B-NP	B-protein	I-group
beta2	beta2	NN	I-NP	I-protein	I-group
-	-	HYPH	B-NP	O	I-group
agonists	agonist	NNS	I-NP	O	E-group
;	;	:	O	O	O

Need	Need	NN	B-NP	O	O
for	for	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
inhalations	inhalation	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
usual	usual	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
short	short	JJ	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
acting	act	VBG	B-VP	O	I-group
,	,	,	O	O	I-group
inhaled	inhale	VBN	B-NP	B-protein	I-group
beta2	beta2	NN	I-NP	I-protein	I-group
-	-	HYPH	B-NP	O	I-group
agonists	agonist	NNS	I-NP	O	E-group
.	.	.	O	O	O

iv	iv	LS	B-LST	O	O
.	.	.	O	O	O

FORADIL	FORADIL	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
substitute	substitute	NN	I-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
inhaled	inhale	VBN	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
changed	change	VBN	I-VP	O	O
and	and	CC	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
stopped	stop	VBN	I-VP	O	O
without	without	IN	B-PP	O	O
consulting	consult	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
,	,	,	O	O	O
even	even	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
feels	feel	NNS	I-NP	O	O
better	well	RBR	B-ADVP	O	O
after	after	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
FORADIL	FORADIL	NN	B-NP	O	S-brand
.	.	.	O	O	O

v.	v.	LS	B-NP	O	O
Patients	Patient	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
cautioned	caution	VBN	I-VP	O	O
regarding	regard	VBG	B-PP	O	O
potential	potential	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
palpitations	palpitation	NNS	B-NP	O	O
or	or	CC	O	O	O
chest	chest	NN	B-NP	O	O
pain	pain	NN	I-NP	O	O
.	.	.	O	O	O

vi	vi	FW	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
FORADIL	FORADIL	NN	B-NP	O	S-brand
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
inhaled	inhale	VBN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
as	as	IN	B-SBAR	O	O
directed	direct	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
.	.	.	O	O	O

vii	vii	FW	B-NP	O	O
.	.	.	O	O	O

Guardians	Guardian	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
FORADIL	FORADIL	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
alerted	alert	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
concern	concern	NN	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
asthma	asthma	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
compliance	compliance	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADJP	O	O
neglect	neglect	JJ	I-ADJP	O	O
of	of	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
overuse	overuse	NN	I-NP	O	O
of	of	IN	B-PP	O	O
short	short	JJ	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
acting	act	VBG	I-NP	O	I-group
beta2	beta2	NN	I-NP	B-protein	I-group
-	-	HYPH	B-PP	O	I-group
agonists	agonist	NNS	B-NP	O	E-group
.	.	.	O	O	O

A	A	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
FOSCAVIR	FOSCAVIR	NN	B-NP	O	S-brand-IN-1
and	and	CC	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
pentamidine	pentamidine	NN	I-NP	O	S-drug-IN-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
four	four	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
Kingdom	Kingdom	NNP	I-NP	O	O
with	with	IN	B-PP	O	O
FOSCAVIR	FOSCAVIR	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
pentamidine	pentamidine	NN	I-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
caused	cause	VBN	I-VP	O	O
hypocalcemia	hypocalcemia	NN	B-NP	O	O
;	;	:	O	O	O

one	one	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
died	die	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypocalcemia	hypocalcemia	NN	I-NP	O	O
.	.	.	O	O	O

Toxicity	Toxicity	NN	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aerosolized	aerosolize	VBN	B-NP	O	O
pentamidine	pentamidine	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
foscarnets	foscarnet	NNS	B-NP	O	O
tendency	tendency	NN	I-NP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
FOSCAVIR	FOSCAVIR	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
potentially	potentially	RB	B-NP	O	O
nephrotoxic	nephrotoxic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug-AD-2
B	B	NN	I-NP	O	E-drug-AD-2
and	and	CC	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
pentamidine	pentamidine	NN	I-NP	O	S-drug-AD-2
unless	unless	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
benefits	benefit	NNS	I-NP	O	O
outweigh	outweigh	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
FOSCAVIR	FOSCAVIR	NN	B-NP	B-protein	S-brand
decreases	decrease	VBZ	B-VP	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ionized	ionize	VBN	B-NP	O	O
calcium	calcium	NN	I-NP	O	O
,	,	,	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
influence	influence	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
calcium	calcium	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
.	.	.	O	O	O

Ganciclovir	Ganciclovir	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
foscarnet	foscarnet	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ganciclovir	ganciclovir	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
13	13	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
either	either	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
or	or	CC	O	O	O
daily	daily	RB	B-VP	O	O
alternating	alternate	VBG	I-VP	O	O
therapy	therapy	NN	B-NP	O	O
for	for	IN	B-PP	O	O
maintenance	maintenance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CMV	CMV	NN	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Metoclopramide	Metoclopramide	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
MONUROL	MONUROL	NN	B-NP	O	S-brand-ME-1
,	,	,	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
increases	increase	VBZ	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
,	,	,	O	O	O
lowers	lower	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fosfomycin	fosfomycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
increase	increase	VBP	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
similar	similar	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fosfomycin	fosfomycin	NN	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
MONUROL	MONUROL	NN	B-NP	O	S-brand
.	.	.	O	O	O

Diuretics	Diuretic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
intravascular	intravascular	JJ	B-NP	O	O
volume	volume	NN	I-NP	O	O
depletion	depletion	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
experience	experience	VB	I-VP	O	O
an	an	DT	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
fosinopril	fosinopril	JJ	B-NP	O	B-drug-EF-2
sodium	sodium	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotensive	hypotensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
either	either	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-EF-1
or	or	CC	O	O	O
increasing	increase	VBG	B-VP	O	O
salt	salt	NN	B-NP	O	O
intake	intake	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
fosinopril	fosinopril	JJ	B-NP	O	B-drug-EF-2
sodium	sodium	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
possible	possible	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
starting	start	VBG	I-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
hours	hour	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
an	an	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	B-PP	O	O
until	until	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
(	(	(	O	O	O
see	see	VB	B-VP	O	O
DOSAGE	DOSAGE	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
ADMINISTRATION	ADMINISTRATION	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Potassium	Potassium	NN	B-NP	O	S-drug
Supplements	Supplement	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
Potassium	Potassium	NN	I-NP	O	B-group
-	-	HYPH	O	O	I-group
Sparing	Spar	VBG	B-VP	O	I-group
Diuretics	Diuretic	NNS	B-NP	O	E-group
:	:	:	O	O	O
Fosinopril	Fosinopril	NNP	B-NP	O	B-drug-EF-1
sodium	sodium	NN	I-NP	O	E-drug-EF-1
can	can	MD	B-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
potassium	potassium	NN	B-NP	O	O
loss	loss	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Potassium	Potassium	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
(	(	(	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug
,	,	,	O	O	O
amiloride	amiloride	NN	B-NP	O	S-drug
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
others	other	NNS	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
potassium	potassium	NN	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
frequently	frequently	RB	B-ADVP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
frequent	frequent	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
antacid	antacid	NN	I-NP	O	S-group-ME-1
(	(	(	O	O	O
aluminum	aluminum	NN	B-NP	O	B-drug-ME-1
hydroxide	hydroxide	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
magnesium	magnesium	NN	B-NP	O	B-drug-ME-1
hydroxide	hydroxide	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
simethicone	simethicone	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
with	with	IN	B-PP	O	O
fosinopril	fosinopril	NN	B-NP	O	S-drug-ME-2
reduced	reduce	VBD	B-VP	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fosinoprilat	fosinoprilat	NN	B-NP	O	S-drug_n
as	as	IN	B-PP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
fosinopril	fosinopril	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
antacids	antacid	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
impair	impair	VB	I-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fosinopril	fosinopril	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
,	,	,	O	O	O
dosing	dosing	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
separated	separate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-ADJP	O	O
:	:	:	O	O	O
Neither	Neither	CC	O	O	O
fosinopril	fosinopril	JJ	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
nor	nor	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
food	food	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
separate	separate	JJ	B-NP	O	O
single	single	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
multiple	multiple	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
chlorthalidone	chlorthalidone	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
propanolol	propanolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug
,	,	,	O	O	O
propantheline	propantheline	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fosinoprilat	fosinoprilat	NN	B-NP	O	S-drug_n
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fosinopril	fosinopril	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
one	one	CD	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
fosinopril	fosinopril	NN	I-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
unbound	unbound	JJ	B-NP	O	O
fosinoprilat	fosinoprilat	NN	I-NP	O	S-drug_n
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
bioavailability	bioavailability	NN	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
(	(	(	O	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
changed	change	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Fosinopril	Fosinopril	NNP	I-NP	O	S-drug
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
low	low	JJ	I-NP	O	O
measurement	measurement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Digi	Digi	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Tab	Tab	NNP	I-NP	O	O
RIA	RIA	NN	I-NP	O	O
Kit	Kit	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Digoxin	Digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
kits	kit	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
Coat	Coat	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
A	A	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
Count	Count	NN	I-NP	O	O
RIA	RIA	NN	I-NP	O	O
Kit	Kit	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
conversion	conversion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fosphenytoin	fosphenytoin	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Conversion	Conversion	NN	B-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phosphatase	phosphatase	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
abundance	abundance	NN	I-NP	O	O
and	and	CC	I-NP	O	O
wide	wide	JJ	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phosphatases	phosphatas	NNS	B-NP	B-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
drugs	drug	NNS	B-NP	O	O
would	would	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
this	this	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
enough	enough	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
affect	affect	VB	I-VP	O	O
conversion	conversion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fosphenytoin	fosphenytoin	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
highly	highly	RB	B-ADVP	O	O
bound	bind	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
albumin	albumin	NN	B-NP	O	O
could	could	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
unbound	unbound	JJ	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fosphenytoin	fosphenytoin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
could	could	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
Cerebyx	Cerebyx	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
bind	bind	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
serum	serum	NN	B-NP	B-protein	O
albumin	albumin	NN	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fosphenytoin	fosphenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Cerebyx	Cerebyx	NN	I-NP	O	S-brand
were	be	VBD	B-VP	O	O
concurrently	concurrently	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
submaximal	submaximal	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Cerebyx	Cerebyx	NN	B-NP	O	S-brand
are	be	VBP	B-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
interact	interact	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
extensively	extensively	RB	I-VP	O	O
bound	bind	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
serum	serum	NN	B-NP	B-protein	O
plasma	plasma	NN	I-NP	I-protein	O
proteins	protein	NNS	I-NP	I-protein	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
prone	prone	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
competitive	competitive	JJ	B-NP	O	O
displacement	displacement	NN	I-NP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
particularly	particularly	RB	B-ADJP	O	O
susceptible	susceptible	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
inhibitory	inhibitory	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
because	because	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
subject	subject	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
saturable	saturable	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
circulating	circulate	VBG	B-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
enhance	enhance	VB	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
drug	drug	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
metabolizing	metabolize	VBG	B-VP	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
commonly	commonly	RB	I-NP	O	O
occurring	occur	VBG	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
listed	list	VBN	I-VP	O	O
below	below	IN	B-PP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-1
concentrations	concentration	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
acute	acute	JJ	B-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug-ME-2
intake	intake	NN	I-NP	O	O
,	,	,	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
chboramphenicol	chboramphenicol	NN	B-NP	O	O
,	,	,	O	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
dicumarol	dicumarol	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
ethosuximide	ethosuximide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
H2	H2	NN	B-NP	B-protein	B-group-ME-2
-	-	HYPH	B-NP	O	I-group-ME-2
antagonists	antagonist	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
halothane	halothane	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
methylphenidate	methylphenidate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
salicylates	salicylate	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
succinimides	succinimide	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
trazodone	trazodone	NN	B-NP	O	S-drug-ME-2

-	-	HYPH	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-1
concentrations	concentration	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
chronic	chronic	JJ	B-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug-ME-2
abuse	abuse	NN	I-NP	O	O
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-ME-2

-	-	HYPH	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
either	either	CC	I-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-1
concentrations	concentration	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
vaiproic	vaiproic	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-ME-2
valproate	valproate	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-1
on	on	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
and	and	CC	I-NP	O	O
sodium	sodium	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug-EF-2
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unpredictable	unpredictable	JJ	B-ADJP	O	O

-	-	HYPH	B-NP	O	O
Although	Although	IN	B-PP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
true	true	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
precipitate	precipitate	VB	I-VP	O	O
seizures	seizure	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
susceptible	susceptible	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
Cerebyx	Cerebyx	NN	B-NP	O	S-brand-EF-2
dosage	dosage	NN	I-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O

-	-	HYPH	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
whose	whose	WP$	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
impaired	impair	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-1
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
coumarin	coumarin	NN	B-NP	O	S-group-EF-2
,	,	,	O	O	O
digitoxin	digitoxin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
doxycycline	doxycycline	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
vitamin	vitamin	NN	B-NP	O	B-group-EF-2
D	D	NN	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Monitoring	Monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
helpful	helpful	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
possible	possible	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
suspected	suspect	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Phenytoin	Phenytoin	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
14	14	CD	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
artifactually	artifactually	RB	B-NP	O	O
low	low	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	O
or	or	CC	I-NP	O	O
metyrapone	metyrapone	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
,	,	,	O	O	O
alkaline	alkaline	NN	B-NP	B-protein	O
phosphatase	phosphatase	NN	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
gamma	gamma	NN	B-NP	B-protein	O
glutamyl	glutamyl	NN	I-NP	I-protein	O
transpeptidase	transpeptidase	NN	I-NP	I-protein	O
(	(	(	O	O	O
GGT	GGT	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Care	Care	NNP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
immunoanalytical	immunoanalytical	JJ	B-NP	O	O
methods	method	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
measure	measure	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
Cerebyx	Cerebyx	NN	B-NP	O	S-brand
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Ergot	Ergot	NN	B-NP	O	O
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
prolonged	prolonged	JJ	B-NP	O	O
vasospastic	vasospastic	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
a	a	DT	B-NP	O	O
theoretical	theoretical	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
,	,	,	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug-AD-1
-	-	HYPH	B-VP	O	O
containing	contain	VBG	I-VP	O	O
or	or	CC	O	O	O
ergot	ergot	NN	B-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
type	type	NN	I-NP	O	I-group-AD-1
medications	medication	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
like	like	IN	B-PP	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	S-drug-AD-1
or	or	CC	O	O	O
methysergide	methysergide	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
and	and	CC	O	O	O
FROVA	FROVA	NN	B-NP	B-protein	S-brand-AD-2
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
(	(	(	O	O	O
see	see	VB	B-VP	O	O
a	a	DT	B-NP	O	O
href	href	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
frova_od.htm	frova_od.htm	NN	B-NP	O	O
#	#	#	B-NP	O	O
CI	CI	NN	I-NP	O	O
CONTRAINDICATIONS	CONTRAINDICATIONS	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
HT1B	HT1B	NN	I-NP	B-protein	O
/	/	SYM	B-NP	O	O
1D	1D	NN	B-NP	O	O
agonists	agonist	NNS	I-NP	O	O
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
FROVA	FROVA	NN	B-NP	B-protein	S-brand
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Selective	Selective	JJ	B-NP	O	B-group-EF-1
serotonin	serotonin	NN	I-NP	O	I-group-EF-1
reuptake	reuptake	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	O	S-group-EF-1
)	)	)	O	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
rarely	rarely	RB	B-ADVP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
weakness	weakness	NN	B-NP	O	O
,	,	,	O	O	O
hyperreflexia	hyperreflexia	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
incoordination	incoordination	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
HT1	HT1	NN	I-NP	O	I-group-EF-2
agonists	agonist	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
frovatriptan	frovatriptan	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	B-protein	S-group-AD-2
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
,	,	,	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
FROVA	FROVA	NN	I-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
commonly	commonly	RB	B-NP	O	O
employed	employ	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Fulvestrant	Fulvestrant	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
strong	strong	JJ	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fulvestrant	fulvestrant	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Carcinogenesis	Carcinogenesis	NN	B-NP	O	O
,	,	,	I-NP	O	O
Mutagenesis	Mutagenesis	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Impairment	Impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Fertility	Fertility	NN	B-NP	O	O
A	A	NN	I-NP	O	O
two	two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
carcinogenesis	carcinogenesis	NN	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
male	male	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
intramuscular	intramuscular	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
rat	rat	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
rat	rat	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
15	15	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
correspond	correspond	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	O	O	O
(	(	(	O	O	O
in	in	IN	B-PP	O	O
females	female	NNS	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
1.3	1.3	CD	B-NP	O	O
-	-	HYPH	O	O	O
,	,	,	O	O	O
1.3	1.3	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
1.6	1.6	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	O	O	O
(	(	(	O	O	O
in	in	IN	B-PP	O	O
males	male	NNS	B-NP	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
[	[	(	O	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
]	]	)	O	O	O
]	]	)	O	O	O
achieved	achieve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
month	month	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
benign	benign	JJ	B-NP	O	O
ovarian	ovarian	JJ	I-NP	O	O
granulosa	granulosa	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
tumors	tumor	NNS	I-NP	O	O
and	and	CC	O	O	O
testicular	testicular	JJ	B-NP	O	O
Leydig	Leydig	NNP	I-NP	O	O
cell	cell	NN	I-NP	O	O
tumors	tumor	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
females	female	NNS	B-NP	O	O
dosed	dose	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
rat	rat	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
15	15	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
males	male	NNS	I-NP	O	O
dosed	dose	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
rat	rat	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Induction	Induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
tumors	tumor	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
endocrine	endocrine	JJ	I-NP	O	O
feedback	feedback	NN	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
gonadotropin	gonadotropin	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
antiestrogen	antiestrogen	NN	I-NP	O	S-group
.	.	.	O	O	O

Fulvestrant	Fulvestrant	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
mutagenic	mutagenic	JJ	B-ADJP	O	O
or	or	CC	I-ADJP	O	O
clastogenic	clastogenic	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
tests	test	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
and	and	CC	I-PP	O	O
without	without	IN	I-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mammalian	mammalian	JJ	I-NP	B-protein	O
liver	liver	NN	I-NP	I-protein	O
metabolic	metabolic	JJ	I-NP	I-protein	O
activation	activation	NN	I-NP	I-protein	O
factor	factor	NN	I-NP	I-protein	O
(	(	(	O	O	O
bacterial	bacterial	JJ	B-NP	O	O
mutation	mutation	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
strains	strain	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Salmonella	Salmonella	NNP	B-NP	O	O
typhimurium	typhimurium	NNP	I-NP	O	O
and	and	CC	O	O	O
Escherichia	Escherichia	FW	B-ADVP	O	O
coli	coli	FW	I-ADVP	O	O
,	,	,	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
cytogenetics	cytogenetic	NNS	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
lymphocytes	lymphocyte	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
mammalian	mammalian	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
mutation	mutation	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mouse	mouse	NN	B-NP	B-cell_type	O
lymphoma	lymphoma	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
micronucleus	micronucleus	NN	I-NP	O	O
test	test	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
fulvestrant	fulvestrant	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
0.01	0.01	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hundredth	hundredth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
[	[	(	O	O	O
BSA	BSA	NN	B-NP	O	O
]	]	)	O	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
and	and	CC	B-PP	O	O
for	for	IN	I-PP	O	O
1	1	CD	B-NP	O	O
week	week	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
mating	mating	NN	B-NP	O	O
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
fertility	fertility	NN	B-NP	O	O
and	and	CC	O	O	O
embryonic	embryonic	JJ	B-NP	O	O
survival	survival	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
fertility	fertility	NN	I-NP	O	O
and	and	CC	O	O	O
embryonic	embryonic	JJ	B-NP	O	O
survival	survival	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
dosed	dose	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
thousandth	thousandth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
BSA	BSA	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Restoration	Restoration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
fertility	fertility	NN	I-NP	O	O
to	to	TO	B-PP	O	O
values	value	NNS	B-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
controls	control	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
29	29	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
period	period	NN	I-NP	O	O
after	after	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
at	at	IN	B-PP	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
twice	twice	RB	B-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
BSA	BSA	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fulvestrant	fulvestrant	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fertility	fertility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
estrogenic	estrogenic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fulvestrant	fulvestrant	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fertility	fertility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
but	but	CC	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
month	month	NN	I-NP	O	O
toxicology	toxicology	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
male	male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
intramuscular	intramuscular	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
rat	rat	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
rat	rat	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
15	15	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
fulvestrant	fulvestrant	NN	I-NP	O	S-drug
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
spermatozoa	spermatozoa	NN	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
seminiferous	seminiferous	JJ	I-NP	O	O
tubules	tubule	NNS	I-NP	O	O
,	,	,	O	O	O
seminiferous	seminiferous	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
atrophy	atrophy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
degenerative	degenerative	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epididymides	epididymide	NNS	I-NP	O	O
.	.	.	O	O	O

Changes	Change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
testes	testis	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
epididymides	epididymide	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
recovered	recover	VBN	I-VP	O	O
20	20	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
cessation	cessation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
fulvestrant	fulvestrant	JJ	I-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
correspond	correspond	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
[	[	(	O	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
]	]	)	O	O	O
achieved	achieve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
.	.	.	O	O	O

Pregnancy	Pregnancy	NNP	B-NP	O	O
Pregnancy	Pregnancy	NNP	I-NP	O	O
Category	Category	NNP	I-NP	O	O
D	D	NNP	I-NP	O	O
:	:	:	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
0.01	0.01	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
IM	IM	NN	B-NP	O	O
;	;	:	O	O	O

approximately	approximately	RB	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hundredth	hundredth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
[	[	(	O	O	O
BSA	BSA	NN	B-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
fulvestrant	fulvestrant	NN	B-NP	O	S-drug
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reversible	reversible	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
fertility	fertility	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
effects	effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
embryo	embryo	NN	B-NP	O	O
/	/	SYM	O	O	O
fetal	fetal	JJ	B-NP	O	O
development	development	NN	I-NP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
estrogenic	estrogenic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Fulvestrant	Fulvestrant	NN	B-NP	O	S-drug
caused	cause	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fetal	fetal	JJ	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
(	(	(	O	O	O
tarsal	tarsal	JJ	B-NP	O	O
flexure	flexure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hind	hind	NN	I-NP	O	O
paw	paw	NN	I-NP	O	O
at	at	IN	B-PP	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
IM	IM	NN	I-NP	O	O
;	;	:	O	O	O

twice	twice	RB	B-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
on	on	IN	B-PP	O	O
BSA	BSA	NN	B-NP	B-protein	O
)	)	)	O	O	O
and	and	CC	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
ossification	ossification	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
odontoid	odontoid	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
ventral	ventral	JJ	I-NP	O	O
tubercle	tubercle	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
cervical	cervical	JJ	I-NP	O	O
vertebra	vertebra	NN	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
0.1	0.1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	O	O	O
day	day	NN	B-NP	O	O
IM	IM	NN	I-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
tenth	tenth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
on	on	IN	B-PP	O	O
BSA	BSA	NN	B-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
organogenesis	organogenesis	NN	B-NP	O	O
.	.	.	O	O	O

Rabbits	Rabbit	NNS	B-NP	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
maintain	maintain	VB	I-VP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
dosed	dose	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
day	day	NN	B-NP	O	O
fulvestrant	fulvestrant	JJ	I-NP	O	S-drug
IM	IM	NN	I-NP	O	O
(	(	(	O	O	O
twice	twice	RB	B-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
on	on	IN	B-PP	O	O
BSA	BSA	NN	B-NP	O	O
)	)	)	O	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
organogenesis	organogenesis	NN	B-NP	O	O
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
rabbits	rabbit	NNS	B-NP	O	O
dosed	dose	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
half	half	PDT	I-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
on	on	IN	B-PP	O	O
BSA	BSA	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
increases	increase	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
placental	placental	JJ	B-NP	O	O
weight	weight	NN	I-NP	O	O
and	and	CC	O	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
implantation	implantation	NN	I-NP	O	O
loss	loss	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
but	but	CC	O	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
observed	observe	VBN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
fetal	fetal	JJ	B-NP	O	O
development	development	NN	I-NP	O	O
.	.	.	O	O	O

Fulvestrant	Fulvestrant	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fetal	fetal	JJ	B-NP	O	O
variations	variation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rabbits	rabbit	NNS	B-NP	O	O
(	(	(	O	O	O
backwards	backward	NNS	B-NP	O	O
displacement	displacement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pelvic	pelvic	JJ	I-NP	O	O
girdle	girdle	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
27	27	CD	B-NP	B-DNA	O
pre	pre	AFX	B-NP	I-DNA	O
-	-	HYPH	I-NP	O	O
sacral	sacral	JJ	I-NP	O	O
vertebrae	vertebra	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
IM	IM	NN	I-NP	O	O
;	;	:	O	O	O

one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
half	half	PDT	I-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
on	on	IN	B-PP	O	O
BSA	BSA	NN	B-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
organogenesis	organogenesis	NN	B-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
pregnancy	pregnancy	NN	B-NP	O	O
could	could	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
maintained	maintain	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rabbit	rabbit	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
fulvestrant	fulvestrant	NN	B-NP	O	S-drug
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
and	and	CC	O	O	O
above	above	RB	B-ADVP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
inadequate	inadequate	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
fully	fully	RB	I-VP	O	O
define	define	VB	I-VP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
fetal	fetal	JJ	B-NP	O	O
development	development	NN	I-NP	O	O
at	at	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
exposures	exposure	NNS	I-NP	O	O
.	.	.	O	O	O

Nursing	Nurse	VBG	B-VP	O	O
Mothers	Mothers	NNP	B-NP	O	O
Fulvestrant	Fulvestrant	NNP	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
milk	milk	NN	I-NP	O	O
at	at	IN	B-PP	O	O
levels	level	NNS	B-NP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
12	12	CD	I-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rodent	rodent	NN	B-NP	O	O
pups	pup	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
fulvestrant	fulvestrant	NN	B-NP	O	S-drug
-	-	HYPH	B-ADVP	O	O
treated	treat	VBN	B-VP	O	O
lactating	lactate	VBG	B-NP	O	O
dams	dam	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
estimated	estimate	VBN	I-VP	O	O
as	as	IN	B-SBAR	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administered	administer	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
fulvestrant	fulvestrant	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
milk	milk	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
many	many	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
milk	milk	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
FASLODEX	FASLODEX	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
nursing	nursing	NN	B-NP	O	O
infants	infant	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decision	decision	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
to	to	TO	B-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
nursing	nursing	NN	B-NP	O	O
or	or	CC	O	O	O
to	to	TO	B-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
taking	take	VBG	B-VP	O	O
into	into	IN	B-PP	O	O
account	account	NN	B-NP	O	O
the	the	DT	B-NP	O	O
importance	importance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
mother	mother	NN	I-NP	O	O
.	.	.	O	O	O

Pediatric	Pediatric	JJ	B-NP	O	O
Use	Use	NN	I-NP	O	O
The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
FASLODEX	FASLODEX	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Geriatric	Geriatric	NNP	B-NP	O	O
Use	Use	NNP	I-NP	O	O
When	When	WRB	B-ADVP	O	O
tumor	tumor	NN	B-NP	O	O
response	response	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
objective	objective	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
under	under	IN	B-PP	O	O
65	65	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
65	65	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
and	and	CC	O	O	O
older	old	JJR	B-ADJP	O	O
,	,	,	O	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
FASLODEX	FASLODEX	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
European	European	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
North	North	JJ	I-NP	O	O
American	American	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
ototoxic	ototoxic	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-group-EF-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Except	Except	IN	B-PP	O	O
in	in	IN	B-PP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
situations	situation	NNS	B-NP	O	O
,	,	,	O	O	O
avoid	avoid	VB	B-VP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ethacrynic	ethacrynic	JJ	B-NP	O	B-drug-AD-2
acid	acid	NN	I-NP	O	E-drug-AD-2
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ototoxicity	ototoxicity	NN	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
salicylates	salicylate	NNS	B-NP	O	S-group-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
as	as	IN	B-PP	O	O
in	in	IN	B-PP	O	O
rheumatic	rheumatic	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
experience	experience	VB	I-VP	O	O
salicylate	salicylate	NN	B-NP	O	S-group
toxicity	toxicity	NN	I-NP	O	O
at	at	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
competitive	competitive	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretory	excretory	JJ	I-NP	O	O
sites	site	NNS	I-NP	O	O
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
tendency	tendency	NN	I-NP	O	O
to	to	TO	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
skeletal	skeletal	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
relaxing	relaxing	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubocurarine	tubocurarine	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug-AD-1
generally	generally	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-AD-2
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
reduce	reduce	VBP	B-VP	O	O
lithiums	lithium	NNS	B-NP	O	O
renal	renal	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
add	add	VB	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
add	add	VB	I-VP	O	O
to	to	TO	B-PP	O	O
or	or	CC	O	O	O
potentiate	potentiate	VB	B-VP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Potentiation	Potentiation	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
ganglionic	ganglionic	JJ	B-NP	O	S-group
or	or	CC	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	B-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
blocking	blocking	NN	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
arterial	arterial	JJ	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
still	still	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
effectively	effectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Tablets	Tablet	NNS	B-NP	O	O
Simultaneous	Simultaneous	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
furosemide	furosemide	NN	I-NP	O	S-drug-EF-2
tablets	tablet	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
diuretic	diuretic	JJ	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
sucralfate	sucralfate	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
separated	separate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
two	two	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Tablets	Tablet	NNS	B-NP	O	O
,	,	,	O	O	O
Injection	Injection	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Oral	Oral	NNP	B-NP	O	O
Solution	Solution	NNP	I-NP	O	O
One	One	CD	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
six	six	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
temporarily	temporarily	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
creatinine	creatinine	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
case	case	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
BUN	BUN	NN	B-NP	B-protein	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
and	and	CC	I-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
weight	weight	NN	B-NP	O	O
gain	gain	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Literature	Literature	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
prostaglandin	prostaglandin	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

Indomethacin	Indomethacin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
plasma	plasma	NN	B-NP	B-protein	O
renin	renin	NN	I-NP	I-protein	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
aldosterone	aldosterone	NN	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
renin	renin	NN	B-NP	B-protein	O
profile	profile	NN	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	CC	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
furosemide	furosemide	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
diuretic	diuretic	JJ	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
(	(	(	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2A6	CYP2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
)	)	)	O	O	O
that	that	WDT	B-NP	O	O
mediate	mediate	VBP	B-VP	O	O
drug	drug	NN	B-NP	O	O
and	and	CC	O	O	O
xenobiotic	xenobiotic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
isoform	isoform	NN	B-NP	O	O
selective	selective	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
substrates	substrate	NNS	I-NP	O	O
and	and	CC	O	O	O
human	human	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
microsomal	microsomal	JJ	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
.	.	.	O	O	O

Only	Only	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
tested	test	VBN	B-VP	O	O
(	(	(	O	O	O
171	171	CD	B-NP	O	O

g	g	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
mL	mL	NN	I-NP	O	O
;	;	:	O	O	O

1	1	CD	B-NP	O	O
mM	mM	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
(	(	(	O	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
isoform	isoform	NN	B-NP	O	O
CYP2A6	CYP2A6	NN	I-NP	B-protein	O
observed	observe	VBN	B-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
isoforms	isoform	NNS	I-NP	O	O
tested	test	VBN	B-VP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
171	171	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
15	15	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
at	at	IN	B-PP	O	O
3600	3600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Gabapentin	Gabapentin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appreciably	appreciably	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
nor	nor	CC	O	O	O
does	do	VBZ	O	O	O
it	it	PRP	B-NP	O	O
interfere	interfere	VB	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
commonly	commonly	RB	B-NP	O	O
coadministered	coadministere	VBN	I-NP	O	O
antiepileptic	antiepileptic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
described	describe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
section	section	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
involving	involve	VBG	B-VP	O	O
healthy	healthy	JJ	B-NP	O	O
adults	adult	NNS	I-NP	O	O
and	and	CC	O	O	O
adult	adult	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
multiple	multiple	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
TID	TID	NN	I-NP	O	O
)	)	)	O	O	O
study	study	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Neurontin	Neurontin	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
epileptic	epileptic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
8	8	CD	B-NP	O	O
)	)	)	O	O	O
maintained	maintain	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
monotherapy	monotherapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Steady	Steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug
and	and	CC	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	B-drug_n
10	10	CD	I-NP	O	I-drug_n
,	,	,	I-NP	O	I-drug_n
11	11	CD	I-NP	O	I-drug_n
epoxide	epoxide	NN	I-NP	O	E-drug_n
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
gabapentin	gabapentin	NN	I-NP	O	S-drug
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
TID	TID	NN	I-NP	O	O
;	;	:	O	O	O

N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
administration	administration	NN	B-NP	O	O
.	.	.	O	O	O

Likewise	Likewise	RB	B-ADVP	O	O
,	,	,	O	O	O
gabapentin	gabapentin	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
unaltered	unaltered	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Valproic	Valproic	JJ	B-NP	O	B-drug
Acid	Acid	NN	I-NP	O	E-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
valproic	valproic	JJ	I-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
concentrations	concentration	NNS	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
and	and	CC	O	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
gabapentin	gabapentin	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
TID	TID	NN	I-NP	O	O
;	;	:	O	O	O

N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
17	17	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
different	different	JJ	B-ADJP	O	O
and	and	CC	O	O	O
neither	neither	DT	B-NP	O	O
were	be	VBD	B-VP	O	O
gabapentin	gabapentin	NN	B-NP	O	S-drug
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
affected	affect	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
:	:	:	O	O	O
Estimates	Estimate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
gabapentin	gabapentin	NN	I-NP	O	S-drug
(	(	(	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
TID	TID	NN	I-NP	O	O
;	;	:	O	O	O

N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
identical	identical	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	I-ADVP	O	O
together	together	RB	I-ADVP	O	O
.	.	.	O	O	O

Naproxen	Naproxen	NNP	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
18	18	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
naproxen	naproxen	NN	B-NP	O	B-drug-ME-1
sodium	sodium	NN	I-NP	O	E-drug-ME-1
capsules	capsule	NNS	I-NP	O	O
(	(	(	O	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
Neurontin	Neurontin	NN	B-NP	B-protein	S-brand-ME-2
(	(	(	O	O	O
125	125	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug
absorbed	absorb	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
15	15	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Gabapentin	Gabapentin	NN	B-NP	B-protein	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
ranges	range	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
known	know	VBN	B-ADJP	O	O
.	.	.	O	O	O

Hydrocodone	Hydrocodone	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Neurontin	Neurontin	NN	B-NP	B-protein	S-brand
(	(	(	O	O	O
125	125	CD	B-NP	O	O
to	to	TO	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
;	;	:	O	O	O

N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
48	48	CD	B-NP	O	O
)	)	)	O	O	O
decreases	decrease	VBZ	B-VP	O	O
hydrocodone	hydrocodone	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
;	;	:	O	O	O

N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
50	50	CD	B-NP	O	O
)	)	)	O	O	O
Cmax	Cmax	NN	B-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
relative	relative	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hydrocodone	hydrocodone	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
;	;	:	O	O	O

Cmax	Cmax	NN	B-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-ADJP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
125	125	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Neurontin	Neurontin	NN	I-NP	O	S-brand
and	and	CC	O	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-ADJP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Neurontin	Neurontin	NN	I-NP	O	S-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Hydrocodone	Hydrocodone	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
gabapentin	gabapentin	NN	B-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
at	at	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Morphine	Morphine	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
article	article	NN	I-NP	O	O
reported	report	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
60	60	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
controlled	control	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
release	release	NN	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug-ME-1
capsule	capsule	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
600	600	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
Neurontin	Neurontin	NN	I-NP	O	S-brand-ME-2
capsule	capsule	NN	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
gabapentin	gabapentin	NN	I-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug
administered	administer	VBN	B-VP	O	O
without	without	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Morphine	Morphine	NN	B-NP	O	S-drug
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameter	parameter	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Neurontin	Neurontin	NN	B-NP	B-protein	S-brand
2	2	CD	B-NP	I-protein	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
at	at	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QID	QID	NN	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
apparent	apparent	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug-ME-2
fell	fall	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
fell	fall	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug-ME-1
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug-ME-2
and	and	CC	I-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
endogenous	endogenous	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
excretion	excretion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug-ME-1
by	by	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
importance	importance	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug
on	on	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptive	Contraceptive	JJ	I-NP	O	S-group
:	:	:	O	O	O
Based	Base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
and	and	CC	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
,	,	,	O	O	O
multiple	multiple	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tablets	tablet	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
and	and	CC	O	O	O
50	50	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
and	and	CC	O	O	O
without	without	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	O	S-drug
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
TID	TID	NN	I-NP	O	O
;	;	:	O	O	O

N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
13	13	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
13	13	CD	B-NP	O	O
%	%	NN	I-NP	O	O
higher	high	JJR	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug-ME-2
;	;	:	O	O	O

this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
importance	importance	NN	I-NP	O	O
.	.	.	O	O	O

Antacid	Antacid	NN	B-NP	O	S-group
(	(	(	O	O	O
Maalox	Maalox	NN	B-NP	O	S-brand
)	)	)	O	O	O
:	:	:	O	O	O
Maalox	Maalox	NN	B-NP	O	S-brand-ME-1
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug-ME-2
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
16	16	CD	B-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
about	about	RB	B-NP	O	O
5	5	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
Maalox	Maalox	NNP	B-NP	O	S-brand-ME-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug-AD-1
be	be	VB	B-VP	O	O
taken	take	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
Maalox	Maalox	NNP	B-NP	O	S-brand-AD-2
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
Probenecid	Probenecid	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
blocker	blocker	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

Gabapentin	Gabapentin	NN	B-NP	O	S-drug
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
and	and	CC	I-PP	O	O
with	with	IN	I-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
comparable	comparable	JJ	B-ADJP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
undergo	undergo	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathway	pathway	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
blocked	block	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Tests	Test	VBZ	B-VP	O	O
Interactions	Interaction	NNS	B-NP	O	O
Because	Because	IN	B-PP	O	O
false	false	JJ	B-NP	O	O
positive	positive	JJ	I-NP	O	O
readings	reading	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Ames	Ames	NNP	I-NP	O	O
N	N	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Multistix	Multistix	NN	I-NP	O	O
SG	SG	NN	I-NP	O	O
dipstick	dipstick	NN	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
when	when	WRB	B-ADVP	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
other	other	JJ	B-NP	O	O
antiepileptic	antiepileptic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
the	the	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
specific	specific	JJ	I-NP	O	O
sulfosalicylic	sulfosalicylic	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
precipitation	precipitation	NN	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
protein	protein	NN	I-NP	O	O

LABORATORY	LABORATORY	NN	B-NP	O	O
TEST	TEST	NN	I-NP	O	O
FINDINGS	FINDINGS	NN	I-NP	O	O
Asymptomatic	Asymptomatic	JJ	B-NP	O	O
,	,	,	I-NP	O	O
transitory	transitory	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
iron	iron	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Omniscan	Omniscan	NNP	B-NP	O	S-brand
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
calcium	calcium	NN	I-NP	O	O
measurements	measurement	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
colorimetric	colorimetric	JJ	I-NP	O	O
(	(	(	O	O	O
complexometric	complexometric	JJ	B-ADJP	O	O
)	)	)	O	O	O
methods	method	NNS	B-NP	O	O
commonly	commonly	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
hospitals	hospital	NNS	B-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
calcium	calcium	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
true	true	JJ	I-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
not	not	RB	O	O	O
to	to	TO	B-VP	O	O
use	use	VB	I-VP	O	O
such	such	JJ	B-NP	O	O
methods	method	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
12	12	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
24	24	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Omniscan	Omniscan	NNP	B-NP	O	S-brand
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
measurements	measurement	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
methods	method	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
remained	remain	VBD	B-VP	O	O
asymptomatic	asymptomatic	JJ	B-ADJP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Vitrasert	Vitrasert	NNP	I-NP	O	S-brand
Implant	Implant	NNP	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
limited	limited	JJ	B-NP	O	O
experience	experience	NN	I-NP	O	O
with	with	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
retinal	retinal	JJ	B-NP	O	O
tamponades	tamponade	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Vitrasert	Vitrasert	NNP	I-NP	O	S-brand
Implant	Implant	NNP	I-NP	O	O
.	.	.	O	O	O

Substances	Substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
inducers	inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gefitinib	gefitinib	NN	B-NP	O	S-drug
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
its	its	PRP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducer	inducer	NN	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
rifampicin	rifampicin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
to	to	TO	B-PP	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	B-ADJP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
and	and	CC	O	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
(	(	(	O	O	O
see	see	VB	B-VP	O	O
CLINICAL	CLINICAL	NN	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Pharmacokinetics	Pharmacokinetics	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Drug	Drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Drug	Drug	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
and	and	CC	O	O	O
DOSAGE	DOSAGE	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
ADMINISTRATION	ADMINISTRATION	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Dosage	Dosage	NN	I-NP	O	O
Adjustment	Adjustment	NN	I-NP	O	O
sections	section	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

International	International	NNP	B-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
(	(	(	O	O	O
INR	INR	NN	B-NP	O	O
)	)	)	O	O	O
elevations	elevation	NNS	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
bleeding	bleed	VBG	B-VP	O	O
events	event	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-1
while	while	IN	B-SBAR	O	O
on	on	IN	B-PP	O	O
IRESSA	IRESSA	NN	B-NP	O	S-brand-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
regularly	regularly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
INR	INR	NN	B-NP	B-protein	O
.	.	.	O	O	O

Substances	Substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
potent	potent	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
decrease	decrease	VBP	B-VP	O	O
gefitinib	gefitinib	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
gefitinib	gefitinib	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
relevant	relevant	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
experiences	experience	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
dose	dose	NN	B-NP	O	O
and	and	CC	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
IRESSA	IRESSA	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
cause	cause	VBP	B-VP	O	O
significant	significant	JJ	B-NP	O	O
sustained	sustained	JJ	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
gastric	gastric	JJ	B-NP	O	O
pH	pH	NN	I-NP	O	O
(	(	(	O	O	O
histamine	histamine	NN	B-NP	O	B-group-ME-1
H2	H2	NN	I-NP	O	I-group-ME-1
-	-	HYPH	B-NP	O	I-group-ME-1
receptor	receptor	NN	I-NP	O	I-group-ME-1
antagonists	antagonist	NNS	I-NP	O	E-group-ME-1
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug-ME-1
or	or	CC	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
IRESSA	IRESSA	NN	B-NP	O	S-brand-ME-2
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
potentially	potentially	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
efficacy	efficacy	NN	B-NP	O	O
.	.	.	O	O	O

Phase	Phase	NN	B-NP	B-protein	O
II	II	CD	I-NP	I-protein	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
where	where	WRB	B-ADVP	O	O
IRESSA	IRESSA	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
vinorelbine	vinorelbine	NN	I-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
IRESSA	IRESSA	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
exacerbate	exacerbate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neutropenic	neutropenic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vinorelbine	vinorelbine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
information	information	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Gemzar	Gemzar	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
,	,	,	O	O	O
see	see	VBP	B-VP	O	O
Drug	Drug	NNP	B-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
under	under	IN	B-PP	O	O
CLINICAL	CLINICAL	NN	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
section	section	NN	I-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	NNP	B-NP	O	O
Laboratory	Laboratory	NNP	I-NP	O	O

increased	increase	VBN	B-NP	O	O
creatine	creatine	NN	I-NP	O	O

positive	positive	JJ	B-NP	O	O
antinuclear	antinuclear	JJ	I-NP	O	O

increased	increase	VBN	B-NP	O	O
bilirubin	bilirubin	NN	I-NP	O	O

increased	increase	VBN	B-NP	O	O
liver	liver	NN	I-NP	O	O

transaminases	transaminase	NNS	B-NP	B-protein	O
(	(	(	O	O	O
AST	AST	NN	B-NP	O	O

(	(	(	O	O	O
SGOT	SGOT	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
ALT	ALT	NN	B-NP	B-protein	O
(	(	(	O	O	O
SGPT	SGPT	NN	B-NP	O	O
)	)	)	O	O	O

increased	increase	VBN	B-NP	O	O
alkaline	alkaline	NN	I-NP	O	O

bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
hypoplasia	hypoplasia	NN	I-NP	O	O

laryngeal	laryngeal	JJ	B-NP	O	O
edema	edema	NN	I-NP	O	O

Lupus	Lupus	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O

exfoliative	exfoliative	JJ	B-NP	O	O
dermatitis	dermatitis	NN	I-NP	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
repeat	repeat	NN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
FACTIVE	FACTIVE	NN	B-NP	O	S-brand
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
repeat	repeat	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
or	or	CC	O	O	O
an	an	DT	B-NP	O	O
ethinylestradiol	ethinylestradiol	NN	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
levonorgestrol	levonorgestrol	NN	I-NP	B-protein	O
oral	oral	JJ	I-NP	I-protein	O
contraceptive	contraceptive	JJ	I-NP	I-protein	B-group
product	product	NN	I-NP	I-protein	E-group
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
FACTIVE	FACTIVE	NN	B-NP	O	S-brand-ME-1
and	and	CC	O	O	O
calcium	calcium	NN	B-NP	O	B-drug-ME-2
carbonate	carbonate	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
an	an	DT	B-NP	O	O
estrogen	estrogen	NN	I-NP	O	S-group-ME-2
/	/	SYM	B-NP	O	O
progesterone	progesterone	NN	I-NP	O	S-drug-ME-2
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group-ME-2
produced	produce	VBD	B-VP	O	O
minor	minor	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
gemifloxacin	gemifloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
without	without	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
FACTIVE	FACTIVE	NN	B-NP	O	S-brand-ME-1
with	with	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
45	45	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
gemifloxacin	gemifloxacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

FACTIVE	FACTIVE	NN	B-NP	O	S-brand
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
some	some	DT	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
test	test	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	B-group-AD-1
antimicrobial	antimicrobial	JJ	B-ADJP	O	E-group-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
.	.	.	O	O	O

Quinolones	Quinolone	NNS	B-NP	O	S-group
form	form	VBP	B-VP	O	O
chelates	chelate	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
alkaline	alkaline	NN	B-NP	O	O
earth	earth	NN	I-NP	O	O
and	and	CC	O	O	O
transition	transition	NN	B-NP	O	O
metals	metal	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
gemifloxacin	gemifloxacin	NN	I-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
antacid	antacid	NN	I-NP	O	S-group
containing	contain	VBG	B-VP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Magnesium	Magnesium	NN	B-NP	O	S-drug-AD-1
-	-	HYPH	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-AD-1
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacids	antacid	NNS	B-NP	O	S-group
,	,	,	O	O	O
products	product	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
ferrous	ferrous	JJ	B-NP	O	B-drug-AD-1
sulfate	sulfate	NN	I-NP	O	E-drug-AD-1
(	(	(	O	O	O
iron	iron	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
,	,	,	O	O	O
multivitamin	multivitamin	NN	B-NP	O	B-group-AD-1
preparations	preparation	NNS	I-NP	O	E-group-AD-1
containing	contain	VBG	B-VP	O	O
zinc	zinc	NN	B-NP	O	S-drug-AD-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
metal	metal	NN	I-NP	O	O
cations	cation	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
Videx	Videx	NN	B-NP	O	S-brand-AD-1
(	(	(	I-NP	O	O
didanosine	didanosine	NN	I-NP	O	S-drug-AD-1
)	)	)	I-NP	O	O
chewable	chewable	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
buffered	buffered	JJ	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
powder	powder	NN	I-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
solution	solution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
3	3	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	B-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
FACTIVE	FACTIVE	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

Sucralfate	Sucralfate	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
FACTIVE	FACTIVE	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	O	O	O
interaction	interaction	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
performed	perform	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Mylotarg	Mylotarg	NN	B-NP	O	S-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
affected	affect	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
ruled	rule	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
.	.	.	O	O	O

Laboratory	Laboratory	NN	B-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O

Mylotarg	Mylotarg	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
routine	routine	JJ	I-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
COPAXONE	COPAXONE	NN	B-NP	O	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
fully	fully	RB	B-ADJP	O	O
evaluated	evaluate	VBN	I-ADJP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
existing	exist	VBG	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
COPAXONE	COPAXONE	NN	B-NP	O	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
commonly	commonly	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
MS	MS	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
for	for	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
28	28	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

COPAXONE	COPAXONE	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
formally	formally	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Interferon	Interferon	NN	B-NP	B-protein	B-drug
beta	beta	NN	I-NP	I-protein	E-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
10	10	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
switched	switch	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Interferon	Interferon	NN	B-NP	B-protein	B-drug
beta	beta	NN	I-NP	I-protein	E-drug
to	to	TO	B-PP	O	O
COPAXONE	COPAXONE	NN	B-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
report	report	VB	I-VP	O	O
any	any	DT	B-NP	O	O
serious	serious	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
unexpected	unexpected	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
thought	think	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sulfonylureas	sulfonylurea	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-EF-2
anti	anti	AFX	I-NP	O	I-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
highly	highly	RB	B-ADVP	O	O
protein	protein	NN	B-NP	O	O
bound	bind	VBD	B-VP	O	O
,	,	,	O	O	O
salicylates	salicylate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
chloramphenicol	chloramphenicol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
coumarins	coumarin	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	B-group-EF-2
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
MICRONASE	MICRONASE	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
MICRONASE	MICRONASE	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
tend	tend	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
phe	phe	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
nothiazines	nothiazine	NNS	I-NP	O	O
,	,	,	O	O	O
thyroid	thyroid	NN	B-NP	B-protein	B-group
products	product	NNS	I-NP	I-protein	E-group
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
nicotinic	nicotinic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
sympathomimet	sympathomimet	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ics	ic	NNS	I-NP	O	O
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blocking	block	VBG	B-VP	O	I-group
drugs	drug	NNS	B-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
MICRONASE	MICRONASE	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
MICRONASE	MICRONASE	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O	S-drug-IN-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
fluoroquinolone	fluoroquinolone	NN	I-NP	O	B-group
antibiotic	antibiotic	NN	I-NP	O	E-group
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
miconazole	miconazole	NN	I-NP	O	S-drug-EF-1
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Whether	Whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
occurs	occur	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
,	,	,	I-NP	O	O
topical	topical	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
vaginal	vaginal	JJ	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
miconazole	miconazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Metformin	Metformin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
NIDDM	NIDDM	NN	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
decreases	decrease	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	B-protein	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
were	be	VBD	B-VP	O	O
highly	highly	RB	B-ADJP	O	O
variable	variable	JJ	I-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
nature	nature	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
correlation	correlation	NN	B-NP	O	O
between	between	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
pharmaco	pharmaco	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
dynamic	dynamic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
makes	make	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
uncertain	uncertain	JJ	B-ADJP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
gly	gly	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
buride	buride	NN	I-NP	O	O
and	and	CC	I-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
either	either	DT	B-NP	O	O
metformin	metformin	NN	I-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
or	or	CC	O	O	O
pharmaco	pharmaco	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
dynamics	dynamic	NNS	I-NP	O	O
.	.	.	O	O	O

Many	Many	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
medicines	medicine	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
glimepiride	glimepiride	NN	B-NP	O	S-drug
or	or	CC	O	O	O
affect	affect	VB	B-VP	O	O
your	your	PRP$	B-NP	O	O
condition	condition	NN	I-NP	O	O
.	.	.	O	O	O

Before	Before	IN	B-PP	O	O
taking	take	VBG	B-VP	O	O
glimepiride	glimepiride	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
tell	tell	VB	B-VP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
medicines	medicine	NNS	I-NP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-2
or	or	CC	O	O	O
another	another	DT	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group-AD-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
magnesium	magnesium	NN	B-NP	O	B-drug-AD-2
/	/	SYM	B-VP	O	I-drug-AD-2
choline	choline	NN	B-NP	O	I-drug-AD-2
salicylate	salicylate	NN	I-NP	O	E-drug-AD-2
(	(	(	O	O	O
Trilisate	Trilisate	NN	B-NP	O	S-brand-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
salsalate	salsalate	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
Disalcid	Disalcid	NN	B-NP	O	S-brand-AD-2
,	,	,	O	O	O
others	other	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
choline	choline	NN	B-NP	O	B-drug-AD-2
salicylate	salicylate	NN	I-NP	O	E-drug-AD-2
(	(	(	O	O	O
Arthropan	Arthropan	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
magnesium	magnesium	NN	B-NP	O	B-drug-AD-2
salicylate	salicylate	NN	I-NP	O	E-drug-AD-2
(	(	(	O	O	O
Magan	Magan	NN	B-NP	O	S-brand-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
bismuth	bismuth	JJ	B-NP	O	B-drug-AD-2
subsalicylate	subsalicylate	NN	I-NP	O	E-drug-AD-2
(	(	(	O	O	O
Pepto	Pepto	NN	B-NP	O	B-brand-AD-2
-	-	HYPH	O	O	I-brand-AD-2
Bismol	Bismol	NN	B-NP	O	E-brand-AD-2
)	)	)	O	O	O
;	;	:	O	O	O

-	-	:	O	O	O
a	a	DT	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drug	drug	NN	I-NP	O	E-group
(	(	(	O	O	O
NSAID	NSAID	NN	B-NP	O	S-group
)	)	)	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
(	(	(	O	O	O
Motrin	Motrin	NNP	B-NP	O	S-brand
,	,	,	O	O	O
Advil	Advil	NNP	B-NP	O	S-brand
,	,	,	O	O	O
Nuprin	Nuprin	NNP	B-NP	O	S-brand
,	,	,	O	O	O
others	other	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug
(	(	(	O	O	O
Orudis	Orudis	NNP	B-NP	O	S-brand
,	,	,	O	O	O
Orudis	Orudis	NNP	B-NP	O	B-brand
KT	KT	NNP	I-NP	O	E-brand
,	,	,	O	O	O
Oruvail	Oruvail	NNP	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug
(	(	(	O	O	O
Voltaren	Voltaren	NNP	B-NP	O	S-brand
,	,	,	O	O	O
Cataflam	Cataflam	NNP	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
etodolac	etodolac	NN	B-NP	O	S-drug
(	(	(	O	O	O
Lodine	Lodine	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
(	(	(	O	O	O
Indocin	Indocin	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
nabumetone	nabumetone	NN	B-NP	O	S-drug
(	(	(	O	O	O
Relafen	Relafen	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
oxaprozin	oxaprozin	NN	B-NP	O	S-drug
(	(	(	O	O	O
Daypro	Daypro	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
(	(	(	O	O	O
Anaprox	Anaprox	NNP	B-NP	O	S-brand
,	,	,	O	O	O
Naprosyn	Naprosyn	NNP	B-NP	O	S-brand
,	,	,	O	O	O
Aleve	Aleve	NNP	B-NP	O	S-brand
)	)	)	O	O	O
;	;	:	O	O	O

-	-	:	O	O	O
a	a	DT	B-NP	O	O
sulfa	sulfa	NN	I-NP	O	O
-	-	HYPH	O	O	O
based	base	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
sulfamethoxazole	sulfamethoxazole	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
trimethoprim	trimethoprim	NN	I-NP	O	S-drug
(	(	(	O	O	O
Bactrim	Bactrim	NNP	B-NP	O	S-brand
,	,	,	O	O	O
Septra	Septra	NNP	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
sulfisoxazole	sulfisoxazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
Gantrisin	Gantrisin	NN	B-NP	B-protein	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
sulfasalazine	sulfasalazine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Azulfidine	Azulfidine	NN	B-NP	O	S-brand
)	)	)	O	O	O
;	;	:	O	O	O

-	-	:	O	O	O
a	a	DT	B-NP	O	O
monoamine	monoamine	NN	I-NP	O	B-group
oxidase	oxidase	NN	I-NP	O	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
(	(	(	O	O	O
MAOI	MAOI	NN	B-NP	O	S-group
)	)	)	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
isocarboxazid	isocarboxazid	NN	B-NP	O	S-drug
(	(	(	O	O	O
Marplan	Marplan	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
tranylcypromine	tranylcypromine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Parnate	Parnate	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
phenelzine	phenelzine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Nardil	Nardil	NN	B-NP	O	S-brand
)	)	)	O	O	O
;	;	:	O	O	O

-	-	:	O	O	O
a	a	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
blocker	blocker	NN	I-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
(	(	(	O	O	O
Inderal	Inderal	JJ	B-ADVP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
atenolol	atenolol	NN	B-NP	O	S-drug
(	(	(	O	O	O
Tenormin	Tenormin	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
acebutolol	acebutolol	NN	B-NP	O	S-drug
(	(	(	O	O	O
Sectral	Sectral	JJ	B-ADVP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
metoprolol	metoprolol	NN	B-NP	O	S-drug
(	(	(	O	O	O
Lopressor	Lopressor	NN	B-NP	B-protein	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
others	other	NNS	B-NP	O	O
;	;	:	O	O	O

-	-	:	O	O	O
a	a	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
(	(	(	O	O	O
water	water	NN	B-NP	O	O
pill	pill	NN	I-NP	O	O
)	)	)	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
(	(	(	O	O	O
HCTZ	HCTZ	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
Hydrodiuril	Hydrodiuril	NNP	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
chlorothiazide	chlorothiazide	NN	B-NP	O	S-drug
(	(	(	O	O	O
Diuril	Diuril	NNP	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
others	other	NNS	B-NP	O	O
;	;	:	O	O	O

-	-	:	O	O	O
a	a	DT	B-NP	O	O
steroid	steroid	NN	I-NP	O	B-group
medicine	medicine	NN	I-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
prednisone	prednisone	NN	B-NP	O	S-drug
(	(	(	O	O	O
Deltasone	Deltasone	NN	B-NP	O	S-brand
,	,	,	O	O	O
Orasone	Orasone	NN	B-NP	O	S-brand
,	,	,	O	O	O
others	other	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug
(	(	(	O	O	O
Medrol	Medrol	NN	B-NP	O	S-brand
,	,	,	O	O	O
others	other	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
prednisolone	prednisolone	NN	B-NP	O	S-drug
(	(	(	O	O	O
Prelone	Prelone	NNP	B-NP	O	S-brand
,	,	,	O	O	O
Pediapred	Pediapred	NNP	B-NP	O	S-brand
,	,	,	O	O	O
others	other	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
others	other	NNS	B-NP	O	O
;	;	:	O	O	O

-	-	:	O	O	O
a	a	DT	B-NP	O	O
phenothiazine	phenothiazine	NN	I-NP	O	S-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
chlorpromazine	chlorpromazine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Thorazine	Thorazine	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
fluphenazine	fluphenazine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Prolixin	Prolixin	NN	B-NP	O	S-brand
,	,	,	O	O	O
Permitil	Permitil	NNP	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
prochlorperazine	prochlorperazine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Compazine	Compazine	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
promethazine	promethazine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Phenergan	Phenergan	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
others	other	NNS	B-NP	O	O
;	;	:	O	O	O

-	-	HYPH	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
(	(	(	O	O	O
Dilantin	Dilantin	NN	B-NP	O	S-brand
)	)	)	O	O	O
;	;	:	O	O	O

-	-	HYPH	B-NP	O	O
isoniazid	isoniazid	NN	I-NP	O	S-drug
(	(	(	O	O	O
Nydrazid	Nydrazid	NN	B-NP	O	S-brand
)	)	)	O	O	O
;	;	:	O	O	O

-	-	HYPH	B-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug
(	(	(	O	O	O
Rifadin	Rifadin	NN	B-NP	O	S-brand
,	,	,	O	O	O
Rifamate	Rifamate	NN	B-NP	O	S-brand
)	)	)	O	O	O
;	;	:	O	O	O

or	or	CC	O	O	O
-	-	HYPH	B-ADJP	O	O
over	over	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
the	the	DT	B-NP	O	O
-	-	HYPH	I-NP	O	O
counter	counter	NN	I-NP	O	O
cough	cough	NN	I-NP	O	O
,	,	,	O	O	O
cold	cold	NN	B-NP	O	O
,	,	,	O	O	O
allergy	allergy	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
weight	weight	NN	B-NP	O	O
loss	loss	NN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

You	You	PRP	B-NP	B-protein	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
a	a	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
or	or	CC	O	O	O
special	special	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
listed	list	VBN	B-VP	O	O
above	above	RB	B-ADVP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
listed	list	VBN	B-VP	O	O
here	here	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
glimepiride	glimepiride	NN	B-NP	O	S-drug
or	or	CC	O	O	O
affect	affect	VB	B-VP	O	O
your	your	PRP$	B-NP	O	O
condition	condition	NN	I-NP	O	O
.	.	.	O	O	O

Talk	Talk	NN	B-NP	O	O
to	to	TO	B-PP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacist	pharmacist	NN	I-NP	O	O
before	before	IN	B-PP	O	O
taking	take	VBG	B-VP	O	O
any	any	DT	B-NP	O	O
prescription	prescription	NN	I-NP	O	O
or	or	CC	B-PP	O	O
over	over	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
the	the	DT	B-NP	O	O
-	-	HYPH	I-NP	O	O
counter	counter	NN	I-NP	O	O
medicines	medicine	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
herbal	herbal	JJ	B-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Immediate	Immediate	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
Extended	Extended	NNP	I-NP	O	O
Release	Release	NNP	I-NP	O	O
Tablets	Tablet	NNPS	I-NP	O	O
The	The	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sulfonylureas	sulfonylurea	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-EF-2
anti	anti	AFX	I-NP	O	I-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
some	some	DT	B-NP	O	O
azoles	azole	NNS	I-NP	O	S-group-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
highly	highly	RB	B-ADVP	O	O
protein	protein	NN	B-NP	O	O
bound	bind	VBD	B-VP	O	O
,	,	,	O	O	O
salicylates	salicylate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
chloramphenicol	chloramphenicol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
coumarins	coumarin	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	B-group-EF-2
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
glipizide	glipizide	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
glipizide	glipizide	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
binding	binding	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
human	human	JJ	B-NP	B-protein	O
serum	serum	NN	I-NP	I-protein	O
proteins	protein	NNS	I-NP	I-protein	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
glipizide	glipizide	NN	B-NP	O	S-drug
binds	bind	VBZ	B-VP	O	O
differently	differently	RB	B-ADVP	O	O
than	than	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
and	and	CC	O	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
salicylate	salicylate	NN	B-NP	O	S-group
or	or	CC	I-NP	O	O
dicumarol	dicumarol	NN	I-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
extrapolating	extrapolate	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
situation	situation	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glipizide	glipizide	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
tend	tend	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
thyroid	thyroid	NN	B-NP	B-protein	B-group
products	product	NNS	I-NP	I-protein	E-group
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
nicotinic	nicotinic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
sympathomimetics	sympathomimetic	NNS	B-NP	O	S-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blocking	block	VBG	B-VP	O	I-group
drugs	drug	NNS	B-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
glipizide	glipizide	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
glipizide	glipizide	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
miconazole	miconazole	NN	I-NP	O	S-drug-IN-1
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-IN-2
agents	agent	NNS	I-NP	O	E-group-IN-2
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Whether	Whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
occurs	occur	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
,	,	,	I-NP	O	O
topical	topical	JJ	I-NP	O	O
,	,	,	I-NP	O	O
or	or	CC	I-NP	O	O
vaginal	vaginal	JJ	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
miconazole	miconazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
glipizide	glipizide	NN	I-NP	O	S-drug-IN-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
glipizide	glipizide	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
following	follow	VBG	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
daily	daily	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
for	for	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
percentage	percentage	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glipizide	glipizide	NN	I-NP	O	S-drug-ME-1
AUC	AUC	NN	I-NP	O	O
after	after	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-2
administration	administration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
56.9	56.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
:	:	:	O	O	O
35	35	CD	B-NP	O	O
to	to	TO	B-PP	O	O
81	81	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Robinul	Robinul	NNP	B-NP	O	S-brand-EF-1
Injection	Injection	NNP	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinergics	anticholinergic	NNS	I-NP	O	S-group-EF-2
or	or	CC	I-NP	O	O
medications	medication	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
antiparkinson	antiparkinson	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
may	may	MD	B-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antimuscarinic	antimuscarinic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Robinul	Robinul	NNP	B-NP	O	S-brand-ME-1
Injection	Injection	NNP	I-NP	O	O
and	and	CC	O	O	O
potassium	potassium	NN	B-NP	O	B-drug-ME-2
chloride	chloride	NN	I-NP	O	E-drug-ME-2
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
wax	wax	NN	I-NP	O	O
matrix	matrix	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	O
chloride	chloride	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
lesions	lesion	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
slower	slow	JJR	I-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
transit	transit	NN	I-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
Factrel	Factrel	NNP	I-NP	O	S-brand
test	test	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
directly	directly	RB	B-ADVP	O	O
affect	affect	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
pituitary	pituitary	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gonadotropins	gonadotropin	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
would	would	MD	B-VP	O	O
include	include	VB	I-VP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
preparations	preparation	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
contain	contain	VBP	B-VP	O	O
androgens	androgen	NNS	B-NP	O	S-group
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
progestins	progestin	NNS	B-NP	O	S-group
,	,	,	O	O	O
or	or	CC	O	O	O
glucocorticoids	glucocorticoid	NNS	B-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
gonadotropin	gonadotropin	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
transiently	transiently	RB	I-VP	O	O
elevated	elevate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug
,	,	,	O	O	O
minimally	minimally	RB	B-VP	O	O
elevated	elevate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
suppressed	suppress	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
Factrel	Factrel	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
blunted	blunt	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
and	and	CC	O	O	O
dopamine	dopamine	NN	B-NP	O	B-group-EF-2
antagonists	antagonist	NNS	I-NP	O	E-group-EF-2
which	which	WDT	B-NP	O	O
cause	cause	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
rise	rise	NN	I-NP	O	O
in	in	IN	B-PP	O	O
prolactin	prolactin	NN	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
confirmed	confirmed	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
ZOLADEX	ZOLADEX	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
,	,	,	O	O	O
Sucralfate	Sucralfate	NNP	B-NP	O	S-drug
,	,	,	O	O	O
Metal	Metal	NNP	B-NP	O	O
Cations	Cations	NNP	I-NP	O	O
,	,	,	O	O	O
Multivitamins	Multivitamins	NNP	B-NP	O	S-group
Quinolones	Quinolones	NNP	I-NP	O	S-group
form	form	NN	I-NP	O	O
chelates	chelate	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
alkaline	alkaline	NN	B-NP	O	O
earth	earth	NN	I-NP	O	O
and	and	CC	O	O	O
transition	transition	NN	B-NP	O	O
metal	metal	NN	I-NP	O	O
cations	cation	NNS	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group-ME-1
with	with	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
with	with	IN	B-PP	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
with	with	IN	B-PP	O	O
metal	metal	NN	B-NP	O	O
cations	cation	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
with	with	IN	B-PP	O	O
multivitamins	multivitamin	NNS	B-NP	O	S-group-ME-2
containing	contain	VBG	B-VP	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
zinc	zinc	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
with	with	IN	B-PP	O	O
formulations	formulation	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
divalent	divalent	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
trivalent	trivalent	JJ	I-NP	O	O
cations	cation	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
VIDEX	VIDEX	NN	B-NP	B-protein	S-brand-ME-2
(	(	(	O	O	O
didanosine	didanosine	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
chewable	chewable	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
buffered	buffered	JJ	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
powder	powder	NN	I-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
solution	solution	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
substantially	substantially	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
considerably	considerably	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
than	than	IN	B-SBAR	O	O
desired	desire	VBN	B-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
4	4	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	B-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	O	S-drug
Theobromine	Theobromine	NN	I-NP	O	S-drug
Grepafloxacin	Grepafloxacin	NN	I-NP	O	S-drug-ME-1
,	,	,	O	O	O
like	like	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
theobromine	theobromine	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
stimulants	stimulant	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
commonly	commonly	RB	I-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
coffee	coffee	NN	B-NP	O	O
and	and	CC	I-NP	O	O
tea	tea	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
enhanced	enhance	VBN	B-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
theobromine	theobromine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Grepafloxacin	Grepafloxacin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
competitive	competitive	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
increase	increase	VBP	B-VP	O	O
when	when	WRB	B-ADVP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
maintained	maintain	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
multi	multi	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
maintained	maintain	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-AD-1
maintenance	maintenance	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
halved	halve	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug-AD-2
and	and	CC	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
initiated	initiate	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
guide	guide	NN	I-NP	O	O
to	to	TO	B-PP	O	O
further	further	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clotting	clotting	NN	B-NP	O	O
time	time	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
some	some	DT	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
test	test	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	B-group-AD-1
antimicrobial	antimicrobial	JJ	B-ADJP	O	E-group-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
Enzymes	Enzyme	NNS	I-NP	I-protein	O
The	The	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
evaluating	evaluate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug-ME-1
inhibits	inhibit	VBZ	B-VP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
C.P.A	C.P.A	NN	B-NP	B-protein	O
.	.	.	O	O	O

substrates	substrate	NNS	B-NP	O	O
,	,	,	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
similar	similar	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
mediated	mediate	VBN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
C.P.A	C.P.A	NN	B-NP	B-protein	O
.	.	.	O	O	O

include	include	VBP	B-VP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
,	,	,	O	O	O
astemizole	astemizole	NN	B-NP	O	S-drug
,	,	,	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
,	,	,	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
C.P.A	C.P.A	NN	B-NP	B-protein	O
.	.	.	O	O	O
substrates	substrate	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
substrates	substrate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
C.P.A	C.P.A	NN	B-NP	B-protein	O
.	.	.	O	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
excluded	exclude	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
grepafloxacin	grepafloxacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Nonsteroidal	Nonsteroidal	JJ	B-NP	O	B-group
Anti	Anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
Drugs	Drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
)	)	)	O	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-EF-1
anti	anti	JJ	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
drug	drug	NN	I-NP	O	E-group-EF-1
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CNS	CNS	NN	B-NP	B-protein	O
stimulation	stimulation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
convulsions	convulsion	NNS	I-NP	O	O
.	.	.	O	O	O

Antidiabetic	Antidiabetic	JJ	B-NP	O	B-group
Agents	Agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
Disturbances	Disturbance	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
and	and	CC	I-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group-EF-2
agent	agent	NN	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
type	type	NN	I-NP	O	I-group-AD-1
anticoagulant	anticoagulant	JJ	I-NP	O	E-group-AD-1
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	O
during	during	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
griseofulvin	griseofulvin	NN	B-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-1
usually	usually	RB	B-ADVP	O	O
depresses	depress	VBZ	B-VP	O	O
griseofulvin	griseofulvin	NN	B-NP	B-protein	S-drug-EF-2
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
necessitate	necessitate	VB	I-VP	O	O
raising	raise	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
griseofulvin	griseofulvin	NN	B-NP	B-protein	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
breakthrough	breakthrough	NN	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
codeine	codeine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
psychotropics	psychotropic	NNS	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
produce	produce	VBP	B-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

Serious	Serious	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
dextromethorphan	dextromethorphan	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
MAOIs	MAOI	NNS	B-NP	B-protein	S-group-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dextromethorphan	dextromethorphan	NN	B-NP	O	B-drug-EF-1
hydrobromide	hydrobromide	NN	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
psychotropics	psychotropic	NNS	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
produce	produce	VBP	B-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

http	http	NN	B-NP	O	O
:	:	:	O	O	O
/	/	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
www.rxlist.com	www.rxlist.com	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
cgi	cgi	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
generic3	generic3	NN	I-NP	O	O
/	/	SYM	O	O	O
guanethidine_od.htm	guanethidine_od.htm	NN	B-NP	O	O

The	The	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
depressant	depressant	NN	I-NP	O	I-group-EF-2
drug	drug	NN	I-NP	O	E-group-EF-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
appreciated	appreciate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug-ME-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
known	know	VBN	B-NP	O	O
microsomal	microsomal	JJ	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
inducer	inducer	NN	I-NP	O	O
(	(	(	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
or	or	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
to	to	TO	B-PP	O	O
two	two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
reportedly	reportedly	RB	B-ADVP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
elimination	elimination	NN	B-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
and	and	CC	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
more	more	RBR	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
achieve	achieve	VB	I-VP	O	O
or	or	CC	I-VP	O	O
maintain	maintain	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
tapering	tapering	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
rebound	rebound	NN	B-NP	O	O
phenomena	phenomenon	NNS	I-NP	O	O
.	.	.	O	O	O

TCAs	TCA	NNS	B-NP	B-protein	S-group-EF-1
decrease	decrease	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Noncardioselective	Noncardioselective	JJ	B-NP	B-protein	B-group-EF-1
beta	beta	SYM	I-NP	I-protein	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
blockers	blocker	NNS	B-NP	O	E-group-EF-1
(	(	(	O	O	O
nadolol	nadolol	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
porpranolol	porpranolol	NN	B-NP	O	O
,	,	,	O	O	O
timolol	timolol	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
exacerbate	exacerbate	VB	I-VP	O	O
rebound	rebound	NN	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug-EF-2
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
blocker	blocker	NN	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
first	first	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
gradual	gradual	JJ	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
guafacine	guafacine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
cardioselective	cardioselective	JJ	I-NP	B-protein	B-group
beta	beta	SYM	I-NP	I-protein	I-group
-	-	HYPH	I-NP	O	I-group
blocker	blocker	NN	I-NP	O	E-group
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
substituted	substitute	VBN	I-VP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
:	:	:	O	O	O
Ten	Ten	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug
,	,	,	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
reported	report	VBD	B-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
safety	safety	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
principal	principal	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
given	give	VBN	B-VP	O	O
(	(	(	O	O	O
number	number	NN	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
parentheses	parenthesis	NNS	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
:	:	:	O	O	O
cardiac	cardiac	JJ	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
(	(	(	O	O	O
115	115	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group
and	and	CC	I-NP	O	O
hypnotics	hypnotic	NNS	I-NP	O	S-group
(	(	(	O	O	O
103	103	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
coronary	coronary	JJ	B-NP	O	B-group
vasodilators	vasodilator	NNS	I-NP	O	E-group
(	(	(	O	O	O
52	52	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemics	hypoglycemic	NNS	I-NP	O	S-group
(	(	(	O	O	O
45	45	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
cough	cough	NN	B-NP	O	O
and	and	CC	O	O	O
cold	cold	JJ	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
(	(	(	O	O	O
45	45	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
(	(	(	O	O	O
38	38	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
antihyperlipidemics	antihyperlipidemic	NNS	B-NP	O	S-group
(	(	(	O	O	O
29	29	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
antigout	antigout	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
24	24	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
(	(	(	O	O	O
18	18	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
bronchodilators	bronchodilator	NNS	B-NP	O	S-group
(	(	(	O	O	O
13	13	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
(	(	(	O	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Laboratory	Laboratory	NN	B-NP	O	O
Test	Test	NN	I-NP	O	O
In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	RB	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
causally	causally	RB	B-ADJP	O	O
related	relate	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
drug	drug	NN	B-NP	O	O
during	during	IN	B-PP	O	O
short	short	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
No	No	DT	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
guanfacine	guanfacine	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
encephalopathic	encephalopathic	JJ	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
(	(	(	O	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
weakness	weakness	NN	B-NP	O	O
,	,	,	I-NP	O	O
lethargy	lethargy	NN	I-NP	O	O
,	,	,	I-NP	O	O
fever	fever	NN	I-NP	O	O
,	,	,	I-NP	O	O
tremulousness	tremulousness	NN	I-NP	O	O
and	and	CC	I-NP	O	O
confusion	confusion	NN	I-NP	O	O
,	,	,	O	O	O
extrapyramidal	extrapyramidal	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
,	,	,	O	O	O
leukocytosis	leukocytosis	NN	B-NP	O	O
,	,	,	O	O	O
elevated	elevated	JJ	B-NP	O	O
serum	serum	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
BUN	BUN	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
FBS	FBS	NN	B-NP	B-protein	O
)	)	)	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
irreversible	irreversible	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
damage	damage	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-1
plus	plus	CC	I-NP	O	O
HALDOL	HALDOL	NN	I-NP	O	S-brand-EF-2
.	.	.	O	O	O

A	A	DT	B-NP	O	O
causal	causal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
these	these	DT	B-NP	O	O
events	event	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
HALDOL	HALDOL	NN	I-NP	O	S-brand
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
such	such	JJ	B-NP	O	O
combined	combine	VBN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurological	neurological	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
discontinued	discontinue	VBD	B-VP	O	O
promptly	promptly	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
appear	appear	VBP	B-VP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
noted	note	VBN	I-VP	O	O
that	that	DT	O	O	O
HALDOL	HALDOL	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
potentiating	potentiate	VBG	B-VP	O	O
CNS	CNS	NN	B-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
opiates	opiate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
schizophrenic	schizophrenic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
coadministered	coadministere	VBN	B-VP	O	O
oral	oral	JJ	B-NP	O	O
haloperidol	haloperidol	NN	I-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
haloperidol	haloperidol	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	NN	I-NP	O	O
of	of	IN	B-PP	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
mean	mean	JJ	I-NP	O	O
scores	score	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Brief	Brief	NNP	I-NP	O	O
Psychiatric	Psychiatric	NNP	I-NP	O	O
Rating	Rating	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
5	5	CD	B-NP	O	O
other	other	JJ	I-NP	O	O
schizophrenic	schizophrenic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
haloperidol	haloperidol	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug
,	,	,	O	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
3.3	3.3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-AD-2
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

FLUOTHANE	FLUOTHANE	NN	B-NP	O	S-brand-EF-1
augments	augment	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
non	non	AFX	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
depolarising	depolarise	VBG	B-VP	O	I-group-EF-2
muscle	muscle	NN	B-NP	O	I-group-EF-2
relaxants	relaxant	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
relaxant	relaxant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

FLUOTHANE	FLUOTHANE	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
augment	augment	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ganglionic	ganglionic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blocking	block	VBG	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubocurarine	tubocurarine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adrenaline	adrenaline	NN	B-NP	O	S-drug-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
anaesthetised	anaesthetise	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
FLUOTHANE	FLUOTHANE	NN	B-NP	O	S-brand-AD-2
as	as	IN	B-SBAR	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
precipitated	precipitate	VBN	I-VP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
this	this	DT	B-NP	O	O
reason	reason	NN	I-NP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adrenaline	adrenaline	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
restricted	restricted	JJ	B-ADJP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	B-group
agent	agent	NN	I-NP	O	E-group
administered	administer	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
appropriate	appropriate	JJ	B-ADJP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
applied	apply	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
sympathomimetics	sympathomimetic	NNS	I-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
for	for	IN	B-PP	O	O
aminophylline	aminophylline	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
and	and	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
precipitate	precipitate	VB	I-VP	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
.	.	.	I-NP	O	O
Drugs	Drugs	NNP	I-NP	O	O
Enhancing	Enhancing	NNP	I-NP	O	O
Heparin	Heparin	NNP	I-NP	O	S-drug
Effect	Effect	NNP	I-NP	O	O
:	:	:	O	O	O
Oral	Oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
:	:	:	O	O	O
Heparin	Heparin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
stage	stage	NN	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
heparin	heparin	NN	B-NP	O	B-drug-AD-1
sodium	sodium	NN	I-NP	O	E-drug-AD-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
dicumarol	dicumarol	NN	B-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	B-drug-AD-2
sodium	sodium	NN	I-NP	O	E-drug-AD-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
5	5	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
or	or	CC	O	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
subcutaneous	subcutaneous	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
before	before	IN	B-SBAR	O	O
blood	blood	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
drawn	draw	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
valid	valid	JJ	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O

Platelet	Platelet	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug-EF-1
acid	acid	NN	I-NP	O	E-drug-EF-1
,	,	,	O	O	O
dextran	dextran	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
hydroxychloroquine	hydroxychloroquine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
others	other	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
platelet	platelet	NN	B-NP	B-cell_type	O
-	-	HYPH	B-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
(	(	(	O	O	O
the	the	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
hemostatic	hemostatic	JJ	I-NP	O	O
defense	defense	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparinized	heparinize	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
bleeding	bleed	VBG	I-VP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
heparin	heparin	NN	B-NP	O	B-drug-EF-2
sodium	sodium	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antithrombin	antithrombin	NN	B-NP	B-protein	B-drug-EF-2
III	III	CD	I-NP	I-protein	E-drug-EF-2
(	(	(	O	O	O
human	human	JJ	O	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hereditary	hereditary	JJ	B-NP	O	O
antithrombin	antithrombin	NN	I-NP	O	O
III	III	CD	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
bleeding	bleeding	NN	B-NP	O	O
,	,	,	O	O	O
reduced	reduce	VBD	B-VP	O	O
dosage	dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
antithrombin	antithrombin	NN	B-NP	B-protein	B-drug-AD-2
III	III	CD	I-NP	I-protein	E-drug-AD-2
(	(	(	O	O	O
human	human	JJ	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

b	b	NN	B-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Decreasing	Decrease	VBG	B-VP	O	O
Heparin	Heparin	NN	B-NP	O	S-drug
Effect	Effect	NN	I-NP	O	O
:	:	:	O	O	O
Digitalis	Digitalis	NNP	B-NP	O	S-group-EF-1
,	,	,	O	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
nicotine	nicotine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
or	or	CC	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
partially	partially	RB	I-VP	O	O
counteract	counteract	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	B-drug-EF-2
sodium	sodium	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Heparin	Heparin	NN	B-NP	O	B-drug
Sodium	Sodium	NN	I-NP	O	E-drug
Injection	Injection	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
mixed	mix	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
droperidol	droperidol	NN	B-NP	O	S-drug
,	,	,	O	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
mitoxantrone	mitoxantrone	NN	B-NP	O	S-drug
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
incompatible	incompatible	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
precipitate	precipitate	NN	I-NP	O	O
may	may	MD	B-VP	O	O
form	form	VB	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Tests	Test	VBZ	B-VP	O	O
Interactions	Interaction	NNS	B-NP	O	O
Hyperaminotransferasemia	Hyperaminotransferasemia	NN	I-NP	O	O
:	:	:	O	O	O
Significant	Significant	JJ	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aminotransferase	aminotransferase	NN	B-NP	B-protein	O
(	(	(	O	O	O
SGOT	SGOT	NN	B-NP	O	O
[	[	(	O	O	O
S	S	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
AST	AST	NN	I-NP	O	O
]	]	)	O	O	O
and	and	CC	O	O	O
SGPT	SGPT	NN	B-NP	O	O
[	[	(	B-NP	O	O
S	S	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
ALT	ALT	NN	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
levels	level	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
percentage	percentage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
and	and	CC	O	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
)	)	)	O	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
received	receive	VBN	I-VP	O	O
heparin	heparin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
aminotransferase	aminotransferase	NN	B-NP	O	O
determinations	determination	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
important	important	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
differential	differential	JJ	I-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	O
infarction	infarction	NN	I-NP	O	O
,	,	,	O	O	O
liver	liver	NN	B-NP	O	O
disease	disease	NN	I-NP	O	O
and	and	CC	O	O	O
pulmonary	pulmonary	JJ	B-NP	O	O
emboli	embolus	NNS	I-NP	O	O
,	,	,	O	O	O
rises	rise	VBZ	B-VP	O	O
that	that	WDT	B-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
caused	cause	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
(	(	(	O	O	O
heparin	heparin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
interpreted	interpret	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Opioids	Opioid	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
strong	strong	JJ	B-NP	O	O
central	central	JJ	I-NP	O	B-group
nervous	nervous	JJ	I-NP	O	I-group
system	system	NN	I-NP	O	I-group
depressants	depressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
but	but	CC	O	O	O
regular	regular	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
develop	develop	VBP	B-VP	O	O
physiological	physiological	JJ	B-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
allowing	allow	VBG	B-VP	O	O
gradually	gradually	RB	B-NP	O	O
increased	increase	VBN	I-NP	O	O
dosages	dosage	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
central	central	JJ	I-NP	O	B-group-EF-1
nervous	nervous	JJ	I-NP	O	I-group-EF-1
system	system	NN	I-NP	O	I-group-EF-1
depressants	depressant	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
heroin	heroin	NN	B-NP	O	S-drug_n-EF-2
may	may	MD	B-VP	O	O
still	still	RB	I-VP	O	O
kill	kill	VB	I-VP	O	O
even	even	RB	B-NP	O	O
experienced	experienced	JJ	I-NP	O	O
users	user	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
their	their	PRP$	B-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
strength	strength	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
usual	usual	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Toxicology	Toxicology	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heroin	heroin	NN	B-NP	O	S-drug_n-EF-1
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
deaths	death	NNS	I-NP	O	O
reveal	reveal	VBP	B-VP	O	O
frequent	frequent	JJ	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
central	central	JJ	I-NP	O	B-group-EF-2
nervous	nervous	JJ	I-NP	O	I-group-EF-2
system	system	NN	I-NP	O	I-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
Valium	Valium	NN	B-NP	O	S-brand-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
rising	rise	VBG	I-NP	O	O
degree	degree	NN	I-NP	O	O
,	,	,	O	O	O
methadone	methadone	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Ironically	Ironically	RB	B-ADVP	O	O
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
often	often	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heroin	heroin	NN	B-NP	O	S-drug
addiction	addiction	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
cause	cause	VBP	B-VP	O	O
much	much	RB	B-NP	O	O
more	more	RBR	I-NP	O	O
severe	severe	JJ	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

Cocaine	Cocaine	NN	B-NP	O	S-drug-EF-1
sometimes	sometimes	RB	B-ADVP	O	O
proves	prove	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
fatal	fatal	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
heroin	heroin	NN	B-NP	O	S-drug_n-EF-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
information	information	NN	I-NP	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

Barbiturates	Barbiturate	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	B-group-EF-2
blockers	blocker	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
hydralazine	hydralazine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
other	other	JJ	B-NP	O	O
potent	potent	JJ	I-NP	O	O
parental	parental	JJ	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
diazoxide	diazoxide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
hydralazine	hydralazine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
continuously	continuously	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
hours	hour	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
any	any	DT	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Profound	Profound	JJ	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
episodes	episode	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
diazoxide	diazoxide	NN	B-NP	O	S-drug-EF-1
infection	infection	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hydralazine	hydralazine	NN	I-NP	O	S-drug-EF-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group
-	-	HYPH	O	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
(	(	(	O	O	O
metoprolol	metoprolol	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
)	)	)	O	O	O
serum	serum	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
pharmacologic	pharmacologic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Monitor	Monitor	NN	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
status	status	NN	I-NP	O	O
.	.	.	O	O	O

Propranolol	Propranolol	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
hydralazines	hydralazine	NNS	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Acebutolol	Acebutolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
atenolol	atenolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
nadolol	nadolol	NN	B-NP	O	S-drug
(	(	(	O	O	O
low	low	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
or	or	CC	O	O	O
no	no	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
pass	pass	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hydralazine	hydralazine	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O

avoid	avoid	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
possible	possible	JJ	B-ADJP	O	O
or	or	CC	O	O	O
closely	closely	RB	B-NP	O	O
monitor	monitor	JJ	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
status	status	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O

When	When	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
or	or	CC	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group
:	:	:	O	O	O
potentiation	potentiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
orthostatic	orthostatic	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Antidiabetic	Antidiabetic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
(	(	(	O	O	O
oral	oral	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
additive	additive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
or	or	CC	I-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
colestipol	colestipol	NN	I-NP	O	S-drug
resins	resin	NNS	I-NP	O	S-group
:	:	:	O	O	O
Absorption	Absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
impaired	impaired	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anionic	anionic	JJ	B-NP	B-protein	B-group-ME-2
exchange	exchange	NN	I-NP	I-protein	I-group-ME-2
resins	resin	NNS	I-NP	I-protein	E-group-ME-2
.	.	.	O	O	O

Single	Single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-ME-1
or	or	CC	O	O	O
colestipol	colestipol	NN	B-NP	O	S-drug-ME-1
resins	resin	NNS	I-NP	O	S-group
bind	bind	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	O	S-drug-ME-2
and	and	CC	O	O	O
reduce	reduce	VB	B-VP	O	O
its	its	PRP$	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
by	by	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
85	85	CD	I-NP	O	O
and	and	CC	I-NP	O	O
43	43	CD	I-NP	O	O
percent	percent	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
ACTH	ACTH	NN	B-NP	O	S-drug
:	:	:	O	O	O
intensified	intensify	VBN	B-NP	O	O
electrolyte	electrolyte	NN	I-NP	O	O
depletion	depletion	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
.	.	.	O	O	O

Pressor	Pressor	NN	B-NP	O	O
amines	amine	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
possible	possible	JJ	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
pressor	pressor	NN	B-NP	O	O
amines	amine	NNS	I-NP	O	O
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
preclude	preclude	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Skeletal	Skeletal	JJ	B-NP	O	B-group
muscle	muscle	NN	I-NP	O	I-group
relaxants	relaxant	NNS	I-NP	O	E-group
,	,	,	O	O	O
nondepolarizing	nondepolarize	VBG	B-VP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
tubocurarine	tubocurarine	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
possible	possible	JJ	B-NP	O	O
increased	increase	VBN	I-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	B-group
relaxant	relaxant	NN	I-NP	O	E-group
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug-AD-1
:	:	:	O	O	O
generally	generally	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-AD-2
.	.	.	O	O	O

Diuretic	Diuretic	JJ	B-NP	O	B-group-MU-1
agents	agent	NNS	I-NP	O	E-group-MU-1
reduce	reduce	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
add	add	VB	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Refer	Refer	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
package	package	NN	I-NP	O	O
insert	insert	NN	I-NP	O	O
for	for	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-1
preparations	preparation	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Hydrochlorothiazide	Hydrochlorothiazide	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-group
-	-	HYPH	I-NP	B-protein	I-group
steroidal	steroidal	JJ	I-NP	I-protein	I-group
Anti	Anti	AFX	I-NP	I-protein	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
Drugs	Drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	B-DNA	B-group-EF-1
-	-	HYPH	I-NP	B-DNA	I-group-EF-1
steroidal	steroidal	JJ	I-NP	I-DNA	I-group-EF-1
anti	anti	AFX	I-NP	I-DNA	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
agent	agent	NN	I-NP	O	E-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
loop	loop	NN	B-NP	O	S-group-EF-2
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	B-group-EF-2
-	-	HYPH	B-VP	O	I-group-EF-2
sparing	spar	VBG	B-NP	O	E-group-EF-2
and	and	CC	I-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
Hydrochlorothiazide	Hydrochlorothiazide	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
non	non	AFX	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	B-DNA	I-group-AD-2
steroidal	steroidal	JJ	B-NP	I-DNA	I-group-AD-2
anti	anti	AFX	I-NP	I-DNA	I-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
narcotic	narcotic	JJ	I-NP	O	B-group-EF-1
analgesics	analgesic	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
antipsychotics	antipsychotic	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
antianxiety	antianxiety	JJ	B-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-1
depressants	depressant	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
hydrocodone	hydrocodone	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug
tablets	tablet	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
combined	combine	VBN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
contemplated	contemplate	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
or	or	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
with	with	IN	B-PP	O	O
hydrocodone	hydrocodone	NN	B-NP	O	S-drug-EF-2
preparations	preparation	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
antidepressant	antidepressant	NN	I-NP	O	S-group
or	or	CC	I-NP	O	O
hydrocodone	hydrocodone	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergics	anticholinergic	NNS	B-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
hydrocodone	hydrocodone	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
paralytic	paralytic	JJ	B-NP	O	O
ileus	ileus	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
information	information	NN	I-NP	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-ADJP	O	O

(	(	(	O	O	O
Effects	Effect	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
;	;	:	O	O	O

dosage	dosage	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Antigout	Antigout	IN	B-PP	O	B-group
medications	medication	NNS	B-NP	O	E-group

(	(	(	O	O	O
Thiazide	Thiazide	DT	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
raise	raise	VB	I-VP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
uric	uric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
;	;	:	O	O	O

dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antigout	antigout	JJ	B-NP	O	B-group
medications	medication	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
hyperuricemia	hyperuricemia	NN	B-NP	O	O
and	and	CC	I-NP	O	O
gout	gout	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Antihypertensive	Antihypertensive	JJ	B-NP	O	B-group
medications	medication	NNS	I-NP	O	E-group
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
,	,	,	I-NP	O	O
especially	especially	RB	I-NP	O	O
diazoxide	diazoxide	NN	I-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
preanesthetic	preanesthetic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
or	or	CC	I-NP	O	O
skeletal	skeletal	JJ	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
muscle	muscle	NN	I-NP	O	I-group
relaxants	relaxant	NNS	I-NP	O	E-group
,	,	,	O	O	O
nondepolarizing	nondepolarize	VBG	B-VP	O	O
,	,	,	O	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O

(	(	(	O	O	O
Effects	Effect	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
;	;	:	O	O	O

dosage	dosage	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Amphotericin	Amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
or	or	CC	O	O	O
Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
or	or	CC	O	O	O
Corticotropin	Corticotropin	NN	B-NP	O	S-drug
(	(	(	O	O	O
ACTH	ACTH	NN	B-NP	O	S-drug
)	)	)	O	O	O

(	(	(	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
intensify	intensify	VB	I-VP	O	O
electrolyte	electrolyte	NN	B-NP	O	O
imbalance	imbalance	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group

(	(	(	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-1
diuretics	diuretic	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-2
toxicity	toxicity	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

(	(	(	O	O	O
May	May	MD	B-VP	O	O
inhibit	inhibit	VBP	I-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
;	;	:	O	O	O

administration	administration	NN	B-NP	O	O
1	1	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	B-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-SBAR	O	O
colestipol	colestipol	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

(	(	(	O	O	O
Thiazide	Thiazide	DT	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
raise	raise	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
;	;	:	O	O	O

for	for	IN	B-PP	O	O
adult	adult	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
onset	onset	NN	I-NP	O	O
diabetics	diabetic	NNS	I-NP	O	O
,	,	,	O	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycemic	hypoglycemic	JJ	B-NP	O	B-group-AD-1
medications	medication	NNS	I-NP	O	E-group-AD-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
during	during	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-AD-2
diuretic	diuretic	JJ	I-NP	O	E-group-AD-2
therapy	therapy	NN	I-NP	O	O
;	;	:	O	O	O

insulin	insulin	NN	B-NP	O	S-drug
requirements	requirement	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
decreased	decrease	VBN	B-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
salts	salt	NNS	I-NP	O	O

(	(	(	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
provoke	provoke	VB	I-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
reduced	reduce	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

(	(	(	O	O	O
Effectiveness	Effectiveness	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
alkalinization	alkalinization	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Nonsteroidal	Nonsteroidal	JJ	B-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group

(	(	(	O	O	O
In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
steroidal	steroidal	JJ	I-NP	O	B-group-EF-1
anti	anti	AFX	I-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
agent	agent	NN	I-NP	O	E-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
loop	loop	NN	B-NP	O	S-group-EF-2
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	B-group-EF-2
sparing	sparing	NN	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
hydroflumethiazide	hydroflumethiazide	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-AD-2
anti	anti	AFX	I-NP	O	I-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

(	(	(	O	O	O
Thiazides	Thiazide	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
arterial	arterial	JJ	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
diminution	diminution	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
preclude	preclude	VB	I-VP	O	O
effectiveness	effectiveness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

(	(	(	O	O	O
Thiazide	Thiazide	DT	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
tubocurarine	tubocurarine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O
)	)	)	O	O	O

DIAGNOSTIC	DIAGNOSTIC	NN	B-NP	O	O
INTERFERENCE	INTERFERENCE	NN	I-NP	O	O
With	With	IN	B-PP	O	O
expected	expect	VBN	B-NP	O	O
physiologic	physiologic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
:	:	:	O	O	O
Blood	Blood	NN	B-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
usually	usually	RB	B-ADVP	O	O
only	only	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
predisposition	predisposition	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
intolerance	intolerance	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Serum	Serum	NN	B-NP	B-protein	O
bilirubin	bilirubin	NN	I-NP	I-protein	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
by	by	IN	B-PP	O	O
displacement	displacement	NN	B-NP	O	O
from	from	IN	B-PP	O	O
albumin	albumin	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Serum	Serum	NN	B-NP	O	O
calcium	calcium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
parathyroid	parathyroid	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Serum	Serum	NN	B-NP	O	O
uric	uric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
)	)	)	O	O	O
Serum	Serum	NN	B-NP	O	O
magnesium	magnesium	NN	I-NP	O	O
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
;	;	:	O	O	O

serum	serum	NN	B-NP	O	O
magnesium	magnesium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
in	in	IN	B-PP	O	O
uremic	uremic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
)	)	)	O	O	O
Serum	Serum	NN	B-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
-	-	HYPH	O	O	O
bound	bind	VBN	B-VP	O	O
iodine	iodine	NN	B-NP	O	O
(	(	(	O	O	O
PBI	PBI	NN	B-NP	O	O
)	)	)	O	O	O
levels	level	NNS	B-NP	O	O
(	(	(	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
)	)	)	O	O	O
Thiazides	Thiazide	NNS	B-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
carrying	carry	VBG	B-VP	O	O
out	out	RP	B-PRT	O	O
tests	test	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
parathyroid	parathyroid	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
narcotic	narcotic	JJ	I-NP	O	B-group-EF-1
analgesics	analgesic	NNS	I-NP	O	O
,	,	,	O	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-1
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
sedative	sedative	JJ	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
hypnotics	hypnotic	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-1
depressants	depressant	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
DILAUDID	DILAUDID	NN	B-NP	O	S-brand-EF-2
may	may	MD	B-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
combined	combine	VBN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
contemplated	contemplate	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Cyanokit	Cyanokit	NN	B-NP	O	S-brand
.	.	.	O	O	O

Prospective	Prospective	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
hydroxyurea	hydroxyurea	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hydroxyurea	hydroxyurea	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
myelosuppressive	myelosuppressive	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
or	or	CC	O	O	O
radiation	radiation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
depression	depression	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
hydroxyurea	hydroxyurea	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
raise	raise	VB	I-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
uric	uric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
level	level	NN	I-NP	O	O
,	,	,	O	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
uricosuric	uricosuric	JJ	B-NP	O	B-group-EF-2
medication	medication	NN	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O

THE	THE	DT	B-NP	O	O
POTENTIATING	POTENTIATING	VBG	I-NP	O	O
ACTION	ACTION	NN	I-NP	O	O
OF	OF	IN	B-PP	O	O
HYDROXYZINE	HYDROXYZINE	NN	B-NP	O	S-drug-EF-1
MUST	MUST	NN	I-NP	O	O
BE	BE	NN	I-NP	O	O
CONSIDERED	CONSIDERED	VBN	B-VP	O	O
WHEN	WHEN	WRB	B-ADVP	O	O
THE	THE	DT	B-NP	O	O
DRUG	DRUG	NNP	I-NP	O	O
IS	IS	NNP	I-NP	O	O
USED	USED	NNP	I-NP	O	O
IN	IN	NNP	I-NP	O	O
CONJUNCTION	CONJUNCTION	NNP	I-NP	O	O
WITH	WITH	NNP	I-NP	O	O
CENTRAL	CENTRAL	NNP	I-NP	O	B-group-EF-2
NERVOUS	NERVOUS	NNP	I-NP	O	I-group-EF-2
SYSTEM	SYSTEM	NNP	I-NP	O	I-group-EF-2
DEPRESSANTS	DEPRESSANTS	NNP	I-NP	O	E-group-EF-2
SUCH	SUCH	NNP	I-NP	O	O
AS	AS	NNP	I-NP	O	O
NARCOTICS	NARCOTICS	NNP	I-NP	O	S-group-EF-2
,	,	,	O	O	O
NON	NON	NN	B-NP	B-protein	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
NARCOTIC	NARCOTIC	NN	I-NP	O	I-group-EF-2
ANALGESICS	ANALGESICS	NNS	I-NP	O	E-group-EF-2
AND	AND	CC	I-NP	O	O
BARBITURATES	BARBITURATES	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
central	central	JJ	B-NP	O	B-group-AD-1
nervous	nervous	JJ	I-NP	O	I-group-AD-1
system	system	NN	I-NP	O	I-group-AD-1
depressants	depressant	NNS	I-NP	O	E-group-AD-1
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
hydroxyzine	hydroxyzine	NN	B-NP	O	S-drug-AD-2
their	their	PRP$	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
drowsiness	drowsiness	NN	B-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warned	warn	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
and	and	CC	O	O	O
cautioned	caution	VBD	B-VP	O	O
against	against	IN	B-PP	O	O
driving	drive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
car	car	NN	I-NP	B-protein	O
or	or	CC	O	O	O
operating	operate	VBG	B-NP	O	O
dangerous	dangerous	JJ	I-NP	O	O
machinery	machinery	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
Atarax	Atarax	NN	B-NP	O	S-brand
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
simultaneous	simultaneous	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	B-group
depressant	depressant	NN	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
cautioned	caution	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Additive	Additive	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
cholinergic	cholinergic	JJ	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
LEVSIN	LEVSIN	NN	B-NP	B-protein	S-brand-EF-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antimuscarinics	antimuscarinic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
amantadine	amantadine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group-EF-2
oxidase	oxidase	NN	I-NP	I-protein	I-group-EF-2
(	(	(	O	O	I-group-EF-2
MAO	MAO	NN	B-NP	O	I-group-EF-2
)	)	)	O	O	I-group-EF-2
inhibitors	inhibitor	NNS	B-NP	O	E-group-EF-2
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
or	or	CC	O	O	O
some	some	DT	B-NP	O	O
antihistamines	antihistamine	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LEVSIN	LEVSIN	NN	B-NP	B-protein	S-brand-ME-2
.	.	.	O	O	O

Administer	Administer	NN	B-NP	B-protein	O
LEVSIN	LEVSIN	NN	I-NP	I-protein	S-brand
before	before	IN	B-PP	O	O
meals	meal	NNS	B-NP	O	O
;	;	:	O	O	O

antacids	antacid	NNS	B-NP	O	S-group
after	after	IN	B-PP	O	O
meals	meal	NNS	B-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	S-drug
Supplements	Supplement	NNS	I-NP	O	O
/	/	SYM	B-VP	O	O
Antacids	Antacid	NNS	B-NP	O	S-group

Products	Product	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
multivalent	multivalent	JJ	I-NP	O	O
cations	cation	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-ME-1
,	,	,	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug-ME-1
,	,	,	I-NP	O	O
iron	iron	NN	I-NP	O	S-drug-ME-1
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Ibandronate	Ibandronate	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Ibandronate	Ibandronate	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
60	60	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
before	before	IN	B-SBAR	O	O
any	any	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
multivalent	multivalent	JJ	B-NP	O	O
cations	cation	NNS	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-2
,	,	,	I-NP	O	O
supplements	supplement	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
vitamins	vitamin	NNS	I-NP	O	S-group-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

H2	H2	NN	B-NP	O	B-group
Blockers	Blocker	NNS	I-NP	O	E-group
and	and	CC	O	O	O
Proton	Proton	NNP	B-NP	O	B-group
Pump	Pump	NNP	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
PPIs	PPI	NNS	B-NP	O	S-group
)	)	)	O	O	O

Of	Of	IN	B-PP	O	O
over	over	IN	B-NP	O	O
3500	3500	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
enrolled	enrol	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Ibandronate	Ibandronate	NN	I-NP	O	S-drug
osteoporosis	osteoporosis	NN	I-NP	O	O
Treatment	Treatment	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Prevention	Prevention	NN	I-NP	O	O
Studies	Study	NNS	I-NP	O	O
,	,	,	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
used	use	VBN	B-VP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
peptic	peptic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
primarily	primarily	RB	B-NP	O	O
H2	H2	NN	I-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
and	and	CC	I-NP	O	O
PPIs	PPI	NNS	I-NP	B-protein	S-group
)	)	)	O	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
upper	upper	JJ	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
experiences	experience	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Ibandronate	Ibandronate	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
over	over	IN	B-NP	O	O
1600	1600	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
enrolled	enrol	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
comparing	compare	VBG	B-VP	O	O
once	once	RB	B-ADVP	O	O
-	-	HYPH	B-ADVP	O	O
monthly	monthly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ibandronate	ibandronate	NN	B-NP	O	S-drug
,	,	,	O	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
anti	anti	AFX	O	O	O
-	-	HYPH	O	O	O
peptic	peptic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
upper	upper	JJ	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
experiences	experience	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Ibandronate	Ibandronate	NN	B-NP	O	S-drug
150	150	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADJP	O	O
monthly	monthly	JJ	I-ADJP	O	O
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Ibandronate	Ibandronate	NN	B-NP	O	S-drug
2.5	2.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
/	/	SYM	I-NP	O	O
Nonsteroidal	Nonsteroidal	JJ	I-NP	O	B-group
Antiinflammatory	Antiinflammatory	JJ	I-NP	O	I-group
Drugs	Drug	NNS	I-NP	O	O
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
)	)	)	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-NP	O	O
osteoporosis	osteoporosis	NN	I-NP	O	O
Treatment	Treatment	NN	I-NP	O	O
Study	Study	NN	I-NP	O	O
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
and	and	CC	O	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
were	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
62	62	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
2946	2946	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
or	or	CC	I-NP	O	O
NSAID	NSAID	NN	I-NP	O	S-group
users	user	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
upper	upper	JJ	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ibandronate	ibandronate	NN	B-NP	O	S-drug
2.5	2.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
(	(	(	O	O	O
28.9	28.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
30.7	30.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
monthly	monthly	JJ	I-NP	O	O
comparison	comparison	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
and	and	CC	O	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
were	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
39	39	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1602	1602	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
upper	upper	JJ	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
or	or	CC	I-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
ibandronate	ibandronate	NN	B-NP	O	S-drug
2.5	2.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
(	(	(	O	O	O
21.7	21.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	O	O	O
monthly	monthly	RB	B-ADVP	O	O
(	(	(	O	O	O
22.0	22.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
since	since	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
bisphosphonates	bisphosphonate	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
all	all	DT	O	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
irritation	irritation	NN	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-AD-1
or	or	CC	I-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-AD-1
with	with	IN	B-PP	O	O
Ibandronate	Ibandronate	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O

Bisphosphonates	Bisphosphonate	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
-	-	HYPH	O	O	O
imaging	image	VBG	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Specific	Specific	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
ibandronate	ibandronate	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ZEVALIN	ZEVALIN	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
the	the	DT	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
benefits	benefit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
weighed	weigh	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
increased	increase	VBN	I-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleeding	NN	B-NP	O	O
and	and	CC	I-NP	O	O
hemorrhage	hemorrhage	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
medications	medication	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
or	or	CC	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
more	more	RBR	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
monitoring	monitor	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
transfusion	transfusion	NN	I-NP	O	O
practices	practice	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
modified	modify	VBN	I-VP	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
prohibited	prohibit	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
receiving	receive	VBG	B-VP	O	O
growth	growth	NN	B-NP	B-protein	O
factor	factor	NN	I-NP	I-protein	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
ZEVALIN	ZEVALIN	NN	I-NP	O	S-brand
therapeutic	therapeutic	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
completion	completion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
.	.	.	O	O	O

Coumarin	Coumarin	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
Type	Type	NN	I-NP	O	I-group
Anticoagulants	Anticoagulant	NNS	I-NP	O	E-group
:	:	:	O	O	O
Several	Several	JJ	B-NP	O	O
short	short	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
controlled	control	VBN	I-NP	O	O
studies	study	NNS	I-NP	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
wshow	wshow	VB	I-VP	O	O
that	that	DT	B-NP	O	O
ibuprofen	ibuprofen	NN	I-NP	O	S-drug
significantly	significantly	RB	B-VP	O	O
affected	affect	VBD	I-VP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
clotting	clot	VBG	I-NP	B-protein	O
factors	factor	NNS	I-NP	I-protein	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
individuals	individual	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
type	type	NN	I-NP	O	I-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
bleeding	bleeding	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-EF-1
anti	anti	AFX	I-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
type	type	NN	I-NP	O	I-group-EF-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
cautious	cautious	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-AD-2
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Animal	Animal	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
wshow	wshow	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-1
given	give	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-EF-2
anti	anti	AFX	I-NP	O	I-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
yields	yield	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
net	net	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
with	with	IN	B-PP	O	O
lowered	lower	VBN	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Single	Single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
failed	fail	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
wshow	wshow	VB	I-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Correlative	Correlative	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ibuprofen	Ibuprofen	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
other	other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-ME-1
anti	anti	AFX	B-NP	O	I-group-ME-1
-	-	HYPH	I-NP	O	I-group-ME-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-ME-1
drugs	drug	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
probably	probably	RB	B-ADVP	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rabbit	rabbit	NN	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
slices	slice	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
indicate	indicate	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-EF-1
could	could	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

H	H	NN	B-NP	O	O
-	-	HYPH	O	O	O
2	2	CD	B-NP	O	O
Antagonists	Antagonist	NNS	I-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
ranitidine	ranitidine	NN	I-NP	O	S-drug
with	with	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
substantive	substantive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
random	random	JJ	B-NP	O	O
observations	observation	NNS	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group-EF-2
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
response	response	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
failure	failure	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
to	to	TO	B-VP	O	O
assure	assure	VB	I-VP	O	O
diuretic	diuretic	JJ	B-NP	O	S-group
efficacy	efficacy	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ibuprofen	Ibuprofen	NN	B-NP	O	S-drug-ME-1
produced	produce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
eleven	eleven	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
minimum	minimum	JJ	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
19	19	CD	B-NP	O	O
%	%	NN	I-NP	O	O
during	during	IN	B-PP	O	O
this	this	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
subjects	subject	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
Read	Read	JJ	B-NP	O	O
circulars	circular	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
preparation	preparation	NN	I-NP	O	O
before	before	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Supraventricular	Supraventricular	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
mask	mask	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
excessive	excessive	JJ	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
particularly	particularly	RB	B-ADJP	O	O
cautious	cautious	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
whose	whose	WP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
above	above	JJ	B-ADJP	O	O
or	or	CC	O	O	O
suspected	suspect	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
above	above	IN	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
effects	effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
or	or	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ibutilide	ibutilide	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blocking	block	VBG	B-VP	O	I-group
agents	agent	NNS	B-NP	O	E-group
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
any	any	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
or	or	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ibutilide	ibutilide	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group
-	-	HYPH	O	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	O	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
any	any	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
or	or	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ibutilide	ibutilide	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

General	General	JJ	B-NP	O	O
No	No	DT	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EXTRANEALs	EXTRANEAL	NNS	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
dialysis	dialysis	NN	I-NP	O	B-group
solutions	solution	NNS	I-NP	O	E-group
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dialyzable	dialyzable	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
dialysis	dialysis	NN	B-NP	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
(	(	(	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
others	other	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	O
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	O
and	and	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Insulin	Insulin	NN	B-NP	B-protein	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
6	6	CD	B-NP	O	O
insulin	insulin	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EXTRANEAL	EXTRANEAL	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
insulin	insulin	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
peritoneal	peritoneal	JJ	I-NP	O	O
cavity	cavity	NN	I-NP	O	O
or	or	CC	B-PP	O	O
on	on	IN	B-PP	O	O
insulins	insulin	NNS	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
EXTRANEAL	EXTRANEAL	NN	B-NP	O	S-brand
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
EXTRANEAL	EXTRANEAL	NN	B-NP	O	S-brand-AD-1
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
insulin	insulin	NN	B-NP	O	S-drug-AD-2
dosage	dosage	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
needed	need	VBN	B-VP	O	O
.	.	.	O	O	O

Heparin	Heparin	NN	B-NP	O	S-drug
:	:	:	O	O	O
No	No	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
incompatibility	incompatibility	NN	B-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
EXTRANEAL	EXTRANEAL	NN	B-NP	O	S-brand
.	.	.	O	O	O

Antibiotics	Antibiotic	NNS	B-NP	O	S-group
:	:	:	O	O	O
No	No	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
evaluating	evaluate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
minimum	minimum	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
(	(	(	O	O	O
MIC	MIC	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
cefazolin	cefazolin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
flucoxacillin	flucoxacillin	NN	I-NP	O	O
,	,	,	O	O	O
ceftazidime	ceftazidime	NN	B-NP	O	S-drug
,	,	,	O	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
amphotericin	amphotericin	NN	B-NP	O	S-drug
demonstrated	demonstrate	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
incompatibility	incompatibility	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
with	with	IN	B-PP	O	O
EXTRANEAL	EXTRANEAL	NN	B-NP	O	S-brand
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Blood	Blood	NN	I-NP	O	O
Glucose	Glucose	NN	I-NP	O	O
Blood	Blood	NN	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
measurement	measurement	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
done	do	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
maltose	maltose	NN	B-NP	O	O
interference	interference	NN	I-NP	O	O
with	with	IN	B-PP	O	O
test	test	NN	B-NP	O	O
results	result	NNS	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-PP	O	O
falsely	falsely	RB	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
devices	device	NNS	I-NP	O	O
and	and	CC	O	O	O
test	test	NN	B-NP	O	O
strips	strip	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
use	use	VBP	B-VP	O	O
glucose	glucose	NN	B-NP	B-protein	O
dehydrogenase	dehydrogenase	NN	I-NP	I-protein	O
pyrroloquinolinequinone	pyrroloquinolinequinone	NN	I-NP	O	O
(	(	(	O	O	O
GDH	GDH	NN	B-NP	O	O
PQQ	PQQ	NN	I-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
methods	method	NNS	I-NP	O	O
,	,	,	O	O	O
GDH	GDH	NN	B-NP	B-protein	O
PQQ	PQQ	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
methods	method	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
measure	measure	VB	I-VP	O	O
glucose	glucose	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
administered	administer	VBN	B-VP	O	O
EXTRANEAL..	EXTRANEAL..	NNP	B-NP	O	O

Serum	Serum	NN	B-NP	B-protein	O
Amylase	Amylase	NN	I-NP	I-protein	O
An	An	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	B-protein	O
amylase	amylase	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
administered	administer	VBN	B-VP	O	O
EXTRANEAL	EXTRANEAL	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Preliminary	Preliminary	JJ	B-NP	O	O
investigations	investigation	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
icodextrin	icodextrin	NN	B-NP	B-protein	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
enzymatic	enzymatic	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
based	base	VBN	I-NP	O	O
amylase	amylase	NN	I-NP	O	O
assays	assay	NNS	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
inaccurately	inaccurately	RB	B-NP	O	O
low	low	JJ	I-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
account	account	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
evaluating	evaluate	VBG	B-VP	O	O
serum	serum	NN	B-NP	B-protein	O
amylase	amylase	NN	I-NP	I-protein	O
levels	level	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
diagnosis	diagnosis	NN	B-NP	O	O
or	or	CC	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pancreatitis	pancreatitis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
EXTRANEAL	EXTRANEAL	NN	B-NP	O	S-brand
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
between	between	IN	B-PP	O	O
EPA	EPA	NNP	B-NP	O	S-drug-IN-1
supplements	supplement	NNS	I-NP	O	O
and	and	CC	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-IN-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
non	non	AFX	I-NP	O	B-group-IN-2
-	-	HYPH	I-NP	B-DNA	I-group-IN-2
steroidal	steroidal	JJ	I-NP	I-DNA	I-group-IN-2
anti	anti	AFX	I-NP	I-DNA	I-group-IN-2
-	-	HYPH	I-NP	O	I-group-IN-2
inflammatory	inflammatory	JJ	I-NP	O	I-group-IN-2
drugs	drug	NNS	I-NP	O	E-group-IN-2
and	and	CC	I-NP	O	O
herbs	herb	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
garlic	garlic	NN	B-NP	O	O
(	(	(	O	O	O
Allium	Allium	NNP	B-NP	O	O
sativum	sativum	NNP	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ginkgo	ginkgo	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
Ginkgo	Ginkgo	NN	B-NP	O	B-drug-IN-2
biloba	biloba	NN	I-NP	O	E-drug-IN-2
)	)	)	O	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
manifested	manifest	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
susceptibility	susceptibility	NN	I-NP	O	O
to	to	TO	B-PP	O	O
bruising	bruise	VBG	B-VP	O	O
,	,	,	O	O	O
nosebleeds	nosebleed	NNS	B-NP	O	O
,	,	,	O	O	O
hemoptysis	hemoptysis	NN	B-NP	O	O
,	,	,	O	O	O
hematemesis	hematemesis	NN	B-NP	O	O
,	,	,	O	O	O
hematuria	hematuria	NN	B-NP	O	O
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stool	stool	NN	I-NP	O	O
.	.	.	O	O	O

Most	Most	JJS	B-NP	O	O
who	who	WP	B-NP	O	O
take	take	VBP	B-VP	O	O
EPA	EPA	NNP	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
above	above	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
herbs	herb	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
suffer	suffer	VB	I-VP	O	O
from	from	IN	B-PP	O	O
these	these	DT	B-NP	O	O
problems	problem	NNS	I-NP	O	O
and	and	CC	O	O	O
if	if	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
occur	occur	VBP	B-VP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
rare	rare	JJ	B-ADJP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
do	do	VBP	B-VP	O	O
occur	occur	VB	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
EPA	EPA	NNP	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
lowered	lower	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

Conflicting	Conflict	VBG	B-NP	O	O
results	result	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
regarding	regard	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
EPA	EPA	NNP	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
glycemic	glycemic	JJ	B-NP	O	O
control	control	NN	I-NP	O	O
in	in	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
diabetics	diabetic	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
intolerance	intolerance	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
type	type	NN	B-NP	O	O
2	2	CD	I-NP	O	O
diabetes	diabete	NNS	I-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
EPA	EPA	NNP	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
might	might	MD	B-VP	O	O
have	have	VB	I-VP	O	O
detrimental	detrimental	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Recent	Recent	JJ	B-NP	O	O
,	,	,	I-NP	O	O
better	good	JJR	I-NP	O	O
designed	design	VBN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
these	these	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
EPA	EPA	NNP	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
detrimental	detrimental	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
,	,	,	O	O	O
insulin	insulin	NN	B-NP	B-protein	O
secretion	secretion	NN	I-NP	O	O
or	or	CC	O	O	O
insulin	insulin	NN	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Diabetics	Diabetic	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
discuss	discuss	VB	I-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
supplements	supplement	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
physicians	physician	NNS	I-NP	O	O
and	and	CC	O	O	O
note	note	VBP	B-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
supplements	supplement	NNS	I-NP	O	O
affect	affect	VBP	B-VP	O	O
their	their	PRP$	B-NP	O	O
glycemic	glycemic	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

Diabetics	Diabetic	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
take	take	VBP	B-VP	O	O
EPA	EPA	NNP	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
physicians	physician	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
-	-	:	O	O	O
Although	Although	IN	B-SBAR	O	O
certain	certain	JJ	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
at	at	IN	B-ADVP	O	O
all	all	DT	I-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
two	two	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
medicines	medicine	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
even	even	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
might	might	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
may	may	MD	B-VP	O	O
want	want	VB	I-VP	O	O
to	to	TO	I-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
precautions	precaution	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
using	use	VBG	I-VP	O	O
idoxuridine	idoxuridine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
especially	especially	RB	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
that	that	IN	B-SBAR	O	O
your	your	PRP$	B-NP	O	O
health	health	NN	I-NP	O	O
care	care	NN	I-NP	O	O
professional	professional	JJ	I-NP	O	O
know	know	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
using	use	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
Eye	Eye	NN	B-NP	O	O
product	product	NN	I-NP	O	O
containing	contain	VBG	B-VP	O	O
boric	boric	JJ	B-NP	O	B-drug-AD-2
acid	acid	NN	I-NP	O	E-drug-AD-2
.	.	.	O	O	O

Boric	Boric	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
idoxuridine	idoxuridine	NN	I-NP	O	S-drug-ME-2
preparation	preparation	NN	I-NP	O	O
causing	cause	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
gritty	gritty	JJ	I-NP	O	O
substance	substance	NN	I-NP	O	O
to	to	TO	B-VP	O	O
form	form	VB	I-VP	O	O
or	or	CC	O	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
preservative	preservative	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
idoxuridine	idoxuridine	NN	I-NP	O	S-drug
preparation	preparation	NN	I-NP	O	O
causing	cause	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
eye	eye	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
alert	alert	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
combined	combine	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
actions	action	NNS	I-NP	O	O
,	,	,	O	O	O
desirable	desirable	JJ	B-ADJP	O	O
or	or	CC	I-ADJP	O	O
undesirable	undesirable	JJ	I-ADJP	O	O
,	,	,	O	O	O
involving	involve	VBG	B-VP	O	O
ifosfamide	ifosfamide	NN	B-NP	O	S-drug
even	even	RB	B-SBAR	O	O
though	though	IN	I-SBAR	O	O
ifosfamide	ifosfamide	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
successfully	successfully	RB	B-ADVP	O	O
concurrently	concurrently	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
other	other	JJ	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
iloprost	iloprost	NN	I-NP	O	S-drug
and	and	CC	O	O	O
either	either	CC	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
captopril	captopril	NN	B-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
iloprost	iloprost	NN	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasodilators	vasodilator	NNS	B-NP	O	S-group-EF-2
and	and	CC	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
iloprost	iloprost	NN	B-NP	O	S-drug-EF-1
inhibits	inhibit	VBZ	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleeding	NN	B-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
maintained	maintain	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

During	During	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
iloprost	iloprost	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
analgesics	analgesic	NNS	B-NP	O	S-group
,	,	,	O	O	O
antipyretics	antipyretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group
antiinflammatories	antiinflammatory	NNS	I-NP	O	E-group
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

Intravenous	Intravenous	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
iloprost	iloprost	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Acetylsalicylic	Acetylsalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
(	(	(	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
iloprost	iloprost	NN	B-NP	O	S-drug
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
,	,	,	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
iloprost	iloprost	NN	B-NP	O	S-drug
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
drug	drug	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
imatinib	imatinib	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
imatinib	imatinib	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
:	:	:	O	O	O
Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
Gleevec	Gleevec	NNP	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
family	family	NN	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

Substances	Substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
)	)	)	O	O	O
activity	activity	NN	B-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
and	and	CC	I-NP	O	O
increase	increase	NN	I-NP	O	O
imatinib	imatinib	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-VP	O	O
imatinib	imatinib	VB	I-VP	O	S-drug
when	when	WRB	B-ADVP	O	O
Gleevec	Gleevec	NNP	B-NP	O	S-brand-ME-1
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
imatinib	imatinib	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
:	:	:	O	O	O
Substances	Substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
inducers	inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
imatinib	imatinib	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
medications	medication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
St	St	NN	I-NP	O	O
.	.	.	O	O	O

Johns	Johns	NNP	B-NP	O	O
Wort	Wort	NNP	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
Gleevec	Gleevec	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Pretreatment	Pretreatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Gleevec	Gleevec	NNP	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
Gleevec	Gleevec	NN	B-NP	O	S-brand
oral	oral	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
by	by	IN	B-PP	O	O
3.8	3.8	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
fold	fold	RB	B-ADVP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
0.05	0.05	CD	I-NP	O	O
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
mean	mean	JJ	B-NP	O	O
cmax	cmax	NN	I-NP	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
where	where	WRB	B-ADVP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducers	inducer	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
,	,	,	O	O	O
alternative	alternative	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
induction	induction	NN	I-NP	O	O
potential	potential	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
altered	alter	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Gleevec	Gleevec	NNP	B-NP	O	S-brand
Gleevec	Gleevec	NNP	I-NP	O	S-brand-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
cmax	cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
substrate	substrate	NN	I-NP	O	O
)	)	)	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
and	and	CC	O	O	O
3.5	3.5	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
by	by	IN	B-PP	O	O
Gleevec	Gleevec	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Particular	Particular	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
Gleevec	Gleevec	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
substrates	substrate	NNS	I-NP	I-protein	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
narrow	narrow	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
window	window	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
pimozide	pimozide	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

Gleevec	Gleevec	NNP	B-NP	O	S-brand-ME-1
will	will	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
plasmaconcentration	plasmaconcentration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
metabolized	metabolize	VBD	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
triazolo	triazolo	AFX	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
dihydropyridine	dihydropyridine	NN	B-NP	O	B-group-ME-2
calcium	calcium	NN	I-NP	O	I-group-ME-2
channel	channel	NN	I-NP	O	I-group-ME-2
blockers	blocker	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
HMG	HMG	NN	I-NP	B-protein	B-group-ME-2
-	-	HYPH	B-NP	O	I-group-ME-2
CoA	CoA	NN	I-NP	O	I-group-ME-2
reductase	reductase	NN	I-NP	O	I-group-ME-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
require	require	VBP	B-VP	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
should	should	MD	B-VP	O	O
receive	receive	VB	I-VP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
molecular	molecular	JJ	I-NP	O	O
weight	weight	NN	I-NP	O	O
or	or	CC	O	O	O
standard	standard	JJ	B-NP	O	O
heparin	heparin	NN	I-NP	O	S-drug
.	.	.	O	O	O

in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
Gleevec	Gleevec	NN	B-NP	O	S-brand
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
CYP2D6	CYP2D6	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
at	at	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
affect	affect	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
substrates	substrate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Gleevec	Gleevec	NN	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
and	and	CC	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
Gleevec	Gleevec	NN	B-NP	O	S-brand
inhibits	inhibit	VBZ	B-VP	O	O
acetaminophen	acetaminophen	NN	B-NP	B-protein	O
O	O	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
glucuronidation	glucuronidation	NN	I-NP	O	O
(	(	(	O	O	O
Ki	Ki	NN	B-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
58.5	58.5	CD	B-NP	O	O
M	M	NN	I-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Gleevec	Gleevec	NN	B-NP	O	S-brand-ME-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
and	and	CC	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
occasional	occasional	JJ	B-NP	O	O
susceptible	susceptible	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
receiving	receive	VBG	I-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
antiparkinsonism	antiparkinsonism	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
atropine	atropine	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
like	like	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
become	become	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
paralytic	paralytic	JJ	B-NP	O	O
ileus	ileus	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Close	Close	JJ	B-NP	O	O
supervision	supervision	NN	I-NP	O	O
and	and	CC	O	O	O
careful	careful	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

Avoid	Avoid	VB	B-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
preparations	preparation	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
decongestants	decongestant	NNS	B-NP	O	S-group-AD-1
and	and	CC	O	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-AD-1
which	which	WDT	B-NP	O	O
contain	contain	VBP	B-VP	O	O
any	any	DT	B-NP	O	O
sympathomimetic	sympathomimetic	JJ	I-NP	O	B-group-AD-1
amine	amine	NN	I-NP	O	E-group-AD-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-2
can	can	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
imipramine	imipramine	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
that	that	IN	B-SBAR	O	O
lower	low	JJR	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Imipramine	Imipramine	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CNS	CNS	NN	B-NP	B-protein	B-group-EF-2
depressant	depressant	NN	I-NP	O	I-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
imipramine	imipramine	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
and	and	CC	O	O	O
decrease	decrease	NN	B-NP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
inducers	inducer	NNS	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
adjustment	adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
imipramine	imipramine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	O	O
The	The	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
metabolizing	metabolize	VBG	B-VP	O	O
isozyme	isozyme	NN	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
debrisoquin	debrisoquin	NN	B-NP	B-protein	O
hydroxylase	hydroxylase	NN	I-NP	I-protein	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
caucasian	caucasian	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
7	7	CD	I-NP	O	O
to	to	TO	I-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caucasians	caucasian	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
so	so	RB	I-VP	O	O
called	call	VBN	I-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

reliable	reliable	JJ	B-NP	O	O
estimates	estimate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
P450	P450	NN	I-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
among	among	IN	B-PP	O	O
Asian	Asian	JJ	B-NP	O	O
,	,	,	I-NP	O	O
African	African	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
populations	population	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
yet	yet	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
.	.	.	O	O	O

Poor	Poor	NN	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
expected	expect	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
(	(	(	O	O	O
TCAs	TCA	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
usual	usual	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Depending	Depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-ADJP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
quite	quite	RB	B-ADJP	O	O
large	large	JJ	I-ADJP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
and	and	CC	O	O	O
make	make	VB	B-VP	O	O
normal	normal	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
resemble	resemble	VBP	B-VP	O	O
p.o	p.o	NN	B-NP	O	O
.	.	.	O	O	O

metabolizers	metabolizer	NNS	B-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
individual	individual	NN	I-NP	O	O
who	who	WP	B-NP	O	O
is	be	VBZ	B-VP	O	O
stable	stable	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
given	give	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TCA	TCA	NN	B-NP	B-protein	S-group
may	may	MD	B-VP	O	O
become	become	VB	I-VP	O	O
abruptly	abruptly	RB	B-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
inhibiting	inhibit	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
include	include	VBP	B-VP	O	O
some	some	DT	O	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
(	(	(	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
;	;	:	O	O	O

cimetidine	cimetidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
many	many	JJ	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	O	O
(	(	(	O	O	O
many	many	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Type	Type	NN	I-NP	O	B-group
1C	1C	NN	I-NP	O	I-group
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	E-group
propafenone	propafenone	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
flecainide	flecainide	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
selective	selective	JJ	I-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
,	,	,	O	O	O
e.	e.	FW	B-ADVP	O	O
g.	g.	FW	I-ADVP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
inhibit	inhibit	VBP	B-VP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
vary	vary	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
to	to	TO	B-PP	O	O
which	which	WDT	B-NP	O	O
SSRI	SSRI	NN	I-NP	B-protein	S-group-IN-1
-	-	HYPH	I-NP	O	O
TCA	TCA	NN	I-NP	O	S-group-IN-2
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
pose	pose	VB	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
problems	problem	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
depend	depend	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	O	S-group
involved	involve	VBN	B-VP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TCA5	TCA5	NN	B-NP	B-protein	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRIs	SSRI	NNS	I-NP	O	S-group
and	and	CC	O	O	O
also	also	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
switching	switch	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
one	one	CD	B-NP	O	O
class	class	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
importance	importance	NN	I-NP	O	O
,	,	,	O	O	O
sufficient	sufficient	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
must	must	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
before	before	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
TCA	TCA	NN	B-NP	B-protein	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
being	be	VBG	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
parent	parent	NN	I-NP	O	O
and	and	CC	O	O	O
active	active	JJ	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
(	(	(	O	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
5	5	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
than	than	IN	B-SBAR	O	O
usually	usually	RB	B-ADVP	O	O
prescribed	prescribe	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
whenever	whenever	WRB	B-ADVP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
cotherapy	cotherapy	NN	B-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
desirable	desirable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
TCA	TCA	NN	B-NP	O	S-group
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
whenever	whenever	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group
is	be	VBZ	B-VP	O	O
going	go	VBG	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
information	information	NN	I-NP	O	O
available	available	JJ	B-ADJP	O	O

Indinavir	Indinavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoform	isoform	NN	I-NP	I-protein	O
CYP3A4	CYP3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
primarily	primarily	RB	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Indinavir	Indinavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
lowered	lower	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

Table	Table	JJ	B-NP	O	O
8	8	CD	I-NP	O	O

Drugs	Drug	NNS	B-NP	O	O
That	That	DT	B-NP	O	O
Should	Should	MD	B-VP	O	O
Not	Not	RB	I-VP	O	O
Be	Be	VB	I-VP	O	O
Coadministered	Coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand

Drug	Drug	NNP	B-NP	O	O
Class	Class	NNP	I-NP	O	O
:	:	NNP	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Name	Name	NNP	I-NP	O	O
Clinical	Clinical	NNP	I-NP	O	O
Comment	Comment	NNP	I-NP	O	O

Antiarrhythmics	Antiarrhythmic	NNS	B-NP	O	S-group
:	:	:	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug

CONTRAINDICATED	CONTRAINDICATED	VBN	B-VP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Ergot	Ergot	NN	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
:	:	:	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
ergonovine	ergonovine	NN	B-NP	O	S-drug
,	,	,	O	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
methylergonovine	methylergonovine	NN	B-NP	O	S-drug

CONTRAINDICATED	CONTRAINDICATED	VBN	B-VP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
acute	acute	JJ	B-NP	O	O
ergot	ergot	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	O
vasospasm	vasospasm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
ischemia	ischemia	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extremities	extremity	NNS	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
tissues	tissue	NNS	I-NP	O	O
.	.	.	O	O	O

Sedative	Sedative	JJ	B-NP	O	S-group
/	/	SYM	I-NP	O	O
hypnotics	hypnotic	NNS	I-NP	O	S-group
:	:	:	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
,	,	,	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug

CONTRAINDICATED	CONTRAINDICATED	VBN	B-VP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
prolonged	prolonged	JJ	B-ADJP	O	O
or	or	CC	O	O	O
increased	increase	VBN	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
or	or	CC	O	O	O
respiratory	respiratory	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

GI	GI	NN	B-NP	O	O
motility	motility	NN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
:	:	:	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug

CONTRAINDICATED	CONTRAINDICATED	VBN	B-VP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Neuroleptic	Neuroleptic	JJ	B-ADJP	O	S-group
:	:	:	O	O	O
pimozide	pimozide	NN	B-NP	O	S-drug

CONTRAINDICATED	CONTRAINDICATED	VBN	B-VP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Herbal	Herbal	JJ	B-NP	O	O
products	product	NNS	I-NP	O	O
:	:	:	O	O	O
St.	St.	NNP	B-NP	O	O
John	John	NNP	I-NP	O	O
s	s	NN	I-NP	O	O
wort	wort	NN	I-NP	O	O
(	(	(	O	O	O
Hypericum	Hypericum	NNP	B-NP	O	O
perforatum	perforatum	NNP	I-NP	O	O
)	)	)	O	O	O

May	May	MD	O	O	O
lead	lead	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
virologic	virologic	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand
or	or	CC	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
protease	protease	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

Antimycobacterial	Antimycobacterial	JJ	B-ADJP	O	S-group
:	:	:	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug

May	May	MD	O	O	O
lead	lead	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
virologic	virologic	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand
or	or	CC	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
protease	protease	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
coadministered	coadministere	VBN	I-NP	O	O
antiretroviral	antiretroviral	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	O	I-group
Reductase	Reductase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
risk	risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
including	include	VBG	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	O
.	.	.	O	O	O

Protease	Protease	NN	B-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
:	:	:	O	O	O
atazanavir	atazanavir	NN	B-NP	O	S-drug

Both	Both	CC	O	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
atazanavir	atazanavir	NN	I-NP	O	S-drug
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
indirect	indirect	JJ	O	O	O
(	(	(	O	O	O
unconjugated	unconjugated	JJ	B-ADJP	O	O
)	)	)	O	O	O
hyperbilirubinemia	hyperbilirubinemia	NN	B-NP	O	O
.	.	.	O	O	O

Combinations	Combination	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
and	and	CC	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
atazanavir	atazanavir	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Table	Table	JJ	B-NP	O	O
9	9	CD	I-NP	O	O

Established	Establish	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
Other	Other	NNP	I-NP	O	O
Potentially	Potentially	NNP	I-NP	O	O
Significant	Significant	NNP	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
:	:	:	O	O	O
Alteration	Alteration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
Dose	Dose	NN	B-NP	O	O
or	or	CC	I-NP	O	O
Regimen	Regimen	NN	I-NP	O	O
May	May	NNP	I-NP	O	O
Be	Be	NNP	I-NP	O	O
Recommended	Recommended	NNP	I-NP	O	O
Based	Based	NNP	I-NP	O	O
on	on	IN	B-PP	O	O
Drug	Drug	NNP	B-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Studies	Study	NNPS	I-NP	O	O
or	or	CC	O	O	O
Predicted	Predict	VBN	B-VP	O	O
Interaction	Interaction	NN	B-NP	O	O

Drug	Drug	NNP	B-NP	O	O
Name	Name	NNP	I-NP	O	O

Clinical	Clinical	NNP	B-NP	O	O
Comment	Comment	NNP	I-NP	O	O

HIV	HIV	NN	B-NP	O	B-group
Antiviral	Antiviral	JJ	I-NP	O	I-group
Agents	Agent	NNS	I-NP	O	E-group

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Dose	Dose	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand-AD-1
to	to	TO	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
taking	take	VBG	B-VP	O	O
delavirdine	delavirdine	NN	B-NP	O	S-drug-AD-2
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Indinavir	Indinavir	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
didanosine	didanosine	NN	I-NP	O	S-drug-AD-2
formulations	formulation	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
buffer	buffer	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
one	one	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
apart	apart	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
empty	empty	JJ	I-NP	O	O
stomach	stomach	NN	I-NP	O	O
.	.	.	O	O	O

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

The	The	DT	B-NP	O	O
optimal	optimal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Increasing	Increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
compensate	compensate	VB	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-ME-1
metabolism	metabolism	NN	I-NP	O	O
due	due	IN	B-PP	O	O
to	to	TO	I-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

The	The	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Indinavir	Indinavir	NN	B-NP	O	S-drug-ME-1
concentrations	concentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

The	The	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Preliminary	Preliminary	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nephrolithiasis	nephrolithiasis	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-EF-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-EF-2
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand
800	800	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
q8h	q8h	NN	I-NP	O	O
.	.	.	O	O	O

saquinavir	saquinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

The	The	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Agents	Agent	NNS	I-NP	O	O

Antiarrhythmics	Antiarrhythmic	NNS	B-NP	O	S-group
:	:	:	O	O	O
bepridil	bepridil	NN	B-NP	O	S-drug
,	,	,	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
(	(	(	O	O	O
systemic	systemic	JJ	B-ADJP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug

antiarrhythmic	antiarrhythmic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
concentration	concentration	NN	I-NP	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
and	and	CC	O	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
antiarrhythmics	antiarrhythmic	NNS	B-NP	O	S-group-AD-1
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

Anticonvulsants	Anticonvulsant	NNS	B-NP	O	S-group
:	:	:	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Use	Use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
effective	effective	JJ	B-ADJP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-EF-2
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Calcium	Calcium	NNP	B-NP	O	B-group
Channel	Channel	NNP	I-NP	O	I-group
Blockers	Blockers	NNP	I-NP	O	E-group
,	,	,	O	O	O
Dihydropyridine	Dihydropyridine	NN	B-NP	O	S-group
:	:	:	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
nicardipine	nicardipine	NN	B-NP	O	S-drug

dihydropyridine	dihydropyridine	NN	B-NP	O	B-group
calcium	calcium	NN	I-NP	O	I-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
concentration	concentration	NN	I-NP	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
and	and	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

clarithromycin	clarithromycin	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

The	The	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	B-protein	I-group
Reductase	Reductase	NN	I-NP	I-protein	I-group
Inhibitor	Inhibitor	NN	I-NP	O	E-group
:	:	:	O	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug

atorvastatin	atorvastatin	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Use	Use	NNP	B-NP	O	O
lowest	low	JJS	I-NP	O	O
possible	possible	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
consider	consider	VB	B-VP	O	O
HMG	HMG	NN	B-NP	B-protein	B-group-AD-1
-	-	HYPH	B-NP	O	I-group-AD-1
CoA	CoA	NN	I-NP	O	I-group-AD-1
reductase	reductase	NN	I-NP	O	I-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
primarily	primarily	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
pravastatin	pravastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
rosuvastatin	rosuvastatin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

Immunosuppressants	Immunosuppressant	NNS	B-NP	O	S-group
:	:	:	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug

immunosuppressant	immunosuppressant	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
concentration	concentration	NN	I-NP	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand
.	.	.	O	O	O

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Dose	Dose	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand-AD-1
to	to	TO	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-2
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Dose	Dose	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand
to	to	TO	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

indinavir	indinavir	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Dose	Dose	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug
to	to	TO	B-PP	O	O
half	half	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
standard	standard	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CRIXIVAN	CRIXIVAN	NN	B-NP	O	S-brand
to	to	TO	B-PP	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
three	three	CD	B-NP	O	O
333	333	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
capsules	capsule	NNS	I-NP	O	O
)	)	)	O	O	O
every	every	DT	B-NP	O	O
8	8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
rifabutin	rifabutin	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
CRIXIVAN	CRIXIVAN	NN	I-NP	O	S-brand-AD-2
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

sildenafil	sildenafil	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Sildenafil	Sildenafil	NN	B-NP	O	S-drug-AD-1
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
exceed	exceed	VB	I-VP	O	O
a	a	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
48	48	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
period	period	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

tadalafil	tadalafil	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Tadalafil	Tadalafil	NN	B-NP	O	S-drug-AD-1
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
exceed	exceed	VB	I-VP	O	O
a	a	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
72	72	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
period	period	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

vardenafil	vardenafil	NN	B-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O

Vardenafil	Vardenafil	NN	B-NP	O	S-drug-AD-1
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
exceed	exceed	VB	I-VP	O	O
a	a	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
24	24	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
period	period	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Note	Note	NNP	B-NP	O	O
:	:	:	O	O	O

=	=	SYM	O	O	O
increase	increase	NN	B-NP	O	O
;	;	:	O	O	O

=	=	SYM	O	O	O
decrease	decrease	NN	B-NP	O	O

In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diflunisal	diflunisal	NN	B-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
significantly	significantly	RB	B-VP	O	O
increased	increase	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
combined	combine	VBN	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
diflunisal	diflunisal	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
hemorrhage	hemorrhage	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
diflunisal	diflunisal	JJ	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
INDOCIN	INDOCIN	NN	I-NP	O	S-brand-AD-2
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
chronic	chronic	JJ	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
3.6	3.6	CD	B-NP	O	O
g	g	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-1
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
decreases	decrease	VBZ	B-VP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-ME-2
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
little	little	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
no	no	DT	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypoprothrombinemia	hypoprothrombinemia	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
any	any	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-AD-1
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-group-AD-2
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
post	post	AFX	O	O	O
-	-	HYPH	O	O	O
marketing	marketing	NN	B-NP	O	O
experience	experience	NN	I-NP	O	O
,	,	,	O	O	O
bleeding	bleed	VBG	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
INDOCIN	INDOCIN	NN	I-NP	O	S-brand-EF-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-AD-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-ME-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
total	total	JJ	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
satisfactory	satisfactory	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand
are	be	VBP	B-VP	O	O
made	make	VBN	I-VP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
small	small	JJ	B-NP	O	O
increments	increment	NNS	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

INDOCIN	INDOCIN	NN	B-NP	O	S-brand-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
non	non	AFX	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	B-DNA	I-group-EF-1
steroidal	steroidal	JJ	I-NP	I-DNA	I-group-EF-1
anti	anti	AFX	I-NP	I-DNA	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADJP	O	O
due	due	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	B-protein	O
prostacyclin	prostacyclin	NN	I-NP	I-protein	O
.	.	.	O	O	O

NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Capsules	Capsule	NNS	B-NP	O	O
INDOCIN	INDOCIN	NN	I-NP	O	S-brand-ME-1
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
t.i.d	t.i.d	NN	I-NP	O	O
.	.	.	O	O	O
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
psychiatric	psychiatric	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
normal	normal	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
consequence	consequence	NN	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
Read	Read	JJ	B-NP	O	O
circulars	circular	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
preparations	preparation	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
monitoring	monitor	VBG	B-VP	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
outset	outset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
combination	combination	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

INDOCIN	INDOCIN	NN	B-NP	O	S-brand-ME-1
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	O	O	O
prolong	prolong	VB	B-VP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
loop	loop	NN	B-NP	O	S-group-EF-2
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	B-group-EF-2
-	-	HYPH	B-ADJP	O	I-group-EF-2
sparing	spar	VBG	I-ADJP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
INDOCIN	INDOCIN	NN	I-NP	O	S-brand
.	.	.	O	O	O

(	(	(	O	O	O
Indomethacin	Indomethacin	NN	B-NP	O	S-drug
)	)	)	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O

INDOCIN	INDOCIN	NN	B-NP	O	S-brand
reduces	reduce	VBZ	B-VP	O	O
basal	basal	JJ	B-NP	B-protein	O
plasma	plasma	NN	I-NP	I-protein	O
renin	renin	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
PRA	PRA	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
those	those	DT	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PRA	PRA	NN	B-NP	B-protein	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
salt	salt	NN	B-NP	O	O
or	or	CC	I-NP	O	O
volume	volume	NN	I-NP	O	O
depletion	depletion	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
facts	fact	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
evaluating	evaluate	VBG	B-VP	O	O
plasma	plasma	NN	B-NP	B-protein	O
renin	renin	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triamterene	triamterene	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-EF-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
reversible	reversible	JJ	B-NP	O	O
acute	acute	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
of	of	IN	I-NP	O	O
four	four	CD	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

INDOCIN	INDOCIN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
triamterene	triamterene	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
.	.	.	O	O	O

INDOCIN	INDOCIN	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
potassium	potassium	NN	I-NP	O	B-group
-	-	HYPH	O	O	I-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
each	each	DT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
potassium	potassium	NN	I-NP	O	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
sparing	spar	VBG	B-VP	O	I-group-EF-2
diuretics	diuretic	NNS	B-NP	O	E-group-EF-2
on	on	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	O
kinetics	kinetic	NNS	I-NP	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Most	Most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
above	above	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
concerning	concern	VBG	B-VP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
,	,	,	O	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
,	,	,	O	O	O
to	to	TO	B-PP	O	O
mechanisms	mechanism	NNS	B-NP	O	O
involving	involve	VBG	B-VP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

Blunting	Blunting	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
adrenoceptor	adrenoceptor	NN	I-NP	O	I-group-EF-1
blocking	block	VBG	B-VP	O	I-group-EF-1
agents	agent	NNS	B-NP	O	E-group-EF-1
by	by	IN	B-PP	O	O
non	non	AFX	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
steroidal	steroidal	JJ	B-NP	O	I-group-EF-2
antiinflammatory	antiinflammatory	JJ	I-NP	O	I-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
including	include	VBG	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
blocking	block	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
hypertension	hypertension	NN	B-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
confirm	confirm	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
obtained	obtain	VBN	I-VP	O	O
.	.	.	O	O	O

INDOCIN	INDOCIN	NN	B-NP	O	S-brand-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
captopril	captopril	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
losartan	losartan	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

False	False	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
negative	negative	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
DST	DST	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
INDOCIN	INDOCIN	NN	B-NP	O	S-brand
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
results	result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DST	DST	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
interpreted	interpret	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
etanercept	etanercept	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
another	another	DT	B-NP	O	O
TNF	TNF	NN	I-NP	B-protein	O
-	-	HYPH	B-ADJP	O	O
blocking	block	VBG	B-VP	O	O
agent	agent	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
anakinra	anakinra	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
an	an	DT	B-NP	O	O
interleukin	interleukin	NN	I-NP	B-protein	B-group
-	-	HYPH	B-NP	O	I-group
1	1	CD	I-NP	O	I-group
antagonist	antagonist	NN	I-NP	O	E-group
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
infections	infection	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neutropenia	neutropenia	NN	B-NP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
benefit	benefit	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
these	these	DT	B-NP	O	O
medicinal	medicinal	JJ	I-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
TNFa	TNFa	NN	I-NP	B-protein	B-group-EF-1
-	-	HYPH	B-VP	O	I-group-EF-1
blocking	block	VBG	B-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
REMICADE	REMICADE	NN	B-NP	O	S-brand-EF-1
)	)	)	O	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
anakinra	anakinra	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
toxicities	toxicity	NNS	I-NP	O	O
.	.	.	O	O	O

Specific	Specific	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
MTX	MTX	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
majority	majority	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
or	or	CC	I-NP	O	O
Crohn	Crohn	NN	I-NP	O	O
s	s	NNS	I-NP	O	O
disease	disease	NN	I-NP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
besides	besides	IN	B-PP	O	O
MTX	MTX	NN	B-NP	B-protein	S-drug
were	be	VBD	B-VP	O	O
nonsteroidal	nonsteroidal	JJ	B-ADJP	O	B-group
anti	anti	AFX	B-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
folic	folic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
Crohn	Crohn	NN	I-NP	O	O
s	s	VBZ	B-VP	O	O
disease	disease	NN	B-NP	O	O
medications	medication	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
antivirals	antiviral	NNS	B-NP	O	S-group
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
6	6	CD	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
MP	MP	NN	I-NP	O	E-drug
/	/	SYM	I-NP	O	O
AZA	AZA	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
aminosalicylates	aminosalicylate	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
psoriatic	psoriatic	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
MTX	MTX	NN	B-NP	B-protein	S-drug
in	in	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
half	half	DT	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group
anti	anti	AFX	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
folic	folic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
and	and	CC	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Crohn	Crohn	NN	B-NP	O	O
s	s	VBZ	B-VP	O	O
disease	disease	NN	B-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
immunosuppressants	immunosuppressant	NNS	B-NP	O	S-group
tended	tend	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
experience	experience	VB	I-VP	O	O
fewer	few	JJR	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
no	no	DT	B-NP	O	O
immunosuppressants	immunosuppressant	NNS	I-NP	O	S-group
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
infliximab	infliximab	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Crohn	Crohn	NN	B-NP	O	O
s	s	VBZ	B-VP	O	O
disease	disease	NN	B-NP	O	O
including	include	VBG	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group
(	(	(	O	O	O
metronidazole	metronidazole	NN	B-NP	O	S-drug
or	or	CC	O	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
aminosalicylates	aminosalicylate	VBZ	B-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
substances	substance	NNS	B-NP	O	O
affect	affect	VBP	B-VP	O	O
glucose	glucose	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
insulin	insulin	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
and	and	CC	O	O	O
particularly	particularly	RB	B-NP	O	O
close	close	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
are	be	VBP	B-VP	O	O
examples	example	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
substances	substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
and	and	CC	I-NP	O	O
susceptibility	susceptibility	NN	I-NP	O	O
to	to	TO	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
:	:	:	O	O	O
oral	oral	JJ	B-NP	O	O
antidiabetes	antidiabete	NNS	I-NP	O	O
products	product	NNS	I-NP	O	O
,	,	,	O	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
,	,	,	O	O	O
fibrates	fibrate	NNS	B-NP	O	S-group
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
propoxyphene	propoxyphene	NN	B-NP	O	S-drug
,	,	,	O	O	O
salicylates	salicylate	NNS	B-NP	O	S-group
,	,	,	O	O	O
somatostatin	somatostatin	NN	B-NP	O	B-group
analog	analog	NN	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
octreotide	octreotide	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
sulfonamide	sulfonamide	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
are	be	VBP	B-VP	O	O
examples	example	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
substances	substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
:	:	:	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
danazol	danazol	NN	B-NP	O	S-drug
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
albuterol	albuterol	NN	B-NP	O	S-drug
,	,	,	O	O	O
terbutaline	terbutaline	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenothiazine	phenothiazine	NN	B-NP	O	B-group
derivatives	derivative	NNS	I-NP	O	E-group
,	,	,	O	O	O
somatropin	somatropin	NN	B-NP	O	S-drug
,	,	,	O	O	O
thyroid	thyroid	JJ	B-NP	O	B-group
hormones	hormone	NNS	I-NP	O	E-group
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
progestogens	progestogen	NNS	B-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-1
salts	salt	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
either	either	CC	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
or	or	CC	I-VP	O	O
weaken	weaken	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug-EF-2
.	.	.	O	O	O

Pentamidine	Pentamidine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
sometimes	sometimes	RB	I-VP	O	O
be	be	VB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sympatholytic	sympatholytic	JJ	B-NP	O	O
medicinal	medicinal	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
or	or	CC	O	O	O
absent	absent	JJ	B-ADJP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
substances	substance	NNS	B-NP	O	O
affect	affect	VBP	B-VP	O	O
glucose	glucose	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
insulin	insulin	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
and	and	CC	O	O	O
particularly	particularly	RB	B-NP	O	O
close	close	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
are	be	VBP	B-VP	O	O
examples	example	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
substances	substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
and	and	CC	I-NP	O	O
susceptibility	susceptibility	NN	I-NP	O	O
to	to	TO	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
:	:	:	O	O	O
oral	oral	JJ	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group
products	product	NNS	I-NP	O	E-group
,	,	,	O	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
,	,	,	O	O	O
fibrates	fibrate	NNS	B-NP	O	S-group
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group
oxidase	oxidase	NN	I-NP	I-protein	I-group
(	(	(	O	O	I-group
MAO	MAO	NN	B-NP	O	I-group
)	)	)	O	O	I-group
inhibitors	inhibitor	NNS	B-NP	O	E-group
,	,	,	O	O	O
propoxyphene	propoxyphene	NN	B-NP	O	S-drug
,	,	,	O	O	O
salicylates	salicylate	NNS	B-NP	O	S-group
,	,	,	O	O	O
somatostatin	somatostatin	NN	B-NP	O	B-group
analog	analog	NN	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
octreotide	octreotide	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
sulfonamide	sulfonamide	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
are	be	VBP	B-VP	O	O
examples	example	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
substances	substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
-	-	HYPH	B-PP	O	O
lowering	lower	VBG	B-NP	O	O
effect	effect	NN	I-NP	O	O
:	:	:	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
niacin	niacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
danazol	danazol	NN	B-NP	O	S-drug
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
salbutamol	salbutamol	NN	B-NP	O	S-drug
,	,	,	O	O	O
terbutaline	terbutaline	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenothiazine	phenothiazine	NN	B-NP	O	B-group
derivatives	derivative	NNS	I-NP	O	E-group
,	,	,	O	O	O
somatropin	somatropin	NN	B-NP	O	S-drug
,	,	,	O	O	O
thyroid	thyroid	JJ	B-NP	O	B-group
hormones	hormone	NNS	I-NP	O	E-group
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
progestogens	progestogen	NNS	B-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
clonidine	clonidine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-1
salts	salt	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
either	either	CC	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
or	or	CC	I-VP	O	O
weaken	weaken	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug-EF-2
.	.	.	O	O	O

Pentamidine	Pentamidine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
sometimes	sometimes	RB	I-VP	O	O
be	be	VB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sympatholytic	sympatholytic	JJ	B-NP	O	O
medicinal	medicinal	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
or	or	CC	O	O	O
absent	absent	JJ	B-ADJP	O	O
.	.	.	O	O	O

Mixing	Mix	VBG	B-VP	O	O
of	of	IN	B-PP	O	O
Insulins	Insulin	NNS	B-NP	B-protein	S-group

A	A	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
24	24	CD	B-NP	O	O
)	)	)	O	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
mixing	mix	VBG	B-VP	O	O
NovoLog	NovoLog	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
NPH	NPH	NN	B-NP	B-protein	B-drug
human	human	JJ	I-NP	I-protein	I-drug
insulin	insulin	NN	I-NP	I-protein	E-drug
immediately	immediately	RB	B-ADVP	O	O
before	before	IN	B-SBAR	O	O
injection	injection	NN	B-NP	O	O
produced	produce	VBD	B-VP	O	O
some	some	DT	B-NP	O	O
attenuation	attenuation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NovoLog	NovoLog	NNP	B-NP	O	S-brand
,	,	,	O	O	O
but	but	CC	O	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
peak	peak	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NovoLog	NovoLog	NN	B-NP	O	S-brand
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
NovoLog	NovoLog	NNP	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
mixed	mix	VBN	B-ADJP	O	O
with	with	IN	B-PP	O	O
NPH	NPH	NN	B-NP	B-protein	B-drug
human	human	JJ	I-NP	I-protein	I-drug
insulin	insulin	NN	I-NP	I-protein	E-drug
,	,	,	O	O	O
NovoLog	NovoLog	NNP	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
drawn	draw	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
syringe	syringe	NN	I-NP	O	O
first	first	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
mixing	mix	VBG	B-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
compatibility	compatibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NovoLog	NovoLog	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
crystalline	crystalline	NN	I-NP	O	O
zinc	zinc	NN	I-NP	O	B-drug
insulin	insulin	NN	I-NP	O	E-drug
preparations	preparation	NNS	I-NP	O	O
,	,	,	O	O	O
NovoLog	NovoLog	NNP	B-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
mixed	mix	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mixing	mix	VBG	B-VP	O	O
NovoLog	NovoLog	NNP	B-NP	O	S-brand
with	with	IN	B-PP	O	O
insulins	insulin	NNS	B-NP	B-protein	S-group
of	of	IN	B-PP	O	O
animal	animal	NN	B-NP	O	O
source	source	NN	I-NP	O	O
or	or	CC	I-NP	O	O
insulin	insulin	NN	I-NP	O	S-drug
preparations	preparation	NNS	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
manufacturers	manufacturer	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Mixtures	Mixture	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
external	external	JJ	B-NP	O	O
subcutaneous	subcutaneous	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
pumps	pump	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
NovoLog	NovoLog	NNP	B-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
mixed	mix	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
insulins	insulin	NNS	I-NP	B-protein	S-group
or	or	CC	O	O	O
diluent	diluent	JJ	B-ADJP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Rebif	Rebif	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
its	its	PRP$	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
neutropenia	neutropenia	NN	B-NP	O	O
and	and	CC	I-NP	O	O
lymphopenia	lymphopenia	NN	I-NP	O	O
,	,	,	O	O	O
proper	proper	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
Rebif	Rebif	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
myelosuppressive	myelosuppressive	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
injury	injury	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Rebif	Rebif	NNP	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
products	product	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
injury	injury	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
when	when	WRB	B-ADVP	O	O
new	new	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
already	already	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
Rebif	Rebif	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
Betaseron	Betaseron	NN	B-NP	O	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
fully	fully	RB	B-ADJP	O	O
evaluated	evaluate	VBN	I-ADJP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
studies	study	NNS	B-NP	O	O
designed	design	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
done	do	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group
or	or	CC	O	O	O
ACTH	ACTH	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
relapses	relapse	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
periods	period	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
28	28	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
180	180	CD	B-NP	O	O
)	)	)	O	O	O
receiving	receive	VBG	B-VP	O	O
Betaseron	Betaseron	NN	B-NP	O	S-brand
.	.	.	O	O	O

Betaseron	Betaseron	NN	B-NP	O	S-brand-ME-1
administration	administration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
three	three	CD	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.025	0.025	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
to	to	TO	B-PP	O	O
2.2	2.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug-ME-2
elimination.14	elimination.14	CD	I-NP	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alternate	alternate	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Betaseron	Betaseron	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
MS	MS	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

ATROVENT	ATROVENT	NNP	B-NP	O	S-brand
Inhalation	Inhalation	NNP	I-NP	O	O
Aerosol	Aerosol	NNP	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group
bronchodilators	bronchodilator	NNS	I-NP	O	E-group
,	,	,	O	O	O
methylxanthines	methylxanthine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
steroids	steroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
commonly	commonly	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
obstructive	obstructive	JJ	I-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
the	the	DT	B-NP	O	O
exception	exception	NN	I-NP	O	O
of	of	IN	B-PP	O	O
albuterol	albuterol	NN	B-NP	O	S-drug
,	,	,	O	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
fully	fully	RB	B-VP	O	O
evaluating	evaluate	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ATROVENT	ATROVENT	NN	B-NP	O	S-brand
Inhalation	Inhalation	NN	I-NP	O	O
Aerosol	Aerosol	NN	I-NP	O	O
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
effectiveness	effectiveness	NN	B-NP	O	O
.	.	.	O	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
ipratropium	ipratropium	NN	B-NP	O	B-drug-EF-1
bromide	bromide	NN	I-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
minimally	minimally	RB	I-VP	O	O
absorbed	absorb	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
circulation	circulation	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
some	some	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concomitantly	concomitantly	RB	B-NP	O	O
used	use	VBN	I-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group-EF-2
medications	medication	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ATROVENT	ATROVENT	NN	B-NP	O	S-brand-AD-1
Inhalation	Inhalation	NN	I-NP	O	O
Aerosol	Aerosol	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	S-group-AD-2
-	-	HYPH	I-NP	O	O
containing	contain	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	B-ADJP	O	O
(	(	(	O	O	O
or	or	CC	O	O	O
pharmacodynamic	pharmacodynamic	JJ	B-ADJP	O	O
)	)	)	O	O	O
interactions	interaction	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
significant	significant	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
formation	formation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxidized	oxidize	VBN	B-NP	O	O
irbesartan	irbesartan	NN	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
CYP	CYP	NN	I-NP	I-protein	O
2C9	2C9	NN	I-NP	I-protein	O
substrates	substrate	NNS	I-NP	I-protein	O
/	/	SYM	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
sulphenazole	sulphenazole	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
tolbutamide	tolbutamide	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
consequences	consequence	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
irbesartan	irbesartan	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
negligible	negligible	JJ	B-ADJP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
whose	whose	WP$	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
dependent	dependent	JJ	B-ADJP	O	O
upon	upon	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
1A1	1A1	NN	I-NP	I-protein	O
,	,	,	O	O	O
1A2,2A6,2B6,2D6,2E1	1A2,2A6,2B6,2D6,2E1	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
separate	separate	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
maintenance	maintenance	NN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
irbesartan	irbesartan	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
irbesartan	irbesartan	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	O	S-drug

The	The	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
myelosuppression	myelosuppression	NN	B-NP	O	O
and	and	CC	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
,	,	,	O	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
exacerbated	exacerbate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antineoplastic	antineoplastic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
having	have	VBG	B-VP	O	O
similar	similar	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
previously	previously	RB	I-VP	O	O
received	receive	VBN	I-VP	O	O
pelvic	pelvic	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
abdominal	abdominal	JJ	I-NP	O	O
irradiation	irradiation	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
myelosuppression	myelosuppression	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
irradiation	irradiation	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
adequately	adequately	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Lymphocytopenia	Lymphocytopenia	NNP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-EF-2
as	as	IN	B-PP	O	O
antiemetic	antiemetic	JJ	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
serious	serious	JJ	B-NP	O	O
opportunistic	opportunistic	JJ	I-NP	O	O
infections	infection	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
complications	complication	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
specifically	specifically	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
lymphocytopenia	lymphocytopenia	NN	B-NP	O	O
.	.	.	O	O	O

Hyperglycemia	Hyperglycemia	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Usually	Usually	RB	B-ADVP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diabetes	diabetes	NN	B-NP	O	O
mellitus	mellitus	NN	I-NP	O	O
or	or	CC	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
intolerance	intolerance	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
probable	probable	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
as	as	IN	B-PP	O	O
antiemetic	antiemetic	JJ	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
,	,	,	O	O	O
contributed	contribute	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
akathisia	akathisia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
weekly	weekly	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
(	(	(	O	O	O
8.5	8.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
4	4	CD	B-NP	O	O
/	/	SYM	O	O	O
47	47	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
prochlorperazine	prochlorperazine	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
as	as	IN	B-PP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand-EF-2
than	than	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
separate	separate	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
1.3	1.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
/	/	SYM	O	O	O
80	80	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
8.5	8.5	CD	I-NP	O	O
%	%	NN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
akathisia	akathisia	NN	B-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
range	range	NN	I-NP	O	O
reported	report	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
prochlorperazine	prochlorperazine	NN	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
premedication	premedication	NN	I-NP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
chemotherapies	chemotherapy	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
laxative	laxative	JJ	B-NP	O	S-group-EF-1
use	use	NN	I-NP	O	O
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand-EF-2
would	would	MD	B-VP	O	O
worsen	worsen	VB	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
or	or	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diarrhea	diarrhea	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
this	this	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
view	view	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dehydration	dehydration	NN	B-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
vomiting	vomit	VBG	B-VP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
diarrhea	diarrhea	NN	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
may	may	MD	B-VP	O	O
wish	wish	VB	I-VP	O	O
to	to	TO	I-VP	O	O
withhold	withhold	VB	I-VP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-1
during	during	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
with	with	IN	B-PP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand-EF-2
and	and	CC	O	O	O
,	,	,	O	O	O
certainly	certainly	RB	B-ADVP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
periods	period	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
vomiting	vomiting	NN	I-NP	O	O
or	or	CC	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
CAMPTOSAR	CAMPTOSAR	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Isocarboxazid	Isocarboxazid	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
Antabuse	Antabuse	NN	B-NP	O	S-brand-AD-2
(	(	(	O	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
Wyeth	Wyeth	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Ayerst	Ayerst	NNP	I-NP	O	O
Laboratories	Laboratories	NNP	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
rats	rat	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
high	high	JJ	B-NP	O	O
intraperitoneal	intraperitoneal	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
MAO	MAO	NN	I-NP	O	B-group-EF-1
inhibitor	inhibitor	NN	I-NP	O	E-group-EF-1
plus	plus	CC	O	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug-EF-2
experienced	experience	VBD	B-VP	O	O
severe	severe	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
death	death	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Isocarboxazid	Isocarboxazid	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
psychotropic	psychotropic	JJ	I-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
is	be	VBZ	B-VP	O	O
generally	generally	RB	I-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
possible	possible	JJ	B-NP	O	O
potentiating	potentiating	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
especially	especially	RB	B-ADJP	O	O
true	true	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
may	may	MD	B-VP	O	O
subject	subject	VB	I-VP	O	O
themselves	themselves	PRP	B-NP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
overdosage	overdosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
consideration	consideration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
monoamine	monoamine	NN	I-NP	O	O
oxidase	oxidase	NN	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Isocarboxazid	Isocarboxazid	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
persist	persist	VB	I-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
substantial	substantial	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
after	after	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
borne	bear	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mind	mind	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
Isocarboxazid	Isocarboxazid	NNP	B-NP	O	S-drug
.	.	.	O	O	O

To	To	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
potentiation	potentiation	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
wishing	wish	VBG	B-VP	O	O
to	to	TO	I-VP	O	O
terminate	terminate	VB	I-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Isocarboxazid	Isocarboxazid	NN	B-NP	O	S-drug
and	and	CC	O	O	O
begin	begin	VB	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
another	another	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
should	should	MD	B-VP	O	O
allow	allow	VB	I-VP	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

May	May	MD	O	O	O
interact	interact	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	O	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
make	make	VB	I-VP	O	O
your	your	PRP$	B-NP	O	O
condition	condition	NN	I-NP	O	O
worse	worse	JJR	B-ADJP	O	O
and	and	CC	O	O	O
prevent	prevent	VB	B-VP	O	O
the	the	DT	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	B-group
bronchodilators	bronchodilator	NNS	I-NP	O	E-group
from	from	IN	B-PP	O	O
working	work	VBG	B-VP	O	O
properly	properly	RB	B-ADVP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug
(	(	(	O	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
problems	problem	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Isoflurane	Isoflurane	NN	B-NP	O	S-drug-EF-1
potentiates	potentiate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
relaxant	relaxant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	B-group-EF-2
relaxants	relaxant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
most	most	RBS	B-ADVP	O	O
notably	notably	RB	I-ADVP	O	O
nondepolarizing	nondepolarize	VBG	B-VP	O	B-group-EF-2
muscle	muscle	NN	B-NP	O	I-group-EF-2
relaxants	relaxant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
MAC	MAC	NN	B-NP	B-protein	O
(	(	(	O	O	O
minimum	minimum	JJ	B-NP	O	O
alveolar	alveolar	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
N	N	NN	B-NP	B-protein	O
2O	2O	NN	I-NP	I-protein	O
.	.	.	O	O	O

See	See	VB	B-VP	O	O
CLINICAL	CLINICAL	JJ	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
.	.	.	O	O	O

Food	Food	NN	B-NP	O	O
:	:	:	O	O	O
Isoniazid	Isoniazid	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
food	food	NN	B-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
food	food	NN	B-NP	O	O
.	.	.	O	O	O

Acetaminophen	Acetaminophen	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug-EF-1
toxicity	toxicity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
Isoniazid	Isoniazid	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
believed	believe	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
resulted	result	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
previously	previously	RB	I-NP	O	O
unrecognized	unrecognized	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug-EF-2
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
proposed	propose	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
current	current	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
induce	induce	VB	I-VP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
450IIE1	450IIE1	NN	I-NP	B-protein	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
mixed	mix	VBN	I-NP	B-protein	O
-	-	HYPH	I-NP	I-protein	O
function	function	NN	I-NP	I-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
that	that	WDT	B-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
generate	generate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
proposed	propose	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-ME-1
resulted	result	VBD	B-VP	O	O
In	In	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
P	P	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
450IIE1	450IIE1	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
liver	liver	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
turn	turn	NN	B-NP	O	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
proportion	proportion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ingested	ingest	VBN	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug-ME-2
being	be	VBG	B-VP	O	O
converted	convert	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
potentiates	potentiate	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
cetaminophen	cetaminophen	NN	I-NP	O	O
hepatoxicity	hepatoxicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Isoniazid	Isoniazid	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
slow	slow	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
its	its	PRP$	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
Carbamazepine	Carbamazepine	VBP	B-VP	O	S-drug-AD-1
levels	level	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
prior	prior	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
signs	sign	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticonvulsant	anticonvulsant	NN	I-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Potential	Potential	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
Isoniazid	Isoniazid	NN	I-NP	O	S-drug-IN-2
may	may	MD	B-VP	O	O
exist	exist	VB	I-VP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Isoniazid	Isoniazid	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

To	To	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
intoxication	intoxication	NN	I-NP	O	O
,	,	,	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticonvulsant	anticonvulsant	NN	I-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
.	.	.	O	O	O

Therophylline	Therophylline	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
recent	recent	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
concomitan	concomitan	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
elevated	elevated	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
instances	instance	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
narrow	narrow	JJ	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
recent	recent	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
study	study	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valproate	valproate	NN	B-NP	O	S-drug-ME-1
when	when	WRB	B-ADVP	O	O
co	co	NN	B-NP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
co	co	NN	B-NP	O	O
administered	administer	VBN	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
valproate	valproate	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
.	.	.	O	O	O

Isoproterenol	Isoproterenol	NN	B-NP	O	B-drug-AD-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-AD-1
injection	injection	NN	I-NP	O	O
and	and	CC	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
because	because	IN	B-SBAR	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
direct	direct	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
stimulants	stimulant	NNS	I-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
combined	combine	VBN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
serious	serious	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
be	be	VB	B-VP	O	O
administered	administer	VBN	I-VP	O	O
alternately	alternately	RB	B-ADVP	O	O
provided	provide	VBN	B-VP	O	O
a	a	DT	B-NP	O	O
proper	proper	JJ	I-NP	O	O
interval	interval	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
elapsed	elapse	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
.	.	.	O	O	O

ISUPREL	ISUPREL	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
at	at	IN	B-ADVP	O	O
all	all	DT	I-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
potent	potent	JJ	B-NP	O	O
inhalational	inhalational	JJ	I-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-AD-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
employed	employ	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
potential	potential	NN	B-NP	O	O
to	to	TO	B-VP	O	O
sensitize	sensitize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
to	to	TO	B-PP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group
amines	amine	NNS	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
vasodilating	vasodilate	VBG	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
isosorbide	isosorbide	NN	B-NP	O	B-drug-EF-1
dinitrate	dinitrate	NN	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
vasodilators	vasodilator	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
in	in	IN	B-PP	O	O
particular	particular	JJ	B-ADJP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
vasodilating	vasodilate	VBG	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
isosorbide	isosorbide	NN	B-NP	O	B-drug-EF-1
mononitrate	mononitrate	NN	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
vasodilators	vasodilator	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
in	in	IN	B-PP	O	O
particular	particular	JJ	B-ADJP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
.	.	.	O	O	O

Marked	Mark	VBN	B-NP	O	O
symptomatic	symptomatic	JJ	I-NP	O	O
orthostatic	orthostatic	JJ	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
calcium	calcium	NN	B-NP	O	B-group-EF-1
channel	channel	NN	I-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
organic	organic	JJ	B-NP	O	B-group-EF-2
nitrates	nitrate	NNS	I-NP	O	E-group-EF-2
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Vitamin	Vitamin	NN	B-NP	O	B-group
A	A	NN	I-NP	O	E-group
:	:	:	O	O	O
Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand-EF-1
to	to	TO	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-EF-2
A	A	NN	I-NP	O	E-group-EF-2
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
taking	take	VBG	B-VP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
supplements	supplement	NNS	I-NP	O	E-group
containing	contain	VBG	B-VP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
A	A	NN	I-NP	O	E-group
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O

Tetracyclines	Tetracycline	NNS	B-NP	O	S-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
tetracyclines	tetracycline	NNS	I-NP	O	S-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
Accutane	Accutane	NN	B-NP	O	S-brand-EF-1
use	use	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
pseudotumor	pseudotumor	NN	B-NP	O	O
cerebri	cerebri	NN	I-NP	O	O
(	(	(	O	O	O
benign	benign	JJ	B-NP	O	O
intracranial	intracranial	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
involved	involve	VBD	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-EF-2

Micro	Micro	AFX	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
dosed	dose	VBN	B-NP	O	O
Progesterone	Progesterone	NN	I-NP	O	S-drug
Preparations	Preparation	NNS	I-NP	O	O
:	:	:	O	O	O
Micro	Micro	NN	B-NP	O	O
-	-	HYPH	O	O	O
dosed	dose	VBN	B-NP	O	O
progesterone	progesterone	NN	I-NP	O	S-drug-EF-1
preparations	preparation	NNS	I-NP	O	O
(	(	(	O	O	O
minipills	minipill	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
contain	contain	VB	I-VP	O	O
an	an	DT	B-NP	O	O
estrogen	estrogen	NN	I-NP	O	S-group
)	)	)	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inadequate	inadequate	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
during	during	IN	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
other	other	JJ	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
are	be	VBP	B-VP	O	O
highly	highly	RB	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
from	from	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
combined	combined	JJ	B-NP	O	B-group
oral	oral	JJ	I-NP	O	I-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
topical	topical	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
injectable	injectable	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
implantable	implantable	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
insertable	insertable	JJ	I-NP	O	O
hormonal	hormonal	JJ	I-NP	O	O
birth	birth	NN	I-NP	O	O
control	control	NN	I-NP	O	O
products	product	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
more	more	RBR	B-ADJP	O	O
frequent	frequent	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
use	use	VBP	B-VP	O	O
only	only	RB	B-NP	O	O
a	a	DT	I-NP	O	O
single	single	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
hormonal	hormonal	JJ	B-NP	O	B-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
differ	differ	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
critically	critically	RB	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
childbearing	childbeare	VBG	B-VP	O	O
potential	potential	NN	B-NP	O	O
to	to	TO	B-VP	O	O
select	select	VB	I-VP	O	O
and	and	CC	O	O	O
commit	commit	VB	B-VP	O	O
to	to	TO	I-VP	O	O
use	use	VB	I-VP	O	O
2	2	CD	B-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
effective	effective	JJ	B-NP	O	O
contraception	contraception	NN	I-NP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
,	,	,	O	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
1	1	CD	I-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
form	form	NN	I-NP	O	O
,	,	,	O	O	O
unless	unless	IN	B-SBAR	O	O
absolute	absolute	JJ	B-NP	O	O
abstinence	abstinence	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
chosen	choose	VBN	I-NP	O	O
method	method	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
undergone	undergo	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
hysterectomy	hysterectomy	NN	I-NP	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Accutane	Accutane	NNP	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
finding	finding	NN	I-NP	O	O
that	that	IN	B-NP	O	O
neither	neither	CC	O	O	O
isotretinoin	isotretinoin	NN	B-NP	O	S-drug
nor	nor	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
induce	induce	VBP	B-VP	O	O
or	or	CC	I-VP	O	O
inhibit	inhibit	VBP	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
2C9	2C9	NN	I-NP	I-protein	O
human	human	JJ	I-NP	I-protein	O
hepatic	hepatic	JJ	I-NP	I-protein	O
P450	P450	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
osteomalacia	osteomalacia	NN	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
assess	assess	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
interactive	interactive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
loss	loss	NN	I-NP	O	O
between	between	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Accutane	Accutane	NN	I-NP	O	S-brand
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
together	together	RB	B-ADVP	O	O

Systemic	Systemic	JJ	B-NP	O	B-group
Corticosteroids	Corticosteroid	NNS	I-NP	O	E-group
:	:	:	O	O	O
Systemic	Systemic	JJ	B-NP	O	B-group
corticosteroids	corticosteroid	NNS	I-NP	O	E-group
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
osteoporosis	osteoporosis	NN	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
assess	assess	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
interactive	interactive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
loss	loss	NN	I-NP	O	O
between	between	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	B-group
corticosteroids	corticosteroid	NNS	I-NP	O	E-group
and	and	CC	I-NP	O	O
Accutane	Accutane	NN	I-NP	O	S-brand
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
together	together	RB	B-ADVP	O	O
.	.	.	O	O	O

Prescribers	Prescriber	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
advised	advise	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
consult	consult	VB	I-VP	O	O
the	the	DT	B-NP	O	O
package	package	NN	I-NP	O	O
insert	insert	NN	I-NP	O	O
of	of	IN	B-PP	O	O
medication	medication	NN	B-NP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
hormonal	hormonal	JJ	B-NP	O	B-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
some	some	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
birth	birth	NN	I-NP	B-protein	O
control	control	NN	I-NP	I-protein	O
products	product	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Accutane	Accutane	NN	B-NP	O	S-brand
use	use	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
depression	depression	NN	B-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Pregnancies	Pregnancy	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
combined	combined	JJ	B-NP	O	B-group
hormonal	hormonal	JJ	I-NP	O	I-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
who	who	WP	B-NP	O	O
also	also	RB	B-ADVP	O	O
used	use	VBD	B-VP	O	O
some	some	DT	B-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
St.	St.	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
Wort	Wort	NNP	I-NP	O	O
.	.	.	O	O	O

Laboratory	Laboratory	NNP	B-NP	O	O
Tests	Test	NNPS	I-NP	O	O
Pregnancy	Pregnancy	NNP	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Female	Female	NNP	I-NP	O	O
patients	patient	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
childbearing	childbeare	VBG	B-VP	O	O
potential	potential	NN	B-NP	O	O
must	must	MD	B-VP	O	O
have	have	VB	I-VP	O	O
negative	negative	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
2	2	CD	B-NP	O	O
urine	urine	NN	I-NP	O	O
or	or	CC	I-NP	O	O
serum	serum	NN	I-NP	O	O
pregnancy	pregnancy	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
25	25	CD	I-NP	O	O
mIU	mIU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
before	before	IN	B-PP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
Accutane	Accutane	NN	I-NP	O	S-brand
prescription	prescription	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prescriber	prescriber	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
decision	decision	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
made	make	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
pursue	pursue	VB	I-VP	O	O
qualification	qualification	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand
(	(	(	O	O	O
a	a	DT	B-NP	O	O
screening	screening	NN	I-NP	O	O
test	test	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
pregnancy	pregnancy	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
a	a	DT	B-NP	O	O
confirmation	confirmation	NN	I-NP	O	O
test	test	NN	I-NP	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
done	do	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
menstrual	menstrual	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
immediately	immediately	RB	B-VP	O	O
preceding	precede	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
beginning	beginning	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
amenorrhea	amenorrhea	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
done	do	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
11	11	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
act	act	NN	I-NP	O	O
of	of	IN	B-PP	O	O
unprotected	unprotected	JJ	B-NP	O	O
sexual	sexual	JJ	I-NP	O	O
intercourse	intercourse	NN	I-NP	O	O
(	(	(	O	O	O
without	without	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
2	2	CD	B-NP	O	O
effective	effective	JJ	I-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
month	month	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
must	must	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
negative	negative	JJ	I-NP	O	O
result	result	NN	I-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
or	or	CC	I-NP	O	O
serum	serum	NN	I-NP	O	O
pregnancy	pregnancy	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
pregnancy	pregnancy	NN	I-NP	O	O
test	test	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
repeated	repeat	VBN	I-VP	O	O
each	each	DT	B-NP	O	O
month	month	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
female	female	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
each	each	DT	B-NP	O	O
prescription	prescription	NN	I-NP	O	O

Lipids	Lipid	NNS	B-NP	O	O
:	:	:	O	O	O
Pretreatment	Pretreatment	NN	B-NP	O	O
and	and	CC	O	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
blood	blood	NN	B-NP	O	O
lipids	lipid	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
obtained	obtain	VBN	I-VP	O	O
under	under	IN	B-PP	O	O
fasting	fast	VBG	B-VP	O	O
conditions	condition	NNS	B-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
consumption	consumption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
36	36	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
before	before	IN	B-PP	O	O
these	these	DT	B-NP	O	O
determinations	determination	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
made	make	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
tests	test	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
performed	perform	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
weekly	weekly	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
biweekly	biweekly	JJ	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
until	until	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertriglyceridemia	hypertriglyceridemia	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
1	1	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
in	in	IN	B-PP	O	O
4	4	CD	B-NP	O	O
on	on	IN	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O

Liver	Liver	NN	B-NP	O	O
Function	Function	NN	I-NP	O	O
Tests	Test	NNS	I-NP	O	O
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
elevations	elevation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
liver	liver	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
hepatitis	hepatitis	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
pretreatment	pretreatment	NN	B-NP	O	O
and	and	CC	O	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
liver	liver	NN	B-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
weekly	weekly	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
biweekly	biweekly	JJ	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
until	until	IN	B-PP	O	O
the	the	DT	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
Accutane	Accutane	NNP	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O

Glucose	Glucose	NN	B-NP	O	O
:	:	:	O	O	O
Some	Some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand
have	have	VBP	B-VP	O	O
experienced	experience	VBN	I-VP	O	O
problems	problem	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
blood	blood	NN	I-NP	O	O
sugar	sugar	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
new	new	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diabetes	diabete	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
causal	causal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O

CPK	CPK	NN	B-NP	B-protein	O
:	:	:	O	O	O
Some	Some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
vigorous	vigorous	JJ	B-NP	O	O
physical	physical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
on	on	IN	B-PP	O	O
Accutane	Accutane	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
experienced	experience	VBN	I-VP	O	O
elevated	elevated	JJ	B-NP	O	O
CPK	CPK	NN	I-NP	B-protein	O
levels	level	NNS	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rare	rare	JJ	B-NP	O	O
postmarketing	postmarketing	JJ	I-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	O
,	,	,	O	O	O
some	some	DT	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
strenuous	strenuous	JJ	B-NP	O	O
physical	physical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
217	217	CD	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
to	to	TO	I-NP	O	O
17	17	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
recalcitrant	recalcitrant	NN	I-NP	O	O
nodular	nodular	JJ	I-NP	O	O
acne	acne	NN	I-NP	O	O
,	,	,	O	O	O
transient	transient	JJ	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
CPK	CPK	NN	B-NP	B-protein	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
those	those	DT	B-NP	O	O
undergoing	undergo	VBG	I-NP	O	O
strenuous	strenuous	JJ	I-NP	O	O
physical	physical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
reported	report	VBN	B-NP	O	O
musculoskeletal	musculoskeletal	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
back	back	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	O
,	,	,	O	O	O
arthralgia	arthralgia	NN	B-NP	O	O
,	,	,	O	O	O
limb	limb	NN	B-NP	O	O
injury	injury	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
muscle	muscle	NN	B-NP	O	O
sprain	sprain	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
approximately	approximately	RB	B-NP	O	O
half	half	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CPK	CPK	NN	I-NP	B-protein	O
elevations	elevation	NNS	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
within	within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
and	and	CC	O	O	O
half	half	NN	B-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
within	within	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

Nitroglycerin	Nitroglycerin	NN	B-NP	O	S-drug
:	:	:	O	O	O
DynaCirc	DynaCirc	NN	B-NP	O	S-brand
(	(	(	O	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
safely	safely	RB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
nitroglycerin	nitroglycerin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

Hydrochlorothiazide	Hydrochlorothiazide	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DynaCirc	DynaCirc	NN	B-NP	O	S-brand
(	(	(	O	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
altered	alter	VBN	B-NP	O	O
pharmacoktnetics	pharmacoktnetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
addition	addition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
existing	exist	VBG	B-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
unexpected	unexpected	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Propranolol	Propranolol	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
bioavailability	bioavailability	NN	I-NP	O	O
.	.	.	O	O	O

Significant	Significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
In	In	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
27	27	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Cmax	Cmax	NN	B-NP	O	O
(	(	(	O	O	O
58	58	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
decreases	decrease	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
tmax	tmax	NN	B-NP	O	O
(	(	(	O	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O

propranolol	propranolol	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
either	either	CC	B-NP	O	O
drug	drug	NN	I-NP	O	O
s	s	NNS	I-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
,	,	,	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
,	,	,	O	O	O
differences	difference	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
between	between	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
given	give	VBN	B-VP	O	O
singly	singly	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
between	between	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
given	give	VBN	B-VP	O	O
singly	singly	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug-ME-2
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sixth	sixth	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
mean	mean	JJ	I-NP	O	O
peak	peak	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
36	36	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
significant	significant	JJ	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
area	area	NN	B-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
(	(	(	O	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
isradipine	isradipine	NN	B-NP	O	S-drug-AD-1
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
currently	currently	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-AD-2
careful	careful	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
for	for	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
and	and	CC	O	O	O
downward	downward	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Rifampicin	Rifampicin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
six	six	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
below	below	IN	B-PP	O	O
detectable	detectable	JJ	B-NP	O	O
limits	limit	NNS	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
rifampicin	rifampicin	NN	B-NP	O	S-drug-ME-1
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
,	,	,	O	O	O
isradipine	isradipine	NN	B-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
markedly	markedly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
abolished	abolish	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
consequence	consequence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
higher	high	JJR	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	RB	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
racemic	racemic	JJ	B-NP	B-protein	O
warfarin	warfarin	NN	I-NP	I-protein	S-drug
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
two	two	CD	B-NP	O	O
single	single	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.7	0.7	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
11	11	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
multipledose	multipledose	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	I-NP	O	O
isradipine	isradipine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
racemic	racemic	JJ	B-NP	B-protein	O
warfarin	warfarin	NN	I-NP	I-protein	S-drug
nor	nor	CC	O	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
binding	binding	NN	I-NP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
was	be	VBD	B-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DynaCirc	DynaCirc	NN	B-NP	O	S-brand
(	(	(	O	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
,	,	,	I-NP	O	O
nonrenal	nonrenal	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
total	total	JJ	I-NP	O	O
body	body	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Fentanyl	Fentanyl	NNP	B-NP	O	S-drug
Anesthesia	Anesthesia	NNP	I-NP	O	O
:	:	:	O	O	O
Severe	Severe	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
fentanyl	fentanyl	NN	B-NP	O	S-drug-EF-1
anesthesia	anesthesia	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
beta	beta	NN	I-NP	O	B-group-EF-2
blocker	blocker	NN	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group-EF-2
channel	channel	NN	I-NP	O	I-group-EF-2
blocker	blocker	NN	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Even	Even	RB	B-SBAR	O	O
though	though	IN	I-SBAR	O	O
such	such	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
DynaCirc	DynaCirc	NN	B-NP	O	S-brand
(	(	(	O	O	O
isradipine	isradipine	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
circulating	circulate	VBG	B-NP	O	O
fluids	fluid	NNS	I-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
an	an	DT	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
major	major	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
hydroxyitraconazole	hydroxyitraconazole	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
primarily	primarily	RB	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
both	both	CC	O	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
unless	unless	IN	B-SBAR	O	O
otherwise	otherwise	RB	B-NP	O	O
specified	specify	VBN	I-NP	O	O
,	,	,	I-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
led	lead	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
rare	rare	JJ	B-NP	O	O
instances	instance	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
dysrhythmias	dysrhythmia	NNS	I-NP	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
death	death	NN	I-NP	O	O
.	.	.	O	O	O

Another	Another	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
azole	azole	NN	I-NP	O	B-group
antifungal	antifungal	JJ	B-ADJP	O	E-group
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
astemizole	astemizole	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
desmethylastermizole	desmethylastermizole	NN	I-NP	O	S-drug_n
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
QT	QT	NN	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
less	less	RBR	I-NP	O	O
pronounced	pronounced	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
biotransformation	biotransformation	NN	I-NP	O	O
system	system	NN	I-NP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
chemical	chemical	JJ	I-NP	O	O
resemblance	resemblance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Human	Human	JJ	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
potently	potently	RB	B-ADVP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
eight	eight	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug-EF-2
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	B-protein	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-1
also	also	RB	B-ADVP	O	O
markedly	markedly	RB	B-ADVP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
biotransformation	biotransformation	NN	I-NP	O	O
system	system	NN	I-NP	O	O
mainly	mainly	RB	B-ADJP	O	O
responsible	responsible	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

therefore	therefore	RB	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
midazolam	midazolam	NN	I-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
triazolam	triazolam	NN	I-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
resulted	result	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
and	and	CC	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
hypnotic	hypnotic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
parenterally	parenterally	RB	B-ADVP	O	O
,	,	,	O	O	O
special	special	JJ	B-NP	O	O
precaution	precaution	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
since	since	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug-ME-2
,	,	,	I-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
led	lead	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
three	three	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug-AD-1
,	,	,	I-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-AD-1
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
frequently	frequently	RB	B-ADVP	O	O
thereafter	thereafter	RB	I-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
three	three	CD	I-NP	O	O
drug	drug	NN	I-NP	O	O
products	product	NNS	I-NP	O	O
adjusted	adjust	VBN	B-VP	O	O
appropriately	appropriately	RB	B-ADVP	O	O
.	.	.	O	O	O

Rhabdomyolysis	Rhabdomyolysis	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
HMG	HMG	NN	B-NP	B-protein	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
CoA	CoA	NN	I-NP	O	I-group-EF-1
reductase	reductase	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
administered	administer	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
(	(	(	O	O	O
at	at	IN	B-PP	O	O
recommended	recommend	VBN	B-NP	O	O
dosages	dosage	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
immunosuppressive	immunosuppressive	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
including	include	VBG	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
or	or	CC	O	O	O
H2antagonists	H2antagonist	NNS	B-NP	O	O
,	,	,	O	O	O
reduced	reduce	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
monitor	monitor	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
taken	take	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-EF-1
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	S-group-EF-2
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
coumarin	coumarin	NN	I-NP	O	S-group-AD-2
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
azole	azole	NN	B-NP	O	B-group-ME-1
antifungal	antifungal	JJ	I-NP	O	I-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
are	be	VBP	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Itraconazole	Itraconazole	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
isoniazid	isoniazid	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Severe	Severe	JJ	B-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
azole	azole	NN	B-NP	O	B-group-EF-1
antifungal	antifungal	JJ	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Tinnitus	Tinnitus	NNP	B-NP	O	O
and	and	CC	O	O	O
decreased	decrease	VBN	B-NP	O	O
hearing	hearing	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
quinidine	quinidine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Edema	Edema	NNP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
dihydropyridine	dihydropyridine	NN	I-NP	O	B-group-EF-2
calcium	calcium	NN	I-NP	O	I-group-EF-2
channel	channel	NN	I-NP	O	I-group-EF-2
blockers	blocker	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Appropriate	Appropriate	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
eight	eight	CD	B-NP	O	O
HIV	HIV	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
infected	infect	VBN	I-NP	O	O
individuals	individual	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
,	,	,	O	O	O
8	8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.4	0.4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Itraconazole	Itraconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
mixing	mixing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
aminoglycoside	aminoglycoside	NN	I-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	I-NP	O	O
lactamtype	lactamtype	NN	I-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-EF-2
(	(	(	O	O	O
penicillins	penicillin	NNS	B-NP	O	S-group-EF-2
or	or	CC	I-NP	O	O
cephalosporins	cephalosporin	NNS	I-NP	O	S-group-EF-2
)	)	)	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
mutual	mutual	JJ	I-NP	O	O
inactivation	inactivation	NN	I-NP	O	O
.	.	.	O	O	O

Even	Even	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
an	an	DT	B-NP	O	O
aminoglycoside	aminoglycoside	NN	I-NP	O	S-group-ME-1
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
penicillin	penicillin	NN	I-NP	B-protein	S-group-ME-2
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
separately	separately	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
routes	route	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	B-protein	S-group
serum	serum	NN	I-NP	I-protein	O
half	half	NN	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
or	or	CC	I-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Usually	Usually	RB	B-ADVP	O	O
,	,	,	O	O	O
such	such	JJ	B-NP	O	O
inactivation	inactivation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
aminoglycoside	aminoglycoside	NN	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
only	only	RB	B-PP	O	O
in	in	IN	I-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
severely	severely	RB	B-NP	O	O
impaired	impaired	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
function..	function..	NN	I-NP	O	O

Prolonged	Prolong	VBN	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
time	time	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group-EF-1
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Ketamine	Ketamine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
compatible	compatible	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
commonly	commonly	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
general	general	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
local	local	JJ	I-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
when	when	WRB	B-ADVP	O	O
an	an	DT	B-NP	O	O
adequate	adequate	JJ	I-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
exchange	exchange	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
NIZORAL	NIZORAL	JJ	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
primarily	primarily	RB	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
both	both	CC	O	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
unless	unless	IN	B-SBAR	O	O
otherwise	otherwise	RB	B-NP	O	O
specified	specify	VBN	I-NP	O	O
,	,	,	I-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
identified	identify	VBN	I-VP	O	O
involving	involve	VBG	B-PP	O	O
NIZORAL	NIZORAL	NN	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
:	:	:	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
tablets	tablet	NNS	I-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
delay	delay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
acid	acid	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
prolonged	prolong	VBN	B-NP	O	O
QT	QT	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-EF-1
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
astemizole	astemizole	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
desmethylastemizole	desmethylastemizole	NN	I-NP	O	S-drug_n
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
QT	QT	NN	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
tablets	tablet	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Human	Human	JJ	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
potently	potently	RB	B-ADVP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
eight	eight	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug-EF-2
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	B-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-1
tablets	tablet	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
tablets	tablet	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
NIZORAL	NIZORAL	NNP	B-NP	O	S-brand
Tablets	Tablet	NNPS	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
NIZORAL	NIZORAL	NN	B-NP	B-protein	S-brand-ME-1
Tablets	Tablet	NNS	I-NP	I-protein	O
with	with	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
triazolam	triazolam	NN	I-NP	O	S-drug-ME-2
has	have	VBZ	B-VP	O	O
resulted	result	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
and	and	CC	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
hypnotic	hypnotic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
or	or	CC	O	O	O
chronic	chronic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
NIZORAL	NIZORAL	NNP	B-NP	O	S-brand
Tablets	Tablet	NNPS	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
parenterally	parenterally	RB	B-ADVP	O	O
,	,	,	O	O	O
special	special	JJ	B-NP	O	O
precaution	precaution	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
since	since	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
.	.	.	O	O	O

Rare	Rare	NN	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
clear	clear	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-AD-1
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
orally	orally	RB	B-ADVP	O	O
,	,	,	O	O	O
imidazole	imidazole	NN	B-NP	O	B-group-EF-1
compounds	compound	NNS	I-NP	O	E-group-EF-1
like	like	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	S-group-EF-2
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
imidazole	imidazole	NN	B-NP	O	B-group-AD-1
drugs	drug	NNS	I-NP	O	E-group-AD-1
and	and	CC	O	O	O
coumarin	coumarin	NN	B-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
and	and	CC	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
severe	severe	JJ	B-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
oral	oral	JJ	B-NP	O	O
miconazole	miconazole	NN	I-NP	O	S-drug-EF-1
(	(	(	O	O	O
an	an	DT	B-NP	O	O
imidazole	imidazole	NN	I-NP	O	S-group
)	)	)	O	O	O
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
such	such	PDT	B-NP	O	O
a	a	DT	I-NP	O	O
potential	potential	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
tablets	tablet	NNS	I-NP	O	O
(	(	(	O	O	O
an	an	DT	B-NP	O	O
imidazole	imidazole	NN	I-NP	O	S-group
)	)	)	O	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
ruled	rule	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
tablets	tablet	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
monitor	monitor	VB	I-VP	O	O
both	both	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
tablets	tablet	NNS	I-NP	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
.	.	.	O	O	O

INH	INH	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
Isoniazid	Isoniazid	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
adversely	adversely	RB	B-ADVP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
loratadine	loratadine	NN	B-NP	O	S-drug-ME-2
to	to	TO	B-PP	O	O
11	11	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
loratadine	loratadine	NN	B-NP	O	S-drug
averaged	average	VBD	B-VP	O	O
302	302	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
142	142	CD	B-NP	O	O
S.D	S.D	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
251	251	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
68	68	CD	B-NP	O	O
S.D	S.D	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
those	those	DT	B-NP	O	O
obtained	obtain	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
descarboethoxyloratadine	descarboethoxyloratadine	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
an	an	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
averaged	average	VBD	B-VP	O	O
155	155	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
27	27	CD	B-NP	O	O
S.D	S.D	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
141	141	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
35	35	CD	B-NP	O	O
S.D	S.D	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
related	relate	VBN	I-NP	O	O
changes	change	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT0	QT0	NN	I-NP	B-DNA	O
on	on	IN	B-PP	O	O
ECG	ECG	NN	B-NP	B-protein	O
taken	take	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
2	2	CD	B-NP	O	O
,	,	,	I-NP	O	O
6	6	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
loratadine	loratadine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

Rare	Rare	NN	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
disulfiram	disulfiram	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
experiences	experience	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
flushing	flushing	NN	B-NP	O	O
,	,	,	O	O	O
rash	rash	NN	B-NP	O	O
,	,	,	O	O	O
peripheral	peripheral	JJ	B-NP	O	O
edema	edema	NN	I-NP	O	O
,	,	,	O	O	O
nausea	nausea	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
headache	headache	NN	B-NP	O	O
.	.	.	O	O	O

Symptoms	Symptom	NNS	B-NP	O	O
resolved	resolve	VBN	B-VP	O	O
within	within	IN	B-PP	O	O
a	a	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
kept	keep	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mind	mind	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
Orudis	Orudis	NNP	B-NP	O	S-brand
doses	dose	VBZ	B-VP	O	O
greater	great	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
or	or	CC	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
highly	highly	RB	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

1	1	LS	B-LST	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	B-drug
hydroxide	hydroxide	NN	I-NP	O	E-drug
and	and	CC	O	O	O
aluminum	aluminum	NN	B-NP	O	B-drug
hydroxide	hydroxide	NN	I-NP	O	E-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
or	or	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
Orudis	Orudis	NNP	B-NP	O	S-brand
.	.	.	O	O	O

2	2	LS	B-LST	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Ketoprofen	Ketoprofen	NNP	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
absorption	absorption	NN	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-1
decreased	decrease	VBD	B-VP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug-ME-2
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
from	from	IN	B-PP	O	O
0.07	0.07	CD	B-NP	O	O
L	L	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
without	without	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
to	to	TO	B-PP	O	O
0.11	0.11	CD	B-NP	O	O
L	L	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
adequately	adequately	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
ketoprofen	ketoprofen	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

3	3	LS	B-LST	O	O
.	.	.	O	O	O

Diuretic	Diuretic	JJ	B-ADJP	O	S-group
:	:	:	O	O	O
Hydrochlorothiazide	Hydrochlorothiazide	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
produces	produce	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
and	and	CC	I-NP	O	O
chloride	chloride	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
hydrochlorothiazide	hydrochlorothiazide	VB	I-VP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
renal	renal	JJ	B-NP	O	O
failure	failure	NN	I-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
.	.	.	O	O	O

4	4	LS	B-LST	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
congestive	congestive	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
failure	failure	NN	I-NP	O	O
where	where	WRB	B-ADVP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
concomitantly	concomitantly	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
,	,	,	O	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

5	5	LS	B-LST	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
controlled	control	VBN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
14	14	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Bleeding	Bleed	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sites	site	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
and	and	CC	I-NP	O	O
GI	GI	NN	I-NP	O	O
bleeding	bleed	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
prostaglandina	prostaglandina	NN	B-NP	O	O
play	play	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hemostasis	hemostasis	NN	B-NP	O	O
and	and	CC	I-NP	O	O
ketoprofen	ketoprofen	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
as	as	RB	B-ADVP	O	O
well	well	RB	I-ADVP	O	O
,	,	,	O	O	O
concurent	concurent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-AD-2
requires	require	VBZ	B-VP	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

6	6	CD	B-NP	O	O
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
Probenecid	Probenecid	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
both	both	CC	O	O	O
free	free	JJ	B-ADJP	O	O
and	and	CC	O	O	O
bound	bind	VBN	B-VP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
reducing	reduce	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
about	about	RB	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
third	third	JJ	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
decreasing	decrease	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
probenecid	probenecid	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

7	7	CD	B-NP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ketoprofen	Ketoprofen	NNP	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
like	like	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-ME-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

8	8	CD	B-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Nonsteroidal	Nonsteroidal	JJ	B-NP	O	B-group-ME-1
anti	anti	AFX	I-NP	O	I-group-ME-1
-	-	HYPH	I-NP	O	I-group-ME-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
steadystate	steadystate	NN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ketoprofen	ketoprofen	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

DRUG	DRUG	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
LABORATORY	LABORATORY	NN	I-NP	O	O
TEST	TEST	NN	I-NP	O	O
INTERACTIONS	INTERACTIONS	NNS	I-NP	O	O
:	:	:	O	O	O
EFFECT	EFFECT	NN	B-NP	O	O
ON	ON	NN	I-NP	O	O
BLOOD	BLOOD	NN	I-NP	O	O
COAGULATION	COAGULATION	NN	I-NP	O	O
Ketoprofen	Ketoprofen	NN	I-NP	O	S-drug
decreases	decrease	VBZ	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
adhesion	adhesion	NN	I-NP	O	O
and	and	CC	I-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
can	can	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
bleeding	bleeding	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
3	3	CD	I-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
count	count	NN	I-NP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
partial	partial	JJ	B-NP	O	O
thromboplastin	thromboplastin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
thrombin	thrombin	NN	B-NP	B-protein	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Ketorolac	Ketorolac	NNP	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	B-protein	O
plasma	plasma	NN	I-NP	I-protein	O
protein	protein	NN	I-NP	I-protein	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
99.2	99.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NNP	B-NP	O	S-drug
,	,	,	O	O	O
Digoxin	Digoxin	NNP	B-NP	O	S-drug
,	,	,	O	O	O
Salicylate	Salicylate	NNP	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
Heparin	Heparin	NN	B-NP	O	S-drug
The	The	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-1
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
only	only	RB	I-VP	O	O
slightly	slightly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ketorolac	ketorolac	NN	B-NP	O	B-drug-ME-2
tromethamine	tromethamine	NN	I-NP	O	E-drug-ME-2
(	(	(	O	O	O
99.5	99.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
control	control	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
99.3	99.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
ketorolac	ketorolac	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
reach	reach	VBP	B-VP	O	O
5	5	CD	B-NP	O	O
to10	to10	NN	I-NP	O	O
m	m	NN	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

Ketorolac	Ketorolac	NNP	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
salicylate	salicylate	NN	B-NP	O	S-group-ME-1
(	(	(	O	O	O
300	300	CD	B-NP	O	O
m	m	NN	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketorolac	ketorolac	NN	B-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
99.2	99.2	CD	I-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
97.5	97.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
representing	represent	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
twofold	twofold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
unbound	unbound	JJ	B-NP	O	O
ketorolac	ketorolac	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Therapeutic	Therapeutic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
,	,	,	O	O	O
piroxicam	piroxicam	NN	B-NP	O	S-drug
,	,	,	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
andtolbutamide	andtolbutamide	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
ketorolac	ketorolac	NN	B-NP	O	B-drug
tromethamine	tromethamine	NN	I-NP	O	E-drug
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
12	12	CD	B-NP	O	O
adult	adult	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
TORADOLORAL	TORADOLORAL	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
,	,	,	O	O	O
causing	cause	VBG	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
another	another	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
TORADOLIV	TORADOLIV	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
IM	IM	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
two	two	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
5000	5000	CD	B-NP	O	O
U	U	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
11	11	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
template	template	NN	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6.4	6.4	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
(	(	(	O	O	O
3.2	3.2	CD	B-NP	O	O
to	to	TO	I-NP	O	O
11.4	11.4	CD	I-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6.0	6.0	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
(	(	(	O	O	O
3.4	3.4	CD	B-NP	O	O
to	to	TO	I-NP	O	O
7.5	7.5	CD	I-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
5.1	5.1	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
(	(	(	O	O	O
3.5	3.5	CD	B-NP	O	O
to	to	TO	I-NP	O	O
8.5	8.5	CD	I-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
indicate	indicate	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
heparin	heparin	NN	I-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
done	do	VBN	I-VP	O	O
extremely	extremely	RB	B-ADVP	O	O
cautiously	cautiously	RB	I-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand-EF-1
IV	IV	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
IM	IM	NN	I-NP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
normovolemic	normovolemic	JJ	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
mean	mean	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand-ME-1
ORAL	ORAL	NN	I-NP	O	O
and	and	CC	I-NP	O	O
probenecid	probenecid	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketorolac	ketorolac	NN	B-NP	O	S-drug
and	and	CC	O	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
ketorolac	ketorolac	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
total	total	JJ	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
approximately	approximately	RB	B-ADVP	O	O
threefold	threefold	RB	I-ADVP	O	O
from	from	IN	B-PP	O	O
5.4	5.4	CD	B-NP	O	O
to	to	TO	I-NP	O	O
17.8	17.8	CD	I-NP	O	O
m	m	NN	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
terminal	terminal	JJ	B-NP	B-protein	O
half	half	NN	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
approximately	approximately	RB	B-ADVP	O	O
twofold	twofold	RB	I-ADVP	O	O
from	from	IN	B-PP	O	O
6.6	6.6	CD	B-NP	O	O
to	to	TO	I-NP	O	O
15.1	15.1	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
probenecid	probenecid	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Inhibition	Inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
-	-	HYPH	O	O	O
inhibiting	inhibit	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-1
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand-ME-2
therapy	therapy	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
,	,	,	O	O	O
enhancing	enhance	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Nondepolarizing	Nondepolarize	VBG	B-VP	O	B-group
Muscle	Muscle	NNP	B-NP	O	I-group
Relaxants	Relaxant	NNPS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
postmarketing	postmarkete	VBG	B-VP	O	O
experience	experience	NN	B-NP	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
TORADOLIV	TORADOLIV	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
IM	IM	NN	I-NP	O	O
and	and	CC	O	O	O
nondepolarizing	nondepolarizing	JJ	B-NP	O	B-group
muscle	muscle	NN	I-NP	O	I-group
relaxants	relaxant	NNS	I-NP	O	E-group
that	that	WDT	B-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
apnea	apnea	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand
with	with	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
formally	formally	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

ACE	ACE	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
volume	volume	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
depleted	deplete	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Antiepileptic	Antiepileptic	JJ	B-NP	O	B-group
Drugs	Drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
Sporadic	Sporadic	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand-EF-1
and	and	CC	O	O	O
antiepileptic	antiepileptic	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-2
,	,	,	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

Psychoactive	Psychoactive	JJ	B-NP	O	B-group
Drugs	Drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
Hallucinations	Hallucination	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand-EF-1
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
psychoactive	psychoactive	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
thiothixene	thiothixene	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

Morphine	Morphine	NN	B-NP	O	S-drug
:	:	:	O	O	O
TORADOLIV	TORADOLIV	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
IM	IM	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
postoperative	postoperative	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	O
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Do	Do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
mix	mix	VB	I-VP	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
syringe	syringe	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
in	in	IN	B-PP	O	O
animal	animal	NN	B-NP	O	O
or	or	CC	O	O	O
human	human	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
that	that	IN	B-SBAR	O	O
TORADOL	TORADOL	NN	B-NP	O	S-brand
induces	induce	VBZ	B-VP	O	O
or	or	CC	I-VP	O	O
inhibits	inhibit	VBZ	I-VP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
metabolizing	metabolize	VBG	B-VP	O	O
itself	itself	PRP	B-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
L	L	NN	I-NP	O	B-drug-EF-1
-	-	HYPH	O	O	I-drug-EF-1
arginine	arginine	NN	B-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
counteract	counteract	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antinaturetic	antinaturetic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporin	cyclosporin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Ibuprofen	Ibuprofen	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
L	L	NN	I-NP	O	B-drug-ME-1
-	-	HYPH	O	O	I-drug-ME-1
arginine	arginine	NN	B-NP	O	E-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-ME-2
if	if	IN	B-SBAR	O	O
taken	take	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Organic	Organic	JJ	B-NP	O	O
nitrates	nitrate	NNS	I-NP	O	S-group
-	-	HYPH	B-NP	O	O
L	L	NN	I-NP	O	B-drug-EF-1
-	-	HYPH	B-NP	O	I-drug-EF-1
arginine	arginine	NN	I-NP	O	E-drug-EF-1
supplements	supplement	NNS	I-NP	O	O
theoretically	theoretically	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
organic	organic	JJ	B-NP	O	O
nitrates	nitrate	NNS	I-NP	O	S-drug-EF-2
if	if	IN	B-SBAR	O	O
taken	take	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Sildenafil	Sildenafil	NN	B-NP	O	B-drug
citrate	citrate	NN	I-NP	O	E-drug
-	-	HYPH	B-VP	O	O
Theoretically	Theoretically	RB	B-ADVP	O	O
,	,	,	O	O	O
L	L	NN	B-NP	O	B-drug-EF-1
-	-	HYPH	I-NP	O	I-drug-EF-1
arginine	arginine	NN	I-NP	O	E-drug-EF-1
supplements	supplement	NNS	I-NP	O	O
taken	take	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
sildenafil	sildenafil	NN	B-NP	O	B-drug-EF-2
citrate	citrate	NN	I-NP	O	E-drug-EF-2
,	,	,	O	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
nutritional	nutritional	JJ	B-NP	O	O
supplement	supplement	NN	I-NP	O	O
,	,	,	O	O	O
food	food	NN	B-NP	O	O
or	or	CC	I-NP	O	O
herb	herb	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Interacts	Interact	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug

No	No	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
known	know	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
glutamic	glutamic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug

Human	Human	JJ	B-NP	O	B-drug
growth	growth	NN	I-NP	O	I-drug
hormone	hormone	NN	I-NP	O	E-drug
-	-	HYPH	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	O	B-drug-ME-1
-	-	HYPH	O	O	I-drug-ME-1
glutamine	glutamine	NN	B-NP	O	E-drug-ME-1
and	and	CC	O	O	O
human	human	JJ	B-NP	O	B-drug-ME-2
growth	growth	NN	I-NP	O	I-drug-ME-2
hormone	hormone	NN	I-NP	O	E-drug-ME-2
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
nutrient	nutrient	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
short	short	JJ	I-NP	O	O
bowel	bowel	NN	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

L	L	NN	B-NP	O	B-drug
-	-	HYPH	O	O	I-drug
glutamine	glutamine	NN	B-NP	O	E-drug
has	have	VBZ	B-VP	O	O
orphan	orphan	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
status	status	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
indication	indication	NN	I-NP	O	O
.	.	.	O	O	O

Indomethacin	Indomethacin	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
Concomitant	Concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	O	B-drug-EF-1
-	-	HYPH	B-NP	O	I-drug-EF-1
glutamine	glutamine	NN	I-NP	O	E-drug-EF-1
and	and	CC	I-NP	O	O
indomethacin	indomethacin	NN	I-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
ameliorate	ameliorate	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
permeability	permeability	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
used	use	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
L	L	NN	B-NP	O	B-drug
-	-	HYPH	O	O	I-drug
glutamine	glutamine	NN	B-NP	O	E-drug
was	be	VBD	B-VP	O	O
21	21	CD	B-NP	O	O
grams	gram	NNS	I-NP	O	O
daily	daily	RB	B-VP	O	O
taken	take	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
divided	divide	VBN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
,	,	,	O	O	O
misoprostol	misoprostol	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
in	in	IN	B-PP	O	O
ameliorating	ameliorate	VBG	B-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
permeability	permeability	NN	I-NP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
one	one	CD	B-NP	O	O
report	report	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
supplemental	supplemental	JJ	B-NP	O	O
L	L	NN	I-NP	O	B-drug-EF-2
-	-	HYPH	O	O	I-drug-EF-2
glutamine	glutamine	NN	B-NP	O	E-drug-EF-2
for	for	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
mucositis	mucositis	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
another	another	DT	B-NP	O	O
report	report	NN	I-NP	O	O
,	,	,	O	O	O
nine	nine	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
decreased	decrease	VBN	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-EF-1
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
supplemental	supplemental	JJ	B-NP	O	O
L	L	NN	I-NP	O	B-drug-EF-2
-	-	HYPH	O	O	I-drug-EF-2
glutamine	glutamine	NN	B-NP	O	E-drug-EF-2
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
gram	gram	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kilogram	kilogram	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Paclitaxel	Paclitaxel	NN	B-NP	O	S-drug
-	-	HYPH	B-ADJP	O	O
In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
report	report	NN	I-NP	O	O
,	,	,	O	O	O
L	L	NN	B-NP	O	B-drug-EF-1
-	-	HYPH	O	O	I-drug-EF-1
glutamine	glutamine	NN	B-NP	O	E-drug-EF-1
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
grams	gram	NNS	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
daily	daily	RB	I-NP	O	O
,	,	,	O	O	O
given	give	VBN	B-VP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
receiving	receive	VBG	B-VP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myalgia	myalgia	NN	B-NP	O	O
and	and	CC	I-NP	O	O
arthralgia	arthralgia	NN	I-NP	O	O
,	,	,	O	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug
.	.	.	O	O	O

Medroxyprogesterone	Medroxyprogesterone	NN	B-NP	O	B-drug
Acetate	Acetate	NN	I-NP	O	E-drug
-	-	HYPH	B-NP	O	O
L	L	NN	I-NP	O	B-drug-EF-1
-	-	HYPH	B-NP	O	I-drug-EF-1
histidine	histidine	NN	I-NP	O	E-drug-EF-1
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
enhance	enhance	VB	I-VP	O	O
(	(	(	O	O	O
in	in	IN	B-PP	O	O
tissue	tissue	NN	B-NP	O	O
culture	culture	NN	I-NP	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
medroxyprogesterone	medroxyprogesterone	NN	B-NP	O	B-drug-EF-2
acetate	acetate	NN	I-NP	O	E-drug-EF-2
in	in	IN	B-PP	O	O
reducing	reduce	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
breast	breast	NN	I-NP	I-cell_type	O
cancer	cancer	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
that	that	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
S	S	NN	I-NP	O	O
phase	phase	NN	I-NP	O	O
.	.	.	O	O	O

H1	H1	NN	B-NP	O	S-group
and	and	CC	I-NP	O	O
H2	H2	NN	I-NP	O	B-group
Blockers	Blocker	NNS	I-NP	O	E-group
-	-	:	O	O	O
Although	Although	IN	O	O	O
not	not	RB	O	O	O
reported	report	VBN	B-VP	O	O
,	,	,	O	O	O
L	L	NN	B-NP	O	B-drug-EF-1
-	-	HYPH	O	O	I-drug-EF-1
histidine	histidine	NN	B-NP	O	E-drug-EF-1
,	,	,	O	O	O
via	via	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
to	to	TO	B-PP	O	O
histamine	histamine	NN	B-NP	O	O
,	,	,	O	O	O
might	might	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
H1	H1	NN	B-NP	B-protein	S-group-EF-2
and	and	CC	I-NP	O	O
H2	H2	NN	I-NP	O	B-group-EF-2
blockers	blocker	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-1
supplements	supplement	NNS	I-NP	O	O
and	and	CC	O	O	O
L	L	NN	B-NP	O	B-drug-ME-2
-	-	HYPH	O	O	I-drug-ME-2
lysine	lysine	NN	B-NP	O	E-drug-ME-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
calcium	calcium	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O

Acetaminophen	Acetaminophen	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
L	L	NN	I-NP	O	B-drug-EF-1
-	-	HYPH	B-NP	O	I-drug-EF-1
methionine	methionine	NN	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-EF-2
overdosage	overdosage	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
taking	take	VBG	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Theoretically	Theoretically	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
potential	potential	JJ	I-NP	O	O
hepatotoxic	hepatotoxic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-ADVP	O	O
well	well	RB	I-ADVP	O	O
.	.	.	O	O	O

Gentamicin	Gentamicin	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
Methionine	Methionine	NN	I-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
protect	protect	VB	I-VP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ototoxic	ototoxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
selective	selective	JJ	I-NP	O	I-group
monoamine	monoamine	NN	I-NP	O	I-group
oxidase	oxidase	NN	I-NP	O	I-group
(	(	(	O	O	I-group
MAO	MAO	NN	B-NP	O	I-group
)	)	)	O	O	I-group
inhibitors	inhibitor	NNS	B-NP	O	E-group
-	-	HYPH	B-PP	O	O
including	include	VBG	B-PP	O	O
phenelzine	phenelzine	NN	B-NP	O	B-drug
sulfate	sulfate	NN	I-NP	O	E-drug
,	,	,	O	O	O
tranylcypromine	tranylcypromine	NN	B-NP	O	B-drug
sulfate	sulfate	NN	I-NP	O	E-drug
and	and	CC	O	O	O
pargyline	pargyline	NN	B-NP	O	S-drug
HC1	HC1	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	O	B-drug-EF-1
-	-	HYPH	O	O	I-drug-EF-1
phenylalanine	phenylalanine	NN	B-NP	O	E-drug-EF-1
and	and	CC	O	O	O
non	non	AFX	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
selective	selective	JJ	I-NP	O	I-group-EF-2
MAO	MAO	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypertension	hypertension	NN	B-NP	O	O
.	.	.	O	O	O

Selegiline	Selegiline	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
L	L	NN	I-NP	O	B-drug-EF-1
-	-	HYPH	O	O	I-drug-EF-1
phenylalanine	phenylalanine	NN	B-NP	O	E-drug-EF-1
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	B-group
MAO	MAO	NN	I-NP	O	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
selegiline	selegiline	NN	I-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
synergistic	synergistic	JJ	B-NP	O	O
antidepressant	antidepressant	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
used	use	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Neuroleptic	Neuroleptic	JJ	B-NP	O	B-group-EF-1
Drugs	Drug	NNS	I-NP	O	E-group-EF-1
-	-	HYPH	B-NP	O	O
L	L	NN	I-NP	O	B-drug-EF-2
-	-	HYPH	B-NP	O	I-drug-EF-2
phenylalanine	phenylalanine	NN	I-NP	O	E-drug-EF-2
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
tardive	tardive	JJ	I-NP	O	O
dyskinesia	dyskinesia	NN	I-NP	O	O
side	side	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
if	if	IN	B-SBAR	O	O
used	use	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
.	.	.	O	O	O

Monoamine	Monoamine	NN	B-NP	B-protein	B-group
oxidase	oxidase	NN	I-NP	I-protein	I-group
(	(	(	O	O	I-group
MAO	MAO	NN	B-NP	O	I-group
)	)	)	O	O	I-group
inhibitors	inhibitor	NNS	B-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
isocarboxazid	isocarboxazid	NN	B-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Marplan	Marplan	NNP	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
phenelzine	phenelzine	NN	B-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Nardil	Nardil	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
procarbazine	procarbazine	NN	B-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Matulane	Matulane	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
selegiline	selegiline	NN	B-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Eldepryl	Eldepryl	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
tranylcypromine	tranylcypromine	NN	B-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Parnate	Parnate	NNP	B-NP	O	S-brand
)	)	)	O	O	O
:	:	:	O	O	O
Using	Use	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
L	L	NN	B-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
tryptophan	tryptophan	NN	I-NP	O	E-drug
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
selective	selective	JJ	I-NP	O	I-group
MAO	MAO	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
including	include	VBG	B-PP	O	O
tranylcypromine	tranylcypromine	NN	B-NP	O	B-drug
sulfate	sulfate	NN	I-NP	O	E-drug
,	,	,	O	O	O
phenelzine	phenelzine	NN	B-NP	O	B-drug
sulfate	sulfate	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
pargyline	pargyline	NN	B-NP	O	S-drug
HC1	HC1	NN	I-NP	O	O
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	O	B-drug-EF-1
-	-	HYPH	O	O	I-drug-EF-1
tyrosine	tyrosine	NN	B-NP	O	E-drug-EF-1
and	and	CC	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
selective	selective	JJ	I-NP	O	O
MAO	MAO	NN	I-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypertension	hypertension	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
survey	survey	NN	I-NP	O	O
,	,	,	O	O	O
2.3	2.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
labetalol	labetalol	NN	B-NP	O	B-drug-EF-1
HCl	HCl	NN	I-NP	O	E-drug-EF-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
experienced	experience	VBD	B-VP	O	O
tremor	tremor	NN	B-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
0.7	0.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
reported	report	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
labetalol	labetalol	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
contribution	contribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
excluded	exclude	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
possessing	possess	VBG	B-VP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-PP	O	O
blocking	block	VBG	B-NP	O	O
properties	property	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
blunt	blunt	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bronchodilator	bronchodilator	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
receptor	receptor	NN	I-NP	O	I-group
agonist	agonist	NN	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
bronchospasm	bronchospasm	NN	B-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
doses	dose	VBZ	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
antiasthmatic	antiasthmatic	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	O	O	I-group
agonist	agonist	NN	B-NP	O	I-group
bronchodilator	bronchodilator	NN	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
labetalol	labetalol	NN	B-NP	O	B-drug-ME-2
HCl	HCl	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
explained	explain	VBN	I-VP	O	O
either	either	CC	O	O	O
by	by	IN	B-PP	O	O
enhanced	enhance	VBN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
or	or	CC	B-PP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
labetalol	labetalol	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
,	,	,	O	O	O
special	special	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
establishing	establish	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
required	require	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
control	control	NN	I-NP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Synergism	Synergism	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug-EF-1
anesthesia	anesthesia	NN	I-NP	O	O
and	and	CC	O	O	O
intravenously	intravenously	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
labetalol	labetalol	NN	I-NP	O	B-drug-EF-2
HCl	HCl	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

During	During	IN	B-PP	O	O
controlled	control	VBN	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
labetalol	labetalol	NN	B-NP	O	B-drug-EF-1
HCl	HCl	NN	I-NP	O	E-drug-EF-1
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
or	or	CC	B-PP	O	O
above	above	IN	B-PP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
and	and	CC	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
venous	venous	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
anesthesiologist	anesthesiologist	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
informed	inform	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
labetalol	labetalol	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
.	.	.	O	O	O

Labetalol	Labetalol	NN	B-NP	O	B-drug-EF-1
HCl	HCl	NN	I-NP	O	E-drug-EF-1
blunts	blunt	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
reflex	reflex	NN	I-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
nitroglycerin	nitroglycerin	NN	B-NP	O	S-drug-EF-2
without	without	IN	B-PP	O	O
preventing	prevent	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
labetalol	labetalol	NN	B-NP	O	B-drug-EF-1
HCl	HCl	NN	I-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
nitroglycerin	nitroglycerin	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
angina	angina	NN	B-NP	O	O
pectoris	pectoris	NN	I-NP	O	O
,	,	,	O	O	O
additional	additional	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Care	Care	NNP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
labetalol	labetalol	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	B-group-AD-2
antagonists	antagonist	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug
type	type	NN	I-NP	O	O
.	.	.	O	O	O

Risk	Risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Anaphylactic	Anaphylactic	JJ	B-NP	B-protein	O
Reaction	Reaction	NN	I-NP	I-protein	O
While	While	IN	B-SBAR	I-protein	O
taking	take	VBG	B-VP	I-protein	O
beta	beta	SYM	B-NP	I-protein	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
anaphylactic	anaphylactic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allergens	allergen	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
reactive	reactive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
,	,	,	O	O	O
either	either	CC	O	O	O
accidental	accidental	JJ	B-NP	O	O
,	,	,	I-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
or	or	CC	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
unresponsive	unresponsive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
allergic	allergic	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
The	The	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
labetalol	labetalol	NN	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
falsely	falsely	RB	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
catecholamines	catecholamine	NNS	I-NP	O	O
,	,	,	O	O	O
metanephrine	metanephrine	NN	B-NP	O	O
,	,	,	O	O	O
normetanephrine	normetanephrine	NN	B-NP	O	O
and	and	CC	O	O	O
vanillylmandelic	vanillylmandelic	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
fluorimetric	fluorimetric	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
photometric	photometric	JJ	I-NP	O	O
methods	method	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
screening	screening	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
suspected	suspect	VBN	B-VP	O	O
of	of	IN	B-PP	O	O
having	have	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
pheochromocytoma	pheochromocytoma	NN	I-NP	O	O
and	and	CC	O	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
labetalol	labetalol	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
performance	performance	NN	I-NP	O	O
liquid	liquid	JJ	I-NP	O	O
chromatographic	chromatographic	JJ	I-NP	O	O
assay	assay	NN	I-NP	O	O
with	with	IN	B-PP	O	O
solid	solid	JJ	B-NP	O	O
phase	phase	NN	I-NP	O	O
extraction	extraction	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
J	J	NNP	B-NP	O	O
Chromatogr	Chromatogr	NNP	I-NP	O	O
385	385	CD	I-NP	O	O
:	:	:	O	O	O
241,1987	241,1987	CD	B-NP	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
employed	employ	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
determining	determine	VBG	B-VP	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
.	.	.	O	O	O

Labetalol	Labetalol	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
positive	positive	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
screening	screen	VBG	B-VP	O	O
urine	urine	NN	B-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
commercially	commercially	RB	I-NP	O	O
available	available	JJ	I-NP	O	O
assay	assay	NN	I-NP	O	O
methods	method	NNS	I-NP	O	O
Toxi	Toxi	AFX	O	B-protein	O
-	-	HYPH	O	O	O
Lab	Lab	NN	B-NP	B-protein	O
A	A	NN	I-NP	I-protein	O
(	(	(	O	O	O
thin	thin	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
layer	layer	NN	I-NP	O	O
chromatographic	chromatographic	JJ	I-NP	O	O
assay	assay	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Emit	Emit	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
d.a.u	d.a.u	NN	I-NP	O	O
.	.	.	O	O	O
(	(	(	O	O	O
radioenzymatic	radioenzymatic	JJ	B-NP	O	O
assay	assay	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
labetalol	labetalol	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
urine	urine	NN	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
using	use	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
techniques	technique	NNS	I-NP	O	O
confirmation	confirmation	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
more	more	JJR	B-NP	O	O
specific	specific	JJ	I-NP	O	O
methods	method	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
a	a	DT	B-NP	O	O
gas	gas	NN	I-NP	B-DNA	O
chromatographic	chromatographic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
mass	mass	NN	I-NP	O	O
spectrometer	spectrometer	NN	I-NP	O	O
technique	technique	NN	I-NP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
preliminary	preliminary	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
rats	rat	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
nonabsorbable	nonabsorbable	JJ	B-NP	O	O
antacids	antacid	NNS	I-NP	O	S-group-ME-1
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
lactulose	lactulose	NN	B-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
lactulose	lactulose	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
drop	drop	NN	I-NP	O	O
in	in	IN	B-PP	O	O
colonic	colonic	JJ	B-NP	O	O
pH	pH	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
desired	desire	VBN	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
consideration	consideration	NN	B-NP	O	O
before	before	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
lactulose	lactulose	NN	B-NP	O	S-drug
.	.	.	O	O	O

Lamivudine	Lamivudine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
predominantly	predominantly	RB	I-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
by	by	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
organic	organic	JJ	I-NP	O	O
cationic	cationic	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
their	their	PRP$	B-NP	O	O
main	main	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
of	of	IN	B-PP	O	O
elimination	elimination	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
active	active	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
organic	organic	JJ	I-NP	O	O
cationic	cationic	JJ	I-NP	O	O
transport	transport	NN	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
trimethoprim	trimethoprim	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
information	information	NN	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TMP	TMP	NN	B-NP	B-protein	S-drug
/	/	SYM	B-NP	O	O
SMX	SMX	NN	I-NP	O	S-drug
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
those	those	DT	B-NP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
Pneumocystis	Pneumocystis	NNP	B-NP	O	O
carinii	carinii	NN	I-NP	O	O
pneumonia	pneumonia	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
regarding	regard	VBG	B-VP	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
renal	renal	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Lamivudine	Lamivudine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
zalcitabine	zalcitabine	NN	I-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
intracellular	intracellular	JJ	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
another	another	DT	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug-AD-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O

Lansoprazole	Lansoprazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
specifically	specifically	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP3A	CYP3A	NN	I-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2C19	CYP2C19	NN	I-NP	B-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
lansoprazole	lansoprazole	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
prednisone	prednisone	NN	B-NP	O	S-drug
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
including	include	VBG	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
lansoprazole	lansoprazole	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
minor	minor	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
direction	direction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
concern	concern	NN	I-NP	O	O
.	.	.	O	O	O

Nonetheless	Nonetheless	RB	B-ADVP	O	O
,	,	,	O	O	O
individual	individual	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
additional	additional	JJ	B-NP	O	O
titration	titration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-AD-1
dosage	dosage	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
lansoprazole	lansoprazole	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
started	start	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
stopped	stop	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
ensure	ensure	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
effective	effective	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Lansoprazole	Lansoprazole	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
no	no	RB	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
amoxicillin	amoxicillin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
examining	examine	VBG	B-VP	O	O
lansoprazole	lansoprazole	NN	B-NP	O	S-drug
30	30	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
omeprazole	omeprazole	NN	I-NP	O	S-drug
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
each	each	DT	B-NP	O	O
administered	administer	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
and	and	CC	I-ADVP	O	O
concomitantly	concomitantly	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug
1	1	CD	I-NP	O	O
gram	gram	NN	I-NP	O	O
,	,	,	O	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
proton	proton	NN	I-NP	O	B-group-ME-1
pump	pump	NN	I-NP	O	I-group-ME-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-ME-1
was	be	VBD	B-VP	O	O
delayed	delay	VBN	I-VP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
proton	proton	NN	B-NP	O	B-group-AD-1
pump	pump	NN	I-NP	O	I-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
30	30	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
sucralfate	sucralfate	VB	I-VP	O	S-drug-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
antacids	antacid	NNS	B-NP	O	S-group
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
lansoprazole	lansoprazole	NN	B-NP	O	S-drug
delayed	delay	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
release	release	NN	I-NP	O	O
capsules	capsule	NNS	I-NP	O	O
;	;	:	O	O	O

this	this	DT	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Lansoprazole	Lansoprazole	NN	B-NP	O	S-drug
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
profound	profound	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
long	long	JJ	I-NP	O	O
lasting	lasting	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastric	gastric	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
theoretically	theoretically	RB	B-ADJP	O	O
possible	possible	JJ	I-ADJP	O	O
that	that	IN	B-SBAR	O	O
lansoprazole	lansoprazole	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
where	where	WRB	B-ADVP	O	O
gastric	gastric	JJ	B-NP	O	O
pH	pH	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
determinant	determinant	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug-ME-2
esters	ester	NNS	I-NP	O	O
,	,	,	O	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
salts	salt	NNS	I-NP	O	O
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Lapatinib	Lapatinib	NNP	B-NP	O	S-drug
on	on	IN	B-PP	O	O
Drug	Drug	NNP	B-NP	O	O
Metabolizing	Metabolizing	NNP	I-NP	O	O
Enzymes	Enzymes	NNP	I-NP	O	O
and	and	CC	O	O	O
Drug	Drug	NNP	B-NP	O	O
Transport	Transport	NNP	I-NP	O	O
Systems	Systems	NNP	I-NP	O	O
Lapatinib	Lapatinib	NNP	I-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2C8	CYP2C8	NN	I-NP	B-protein	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
at	at	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
and	and	CC	O	O	O
dose	dose	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
substrate	substrate	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
dosing	dosing	NN	B-NP	O	O
lapatinib	lapatinib	NN	I-NP	O	S-drug
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
narrow	narrow	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
windows	window	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
or	or	CC	I-NP	O	O
CYP2C8	CYP2C8	NN	I-NP	B-protein	O
.	.	.	O	O	O

Lapatinib	Lapatinib	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
:	:	:	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
or	or	CC	I-NP	O	O
UGT	UGT	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Lapatinib	Lapatinib	NN	B-NP	B-protein	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
human	human	JJ	B-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
TYKERB	TYKERB	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Pgp	Pgp	NN	B-NP	B-protein	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
Inhibit	Inhibit	VBP	B-VP	O	O
or	or	CC	I-VP	O	O
Induce	Induce	VBP	I-VP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
Enzymes	Enzyme	NNS	I-NP	I-protein	O
Lapatinib	Lapatinib	NN	I-NP	B-protein	S-drug
undergoes	undergo	VBZ	B-VP	O	O
extensive	extensive	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
strong	strong	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
alter	alter	VBP	B-VP	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
must	must	MD	B-VP	O	O
receive	receive	VB	I-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
strong	strong	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
or	or	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
strong	strong	JJ	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
systemic	systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
3.6	3.6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
and	and	CC	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
1.7	1.7	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducer	inducer	NN	I-NP	O	O
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
at	at	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
and	and	CC	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
17	17	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
systemic	systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
approximately	approximately	RB	B-NP	O	O
72	72	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	IN	B-SBAR	O	O
Inhibit	Inhibit	NNP	B-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Transport	Transport	NNP	I-NP	O	O
Systems	Systems	NNP	I-NP	O	O
Lapatinib	Lapatinib	NNP	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
efflux	efflux	NN	I-NP	O	O
transporter	transporter	NN	I-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	O	O	O
glycoprotein	glycoprotein	NN	B-NP	B-protein	O
(	(	(	O	O	O
Pgp	Pgp	NN	B-NP	B-protein	O
,	,	,	O	O	O
ABCB1	ABCB1	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
TYKERB	TYKERB	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
Pgp	Pgp	NN	B-NP	B-protein	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Chemotherapy	Chemotherapy	NNP	I-NP	O	O
Agents	Agent	NNPS	I-NP	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
separate	separate	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
capecitabine	capecitabine	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
meaningfully	meaningfully	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
agent	agent	NN	B-NP	O	O
(	(	(	O	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
capecitabine	capecitabine	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
precipitation	precipitation	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
when	when	WRB	B-ADVP	O	O
eye	eye	NN	B-NP	O	O
drops	drop	VBZ	B-VP	O	O
containing	contain	VBG	I-VP	O	O
thimerosal	thimerosal	NN	B-NP	O	S-drug_n
are	be	VBP	B-VP	O	O
mixed	mix	VBN	B-ADJP	O	O
with	with	IN	B-PP	O	O
latanoprost	latanoprost	NN	B-NP	O	S-drug
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
5	5	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
applications	application	NNS	B-NP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Charcoal	Charcoal	NN	I-NP	O	S-drug
Administration	Administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-ME-1
or	or	CC	O	O	O
activated	activate	VBN	B-VP	O	B-drug-ME-1
charcoal	charcoal	NN	B-NP	O	E-drug-ME-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
13	13	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
volunteers	volunteer	NNS	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
96	96	CD	B-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
M1	M1	NN	I-NP	O	O
(	(	(	O	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
leflunomide	leflunomide	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
concentration	concentration	NN	B-NP	O	O
.	.	.	O	O	O

Hepatotoxic	Hepatotoxic	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
Increased	Increase	VBD	B-VP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
leflunomide	leflunomide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
hepatotoxic	hepatotoxic	JJ	B-NP	O	O
substances	substance	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
also	also	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
leflunomide	leflunomide	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
30	30	CD	B-NP	O	O
)	)	)	O	O	O
combination	combination	NN	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ARAVA	ARAVA	NN	B-NP	B-protein	S-brand-EF-1
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
5	5	CD	B-NP	O	O
of	of	IN	B-PP	O	O
30	30	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
resolved	resolve	VBD	B-VP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
with	with	IN	B-PP	O	O
continuation	continuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
after	after	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
leflunomide	leflunomide	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
another	another	DT	B-NP	O	O
5	5	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
also	also	RB	I-NP	O	O
resolved	resolve	VBN	I-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
with	with	IN	B-PP	O	O
continuation	continuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
after	after	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
leflunomide	leflunomide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
met	meet	VBD	B-VP	O	O
ACR	ACR	NN	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
biopsy	biopsy	NN	I-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
:	:	:	O	O	O
Roegnik	Roegnik	NNP	B-NP	O	O
Grade	Grade	NNP	I-NP	O	O
I	I	NNP	I-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
:	:	:	O	O	O
Roegnik	Roegnik	NNP	B-NP	O	O
Grade	Grade	NNP	I-NP	O	O
IIIa	IIIa	NNP	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

NSAIDs	NSAID	NNS	B-NP	O	S-group
:	:	:	O	O	O
In	In	FW	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
M1	M1	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
increases	increase	NNS	B-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
13	13	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
free	free	JJ	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ibuprofen	ibuprofen	NN	I-NP	O	S-drug
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
extensive	extensive	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
differential	differential	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Tolbutamide	Tolbutamide	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
M1	M1	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
increases	increase	NNS	B-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
13	13	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
free	free	JJ	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Following	Follow	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ARAVA	ARAVA	NN	B-NP	B-protein	S-brand-ME-1
to	to	TO	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
M1	M1	NN	B-NP	O	O
peak	peak	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
(	(	(	O	O	O
~	~	SYM	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
over	over	IN	B-PP	O	O
those	those	DT	B-NP	O	O
seen	see	VBN	B-VP	O	O
when	when	WRB	B-ADVP	O	O
ARAVA	ARAVA	NN	B-NP	B-protein	S-brand
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ARAVA	ARAVA	NN	B-NP	B-protein	S-brand
levels	level	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
continue	continue	VB	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
both	both	CC	O	O	O
ARAVA	ARAVA	NN	B-NP	B-protein	S-brand-AD-1
and	and	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
INR	INR	NN	I-NP	B-protein	O
(	(	(	O	O	O
International	International	NNP	B-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
ARAVA	ARAVA	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	B-VP	O	O
administered	administer	VBN	I-VP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
rarely	rarely	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
and	and	CC	O	O	O
nonclinical	nonclinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
REVLIMID	REVLIMID	NN	B-NP	O	S-brand
(	(	(	O	O	O
lenalidomide	lenalidomide	NN	B-NP	O	S-drug
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
neither	neither	DT	B-NP	O	O
metabolized	metabolize	VBN	B-ADJP	O	O
by	by	IN	B-PP	O	O
nor	nor	CC	O	O	O
inhibits	inhibit	VBZ	B-VP	O	O
or	or	CC	I-VP	O	O
induces	induce	VBZ	I-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
pathway	pathway	NN	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
lenalidomide	lenalidomide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
or	or	CC	I-VP	O	O
be	be	VB	I-VP	O	O
subject	subject	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
based	base	VBN	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lenalidomide	lenalidomide	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
R	R	NN	B-NP	B-protein	B-drug
-	-	HYPH	B-NP	O	E-drug
and	and	CC	I-NP	O	O
S	S	NN	I-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
warfarin	warfarin	NN	I-NP	O	E-drug
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
25	25	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
lenalidomide	lenalidomide	NN	I-NP	O	S-drug
.	.	.	O	O	O

Expected	Expect	VBN	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
laboratory	laboratory	NN	B-NP	O	O
assessments	assessment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PT	PT	NN	B-NP	O	O
and	and	CC	I-NP	O	O
INR	INR	NN	I-NP	B-protein	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
these	these	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
lenalidomide	lenalidomide	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
thrombolytics	thrombolytic	NNS	B-NP	O	S-group
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
rt	rt	NN	B-NP	O	O
-	-	HYPH	O	O	O
PA	PA	NN	B-NP	O	O
or	or	CC	O	O	O
streptokinase	streptokinase	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
may	may	MD	B-VP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
complications	complication	NNS	B-NP	O	O
-	-	:	O	O	O
considerably	considerably	RB	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
REFLUDAN	REFLUDAN	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
aPTT	aPTT	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group
derivatives	derivative	NNS	I-NP	O	E-group
(	(	(	O	O	O
vitamin	vitamin	NN	B-NP	O	B-group
K	K	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
)	)	)	O	O	O
and	and	CC	O	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
affect	affect	VBP	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Femara	Femara	NNP	B-NP	O	S-brand
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
-	-	HYPH	I-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
See	See	VB	B-VP	O	O
CLINICAL	CLINICAL	NN	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
)	)	)	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Femara	Femara	NNP	B-NP	O	S-brand-ME-1
and	and	CC	O	O	O
tamoxifen	tamoxifen	NN	B-NP	O	S-drug-ME-2
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
letrozole	letrozole	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
on	on	IN	B-PP	O	O
average	average	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
experience	experience	NN	I-NP	O	O
to	to	TO	B-PP	O	O
date	date	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Femara	Femara	NNP	B-NP	O	S-brand
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticancer	anticancer	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	O	O	O
Laboratory	Laboratory	NN	B-NP	O	O
Test	Test	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
None	None	NN	I-NP	O	O
observed	observe	VBN	B-VP	O	O
.	.	.	O	O	O

Folic	Folic	JJ	B-NP	O	B-drug-EF-1
acid	acid	NN	I-NP	O	E-drug-EF-1
in	in	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
amounts	amount	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
counteract	counteract	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antiepileptic	antiepileptic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-EF-2
,	,	,	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
primidone	primidone	NN	I-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
susceptible	susceptible	JJ	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Preliminary	Preliminary	JJ	B-NP	O	O
animal	animal	NN	I-NP	O	O
and	and	CC	O	O	O
human	human	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
small	small	JJ	B-NP	O	O
quantities	quantity	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
systemically	systemically	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
leucovorin	leucovorin	NN	I-NP	O	S-drug
enter	enter	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
CSF	CSF	NN	I-NP	B-protein	O
primarily	primarily	RB	B-ADVP	O	O
as	as	IN	B-PP	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
methyltetrahydro	methyltetrahydro	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
folate	folate	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
,	,	,	O	O	O
remain	remain	VBP	B-VP	O	O
1	1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
3	3	CD	I-NP	O	O
orders	order	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
magnitude	magnitude	NN	B-NP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
leucovorin	leucovorin	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intrathecally	intrathecally	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Leucovorin	Leucovorin	NN	B-NP	B-protein	S-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	B-drug-EF-2
-	-	HYPH	I-NP	O	I-drug-EF-2
fluorouracil	fluorouracil	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

ERGAMISOL	ERGAMISOL	NN	B-NP	O	S-brand-EF-1
(	(	(	O	O	O
levamisole	levamisole	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
ANTABUSE	ANTABUSE	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
monitor	monitor	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
beyond	beyond	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
levamisole	levamisole	NN	I-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	B-drug-AD-2
sodium	sodium	NN	I-NP	O	E-drug-AD-2
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
coumarin	coumarin	NN	I-NP	O	S-group
-	-	HYPH	B-VP	O	O
like	like	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
Keppra	Keppra	NNP	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
produce	produce	VB	I-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
be	be	VB	B-VP	O	O
subject	subject	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
,	,	,	O	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Levetiracetam	Levetiracetam	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
major	major	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
well	well	RB	B-PP	O	O
above	above	IN	I-PP	O	O
cmax	cmax	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
achieved	achieve	VBN	B-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
range	range	NN	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
neither	neither	DT	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nor	nor	CC	B-NP	O	O
high	high	JJ	I-NP	O	O
affinity	affinity	NN	I-NP	O	O
substrates	substrate	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
human	human	JJ	B-NP	B-protein	O
liver	liver	NN	I-NP	I-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P450	P450	NN	I-NP	I-protein	O
isoforms	isoform	NNS	I-NP	I-protein	O
,	,	,	O	O	O
epoxide	epoxide	NN	B-NP	B-protein	O
hydrolase	hydrolase	NN	I-NP	I-protein	O
or	or	CC	I-NP	O	O
UDP	UDP	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
glucuronidation	glucuronidation	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
glucuronidation	glucuronidation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
.	.	.	O	O	O

Levetiracetam	Levetiracetam	NNP	B-NP	O	S-drug
circulates	circulate	VBZ	B-VP	O	O
largely	largely	RB	B-ADJP	O	O
unbound	unbound	JJ	I-ADJP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
bound	bind	VBN	B-VP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
;	;	:	O	O	O

clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
through	through	IN	B-PP	O	O
competition	competition	NN	B-NP	O	O
for	for	IN	B-PP	O	O
protein	protein	NN	B-NP	B-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
are	be	VBP	B-VP	O	O
therefore	therefore	RB	B-ADVP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
(	(	(	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
valproate	valproate	NN	B-NP	O	S-drug
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
through	through	IN	B-PP	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
screening	screening	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
Between	Between	NNP	I-NP	O	O
Keppra	Keppra	NNP	I-NP	O	S-brand
And	And	NNP	I-NP	O	O
Other	Other	NNP	I-NP	O	O
Antiepileptic	Antiepileptic	NNP	I-NP	O	B-group
Drugs	Drugs	NNP	I-NP	O	E-group
(	(	(	O	O	O
AEDs	AEDs	NNP	O	O	S-group
)	)	)	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug
Keppra	Keppra	NN	I-NP	O	S-brand
(	(	(	O	O	O
3000	3000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
refractory	refractory	JJ	B-NP	O	O
epilepsy	epilepsy	NN	I-NP	O	O
.	.	.	O	O	O

Pharmacokinetics	Pharmacokinetic	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Valproate	Valproate	NNP	B-NP	O	S-drug
Keppra	Keppra	NNP	I-NP	O	S-brand
(	(	(	O	O	O
1500	1500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
valproate	valproate	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	O	S-drug
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
modify	modify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
or	or	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
or	or	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
also	also	RB	B-ADVP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
ucb	ucb	NN	B-NP	O	O
L057	L057	NN	I-NP	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
Keppra	Keppra	NNP	B-NP	O	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
AEDs	AED	NNS	I-NP	O	S-group
(	(	(	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
gabapentin	gabapentin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
lamotrigine	lamotrigine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
primidone	primidone	NN	B-NP	O	S-drug
and	and	CC	O	O	O
valproate	valproate	NN	B-NP	O	S-drug
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
assessed	assess	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
evaluating	evaluate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
AEDs	AED	NNS	I-NP	O	S-group
during	during	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
AEDs	AED	NNS	I-NP	O	S-group
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
AEDs	AED	NNS	I-NP	O	S-group
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
AEDs	AED	NNS	B-NP	O	S-group
in	in	IN	B-PP	O	O
Pediatric	Pediatric	NNP	B-NP	O	O
Patients	Patient	NNPS	I-NP	O	O
There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
about	about	IN	B-NP	O	O
a	a	DT	I-NP	O	O
22	22	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
apparent	apparent	JJ	B-NP	O	O
total	total	JJ	I-NP	O	O
body	body	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug-ME-1
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
enzyme	enzyme	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
inducing	induce	VBG	B-VP	O	O
AEDs	AED	NNS	B-NP	O	S-group-ME-2
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
recommended.Levetiracetam	recommended.Levetiracetam	NN	B-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
valproate	valproate	NN	B-NP	O	S-drug
,	,	,	O	O	O
topiramate	topiramate	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
lamotrigine	lamotrigine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
Oral	Oral	NNP	I-NP	O	O
Contraceptives	Contraceptive	NNPS	I-NP	O	S-group
Keppra	Keppra	NNP	I-NP	O	S-brand
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group
containing	contain	VBG	B-VP	O	O
0.03	0.03	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	O	O	O
0.15	0.15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
levonorgestrel	levonorgestrel	NN	I-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
luteinizing	luteinize	VBG	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
and	and	CC	I-NP	O	O
progesterone	progesterone	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
impairment	impairment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
contraceptive	contraceptive	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Digoxin	Digoxin	NNP	B-NP	O	S-drug
Keppra	Keppra	NNP	I-NP	O	S-brand
(	(	(	O	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
(	(	(	O	O	O
ECG	ECG	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
0.25	0.25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
every	every	DT	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Warfarin	Warfarin	NNP	B-NP	O	S-drug
Keppra	Keppra	NNP	I-NP	O	S-brand
(	(	(	O	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
R	R	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
S	S	NN	I-NP	O	B-drug
warfarin	warfarin	NN	I-NP	O	E-drug
.	.	.	O	O	O

Prothrombin	Prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
Probenecid	Probenecid	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
blocking	block	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
administered	administer	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
four	four	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	O	S-drug
1000	1000	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
.	.	.	O	O	O

Cssmax	Cssmax	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
ucb	ucb	NN	B-NP	B-protein	O
L057	L057	NN	I-NP	I-protein	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
approximately	approximately	RB	I-VP	O	O
doubled	double	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
excreted	excrete	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
remained	remain	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ucb	ucb	NN	B-NP	B-protein	O
L057	L057	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
decreased	decrease	VBD	B-VP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
probably	probably	RB	B-ADVP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
competitive	competitive	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ucb	ucb	NN	B-NP	B-protein	O
L057	L057	NN	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Keppra	Keppra	NNP	B-NP	O	S-brand
on	on	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
BETAGAN	BETAGAN	NN	B-NP	O	S-brand
used	use	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
has	have	VBZ	B-VP	O	O
little	little	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
no	no	DT	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
pupil	pupil	NN	B-NP	O	O
size	size	NN	I-NP	O	O
,	,	,	O	O	O
mydriasis	mydriasis	NN	B-NP	O	O
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
BETAGAN	BETAGAN	NN	B-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Close	Close	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
blocker	blocker	NN	I-NP	O	E-group-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
catecholamine	catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
possible	possible	JJ	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
production	production	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
marked	marked	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
vertigo	vertigo	RB	B-ADVP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
or	or	CC	O	O	O
postural	postural	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	B-protein	O
receiving	receive	VBG	B-VP	I-protein	O
beta	beta	SYM	B-NP	I-protein	B-group-AD-1
-	-	HYPH	B-PP	O	I-group-AD-1
adrenergic	adrenergic	JJ	B-NP	O	I-group-AD-1
blocking	block	VBG	I-NP	O	I-group-AD-1
agents	agent	NNS	I-NP	O	E-group-AD-1
along	along	IN	B-PP	O	O
with	with	IN	B-PP	O	O
either	either	CC	B-NP	O	O
oral	oral	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
calcium	calcium	NN	I-NP	O	B-group-AD-2
antagonists	antagonist	NNS	I-NP	O	E-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
atrioventricular	atrioventricular	JJ	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
,	,	,	O	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
failure	failure	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
altogether	altogether	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-1
blocking	block	VBG	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
with	with	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-2
and	and	CC	I-NP	O	O
calcium	calcium	NN	I-NP	O	B-group-EF-2
antagonists	antagonist	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
prolonging	prolong	VBG	B-VP	O	O
atrioventricular	atrioventricular	JJ	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Phenothiazine	Phenothiazine	NN	B-NP	O	B-group-ME-1
-	-	HYPH	B-NP	O	I-group-ME-1
related	relate	VBN	I-NP	O	I-group-ME-1
compounds	compound	NNS	I-NP	O	E-group-ME-1
and	and	CC	O	O	O
beta	beta	SYM	B-NP	O	B-group-ME-2
-	-	HYPH	O	O	I-group-ME-2
adrenergic	adrenergic	JJ	B-NP	O	I-group-ME-2
blocking	block	VBG	I-NP	O	I-group-ME-2
agents	agent	NNS	I-NP	O	E-group-ME-2
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
hypotensite	hypotensite	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
s	s	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Chirocaine	Chirocaine	NNP	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
local	local	JJ	I-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-AD-2
or	or	CC	I-NP	O	O
agents	agent	NNS	I-NP	O	O
structurally	structurally	RB	B-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
amide	amide	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
local	local	JJ	I-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	O
since	since	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
isoform	isoform	NN	I-NP	I-protein	O
and	and	CC	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
isoform	isoform	NN	I-NP	O	O
mediate	mediate	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
desbutyl	desbutyl	NN	B-NP	O	B-drug_n
levobupivacaine	levobupivacaine	NN	I-NP	O	E-drug_n
and	and	CC	O	O	O
3	3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
hydroxy	hydroxy	NN	I-NP	O	I-drug_n
levobupivacaine	levobupivacaine	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-NP	O	O
agents	agent	NNS	I-NP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
concomitantly	concomitantly	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Chirocaine	Chirocaine	NNP	B-NP	O	S-brand
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	B-protein	O
family	family	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
Chirocaine	Chirocaine	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducers	inducer	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
,	,	,	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
azole	azole	NN	B-NP	O	O
antimycotics	antimycotic	NNS	I-NP	O	O
e.g	e.g	NN	I-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

certain	certain	JJ	B-NP	O	O
protease	protease	NN	I-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
e.g	e.g	NN	I-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ritanovir	ritanovir	NN	B-NP	O	O
;	;	:	O	O	O

macrolide	macrolide	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
e.g	e.g	NN	I-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
;	;	:	O	O	O

and	and	CC	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
e.g	e.g	NN	I-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
inducers	inducer	NNS	I-NP	O	O
(	(	(	O	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
furafylline	furafylline	NN	B-NP	O	S-drug
and	and	CC	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
concurrently	concurrently	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
and	and	CC	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
levobupivacaine	levobupivacaine	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
rise	rise	VB	I-VP	O	O
resulting	result	VBG	I-VP	O	O
in	in	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
.	.	.	O	O	O

Specific	Specific	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Levofloxacin	Levofloxacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-MU-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
elevate	elevate	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
enhance	enhance	VB	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
transient	transient	JJ	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
systemic	systemic	JJ	B-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug-EF-2
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
CNS	CNS	NNPS	I-NP	B-protein	O
Agents	Agent	NNPS	I-NP	O	O
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Levo	Levo	NNP	B-NP	O	B-brand-EF-1
-	-	HYPH	I-NP	O	I-brand-EF-1
Dromoran	Dromoran	NNP	I-NP	O	E-brand-EF-1
with	with	IN	B-PP	O	O
all	all	DT	B-NP	O	O
central	central	JJ	I-NP	O	B-group-EF-2
nervous	nervous	JJ	I-NP	O	I-group-EF-2
system	system	NN	I-NP	O	I-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
hypnotics	hypnotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
opioids	opioid	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
skeletal	skeletal	JJ	B-NP	O	B-group-EF-2
muscle	muscle	NN	I-NP	O	I-group-EF-2
relaxants	relaxant	NNS	I-NP	O	E-group-EF-2
and	and	CC	I-NP	O	O
antihistamines	antihistamine	NNS	I-NP	O	S-group-EF-2
)	)	)	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Respiratory	Respiratory	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
,	,	,	O	O	O
hypotension	hypotension	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
profound	profound	JJ	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
or	or	CC	I-NP	O	O
coma	coma	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
combined	combine	VBN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
contemplated	contemplate	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
and	and	CC	O	O	O
Levo	Levo	NNP	B-NP	O	B-brand-AD-1
-	-	HYPH	O	O	I-brand-AD-1
Dromoran	Dromoran	NNP	B-NP	O	E-brand-AD-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
MAO	MAO	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Most	Most	JJS	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
involving	involve	VBG	B-VP	O	O
Levo	Levo	NNP	B-NP	O	B-brand
-	-	HYPH	I-NP	O	I-brand
Dromoran	Dromoran	NNP	I-NP	O	E-brand
reported	report	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
manufacturer	manufacturer	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
FDA	FDA	NNP	I-NP	O	O
have	have	VBP	B-VP	O	O
involved	involve	VBN	I-VP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
initial	initial	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
or	or	CC	O	O	O
too	too	RB	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
to	to	TO	B-PP	O	O
nonopioid	nonopioid	JJ	B-NP	O	O
tolerant	tolerant	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
simultaneous	simultaneous	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levorphanol	levorphanol	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
affecting	affect	VBG	B-VP	O	O
respiration	respiration	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levorphanol	levorphanol	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
along	along	IN	B-PP	O	O
with	with	IN	B-PP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
affecting	affect	VBG	B-VP	O	O
respiration	respiration	NN	B-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Mixed	Mix	VBN	B-NP	O	B-group
Agonist	Agonist	NN	I-NP	O	I-group
/	/	SYM	B-NP	O	I-group
Antagonist	Antagonist	NN	I-NP	O	I-group
Opioid	Opioid	JJ	I-NP	O	I-group
Analgesics	Analgesic	NNS	I-NP	O	E-group
:	:	:	O	O	O
Agonist	Agonist	NN	B-NP	O	B-group-AD-1
/	/	SYM	O	O	I-group-AD-1
antagonist	antagonist	NN	B-NP	O	I-group-AD-1
analgesics	analgesic	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
pentazocine	pentazocine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
nalbuphine	nalbuphine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
dezocine	dezocine	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
buprenorphine	buprenorphine	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
should	should	MD	B-VP	O	O
NOT	NOT	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
has	have	VBZ	B-VP	O	O
received	receive	VBN	I-VP	O	O
or	or	CC	O	O	O
is	be	VBZ	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pure	pure	JJ	I-NP	O	B-group-AD-1
agonist	agonist	NN	I-NP	O	I-group-AD-1
opioid	opioid	JJ	I-NP	O	I-group-AD-1
analgesic	analgesic	JJ	I-NP	O	E-group-AD-1
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Levo	Levo	NNP	B-NP	O	B-brand-AD-2
-	-	HYPH	B-VP	O	I-brand-AD-2
Dromoran	Dromoran	NNP	B-NP	O	E-brand-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
opioid	opioid	NN	B-NP	O	S-group
-	-	HYPH	O	O	O
dependent	dependent	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
mixed	mix	VBN	B-NP	O	B-group
agonist	agonist	NN	I-NP	O	I-group
/	/	SYM	B-NP	O	I-group
antagonist	antagonist	NN	B-NP	O	I-group
analgesics	analgesic	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
precipitate	precipitate	VB	I-VP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
Important	Important	JJ	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
To	To	TO	B-PP	O	O
Date	Date	NNP	B-NP	O	O
Levosimendan	Levosimendan	NNP	I-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
captopril	captopril	NN	B-NP	O	S-drug
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
,	,	,	O	O	O
felodipine	felodipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
isosorbide	isosorbide	NN	B-NP	O	B-drug
mononitrate	mononitrate	NN	I-NP	O	E-drug
,	,	,	O	O	O
carvedilol	carvedilol	NN	B-NP	O	S-drug
,	,	,	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
and	and	CC	I-NP	O	O
relative	relative	JJ	I-NP	O	O
importance	importance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
noted	note	VBN	B-VP	O	O
below	below	IN	B-PP	O	O
are	be	VBP	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
patient	patient	NN	B-NP	O	O
specific	specific	JJ	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
vary	vary	VB	I-VP	O	O
by	by	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
gender	gender	NN	B-NP	O	O
,	,	,	O	O	O
race	race	NN	B-NP	O	O
,	,	,	O	O	O
intercurrent	intercurrent	JJ	B-NP	O	O
illnesses	illness	NNS	I-NP	O	O
,	,	,	O	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
additional	additional	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
timing	timing	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Any	Any	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
alters	alter	VBZ	B-VP	O	O
thyroid	thyroid	NN	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
,	,	,	O	O	O
secretion	secretion	NN	B-NP	O	O
,	,	,	O	O	O
distribution	distribution	NN	B-NP	O	O
,	,	,	O	O	O
effect	effect	NN	B-NP	O	O
on	on	IN	B-PP	O	O
target	target	NN	B-NP	O	O
tissues	tissue	NNS	I-NP	O	O
,	,	,	O	O	O
metabolism	metabolism	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
elimination	elimination	NN	B-NP	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
optimal	optimal	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levothyroxine	levothyroxine	NN	B-NP	O	S-drug
sodium	sodium	NN	I-NP	O	O
.	.	.	O	O	O

Levothyroxine	Levothyroxine	NN	B-NP	O	B-drug
Sodium	Sodium	NN	I-NP	O	E-drug
Absorption	Absorption	NN	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
bind	bind	VB	I-VP	O	O
and	and	CC	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
levothyroxine	levothyroxine	NN	B-NP	O	B-drug-ME-1
sodium	sodium	NN	I-NP	O	E-drug-ME-1
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
:	:	:	O	O	O
aluminum	aluminum	NN	B-NP	O	B-drug-ME-2
hydoxide	hydoxide	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
cholestyramine	cholestyramine	NN	B-NP	B-protein	S-drug-ME-2
resin	resin	NN	I-NP	I-protein	O
,	,	,	O	O	O
colestipol	colestipol	NN	B-NP	O	B-drug-ME-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
ferrous	ferrous	JJ	B-NP	O	B-drug-ME-2
sulfate	sulfate	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-ME-2
polystyrene	polystyrene	NN	I-NP	O	I-drug-ME-2
sulfonate	sulfonate	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
soybean	soybean	NN	B-NP	O	O
flour	flour	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
infant	infant	NN	B-NP	O	O
formula	formula	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Binding	Binding	NN	B-NP	O	O
to	to	TO	B-PP	O	O
Serum	Serum	NN	B-NP	B-protein	O
Proteins	Protein	NNS	I-NP	I-protein	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
either	either	CC	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
levothyroxine	levothyroxine	NN	B-NP	O	B-drug-ME-1
sodium	sodium	NN	I-NP	O	E-drug-ME-1
binding	binding	NN	I-NP	O	O
to	to	TO	B-PP	O	O
serum	serum	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
or	or	CC	O	O	O
alter	alter	VB	B-VP	O	O
the	the	DT	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	B-protein	O
binding	binding	NN	I-NP	I-protein	O
proteins	protein	NNS	I-NP	I-protein	O
:	:	:	O	O	O
androgens	androgen	NNS	B-NP	O	S-group-ME-2
and	and	CC	O	O	O
related	related	JJ	B-NP	O	O
anabolic	anabolic	JJ	I-NP	O	B-group-ME-2
hormones	hormone	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
asparaginase	asparaginase	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clofibrate	clofibrate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group-ME-2
and	and	CC	O	O	O
estrogen	estrogen	NN	B-NP	O	B-group-ME-2
-	-	HYPH	O	O	I-group-ME-2
containing	contain	VBG	B-VP	O	I-group-ME-2
compounds	compound	NNS	B-NP	O	E-group-ME-2
,	,	,	O	O	O
5	5	CD	B-NP	O	B-drug-ME-2
-	-	HYPH	I-NP	O	I-drug-ME-2
fluorouracil	fluorouracil	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
glucocorticoids	glucocorticoid	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
meclofenamic	meclofenamic	JJ	B-NP	O	B-drug-ME-2
acid	acid	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
mefenamic	mefenamic	JJ	B-NP	O	B-drug-ME-2
acid	acid	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
methadone	methadone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
perphenazine	perphenazine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
salicylates	salicylate	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
tamoxifen	tamoxifen	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Thyroid	Thyroid	NNP	B-NP	O	O
Physiology	Physiology	NNP	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
thyroid	thyroid	NN	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
or	or	CC	I-NP	O	O
TSH	TSH	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
generally	generally	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
effects	effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
,	,	,	O	O	O
secretion	secretion	NN	B-NP	O	O
,	,	,	O	O	O
distribution	distribution	NN	B-NP	O	O
,	,	,	O	O	O
metabolism	metabolism	NN	B-NP	O	O
,	,	,	O	O	O
hormone	hormone	NN	B-NP	O	O
action	action	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
elimination	elimination	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
altered	alter	VBN	B-NP	O	O
TSH	TSH	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
:	:	:	O	O	O
aminoglutethimide	aminoglutethimide	NN	B-NP	O	S-drug
,	,	,	O	O	O
p	p	NN	B-NP	O	B-drug
-	-	HYPH	O	O	I-drug
aminosalicylic	aminosalicylic	JJ	B-NP	O	I-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug
,	,	,	O	O	O
androgens	androgen	NNS	B-NP	O	S-group
and	and	CC	O	O	O
related	related	JJ	B-NP	O	O
anabolic	anabolic	JJ	I-NP	O	O
hormones	hormone	NNS	I-NP	O	O
,	,	,	O	O	O
complex	complex	JJ	B-NP	O	O
anions	anion	NNS	I-NP	O	O
(	(	(	O	O	O
thiocyanate	thiocyanate	NN	B-NP	O	S-drug
,	,	,	O	O	O
perchlorate	perchlorate	NN	B-NP	O	S-drug
,	,	,	O	O	O
pertechnetate	pertechnetate	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
antithyroid	antithyroid	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
b	b	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
chloral	chloral	JJ	B-NP	O	B-drug
hydrate	hydrate	NN	I-NP	O	E-drug
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
dopamine	dopamine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
dopamine	dopamine	NN	I-NP	O	B-group
agonists	agonist	NNS	I-NP	O	E-group
,	,	,	O	O	O
ethionamide	ethionamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
glucocorticoids	glucocorticoid	NNS	B-NP	O	S-group
,	,	,	O	O	O
heparin	heparin	NN	B-NP	O	S-drug
,	,	,	O	O	O
hepatic	hepatic	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
,	,	,	O	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
iodinated	iodinate	VBN	B-VP	O	O
cholestographic	cholestographic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
iodine	iodine	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
containing	contain	VBG	B-VP	O	I-group
compounds	compound	NNS	B-NP	O	E-group
,	,	,	O	O	O
levodopa	levodopa	NN	B-NP	O	S-drug
,	,	,	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug
,	,	,	O	O	O
6	6	CD	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
mercaptopurine	mercaptopurine	NN	I-NP	O	E-drug
,	,	,	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug
,	,	,	O	O	O
mitotane	mitotane	NN	B-NP	O	S-drug
,	,	,	O	O	O
nitroprusside	nitroprusside	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
resorcinol	resorcinol	NN	B-NP	O	S-drug
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
,	,	,	O	O	O
somatostatin	somatostatin	NN	B-NP	O	B-group
analogs	analog	NNS	I-NP	O	E-group
,	,	,	O	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group
,	,	,	O	O	O
sulfonylureas	sulfonylurea	NNS	B-NP	O	S-group
,	,	,	O	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
.	.	.	O	O	O

Adrenocorticoids	Adrenocorticoid	NNS	B-NP	O	O
:	:	:	O	O	O
Metabolic	Metabolic	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adrenocorticoids	adrenocorticoid	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
hypothyroid	hypothyroid	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
hyperthyroid	hyperthyroid	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
change	change	VB	I-VP	O	O
with	with	IN	B-PP	O	O
changing	change	VBG	B-NP	O	O
thyroid	thyroid	JJ	I-NP	O	O
status	status	NN	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amiodarone	Amiodarone	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypothyroidism	hypothyroidism	NN	B-NP	O	O
or	or	CC	I-NP	O	O
hyperthyroidism	hyperthyroidism	NN	I-NP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
(	(	(	O	O	O
Oral	Oral	NNP	B-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
hypoprothrombinemic	hypoprothrombinemic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
,	,	,	O	O	O
apparently	apparently	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
catabloism	catabloism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B-protein	O
K	K	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	I-protein	O
dependent	dependent	JJ	I-NP	I-protein	O
clotting	clotting	NN	I-NP	I-protein	O
factors	factor	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Antidiabetic	Antidiabetic	JJ	B-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
(	(	(	O	O	O
Insulin	Insulin	NNP	B-NP	O	S-drug
,	,	,	O	O	O
Sulfonylureas	Sulfonylureas	NNP	B-NP	O	S-group
)	)	)	O	O	O
:	:	:	O	O	O
Requirements	Requirement	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
hypothyroid	hypothyroid	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
diabetes	diabetes	NN	B-NP	O	O
mellitus	mellitus	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
subsequently	subsequently	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

b	b	SYM	O	O	B-group
-	-	:	O	O	I-group
Adrenergic	Adrenergic	NNP	B-NP	O	I-group
Blocking	Blocking	NNP	I-NP	O	I-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Actions	Action	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-PP	O	I-group
blocking	block	VBG	B-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
impaired	impair	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
hypothyroid	hypothyroid	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
become	become	VBP	B-VP	O	O
euthyroid	euthyroid	JJ	B-ADJP	O	O
.	.	.	O	O	O

Cytokines	Cytokine	NNS	B-NP	B-protein	S-group
(	(	(	O	O	O
interferon	interferon	NN	B-NP	B-protein	S-group
,	,	,	I-NP	O	O
interleukin	interleukin	NN	I-NP	B-protein	S-group
)	)	)	O	O	O
:	:	:	O	O	O
Cytokines	Cytokine	NNS	B-NP	B-protein	S-group
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
both	both	CC	O	O	O
hyperthyroidism	hyperthyroidism	NN	B-NP	O	O
and	and	CC	I-NP	O	O
hypothyroidism	hypothyroidism	NN	I-NP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	B-group
Glycosides	Glycoside	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Therapeutic	Therapeutic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
digitalis	digitalis	NN	I-NP	O	S-group
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
hyperthyroidism	hyperthyroidism	NN	B-NP	O	O
or	or	CC	O	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
hypothyroid	hypothyroid	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
becomes	become	VBZ	B-VP	O	O
euthyroid	euthyroid	JJ	B-ADJP	O	O
.	.	.	O	O	O

Ketamine	Ketamine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Marked	Mark	VBN	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levothyroxine	levothyroxine	NN	B-NP	O	B-drug-EF-1
sodium	sodium	NN	I-NP	O	E-drug-EF-1
and	and	CC	I-NP	O	O
ketamine	ketamine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Maprotiline	Maprotiline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Risk	Risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
.	.	.	O	O	O

Sodium	Sodium	NN	B-NP	O	B-drug
Iodide	Iodide	NN	I-NP	O	E-drug
(	(	(	O	O	O
123I	123I	NN	B-NP	O	O
and	and	CC	O	O	O
131I	131I	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
Sodium	Sodium	NNP	B-NP	O	B-drug
Pertechnetate	Pertechnetate	NNP	I-NP	O	I-drug
Tc99m	Tc99m	NN	I-NP	O	E-drug
:	:	:	O	O	O
Uptake	Uptake	NN	B-NP	O	O
of	of	IN	B-PP	O	O
radiolabeled	radiolabele	VBN	B-NP	O	O
ions	ion	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

Somatrem	Somatrem	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Somatropin	Somatropin	NN	I-NP	O	S-drug
:	:	:	O	O	O
Excessive	Excessive	JJ	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	B-group
hormone	hormone	NN	I-NP	O	E-group
may	may	MD	B-VP	O	O
accelerate	accelerate	VB	I-VP	O	O
epiphyseal	epiphyseal	JJ	B-NP	O	O
closure	closure	NN	I-NP	O	O
.	.	.	O	O	O

Untreated	Untreated	JJ	B-NP	O	O
hypothyroidism	hypothyroidism	NN	I-NP	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
growth	growth	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
somatrem	somatrem	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
somatropin	somatropin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Theophylline	Theophylline	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
in	in	IN	B-PP	O	O
hypothyroid	hypothyroid	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
return	return	VB	B-VP	O	O
toward	toward	IN	B-PP	O	O
normal	normal	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
euthyroid	euthyroid	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
.	.	.	O	O	O

Tricyclic	Tricyclic	JJ	B-NP	O	B-group
Antidepressants	Antidepressant	NNS	I-NP	O	E-group
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
catecholamine	catecholamine	NN	I-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
.	.	.	O	O	O

Onset	Onset	NN	B-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tricyclics	tricyclic	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
accelerated	accelerate	VBN	I-VP	O	O
.	.	.	O	O	O

Sympathomimetic	Sympathomimetic	JJ	B-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Possible	Possible	JJ	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	B-group
solutions	solution	NNS	I-NP	O	E-group
containing	contain	VBG	B-VP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-1
or	or	CC	O	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
or	or	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
,	,	,	I-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

Phenothiazines	Phenothiazine	NNS	B-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
butyrophenones	butyrophenone	NNS	I-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
or	or	CC	I-VP	O	O
reverse	reverse	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
generally	generally	RB	I-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
situations	situation	NNS	B-NP	O	O
when	when	WRB	B-ADVP	O	O
concurrent	concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-NP	O	O
,	,	,	I-NP	O	O
careful	careful	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasopressor	vasopressor	NN	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
obstetric	obstetric	JJ	B-NP	O	O
blocks	block	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ergot	ergot	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
type	type	NN	I-NP	O	I-group
oxytocic	oxytocic	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
,	,	,	I-NP	O	O
persistent	persistent	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
or	or	CC	O	O	O
cerebrovascular	cerebrovascular	JJ	B-NP	O	O
accidents	accident	NNS	I-NP	O	O
.	.	.	O	O	O

Lincomycin	Lincomycin	NN	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
blocking	block	VBG	I-NP	O	O
properties	property	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	B-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
such	such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Antagonism	Antagonism	NN	B-NP	O	O
between	between	IN	B-PP	O	O
lincomycin	lincomycin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug-EF-2
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
possible	possible	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Oils	Oil	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
absorption	absorption	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
creams	cream	NNS	B-NP	O	O
,	,	,	I-NP	O	O
ointments	ointment	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
oils	oil	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Monoamine	Monoamine	NN	B-NP	B-protein	O
Oxidase	Oxidase	NN	I-NP	I-protein	O
Inhibition	Inhibition	NN	I-NP	O	O
:	:	:	O	O	O
Linezolid	Linezolid	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
reversible	reversible	JJ	I-NP	O	O
,	,	,	I-NP	O	O
nonselective	nonselective	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
linezolid	linezolid	NN	B-NP	O	S-drug-IN-1
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
adrenergic	adrenergic	JJ	B-NP	O	S-group-IN-2
and	and	CC	I-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	B-group-IN-2
agents	agent	NNS	I-NP	O	E-group-IN-2
.	.	.	O	O	O

Adrenergic	Adrenergic	NNP	B-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Some	Some	DT	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
ZYVOX	ZYVOX	NN	B-NP	B-protein	S-brand-EF-1
may	may	MD	B-VP	O	O
experience	experience	VB	I-VP	O	O
a	a	DT	B-NP	O	O
reversible	reversible	JJ	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
indirect	indirect	JJ	B-ADJP	O	O
-	-	HYPH	O	O	O
acting	act	VBG	B-VP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
vasopressor	vasopressor	NN	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Commonly	Commonly	RB	B-NP	O	O
used	use	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenylpropanolamine	phenylpropanolamine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
pseudoephedrine	pseudoephedrine	NN	I-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
specifically	specifically	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Initial	Initial	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adrenergic	adrenergic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
dopamine	dopamine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	O	S-drug
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
and	and	CC	O	O	O
titrated	titrate	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Serotonergic	Serotonergic	NNP	B-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
linezolid	linezolid	NN	B-NP	O	S-drug
and	and	CC	O	O	O
serotonergic	serotonergic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Phase	Phase	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
2	2	CD	I-NP	O	O
or	or	CC	I-NP	O	O
3	3	CD	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Spontaneous	Spontaneous	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZYVOX	ZYVOX	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	O	O	O
serotonergic	serotonergic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	S-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
selective	selective	JJ	B-NP	O	B-group-EF-2
serotonin	serotonin	NN	I-NP	O	I-group-EF-2
reuptake	reuptake	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ZYVOX	ZYVOX	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cognitive	cognitive	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
,	,	,	O	O	O
hyperpyrexia	hyperpyrexia	NN	B-NP	O	O
,	,	,	O	O	O
hyperreflexia	hyperreflexia	NN	B-NP	O	O
,	,	,	O	O	O
incoordination	incoordination	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
any	any	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
occur	occur	VBP	B-VP	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
consider	consider	VB	I-VP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
one	one	CD	I-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
ZYVOX	ZYVOX	NN	B-NP	B-protein	S-brand-AD-1
or	or	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Anticoagulants	Anticoagulant	NNS	I-NP	O	S-group
:	:	:	O	O	O
Thyroid	Thyroid	JJ	B-NP	O	B-group
hormones	hormone	NNS	I-NP	O	E-group
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
catabolism	catabolism	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B-protein	O
K	K	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	I-protein	O
dependent	dependent	JJ	I-NP	I-protein	O
clotting	clotting	NN	I-NP	I-protein	O
factors	factor	NNS	I-NP	I-protein	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
being	be	VBG	I-VP	O	O
given	give	VBN	I-VP	O	O
,	,	,	O	O	O
compensatory	compensatory	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
clotting	clot	VBG	B-VP	O	O
factor	factor	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
impaired	impaired	JJ	B-ADJP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
stabilized	stabilize	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-AD-1
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
require	require	VB	I-VP	O	O
thyroid	thyroid	JJ	B-NP	O	S-group-AD-2
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
watched	watch	VBN	I-VP	O	O
very	very	RB	B-ADVP	O	O
closely	closely	RB	I-ADVP	O	O
when	when	WRB	B-ADVP	O	O
thyroid	thyroid	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
started	start	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
truly	truly	RB	B-ADJP	O	O
hypothyroid	hypothyroid	JJ	I-ADJP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
special	special	JJ	I-NP	O	O
precautions	precaution	NNS	I-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
begun	begin	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
already	already	RB	B-ADVP	O	O
stabilized	stabilize	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
maintenance	maintenance	NN	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Insulin	Insulin	NN	B-NP	B-protein	S-drug
or	or	CC	O	O	O
Oral	Oral	JJ	B-NP	O	O
Hypoglycemics	Hypoglycemic	NNS	I-NP	O	S-group
:	:	:	O	O	O
Initiating	Initiate	VBG	B-VP	O	O
thyroid	thyroid	JJ	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	S-group
requirements	requirement	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
seen	see	VBN	B-VP	O	O
are	be	VBP	B-VP	O	O
poorly	poorly	RB	I-VP	O	O
understood	understand	VBN	I-VP	O	O
and	and	CC	O	O	O
depend	depend	VB	B-VP	O	O
upon	upon	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
factors	factor	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
dose	dose	NN	B-NP	O	O
and	and	CC	I-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thyroid	thyroid	JJ	B-NP	O	B-group
preparations	preparation	NNS	I-NP	O	E-group
and	and	CC	O	O	O
endocrine	endocrine	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemics	hypoglycemic	NNS	I-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
watched	watch	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
thyroid	thyroid	JJ	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug-ME-1
binds	bind	VBZ	B-VP	O	O
both	both	CC	O	O	O
T4	T4	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
T3	T3	NN	I-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intestine	intestine	NN	I-NP	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
impairing	impair	VBG	B-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
thyroid	thyroid	JJ	I-NP	O	B-group
hormones	hormone	NNS	I-NP	O	E-group
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
easily	easily	RB	I-VP	O	O
removed	remove	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
4	4	CD	B-NP	O	O
to	to	TO	I-NP	O	O
5	5	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
elapse	elapse	VB	I-VP	O	O
between	between	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
thyroid	thyroid	NN	I-NP	O	B-group-AD-2
hormones	hormone	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Estrogen	Estrogen	NN	B-NP	O	S-group
,	,	,	O	O	O
Oral	Oral	NNP	B-NP	O	O
Contraceptives	Contraceptive	NNPS	I-NP	O	S-group
:	:	:	O	O	O
Estrogens	Estrogen	NNS	B-NP	O	S-group
tend	tend	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
serum	serum	NN	B-NP	B-protein	O
thyroxine	thyroxine	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
binding	bind	VBG	B-VP	I-protein	O
globulin	globulin	NN	B-NP	I-protein	O
(	(	(	O	O	O
TBg	TBg	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonfunctioning	nonfunctioning	JJ	I-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
gland	gland	NN	I-NP	O	O
who	who	WP	B-NP	O	O
is	be	VBZ	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
thyroid	thyroid	JJ	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
free	free	JJ	B-NP	O	O
levothyroxine	levothyroxine	NN	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
estrogens	estrogen	NNS	B-NP	O	S-group-ME-2
are	be	VBP	B-VP	O	O
started	start	VBN	I-VP	O	O
thus	thus	RB	B-ADVP	O	O
increasing	increase	VBG	B-VP	O	O
thyroid	thyroid	JJ	B-NP	O	S-group
requirements	requirement	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
gland	gland	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
sufficient	sufficient	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
free	free	JJ	I-NP	O	O
thyroxine	thyroxine	NN	I-NP	O	O
will	will	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
compensatory	compensatory	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
thyroxine	thyroxine	NN	B-NP	O	O
output	output	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
without	without	IN	B-PP	O	O
a	a	DT	B-NP	O	O
functioning	function	VBG	I-NP	O	O
thyroid	thyroid	NN	I-NP	O	S-group-AD-1
gland	gland	NN	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
thyroid	thyroid	JJ	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
estrogens	estrogen	NNS	B-NP	O	S-group-AD-2
or	or	CC	I-NP	O	O
estrogen	estrogen	NN	I-NP	O	S-group
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-AD-2
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
.	.	.	O	O	O

Tricyclic	Tricyclic	JJ	B-NP	O	B-group
Antidepressants	Antidepressant	NNS	I-NP	O	E-group
:	:	:	O	O	O
Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
thyroid	thyroid	JJ	B-NP	B-protein	B-group-EF-1
products	product	NNS	I-NP	I-protein	E-group-EF-1
with	with	IN	B-PP	O	O
imipramine	imipramine	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
receptor	receptor	NN	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
and	and	CC	O	O	O
enhance	enhance	VBP	B-VP	O	O
antidepressant	antidepressant	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
transient	transient	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Thyroid	Thyroid	JJ	B-NP	O	B-group
hormone	hormone	NN	I-NP	O	E-group
activity	activity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	S-group
:	:	:	O	O	O
Thyroid	Thyroid	JJ	B-NP	O	B-group-EF-1
preparations	preparation	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Thyroid	Thyroid	JJ	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	O
replacement	replacement	NN	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
metabolic	metabolic	JJ	B-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
requires	require	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Ketamine	Ketamine	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
thyroid	thyroid	JJ	I-NP	O	B-group-EF-1
preparation	preparation	NN	I-NP	O	E-group-EF-1
,	,	,	O	O	O
this	this	DT	B-NP	O	O
parenteral	parenteral	JJ	I-NP	O	O
anesthetic	anesthetic	NN	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypertension	hypertension	NN	B-NP	O	O
and	and	CC	I-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	O	O	O
be	be	VB	B-VP	O	O
prepared	prepare	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
treat	treat	VB	I-VP	O	O
hypertension	hypertension	NN	B-NP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Vasopressors	Vasopressor	NNS	B-NP	O	O
:	:	:	O	O	O
Thyroxine	Thyroxine	NN	B-NP	O	S-drug-EF-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
into	into	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
thyroid	thyroid	JJ	B-NP	O	B-group
preparations	preparation	NNS	I-NP	O	E-group
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
precipitating	precipitate	VBG	B-VP	O	O
coronary	coronary	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
moieties	moiety	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
laboratory	laboratory	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
performed	perform	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	B-group
hormone	hormone	NN	I-NP	O	E-group
therapy	therapy	NN	I-NP	O	O
:	:	:	O	O	O
androgens	androgen	NNS	B-NP	O	S-group
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
containing	contain	VBG	B-VP	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
,	,	,	O	O	O
iodine	iodine	NN	B-NP	O	S-group
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
numerous	numerous	JJ	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
salicylates	salicylate	NNS	B-NP	O	S-group
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Changes	Change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
TBg	TBg	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
consideration	consideration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interpretation	interpretation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
T4	T4	NN	B-NP	O	O
and	and	CC	I-NP	O	O
T3	T3	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
unbound	unbound	JJ	I-NP	O	O
(	(	(	O	O	O
free	free	JJ	B-ADJP	O	O
)	)	)	O	O	O
hormone	hormone	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
measured	measure	VBN	I-VP	O	O
.	.	.	O	O	O

Pregnancy	Pregnancy	NN	B-NP	O	O
estrogens	estrogen	NNS	I-NP	O	S-group
and	and	CC	I-NP	O	O
estrogen	estrogen	NN	I-NP	O	S-group
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
increase	increase	VBP	B-VP	O	O
TBg	TBg	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

TBg	TBg	NN	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
infectious	infectious	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	O
.	.	.	O	O	O

Decreases	Decrease	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
TBg	TBg	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
nephrosis	nephrosis	NN	B-NP	O	O
,	,	,	O	O	O
acromegaly	acromegaly	RB	B-ADVP	O	O
and	and	CC	O	O	O
after	after	IN	B-PP	O	O
androgen	androgen	NN	B-NP	O	S-group
or	or	CC	I-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Familial	Familial	JJ	B-NP	O	O
hyper	hyper	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
or	or	CC	O	O	O
hypo	hypo	AFX	O	O	O
-	-	HYPH	B-NP	O	O
thyroxine	thyroxine	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
binding	binding	NN	I-NP	O	O
-	-	HYPH	O	O	O
globulinemias	globulinemia	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TBg	TBg	NN	B-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
approximates	approximate	VBZ	B-VP	O	O
1	1	CD	B-NP	O	O
in	in	IN	B-PP	O	O
9000	9000	CD	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thyroxine	thyroxine	NN	B-NP	O	O
by	by	IN	B-PP	O	O
thyroxine	thyroxine	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
binding	bind	VBG	B-VP	I-protein	O
prealbumin	prealbumin	NN	B-NP	I-protein	O
(	(	(	O	O	O
TBPA	TBPA	NN	B-NP	B-protein	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
salicylates	salicylate	NNS	B-NP	O	S-group

-	-	HYPH	B-NP	O	O
Medicinal	Medicinal	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
dietary	dietary	JJ	I-NP	O	O
iodine	iodine	NN	I-NP	O	S-group
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
all	all	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
tests	test	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
radio	radio	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
iodine	iodine	NN	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
producing	produce	VBG	B-VP	O	O
low	low	JJ	B-NP	O	O
uptakes	uptake	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
reflective	reflective	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
true	true	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hormone	hormone	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O

-	-	HYPH	O	O	O
The	The	DT	B-NP	O	O
persistence	persistence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
laboratory	laboratory	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypothyroidism	hypothyroidism	NN	B-NP	O	O
in	in	IN	B-PP	O	O
spite	spite	NN	B-NP	O	O
of	of	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
replacement	replacement	NN	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
either	either	CC	O	O	O
poor	poor	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
compliance	compliance	NN	I-NP	O	O
,	,	,	O	O	O
poor	poor	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
,	,	,	O	O	O
excessive	excessive	JJ	B-NP	O	O
fecal	fecal	JJ	I-NP	O	O
loss	loss	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
inactivity	inactivity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
preparation	preparation	NN	I-NP	O	O
.	.	.	O	O	O

Intracellular	Intracellular	JJ	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	B-group
hormone	hormone	NN	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
quite	quite	RB	B-ADJP	O	O
rare	rare	JJ	I-ADJP	O	O
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	O
acidifying	acidify	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
ammonium	ammonium	NN	B-NP	O	B-drug-ME-1
chloride	chloride	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	I-drug-ME-1
phosphate	phosphate	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ionized	ionize	VBN	I-NP	O	O
species	specie	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	B-protein	S-drug-ME-2
molecule	molecule	NN	I-NP	I-protein	O
,	,	,	O	O	O
thereby	thereby	RB	B-ADVP	O	O
increasing	increase	VBG	B-VP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
lower	low	JJR	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
efficacy	efficacy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group
.	.	.	O	O	O

Adrenergic	Adrenergic	JJ	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
Adrenergic	Adrenergic	JJ	B-NP	O	B-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
are	be	VBP	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Antidepressants	Antidepressant	NNS	B-NP	O	S-group
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	S-group
Amphetamines	Amphetamine	NNS	I-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-drug-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-drug-EF-2
or	or	CC	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O

d	d	LS	B-LST	O	B-drug-ME-1
-	-	:	O	O	I-drug-ME-1
amphetamine	amphetamine	NN	B-NP	O	E-drug-ME-1
with	with	IN	B-PP	O	O
desipramine	desipramine	NN	B-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
protriptyline	protriptyline	NN	I-NP	O	S-drug-ME-2
and	and	CC	O	O	O
possibly	possibly	RB	B-ADVP	O	O
other	other	JJ	B-NP	O	O
tricyclics	tricyclic	NNS	I-NP	O	S-group-ME-2
cause	cause	VBP	B-VP	O	O
striking	striking	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
sustained	sustained	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d	d	NN	B-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
amphetamine	amphetamine	NN	I-NP	O	E-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
;	;	:	O	O	O

cardiovascular	cardiovascular	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
MAOI	MAOI	NN	I-NP	O	B-group-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
a	a	DT	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furazolidone	furazolidone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
slow	slow	JJ	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
slowing	slow	VBG	B-VP	O	O
potentiates	potentiate	VBZ	B-VP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
their	their	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
monoamines	monoamine	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
adrenergic	adrenergic	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
endings	ending	NNS	I-NP	O	O
;	;	:	O	O	O

this	this	DT	B-NP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
headaches	headache	NNS	B-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
crisis	crisis	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxic	toxic	JJ	B-NP	O	O
neurological	neurological	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
malignant	malignant	JJ	B-NP	O	O
hyperpyrexia	hyperpyrexia	NN	I-NP	O	O
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
,	,	,	O	O	O
sometimes	sometimes	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
.	.	.	O	O	O

Antihistamines	Antihistamine	NNS	B-NP	O	S-group
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
counteract	counteract	VB	I-VP	O	O
the	the	DT	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Antihypertensives	Antihypertensive	NNS	B-NP	O	S-group
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihypertensives	antihypertensive	NNS	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Chlorpromazine	Chlorpromazine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Chlorpromazine	Chlorpromazine	NN	B-NP	O	S-drug-EF-1
blocks	block	VBZ	B-VP	O	O
dopamine	dopamine	NN	B-NP	O	O
and	and	CC	I-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	B-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
stimulant	stimulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-EF-2
and	and	CC	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-group
poisoning	poisoning	NN	I-NP	O	O
.	.	.	O	O	O

Ethosuximide	Ethosuximide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
delay	delay	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethosuximide	ethosuximide	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Haloperidol	Haloperidol	NN	B-NP	O	S-drug
:	:	:	O	O	O
Haloperidol	Haloperidol	NN	B-NP	O	S-drug-EF-1
blocks	block	VBZ	B-VP	O	O
dopamine	dopamine	NN	B-NP	B-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
stimulant	stimulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	B-drug
carbonate	carbonate	NN	I-NP	O	E-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
anorectic	anorectic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
stimulatory	stimulatory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	B-drug-EF-2
carbonate	carbonate	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Meperidine	Meperidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
potentiate	potentiate	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meperidine	meperidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Methenamine	Methenamine	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
Urinary	Urinary	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-group-ME-1
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
efficacy	efficacy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
acidifying	acidify	VBG	B-VP	O	O
agents	agent	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
methenamine	methenamine	NN	B-NP	O	S-drug-ME-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Norepinephrine	Norepinephrine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
enhance	enhance	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
delay	delay	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
delay	delay	VB	I-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
.	.	.	O	O	O

Propoxyphene	Propoxyphene	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
propoxyphene	propoxyphene	NN	B-NP	O	S-drug-EF-1
overdosage	overdosage	NN	I-NP	O	O
,	,	,	O	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug-EF-2
CNS	CNS	NN	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
potentiated	potentiated	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
convulsions	convulsion	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Veratrum	Veratrum	NN	B-NP	O	B-group
alkaloids	alkaloid	NNS	I-NP	O	E-group
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group-EF-1
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
veratrum	veratrum	NN	B-NP	O	B-group-EF-2
alkaloids	alkaloid	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
Amphetamines	Amphetamine	NNS	B-NP	O	S-group
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
greatest	great	JJS	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
evening	evening	NN	I-NP	O	O
.	.	.	O	O	O

Amphetamines	Amphetamine	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
steroid	steroid	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
.	.	.	O	O	O

Hypotension	Hypotension	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Patients	Patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
Diuretic	Diuretic	JJ	B-NP	O	O
Therapy	Therapy	NN	I-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
especially	especially	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
diuretic	diuretic	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
recently	recently	RB	I-VP	O	O
instituted	institute	VBN	I-VP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
experience	experience	VB	I-VP	O	O
an	an	DT	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotensive	hypotensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
either	either	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-EF-1
or	or	CC	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
salt	salt	NN	I-NP	O	O
intake	intake	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
continue	continue	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-AD-1
,	,	,	I-NP	O	O
initiate	initiate	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand-AD-2
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
provide	provide	VBP	B-VP	O	O
close	close	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
supervision	supervision	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
until	until	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-EF-1
is	be	VBZ	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand-EF-2
,	,	,	O	O	O
an	an	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
usually	usually	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ACE	ACE	NN	I-NP	O	B-group-AD-1
inhibitor	inhibitor	NN	I-NP	O	E-group-AD-1
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-AD-2
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-group
-	-	HYPH	I-NP	B-protein	I-group
steroidal	steroidal	JJ	I-NP	I-protein	I-group
Anti	Anti	AFX	I-NP	I-protein	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
compromised	compromise	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
being	be	VBG	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
non	non	AFX	B-NP	O	B-group-EF-1
-	-	HYPH	I-NP	B-DNA	I-group-EF-1
steroidal	steroidal	JJ	I-NP	I-DNA	I-group-EF-1
anti	anti	AFX	I-NP	I-DNA	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lisinopril	lisinopril	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
usually	usually	RB	B-ADVP	O	O
reversible	reversible	JJ	B-ADJP	O	O
.	.	.	O	O	O

Reports	Report	NNS	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
lisinopril	lisinopril	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
consideration	consideration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
36	36	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
mild	mild	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
where	where	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand
alone	alone	RB	B-ADVP	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
significant	significant	JJ	B-ADJP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Agents	Agent	NNS	I-NP	O	O
:	:	:	O	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
nitrates	nitrate	NNS	B-NP	O	S-group
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
included	include	VBD	B-VP	O	O
post	post	NN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
infarction	infarction	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
intravenous	intravenous	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
transdermal	transdermal	JJ	I-NP	O	O
nitroglycerin	nitroglycerin	NN	I-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
when	when	WRB	B-ADVP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
food	food	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stomach	stomach	NN	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand
.	.	.	O	O	O

Agents	Agent	NNPS	B-NP	O	O
Increasing	Increasing	NNP	I-NP	O	O
Serum	Serum	NNP	I-NP	O	O
Potassium	Potassium	NNP	I-NP	O	O
:	:	:	O	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand-EF-1
attenuates	attenuate	VBZ	B-VP	O	O
potassium	potassium	NN	B-NP	O	O
loss	loss	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
thiazide	thiazide	NN	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
type	type	NN	I-NP	O	I-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
sparing	spar	VBG	B-VP	O	I-group-EF-2
diuretics	diuretic	NNS	B-NP	O	E-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
amiloride	amiloride	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	S-drug-EF-2
supplements	supplement	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
potassium	potassium	NN	B-NP	O	O
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
salt	salt	NN	B-NP	O	O
substitutes	substitute	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
demonstrated	demonstrate	VBN	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
frequent	frequent	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
.	.	.	O	O	O

Potassium	Potassium	NN	B-NP	O	O
sparing	spar	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
generally	generally	RB	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Lithium	Lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
cause	cause	VBP	B-VP	O	O
elimination	elimination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
usually	usually	RB	B-ADJP	O	O
reversible	reversible	JJ	I-ADJP	O	O
upon	upon	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
ACE	ACE	NN	I-NP	O	B-group-EF-2
inhibitor	inhibitor	NN	I-NP	O	E-group-EF-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
frequently	frequently	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
PRINIVIL	PRINIVIL	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Lofexidine	Lofexidine	NN	I-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
depressive	depressive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
sedatives	sedative	NNS	I-NP	O	S-group-EF-2

-	-	HYPH	B-NP	O	O
Lofexidine	Lofexidine	NN	I-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
hypertensive	hypertensive	JJ	I-NP	O	I-group-EF-2
drug	drug	NN	I-NP	O	E-group-EF-2
therapy	therapy	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Concomitant	Concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lofexidine	lofexidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
three	three	CD	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
46	46	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
,	,	,	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
and	and	CC	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
where	where	WRB	B-ADVP	O	O
patients	patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
measurable	measurable	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
estimates	estimate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

Though	Though	IN	B-SBAR	O	O
individual	individual	JJ	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
fluctuated	fluctuate	VBD	B-VP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
inter	inter	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
action	action	NN	B-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
and	and	CC	I-NP	O	O
sucralfate	sucralfate	NN	I-NP	O	S-drug
:	:	:	O	O	O
Sucralfate	Sucralfate	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
antacids	antacid	NNS	I-NP	O	S-group
containing	contain	VBG	B-VP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-ME-1
or	or	CC	I-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug-ME-1
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
formulations	formulation	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
divalent	divalent	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
trivalent	trivalent	JJ	I-NP	O	O
cations	cation	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Videx	Videx	NN	B-NP	O	S-brand-ME-1
(	(	(	O	O	O
didanosine	didanosine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
,	,	,	O	O	O
chewable	chewable	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
buffered	buffered	JJ	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
powder	powder	NN	I-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
solution	solution	NN	I-NP	O	O
can	can	MD	B-VP	O	O
form	form	VB	I-VP	O	O
chelation	chelation	NN	B-NP	B-protein	O
complexes	complex	NNS	I-NP	I-protein	O
with	with	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
interfere	interfere	VB	B-VP	O	O
with	with	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
.	.	.	O	O	O

Sucralfate	Sucralfate	NN	B-NP	O	S-drug-ME-1
administered	administer	VBN	B-VP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-SBAR	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
slower	slow	JJR	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
(	(	(	O	O	O
mean	mean	JJ	B-NP	O	O
C	C	NN	I-NP	O	O
max	max	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
mean	mean	JJ	I-NP	O	O
T	T	NN	I-NP	O	O
max	max	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
1	1	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
lesser	less	JJR	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
(	(	(	O	O	O
mean	mean	JJ	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Magnesium	Magnesium	NN	B-NP	O	S-drug-ME-1
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug-ME-1
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacids	antacid	NNS	B-NP	O	S-group-ME-1
,	,	,	O	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
significantly	significantly	RB	B-VP	O	O
decreased	decrease	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
(	(	(	O	O	O
48	48	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Separating	Separate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antacid	antacid	NN	B-NP	O	S-group-ME-1
and	and	CC	I-NP	O	O
lomefloxacin	lomefloxacin	NN	I-NP	O	S-drug-ME-2
minimizes	minimize	VBZ	B-VP	O	O
this	this	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
precede	precede	VB	I-VP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
dosing	dosing	NN	I-NP	O	O
by	by	IN	B-PP	O	O
4	4	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
or	or	CC	O	O	O
follow	follow	VB	B-VP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
dosing	dosing	NN	I-NP	O	O
by	by	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Two	Two	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
(	(	(	O	O	O
equivalent	equivalent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
1	1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
3	3	CD	I-NP	O	O
cups	cup	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
American	American	JJ	B-NP	O	O
coffee	coffee	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
16	16	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
,	,	,	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
blood	blood	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
after	after	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
dosed	dose	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
qd	qd	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
or	or	CC	O	O	O
clinically	clinically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
major	major	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
paraxanthine	paraxanthine	NN	B-NP	O	S-drug_n
.	.	.	O	O	O

No	No	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
individuals	individual	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
consume	consume	VBP	B-VP	O	O
greater	great	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
geriatric	geriatric	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
,	,	,	O	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
generally	generally	RB	I-VP	O	O
believed	believe	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
susceptible	susceptible	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
moderate	moderate	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
marked	marked	JJ	B-NP	O	O
interference	interference	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
accompany	accompany	VBP	B-VP	O	O
high	high	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interference	interference	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
resulted	result	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
half	half	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Elevated	Elevate	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
members	member	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	B-group-ME-2
class	class	NN	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Omeprazole	Omeprazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
,	,	,	O	O	O
C	C	NN	B-NP	B-protein	O
max	max	NN	I-NP	I-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
T	T	NN	B-NP	O	O
max	max	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
qd	qd	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
13	13	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

Changes	Change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
,	,	,	O	O	O
C	C	NN	B-NP	B-protein	O
max	max	NN	I-NP	I-protein	O
,	,	,	O	O	O
C	C	NN	B-NP	O	O
min	min	NN	I-NP	O	O
or	or	CC	O	O	O
T	T	NN	B-NP	O	O
max	max	NN	I-NP	O	O
(	(	(	O	O	O
although	although	IN	B-SBAR	O	O
C	C	NN	B-NP	B-protein	O
max	max	NN	I-NP	I-protein	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
extended	extend	VBN	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
capsules	capsule	NNS	I-NP	O	O
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
tid	tid	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
qd	qd	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
five	five	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
15	15	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
males	male	NNS	I-NP	O	O
.	.	.	O	O	O

Lomefloxacin	Lomefloxacin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
Probenecid	Probenecid	NN	B-NP	O	S-drug
slows	slow	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lome	lome	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
floxacin	floxacin	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
63	63	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
increases	increase	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
T	T	NN	I-NP	O	O
max	max	NN	I-NP	O	O
and	and	CC	O	O	O
mean	mean	JJ	B-NP	O	O
C	C	NN	I-NP	O	O
max	max	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
.	.	.	O	O	O

Terfenadine	Terfenadine	NN	B-NP	O	S-drug
:	:	:	O	O	O
No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
or	or	CC	O	O	O
corrected	correct	VBN	B-NP	O	O
QT	QT	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
metabolite	metabolite	NN	I-NP	O	O
or	or	CC	I-NP	O	O
lomefloxacin	lomefloxacin	NN	I-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
in	in	IN	B-PP	O	O
28	28	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
males	male	NNS	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Quinolones	Quinolone	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group-EF-2
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	B-protein	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-ADVP	O	O
clinically	clinically	RB	I-ADVP	O	O
or	or	CC	I-ADVP	O	O
statistically	statistically	RB	I-ADVP	O	O
significant	significant	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
or	or	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
enantiomer	enantiomer	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
7	7	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
males	male	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
both	both	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
lomefloxacin	lomefloxacin	NN	I-NP	O	S-drug
under	under	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
b	b	NN	I-NP	O	B-group-ME-1
-	-	HYPH	B-NP	O	I-group-ME-1
lactam	lactam	NN	I-NP	O	I-group-ME-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
renal	renal	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
loracarbef	loracarbef	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
for	for	IN	B-PP	O	O
loracarbef	loracarbef	NN	B-NP	O	S-drug
.	.	.	O	O	O

Loratadine	Loratadine	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
controlled	control	VBN	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	B-protein	O
0	0	CD	I-NP	I-protein	O
-	-	HYPH	O	O	O
24	24	CD	B-NP	O	O
hrs	hr	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
loratadine	loratadine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
descarboethoxyloratadine	descarboethoxyloratadine	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
loratadine	loratadine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
each	each	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
24	24	CD	B-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
study	study	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
loratadine	loratadine	NN	B-NP	O	S-drug
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
electrocardiographic	electrocardiographic	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
,	,	,	O	O	O
clinical	clinical	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
,	,	,	O	O	O
vital	vital	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
QTc	QTc	NN	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sedation	sedation	NN	B-NP	O	O
or	or	CC	I-NP	O	O
syncope	syncope	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	B-protein	O
0	0	CD	I-NP	I-protein	O
-	-	HYPH	O	O	O
24	24	CD	B-NP	O	O
hrs	hr	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
loratadine	loratadine	NN	B-NP	O	S-drug-ME-2
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
above	above	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
summarized	summarize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
TABLE	TABLE	NN	B-NP	B-DNA	O
1	1	CD	I-NP	I-DNA	O
.	.	.	O	O	O

TABLE	TABLE	NN	B-NP	O	O
1	1	CD	I-NP	O	O
Effects	Effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
Plasma	Plasma	NN	B-NP	O	O
Concentrations	Concentration	NNS	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	B-protein	O
0	0	CD	I-NP	I-protein	O
-	-	HYPH	O	O	O
24	24	CD	B-NP	O	O
hrs	hr	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
Loratadine	Loratadine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Descarboethoxyloratadine	Descarboethoxyloratadine	NN	I-NP	O	S-drug
After	After	IN	B-PP	O	O
10	10	CD	B-NP	O	O
Days	Day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Coadministration	Coadministration	NN	B-NP	O	O
(	(	(	O	O	O
Loratadine	Loratadine	NN	B-NP	O	S-drug
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
Normal	Normal	JJ	B-NP	O	O
Volunteers	Volunteer	NNS	I-NP	O	O

Loratadine	Loratadine	NNP	B-NP	O	S-drug
Descarboethoxyloratadine	Descarboethoxyloratadine	NNP	I-NP	O	S-drug

Erythromycin	Erythromycin	NN	B-NP	O	S-drug
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
q8h	q8h	NN	I-NP	O	O
)	)	)	O	O	O
+	+	SYM	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
46	46	CD	B-NP	O	O
%	%	NN	I-NP	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
(	(	(	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
qid	qid	NN	I-NP	O	O
)	)	)	O	O	O
+	+	SYM	O	O	O
103	103	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
6	6	CD	B-NP	O	O
%	%	NN	I-NP	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
q12h	q12h	NN	I-NP	O	O
)	)	)	O	O	O
+	+	SYM	O	O	O
307	307	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
73	73	CD	B-NP	O	O
%	%	NN	I-NP	O	O

There	There	EX	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
and	and	CC	I-NP	O	O
loratadine	loratadine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Tablets	Tablet	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-EF-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
lorazepam	lorazepam	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
produce	produce	VBP	B-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
or	or	CC	I-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Injection	Injection	NN	B-NP	O	O
:	:	:	O	O	O
Lorazepam	Lorazepam	NN	B-NP	O	S-drug-EF-1
injection	injection	NN	I-NP	O	O
,	,	,	O	O	O
like	like	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
injectable	injectable	JJ	I-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group-EF-1
,	,	,	O	O	O
produces	produce	VBZ	B-VP	O	O
depression	depression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ethyl	ethyl	NN	B-NP	O	B-drug-EF-2
alcohol	alcohol	NN	I-NP	O	E-drug-EF-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
MAO	MAO	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
antidepressants.When	antidepressants.When	JJ	I-NP	O	O
scopolamine	scopolamine	NN	I-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
injectable	injectable	JJ	B-NP	O	O
lorazepam	lorazepam	NN	I-NP	O	S-drug-EF-2
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sedation	sedation	NN	B-NP	O	O
,	,	,	O	O	O
hallucinations	hallucination	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
irrational	irrational	JJ	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	B-protein	S-drug-ME-1
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
losartan	losartan	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
,	,	,	O	O	O
two	two	CD	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
conversion	conversion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
losartan	losartan	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
intravenous	intravenous	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
losartan	losartan	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Fluconazole	Fluconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2C9	2C9	NN	I-NP	I-protein	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
active	active	JJ	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
losartan	losartan	NN	B-NP	O	S-drug-ME-2
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
consequences	consequence	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
losartan	losartan	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2C9	2C9	NN	I-NP	I-protein	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
examined	examine	VBN	I-VP	O	O
.	.	.	O	O	O

Subjects	Subject	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
metabolize	metabolize	VB	I-VP	O	O
losartan	losartan	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
active	active	JJ	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
,	,	,	I-NP	O	O
rare	rare	JJ	I-NP	O	O
defect	defect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2C9	2C9	NN	I-NP	I-protein	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
conversion	conversion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
losartan	losartan	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
primarily	primarily	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
2C9	2C9	NN	I-NP	I-protein	O
and	and	CC	B-NP	O	O
not	not	RB	I-NP	O	O
P450	P450	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
block	block	VBP	B-VP	O	O
angiotensin	angiotensin	NN	B-NP	B-protein	O
II	II	CD	I-NP	I-protein	O
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug
,	,	,	O	O	O
amiloride	amiloride	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
salt	salt	NN	B-NP	O	O
substitutes	substitute	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
potassium	potassium	NN	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
losartan	losartan	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
blunted	blunt	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	B-group
-	-	HYPH	I-NP	B-DNA	I-group
steroidal	steroidal	JJ	I-NP	I-DNA	I-group
anti	anti	AFX	I-NP	I-DNA	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drug	drug	NN	I-NP	O	E-group
indomethacin	indomethacin	NN	I-NP	O	S-drug-EF-2

CYP3A4	CYP3A4	NN	B-NP	B-protein	O
Interactions	Interaction	NNS	I-NP	O	O

Lovastatin	Lovastatin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
but	but	CC	O	O	O
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitory	inhibitory	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Potent	Potent	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
below	below	IN	B-ADVP	O	O
)	)	)	O	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
by	by	IN	B-PP	O	O
reducing	reduce	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Pharmacokinetics	Pharmacokinetic	NNS	B-NP	O	O
.	.	.	O	O	O

Itraconazole	Itraconazole	NN	B-NP	O	S-drug
Ketoconazole	Ketoconazole	NN	I-NP	O	S-drug
Erythromycin	Erythromycin	NN	I-NP	O	S-drug
Clarithromycin	Clarithromycin	NN	I-NP	O	S-drug
Telithromycin	Telithromycin	NN	I-NP	O	S-drug
HIV	HIV	NN	I-NP	O	B-group
protease	protease	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
Nefazodone	Nefazodone	NN	I-NP	O	S-drug
Cyclosporine	Cyclosporine	NN	I-NP	O	S-drug
Large	Large	JJ	I-NP	O	O
quantities	quantity	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
quart	quart	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
)	)	)	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
myopathy	myopathy	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
lipid	lipid	NN	I-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
potent	potent	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
myopathy	myopathy	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

See	See	NNP	B-NP	O	O
WARNINGS	WARNINGS	NNP	I-NP	O	O
,	,	,	O	O	O
Myopathy	Myopathy	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Rhabdomyolysis	Rhabdomyolysis	NN	I-NP	O	O
.	.	.	O	O	O

Gemfibrozil	Gemfibrozil	NN	B-NP	O	S-drug
Other	Other	JJ	I-NP	O	O
fibrates	fibrate	NNS	I-NP	O	S-group
Niacin	Niacin	NN	I-NP	O	S-drug
(	(	(	O	O	O
nicotinic	nicotinic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
)	)	)	O	O	O
(	(	(	O	O	O
=	=	SYM	O	O	O
1	1	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O

Other	Other	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O

Danazol	Danazol	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
rhabdomyolysis	rhabdomyolysis	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
danazol	danazol	NN	B-NP	O	S-drug-EF-1
particularly	particularly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
see	see	VB	B-VP	O	O
WARNINGS	WARNINGS	NNS	B-NP	O	O
,	,	,	O	O	O
Myopathy	Myopathy	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Rhabdomyolysis	Rhabdomyolysis	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
Verapamil	Verapamil	NN	I-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
rhabdomyolysis	rhabdomyolysis	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
either	either	CC	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
closely	closely	RB	I-NP	O	O
related	related	JJ	I-NP	O	O
member	member	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
HMG	HMG	NN	I-NP	B-protein	B-group-EF-2
-	-	HYPH	B-NP	O	I-group-EF-2
CoA	CoA	NN	I-NP	B-protein	I-group-EF-2
reductase	reductase	NN	I-NP	I-protein	I-group-EF-2
inhibitor	inhibitor	NN	I-NP	O	I-group-EF-2
class	class	NN	I-NP	O	E-group-EF-2
(	(	(	O	O	O
see	see	VB	B-VP	O	O
WARNINGS	WARNINGS	NNS	B-NP	O	O
,	,	,	O	O	O
Myopathy	Myopathy	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Rhabdomyolysis	Rhabdomyolysis	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Coumarin	Coumarin	NN	B-NP	O	B-group
Anticoagulants	Anticoagulant	NNS	I-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
warfarin	warfarin	VB	I-VP	O	S-drug
treated	treat	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
another	another	DT	B-NP	O	O
HMG	HMG	NN	I-NP	B-protein	B-group-EF-1
-	-	HYPH	B-NP	O	I-group-EF-1
CoA	CoA	NN	I-NP	B-protein	I-group-EF-1
reductase	reductase	NN	I-NP	I-protein	I-group-EF-1
inhibitor	inhibitor	NN	I-NP	O	E-group-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
less	less	JJR	I-NP	O	O
than	than	IN	I-NP	O	O
two	two	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
second	second	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
low	low	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
bleeding	bleed	VBG	B-VP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
increased	increase	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-EF-1
anticoagulants	anticoagulant	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-AD-1
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
be	be	VB	B-VP	O	O
determined	determine	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-AD-2
and	and	CC	O	O	O
frequently	frequently	RB	B-ADVP	O	O
enough	enough	RB	I-ADVP	O	O
during	during	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
to	to	TO	B-VP	O	O
insure	insure	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
alteration	alteration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
occurs	occur	VBZ	B-VP	O	O
.	.	.	O	O	O

Once	Once	RB	O	O	O
a	a	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
documented	document	VBN	I-VP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
usually	usually	RB	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
changed	change	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
repeated	repeat	VBN	I-VP	O	O
.	.	.	O	O	O

Lovastatin	Lovastatin	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
bleeding	bleeding	NN	B-NP	O	O
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
not	not	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
.	.	.	O	O	O

Propranolol	Propranolol	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	NNP	B-NP	O	O
Hypoglycemic	Hypoglycemic	NNP	I-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MEVACOR	MEVACOR	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
hypercholesterolemic	hypercholesterolemic	JJ	B-NP	O	O
noninsulin	noninsulin	NN	I-NP	O	O
dependent	dependent	JJ	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
glipizide	glipizide	NN	B-NP	O	S-drug
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
chlorpropamide	chlorpropamide	NN	B-NP	O	S-drug

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rare	rare	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
depression	depression	NN	I-NP	O	O
,	,	,	O	O	O
stupor	stupor	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
hypotension	hypotension	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
loxapine	loxapine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
lorazepam	lorazepam	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
loxapine	loxapine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
CNS	CNS	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
active	active	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
loxapine	loxapine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
active	active	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lymecycline	lymecycline	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
simultaneous	simultaneous	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indigestion	indigestion	NN	B-NP	O	O
remedies	remedy	NNS	I-NP	O	O
,	,	,	O	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
zinc	zinc	NN	I-NP	O	S-drug-ME-2
supplements	supplement	NNS	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
less	less	RBR	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
while	while	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
lymecycline	lymecycline	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Warfarin	Warfarin	NNP	B-NP	O	S-drug-EF-1
:	:	:	O	O	O
Meclofenamate	Meclofenamate	NN	B-NP	O	B-drug-EF-2
sodium	sodium	NN	I-NP	O	E-drug-EF-2
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
meclofenamate	meclofenamate	NN	B-NP	O	B-drug-AD-1
sodium	sodium	NN	I-NP	O	E-drug-AD-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
excessive	excessive	JJ	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-1
may	may	MD	B-VP	O	O
lower	lower	VB	I-VP	O	O
meclofenamate	meclofenamate	NN	B-NP	O	B-drug-ME-2
sodium	sodium	NN	I-NP	O	E-drug-ME-2
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
competing	compete	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
protein	protein	NN	B-NP	B-DNA	O
-	-	HYPH	O	I-DNA	O
binding	bind	VBG	B-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meclofenamate	meclofenamate	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
meclofenamate	meclofenamate	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Meclofenamate	Meclofenamate	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Greater	Greater	JJ	B-NP	O	O
fecal	fecal	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
loss	loss	NN	I-NP	O	O
results	result	VBZ	B-VP	O	O
from	from	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
from	from	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Propoxyphene	Propoxyphene	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propoxyphene	propoxyphene	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meclofenamate	meclofenamate	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	B-drug
hydroxides	hydroxide	NNS	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
meclofenamate	meclofenamate	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-AD-1
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ponstel	Ponstel	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
generally	generally	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
competitively	competitively	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
accumulation	accumulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rabbit	rabbit	NN	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
slices	slice	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
indicate	indicate	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
could	could	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Reports	Report	NNS	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
consideration	consideration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
post	post	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
marketing	market	VBG	B-VP	O	O
observations	observation	NNS	B-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group-EF-2
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
response	response	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ponstel	Ponstel	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
failure	failure	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
to	to	TO	B-VP	O	O
assure	assure	VB	I-VP	O	O
diuretic	diuretic	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
produced	produce	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
minimum	minimum	JJ	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
NSAID	NSAID	NN	I-NP	O	S-group
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
subjects	subject	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-EF-2
on	on	IN	B-PP	O	O
GI	GI	NN	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
synergistic	synergistic	JJ	B-ADJP	O	O
,	,	,	O	O	O
such	such	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
together	together	RB	B-ADVP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
GI	GI	NN	I-NP	O	O
bleeding	bleed	VBG	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
study	study	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
ingestion	ingestion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
antacid	antacid	NN	I-NP	O	S-group
containing	contain	VBG	B-VP	O	O
1.7	1.7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
gram	gram	NN	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	B-drug-ME-1
hydroxide	hydroxide	NN	I-NP	O	E-drug-ME-1
with	with	IN	B-PP	O	O
500	500	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mefenamic	mefenamic	JJ	B-NP	O	B-drug-ME-2
acid	acid	NN	I-NP	O	E-drug-ME-2
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mefenamic	mefenamic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
by	by	IN	B-PP	O	O
125	125	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
36	36	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O
A	A	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
including	include	VBG	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
lovastatin	lovastatin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
trimethoprim	trimethoprim	NN	I-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mefenamic	mefenamic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
altered	alter	VBN	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Ponstel	Ponstel	NNP	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
explored	explore	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
detail	detail	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
one	one	CD	B-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiopulmonary	cardiopulmonary	JJ	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
full	full	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
taking	take	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
beta	beta	NN	I-NP	O	B-group
blocker	blocker	NN	I-NP	O	E-group
(	(	(	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Mefloquineuine	Mefloquineuine	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
compromised	compromise	VBN	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
benefits	benefit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
weighed	weigh	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
danger	danger	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
,	,	,	O	O	O
halofantrine	halofantrine	NN	B-NP	O	S-drug-AD-1
must	must	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
or	or	CC	O	O	O
subsequent	subsequent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
related	related	JJ	I-NP	O	O
compounds	compound	NNS	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
quinine	quinine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
chloroquine	chloroquine	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
electrocardiographic	electrocardiographic	JJ	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
malaria	malaria	NN	I-NP	O	O
,	,	,	O	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
delayed	delay	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
12	12	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
evidence	evidence	NN	B-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
halofantrine	halofantrine	NN	B-NP	O	S-drug
after	after	IN	B-SBAR	O	O
Mefloquineuine	Mefloquineuine	NN	B-NP	O	O
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
lengthening	lengthening	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

Clinically	Clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
QTc	QTc	NN	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Mefloquineuine	Mefloquineuine	NN	B-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
only	only	RB	I-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
kind	kind	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
theoretically	theoretically	RB	B-ADVP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
alter	alter	VB	I-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
anti	anti	AFX	B-NP	O	B-drug-EF-2
-	-	HYPH	I-NP	O	I-drug-EF-2
arrhythmic	arrhythmic	JJ	B-ADJP	O	E-drug-EF-2
or	or	CC	O	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group-EF-2
channel	channel	NN	I-NP	O	I-group-EF-2
blockers	blocker	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
H1	H1	NN	B-NP	B-protein	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
blocking	block	VBG	B-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
and	and	CC	I-NP	O	O
phenothiazines	phenothiazine	NNS	I-NP	O	S-group-EF-2
)	)	)	O	O	O
might	might	MD	B-VP	O	O
also	also	RB	I-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
conclusively	conclusively	RB	B-ADVP	O	O
establish	establish	VBP	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Mefloquineuine	Mefloquineuine	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
above	above	RB	I-NP	O	O
listed	list	VBN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	S-group-EF-1
(	(	(	O	O	O
eg	eg	FW	O	O	O
,	,	,	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug-EF-1
acid	acid	NN	I-NP	O	E-drug-EF-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-EF-1
or	or	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
seizure	seizure	NN	B-NP	O	O
control	control	NN	I-NP	O	O
by	by	IN	B-PP	O	O
lowering	lower	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticonvulsant	anticonvulsant	NN	I-NP	O	S-group
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
concurrently	concurrently	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
antiseizure	antiseizure	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Mefloquine	Mefloquine	NN	I-NP	O	S-drug
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
antiseizure	antiseizure	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
monitored	monitor	VBN	B-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjusted	adjust	VBN	B-VP	O	O
appropriately	appropriately	RB	B-ADVP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
taken	take	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
live	live	JJ	I-NP	O	B-group-EF-2
typhoid	typhoid	JJ	I-NP	O	I-group-EF-2
vaccines	vaccine	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
attenuation	attenuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
immunization	immunization	NN	B-NP	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
excluded	exclude	VBN	I-VP	O	O
.	.	.	O	O	O

Vaccinations	Vaccination	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
attenuated	attenuate	VBN	B-NP	O	O
live	live	JJ	I-NP	O	O
bacteria	bacteria	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
be	be	VB	I-VP	O	O
completed	complete	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
3	3	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Mefloquine	Mefloquine	NN	B-NP	O	S-drug-AD-1
on	on	IN	B-PP	O	O
travelers	traveler	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
comedication	comedication	NN	B-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-NP	O	O
diabetics	diabetic	NNS	I-NP	O	O
or	or	CC	O	O	O
patients	patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
checked	check	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
departure	departure	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sulfadoxine	sulfadoxine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
pyrimethamine	pyrimethamine	NN	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
.	.	.	O	O	O

Broad	Broad	NNP	B-NP	O	B-group
-	-	HYPH	O	O	I-group
Spectrum	Spectrum	NNP	B-NP	O	I-group
Antibiotics	Antibiotic	NNPS	I-NP	O	E-group
-	-	HYPH	B-NP	O	O
Broad	Broad	NN	I-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
spectrum	spectrum	NN	I-NP	O	I-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
sterilize	sterilize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bowel	bowel	NN	I-NP	O	O
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
the	the	DT	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group
K	K	NN	I-NP	O	E-group
contribution	contribution	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
microflora	microflora	NN	I-NP	O	O
.	.	.	O	O	O

Cephalosporins	Cephalosporin	NNS	B-NP	O	S-group
-	-	HYPH	O	O	O
Cephalosporins	Cephalosporin	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
side	side	NN	B-NP	O	O
chains	chain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
N	N	NN	B-NP	O	O
-	-	HYPH	O	O	O
methylthiotetrazole	methylthiotetrazole	NN	B-NP	O	O
(	(	(	O	O	O
cefmenoxime	cefmenoxime	NN	B-NP	O	S-drug
,	,	,	O	O	O
cefoperazone	cefoperazone	NN	B-NP	O	S-drug
,	,	,	O	O	O
cefotetan	cefotetan	NN	B-NP	O	S-drug
,	,	,	O	O	O
cefamandole	cefamandole	NN	B-NP	O	S-drug
,	,	,	O	O	O
latamoxef	latamoxef	JJ	B-ADJP	O	S-drug
)	)	)	O	O	O
or	or	CC	O	O	O
methylthiadiazole	methylthiadiazole	NN	B-NP	O	O
(	(	(	O	O	O
cefazolin	cefazolin	NN	B-NP	O	S-drug
)	)	)	O	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
vitamin	vitamin	NN	B-NP	O	O
K	K	NN	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hypoprothrombinemia	hypoprothrombinemia	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
cephalosporins	cephalosporin	NNS	I-NP	O	S-group
are	be	VBP	B-VP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
vitamin	vitamin	NN	I-NP	I-protein	O
K	K	NN	I-NP	I-protein	O
epoxide	epoxide	NN	I-NP	I-protein	O
reductase	reductase	NN	I-NP	I-protein	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
Concomitant	Concomitant	JJ	I-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group-ME-2
K	K	NN	I-NP	O	E-group-ME-2
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
K	K	NN	I-NP	O	E-group
.	.	.	O	O	O

Colestipol	Colestipol	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
Concomitant	Concomitant	JJ	I-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
colestipol	colestipol	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group-ME-2
K	K	NN	I-NP	O	E-group-ME-2
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
K	K	NN	I-NP	O	E-group
.	.	.	O	O	O

Mineral	Mineral	JJ	B-NP	O	B-drug_n
Oil	Oil	NN	I-NP	B-protein	E-drug_n
-	-	HYPH	B-NP	O	O
Concomitant	Concomitant	JJ	I-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mineral	mineral	JJ	B-NP	O	B-drug_n-ME-1
oil	oil	NN	I-NP	O	E-drug_n-ME-1
and	and	CC	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group-ME-2
K	K	NN	I-NP	O	E-group-ME-2
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
K	K	NN	I-NP	O	E-group
.	.	.	O	O	O

Orlistat	Orlistat	NNP	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
Orlistat	Orlistat	NNP	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-ME-2
K	K	NN	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Salicylates	Salicylate	NNS	B-NP	O	S-group
-	-	HYPH	O	O	O
Salicylates	Salicylate	NNS	B-NP	O	S-group
in	in	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
vitamin	vitamin	NN	B-NP	B-protein	O
K	K	NN	I-NP	I-protein	O
epoxide	epoxide	NN	I-NP	I-protein	O
reductase	reductase	NN	I-NP	I-protein	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	O
K	K	NN	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
-	-	HYPH	I-NP	O	O
Vitamin	Vitamin	NN	I-NP	B-protein	B-group-EF-1
K	K	NN	I-NP	I-protein	E-group-EF-1
can	can	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2

Nabilone	Nabilone	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
other	other	JJ	B-NP	O	O
psychoactive	psychoactive	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
or	or	CC	O	O	O
CNS	CNS	NN	B-NP	O	B-group-AD-2
depressants	depressant	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-AD-2
and	and	CC	O	O	O
narcotic	narcotic	JJ	B-NP	O	B-group-AD-2
analgesics	analgesic	NNS	I-NP	O	E-group-AD-2
,	,	,	B-PP	O	O
or	or	CC	I-PP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
psychiatric	psychiatric	JJ	B-NP	O	O
disorder	disorder	NN	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
manic	manic	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
depressive	depressive	JJ	I-NP	O	O
illness	illness	NN	I-NP	O	O
and	and	CC	I-NP	O	O
schizophrenia	schizophrenia	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Nabilone	Nabilone	NNP	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
secobarbitone	secobarbitone	NN	B-NP	O	B-brand-EF-2
sodium	sodium	NN	I-NP	O	E-brand-EF-2
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
codeine	codeine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
affinity	affinity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
,	,	,	O	O	O
6MNA	6MNA	NN	B-NP	O	S-drug_n
may	may	MD	B-VP	O	O
displace	displace	VB	I-VP	O	O
other	other	JJ	B-NP	O	O
protein	protein	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
binding	bind	VBG	I-NP	O	O
site	site	NN	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
nabumetone	nabumetone	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-MU-M
since	since	IN	B-SBAR	O	O
interactions	interaction	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
seen	see	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-IN-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacid	antacid	NN	B-NP	O	S-group
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6MNA	6MNA	NN	B-NP	O	S-drug_n
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
food	food	NN	B-NP	O	O
or	or	CC	I-NP	O	O
milk	milk	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
more	more	RBR	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6MNA	6MNA	NN	B-NP	O	S-drug_n
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	B-protein	B-group-IN-1
-	-	HYPH	B-NP	I-protein	I-group-IN-1
adrenergic	adrenergic	JJ	I-NP	I-protein	I-group-IN-1
receptor	receptor	NN	I-NP	I-protein	I-group-IN-1
blocking	block	VBG	B-VP	O	I-group-IN-1
agents	agent	NNS	B-NP	O	E-group-IN-1
:	:	:	O	O	O
Anesthetics	Anesthetic	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
general	general	JJ	B-ADJP	O	O
:	:	:	O	O	O
exaggeration	exaggeration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
.	.	.	O	O	O

Antidiabetic	Antidiabetic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
oral	oral	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
or	or	CC	I-NP	O	O
hyperglycemia	hyperglycemia	NN	I-NP	O	O
;	;	:	O	O	O

adjust	adjust	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antidiabetic	antidiabetic	JJ	B-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
accordingly	accordingly	RB	B-ADVP	O	O
.	.	.	O	O	O

Catecholamine	Catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
additive	additive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
;	;	:	O	O	O

monitor	monitor	NN	B-NP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
excessive	excessive	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
vertigo	vertigo	NN	B-NP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
,	,	,	O	O	O
postural	postural	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Response	Response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
Treatment	Treatment	NNP	B-NP	O	O
for	for	IN	B-PP	O	O
Anaphylactic	Anaphylactic	NNP	B-NP	O	O
Reaction	Reaction	NNP	I-NP	O	O
:	:	:	O	O	O
While	While	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
anaphylactic	anaphylactic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allergens	allergen	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
reactive	reactive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
,	,	,	O	O	O
either	either	CC	O	O	O
accidental	accidental	JJ	B-NP	O	O
,	,	,	I-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
or	or	CC	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
unresponsive	unresponsive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
allergic	allergic	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
based	base	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
SYNAREL	SYNAREL	NN	B-NP	O	S-brand
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
nafarelin	nafarelin	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
peptide	peptide	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
degraded	degrade	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
peptidase	peptidase	NN	B-NP	B-protein	O
and	and	CC	B-PP	O	O
not	not	RB	B-PP	O	O
by	by	IN	I-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
only	only	RB	B-NP	O	O
about	about	RB	I-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
bound	bind	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
C	C	NN	I-NP	O	O
,	,	,	O	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Tetracycline	Tetracycline	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
bacteriostatic	bacteriostatic	JJ	I-NP	O	B-group
antibiotic	antibiotic	NN	I-NP	O	E-group
,	,	,	O	O	O
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bactericidal	bactericidal	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
penicillin	penicillin	NN	B-NP	B-protein	S-drug-EF-2
and	and	CC	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
information	information	NN	I-NP	O	O
available	available	JJ	B-ADJP	O	O

Elevated	Elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	S-group-ME-2
use	use	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
monitoring	monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
and	and	CC	O	O	O
dosage	dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
adjusted	adjust	VBN	B-VP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
required	require	VBN	B-VP	O	O
.	.	.	O	O	O

Quinolones	Quinolone	NNS	B-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
.	.	.	O	O	O

Quinolones	Quinolone	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
nalidixic	nalidixic	JJ	B-NP	O	B-drug-EF-1
acid	acid	NN	I-NP	O	E-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
test	test	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Nitrofurantoin	Nitrofurantoin	NNP	B-NP	O	S-drug-EF-1
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nalidixic	nalidixic	JJ	B-NP	O	B-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
,	,	,	O	O	O
aluminum	aluminum	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
calcium	calcium	NN	B-NP	O	S-drug
;	;	:	O	O	O

sucralfate	sucralfate	JJ	B-NP	O	S-drug
or	or	CC	I-NP	O	O
divalent	divalent	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
trivalent	trivalent	JJ	I-NP	O	O
cations	cation	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
iron	iron	NN	B-NP	O	S-drug
;	;	:	O	O	O

multivitamins	multivitamin	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
zinc	zinc	NN	B-NP	O	S-drug
;	;	:	O	O	O

and	and	CC	O	O	O
Videx	Videx	NNP	B-NP	O	S-brand-ME-1
,	,	,	O	O	O
(	(	(	O	O	O
Didanosine	Didanosine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
,	,	,	O	O	O
chewable	chewable	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
buffered	buffered	JJ	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
powder	powder	NN	I-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
solution	solution	NN	I-NP	O	O
may	may	MD	B-VP	O	O
substantially	substantially	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
considerably	considerably	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
than	than	IN	B-SBAR	O	O
desired	desire	VBN	B-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
period	period	NN	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	I-PP	O	O
within	within	IN	I-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
period	period	NN	I-NP	O	O
after	after	IN	B-PP	O	O
nalidixic	nalidixic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Elevated	Elevated	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-1
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
made	make	VBN	B-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
possible	possible	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
REVIA	REVIA	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
other	other	JJ	B-ADJP	O	O
than	than	IN	B-SBAR	O	O
opiates	opiate	NNS	B-NP	O	S-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
REVIA	REVIA	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
REVIA	REVIA	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	I-NP	O	O
disulfiram	disulfiram	NN	I-NP	O	S-drug-EF-2
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
hepatotoxic	hepatotoxic	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
ordinarily	ordinarily	RB	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
unless	unless	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
probable	probable	JJ	I-NP	O	O
benefits	benefit	NNS	I-NP	O	O
outweigh	outweigh	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
risks	risk	NNS	I-NP	O	O
.	.	.	O	O	O

Lethargy	Lethargy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
somnolence	somnolence	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
REVIA	REVIA	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	I-NP	O	O
thioridazine	thioridazine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
REVIA	REVIA	NN	B-NP	B-protein	S-brand-EF-1
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
benefit	benefit	VB	I-VP	O	O
from	from	IN	B-PP	O	O
opioid	opioid	JJ	B-NP	O	S-group-EF-2
containing	contain	VBG	I-NP	O	O
medicines	medicine	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cough	cough	NN	B-NP	O	O
and	and	CC	O	O	O
cold	cold	JJ	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
,	,	,	O	O	O
antidiarrheal	antidiarrheal	JJ	B-NP	O	O
preparations	preparation	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
opioid	opioid	JJ	B-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
emergency	emergency	NN	I-NP	O	O
situation	situation	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
opioid	opioid	JJ	B-NP	O	O
analgesia	analgesia	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
REVIA	REVIA	NN	B-NP	B-protein	S-brand-EF-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
opioid	opioid	NN	B-NP	O	S-group-EF-2
required	require	VBN	B-VP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
usual	usual	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
resulting	result	VBG	I-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
depression	depression	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
deeper	deep	JJR	B-ADJP	O	O
and	and	CC	O	O	O
more	more	RBR	B-ADJP	O	O
prolonged	prolonged	JJ	I-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
states	state	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
anion	anion	NN	I-NP	O	O
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
affinity	affinity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
displace	displace	VB	I-VP	O	O
from	from	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
binding	bind	VBG	I-NP	O	O
sites	site	NNS	I-NP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	B-ADVP	O	O
albumin	albumin	NN	B-NP	B-protein	O
-	-	HYPH	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
.	.	.	O	O	O

Theoretically	Theoretically	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
naproxen	naproxen	NN	I-NP	O	S-drug
anion	anion	NN	I-NP	O	O
itself	itself	PRP	B-NP	O	O
could	could	MD	B-VP	O	O
likewise	likewise	RB	I-VP	O	O
be	be	VB	I-VP	O	O
displaced	displace	VBN	I-VP	O	O
.	.	.	O	O	O

Short	Short	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
controlled	control	VBN	I-NP	O	O
studies	study	NNS	I-NP	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
show	show	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
affects	affect	VBZ	B-VP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
individuals	individual	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
type	type	NN	I-NP	O	I-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
nonetheless	nonetheless	RB	B-ADVP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
interactions	interaction	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
seen	see	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
class	class	NN	I-NP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
hydantoin	hydantoin	NN	I-NP	O	S-group
,	,	,	I-NP	O	O
sulfonamide	sulfonamide	NN	I-NP	O	S-group
or	or	CC	I-NP	O	O
sulfonylurea	sulfonylurea	NN	I-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
to	to	TO	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naproxen	naproxen	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
naproxen	naproxen	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
displaced	displace	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
binding	bind	VBG	I-NP	O	O
sites	site	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-AD-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
peak	peak	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
some	some	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
class	class	NN	I-NP	O	O
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Naproxen	Naproxen	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
beta	beta	SYM	I-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
blockers	blocker	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug-ME-1
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
increases	increase	VBZ	B-VP	O	O
naproxen	naproxen	JJ	B-NP	O	S-drug-ME-2
anion	anion	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
extends	extend	VBZ	B-VP	O	O
its	its	PRP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
naproxen	naproxen	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Naproxen	Naproxen	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	O	B-drug-ME-1
sodium	sodium	NN	I-NP	O	E-drug-ME-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
animal	animal	NN	I-NP	O	O
model	model	NN	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
/	/	NNP	I-NP	O	O
Laboratory	Laboratory	NNP	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
Naproxen	Naproxen	NNP	I-NP	O	S-drug
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
platelet	platelet	NN	B-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
and	and	CC	O	O	O
prolong	prolong	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
kept	keep	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mind	mind	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
bleeding	bleed	VBG	B-VP	O	O
times	time	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
values	value	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
17	17	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
ketogenic	ketogenic	JJ	I-NP	O	O
steroids	steroid	NNS	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
m	m	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
dinitrobenzene	dinitrobenzene	NN	I-NP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
assay	assay	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
17	17	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hydroxy	hydroxy	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	O
measurements	measurement	NNS	I-NP	O	O
(	(	(	O	O	O
Porter	Porter	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Silber	Silber	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
)	)	)	O	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
artifactually	artifactually	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
be	be	VB	B-VP	O	O
temporarily	temporarily	RB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
72	72	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
adrenal	adrenal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
performed	perform	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
Porter	Porter	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Silber	Silber	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

Naproxen	Naproxen	NNP	B-NP	O	S-drug
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
assays	assay	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hydroxy	hydroxy	NN	I-NP	O	O
indoleacetic	indoleacetic	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
(	(	(	O	O	O
5HIAA	5HIAA	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Ergot	Ergot	NN	B-NP	O	S-group
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
prolonged	prolonged	JJ	B-NP	O	O
vasospastic	vasospastic	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
theoretical	theoretical	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
,	,	,	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug-AD-1
-	-	HYPH	B-VP	O	O
containing	contain	VBG	I-VP	O	O
or	or	CC	O	O	O
ergot	ergot	NN	B-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
type	type	NN	I-NP	O	I-group-AD-1
medications	medication	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
like	like	IN	B-PP	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	S-drug-AD-1
or	or	CC	O	O	O
methysergide	methysergide	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
and	and	CC	O	O	O
naratriptan	naratriptan	NN	B-NP	O	S-drug-AD-2
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naratriptan	naratriptan	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
5	5	CD	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
HT1	HT1	NN	I-NP	O	I-group
agonists	agonist	NNS	I-NP	O	E-group
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
migraine	migraine	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
their	their	PRP$	B-NP	O	O
vasospastic	vasospastic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
naratriptan	naratriptan	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
5	5	CD	I-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
HT1	HT1	NN	I-NP	O	I-group-AD-2
agonists	agonist	NNS	I-NP	O	E-group-AD-2
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Selective	Selective	JJ	B-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	O	S-group
)	)	)	O	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
rarely	rarely	RB	B-ADVP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
weakness	weakness	NN	B-NP	O	O
,	,	,	O	O	O
hyperreflexia	hyperreflexia	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
incoordination	incoordination	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
HTv	HTv	NN	I-NP	O	O
agonists	agonist	NNS	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
naratriptan	naratriptan	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	B-protein	S-group-AD-2
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
,	,	,	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
AMERGE	AMERGE	VBP	B-VP	O	S-brand
Tablets	Tablet	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
commonly	commonly	RB	B-NP	O	O
employed	employ	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
,	,	,	O	O	O
interferon	interferon	NN	B-NP	B-protein	B-drug-ME-1
beta	beta	SYM	O	I-protein	I-drug-ME-1
-	-	HYPH	O	O	I-drug-ME-1
1a	1a	NN	B-NP	O	E-drug-ME-1
(	(	(	O	O	O
AVONEX	AVONEX	NN	B-NP	O	S-brand-ME-1
30	30	CD	I-NP	O	O
mcg	mcg	NN	I-NP	O	O
IM	IM	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
weekly	weekly	RB	I-ADVP	O	O
)	)	)	O	O	O
reduced	reduce	VBD	B-VP	O	O
TYSABRI	TYSABRI	NN	B-NP	O	S-brand-ME-2
clearance	clearance	NN	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
similarity	similarity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TYSABRI	TYSABRI	NN	I-NP	O	S-brand
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
between	between	IN	B-PP	O	O
Study	Study	NN	B-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
without	without	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	B-NP	O	O
AVONEX	AVONEX	NN	I-NP	O	S-brand
)	)	)	O	O	O
and	and	CC	O	O	O
Study	Study	NN	B-NP	B-protein	O
2	2	CD	I-NP	I-protein	O
(	(	(	O	O	O
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	B-NP	O	O
AVONEX	AVONEX	NN	I-NP	O	S-brand
)	)	)	O	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clearance	clearance	NN	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
necessitate	necessitate	VB	I-VP	O	O
reduction	reduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TYSABRI	TYSABRI	NN	I-NP	O	S-brand
dose	dose	NN	I-NP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
safety	safety	NN	B-NP	O	O
,	,	,	O	O	O
General	General	NNP	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
sclerosis	sclerosis	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
TYSABRI	TYSABRI	NN	B-NP	O	S-brand
and	and	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
interferon	interferon	NN	I-NP	B-protein	B-drug
beta	beta	SYM	O	I-protein	I-drug
-	-	HYPH	O	O	I-drug
1a	1a	NN	B-NP	O	E-drug
(	(	(	O	O	O
AVONEX	AVONEX	NN	B-NP	O	S-brand
30	30	CD	I-NP	O	O
mcg	mcg	NN	I-NP	O	O
IM	IM	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
weekly	weekly	RB	I-ADVP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
glatiramer	glatiramer	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
were	be	VBD	B-VP	O	O
inconclusive	inconclusive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
regard	regard	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
interferon	interferon	NN	I-NP	B-protein	E-drug
or	or	CC	I-NP	O	O
glatiramer	glatiramer	NN	I-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
Starlix	Starlix	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
predominantly	predominantly	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
CYP2C9	CYP2C9	NN	I-NP	O	O
(	(	(	O	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
lesser	less	JJR	I-NP	O	O
extent	extent	NN	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Starlix	Starlix	NNP	B-NP	O	S-brand-ME-1
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP2C9	CYP2C9	NN	I-NP	B-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
as	as	IN	B-SBAR	O	O
indicated	indicate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
metabolic	metabolic	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
.	.	.	O	O	O

Glyburide	Glyburide	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
,	,	,	I-NP	O	O
multiple	multiple	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Type	Type	NN	B-NP	O	O
2	2	CD	B-NP	O	O
diabetes	diabete	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
120	120	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Starlix	Starlix	NNP	B-NP	O	S-brand
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
before	before	IN	B-PP	O	O
meals	meal	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
1	1	CD	B-NP	O	O
day	day	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

Metformin	Metformin	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
Starlix	Starlix	NNP	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
daily	daily	RB	I-NP	O	O
before	before	IN	B-SBAR	O	O
meals	meal	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
metformin	metformin	NN	B-NP	O	S-drug
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
daily	daily	RB	B-ADJP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Type	Type	NN	B-NP	O	O
2	2	CD	B-NP	O	O
diabetes	diabete	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
Starlix	Starlix	NNP	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
before	before	IN	B-SBAR	O	O
meals	meal	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NNP	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
Starlix	Starlix	NNP	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
daily	daily	RB	I-NP	O	O
before	before	IN	B-PP	O	O
meals	meal	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
four	four	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
30	30	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

Prothrombin	Prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

Diclofenac	Diclofenac	NN	B-NP	O	S-drug
:	:	:	O	O	O
Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
morning	morning	NN	B-NP	O	O
and	and	CC	I-NP	O	O
lunch	lunch	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Starlix	Starlix	NN	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
75	75	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

Nateglinide	Nateglinide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
(	(	(	O	O	O
98	98	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
mainly	mainly	RB	B-NP	O	O
albumin	albumin	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
displacement	displacement	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
highly	highly	RB	B-NP	O	O
protein	protein	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
captopril	captopril	NN	B-NP	O	S-drug
,	,	,	O	O	O
nicardipine	nicardipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
pravastatin	pravastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
metformin	metformin	NN	B-NP	O	S-drug
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nateglinide	nateglinide	NN	B-NP	B-protein	S-drug
protein	protein	NN	I-NP	I-protein	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
nateglinide	nateglinide	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
,	,	,	O	O	O
nicardipine	nicardipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
prudent	prudent	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
setting	setting	NN	I-NP	O	O
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	B-group-EF-1
anti	anti	AFX	I-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
)	)	)	O	O	O
,	,	,	O	O	O
salicylates	salicylate	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-1
oxidase	oxidase	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
non	non	AFX	B-NP	B-protein	B-group-EF-1
-	-	HYPH	I-NP	I-protein	I-group-EF-1
selective	selective	JJ	B-NP	I-protein	I-group-EF-1
beta	beta	SYM	I-NP	I-protein	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
adrenergic	adrenergic	JJ	I-NP	O	I-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
blocking	block	VBG	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Starlix	Starlix	NNP	B-NP	O	S-brand-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
thiazides	thiazide	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
thyroid	thyroid	NN	B-NP	B-protein	B-group-EF-1
products	product	NNS	I-NP	I-protein	E-group-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
sympathomimetics	sympathomimetic	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Starlix	Starlix	NNP	B-NP	O	S-brand-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
or	or	CC	O	O	O
withdrawn	withdraw	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
Starlix	Starlix	NNP	B-NP	O	S-brand
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
glycemic	glycemic	JJ	B-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
Tilade	Tilade	NNP	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
asthma	asthma	NN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
inhaled	inhale	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
oral	oral	JJ	I-NP	O	O
bronchodilators	bronchodilator	NNS	I-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
inhaled	inhale	VBD	B-VP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
or	or	CC	O	O	O
laboratory	laboratory	NN	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Nelfinavir	Nelfinavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
(	(	(	O	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A	3A	NN	I-NP	I-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
primarily	primarily	RB	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
dihydropyridine	dihydropyridine	NN	B-NP	O	B-group
calcium	calcium	NN	I-NP	O	I-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
)	)	)	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
both	both	CC	O	O	O
its	its	PRP$	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Nelfinavir	Nelfinavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
proof	proof	NN	B-NP	O	O
by	by	IN	B-PP	O	O
C.P.A	C.P.A	NN	B-NP	B-protein	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
reduce	reduce	VB	B-VP	O	O
its	its	PRP$	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
known	know	VBN	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
,	,	,	O	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
dapsone	dapsone	NN	I-NP	O	S-drug
,	,	,	O	O	O
trimethoprim	trimethoprim	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
sulfamethoxazole	sulfamethoxazole	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
clarithromycin	clarithromycin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
fluconazole	fluconazole	NN	I-NP	O	S-drug
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
That	That	DT	B-NP	O	O
Should	Should	MD	B-VP	O	O
Not	Not	RB	I-VP	O	O
Be	Be	VB	I-VP	O	O
Coadministered	Coadministere	VBN	I-VP	O	O
With	With	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-AD-1
Antiarrhythmics	Antiarrhythmic	NNS	I-NP	O	S-group-AD-2
:	:	:	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-AD-2
Antihistamines	Antihistamine	NNS	I-NP	O	S-group-AD-2
:	:	:	O	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-2
Antimigraine	Antimigraine	NNP	I-NP	O	O
:	:	:	O	O	O
ergot	ergot	VB	B-VP	O	B-group-AD-2
derivatives	derivative	NNS	B-NP	O	E-group-AD-2
Antimycobacterial	Antimycobacterial	JJ	B-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
:	:	:	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-AD-2
Benzodiazepines	Benzodiazepine	NNS	I-NP	O	S-group-AD-2
midazolam	midazolam	NN	I-NP	O	S-drug-AD-2
,	,	,	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug-AD-2
GI	GI	NN	I-NP	O	O
motility	motility	NN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
:	:	:	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-AD-2

Drugs	Drug	NNS	B-NP	O	O
Which	Which	WDT	B-NP	O	O
Require	Require	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
Dose	Dose	NNP	I-NP	O	O
Reduction	Reduction	NN	I-NP	O	O
When	When	WRB	B-ADVP	O	O
Coadminstered	Coadminstere	VBN	B-VP	O	O
With	With	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-AD-1
Antimycobacterial	Antimycobacterial	JJ	I-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
:	:	:	O	O	O
rifabutin	rifabutin	NN	B-NP	O	S-drug-AD-2

*	*	SYM	O	O	O
This	This	DT	B-NP	O	O
table	table	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
all	all	RB	B-ADJP	O	O
inclusive	inclusive	JJ	I-ADJP	O	O
*	*	SYM	O	O	O
*	*	SYM	B-NP	O	O
VIRACEPT	VIRACEPT	NN	I-NP	O	S-brand
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
effective	effective	JJ	B-ADJP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
nelfinavir	nelfinavir	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O

Terfenadine	Terfenadine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
unchanged	unchanged	JJ	B-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-2
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
/	/	SYM	I-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
,	,	,	O	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
also	also	RB	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Anti	Anti	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	B-protein	I-group
HIV	HIV	NN	I-NP	I-protein	I-group
Protease	Protease	NN	I-NP	I-protein	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group

Indinavir	Indinavir	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
83	83	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
51	51	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
A.C	A.C	NN	I-NP	O	O
.	.	.	O	O	O

Currently	Currently	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
available	available	JJ	B-ADJP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Ritonavir	Ritonavir	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
152	152	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
very	very	RB	B-NP	O	O
little	little	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
A.C	A.C	NN	I-NP	O	O
.	.	.	O	O	O

Currently	Currently	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
available	available	JJ	B-ADJP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Saquinavir	Saquinavir	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
using	use	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
soft	soft	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
gelatin	gelatin	NN	I-NP	O	O
capsule	capsule	NN	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
1200mg	1200mg	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
18	18	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
A.C	A.C	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
hard	hard	JJ	I-NP	O	O
gelatin	gelatin	NN	I-NP	O	O
capsules	capsule	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
tid	tid	NN	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

Currently	Currently	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
available	available	JJ	B-ADJP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Antifungal	Antifungal	JJ	B-NP	O	B-group
Agents	Agent	NNS	I-NP	O	E-group

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
35	35	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
A.C	A.C	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
change	change	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
VIRACEPT	VIRACEPT	NN	I-NP	O	S-brand
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Anti	Anti	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
HIV	HIV	NN	I-NP	O	I-group
Reverse	Reverse	JJ	I-NP	O	I-group
Transcriptase	Transcriptase	NN	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group

Didanosine	Didanosine	NN	B-NP	O	S-drug
:	:	:	O	O	O
It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
didanosine	didanosine	NN	B-NP	O	S-drug
be	be	VB	B-VP	O	O
administered	administer	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
empty	empty	JJ	I-NP	O	O
stomach	stomach	NN	I-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
(	(	(	O	O	O
with	with	IN	B-PP	O	O
food	food	NN	B-NP	O	O
)	)	)	O	O	O
one	one	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
after	after	IN	B-PP	O	O
or	or	CC	B-NP	O	O
more	more	JJR	I-NP	O	O
than	than	IN	I-NP	O	O
two	two	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

A	A	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
needed	need	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

Little	Little	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
no	no	DT	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
stavudine	stavudine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Antimycobacterial	Antimycobacterial	JJ	B-NP	O	B-group
Agents	Agent	NNS	I-NP	O	E-group

Rifabutin	Rifabutin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug-ME-1
and	and	CC	I-NP	O	O
VIRACEPT	VIRACEPT	NN	I-NP	O	S-brand-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
32	32	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
207	207	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
A.C	A.C	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	O	S-drug-AD-1
be	be	VB	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
half	half	PDT	I-NP	O	O
the	the	DT	I-NP	O	O
usual	usual	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
VIRACEPT	VIRACEPT	NN	I-NP	O	S-brand-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
82	82	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
A.C	A.C	NN	I-NP	O	O
.	.	.	O	O	O

VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group

Ethinyl	Ethinyl	NN	B-NP	O	B-drug
Estradiol	Estradiol	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
Norethindrone	Norethindrone	NN	I-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand-ME-1
with	with	IN	B-PP	O	O
OVCON	OVCON	NN	B-NP	B-protein	B-brand-ME-2
-	-	HYPH	B-NP	O	I-brand-ME-2
35	35	CD	I-NP	O	E-brand-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
47	47	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
18	18	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Alternate	Alternate	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
additional	additional	JJ	I-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	O
measures	measure	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
VIRACEPT	VIRACEPT	NN	B-NP	O	S-brand

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
serial	serial	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
nephrotoxic	nephrotoxic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
possible	possible	JJ	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
ototoxicity	ototoxicity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
neomycin	neomycin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
serial	serial	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
aminoglycosides	aminoglycoside	NNS	I-NP	O	S-group
and	and	CC	I-NP	O	O
polymyxins	polymyxin	NNS	I-NP	O	S-group
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
neomycin	neomycin	NN	B-NP	O	O
s	s	NNS	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
ototoxicity	ototoxicity	NN	B-NP	O	O
and	and	CC	O	O	O
potentiate	potentiate	VB	B-VP	O	O
neomycin	neomycin	NN	B-NP	O	B-drug
sulfate	sulfate	NN	I-NP	O	E-drug
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	blocking	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
neomycin	neomycin	NN	I-NP	O	S-drug-ME-1
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
penicillin	penicillin	NN	B-NP	O	B-drug-ME-2
V	V	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-drug-ME-2
B	B	NN	I-NP	O	I-drug-ME-2
-	-	HYPH	O	O	I-drug-ME-2
12	12	CD	B-NP	O	E-drug-ME-2
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
5	5	CD	B-NP	O	B-drug-ME-2
-	-	HYPH	I-NP	O	I-drug-ME-2
fluorouracil	fluorouracil	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
also	also	RB	B-ADVP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
neomycin	neomycin	NN	I-NP	O	B-drug-EF-1
sulfate	sulfate	NN	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	S-group-EF-2
in	in	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-2
by	by	IN	B-PP	O	O
decreasing	decrease	VBG	B-VP	O	O
vitamin	vitamin	NN	B-NP	O	O
K	K	NN	I-NP	O	O
availability	availability	NN	I-NP	O	O
.	.	.	O	O	O

Certain	Certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
neomycin	neomycin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
streptomycin	streptomycin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
kanamycin	kanamycin	NN	I-NP	O	S-drug
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
mild	mild	JJ	I-NP	O	O
but	but	CC	I-NP	O	O
definite	definite	JJ	I-NP	O	O
nondepolarizing	nondepolarizing	JJ	I-NP	O	O
blocking	blocking	NN	I-NP	O	O
action	action	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
accentuate	accentuate	VB	I-VP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
block	block	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myasthenic	myasthenic	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
only	only	RB	B-ADVP	O	O
where	where	WRB	I-ADVP	O	O
definitely	definitely	RB	B-ADVP	O	O
indicated	indicate	VBN	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	O	O	O
careful	careful	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
adjunctive	adjunctive	JJ	B-NP	O	O
anticholinesterase	anticholinesterase	NN	I-NP	O	S-group-AD-2
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Local	Local	JJ	B-ADJP	O	O
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
,	,	,	O	O	O
antiarrhythmic	antiarrhythmic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
interfere	interfere	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
transmission	transmission	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
at	at	IN	B-ADVP	O	O
all	all	DT	I-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
myasthenia	myasthenia	NN	B-NP	O	O
gravis	gravis	NN	I-NP	O	O
;	;	:	O	O	O

the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Prostigmin	Prostigmin	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
trials	trial	NNS	I-NP	O	O
specifically	specifically	RB	B-VP	O	O
examining	examine	VBG	I-VP	O	O
potential	potential	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Natrecor	Natrecor	NNP	B-NP	O	S-brand
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
many	many	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
except	except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
symptomatic	symptomatic	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
ACE	ACE	NN	I-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Natrecor	Natrecor	NNP	B-NP	O	S-brand
with	with	IN	B-PP	O	O
IV	IV	CD	B-NP	O	O
vasodilators	vasodilator	NNS	I-NP	O	S-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
nitroglycerin	nitroglycerin	NN	B-NP	O	S-drug
,	,	,	O	O	O
nitroprusside	nitroprusside	NN	B-NP	O	S-drug
,	,	,	O	O	O
milrinone	milrinone	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
IV	IV	CD	B-NP	O	O
ACE	ACE	NN	I-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
(	(	(	O	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Natrecor	Natrecor	NNP	B-NP	O	S-brand
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Netilmicin	Netilmicin	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
loop	loop	NN	I-NP	O	B-group-AD-2
diuretics	diuretic	NNS	I-NP	O	E-group-AD-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-AD-2
and	and	CC	O	O	O
ethacrynic	ethacrynic	JJ	B-NP	O	B-drug-AD-2
acid	acid	NN	I-NP	O	E-drug-AD-2
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ototoxicity	ototoxicity	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Nevirapine	Nevirapine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
principally	principally	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
2B6	2B6	NN	I-NP	B-protein	O
.	.	.	O	O	O

Nevirapine	Nevirapine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-SBAR	O	O
expected	expect	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
occur	occur	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
listed	list	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
CLINICAL	CLINICAL	NNP	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NNP	I-NP	O	O
,	,	,	O	O	O
Table	Table	NNP	B-NP	O	O
1	1	CD	I-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
comments	comment	NNS	I-NP	O	O
about	about	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
modifications	modification	NNS	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
these	these	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
listed	list	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Table	Table	JJ	B-NP	B-protein	O
3	3	CD	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
inTables	inTable	NNS	I-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
are	be	VBP	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
conducted	conduct	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
seropositive	seropositive	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
unless	unless	IN	B-SBAR	O	O
otherwise	otherwise	RB	B-ADVP	O	O
indicated	indicate	VBN	B-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
established	establish	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potential	potential	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
classes	class	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
listed	list	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Table	Table	JJ	B-NP	B-protein	O
4	4	CD	I-NP	I-protein	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
specific	specific	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
seropositive	seropositive	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
classes	class	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
listed	list	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
Table	Table	JJ	B-NP	O	O
4	4	CD	I-NP	O	O
,	,	,	O	O	O
additional	additional	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administering	administer	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-IN-1
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
antithrombotic	antithrombotic	JJ	I-NP	B-protein	B-group
agent	agent	NN	I-NP	I-protein	E-group
warfarin	warfarin	NN	I-NP	I-protein	S-drug-IN-2
is	be	VBZ	B-VP	O	O
complex	complex	JJ	B-ADJP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
giving	give	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
change	change	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
coagulation	coagulation	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
frequently	frequently	RB	B-ADVP	O	O
.	.	.	O	O	O

Table	Table	JJ	B-NP	O	O
3	3	CD	I-NP	O	O
Established	Established	NNP	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
:	:	:	O	O	O
Alteration	Alteration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
Dose	Dose	NN	B-NP	O	O
or	or	CC	I-NP	O	O
Regimen	Regimen	NN	I-NP	O	O
May	May	NNP	I-NP	O	O
Be	Be	NNP	I-NP	O	O
Recommended	Recommended	NNP	I-NP	O	O
Based	Based	NNP	I-NP	O	O
on	on	IN	B-PP	O	O
Drug	Drug	NNP	B-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Studies	Study	NNPS	I-NP	O	O

Drug	Drug	NNP	B-NP	O	O
Name	Name	NNP	I-NP	O	O

Effect	Effect	NN	B-NP	O	O
on	on	IN	B-PP	O	O
Concentration	Concentration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Nevirapine	Nevirapine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
Drug	Drug	NN	I-NP	O	O

Clinical	Clinical	NNP	B-NP	O	O
Comment	Comment	NNP	I-NP	O	O

Clarithromycin	Clarithromycin	NN	B-NP	O	S-drug
14OH	14OH	NN	I-NP	O	O
-	-	HYPH	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	O

Clarithromycin	Clarithromycin	NN	B-NP	O	S-drug-ME-1
exposure	exposure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
14	14	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
OH	OH	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
increased.Because	increased.Because	IN	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
activity	activity	NN	B-NP	O	O
against	against	IN	B-PP	O	O
Mycobacteriumavium	Mycobacteriumavium	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
intracellulare	intracellulare	JJ	I-NP	I-protein	O
complex	complex	NN	I-NP	I-protein	O
,	,	,	O	O	O
overallactivity	overallactivity	NN	B-NP	O	O
against	against	IN	B-PP	O	O
this	this	DT	B-NP	O	O
pathogen	pathogen	NN	I-NP	O	O
may	may	MD	B-VP	O	O
bealtered	bealtere	VBN	I-VP	O	O
.	.	.	O	O	O

Alternatives	Alternative	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Appropriate	Appropriate	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Ethinyl	Ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	O	O	O
Norethindrone	Norethindrone	NN	B-NP	O	S-drug

Ethinyl	Ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
Norethindrone	Norethindrone	NN	I-NP	O	S-drug

Oral	Oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-AD-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
hormonalmethods	hormonalmethod	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
birth	birth	NN	B-NP	O	O
control	control	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
usedas	usedas	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sole	sole	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
inwomen	inwoman	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
nevirapinemay	nevirapinemay	NN	B-NP	O	O
lower	low	JJR	B-ADVP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
thesemedications	thesemedication	NNS	B-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
alternative	alternative	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
additional	additional	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
tonevirapine	tonevirapine	NN	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
inconcomitant	inconcomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	O
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

Appropriate	Appropriate	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
arenot	arenot	RB	B-VP	O	O
established	establish	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
thedosage	thedosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Nevirapine	Nevirapine	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
beadministered	beadministere	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
becausedecreases	becausedecrease	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
plasmaconcentrations	plasmaconcentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Lopinavir	Lopinavir	NN	B-NP	O	S-drug
/	/	SYM	O	O	O
Ritonavir	Ritonavir	NN	B-NP	O	S-drug

A	A	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lopinavir	lopinavir	NN	B-NP	O	S-drug-AD-1
/	/	SYM	B-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug-AD-1
to	to	TO	B-PP	O	O
533	533	CD	B-NP	O	O
/	/	SYM	O	O	O
133	133	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
food	food	NN	B-NP	O	O
isrecommended	isrecommende	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Methadone	Methadone	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
;	;	:	O	O	O
increased	increase	VBN	B-NP	O	O
dosages	dosage	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
opiate	opiate	NN	B-NP	O	S-group
withdrawal	withdrawal	NN	I-NP	O	O
.	.	.	O	O	O
Methadone	Methadone	NN	B-NP	O	S-drug-AD-1
maintained	maintain	VBD	B-VP	O	O
patients	patient	NNS	B-NP	O	O
beginning	begin	VBG	B-VP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-AD-2
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
forevidence	forevidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
and	and	CC	I-NP	O	O
methadone	methadone	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
.	.	.	O	O	O

Nelfinavir	Nelfinavir	NN	B-NP	O	S-drug
M8	M8	NN	I-NP	O	O

The	The	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
for	for	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
incombination	incombination	NN	I-NP	O	O
with	with	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
,	,	,	O	O	O
with	with	IN	B-PP	O	O
respectto	respectto	NN	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Rifabutin	Rifabutin	NN	B-NP	B-protein	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
concentrationswere	concentrationswere	VBD	B-VP	O	O
moderately	moderately	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
highintersubject	highintersubject	VB	I-VP	O	O
variability	variability	NN	B-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
somepatients	somepatient	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
experience	experience	VB	I-VP	O	O
large	large	JJ	B-NP	O	O
increases	increase	VBZ	B-VP	O	O
inrifabutin	inrifabutin	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
at	at	IN	B-PP	O	O
higher	high	JJR	B-ADJP	O	O
riskfor	riskfor	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Nevirapine	Nevirapine	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
beadministered	beadministere	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
becausedecreases	becausedecrease	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
plasmaconcentrations	plasmaconcentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
ofthe	ofthe	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Physicians	Physician	NNS	B-NP	O	O
needing	need	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
treatpatients	treatpatient	NNS	B-NP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
infected	infect	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
tuberculosis	tuberculosis	NN	B-NP	O	O
andusing	anduse	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
nevirapine	nevirapine	NN	I-NP	O	S-drug
containing	contain	VBG	B-VP	O	O
regimen	regimen	NN	B-NP	O	O
mayuse	mayuse	NN	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug
instead	instead	RB	B-ADVP	O	O
.	.	.	O	O	O

Appropriate	Appropriate	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
arenot	arenot	RB	B-VP	O	O
established	establish	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
thedosage	thedosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

aBased	aBase	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
narcotic	narcotic	JJ	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
methadone	methadone	NN	I-NP	O	S-drug-EF-2
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methadone	methadone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Table	Table	JJ	B-NP	O	O
4	4	CD	I-NP	O	O
Potential	Potential	NNP	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
:	:	:	O	O	O
Use	Use	NN	B-NP	O	O
With	With	IN	B-PP	O	O
Caution	Caution	NN	B-NP	O	O
,	,	,	O	O	O
Dose	Dose	VBP	B-VP	O	O
Adjustment	Adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Co	Co	NN	B-NP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
Drug	Drug	NNP	B-NP	O	O
May	May	NNP	I-NP	O	O
Be	Be	NNP	I-NP	O	O
Needed	Need	VBD	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
Possible	Possible	JJ	B-NP	O	O
Decrease	Decrease	NNP	I-NP	O	O
in	in	IN	B-PP	O	O
Clinical	Clinical	NNP	B-NP	O	O
Effect	Effect	NNP	I-NP	O	O

Examples	Example	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Drugs	Drugs	NNP	B-NP	O	O
in	in	IN	B-PP	O	O
Which	Which	NNP	B-NP	O	O
Plasma	Plasma	NNP	I-NP	O	O
Concentrations	Concentration	NNPS	I-NP	O	O
May	May	NNP	I-NP	O	O
Be	Be	NNP	I-NP	O	O
Decreased	Decreased	NNP	I-NP	O	O
By	By	IN	B-PP	O	O
Co	Co	NNP	B-NP	O	O
-	-	HYPH	B-NP	O	O
administration	administration	NN	I-NP	O	O
With	With	IN	B-PP	O	O
Nevirapine	Nevirapine	NN	B-NP	O	S-drug

Drug	Drug	NNP	B-NP	O	O
Class	Class	NNP	I-NP	O	O
Examples	Examples	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Drugs	Drugs	NNP	B-NP	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
,	,	,	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug
,	,	,	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
ethosuximide	ethosuximide	NN	B-NP	O	S-drug

Calcium	Calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group

Diltiazem	Diltiazem	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug

Cancer	Cancer	NN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O

Ergot	Ergot	NN	B-NP	O	B-group
alkaloids	alkaloid	NNS	I-NP	O	E-group

Cyclosporin	Cyclosporin	NN	B-NP	O	S-drug
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug

Motility	Motility	NN	B-NP	O	O
agents	agent	NNS	I-NP	O	O

Opiate	Opiate	NN	B-NP	O	B-group
agonists	agonist	NNS	I-NP	O	E-group

Examples	Example	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Drugs	Drugs	NNP	B-NP	O	O
in	in	IN	B-PP	O	O
Which	Which	NNP	B-NP	O	O
Plasma	Plasma	NNP	I-NP	O	O
Concentrations	Concentration	NNPS	I-NP	O	O
May	May	NNP	I-NP	O	O
Be	Be	NNP	I-NP	O	O
Increased	Increased	NNP	I-NP	O	O
By	By	IN	B-PP	O	O
Co	Co	NNP	B-NP	O	O
-	-	HYPH	B-NP	O	O
administration	administration	NN	I-NP	O	O
With	With	IN	B-PP	O	O
Nevirapine	Nevirapine	NN	B-NP	O	S-drug

Potential	Potential	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
.	.	.	O	O	O

Monitoring	Monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Fat	Fat	NN	B-NP	O	O
redistribution	redistribution	NN	I-NP	O	O
:	:	:	O	O	O
Redistribution	Redistribution	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
body	body	NN	B-NP	O	O
fat	fat	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
central	central	JJ	B-NP	O	O
obesity	obesity	NN	I-NP	O	O
,	,	,	O	O	O
dorsocervical	dorsocervical	JJ	B-NP	O	O
fat	fat	NN	I-NP	O	O
enlargement	enlargement	NN	I-NP	O	O
(	(	(	O	O	O
buffalo	buffalo	NN	B-NP	O	O
hump	hump	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
peripheral	peripheral	JJ	B-NP	O	O
wasting	wasting	NN	I-NP	O	O
,	,	,	O	O	O
facial	facial	JJ	B-NP	O	O
wasting	wasting	NN	I-NP	O	O
,	,	,	O	O	O
breast	breast	NN	B-NP	O	O
enlargement	enlargement	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
cushingoid	cushingoid	JJ	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
antiretroviral	antiretroviral	JJ	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
and	and	CC	I-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
consequences	consequence	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
events	event	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
currently	currently	RB	B-ADJP	O	O
unknown	unknown	JJ	I-ADJP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
causal	causal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O

Interactions	Interaction	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug
B3	B3	NN	I-NP	O	E-drug
(	(	(	O	O	O
Niacin	Niacin	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Antihypertensive	Antihypertensive	JJ	B-NP	O	S-group
Therapy	Therapy	NN	I-NP	O	O
:	:	:	O	O	O
Nicotinic	Nicotinic	JJ	B-NP	O	B-drug-EF-1
acid	acid	NN	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ganglionic	ganglionic	JJ	B-NP	O	B-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
vasoactive	vasoactive	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
postural	postural	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nicotinic	nicotinic	JJ	B-NP	O	B-drug-ME-2
acid	acid	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-ADJP	O	O
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug
or	or	CC	O	O	O
hot	hot	JJ	B-NP	O	O
drinks	drink	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
flushing	flushing	NN	B-NP	O	O
and	and	CC	I-NP	O	O
pruritus	pruritus	NN	I-NP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
ingestion	ingestion	NN	I-NP	O	O
.	.	.	O	O	O

Beta	Beta	SYM	B-NP	B-protein	B-group
-	-	:	O	O	I-group
Blockers	Blocker	NNS	B-NP	O	E-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
controlled	control	VBN	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
adrenergic	adrenergic	JJ	B-NP	B-protein	B-group
beta	beta	SYM	I-NP	I-protein	I-group
-	-	HYPH	I-NP	O	I-group
receptor	receptor	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
frequently	frequently	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
nicardipine	nicardipine	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
nicardipine	nicardipine	NN	B-NP	O	B-drug-ME-2
HCl	HCl	NN	I-NP	O	E-drug-ME-2
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Some	Some	DT	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group-ME-1
blockers	blocker	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	B-group-ME-2
preparations	preparation	NNS	I-NP	O	E-group-ME-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
.	.	.	O	O	O

Nicardipine	Nicardipine	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
usually	usually	RB	B-ADVP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-AD-1
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
nicardipine	nicardipine	NN	B-NP	O	B-drug-AD-2
HCl	HCl	NN	I-NP	O	E-drug-AD-2
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
.	.	.	O	O	O

Maalox	Maalox	NN	B-NP	O	S-brand
*	*	SYM	I-NP	O	O
Coadministration	Coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Maalox	Maalox	NNP	B-NP	O	B-brand
TC	TC	NNP	I-NP	O	E-brand
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
nicardipine	nicardipine	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Even	Even	RB	B-SBAR	O	O
though	though	IN	I-SBAR	O	O
such	such	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
seen	see	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
nicardipine	nicardipine	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
circulating	circulate	VBG	B-NP	O	O
fluids	fluid	NNS	I-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
an	an	DT	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nicardipine	nicardipine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
reduced	reduce	VBD	B-VP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nicardipine	nicardipine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
,	,	,	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
plasma	plasma	NN	I-NP	I-cell_type	O
(	(	(	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nicardipine	nicardipine	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

Physiological	Physiological	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
smoking	smoking	NN	B-NP	O	O
cessation	cessation	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
nicotine	nicotine	NN	B-NP	O	S-drug
replacement	replacement	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
and	and	CC	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
.	.	.	O	O	O

Doses	Dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
and	and	CC	I-NP	O	O
perhaps	perhaps	RB	I-NP	O	O
other	other	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
successfully	successfully	RB	B-VP	O	O
quit	quit	VBP	I-VP	O	O
smoking	smoking	NN	B-NP	O	O
.	.	.	O	O	O

Beta	Beta	SYM	O	B-protein	B-group
-	-	HYPH	O	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
Blocking	Blocking	NNPS	I-NP	O	I-group
Agents	Agent	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Experience	Experience	NN	B-NP	O	O
in	in	IN	B-PP	O	O
over	over	IN	B-NP	O	O
1400	1400	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
comparative	comparative	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	O	O	I-group-EF-2
blocking	block	VBG	B-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
is	be	VBZ	B-VP	O	O
usually	usually	RB	B-ADVP	O	O
well	well	RB	B-ADJP	O	O
tolerated	tolerate	VBN	I-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
occasional	occasional	JJ	B-NP	O	O
literature	literature	NN	I-NP	O	O
reports	report	NNS	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
of	of	IN	B-PP	O	O
congestive	congestive	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
failure	failure	NN	I-NP	O	O
,	,	,	O	O	O
severe	severe	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
or	or	CC	I-NP	O	O
exacerbation	exacerbation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angina	angina	NN	B-NP	O	O
.	.	.	O	O	O

Long	Long	NNP	B-NP	O	O
Acting	Acting	NNP	I-NP	O	O
Nitrates	Nitrates	NNP	I-NP	O	S-group
:	:	:	O	O	O
Nifedipine	Nifedipine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
safely	safely	RB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nitrates	nitrate	NNS	B-NP	O	S-group
,	,	,	O	O	O
but	but	CC	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
controlled	controlled	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antianginal	antianginal	JJ	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	S-group
:	:	:	O	O	O
Immediate	Immediate	NNP	B-NP	O	O
Release	Release	NNP	I-NP	O	O
Capsules	Capsules	NNP	I-NP	O	O
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
isolated	isolate	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug-IN-2
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-AD-1
levels	level	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
,	,	,	O	O	O
adjusting	adjust	VBG	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug-AD-2
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
possible	possible	JJ	B-ADJP	O	O
over	over	AFX	B-PRT	O	O
-	-	HYPH	B-VP	O	O
or	or	CC	O	O	O
under	under	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
digitalization	digitalization	NN	I-NP	O	O
.	.	.	O	O	O

Extended	Extended	NNP	B-NP	O	O
Release	Release	NNP	I-NP	O	O
Tablets	Tablet	NNPS	I-NP	O	O
:	:	:	O	O	O
Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
9	9	CD	B-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
45	45	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Another	Another	DT	B-NP	O	O
investigator	investigator	NN	I-NP	O	O
found	find	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
13	13	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
uncontrolled	uncontrolled	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
over	over	IN	B-NP	O	O
200	200	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
congestive	congestive	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
failure	failure	NN	I-NP	O	O
during	during	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
measured	measure	VBN	I-VP	O	O
,	,	,	O	O	O
digitalis	digitalis	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
isolated	isolate	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-AD-1
levels	level	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
,	,	,	O	O	O
adjusting	adjust	VBG	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug-AD-2
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
possible	possible	JJ	B-ADJP	O	O
over	over	AFX	B-PRT	O	O
-	-	HYPH	B-VP	O	O
or	or	CC	O	O	O
under	under	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
digitalization	digitalization	NN	I-NP	O	O
.	.	.	O	O	O

Quinidine	Quinidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Immediate	Immediate	NNP	B-NP	O	O
Release	Release	NNP	I-NP	O	O
Capsules	Capsules	NNP	I-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rare	rare	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug-ME-2
(	(	(	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Coumarin	Coumarin	NN	B-NP	O	B-group
Anticoagulants	Anticoagulant	NNS	I-NP	O	E-group
:	:	:	O	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rare	rare	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-EF-1
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-EF-1
to	to	TO	B-PP	O	O
whom	whom	WP	B-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug-EF-2
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
to	to	TO	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
uncertain	uncertain	JJ	B-ADJP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
6	6	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
peak	peak	NN	B-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
80	80	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
area	area	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
under	under	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
the	the	DT	B-NP	O	O
-	-	HYPH	I-NP	O	O
curve	curve	NN	I-NP	O	O
(	(	(	O	O	O
74	74	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
week	week	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
and	and	CC	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug-ME-2
at	at	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
.	.	.	O	O	O

Ranitidine	Ranitidine	NN	B-NP	O	S-drug
produced	produce	VBD	B-VP	O	O
smaller	small	JJR	B-ADJP	O	O
,	,	,	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
system	system	NN	I-NP	O	O
probably	probably	RB	B-ADVP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
pass	pass	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug-AD-1
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
currently	currently	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
cautious	cautious	JJ	B-NP	O	O
titration	titration	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
nilutamide	nilutamide	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
liver	liver	NN	B-NP	B-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
requiring	require	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
systems	system	NNS	I-NP	O	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
margin	margin	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
K	K	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
could	could	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
delayed	delay	VBN	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
and	and	CC	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
serum	serum	NN	I-NP	B-protein	O
half	half	NN	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
level	level	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
others	other	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
modified	modify	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
nilutamide	nilutamide	NN	B-NP	O	S-drug
.	.	.	O	O	O

For	For	IN	B-PP	O	O
example	example	NN	B-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
vitamin	vitamin	NN	B-NP	O	B-group-AD-1
K	K	NN	I-NP	O	I-group-AD-1
antagonists	antagonist	NNS	I-NP	O	E-group-AD-1
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
nilutamide	nilutamide	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
K	K	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group-EF-1
channel	channel	NN	I-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Nimotop	Nimotop	NNP	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
Europe	Europe	NNP	B-NP	O	O
,	,	,	O	O	O
Nimotop	Nimotop	NNP	B-NP	O	S-brand-EF-1
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
intensify	intensify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group-EF-2
compounds	compound	NNS	I-NP	O	E-group-EF-2
taken	take	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
suffering	suffer	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	O
;	;	:	O	O	O

this	this	DT	B-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
North	North	JJ	B-NP	O	O
American	American	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
peak	peak	JJ	I-NP	O	O
nimodipine	nimodipine	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
90	90	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
one	one	CD	I-NP	O	O
week	week	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
1,000	1,000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
and	and	CC	O	O	O
nimodipine	nimodipine	NN	B-NP	O	S-drug-ME-2
at	at	IN	B-PP	O	O
90	90	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
by	by	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
first	first	JJ	B-NP	O	O
pass	pass	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nimodipine	nimodipine	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
30	30	CD	I-NP	O	O
to	to	TO	I-NP	O	O
45	45	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nisoldipine	nisoldipine	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	B-drug-ME-2
400	400	CD	I-NP	O	I-drug-ME-2
mg	mg	NN	I-NP	O	E-drug-ME-2
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
.	.	.	O	O	O

Ranitidine	Ranitidine	NN	B-NP	O	S-drug
150	150	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
interact	interact	VB	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
nisoldipine	nisoldipine	NN	B-NP	O	S-drug
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
15	15	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
histamine	histamine	NN	B-NP	B-protein	B-group
H2	H2	NN	I-NP	I-protein	I-group
receptor	receptor	NN	I-NP	I-protein	I-group
antagonist	antagonist	NN	I-NP	O	E-group
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
SULAR	SULAR	NN	I-NP	O	S-brand-ME-2
tablets	tablet	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
epileptic	epileptic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
lowered	lower	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
nisoldipine	nisoldipine	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
undetectable	undetectable	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
SULAR	SULAR	NN	B-NP	B-protein	S-brand-AD-1
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
any	any	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducer	inducer	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
and	and	CC	O	O	O
alternative	alternative	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
nisoldipine	nisoldipine	NN	B-NP	B-protein	S-drug
and	and	CC	O	I-protein	O
beta	beta	SYM	O	I-protein	B-group
-	-	HYPH	O	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
(	(	(	O	O	O
atenolol	atenolol	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
variable	variable	JJ	B-ADJP	O	O
and	and	CC	O	O	O
not	not	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
.	.	.	O	O	O

Propranolol	Propranolol	NN	B-NP	O	S-drug-EF-1
attenuated	attenuate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
immediate	immediate	JJ	B-NP	O	O
release	release	NN	I-NP	O	O
nisoldipine	nisoldipine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SULAR	SULAR	NN	B-NP	B-protein	S-brand-EF-1
tended	tend	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
greater	great	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
atenolol	atenolol	NN	B-NP	O	S-drug-EF-2
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
no	no	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Quinidine	Quinidine	NN	B-NP	O	S-drug-ME-1
at	at	IN	B-PP	O	O
648	648	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
bid	bid	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
nisoldipine	nisoldipine	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
26	26	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	B-CONJP	O	O
not	not	RB	I-CONJP	O	O
the	the	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
immediate	immediate	JJ	I-NP	O	O
release	release	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	B-CONJP	O	O
not	not	RB	I-CONJP	O	O
the	the	DT	B-NP	O	O
coat	coat	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
core	core	NN	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nisoldipine	nisoldipine	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
quinidine	quinidine	NN	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ECG	ECG	NN	B-NP	O	O
changes	change	NNS	I-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
nisoldipine	nisoldipine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Tizoxanide	Tizoxanide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
(	(	(	O	O	O
99.9	99.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
nitazoxanide	nitazoxanide	NN	B-NP	O	S-drug-ME-1
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
highly	highly	RB	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
narrow	narrow	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
indices	index	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
competition	competition	NN	B-NP	O	O
for	for	IN	B-PP	O	O
binding	bind	VBG	B-NP	B-DNA	O
sites	site	NNS	I-NP	I-DNA	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
tizoxanide	tizoxanide	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
would	would	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
nitazoxanide	nitazoxanide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
either	either	CC	O	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
or	or	CC	O	O	O
inhibit	inhibit	VB	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypoxic	hypoxic	JJ	B-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
excluded	exclude	VBN	I-VP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
available	available	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
.	.	.	O	O	O

INOmax	INOmax	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
tolazoline	tolazoline	NN	B-NP	O	S-drug
,	,	,	O	O	O
dopamine	dopamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
dobutamine	dobutamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
steroids	steroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
surfactant	surfactant	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
ventilation	ventilation	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
study	study	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
,	,	,	O	O	O
nitric	nitric	JJ	B-NP	O	B-group-EF-1
oxide	oxide	NN	I-NP	O	I-group-EF-1
donor	donor	NN	I-NP	O	I-group-EF-1
compounds	compound	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug-EF-1
nitroprusside	nitroprusside	NN	I-NP	O	E-drug-EF-1
and	and	CC	O	O	O
nitroglycerin	nitroglycerin	NN	B-NP	B-protein	S-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
with	with	IN	B-PP	O	O
INOmax	INOmax	NN	B-NP	B-protein	S-brand-EF-2
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
methemoglobinemia	methemoglobinemia	NN	B-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
prilocaine	prilocaine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methaemoglobinaemia	methaemoglobinaemia	NN	B-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
infants	infant	NNS	B-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
specifically	specifically	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
present	present	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
,	,	,	I-NP	O	O
parenteral	parenteral	JJ	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
topical	topical	JJ	B-NP	O	O
formulations	formulation	NNS	I-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
magnesium	magnesium	NN	B-NP	O	B-drug-ME-1
trisilicate	trisilicate	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
nitrofurantoin	nitrofurantoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
reduce	reduce	VBP	B-VP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
probably	probably	RB	B-ADVP	O	O
is	be	VBZ	B-VP	O	O
adsorption	adsorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nitrofurantoin	nitrofurantoin	NN	B-NP	O	S-drug-ME-1
onto	onto	IN	B-PP	O	O
the	the	DT	B-NP	O	O
surface	surface	NN	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	B-drug-ME-2
trisilicate	trisilicate	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

Uricosuric	Uricosuric	JJ	B-NP	O	B-group-ME-1
drugs	drug	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
sulfinpyrazone	sulfinpyrazone	NN	I-NP	O	S-drug-ME-1
,	,	,	O	O	O
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nitrofurantoin	nitrofurantoin	NN	B-NP	B-protein	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
resulting	result	VBG	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
nitrofurantoin	nitrofurantoin	NN	B-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
urinary	urinary	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
lessen	lessen	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
antibacterial	antibacterial	JJ	B-ADJP	O	S-group
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nitrofurantoin	nitrofurantoin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Benedict	Benedict	NNP	B-NP	O	O
s	s	NNS	I-NP	O	O
and	and	CC	O	O	O
Fehling	Fehle	VBG	B-VP	O	O
s	s	NNS	B-NP	O	O
solutions	solution	NNS	I-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
with	with	IN	I-PP	O	O
the	the	DT	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
enzymatic	enzymatic	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
vasodilating	vasodilate	VBG	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nitroglycerin	nitroglycerin	NN	B-NP	B-protein	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
vasodilators	vasodilator	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
in	in	IN	B-PP	O	O
particular	particular	JJ	B-ADJP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
.	.	.	O	O	O

Marked	Mark	VBN	B-NP	O	O
symptomatic	symptomatic	JJ	I-NP	O	O
orthostatic	orthostatic	JJ	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
calcium	calcium	NN	B-NP	O	B-group-EF-1
channel	channel	NN	I-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
organic	organic	JJ	B-NP	O	O
nitrates	nitrate	NNS	I-NP	O	S-group-EF-2
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug-EF-1
nitroprusside	nitroprusside	NN	I-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
augmented	augment	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
other	other	JJ	I-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ganglionic	ganglionic	JJ	B-NP	O	B-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
negative	negative	JJ	B-NP	O	O
inotropic	inotropic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
inhaled	inhale	VBD	B-VP	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
nizatidine	nizatidine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
,	,	,	O	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug
,	,	,	O	O	O
lorazepam	lorazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Nizatidine	Nizatidine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	I-protein	O
450	450	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
linked	link	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	O	O	O
metabolizing	metabolize	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
system	system	NN	I-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
mediated	mediate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
very	very	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
(	(	(	O	O	O
3900	3900	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-1
daily	daily	RB	B-ADVP	O	O
,	,	,	O	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
nizatidine	nizatidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
progestin	progestin	NN	B-NP	O	S-group-EF-1
-	-	HYPH	O	O	O
only	only	JJ	B-NP	O	O
pills	pill	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
-	-	HYPH	O	O	O
inducing	induce	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
anticonvulsants	anticonvulsant	NNS	I-NP	B-protein	S-group
phenytoin	phenytoin	NN	I-NP	I-protein	S-drug-EF-2
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
antituberculosis	antituberculosis	JJ	I-NP	B-protein	B-group
drug	drug	NN	I-NP	I-protein	E-group
rifampin	rifampin	NN	I-NP	I-protein	S-drug-EF-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
broad	broad	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
spectrum	spectrum	NN	I-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
.	.	.	O	O	O

Elevated	Elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
quinolone	quinolone	NN	I-NP	O	S-group-ME-2
use	use	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
monitoring	monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
and	and	CC	O	O	O
dosage	dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
adjusted	adjust	VBN	B-VP	O	O
as	as	IN	B-SBAR	O	O
required	require	VBN	B-VP	O	O
.	.	.	O	O	O

Elevated	Elevated	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
made	make	VBN	B-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Quinolones	Quinolone	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
or	or	CC	O	O	O
similar	similar	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinolones	quinolone	NNS	B-NP	O	S-group-EF-1
including	include	VBG	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
a	a	DT	B-NP	O	O
sulfonylurea	sulfonylurea	NN	I-NP	O	B-group
agent	agent	NN	I-NP	O	E-group
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
rare	rare	JJ	B-NP	O	O
occasions	occasion	NNS	I-NP	O	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
monitoring	monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

Diminished	Diminish	VBN	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
norfloxacin	norfloxacin	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nitrofurantoin	nitrofurantoin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
since	since	IN	B-SBAR	O	O
nitrofurantoin	nitrofurantoin	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antibacterial	antibacterial	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Norfloxacin	Norfloxacin	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
.	.	.	O	O	O

Multivitamins	Multivitamin	NNS	B-NP	O	S-group-AD-1
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
products	product	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
iron	iron	NN	B-NP	O	S-drug-AD-1
or	or	CC	I-NP	O	O
zinc	zinc	NN	I-NP	O	S-drug-AD-1
,	,	,	O	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-1
or	or	CC	O	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
within	within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
serum	serum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Videx	Videx	NN	B-NP	O	S-brand-AD-1
(	(	(	I-NP	O	O
Didanosine	Didanosine	NN	I-NP	O	S-drug-AD-1
)	)	)	I-NP	O	O
chewable	chewable	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
buffered	buffered	JJ	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
powder	powder	NN	I-NP	O	O
for	for	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
solution	solution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
within	within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
serum	serum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
quinolones	quinolone	NNS	I-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
.	.	.	O	O	O

Reduced	Reduce	VBN	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
breakthrough	breakthrough	NN	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
and	and	CC	O	O	O
menstrual	menstrual	JJ	B-NP	O	O
irregularities	irregularity	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
association	association	NN	I-NP	O	O
,	,	,	O	O	O
though	though	IN	B-SBAR	O	O
less	less	RBR	B-ADJP	O	O
marked	marked	JJ	I-ADJP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
griseofulvin	griseofulvin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
topiramate	topiramate	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
possibly	possibly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ampicillin	ampicillin	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
tetracyclines	tetracycline	NNS	I-NP	O	S-group
72	72	CD	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
hormonal	hormonal	JJ	B-NP	O	B-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
herbal	herbal	JJ	I-NP	O	O
supplement	supplement	NN	I-NP	O	O
St.	St.	NNP	I-NP	O	O
Johns	Johns	NNP	I-NP	O	O
Wort	Wort	NNP	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
some	some	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	S-group
users	user	NNS	I-NP	O	O
experiencing	experience	VBG	B-VP	O	O
breakthrough	breakthrough	NN	B-NP	O	O
bleeding	bleed	VBG	B-VP	O	O
shortly	shortly	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
St.	St.	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
Wort	Wort	NNP	I-NP	O	O
.	.	.	O	O	O

Pregnancies	Pregnancy	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
combined	combined	JJ	B-NP	O	B-group
hormonal	hormonal	JJ	I-NP	O	I-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
who	who	WP	B-NP	O	O
also	also	RB	B-ADVP	O	O
used	use	VBD	B-VP	O	O
some	some	DT	B-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
St.	St.	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
Wort	Wort	NNP	I-NP	O	O
.	.	.	O	O	O

Healthcare	Healthcare	NNP	B-NP	O	O
prescribers	prescriber	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
advised	advise	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
consult	consult	VB	I-VP	O	O
the	the	DT	B-NP	O	O
package	package	NN	I-NP	O	O
inserts	insert	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
medication	medication	NN	B-NP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
.	.	.	O	O	O

Steady	Steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-1
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
fluctuate	fluctuate	VB	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
is	be	VBZ	B-VP	O	O
either	either	RB	I-VP	O	O
added	add	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
deleted	delete	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
.	.	.	O	O	O

Serious	Serious	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
(	(	(	O	O	O
severe	severe	JJ	B-NP	O	O
dry	dry	JJ	I-NP	O	O
mouth	mouth	NN	I-NP	O	O
,	,	,	O	O	O
urinary	urinary	JJ	B-NP	O	O
retention	retention	NN	I-NP	O	O
,	,	,	O	O	O
blurred	blur	VBD	B-VP	O	O
vision	vision	NN	B-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
elevations	elevation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
when	when	WRB	B-ADVP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-EF-2
is	be	VBZ	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
-	-	HYPH	I-NP	O	O
than	than	IN	B-SBAR	O	O
expected	expect	VBN	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-ME-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
therapy	therapy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
already	already	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
well	well	RB	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
controlled	control	VBN	B-VP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-ME-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-2
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
cime	cime	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
tidine	tidine	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
compromised	compromise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-EF-2
is	be	VBZ	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
cited	cite	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
previously	previously	RB	B-NP	O	O
stable	stable	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group-ME-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
nortriptyline	nortriptyline	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	B-drug-ME-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Fluoxetine	Fluoxetine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
norfluoxe	norfluoxe	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
tine	tine	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
long	long	RB	B-NP	O	O
half	half	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
lives	life	NNS	I-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
to	to	TO	I-NP	O	O
16	16	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
norfluoxetine	norfluoxetine	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
,	,	,	O	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
strategies	strategy	NNS	B-NP	O	O
during	during	IN	B-PP	O	O
conversion	conversion	NN	B-NP	O	O
from	from	IN	B-PP	O	O
one	one	CD	B-NP	O	O
drug	drug	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-1
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-EF-2
antidepressant	antidepressant	NN	I-NP	O	E-group-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
stimulating	stimulating	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
depressed	depressed	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Close	Close	JJ	B-NP	O	O
supervision	supervision	NN	I-NP	O	O
and	and	CC	O	O	O
careful	careful	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
required	require	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
nortriptyline	nortriptyline	NN	B-NP	O	B-drug-AD-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-AD-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
or	or	CC	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
informed	inform	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exaggerated	exaggerate	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Metabolized	Metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
P450IID6	P450IID6	NN	B-NP	B-protein	O
A	A	NN	I-NP	I-protein	O
subset	subset	NN	I-NP	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
population	population	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
activity	activity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
drug	drug	NN	I-NP	B-protein	O
metabolizing	metabolize	VBG	B-VP	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoenzyme	isoenzyme	NN	I-NP	I-protein	O
P450IID6	P450IID6	NN	I-NP	I-protein	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
referred	refer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
as	as	IN	B-PP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
debrisoquin	debrisoquin	NN	B-NP	O	S-drug
,	,	,	O	O	O
dextromethorphan	dextromethorphan	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
.	.	.	O	O	O

These	These	DT	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-SBAR	O	O
expected	expect	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
usual	usual	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
many	many	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
(	(	(	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
selective	selective	JJ	B-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
others	other	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
thus	thus	RB	B-VP	O	O
may	may	MD	I-VP	O	O
make	make	VB	I-VP	O	O
normal	normal	JJ	B-NP	O	O
metab	metab	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
olizers	olizer	NNS	I-NP	O	O
resemble	resemble	VBP	B-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
regard	regard	NN	B-NP	O	O
to	to	TO	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450IID6	P450IID6	NN	I-NP	I-protein	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
than	than	IN	B-SBAR	O	O
usually	usually	RB	B-ADVP	O	O
prescribed	prescribe	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
other	other	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group-AD-2
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
Type	Type	NN	B-NP	O	B-group-AD-2
1C	1C	NN	I-NP	O	I-group-AD-2
antiarrhythmics	antiarrhythmic	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
propafenone	propafenone	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
flecainide	flecainide	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
encainide	encainide	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
approached	approach	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Oxcarbazepine	Oxcarbazepine	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
and	and	CC	O	O	O
induce	induce	VB	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
/	/	SYM	O	O	O
5	5	CD	B-NP	O	O
with	with	IN	B-PP	O	O
potentially	potentially	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
several	several	JJ	B-NP	O	O
AED	AED	NN	I-NP	O	S-group-ME-1
s	s	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
inducers	inducer	NNS	I-NP	I-protein	O
can	can	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oxcarbazepine	oxcarbazepine	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
MHD	MHD	NN	I-NP	O	S-drug_n
.	.	.	O	O	O

Oxcarbazepine	Oxcarbazepine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
capacity	capacity	NN	I-NP	O	O
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
oxcarbazepine	oxcarbazepine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
pharmacologically	pharmacologically	RB	I-NP	O	O
active	active	JJ	I-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
monohydroxy	monohydroxy	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
(	(	(	O	O	O
MHD	MHD	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
little	little	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
no	no	DT	I-NP	O	O
capacity	capacity	NN	I-NP	O	O
to	to	TO	B-VP	O	O
function	function	VB	I-VP	O	O
as	as	IN	B-PP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	B-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
evaluated	evaluate	VBN	B-VP	O	O
(	(	(	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2A6	CYP2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP4A9	CYP4A9	NN	B-NP	B-protein	O
and	and	CC	O	O	O
CYP4A11	CYP4A11	NN	B-NP	B-protein	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
exception	exception	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
/	/	SYM	B-NP	O	O
5	5	CD	B-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
/	/	SYM	B-NP	O	O
5	5	CD	B-NP	O	O
by	by	IN	B-PP	O	O
OXC	OXC	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
MHD	MHD	NN	I-NP	O	S-drug_n
did	do	VBD	B-VP	O	O
occur	occur	VB	I-VP	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
2C19	2C19	NN	I-NP	O	O
by	by	IN	B-PP	O	O
OXC	OXC	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
MHD	MHD	NN	I-NP	O	S-drug_n
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
relevant	relevant	JJ	I-ADJP	O	O
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
UDP	UDP	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
glucuronyl	glucuronyl	NN	I-NP	B-protein	O
transferase	transferase	NN	I-NP	I-protein	O
level	level	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
.	.	.	O	O	O

Increases	Increase	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
MHD	MHD	NN	B-NP	O	S-drug_n
and	and	CC	O	O	O
47	47	CD	B-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
oxcarbazepine	oxcarbazepine	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
MHD	MHD	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
the	the	DT	B-NP	O	O
predominant	predominant	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
substrate	substrate	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
only	only	RB	B-NP	O	O
a	a	DT	I-NP	O	O
weak	weak	JJ	I-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
UDP	UDP	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
glucuronyl	glucuronyl	NN	I-NP	B-protein	O
transferase	transferase	NN	I-NP	I-protein	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
mainly	mainly	RB	I-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
conjugation	conjugation	NN	B-NP	O	O
through	through	IN	B-PP	O	O
UDP	UDP	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
glucuronyl	glucuronyl	NN	B-NP	B-protein	O
transferase	transferase	NN	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
lamotrigine	lamotrigine	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
oxcarbazepine	oxcarbazepine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
MHD	MHD	NN	I-NP	O	S-drug_n
induce	induce	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
subgroup	subgroup	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A	3A	NN	I-NP	I-protein	O
family	family	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	O	O	O
CYP3A5	CYP3A5	NN	B-NP	B-protein	O
)	)	)	O	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dihydropyridine	dihydropyridine	NN	B-NP	O	B-group
calcium	calcium	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
binding	binding	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MHD	MHD	NN	B-NP	B-protein	S-drug_n
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
low	low	JJ	B-ADJP	O	O
(	(	(	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
through	through	IN	B-PP	O	O
competition	competition	NN	B-NP	O	O
for	for	IN	B-PP	O	O
protein	protein	NN	B-NP	B-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
are	be	VBP	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
.	.	.	O	O	O

Antiepileptic	Antiepileptic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
Potential	Potential	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
Trileptal	Trileptal	JJ	B-NP	O	S-brand
and	and	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
AEDs	AED	NNS	I-NP	O	S-group
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
AUCs	AUC	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
Cmin	Cmin	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
summarized	summarize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Table	Table	JJ	B-NP	O	O
2	2	CD	I-NP	O	O
:	:	:	O	O	O
Table	Table	JJ	B-NP	O	O
2	2	CD	I-NP	O	O
:	:	:	O	O	O
Summary	Summary	NN	B-NP	O	O
of	of	IN	B-PP	O	O
AED	AED	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Trileptal	Trileptal	NN	B-NP	O	S-brand

AED	AED	VBN	B-NP	B-protein	S-group
Co	Co	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
administered	administer	VBN	B-VP	O	O

Dose	Dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
AED	AED	NN	B-NP	O	S-group
(	(	(	O	O	O
mg	mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O

Trileptal	Trileptal	JJ	B-NP	O	S-brand
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
mg	mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O

Influence	Influence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Trileptal	Trileptal	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
AED	AED	VBN	B-NP	O	S-group
Concentration	Concentration	NN	I-NP	O	O
(	(	(	O	O	O
Mean	Mean	NN	B-NP	O	O
change	change	NN	I-NP	O	O
,	,	,	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
Confidence	Confidence	NN	I-NP	O	O
Interval	Interval	NN	I-NP	O	O
)	)	)	O	O	O

Influence	Influence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
AED	AED	NN	B-NP	O	S-group
On	On	IN	B-PP	O	O
MHD	MHD	NN	B-NP	O	S-drug_n
Concentration	Concentration	NN	I-NP	O	O
(	(	(	O	O	O
Mean	Mean	NN	B-NP	O	O
change	change	NN	I-NP	O	O
,	,	,	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
Confidence	Confidence	NN	I-NP	O	O
Interval	Interval	NN	I-NP	O	O
)	)	)	O	O	O

400	400	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2000	2000	CD	I-NP	O	O

nc1	nc1	NN	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
[	[	(	O	O	O
CI	CI	NN	B-NP	O	O
:	:	:	O	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
,	,	,	O	O	O
57	57	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
]	]	)	O	O	O

100	100	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
150	150	CD	I-NP	O	O

600	600	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1800	1800	CD	I-NP	O	O

14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
[	[	(	O	O	O
CI	CI	NN	B-NP	O	O
:	:	:	O	O	O
2	2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
,	,	,	O	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
]	]	)	O	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
[	[	(	O	O	O
CI	CI	NN	B-NP	O	O
:	:	:	O	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
,	,	,	O	O	O
51	51	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
]	]	)	O	O	O

250	250	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
500	500	CD	I-NP	O	O

600	600	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1800	1800	CD	I-NP	O	O

nc1,2	nc1,2	NN	B-NP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
[	[	(	O	O	O
CI	CI	NN	B-NP	O	O
:	:	:	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
,	,	,	O	O	O
48	48	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
]	]	)	O	O	O

1200	1200	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2400	2400	CD	I-NP	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase3	increase3	NN	I-NP	O	O
[	[	(	O	O	O
CI	CI	NN	B-NP	O	O
:	:	:	O	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
,	,	,	O	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
]	]	)	O	O	O

Valproic	Valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug

400	400	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2800	2800	CD	I-NP	O	O

600	600	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1800	1800	CD	I-NP	O	O

nc1	nc1	NN	B-NP	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
[	[	(	O	O	O
CI	CI	NN	B-NP	O	O
:	:	:	O	O	O
13	13	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
,	,	,	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
]	]	)	O	O	O

1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
nc	nc	NN	I-NP	O	O
denotes	denote	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
of	of	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
Pediatrics	Pediatric	NNPS	I-NP	B-protein	O
3	3	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
Mean	Mean	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
Trileptal	Trileptal	JJ	I-NP	O	S-brand
doses	dose	NNS	I-NP	O	O
In	In	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
Trileptal	Trileptal	NNP	B-NP	O	S-brand-ME-2
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
above	above	IN	B-PP	O	O
1200	1200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Trileptal	Trileptal	NNP	B-NP	O	S-brand-AD-1
greater	great	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
1200	1200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
during	during	IN	B-PP	O	O
adjunctive	adjunctive	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-AD-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
level	level	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
small	small	JJ	B-ADJP	O	O
(	(	(	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
Trileptal	Trileptal	NN	B-NP	O	S-brand-ME-2
.	.	.	O	O	O

Strong	Strong	JJ	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	.	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MHD	MHD	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
29	29	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
autoinduction	autoinduction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Trileptal	Trileptal	NN	B-NP	O	S-brand
.	.	.	O	O	O

Hormonal	Hormonal	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
Co	Co	AFX	O	O	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Trileptal	Trileptal	NN	B-NP	O	S-brand-ME-1
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
hormonal	hormonal	JJ	I-NP	O	O
components	component	NNS	I-NP	O	O
,	,	,	O	O	O
ethinylestradiol	ethinylestradiol	NN	B-NP	O	S-drug
(	(	(	O	O	O
EE	EE	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
levonorgestrel	levonorgestrel	NN	B-NP	O	S-drug
(	(	(	O	O	O
LNG	LNG	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
EE	EE	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
48	48	CD	B-NP	O	O
%	%	NN	I-NP	O	O
[	[	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
22	22	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
65	65	CD	I-NP	O	O
]	]	)	O	O	O
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
study	study	NN	I-NP	O	O
and	and	CC	O	O	O
52	52	CD	B-NP	O	O
%	%	NN	I-NP	O	O
[	[	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
38	38	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
52	52	CD	I-NP	O	O
]	]	)	O	O	O
in	in	IN	B-PP	O	O
another	another	DT	B-NP	O	O
study	study	NN	I-NP	O	O
[	[	(	O	O	O
1,2	1,2	CD	B-NP	O	O
]	]	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
LNG	LNG	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
32	32	CD	B-NP	O	O
%	%	NN	I-NP	O	O
[	[	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
20	20	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
45	45	CD	I-NP	O	O
]	]	)	O	O	O
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
study	study	NN	I-NP	O	O
and	and	CC	O	O	O
52	52	CD	B-NP	O	O
%	%	NN	I-NP	O	O
[	[	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
42	42	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
52	52	CD	I-NP	O	O
]	]	)	O	O	O
in	in	IN	B-PP	O	O
another	another	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Trileptal	Trileptal	NN	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
hormonal	hormonal	JJ	B-NP	O	B-group-EF-2
contraceptives	contraceptive	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
render	render	VB	I-VP	O	O
these	these	DT	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
less	less	RBR	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
implant	implant	JJ	I-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	B-group
Antagonists	Antagonist	NNS	I-NP	O	O
:	:	:	O	O	O
After	After	IN	B-NP	O	O
repeated	repeat	VBN	B-VP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Trileptal	Trileptal	NNP	B-NP	O	S-brand-ME-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
felodipine	felodipine	NN	B-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
lowered	lower	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
[	[	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
20	20	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
33	33	CD	I-NP	O	O
]	]	)	O	O	O
.	.	.	O	O	O

Verapamil	Verapamil	NN	B-NP	O	S-drug
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
[	[	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
18	18	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
27	27	CD	I-NP	O	O
]	]	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MHD	MHD	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
Cimetidine	Cimetidine	NN	I-NP	O	S-drug
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
dextropropoxyphene	dextropropoxyphene	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MHD	MHD	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
wshow	wshow	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
either	either	CC	B-NP	O	O
single	single	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
repeated	repeat	VBN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Trileptal	Trileptal	NNP	B-NP	O	S-brand
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Phase	Phase	NN	I-NP	O	O
I	I	CD	I-NP	O	O
trial	trial	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
escalating	escalate	VBG	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	O	S-brand
(	(	(	O	O	O
110	110	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
(	(	(	O	O	O
50	50	CD	B-NP	O	O
or	or	CC	I-NP	O	O
75	75	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
)	)	)	O	O	O
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
sequential	sequential	JJ	B-NP	O	O
infusions	infusion	NNS	I-NP	O	O
,	,	,	O	O	O
myelosuppression	myelosuppression	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
profound	profound	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand-EF-1
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug-EF-2
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alternate	alternate	JJ	I-NP	B-DNA	O
sequence	sequence	NN	I-NP	I-DNA	O
(	(	(	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
before	before	IN	B-PP	I-protein	O
cisplatin	cisplatin	NN	B-NP	I-protein	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
33	33	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
catalyzed	catalyze	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoen	isoen	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	I-protein	O
zymes	zyme	NNS	I-NP	I-protein	O
CYP2C8	CYP2C8	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
formal	formal	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
substrates	substrate	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
CYP2C8	CYP2C8	NN	I-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
.	.	.	O	O	O

Potential	Potential	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
protease	protease	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Reports	Report	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
(	(	(	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
doxorubicinol	doxorubicinol	NN	I-NP	O	S-drug_n
)	)	)	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	O	S-drug-ME-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
.	.	.	O	O	O

Hematology	Hematology	NN	B-NP	O	O
:	:	:	O	O	O
TAXOL	TAXOL	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
neutrophil	neutrophil	NN	I-NP	O	O
counts	count	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
1,500	1,500	CD	I-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
/	/	SYM	B-NP	O	O
mm3	mm3	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myelotoxicity	myelotoxicity	NN	B-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
frequent	frequent	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
counts	count	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
performed	perform	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
re	re	AFX	B-ADJP	O	O
-	-	HYPH	I-ADJP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
cycles	cycle	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
until	until	IN	B-SBAR	O	O
neutrophils	neutrophil	NNS	B-NP	B-cell_type	O
recover	recover	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
level	level	NN	I-NP	O	O
1500	1500	CD	B-NP	O	O
cells	cell	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mm3	mm3	NN	I-NP	O	O
and	and	CC	I-NP	O	O
platelets	platelet	NNS	I-NP	B-cell_type	O
recover	recover	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
level	level	NN	I-NP	O	O
100,000	100,000	CD	B-NP	O	O
cells	cell	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mm3	mm3	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	O
(	(	(	O	O	O
500	500	CD	B-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
/	/	SYM	O	O	O
mm3	mm3	NN	B-NP	O	O
for	for	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
)	)	)	O	O	O
during	during	IN	B-PP	O	O
a	a	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
for	for	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
courses	course	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
advanced	advance	VBN	B-NP	O	O
HIV	HIV	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
and	and	CC	O	O	O
poor	poor	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
risk	risk	NN	I-NP	O	O
AIDS	AIDS	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
Kaposi	Kaposi	NN	I-NP	O	O
s	s	NNS	I-NP	O	O
sarcoma	sarcoma	NN	I-NP	O	O
,	,	,	O	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
disease	disease	NN	I-NP	O	O
,	,	,	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
initiated	initiate	VBN	I-VP	O	O
and	and	CC	O	O	O
repeated	repeat	VBN	B-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
neutrophil	neutrophil	NN	I-NP	B-cell_type	O
count	count	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
1000	1000	CD	I-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
/	/	SYM	B-NP	O	O
mm3	mm3	NN	B-NP	O	O
.	.	.	O	O	O

Hypersensitivity	Hypersensitivity	NN	B-NP	O	O
Reactions	Reaction	NNS	I-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
products	product	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
Cremophor	Cremophor	NNP	B-NP	O	O
EL	EL	NNP	I-NP	O	O
(	(	(	O	O	O
eg	eg	NN	B-NP	O	O
,	,	,	O	O	O
cyclosporin	cyclosporin	NN	B-NP	O	S-drug-AD-1
for	for	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
concentrate	concentrate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
teniposide	teniposide	NN	I-NP	O	S-drug-AD-1
for	for	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
concentrate	concentrate	NN	I-NP	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand-AD-2
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
premedicated	premedicate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
diphen	diphen	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
hydramine	hydramine	NN	I-NP	O	O
and	and	CC	I-NP	O	O
H2	H2	NN	I-NP	O	B-group
antagonists	antagonist	NNS	I-NP	O	E-group
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Minor	Minor	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
flushing	flushing	NN	B-NP	O	O
,	,	,	O	O	O
skin	skin	NN	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
,	,	,	O	O	O
dyspnea	dyspnea	NN	B-NP	O	O
,	,	,	O	O	O
hypotension	hypotension	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
tachycardia	tachycardia	NN	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
require	require	VB	I-VP	O	O
interruption	interruption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
severe	severe	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
requiring	require	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
dyspnea	dyspnea	NN	B-NP	O	O
requiring	require	VBG	B-VP	O	O
bronchodilators	bronchodilator	NNS	B-NP	O	S-group
,	,	,	O	O	O
angioedema	angioedema	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
generalized	generalize	VBN	B-NP	O	O
urticaria	urticaria	NNS	I-NP	O	O
require	require	VBP	B-VP	O	O
immediate	immediate	JJ	B-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
aggressive	aggressive	JJ	B-NP	O	O
symptomatic	symptomatic	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
developed	develop	VBN	I-VP	O	O
severe	severe	JJ	B-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
rechallenged	rechallenge	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O	O
:	:	:	O	O	O
Hypotension	Hypotension	NN	B-NP	O	O
,	,	,	O	O	O
bradycardia	bradycardia	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
hypertension	hypertension	NN	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
but	but	CC	O	O	O
generally	generally	RB	B-VP	O	O
do	do	VBP	I-VP	O	O
not	not	RB	I-VP	O	O
require	require	VB	I-VP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Occasionally	Occasionally	RB	B-ADVP	O	O
TAXOL	TAXOL	NN	B-NP	O	S-brand
infusions	infusion	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
interrupted	interrupt	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
because	because	RB	B-PP	O	O
of	of	IN	I-PP	O	O
initial	initial	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
recurrent	recurrent	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

Frequent	Frequent	JJ	B-NP	O	O
vital	vital	JJ	I-NP	O	O
sign	sign	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
hour	hour	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	O	S-brand
infusion	infusion	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Continuous	Continuous	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
required	require	VBN	I-VP	O	O
except	except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
.	.	.	O	O	O

Nervous	Nervous	JJ	B-NP	O	O
System	System	NN	I-NP	O	O
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
frequent	frequent	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
symptomatology	symptomatology	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unusual	unusual	JJ	B-ADJP	O	O
and	and	CC	O	O	O
requires	require	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
for	for	IN	B-PP	O	O
all	all	DT	B-NP	O	O
subsequentcourses	subsequentcours	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
contains	contain	VBZ	B-VP	O	O
dehydrated	dehydrate	VBN	B-NP	O	O
alcohol	alcohol	NN	I-NP	O	O
USP	USP	NN	I-NP	O	O
,	,	,	O	O	O
396	396	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
;	;	:	O	O	O

consideration	consideration	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
possible	possible	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Hepatic	Hepatic	JJ	B-ADJP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
limited	limited	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
myelotoxicity	myelotoxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exacerbated	exacerbate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
total	total	JJ	I-NP	O	O
bilirubin	bilirubin	NN	I-NP	O	O
2	2	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
ULN	ULN	NN	I-NP	O	O
.	.	.	O	O	O

Extreme	Extreme	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
to	to	TO	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
recommended	recommend	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
DOSAGE	DOSAGE	NNP	B-NP	O	O
AND	AND	CC	I-NP	O	O
ADMINISTRATION	ADMINISTRATION	NNP	I-NP	O	O
,	,	,	O	O	O
Table	Table	NNP	B-NP	O	O
17	17	CD	I-NP	O	O
.	.	.	O	O	O

InjectionSite	InjectionSite	JJ	B-NP	O	O
Reaction	Reaction	NN	I-NP	O	O
:	:	:	O	O	O
Injection	Injection	NN	B-NP	O	O
site	site	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
reactions	reaction	NNS	B-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
extravasation	extravasation	NN	B-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
usually	usually	RB	B-ADVP	O	O
mild	mild	JJ	B-ADJP	O	O
and	and	CC	O	O	O
consisted	consist	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
erythema	erythema	NN	B-NP	O	O
,	,	,	O	O	O
tenderness	tenderness	NN	B-NP	O	O
,	,	,	O	O	O
skin	skin	NN	B-NP	O	O
discoloration	discoloration	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
swelling	swell	VBG	B-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	B-DNA	O
site	site	NN	I-NP	I-DNA	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
more	more	RBR	B-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
24	24	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

Recurrence	Recurrence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
skin	skin	NN	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
site	site	NN	I-NP	O	O
of	of	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
extravasation	extravasation	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	B-protein	S-brand
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
different	different	JJ	I-NP	O	O
site	site	NN	I-NP	O	O
,	,	,	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
recall	recall	NN	B-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
rarely	rarely	RB	B-ADVP	O	O
.	.	.	O	O	O

Rare	Rare	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
more	more	RBR	B-NP	O	O
severe	severe	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phlebitis	phlebitis	NN	B-NP	O	O
,	,	,	O	O	O
cellulitis	cellulitis	NN	B-NP	O	O
,	,	,	O	O	O
induration	induration	NN	B-NP	O	O
,	,	,	O	O	O
skin	skin	NN	B-NP	O	O
exfoliation	exfoliation	NN	I-NP	O	O
,	,	,	O	O	O
necrosis	necrosis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
fibrosis	fibrosis	NN	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
received	receive	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
part	part	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
continuing	continue	VBG	I-NP	O	O
surveillance	surveillance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TAXOL	TAXOL	NN	B-NP	O	S-brand
safety	safety	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
site	site	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
either	either	CC	O	O	O
occurred	occur	VBD	B-VP	O	O
during	during	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prolonged	prolong	VBN	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
or	or	CC	O	O	O
was	be	VBD	B-VP	O	O
delayed	delay	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
week	week	NN	I-NP	O	O
to	to	TO	B-PP	O	O
ten	ten	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
extravasation	extravasation	NN	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
at	at	IN	B-PP	O	O
this	this	DT	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
extravasation	extravasation	NN	B-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
closely	closely	RB	I-VP	O	O
monitor	monitor	VB	I-VP	O	O
the	the	DT	B-NP	O	O
infusion	infusion	NN	I-NP	B-DNA	O
site	site	NN	I-NP	I-DNA	O
for	for	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
infiltration	infiltration	NN	I-NP	O	O
during	during	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand-ME-1
once	once	RB	B-ADJP	O	O
weekly	weekly	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P450	P450	NN	B-NP	B-protein	O
1A2	1A2	NN	I-NP	I-protein	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
considered	consider	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
both	both	CC	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
PEGASYS	PEGASYS	NN	I-NP	O	S-brand-AD-2
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
representative	representative	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
2C9	2C9	NN	I-NP	I-protein	O
,	,	,	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
2C19	2C19	NN	I-NP	I-protein	O
,	,	,	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
or	or	CC	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	O
C	C	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
COPEGUS	COPEGUS	NN	B-NP	O	S-brand
,	,	,	O	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
treatment	treatment	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
ribavirin	ribavirin	NN	B-NP	O	S-drug
distribution	distribution	NN	I-NP	O	O
or	or	CC	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

Nucleoside	Nucleoside	NNP	B-NP	O	O
Analogues	Analogues	NNP	I-NP	O	O
Didanosine	Didanosine	NNP	I-NP	O	S-drug
Co	Co	NNP	I-NP	O	O
-	-	HYPH	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
COPEGUS	COPEGUS	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
didanosine	didanosine	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Reports	Report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
peripheral	peripheral	JJ	B-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	O
,	,	,	O	O	O
pancreatitis	pancreatitis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
symptomatic	symptomatic	JJ	B-NP	O	O
hyperlactatemia	hyperlactatemia	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
lactic	lactic	JJ	I-NP	O	O
acidosis	acidosis	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Stavudine	Stavudine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Zidovudine	Zidovudine	NN	I-NP	B-protein	S-drug
Ribavirin	Ribavirin	NN	I-NP	I-protein	S-drug-EF-1
can	can	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
antiviral	antiviral	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stavudine	stavudine	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug-EF-2
against	against	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
either	either	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Carcinogenesis	Carcinogenesis	NNP	B-NP	O	O
,	,	,	O	O	O
Mutagenesis	Mutagenesis	NNP	B-NP	O	O
,	,	,	O	O	O
Impairment	Impairment	NNP	B-NP	O	O
of	of	IN	B-PP	O	O
Fertility	Fertility	NNP	B-NP	O	O
Carcinogenesis	Carcinogenesis	NNP	I-NP	O	O
PEGASYS	PEGASYS	NNP	I-NP	O	S-brand
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
tested	test	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
carcinogenic	carcinogenic	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
.	.	.	O	O	O

Mutagenesis	Mutagenesis	NN	B-NP	O	O
PEGASYS	PEGASYS	NN	I-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
DNA	DNA	NN	B-NP	O	O
damage	damage	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
tested	test	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Ames	Ames	NNP	I-NP	O	O
bacterial	bacterial	JJ	I-NP	O	O
mutagenicity	mutagenicity	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
chromosomal	chromosomal	JJ	I-NP	O	O
aberration	aberration	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
lymphocytes	lymphocyte	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
either	either	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
or	or	CC	I-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
activation	activation	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
With	With	IN	B-PP	O	O
Ribavirin	Ribavirin	NN	B-NP	B-protein	S-drug
Ribavirin	Ribavirin	NN	I-NP	I-protein	S-drug
is	be	VBZ	B-VP	O	O
genotoxic	genotoxic	JJ	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
mutagenic	mutagenic	JJ	I-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
carcinogenic	carcinogenic	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
fully	fully	RB	B-ADJP	O	O
determined	determine	VBN	I-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
p53	p53	NN	I-NP	O	O
(	(	(	O	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
)	)	)	O	O	O
mouse	mouse	NN	B-NP	O	O
carcinogenicity	carcinogenicity	NN	I-NP	O	O
study	study	NN	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	IN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
tolerated	tolerate	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
ribavirin	ribavirin	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
oncogenic	oncogenic	JJ	B-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
body	body	NN	I-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
basis	basis	NN	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
0.5	0.5	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
maximum	maximum	JJ	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
human	human	JJ	I-NP	B-protein	O
24	24	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
carcinogenic	carcinogenic	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
ongoing	ongoe	VBG	I-VP	O	O
.	.	.	O	O	O

Mutagenesis	Mutagenesis	NN	B-NP	O	O
Impairment	Impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Fertility	Fertility	NN	B-NP	O	O
PEGASYS	PEGASYS	NN	I-NP	O	S-brand
may	may	MD	B-VP	O	O
impair	impair	VB	I-VP	O	O
fertility	fertility	NN	B-NP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
.	.	.	O	O	O

Prolonged	Prolonged	JJ	B-NP	O	O
menstrual	menstrual	JJ	I-NP	O	O
cycles	cycle	NNS	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
amenorrhea	amenorrhea	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
cynomolgus	cynomolgus	NN	I-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
given	give	VBN	B-VP	O	O
sc	sc	NN	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
600	600	CD	B-NP	O	O
m	m	NN	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
7200	7200	CD	B-NP	O	O
m	m	NN	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
every	every	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
one	one	CD	B-NP	O	O
month	month	NN	I-NP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
180	180	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
weekly	weekly	JJ	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
60	60	CD	I-NP	O	O
kg	kg	NN	I-NP	O	O
person	person	NN	I-NP	O	O
(	(	(	O	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Menstrual	Menstrual	JJ	B-NP	O	O
cycle	cycle	NN	I-NP	O	O
irregularities	irregularity	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
both	both	CC	O	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
and	and	CC	I-NP	O	O
delay	delay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
17b	17b	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
estradiol	estradiol	NN	I-NP	O	O
and	and	CC	I-NP	O	O
progesterone	progesterone	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
to	to	TO	B-PP	O	O
female	female	JJ	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
return	return	NN	I-NP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
menstrual	menstrual	JJ	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
followed	follow	VBD	B-VP	O	O
cessation	cessation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Every	Every	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
with	with	IN	B-PP	O	O
100m	100m	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
(	(	(	O	O	O
1200m	1200m	NN	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
)	)	)	O	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
(	(	(	O	O	O
equivalent	equivalent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
30	30	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
human	human	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cycle	cycle	NN	B-NP	O	O
duration	duration	NN	I-NP	O	O
or	or	CC	O	O	O
reproductive	reproductive	JJ	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
status	status	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
fertility	fertility	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
fertility	fertility	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
Rhesus	Rhesus	NN	I-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
pegylated	pegylate	VBN	I-NP	O	B-drug
interferon	interferon	NN	I-NP	B-protein	I-drug
alfa	alfa	NN	I-NP	I-protein	I-drug
-	-	HYPH	B-NP	O	I-drug
2a	2a	NN	I-NP	O	E-drug
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
25	25	CD	I-NP	O	O
x	x	SYM	I-NP	O	O
106	106	CD	I-NP	O	O
IU	IU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Pregnancy	Pregnancy	NNP	B-NP	O	O
Pregnancy	Pregnancy	NNP	I-NP	O	O
:	:	:	O	O	O
Category	Category	NNP	B-NP	O	O
C	C	NNP	I-NP	O	O
PEGASYS	PEGASYS	NNP	I-NP	O	S-brand
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
teratogenic	teratogenic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Non	Non	AFX	B-NP	B-protein	B-drug
-	-	HYPH	I-NP	O	I-drug
pegylated	pegylate	VBN	B-NP	O	I-drug
interferon	interferon	NN	I-NP	B-protein	I-drug
alfa	alfa	NN	I-NP	I-protein	I-drug
-	-	HYPH	B-NP	O	I-drug
2a	2a	NN	I-NP	O	E-drug
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
Rhesus	Rhesus	NN	I-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
to	to	TO	I-NP	O	O
500	500	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
weekly	weekly	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
abortions	abortion	NNS	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
teratogenic	teratogenic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
offspring	offspring	NN	I-NP	O	O
delivered	deliver	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
term	term	NN	B-NP	O	O
.	.	.	O	O	O

PEGASYS	PEGASYS	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
assumed	assume	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
abortifacient	abortifacient	JJ	B-NP	O	O
potential	potential	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
adequate	adequate	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

PEGASYS	PEGASYS	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
only	only	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
benefit	benefit	NN	I-NP	O	O
justifies	justify	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
fetus	fetus	NN	I-NP	O	O
.	.	.	O	O	O

PEGASYS	PEGASYS	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
childbearing	childbeare	VBG	B-VP	O	O
potential	potential	NN	B-NP	O	O
only	only	RB	B-ADVP	O	O
when	when	WRB	I-ADVP	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
using	use	VBG	I-VP	O	O
effective	effective	JJ	B-NP	O	O
contraception	contraception	NN	I-NP	O	O
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

Pregnancy	Pregnancy	NN	B-NP	O	O
:	:	:	O	O	O
Category	Category	NN	B-NP	O	O
X	X	NN	I-NP	O	O
:	:	:	O	O	O
Use	Use	NN	B-NP	O	O
With	With	IN	B-PP	O	O
Ribavirin	Ribavirin	NN	B-NP	B-protein	S-drug
(	(	(	O	O	O
see	see	VB	B-VP	O	O
CONTRAINDICATIONS	CONTRAINDICATIONS	NNS	B-NP	O	O
)	)	)	O	O	O
Significant	Significant	JJ	B-NP	O	O
teratogenic	teratogenic	JJ	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
embryocidal	embryocidal	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
animal	animal	JJ	I-NP	O	O
species	specie	NNS	I-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

COPEGUS	COPEGUS	NN	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
pregnant	pregnant	JJ	B-ADJP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
male	male	JJ	I-NP	O	O
partners	partner	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
pregnant	pregnant	JJ	B-ADJP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
pregnancy	pregnancy	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
or	or	CC	I-NP	O	O
partner	partner	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
or	or	CC	B-PP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
6	6	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
cessation	cessation	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
COPEGUS	COPEGUS	NNP	I-NP	O	S-brand
Pregnancy	Pregnancy	NNP	I-NP	O	O
Registry	Registry	NNP	I-NP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
800	800	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
526	526	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
6367	6367	CD	I-NP	O	O
.	.	.	O	O	O

Nursing	Nurse	VBG	B-VP	O	O
Mothers	Mother	NNS	B-NP	O	O
It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
peginterferon	peginterferon	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
ribavirin	ribavirin	NN	I-NP	O	S-drug
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
components	component	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
milk	milk	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
orally	orally	RB	B-NP	O	O
ingested	ingest	VBN	I-NP	O	O
peginterferon	peginterferon	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
ribavirin	ribavirin	NN	I-NP	O	S-drug
from	from	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
milk	milk	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nursing	nursing	NN	I-NP	O	O
infant	infant	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
nursing	nursing	NN	B-NP	O	O
infants	infant	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decision	decision	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
to	to	TO	B-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
nursing	nursing	NN	B-NP	O	O
or	or	CC	I-NP	O	O
discontinue	discontinue	NN	I-NP	O	O
PEGASYS	PEGASYS	NN	I-NP	O	S-brand
and	and	CC	O	O	O
COPEGUS	COPEGUS	NN	B-NP	O	S-brand
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Pediatric	Pediatric	JJ	B-NP	O	O
Use	Use	NN	I-NP	O	O
The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
,	,	,	O	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
COPEGUS	COPEGUS	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
below	below	IN	B-PP	O	O
the	the	DT	B-NP	O	O
age	age	NN	I-NP	O	O
of	of	IN	B-PP	O	O
18	18	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

PEGASYS	PEGASYS	NN	B-NP	O	S-brand
contains	contain	VBZ	B-VP	O	O
benzyl	benzyl	NN	B-NP	O	B-drug_n
alcohol	alcohol	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

Benzyl	Benzyl	NN	B-NP	O	B-drug_n
alcohol	alcohol	NN	I-NP	O	E-drug_n
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurological	neurological	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
neonates	neonate	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
infants	infant	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
sometimes	sometimes	RB	B-ADJP	O	O
fatal	fatal	JJ	I-ADJP	O	O
.	.	.	O	O	O

Geriatric	Geriatric	JJ	B-NP	O	O
Use	Use	NN	I-NP	O	O
Younger	Younger	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
higher	high	JJR	B-NP	O	O
virologic	virologic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
COPEGUS	COPEGUS	NN	B-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
include	include	VB	I-VP	O	O
sufficient	sufficient	JJ	B-NP	O	O
numbers	number	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
aged	age	VBN	B-VP	O	O
65	65	CD	B-NP	O	O
or	or	CC	O	O	O
over	over	RP	B-PRT	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
respond	respond	VBP	B-VP	O	O
differently	differently	RB	B-ADVP	O	O
from	from	IN	B-PP	O	O
younger	young	JJR	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
alpha	alpha	NN	B-NP	B-protein	B-drug
interferons	interferon	NNS	I-NP	I-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
CNS	CNS	NN	B-NP	B-protein	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
systemic	systemic	JJ	B-ADJP	O	O
(	(	(	O	O	O
eg	eg	FW	O	O	O
,	,	,	O	O	O
flu	flu	NN	B-NP	O	O
-	-	HYPH	O	O	O
like	like	JJ	O	O	O
)	)	)	O	O	O
effects	effect	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
severe	severe	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
caution	caution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PEGASYS	PEGASYS	NN	B-NP	O	S-brand
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
population	population	NN	I-NP	O	O
.	.	.	O	O	O

PEGASYS	PEGASYS	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
COPEGUS	COPEGUS	NN	I-NP	O	S-brand
are	be	VBP	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxic	toxic	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
greater	great	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
more	more	RBR	B-ADJP	O	O
likely	likely	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
care	care	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
selection	selection	NN	I-NP	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

PEGASYS	PEGASYS	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
50	50	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
and	and	CC	I-NP	O	O
COPEGUS	COPEGUS	NN	I-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
50	50	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	B-NP	O	O

Aminoglycosides	Aminoglycoside	NNS	B-NP	O	S-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
mixing	mixing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
piperacillin	piperacillin	NN	B-NP	B-protein	S-drug-EF-1
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
aminoglycoside	aminoglycoside	NN	I-NP	O	S-group-EF-2
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
substantial	substantial	JJ	B-NP	O	O
inactivation	inactivation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
aminoglycoside	aminoglycoside	NN	I-NP	O	S-group
.	.	.	O	O	O

Vecuronium	Vecuronium	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
perioperative	perioperative	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
piperacillin	piperacillin	NN	B-NP	B-protein	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
implicated	implicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vecuronium	vecuronium	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
piperacillin	piperacillin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
perioperatively	perioperatively	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
controlled	control	VBN	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
ureidopenicillins	ureidopenicillin	NNS	I-NP	B-protein	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
piperacillin	piperacillin	NN	B-NP	B-protein	S-drug-EF-1
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vecuronium	vecuronium	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
their	their	PRP$	B-NP	O	O
similar	similar	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
depolarizing	depolarize	VBG	B-VP	O	I-group-EF-1
muscle	muscle	NN	B-NP	O	I-group-EF-1
relaxants	relaxant	NNS	I-NP	O	E-group-EF-1
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
piperacillin	piperacillin	NN	B-NP	B-protein	S-drug-EF-2
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
before	before	IN	B-PP	O	O
intramuscular	intramuscular	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PIPRACIL	PIPRACIL	NN	B-NP	O	S-brand-ME-2
produces	produce	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
piperacillin	piperacillin	NN	B-NP	O	S-drug
peak	peak	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
about	about	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
:	:	:	O	O	O
Coagulation	Coagulation	NN	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
tested	test	VBN	I-VP	O	O
more	more	RBR	B-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
and	and	CC	O	O	O
monitored	monitor	VBN	B-VP	O	O
regularly	regularly	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
system	system	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
thrombocyte	thrombocyte	NN	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
Piperacillin	Piperacillin	NN	B-NP	O	B-drug-ME-1
sodium	sodium	NN	I-NP	O	E-drug-ME-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
drug	drug	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
As	As	IN	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
penicillins	penicillin	NNS	I-NP	B-protein	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PIPRACIL	PIPRACIL	NN	B-NP	B-protein	S-brand
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
false	false	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
copper	copper	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
glucose	glucose	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
enzymatic	enzymatic	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
oxidase	oxidase	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
positive	positive	JJ	B-NP	O	O
test	test	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
Bio	Bio	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Rad	Rad	NNP	I-NP	O	O
Laboratories	Laboratories	NNP	I-NP	O	O
Platelia	Platelia	NNP	I-NP	O	O
Aspergillus	Aspergillus	NNP	I-NP	O	O
EIA	EIA	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
piperacillin	piperacillin	NN	B-NP	B-protein	S-drug
/	/	SYM	B-NP	O	O
tazobactam	tazobactam	NN	I-NP	O	S-drug
injection	injection	NN	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
subsequently	subsequently	RB	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
free	free	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
Aspergillus	Aspergillus	NN	B-NP	O	O
infection	infection	NN	I-NP	O	O
.	.	.	O	O	O

Cross	Cross	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
Aspergillus	Aspergillus	NN	I-NP	O	O
polysaccharides	polysaccharide	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
polyfuranoses	polyfuranos	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Bio	Bio	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Rad	Rad	NNP	I-NP	O	O
Laboratories	Laboratories	NNP	I-NP	O	O
Platelia	Platelia	NNP	I-NP	O	O
Aspergillus	Aspergillus	NNP	I-NP	O	O
EIA	EIA	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
positive	positive	JJ	B-NP	O	O
test	test	NN	I-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
piperacillin	piperacillin	NN	B-NP	B-protein	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
interpreted	interpret	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
and	and	CC	O	O	O
confirmed	confirm	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
methods	method	NNS	I-NP	O	O
.	.	.	O	O	O

Phenothiazines	Phenothiazines	NN	B-NP	O	S-group
-	-	HYPH	O	O	O
Taking	Take	VBG	B-VP	O	O
piperazine	piperazine	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
phenothiazine	phenothiazine	NN	I-NP	O	S-group-EF-2
together	together	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	O
(	(	(	O	O	O
seizures	seizure	NNS	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Pyrantel	Pyrantel	NN	B-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Antiminth	Antiminth	JJ	B-ADJP	O	S-drug
)	)	)	O	O	O
-	-	HYPH	O	O	O
Taking	Take	VBG	B-VP	O	O
piperazine	piperazine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
pyrantel	pyrantel	NN	I-NP	O	S-drug-EF-2
together	together	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
piperazine	piperazine	NN	B-NP	O	S-drug
.	.	.	O	O	O

ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Reports	Report	NNS	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Angiotensin	Angiotensin	NNP	B-NP	O	B-group-EF-2
Converting	Convert	VBG	B-VP	O	I-group-EF-2
Enzyme	Enzyme	NN	B-NP	B-protein	I-group-EF-2
(	(	(	O	O	I-group-EF-2
ACE	ACE	NN	B-NP	O	I-group-EF-2
)	)	)	O	O	I-group-EF-2
inhibitors	inhibitor	NNS	B-NP	O	E-group-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
mild	mild	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand-EF-1
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ACE	ACE	NN	I-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
benazepril	benazepril	NN	I-NP	O	S-drug-EF-2
,	,	,	O	O	O
10	10	CD	B-NP	O	O
to	to	TO	I-NP	O	O
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
about	about	RB	B-NP	O	O
3	3	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
consideration	consideration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand-AD-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GI	GI	NN	B-NP	O	O
ulceration	ulceration	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
12	12	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
endoscopy	endoscopy	NN	I-NP	O	O
study	study	NN	I-NP	O	O
conducted	conduct	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
OA	OA	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
endoscopic	endoscopic	JJ	B-NP	O	O
gastroduodenal	gastroduodenal	JJ	I-NP	O	O
ulcers	ulcer	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
81	81	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
enteric	enteric	JJ	B-NP	O	O
coated	coated	JJ	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand
plus	plus	CC	O	O	O
VIOXX	VIOXX	NN	B-NP	O	S-brand
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
taking	take	VBG	B-VP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
2400	2400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
alone	alone	RB	I-ADVP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand
plus	plus	CC	O	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
,	,	,	O	O	O
VIOXX	VIOXX	NN	B-NP	O	S-brand
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	B-cell_type	O
platelet	platelet	NN	I-NP	I-cell_type	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
81	81	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ex	ex	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
platelet	platelet	NN	I-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
and	and	CC	O	O	O
serum	serum	NN	B-NP	O	O
TXB2	TXB2	NN	I-NP	O	O
generation	generation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clotting	clot	VBG	B-VP	O	O
blood	blood	NN	B-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substitute	substitute	NN	I-NP	O	O
for	for	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
for	for	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
antiplatelet	antiplatelet	JJ	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
indication	indication	NN	I-NP	O	O
for	for	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
.	.	.	O	O	O

Prospective	Prospective	JJ	B-NP	O	O
,	,	,	I-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
[	[	(	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
]	]	)	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
AUC0	AUC0	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
120hr	120hr	NN	B-NP	O	O
by	by	IN	B-PP	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
t1	t1	NN	I-NP	O	O
/	/	SYM	O	O	O
2	2	CD	B-NP	O	O
by	by	IN	B-PP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
clinically	clinically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Rofecoxib	Rofecoxib	NN	B-NP	O	S-drug
75	75	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
11	11	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
or	or	CC	O	O	O
renal	renal	JJ	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
0.5	0.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
post	post	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
marketing	market	VBG	B-VP	O	O
observations	observation	NNS	B-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group-EF-2
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
response	response	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
any	any	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
produced	produce	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
post	post	AFX	O	O	O
-	-	HYPH	O	O	O
marketing	market	VBG	B-VP	O	O
experience	experience	NN	B-NP	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand-AD-1
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
subjects	subject	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
VIOXX	VIOXX	NN	I-NP	O	S-brand
12.5	12.5	CD	I-NP	O	O
,	,	,	I-NP	O	O
25	25	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
each	each	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
administered	administer	VBN	B-VP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
24hr	24hr	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
single	single	JJ	B-NP	O	O
weekly	weekly	JJ	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
7.5	7.5	CD	B-NP	O	O
to	to	TO	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
recommended	recommend	VBN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
VIOXX	VIOXX	NN	B-NP	O	S-brand-ME-1
75	75	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
administered	administer	VBN	B-VP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
24hr	24hr	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
7.5	7.5	CD	I-NP	O	O
to	to	TO	I-NP	O	O
15	15	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
week	week	NN	I-NP	O	O
for	for	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
postdose	postdose	VBP	B-VP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
proportion	proportion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
(	(	(	O	O	O
94	94	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
subsequently	subsequently	RB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-1
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
88	88	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
below	below	IN	B-PP	O	O
the	the	DT	B-NP	O	O
measurable	measurable	JJ	I-NP	O	O
limit	limit	NN	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Standard	Standard	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
continued	continue	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand-AD-1
and	and	CC	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Oral	Oral	NNP	B-NP	O	O
Contraceptives	Contraceptive	NNPS	I-NP	O	S-group
Rofecoxib	Rofecoxib	NNP	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
any	any	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
norethindrone	norethindrone	NN	I-NP	O	S-drug
.	.	.	O	O	O

Prednisone	Prednisone	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
prednisolone	prednisolone	NN	I-NP	O	S-drug
:	:	:	O	O	O
Rofecoxib	Rofecoxib	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
any	any	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
prednisolone	prednisolone	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
prednisone	prednisone	NN	I-NP	O	S-drug
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand-ME-1
with	with	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
600	600	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
produced	produce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
approximate	approximate	JJ	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
starting	start	VBG	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
osteoarthritis	osteoarthritis	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
VIOXX	VIOXX	NN	I-NP	O	S-brand-ME-1
12.5	12.5	CD	I-NP	O	O
,	,	,	I-NP	O	O
25	25	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
administered	administer	VBN	B-VP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	O	O	O
)	)	)	O	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
38	38	CD	B-NP	O	O
to	to	TO	I-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
administered	administer	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
300	300	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
.	.	.	O	O	O

Adequate	Adequate	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand-AD-1
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
changed	change	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
modest	modest	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	I-protein	O
CYP	CYP	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
1A2	1A2	NN	B-NP	I-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
1A2	1A2	NN	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
amitriptyline	amitriptyline	NN	B-NP	O	S-drug
,	,	,	O	O	O
tacrine	tacrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
zileuton	zileuton	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Anticoagulant	Anticoagulant	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
few	few	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
or	or	CC	I-VP	O	O
changing	change	VBG	I-VP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand-AD-1
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
similar	similar	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
complications	complication	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
multiple	multiple	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
rofecoxib	rofecoxib	NN	I-NP	O	S-drug-EF-2
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
measured	measure	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
8	8	CD	I-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
11	11	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
post	post	AFX	O	O	O
-	-	HYPH	O	O	O
marketing	marketing	NN	B-NP	O	O
experience	experience	NN	I-NP	O	O
,	,	,	O	O	O
bleeding	bleed	VBG	B-VP	O	O
events	event	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
predominantly	predominantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
VIOXX	VIOXX	NN	B-NP	B-protein	S-brand-EF-1
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

DRUG	DRUG	NN	B-NP	O	O
INTERACTIONS	INTERACTIONS	NNS	I-NP	O	O

Several	Several	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
completed	complete	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
both	both	CC	O	O	O
INVIRASE	INVIRASE	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
FORTOVASE	FORTOVASE	NN	I-NP	B-protein	S-brand
.	.	.	O	O	O

Observations	Observation	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
FORTOVASE	FORTOVASE	NN	B-NP	B-protein	S-brand
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
predictive	predictive	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
INVIRASE	INVIRASE	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
,	,	,	O	O	O
prescribers	prescriber	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
also	also	RB	I-VP	O	O
refer	refer	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
prescribing	prescribe	VBG	I-NP	O	O
information	information	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
regarding	regard	VBG	B-VP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	O	O	O
Glycoprotein	Glycoprotein	NN	B-NP	B-protein	O
(	(	(	O	O	O
Pgp	Pgp	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
affect	affect	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
Pgp	Pgp	NN	B-NP	B-protein	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
modify	modify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
might	might	MD	B-VP	O	O
also	also	RB	I-VP	O	O
modify	modify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
or	or	CC	I-NP	O	O
Pgp	Pgp	NN	I-NP	B-protein	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
specifically	specifically	RB	B-ADVP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
expected	expect	VBN	I-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
and	and	CC	I-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
listed	list	VBN	I-VP	O	O
CONTRAINDICATIONS	CONTRAINDICATIONS	NNS	B-NP	O	O
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
INVIRASE	INVIRASE	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug
are	be	VBP	B-VP	O	O
included	include	VBN	I-VP	O	O
below	below	RB	B-ADVP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
recommendations	recommendation	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
either	either	CC	O	O	O
drug	drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
or	or	CC	O	O	O
predicted	predict	VBN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
expected	expect	VBN	I-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
and	and	CC	I-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
or	or	CC	O	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
some	some	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
induced	induce	VBN	I-VP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
That	That	DT	B-NP	O	O
Should	Should	MD	B-VP	O	O
Not	Not	RB	I-VP	O	O
Be	Be	VB	I-VP	O	O
Coadministered	Coadministere	VBN	I-VP	O	O
With	With	IN	B-PP	O	O
INVIRASE	INVIRASE	NN	B-NP	B-protein	S-brand
/	/	SYM	O	O	O
Ritonavir	Ritonavir	NN	B-NP	O	S-drug

Drug	Drug	NNP	B-NP	O	O
Class	Class	NNP	I-NP	O	O
:	:	NNP	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Name	Name	NNP	I-NP	O	O
Clinical	Clinical	NNP	I-NP	O	O
Comment	Comment	NNP	I-NP	O	O

Antiarrhythmics	Antiarrhythmic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Amiodarone	Amiodarone	NN	B-NP	O	S-drug
,	,	,	O	O	O
bepridil	bepridil	NN	B-NP	O	S-drug
,	,	,	O	O	O
flecainide	flecainide	NN	B-NP	O	S-drug
,	,	,	O	O	O
propafenone	propafenone	NN	B-NP	O	S-drug
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
CONTRAINDICATED	CONTRAINDICATED	VBD	B-VP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
.	.	.	O	O	O

Antihistamines	Antihistamine	NNS	B-NP	O	S-drug
:	:	:	O	O	O
astemizole	astemizole	NN	B-NP	O	S-drug
*	*	SYM	B-NP	O	O
,	,	,	O	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
*	*	SYM	I-NP	O	O
CONTRAINDICATED	CONTRAINDICATED	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Ergot	Ergot	NNP	B-NP	O	B-group
Derivatives	Derivative	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Dihydroergotamine	Dihydroergotamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
ergonovine	ergonovine	NN	B-NP	O	S-drug
,	,	,	O	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
methylergonovine	methylergonovine	JJ	B-NP	O	S-drug
CONTRAINDICATED	CONTRAINDICATED	NN	I-NP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
life	life	NN	I-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
acute	acute	JJ	B-NP	O	O
ergot	ergot	NN	I-NP	O	S-group
toxicity	toxicity	NN	I-NP	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	O
vasospasm	vasospasm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
ischemia	ischemia	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extremities	extremity	NNS	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
tissues	tissue	NNS	I-NP	O	O
.	.	.	O	O	O

Antimycobacterial	Antimycobacterial	JJ	B-NP	O	B-group
Agents	Agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
CONTRAINDICATED	CONTRAINDICATED	VBN	B-VP	O	O
since	since	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
product	product	NN	I-NP	O	O
with	with	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
antiretroviral	antiretroviral	JJ	I-NP	O	S-group
regimen	regimen	NN	I-NP	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

Garlic	Garlic	NNP	B-NP	O	O
Capsules	Capsules	NNP	I-NP	O	O
Garlic	Garlic	NNP	I-NP	O	O
capsules	capsule	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
(	(	(	O	O	O
FORTOVASE	FORTOVASE	NN	B-NP	O	S-brand
)	)	)	O	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sole	sole	JJ	I-NP	O	O
protease	protease	NN	I-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
saquinavir	saquinavir	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
INVIRASE	INVIRASE	NN	B-NP	B-protein	S-brand
/	/	SYM	B-NP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
FORTOVASE	FORTOVASE	NN	I-NP	B-protein	S-brand
/	/	SYM	B-NP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
garlic	garlic	NN	I-NP	O	O
capsules	capsule	NNS	I-NP	O	O
.	.	.	O	O	O

GI	GI	NNP	B-NP	O	O
Motility	Motility	NNP	I-NP	O	O
Agent	Agent	NNP	I-NP	O	O
:	:	:	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
*	*	SYM	I-NP	O	O
CONTRAINDICATED	CONTRAINDICATED	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Herbal	Herbal	NNP	B-NP	O	O
Products	Product	NNPS	I-NP	O	O
:	:	:	O	O	O
St.	St.	NNP	B-NP	O	O
John	John	NNP	I-NP	O	O
s	s	NN	I-NP	O	O
wort	wort	NN	I-NP	O	O
(	(	(	O	O	O
hypericum	hypericum	NN	B-NP	O	O
perforatum	perforatum	NN	I-NP	O	O
)	)	)	O	O	O
WARNING	WARNING	NN	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
virologic	virologic	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
INVIRASE	INVIRASE	NN	B-NP	B-protein	S-brand
or	or	CC	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
protease	protease	NN	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
.	.	.	O	O	O

HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	O	I-group
Reductase	Reductase	NN	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug
WARNING	WARNING	NN	I-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
risk	risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
including	include	VBG	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	O
.	.	.	O	O	O

Sedatives	Sedative	NNS	B-NP	O	S-group
/	/	SYM	B-NP	O	O
Hypnotics	Hypnotic	NNS	I-NP	O	S-group
:	:	:	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug
,	,	,	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
CONTRAINDICATED	CONTRAINDICATED	VBD	B-VP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
prolonged	prolonged	JJ	B-ADJP	O	O
or	or	CC	O	O	O
increased	increase	VBN	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
or	or	CC	O	O	O
respiratory	respiratory	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
.	.	.	O	O	O

*	*	SYM	O	B-cell_type	O
No	No	DT	B-ADVP	I-cell_type	O
longer	longer	RBR	I-ADVP	O	O
marketed	market	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
US	US	NNP	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
That	That	DT	B-NP	O	O
Are	Be	VBP	B-VP	O	O
Mainly	Mainly	RB	I-VP	O	O
Metabolized	Metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O

Although	Although	IN	B-SBAR	O	O
specific	specific	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
mainly	mainly	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group-ME-1
channel	channel	NN	I-NP	O	I-group-ME-1
blockers	blocker	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
dapsone	dapsone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
disopyramide	disopyramide	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
quinine	quinine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
ergot	ergot	NN	B-NP	O	B-group-ME-1
derivatives	derivative	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
pimozide	pimozide	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
fentanyl	fentanyl	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
alfentanyl	alfentanyl	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
alprazolam	alprazolam	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
triazolam	triazolam	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
elevated	elevate	VBN	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
INVIRASE	INVIRASE	NN	B-NP	B-protein	S-brand-AD-1
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug
label	label	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reviewed	review	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
additional	additional	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Inducers	Inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O

Coadministration	Coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
potent	potent	JJ	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Sulfacetamide	Sulfacetamide	NN	B-NP	O	S-drug-IN-1
preparations	preparation	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
incompatible	incompatible	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
silver	silver	JJ	B-NP	O	S-drug-IN-2
preparations	preparation	NNS	I-NP	O	O
.	.	.	O	O	O

Sulfapyridine	Sulfapyridine	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
Acetaminophen	Acetaminophen	NN	I-NP	O	S-drug-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Tylenol	Tylenol	NN	B-NP	O	S-brand-IN-2
)	)	)	O	O	O
(	(	(	O	O	O
with	with	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
use	use	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Amiodarone	Amiodarone	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Cordarone	Cordarone	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Anabolic	Anabolic	JJ	I-NP	O	B-group
steroids	steroid	NNS	I-NP	O	E-group
(	(	(	O	O	O
nandrolone	nandrolone	NN	B-NP	O	S-drug
[	[	(	I-NP	O	O
e.g	e.g	NN	I-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	I-NP	O	O
Anabolin	Anabolin	NN	I-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
oxandrolone	oxandrolone	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Anavar	Anavar	NNP	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
oxymetholone	oxymetholone	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Anadrol	Anadrol	NN	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
stanozolol	stanozolol	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Winstrol	Winstrol	NNP	B-NP	O	S-brand
]	]	)	O	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Androgens	Androgen	NNS	I-NP	O	S-group
(	(	(	O	O	O
male	male	JJ	B-NP	O	O
hormones	hormone	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Antithyroid	Antithyroid	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
medicine	medicine	NN	B-NP	O	O
for	for	IN	B-PP	O	O
overactive	overactive	JJ	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Carbamazepine	Carbamazepine	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Tegretol	Tegretol	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Carmustine	Carmustine	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
BiCNU	BiCNU	NN	B-NP	B-protein	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Chloroquine	Chloroquine	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Aralen	Aralen	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Dantrolene	Dantrolene	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Dantrium	Dantrium	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Daunorubicin	Daunorubicin	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Cerubidine	Cerubidine	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Disulfiram	Disulfiram	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Antabuse	Antabuse	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Divalproex	Divalproex	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Depakote	Depakote	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Estrogens	Estrogen	NNS	I-NP	O	S-group
(	(	(	O	O	O
female	female	JJ	B-NP	O	O
hormones	hormone	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Etretinate	Etretinate	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Tegison	Tegison	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Gold	Gold	NN	I-NP	O	S-drug
salts	salt	NNS	I-NP	O	O
(	(	(	O	O	O
medicine	medicine	NN	B-NP	O	O
for	for	IN	B-PP	O	O
arthritis	arthritis	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Hydroxychloroquine	Hydroxychloroquine	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Plaquenil	Plaquenil	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Mercaptopurine	Mercaptopurine	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Purinethol	Purinethol	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Naltrexone	Naltrexone	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Trexan	Trexan	NN	B-NP	O	S-brand
)	)	)	O	O	O
(	(	(	O	O	O
with	with	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
use	use	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Oral	Oral	JJ	I-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
(	(	(	O	O	O
birth	birth	NN	B-NP	O	O
control	control	NN	I-NP	O	O
pills	pill	NNS	I-NP	O	O
)	)	)	O	O	O
containing	contain	VBG	B-VP	O	O
estrogen	estrogen	NN	B-NP	O	S-group
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Other	Other	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
infectives	infective	NNS	I-NP	O	E-group
by	by	IN	B-PP	O	O
mouth	mouth	NN	B-NP	O	O
or	or	CC	B-PP	O	O
by	by	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
(	(	(	O	O	O
medicine	medicine	NN	B-NP	O	O
for	for	IN	B-PP	O	O
infection	infection	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Phenothiazines	Phenothiazine	NNS	I-NP	O	S-group
(	(	(	O	O	O
acetophenazine	acetophenazine	NN	B-NP	O	S-drug
[	[	(	I-NP	O	O
e.g	e.g	NN	I-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Tindal	Tindal	NNP	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
chlorpromazine	chlorpromazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Thorazine	Thorazine	NN	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
fluphenazine	fluphenazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Prolixin	Prolixin	NN	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
mesoridazine	mesoridazine	NN	B-NP	O	S-brand
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Serentil	Serentil	NN	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
perphenazine	perphenazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Trilafon	Trilafon	NNP	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
prochlorperazine	prochlorperazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Compazine	Compazine	NN	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
promazine	promazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Sparine	Sparine	NN	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
promethazine	promethazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Phenergan	Phenergan	NN	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
thioridazine	thioridazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Mellaril	Mellaril	NNP	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
trifluoperazine	trifluoperazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Stelazine	Stelazine	NN	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
triflupromazine	triflupromazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Vesprin	Vesprin	NN	B-NP	O	S-brand
]	]	)	O	O	O
,	,	,	O	O	O
trimeprazine	trimeprazine	NN	B-NP	O	S-drug
[	[	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Temaril	Temaril	NNP	B-NP	O	S-brand
]	]	)	O	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Plicamycin	Plicamycin	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Mithracin	Mithracin	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Valproic	Valproic	JJ	I-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Depakene	Depakene	NN	B-NP	O	S-brand
)	)	)	O	O	O
Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sulfapyridine	sulfapyridine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
affecting	affect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Acetohydroxamic	Acetohydroxamic	JJ	I-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Lithostat	Lithostat	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Dapsone	Dapsone	NN	I-NP	O	S-drug
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Furazolidone	Furazolidone	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Furoxone	Furoxone	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Nitrofurantoin	Nitrofurantoin	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Furadantin	Furadantin	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Primaquine	Primaquine	NN	I-NP	O	S-drug
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Procainamide	Procainamide	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Pronestyl	Pronestyl	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Quinidine	Quinidine	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Quinidex	Quinidex	NNP	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Quinine	Quinine	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Quinamm	Quinamm	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Sulfoxone	Sulfoxone	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Diasone	Diasone	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Vitamin	Vitamin	NN	I-NP	B-protein	B-group
K	K	NN	I-NP	I-protein	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
AquaMEPHYTON	AquaMEPHYTON	NN	B-NP	O	S-brand
,	,	,	O	O	O
Synkayvite	Synkayvite	NN	B-NP	O	S-brand
)	)	)	O	O	O
Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sulfapyridine	sulfapyridine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
affecting	affect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Anticoagulants	Anticoagulant	NNS	I-NP	O	S-group
(	(	(	O	O	O
blood	blood	NN	B-NP	O	B-group
thinners	thinner	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Ethotoin	Ethotoin	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Peganone	Peganone	NN	B-NP	O	S-brand
)	)	)	O	O	O
or	or	CC	O	O	O

-	-	HYPH	B-NP	O	O
Mephenytoin	Mephenytoin	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Mesantoin	Mesantoin	NN	B-NP	O	S-brand
)	)	)	O	O	O
Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sulfapyridine	sulfapyridine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O

-	-	HYPH	B-NP	O	O
Antidiabetics	Antidiabetic	NNS	I-NP	O	S-group
,	,	,	O	O	O
oral	oral	JJ	B-ADJP	O	O
(	(	(	O	O	O
diabetes	diabetes	NN	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
you	you	PRP	B-NP	O	O
take	take	VBP	B-VP	O	O
by	by	IN	B-PP	O	O
mouth	mouth	NN	B-NP	O	O
)	)	)	O	O	O
Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
antidiabetics	antidiabetic	NNS	I-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
sulfapyridine	sulfapyridine	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
affecting	affect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
antidiabetics	antidiabetic	NNS	I-NP	O	S-group

-	-	HYPH	B-NP	O	O
Methotrexate	Methotrexate	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Mexate	Mexate	NN	B-NP	O	S-brand
)	)	)	O	O	O
Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
sulfapyridine	sulfapyridine	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
affecting	affect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
side	side	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug

-	-	HYPH	B-NP	O	O
Methyldopa	Methyldopa	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Aldomet	Aldomet	NNP	B-NP	O	S-brand
)	)	)	O	O	O
Use	Use	NNP	B-NP	O	O
of	of	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
sulfapyridine	sulfapyridine	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
affecting	affect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O

-	-	HYPH	B-NP	O	O
Phenytoin	Phenytoin	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Dilantin	Dilantin	NN	B-NP	O	S-brand
)	)	)	O	O	O
Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
sulfapyridine	sulfapyridine	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
affecting	affect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
side	side	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug

In	In	IN	B-PP	O	O
evaluating	evaluate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
among	among	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	B-NP	O	O
antiepilepsy	antiepilepsy	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
AEDs	AED	NNS	B-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
whether	whether	IN	B-SBAR	O	O
or	or	CC	O	O	O
not	not	RB	O	O	O
an	an	DT	B-NP	O	O
AED	AED	NN	I-NP	O	S-group
induces	induce	VBZ	B-VP	O	O
or	or	CC	O	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
metabolic	metabolic	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
consideration	consideration	NN	I-NP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug
are	be	VBP	B-VP	O	O
ge	ge	NN	B-NP	O	O
nerally	nerally	RB	B-VP	O	O
classified	classify	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
enzyme	enzyme	NN	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
;	;	:	O	O	O

valproate	valproate	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
gabapentin	gabapentin	NN	I-NP	B-protein	S-drug
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
.	.	.	O	O	O

GABITRIL	GABITRIL	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
inducing	induce	VBG	I-NP	O	O
AED	AED	NN	I-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
described	describe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
section	section	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
involving	involve	VBG	B-VP	O	O
either	either	CC	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	B-NP	O	O
or	or	CC	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
GABITRIL	GABITRIL	NN	B-NP	B-protein	S-brand
on	on	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
Antiepilepsy	Antiepilepsy	JJ	I-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
(	(	(	O	O	O
AEDs	AED	NNS	B-NP	O	S-group
)	)	)	O	O	O
:	:	:	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Tiagabine	Tiagabine	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Tiagabine	Tiagabine	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
epoxide	epoxide	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	O
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	O	S-drug
:	:	:	O	O	O
Tiagabine	Tiagabine	NN	B-NP	O	S-drug-ME-1
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
(	(	(	O	O	O
about	about	RB	B-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
Primidone	Primidone	NN	I-NP	O	S-drug
:	:	:	O	O	O
No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
examining	examine	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
regimens	regimen	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
primidone	primidone	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
limited	limited	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
three	three	CD	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	I-NP	O	O
studies	study	NNS	I-NP	O	O
caused	cause	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
systematic	systematic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
primidone	primidone	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
Antiepilepsy	Antiepilepsy	JJ	I-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
(	(	(	O	O	O
AEDs	AED	NNS	B-NP	O	S-group
)	)	)	O	O	O
on	on	IN	B-PP	O	O
GABITRIL	GABITRIL	NN	B-NP	O	S-brand
:	:	:	O	O	O
Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Population	Population	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
analyses	analysis	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug-ME-1
clearance	clearance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
greater	great	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
inducing	induce	VBG	B-VP	O	O
AEDs	AED	NNS	B-NP	O	S-group
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Population	Population	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
analyses	analysis	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug-ME-1
clearance	clearance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
greater	great	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
inducing	induce	VBG	B-VP	O	O
AEDs	AED	NNS	B-NP	O	S-group
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
(	(	(	O	O	O
Primidone	Primidone	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Population	Population	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
analyses	analysis	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug-ME-1
clearance	clearance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
greater	great	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
primidone	primidone	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
inducing	induce	VBG	B-VP	O	O
AEDs	AED	NNS	B-NP	O	S-group
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
valproate	valproate	NN	B-NP	O	S-drug
chronically	chronically	RB	B-ADVP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
valproate	valproate	NN	B-NP	O	S-drug-ME-1
significantly	significantly	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug-ME-2
binding	binding	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
from	from	IN	B-PP	O	O
96.3	96.3	CD	B-NP	O	O
to	to	TO	B-PP	O	O
94.8	94.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
free	free	JJ	I-NP	O	O
tiagabine	tiagabine	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
finding	finding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
GABITRIL	GABITRIL	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
(	(	(	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
chronically	chronically	RB	B-ADVP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
R	R	NN	B-NP	B-protein	B-drug
-	-	HYPH	B-NP	O	I-drug
warfarin	warfarin	NN	I-NP	O	E-drug
or	or	CC	I-NP	O	O
S	S	NN	I-NP	O	B-drug
-	-	HYPH	O	O	I-drug
warfarin	warfarin	NN	B-NP	O	E-drug
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
given	give	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Prothrombin	Prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
daily	daily	JJ	I-NP	O	O
trough	trough	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Ethanol	Ethanol	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
Triazolam	Triazolam	NN	I-NP	O	S-drug
:	:	:	O	O	O
No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
triazolam	triazolam	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.125	0.125	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
together	together	RB	B-ADVP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Tiagabine	Tiagabine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
no	no	RB	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
triazo	triazo	NN	B-NP	O	O
lam	lam	NN	I-NP	O	O
or	or	CC	I-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
depress	depress	VB	I-VP	O	O
the	the	DT	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	I-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug-AD-1
or	or	CC	I-NP	O	O
triazolam	triazolam	NN	I-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
Multiple	Multiple	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
(	(	(	O	O	O
8	8	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
monotherapy	monotherapy	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
childbearing	childbeare	VBG	B-VP	O	O
age	age	NN	B-NP	O	O
.	.	.	O	O	O

Antipyrine	Antipyrine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Antipyrine	Antipyrine	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	B-ADJP	O	O
significantly	significantly	RB	I-ADJP	O	O
different	different	JJ	I-ADJP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
multiple	multiple	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
induction	induction	NN	B-NP	O	O
or	or	CC	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	B-protein	O
microsomal	microsomal	JJ	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
systems	system	NNS	I-NP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
GABITRIL	GABITRIL	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
Highly	Highly	NNP	B-NP	O	O
Protein	Protein	NNP	I-NP	O	O
Bound	Bound	NNP	I-NP	O	O
Drugs	Drug	NNPS	I-NP	O	O
:	:	:	O	O	O
In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
96	96	CD	B-NP	O	O
%	%	NN	I-NP	O	O
bound	bind	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	B-protein	O
plasma	plasma	NN	I-NP	I-protein	O
protein	protein	NN	I-NP	I-protein	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
highly	highly	RB	I-NP	O	O
protein	protein	NN	I-NP	O	O
bound	bind	VBD	B-VP	O	O
compounds	compound	NNS	B-NP	O	O
.	.	.	O	O	O

Such	Such	PDT	B-NP	O	O
an	an	DT	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
can	can	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
higher	high	JJR	B-NP	O	O
free	free	JJ	I-NP	O	O
fractions	fraction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
tiagabine	tiagabine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
competing	compete	VBG	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
both	both	CC	B-PP	O	O
with	with	IN	I-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
rapidly	rapidly	RB	I-NP	O	O
hydrolyzed	hydrolyze	VBN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
prodrug	prodrug	NN	I-NP	O	O
form	form	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
trials	trial	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
prodrug	prodrug	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
section	section	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
relate	relate	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

General	General	NNP	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
,	,	,	O	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
predominantly	predominantly	RB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
and	and	CC	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
with	with	IN	B-PP	O	O
glucuronidation	glucuronidation	NN	B-NP	O	O
being	be	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
(	(	(	O	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
route	route	NN	B-NP	O	O
of	of	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
2C19	2C19	NN	I-NP	I-protein	O
(	(	(	O	O	O
IC50	IC50	NN	B-NP	O	O
=	=	JJ	B-VP	O	O
6	6	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-PP	O	O
mL	mL	NN	B-NP	O	O
or	or	CC	O	O	O
19	19	CD	B-NP	O	O
M	M	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
(	(	(	O	O	O
IC50	IC50	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
13	13	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	B-NP	O	O
or	or	CC	O	O	O
41	41	CD	B-NP	O	O
M	M	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
weak	weak	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
(	(	(	O	O	O
IC50	IC50	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
31	31	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
or	or	CC	O	O	O
100	100	CD	B-NP	O	O
M	M	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
IC50	IC50	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
44	44	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	B-NP	O	O
or	or	CC	O	O	O
141	141	CD	B-NP	O	O
M	M	NN	I-NP	O	O
)	)	)	O	O	O
..	..	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GI	GI	NN	B-NP	O	O
ulceration	ulceration	NN	I-NP	O	O
and	and	CC	O	O	O
complications	complication	NNS	B-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
valdecoxib	valdecoxib	VB	I-VP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	B-protein	O
platelet	platelet	NN	I-NP	I-protein	O
effect	effect	NN	I-NP	I-protein	O
valdecoxib	valdecoxib	NN	I-NP	I-protein	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substitute	substitute	NN	I-NP	O	O
for	for	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
for	for	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
parallel	parallel	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
comparing	compare	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
prodrug	prodrug	NN	I-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
vs	vs	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
9	9	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
arachidonate	arachidonate	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
or	or	CC	I-NP	O	O
collagen	collagen	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
stimulated	stimulate	VBN	I-NP	O	O
platelet	platelet	NN	I-NP	O	O
aggregation	aggregation	NN	I-NP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
Valdecoxib	Valdecoxib	NN	B-NP	O	B-drug
10	10	CD	I-NP	O	I-drug
mg	mg	NN	I-NP	O	E-drug
BID	BID	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
show	show	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
or	or	CC	O	O	O
renal	renal	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

ACE	ACE	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Reports	Report	NNS	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
consideration	consideration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
BEXTRA	BEXTRA	NN	B-NP	O	S-brand-AD-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
post	post	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
marketing	market	VBG	B-VP	O	O
observations	observation	NNS	B-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group-EF-2
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
response	response	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

Anticonvulsants	Anticonvulsant	NNS	B-NP	O	S-group
(	(	(	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Steady	Steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
for	for	IN	B-PP	O	O
12	12	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
27	27	CD	B-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
(	(	(	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
for	for	IN	B-PP	O	O
12	12	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
a	a	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inducer	inducer	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
already	already	RB	B-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
symptom	symptom	NN	B-NP	O	O
control	control	NN	I-NP	O	O
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-AD-2
coadministration	coadministration	NN	I-NP	O	O
.	.	.	O	O	O

Valdecoxib	Valdecoxib	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
(	(	(	O	O	O
a	a	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
2C9	2C9	NN	I-NP	I-protein	O
and	and	CC	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
2C19	2C19	NN	I-NP	I-protein	O
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticonvulsants	anticonvulsant	NNS	I-NP	O	S-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

Routine	Routine	NN	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
BEXTRA	BEXTRA	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
either	either	RB	I-VP	O	O
initiated	initiate	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Dextromethorphan	Dextromethorphan	NN	B-NP	O	S-drug
:	:	:	O	O	O
Dextromethorphan	Dextromethorphan	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
and	and	CC	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
lesser	less	JJR	I-NP	O	O
extent	extent	NN	I-NP	O	O
by	by	IN	B-PP	O	O
3A4	3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dextromethorphan	dextromethorphan	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
these	these	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
weak	weak	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2D6	2D6	NN	B-NP	B-protein	O
.	.	.	O	O	O

Even	Even	RB	B-ADVP	O	O
so	so	RB	I-ADVP	O	O
dextromethorphan	dextromethorphan	IN	B-PP	O	S-drug-ME-1
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-ME-2
were	be	VBD	B-VP	O	O
almost	almost	RB	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
2D6	2D6	NN	I-NP	I-protein	O
poor	poor	JJ	I-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
dose	dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Valdecoxib	Valdecoxib	NNP	B-NP	O	S-drug-ME-1
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
produced	produce	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-2
serum	serum	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
(	(	(	O	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
34	34	CD	I-NP	O	O
%	%	NN	I-NP	O	O
higher	high	JJR	B-NP	O	O
serum	serum	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
or	or	CC	I-VP	O	O
changing	change	VBG	I-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
BEXTRA	BEXTRA	NN	B-NP	O	S-brand-AD-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	B-drug
carbonate	carbonate	NN	I-NP	O	E-drug
(	(	(	O	O	O
450	450	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
BEXTRA	BEXTRA	NN	B-NP	O	S-brand
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Valdecoxib	Valdecoxib	NN	B-NP	O	S-drug-MU-1
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
exposures	exposure	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
R	R	NN	B-NP	B-protein	B-drug-ME-2
-	-	HYPH	B-NP	I-protein	I-drug-ME-2
warfarin	warfarin	NN	I-NP	I-protein	E-drug-ME-2
and	and	CC	I-NP	O	O
S	S	NN	I-NP	O	B-drug-ME-2
-	-	HYPH	O	O	I-drug-ME-2
warfarin	warfarin	NN	B-NP	O	E-drug-ME-2
(	(	(	O	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
(	(	(	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
measured	measure	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
mean	mean	JJ	B-NP	O	O
INR	INR	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
only	only	RB	B-VP	O	O
slightly	slightly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
-	-	HYPH	B-ADVP	O	O
to	to	TO	B-PP	O	O
-	-	HYPH	B-NP	O	O
day	day	NN	I-NP	O	O
variability	variability	NN	I-NP	O	O
in	in	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
INR	INR	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Anticoagulant	Anticoagulant	JJ	B-NP	O	S-brand
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
few	few	JJ	I-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
BEXTRA	BEXTRA	NN	B-NP	O	S-brand-AD-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
similar	similar	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Fluconazole	Fluconazole	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Ketoconazole	Ketoconazole	NN	I-NP	O	S-drug
:	:	:	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
fluconazole	fluconazole	NN	I-NP	O	S-drug
are	be	VBP	B-VP	O	O
predominantly	predominantly	RB	B-ADVP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
2C9	2C9	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-ME-1
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
fluconazole	fluconazole	NN	I-NP	O	S-drug-ME-2
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
62	62	CD	B-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Glyburide	Glyburide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Glyburide	Glyburide	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
2C9	2C9	NN	I-NP	I-protein	O
substrate	substrate	NN	I-NP	I-protein	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
or	or	CC	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
(	(	(	O	O	O
exposure	exposure	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
(	(	(	O	O	O
day	day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
(	(	(	O	O	O
days	day	NNS	B-NP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
7	7	CD	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
(	(	(	O	O	O
exposure	exposure	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
(	(	(	O	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
and	and	CC	O	O	O
insulin	insulin	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
(	(	(	O	O	O
day	day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
(	(	(	O	O	O
days	day	NNS	B-NP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
7	7	CD	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
glyburide	glyburide	NN	I-NP	O	S-drug
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	B-protein	S-drug
AUC0	AUC0	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
12	12	CD	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
16	16	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
Cmax	Cmax	NN	I-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
16	16	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
glucose	glucose	NN	B-NP	B-protein	O
AUC0	AUC0	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
24	24	CD	I-NP	O	O
.	.	.	O	O	O

Insulin	Insulin	NN	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
coadministration	coadministration	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
variability	variability	NN	I-NP	O	O
and	and	CC	O	O	O
individual	individual	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
above	above	IN	B-NP	O	O
or	or	CC	I-NP	O	O
near	near	IN	I-NP	O	O
70	70	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
dL	dL	NN	I-NP	O	O
,	,	,	O	O	O
dose	dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug-AD-1
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-AD-2
coadministration	coadministration	NN	I-NP	O	O
(	(	(	O	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
indicated	indicate	VBN	I-VP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
higher	high	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
valdecoxib	valdecoxib	NN	I-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Omeprazole	Omeprazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Omeprazole	Omeprazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
substrate	substrate	NN	I-NP	I-protein	O
and	and	CC	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
2C19	2C19	NN	I-NP	I-protein	O
substrate	substrate	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
.	.	.	O	O	O

Valdecoxib	Valdecoxib	NN	B-NP	O	S-drug
steady	steady	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-ME-1
increased	increase	VBD	B-VP	O	O
exposure	exposure	NN	B-NP	O	O
of	of	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
46	46	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
whose	whose	WP$	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
sensitive	sensitive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
pH	pH	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
negatively	negatively	RB	I-VP	O	O
impacted	impact	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
valdecoxib	valdecoxib	NN	I-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
(	(	(	O	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
360	360	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Zollinger	Zollinger	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
Ellison	Ellison	NN	B-NP	O	O
(	(	(	O	O	O
ZE	ZE	NN	B-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
current	current	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
higher	high	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
omeprazole	omeprazole	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
Valdecoxib	Valdecoxib	NN	B-NP	O	S-drug
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	S-group
norethindrone	norethindrone	NN	I-NP	O	S-drug
/	/	SYM	B-VP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
35	35	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
combination	combination	NN	I-NP	O	O
,	,	,	O	O	O
Ortho	Ortho	NNP	B-NP	O	B-brand
-	-	HYPH	O	O	I-brand
Novum	Novum	NNP	B-NP	O	E-brand
1	1	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
35	35	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
Ortho	Ortho	AFX	O	O	B-brand-ME-2
-	-	HYPH	O	O	I-brand-ME-2
Novum	Novum	NN	B-NP	B-protein	E-brand-ME-2
1	1	CD	I-NP	I-protein	O
/	/	SYM	B-NP	O	O
35	35	CD	I-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
by	by	IN	B-PP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
34	34	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
little	little	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
contraceptive	contraceptive	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
exposures	exposure	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
terms	term	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
safety	safety	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
exposures	exposure	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
consideration	consideration	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
selecting	select	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group-AD-1
for	for	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Diazepam	Diazepam	NN	B-NP	O	S-drug
:	:	:	O	O	O
Diazepam	Diazepam	NN	B-NP	O	S-drug
(	(	(	O	O	O
Valium	Valium	NN	B-NP	O	S-brand
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
and	and	CC	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
2C19	2C19	NN	I-NP	I-protein	O
substrate	substrate	NN	I-NP	I-protein	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
12	12	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
substantially	substantially	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
12	12	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
valdecoxib	valdecoxib	NN	B-NP	O	S-drug-EF-1
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
warrant	warrant	VB	I-VP	O	O
dosage	dosage	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
experience	experience	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
sedative	sedative	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-EF-2
under	under	IN	B-PP	O	O
this	this	DT	B-NP	O	O
circumstance	circumstance	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
cautioned	caution	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
engaging	engage	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
hazardous	hazardous	JJ	B-NP	O	O
activities	activity	NNS	I-NP	O	O
requiring	require	VBG	B-VP	O	O
complete	complete	JJ	B-NP	O	O
mental	mental	JJ	I-NP	O	O
alertness	alertness	NN	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
operating	operate	VBG	B-NP	O	O
machinery	machinery	NN	I-NP	O	O
or	or	CC	O	O	O
driving	drive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
motor	motor	NN	I-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
:	:	:	O	O	O
Studies	Study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
primarily	primarily	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	I-protein	O
CYP	CYP	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
isoforms	isoform	NNS	B-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
/	/	SYM	O	O	O
5	5	CD	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
lesser	less	JJR	I-NP	O	O
degree	degree	NN	I-NP	O	O
by	by	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
are	be	VBP	B-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
:	:	:	O	O	O
Cytochrome	Cytochrome	NN	B-NP	O	O
P450	P450	NN	I-NP	O	O
Inhibitors	Inhibitor	NNS	I-NP	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
bioavailability	bioavailability	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
maximum	maximum	JJ	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
(	(	(	O	O	O
Cmax	Cmax	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Vardenafil	Vardenafil	NNP	I-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

Erythromycin	Erythromycin	NN	B-NP	B-protein	S-drug-ME-1
(	(	(	O	I-protein	O
500	500	CD	B-NP	I-protein	O
mg	mg	NN	I-NP	I-protein	O
t.i.d	t.i.d	NN	I-NP	I-protein	O
)	)	)	O	I-protein	O
produced	produce	VBD	B-VP	I-protein	O
a	a	DT	B-NP	I-protein	O
4	4	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Vardenafil	Vardenafil	NN	B-NP	O	S-drug
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
not	not	RB	O	O	O
to	to	TO	B-VP	O	O
exceed	exceed	VB	I-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-AD-1
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
24	24	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
period	period	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Vardenafil	Vardenafil	NN	B-NP	O	S-drug
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
Vardenafil	Vardenafil	NN	I-NP	O	S-drug-AD-1
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
exceeded	exceed	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-NP	O	O
daily	daily	JJ	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
2.5	2.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
exceeded	exceed	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
24	24	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
period	period	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
.	.	.	O	O	O

HIV	HIV	NN	B-NP	O	B-group
Protease	Protease	NN	I-NP	O	I-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
Indinavir	Indinavir	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
t.i.d	t.i.d	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Vardenafil	Vardenafil	NN	B-NP	O	S-drug-ME-2
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
16	16	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
7	7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
not	not	RB	O	O	O
to	to	TO	B-VP	O	O
exceed	exceed	VB	I-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
2.5	2.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
Vardenafil	Vardenafil	NNP	I-NP	O	S-drug-AD-1
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
24	24	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
period	period	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Ritonavir	Ritonavir	NN	B-NP	B-protein	S-drug-ME-1
(	(	(	O	I-protein	O
600	600	CD	B-NP	I-protein	O
mg	mg	NN	I-NP	I-protein	O
b.i.d	b.i.d	NN	I-NP	I-protein	O
.	.	.	O	I-protein	O
)	)	)	O	I-protein	O
co	co	AFX	B-NP	I-protein	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Vardenafil	Vardenafil	NN	B-NP	O	S-drug-ME-2
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
49	49	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
13	13	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
Cmax	Cmax	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
consequence	consequence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blocking	block	VBG	B-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug-ME-1
by	by	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
highly	highly	RB	I-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
also	also	RB	B-ADVP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
.	.	.	O	O	O

Ritonavir	Ritonavir	NN	B-NP	O	S-drug-ME-1
significantly	significantly	RB	B-VP	O	O
prolonged	prolong	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug-ME-2
to	to	TO	B-PP	O	O
26	26	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
not	not	RB	O	O	O
to	to	TO	B-VP	O	O
exceed	exceed	VB	I-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
2.5	2.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
Vardenafil	Vardenafil	NNP	I-NP	O	S-drug-AD-1
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
72	72	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
period	period	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Other	Other	NNP	B-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
No	No	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
:	:	:	O	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
Maalox	Maalox	NN	B-NP	O	S-brand
,	,	,	O	O	O
and	and	CC	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
study	study	NN	I-NP	O	O
,	,	,	O	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug
on	on	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
:	:	:	O	O	O
Vardenafil	Vardenafil	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
2A6	2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
2E1	2E1	NN	B-NP	B-protein	O
(	(	(	O	O	O
Ki	Ki	NN	B-NP	O	O
100uM	100uM	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Weak	Weak	JJ	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
toward	toward	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
isoforms	isoform	NNS	I-NP	O	O
(	(	(	O	O	O
CYP2C8	CYP2C8	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
2C19	2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
2D6	2D6	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
Ki	Ki	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
excess	excess	NN	B-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
achieved	achieve	VBN	B-VP	O	O
following	follow	VBG	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
M1	M1	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
Ki	Ki	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1.4	1.4	CD	B-NP	O	O
uM	uM	NN	I-NP	O	O
toward	toward	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
about	about	IN	B-NP	O	O
20	20	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
M1	M1	NN	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
an	an	DT	B-NP	O	O
80	80	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
Vardenafil	Vardenafil	NNP	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
:	:	:	O	O	O
Nitrates	Nitrate	NNS	B-NP	O	S-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
lowering	lower	VBG	B-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
sublingual	sublingual	JJ	B-NP	O	O
nitrates	nitrate	NNS	I-NP	O	S-group-ME-1
(	(	(	O	O	O
0.4	0.4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
taken	take	VBN	B-VP	O	O
1	1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
,	,	,	I-NP	O	O
4	4	CD	I-NP	O	O
and	and	CC	I-NP	O	O
8	8	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
middle	middle	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
aged	aged	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
NTG	NTG	NN	I-NP	B-protein	S-drug
.	.	.	O	O	O

Potentiation	Potentiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nitrates	nitrate	NNS	B-NP	O	S-group
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ischemic	ischemic	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
nitrates	nitrate	NNS	B-NP	O	S-group-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Nifedipine	Nifedipine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Vardenafil	Vardenafil	NN	B-NP	O	S-drug
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
slow	slow	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
release	release	NN	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug
30	30	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
or	or	CC	O	O	O
60	60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
,	,	,	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
relative	relative	JJ	I-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
maximum	maximum	JJ	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
(	(	(	O	O	O
Cmax	Cmax	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Nifedipine	Nifedipine	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
whose	whose	WP$	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
controlled	control	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-EF-2
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
mean	mean	JJ	B-NP	O	O
additional	additional	JJ	I-NP	O	O
supine	supine	NN	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
reductions	reduction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
5	5	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

Alpha	Alpha	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-EF-1
10	10	CD	I-NP	O	O
or	or	CC	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
either	either	CC	O	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
or	or	CC	O	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terazosin	terazosin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
significant	significant	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
developed	develop	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
substantial	substantial	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-EF-1
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
terazosin	terazosin	NN	I-NP	O	S-drug-EF-2
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
6	6	CD	B-NP	O	O
of	of	IN	B-PP	O	O
8	8	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
standing	standing	JJ	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
85	85	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-EF-1
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
terazosin	terazosin	NN	I-NP	O	S-drug-EF-2
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
of	of	IN	B-PP	O	O
9	9	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
standing	standing	JJ	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
85	85	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-EF-1
dosing	dosing	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
separated	separate	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
terazosin	terazosin	NN	B-NP	O	S-drug-EF-2
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
by	by	IN	B-PP	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
7	7	CD	B-NP	O	O
of	of	IN	B-PP	O	O
28	28	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug
experienced	experience	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
standing	stand	VBG	B-VP	O	O
systolic	systolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
below	below	IN	B-PP	O	O
85	85	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
tamsulosin	tamsulosin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
of	of	IN	B-PP	O	O
24	24	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
dosed	dose	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Vardenafil	Vardenafil	NN	B-NP	O	S-drug-EF-1
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tamsulosin	tamsulosin	NN	I-NP	O	S-drug-EF-2
0.4	0.4	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
separated	separate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
standing	standing	JJ	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
below	below	IN	B-PP	O	O
85	85	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
of	of	IN	I-NP	O	O
16	16	CD	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
dosed	dose	VBN	B-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-EF-1
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tamsulosin	tamsulosin	NN	I-NP	O	S-drug-EF-2
0.4	0.4	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
standing	standing	JJ	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
below	below	IN	B-PP	O	O
85	85	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
alpha	alpha	SYM	B-NP	O	B-group
-	-	HYPH	O	O	I-group
blockers	blocker	NNS	B-NP	O	E-group
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
completely	completely	RB	B-ADJP	O	O
evaluated	evaluate	VBN	I-ADJP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
safely	safely	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
these	these	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
alpha	alpha	SYM	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
blocker	blocker	NN	I-NP	O	E-group-AD-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Ritonavir	Ritonavir	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug
:	:	:	O	O	O
Upon	Upon	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Upon	Upon	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
TID	TID	NN	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
:	:	:	O	O	O
Alcohol	Alcohol	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
:	:	:	O	O	O
approximately	approximately	RB	B-NP	O	O
40	40	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absolute	absolute	JJ	B-NP	O	O
alcohol	alcohol	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
70	70	CD	I-NP	O	O
kg	kg	NN	I-NP	O	O
person	person	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
vardenafil	vardenafil	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
dosed	dose	VBN	B-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

Vardenafil	Vardenafil	NN	B-NP	O	S-drug
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
observation	observation	NN	I-NP	O	O
period	period	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Vardenafil	Vardenafil	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
time	time	NN	B-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
(	(	(	O	O	O
two	two	CD	B-NP	O	O
81	81	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
:	:	:	O	O	O
Vardenafil	Vardenafil	NNP	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
(	(	(	O	O	O
glucose	glucose	NN	B-NP	O	O
and	and	CC	O	O	O
insulin	insulin	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Zidovudine	Zidovudine	NN	B-NP	O	S-drug
:	:	:	O	O	O
There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
ZDV	ZDV	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
zalcitabine	zalcitabine	NN	I-NP	O	S-drug
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
clinically	clinically	RB	B-ADVP	O	O
.	.	.	O	O	O

Zalcitabine	Zalcitabine	NN	B-NP	O	S-drug-EF-1
also	also	RB	B-ADVP	O	O
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intracellular	intracellular	JJ	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZDV	ZDV	NN	B-NP	B-protein	S-drug-EF-2
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
shown	show	VBN	B-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
in	in	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	B-cell_type	O
blood	blood	NN	I-NP	I-cell_type	O
mononuclear	mononuclear	JJ	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
other	other	JJ	I-NP	O	O
cell	cell	NN	I-NP	B-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
(	(	(	O	O	O
U937	U937	NN	B-NP	B-cell_line	O
and	and	CC	I-NP	O	O
Molt	Molt	NN	I-NP	B-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
4	4	CD	I-NP	I-cell_line	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
didanosine	didanosine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
stavudine	stavudine	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intracellular	intracellular	JJ	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	B-cell_type	O
blood	blood	NN	I-NP	I-cell_type	O
mononuclear	mononuclear	JJ	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

Lamivudine	Lamivudine	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	B-cell_type	O
blood	blood	NN	I-NP	I-cell_type	O
mononuclear	mononuclear	JJ	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
U937	U937	NN	B-NP	B-cell_line	O
and	and	CC	I-NP	O	O
Molt	Molt	NN	I-NP	B-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
4	4	CD	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug-EF-1
significantly	significantly	RB	B-ADVP	O	O
inhibited	inhibit	VBD	B-VP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug-EF-2
phosphorylation	phosphorylation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
already	already	RB	I-VP	O	O
seen	see	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
corresponding	correspond	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
relevant	relevant	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
intracellular	intracellular	JJ	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
three	three	CD	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
zalcitabine	zalcitabine	NN	I-NP	O	O
triphosphate	triphosphate	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
.	.	.	O	O	O

Zalcitabine	Zalcitabine	NN	B-NP	O	S-drug-EF-1
inhibited	inhibit	VBD	B-VP	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug-EF-2
phosphorylation	phosphorylation	NN	I-NP	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
ratios	ratio	NNS	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
and	and	CC	I-NP	O	O
100	100	CD	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phosphorylated	phosphorylate	VBN	B-NP	O	O
lamivudine	lamivudine	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
efficient	efficient	JJ	I-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
deoxycytidine	deoxycytidine	NN	B-NP	B-protein	O
kinase	kinase	NN	I-NP	I-protein	O
than	than	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug
.	.	.	O	O	O

These	These	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
lamivudine	lamivudine	NN	I-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
sub	sub	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
phosphorylated	phosphorylate	VBN	I-NP	O	O
zalcitabine	zalcitabine	NN	I-NP	O	S-drug
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
antiretroviral	antiretroviral	JJ	I-NP	O	S-group
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
how	how	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
translates	translate	VBZ	B-VP	O	O
into	into	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
consequences	consequence	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
lamivudine	lamivudine	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Saquinavir	Saquinavir	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIVID	HIVID	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
ZDV	ZDV	NN	B-NP	B-protein	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
(	(	(	O	O	O
as	as	IN	B-PP	O	O
triple	triple	JJ	B-NP	O	O
combination	combination	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
absorption	absorption	NN	B-NP	O	O
,	,	,	O	O	O
metabolism	metabolism	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
elimination	elimination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
.	.	.	O	O	O

Drugs	Drugs	NNP	B-NP	O	O
Associated	Associated	NNP	I-NP	O	O
With	With	IN	B-PP	O	O
Peripheral	Peripheral	NNP	B-NP	O	O
Neuropathy	Neuropathy	NNP	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIVID	HIVID	NN	B-NP	B-protein	S-drug
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
peripheral	peripheral	JJ	B-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
where	where	WRB	B-ADVP	O	O
possible	possible	JJ	B-ADJP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	O
include	include	VBP	B-VP	O	O
antiretroviral	antiretroviral	JJ	B-NP	O	B-drug
nucleoside	nucleoside	NN	I-NP	O	I-drug
analogues	analogue	NNS	I-NP	O	E-drug
,	,	,	O	O	O
chloramphenicol	chloramphenicol	NN	B-NP	O	S-drug
,	,	,	O	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
dapsone	dapsone	NN	B-NP	O	S-drug
,	,	,	O	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug
,	,	,	O	O	O
ethionamide	ethionamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
glutethimide	glutethimide	NN	B-NP	O	S-drug
,	,	,	O	O	O
gold	gold	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydralazine	hydralazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
iodoquinol	iodoquinol	NN	B-NP	O	S-drug
,	,	,	O	O	O
isoniazid	isoniazid	NN	B-NP	O	S-drug
,	,	,	O	O	O
metronidazole	metronidazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
nitrofurantoin	nitrofurantoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ribavirin	ribavirin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
vincristine	vincristine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIVID	HIVID	NN	B-NP	B-protein	S-drug-AD-1
with	with	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Intravenous	Intravenous	JJ	B-NP	O	O
Pentamidine	Pentamidine	NN	I-NP	O	S-drug
:	:	:	O	O	O
Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
HIVID	HIVID	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
interrupted	interrupt	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
pancreatitis	pancreatitis	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Death	Death	NN	B-NP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
fulminant	fulminant	JJ	B-NP	O	O
pancreatitis	pancreatitis	NN	I-NP	O	O
possibly	possibly	RB	B-ADJP	O	O
related	related	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
pentamidine	pentamidine	NN	I-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
HIVID	HIVID	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
intravenous	intravenous	JJ	B-NP	O	O
pentamidine	pentamidine	NN	I-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
treat	treat	VB	I-VP	O	O
Pneumocystis	Pneumocystis	NNP	B-NP	O	O
carinii	carinii	NN	I-NP	O	O
pneumonia	pneumonia	NN	I-NP	O	O
,	,	,	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
HIVID	HIVID	NN	B-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
interrupted	interrupt	VBN	I-VP	O	O
.	.	.	O	O	O

Amphotericin	Amphotericin	NN	B-NP	O	S-drug
,	,	,	O	O	O
Foscarnet	Foscarnet	NNP	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
Aminoglycosides	Aminoglycoside	NNS	B-NP	O	S-group
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	S-drug-MU-1
,	,	,	O	O	O
foscarnet	foscarnet	NN	B-NP	O	S-drug-MU-1
,	,	,	O	O	O
and	and	CC	O	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group-MU-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
peripheral	peripheral	JJ	B-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
HIVID	HIVID	NN	I-NP	B-protein	S-drug-EF-2
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
interfering	interfere	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
thereby	thereby	RB	B-VP	O	O
raising	raise	VBG	I-VP	O	O
systemic	systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
require	require	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
HIVID	HIVID	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
frequent	frequent	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
laboratory	laboratory	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
with	with	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
any	any	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
Cimetidine	Cimetidine	NN	I-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
or	or	CC	I-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug-ME-1
decreases	decrease	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
most	most	RBS	B-ADJP	O	O
likely	likely	JJ	I-ADJP	O	O
by	by	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug
reduced	reduce	VBN	B-VP	O	O
if	if	IN	B-SBAR	O	O
warranted	warrant	VBN	B-VP	O	O
.	.	.	O	O	O

Magnesium	Magnesium	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Aluminum	Aluminum	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
Antacid	Antacid	NNP	B-NP	O	B-group
Products	Product	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Absorption	Absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
moderately	moderately	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
/	/	SYM	B-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacid	antacid	NN	B-NP	B-protein	B-group
products	product	NNS	I-NP	I-protein	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
,	,	,	O	O	O
hence	hence	RB	B-NP	O	O
zalcitabine	zalcitabine	NN	I-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
ingested	ingest	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-AD-2
/	/	SYM	B-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug-AD-2
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-2
.	.	.	O	O	O

Metoclopramide	Metoclopramide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Bioavailability	Bioavailability	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
mildly	mildly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
metoclopramide	metoclopramide	NN	I-NP	O	S-drug-ME-2
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Doxorubicin	Doxorubicin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Doxorubicin	Doxorubicin	NN	B-NP	O	S-drug-EF-1
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug-EF-2
phosphorylation	phosphorylation	NN	I-NP	O	O
(	(	(	O	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
phosphate	phosphate	NN	I-NP	O	O
formation	formation	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
U937	U937	NN	B-NP	B-cell_line	O
/	/	SYM	B-NP	I-cell_line	O
Molt	Molt	NN	I-NP	I-cell_line	O
4	4	CD	B-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
zalcitabine	zalcitabine	NN	B-NP	O	S-drug
activity	activity	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
lessened	lessen	VBN	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
formation	formation	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
results	result	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
all	all	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mechanisms	mechanism	NNS	B-NP	O	O
.	.	.	O	O	O

CNS	CNS	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
Active	Active	JJ	I-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
Ethanol	Ethanol	NN	I-NP	O	S-drug
:	:	:	O	O	O
Sonata	Sonata	NNP	B-NP	O	S-brand-EF-1
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
potentiated	potentiate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
impairing	impair	VBG	B-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	B-protein	S-drug-EF-2
0.75	0.75	CD	I-NP	I-protein	O
g	g	NN	I-NP	I-protein	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
balance	balance	NN	B-NP	O	O
testing	testing	NN	I-NP	O	O
and	and	CC	O	O	O
reaction	reaction	NN	B-NP	O	O
time	time	NN	I-NP	O	O
for	for	IN	B-PP	O	O
1	1	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
after	after	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
digit	digit	NN	I-NP	O	O
symbol	symbol	NN	I-NP	O	O
substitution	substitution	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
DSST	DSST	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
symbol	symbol	NN	B-NP	O	O
copying	copying	NN	I-NP	O	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
variability	variability	NN	I-NP	O	O
component	component	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
divided	divide	VBN	I-NP	O	O
attention	attention	NN	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
;	;	:	O	O	O

zaleplon	zaleplon	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Imipramine	Imipramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Sonata	Sonata	NNP	B-NP	O	S-brand-EF-1
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
imipramine	imipramine	NN	I-NP	O	S-drug-EF-2
75	75	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
alertness	alertness	NN	I-NP	O	O
and	and	CC	O	O	O
impaired	impaired	JJ	B-NP	O	O
psychomotor	psychomotor	NN	I-NP	O	O
performance	performance	NN	I-NP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
pharmacodynamic	pharmacodynamic	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Paroxetine	Paroxetine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Sonata	Sonata	NNP	B-NP	O	S-brand
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
paroxetine	paroxetine	NN	I-NP	O	S-drug
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
any	any	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
on	on	IN	B-PP	O	O
psychomotor	psychomotor	NN	B-NP	O	O
performance	performance	NN	I-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Sonata	Sonata	NNP	B-NP	O	S-brand
,	,	,	O	O	O
reflecting	reflect	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
in	in	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
s	s	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Thioridazine	Thioridazine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Sonata	Sonata	NNP	B-NP	O	S-brand-EF-1
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
thioridazine	thioridazine	NN	I-NP	O	S-drug-EF-2
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
alertness	alertness	NN	I-NP	O	O
and	and	CC	O	O	O
impaired	impaired	JJ	B-NP	O	O
psychomotor	psychomotor	NN	I-NP	O	O
performance	performance	NN	I-NP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
pharmacodynamic	pharmacodynamic	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Venlafaxine	Venlafaxine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	O	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
venlafaxine	venlafaxine	NN	B-NP	O	S-drug
ER	ER	NN	I-NP	B-protein	O
(	(	(	O	O	O
extended	extend	VBN	B-NP	O	O
release	release	NN	I-NP	O	O
)	)	)	O	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
venlafaxine	venlafaxine	NN	I-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
venlafaxine	venlafaxine	NN	I-NP	O	S-drug
ER	ER	NN	I-NP	B-protein	O
.	.	.	O	O	O

Promethazine	Promethazine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
promethazine	promethazine	NN	I-NP	O	S-drug-ME-2
(	(	(	O	O	O
10	10	CD	B-NP	O	O
and	and	CC	I-NP	O	O
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
15	15	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
maximal	maximal	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
,	,	,	O	O	O
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	O	O	O
time	time	NN	B-NP	O	O
curve	curve	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
promethazine	promethazine	NN	I-NP	O	S-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
2	2	CD	I-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
That	That	DT	B-NP	O	O
Induce	Induce	NNP	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
Rifampin	Rifampin	NN	I-NP	O	S-drug
:	:	:	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
ordinarily	ordinarily	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
minor	minor	JJ	I-NP	B-protein	O
metabolizing	metabolize	VBG	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
.	.	.	O	O	O

Multiple	Multiple	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inducer	inducer	NN	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-ME-1
(	(	(	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
24	24	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
q24h	q24h	NN	B-NP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
reduced	reduce	VBN	B-NP	O	O
zaleplon	zaleplon	NN	I-NP	O	S-drug-ME-2
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	O	O
inducer	inducer	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
not	not	RB	O	O	O
posing	pose	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
concern	concern	NN	I-NP	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
could	could	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
ineffectiveness	ineffectiveness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
.	.	.	O	O	O

An	An	DT	B-NP	O	O
alternative	alternative	JJ	I-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
substrate	substrate	NN	I-NP	O	O
hypnotic	hypnotic	JJ	I-NP	O	B-group
agent	agent	NN	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inducers	inducer	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
That	That	DT	B-NP	O	O
Inhibit	Inhibit	VBP	B-VP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
CYP3A4	CYP3A4	NN	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
minor	minor	JJ	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
sum	sum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
desethylzaleplon	desethylzaleplon	NN	B-NP	O	O
(	(	(	O	O	O
formed	form	VBN	B-VP	O	O
via	via	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
,	,	,	O	O	O
5	5	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
oxo	oxo	NN	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
desethylzaleplon	desethylzaleplon	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
5	5	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
oxo	oxo	NN	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
desethylzaleplon	desethylzaleplon	NN	I-NP	O	I-drug_n
glucuronide	glucuronide	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
account	account	VBP	B-VP	O	O
for	for	IN	B-PP	O	O
only	only	RB	B-NP	O	O
9	9	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
zaleplon	zaleplon	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
,	,	,	I-NP	O	O
oral	oral	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
,	,	,	I-NP	O	O
selective	selective	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
34	34	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
zaleplons	zaleplon	NNS	B-NP	O	O
maximal	maximal	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	O	O	O
time	time	NN	B-NP	O	O
curve	curve	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
strong	strong	JJ	I-NP	O	O
selective	selective	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
can	can	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

A	A	DT	B-NP	O	O
routine	routine	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Drugs	Drugs	NNP	B-NP	O	O
That	That	NNP	I-NP	O	O
Inhibit	Inhibit	NNP	I-NP	O	O
Aldehyde	Aldehyde	NNP	I-NP	O	O
Oxidase	Oxidase	NNP	I-NP	O	O
The	The	DT	B-NP	O	O
aldehyde	aldehyde	NN	I-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
less	less	RBR	B-VP	O	O
well	well	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Diphenhydramine	Diphenhydramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Diphenhydramine	Diphenhydramine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
weak	weak	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aldehyde	aldehyde	NN	B-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
liver	liver	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
its	its	PRP$	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
diphenhydramine	diphenhydramine	NN	I-NP	O	S-drug
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
both	both	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
.	.	.	O	O	O

Drugs	Drugs	NNP	B-NP	O	O
That	That	NNP	I-NP	O	O
Inhibit	Inhibit	NNP	I-NP	O	O
Both	Both	CC	O	O	O
Aldehyde	Aldehyde	NNP	B-NP	B-protein	O
Oxidase	Oxidase	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
Cimetidine	Cimetidine	NN	I-NP	O	S-drug
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
inhibits	inhibit	VBZ	B-VP	O	O
both	both	CC	O	O	O
aldehyde	aldehyde	NN	B-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
(	(	(	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
secondary	secondary	JJ	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Sonata	Sonata	NNP	B-NP	O	S-brand-ME-1
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
produced	produce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
85	85	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
.	.	.	O	O	O

An	An	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
concomitantly	concomitantly	RB	I-VP	O	O
being	be	VBG	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Highly	Highly	RB	B-ADVP	O	O
Bound	Bind	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
Plasma	Plasma	NN	B-NP	O	O
Protein	Protein	NN	I-NP	O	O
Zaleplon	Zaleplon	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
highly	highly	RB	B-ADJP	O	O
bound	bind	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
(	(	(	O	O	O
fraction	fraction	NN	B-NP	O	O
bound	bind	VBD	B-VP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
sensitive	sensitive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Sonata	Sonata	NNP	B-NP	O	S-brand
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
taking	take	VBG	B-VP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-NP	O	O
protein	protein	NN	I-NP	O	O
bound	bind	VBD	B-VP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
transient	transient	JJ	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Narrow	Narrow	NNP	I-NP	O	O
Therapeutic	Therapeutic	NNP	I-NP	O	O
Index	Index	NNP	I-NP	O	O
Digoxin	Digoxin	NNP	I-NP	O	S-drug
:	:	:	O	O	O
Sonata	Sonata	NNP	B-NP	O	S-brand
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.375	0.375	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
q24h	q24h	NN	I-NP	O	O
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Multiple	Multiple	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Sonata	Sonata	NNP	B-NP	O	S-brand
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
q24h	q24h	NN	I-NP	O	O
for	for	IN	B-PP	O	O
13	13	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
R	R	NN	B-NP	O	O
+	+	SYM	B-ADJP	O	O
)	)	)	O	O	O
-	-	HYPH	O	O	O
or	or	CC	O	O	O
(	(	(	O	O	O
S	S	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
enantiomers	enantiomer	NNS	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
(	(	(	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
)	)	)	O	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
25	25	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Drugs	Drugs	NNP	B-NP	O	O
That	That	NNP	I-NP	O	O
Alter	Alter	NNP	I-NP	O	O
Renal	Renal	NNP	I-NP	O	O
Excretion	Excretion	NNP	I-NP	O	O
Ibuprofen	Ibuprofen	NNP	I-NP	O	S-drug
:	:	:	O	O	O
Ibuprofen	Ibuprofen	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
consequently	consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
alter	alter	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ibuprofen	ibuprofen	NN	I-NP	O	S-drug
following	follow	VBG	B-PP	O	O
single	single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
expected	expect	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
zaleplon	zaleplon	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
unchanged	unchanged	JJ	B-NP	O	O
zaleplon	zaleplon	NN	I-NP	O	S-drug
accounts	account	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
1	1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administered	administer	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
fluoroquinolones	fluoroquinolone	NNS	I-NP	O	S-group
for	for	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
tract	tract	NN	I-NP	O	O
infections	infection	NNS	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
review	review	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
fluoroquinolones	fluoroquinolone	NNS	I-NP	O	S-group
are	be	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
rapidly	rapidly	RB	I-NP	O	O
growing	grow	VBG	I-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
broad	broad	JJ	I-NP	O	O
spectrum	spectrum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
activity	activity	NN	B-NP	O	O
against	against	IN	B-PP	O	O
gram	gram	NN	B-NP	O	O
-	-	HYPH	O	O	O
negative	negative	JJ	B-ADJP	O	O
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
gram	gram	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
aerobic	aerobic	JJ	I-NP	O	O
bacteria	bacteria	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
norfloxacin	norfloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ofloxacin	ofloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
enoxacin	enoxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
lomefloxacin	lomefloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
extensively	extensively	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
efficacy	efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
traditional	traditional	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
complicated	complicate	VBN	B-NP	O	O
or	or	CC	I-NP	O	O
uncomplicated	uncomplicated	JJ	I-NP	O	O
urinary	urinary	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
infections	infection	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
prostatitis	prostatitis	NN	I-NP	O	O
.	.	.	O	O	O

Advantages	Advantage	NNS	B-NP	O	O
offered	offer	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group
include	include	VBP	B-VP	O	O
optimal	optimal	JJ	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
,	,	,	O	O	O
effectiveness	effectiveness	NN	B-NP	O	O
against	against	IN	B-PP	O	O
multidrug	multidrug	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
resistant	resistant	JJ	I-NP	O	O
organisms	organism	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
even	even	RB	B-ADVP	O	O
when	when	WRB	I-ADVP	O	O
parenteral	parenteral	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-drug
are	be	VBP	B-VP	O	O
generally	generally	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
fluoroquinolones	fluoroquinolone	NNS	I-NP	O	S-group
are	be	VBP	B-VP	O	O
also	also	RB	B-ADVP	O	O
extensively	extensively	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
urologic	urologic	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

Progestin	Progestin	NN	B-NP	B-protein	O
-	-	HYPH	B-VP	O	O
only	only	RB	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraception	contraception	NN	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
comprehensive	comprehensive	JJ	I-NP	O	O
review	review	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
provide	provide	VB	I-VP	O	O
information	information	NN	B-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
package	package	NN	I-NP	O	O
insert	insert	NN	I-NP	O	O
labeling	labeling	NN	I-NP	O	O
of	of	IN	B-PP	O	O
progestin	progestin	NN	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
only	only	RB	B-NP	O	I-group
oral	oral	JJ	I-NP	O	I-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
(	(	(	O	O	O
POC	POC	NN	B-NP	B-protein	S-group
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
US	US	NNP	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
comprehensive	comprehensive	JJ	I-NP	O	O
review	review	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
made	make	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
norgestrel	norgestrel	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.075	0.075	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.35	0.35	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
where	where	WRB	B-ADVP	O	O
applicable	applicable	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
goal	goal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
review	review	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
cite	cite	VB	I-VP	O	O
primary	primary	JJ	B-NP	O	O
sources	source	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
virtually	virtually	RB	B-NP	O	O
all	all	DT	I-NP	O	O
research	research	NN	I-NP	O	O
specific	specific	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
POPs	POP	NNS	B-NP	B-protein	O
since	since	IN	B-PP	O	O
1975	1975	CD	B-NP	O	O
.	.	.	O	O	O

Conclusions	Conclusion	NNS	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
support	support	VBP	B-VP	O	O
these	these	DT	B-NP	O	O
conclusions	conclusion	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
each	each	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
section	section	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
introductory	introductory	JJ	I-NP	O	O
chapter	chapter	NN	I-NP	O	O
discusses	discuss	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
advantages	advantage	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
disadvantages	disadvantage	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
POCs	POC	NNS	B-NP	B-protein	S-group
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
and	and	CC	I-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Future	Future	JJ	B-NP	O	O
trends	trend	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
predicted	predict	VBN	I-VP	O	O
.	.	.	O	O	O

Chapter	Chapter	NN	B-NP	B-protein	O
2	2	CD	I-NP	I-protein	O
considers	consider	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
mode	mode	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ovulation	ovulation	NN	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
;	;	:	O	O	O

suppression	suppression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
midcycle	midcycle	NN	B-NP	B-protein	O
gonadotropin	gonadotropin	NN	I-NP	I-protein	O
peaks	peak	NNS	I-NP	I-protein	O
;	;	:	O	O	O

changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
cervical	cervical	JJ	B-NP	O	O
mucus	mucus	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
endometrium	endometrium	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
fallopian	fallopian	JJ	I-NP	O	O
tubes	tube	NNS	I-NP	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
implications	implication	NNS	I-NP	O	O
.	.	.	O	O	O

Chapter	Chapter	NN	B-NP	O	O
3	3	CD	I-NP	O	O
covers	cover	NNS	I-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
(	(	(	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
,	,	,	O	O	O
pharmacodynamics	pharmacodynamic	NNS	B-NP	O	O
and	and	CC	O	O	O
potency	potency	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
implications	implication	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
next	next	JJ	I-NP	O	O
chapter	chapter	NN	I-NP	O	O
presents	present	VBZ	B-VP	O	O
information	information	NN	B-NP	O	O
on	on	IN	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
pregnancy	pregnancy	NN	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
terms	term	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
rates	rate	NNS	I-NP	O	O
,	,	,	O	O	O
compliance	compliance	NN	B-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
ectopic	ectopic	JJ	B-NP	O	O
pregnancies	pregnancy	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
outcome	outcome	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pregnancies	pregnancy	NNS	B-NP	O	O
conceived	conceive	VBN	B-VP	O	O
while	while	IN	B-SBAR	O	O
using	use	VBG	B-VP	O	O
POCs	POC	NNS	B-NP	B-protein	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
fertility	fertility	NN	B-NP	O	O
following	follow	VBG	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
.	.	.	O	O	O

Chapter	Chapter	NN	B-NP	B-protein	O
5	5	CD	I-NP	I-protein	O
focuses	focus	VBZ	B-VP	O	O
on	on	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
specifically	specifically	RB	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
carbohydrate	carbohydrate	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	I-NP	O	O
diabetes	diabetes	NN	I-NP	O	O
,	,	,	O	O	O
coagulation	coagulation	NN	B-NP	B-protein	O
factors	factor	NNS	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
next	next	JJ	I-NP	O	O
chapter	chapter	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
chapter	chapter	NN	B-NP	B-protein	O
7	7	CD	I-NP	I-protein	O
presents	present	VBZ	B-VP	O	O
findings	finding	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
endometrial	endometrial	JJ	B-NP	O	O
,	,	,	I-NP	O	O
ovarian	ovarian	JJ	I-NP	O	O
,	,	,	I-NP	O	O
cervical	cervical	JJ	I-NP	O	O
,	,	,	I-NP	O	O
breast	breast	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
cancers	cancer	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
host	host	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
considerations	consideration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
chapter	chapter	NN	B-NP	O	O
8	8	CD	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
persistent	persistent	JJ	B-NP	O	O
ovarian	ovarian	JJ	I-NP	O	O
follicles	follicle	NNS	I-NP	O	O
;	;	:	O	O	O

reproductive	reproductive	JJ	B-NP	O	O
tract	tract	NN	I-NP	O	O
infections	infection	NNS	I-NP	O	O
;	;	:	O	O	O

abnormal	abnormal	JJ	B-NP	O	O
vaginal	vaginal	JJ	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
;	;	:	O	O	O

uterine	uterine	JJ	B-NP	O	O
fibroids	fibroid	NNS	I-NP	O	O
;	;	:	O	O	O

gestational	gestational	JJ	B-NP	O	O
trophoblastic	trophoblastic	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
;	;	:	O	O	O

benign	benign	JJ	B-NP	O	O
breast	breast	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
;	;	:	O	O	O

diseases	disease	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
,	,	,	O	O	O
gallbladder	gallbladder	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
bowel	bowel	NN	B-NP	O	O
;	;	:	O	O	O

endocrine	endocrine	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
;	;	:	O	O	O

epilepsy	epilepsy	NN	B-NP	O	O
;	;	:	O	O	O

bone	bone	NN	B-NP	O	O
density	density	NN	I-NP	O	O
;	;	:	O	O	O

sickle	sickle	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
;	;	:	O	O	O

ocular	ocular	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
;	;	:	O	O	O

surgery	surgery	NN	B-NP	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
overdose	overdose	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
4	4	CD	I-NP	O	O
chapters	chapter	NNS	I-NP	O	O
cover	cover	VBP	B-VP	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
and	and	CC	O	O	O
laboratory	laboratory	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
,	,	,	O	O	O
common	common	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
breast	breast	NN	B-NP	O	O
feeding	feeding	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
effective	effective	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
POCs	POC	NNS	B-NP	B-cell_type	S-group
.	.	.	O	O	O

Information	Information	NN	B-NP	O	O
on	on	IN	B-PP	O	O
precautions	precaution	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
contraindications	contraindication	NNS	I-NP	O	O
,	,	,	O	O	O
indications	indication	NNS	B-NP	O	O
,	,	,	O	O	O
use	use	NN	B-NP	O	O
instructions	instruction	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
instructions	instruction	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
appropriate	appropriate	JJ	B-NP	O	O
actions	action	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
missing	miss	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
pill	pill	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
appended	append	VBN	I-VP	O	O
.	.	.	O	O	O

Antimicrobial	Antimicrobial	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ganoderma	Ganoderma	NNP	B-NP	O	B-drug_n
lucidum	lucidum	NNP	I-NP	O	I-drug_n
extract	extract	NN	I-NP	O	E-drug_n
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
.	.	.	O	O	O

Antimicrobial	Antimicrobial	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GL	GL	NN	B-NP	B-protein	S-drug_n
(	(	(	O	O	O
the	the	DT	B-NP	O	O
aqueous	aqueous	JJ	I-NP	O	O
extract	extract	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
carpophores	carpophore	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Ganoderma	Ganoderma	NN	B-NP	O	O
lucidum	lucidum	NN	I-NP	O	O
(	(	(	O	O	O
FR	FR	NN	B-NP	O	O
)	)	)	O	O	O
KARST	KARST	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
against	against	IN	B-PP	O	O
Gram	Gram	NN	B-NP	O	O
positive	positive	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
Gram	Gram	NN	I-NP	O	O
negative	negative	JJ	I-NP	O	O
bacteria	bacteria	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
serial	serial	JJ	B-NP	O	O
broth	broth	NN	I-NP	O	O
dilution	dilution	NN	I-NP	O	O
method	method	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
expressed	express	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
minimal	minimal	JJ	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
(	(	(	O	O	O
MIC	MIC	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
fifteen	fifteen	CD	B-NP	O	O
species	specie	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bacteria	bacteria	NNS	B-NP	O	O
tested	test	VBN	B-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GL	GL	NN	B-NP	B-protein	S-drug_n
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
potent	potent	JJ	I-NP	O	O
against	against	IN	B-PP	O	O
Micrococcus	Micrococcus	NNP	B-NP	O	O
luteus	luteus	NNP	I-NP	O	O
(	(	(	O	O	O
MIC	MIC	NN	B-NP	O	O
,	,	,	O	O	O
0.75	0.75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antimicrobial	antimicrobial	JJ	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
GL	GL	NN	B-NP	B-protein	S-drug_n
with	with	IN	B-PP	O	O
four	four	CD	B-NP	O	O
kinds	kind	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group
(	(	(	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug
,	,	,	O	O	O
cefazolin	cefazolin	NN	B-NP	O	S-drug
,	,	,	O	O	O
oxytetracycline	oxytetracycline	NN	B-NP	O	S-drug
and	and	CC	O	O	O
chloramphenicol	chloramphenicol	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
fractional	fractional	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
index	index	NN	I-NP	O	O
(	(	(	O	O	O
FICI	FICI	NN	B-NP	B-protein	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
checkerboard	checkerboard	NN	B-NP	O	O
assay	assay	NN	I-NP	O	O
for	for	IN	B-PP	O	O
each	each	DT	B-NP	O	O
strain	strain	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	O
combinations	combination	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
GL	GL	NN	B-NP	B-protein	S-drug_n-EF-1
with	with	IN	B-PP	O	O
four	four	CD	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-EF-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
instances	instance	NNS	I-NP	O	O
,	,	,	O	O	O
synergism	synergism	NN	B-NP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
instances	instance	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antagonism	antagonism	NN	B-NP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
instances	instance	NNS	I-NP	O	O
.	.	.	O	O	O

Synergism	Synergism	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
GL	GL	NN	B-NP	B-protein	S-drug_n-EF-1
was	be	VBD	B-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cefazolin	cefazolin	NN	B-NP	O	S-drug-EF-2
against	against	IN	B-PP	O	O
Bacillus	Bacillus	NN	B-NP	O	O
subtilis	subtilis	NN	I-NP	O	O
and	and	CC	O	O	O
Klebsiella	Klebsiella	NN	B-NP	O	O
oxytoca	oxytoca	NN	I-NP	O	O
.	.	.	O	O	O

Death	Death	NN	B-NP	O	O
in	in	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
users	user	NNS	I-NP	O	O
:	:	:	O	O	O
causes	cause	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
rates	rate	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
world	world	NN	I-NP	O	O
medical	medical	JJ	I-NP	O	O
literature	literature	NN	I-NP	O	O
contains	contain	VBZ	B-VP	O	O
43	43	CD	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
deaths	death	NNS	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
amphetamines	amphetamine	NNS	B-NP	O	S-drug
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
35	35	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
included	include	VBD	B-VP	O	O
seven	seven	CD	B-NP	O	O
cerebrovascular	cerebrovascular	JJ	I-NP	O	O
accidents	accident	NNS	I-NP	O	O
,	,	,	O	O	O
six	six	CD	B-NP	O	O
sudden	sudden	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
deaths	death	NNS	I-NP	O	O
,	,	,	O	O	O
three	three	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hyperpyrexia	hyperpyrexia	NN	B-NP	O	O
,	,	,	O	O	O
eight	eight	CD	B-NP	O	O
poisonings	poisoning	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
uncertain	uncertain	JJ	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
and	and	CC	O	O	O
seven	seven	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
medical	medical	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
;	;	:	O	O	O

the	the	DT	B-NP	O	O
remainder	remainder	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
uncertain	uncertain	JJ	B-NP	O	O
cause	cause	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
Ontario	Ontario	NNP	B-NP	O	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
1972	1972	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1973	1973	CD	I-NP	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
26	26	CD	B-NP	O	O
deaths	death	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
users	user	NNS	I-NP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
16	16	CD	B-NP	O	O
were	be	VBD	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
accident	accident	NN	B-NP	O	O
suicide	suicide	NN	I-NP	O	O
or	or	CC	I-NP	O	O
homicide	homicide	NN	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
remaining	remain	VBG	I-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
two	two	CD	B-NP	O	O
were	be	VBD	B-VP	O	O
cardiac	cardiac	JJ	B-ADJP	O	O
,	,	,	O	O	O
two	two	CD	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
rest	rest	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
mixed	mix	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
overdose	overdose	NN	I-NP	O	O
.	.	.	O	O	O

Pulmonary	Pulmonary	JJ	B-NP	O	O
granulomata	granuloma	NNS	I-NP	O	O
,	,	,	O	O	O
subacute	subacute	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
lesions	lesion	NNS	I-NP	O	O
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
use	use	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
common	common	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
autopsy	autopsy	NN	B-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
estimated	estimate	VBN	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
regular	regular	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
Ontario	Ontario	NNP	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
four	four	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
as	as	RB	I-NP	O	O
high	high	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
alcoholics	alcoholic	NNS	B-NP	O	O
and	and	CC	O	O	O
heroin	heroin	NN	B-NP	O	S-drug_n
addicts	addict	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
absolute	absolute	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
deaths	death	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
far	far	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
deaths	death	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
heroin	heroin	NN	I-NP	O	S-drug_n
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

Ascorbic	Ascorbic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
cold	cold	NN	I-NP	O	O
.	.	.	O	O	O

Evaluation	Evaluation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
reviewed	review	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
relating	relate	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pharmacologic	pharmacologic	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ascorbic	ascorbic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
and	and	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
cold	cold	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
one	one	CD	B-NP	O	O
study	study	NN	I-NP	O	O
tentatively	tentatively	RB	B-VP	O	O
supports	support	VBZ	I-VP	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ascorbic	ascorbic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
efficacious	efficacious	JJ	B-ADJP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
confirm	confirm	VB	I-VP	O	O
the	the	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
clear	clear	JJ	I-NP	O	O
,	,	,	I-NP	O	O
reproducible	reproducible	JJ	I-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
emerged	emerge	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
currently	currently	RB	B-ADVP	O	O
little	little	JJ	B-NP	O	O
adequate	adequate	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
such	such	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ascorbic	ascorbic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
many	many	JJ	B-NP	O	O
such	such	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
hypothesized	hypothesize	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
unrestricted	unrestricted	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ascorbic	ascorbic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
for	for	IN	B-PP	O	O
these	these	DT	B-NP	O	O
purposes	purpose	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
advocated	advocate	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
currently	currently	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
.	.	.	O	O	O

Optimal	Optimal	JJ	B-NP	O	O
designs	design	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
individual	individual	NN	I-NP	O	O
and	and	CC	I-NP	O	O
joint	joint	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
general	general	JJ	I-NP	O	O
logistic	logistic	JJ	I-NP	O	O
regression	regression	NN	I-NP	O	O
models	model	NNS	I-NP	O	O
.	.	.	O	O	O

Interest	Interest	NN	B-NP	O	O
in	in	IN	B-PP	O	O
administering	administer	VBG	B-VP	O	O
compounds	compound	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
lies	lie	VBZ	B-VP	O	O
both	both	CC	B-PP	O	O
in	in	IN	B-PP	O	O
enhancing	enhance	VBG	B-VP	O	O
efficacious	efficacious	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
limiting	limit	VBG	B-VP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
much	much	JJ	B-NP	O	O
statistical	statistical	JJ	I-NP	O	O
work	work	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
focused	focus	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
mathematical	mathematical	JJ	B-NP	O	O
functions	function	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
model	model	VB	I-VP	O	O
the	the	DT	B-NP	O	O
joint	joint	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
response	response	NN	I-NP	O	O
curves	curve	NNS	I-NP	O	O
,	,	,	O	O	O
relatively	relatively	RB	B-NP	O	O
little	little	JJ	I-NP	O	O
work	work	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
regard	regard	NN	B-NP	O	O
to	to	TO	B-PP	O	O
designing	design	VBG	B-VP	O	O
experiments	experiment	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
assessing	assess	VBG	B-VP	O	O
joint	joint	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
parametric	parametric	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
response	response	NN	I-NP	O	O
models	model	NNS	I-NP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
logistic	logistic	JJ	I-NP	O	O
probability	probability	NN	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
proposed	propose	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
models	model	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
typically	typically	RB	B-ADVP	O	O
nonlinear	nonlinear	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
as	as	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
nonlinear	nonlinear	JJ	I-NP	O	O
weighted	weight	VBD	B-VP	O	O
least	least	JJS	B-NP	O	O
squares	square	NNS	I-NP	O	O
approach	approach	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
employed	employ	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
designing	design	VBG	B-VP	O	O
experiments	experiment	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
approach	approach	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
applicable	applicable	JJ	B-ADJP	O	O
across	across	IN	B-PP	O	O
a	a	DT	B-NP	O	O
wide	wide	JJ	I-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
settings	setting	NNS	B-NP	O	O
commonly	commonly	RB	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
joint	joint	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
continuous	continuous	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
discrete	discrete	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
,	,	,	O	O	O
alternative	alternative	JJ	B-NP	O	O
error	error	NN	I-NP	O	O
structures	structure	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
nonzero	nonzero	JJ	B-NP	O	O
background	background	NN	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
,	,	,	O	O	O
designs	design	NNS	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expressed	express	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
terms	term	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
proportionate	proportionate	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
individual	individual	JJ	I-NP	O	O
compounds	compound	NNS	I-NP	O	O
rather	rather	RB	B-CONJP	O	O
than	than	IN	I-CONJP	O	O
dose	dose	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
thereby	thereby	RB	B-VP	O	O
providing	provide	VBG	I-VP	O	O
for	for	IN	B-PP	O	O
results	result	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
applicable	applicable	JJ	B-ADJP	O	O
across	across	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
precursor	precursor	NN	I-NP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
effort	effort	NN	I-NP	O	O
,	,	,	O	O	O
optimal	optimal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
minimal	minimal	JJ	I-NP	O	O
experimental	experimental	JJ	I-NP	O	O
designs	design	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
compound	compound	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
have	have	VB	I-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
developed	develop	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
proposed	propose	VBN	I-NP	O	O
methodology	methodology	NN	I-NP	O	O
for	for	IN	B-PP	O	O
deriving	derive	VBG	B-VP	O	O
experimental	experimental	JJ	B-NP	O	O
designs	design	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
applied	apply	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
any	any	DT	B-NP	O	O
nonlinear	nonlinear	JJ	I-NP	O	O
regression	regression	NN	I-NP	O	O
model	model	NN	I-NP	O	O
,	,	,	O	O	O
primary	primary	JJ	B-NP	O	O
focus	focus	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
nonadditive	nonadditive	JJ	I-NP	O	O
independent	independent	JJ	I-NP	O	O
joint	joint	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
(	(	(	O	O	O
IJA	IJA	NN	B-NP	O	O
)	)	)	O	O	O
models	model	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
combined	combined	JJ	I-NP	O	O
exposures	exposure	NNS	I-NP	O	O
proposed	propose	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Barton	Barton	NNP	B-NP	O	O
,	,	,	O	O	O
Braunberg	Braunberg	NNP	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Friedman	Friedman	NNP	B-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Differential	Differential	JJ	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tyrosine	tyrosine	NN	B-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
tumor	tumor	NN	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
by	by	IN	B-PP	O	O
contortrostatin	contortrostatin	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
a	a	DT	B-NP	O	O
homodimeric	homodimeric	JJ	I-NP	B-protein	O
disintegrin	disintegrin	NN	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
monomeric	monomeric	JJ	B-NP	O	O
disintegrins	disintegrin	NNS	I-NP	O	O
echistatin	echistatin	NN	I-NP	O	S-drug_n
and	and	CC	I-NP	O	O
flavoridin	flavoridin	NN	I-NP	O	S-drug_n
.	.	.	O	O	O

The	The	DT	B-NP	O	O
homodimeric	homodimeric	JJ	I-NP	B-protein	O
disintegrin	disintegrin	NN	I-NP	I-protein	O
contortrostatin	contortrostatin	NN	I-NP	I-protein	S-drug_n
was	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
directly	directly	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
monomeric	monomeric	JJ	I-NP	O	O
disintegrins	disintegrin	NNS	I-NP	O	O
echistatin	echistatin	NN	I-NP	O	S-drug_n
and	and	CC	I-NP	O	O
flavoridin	flavoridin	NN	I-NP	O	S-drug_n
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
affect	affect	VB	I-VP	O	O
protein	protein	NN	B-NP	O	O
tyrosine	tyrosine	NN	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
tumor	tumor	NN	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
contortrostatin	contortrostatin	NN	B-NP	O	S-drug_n
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
dramatic	dramatic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tyrosine	tyrosine	NN	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
status	status	NN	I-NP	O	O
of	of	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
proteins	protein	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
T24	T24	NN	B-NP	B-cell_line	O
human	human	JJ	I-NP	I-cell_line	O
bladder	bladder	NN	I-NP	I-cell_line	O
cancer	cancer	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
robust	robust	JJ	B-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phosphorylation	phosphorylation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
proteins	protein	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
120	120	CD	B-NP	B-protein	O
-	-	HYPH	I-NP	I-protein	O
140	140	CD	I-NP	I-protein	O
kDa	kDa	NN	I-NP	I-protein	O
.	.	.	O	O	O

Echistatin	Echistatin	NN	B-NP	O	S-drug_n-EF-1
alone	alone	RB	B-ADVP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
tyrosine	tyrosine	NN	B-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
T24	T24	NN	B-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
,	,	,	O	O	O
but	but	CC	O	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependently	dependently	RB	B-ADVP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
contortrostatin	contortrostatin	NN	B-NP	O	S-drug_n-EF-2
when	when	WRB	B-ADVP	O	O
both	both	DT	B-NP	O	O
are	be	VBP	B-VP	O	O
added	add	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
proteins	protein	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
undergo	undergo	VBP	B-VP	O	O
tyrosine	tyrosine	NN	B-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	I-PP	O	O
to	to	TO	I-PP	O	O
contortrostatin	contortrostatin	NN	B-NP	O	S-drug_n
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
CAS	CAS	NNP	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
130	130	CD	I-NP	B-protein	O
kDa	kDa	NN	I-NP	I-protein	O
adapter	adapter	NN	I-NP	I-protein	O
protein	protein	NN	I-NP	I-protein	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
integrin	integrin	NN	B-NP	B-protein	O
signaling	signaling	NN	I-NP	O	O
.	.	.	O	O	O

Flavoridin	Flavoridin	NN	B-NP	B-protein	S-drug_n-EF-1
alone	alone	RB	B-ADVP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
CAS	CAS	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
can	can	MD	B-VP	O	O
completely	completely	RB	I-VP	O	O
block	block	VB	I-VP	O	O
contortrostatin	contortrostatin	NN	B-NP	O	S-drug_n-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
protein	protein	NN	I-NP	O	O
in	in	IN	B-PP	O	O
MDA	MDA	NN	B-NP	B-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
MB	MB	NN	I-NP	I-cell_line	O
-	-	SYM	I-NP	I-cell_line	O
435	435	CD	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
observations	observation	NNS	I-NP	O	O
strongly	strongly	RB	B-VP	O	O
suggest	suggest	VBP	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
homodimeric	homodimeric	JJ	I-NP	O	O
structure	structure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contortrostatin	contortrostatin	NN	B-NP	O	S-drug_n
functionally	functionally	RB	B-ADVP	O	O
distinguishes	distinguish	VBZ	B-VP	O	O
it	it	PRP	B-NP	O	O
from	from	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
monomeric	monomeric	JJ	I-NP	O	O
members	member	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
disintegrin	disintegrin	NN	I-NP	B-protein	O
family	family	NN	I-NP	I-protein	O
.	.	.	O	O	O

Modification	Modification	NN	B-NP	O	O
of	of	IN	B-PP	O	O
surface	surface	NN	B-NP	O	O
histidine	histidine	NN	I-NP	O	O
residues	residue	NNS	I-NP	O	O
abolishes	abolish	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Clostridium	Clostridium	NN	B-NP	B-protein	B-drug_n
difficile	difficile	JJ	I-NP	I-protein	I-drug_n
toxin	toxin	NN	I-NP	I-protein	I-drug_n
A	A	NN	I-NP	I-protein	E-drug_n
.	.	.	O	O	O

Clostridium	Clostridium	NN	B-NP	O	B-drug_n
difficile	difficile	JJ	I-NP	O	I-drug_n
toxin	toxin	NN	I-NP	O	I-drug_n
A	A	NN	I-NP	O	E-drug_n
displays	display	VBZ	B-VP	O	O
both	both	CC	O	O	O
cytotoxic	cytotoxic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
enterotoxic	enterotoxic	JJ	I-NP	O	O
activities	activity	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
recently	recently	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
toxin	toxin	NN	B-NP	O	B-drug_n
A	A	NN	I-NP	O	E-drug_n
exerts	exert	VBZ	B-VP	O	O
its	its	PRP$	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glucosylation	glucosylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
small	small	JJ	I-NP	B-protein	O
GTP	GTP	NN	I-NP	I-protein	O
-	-	HYPH	B-VP	I-protein	O
binding	bind	VBG	B-NP	I-protein	O
proteins	protein	NNS	I-NP	I-protein	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Rho	Rho	NN	I-NP	B-protein	O
family	family	NN	I-NP	I-protein	O
.	.	.	O	O	O

Diethyl	Diethyl	NN	B-NP	O	B-drug_n
pyrocarbonate	pyrocarbonate	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
at	at	IN	B-PP	O	O
pH	pH	NN	B-NP	O	O
7.0	7.0	CD	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
chemically	chemically	RB	I-VP	O	O
modify	modify	VB	I-VP	O	O
exposed	expose	VBN	B-NP	O	O
histidine	histidine	NN	I-NP	O	O
residues	residue	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
toxin	toxin	NN	B-NP	B-protein	B-drug_n
A	A	NN	I-NP	I-protein	E-drug_n
.	.	.	O	O	O

Modification	Modification	NN	B-NP	O	O
of	of	IN	B-PP	O	O
toxin	toxin	NN	B-NP	B-protein	B-drug_n
A	A	NN	I-NP	I-protein	E-drug_n
with	with	IN	B-PP	O	O
diethyl	diethyl	NN	B-NP	O	B-drug_n
pyrocarbonate	pyrocarbonate	NN	I-NP	O	E-drug_n
abolished	abolish	VBD	B-VP	O	O
both	both	CC	O	O	O
its	its	PRP$	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxin	toxin	NN	I-NP	O	O
to	to	TO	B-VP	O	O
bind	bind	VB	I-VP	O	O
Zn	Zn	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
Sepharose	Sepharose	NN	I-NP	O	O
gel	gel	NN	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
toxin	toxin	NN	B-NP	O	B-drug_n
A	A	NN	I-NP	O	E-drug_n
with	with	IN	B-PP	O	O
[	[	(	O	O	O
(	(	(	O	O	O
14	14	CD	O	O	O
)	)	)	O	O	O
C	C	NN	B-NP	O	O
]	]	)	O	O	O
-	-	HYPH	B-NP	O	O
diethyl	diethyl	NN	I-NP	O	B-drug_n
pyrocarbonate	pyrocarbonate	NN	I-NP	O	E-drug_n
revealed	reveal	VBD	B-VP	O	O
concentration	concentration	NN	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
labelling	labelling	NN	I-NP	O	O
of	of	IN	B-PP	O	O
histidine	histidine	NN	B-NP	O	O
residues	residue	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxin	toxin	NN	I-NP	B-protein	O
molecules	molecule	NNS	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diethyl	diethyl	NN	B-NP	O	B-drug_n
pyrocarbonate	pyrocarbonate	NN	I-NP	O	E-drug_n
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reversed	reverse	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
hydroxylamine	hydroxylamine	NN	B-NP	O	S-drug_n
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
modified	modify	VBN	I-NP	O	O
histidine	histidine	NN	I-NP	O	O
residues	residue	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
toxin	toxin	NN	B-NP	O	B-drug_n
A	A	NN	I-NP	O	E-drug_n
are	be	VBP	B-VP	O	O
critical	critical	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Histidine	Histidine	NN	B-NP	O	O
modification	modification	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glucosyl	glucosyl	NN	I-NP	B-protein	O
transferase	transferase	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxin	toxin	NN	B-NP	B-protein	B-drug_n
A	A	NN	I-NP	I-protein	E-drug_n
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
modification	modification	NN	B-NP	O	O
abolished	abolish	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
'	'	``	I-NP	O	O
cold	cold	NN	I-NP	O	O
'	'	POS	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxin	toxin	NN	B-NP	O	O
to	to	TO	B-PP	O	O
bovine	bovine	JJ	B-NP	B-protein	O
thyroglobulin	thyroglobulin	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
ELISA	ELISA	NN	I-NP	O	O
and	and	CC	O	O	O
reduced	reduce	VBD	B-VP	O	O
ligand	ligand	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
rabbit	rabbit	NN	I-NP	O	O
erythrocyte	erythrocyte	NN	I-NP	O	O
haemagglutination	haemagglutination	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
histidine	histidine	NN	I-NP	O	O
residues	residue	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
crucial	crucial	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
binding	binding	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxin	toxin	NN	B-NP	B-protein	B-drug_n
A	A	NN	I-NP	I-protein	E-drug_n
.	.	.	O	O	O

Exposed	Expose	VBN	B-NP	O	O
histidines	histidine	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
toxin	toxin	NN	B-NP	O	B-drug_n
A	A	NN	I-NP	O	E-drug_n
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
zinc	zinc	NN	B-NP	O	S-drug
chelation	chelation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
exploited	exploit	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
purification	purification	NN	I-NP	O	O
protocol	protocol	NN	I-NP	O	O
for	for	IN	B-PP	O	O
toxin	toxin	NN	B-NP	O	B-drug_n
A	A	NN	I-NP	O	E-drug_n
using	use	VBG	B-VP	O	O
zinc	zinc	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
chelating	chelate	VBG	B-VP	O	O
chromatography	chromatography	NN	B-NP	O	O
.	.	.	O	O	O

Note	Note	NNP	B-NP	O	O
:	:	:	O	O	O
dissolution	dissolution	NN	B-NP	O	O
of	of	IN	B-PP	O	O
aerosol	aerosol	NN	B-NP	O	O
particles	particle	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
budesonide	budesonide	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
Survanta	Survanta	NNP	B-NP	O	S-brand
,	,	,	O	O	O
a	a	DT	B-NP	O	O
model	model	NN	I-NP	O	O
lung	lung	NN	I-NP	O	B-group
surfactant	surfactant	NN	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	B-group
surfactant	surfactant	JJ	I-NP	O	E-group
extract	extract	NN	I-NP	O	O
from	from	IN	B-PP	O	O
bovine	bovine	JJ	B-NP	O	O
lung	lung	NN	I-NP	O	O
,	,	,	O	O	O
Survanta	Survanta	NN	B-NP	O	S-brand
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dissolution	dissolution	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aerosol	aerosol	NN	B-NP	O	O
particles	particle	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
budesonide	budesonide	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

Aerosol	Aerosol	NN	B-NP	O	O
particles	particle	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
budesonide	budesonide	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
generated	generate	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
an	an	DT	B-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug
solution	solution	NN	I-NP	O	O
,	,	,	O	O	O
dried	dry	VBN	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
collected	collect	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cascade	cascade	NN	I-NP	O	O
impactor	impactor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
characterization	characterization	NN	B-NP	O	O
or	or	CC	B-PP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
liquid	liquid	JJ	I-NP	O	O
impinger	impinger	NN	I-NP	O	O
for	for	IN	B-PP	O	O
dissolution	dissolution	NN	B-NP	O	O
experiments	experiment	NNS	I-NP	O	O
.	.	.	O	O	O

Powder	Powder	NN	B-NP	O	O
x	x	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
ray	ray	NN	I-NP	O	O
diffraction	diffraction	NN	I-NP	O	O
,	,	,	O	O	O
differential	differential	JJ	B-NP	O	O
scanning	scanning	NN	I-NP	O	O
calorimetry	calorimetry	NN	I-NP	O	O
,	,	,	O	O	O
differential	differential	JJ	B-NP	O	O
thermal	thermal	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
scanning	scanning	NN	B-NP	O	O
electron	electron	NN	I-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
characterize	characterize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
aerosol	aerosol	NN	I-NP	O	O
particles	particle	NNS	I-NP	O	O
and	and	CC	O	O	O
starting	start	VBG	B-VP	O	O
material	material	NN	B-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
phase	phase	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
aerosol	aerosol	NN	I-NP	O	O
particles	particle	NNS	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
contain	contain	VB	I-VP	O	O
residual	residual	JJ	B-NP	O	O
solvent	solvent	NN	I-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dissolution	dissolution	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
aerosol	aerosol	NN	I-NP	O	O
particles	particle	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
saline	saline	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
low	low	JJ	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
variable	variable	JJ	I-ADJP	O	O
.	.	.	O	O	O

Survanta	Survanta	NN	B-NP	O	S-brand
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dissolution	dissolution	NN	B-NP	O	O
of	of	IN	B-PP	O	O
budesonide	budesonide	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
proportion	proportion	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
added	add	VBN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
verified	verify	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
equilibrium	equilibrium	NN	B-NP	O	O
solubilization	solubilization	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Survanta	Survanta	NN	B-NP	O	S-brand
also	also	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
rate	rate	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dissolution	dissolution	NN	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
manner	manner	NN	I-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug_n
dodecyl	dodecyl	NN	I-NP	O	I-drug_n
sulfate	sulfate	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

Analysis	Analysis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
budesonide	budesonide	NN	B-NP	O	S-drug
following	follow	VBG	B-PP	O	O
ultracentrifugation	ultracentrifugation	NN	B-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
rapid	rapid	JJ	B-NP	O	O
equilibration	equilibration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
budesonide	budesonide	NN	B-NP	O	S-drug
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Survanta	Survanta	NN	I-NP	O	S-brand
and	and	CC	I-NP	O	O
aqueous	aqueous	JJ	I-NP	O	O
phase	phase	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
lung	lung	NN	B-NP	B-protein	B-group
surfactant	surfactant	NN	I-NP	I-protein	E-group
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enhancing	enhance	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dissolution	dissolution	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
administered	administer	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
lung	lung	NN	I-NP	O	O
.	.	.	O	O	O

Activation	Activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
effector	effector	NN	I-NP	O	O
immediate	immediate	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
early	early	JJ	I-NP	O	O
gene	gene	NN	I-NP	O	O
arc	arc	NN	I-NP	O	O
by	by	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
immediate	immediate	JJ	B-NP	B-DNA	O
-	-	HYPH	I-NP	I-DNA	O
early	early	JJ	I-NP	I-DNA	O
genes	gene	NNS	I-NP	I-DNA	O
(	(	(	O	O	O
IEGs	IEG	NNS	B-NP	B-DNA	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
thought	think	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
play	play	VB	I-VP	O	O
a	a	DT	B-NP	O	O
critical	critical	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mediating	mediate	VBG	B-VP	O	O
stimulus	stimulus	NN	B-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
neural	neural	JJ	I-NP	O	O
plasticity	plasticity	NN	I-NP	O	O
,	,	,	O	O	O
IEG	IEG	NN	B-NP	O	O
response	response	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	O	S-drug
(	(	(	O	O	O
METH	METH	NN	B-NP	O	S-drug
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
characterized	characterize	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
define	define	VB	I-VP	O	O
the	the	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
gene	gene	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
underlie	underlie	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
lasting	last	VBG	B-VP	O	O
behavioral	behavioral	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
transcription	transcription	NN	I-NP	B-protein	O
factor	factor	NN	I-NP	I-protein	O
IEGs	IEG	NNS	I-NP	B-protein	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
,	,	,	O	O	O
little	little	JJ	B-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
about	about	IN	B-PP	O	O
effector	effector	NN	B-NP	O	O
IEGs	IEG	NNS	I-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
examined	examine	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
METH	METH	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
affects	affect	VBZ	B-VP	O	O
expression	expression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
effector	effector	NN	I-NP	O	O
IEG	IEG	NN	I-NP	O	O
arc	arc	NN	I-NP	O	O
(	(	(	O	O	O
activity	activity	NN	B-NP	O	O
-	-	HYPH	O	O	O
regulated	regulate	VBN	B-VP	O	O
,	,	,	O	O	O
cytoskeleton	cytoskeleton	NN	B-NP	O	O
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
)	)	)	O	O	O
that	that	WDT	B-NP	O	O
encodes	encode	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
protein	protein	NN	I-NP	O	O
with	with	IN	B-PP	O	O
homology	homology	NN	B-NP	O	O
to	to	TO	B-PP	O	O
spectrin	spectrin	NN	B-NP	O	O
.	.	.	O	O	O

Using	Use	VBG	B-VP	O	O
in	in	FW	B-NP	O	O
situ	situ	FW	I-NP	O	O
hybridization	hybridization	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
observed	observe	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
METH	METH	NN	B-NP	O	S-drug-EF-1
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
transient	transient	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
arc	arc	NN	B-NP	B-RNA	O
mRNA	mRNA	NN	I-NP	I-RNA	O
level	level	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
striatum	striatum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
abolished	abolish	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
dopamine	dopamine	NN	I-NP	O	O
D1	D1	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
SCH	SCH	NN	I-NP	O	B-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
23390	23390	CD	I-NP	O	E-drug_n-EF-2
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
by	by	IN	I-PP	O	O
an	an	DT	B-NP	O	O
atypical	atypical	JJ	I-NP	O	B-group
neuroleptic	neuroleptic	JJ	I-NP	O	E-group
clozapine	clozapine	NN	I-NP	O	S-drug
.	.	.	O	O	O

METH	METH	NN	B-NP	O	S-drug
induced	induce	VBD	B-VP	O	O
arc	arc	NN	B-NP	B-RNA	O
mRNA	mRNA	NN	I-NP	I-RNA	O
in	in	IN	B-PP	O	O
layers	layer	NNS	B-NP	O	O
IV	IV	CD	B-NP	O	O
and	and	CC	I-NP	O	O
VI	VI	CD	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cortex	cortex	NN	I-NP	B-protein	O
which	which	WDT	B-NP	I-protein	O
dopamine	dopamine	NN	I-NP	I-protein	O
receptor	receptor	NN	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
localized	localized	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
D1	D1	NN	B-NP	B-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
coupled	couple	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
arc	arc	NN	B-NP	B-DNA	O
gene	gene	NN	I-NP	I-DNA	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
functional	functional	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
structural	structural	JJ	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
neural	neural	JJ	B-NP	O	O
plasticity	plasticity	NN	I-NP	O	O
triggered	trigger	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
METH	METH	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
DCG	DCG	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	B-NP	I-protein	I-drug_n
IV	IV	CD	I-NP	I-protein	E-drug_n
and	and	CC	O	O	O
L	L	NN	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
CCG	CCG	NN	I-NP	B-protein	I-drug_n
-	-	HYPH	B-NP	I-protein	I-drug_n
1	1	CD	I-NP	I-protein	E-drug_n
upon	upon	IN	B-PP	O	O
phencyclidine	phencyclidine	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
PCP	PCP	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
locomotion	locomotion	NN	I-NP	O	O
and	and	CC	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
repeated	repeat	VBN	I-NP	O	O
i.p	i.p	NN	I-NP	O	O
.	.	.	O	O	O

injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phencyclidine	phencyclidine	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
PCP	PCP	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
measuring	measure	VBG	B-VP	O	O
locomotor	locomotor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
stereotyped	stereotype	VBD	B-VP	O	O
behavior	behavior	NN	B-NP	O	O
.	.	.	O	O	O

Then	Then	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
metabotropic	metabotropic	JJ	B-NP	B-protein	O
glutamate	glutamate	NN	I-NP	I-protein	O
receptor	receptor	NN	I-NP	I-protein	O
(	(	(	O	O	O
mGluR	mGluR	NN	B-NP	O	O
)	)	)	O	O	O
agonists	agonist	NNS	B-NP	O	O
,	,	,	O	O	O
DCG	DCG	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	O	O	I-drug_n
IV	IV	CD	B-NP	O	E-drug_n
and	and	CC	O	O	O
L	L	NN	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
CCG	CCG	NN	I-NP	B-protein	I-drug_n
-	-	HYPH	O	O	I-drug_n
1	1	CD	B-NP	O	E-drug_n
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
above	above	JJ	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
PCP	PCP	NN	B-NP	O	S-drug_n
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
DCG	DCG	NN	B-NP	B-protein	B-drug_n-EF-1
-	-	HYPH	B-NP	I-protein	I-drug_n-EF-1
IV	IV	CD	I-NP	I-protein	E-drug_n-EF-1
were	be	VBD	B-VP	O	O
very	very	RB	B-ADJP	O	O
strong	strong	JJ	I-ADJP	O	O
and	and	CC	O	O	O
completely	completely	RB	B-VP	O	O
depressed	depress	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
PCP	PCP	NN	I-NP	B-DNA	S-drug_n-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperlocomotion	hyperlocomotion	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
CCG	CCG	NN	I-NP	B-protein	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1	1	CD	I-NP	O	E-drug_n
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
so	so	RB	B-ADJP	O	O
strong	strong	JJ	I-ADJP	O	O
.	.	.	O	O	O

Repeated	Repeat	VBN	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PCP	PCP	NN	B-NP	B-protein	S-drug_n
for	for	IN	B-PP	O	O
20	20	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
into	into	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
induced	induce	VBD	B-VP	O	O
lower	low	JJR	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
acutely	acutely	RB	B-NP	O	O
injected	inject	VBN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
related	relate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
negative	negative	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
some	some	DT	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PCP	PCP	NN	B-NP	B-protein	S-drug_n
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
behavioral	behavioral	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
,	,	,	O	O	O
Northern	Northern	NN	B-NP	O	O
blot	blot	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
RNA	RNA	NN	I-NP	O	O
from	from	IN	B-PP	O	O
prefrontal	prefrontal	JJ	B-NP	O	O
cortical	cortical	JJ	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
PCP	PCP	NN	B-NP	B-protein	S-drug_n
,	,	,	O	O	O
DCG	DCG	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	O	O	I-drug_n
IV	IV	CD	B-NP	O	E-drug_n
,	,	,	O	O	O
and	and	CC	O	O	O
L	L	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	B-NP	I-protein	I-drug_n
CCG	CCG	NN	I-NP	I-protein	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1	1	CD	I-NP	O	E-drug_n
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
.	.	.	O	O	O

Behavioral	Behavioral	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
cocaine	cocaine	NN	I-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
selectively	selectively	RB	B-VP	O	O
bred	breed	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
differential	differential	JJ	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
pentobarbital	pentobarbital	NN	B-NP	O	S-drug
.	.	.	O	O	O

Mice	Mouse	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
20th	20th	JJ	I-NP	O	O
generation	generation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
three	three	CD	B-NP	O	O
lines	line	NNS	I-NP	O	O
divergently	divergently	RB	B-VP	O	O
selected	select	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
pentobarbital	pentobarbital	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
sedation	sedation	NN	I-NP	O	O
times	time	NNS	I-NP	O	O
[	[	(	O	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
sedation	sedation	NN	I-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
LST	LST	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
short	short	JJ	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
SST	SST	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
randomly	randomly	RB	B-VP	O	O
bred	breed	VBN	I-VP	O	O
control	control	NN	B-NP	O	O
(	(	(	O	O	O
RBC	RBC	NN	B-NP	B-protein	O
)	)	)	O	O	O
]	]	)	O	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
sensitization	sensitization	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
lines	line	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
variable	variable	JJ	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
locomotor	locomotor	NN	B-NP	O	O
activities	activity	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
.	.	.	O	O	O

At	At	IN	B-PP	O	O
a	a	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
cocaine	cocaine	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
and	and	CC	O	O	O
long	long	JJ	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
period	period	NN	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
twice	twice	RB	B-NP	O	O
a	a	DT	I-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
14	14	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
LST	LST	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
tolerance	tolerance	NN	B-NP	O	O
development	development	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
activities	activity	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SST	SST	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	B-ADJP	O	O
significantly	significantly	RB	I-ADJP	O	O
different	different	JJ	I-ADJP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
RBC	RBC	NN	I-NP	B-protein	O
group	group	NN	I-NP	I-protein	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
shorter	short	JJR	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
period	period	NN	I-NP	O	O
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
SST	SST	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
behavioral	behavioral	JJ	B-NP	O	O
sensitization	sensitization	NN	I-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
RBC	RBC	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
LST	LST	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
develop	develop	VB	I-VP	O	O
sensitization	sensitization	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
different	different	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
locomotor	locomotor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
genetic	genetic	JJ	B-NP	B-protein	O
factors	factor	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
play	play	VB	I-VP	O	O
a	a	DT	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
determining	determine	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Dopamine	Dopamine	NN	B-NP	O	O
(	(	(	O	O	O
DA	DA	NN	B-NP	O	O
)	)	)	O	O	O
levels	level	NNS	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
differ	differ	VB	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
either	either	CC	O	O	O
striatum	striatum	NN	B-NP	O	O
(	(	(	O	O	O
STR	STR	NN	B-NP	B-protein	O
)	)	)	O	O	O
or	or	CC	O	O	O
nucleus	nucleus	NN	B-NP	O	O
accumbens	accumbens	NN	I-NP	O	O
(	(	(	O	O	O
NAC	NAC	NN	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cocaine	cocaine	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
their	their	PRP$	B-NP	O	O
corresponding	correspond	VBG	I-NP	O	O
saline	saline	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
controls	control	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
affinity	affinity	NN	I-NP	O	O
(	(	(	O	O	O
Kd	Kd	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
D2	D2	NN	B-NP	B-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
NAC	NAC	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
,	,	,	O	O	O
without	without	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
density	density	NN	B-NP	O	O
(	(	(	O	O	O
Bmax	Bmax	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cocaine	cocaine	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
SST	SST	NN	I-NP	O	O
and	and	CC	I-NP	O	O
RBC	RBC	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
density	density	NN	I-NP	O	O
of	of	IN	B-PP	O	O
D2	D2	NN	B-NP	B-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SST	SST	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
RBC	RBC	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
STR	STR	NN	I-NP	B-protein	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
groups	group	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
change	change	NN	B-NP	O	O
in	in	IN	B-PP	O	O
Kd	Kd	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
LST	LST	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
show	show	VB	I-VP	O	O
any	any	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Kd	Kd	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Bmax	Bmax	NN	I-NP	O	O
in	in	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
STR	STR	NN	I-NP	B-protein	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
NAC	NAC	NN	I-NP	O	O
.	.	.	O	O	O

Taken	Take	VBN	B-VP	O	O
together	together	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Kd	Kd	NN	I-NP	O	O
of	of	IN	B-PP	O	O
D2	D2	NN	B-NP	B-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
NAC	NAC	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Bmax	Bmax	NN	I-NP	O	O
of	of	IN	B-PP	O	O
D2	D2	NN	B-NP	B-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
STR	STR	NN	I-NP	B-protein	O
may	may	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
locomotor	locomotor	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
mouse	mouse	NN	I-NP	B-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
Methoxycoronaridine	Methoxycoronaridine	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	B-cell_type	E-drug_n
)	)	)	O	O	O
and	and	CC	O	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n
:	:	:	O	O	O
comparison	comparison	NN	B-NP	O	O
of	of	IN	B-PP	O	O
antiaddictive	antiaddictive	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
toxicity	toxicity	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
mechanisms	mechanism	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
.	.	.	O	O	O

18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
iboga	iboga	NN	I-NP	O	O
alkaloid	alkaloid	JJ	I-NP	O	O
congener	congener	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
being	be	VBG	I-VP	O	O
developed	develop	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
abuse	abuse	NN	I-NP	O	O
.	.	.	O	O	O

Like	Like	IN	B-PP	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
decreases	decrease	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
self	self	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
cocaine	cocaine	NN	I-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
self	self	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
nicotine	nicotine	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
;	;	:	O	O	O

unlike	unlike	IN	B-PP	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	B-cell_type	E-drug_n
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
responding	respond	VBG	I-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nondrug	nondrug	JJ	I-NP	O	O
reinforcer	reinforcer	NN	I-NP	O	O
(	(	(	O	O	O
water	water	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n
and	and	CC	O	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	O	E-drug_n
ameliorate	ameliorate	JJ	I-NP	O	O
opioid	opioid	JJ	I-NP	O	S-group
withdrawal	withdrawal	NN	I-NP	O	O
signs	sign	NNS	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n
and	and	CC	O	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	O	E-drug_n
decrease	decrease	VBP	B-VP	O	O
extracellular	extracellular	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nucleus	nucleus	NN	I-NP	O	O
accumbens	accumben	VBZ	B-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
only	only	RB	B-NP	O	O
ibogaine	ibogaine	NN	I-NP	O	S-drug_n
increases	increase	VBZ	B-VP	O	O
extracellular	extracellular	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nucleus	nucleus	NN	I-NP	O	O
accumbens	accumbens	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n-EF-1
and	and	CC	O	O	O
18	18	CD	B-NP	O	B-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
MC	MC	NN	I-NP	O	E-drug_n-EF-1
block	block	VBP	B-VP	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
and	and	CC	I-NP	O	O
nicotine	nicotine	NN	I-NP	O	S-drug-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dopamine	dopamine	NN	I-NP	O	O
release	release	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nucleus	nucleus	NN	I-NP	O	O
accumbens	accumben	NNS	I-NP	O	O
;	;	:	O	O	O

only	only	RB	B-NP	O	O
ibogaine	ibogaine	NN	I-NP	O	S-drug_n-EF-1
enhances	enhance	VBZ	B-VP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
accumbal	accumbal	JJ	B-NP	O	O
dopamine	dopamine	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n
and	and	CC	O	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	B-cell_type	E-drug_n
enhance	enhance	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
stereotypic	stereotypic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
stimulants	stimulant	NNS	B-NP	O	O
.	.	.	O	O	O

Ibogaine	Ibogaine	NN	B-NP	O	S-drug_n-EF-1
attenuates	attenuate	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
18	18	CD	B-NP	O	B-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
MC	MC	NN	I-NP	O	E-drug_n-EF-1
potentiates	potentiate	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
locomotor	locomotor	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O

both	both	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
attenuate	attenuate	VBP	B-VP	O	O
morphine	morphine	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
locomotion	locomotion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
experienced	experience	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Ibogaine	Ibogaine	NN	B-NP	O	S-drug_n
produces	produce	VBZ	B-VP	O	O
whole	whole	JJ	B-NP	O	O
body	body	NN	I-NP	O	O
tremors	tremor	NNS	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
cerebellar	cerebellar	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
;	;	:	O	O	O

18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	B-cell_type	E-drug_n
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Ibogaine	Ibogaine	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	B-NP	O	O
18	18	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
decreases	decrease	VBZ	B-VP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
ibogaine	ibogaine	NN	I-NP	O	S-drug_n
have	have	VBP	B-VP	O	O
similar	similar	JJ	B-NP	O	O
affinities	affinity	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
kappa	kappa	NN	B-NP	O	O
opioid	opioid	NN	I-NP	O	O
and	and	CC	O	O	O
possibly	possibly	RB	B-NP	O	O
nicotinic	nicotinic	JJ	I-NP	B-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
,	,	,	O	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	B-cell_type	E-drug_n
has	have	VBZ	B-VP	O	O
much	much	RB	B-NP	O	O
lower	low	JJR	I-NP	O	O
affinities	affinity	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n
for	for	IN	B-PP	O	O
NMDA	NMDA	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
sigma	sigma	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
2	2	CD	I-NP	I-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
,	,	,	O	O	O
sodium	sodium	NN	B-NP	B-protein	O
channels	channel	NNS	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
HT	HT	NN	I-NP	B-DNA	O
transporter	transporter	NN	I-NP	I-DNA	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
18	18	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
ibogaine	ibogaine	NN	I-NP	O	S-drug_n
are	be	VBP	B-VP	O	O
sequestered	sequester	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
fat	fat	NN	B-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
like	like	IN	B-PP	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	O	E-drug_n
probably	probably	RB	B-ADVP	O	O
has	have	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
18	18	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
MC	MC	NN	I-NP	B-cell_type	E-drug_n
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
narrower	narrow	JJR	I-NP	O	O
spectrum	spectrum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
actions	action	NNS	B-NP	O	O
and	and	CC	O	O	O
will	will	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
substantially	substantially	RB	I-NP	O	O
greater	great	JJR	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
index	index	NN	I-NP	O	O
than	than	IN	B-PP	O	O
ibogaine	ibogaine	NN	B-NP	O	S-drug_n
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
implications	implication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-IN-1
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
five	five	CD	B-NP	O	O
sedatives	sedative	NNS	I-NP	O	S-group-IN-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
intensity	intensity	NN	I-NP	O	O
,	,	,	I-NP	O	O
uniformity	uniformity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
time	time	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-group
interference	interference	NN	I-NP	O	O
by	by	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
secobarbital	secobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
glutethimide	glutethimide	NN	B-NP	O	S-drug
,	,	,	O	O	O
chloral	chloral	JJ	B-NP	O	B-drug
hydrate	hydrate	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
methaqualone	methaqualone	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
systematically	systematically	RB	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
16	16	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
coumarin	coumarin	NN	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
subject	subject	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
individualized	individualize	VBN	I-NP	O	O
fixed	fix	VBN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
served	serve	VBD	B-VP	O	O
as	as	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
own	own	JJ	I-NP	O	O
pre	pre	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
postsedative	postsedative	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

Prothrombin	Prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
four	four	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
weekly	weekly	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
five	five	CD	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
.	.	.	O	O	O

Anticoagulant	Anticoagulant	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
secobarbital	secobarbital	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
glutethimide	glutethimide	NN	I-NP	O	S-drug
;	;	:	O	O	O

there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
test	test	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chloral	chloral	JJ	B-NP	O	B-drug
hydrate	hydrate	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
methaqualone	methaqualone	NN	I-NP	O	S-drug
.	.	.	O	O	O

Barbiturates	Barbiturate	NNS	B-NP	O	S-group-AD-1
and	and	CC	I-NP	O	O
glutethimide	glutethimide	NN	I-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
these	these	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
decreasing	decrease	VBG	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
survey	survey	NN	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
medical	medical	JJ	I-NP	O	O
records	record	NNS	I-NP	O	O
.	.	.	O	O	O

Chloral	Chloral	JJ	B-NP	O	B-drug-IN-1
hydrate	hydrate	NN	I-NP	O	E-drug-IN-1
and	and	CC	I-NP	O	O
methaqualone	methaqualone	NN	I-NP	O	S-drug-IN-1
interact	interact	VBP	B-VP	O	O
pharmacologically	pharmacologically	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
orally	orally	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	B-group-IN-2
agents	agent	NNS	I-NP	O	E-group-IN-2
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
clinically	clinically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
chloral	chloral	JJ	B-NP	O	B-drug
hydrate	hydrate	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
methaqualone	methaqualone	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
safely	safely	RB	B-ADVP	O	O
without	without	IN	B-PP	O	O
additional	additional	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
test	test	NN	I-NP	O	O
monitoring	monitor	VBG	B-VP	O	O
during	during	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
temperatures	temperature	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
microtubules	microtubule	NNS	B-NP	B-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	B-DNA	O
myelinated	myelinated	JJ	I-NP	I-DNA	O
axons	axon	NNS	I-NP	I-DNA	O
of	of	IN	B-PP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
ganglionic	ganglionic	JJ	I-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
nerves	nerve	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
temperature	temperature	NN	B-NP	O	O
changes	change	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
microtubules	microtubule	NNS	B-NP	B-protein	O
in	in	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	B-DNA	O
myelinated	myelinated	JJ	I-NP	I-DNA	O
axons	axon	NNS	I-NP	I-DNA	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cat	cat	NN	B-NP	O	O
inferior	inferior	JJ	I-NP	O	O
mesenteric	mesenteric	JJ	I-NP	O	O
ganglion	ganglion	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
hypogastric	hypogastric	JJ	I-NP	O	O
nerve	nerve	NN	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
incubated	incubate	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
temperatures	temperature	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Eagles	Eagle	NNS	B-NP	O	O
minimal	minimal	JJ	B-NP	O	O
essential	essential	JJ	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
culture	culture	NN	I-NP	O	O
medium	medium	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
37	37	CD	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
C	C	JJ	B-ADJP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	B-DNA	O
myelinated	myelinated	JJ	I-NP	I-DNA	O
axons	axon	NNS	I-NP	I-DNA	O
contained	contain	VBD	B-VP	O	O
28.4	28.4	CD	B-NP	O	O
plus	plus	CC	B-NP	O	O
or	or	CC	O	O	O
minus	minus	CC	O	O	O
0.8	0.8	CD	B-NP	O	O
S.E.M	S.E.M	NN	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
54	54	CD	B-NP	O	O
)	)	)	O	O	O
microtubules	microtubule	NNS	B-NP	B-protein	O
per	per	IN	B-PP	O	O
axon	axon	NN	B-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
incubation	incubation	NN	B-NP	O	O
at	at	IN	B-PP	O	O
0	0	CD	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
C	C	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
h	h	NN	I-NP	O	O
this	this	DT	B-NP	O	O
number	number	NN	I-NP	O	O
fell	fall	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
2.3	2.3	CD	B-NP	O	O
plus	plus	CC	O	O	O
or	or	CC	O	O	O
minus	minus	CC	O	O	O
0.1	0.1	CD	B-NP	O	O
S.E.M	S.E.M	NN	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
41	41	CD	B-NP	O	O
)	)	)	O	O	O
but	but	CC	O	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
nerves	nerve	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
rewarmed	rewarme	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
microtubules	microtubule	NNS	B-NP	B-protein	O
on	on	IN	B-PP	O	O
cooling	cool	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
nerves	nerve	NNS	I-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
reappearance	reappearance	NN	I-NP	O	O
on	on	IN	B-PP	O	O
rewarming	rewarming	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
process	process	NN	I-NP	O	O
;	;	:	O	O	O

it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
independent	independent	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nueronal	nueronal	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
body	body	NN	I-NP	O	O
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
axon	axon	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
preservation	preservation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
microtubules	microtubule	NNS	I-NP	B-protein	O
was	be	VBD	B-VP	O	O
improved	improve	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
D2O	D2O	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
incubation	incubation	NN	I-NP	O	O
medium	medium	NN	I-NP	O	O
.	.	.	O	O	O

Reformed	Reform	VBN	B-NP	O	O
microtubules	microtubule	NNS	I-NP	B-protein	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
function	function	VB	I-VP	O	O
normally	normally	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
their	their	PRP$	B-NP	O	O
possible	possible	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
transport	transport	NN	I-NP	O	O
of	of	IN	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	O	O
storage	storage	NN	I-NP	O	O
vesicles	vesicle	NNS	I-NP	O	O
along	along	IN	B-PP	O	O
the	the	DT	B-NP	O	O
axons	axon	NNS	I-NP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
125I	125I	NN	I-NP	B-protein	O
-	-	HYPH	B-VP	I-protein	O
labelled	label	VBN	B-NP	I-protein	O
antigen	antigen	NN	I-NP	I-protein	O
:	:	:	O	O	O
Validation	Validation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
method	method	NN	B-NP	O	O
and	and	CC	I-NP	O	O
observations	observation	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

1	1	LS	B-LST	O	O
.	.	.	O	O	O

Determinations	Determination	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
utilizing	utilize	VBG	B-VP	O	O
commercially	commercially	RB	B-NP	O	O
available	available	JJ	I-NP	O	O
kits	kit	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
125I	125I	NN	I-NP	B-protein	O
-	-	HYPH	B-VP	I-protein	O
labelled	label	VBN	B-NP	I-protein	O
antigen	antigen	NN	I-NP	I-protein	O
were	be	VBD	B-VP	O	O
precise	precise	JJ	B-ADJP	O	O
and	and	CC	O	O	O
not	not	RB	B-ADJP	O	O
materially	materially	RB	I-ADJP	O	O
different	different	JJ	I-ADJP	O	O
from	from	IN	B-PP	O	O
results	result	NNS	B-NP	O	O
obtained	obtain	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
3H	3H	NN	I-NP	B-protein	O
-	-	HYPH	O	I-protein	O
labelled	label	VBN	B-NP	I-protein	O
antigen	antigen	NN	I-NP	I-protein	O
.	.	.	O	O	O

2	2	LS	B-LST	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
approximate	approximate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
level	level	NN	I-NP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
drawn	draw	VBN	I-VP	O	O
either	either	CC	O	O	O
before	before	IN	B-SBAR	O	O
or	or	CC	O	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
six	six	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
tablet	tablet	NN	I-NP	O	O
.	.	.	O	O	O

3	3	LS	B-LST	O	O
.	.	.	O	O	O

Concomitantly	Concomitantly	RB	B-NP	O	O
given	give	VBN	I-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tablet	tablet	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

4	4	LS	B-LST	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
digitalized	digitalize	VBN	I-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
slow	slow	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
correlated	correlate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
,	,	,	O	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
negative	negative	JJ	I-NP	O	O
chronotropic	chronotropic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

5	5	LS	B-LST	O	O
.	.	.	O	O	O

Maximal	Maximal	JJ	B-NP	O	O
exercise	exercise	NN	I-NP	O	O
testing	testing	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
maneuver	maneuver	NN	I-NP	O	O
often	often	RB	B-ADVP	O	O
applied	apply	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
level	level	NN	I-NP	O	O
.	.	.	O	O	O

Combinations	Combination	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
phencyclidine	phencyclidine	NN	I-NP	O	S-drug_n
:	:	:	O	O	O
effects	effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
discrimination	discrimination	NN	I-NP	O	O
and	and	CC	O	O	O
behavioral	behavioral	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Phencyclidine	Phencyclidine	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
PCP	PCP	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
produces	produce	VBZ	B-VP	O	O
psychotomimetic	psychotomimetic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
resemble	resemble	VBP	B-VP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
effort	effort	NN	I-NP	O	O
to	to	TO	B-VP	O	O
screen	screen	VB	I-VP	O	O
compounds	compound	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
antipsychotic	antipsychotic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
preclinical	preclinical	JJ	B-NP	O	O
researchers	researcher	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
block	block	VBP	B-VP	O	O
PCP	PCP	NN	B-NP	B-protein	S-drug_n
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
behaviors	behavior	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
atypical	atypical	JJ	I-NP	O	B-group
antipsychotic	antipsychotic	JJ	I-NP	O	E-group
clozapine	clozapine	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PCP	PCP	NN	B-NP	B-protein	S-drug_n
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
lever	lever	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
discrimination	discrimination	NN	I-NP	O	O
and	and	CC	O	O	O
mixed	mix	VBD	B-VP	O	O
signalled	signal	VBN	I-VP	O	O
-	-	HYPH	B-NP	O	O
unsignalled	unsignalled	JJ	I-NP	O	O
differential	differential	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
reinforcement	reinforcement	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
of	of	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
low	low	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
rates	rate	NNS	I-NP	O	O
(	(	(	O	O	O
DRL	DRL	NN	B-NP	O	O
)	)	)	O	O	O
procedures	procedure	NNS	B-NP	O	O
.	.	.	O	O	O

PCP	PCP	NN	B-NP	O	S-drug_n
produced	produce	VBD	B-VP	O	O
distinctive	distinctive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
task	task	NN	I-NP	O	O
:	:	:	O	O	O
it	it	PRP	B-NP	O	O
substituted	substitute	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
training	training	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
PCP	PCP	NN	B-NP	O	S-drug_n
discrimination	discrimination	NN	I-NP	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
responses	response	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
short	short	JJ	O	O	O
(	(	(	O	O	O
<	<	SYM	O	O	O
3	3	CD	B-NP	O	O
s	s	NN	I-NP	O	O
)	)	)	O	O	O
interresponse	interresponse	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
increasing	increase	VBG	B-VP	O	O
overall	overall	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DRL	DRL	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
with	with	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PCP	PCP	NN	B-NP	B-protein	S-drug_n
in	in	IN	B-PP	O	O
either	either	DT	B-NP	O	O
procedure	procedure	NN	I-NP	O	O
even	even	RB	B-ADVP	O	O
when	when	WRB	I-ADVP	O	O
tested	test	VBN	B-VP	O	O
up	up	RP	B-PRT	O	O
to	to	TO	B-PP	O	O
doses	dose	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
produced	produce	VBD	B-VP	O	O
pharmacological	pharmacological	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
acute	acute	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
with	with	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
behaviors	behavior	NNS	B-NP	O	O
most	most	RBS	B-VP	O	O
closely	closely	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
PCP	PCP	NN	B-NP	O	S-drug_n
intoxication	intoxication	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
bring	bring	VBP	B-VP	O	O
into	into	IN	B-PP	O	O
question	question	NN	B-NP	O	O
the	the	DT	B-NP	O	O
utility	utility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
PCP	PCP	NN	B-NP	O	S-drug_n
combination	combination	NN	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
screen	screen	VB	I-VP	O	O
for	for	IN	B-PP	O	O
antipsychotic	antipsychotic	JJ	B-NP	O	O
potential	potential	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
chronic	chronic	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antipsychotics	antipsychotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
future	future	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
focus	focus	VB	I-VP	O	O
on	on	IN	B-PP	O	O
investigation	investigation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
PCP	PCP	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
resveratrol	resveratrol	NN	B-NP	O	S-drug_n
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
vasorelaxation	vasorelaxation	NN	I-NP	O	O
differs	differ	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mesenteric	mesenteric	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
arteries	artery	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lean	lean	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
obese	obese	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Resveratrol	Resveratrol	NN	B-NP	O	S-drug_n
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
vasorelaxation	vasorelaxation	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
(	(	(	I-NP	O	O
s	s	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
resveratrol	resveratrol	NN	B-NP	O	S-drug_n
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
vasorelaxation	vasorelaxation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
resistance	resistance	NN	B-NP	O	O
mesenteric	mesenteric	JJ	I-NP	O	O
arteries	artery	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
lean	lean	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
dietary	dietary	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
obese	obese	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Compared	Compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
lean	lean	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
arteries	artery	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
dietary	dietary	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
obese	obese	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
significant	significant	JJ	B-ADJP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	O	O	O
)	)	)	O	O	O
endothelial	endothelial	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
indicated	indicate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
maximal	maximal	JJ	B-NP	O	O
acetylcholine	acetylcholine	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
vasorelaxation	vasorelaxation	NN	I-NP	O	O
.	.	.	O	O	O

Resveratrol	Resveratrol	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
35	35	CD	I-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
)	)	)	O	O	O
induced	induce	VBD	B-VP	O	O
concentration	concentration	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
relaxation	relaxation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mesenteric	mesenteric	JJ	B-NP	O	O
arteries	artery	NNS	I-NP	O	O
preconstricted	preconstricte	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	O	S-drug
(	(	(	O	O	O
8	8	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
KCl	KCl	NN	B-NP	O	S-drug
(	(	(	O	O	O
125	125	CD	B-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
both	both	CC	B-NP	O	O
lean	lean	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
dietary	dietary	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
obese	obese	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
achieving	achieve	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
relaxation	relaxation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
>	>	JJR	B-NP	O	O
95	95	CD	I-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
35	35	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
L	L	NN	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
NAME	NAME	NN	B-NP	O	E-drug_n
(	(	(	O	O	O
100	100	CD	B-NP	O	O
and	and	CC	I-NP	O	O
300	300	CD	I-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
reseveratrol	reseveratrol	NN	B-NP	O	S-drug_n
on	on	IN	B-PP	O	O
arteries	artery	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
dietary	dietary	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
obese	obese	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
giving	give	VBG	B-VP	O	O
superimposed	superimpose	VBN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
responses	response	NNS	I-NP	O	O
curves	curve	NNS	I-NP	O	O
.	.	.	O	O	O

Indomethacin	Indomethacin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
ineffective	ineffective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
altering	alter	VBG	B-VP	O	O
resveratrol	resveratrol	NN	B-NP	O	S-drug_n
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
arteries	artery	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
both	both	CC	B-NP	O	O
lean	lean	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
dietary	dietary	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
obese	obese	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
precontracted	precontracte	VBN	I-NP	O	O
arteries	artery	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
dietary	dietary	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
obese	obese	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
responses	response	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
resveratrol	resveratrol	NN	B-NP	O	S-drug_n
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
attenuated	attenuate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
endothelial	endothelial	JJ	B-NP	O	O
denudation	denudation	NN	I-NP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
action	action	NN	I-NP	O	O
independent	independent	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
endothelium	endothelium	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
:	:	:	O	O	O
(	(	(	B-LST	O	O
a	a	LS	I-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
maximal	maximal	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
resveratrol	resveratrol	NN	B-NP	O	S-drug_n
on	on	IN	B-PP	O	O
resistance	resistance	NN	B-NP	O	O
arteries	artery	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
lean	lean	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
dietary	dietary	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
obese	obese	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
effected	effect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
endothelial	endothelial	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
(	(	(	B-LST	O	O
b	b	LS	I-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
resveratrol	resveratrol	NN	B-NP	O	S-drug_n
in	in	IN	B-PP	O	O
lean	lean	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
(	(	(	O	O	O
where	where	WRB	B-ADVP	O	O
endothelial	endothelial	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
impaired	impair	VBN	I-VP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
dietary	dietary	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
obese	obese	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
NO	NO	NN	B-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
taken	take	VBN	B-NP	O	O
1	1	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
(	(	(	O	O	O
IDV	IDV	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
didanosine	didanosine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
IDV	IDV	NN	B-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
,	,	,	O	O	O
despite	despite	IN	B-PP	O	O
persistent	persistent	JJ	B-NP	O	O
buffering	buffering	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
didanosine	didanosine	NN	I-NP	O	S-drug-ME-2
significantly	significantly	RB	B-ADVP	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
but	but	CC	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
how	how	WRB	B-ADVP	O	O
soon	soon	RB	I-ADVP	O	O
after	after	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
safely	safely	RB	B-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
compared	compare	VBD	B-VP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
and	and	CC	O	O	O
gastric	gastric	JJ	B-NP	O	O
pH	pH	NN	I-NP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
human	human	JJ	I-NP	O	O
immunodeficiency	immunodeficiency	NN	I-NP	O	O
virus	virus	NN	I-NP	O	O
-	-	HYPH	O	O	O
positive	positive	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
versus	versus	IN	B-NP	O	O
800	800	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
1	1	CD	B-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
gastric	gastric	JJ	I-NP	O	O
pH	pH	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug-ME-2
administration	administration	NN	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-cell_type	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
time	time	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
from	from	IN	B-PP	O	O
time	time	NN	B-NP	O	O
zero	zero	CD	B-NP	O	O
to	to	TO	I-NP	O	O
8	8	CD	I-NP	O	O
h	h	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Indinavir	Indinavir	NN	B-NP	O	S-drug-AD-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
light	light	JJ	I-NP	O	O
meal	meal	NN	I-NP	O	O
1	1	CD	I-NP	O	O
h	h	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
didanosine	didanosine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

A	A	DT	B-NP	O	O
proposed	propose	VBN	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cAMP	cAMP	NN	B-NP	O	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
by	by	IN	B-PP	O	O
carbachol	carbachol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Acid	Acid	NN	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
isolated	isolate	VBN	B-NP	O	O
rabbit	rabbit	NN	I-NP	O	O
gastric	gastric	JJ	I-NP	O	O
glands	gland	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
[	[	(	O	O	O
(	(	(	O	O	O
14	14	CD	O	O	O
)	)	)	O	O	O
C	C	NN	B-NP	O	O
]	]	)	O	O	O
aminopyrine	aminopyrine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Stimulation	Stimulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glands	gland	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
carbachol	carbachol	NN	B-NP	O	S-drug
synergistically	synergistically	RB	B-ADVP	O	O
augmented	augment	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
dibutyryl	dibutyryl	NN	B-NP	O	O
cAMP	cAMP	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
augmentation	augmentation	NN	I-NP	O	O
persisted	persist	VBD	B-VP	O	O
even	even	RB	B-ADVP	O	O
after	after	IN	B-SBAR	O	O
carbachol	carbachol	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
washed	wash	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
resistant	resistant	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
chelated	chelated	JJ	B-NP	O	O
extracellular	extracellular	JJ	I-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
and	and	CC	B-PP	O	O
to	to	TO	B-PP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
protein	protein	NN	B-NP	B-protein	O
kinase	kinase	NN	I-NP	I-protein	O
C	C	NN	I-NP	I-protein	O
or	or	CC	O	O	O
calmodulin	calmodulin	NN	B-NP	B-protein	O
kinase	kinase	NN	I-NP	I-protein	O
II	II	CD	I-NP	I-protein	O
.	.	.	O	O	O

Cytochalasin	Cytochalasin	NN	B-NP	O	B-drug_n-EF-1
D	D	NN	I-NP	O	E-drug_n-EF-1
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
microM	microM	NN	I-NP	O	O
preferentially	preferentially	RB	B-ADVP	O	O
blocked	block	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
secretory	secretory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbachol	carbachol	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
synergism	synergism	NN	I-NP	O	O
with	with	IN	B-PP	O	O
cAMP	cAMP	NN	B-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
it	it	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
histamine	histamine	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
or	or	CC	I-NP	O	O
cAMP	cAMP	NN	I-NP	O	O
-	-	HYPH	O	O	O
stimulated	stimulate	VBN	B-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
within	within	IN	B-PP	O	O
15	15	CD	B-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

Cytochalasin	Cytochalasin	NN	B-NP	O	B-drug_n-EF-1
D	D	NN	I-NP	O	E-drug_n-EF-1
inhibited	inhibit	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
carbachol	carbachol	NN	I-NP	O	S-drug-EF-2
-	-	HYPH	B-VP	O	O
stimulated	stimulate	VBN	B-NP	O	O
intracellular	intracellular	JJ	I-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
concentration	concentration	NN	B-NP	O	O
(	(	(	O	O	O
[	[	(	O	O	O
Ca	Ca	NN	O	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
]	]	)	O	O	O
(	(	(	B-LST	O	O
i	i	LS	I-LST	O	O
)	)	)	O	O	O
)	)	)	O	O	O
increase	increase	VBP	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
release	release	VB	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
store	store	NN	B-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glands	gland	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cytochalasin	cytochalasin	NN	B-NP	B-protein	B-drug_n
D	D	NN	I-NP	I-protein	E-drug_n
redistributed	redistribute	VBD	B-VP	I-protein	O
type	type	NN	B-NP	I-protein	O
3	3	CD	I-NP	I-protein	O
inositol	inositol	NN	I-NP	I-protein	O
1,4,5	1,4,5	CD	B-NP	I-protein	O
-	-	HYPH	I-NP	I-protein	O
trisphosphate	trisphosphate	NN	I-NP	I-protein	O
receptor	receptor	NN	I-NP	I-protein	O
(	(	(	O	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
subtype	subtype	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
parietal	parietal	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
containing	contain	VBG	B-VP	O	O
membranes	membrane	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
size	size	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
microsomal	microsomal	JJ	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
dissociation	dissociation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
store	store	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
intracellular	intracellular	JJ	B-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
release	release	NN	B-NP	O	O
by	by	IN	B-PP	O	O
cholinergic	cholinergic	JJ	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
critical	critical	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
determining	determine	VBG	B-VP	O	O
synergism	synergism	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cAMP	cAMP	NN	B-NP	O	O
in	in	IN	B-PP	O	O
parietal	parietal	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
activation	activation	NN	I-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
functional	functional	JJ	B-NP	O	O
coupling	coupling	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
store	store	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
actin	actin	NN	B-NP	B-protein	O
microfilaments	microfilament	NNS	I-NP	O	O
.	.	.	O	O	O

Interference	Interference	NN	B-NP	O	O
of	of	IN	B-PP	O	O
biocytin	biocytin	NN	B-NP	O	O
with	with	IN	B-PP	O	O
opioid	opioid	NN	B-NP	O	S-group
-	-	HYPH	B-NP	O	O
evoked	evoke	VBN	I-NP	O	O
hyperpolarization	hyperpolarization	NN	I-NP	O	O
and	and	CC	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rat	rat	NN	B-NP	B-protein	O
spinal	spinal	JJ	I-NP	I-protein	O
substantia	substantia	NN	I-NP	I-protein	O
gelatinosa	gelatinosa	NN	I-NP	I-protein	O
neurons	neuron	NNS	I-NP	I-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
,	,	,	O	O	O
preliminary	preliminary	JJ	B-NP	B-cell_type	O
whole	whole	JJ	I-NP	I-cell_type	O
-	-	HYPH	I-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
,	,	,	O	O	O
tight	tight	JJ	B-NP	O	O
seal	seal	NN	I-NP	O	O
recordings	recording	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rat	rat	NN	B-NP	B-protein	O
spinal	spinal	JJ	I-NP	I-protein	O
substantia	substantia	NN	I-NP	I-protein	O
gelatinosa	gelatinosa	NN	I-NP	I-protein	O
neurons	neuron	NNS	I-NP	I-protein	O
including	include	VBG	B-PP	I-protein	O
biocytin	biocytin	NN	B-NP	I-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patch	patch	NN	I-NP	O	O
pipette	pipette	NN	I-NP	O	O
yielded	yield	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significantly	significantly	RB	I-NP	O	O
smaller	small	JJR	I-NP	O	O
proportion	proportion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
hyperpolarized	hyperpolarize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
selective	selective	JJ	B-NP	O	B-group
opioid	opioid	JJ	I-NP	O	I-group
agonists	agonist	NNS	I-NP	O	E-group
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
recordings	recording	NNS	B-NP	B-protein	O
without	without	IN	B-PP	I-protein	O
biocytin	biocytin	NN	B-NP	I-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
biocytin	biocytin	NN	B-NP	O	O
inclusion	inclusion	NN	I-NP	O	O
on	on	IN	B-PP	O	O
opioid	opioid	JJ	B-NP	O	S-group
responses	response	NNS	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
membrane	membrane	NN	I-NP	O	O
properties	property	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
whole	whole	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
cell	cell	NN	I-NP	O	O
,	,	,	O	O	O
tight	tight	JJ	B-NP	O	O
seal	seal	NN	I-NP	O	O
recordings	recording	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
neurons	neuron	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
percentage	percentage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
hyperpolarized	hyperpolarize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
mu	mu	SYM	B-NP	O	B-group
-	-	HYPH	B-NP	O	E-group
,	,	,	O	O	O
delta	delta	NN	B-NP	O	B-group
(	(	(	O	O	I-group
1	1	CD	B-NP	O	I-group
)	)	)	O	O	I-group
-	-	HYPH	O	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
kappa	kappa	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
selective	selective	JJ	I-NP	O	I-group
opioids	opioid	NNS	I-NP	O	E-group
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-NP	O	O
<	<	JJR	I-NP	O	O

or	or	CC	O	O	O
=	=	SYM	B-NP	O	O
0.2	0.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
biocytin	biocytin	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recording	record	VBG	I-NP	O	O
pipette	pipette	NN	I-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	B-protein	O
recorded	record	VBN	B-VP	I-protein	O
without	without	IN	B-PP	I-protein	O
biocytin	biocytin	NN	B-NP	I-protein	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
significantly	significantly	RB	I-NP	O	O
higher	high	JJR	I-NP	O	O
proportion	proportion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
fired	fire	VBD	B-VP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
potentials	potential	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
either	either	CC	B-NP	O	O
0.05	0.05	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
0.2	0.2	CD	I-NP	O	O
or	or	CC	I-NP	O	O
1	1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
biocytin	biocytin	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
no	no	DT	B-NP	O	O
biocytin	biocytin	NN	I-NP	O	O
.	.	.	O	O	O

Resting	Rest	VBG	B-VP	O	O
membrane	membrane	NN	B-NP	O	O
potential	potential	NN	I-NP	O	O
,	,	,	O	O	O
input	input	NN	B-NP	O	O
impedance	impedance	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
proportion	proportion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
displaying	display	VBG	B-VP	O	O
transient	transient	JJ	B-NP	O	O
outward	outward	JJ	I-NP	O	O
rectification	rectification	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
each	each	DT	O	O	O
significantly	significantly	RB	B-VP	O	O
altered	alter	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
recorded	record	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-NP	O	O
0.05	0.05	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
0.2	0.2	CD	I-NP	O	O
%	%	NN	I-NP	O	O
biocytin	biocytin	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
relatively	relatively	RB	I-NP	O	O
specific	specific	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diverse	diverse	JJ	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
channel	channel	NN	I-NP	O	O
types	type	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
efficient	efficient	JJ	B-NP	O	O
labeling	labeling	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
achieved	achieve	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
0.1	0.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
biocytin	biocytin	NN	I-NP	O	O
with	with	IN	B-PP	O	O
whole	whole	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
cell	cell	NN	I-NP	O	O
recording	recording	NN	I-NP	O	O
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
stability	stability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nucleophosmin	nucleophosmin	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
B23	B23	NN	I-NP	B-protein	O
in	in	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
apoptotic	apoptotic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ras	ras	NN	B-NP	O	O
during	during	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
deprivation	deprivation	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
obtained	obtain	VBD	B-VP	O	O
evidence	evidence	NN	B-NP	O	O
that	that	IN	B-SBAR	O	O
increased	increase	VBN	B-NP	O	O
stability	stability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nucleophosmin	nucleophosmin	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
B23	B23	NN	I-NP	B-protein	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
antiapoptotic	antiapoptotic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ras	ras	NN	B-NP	O	O
during	during	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
deprivation	deprivation	NN	I-NP	O	O
.	.	.	O	O	O

Nucleophosmin	Nucleophosmin	NN	B-NP	B-protein	O
/	/	SYM	I-NP	O	O
B23	B23	NN	I-NP	B-protein	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
-	-	HYPH	O	O	O
deprived	deprive	VBN	B-VP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
)	)	)	O	O	O
NIH	NIH	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
3T3	3T3	NN	I-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
highly	highly	RB	B-ADJP	O	O
unstable	unstable	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
4	4	CD	I-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
nucleophosmin	nucleophosmin	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
B23	B23	NN	I-NP	B-protein	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
deprived	deprive	VBN	B-NP	I-protein	O
ras	ras	NN	I-NP	I-protein	O
-	-	HYPH	B-VP	O	O
transformed	transform	VBN	I-VP	B-cell_line	O
(	(	(	O	I-cell_line	O
RAS	RAS	NN	B-NP	I-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
3T3	3T3	NN	I-NP	I-cell_line	O
)	)	)	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
was	be	VBD	B-VP	O	O
as	as	RB	B-ADJP	O	O
stable	stable	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
-	-	HYPH	O	O	O
supplemented	supplement	VBN	B-NP	O	O
NIH	NIH	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
3T3	3T3	NN	I-NP	B-cell_line	O
or	or	CC	I-NP	O	O
RAS	RAS	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
3T3	3T3	NN	I-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
RAS	RAS	NN	B-NP	B-cell_line	O
-	-	HYPH	I-NP	I-cell_line	O
3T3	3T3	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
with	with	IN	B-PP	O	O
nucleophosmin	nucleophosmin	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
B23	B23	NN	I-NP	B-protein	O
antisense	antisense	JJ	I-NP	O	O
oligomer	oligomer	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
potentiated	potentiate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
deprivation	deprivation	NN	I-NP	O	O
.	.	.	O	O	O

Much	Much	RB	B-NP	O	O
less	less	JJR	I-NP	O	O
caspase	caspase	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
3	3	CD	B-NP	O	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lysate	lysate	NN	I-NP	O	O
derived	derive	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
serum	serum	NN	B-NP	B-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
deprived	deprive	VBN	I-NP	I-cell_line	O
RAS	RAS	NN	I-NP	I-cell_line	O
-	-	HYPH	I-NP	I-cell_line	O
3T3	3T3	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lysate	lysate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	B-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
deprived	deprive	VBN	I-NP	I-cell_line	O
NIH	NIH	NN	I-NP	I-cell_line	O
-	-	HYPH	I-NP	I-cell_line	O
3T3	3T3	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

Cell	Cell	NN	B-NP	B-protein	O
permeable	permeable	JJ	I-NP	I-protein	O
caspase	caspase	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
added	add	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medium	medium	NN	I-NP	O	O
blocked	block	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nucleophosmin	nucleophosmin	NN	B-NP	B-protein	O
/	/	SYM	B-NP	O	O
B23	B23	NN	I-NP	B-protein	O
and	and	CC	I-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
deprivation	deprivation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
NIH	NIH	NN	B-NP	B-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
3T3	3T3	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
promoted	promote	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nucleolin	nucleolin	NN	B-NP	B-protein	O
/	/	SYM	B-NP	O	O
C23	C23	NN	I-NP	B-protein	O
in	in	IN	B-PP	O	O
NIH	NIH	NN	B-NP	B-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
3T3	3T3	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
during	during	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
deprivation	deprivation	NN	I-NP	O	O
.	.	.	O	O	O

Unlike	Unlike	IN	B-PP	O	O
nucleolin	nucleolin	NN	B-NP	B-protein	O
/	/	SYM	B-NP	O	O
C23	C23	NN	I-NP	B-protein	O
,	,	,	O	O	O
down	down	RB	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nucleophosmin	nucleophosmin	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
B23	B23	NN	I-NP	B-protein	O
was	be	VBD	B-VP	O	O
thus	thus	RB	B-ADVP	O	O
not	not	RB	O	O	O
proliferation	proliferation	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
dependent	dependent	JJ	B-NP	O	O
but	but	CC	I-NP	O	O
caspase	caspase	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
-	-	HYPH	O	O	O
dependent	dependent	JJ	B-ADJP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
important	important	JJ	B-NP	O	O
relationships	relationship	NNS	I-NP	O	O
among	among	IN	B-PP	O	O
ras	ras	NN	B-NP	O	O
,	,	,	O	O	O
nucleophosmin	nucleophosmin	NN	B-NP	O	O
/	/	SYM	B-VP	O	O
B23	B23	NN	B-NP	B-protein	O
,	,	,	O	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
caspase	caspase	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
.	.	.	O	O	O

Suppression	Suppression	NN	B-NP	O	O
by	by	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-EF-1
of	of	IN	B-PP	O	O
bombesin	bombesin	NN	B-NP	O	S-drug_n-EF-2
-	-	HYPH	O	O	O
enhanced	enhance	VBN	B-VP	O	O
peritoneal	peritoneal	JJ	B-NP	O	O
metastasis	metastasis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
adenocarcinomas	adenocarcinoma	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
azoxymethane	azoxymethane	NN	B-NP	O	S-drug_n
in	in	IN	B-PP	O	O
wistar	wistar	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
combined	combined	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bombesin	bombesin	NN	B-NP	O	S-drug_n
and	and	CC	O	O	O
verapamil	verapamil	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
(	(	(	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blocker	blocker	NN	I-NP	O	E-group
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
peritoneal	peritoneal	JJ	B-NP	O	O
metastasis	metastasis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
adenocarcinomas	adenocarcinoma	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
azoxymethane	azoxymethane	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
AOM	AOM	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
labeling	labeling	NN	I-NP	O	O
index	index	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
cancers	cancer	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
From	From	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beginning	beginning	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
experiment	experiment	NN	I-NP	O	O
,	,	,	O	O	O
rats	rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
10	10	CD	B-NP	O	O
weekly	weekly	JJ	I-NP	O	O
subcutaneous	subcutaneous	JJ	I-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
AOM	AOM	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
7.4	7.4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
subcutaneous	subcutaneous	JJ	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bombesin	bombesin	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
40	40	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
every	every	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
from	from	IN	B-PP	O	O
week	week	NN	B-NP	O	O
16	16	CD	I-NP	O	O
,	,	,	O	O	O
intraperitoneal	intraperitoneal	JJ	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
or	or	CC	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
every	every	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
until	until	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
fo	fo	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
experiment	experiment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
week	week	NN	B-NP	O	O
45	45	CD	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Bombesin	Bombesin	NN	B-NP	O	S-drug_n
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
tumors	tumor	NNS	I-NP	O	O
and	and	CC	O	O	O
cancer	cancer	NN	B-NP	O	O
metastasis	metastasis	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
peritoneum	peritoneum	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
either	either	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
little	little	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
no	no	DT	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
carcinogenesis	carcinogenesis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
bombesin	bombesin	NN	B-NP	O	S-drug_n
or	or	CC	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
location	location	NN	I-NP	O	O
,	,	,	O	O	O
histologic	histologic	JJ	B-NP	O	O
type	type	NN	I-NP	O	O
,	,	,	O	O	O
depth	depth	NN	B-NP	O	O
of	of	IN	B-PP	O	O
involvement	involvement	NN	B-NP	O	O
,	,	,	O	O	O
labeling	label	VBG	B-VP	O	O
index	index	NN	B-NP	O	O
,	,	,	O	O	O
apoptotic	apoptotic	JJ	B-NP	O	O
index	index	NN	I-NP	O	O
or	or	CC	O	O	O
tumor	tumor	NN	B-NP	O	O
vascularity	vascularity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
cancers	cancer	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	O
metastasis	metastasis	NN	I-NP	O	O
.	.	.	O	O	O

Verapamil	Verapamil	NN	B-NP	O	S-drug-EF-1
also	also	RB	B-ADVP	O	O
significantly	significantly	RB	B-VP	O	O
decreased	decrease	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lymphatic	lymphatic	JJ	B-NP	O	O
invasion	invasion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adenocarcinomas	adenocarcinoma	NNS	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
bombesin	bombesin	NN	B-NP	O	S-drug_n-EF-2
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
cancer	cancer	NN	B-NP	O	O
metastasis	metastasis	NN	I-NP	O	O
through	through	IN	B-PP	O	O
actions	action	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
growth	growth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
cancers	cancer	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	B-protein	B-drug-IN-1
F2alpha	F2alpha	NN	I-NP	I-protein	E-drug-IN-1
and	and	CC	I-NP	O	O
oxytocin	oxytocin	NN	I-NP	O	S-drug-IN-2
in	in	IN	B-PP	O	O
placental	placental	JJ	B-NP	B-cell_type	O
vessels	vessel	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	B-protein	B-drug
F2alpha	F2alpha	NN	I-NP	I-protein	E-drug
and	and	CC	O	O	O
synthetic	synthetic	JJ	B-NP	O	O
oxytocin	oxytocin	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
placental	placental	JJ	B-NP	O	O
vessels	vessel	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Resistance	Resistance	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
near	near	IN	B-PP	O	O
the	the	DT	B-NP	O	O
placental	placental	JJ	I-NP	O	O
margin	margin	NN	I-NP	O	O
after	after	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
term	term	NN	I-NP	O	O
delivery	delivery	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
experiments	experiment	NNS	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
oxytocin	oxytocin	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
PGF2alpha	PGF2alpha	NN	B-NP	O	S-drug
.	.	.	O	O	O

PGF2alpha	PGF2alpha	NN	B-NP	O	S-drug-EF-1
produced	produce	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
increased	increase	VBN	I-NP	O	O
vasoconstriction	vasoconstriction	NN	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxytocin	oxytocin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
experiments	experiment	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
perfusion	perfusion	NN	I-NP	O	O
medium	medium	NN	I-NP	O	O
contained	contain	VBD	B-VP	O	O
oxytocin	oxytocin	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PGF2alpha	PGF2alpha	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
after	after	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
remained	remain	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
experiments	experiment	NNS	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
thus	thus	RB	B-ADVP	O	O
an	an	DT	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
thus	thus	RB	B-ADVP	O	O
an	an	DT	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PGF2alpha	PGF2alpha	NN	B-NP	B-protein	S-drug-EF-1
upon	upon	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
placental	placental	JJ	B-NP	B-cell_type	O
vessels	vessel	NNS	I-NP	I-cell_type	O
to	to	TO	B-PP	O	O
oxytocin	oxytocin	NN	B-NP	O	S-drug-EF-2
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
overdose	overdose	NN	I-NP	O	O
recognized	recognize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
assay	assay	NN	I-NP	O	O
.	.	.	O	O	O

Altered	Alter	VBN	B-NP	O	O
mental	mental	JJ	I-NP	O	O
status	status	NN	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adolescent	adolescent	NN	I-NP	O	O
presents	present	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
challenge	challenge	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
clinician	clinician	NN	I-NP	O	O
depends	depend	VBZ	B-VP	O	O
on	on	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
therapy	therapy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
prognosis	prognosis	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adolescent	adolescent	NN	I-NP	O	O
with	with	IN	B-PP	O	O
altered	altered	JJ	B-NP	O	O
consciousness	consciousness	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-EF-1
overdose	overdose	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group-EF-2
antidepressant	antidepressant	NN	I-NP	O	E-group-EF-2
level	level	NN	I-NP	O	O
to	to	TO	B-VP	O	O
alert	alert	VB	I-VP	O	O
clinicians	clinician	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
cross	cross	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
reactivity	reactivity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
toxicology	toxicology	NN	I-NP	O	O
screen	screen	NN	I-NP	O	O
for	for	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Cypermethrin	Cypermethrin	NN	B-NP	B-protein	S-drug-EF-1
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
brain	brain	NN	I-NP	O	O
and	and	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
prevented	prevent	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-drug-EF-2
E	E	NN	I-NP	O	E-drug-EF-2
or	or	CC	I-NP	O	O
allopurinol	allopurinol	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Considering	Consider	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reactive	reactive	JJ	B-NP	O	O
oxygen	oxygen	NN	I-NP	O	O
species	specie	NNS	I-NP	O	O
(	(	(	O	O	O
ROS	ROS	NN	B-NP	O	O
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
implicated	implicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
pesticides	pesticide	NNS	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
designed	design	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
induction	induction	NN	I-NP	O	O
by	by	IN	B-PP	O	O
cypermethrin	cypermethrin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
Type	Type	NN	I-NP	O	B-drug_n
II	II	CD	I-NP	O	I-drug_n
pyrethroid	pyrethroid	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

Either	Either	CC	O	O	O
single	single	JJ	B-ADJP	O	O
(	(	(	O	O	O
170	170	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
repeated	repeat	VBN	B-VP	O	O
(	(	(	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cypermethrin	cypermethrin	NN	B-NP	B-protein	S-drug
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
significant	significant	JJ	B-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
was	be	VBD	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thiobarbituric	thiobarbituric	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
reactive	reactive	JJ	I-NP	O	O
substances	substance	NNS	I-NP	O	O
(	(	(	O	O	O
TBARS	TBARS	NNS	B-NP	B-protein	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
tissues	tissue	NNS	I-NP	O	O
,	,	,	O	O	O
either	either	CC	O	O	O
4	4	CD	B-NP	O	O
or	or	CC	I-NP	O	O
24	24	CD	I-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Much	Much	RB	B-NP	O	O
higher	high	JJR	I-NP	O	O
changes	change	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
h	h	NN	I-NP	O	O
up	up	IN	B-PP	O	O
to	to	TO	B-PP	O	O
nearly	nearly	RB	B-NP	O	O
4	4	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
control	control	NN	I-NP	O	O
at	at	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
for	for	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Reduced	Reduce	VBN	B-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
glutathione	glutathione	NN	I-NP	O	O
(	(	(	O	O	O
total	total	JJ	B-NP	O	O
GSH	GSH	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
elevation	elevation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
conjugated	conjugate	VBN	B-NP	O	O
dienes	diene	NNS	I-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
by	by	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
h	h	NN	I-NP	O	O
)	)	)	O	O	O
also	also	RB	B-ADVP	O	O
indicated	indicate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
insult	insult	NN	I-NP	O	O
.	.	.	O	O	O

Glutathione	Glutathione	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
S	S	NN	I-NP	O	O
-	-	HYPH	O	O	O
transferase	transferase	NN	B-NP	O	O
(	(	(	O	O	O
GST	GST	NN	B-NP	B-protein	O
)	)	)	O	O	O
activity	activity	NN	B-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
differ	differ	VB	I-VP	O	O
from	from	IN	B-PP	O	O
control	control	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
any	any	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
or	or	CC	B-PP	O	O
at	at	IN	B-PP	O	O
any	any	DT	B-NP	O	O
time	time	NN	I-NP	O	O
point	point	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
.	.	.	O	O	O

Pretreatment	Pretreatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
ip	ip	JJ	B-ADJP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug-EF-1
E	E	NN	I-NP	O	E-drug-EF-1
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
,	,	,	O	O	O
ig	ig	NN	B-NP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
4th	4th	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
provided	provide	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
protection	protection	NN	I-NP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TBARS	TBARS	NN	B-NP	B-protein	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
,	,	,	O	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
cypermethrin	cypermethrin	NN	I-NP	O	S-drug-EF-2
administration	administration	NN	I-NP	O	O
within	within	IN	B-PP	O	O
4	4	CD	B-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
cypermethrin	cypermethrin	NN	B-NP	O	S-drug-EF-1
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
radical	radical	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
damage	damage	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
indicated	indicate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
cerebral	cerebral	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
lipid	lipid	NN	I-NP	O	O
peroxidation	peroxidation	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
prevented	prevent	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
allopurinol	allopurinol	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
Vitamin	Vitamin	NN	I-NP	O	B-drug-EF-2
E	E	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ginsenosides	ginsenoside	NNS	B-NP	O	S-drug_n
on	on	IN	B-PP	O	O
voltage	voltage	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
channel	channel	NN	B-NP	O	O
subtypes	subtype	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
bovine	bovine	JJ	B-NP	B-cell_type	O
chromaffin	chromaffin	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
we	we	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
ginsenosides	ginsenoside	NNS	B-NP	O	S-drug_n
inhibit	inhibit	VBP	B-VP	O	O
high	high	JJ	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
voltage	voltage	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
channels	channel	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
neuronal	neuronal	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
show	show	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
ginsenosides	ginsenoside	NNS	B-NP	O	S-drug_n
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ca	Ca	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
currents	current	NNS	B-NP	O	O
discriminates	discriminate	VBZ	B-VP	O	O
among	among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
various	various	JJ	I-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
channel	channel	NN	B-NP	O	O
subtypes	subtype	NNS	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
five	five	CD	I-NP	O	O
different	different	JJ	I-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
channel	channel	NN	B-NP	O	O
subtypes	subtype	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
neuronal	neuronal	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ginsenosides	ginsenoside	NNS	B-NP	O	S-drug_n
on	on	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
voltage	voltage	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
channel	channel	NN	B-NP	O	O
subtypes	subtype	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
their	their	PRP$	B-NP	O	O
selective	selective	JJ	I-NP	O	B-group
Ca	Ca	NN	I-NP	O	I-group
(	(	(	O	O	I-group
2	2	CD	O	O	I-group
+	+	SYM	O	O	I-group
)	)	)	O	O	I-group
channel	channel	NN	B-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
nimodipine	nimodipine	NN	B-NP	O	S-drug
(	(	(	O	O	O
L	L	NN	B-NP	O	O
-	-	HYPH	O	O	O
type	type	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
omega	omega	SYM	O	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
conotoxin	conotoxin	NN	B-NP	O	I-drug_n
GVIA	GVIA	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
N	N	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
type	type	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
omega	omega	SYM	O	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
agatoxin	agatoxin	NN	B-NP	O	I-drug_n
IVA	IVA	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
type	type	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
bovine	bovine	JJ	B-NP	B-cell_type	O
chromaffin	chromaffin	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
could	could	MD	B-VP	O	O
observe	observe	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
ginsenosides	ginsenoside	NNS	B-NP	O	S-drug_n
inhibited	inhibit	VBD	B-VP	O	O
high	high	JJ	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
voltage	voltage	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
currents	current	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
IC	IC	NN	I-NP	O	O
(	(	(	O	O	O
50	50	CD	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
about	about	IN	B-NP	O	O
120	120	CD	I-NP	O	O
microgram	microgram	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
.	.	.	O	O	O

Nimodipine	Nimodipine	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
ginsenosides	ginsenoside	NNS	B-NP	O	S-drug_n
response	response	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ginsenosides	ginsenoside	NNS	B-NP	O	S-drug_n
are	be	VBP	B-VP	O	O
negatively	negatively	RB	I-VP	O	O
coupled	couple	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
three	three	CD	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	B-protein	O
channels	channel	NNS	I-NP	I-protein	O
in	in	IN	B-PP	O	O
bovine	bovine	JJ	B-NP	B-cell_type	O
chromaffin	chromaffin	NN	I-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
an	an	DT	B-NP	O	O
omega	omega	SYM	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
conotoxin	conotoxin	NN	I-NP	O	I-drug_n
GVIA	GVIA	NN	I-NP	O	E-drug_n
-	-	HYPH	B-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
)	)	)	I-NP	O	O
channel	channel	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
omega	omega	SYM	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
agatoxin	agatoxin	NN	I-NP	O	I-drug_n
IVA	IVA	NN	I-NP	O	E-drug_n
-	-	HYPH	B-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
)	)	)	I-NP	O	O
channel	channel	NN	I-NP	O	O
and	and	CC	I-NP	O	O
nimodipine	nimodipine	NN	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
omega	omega	SYM	O	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
conotoxin	conotoxin	NN	B-NP	O	I-drug_n
GVIA	GVIA	NN	I-NP	O	E-drug_n
/	/	SYM	O	O	O
omega	omega	SYM	O	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
agatoxin	agatoxin	NN	B-NP	O	I-drug_n
VIA	VIA	NN	I-NP	O	E-drug_n
-	-	HYPH	O	O	O
resistant	resistant	JJ	O	O	O
(	(	(	O	O	O
presumptive	presumptive	JJ	B-NP	O	O
Q	Q	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
)	)	)	I-NP	O	O
channel	channel	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
voltage	voltage	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
subtypes	subtype	NNS	B-NP	O	O
by	by	IN	B-PP	O	O
ginsenosides	ginsenoside	NNS	B-NP	O	S-drug_n
in	in	IN	B-PP	O	O
bovine	bovine	JJ	B-NP	B-cell_type	O
chromaffin	chromaffin	NN	I-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cellular	cellular	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antistress	antistress	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ginseng	ginseng	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
KRM	KRM	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1648	1648	CD	I-NP	O	E-drug_n
,	,	,	O	O	O
either	either	CC	O	O	O
singly	singly	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ofloxacin	ofloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
against	against	IN	B-PP	O	O
Mycobacterium	Mycobacterium	NN	B-NP	O	O
ulcerans	ulceran	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
benzoxazinorifamycin	benzoxazinorifamycin	NN	I-NP	O	S-drug_n
,	,	,	O	O	O
KRM	KRM	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	O	O	I-drug_n
1648	1648	CD	B-NP	O	E-drug_n
,	,	,	O	O	O
either	either	CC	O	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ofloxacin	ofloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
against	against	IN	B-PP	O	O
two	two	CD	B-NP	O	O
type	type	NN	I-NP	O	O
strains	strain	NNS	I-NP	O	O
and	and	CC	O	O	O
six	six	CD	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
isolates	isolate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Mycobacterium	Mycobacterium	NN	B-NP	O	O
ulcerans	ulceran	NNS	I-NP	O	O
.	.	.	O	O	O

Growth	Growth	NN	B-NP	O	O
of	of	IN	B-PP	O	O
M	M	NN	B-NP	O	O
.	.	.	O	O	O

ulcerans	ulceran	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
plate	plate	NN	B-NP	O	O
counts	count	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
BACTEC	BACTEC	NN	I-NP	O	O
radiometric	radiometric	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
minimal	minimal	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
minimal	minimal	JJ	B-NP	O	O
bactericidal	bactericidal	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
KRM	KRM	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	O	O	I-drug_n
1648	1648	CD	B-NP	O	E-drug_n
against	against	IN	B-PP	O	O
M	M	NN	B-NP	O	O
.	.	.	O	O	O

ulcerans	ulceran	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
between	between	IN	B-PP	O	O
0.012	0.012	CD	B-NP	O	O
and	and	CC	I-NP	O	O
0.025	0.025	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
corresponding	correspond	VBG	B-VP	O	O
values	value	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.1	0.1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.8	0.8	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
and	and	CC	O	O	O
0.1	0.1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.4	0.4	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ofloxacin	ofloxacin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
KRM	KRM	NN	B-NP	B-protein	B-drug_n-EF-2
-	-	HYPH	O	O	I-drug_n-EF-2
1648	1648	CD	B-NP	O	E-drug_n-EF-2
exhibited	exhibit	VBD	B-VP	O	O
strong	strong	JJ	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
only	only	RB	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
or	or	CC	O	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
ofloxacin	ofloxacin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
KRM	KRM	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1648	1648	CD	I-NP	O	E-drug_n
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
great	great	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
M	M	NN	B-NP	O	O
.	.	.	O	O	O

ulcerans	ulceran	NNS	B-NP	O	O
infection	infection	NN	I-NP	O	O
.	.	.	O	O	O

Inhibitory	Inhibitory	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ruthenium	ruthenium	NN	B-NP	O	B-drug_n
red	red	VBN	B-VP	O	E-drug_n
on	on	IN	B-PP	O	O
inositol	inositol	NN	B-NP	O	O
1,4	1,4	CD	I-NP	O	O
,	,	,	I-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
trisphosphate	trisphosphate	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
responses	response	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	B-cell_type	O
megakaryocytes	megakaryocyte	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ruthenium	ruthenium	NN	B-NP	O	B-drug_n
red	red	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
RR	RR	NN	B-NP	B-protein	S-drug_n
)	)	)	O	O	O
on	on	IN	B-PP	O	O
inositol	inositol	NN	B-NP	B-protein	B-drug_n
1,4,5	1,4,5	CD	I-NP	I-protein	I-drug_n
-	-	HYPH	O	O	I-drug_n
trisphosphate	trisphosphate	NN	B-NP	O	E-drug_n
(	(	(	O	O	O
InsP	InsP	NN	B-NP	O	B-drug_n
(	(	(	O	O	I-drug_n
3	3	CD	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
responses	response	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	B-cell_type	O
bone	bone	NN	I-NP	I-cell_type	O
marrow	marrow	NN	I-NP	I-cell_type	O
megakaryocytes	megakaryocyte	NNS	I-NP	I-cell_type	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patch	patch	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
clamp	clamp	NN	I-NP	O	O
whole	whole	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
cell	cell	NN	I-NP	O	O
recording	recording	NN	I-NP	O	O
technique	technique	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
fura	fura	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
microfluorometry	microfluorometry	NN	I-NP	O	O
.	.	.	O	O	O

Internal	Internal	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
InsP	InsP	NN	B-NP	B-protein	B-drug_n
(	(	(	O	O	I-drug_n
3	3	CD	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
(	(	(	O	O	O
100	100	CD	B-NP	O	O
microM	microM	NN	I-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
intracellular	intracellular	JJ	B-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
concentration	concentration	NN	B-NP	O	O
(	(	(	O	O	O
[	[	(	O	O	O
Ca	Ca	NN	O	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
]	]	)	O	O	O
(	(	(	B-LST	O	O
i	i	LS	I-LST	O	O
)	)	)	O	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
activated	activate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
Ca	Ca	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
K	K	NN	I-NP	O	O
(	(	(	O	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
current	current	JJ	B-ADJP	O	O
.	.	.	O	O	O

Administering	Administer	VBG	B-VP	O	O
InsP	InsP	NN	B-NP	B-protein	B-drug_n-EF-1
(	(	(	O	O	I-drug_n-EF-1
3	3	CD	B-NP	O	I-drug_n-EF-1
)	)	)	O	O	E-drug_n-EF-1
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
RR	RR	NN	B-NP	O	S-drug_n-EF-2
(	(	(	O	O	O
100	100	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
500	500	CD	I-NP	O	O
microM	microM	NN	I-NP	O	O
)	)	)	O	O	O
inhibited	inhibit	VBD	B-VP	O	O
InsP	InsP	NN	B-NP	B-protein	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
responses	response	NNS	I-NP	O	O
(	(	(	O	O	O
both	both	CC	O	O	O
Ca	Ca	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
current	current	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
fashion	fashion	NN	I-NP	O	O
.	.	.	O	O	O

Pretreatment	Pretreatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
megakaryocytes	megakaryocyte	NNS	B-NP	B-cell_type	O
with	with	IN	B-PP	O	O
extracellular	extracellular	JJ	B-NP	O	O
RR	RR	NN	I-NP	O	S-drug_n-EF-1
(	(	(	O	O	O
50	50	CD	B-NP	O	O
microM	microM	NN	I-NP	O	O
)	)	)	O	O	O
also	also	RB	B-ADVP	O	O
inhibited	inhibit	VBD	B-VP	O	O
InsP	InsP	NN	B-NP	B-protein	B-drug_n-EF-2
(	(	(	O	O	I-drug_n-EF-2
3	3	CD	B-NP	O	I-drug_n-EF-2
)	)	)	O	O	E-drug_n-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
responses	response	NNS	I-NP	O	O
.	.	.	O	O	O

Intracellular	Intracellular	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
extracellular	extracellular	JJ	I-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
RR	RR	NN	B-NP	B-protein	S-drug_n
reduced	reduce	VBD	B-VP	O	O
ADP	ADP	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
[	[	(	O	O	O
Ca	Ca	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
+	+	SYM	O	O	O
)	)	)	O	O	O
]	]	)	O	O	O
(	(	(	O	O	O
i	i	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
isolated	isolate	VBN	B-NP	B-cell_type	O
single	single	JJ	I-NP	I-cell_type	O
pancreatic	pancreatic	JJ	I-NP	I-cell_type	O
acinar	acinar	JJ	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
RR	RR	NN	B-NP	B-protein	S-drug_n
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
InsP	InsP	NN	B-NP	B-protein	B-drug_n
(	(	(	O	O	I-drug_n
3	3	CD	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
responses	response	NNS	I-NP	O	O
.	.	.	O	O	O

Taken	Take	VBN	B-VP	O	O
together	together	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
site	site	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
RR	RR	NN	B-NP	B-protein	S-drug_n
is	be	VBZ	B-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
InsP	InsP	NN	I-NP	B-protein	O
(	(	(	O	I-protein	O
3	3	CD	B-NP	I-protein	O
)	)	)	O	I-protein	O
receptor	receptor	NN	B-NP	I-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
closely	closely	RB	I-NP	O	O
associated	associate	VBN	I-NP	O	O
proteins	protein	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
RR	RR	NN	B-NP	B-protein	S-drug_n
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
useful	useful	JJ	I-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
tool	tool	NN	I-NP	O	O
with	with	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
InsP	InsP	NN	I-NP	O	B-drug_n
(	(	(	O	O	I-drug_n
3	3	CD	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
responses	response	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
megakaryocytes	megakaryocyte	NNS	B-NP	B-cell_type	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cyclooxygenase	cyclooxygenase	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
(	(	(	O	O	O
COX	COX	NN	B-NP	O	O
-	-	HYPH	O	O	O
2	2	CD	O	O	O
)	)	)	O	O	O
inhibitor	inhibitor	NN	B-NP	O	O
,	,	,	O	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug
,	,	,	O	O	O
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subject	subject	NN	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug
(	(	(	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
for	for	IN	B-PP	O	O
11	11	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	O	O	O
randomized	randomize	VBN	B-VP	O	O
,	,	,	O	O	O
balanced	balance	VBN	B-VP	O	O
,	,	,	O	O	O
two	two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
period	period	NN	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
0.5	0.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
elixir	elixir	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
7th	7th	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
11	11	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
period	period	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
separated	separate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
14	14	CD	B-NP	O	O
to	to	TO	I-NP	O	O
21	21	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Samples	Sample	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
immunoreactive	immunoreactive	JJ	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
collected	collect	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
120	120	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
groups	group	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
calculated	calculate	VBN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
infinity	infinity	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	O	O	O
24	24	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
geometric	geometric	JJ	I-NP	O	O
mean	mean	JJ	I-NP	O	O
ratios	ratio	NNS	I-NP	O	O
(	(	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
(	(	(	O	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug
+	+	SYM	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
/	/	SYM	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
1.04	1.04	CD	B-NP	O	O
(	(	(	O	O	O
0.94	0.94	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.14	1.14	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
1.02	1.02	CD	B-NP	O	O
(	(	(	O	O	O
0.94	0.94	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.09	1.09	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
1.00	1.00	CD	B-NP	O	O
(	(	(	O	O	O
0.91	0.91	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.10	1.10	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
median	median	JJ	I-NP	O	O
tmax	tmax	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
0.5	0.5	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
both	both	DT	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
harmonic	harmonic	JJ	I-NP	O	O
mean	mean	JJ	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
45.7	45.7	CD	B-NP	O	O
and	and	CC	I-NP	O	O
43.4	43.4	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug
+	+	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
treatments	treatment	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
renally	renally	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
(	(	(	O	O	O
SD	SD	NN	B-NP	O	O
)	)	)	O	O	O
cumulative	cumulative	JJ	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
immunoreactive	immunoreactive	JJ	B-NP	B-protein	O
digoxin	digoxin	NN	I-NP	I-protein	S-drug
after	after	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
rofecoxib	rofecoxib	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
228.2	228.2	CD	B-NP	O	O
(	(	(	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
30.8	30.8	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
235.1	235.1	CD	B-NP	O	O
(	(	(	O	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
39.1	39.1	CD	O	O	O
)	)	)	O	O	O
micrograms	microgram	NNS	B-NP	O	O
/	/	SYM	O	O	O
120	120	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Transient	Transient	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
minor	minor	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
on	on	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
and	and	CC	I-NP	O	O
rofecoxib	rofecoxib	NN	I-NP	O	S-drug
treatments	treatment	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
-	-	HYPH	B-PP	O	O
related	relate	VBN	B-NP	O	O
pattern	pattern	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
apparent	apparent	JJ	B-ADJP	O	O
.	.	.	O	O	O

Rofecoxib	Rofecoxib	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
or	or	CC	O	O	O
renal	renal	JJ	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
cyclophosphamide	cyclophosphamide	NN	I-NP	O	S-drug
,	,	,	O	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
vincristine	vincristine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
prednisone	prednisone	NN	B-NP	O	S-drug
chemotherapy	chemotherapy	NN	I-NP	O	O
plus	plus	CC	O	O	O
highly	highly	RB	B-NP	O	B-group
active	active	JJ	I-NP	O	I-group
antiretroviral	antiretroviral	JJ	I-NP	O	E-group
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
immunodeficiency	immunodeficiency	NN	I-NP	O	O
virus	virus	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-VP	O	O
,	,	,	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
Hodgkin	Hodgkin	NN	I-NP	O	O
lymphoma	lymphoma	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
feasibility	feasibility	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
and	and	CC	O	O	O
highly	highly	RB	B-NP	O	B-group
active	active	JJ	I-NP	O	I-group
antiretroviral	antiretroviral	JJ	I-NP	O	E-group
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
HAART	HAART	NN	B-NP	B-protein	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
still	still	RB	B-ADVP	O	O
unknown	unknown	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
immunodeficiency	immunodeficiency	NN	I-NP	O	O
virus	virus	NN	I-NP	O	O
(	(	(	O	O	O
HIV	HIV	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
related	related	JJ	I-NP	O	O
malignancies	malignancy	NNS	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
impact	impact	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
plus	plus	CC	I-NP	O	O
HAART	HAART	NN	I-NP	B-protein	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
related	relate	VBN	I-ADJP	O	O
,	,	,	O	O	O
systemic	systemic	JJ	B-ADJP	O	O
,	,	,	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
Hodgkin	Hodgkin	NN	B-NP	O	O
lymphoma	lymphoma	NN	I-NP	O	O
(	(	(	O	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
NHL	NHL	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
compared	compare	VBD	B-VP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
24	24	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
NHL	NHL	NN	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cyclophosphamide	cyclophosphamide	NN	I-NP	O	S-drug
,	,	,	O	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
vincristine	vincristine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
prednisone	prednisone	NN	B-NP	O	S-drug
(	(	(	O	O	O
CHOP	CHOP	NN	B-NP	O	O
)	)	)	O	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
plus	plus	CC	O	O	O
HAART	HAART	NN	B-NP	B-protein	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
80	80	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CHOP	CHOP	NN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
CHOP	CHOP	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
teniposide	teniposide	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
prednisone	prednisone	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	O	S-drug
plus	plus	CC	O	O	O
bleomycin	bleomycin	NN	B-NP	O	S-drug
)	)	)	O	O	O
without	without	IN	B-PP	O	O
receiving	receive	VBG	B-VP	O	O
antiretroviral	antiretroviral	JJ	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
enrolled	enrol	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
sequential	sequential	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
performed	perform	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Aviano	Aviano	NNP	I-NP	O	O
Cancer	Cancer	NNP	I-NP	O	O
Center	Center	NNP	I-NP	O	O
,	,	,	O	O	O
Italy	Italy	NNP	B-NP	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
April	April	NNP	B-NP	O	O
1988	1988	CD	I-NP	O	O
to	to	TO	B-PP	O	O
December	December	NNP	B-NP	O	O
1998	1998	CD	I-NP	O	O
.	.	.	O	O	O

HAART	HAART	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
from	from	IN	B-PP	O	O
January	January	NNP	B-NP	O	O
1997	1997	CD	I-NP	O	O
.	.	.	O	O	O

Antiretroviral	Antiretroviral	JJ	B-NP	O	S-group
regimens	regimen	NNS	I-NP	O	O
consisted	consist	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
reverse	reverse	JJ	I-NP	B-protein	B-group
transcriptase	transcriptase	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
protease	protease	NN	I-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
two	two	CD	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
matched	match	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
regard	regard	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patient	patient	NN	B-NP	O	O
demographics	demographic	NNS	I-NP	O	O
,	,	,	O	O	O
NHL	NHL	NN	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
,	,	,	O	O	O
HIV	HIV	NN	B-NP	O	O
status	status	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cycles	cycle	NNS	B-NP	O	O
and	and	CC	O	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
response	response	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Severe	Severe	JJ	B-NP	O	O
anemia	anemia	NN	I-NP	O	O
(	(	(	O	O	O
Grade	Grade	NN	B-NP	B-protein	O
3	3	CD	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
4	4	CD	I-NP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
World	World	NNP	I-NP	O	O
Health	Health	NNP	I-NP	O	O
Organization	Organization	NNP	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
CHOP	CHOP	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
HAART	HAART	NN	I-NP	B-protein	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
CHOP	CHOP	NN	B-NP	B-protein	O
alone	alone	RB	B-ADVP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs.	vs.	IN	B-PP	O	O
7	7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Leukopenia	Leukopenia	NNP	B-NP	O	O
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
colony	colony	NN	B-NP	O	O
stimulating	stimulating	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
support	support	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CHOP	CHOP	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
HAART	HAART	NN	I-NP	O	O
group	group	NN	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
92	92	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs.	vs.	IN	B-PP	O	O
66	66	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.03	0.03	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Seventeen	Seventeen	CD	B-NP	O	O
percent	percent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CHOP	CHOP	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
HAART	HAART	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
severe	severe	JJ	B-NP	O	O
autonomic	autonomic	JJ	I-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
none	none	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CHOP	CHOP	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
neurotoxicity	neurotoxicity	NN	B-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.002	0.002	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
median	median	JJ	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
,	,	,	O	O	O
opportunistic	opportunistic	JJ	B-NP	O	O
infection	infection	NN	I-NP	O	O
(	(	(	O	O	O
OI	OI	NN	B-NP	O	O
)	)	)	O	O	O
rates	rate	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CHOP	CHOP	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
HAART	HAART	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CHOP	CHOP	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs.	vs.	IN	B-PP	O	O
52	52	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.05	0.05	CD	B-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs.	vs.	IN	B-PP	O	O
85	85	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
for	for	IN	B-PP	O	O
CHOP	CHOP	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
HAART	HAART	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reached	reach	VBN	I-VP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
medial	medial	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CHOP	CHOP	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
7	7	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.03	0.03	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CHOP	CHOP	NN	B-NP	B-protein	O
plus	plus	CC	I-NP	O	O
HAART	HAART	NN	I-NP	B-protein	O
is	be	VBZ	B-VP	O	O
feasible	feasible	JJ	B-ADJP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
morbidity	morbidity	NN	I-NP	O	O
from	from	IN	B-PP	O	O
OIs	OI	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	O	O	O
NHL	NHL	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
directed	direct	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
cross	cross	VB	I-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
antiretroviral	antiretroviral	JJ	B-NP	O	S-group-AD-1
and	and	CC	I-NP	O	O
antineoplastic	antineoplastic	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
impact	impact	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combined	combine	VBN	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
plus	plus	CC	I-NP	O	O
HAART	HAART	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
on	on	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
survival	survival	NN	I-NP	O	O
needs	need	VBZ	B-VP	O	O
urgently	urgently	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
prospective	prospective	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
on	on	IN	B-PP	O	O
glycemia	glycemia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-ADJP	O	O
and	and	CC	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Diabetic	Diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
higher	high	JJR	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
depression	depression	NN	B-NP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
antidepressant	antidepressant	JJ	B-NP	O	B-group-IN-1
drugs	drug	NNS	I-NP	O	E-group-IN-1
can	can	MD	B-VP	O	O
directly	directly	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
or	or	CC	O	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
hypoglycemic	hypoglycemic	JJ	B-NP	O	B-group-IN-2
agents	agent	NNS	I-NP	O	E-group-IN-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
depression	depression	NN	B-NP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
take	take	VB	I-VP	O	O
into	into	IN	B-PP	O	O
account	account	NN	B-NP	O	O
variations	variation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
glycemic	glycemic	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
times	time	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
comparison	comparison	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
available	available	JJ	I-NP	O	O
antidepressant	antidepressant	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
important	important	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
interference	interference	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	S-group
with	with	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diabetic	diabetic	JJ	O	O	O
and	and	CC	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
experiment	experiment	NN	I-NP	O	O
,	,	,	O	O	O
male	male	JJ	B-NP	O	O
adult	adult	JJ	I-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
fasted	fast	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
12	12	CD	B-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

Imipramine	Imipramine	NN	B-NP	O	S-drug
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
moclobemide	moclobemide	NN	B-NP	O	S-drug
(	(	(	O	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
clonazepam	clonazepam	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
(	(	(	O	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
vehicle	vehicle	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
,	,	,	O	O	O
fasting	fast	VBG	B-VP	O	O
glycemia	glycemia	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
glucose	glucose	NN	I-NP	O	S-drug
overload	overload	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
glucose	glucose	NN	I-NP	O	S-drug
solution	solution	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
and	and	CC	O	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
30	30	CD	B-NP	O	O
,	,	,	I-NP	O	O
60	60	CD	I-NP	O	O
and	and	CC	I-NP	O	O
90	90	CD	I-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

Imipramine	Imipramine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
clonazepam	clonazepam	NN	I-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
fasting	fast	VBG	I-VP	O	O
or	or	CC	O	O	O
overload	overload	JJ	B-NP	O	O
glycemia	glycemia	NN	I-NP	O	O
.	.	.	O	O	O

Fluoxetine	Fluoxetine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
moclobemide	moclobemide	NN	I-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	S-drug
at	at	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
times	time	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
overload	overload	NN	I-NP	O	O
.	.	.	O	O	O

Sertraline	Sertraline	NN	B-NP	O	S-drug
neutralized	neutralize	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glycemia	glycemia	NN	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
glucose	glucose	NN	I-NP	O	S-drug
overload	overload	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
experiment	experiment	NN	I-NP	O	O
,	,	,	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
streptozotocin	streptozotocin	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
fasted	fast	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
estimation	estimation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
glucose	glucose	NN	B-NP	B-protein	S-drug
tolerance	tolerance	NN	I-NP	I-protein	O
30	30	CD	I-NP	I-protein	O
min	min	NN	I-NP	I-protein	O
after	after	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	S-drug
overload	overload	NN	I-NP	O	O
.	.	.	O	O	O

Again	Again	RB	B-ADVP	O	O
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
neutralized	neutralize	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
glycemia	glycemia	NN	B-NP	O	O
after	after	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	S-drug
overload	overload	NN	I-NP	O	O
both	both	CC	B-PP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-ADJP	O	O
and	and	CC	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
raise	raise	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
question	question	NN	I-NP	O	O
of	of	IN	B-PP	O	O
whether	whether	IN	B-SBAR	O	O
sertraline	sertraline	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
best	good	JJS	I-NP	O	O
choice	choice	NN	I-NP	O	O
for	for	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
for	for	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
antihyperglycemic	antihyperglycemic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Clonazepam	Clonazepam	NN	B-NP	O	S-drug
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

Activity	Activity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
buforin	buforin	NN	B-NP	B-protein	B-drug_n
II	II	CD	I-NP	I-protein	E-drug_n
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
minocycline	minocycline	NN	I-NP	O	S-drug
against	against	IN	B-PP	O	O
Cryptosporidium	Cryptosporidium	NN	B-NP	O	O
parvum	parvum	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cell	cell	NN	B-NP	B-cell_line	O
culture	culture	NN	I-NP	I-cell_line	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
anti	anti	AFX	O	O	O
-	-	HYPH	O	O	O
cryptosporidial	cryptosporidial	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
buforin	buforin	NN	B-NP	B-protein	B-drug_n
II	II	CD	I-NP	I-protein	E-drug_n
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
minocycline	minocycline	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Buforin	Buforin	NN	B-NP	B-protein	B-drug_n
II	II	CD	I-NP	I-protein	E-drug_n
showed	show	VBD	B-VP	O	O
moderate	moderate	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
increased	increase	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
increasing	increase	VBG	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
55.7	55.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
growth	growth	NN	B-NP	O	O
at	at	IN	B-PP	O	O
20	20	CD	B-NP	O	O
microM	microM	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
or	or	CC	O	O	O
minocycline	minocycline	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
parasite	parasite	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
tested	test	VBN	B-VP	O	O
.	.	.	O	O	O

Buforin	Buforin	NN	B-NP	B-protein	B-drug_n-EF-1
II	II	CD	I-NP	I-protein	E-drug_n-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
active	active	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
Cryptosporidium	Cryptosporidium	NN	B-NP	O	O
parvum	parvum	NN	I-NP	O	O
growth	growth	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
upon	upon	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
minocycline	minocycline	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dofetillide	dofetillide	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
,	,	,	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
variables	variable	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dofetilide	dofetilide	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
necessitate	necessitate	VB	I-VP	O	O
an	an	DT	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Anaesthesia	Anaesthesia	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
epileptic	epileptic	JJ	I-NP	O	O
pateint	pateint	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
review	review	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
review	review	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
presented	present	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
problems	problem	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
arise	arise	VB	I-VP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
anaesthesia	anaesthesia	NN	B-NP	O	O
for	for	IN	B-PP	O	O
epileptic	epileptic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
precipitating	precipitate	VBG	B-VP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Numerous	Numerous	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
some	some	DT	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenobarbitone	phenobarbitone	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
affect	affect	VBP	B-VP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
microsomal	microsomal	JJ	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
systems	system	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	O
occurring	occur	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
susceptible	susceptible	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
anaesthetic	anaesthetic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
inducing	induce	VBG	B-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
excitability	excitability	NN	I-NP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
halothane	halothane	NN	I-NP	O	S-drug-IN-2
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intramuscularly	intramuscularly	RB	B-NP	O	O
injected	inject	VBN	I-NP	O	O
ketamine	ketamine	NN	I-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
N	N	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
demethylated	demethylate	VBN	I-VP	O	O
metabolite	metabolite	NN	B-NP	O	O
(	(	(	O	O	O
metabolite	metabolite	NN	B-NP	O	O
I	I	CD	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
,	,	,	I-NP	O	O
10	10	CD	I-NP	O	O
,	,	,	I-NP	O	O
20	20	CD	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
20	20	CD	B-NP	O	O
,	,	,	I-NP	O	O
50	50	CD	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metabolite	metabolite	NN	B-NP	O	O
I	I	CD	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
produced	produce	VBD	B-VP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
10	10	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypnosis	hypnosis	NN	B-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
halothane	halothane	NN	B-NP	O	S-drug-ME-1
anesthetic	anesthetic	NN	I-NP	O	O
requirement	requirement	NN	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	I-NP	O	O
MAC	MAC	NN	I-NP	B-protein	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
depressed	depress	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
fashion	fashion	NN	I-NP	O	O
as	as	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
as	as	IN	I-NP	O	O
56	56	CD	I-NP	O	O
%	%	NN	I-NP	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
and	and	CC	O	O	O
as	as	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
as	as	IN	I-NP	O	O
14	14	CD	I-NP	O	O
%	%	NN	I-NP	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
im	im	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
MAC	MAC	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
correlated	correlate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
brain	brain	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
metabolite	metabolite	NN	B-NP	O	O
I	I	CD	I-NP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
ketamine	ketamine	NN	I-NP	O	S-drug
:	:	:	O	O	O
metabolite	metabolite	NN	B-NP	O	O
I	I	CD	I-NP	O	O
potency	potency	NN	I-NP	O	O
ration	ration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
3	3	CD	B-NP	O	O
:	:	:	O	O	O
1	1	CD	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug-ME-1
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-cell_type	O
and	and	CC	I-NP	O	O
brain	brain	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
longer	longer	RBR	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug-ME-2
than	than	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
ketamine	ketamine	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
acting	act	VBG	I-NP	O	O
drug	drug	NN	I-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug-EF-2
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
further	further	RBR	B-ADVP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
action	action	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-IN-2
:	:	:	O	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-IN-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
well	well	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	B-protein	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-ME-2
requirements	requirement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
ingesting	ingest	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
unusually	unusually	RB	I-NP	O	O
high	high	JJ	I-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Withdrawal	Withdrawal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-ME-2
requirement	requirement	NN	I-NP	O	O
by	by	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
microsomal	microsomal	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
and	and	CC	O	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
catabolism	catabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-EF-1
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
requirement	requirement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
maximal	maximal	JJ	B-NP	O	O
5	5	CD	I-NP	O	O
to	to	TO	I-NP	O	O
7	7	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
extended	extend	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
length	length	NN	I-NP	O	O
of	of	IN	B-PP	O	O
time	time	NN	B-NP	O	O
after	after	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
withdrawal	withdrawal	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
.	.	.	O	O	O

Thiolated	Thiolate	VBN	B-NP	O	B-drug_n
carboxymethylcellulose	carboxymethylcellulose	NN	I-NP	O	E-drug_n
:	:	:	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
permeation	permeation	NN	I-NP	O	O
enhancing	enhance	VBG	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
peptide	peptide	NN	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug_n
carboxymethylcellulose	carboxymethylcellulose	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
NaCMC	NaCMC	NN	B-NP	B-protein	S-drug_n
)	)	)	O	O	O
and	and	CC	O	O	O
carboxymethylcellulose	carboxymethylcellulose	NN	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
cysteine	cysteine	NN	B-NP	O	E-drug_n
(	(	(	O	O	O
CMC	CMC	NN	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
Cys	Cys	NN	I-NP	O	E-drug_n
)	)	)	O	O	O
conjugates	conjugate	VBZ	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
permeation	permeation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B-protein	B-drug
fluorescein	fluorescein	NN	I-NP	I-protein	E-drug
(	(	(	O	O	O
NaFlu	NaFlu	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
model	model	NN	B-NP	O	O
peptide	peptide	NN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
bacitracin	bacitracin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
.	.	.	O	O	O

Cysteine	Cysteine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
covalently	covalently	RB	I-VP	O	O
linked	link	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
carbodiimide	carbodiimide	NN	B-NP	B-protein	O
activated	activated	JJ	I-NP	I-protein	O
NaCMC	NaCMC	NN	I-NP	I-protein	S-drug_n
.	.	.	O	O	O

Iodometric	Iodometric	JJ	B-NP	O	O
titration	titration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
polymer	polymer	NN	I-NP	O	O
conjugates	conjugate	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
immobilised	immobilised	JJ	B-NP	O	O
cysteine	cysteine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Permeation	Permeation	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
guinea	guinea	NN	B-NP	O	O
pig	pig	NN	I-NP	O	O
small	small	JJ	I-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
mucosa	mucosa	NN	I-NP	O	O
mounted	mount	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
Ussing	Usse	VBG	B-VP	O	O
-	-	HYPH	B-NP	O	O
type	type	NN	I-NP	O	O
chamber	chamber	NN	I-NP	O	O
.	.	.	O	O	O

Unmodified	Unmodified	JJ	B-NP	O	O
NaCMC	NaCMC	NN	I-NP	O	S-drug_n
(	(	(	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
m	m	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
v	v	NN	I-NP	O	O
)	)	)	O	O	O
significantly	significantly	RB	B-ADVP	O	O
improved	improve	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
transport	transport	NN	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	O	O	O
P	P	NN	B-NP	O	O
(	(	(	O	O	O
app	app	NN	B-NP	O	O
)	)	)	O	O	O
polymer	polymer	NN	B-NP	O	O
/	/	SYM	O	O	O
P	P	NN	B-NP	O	O
(	(	(	O	O	O
app	app	NN	B-NP	O	O
)	)	)	O	O	O
control	control	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
NaFlu	NaFlu	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
1.3	1.3	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1	1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
m	m	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
v	v	NN	I-NP	O	O
)	)	)	O	O	O
NaCMC	NaCMC	NN	B-NP	O	S-drug_n
conjugated	conjugate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
cysteine	cysteine	NN	B-NP	O	S-drug
further	further	RBR	B-ADVP	O	O
enhanced	enhance	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
permeation	permeation	NN	I-NP	O	O
.	.	.	O	O	O

Cysteine	Cysteine	NN	B-NP	O	S-drug
conjugation	conjugation	NN	I-NP	O	O
at	at	IN	B-PP	O	O
3.6	3.6	CD	B-NP	O	O
,	,	,	I-NP	O	O
5.3	5.3	CD	I-NP	O	O
and	and	CC	I-NP	O	O
7.3	7.3	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
m	m	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
R	R	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
1.4	1.4	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.7	1.7	CD	I-NP	O	O
and	and	CC	I-NP	O	O
1.8	1.8	CD	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Decreasing	Decrease	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CMC	CMC	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
Cys	Cys	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
exhibiting	exhibit	VBG	B-VP	O	O
7.3	7.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
m	m	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
immobilised	immobilised	JJ	B-NP	O	O
cysteine	cysteine	NN	I-NP	O	S-drug
(	(	(	O	O	O
CMC	CMC	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
Cys7.3	Cys7.3	NN	I-NP	B-protein	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
m	m	NN	B-NP	O	O
/	/	SYM	O	O	O
v	v	NN	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
m	m	NN	B-NP	O	O
/	/	SYM	O	O	O
v	v	NN	B-NP	O	O
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
R	R	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NaFlu	NaFlu	NN	B-NP	O	S-drug
from	from	IN	B-PP	O	O
1.8	1.8	CD	B-NP	O	O
to	to	TO	B-PP	O	O
1.2	1.2	CD	B-NP	O	O
.	.	.	O	O	O

NaCMC	NaCMC	NN	B-NP	O	S-drug_n
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
m	m	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
v	v	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
cysteine	cysteine	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
R	R	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NaFlu	NaFlu	NN	B-NP	O	S-drug
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
NaCMC	NaCMC	NN	B-NP	B-protein	S-drug_n
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Formulation	Formulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fluorescence	fluorescence	NN	B-NP	O	O
labelled	label	VBN	I-NP	O	O
bacitracin	bacitracin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
in	in	IN	B-PP	O	O
unconjugated	unconjugated	JJ	B-NP	O	O
NaCMC	NaCMC	NN	I-NP	O	S-drug_n
(	(	(	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
m	m	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
v	v	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
improve	improve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
permeation	permeation	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
m	m	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
v	v	NN	I-NP	O	O
)	)	)	O	O	O
CMC	CMC	NN	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
Cys7.3	Cys7.3	NN	I-NP	B-protein	O
a	a	DT	B-NP	O	O
significantly	significantly	RB	I-NP	O	O
improved	improve	VBN	I-NP	O	O
permeation	permeation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
1.3	1.3	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Conjugation	Conjugation	NN	B-NP	O	O
at	at	IN	B-PP	O	O
NaCMC	NaCMC	NN	B-NP	O	S-drug_n
with	with	IN	B-PP	O	O
cysteine	cysteine	NN	B-NP	B-protein	S-drug
moieties	moiety	NNS	I-NP	I-protein	O
significantly	significantly	RB	B-ADVP	O	O
improves	improve	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
permeation	permeation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hydrophilic	hydrophilic	JJ	I-NP	O	O
molecule	molecule	NN	I-NP	O	O
NaFlu	NaFlu	NN	I-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
model	model	NN	I-NP	O	O
peptide	peptide	NN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
bacitracin	bacitracin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
this	this	DT	B-NP	O	O
conjugated	conjugate	VBN	I-NP	O	O
system	system	NN	I-NP	O	O
maybe	maybe	RB	B-ADJP	O	O
useful	useful	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
peroral	peroral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
peptide	peptide	NN	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
future	future	NN	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
antibiotic	antibiotic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

Understanding	Understand	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
breadth	breadth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
available	available	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dermatologist	dermatologist	NN	I-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
associated	associate	VBN	I-NP	O	O
side	side	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
effect	effect	NN	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
and	and	CC	O	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
allows	allow	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
clinician	clinician	NN	I-NP	O	O
to	to	TO	B-VP	O	O
offer	offer	VB	I-VP	O	O
patients	patient	NNS	B-NP	O	O
optimal	optimal	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cutaneous	cutaneous	JJ	B-NP	O	O
infectious	infectious	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
:	:	:	O	O	O
How	How	WRB	B-ADVP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
them	them	PRP	B-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
theraputic	theraputic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
recognized	recognize	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
increasingly	increasingly	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
causes	cause	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
at	at	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
usual	usual	JJ	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
,	,	,	O	O	O
under	under	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
,	,	,	O	O	O
produce	produce	VBP	B-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
endangering	endanger	VBG	B-VP	O	O
proportions	proportion	NNS	B-NP	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
recognition	recognition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
of	of	IN	B-PP	O	O
importance	importance	NN	B-NP	O	O
to	to	TO	B-PP	O	O
all	all	DT	B-NP	O	O
physciains	physciain	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
especially	especially	RB	B-ADVP	O	O
so	so	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinician	clinician	NN	I-NP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
welfare	welfare	NN	I-NP	O	O
of	of	IN	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
aerospace	aerospace	NN	I-NP	O	O
environment	environment	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
attempts	attempt	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
provide	provide	VB	I-VP	O	O
a	a	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
understanding	understanding	NN	I-NP	O	O
and	and	CC	I-NP	O	O
identifications	identification	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
important	important	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Guidelines	Guideline	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
provided	provide	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
assist	assist	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clinician	clinician	NN	I-NP	O	O
in	in	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
logical	logical	JJ	I-NP	O	O
approach	approach	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
identification	identification	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
serious	serious	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
encountered	encounter	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pateint	pateint	NN	I-NP	O	O
.	.	.	O	O	O

Only	Only	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
knowledge	knowledge	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
can	can	MD	O	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
be	be	VB	B-VP	O	O
altered	alter	VBN	I-VP	O	O
so	so	RB	B-SBAR	O	O
as	as	IN	I-SBAR	O	O
to	to	TO	B-VP	O	O
provide	provide	VB	I-VP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
necessary	necessary	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
while	while	IN	B-SBAR	O	O
avoiding	avoid	VBG	B-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
Interaction	Interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
males	male	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
objective	objective	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug
or	or	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	O
breath	breath	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
ERMBT	ERMBT	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
four	four	CD	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
cohorts	cohort	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
(	(	(	O	O	O
1,200	1,200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-NP	O	O
a	a	DT	I-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
7	7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
washout	washout	NN	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
either	either	CC	O	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug
(	(	(	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
[	[	(	O	O	O
QD	QD	NN	B-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
(	(	(	O	O	O
cohort	cohort	JJ	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
(	(	(	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
cohort	cohort	JJ	B-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Cohort	Cohort	NNP	B-NP	O	O
1	1	CD	I-NP	O	O
then	then	RB	B-ADVP	O	O
received	receive	VBD	B-VP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
plus	plus	CC	O	O	O
rifabutin	rifabutin	NN	B-NP	O	S-drug
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
cohort	cohort	JJ	B-NP	O	O
2	2	CD	I-NP	O	O
received	receive	VBD	B-VP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
plus	plus	CC	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Serial	Serial	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
samples	sample	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
25	25	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
O	O	NN	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
desacetyl	desacetyl	NN	I-NP	O	I-drug_n
metabolites	metabolite	NNS	I-NP	O	E-drug_n
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
performance	performance	NN	I-NP	O	O
liquid	liquid	NN	I-NP	O	O
chromatography	chromatography	NN	I-NP	O	O
.	.	.	O	O	O

Rifabutin	Rifabutin	NN	B-NP	B-protein	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
's	's	POS	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug-ME-1
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
ss	ss	NN	B-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug-ME-2
by	by	IN	B-PP	O	O
2.93	2.93	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
(	(	(	O	O	O
ss	ss	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	B-drug_n-ME-2
-	-	HYPH	I-NP	O	I-drug_n-ME-2
O	O	NN	I-NP	B-protein	I-drug_n-ME-2
-	-	HYPH	O	I-protein	I-drug_n-ME-2
desacetylrifabutin	desacetylrifabutin	NN	B-NP	I-protein	E-drug_n-ME-2
by	by	IN	B-PP	O	O
13.3	13.3	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug-ME-1
significantly	significantly	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
(	(	(	O	O	O
ss	ss	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
82	82	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ERMBT	ERMBT	NN	I-NP	B-protein	O
by	by	IN	B-PP	O	O
83	83	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ERMBT	ERMBT	NN	I-NP	B-protein	O
after	after	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
187	187	CD	B-NP	O	O
and	and	CC	I-NP	O	O
156	156	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug
plus	plus	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug-EF-1
plus	plus	CC	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug-EF-2
was	be	VBD	B-VP	O	O
poorly	poorly	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	O	O
of	of	IN	B-PP	O	O
11	11	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
discontinued	discontinue	VBD	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug-ME-1
markedly	markedly	RB	B-ADVP	O	O
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amprenavir	amprenavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
coadministration	coadministration	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug-ME-1
significantly	significantly	RB	B-ADVP	O	O
decreases	decrease	VBZ	B-VP	O	O
clearance	clearance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifabutin	rifabutin	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
25	25	CD	B-NP	O	B-drug_n-ME-2
-	-	HYPH	I-NP	O	I-drug_n-ME-2
O	O	NN	I-NP	B-protein	I-drug_n-ME-2
-	-	HYPH	I-NP	I-protein	I-drug_n-ME-2
desacetylrifabutin	desacetylrifabutin	NN	I-NP	I-protein	E-drug_n-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
poorly	poorly	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
.	.	.	O	O	O

Amprenavir	Amprenavir	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
ERMBT	ERMBT	NN	I-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug
are	be	VBP	B-VP	O	O
equipotent	equipotent	JJ	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ERMBT	ERMBT	NN	I-NP	B-protein	O
.	.	.	O	O	O

New	New	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
type	type	NN	B-NP	O	O
2	2	CD	I-NP	O	O
diabetes	diabete	NNS	I-NP	O	O
mellitus	mellitus	NN	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
glitazones	glitazone	NNS	I-NP	O	S-group
or	or	CC	I-NP	O	O
insulin	insulin	NN	I-NP	O	O
sensitizers	sensitizer	NNS	I-NP	O	O
.	.	.	O	O	O

Type	Type	NN	B-NP	O	O
2	2	CD	I-NP	O	O
diabetes	diabetes	NN	I-NP	O	O
mellitus	mellitus	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
growing	grow	VBG	I-NP	O	O
problem	problem	NN	I-NP	O	O
not	not	RB	B-CONJP	O	O
only	only	RB	I-CONJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
States	State	NNPS	I-NP	O	O
but	but	CC	B-CONJP	O	O
also	also	RB	I-CONJP	O	O
across	across	IN	B-PP	O	O
the	the	DT	B-NP	O	O
world	world	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
now	now	RB	B-ADVP	O	O
strong	strong	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
intensive	intensive	JJ	B-NP	O	O
control	control	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
can	can	MD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
and	and	CC	I-VP	O	O
retard	retard	VB	I-VP	O	O
the	the	DT	B-NP	O	O
microvascular	microvascular	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
retinopathy	retinopathy	NN	B-NP	O	O
,	,	,	O	O	O
nephropathy	nephropathy	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
neuropathy	neuropathy	NN	B-NP	O	O
.	.	.	O	O	O

Ultimately	Ultimately	RB	B-ADVP	O	O
however	however	RB	I-ADVP	O	O
,	,	,	O	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
type	type	NN	B-NP	O	O
2	2	CD	I-NP	O	O
diabetics	diabetic	NNS	I-NP	O	O
die	die	VBP	B-VP	O	O
from	from	IN	B-PP	O	O
macrovascular	macrovascular	JJ	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atherosclerotic	atherosclerotic	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
intricately	intricately	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	O
resistance	resistance	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
pathophysiologic	pathophysiologic	JJ	I-NP	O	O
abnormality	abnormality	NN	I-NP	O	O
in	in	IN	B-PP	O	O
type	type	NN	B-NP	O	O
2	2	CD	I-NP	O	O
diabetes	diabete	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
strong	strong	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
insulin	insulin	NN	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
not	not	RB	B-CONJP	O	O
only	only	RB	I-CONJP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	B-CONJP	O	O
also	also	RB	I-CONJP	O	O
dyslipidemia	dyslipidemia	NN	B-NP	O	O
,	,	,	O	O	O
hypertension	hypertension	NN	B-NP	O	O
,	,	,	O	O	O
hypercoagulation	hypercoagulation	NN	B-NP	O	O
,	,	,	O	O	O
vasculopathy	vasculopathy	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
ultimately	ultimately	RB	B-NP	O	O
atherosclerotic	atherosclerotic	JJ	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
cluster	cluster	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
termed	term	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
insulin	insulin	NN	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
or	or	CC	O	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
dysmetabolic	dysmetabolic	JJ	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
thiazolidinediones	thiazolidinedione	NNS	I-NP	O	S-group
(	(	(	O	O	O
rosiglitazone	rosiglitazone	NN	B-NP	O	S-drug
and	and	CC	O	O	O
pioglitazone	pioglitazone	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
``	``	``	O	O	O
insulin	insulin	NN	B-NP	B-protein	O
sensitizers	sensitizer	NNS	I-NP	I-protein	O
``	``	``	O	O	O

and	and	CC	O	O	O
exert	exert	VB	B-VP	O	O
direct	direct	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	O
resistance	resistance	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
not	not	RB	B-VP	O	O
only	only	RB	I-VP	O	O
improve	improve	VB	I-VP	O	O
insulin	insulin	NN	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
and	and	CC	O	O	O
glycemic	glycemic	JJ	B-NP	O	O
control	control	NN	I-NP	O	O
with	with	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
insulin	insulin	NN	I-NP	O	O
requirements	requirement	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
also	also	RB	B-ADVP	O	O
have	have	VBP	B-VP	O	O
potentially	potentially	RB	B-NP	O	O
favorable	favorable	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
components	component	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
dysmetabolic	dysmetabolic	JJ	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

Long	Long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
insulin	insulin	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
sensitizing	sensitize	VBG	B-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glitazones	glitazone	NNS	I-NP	O	S-group
can	can	MD	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
or	or	CC	I-VP	O	O
delay	delay	VB	I-VP	O	O
premature	premature	JJ	B-NP	O	O
atherosclerotic	atherosclerotic	JJ	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
,	,	,	O	O	O
morbidity	morbidity	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
death	death	NN	B-NP	O	O
.	.	.	O	O	O

Responses	Response	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
arginine	arginine	NN	B-NP	O	S-drug
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
perfused	perfuse	VBN	I-NP	O	O
pancreas	pancreas	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
genetically	genetically	RB	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
Chinese	Chinese	JJ	I-NP	O	O
hamster	hamster	NN	I-NP	O	O
.	.	.	O	O	O

Nonketotic	Nonketotic	JJ	B-NP	O	O
,	,	,	I-NP	O	O
genetically	genetically	RB	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
Cinese	Cinese	JJ	I-NP	O	O
hamsters	hamster	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
subnormal	subnormal	JJ	B-NP	O	O
pancreatic	pancreatic	JJ	I-NP	O	O
insulin	insulin	NN	I-NP	O	O
release	release	NN	I-NP	O	O
and	and	CC	O	O	O
impaired	impaired	JJ	B-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucagon	glucagon	NN	B-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	I-PP	O	O
to	to	TO	I-PP	O	O
glucose	glucose	NN	B-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pancreatic	pancreatic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
dynamic	dynamic	JJ	B-NP	O	O
insulin	insulin	NN	I-NP	O	O
and	and	CC	I-NP	O	O
glucagon	glucagon	NN	I-NP	O	O
release	release	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
perfused	perfuse	VBN	I-NP	O	O
pancreases	pancreas	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
Chinese	Chinese	JJ	I-NP	O	O
hamsters	hamster	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
various	various	JJ	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
arginine	arginine	NN	B-NP	O	S-drug
(	(	(	O	O	O
20mM	20mM	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
glucose	glucose	NN	B-NP	O	S-drug
(	(	(	O	O	O
100	100	CD	B-NP	O	O
or	or	CC	I-NP	O	O
150	150	CD	I-NP	O	O
mg.	mg.	NN	I-NP	O	O
per	per	IN	B-PP	O	O
100	100	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mM	mM	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
caused	cause	VBD	B-VP	O	O
identical	identical	JJ	B-NP	O	O
insulin	insulin	NN	I-NP	O	O
and	and	CC	I-NP	O	O
glucagon	glucagon	NN	I-NP	O	O
release	release	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diabetics	diabetic	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
normals	normal	NNS	I-NP	O	O
.	.	.	O	O	O

Glucose	Glucose	NN	B-NP	O	S-drug
,	,	,	O	O	O
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
subnormal	subnormal	JJ	B-NP	O	O
insulin	insulin	NN	I-NP	O	O
release	release	NN	I-NP	O	O
and	and	CC	O	O	O
less	less	JJR	B-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucagon	glucagon	NN	B-NP	O	O
release	release	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diabectics	diabectic	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
normals	normal	NNS	I-NP	O	O
.	.	.	O	O	O

Arginine	Arginine	NN	B-NP	O	S-drug
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
glucose	glucose	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
excessive	excessive	JJ	B-NP	O	O
glucagon	glucagon	NN	I-NP	O	O
release	release	NN	I-NP	O	O
but	but	CC	O	O	O
nearly	nearly	RB	B-NP	O	O
normal	normal	JJ	I-NP	O	O
insulin	insulin	NN	I-NP	O	O
release	release	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diabetics	diabetic	NNS	I-NP	O	O
.	.	.	O	O	O

Arginine	Arginine	NN	B-NP	O	S-drug
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
excessive	excessive	JJ	B-NP	O	O
glucagon	glucagon	NN	I-NP	O	O
release	release	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diabetics	diabetic	NNS	I-NP	O	O
and	and	CC	O	O	O
undetectable	undetectable	JJ	B-NP	O	O
insulin	insulin	NN	I-NP	O	O
release	release	NN	I-NP	O	O
in	in	IN	B-PP	O	O
either	either	CC	B-NP	O	O
diabetics	diabetic	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
normals	normal	NNS	I-NP	O	O
.	.	.	O	O	O

Pancreatic	Pancreatic	JJ	B-NP	O	O
content	content	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
perfusion	perfusion	NN	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
correlate	correlate	VB	I-VP	O	O
with	with	IN	B-PP	O	O
release	release	NN	B-NP	O	O
during	during	IN	B-PP	O	O
perfusion	perfusion	NN	B-NP	O	O
.	.	.	O	O	O

Infusion	Infusion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
arginine	arginine	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
markedly	markedly	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
extractable	extractable	JJ	B-NP	B-protein	O
pancreatic	pancreatic	JJ	I-NP	I-protein	O
insulin	insulin	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
glucagon	glucagon	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pancreatic	pancreatic	JJ	I-NP	O	O
alpha	alpha	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
Chinese	Chinese	JJ	I-NP	O	O
hamster	hamster	NN	I-NP	O	O
responds	respond	VBZ	B-VP	O	O
excessively	excessively	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
arginine	arginine	NN	B-NP	O	S-drug
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
is	be	VBZ	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
diabetic	diabetic	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
defect	defect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
acute	acute	JJ	B-NP	O	O
insulin	insulin	NN	I-NP	O	O
release	release	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	S-drug
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
confirm	confirm	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
Chinese	Chinese	JJ	I-NP	O	O
hamster	hamster	NN	I-NP	O	O
's	's	POS	B-NP	O	O
alpha	alpha	NN	I-NP	O	O
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	O
cells	cell	NNS	B-NP	O	O
respond	respond	VBP	B-VP	O	O
normally	normally	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
but	but	CC	O	O	O
are	be	VBP	B-VP	O	O
relatively	relatively	RB	B-ADJP	O	O
insensitive	insensitive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
glucose	glucose	NN	B-NP	O	S-drug
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
etofibrate	etofibrate	NN	B-NP	O	S-drug
upon	upon	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chylomicron	chylomicron	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
emulsions	emulsion	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Slow	Slow	JJ	B-NP	O	O
chylomicron	chylomicron	NN	I-NP	O	O
intravascular	intravascular	JJ	I-NP	O	O
catabolism	catabolism	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
and	and	CC	O	O	O
screening	screening	NN	B-NP	O	O
for	for	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
speed	speed	VB	I-VP	O	O
-	-	HYPH	B-ADJP	O	O
up	up	RP	B-PRT	O	O
this	this	DT	B-NP	O	O
process	process	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
important	important	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
etofibrate	etofibrate	NN	B-NP	O	S-drug
upon	upon	IN	B-PP	O	O
chylomicron	chylomicron	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
determination	determination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
kinetics	kinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
chylomicron	chylomicron	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
emulsion	emulsion	NN	I-NP	O	O
model	model	NN	I-NP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
,	,	,	O	O	O
aged	age	VBN	B-VP	O	O
59	59	CD	B-NP	O	O
+	+	SYM	I-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
11	11	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
(	(	(	O	O	O
total	total	JJ	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	O	O
:	:	:	O	O	O
240	240	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
41	41	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	I-NP	O	O
;	;	:	O	O	O
triglycerides	triglyceride	NNS	B-NP	O	O
:	:	:	O	O	O
188	188	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
42	42	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	I-NP	O	O
)	)	)	O	O	O
submitted	submit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
,	,	,	O	O	O
crossover	crossover	RB	B-ADVP	O	O
,	,	,	O	O	O
double	double	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
g	g	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
etofibrate	etofibrate	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
for	for	IN	B-PP	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
month	month	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
month	month	NN	I-NP	O	O
washout	washout	NN	I-NP	O	O
period	period	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
inserted	insert	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
periods	period	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
intravenously	intravenously	RB	I-VP	O	O
injected	inject	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
chylomicron	chylomicron	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
emulsion	emulsion	NN	I-NP	O	O
doubly	doubly	RB	B-VP	O	O
labeled	label	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
14C	14C	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
cholesteryl	cholesteryl	NN	I-NP	O	O
oleate	oleate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
3H	3H	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
triolein	triolein	NN	I-NP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
and	and	CC	B-PP	O	O
after	after	IN	B-PP	O	O
treatments	treatment	NNS	B-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
etofibrate	etofibrate	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
decrease	decrease	NN	B-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	O	O
and	and	CC	I-NP	O	O
triglyceride	triglyceride	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
trend	trend	NN	I-NP	O	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
density	density	NN	I-NP	O	O
lipoprotein	lipoprotein	NN	I-NP	O	O
cholesterol	cholesterol	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Etofibrate	Etofibrate	NN	B-NP	O	S-drug-EF-1
elicited	elicit	VBD	B-VP	O	O
62	62	CD	B-NP	O	O
%	%	NN	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
heparin	heparin	NN	I-NP	O	S-drug-EF-2
lipolytic	lipolytic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
100	100	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
3H	3H	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
triglyceride	triglyceride	NN	I-NP	O	O
fractional	fractional	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

14C	14C	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
cholesterol	cholesterol	NN	I-NP	O	O
ester	ester	NN	I-NP	O	O
fractional	fractional	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
260	260	CD	B-NP	O	O
%	%	NN	I-NP	O	O
greater	great	JJR	B-ADJP	O	O
after	after	IN	B-PP	O	O
etofibrate	etofibrate	NN	B-NP	O	S-drug
than	than	IN	B-PP	O	O
after	after	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
etofibrate	etofibrate	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
both	both	CC	O	O	O
chylomicron	chylomicron	NN	B-NP	O	O
lipolysis	lipolysis	NN	I-NP	O	O
and	and	CC	O	O	O
remnant	remnant	NN	B-NP	O	O
removal	removal	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
improve	improve	VB	I-VP	O	O
this	this	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
future	future	JJ	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mode	mode	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxic	toxic	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pesticide	pesticide	NN	I-NP	O	O
gliftor	gliftor	NN	I-NP	O	S-drug_n
:	:	:	O	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
difluoroacetone	difluoroacetone	NN	I-NP	O	E-drug_n
to	to	TO	B-PP	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	O	O	I-drug_n
erythro	erythro	AFX	B-NP	B-cell_type	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
fluorocitrate	fluorocitrate	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

The	The	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
toxicology	toxicology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
difluoroacetone	difluoroacetone	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
ingredient	ingredient	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pesticide	pesticide	NN	I-NP	O	O
Gliftor	Gliftor	NN	I-NP	O	S-drug_n
(	(	(	O	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
difluoro	difluoro	AFX	O	O	I-drug_n
-	-	HYPH	B-NP	B-protein	I-drug_n
2	2	CD	I-NP	I-protein	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
propanol	propanol	NN	I-NP	O	E-drug_n
)	)	)	O	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Rat	Rat	NN	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
homogenates	homogenate	NNS	I-NP	O	O
supplemented	supplement	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
coenzyme	coenzyme	NN	B-NP	O	O
A	A	NN	I-NP	O	O
,	,	,	O	O	O
ATP	ATP	NN	B-NP	O	O
,	,	,	O	O	O
oxaloacetate	oxaloacetate	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Mg2	Mg2	NN	B-NP	B-protein	O
+	+	SYM	B-NP	O	O
converted	convert	VBD	B-VP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
difluoroacetone	difluoroacetone	NN	I-NP	O	E-drug_n
to	to	TO	B-PP	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	O	O	I-drug_n
erythro	erythro	AFX	O	B-cell_type	I-drug_n
-	-	HYPH	O	O	I-drug_n
fluorocitrate	fluorocitrate	NN	B-NP	O	E-drug_n
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
difluoroacetone	difluoroacetone	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
1	1	CD	O	O	O
)	)	)	O	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	O	O	I-drug_n
erythro	erythro	AFX	B-NP	B-cell_type	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
fluorocitrate	fluorocitrate	NN	I-NP	O	E-drug_n
synthesis	synthesis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
preceded	precede	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
fluoride	fluoride	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
citrate	citrate	NN	B-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
dosed	dose	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
1,3	1,3	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	O	O	I-drug_n
difluoroacetone	difluoroacetone	NN	B-NP	O	E-drug_n
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
display	display	VB	I-VP	O	O
the	the	DT	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
3	3	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
lag	lag	NN	I-NP	O	O
phase	phase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
either	either	CC	O	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	O	O	I-drug_n
erythro	erythro	AFX	B-NP	B-cell_type	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
fluorocitrate	fluorocitrate	NN	I-NP	O	E-drug_n
synthesis	synthesis	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
citrate	citrate	NN	B-NP	O	O
and	and	CC	I-NP	O	O
fluoride	fluoride	NN	I-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
characteristic	characteristic	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
dosed	dose	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
1,3	1,3	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	O	O	I-drug_n
difluoro	difluoro	AFX	O	O	I-drug_n
-	-	HYPH	B-NP	B-protein	I-drug_n
2	2	CD	I-NP	I-protein	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
propanol	propanol	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
conversion	conversion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
difluoro	difluoro	AFX	O	O	I-drug_n
-	-	HYPH	B-NP	B-protein	I-drug_n
2	2	CD	I-NP	I-protein	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
propanol	propanol	NN	I-NP	O	E-drug_n
to	to	TO	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
difluoroacetone	difluoroacetone	NN	I-NP	O	E-drug_n
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
NAD	NAD	NN	I-NP	O	O
+	+	SYM	B-VP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
oxidation	oxidation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
-	-	HYPH	O	O	O
limiting	limit	VBG	B-VP	O	O
step	step	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	B-protein	O
product	product	NN	I-NP	I-protein	O
,	,	,	O	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	O	O	I-drug_n
erythro	erythro	AFX	O	B-cell_type	I-drug_n
-	-	HYPH	O	O	I-drug_n
fluorocitrate	fluorocitrate	NN	B-NP	O	E-drug_n
from	from	IN	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	B-ADJP	O	I-drug_n
difluoro	difluoro	AFX	O	O	I-drug_n
-	-	HYPH	B-NP	B-protein	I-drug_n
2	2	CD	I-NP	I-protein	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
propanol	propanol	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

Prior	Prior	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	B-drug-EF-1
-	-	HYPH	I-NP	O	I-drug-EF-1
methylpyrazole	methylpyrazole	NN	I-NP	O	E-drug-EF-1
(	(	(	O	O	O
90	90	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
1	1	CD	O	O	O
)	)	)	O	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
conversion	conversion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n-EF-2
-	-	HYPH	O	O	I-drug_n-EF-2
difluoro	difluoro	AFX	O	O	I-drug_n-EF-2
-	-	HYPH	B-NP	B-protein	I-drug_n-EF-2
2	2	CD	I-NP	I-protein	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
propanol	propanol	NN	I-NP	O	E-drug_n-EF-2
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
1	1	CD	O	O	O
)	)	)	O	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	O	O	I-drug_n
erythro	erythro	AFX	B-NP	B-cell_type	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
fluorocitrate	fluorocitrate	NN	I-NP	O	E-drug_n
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
eliminate	eliminate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
fluoride	fluoride	NN	I-NP	O	O
and	and	CC	I-NP	O	O
citrate	citrate	NN	I-NP	O	O
elevations	elevation	NNS	I-NP	O	O
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
difluoro	difluoro	AFX	O	O	I-drug_n
-	-	HYPH	B-NP	B-protein	I-drug_n
2	2	CD	I-NP	I-protein	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
propanol	propanol	NN	I-NP	O	E-drug_n
-	-	HYPH	B-NP	O	O
intoxicated	intoxicate	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
methylpyrazole	methylpyrazole	NN	I-NP	O	E-drug
(	(	(	O	O	O
90	90	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
1	1	CD	O	O	O
)	)	)	O	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
difluoroacetone	difluoroacetone	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
1	1	CD	O	O	O
)	)	)	O	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
ineffective	ineffective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
preventing	prevent	VBG	B-VP	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	O	O	I-drug_n
erythro	erythro	AFX	B-NP	B-cell_type	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
fluorocitrate	fluorocitrate	NN	I-NP	O	E-drug_n
synthesis	synthesis	NN	I-NP	O	O
and	and	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
diminish	diminish	VB	I-VP	O	O
fluoride	fluoride	NN	B-NP	O	O
or	or	CC	I-NP	O	O
citrate	citrate	NN	I-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
prophylactic	prophylactic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
antidotal	antidotal	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	B-drug-EF-1
-	-	HYPH	I-NP	O	I-drug-EF-1
methylpyrazole	methylpyrazole	NN	I-NP	O	E-drug-EF-1
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
1,3	1,3	NN	B-NP	B-protein	B-drug_n-EF-2
-	-	HYPH	O	O	I-drug_n-EF-2
difluoro	difluoro	AFX	O	O	I-drug_n-EF-2
-	-	HYPH	B-NP	B-protein	I-drug_n-EF-2
2	2	CD	I-NP	I-protein	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
propanol	propanol	NN	I-NP	O	E-drug_n-EF-2
derive	derive	VBP	B-VP	O	O
from	from	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
capacity	capacity	NN	I-NP	O	O
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
NAD	NAD	NN	I-NP	O	O
+	+	SYM	B-VP	O	O
-	-	HYPH	O	O	O
dependent	dependent	JJ	B-NP	O	O
oxidation	oxidation	NN	I-NP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
converting	convert	VBG	B-VP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
difluoro	difluoro	AFX	O	O	I-drug_n
-	-	HYPH	B-NP	B-protein	I-drug_n
2	2	CD	I-NP	I-protein	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
propanol	propanol	NN	I-NP	O	E-drug_n
to	to	TO	B-PP	O	O
1,3	1,3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
difluoroacetone	difluoroacetone	NN	I-NP	O	E-drug_n
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
committed	commit	VBN	I-NP	O	O
step	step	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
.	.	.	O	O	O

Pharmacology	Pharmacology	NN	B-NP	O	O
and	and	CC	I-NP	O	O
pharmacotherapy	pharmacotherapy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
comorbidity	comorbidity	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mortality	mortality	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
regimens	regimen	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
frequently	frequently	RB	B-ADJP	O	O
complex	complex	JJ	I-ADJP	O	O
and	and	CC	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
several	several	JJ	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
directly	directly	RB	B-VP	O	O
affect	affect	VBP	I-VP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
article	article	NN	I-NP	O	O
reviews	review	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
impact	impact	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	O	O	O
identifies	identify	VBZ	B-VP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
these	these	DT	B-NP	O	O
and	and	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
commonly	commonly	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
classes	class	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
discussed	discuss	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
relationship	relationship	NN	B-NP	O	O
to	to	TO	B-PP	O	O
their	their	PRP$	B-NP	O	O
differential	differential	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
and	and	CC	I-NP	O	O
progression	progression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Green	Green	JJ	B-NP	O	B-drug
tea	tea	NN	I-NP	O	I-drug
polyphenols	polyphenol	NNS	I-NP	O	E-drug
as	as	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
enhancers	enhancer	NNS	I-NP	O	S-drug
of	of	IN	B-PP	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
mouse	mouse	NN	I-NP	B-DNA	O
mammary	mammary	JJ	I-NP	I-DNA	O
tumor	tumor	NN	I-NP	I-DNA	O
virus	virus	NN	I-NP	I-DNA	O
gene	gene	NN	I-NP	I-DNA	O
expression	expression	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
natural	natural	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
synthetic	synthetic	JJ	I-NP	O	O
galloyl	galloyl	NN	I-NP	O	O
esters	ester	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
gene	gene	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
rat	rat	NN	B-NP	B-cell_line	O
fibroblast	fibroblast	NN	I-NP	I-cell_line	O
3Y1	3Y1	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
stably	stably	RB	B-VP	O	O
transfected	transfecte	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
luciferase	luciferase	NN	I-NP	B-DNA	O
reporter	reporter	NN	I-NP	I-DNA	O
gene	gene	NN	I-NP	I-DNA	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
transcriptional	transcriptional	JJ	I-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mouse	mouse	NN	I-NP	B-DNA	O
mammary	mammary	JJ	I-NP	I-DNA	O
tumor	tumor	NN	I-NP	I-DNA	O
virus	virus	NN	I-NP	I-DNA	O
promoter	promoter	NN	I-NP	I-DNA	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
glucocorticoid	glucocorticoid	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
gene	gene	NN	I-NP	O	O
transcription	transcription	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
strongly	strongly	RB	I-VP	O	O
suppressed	suppress	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
synthetic	synthetic	JJ	B-NP	O	O
alkyl	alkyl	NN	I-NP	O	O
esters	ester	NNS	I-NP	O	O
;	;	:	O	O	O

n	n	AFX	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
dodecyl	dodecyl	NN	I-NP	O	I-drug
gallate	gallate	NN	I-NP	O	E-drug
showed	show	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
(	(	(	O	O	O
66	66	CD	B-NP	O	O
%	%	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
microM	microM	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
far	far	RB	B-ADJP	O	O
more	more	RBR	I-ADJP	O	O
potent	potent	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
crude	crude	JJ	B-NP	O	O
tannic	tannic	JJ	I-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
.	.	.	O	O	O

n	n	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
Octyl	Octyl	NN	I-NP	O	O
and	and	CC	I-NP	O	O
n	n	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
cetyl	cetyl	NN	I-NP	O	O
gallate	gallate	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
showed	show	VBD	B-VP	O	O
good	good	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
gallic	gallic	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
itself	itself	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
so	so	RB	B-ADJP	O	O
active	active	JJ	I-ADJP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hydrophobic	hydrophobic	JJ	B-NP	B-protein	O
side	side	NN	I-NP	I-protein	O
chain	chain	NN	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
important	important	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
suppressive	suppressive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
surprisingly	surprisingly	RB	B-ADVP	O	O
,	,	,	O	O	O
green	green	JJ	B-NP	B-protein	B-drug
tea	tea	NN	I-NP	I-protein	I-drug
gallocatechins	gallocatechin	NNS	I-NP	I-protein	E-drug
,	,	,	O	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
epigallocatechin	epigallocatechin	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
3	3	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
O	O	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
gallate	gallate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
theasinensin	theasinensin	NN	I-NP	O	O
A	A	NN	I-NP	O	O
,	,	,	O	O	O
potently	potently	RB	B-VP	O	O
enhanced	enhance	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
promoter	promoter	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
182	182	CD	B-NP	O	O
and	and	CC	I-NP	O	O
247	247	CD	I-NP	O	O
%	%	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
microM	microM	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glucocorticoid	glucocorticoid	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
gene	gene	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antioxidative	antioxidative	JJ	I-NP	O	O
gallates	gallate	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
of	of	IN	B-PP	O	O
great	great	JJ	B-NP	O	O
interest	interest	NN	I-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
point	point	NN	I-NP	O	O
of	of	IN	B-PP	O	O
view	view	NN	B-NP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
sirolimus	sirolimus	NN	I-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

AIM	AIM	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
BACKGROUND	BACKGROUND	NN	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
macrolide	macrolide	NN	I-NP	O	B-group
immunosuppressant	immunosuppressant	NN	I-NP	O	E-group
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blocker	blocker	NN	I-NP	O	E-group
diltiazem	diltiazem	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
18	18	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
previously	previously	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
immunosuppressive	immunosuppressive	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
and	and	CC	B-PP	O	O
for	for	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	B-group
antagonists	antagonist	NNS	I-NP	O	E-group
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Healthy	Healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
20	20	CD	B-NP	O	O
to	to	TO	B-PP	O	O
43	43	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
old	old	JJ	B-ADJP	O	O
participated	participate	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
,	,	,	I-NP	O	O
three	three	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
randomized	randomize	VBN	B-VP	O	O
,	,	,	O	O	O
crossover	crossover	NN	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
120	120	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
given	give	VBN	B-VP	O	O
together	together	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
three	three	CD	I-NP	O	O
study	study	NN	I-NP	O	O
periods	period	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
separated	separate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
21	21	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
washout	washout	NN	I-NP	O	O
phase	phase	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
geometric	geometric	JJ	I-NP	O	O
mean	mean	JJ	I-NP	O	O
(	(	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
)	)	)	I-NP	O	O
whole	whole	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
sirolimus	sirolimus	NN	I-NP	O	S-drug-ME-1
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
time	time	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
curve	curve	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
35	35	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
736	736	CD	B-NP	O	O
to	to	TO	B-PP	O	O
1178	1178	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
x	x	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
mL	mL	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
maximum	maximum	JJ	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
81	81	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
67	67	CD	B-NP	O	O
to	to	TO	B-PP	O	O
96	96	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
coadministration	coadministration	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
decreased	decrease	VBD	B-VP	O	O
slightly	slightly	RB	B-ADVP	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
79	79	CD	B-NP	O	O
to	to	TO	B-PP	O	O
67	67	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Apparent	Apparent	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	I-NP	O	O
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
distribution	distribution	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
decreased	decrease	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
45	45	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
maximum	maximum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
time	time	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
,	,	,	O	O	O
desacetyldiltiazem	desacetyldiltiazem	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
and	and	CC	O	O	O
desmethyldiltiazem	desmethyldiltiazem	NN	B-NP	O	S-drug_n
were	be	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
diastolic	diastolic	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
or	or	CC	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
electrocardiographic	electrocardiographic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Single	Single	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug-ME-1
coadministration	coadministration	NN	I-NP	O	O
leads	lead	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
higher	high	JJR	B-NP	O	O
sirolimus	sirolimus	NN	I-NP	O	S-drug-ME-2
exposure	exposure	NN	I-NP	O	O
,	,	,	O	O	O
presumably	presumably	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
pass	pass	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
pronounced	pronounced	JJ	I-NP	O	O
intersubject	intersubject	JJ	I-NP	O	O
variability	variability	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sirolimus	sirolimus	NN	I-NP	O	S-drug-AD-1
-	-	HYPH	B-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug-AD-2
interaction	interaction	NN	I-NP	O	O
,	,	,	O	O	O
whole	whole	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
sirolimus	sirolimus	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug-ME-1
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
CYP2C9	CYP2C9	NN	I-NP	B-protein	O
catalyzed	catalyze	VBD	B-VP	O	O
biotransformation	biotransformation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
objective	objective	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
tolbutamide	tolbutamide	NN	I-NP	O	S-drug
to	to	TO	B-VP	O	O
confirm	confirm	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
,	,	,	I-NP	O	O
randomized	randomize	VBN	I-NP	O	O
,	,	,	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
design	design	NN	I-NP	O	O
with	with	IN	B-PP	O	O
14	14	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
participants	participant	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
period	period	NN	B-NP	O	O
A	A	NN	I-NP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
took	take	VBD	B-VP	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
orally	orally	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
period	period	NN	B-NP	O	O
B	B	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
assigned	assign	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
group	group	NN	I-NP	O	O
took	take	VBD	B-VP	O	O
either	either	CC	O	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
or	or	CC	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	B-NP	O	O
day	day	NN	I-NP	O	O
-	-	SYM	O	O	O
3	3	CD	B-NP	O	O
to	to	TO	B-PP	O	O
day	day	NN	B-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
then	then	RB	B-ADVP	O	O
took	take	VBD	B-VP	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
day	day	NN	B-NP	O	O
0	0	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
both	both	DT	B-NP	O	O
periods	period	NNS	I-NP	O	O
,	,	,	I-NP	O	O
blood	blood	NN	I-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
sampled	sample	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
regular	regular	JJ	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
urine	urine	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
two	two	CD	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
,	,	,	O	O	O
4	4	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
hydroxytolbutamide	hydroxytolbutamide	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
carboxytolbutamide	carboxytolbutamide	NN	I-NP	O	S-drug_n
by	by	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
HPLC	HPLC	NN	B-NP	B-protein	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
During	During	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
median	median	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
from	from	IN	B-PP	O	O
845	845	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
to	to	TO	B-PP	O	O
688	688	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
among	among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
reached	reach	VBD	B-VP	O	O
borderline	borderline	JJ	B-NP	O	O
statistical	statistical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
group	group	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
by	by	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
hydroxytolbutamide	hydroxytolbutamide	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
carboxytolbutamide	carboxytolbutamide	NN	I-NP	O	S-drug_n
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
901	901	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
to	to	TO	B-PP	O	O
318	318	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
group	group	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
and	and	CC	B-PP	O	O
from	from	IN	B-PP	O	O
723	723	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
to	to	TO	B-PP	O	O
457	457	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
group	group	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
tendency	tendency	NN	I-NP	O	O
toward	toward	IN	B-PP	O	O
a	a	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
pronounced	pronounced	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hydroxylation	hydroxylation	NN	I-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
statistically	statistically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Fluvoxamine	Fluvoxamine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

Longitudinal	Longitudinal	JJ	B-NP	O	O
assessment	assessment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
everolimus	everolimus	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
de	de	FW	B-NP	O	O
novo	novo	FW	I-NP	O	O
renal	renal	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
recipients	recipient	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
year	year	NN	I-NP	O	O
:	:	:	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
,	,	,	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
response	response	NN	B-NP	O	O
relationships	relationship	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
influence	influence	NN	B-NP	O	O
on	on	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
objective	objective	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
characterize	characterize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
everolimus	everolimus	NN	B-NP	O	S-drug
and	and	CC	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
(	(	(	O	O	O
INN	INN	NN	B-NP	O	O
,	,	,	O	O	O
ciclosporin	ciclosporin	NN	B-NP	O	S-drug
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
de	de	FW	B-NP	O	O
novo	novo	FW	I-NP	O	O
kidney	kidney	NN	I-NP	O	O
allograft	allograft	NN	I-NP	O	O
recipients	recipient	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
year	year	NN	I-NP	O	O
after	after	IN	B-PP	O	O
transplantation	transplantation	NN	B-NP	O	O
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
multicenter	multicenter	JJ	I-NP	O	O
randomized	randomize	VBN	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
101	101	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
assigned	assign	VBN	I-VP	O	O
1	1	CD	B-NP	O	O
:	:	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
:	:	SYM	I-NP	O	O
1	1	CD	I-NP	O	O
to	to	TO	B-VP	O	O
receive	receive	VB	I-VP	O	O
everolimus	everolimus	NN	B-NP	O	S-drug
tablets	tablet	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
prednisone	prednisone	NN	I-NP	O	S-drug
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
sampling	sample	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
everolimus	everolimus	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
weeks	week	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
4	4	CD	B-NP	O	O
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
on	on	IN	B-PP	O	O
months	month	NNS	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	I-NP	O	O
6	6	CD	I-NP	O	O
,	,	,	I-NP	O	O
9	9	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
12	12	CD	B-NP	O	O
.	.	.	O	O	O

Everolimus	Everolimus	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
proportionality	proportionality	NN	I-NP	O	O
and	and	CC	I-NP	O	O
stability	stability	NN	I-NP	O	O
over	over	IN	B-PP	O	O
time	time	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
context	context	NN	I-NP	O	O
of	of	IN	B-PP	O	O
linear	linear	JJ	B-NP	O	O
regression	regression	NN	I-NP	O	O
and	and	CC	I-NP	O	O
ANOVA	ANOVA	NN	I-NP	O	O
models	model	NNS	I-NP	O	O
.	.	.	O	O	O

Everolimus	Everolimus	NN	B-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
response	response	NN	I-NP	O	O
relationships	relationship	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
area	area	NN	B-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	O	O	O
time	time	NN	B-NP	O	O
curve	curve	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
platelets	platelet	NNS	B-NP	B-cell_type	O
,	,	,	O	O	O
leukocytes	leukocyte	NNS	B-NP	B-cell_type	O
,	,	,	O	O	O
and	and	CC	O	O	O
lipids	lipid	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
explored	explore	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
effect	effect	NN	I-NP	O	O
model	model	NN	I-NP	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
dosing	dosing	NN	I-NP	O	O
and	and	CC	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
everolimus	everolimus	NN	B-NP	O	S-drug
exposure	exposure	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
context	context	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ANOVA	ANOVA	NN	B-NP	B-protein	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Everolimus	Everolimus	NN	B-NP	O	S-drug
steady	steady	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reached	reach	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
or	or	CC	I-PP	O	O
before	before	IN	I-PP	O	O
day	day	NN	B-NP	O	O
7	7	CD	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
postoperative	postoperative	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
maximum	maximum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
proportional	proportional	JJ	B-ADJP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
full	full	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
range	range	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
assessed	assess	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
full	full	JJ	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
evidence	evidence	NN	B-NP	O	O
for	for	IN	B-PP	O	O
longitudinal	longitudinal	JJ	B-NP	O	O
stability	stability	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
of	of	IN	B-PP	O	O
everolimus	everolimus	NN	B-NP	O	S-drug
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interindividual	interindividual	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
variability	variability	NN	I-NP	O	O
for	for	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
85.4	85.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
intraindividual	intraindividual	JJ	I-NP	O	O
,	,	,	I-NP	O	O
interoccasion	interoccasion	NN	I-NP	O	O
variability	variability	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
40.8	40.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Age	Age	NN	B-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
17	17	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
69	69	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
weight	weight	NN	B-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
49	49	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
106	106	CD	I-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sex	sex	NN	B-NP	O	O
(	(	(	O	O	O
65	65	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
and	and	CC	O	O	O
36	36	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
significant	significant	JJ	B-NP	O	O
contributors	contributor	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
variability	variability	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increasing	increase	VBG	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
transient	transient	JJ	B-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	O
(	(	(	O	O	O
or	or	CC	O	O	O
=	=	SYM	O	O	O
100	100	CD	B-NP	O	O
x	x	SYM	B-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
)	)	)	O	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
increasing	increase	VBG	B-NP	O	O
everolimus	everolimus	NN	I-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.03	.03	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
trough	trough	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
temporal	temporal	JJ	I-NP	O	O
patterns	pattern	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
regardless	regardless	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	I-NP	O	O
everolimus	everolimus	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
level	level	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.13	.13	CD	B-NP	O	O
,	,	,	O	O	O
.82	.82	CD	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
.76	.76	CD	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Everolimus	Everolimus	NN	B-NP	O	S-drug
exhibited	exhibit	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
proportional	proportional	JJ	B-NP	O	O
,	,	,	I-NP	O	O
stable	stable	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
year	year	NN	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
a	a	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
everolimus	everolimus	NN	B-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
differential	differential	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
dosing	dosing	NN	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

ADL	ADL	NN	B-NP	B-protein	B-drug-EF-1
8	8	CD	I-NP	I-protein	I-drug-EF-1
-	-	HYPH	I-NP	O	I-drug-EF-1
2698	2698	CD	I-NP	O	E-drug-EF-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
trans	trans	AFX	I-NP	O	O
-	-	HYPH	I-NP	B-protein	O
3,4	3,4	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
dimethyl	dimethyl	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
4	4	CD	I-NP	I-protein	O
-	-	HYPH	O	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hydroxyphenyl	hydroxyphenyl	NN	I-NP	O	O
)	)	)	O	O	O
piperidine	piperidine	NN	B-NP	O	O
,	,	,	O	O	O
prevents	prevent	VBZ	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug-EF-2
without	without	IN	B-PP	O	O
affecting	affect	VBG	B-VP	O	O
analgesia	analgesia	NN	B-NP	O	O
.	.	.	O	O	O

ADL	ADL	NN	B-NP	B-protein	B-drug-EF-1
-	-	HYPH	B-NP	I-protein	I-drug-EF-1
8	8	CD	I-NP	I-protein	I-drug-EF-1
-	-	HYPH	I-NP	O	I-drug-EF-1
2698	2698	CD	I-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
peripherally	peripherally	RB	I-NP	O	B-group
restricted	restricted	JJ	I-NP	O	I-group
opioid	opioid	JJ	I-NP	O	I-group
antagonist	antagonist	NN	I-NP	O	E-group
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
selectively	selectively	RB	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
opioid	opioid	NN	B-NP	O	S-group-EF-2
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
reversing	reverse	VBG	B-VP	O	O
analgesia	analgesia	NN	B-NP	O	O
.	.	.	O	O	O

Gastrointestinal	Gastrointestinal	JJ	B-NP	O	O
transit	transit	NN	I-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
lactulose	lactulose	NN	B-NP	O	O
hydrogen	hydrogen	NN	I-NP	O	O
breath	breath	NN	I-NP	O	O
test	test	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
14	14	CD	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
and	and	CC	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
(	(	(	O	O	O
0.05	0.05	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
x	x	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
ADL	ADL	NN	I-NP	B-protein	B-drug
8	8	CD	I-NP	I-protein	I-drug
-	-	HYPH	I-NP	O	I-drug
2698	2698	CD	I-NP	O	E-drug
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
(	(	(	O	O	O
0.05	0.05	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
x	x	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	O	O	O
cross	cross	AFX	O	O	O
-	-	HYPH	O	O	O
over	over	IN	B-PP	O	O
study	study	NN	B-NP	O	O
.	.	.	O	O	O

Morphine	Morphine	NN	B-NP	O	S-drug
prolonged	prolong	VBD	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
transit	transit	NN	I-NP	O	O
time	time	NN	I-NP	O	O
from	from	IN	B-PP	O	O
69	69	CD	B-NP	O	O
to	to	TO	I-NP	O	O
103	103	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.005	.005	CD	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

Morphine	Morphine	NN	B-NP	O	S-drug-EF-1
prolonged	prolong	VBD	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
transit	transit	NN	I-NP	O	O
time	time	NN	I-NP	O	O
from	from	IN	B-PP	O	O
69	69	CD	B-NP	O	O
to	to	TO	I-NP	O	O
103	103	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.005	.005	CD	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
prevented	prevent	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ADL	ADL	NN	B-NP	B-protein	B-drug-EF-2
8	8	CD	I-NP	I-protein	I-drug-EF-2
-	-	HYPH	I-NP	O	I-drug-EF-2
2698	2698	CD	I-NP	O	E-drug-EF-2
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.004	.004	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Postoperatively	Postoperatively	RB	B-ADVP	O	O
,	,	,	O	O	O
45	45	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
assigned	assign	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
fashion	fashion	NN	I-NP	O	O
to	to	TO	B-VP	O	O
receive	receive	VB	I-VP	O	O
ADL	ADL	NN	B-NP	B-protein	B-drug
8	8	CD	I-NP	I-protein	I-drug
-	-	HYPH	I-NP	O	I-drug
2698	2698	CD	I-NP	O	E-drug
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
and	and	CC	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
(	(	(	O	O	O
0.15	0.15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
to	to	TO	B-VP	O	O
receive	receive	VB	I-VP	O	O
oral	oral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
.	.	.	O	O	O

Analgesia	Analgesia	NN	B-NP	O	O
and	and	CC	I-NP	O	O
pupil	pupil	NN	I-NP	O	O
constriction	constriction	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
.	.	.	O	O	O

Morphine	Morphine	NN	B-NP	O	S-drug
analgesia	analgesia	NN	I-NP	O	O
and	and	CC	O	O	O
pupil	pupil	NN	B-NP	O	O
constriction	constriction	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
ADL	ADL	NN	B-NP	B-protein	B-drug
8	8	CD	I-NP	I-protein	I-drug
-	-	HYPH	I-NP	O	I-drug
2698	2698	CD	I-NP	O	E-drug
and	and	CC	O	O	O
differed	differ	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.002	.002	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ADL	ADL	NN	B-NP	B-protein	B-drug-EF-1
8	8	CD	I-NP	I-protein	I-drug-EF-1
-	-	HYPH	I-NP	O	I-drug-EF-1
2698	2698	CD	I-NP	O	E-drug-EF-1
prevents	prevent	VBZ	B-VP	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
transit	transit	NN	I-NP	O	O
time	time	NN	I-NP	O	O
by	by	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
selective	selective	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
opioid	opioid	JJ	I-NP	O	O
anitagonism	anitagonism	NN	I-NP	O	O
without	without	IN	B-PP	O	O
affecting	affect	VBG	B-VP	O	O
central	central	JJ	B-NP	O	O
opioid	opioid	JJ	I-NP	O	O
analgesia	analgesia	NN	I-NP	O	O
.	.	.	O	O	O

Restoration	Restoration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug
susceptibility	susceptibility	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Enterococcus	Enterococcus	NNP	B-NP	O	O
faecalis	faecalis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
antiresistance	antiresistance	NN	B-NP	O	O
determinant	determinant	JJ	I-NP	O	O
gene	gene	NN	I-NP	O	O
transfer	transfer	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
assessed	assess	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gene	gene	NN	B-NP	O	O
transfer	transfer	NN	I-NP	O	O
to	to	TO	B-VP	O	O
reverse	reverse	VB	I-VP	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug
resistance	resistance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
class	class	NN	B-NP	O	O
A	A	NN	I-NP	O	O
(	(	(	O	O	O
VanA	VanA	NN	B-NP	B-protein	O
)	)	)	O	O	O
glycopeptide	glycopeptide	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
Enterococcus	Enterococcus	NNP	I-NP	O	O
faecalis	faecalis	NN	I-NP	O	O
.	.	.	O	O	O

Recombinant	Recombinant	JJ	B-NP	B-protein	O
shuttle	shuttle	NN	I-NP	I-protein	O
vectors	vector	NNS	I-NP	I-protein	O
containing	contain	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
vanH	vanH	NN	I-NP	B-DNA	O
promoter	promoter	NN	I-NP	I-DNA	O
-	-	HYPH	B-NP	O	O
vanA	vanA	NN	I-NP	O	O
antisense	antisense	JJ	I-NP	O	O
gene	gene	NN	I-NP	O	O
cassette	cassette	NN	I-NP	O	O
fully	fully	RB	B-VP	O	O
restored	restore	VBD	I-VP	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug
susceptibility	susceptibility	NN	I-NP	O	O
through	through	IN	B-PP	O	O
a	a	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
transcriptional	transcriptional	JJ	I-NP	O	O
activator	activator	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
domain	domain	NN	I-NP	O	O
decoy	decoy	NN	I-NP	O	O
and	and	CC	O	O	O
inducible	inducible	JJ	B-NP	O	O
vanA	vanA	NN	I-NP	O	O
antisense	antisense	JJ	I-NP	O	O
RNA	RNA	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Rhabdomyolysis	Rhabdomyolysis	NN	B-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
clarithromycin	clarithromycin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
report	report	VB	I-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	O
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
simvastatin	simvastatin	NN	I-NP	O	S-drug
.	.	.	O	O	O

CASE	CASE	NN	B-NP	O	O
SUMMARY	SUMMARY	NN	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
64	64	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
African	African	JJ	I-NP	O	O
-	-	HYPH	B-NP	O	O
American	American	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
for	for	IN	B-PP	O	O
worsening	worsen	VBG	B-VP	O	O
renal	renal	JJ	B-NP	O	O
failure	failure	NN	I-NP	O	O
,	,	,	O	O	O
elevated	elevated	JJ	B-NP	O	O
creatine	creatine	NN	I-NP	B-protein	O
phosphokinase	phosphokinase	NN	I-NP	I-protein	O
,	,	,	O	O	O
diffuse	diffuse	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
pain	pain	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
severe	severe	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
weakness	weakness	NN	I-NP	O	O
.	.	.	O	O	O

About	About	IN	B-NP	O	O
three	three	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
admission	admission	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
started	start	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
for	for	IN	B-PP	O	O
sinusitis	sinusitis	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug
for	for	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
six	six	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
aggressively	aggressively	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
hydration	hydration	NN	I-NP	O	O
,	,	,	O	O	O
sodium	sodium	NN	B-NP	O	B-drug
bicarbonate	bicarbonate	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
hemodialysis	hemodialysis	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
biopsy	biopsy	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
necrotizing	necrotize	VBG	I-VP	O	O
myopathy	myopathy	NN	B-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
toxin	toxin	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
continued	continue	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
receive	receive	VB	I-VP	O	O
intermittent	intermittent	JJ	B-NP	O	O
hemodialysis	hemodialysis	NN	I-NP	O	O
until	until	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
death	death	NN	I-NP	O	O
from	from	IN	B-PP	O	O
infectious	infectious	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
three	three	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
several	several	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
have	have	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
his	his	PRP$	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
developing	develop	VBG	B-NP	O	O
rhabdomyolysis	rhabdomyolysis	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
.	.	.	O	O	O

DISCUSSION	DISCUSSION	NN	B-NP	O	O
:	:	:	O	O	O
Clarithromycin	Clarithromycin	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
macrolide	macrolide	NN	B-NP	O	B-group-EF-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
hydroxymethylglutaryl	hydroxymethylglutaryl	NN	I-NP	O	B-group-EF-2
coenzyme	coenzyme	NN	I-NP	O	I-group-EF-2
A	A	NN	I-NP	O	I-group-EF-2
(	(	(	O	O	I-group-EF-2
HMG	HMG	NN	B-NP	B-protein	I-group-EF-2
-	-	HYPH	B-NP	O	I-group-EF-2
CoA	CoA	NN	I-NP	O	I-group-EF-2
)	)	)	O	O	I-group-EF-2
reductase	reductase	NN	B-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
have	have	VBP	B-VP	O	O
resulted	result	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
,	,	,	O	O	O
underlying	underlie	VBG	B-VP	O	O
renal	renal	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	B-NP	O	I-group
CoA	CoA	NN	I-NP	B-protein	I-group
reductase	reductase	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Macrolide	Macrolide	NN	B-NP	O	B-group-ME-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-1
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	B-NP	O	I-group
CoA	CoA	NN	I-NP	O	I-group
reductase	reductase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
cerivastatin	cerivastatin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
rhabdomyolysis	rhabdomyolysis	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
or	or	CC	O	O	O
those	those	DT	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
concurrently	concurrently	RB	I-VP	O	O
taking	take	VBG	I-VP	O	O
medications	medication	NNS	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	O
.	.	.	O	O	O

Toxicity	Toxicity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cadmium	cadmium	NN	B-NP	O	O
and	and	CC	I-NP	O	O
zinc	zinc	NN	I-NP	O	S-drug
to	to	TO	B-PP	O	O
encystment	encystment	NN	B-NP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
excystment	excystment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Parorchis	Parorchis	NNP	B-NP	O	O
acanthus	acanthus	RB	B-ADVP	O	O
(	(	(	O	O	O
Digenea	Digenea	NNP	B-NP	O	O
:	:	:	O	O	O
Philophthalmidae	Philophthalmidae	NNP	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cadmium	cadmium	NN	B-NP	O	O
,	,	,	I-NP	O	O
zinc	zinc	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
cadmium	cadmium	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
zinc	zinc	NN	B-NP	O	O
mixtures	mixture	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
1000	1000	CD	B-NP	O	O
to	to	TO	I-NP	O	O
50000	50000	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
cercariae	cercariae	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
metacercariae	metacercariae	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Parorchis	Parorchis	NNP	B-NP	O	O
acanthus	acanthus	RB	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dog	dog	NN	I-NP	O	O
whelk	whelk	NN	I-NP	O	O
Nucella	Nucella	NN	I-NP	O	O
lapillus	lapillus	NN	I-NP	O	O
.	.	.	O	O	O

Cercarial	Cercarial	JJ	B-NP	O	O
encystment	encystment	NN	I-NP	O	O
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
25000	25000	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
or	or	CC	O	O	O
higher	high	JJR	B-ADJP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
impaired	impair	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
all	all	DT	B-NP	O	O
test	test	NN	I-NP	O	O
metals	metal	NNS	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
only	only	RB	B-NP	O	O
zinc	zinc	NN	I-NP	O	S-drug
demonstrated	demonstrate	VBD	B-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
.	.	.	O	O	O

Mixtures	Mixture	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cadmium	cadmium	NN	B-NP	O	O
and	and	CC	I-NP	O	O
zinc	zinc	NN	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
metal	metal	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
but	but	CC	O	O	O
only	only	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
50000	50000	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
.	.	.	O	O	O

Excystment	Excystment	NN	B-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
was	be	VBD	B-VP	O	O
only	only	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cercariae	cercariae	NNS	B-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
cadmium	cadmium	NN	B-NP	O	O
/	/	SYM	O	O	O
zinc	zinc	NN	B-NP	O	O
mixtures	mixture	NNS	I-NP	O	O
whilst	whilst	IN	B-PP	O	O
encysting	encyste	VBG	B-NP	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
four	four	CD	I-NP	O	O
h	h	NN	I-NP	O	O
exposures	exposure	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fully	fully	RB	B-NP	O	O
formed	form	VBN	I-NP	O	O
cysts	cyst	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
excystment	excystment	NN	B-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
excystment	excystment	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2	2	CD	I-NP	O	O
h	h	NN	I-NP	O	O
period	period	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
widespread	widespread	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
cercariae	cercariae	NN	B-NP	O	O
-	-	HYPH	O	O	O
exposed	expose	VBN	B-NP	O	O
P	P	NN	I-NP	O	O
.	.	.	O	O	O

acanthus	acanthus	RB	B-ADVP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
excystment	excystment	NN	B-NP	O	O
rates	rate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cyst	cyst	NN	B-NP	B-DNA	O
-	-	HYPH	B-NP	I-DNA	O
exposed	expose	VBN	I-NP	I-DNA	O
parasites	parasite	NNS	I-NP	I-DNA	O
.	.	.	O	O	O

Toxicity	Toxicity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cadmium	cadmium	NN	B-NP	O	O
and	and	CC	I-NP	O	O
zinc	zinc	NN	I-NP	O	S-drug
to	to	TO	B-PP	O	O
miracidia	miracidia	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Schistosoma	Schistosoma	NNP	B-NP	O	O
mansoni	mansoni	NNP	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
objectives	objective	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
elucidate	elucidate	VB	I-VP	O	O
metal	metal	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
hatching	hatching	NN	B-NP	O	O
,	,	,	I-NP	O	O
survival	survival	NN	I-NP	O	O
and	and	CC	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
behaviour	behaviour	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Schistosoma	Schistosoma	NNP	B-NP	O	O
mansoni	mansoni	NNP	I-NP	O	O
miracidia	miracidia	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cadmium	cadmium	NN	B-NP	O	O
,	,	,	O	O	O
zinc	zinc	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
cadmium	cadmium	NN	B-NP	O	O
/	/	SYM	O	O	O
zinc	zinc	NN	B-NP	O	O
mixtures	mixture	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
10000	10000	CD	B-NP	O	O
to	to	TO	I-NP	O	O
10	10	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
l	l	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Metal	Metal	NN	B-NP	O	O
mixture	mixture	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
investigation	investigation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
equal	equal	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metals	metal	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hatching	hatching	NN	I-NP	O	O
of	of	IN	B-PP	O	O
miracidia	miracidia	NN	B-NP	O	O
from	from	IN	B-PP	O	O
eggs	egg	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
1000	1000	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
10000	10000	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
metals	metal	NNS	I-NP	O	O
.	.	.	O	O	O

Metal	Metal	NN	B-NP	O	O
mixtures	mixture	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
egg	egg	NN	B-NP	O	S-drug
hatching	hatching	NN	I-NP	O	O
.	.	.	O	O	O

Survival	Survival	NN	B-NP	O	O
of	of	IN	B-PP	O	O
miracidia	miracidia	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
metal	metal	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
except	except	IN	B-PP	O	O
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
for	for	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
metal	metal	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
where	where	WRB	B-ADVP	O	O
survival	survival	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
above	above	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

Miracidia	Miracidia	NNP	B-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
behaviour	behaviour	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
briefly	briefly	NN	B-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
heavy	heavy	JJ	B-NP	O	O
metals	metal	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
metal	metal	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
miracidia	miracidia	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
briefly	briefly	RB	I-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Importance	Importance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pharmacogenetics	pharmacogenetic	NNS	B-NP	O	O
]	]	)	O	O	O
;	;	:	O	O	O
Pharmacogenetics	Pharmacogenetics	NNP	B-NP	O	O
deals	deal	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
genetic	genetic	JJ	B-NP	O	O
variation	variation	NN	I-NP	O	O
.	.	.	O	O	O

Differences	Difference	NNS	B-NP	O	O
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

Genetic	Genetic	JJ	B-NP	O	O
variation	variation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
slow	slow	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
important	important	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
example	example	NN	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	S-group
or	or	CC	O	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
.	.	.	O	O	O

Genetic	Genetic	JJ	B-NP	O	O
variation	variation	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
occurs	occur	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
proteins	protein	NNS	B-NP	O	O
interacting	interact	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O

asthma	asthma	NN	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
antipsychotics	antipsychotic	NNS	I-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
selection	selection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
dosages	dosage	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
improved	improve	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
reduced	reduce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pharmacogenetic	pharmacogenetic	JJ	B-NP	O	O
investigations	investigation	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
important	important	JJ	B-ADJP	O	O
also	also	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
case	case	NN	B-NP	O	O
of	of	IN	B-PP	O	O
medical	medical	JJ	B-NP	O	O
examinations	examination	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
insurances	insurance	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
job	job	NN	I-NP	O	O
appointments	appointment	NNS	I-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
turn	turn	VB	I-VP	O	O
out	out	RP	B-PRT	O	O
to	to	TO	B-VP	O	O
need	need	VB	I-VP	O	O
expensive	expensive	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
or	or	CC	O	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
susceptible	susceptible	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
certain	certain	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
genetic	genetic	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
instances	instance	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
regulated	regulate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Quetiapine	Quetiapine	NN	B-NP	O	B-drug
fumarate	fumarate	NN	I-NP	O	E-drug
(	(	(	O	O	O
'	'	``	O	O	O
Seroquel	Seroquel	NNP	B-NP	O	S-brand
'	'	''	O	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
newly	newly	RB	I-NP	O	O
introduced	introduce	VBN	I-NP	O	O
atypical	atypical	JJ	I-NP	O	B-group
antipsychotic	antipsychotic	JJ	I-NP	O	E-group
with	with	IN	B-PP	O	O
demonstrated	demonstrate	VBN	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
positive	positive	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
negative	negative	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
extensively	extensively	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
,	,	,	O	O	O
predominantly	predominantly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
or	or	CC	I-VP	O	O
inhibit	inhibit	VBP	I-VP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
quetiapine	quetiapine	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-1
did	do	VBD	B-VP	O	O
indeed	indeed	RB	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clearance	clearance	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
DSM	DSM	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
IV	IV	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
diagnosed	diagnose	VBN	I-NP	O	O
schizophrenia	schizophrenia	NN	I-NP	O	O
,	,	,	O	O	O
schizoaffective	schizoaffective	JJ	B-NP	O	O
disorder	disorder	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
bipolar	bipolar	JJ	B-NP	O	O
disorder	disorder	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
and	and	CC	O	O	O
that	that	DT	O	O	O
caution	caution	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
or	or	CC	I-VP	O	O
induce	induce	VBP	I-VP	O	O
cytochromes	cytochrome	NNS	B-NP	B-protein	O
,	,	,	O	O	O
particularly	particularly	RB	B-NP	O	O
P450	P450	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
coadministered	coadministere	VBN	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
coadministered	coadministere	VBN	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Acetaminophen	Acetaminophen	NN	B-NP	O	S-drug
,	,	,	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
were	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
pooled	pool	VBN	B-NP	O	O
human	human	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
at	at	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
each	each	DT	B-NP	O	O
preparation	preparation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
one	one	CD	B-NP	O	O
additional	additional	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
at	at	IN	B-PP	O	O
three	three	CD	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
toxic	toxic	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
eight	eight	CD	I-NP	O	O
target	target	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
added	add	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
combinations	combination	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
:	:	:	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
/	/	SYM	B-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug
.	.	.	O	O	O

acetaminophen	acetaminophen	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
,	,	,	O	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
quinidine	quinidine	NN	I-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
/	/	SYM	B-VP	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
/	/	SYM	B-VP	O	O
lidocaine	lidocaine	NN	B-NP	O	S-drug
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
/	/	SYM	B-VP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
without	without	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
added	add	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
supplemented	supplement	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
three	three	CD	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
dialyzed	dialyze	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
phosphate	phosphate	NN	B-NP	O	O
buffer	buffer	NN	I-NP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-VP	O	O
dialyzed	dialyze	VBN	I-VP	O	O
were	be	VBD	B-VP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
both	both	CC	B-PP	O	O
alone	alone	RB	I-PP	O	O
at	at	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
three	three	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
percentage	percentage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
preparation	preparation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
.	.	.	O	O	O

Acetaminophen	Acetaminophen	NN	B-NP	O	S-drug-ME-1
diminished	diminish	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
net	net	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5.7	5.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
percentage	percentage	NN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
[	[	(	O	O	O
FDF	FDF	NN	B-NP	B-protein	O
]	]	)	O	O	O
,	,	,	O	O	O
11.0	11.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
662	662	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
and	and	CC	B-PP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
net	net	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
of	of	IN	B-PP	O	O
7.1	7.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
percentage	percentage	NN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
FDF	FDF	NN	B-NP	B-protein	O
,	,	,	O	O	O
13.7	13.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
1324	1324	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug-ME-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
net	net	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6.8	6.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
percentage	percentage	NN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
FDF	FDF	NN	B-NP	B-protein	O
,	,	,	O	O	O
8.8	8.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
277.5	277.5	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
;	;	:	O	O	O

phenobarbital	phenobarbital	NN	B-NP	O	S-drug
reduced	reduce	VBD	B-VP	O	O
it	it	PRP	B-NP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
net	net	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6.6	6.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
percentage	percentage	NN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
FDF	FDF	NN	B-NP	B-protein	O
,	,	,	O	O	O
8.5	8.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
431	431	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
.	.	.	O	O	O

Valproic	Valproic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
diminished	diminish	VBD	B-VP	O	O
binding	binding	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
net	net	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
of	of	IN	B-PP	O	O
9.9	9.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
percentage	percentage	NN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
FDF	FDF	NN	B-NP	B-protein	O
,	,	,	O	O	O
21.2	21.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
1732	1732	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
combinations	combination	NNS	I-NP	O	O
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Coingestion	Coingestion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug-EF-1
acid	acid	NN	I-NP	O	E-drug-EF-1
with	with	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-EF-2
at	at	IN	B-PP	O	O
high	high	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
toxic	toxic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
decreases	decrease	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
target	target	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
resulting	result	VBG	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
enhanced	enhance	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	O
intoxication	intoxication	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	O
intoxication	intoxication	NN	I-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
serotonin	serotonin	NN	I-NP	O	O
reuptake	reuptake	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
dramatically	dramatically	RB	B-ADVP	O	O
from	from	IN	B-PP	O	O
16.6	16.6	CD	B-NP	O	O
to	to	TO	I-NP	O	O
49.1	49.1	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	O	O	O
mL	mL	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
daily	daily	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	S-drug
had	have	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
changed	change	VBN	I-VP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
ataxia	ataxia	NN	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
typical	typical	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
genotypes	genotype	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
2C19	2C19	NN	I-NP	B-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
homozygous	homozygous	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
wild	wild	JJ	I-NP	B-DNA	O
-	-	HYPH	I-NP	I-DNA	O
type	type	NN	I-NP	I-DNA	O
alleles	allele	NNS	I-NP	I-DNA	O
(	(	(	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	S-drug
*	*	SYM	B-NP	I-protein	O
1	1	CD	I-NP	I-protein	O
/	/	SYM	I-NP	I-protein	O
*	*	SYM	I-NP	I-protein	O
1	1	CD	I-NP	I-protein	O
and	and	CC	I-NP	O	O
2C19	2C19	CD	I-NP	O	O
*	*	SYM	I-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
*	*	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	S-drug
and	and	CC	O	O	O
2C19	2C19	NN	B-NP	O	O
by	by	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Vancomycin	Vancomycin	NN	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
reversal	reversal	NN	I-NP	O	O
in	in	IN	B-PP	O	O
enterococci	enterococci	NNS	B-NP	O	O
by	by	IN	B-PP	O	O
flavonoids	flavonoid	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
vancomycin	vancomycin	NN	I-NP	O	O
-	-	HYPH	O	O	O
resistant	resistant	JJ	B-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
enterococci	enterococci	NNS	B-NP	O	O
(	(	(	O	O	O
VRE	VRE	NN	B-NP	B-DNA	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
for	for	IN	B-PP	O	O
concern	concern	NN	B-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
we	we	PRP	B-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
galangin	galangin	NN	B-NP	O	S-drug
or	or	CC	O	O	O
3,7	3,7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
dihydroxyflavone	dihydroxyflavone	NN	I-NP	O	O
with	with	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
sensitize	sensitize	VB	I-VP	O	O
resistant	resistant	JJ	B-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Enterococcus	Enterococcus	NNP	B-NP	O	O
faecalis	faecalis	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Enterococcus	Enterococcus	NN	I-NP	O	O
faecium	faecium	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
strains	strain	NNS	I-NP	O	O
.	.	.	O	O	O

Minimum	Minimum	JJ	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
MICs	MIC	NNS	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
viable	viable	JJ	B-NP	O	O
counts	count	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Iso	Iso	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
sensitest	sensitest	NN	I-NP	O	O
broth	broth	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
microtitre	microtitre	NN	I-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

MICs	MIC	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug
against	against	IN	B-PP	O	O
67	67	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
resistant	resistant	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
isolates	isolate	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
type	type	NN	I-NP	O	O
strain	strain	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enterococci	enterococci	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
lowered	lower	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
>	>	JJR	B-NP	O	O
250	250	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
mL	mL	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
1	1	CD	B-NP	O	O

4	4	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
mL	mL	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
galangin	galangin	NN	B-NP	O	S-drug
(	(	(	O	O	O
12.5	12.5	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
mL	mL	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
3,7	3,7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
dihydroxyflavone	dihydroxyflavone	NN	I-NP	O	O
(	(	(	O	O	O
6.25	6.25	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
mL	mL	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Viable	Viable	JJ	B-NP	O	O
counts	count	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
type	type	NN	B-NP	O	O
culture	culture	NN	I-NP	O	O
E	E	NN	I-NP	O	O
.	.	.	O	O	O

faecalis	faecalis	NN	B-NP	O	O
ATCC	ATCC	NN	I-NP	O	O
51299	51299	CD	I-NP	O	O
showed	show	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
flavonoids	flavonoid	NNS	I-NP	O	O
alone	alone	RB	B-NP	O	O
significantly	significantly	RB	I-NP	O	O
lowered	lower	VBN	I-NP	O	O
numbers	number	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
colony	colony	NN	B-NP	B-protein	O
forming	form	VBG	B-VP	I-protein	O
units	unit	NNS	B-NP	I-protein	O
(	(	(	O	O	O
CFUs	CFU	NNS	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

CFUs	CFU	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
)	)	)	O	O	O
CFU	CFU	NN	B-NP	O	O
mL	mL	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
by	by	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug
/	/	SYM	B-VP	O	O
flavone	flavone	NN	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
combinational	combinational	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
in	in	IN	B-PP	O	O
reversing	reverse	VBG	B-VP	O	O
vancomycin	vancomycin	NN	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enterococci	enterococci	NNS	B-NP	O	O
highlights	highlight	VBZ	B-VP	O	O
novel	novel	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
targets	target	NNS	I-NP	O	O
and	and	CC	O	O	O
has	have	VBZ	B-VP	O	O
importance	importance	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
design	design	NN	I-NP	O	O
of	of	IN	B-PP	O	O
new	new	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
regimes	regime	NNS	I-NP	O	O
against	against	IN	B-PP	O	O
resistant	resistant	JJ	B-NP	O	O
pathogens	pathogen	NNS	I-NP	O	O
.	.	.	O	O	O

Glucose	Glucose	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
exert	exert	VBP	B-VP	O	O
additive	additive	JJ	B-NP	O	O
ocular	ocular	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
renal	renal	JJ	I-NP	O	O
vasodilator	vasodilator	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
humans	human	NNS	I-NP	O	O
.	.	.	O	O	O

AIMS	AIMS	NNS	B-NP	O	O
/	/	SYM	B-NP	O	O
HYPOTHESIS	HYPOTHESIS	NN	I-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
evidence	evidence	NN	B-NP	O	O
that	that	IN	B-SBAR	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
glucose	glucose	NN	I-NP	O	S-drug
cause	cause	VBP	B-VP	O	O
renal	renal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
ocular	ocular	JJ	I-NP	O	O
vasodilation	vasodilation	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
currently	currently	RB	B-ADVP	O	O
no	no	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
hyperglycaemia	hyperglycaemia	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hyperinsulinaemia	hyperinsulinaemia	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
ocular	ocular	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
insulin	insulin	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
carried	carry	VBD	B-VP	O	O
out	out	RP	B-PRT	O	O
two	two	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
way	way	NN	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
(	(	(	O	O	O
each	each	DT	B-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
9	9	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
study	study	NN	B-NP	O	O
one	one	CD	I-NP	O	O
,	,	,	O	O	O
hyperglycaemic	hyperglycaemic	JJ	B-NP	O	O
clamps	clamp	NNS	I-NP	O	O
(	(	(	O	O	O
5.6	5.6	CD	B-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
,	,	,	O	O	O
11.1	11.1	CD	B-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
16.7	16.7	CD	I-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
during	during	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
or	or	CC	O	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
(	(	(	O	O	O
dose	dose	NN	B-NP	O	O
1	1	CD	I-NP	O	O
:	:	SYM	O	O	O
1	1	CD	B-NP	O	O
mU	mU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
;	;	:	O	O	O
dose	dose	NN	B-NP	O	O
2	2	CD	I-NP	O	O
:	:	SYM	I-NP	O	O
2	2	CD	I-NP	O	O
mU	mU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
infusion	infusion	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
identical	identical	JJ	B-NP	O	O
but	but	CC	I-NP	O	O
endogenous	endogenous	JJ	I-NP	O	O
insulin	insulin	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
blocked	block	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
somatostatin	somatostatin	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
,	,	,	O	O	O
glomerular	glomerular	JJ	B-NP	O	O
filtration	filtration	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	O	O	O
pulsatile	pulsatile	JJ	B-NP	O	O
choroidal	choroidal	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
paraaminohippurate	paraaminohippurate	NN	I-NP	O	O
method	method	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
inulin	inulin	NN	I-NP	O	O
method	method	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
laser	laser	NN	I-NP	O	O
interferometric	interferometric	JJ	I-NP	O	O
measurement	measurement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fundus	fundus	NN	B-NP	O	O
pulsation	pulsation	NN	I-NP	O	O
amplitude	amplitude	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Insulin	Insulin	NN	B-NP	B-protein	S-drug
increased	increase	VBD	B-VP	O	O
renal	renal	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
and	and	CC	O	O	O
fundus	fundus	NN	B-NP	O	O
pulsation	pulsation	NN	I-NP	O	O
amplitude	amplitude	NN	I-NP	O	O
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
the	the	DT	B-NP	O	O
glomerular	glomerular	JJ	I-NP	O	O
filtration	filtration	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

Hyperglycaemia	Hyperglycaemia	NN	B-NP	O	O
increased	increase	VBD	B-VP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
renal	renal	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
ocular	ocular	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
studied	study	VBN	B-VP	O	O
.	.	.	O	O	O

Haemodynamic	Haemodynamic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
glucose	glucose	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
were	be	VBD	B-VP	O	O
additive	additive	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
somatostatin	somatostatin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
under	under	IN	I-PP	O	O
basal	basal	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
/	/	SYM	B-NP	O	O
INTERPRETATION	INTERPRETATION	NN	I-NP	O	O
:	:	SYM	B-NP	O	O
Glucose	Glucose	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
can	can	MD	B-VP	O	O
exert	exert	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
vasodilator	vasodilator	NN	I-NP	O	O
properties	property	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
ocular	ocular	JJ	I-NP	O	O
circulation	circulation	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
find	find	VB	I-VP	O	O
out	out	RP	B-PRT	O	O
whether	whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
observation	observation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
regional	regional	JJ	I-NP	O	O
perfusion	perfusion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diabetes	diabetes	NN	B-NP	O	O
longitudinal	longitudinal	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Type	Type	NN	B-NP	O	O
I	I	CD	I-NP	O	O
(	(	(	O	O	O
insulin	insulin	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
dependent	dependent	JJ	O	O	O
)	)	)	O	O	O
diabetes	diabetes	NN	B-NP	O	O
mellitus	mellitus	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

Lack	Lack	NN	B-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
levofloxacin	levofloxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
oxycodone	oxycodone	NN	I-NP	O	S-drug
:	:	:	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
and	and	CC	O	O	O
drug	drug	NN	B-NP	O	O
disposition	disposition	NN	I-NP	O	O
.	.	.	O	O	O

Previous	Previous	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
trovafloxacin	trovafloxacin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O	S-drug-ME-1
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
opiate	opiate	NN	I-NP	O	S-group-ME-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
36	36	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
for	for	IN	B-PP	O	O
trovafloxacin	trovafloxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O	S-drug
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
failures	failure	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
oxycodone	oxycodone	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
levofloxacin	levofloxacin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Eight	Eight	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
label	label	NN	I-NP	O	O
,	,	,	O	O	O
two	two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
way	way	NN	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
to	to	TO	B-VP	O	O
receive	receive	VB	I-VP	O	O
oxycodone	oxycodone	NN	B-NP	O	S-drug
,	,	,	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
p.o	p.o	NN	I-NP	O	O
.	.	.	O	O	O

Q4H	Q4H	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
levofloxacin	levofloxacin	NN	B-NP	O	S-drug
,	,	,	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
p.o	p.o	NN	I-NP	O	O
.	.	.	O	O	O

1	1	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
after	after	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
oxycodone	oxycodone	NN	I-NP	O	S-drug
or	or	CC	I-NP	O	O
levofloxacin	levofloxacin	NN	I-NP	O	S-drug
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
p.o	p.o	NN	I-NP	O	O
.	.	.	O	O	O

alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
drawn	draw	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
0	0	CD	B-NP	O	O
,	,	,	I-NP	O	O
0.5	0.5	CD	I-NP	O	O
,	,	,	I-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
1.5	1.5	CD	I-NP	O	O
,	,	,	I-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	I-NP	O	O
4	4	CD	I-NP	O	O
,	,	,	I-NP	O	O
6	6	CD	I-NP	O	O
,	,	,	I-NP	O	O
8	8	CD	I-NP	O	O
,	,	,	I-NP	O	O
12	12	CD	I-NP	O	O
,	,	,	I-NP	O	O
18	18	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
,	,	,	O	O	O
tmax	tmax	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
determinations	determination	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
>	>	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
48.59	48.59	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
8.52	8.52	CD	B-NP	O	O
vs.	vs.	IN	B-PP	O	O
49.9	49.9	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
9.93	9.93	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
Cmax	Cmax	NN	B-NP	O	O
(	(	(	O	O	O
7.73	7.73	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.6	2.6	CD	B-NP	O	O
vs.	vs.	IN	B-PP	O	O
6.6	6.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.0	2.0	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
tmax	tmax	NN	B-NP	O	O
(	(	(	O	O	O
1.1	1.1	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.6	0.6	CD	B-NP	O	O
vs.	vs.	IN	B-PP	O	O
1.6	1.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.1	1.1	CD	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
levofloxacin	levofloxacin	NN	B-NP	O	S-drug
versus	versus	IN	B-PP	O	O
levofloxacin	levofloxacin	NN	B-NP	O	S-drug
/	/	SYM	B-NP	O	O
oxycodone	oxycodone	NN	I-NP	O	S-drug
regimens	regimen	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
oxycodone	oxycodone	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
levofloxacin	levofloxacin	NN	I-NP	O	S-drug
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
without	without	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
,	,	,	O	O	O
Cmax	Cmax	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
tmax	tmax	NN	B-NP	O	O
.	.	.	O	O	O

Lack	Lack	NN	B-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
dideoxyinosine	dideoxyinosine	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
infected	infect	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
infected	infect	VBN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
dideoxyinosine	dideoxyinosine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
used	use	VBD	B-VP	O	O
12	12	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug
study	study	NN	I-NP	O	O
dosed	dose	VBD	B-VP	O	O
subjects	subject	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
1200	1200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
7	7	CD	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
later	later	RB	B-ADVP	O	O
changed	change	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
[	[	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
5	5	CD	B-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
8	8	CD	B-NP	O	O
to	to	TO	B-PP	O	O
21	21	CD	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
21	21	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
five	five	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
/	/	SYM	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Subjects	Subject	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dideoxyinosine	dideoxyinosine	NN	B-NP	O	S-drug
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
1200	1200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
or	or	CC	O	O	O
an	an	DT	B-NP	O	O
equivalent	equivalent	JJ	I-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
8	8	CD	B-NP	O	O
to	to	TO	B-PP	O	O
21	21	CD	B-NP	O	O
.	.	.	O	O	O

Antiretroviral	Antiretroviral	JJ	B-NP	O	S-group
plasma	plasma	NN	I-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
sampling	sampling	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
7	7	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
21	21	CD	B-NP	O	O
for	for	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
7	7	CD	B-NP	O	O
and	and	CC	I-NP	O	O
21	21	CD	I-NP	O	O
for	for	IN	B-PP	O	O
dideoxyinosine	dideoxyinosine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Peripheral	Peripheral	JJ	B-NP	B-cell_type	O
mononuclear	mononuclear	JJ	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
collected	collect	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
quantitation	quantitation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phosphorylated	phosphorylate	VBN	B-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Azithromycin	Azithromycin	NN	B-NP	O	S-drug-ME-1
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
impact	impact	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug-ME-2
tmax	tmax	NN	I-NP	O	O
by	by	IN	B-PP	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
intracellular	intracellular	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
phosphorylated	phosphorylate	VBN	B-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
110	110	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Azithromycin	Azithromycin	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
dideoxyinosine	dideoxyinosine	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
safely	safely	RB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
both	both	CC	O	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
dideoxyinosine	dideoxyinosine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
midazolam	midazolam	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antinociceptive	antinociceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
metamizol	metamizol	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
indomethacin	indomethacin	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
antinociceptive	antinociceptive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
metamizol	metamizol	NN	B-NP	O	S-drug
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mouse	mouse	NN	I-NP	O	O
model	model	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
flick	flick	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hot	hot	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
plate	plate	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
.	.	.	O	O	O

Benzodiazepines	Benzodiazepine	NNS	B-NP	O	S-group
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
applying	apply	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

Measurement	Measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nociception	nociception	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-PP	O	O
benzodiazepine	benzodiazepine	NN	B-NP	O	S-group
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Diazepam	Diazepam	NN	B-NP	O	S-drug-EF-1
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
and	and	CC	O	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
injected	inject	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antinociceptive	antinociceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-EF-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
antinociceptive	antinociceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metamizol	metamizol	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
only	only	RB	B-PP	O	O
in	in	IN	I-PP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
flick	flick	NN	I-NP	O	O
test	test	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Midazolam	Midazolam	NN	B-NP	O	S-drug-EF-1
used	use	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
1.25	1.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
and	and	CC	O	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
antinociceptive	antinociceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
metamizol	metamizol	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
only	only	RB	B-PP	O	O
in	in	IN	I-PP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
flick	flick	NN	I-NP	O	O
test	test	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Pharmacological	Pharmacological	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
depression	depression	NN	B-NP	O	O
:	:	:	O	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Depression	Depression	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
reaching	reach	VBG	I-VP	O	O
epidemic	epidemic	JJ	B-NP	O	O
proportions	proportion	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
western	western	JJ	I-NP	O	O
world	world	NN	I-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
each	each	DT	B-NP	O	O
successive	successive	JJ	I-NP	O	O
generation	generation	NN	I-NP	O	O
more	more	JJR	B-NP	O	O
people	people	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
becoming	become	VBG	I-VP	O	O
more	more	RBR	B-VP	O	O
severely	severely	RB	I-VP	O	O
depressed	depress	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
younger	young	JJR	I-NP	O	O
age	age	NN	I-NP	O	O
.	.	.	O	O	O

Influence	Influence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
estradiol	estradiol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
progesterone	progesterone	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rat	rat	NN	B-NP	B-protein	O
thoracic	thoracic	JJ	I-NP	I-protein	O
aorta	aorta	NN	I-NP	I-protein	O
to	to	TO	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
high	high	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
estradiol	estradiol	NN	B-NP	O	S-drug
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
of	of	IN	B-PP	O	O
progesterone	progesterone	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
thoracic	thoracic	JJ	I-NP	O	O
aorta	aorta	NN	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
ovariectomy	ovariectomy	NN	I-NP	O	O
,	,	,	O	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
s.c	s.c	NN	I-NP	O	O
.	.	.	O	O	O

injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vehicle	vehicle	NN	B-NP	O	O
(	(	(	O	O	O
corn	corn	NN	B-NP	O	O
oil	oil	NN	I-NP	O	O
,	,	,	O	O	O
0.1	0.1	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
estradiol	estradiol	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
or	or	CC	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
progesterone	progesterone	NN	B-NP	O	S-drug
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ninth	ninth	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
sacrificed	sacrifice	VBN	I-VP	O	O
and	and	CC	O	O	O
aortic	aortic	JJ	B-NP	O	O
rings	ring	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
endothelium	endothelium	NN	B-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
generate	generate	VB	I-VP	O	O
concentration	concentration	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
response	response	NN	I-NP	O	O
curves	curve	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	O	S-drug
.	.	.	O	O	O

Aortic	Aortic	JJ	B-NP	O	O
rings	ring	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
intact	intact	JJ	B-NP	O	O
endothelium	endothelium	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
estradiol	estradiol	NN	B-NP	O	S-drug-EF-1
group	group	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
supersensitive	supersensitive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	O	S-drug-EF-2
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
or	or	CC	I-NP	O	O
low	low	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
estradiol	estradiol	NN	B-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
pD2	pD2	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
=	=	SYM	B-VP	O	O
7.86	7.86	CD	B-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
0.09	0.09	CD	I-NP	O	O
,	,	,	I-NP	O	O
7.30	7.30	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
0.11	0.11	CD	B-NP	O	O
and	and	CC	I-NP	O	O
7.35	7.35	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-VP	O	O
0.04	0.04	CD	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Endothelium	Endothelium	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
intact	intact	JJ	I-NP	O	O
aortic	aortic	JJ	I-NP	O	O
rings	ring	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
estradiol	estradiol	NN	I-NP	O	S-drug-EF-1
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
supersensitive	supersensitive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	O	S-drug-EF-2
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
vehicle	vehicle	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
,	,	,	O	O	O
progesterone	progesterone	NN	B-NP	O	S-drug
-	-	HYPH	B-ADJP	O	O
and	and	CC	O	O	O
progesterone	progesterone	NN	B-NP	O	S-drug
+	+	SYM	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
estradiol	estradiol	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
pD2	pD2	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
=	=	SYM	B-VP	O	O
7.77	7.77	CD	B-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
0.12	0.12	CD	I-NP	O	O
,	,	,	I-NP	O	O
7.21	7.21	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
0.13	0.13	CD	I-NP	O	O
,	,	,	I-NP	O	O
6.93	6.93	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
0.04	0.04	CD	B-NP	O	O
and	and	CC	I-NP	O	O
7.22	7.22	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-VP	O	O
0.18	0.18	CD	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
among	among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pD2	pD2	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
aortic	aortic	JJ	B-NP	O	O
rings	ring	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
endothelium	endothelium	NN	B-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
endothelium	endothelium	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
dependent	dependent	JJ	B-ADJP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Drug	Drug	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erection	erection	NN	B-NP	O	O
disorders	disorder	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
]	]	)	I-NP	O	O
Erectile	Erectile	JJ	I-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
condition	condition	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
arrival	arrival	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
erection	erection	NN	I-NP	O	B-group
-	-	HYPH	O	O	I-group
supporting	support	VBG	B-VP	O	I-group
medication	medication	NN	B-NP	O	E-group
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
want	want	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
know	know	VB	I-VP	O	O
how	how	WRB	B-ADVP	O	O
safe	safe	JJ	B-NP	O	O
sexual	sexual	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
general	general	JJ	B-ADJP	O	O
and	and	CC	O	O	O
during	during	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
erection	erection	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
supporting	support	VBG	B-VP	O	I-group
medication	medication	NN	B-NP	O	E-group
in	in	IN	B-PP	O	O
particular	particular	JJ	B-ADJP	O	O
.	.	.	O	O	O

Sexual	Sexual	JJ	B-NP	O	O
intercourse	intercourse	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
partner	partner	NN	I-NP	O	O
causes	cause	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
than	than	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
daily	daily	JJ	I-NP	O	O
activities	activity	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ironing	iron	VBG	B-VP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
kilometers	kilometer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
walking	walk	VBG	B-VP	O	O
without	without	IN	B-PP	O	O
climbing	climbing	NN	B-NP	O	O
,	,	,	O	O	O
paperhanging	paperhanging	NN	B-NP	O	O
,	,	,	O	O	O
playing	play	VBG	B-VP	O	O
golf	golf	NN	B-NP	O	O
or	or	CC	I-NP	O	O
gardening	gardening	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
relative	relative	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	O
infarction	infarction	NN	I-NP	O	O
during	during	IN	B-PP	O	O
sexual	sexual	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
for	for	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
persons	person	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
morbidity	morbidity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
among	among	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
sildenafil	sildenafil	NN	B-NP	O	S-drug
.	.	.	O	O	O

Sildenafil	Sildenafil	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
long	long	RB	B-ADVP	O	B-group-AD-2
-	-	HYPH	O	O	I-group-AD-2
acting	act	VBG	B-VP	O	I-group-AD-2
nitrates	nitrate	NNS	B-NP	O	E-group-AD-2
or	or	CC	O	O	O
who	who	WP	B-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
use	use	VB	I-VP	O	O
short	short	JJ	B-ADJP	O	B-group-AD-2
-	-	HYPH	B-PP	O	I-group-AD-2
acting	act	VBG	B-NP	O	I-group-AD-2
nitrates	nitrate	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
sharp	sharp	JJ	I-NP	O	O
fall	fall	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
receptor	receptor	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
antagonists	antagonist	NNS	I-NP	O	E-group
,	,	,	O	O	O
thiazide	thiazide	NN	B-NP	O	S-group
and	and	CC	I-NP	O	O
loop	loop	NN	I-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
and	and	CC	O	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
.	.	.	O	O	O

Before	Before	IN	B-PP	O	O
prescribing	prescribe	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
symptomatic	symptomatic	JJ	I-NP	O	O
(	(	(	O	O	O
pharmaceutical	pharmaceutical	JJ	B-ADJP	O	O
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
erection	erection	NN	I-NP	O	O
disorder	disorder	NN	I-NP	O	O
,	,	,	O	O	O
attention	attention	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
tot	tot	NN	B-NP	O	O
the	the	DT	B-NP	O	O
sexological	sexological	JJ	I-NP	O	O
,	,	,	I-NP	O	O
psychological	psychological	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
medical	medical	JJ	I-NP	O	O
backgrounds	background	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
disorder	disorder	NN	I-NP	O	O
.	.	.	O	O	O

Secondary	Secondary	JJ	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atherosclerotic	atherosclerotic	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
also	also	RB	B-ADVP	O	O
important	important	JJ	B-ADJP	O	O
:	:	:	O	O	O
regulation	regulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
sugar	sugar	NN	I-NP	O	O
level	level	NN	I-NP	O	O
,	,	,	O	O	O
hyperlipidaemia	hyperlipidaemia	NN	B-NP	O	O
and	and	CC	I-NP	O	O
obesity	obesity	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
a	a	DT	B-NP	O	O
change	change	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lifestyle	lifestyle	NN	B-NP	O	O
(	(	(	O	O	O
giving	give	VBG	B-VP	O	O
up	up	RP	B-PRT	O	O
smoking	smoking	NN	B-NP	O	O
,	,	,	O	O	O
adapting	adapt	VBG	B-VP	O	O
of	of	IN	B-PP	O	O
diet	diet	NN	B-NP	O	O
and	and	CC	O	O	O
more	more	RBR	B-NP	O	O
physical	physical	JJ	I-NP	O	O
exertion	exertion	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
very	very	RB	I-NP	O	O
low	low	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
capacity	capacity	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
refrain	refrain	VB	I-VP	O	O
from	from	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
erection	erection	NN	I-NP	O	O
disorder	disorder	NN	I-NP	O	O
.	.	.	O	O	O

Influence	Influence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
and	and	CC	O	O	O
QTc	QTc	NN	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

STUDY	STUDY	NN	B-NP	O	O
OBJECTIVE	OBJECTIVE	NN	I-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
and	and	CC	O	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
men	man	NNS	I-NP	O	O
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
Open	Open	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
label	label	NN	I-NP	O	O
,	,	,	O	O	O
three	three	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
phase	phase	NN	I-NP	O	O
,	,	,	O	O	O
sequential	sequential	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

SETTING	SETTING	NN	B-NP	O	O
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
research	research	NN	I-NP	O	O
center	center	NN	I-NP	O	O
.	.	.	O	O	O

SUBJECTS	SUBJECTS	NNS	B-NP	O	O
:	:	:	O	O	O
Twelve	Twelve	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

INTERVENTIONS	INTERVENTIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Each	Each	DT	B-NP	O	O
subject	subject	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
sequence	sequence	NN	I-NP	O	O
:	:	:	O	O	O
baseline	baseline	NN	B-NP	O	O
;	;	:	O	O	O

phase	phase	NN	B-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
days	day	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
4	4	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
/	/	SYM	I-NP	O	O
day	day	NN	I-NP	O	O
;	;	:	O	O	O

washout	washout	NN	B-NP	O	O
(	(	(	O	O	O
days	day	NNS	B-NP	O	O
7	7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
13	13	CD	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

phase	phase	NN	B-NP	O	O
2	2	CD	I-NP	O	O
(	(	(	O	O	O
days	day	NNS	B-NP	O	O
14	14	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
44	44	CD	I-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
phase	phase	NN	B-NP	O	O
3	3	CD	I-NP	O	O
(	(	(	O	O	O
days	day	NNS	B-NP	O	O
45	45	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
52	52	CD	I-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
4	4	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
days	day	NNS	B-NP	O	O
45	45	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
51	51	CD	I-NP	O	O
)	)	)	O	O	O
plus	plus	CC	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
days	day	NNS	B-NP	O	O
45	45	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
52	52	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

MEASUREMENTS	MEASUREMENTS	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
MAIN	MAIN	NN	I-NP	O	O
RESULTS	RESULTS	NNS	I-NP	O	O
:	:	:	O	O	O
Blood	Blood	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
drawn	draw	VBN	I-VP	O	O
and	and	CC	O	O	O
12	12	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
lead	lead	NN	I-NP	O	O
electrocardiograms	electrocardiogram	NNS	I-NP	O	O
performed	perform	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
specified	specify	VBN	B-NP	O	O
time	time	NN	I-NP	O	O
points	point	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
morning	morning	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
phases	phase	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
were	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
morning	morning	NN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
3rd	3rd	NN	I-NP	O	O
,	,	,	O	O	O
4th	4th	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
5th	5th	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phases	phase	NNS	B-NP	B-protein	O
1	1	CD	I-NP	I-protein	O
and	and	CC	I-NP	I-protein	O
3	3	CD	I-NP	I-protein	O
.	.	.	O	O	O

Electrocardiograms	Electrocardiogram	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
done	do	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
washout	washout	NN	I-NP	O	O
period	period	NN	I-NP	O	O
and	and	CC	O	O	O
phase	phase	NN	B-NP	O	O
2	2	CD	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-ME-1
significantly	significantly	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
corrected	correct	VBN	B-NP	O	O
QT	QT	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
with	with	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cisapride	Cisapride	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
with	with	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Cisapride	Cisapride	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
safely	safely	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
low	low	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
dosages	dosage	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Olanzapine	Olanzapine	NN	B-NP	O	S-drug
:	:	:	O	O	O
an	an	DT	B-NP	O	O
updated	update	VBN	I-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
.	.	.	O	O	O

Olanzapine	Olanzapine	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
thienobenzodiazepine	thienobenzodiazepine	NN	I-NP	O	B-group
derivative	derivative	NN	I-NP	O	E-group
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	B-group
generation	generation	NN	I-NP	O	I-group
(	(	(	O	O	I-group
atypical	atypical	JJ	B-ADJP	O	I-group
)	)	)	O	O	I-group
antipsychotic	antipsychotic	JJ	B-NP	O	I-group
agent	agent	NN	I-NP	O	E-group
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
proven	prove	VBN	I-VP	O	O
efficacy	efficacy	NN	B-NP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
negative	negative	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
.	.	.	O	O	O

Compared	Compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
conventional	conventional	JJ	B-NP	O	B-group
antipsychotics	antipsychotic	NNS	I-NP	O	E-group
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
greater	great	JJR	B-NP	O	O
affinity	affinity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	B-protein	O
5	5	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
HT2A	HT2A	NN	I-NP	B-protein	O
than	than	IN	B-PP	O	O
for	for	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	B-protein	O
D2	D2	NN	I-NP	I-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
,	,	,	I-NP	O	O
well	well	RB	I-NP	O	O
controlled	controlled	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
or	or	CC	O	O	O
related	related	JJ	B-NP	O	O
psychoses	psychos	NNS	I-NP	O	O
,	,	,	O	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
5	5	CD	I-NP	O	O
to	to	TO	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
superior	superior	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
5	5	CD	I-NP	O	O
to	to	TO	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
in	in	IN	B-PP	O	O
overall	overall	JJ	B-NP	O	O
improvements	improvement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
psychopathology	psychopathology	NN	B-NP	O	O
rating	rating	NN	I-NP	O	O
scales	scale	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
depressive	depressive	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
negative	negative	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
comparable	comparable	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
effects	effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
positive	positive	JJ	B-NP	O	O
psychotic	psychotic	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
relapse	relapse	NN	B-NP	O	O
(	(	(	O	O	O
rehospitalisation	rehospitalisation	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
comparative	comparative	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
(	(	(	O	O	O
28	28	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
week	week	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
risperidone	risperidone	NN	I-NP	O	S-drug
,	,	,	O	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
10	10	CD	I-NP	O	O
to	to	TO	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
proved	prove	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
more	more	RBR	I-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
than	than	IN	B-SBAR	O	O
risperidone	risperidone	NN	B-NP	O	S-drug
4	4	CD	I-NP	O	O
to	to	TO	I-NP	O	O
12	12	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
negative	negative	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
depressive	depressive	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
on	on	IN	I-PP	O	O
overall	overall	JJ	B-NP	O	O
psychopathology	psychopathology	NN	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
preliminary	preliminary	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
an	an	DT	B-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
controlled	control	VBN	I-NP	O	O
study	study	NN	I-NP	O	O
suggested	suggest	VBD	B-VP	O	O
risperidone	risperidone	NN	B-NP	O	S-drug
2	2	CD	I-NP	O	O
to	to	TO	I-NP	O	O
6	6	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
superior	superior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
5	5	CD	I-NP	O	O
to	to	TO	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
against	against	IN	B-PP	O	O
positive	positive	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
anxiety	anxiety	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
depressive	depressive	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
on	on	IN	B-PP	O	O
measures	measure	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
overall	overall	JJ	B-NP	O	O
psychopathology	psychopathology	NN	I-NP	O	O
.	.	.	O	O	O

Improvements	Improvement	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
seen	see	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
controlled	control	VBN	B-VP	O	O
study	study	NN	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
phase	phase	NN	I-NP	O	O
schizophrenia	schizophrenia	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
seen	see	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
risperidone	risperidone	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
haloperidol	haloperidol	NN	I-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
preliminary	preliminary	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
an	an	DT	B-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
trial	trial	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
comparable	comparable	JJ	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	O
enhancing	enhance	VBG	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
risperidone	risperidone	NN	I-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
or	or	CC	O	O	O
schizoaffective	schizoaffective	JJ	B-NP	O	O
disorder	disorder	NN	I-NP	O	O
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
benefits	benefit	NNS	B-NP	O	O
against	against	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
aggression	aggression	NN	B-NP	O	O
and	and	CC	I-NP	O	O
agitation	agitation	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
other	other	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
strongly	strongly	RB	B-ADVP	O	O
support	support	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
depressive	depressive	JJ	B-NP	O	O
symptomatology	symptomatology	NN	I-NP	O	O
.	.	.	O	O	O

Olanzapine	Olanzapine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
significantly	significantly	RB	B-NP	O	O
fewer	few	JJR	I-NP	O	O
extrapyramidal	extrapyramidal	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
risperidone	risperidone	NN	I-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
agranulocytosis	agranulocytosis	NN	B-NP	O	O
as	as	IN	B-SBAR	O	O
seen	see	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
hyperprolactinaemia	hyperprolactinaemia	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
seen	see	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
reported	report	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
bodyweight	bodyweight	JJ	B-NP	O	O
gain	gain	NN	I-NP	O	O
,	,	,	O	O	O
somnolence	somnolence	NN	B-NP	O	O
,	,	,	O	O	O
dizziness	dizziness	NN	B-NP	O	O
,	,	,	O	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
(	(	(	O	O	O
constipation	constipation	NN	B-NP	O	O
and	and	CC	O	O	O
dry	dry	JJ	B-NP	O	O
mouth	mouth	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
transient	transient	JJ	B-NP	O	O
asymptomatic	asymptomatic	JJ	I-NP	O	O
liver	liver	NN	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
elevations	elevation	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
with	with	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
reported	report	VBN	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
more	more	RBR	I-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
3.5	3.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
dry	dry	JJ	B-NP	O	O
mouth	mouth	NN	I-NP	O	O
,	,	,	O	O	O
bodyweight	bodyweight	NN	B-NP	O	O
gain	gain	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
appetite	appetite	NN	B-NP	O	O
and	and	CC	O	O	O
compared	compare	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	O	S-drug
,	,	,	O	O	O
only	only	RB	B-NP	O	O
bodyweight	bodyweight	NN	I-NP	O	O
gain	gain	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
more	more	RBR	I-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
acquisition	acquisition	NN	I-NP	O	O
cost	cost	NN	I-NP	O	O
of	of	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
offset	offset	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
reductions	reduction	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
costs	cost	NNS	I-NP	O	O
(	(	(	O	O	O
inpatient	inpatient	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
outpatient	outpatient	NN	B-NP	O	O
services	service	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
.	.	.	O	O	O

Pharmacoeconomic	Pharmacoeconomic	JJ	B-NP	O	O
analyses	analysis	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
even	even	RB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
direct	direct	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
costs	cost	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Compared	Compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	O	S-drug
,	,	,	O	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
overall	overall	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
costs	cost	NNS	I-NP	O	O
,	,	,	O	O	O
despite	despite	IN	B-PP	O	O
the	the	DT	B-NP	O	O
several	several	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	I-NP	O	O
higher	high	JJR	I-NP	O	O
daily	daily	JJ	I-NP	O	O
acquisition	acquisition	NN	I-NP	O	O
cost	cost	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Olanzapine	Olanzapine	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
improves	improve	VBZ	B-VP	O	O
quality	quality	NN	B-NP	O	O
of	of	IN	B-PP	O	O
life	life	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
and	and	CC	O	O	O
related	related	JJ	B-NP	O	O
psychoses	psychos	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
extent	extent	NN	I-NP	O	O
than	than	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
to	to	TO	B-PP	O	O
broadly	broadly	RB	B-NP	O	O
the	the	DT	I-NP	O	O
same	same	JJ	I-NP	O	O
extent	extent	NN	I-NP	O	O
as	as	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	O	S-drug
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Olanzapine	Olanzapine	NN	B-NP	O	S-drug
demonstrated	demonstrate	VBD	B-VP	O	O
superior	superior	JJ	B-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
phase	phase	NN	I-NP	O	O
schizophrenia	schizophrenia	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
first	first	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
episode	episode	NN	I-NP	O	O
or	or	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
schizophrenia	schizophrenia	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
and	and	CC	O	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
superiority	superiority	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
risperidone	risperidone	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
negative	negative	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
depressive	depressive	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
support	support	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
choice	choice	NN	I-NP	O	O
of	of	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	O	S-drug
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	I-NP	O	O
option	option	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
phase	phase	NN	I-NP	O	O
and	and	CC	B-PP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
emerging	emerge	VBG	I-NP	O	O
roles	role	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
non	non	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	B-protein	I-group
nucleoside	nucleoside	NN	I-NP	I-protein	I-group
reverse	reverse	JJ	I-NP	I-protein	I-group
transcriptase	transcriptase	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
in	in	IN	B-PP	O	O
antiretroviral	antiretroviral	JJ	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
availability	availability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
non	non	AFX	I-NP	O	B-group
-	-	HYPH	I-NP	B-protein	I-group
nucleoside	nucleoside	NN	I-NP	I-protein	I-group
reverse	reverse	JJ	I-NP	I-protein	I-group
transcriptase	transcriptase	NN	I-NP	I-protein	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
(	(	(	O	O	O
NNRTI	NNRTI	NN	B-NP	O	S-group
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
antiretroviral	antiretroviral	JJ	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
concerns	concern	NNS	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
protease	protease	NN	B-NP	O	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
(	(	(	O	O	O
PI	PI	NN	B-NP	O	S-group
)	)	)	O	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
led	lead	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
significant	significant	JJ	B-NP	O	O
shifts	shift	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
practices	practice	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
infection	infection	NN	I-NP	O	O
.	.	.	O	O	O

NNRTI	NNRTI	NN	B-NP	B-protein	S-group
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
several	several	JJ	B-NP	O	O
advantages	advantage	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
PI	PI	NN	B-NP	B-protein	S-group
-	-	HYPH	O	O	O
based	base	VBN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
more	more	RBR	B-NP	O	O
convenient	convenient	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
,	,	,	O	O	O
lower	low	JJR	B-NP	O	O
tablet	tablet	NN	I-NP	O	O
volume	volume	NN	I-NP	O	O
,	,	,	O	O	O
fewer	few	JJR	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
central	central	JJ	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
penetration	penetration	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
prospective	prospective	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
currently	currently	RB	B-ADVP	O	O
exist	exist	VBP	B-VP	O	O
comparing	compare	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
3	3	CD	I-NP	O	O
approved	approve	VBN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
,	,	,	O	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
delavirdine	delavirdine	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
nevirapine	nevirapine	NN	I-NP	O	S-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
compared	compare	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
triple	triple	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PI	PI	NN	I-NP	O	S-group
indinavir	indinavir	NN	I-NP	O	S-drug
over	over	IN	B-PP	O	O
48	48	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
being	be	VBG	B-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
regimens	regimen	NNS	I-NP	O	O
and	and	CC	O	O	O
superiority	superiority	NN	B-NP	O	O
observed	observe	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
.	.	.	O	O	O

A	A	DT	B-NP	O	O
smaller	small	JJR	I-NP	O	O
24	24	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
study	study	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
superior	superior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
PI	PI	NN	I-NP	B-DNA	S-group
nelfinavir	nelfinavir	NN	I-NP	I-DNA	S-drug
.	.	.	O	O	O

Limited	Limit	VBN	B-NP	O	O
comparative	comparative	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
viral	viral	JJ	I-NP	O	O
loads	load	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nevirapine	nevirapine	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
or	or	CC	I-NP	O	O
delavirdine	delavirdine	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
based	base	VBN	B-NP	O	O
regimens	regimen	NNS	I-NP	O	O
currently	currently	RB	B-ADVP	O	O
exist	exist	VBP	B-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
cohort	cohort	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
and	and	CC	O	O	O
selected	select	VBN	B-NP	O	O
patient	patient	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
comparable	comparable	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
PI	PI	NN	B-NP	B-protein	S-group
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
superiority	superiority	NN	I-NP	O	O
of	of	IN	B-PP	O	O
efavirenz	efavirenz	NN	B-NP	O	S-drug
over	over	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
comparative	comparative	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
viral	viral	JJ	I-NP	O	O
loads	load	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
experienced	experience	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
available	available	JJ	B-NP	O	O
uncontrolled	uncontrolled	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
contribute	contribute	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
regimen	regimen	VB	I-VP	O	O
efficacy	efficacy	NN	B-NP	O	O
in	in	IN	B-PP	O	O
NNRTI	NNRTI	NN	B-NP	B-protein	S-group
-	-	HYPH	B-NP	O	O
na	na	NN	I-NP	O	O
ve	ve	NN	I-NP	O	O
,	,	,	O	O	O
treatment	treatment	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
experienced	experience	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Efavirenz	Efavirenz	NNP	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
superiority	superiority	NN	B-NP	O	O
over	over	IN	B-PP	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
nucleoside	nucleoside	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
experienced	experience	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
combining	combine	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
2	2	CD	I-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
represent	represent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
best	good	JJS	I-NP	O	O
approach	approach	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
circumstances	circumstance	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NNRTIs	NNRTI	NNS	B-NP	B-protein	S-group
appears	appear	VBZ	B-VP	O	O
generally	generally	RB	B-ADVP	O	O
good	good	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
few	few	JJ	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
discontinuing	discontinue	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
majority	majority	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
NNRTIs	NNRTI	NNS	B-NP	O	S-group
occur	occur	VBP	B-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
month	month	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
are	be	VBP	B-VP	O	O
predictable	predictable	JJ	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
manageable	manageable	JJ	I-ADJP	O	O
without	without	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
interruption	interruption	NN	I-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Pharmacologic	Pharmacologic	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
:	:	:	O	O	O
corrective	corrective	JJ	B-NP	O	O
measures	measure	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
basic	basic	JJ	I-NP	O	O
area	area	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rural	rural	JJ	B-NP	O	O
health	health	NN	I-NP	O	O
]	]	)	I-NP	O	O
OBJECTIVES	OBJECTIVES	NNS	I-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
(	(	(	O	O	O
PICR	PICR	NN	B-NP	B-protein	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
authorization	authorization	NN	I-NP	O	O
cards	card	NNS	I-NP	O	O
(	(	(	O	O	O
MAC	MAC	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
chronically	chronically	RB	I-NP	O	O
ill	ill	JJ	I-NP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
establish	establish	VB	I-VP	O	O
strategies	strategy	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
minimise	minimise	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
Cross	Cross	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
sectional	sectional	JJ	I-NP	O	O
descriptive	descriptive	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

SETTING	SETTING	NN	B-NP	O	O
:	:	:	O	O	O
Rural	Rural	JJ	B-NP	O	O
primary	primary	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
centre	centre	NN	I-NP	O	O
.	.	.	O	O	O

PATIENTS	PATIENTS	NNS	B-NP	O	O
:	:	:	O	O	O
Random	Random	NN	B-NP	O	O
sample	sample	NN	I-NP	O	O
of	of	IN	B-PP	O	O
626	626	CD	B-NP	O	O
MAC	MAC	NNP	I-NP	O	O
out	out	IN	B-PP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1306	1306	CD	B-NP	O	O
.	.	.	O	O	O

MEASUREMENTS	MEASUREMENTS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
MAIN	MAIN	NN	I-NP	O	O
RESULTS	RESULTS	NNS	I-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
December	December	NNP	B-NP	O	O
1998	1998	CD	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
gathered	gather	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
every	every	DT	B-NP	O	O
MAC	MAC	NN	I-NP	B-protein	O
with	with	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
one	one	CD	I-NP	O	O
drug	drug	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
:	:	:	O	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
sex	sex	NN	B-NP	O	O
,	,	,	O	O	O
number	number	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
,	,	,	O	O	O
intrinsic	intrinsic	JJ	B-NP	O	O
value	value	NN	I-NP	O	O
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
prescribed	prescribe	VBN	B-VP	O	O
,	,	,	O	O	O
daily	daily	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	O	O	O
pharmacological	pharmacological	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
(	(	(	O	O	O
PI	PI	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
classified	classify	VBN	B-VP	O	O
(	(	(	O	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
scale	scale	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Hansten	Hansten	NNP	B-NP	O	O
1996	1996	CD	I-NP	O	O
)	)	)	O	O	O
into	into	IN	B-PP	O	O
light	light	NN	B-NP	O	O
and	and	CC	O	O	O
clinically	clinically	RB	B-ADJP	O	O
relevant	relevant	JJ	I-ADJP	O	O
.	.	.	O	O	O

Statistical	Statistical	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
:	:	:	O	O	O
Mantel	Mantel	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Haenszel	Haenszel	NNP	I-NP	O	O
(	(	(	O	O	O
alpha	alpha	SYM	B-NP	O	O
=	=	SYM	B-VP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
'	'	POS	B-NP	O	O
mean	mean	JJ	I-NP	O	O
age	age	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
69.1	69.1	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.2	1.2	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
per	per	IN	B-PP	O	O
MAC	MAC	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
4	4	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.2	0.2	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

341	341	CD	B-NP	O	O
PI	PI	NN	I-NP	O	O
affecting	affect	VBG	B-VP	O	O
197	197	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
31.5	31.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
3.6	3.6	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

24.9	24.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4.5	4.5	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
PICR	PICR	NN	B-NP	B-protein	O
,	,	,	O	O	O
detected	detect	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
11.7	11.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.5	2.5	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
MAC	MAC	NNP	I-NP	B-cell_type	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
existence	existence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PI	PI	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
prescribed	prescribe	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
each	each	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
26	26	CD	B-NP	O	O
PI	PI	NN	I-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
intrinsic	intrinsic	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
(	(	(	O	O	O
7.6	7.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.8	2.8	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

74.1	74.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
9.3	9.3	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
PICR	PICR	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
simple	simple	JJ	B-NP	O	O
recommendations	recommendation	NNS	I-NP	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
the	the	DT	B-NP	O	O
remaining	remain	VBG	I-NP	O	O
25.9	25.9	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
9.3	9.3	CD	B-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
monitoring	monitor	VBG	B-VP	O	O
and	and	CC	O	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
important	important	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
most	most	RBS	B-VP	O	O
commonly	commonly	RB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PICR	PICR	NN	I-NP	B-protein	O
so	so	RB	B-SBAR	O	O
as	as	IN	I-SBAR	O	O
to	to	TO	B-VP	O	O
establish	establish	VB	I-VP	O	O
corrective	corrective	JJ	B-NP	O	O
measures	measure	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
minimise	minimise	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
arising	arise	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
educational	educational	JJ	I-NP	O	O
messages	message	NNS	I-NP	O	O
advise	advise	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
over	over	IN	B-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PICR	PICR	NN	I-NP	B-protein	O
detected	detect	VBN	B-VP	O	O
.	.	.	O	O	O

Prescribing	Prescribe	VBG	B-VP	O	O
.	.	.	O	O	O

Keys	Key	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
maximizing	maximize	VBG	B-VP	O	O
benefit	benefit	NN	B-NP	O	O
while	while	IN	B-SBAR	O	O
avoiding	avoid	VBG	B-VP	O	O
adverse	adverse	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
prescribing	prescribe	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
some	some	DT	B-NP	O	O
physicians	physician	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
overly	overly	RB	B-ADJP	O	O
cautious	cautious	JJ	I-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
strategy	strategy	NN	I-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
less	less	JJR	I-NP	O	O
than	than	IN	B-PP	O	O
optimal	optimal	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reluctance	reluctance	NN	I-NP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
aggressively	aggressively	RB	B-ADVP	O	O
is	be	VBZ	B-VP	O	O
understandable	understandable	JJ	B-ADJP	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
geriatric	geriatric	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
susceptible	susceptible	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
key	key	NN	I-NP	O	O
to	to	TO	B-PP	O	O
maximizing	maximize	VBG	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
lies	lie	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
individualizing	individualize	VBG	B-VP	O	O
it	it	PRP	B-NP	O	O
as	as	RB	B-ADVP	O	O
much	much	RB	I-ADVP	O	O
as	as	IN	B-PP	O	O
possible	possible	JJ	B-ADJP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
steps	step	NNS	B-NP	O	O
physicians	physician	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
take	take	VB	I-VP	O	O
to	to	TO	B-VP	O	O
ensure	ensure	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
their	their	PRP$	B-NP	O	O
patients	patient	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
being	be	VBG	I-VP	O	O
undertreated	undertreate	VBN	I-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
steps	step	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
regular	regular	JJ	B-NP	O	O
reevaluations	reevaluation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dosages	dosage	NNS	B-NP	O	O
and	and	CC	O	O	O
plasma	plasma	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
recognition	recognition	NN	B-NP	O	O
and	and	CC	I-NP	O	O
understanding	understanding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
avoidance	avoidance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Close	Close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
allows	allow	VBZ	B-VP	O	O
physicians	physician	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
minimize	minimize	VB	I-VP	O	O
risks	risk	NNS	B-NP	O	O
,	,	,	O	O	O
maximize	maximize	VB	B-VP	O	O
benefits	benefit	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
get	get	VB	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
out	out	IN	B-PP	O	O
of	of	IN	B-PP	O	O
what	what	WP	B-NP	O	O
modern	modern	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
do	do	VB	I-VP	O	O
to	to	TO	B-VP	O	O
help	help	VB	I-VP	O	O
older	old	JJR	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Sildenafil	Sildenafil	NN	B-NP	O	B-drug
citrate	citrate	NN	I-NP	O	E-drug
:	:	:	O	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
update	update	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Since	Since	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
approval	approval	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
US	US	NNP	I-NP	O	O
Food	Food	NNP	I-NP	O	O
and	and	CC	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Administration	Administration	NNP	I-NP	O	O
in	in	IN	B-PP	O	O
March	March	NNP	B-NP	O	O
1998	1998	CD	I-NP	O	O
,	,	,	O	O	O
sildenafil	sildenafil	NN	B-NP	O	B-drug
citrate	citrate	NN	I-NP	O	E-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
millions	million	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
men	man	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erectile	erectile	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
.	.	.	O	O	O

Recent	Recent	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
and	and	CC	O	O	O
consensus	consensus	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
expanded	expand	VBN	I-VP	O	O
our	our	PRP$	B-NP	O	O
understanding	understanding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
safety	safety	NN	B-NP	O	O
,	,	,	O	O	O
contraindications	contraindication	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
reviews	review	VBZ	B-VP	O	O
recent	recent	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sildenafil	sildenafil	NN	B-NP	O	S-drug
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
socioeconomic	socioeconomic	JJ	B-NP	B-protein	O
factors	factor	NNS	I-NP	I-protein	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
focus	focus	NN	I-NP	O	O
on	on	IN	B-PP	O	O
specific	specific	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
populations	population	NNS	I-NP	O	O
(	(	(	O	O	O
prostate	prostate	NN	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
,	,	,	O	O	O
diabetes	diabetes	NN	B-NP	O	O
mellitus	mellitus	NN	I-NP	O	O
,	,	,	O	O	O
ischemic	ischemic	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
,	,	,	O	O	O
spinal	spinal	JJ	B-NP	O	O
cord	cord	NN	I-NP	O	O
injuries	injury	NNS	I-NP	O	O
,	,	,	O	O	O
neurologic	neurologic	JJ	B-NP	O	O
disorders	disorder	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
case	case	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
commentaries	commentary	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
editorials	editorial	NNS	I-NP	O	O
concerning	concern	VBG	B-PP	O	O
sildenafil	sildenafil	NN	B-NP	O	S-drug
published	publish	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
international	international	JJ	I-NP	O	O
literature	literature	NN	I-NP	O	O
between	between	IN	B-PP	O	O
January	January	NNP	B-NP	O	O
1999	1999	CD	I-NP	O	O
and	and	CC	O	O	O
August	August	NNP	B-NP	O	O
2000	2000	CD	I-NP	O	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
searches	search	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
MEDLINE	MEDLINE	NNP	B-NP	O	O
,	,	,	O	O	O
PREMEDLINE	PREMEDLINE	NNP	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
International	International	NNP	B-NP	O	O
Pharmaceutical	Pharmaceutical	NNP	I-NP	O	O
Abstracts	Abstract	NNPS	I-NP	O	O
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
terms	term	NNS	I-NP	O	O
sildenafil	sildenafil	NN	I-NP	O	S-drug
,	,	,	O	O	O
Viagra	Viagra	NNP	B-NP	O	S-brand
,	,	,	O	O	O
and	and	CC	O	O	O
erectile	erectile	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Sildenafil	Sildenafil	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
effectiveness	effectiveness	NN	B-NP	O	O
in	in	IN	B-PP	O	O
men	man	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
erectile	erectile	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
prostatectomy	prostatectomy	NN	B-NP	O	O
,	,	,	O	O	O
radiation	radiation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
diabetes	diabetes	NN	B-NP	O	O
mellitus	mellitus	NN	I-NP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
neurologic	neurologic	JJ	I-NP	O	O
disorders	disorder	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
drug	drug	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
selective	selective	JJ	B-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
[	[	(	O	O	O
SSRIs	SSRI	NNS	B-NP	O	S-group
]	]	)	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
as	as	RB	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
sexual	sexual	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
exception	exception	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SSRI	SSRI	NN	B-NP	B-protein	S-group
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
sexual	sexual	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
disorders	disorder	NNS	I-NP	O	O
unrelated	unrelated	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
sexual	sexual	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
esophageal	esophageal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
respond	respond	VB	I-VP	O	O
to	to	TO	B-PP	O	O
sildenafil	sildenafil	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
,	,	,	O	O	O
sildenafil	sildenafil	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
acceptable	acceptable	JJ	I-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
moderate	moderate	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
severe	severe	JJ	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
or	or	CC	O	O	O
those	those	DT	B-NP	O	O
taking	take	VBG	I-NP	O	O
nitrate	nitrate	NN	I-NP	O	S-group-EF-1
therapy	therapy	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
potentially	potentially	RB	B-NP	O	O
serious	serious	JJ	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
sildenafil	sildenafil	NN	B-NP	O	S-drug-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
isozyme	isozyme	NN	I-NP	I-protein	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
metabolizes	metabolize	VBZ	B-VP	O	O
sildenafil	sildenafil	NN	B-NP	O	S-drug
,	,	,	O	O	O
may	may	MD	B-VP	O	O
experience	experience	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
from	from	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sildenafil	sildenafil	NN	B-NP	O	S-drug
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Sildenafil	Sildenafil	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
first	first	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
erectile	erectile	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
men	man	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
decision	decision	NN	I-NP	O	O
to	to	TO	B-VP	O	O
prescribe	prescribe	VB	I-VP	O	O
this	this	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
should	should	MD	B-VP	O	O
include	include	VB	I-VP	O	O
such	such	JJ	B-NP	O	O
considerations	consideration	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cost	cost	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
risk	risk	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
benefit	benefit	NN	I-NP	O	O
balance	balance	NN	I-NP	O	O
,	,	,	O	O	O
patient	patient	NN	B-NP	O	O
access	access	NN	I-NP	O	O
,	,	,	O	O	O
drug	drug	NN	B-NP	O	O
distribution	distribution	NN	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
prescription	prescription	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
coverage	coverage	NN	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
hydrocortisone	hydrocortisone	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
subjective	subjective	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
d	d	VB	I-VP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
amphetamine	amphetamine	NN	I-NP	O	E-drug
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

RATIONALE	RATIONALE	NN	B-NP	O	O
:	:	:	O	O	O
Stress	Stress	NN	B-NP	O	O
and	and	CC	I-NP	O	O
glucocorticoids	glucocorticoid	NNS	I-NP	O	S-group
facilitate	facilitate	VBP	B-VP	O	O
and	and	CC	I-VP	O	O
reinstate	reinstate	VBP	I-VP	O	O
psychostimulant	psychostimulant	JJ	O	B-protein	O
self	self	AFX	O	I-protein	O
-	-	HYPH	O	O	O
administration	administration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
rodents	rodent	NNS	B-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
stress	stress	NN	B-NP	O	O
and	and	CC	I-NP	O	O
glucocorticoids	glucocorticoid	NNS	I-NP	O	S-group
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subjective	subjective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
psychostimulants	psychostimulant	NNS	B-NP	O	S-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
well	well	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
hydrocortisone	hydrocortisone	NN	I-NP	O	S-drug
pretreatment	pretreatment	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subjective	subjective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
d	d	NN	B-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
amphetamine	amphetamine	NN	I-NP	O	E-drug
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Hydrocortisone	Hydrocortisone	NN	B-NP	O	S-drug
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
d	d	NN	B-NP	O	B-drug
-	-	HYPH	O	O	I-drug
amphetamine	amphetamine	NN	B-NP	O	E-drug
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
orally	orally	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
16	16	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
female	female	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
four	four	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
session	session	NN	I-NP	O	O
,	,	,	O	O	O
placebo	placebo	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-VP	O	O
,	,	,	O	O	O
within	within	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
subject	subject	NN	I-NP	O	O
,	,	,	O	O	O
crossover	crossover	NN	B-NP	O	O
design	design	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
stomach	stomach	NN	B-NP	O	O
irritation	irritation	NN	I-NP	O	O
,	,	,	O	O	O
subjects	subject	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
rantidine	rantidine	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
before	before	IN	B-PP	O	O
each	each	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
session	session	NN	I-NP	O	O
.	.	.	O	O	O

Dependent	Dependent	JJ	B-NP	O	O
measures	measure	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
self	self	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
reported	report	VBN	I-NP	O	O
mood	mood	NN	I-NP	O	O
and	and	CC	I-NP	O	O
subjective	subjective	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
(	(	(	O	O	O
Addiction	Addiction	NN	B-NP	O	O
Research	Research	NNP	I-NP	O	O
Center	Center	NNP	I-NP	O	O
inventory	inventory	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mood	mood	NN	B-NP	O	O
states	state	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
visual	visual	JJ	B-NP	O	O
analogue	analogue	NN	I-NP	O	O
scales	scale	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
vital	vital	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
,	,	,	O	O	O
salivary	salivary	JJ	B-NP	O	O
cortisol	cortisol	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
psychomotor	psychomotor	NN	B-NP	O	O
performance	performance	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Hydrocortisone	Hydrocortisone	NN	B-NP	O	S-drug
elevated	elevate	VBD	B-VP	O	O
salivary	salivary	JJ	B-NP	O	O
cortisol	cortisol	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
produced	produce	VBD	B-VP	O	O
modest	modest	JJ	B-NP	O	O
dysphoria	dysphoria	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
reduced	reduce	VBN	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
'	'	POS	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
wanting	want	VBG	B-VP	O	O
more	more	JJR	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
hydrocortisone	hydrocortisone	NN	B-NP	O	S-drug
pretreatment	pretreatment	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
physiological	physiological	JJ	I-NP	O	O
,	,	,	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
,	,	,	I-NP	O	O
or	or	CC	I-NP	O	O
subjective	subjective	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
d	d	NN	B-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
amphetamine	amphetamine	NN	I-NP	O	E-drug
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
glucocorticoids	glucocorticoid	NNS	B-NP	O	S-group
in	in	IN	B-PP	O	O
rodent	rodent	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cortisol	cortisol	NN	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
psychostimulant	psychostimulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
d	d	NN	B-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
amphetamine	amphetamine	NN	I-NP	O	E-drug
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
Innovar	Innovar	NNP	B-NP	O	S-brand
anesthesia	anesthesia	NN	I-NP	O	O
on	on	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group
tolerance	tolerance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
comparison	comparison	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group
tolerance	tolerance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
anesthetized	anesthetize	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
Innovar	Innovar	NNP	B-NP	O	B-brand-EF-1
Vet	Vet	NNP	I-NP	O	E-brand-EF-1
,	,	,	O	O	O
or	or	CC	O	O	O
pentobarbital	pentobarbital	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	O	S-drug-EF-2
needed	need	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
LD50	LD50	NN	I-NP	B-protein	O
of	of	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	O	S-drug
,	,	,	O	O	O
with	with	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
Innovar	Innovar	NN	I-NP	O	S-brand
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
pentobarbital	pentobarbital	NN	B-NP	O	S-drug
.	.	.	O	O	O

Ventricular	Ventricular	JJ	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
generally	generally	RB	I-VP	O	O
converted	convert	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
sinus	sinus	NN	B-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Innovar	Innovar	NNP	B-NP	O	S-brand-EF-2
,	,	,	O	O	O
ketamine	ketamine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
droperidol	droperidol	NN	B-NP	O	S-drug-EF-2
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
after	after	IN	I-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fentayl	fentayl	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
after	after	IN	B-PP	O	O
pentobarbital	pentobarbital	NN	B-NP	O	S-drug
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
oxytocin	oxytocin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
antidiuretic	antidiuretic	JJ	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
milk	milk	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
by	by	IN	B-PP	O	O
alveoli	alveolus	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mammary	mammary	JJ	I-NP	O	O
gland	gland	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lactating	lactate	VBG	B-VP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
exogenous	exogenous	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
endogenous	endogenous	JJ	I-NP	O	O
oxytocin	oxytocin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
vasopressin	vasopressin	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
milk	milk	NN	B-NP	O	O
ejection	ejection	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alveoli	alveolus	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mammary	mammary	JJ	I-NP	O	O
gland	gland	NN	I-NP	O	O
in	in	IN	B-PP	O	O
lactating	lactate	VBG	B-VP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
and	and	CC	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxytocin	oxytocin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
milk	milk	NN	B-NP	O	O
ejection	ejection	NN	I-NP	O	O
by	by	IN	B-PP	O	O
vasopressin	vasopressin	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
principles	principle	NNS	I-NP	O	O
observed	observe	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
fo	fo	VBP	B-VP	O	O
these	these	DT	B-NP	O	O
hormones	hormone	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
deprived	deprive	VBN	B-VP	O	O
of	of	IN	B-PP	O	O
water	water	NN	B-NP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
and	and	CC	O	O	O
then	then	RB	B-VP	O	O
allowed	allow	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
drink	drink	VB	I-VP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
gentamicin	gentamicin	NN	I-NP	O	S-drug-IN-2
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
minimal	minimal	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
gentamicin	gentamicin	NN	I-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
combinations	combination	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
microdilution	microdilution	NN	I-NP	O	O
method	method	NN	I-NP	O	O
for	for	IN	B-PP	O	O
163	163	CD	B-NP	O	O
aerobic	aerobic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
facultative	facultative	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
anaerobic	anaerobic	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
isolates	isolate	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
77	77	CD	I-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Staphylococcus	Staphylococcus	NNP	B-NP	O	O
aureus	aureus	NNP	I-NP	O	O
,	,	,	O	O	O
Diplococcus	Diplococcus	NNP	B-NP	O	O
pneumoniae	pneumoniae	NNP	I-NP	O	O
,	,	,	O	O	O
Streptococcus	Streptococcus	NNP	B-NP	O	O
pyogenes	pyogene	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
anaerobic	anaerobic	JJ	B-NP	O	O
bacteria	bacteria	NNS	I-NP	O	O
(	(	(	O	O	O
except	except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
three	three	CD	B-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Clostridium	Clostridium	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
1.6	1.6	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
or	or	CC	I-NP	O	O
less	less	JJR	I-NP	O	O
of	of	IN	B-PP	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug
per	per	IN	B-PP	O	O
ml	ml	NN	B-NP	O	O
.	.	.	O	O	O

Gentamicin	Gentamicin	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
tested	test	VBN	B-VP	O	O
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
to	to	TO	O	O	O
100	100	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

for	for	IN	B-PP	O	O
some	some	DT	B-NP	O	O
strains	strain	NNS	I-NP	O	O
combinations	combination	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
synergistic	synergistic	JJ	B-ADJP	O	O
.	.	.	O	O	O

Sixty	Sixty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
two	two	CD	I-NP	O	O
(	(	(	O	O	O
94	94	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
66	66	CD	B-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Enterobacteriaceae	Enterobacteriaceae	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
Pseudomonas	Pseudomonas	NNP	I-NP	O	O
aeruginosa	aeruginosa	NNP	I-NP	O	O
were	be	VBD	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
6.2	6.2	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
or	or	CC	I-NP	O	O
less	less	JJR	I-NP	O	O
of	of	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug
per	per	IN	B-PP	O	O
ml	ml	NN	B-NP	O	O
.	.	.	O	O	O

Combinations	Combination	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
gentamicin	gentamicin	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
indifferent	indifferent	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
29	29	CD	B-NP	O	O
strains	strain	NNS	I-NP	O	O
and	and	CC	O	O	O
synergistic	synergistic	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
33	33	CD	B-NP	O	O
strains	strain	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
20	20	CD	I-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
enterococcus	enterococcus	NN	B-NP	O	O
,	,	,	O	O	O
three	three	CD	B-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Clostridium	Clostridium	NN	B-NP	O	O
,	,	,	O	O	O
three	three	CD	B-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Escherichia	Escherichia	NNP	B-NP	O	O
coli	coli	NNP	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
strain	strain	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Proteus	Proteus	NNP	B-NP	O	O
rettgeri	rettgeri	NNP	I-NP	O	O
were	be	VBD	B-VP	O	O
resistant	resistant	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
both	both	CC	O	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug
(	(	(	O	O	O
minimal	minimal	JJ	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
3.1	3.1	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug
(	(	(	O	O	O
minimal	minimal	JJ	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
6.2	6.2	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Combinations	Combination	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
gentamicin	gentamicin	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
indifferent	indifferent	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
16	16	CD	B-NP	O	O
and	and	CC	O	O	O
synergistic	synergistic	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
11	11	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
strains	strain	NNS	I-NP	O	O
.	.	.	O	O	O

Except	Except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
isolates	isolate	NNS	I-NP	O	O
,	,	,	O	O	O
synergy	synergy	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
usually	usually	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
readily	readily	RB	B-ADJP	O	O
obtainable	obtainable	JJ	I-ADJP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

Antagonism	Antagonism	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
never	never	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Molecular	Molecular	JJ	B-NP	O	O
basis	basis	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
for	for	IN	B-PP	O	O
yeast	yeast	NN	B-NP	O	O
and	and	CC	I-NP	O	O
filipin	filipin	NN	I-NP	O	S-drug_n
for	for	IN	B-PP	O	O
animal	animal	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
polyene	polyene	NN	I-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
,	,	,	O	O	O
many	many	JJ	B-NP	O	O
,	,	,	O	O	O
like	like	IN	B-PP	O	O
filipin	filipin	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
clinically	clinically	RB	B-ADVP	O	O
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
toxic	toxic	JJ	B-ADJP	O	O
;	;	:	O	O	O

amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
useful	useful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
fungal	fungal	JJ	I-NP	O	O
infections	infection	NNS	I-NP	O	O
because	because	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
less	less	RBR	B-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
filipin	filipin	NN	B-NP	O	S-drug_n
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
rationalized	rationalize	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cellular	cellular	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
molecular	molecular	JJ	I-NP	O	O
level	level	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
observations	observation	NNS	I-NP	O	O
:	:	:	O	O	O
(	(	(	B-LST	O	O
i	i	LS	I-LST	O	O
)	)	)	O	O	O
these	these	DT	B-NP	O	O
polyene	polyene	NN	I-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
showed	show	VBD	B-VP	O	O
differential	differential	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cells	cell	NNS	B-NP	O	O
;	;	:	O	O	O

filipin	filipin	NN	B-NP	O	S-drug_n
was	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
potent	potent	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
lysing	lyse	VBG	B-VP	O	O
human	human	JJ	B-NP	B-cell_type	O
red	red	JJ	I-NP	I-cell_type	O
blood	blood	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
was	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
potent	potent	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
yeast	yeast	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
growth	growth	NN	I-NP	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
(	(	(	B-LST	O	O
ii	ii	LS	I-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
filipin	filipin	NN	B-NP	O	S-drug_n
were	be	VBD	B-VP	O	O
more	more	RBR	I-VP	O	O
efficiently	efficiently	RB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
added	add	VBN	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
sterol	sterol	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
were	be	VBD	B-VP	O	O
more	more	RBR	I-VP	O	O
efficiently	efficiently	RB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ergosterol	ergosterol	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
sterol	sterol	NN	I-NP	O	O
in	in	IN	B-PP	O	O
yeast	yeast	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
simplest	simple	JJS	I-NP	O	O
inference	inference	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
polyenes	polyene	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
relative	relative	JJ	I-NP	O	O
avidities	avidity	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
predominant	predominant	JJ	I-NP	O	O
sterol	sterol	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cell	cell	NN	B-NP	O	O
membranes	membrane	NNS	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
miconazole	miconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
miconazole	miconazole	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
respiration	respiration	NN	B-NP	O	O
and	and	CC	I-NP	O	O
cell	cell	NN	I-NP	O	O
permeability	permeability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Candida	Candida	NNP	B-NP	O	O
albicans	albicans	NNP	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antifungal	antifungal	JJ	I-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
,	,	,	O	O	O
miconazole	miconazole	NN	B-NP	O	B-drug
nitrate	nitrate	NN	I-NP	O	E-drug
,	,	,	O	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
growth	growth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
species	specie	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Candida	Candida	NNP	B-NP	O	O
.	.	.	O	O	O

Candida	Candida	NNP	B-NP	O	O
albicans	albican	NNS	I-NP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathogenic	pathogenic	JJ	I-NP	O	O
species	specie	NNS	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
totally	totally	RB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
10	10	CD	I-NP	O	O
mug	mug	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
ml	ml	NN	I-NP	O	O
.	.	.	O	O	O

Endogenous	Endogenous	JJ	B-NP	O	O
respiration	respiration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
as	as	RB	B-ADJP	O	O
high	high	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
/	/	SYM	O	O	O
ml	ml	NN	B-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
exogenous	exogenous	JJ	B-NP	O	O
respiration	respiration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
markedly	markedly	RB	B-ADJP	O	O
sensitive	sensitive	JJ	I-ADJP	O	O
and	and	CC	O	O	O
inhibited	inhibit	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
85	85	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
permeability	permeability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cell	cell	NN	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
changed	change	VBN	I-VP	O	O
as	as	IN	B-SBAR	O	O
evidenced	evidence	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
leakage	leakage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
260	260	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
nm	nm	NN	I-NP	O	O
absorbing	absorb	VBG	I-NP	O	O
materials	material	NNS	I-NP	O	O
,	,	,	O	O	O
amino	amino	NN	B-NP	O	O
acids	acid	NNS	I-NP	O	O
,	,	,	O	O	O
proteins	protein	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
inorganic	inorganic	JJ	B-NP	O	O
cations	cation	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
we	we	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
clearly	clearly	RB	B-VP	O	O
show	show	VBP	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
alters	alter	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
cellular	cellular	JJ	I-NP	O	O
permeability	permeability	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
thus	thus	RB	O	O	O
the	the	DT	B-NP	O	O
exogenous	exogenous	JJ	I-NP	O	O
respiration	respiration	NN	I-NP	O	O
becomes	become	VBZ	B-VP	O	O
sensitive	sensitive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
distribution	distribution	NN	B-NP	O	O
and	and	CC	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cloxacillin	cloxacillin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

According	Accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
Gibaldi	Gibaldi	NNP	B-NP	O	O
et	et	FW	I-NP	O	O
al	al	FW	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
1968	1968	CD	B-NP	O	O
,	,	,	I-NP	O	O
1970	1970	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
penicillins	penicillin	NNS	B-NP	B-protein	S-group-ME-1
and	and	CC	O	O	O
cephaloridine	cephaloridine	NN	B-NP	O	S-drug-ME-1
reached	reach	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-2
are	be	VBP	B-VP	O	O
due	due	JJ	B-ADJP	O	O
not	not	RB	B-CONJP	O	O
only	only	RB	I-CONJP	O	O
to	to	TO	B-PP	O	O
slower	slow	JJR	B-NP	O	O
renal	renal	JJ	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
but	but	CC	B-CONJP	O	O
also	also	RB	I-CONJP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
altered	altered	JJ	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
distribution	distribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cloxacillin	cloxacillin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
and	and	CC	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cloxacillin	cloxacillin	NN	B-NP	B-protein	S-drug
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
six	six	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
five	five	CD	B-NP	O	O
lacking	lack	VBG	I-NP	O	O
kidney	kidney	NN	I-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
partially	partially	RB	I-NP	O	O
impaired	impaired	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
or	or	CC	I-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
distribution	distribution	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cloxacillin	cloxacillin	NN	B-NP	B-protein	S-drug
with	with	IN	B-PP	O	O
and	and	CC	I-PP	O	O
without	without	IN	I-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
(	(	(	O	O	O
13.0	13.0	CD	B-NP	O	O
and	and	CC	I-NP	O	O
12.6	12.6	CD	I-NP	O	O
liters	liter	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Gibaldi	Gibaldi	NNP	B-NP	O	O
et	et	FW	I-NP	O	O
al	al	FW	I-NP	O	O
.	.	.	O	O	O

could	could	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
cloxacillin	cloxacillin	NN	B-NP	B-protein	S-drug
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
lacking	lack	VBG	B-VP	O	O
kidney	kidney	NN	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
spite	spite	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
constant	constant	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug
(	(	(	O	O	O
from	from	IN	B-PP	O	O
0.326	0.326	CD	B-NP	O	O
to	to	TO	I-NP	O	O
0.263	0.263	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
h	h	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
explained	explain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
by	by	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cloxacillin	cloxacillin	NN	B-NP	B-protein	S-drug-ME-2
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

Behavioral	Behavioral	JJ	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
link	link	NN	I-NP	O	O
between	between	IN	B-PP	O	O
smoking	smoking	NN	B-NP	O	O
and	and	CC	I-NP	O	O
drinking	drinking	NN	I-NP	O	O
.	.	.	O	O	O

Many	Many	JJ	B-NP	O	O
people	people	NNS	I-NP	O	O
use	use	VBP	B-VP	O	O
both	both	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
and	and	CC	O	O	O
nicotine	nicotine	NN	B-NP	O	S-drug
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cigarettes	cigarette	NNS	B-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
tobacco	tobacco	NN	I-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
differ	differ	VBP	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
they	they	PRP	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
act	act	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
target	target	NN	I-NP	B-DNA	O
sites	site	NNS	I-NP	I-DNA	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
share	share	VB	I-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
partly	partly	RB	B-NP	O	O
share	share	NN	I-NP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
nicotine	nicotine	NN	I-NP	O	S-drug
use	use	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
precipitated	precipitate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
personality	personality	NN	I-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
user	user	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
impulsivity	impulsivity	NN	B-NP	O	O
and	and	CC	I-NP	O	O
sensation	sensation	NN	I-NP	O	O
seeking	seeking	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dependence	dependence	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
similar	similar	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
nicotine	nicotine	NN	I-NP	O	S-drug
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
certain	certain	JJ	B-NP	B-protein	O
factors	factor	NNS	I-NP	I-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
reinforcing	reinforce	VBG	B-VP	O	O
drug	drug	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
conditioning	condition	VBG	B-VP	O	O
processes	process	NNS	B-NP	O	O
,	,	,	O	O	O
automatic	automatic	JJ	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
stress	stress	NN	B-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dependence	dependence	NN	B-NP	O	O
on	on	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
tolerance	tolerance	NN	B-NP	O	O
and	and	CC	I-NP	O	O
sensitization	sensitization	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
'	'	POS	B-NP	O	O
actions	action	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
dependence	dependence	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
review	review	NN	I-NP	O	O
discusses	discuss	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
chemical	chemical	NN	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
neurotransmitter	neurotransmitter	NN	B-NP	O	O
)	)	)	O	O	O
systems	system	NNS	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
to	to	TO	B-PP	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Dose	Dose	NN	B-NP	O	O
-	-	HYPH	O	O	O
time	time	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
competitive	competitive	JJ	B-NP	O	O
displacement	displacement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
radiopertechnetate	radiopertechnetate	NN	B-NP	O	S-drug
by	by	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug_n
perchlorate	perchlorate	NN	I-NP	O	E-drug_n
following	follow	VBG	B-PP	O	O
oral	oral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
]	]	)	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug_n
perchlorate	perchlorate	NN	I-NP	O	E-drug_n
in	in	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
fractions	fraction	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
of	of	IN	B-PP	O	O
displacement	displacement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
radiopertechnetate	radiopertechnetate	NN	B-NP	O	S-drug
,	,	,	O	O	O
in	in	IN	B-PP	O	O
dependence	dependence	NN	B-NP	O	O
on	on	IN	B-PP	O	O
application	application	NN	B-NP	O	O
mode	mode	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
perchlorate	perchlorate	NN	I-NP	O	S-drug_n
was	be	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
competitive	competitive	JJ	B-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
organs	organ	NNS	B-NP	O	O
actively	actively	RB	B-VP	O	O
concentrating	concentrate	VBG	I-VP	O	O
pertechnetate	pertechnetate	NN	B-NP	O	S-drug
as	as	IN	B-PP	O	O
effective	effective	JJ	B-ADJP	O	O
as	as	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
1000	1000	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
ClO	ClO	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	O	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
or	or	CC	O	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
orally	orally	RB	B-NP	O	O
30	30	CD	I-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
radiopertechnetate	radiopertechnetate	NN	B-NP	O	S-drug
.	.	.	O	O	O

An	An	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
perchlorate	perchlorate	NN	B-NP	O	S-drug_n-ME-1
given	give	VBN	B-VP	O	O
later	later	RB	B-ADVP	O	O
also	also	RB	B-ADVP	O	O
produces	produce	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
complete	complete	JJ	I-NP	O	O
and	and	CC	O	O	O
immediately	immediately	RB	B-VP	O	O
beginning	begin	VBG	I-VP	O	O
depletion	depletion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pertechnetate	pertechnetate	NN	B-NP	O	S-drug-ME-2
already	already	RB	B-VP	O	O
accumulated	accumulate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
,	,	,	O	O	O
within	within	IN	B-PP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
195	195	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
99m	99m	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
TcO	TcO	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
injection	injection	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
corresponding	corresponding	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
result	result	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
incomplete	incomplete	JJ	B-NP	O	O
depletion	depletion	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
becomes	become	VBZ	B-VP	O	O
complete	complete	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
additional	additional	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
perchlorate	perchlorate	NN	B-NP	O	S-drug_n
offers	offer	VBZ	B-VP	O	O
advantages	advantage	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Herbal	Herbal	JJ	B-NP	O	O
remedies	remedy	NNS	I-NP	O	O
,	,	,	O	O	O
nephropathies	nephropathy	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
herbal	herbal	JJ	B-NP	O	O
remedies	remedy	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
becoming	become	VBG	I-VP	O	O
increasingly	increasingly	RB	B-ADJP	O	O
popular	popular	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
States	State	NNPS	I-NP	O	O
.	.	.	O	O	O

Research	Research	NNP	B-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
herbal	herbal	JJ	B-NP	O	O
remedy	remedy	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
herbal	herbal	JJ	B-NP	O	O
remedies	remedy	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
detrimental	detrimental	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
compromised	compromise	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
or	or	CC	O	O	O
renal	renal	JJ	B-NP	O	O
failure	failure	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
at	at	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
for	for	IN	B-PP	O	O
further	further	JJ	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
damage	damage	NN	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
complications	complication	NNS	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
interactions	interaction	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
herbal	herbal	JJ	B-NP	O	O
remedies	remedy	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
complex	complex	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
article	article	NN	I-NP	O	O
will	will	MD	B-VP	O	O
describe	describe	VB	I-VP	O	O
the	the	DT	B-NP	O	O
escalating	escalate	VBG	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
herbal	herbal	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
hazards	hazard	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
herbal	herbal	JJ	B-NP	O	O
remedy	remedy	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
among	among	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Sirolimus	Sirolimus	NN	B-NP	O	S-drug
:	:	:	O	O	O
mammalian	mammalian	JJ	B-NP	O	O
target	target	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rapamycin	rapamycin	NN	B-NP	O	S-drug
inhibitor	inhibitor	NN	I-NP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
kidney	kidney	NN	B-NP	O	O
rejection	rejection	NN	I-NP	O	O
.	.	.	O	O	O

Current	Current	JJ	B-NP	O	O
immunosuppressive	immunosuppressive	JJ	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
but	but	CC	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Sirolimus	Sirolimus	NNP	B-NP	O	S-drug
works	work	VBZ	B-VP	O	O
differently	differently	RB	B-ADVP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
immunosuppressants	immunosuppressant	NNS	I-NP	O	S-group
currently	currently	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
except	except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
overlap	overlap	VB	I-VP	O	O
to	to	TO	B-PP	O	O
any	any	DT	B-NP	O	O
great	great	JJ	I-NP	O	O
extent	extent	NN	I-NP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
additional	additional	JJ	B-NP	O	O
research	research	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	O
recipients	recipient	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug
,	,	,	O	O	O
might	might	MD	B-VP	O	O
have	have	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rejection	rejection	NN	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
,	,	,	O	O	O
permit	permit	VBP	B-VP	O	O
reductions	reduction	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
permit	permit	NN	B-NP	O	O
steroid	steroid	NN	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
(	(	(	O	O	O
Kelly	Kelly	NNP	B-NP	O	O
,	,	,	O	O	O
1999	1999	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug
,	,	,	O	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
cocaine	cocaine	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
bar	bar	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
press	press	NN	I-NP	O	O
behavior	behavior	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
genetically	genetically	RB	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
two	two	CD	B-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pointer	pointer	NN	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
benzodiazepine	benzodiazepine	NN	I-NP	O	S-group
(	(	(	O	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug
)	)	)	O	O	O
facilitates	facilitate	VBZ	B-VP	O	O
acquisition	acquisition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
goal	goal	NN	B-NP	O	O
-	-	HYPH	O	O	O
directed	direct	VBN	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
in	in	IN	B-PP	O	O
``	``	``	O	O	O
genetically	genetically	RB	B-ADJP	O	O
nervous	nervous	JJ	I-ADJP	O	O
``	``	``	O	O	O

subjects	subject	NNS	B-NP	O	O
.	.	.	O	O	O

Continued	Continue	VBN	B-NP	O	O
admistration	admistration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
maintain	maintain	VB	I-VP	O	O
barpress	barpress	NN	B-NP	O	O
response	response	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
strain	strain	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
amphetamine	amphetamine	NN	I-NP	O	S-drug
,	,	,	O	O	O
compounds	compound	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
inhibit	inhibit	VBP	B-VP	O	O
neuronal	neuronal	JJ	B-NP	O	O
reuptake	reuptake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	O
,	,	,	O	O	O
disrupts	disrupt	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
genetically	genetically	RB	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
E	E	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
strain	strain	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
far	far	RB	I-NP	O	O
greater	great	JJR	I-NP	O	O
extent	extent	NN	I-NP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
A	A	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
strain	strain	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
after	after	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chlordiazepoxide	chlordiazepoxide	NN	B-NP	O	S-drug
,	,	,	O	O	O
withdrawal	withdrawal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
not	not	RB	B-CONJP	O	O
only	only	RB	I-CONJP	O	O
re	re	AFX	O	O	O
-	-	HYPH	O	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
almost	almost	RB	B-NP	O	O
complete	complete	JJ	I-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bar	bar	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
press	press	NN	I-NP	O	O
response	response	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
E	E	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
strain	strain	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
but	but	CC	O	O	O
also	also	RB	B-ADVP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
temporary	temporary	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acquired	acquire	VBN	I-NP	O	O
behavioral	behavioral	NN	I-NP	O	O
response	response	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
A	A	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
strain	strain	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Development	Development	NN	B-NP	O	O
and	and	CC	I-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

Fluvastatin	Fluvastatin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
synthetic	synthetic	JJ	I-NP	O	B-group
3	3	CD	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
hydroxy	hydroxy	NN	I-NP	O	I-group
-	-	HYPH	B-NP	O	I-group
3	3	CD	I-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
methylglutaryl	methylglutaryl	NN	I-NP	O	I-group
coenzyme	coenzyme	NN	I-NP	O	I-group
A	A	NN	I-NP	O	I-group
(	(	(	O	O	I-group
HMGCoA	HMGCoA	NN	B-NP	B-protein	I-group
)	)	)	O	O	I-group
reductase	reductase	NN	B-NP	O	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
approved	approve	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
extensively	extensively	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
since	since	IN	B-PP	O	O
1986	1986	CD	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
structurally	structurally	RB	B-ADJP	O	O
distinct	distinct	JJ	I-ADJP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
currently	currently	RB	I-NP	O	O
available	available	JJ	I-NP	O	O
HMGCoA	HMGCoA	NN	I-NP	O	B-group
reductase	reductase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
pravastatin	pravastatin	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
unique	unique	JJ	B-NP	O	O
biopharmaceutical	biopharmaceutical	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
class	class	NN	I-NP	O	O
.	.	.	O	O	O

Absorption	Absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
virtually	virtually	RB	B-ADJP	O	O
complete	complete	JJ	I-ADJP	O	O
across	across	IN	B-PP	O	O
all	all	DT	B-NP	O	O
species	specie	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
man	man	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
food	food	NN	B-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
limited	limit	VBN	I-VP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
fluvastatin	fluvastatin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
subject	subject	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
first	first	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
pass	pass	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
30	30	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
95	95	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
biliary	biliary	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
2	2	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
being	be	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
parent	parent	NN	I-NP	O	O
compound	compound	NN	I-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
circulating	circulate	VBG	B-VP	O	O
active	active	JJ	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
or	or	CC	O	O	O
accumulation	accumulation	NN	B-NP	O	O
during	during	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
food	food	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	B-protein	S-drug
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
marked	marked	JJ	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
-	-	HYPH	O	O	O
-	-	SYM	B-NP	O	O
from	from	IN	B-PP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
comparison	comparison	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
evening	evening	NN	I-NP	O	O
meal	meal	NN	I-NP	O	O
or	or	CC	B-PP	O	O
at	at	IN	B-PP	O	O
bedtime	bedtime	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
revealed	reveal	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
(	(	(	O	O	O
area	area	NN	B-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pharmacodynamic	pharmacodynamic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
(	(	(	O	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
density	density	NN	I-NP	O	O
lipoprotein	lipoprotein	NN	I-NP	O	O
cholesterol	cholesterol	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
)	)	)	O	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
ascertained	ascertain	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
mealtime	mealtime	NN	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
and	and	CC	O	O	O
bedtime	bedtime	NN	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
demographic	demographic	JJ	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Relative	Relative	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug
do	do	VBP	B-VP	O	O
not	not	RB	B-ADJP	O	O
vary	vary	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
age	age	NN	B-NP	O	O
or	or	CC	I-NP	O	O
gender	gender	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
population	population	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2.5	2.5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
the	the	DT	I-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
minimal	minimal	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
limited	limited	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
group	group	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
currently	currently	RB	B-ADJP	O	O
underway	underway	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
this	this	DT	B-NP	O	O
further	further	RBR	B-ADVP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	B-protein	S-drug
and	and	CC	O	O	O
several	several	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
it	it	PRP	B-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
an	an	DT	B-NP	O	O
anionic	anionic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
binding	bind	VBG	I-NP	O	O
resin	resin	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
considerable	considerable	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
lowering	lower	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug-ME-2
bioavailability	bioavailability	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
even	even	RB	B-ADVP	O	O
when	when	WRB	I-ADVP	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
4	4	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
this	this	DT	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
diminished	diminish	VBN	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
either	either	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
or	or	CC	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
fluvastatin	fluvastatin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
additional	additional	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
niacin	niacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
any	any	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
administration	administration	NN	B-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
population	population	NN	I-NP	O	O
chronically	chronically	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
no	no	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
relative	relative	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
control	control	NN	B-NP	O	O
data	datum	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
generated	generate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
date	date	NN	B-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug
thus	thus	RB	B-ADVP	O	O
support	support	VB	B-VP	O	O
its	its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
broad	broad	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypercholesterolaemic	hypercholesterolaemic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Tumor	Tumor	NN	B-NP	O	O
phenotype	phenotype	NN	I-NP	O	O
and	and	CC	O	O	O
susceptibility	susceptibility	NN	B-NP	O	O
to	to	TO	B-PP	O	O
progression	progression	NN	B-NP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subpopulations	subpopulation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
initiated	initiate	VBN	B-NP	B-cell_type	O
murine	murine	JJ	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

Currently	Currently	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
conceived	conceive	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
events	event	NNS	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
hits	hit	NNS	B-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
required	require	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tumors	tumor	NNS	B-NP	O	O
by	by	IN	B-PP	O	O
chemical	chemical	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
phase	phase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
sequence	sequence	NN	I-NP	O	O
,	,	,	O	O	O
initiation	initiation	NN	B-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
one	one	CD	I-NP	O	O
event	event	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
genetic	genetic	JJ	I-NP	O	O
apparatus	apparatus	NN	I-NP	O	O
.	.	.	O	O	O

Analyses	Analysis	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
sequence	sequence	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
usually	usually	RB	B-ADVP	O	O
give	give	VBP	B-VP	O	O
little	little	JJ	B-NP	O	O
consideration	consideration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
nature	nature	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
target	target	NN	I-NP	B-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
or	or	CC	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
resultant	resultant	JJ	I-NP	O	O
tumors	tumor	NNS	I-NP	O	O
.	.	.	O	O	O

Vesselinovitch	Vesselinovitch	NNP	B-NP	O	O
et	et	FW	I-NP	O	O
al	al	FW	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
Cancer	Cancer	NNP	B-NP	O	O
Res	Res	NNP	I-NP	O	O
.	.	.	O	O	O
,	,	,	O	O	O
38	38	CD	B-NP	O	O
:	:	:	O	O	O
2003	2003	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2010	2010	CD	I-NP	O	O
,	,	,	I-NP	O	O
1978	1978	CD	I-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
,	,	,	I-NP	O	O
small	small	JJ	I-NP	O	O
pulse	pulse	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carcinogen	carcinogen	NN	B-NP	O	O
can	can	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
early	early	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
numerous	numerous	JJ	I-NP	O	O
liver	liver	NN	I-NP	O	O
tumors	tumor	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
neonatally	neonatally	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
genetic	genetic	JJ	I-NP	O	O
predisposition	predisposition	NN	I-NP	O	O
to	to	TO	B-PP	O	O
hepatotumorigenesis	hepatotumorigenesis	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
nonpredisposed	nonpredisposed	JJ	I-NP	O	O
strain	strain	NN	I-NP	O	O
C57BL	C57BL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
6N	6N	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
highly	highly	RB	B-ADJP	O	O
susceptible	susceptible	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
diethylnitrosamine	diethylnitrosamine	NN	B-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neonatal	neonatal	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

C57BL	C57BL	NN	B-NP	B-protein	O
/	/	SYM	I-NP	O	O
6N	6N	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
large	large	JJ	B-NP	O	O
numbers	number	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
three	three	CD	I-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
tumors	tumor	NNS	I-NP	O	O
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
livers	liver	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
genetically	genetically	RB	B-NP	O	O
predisposed	predispose	VBN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
required	require	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
stimulus	stimulus	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dietary	dietary	JJ	B-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug
for	for	IN	B-PP	O	O
growth	growth	NN	B-NP	O	O
.	.	.	O	O	O

Tumors	Tumor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
more	more	RBR	B-NP	O	O
malignant	malignant	JJ	I-NP	O	O
phenotype	phenotype	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
genetically	genetically	RB	B-NP	O	O
predisposed	predispose	VBN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
(	(	(	O	O	O
C57BL	C57BL	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
6N	6N	NN	I-NP	O	O
X	X	SYM	I-NP	O	O
C3H	C3H	NN	I-NP	B-protein	O
/	/	SYM	I-NP	O	O
HeN	HeN	NN	I-NP	B-protein	O
F1	F1	NN	I-NP	I-protein	O
)	)	)	O	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
one	one	CD	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carcinogen	carcinogen	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
phenotype	phenotype	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tumor	tumor	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
results	result	VBZ	B-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pulse	pulse	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
chemical	chemical	JJ	I-NP	O	O
carcinogen	carcinogen	NN	I-NP	O	O
may	may	MD	B-VP	O	O
depend	depend	VB	I-VP	O	O
upon	upon	IN	B-PP	O	O
the	the	DT	B-NP	O	O
target	target	NN	I-NP	B-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
initiated	initiate	VBN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
result	result	VBP	B-VP	O	O
from	from	IN	B-PP	O	O
this	this	DT	B-NP	O	O
hit	hit	NN	I-NP	O	O
may	may	MD	B-VP	O	O
vary	vary	VB	I-VP	O	O
from	from	IN	B-PP	O	O
those	those	DT	B-NP	O	O
that	that	WDT	B-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
very	very	RB	B-NP	O	O
little	little	JJ	I-NP	O	O
progression	progression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cell	cell	NN	B-NP	O	O
type	type	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
or	or	CC	O	O	O
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
require	require	VB	I-VP	O	O
exogenous	exogenous	JJ	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
growth	growth	NN	B-NP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
progress	progress	VB	I-VP	O	O
very	very	RB	B-ADVP	O	O
rapidly	rapidly	RB	I-ADVP	O	O
to	to	TO	B-PP	O	O
fully	fully	RB	B-NP	O	O
malignant	malignant	JJ	I-NP	O	O
behavior	behavior	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
might	might	MD	B-VP	O	O
arise	arise	VB	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
hit	hit	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
genetically	genetically	RB	I-NP	B-cell_line	O
initiated	initiate	VBN	I-NP	I-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
rapid	rapid	JJ	I-NP	O	O
progression	progression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	O
type	type	NN	I-NP	O	O
.	.	.	O	O	O

Analgesic	Analgesic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistaminics	antihistaminic	NNS	B-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
provides	provide	VBZ	B-VP	O	O
considerable	considerable	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
several	several	JJ	B-NP	O	O
,	,	,	I-NP	O	O
but	but	CC	I-NP	O	O
not	not	RB	I-NP	O	O
all	all	DT	B-NP	O	O
antihistaminics	antihistaminic	NNS	I-NP	O	S-group
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
indeed	indeed	RB	B-ADVP	O	O
analgesic	analgesic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
and	and	CC	O	O	O
some	some	DT	B-NP	O	O
are	be	VBP	B-VP	O	O
analgesic	analgesic	JJ	B-NP	O	B-group
adjuvants	adjuvant	NNS	I-NP	O	E-group
as	as	RB	B-ADVP	O	O
well	well	RB	I-ADVP	O	O
.	.	.	O	O	O

Those	Those	DT	B-NP	O	O
for	for	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
effectiveness	effectiveness	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
includes	include	VBZ	B-VP	O	O
diphenhydramine	diphenhydramine	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydroxyzine	hydroxyzine	NN	B-NP	O	S-drug
,	,	,	O	O	O
orphenadrine	orphenadrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
pyrilamine	pyrilamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenyltoloxamine	phenyltoloxamine	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
promethazine	promethazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
methdilazine	methdilazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
tripelennamine	tripelennamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
proposed	propose	VBN	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
analgesic	analgesic	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihistaminics	antihistaminic	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
reviewed	review	VBN	I-VP	O	O
and	and	CC	I-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
one	one	CD	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
exists	exist	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
considerable	considerable	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
histaminergic	histaminergic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
serotoninergic	serotoninergic	JJ	I-NP	O	O
central	central	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
nociception	nociception	NN	B-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
antihistaminic	antihistaminic	JJ	B-NP	O	S-group
drugs	drug	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
modulate	modulate	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
responses	response	NNS	I-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
role	role	NN	I-NP	O	O
for	for	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	O
and	and	CC	I-NP	O	O
dopamine	dopamine	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antihistaminics	antihistaminic	NNS	B-NP	O	S-group
on	on	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
less	less	RBR	I-VP	O	O
well	well	RB	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Still	Still	RB	B-NP	O	O
other	other	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
proposed	propose	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
understanding	understanding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pain	pain	NN	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
aid	aid	VB	I-VP	O	O
in	in	IN	B-PP	O	O
elucidating	elucidate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihistaminics	antihistaminic	NNS	B-NP	O	S-group
in	in	IN	B-PP	O	O
analgesia	analgesia	NN	B-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
The	The	DT	B-NP	O	O
GABA	GABA	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
ergic	ergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
and	and	CC	I-NP	O	O
brain	brain	NN	I-NP	O	O
edema	edema	NN	I-NP	O	O
]	]	)	O	O	O
It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
traumatic	traumatic	JJ	I-NP	O	O
edemas	edema	NNS	I-NP	O	O
that	that	IN	B-NP	O	O
picrotoxin	picrotoxin	NN	B-NP	O	S-drug_n-EF-1
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
removes	remove	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
antiedematous	antiedematous	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
phenazepam	phenazepam	NN	B-NP	O	S-drug_n-EF-2
,	,	,	O	O	O
phenibut	phenibut	NN	B-NP	O	S-drug_n-EF-2
and	and	CC	I-NP	O	O
amizyl	amizyl	NN	I-NP	O	S-drug_n-EF-2
and	and	CC	O	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phentolamine	phentolamine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
picrotoxin	picrotoxin	NN	B-NP	O	S-drug_n
is	be	VBZ	B-VP	O	O
minimized	minimize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
such	such	PDT	B-NP	O	O
an	an	DT	I-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Prolonged	Prolonged	JJ	B-NP	O	O
daily	daily	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
picrotoxin	picrotoxin	NN	B-NP	B-protein	S-drug_n
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
brain	brain	NN	B-NP	O	O
edema	edema	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
GABA	GABA	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
included	include	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
a	a	DT	B-NP	O	O
complex	complex	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
measures	measure	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
edema	edema	NN	B-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Stimulation	Stimulation	NN	B-NP	O	O
by	by	IN	B-PP	O	O
cerulein	cerulein	NN	B-NP	O	S-drug_n
-	-	HYPH	B-VP	O	O
-	-	HYPH	B-NP	O	O
an	an	DT	B-NP	O	O
analog	analog	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
octapeptide	octapeptide	NN	I-NP	B-protein	O
cholecystokinin	cholecystokinin	NN	I-NP	I-protein	O
-	-	HYPH	O	O	O
-	-	SYM	B-NP	O	O
of	of	IN	B-PP	O	O
3H	3H	NN	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
spiroperidol	spiroperidol	NN	I-NP	O	E-drug_n
binding	binding	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuroleptics	neuroleptic	NNS	B-NP	O	S-group
]	]	)	O	O	O
It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
experiments	experiment	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
white	white	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
prolonged	prolong	VBD	B-VP	O	O
administration	administration	NN	B-NP	O	O
(	(	(	O	O	O
twice	twice	RB	B-NP	O	O
a	a	DT	I-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
pyreneperone	pyreneperone	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
3H	3H	NN	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
spiroperidol	spiroperidol	NN	I-NP	B-DNA	E-drug_n
and	and	CC	I-NP	I-DNA	O
low	low	JJ	I-NP	I-DNA	O
affinity	affinity	NN	I-NP	I-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
for	for	IN	B-PP	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
subcortical	subcortical	JJ	B-NP	O	O
structures	structure	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
3H	3H	NN	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
spiroperidol	spiroperidol	NN	I-NP	O	E-drug_n
binding	binding	NN	I-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	B-DNA	O
affinity	affinity	NN	I-NP	I-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
for	for	IN	B-PP	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
both	both	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
frontal	frontal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
and	and	CC	O	O	O
subcortical	subcortical	JJ	B-NP	O	O
structures	structure	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
forebrain	forebrain	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
prolonged	prolong	VBN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuroleptics	neuroleptic	NNS	B-NP	O	S-group
the	the	DT	B-NP	O	O
displacing	displacing	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cerulein	cerulein	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
an	an	DT	B-NP	O	O
analog	analog	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cholecystokinin	cholecystokinin	NN	B-NP	O	O
octapeptide	octapeptide	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
replaced	replace	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stimulant	stimulant	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
on	on	IN	B-PP	O	O
3H	3H	NN	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
spiroperidol	spiroperidol	NN	I-NP	O	E-drug_n
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
assumed	assume	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
increased	increase	VBN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
3H	3H	NN	B-NP	B-DNA	B-drug_n
-	-	HYPH	I-NP	I-DNA	I-drug_n
spiroperidol	spiroperidol	NN	I-NP	I-DNA	E-drug_n
and	and	CC	O	I-DNA	O
high	high	JJ	B-NP	I-DNA	O
affinity	affinity	NN	I-NP	I-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
for	for	IN	B-PP	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
dopamine2	dopamine2	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
serotonin2	serotonin2	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
underlies	underlie	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuroleptics	neuroleptic	NNS	B-NP	O	S-group
after	after	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Cholecystokinin	Cholecystokinin	NN	B-NP	O	O
octapeptide	octapeptide	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
necessary	necessary	JJ	I-NP	B-protein	O
factor	factor	NN	I-NP	I-protein	O
for	for	IN	B-PP	O	O
realization	realization	NN	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuroleptics	neuroleptic	NNS	B-NP	O	S-group
.	.	.	O	O	O

Dual	Dual	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
palytoxin	palytoxin	NN	I-NP	O	S-drug_n
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
contraction	contraction	NN	I-NP	O	O
and	and	CC	I-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	O
release	release	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
guinea	guinea	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
pig	pig	NN	I-NP	O	O
vas	vas	NN	I-NP	O	O
deferens	deferen	NNS	I-NP	O	O
.	.	.	O	O	O

Palytoxin	Palytoxin	NN	B-NP	B-protein	S-drug_n
(	(	(	O	O	O
PTX	PTX	NN	B-NP	B-protein	S-drug_n
)	)	)	O	O	O
,	,	,	O	O	O
C129H223N3O54	C129H223N3O54	NN	B-NP	B-protein	O
,	,	,	O	O	O
isolated	isolate	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
marine	marine	JJ	B-NP	O	O
coelenterates	coelenterate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Palythoa	Palythoa	NNP	B-NP	O	O
tuberculosa	tuberculosa	NNP	I-NP	O	O
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
rapid	rapid	JJ	I-NP	O	O
contraction	contraction	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
slow	slow	JJ	I-NP	O	O
phasic	phasic	JJ	I-NP	O	O
contraction	contraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
guinea	guinea	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
pig	pig	NN	I-NP	O	O
vas	vas	NN	I-NP	O	O
deferens	deferen	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
5	5	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
PTX	PTX	NN	B-NP	B-protein	S-drug_n-EF-2
(	(	(	O	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
8	8	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
)	)	)	O	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
contraction	contraction	NN	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
contraction	contraction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phentolamine	phentolamine	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
6	6	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
contraction	contraction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
selectively	selectively	RB	B-ADVP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
ouabain	ouabain	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
applied	apply	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phentolamine	phentolamine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
both	both	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
second	second	JJ	I-NP	O	O
contractile	contractile	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
PTX	PTX	NN	B-NP	B-protein	S-drug_n
were	be	VBD	B-VP	O	O
abolished	abolish	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
depleted	deplete	VBN	B-NP	O	O
solution	solution	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
contractile	contractile	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
PTX	PTX	NN	B-NP	B-protein	S-drug_n
was	be	VBD	B-VP	O	O
rather	rather	RB	B-ADJP	O	O
potentiated	potentiate	VBN	I-ADJP	O	O
.	.	.	O	O	O

PTX	PTX	NN	B-NP	O	S-drug_n
caused	cause	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
.	.	.	O	O	O

Exposure	Exposure	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
to	to	TO	B-PP	O	O
ouabain	ouabain	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
5	5	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
)	)	)	O	O	O
markedly	markedly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
PTX	PTX	NN	I-NP	B-protein	S-drug_n-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
release	release	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
second	second	JJ	I-NP	O	O
contractile	contractile	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
PTX	PTX	NN	B-NP	B-protein	S-drug_n
have	have	VBP	B-VP	O	O
entirely	entirely	RB	B-NP	O	O
different	different	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	O
from	from	IN	B-PP	O	O
nerves	nerve	NNS	B-NP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	O	S-drug
through	through	IN	B-PP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	O
release	release	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	O
release	release	NN	I-NP	O	O
but	but	CC	O	O	O
presumably	presumably	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
on	on	IN	B-PP	O	O
smooth	smooth	JJ	B-NP	B-cell_type	O
muscle	muscle	NN	I-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PTX	PTX	NN	B-NP	B-protein	S-drug_n
was	be	VBD	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
relation	relation	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Na	Na	NN	B-NP	O	O
,	,	,	O	O	O
K	K	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
ATPase	ATPase	NN	I-NP	I-protein	O
.	.	.	O	O	O

[	[	(	O	O	O
Quantitative	Quantitative	JJ	B-NP	O	O
approach	approach	NN	I-NP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
incisive	incisive	JJ	B-NP	O	O
neuroleptics	neuroleptic	NNS	I-NP	O	S-group
by	by	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
]	]	)	O	O	O
;	;	:	O	O	O
The	The	DT	B-NP	O	O
problems	problem	NNS	I-NP	O	O
encountered	encounter	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
longterm	longterm	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
psychotic	psychotic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
neuroleptics	neuroleptic	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
illustrated	illustrate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
six	six	CD	B-NP	O	O
typical	typical	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
reports	report	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
had	have	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
acute	acute	JJ	I-NP	O	O
episode	episode	NN	I-NP	O	O
despite	despite	IN	B-PP	O	O
seemingly	seemingly	RB	B-NP	O	O
adequate	adequate	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
selected	select	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
six	six	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
neuroleptics	neuroleptic	NNS	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
inappropriate	inappropriate	JJ	B-ADJP	O	O
,	,	,	O	O	O
being	be	VBG	B-VP	O	O
either	either	CC	O	O	O
too	too	RB	B-ADJP	O	O
high	high	JJ	I-ADJP	O	O
or	or	CC	O	O	O
too	too	RB	B-ADJP	O	O
low	low	JJ	I-ADJP	O	O
as	as	IN	B-SBAR	O	O
judged	judge	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Ways	Way	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
improving	improve	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
adequacy	adequacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
psychotic	psychotic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
neuroleptics	neuroleptic	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Intestinal	Intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
arsenate	arsenate	NN	B-NP	O	S-drug_n
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
chick	chick	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
arsenate	arsenate	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
As	As	IN	B-SBAR	O	B-drug_n
(	(	(	O	O	I-drug_n
V	V	NN	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
chick	chick	NN	I-NP	O	O
by	by	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
situ	situ	FW	I-NP	O	O
ligated	ligate	VBN	B-VP	O	O
duodenal	duodenal	JJ	B-NP	O	O
loop	loop	NN	I-NP	O	O
technique	technique	NN	I-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
this	this	DT	B-NP	O	O
procedure	procedure	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
arsenate	arsenate	NN	B-NP	O	S-drug_n
is	be	VBZ	B-VP	O	O
rapidly	rapidly	RB	B-VP	O	O
and	and	CC	I-VP	O	O
essentially	essentially	RB	I-VP	O	O
completely	completely	RB	I-VP	O	O
absorbed	absorb	VBN	I-VP	O	O
(	(	(	O	O	O
80	80	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
95	95	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lumen	lumen	NN	I-NP	O	O
at	at	IN	B-PP	O	O
As	As	IN	O	O	B-drug_n
(	(	(	O	O	I-drug_n
V	V	NN	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
concentrations	concentration	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
5	5	CD	I-NP	O	O
mM	mM	NN	I-NP	O	O
,	,	,	O	O	O
declining	decline	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
about	about	IN	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
at	at	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mM	mM	NN	I-NP	O	O
.	.	.	O	O	O

Transfer	Transfer	NN	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
lumen	lumen	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
mucosal	mucosal	JJ	I-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
at	at	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
As	A	NNS	I-NP	O	B-drug_n
(	(	(	O	O	I-drug_n
V	V	NN	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
concentration	concentration	NN	B-NP	O	O
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
mM	mM	NN	I-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
rapid	rapid	JJ	B-ADJP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
transfer	transfer	NN	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mucosal	mucosal	JJ	I-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
occurs	occur	VBZ	B-VP	O	O
more	more	RBR	B-ADVP	O	O
slowly	slowly	RB	I-ADVP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
As	A	NNS	I-NP	O	B-drug_n
(	(	(	O	O	I-drug_n
V	V	NN	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
concentrations	concentration	NNS	B-NP	O	O
greater	great	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
1	1	CD	I-NP	O	O
mM	mM	NN	I-NP	O	O
,	,	,	O	O	O
fractional	fractional	JJ	B-NP	O	O
mucosal	mucosal	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
As	A	NNS	B-NP	O	B-drug_n
(	(	(	O	O	I-drug_n
V	V	NN	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
remains	remain	VBZ	B-VP	O	O
constant	constant	JJ	B-ADJP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
fractional	fractional	JJ	B-NP	O	O
transfer	transfer	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
declines	decline	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
total	total	JJ	B-NP	O	O
mucosal	mucosal	JJ	I-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
As	A	NNS	B-NP	O	B-drug_n
(	(	(	O	O	I-drug_n
V	V	NN	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
and	and	CC	O	O	O
that	that	WDT	B-NP	O	O
transferred	transfer	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
linear	linear	JJ	I-NP	O	O
logarithmic	logarithmic	JJ	I-NP	O	O
fashion	fashion	NN	I-NP	O	O
from	from	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
to	to	TO	I-NP	O	O
5	5	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
As	As	IN	B-SBAR	O	B-drug_n
(	(	(	O	O	I-drug_n
V	V	NN	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
As	As	IN	B-SBAR	O	B-drug_n
(	(	(	O	O	I-drug_n
V	V	NN	B-NP	O	I-drug_n
)	)	)	O	O	E-drug_n
readily	readily	RB	B-ADVP	O	O
penetrates	penetrate	VBZ	B-VP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
mucosal	mucosal	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
serosal	serosal	JJ	I-NP	O	O
surfaces	surface	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epithelial	epithelial	JJ	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
arsenate	arsenate	NN	B-NP	O	S-drug_n
and	and	CC	I-NP	O	O
phosphate	phosphate	NN	I-NP	O	S-drug
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
share	share	VB	I-VP	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
transport	transport	NN	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duodenum	duodenum	NN	I-NP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
any	any	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
at	at	IN	B-PP	O	O
this	this	DT	B-NP	O	O
level	level	NN	I-NP	O	O
.	.	.	O	O	O

Vitamin	Vitamin	NN	B-NP	O	B-drug-ME-1
D3	D3	NN	I-NP	O	E-drug-ME-1
administration	administration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
rachitic	rachitic	JJ	B-NP	O	O
chicks	chick	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
significantly	significantly	RB	B-VP	O	O
elevating	elevate	VBG	I-VP	O	O
duodenal	duodenal	JJ	B-NP	O	O
arsenate	arsenate	NN	I-NP	O	S-drug_n-ME-2
absorption	absorption	NN	I-NP	O	O
,	,	,	O	O	O
acting	act	VBG	B-VP	O	O
primarily	primarily	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
serosal	serosal	JJ	B-NP	O	O
transport	transport	NN	I-NP	O	O
.	.	.	O	O	O

Spermine	Spermine	NN	B-NP	O	S-drug
promotes	promote	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
translocation	translocation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phosphatidate	phosphatidate	NN	B-NP	B-protein	O
phosphohydrolase	phosphohydrolase	NN	I-NP	I-protein	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytosol	cytosol	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
microsomal	microsomal	JJ	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rat	rat	NN	B-NP	B-protein	O
liver	liver	NN	I-NP	I-protein	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oleate	oleate	NN	B-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
respect	respect	NN	I-NP	O	O
.	.	.	O	O	O

Spermine	Spermine	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
mM	mM	NN	I-NP	O	O
)	)	)	O	O	O
promoted	promote	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
translocation	translocation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phosphatidate	phosphatidate	NN	B-NP	B-protein	O
phosphohydrolase	phosphohydrolase	NN	I-NP	I-protein	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
soluble	soluble	JJ	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
microsomal	microsomal	JJ	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cell	cell	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
free	free	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
derived	derive	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
spermidine	spermidine	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mM	mM	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
putrescine	putrescine	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mM	mM	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
translocation	translocation	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
added	add	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Spermine	Spermine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
lesser	less	JJR	I-NP	O	O
extent	extent	NN	I-NP	O	O
,	,	,	O	O	O
spermidine	spermidine	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
enhanced	enhance	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
translocating	translocate	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oleate	oleate	NN	B-NP	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
its	its	PRP$	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
in	in	IN	B-PP	O	O
transferring	transfer	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
phosphohydrolase	phosphohydrolase	NN	I-NP	B-protein	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
soluble	soluble	JJ	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
microsomal	microsomal	JJ	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
proposed	propose	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
phosphohydrolase	phosphohydrolase	NN	I-NP	B-protein	O
becomes	become	VBZ	B-VP	O	O
metabolically	metabolically	RB	B-ADJP	O	O
active	active	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
combines	combine	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
membranes	membrane	NNS	B-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
polyamines	polyamine	NNS	B-NP	O	O
might	might	MD	B-VP	O	O
help	help	VB	I-VP	O	O
to	to	TO	I-VP	O	O
regulate	regulate	VB	I-VP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
could	could	MD	B-VP	O	O
facilitate	facilitate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fatty	fatty	JJ	B-NP	O	O
acids	acid	NNS	I-NP	O	O
and	and	CC	O	O	O
enable	enable	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
capacity	capacity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
triacylglycerol	triacylglycerol	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
to	to	TO	B-VP	O	O
match	match	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
availability	availability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fatty	fatty	JJ	B-NP	O	O
acids	acid	NNS	I-NP	O	O
.	.	.	O	O	O

Influence	Influence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
on	on	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
arachidonic	arachidonic	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Available	Available	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
arachidonic	arachidonic	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
important	important	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
hemostasis	hemostasis	NN	B-NP	O	O
and	and	CC	O	O	O
regulation	regulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vascular	vascular	JJ	B-NP	O	O
tone	tone	NN	I-NP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
membrane	membrane	NN	I-NP	O	O
and	and	CC	O	O	O
intracellular	intracellular	JJ	B-NP	O	O
mobilization	mobilization	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	O
ions	ion	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
intimately	intimately	RB	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
platelet	platelet	VB	I-VP	O	O
activation	activation	NN	B-NP	O	O
and	and	CC	O	O	O
release	release	NN	B-NP	O	O
of	of	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
contents	content	NNS	I-NP	O	O
.	.	.	O	O	O

Release	Release	NN	B-NP	O	O
of	of	IN	B-PP	O	O
arachidonic	arachidonic	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
from	from	IN	B-PP	O	O
membrane	membrane	NN	B-NP	O	O
phospholipids	phospholipid	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
subsequent	subsequent	JJ	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
and	and	CC	I-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasoconstrictor	vasoconstrictor	NN	B-NP	B-protein	O
thromboxane	thromboxane	NN	I-NP	I-protein	O
A2	A2	NN	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
regulated	regulate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
movement	movement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	O
ions	ion	NNS	I-NP	O	O
.	.	.	O	O	O

Adenosine	Adenosine	NN	B-NP	O	O
3	3	CD	I-NP	O	O
'	'	SYM	B-NP	O	O
:	:	:	O	O	O
5	5	CD	B-NP	O	O
'	'	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
cyclic	cyclic	JJ	I-NP	O	O
phosphate	phosphate	NN	I-NP	O	O
in	in	IN	B-PP	O	O
turn	turn	NN	B-NP	O	O
controls	control	VBZ	B-VP	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	O	O
ions	ion	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
platelets	platelet	NNS	B-NP	B-cell_type	O
and	and	CC	O	O	O
regulates	regulate	VBZ	B-VP	O	O
calcium	calcium	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Slow	Slow	JJ	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
channel	channel	NN	I-NP	O	I-group
calcium	calcium	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug
,	,	,	O	O	O
inhibit	inhibit	VBP	B-VP	O	O
platelet	platelet	NN	B-NP	B-cell_type	O
activation	activation	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
adhesion	adhesion	NN	I-NP	O	O
intravascularly	intravascularly	RB	B-ADVP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
platelet	platelet	NN	B-NP	O	O
nucleotide	nucleotide	NN	I-NP	O	O
release	release	NN	I-NP	O	O
and	and	CC	O	O	O
thromboxane	thromboxane	NN	B-NP	O	O
A2	A2	NN	I-NP	O	O
generation	generation	NN	I-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
preliminary	preliminary	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
calcium	calcium	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
also	also	RB	B-ADVP	O	O
increase	increase	VBP	B-VP	O	O
generation	generation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vasodilator	vasodilator	NN	B-NP	O	O
and	and	CC	I-NP	O	O
platelet	platelet	NN	I-NP	B-protein	O
antiaggregant	antiaggregant	JJ	I-NP	I-protein	O
prostacyclin	prostacyclin	NN	I-NP	I-protein	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
in	in	IN	B-PP	O	O
platelet	platelet	NN	B-NP	B-cell_type	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
on	on	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
arachidonic	arachidonic	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
could	could	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
to	to	TO	B-PP	O	O
their	their	PRP$	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ischemic	ischemic	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Differential	Differential	JJ	B-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
naloxone	naloxone	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
blocking	block	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
flick	flick	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
intraventricular	intraventricular	JJ	B-NP	B-protein	O
beta	beta	SYM	I-NP	I-protein	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
endorphin	endorphin	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
proposed	propose	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
opioids	opioid	NNS	I-NP	O	S-group
applied	apply	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
supraspinal	supraspinal	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
sites	site	NNS	I-NP	O	O
produced	produce	VBD	B-VP	O	O
their	their	PRP$	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
activation	activation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
descending	descend	VBG	I-NP	O	O
pain	pain	NN	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
systems	system	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
endorphinergic	endorphinergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
by	by	IN	B-PP	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
naloxone	naloxone	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
production	production	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tail	tail	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
flick	flick	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
intraventricular	intraventricular	JJ	B-NP	B-protein	O
beta	beta	SYM	I-NP	I-protein	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
endorphin	endorphin	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
then	then	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Intraventricular	Intraventricular	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
endorphin	endorphin	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
produced	produce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
flick	flick	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
heat	heat	NN	I-NP	O	O
stimulus	stimulus	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Intrathecal	Intrathecal	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naloxone	naloxone	NN	B-NP	O	S-drug-EF-1
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
0.4	0.4	CD	B-NP	O	O
to	to	TO	I-NP	O	O
40	40	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
flick	flick	NN	I-NP	O	O
response	response	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
intraventricular	intraventricular	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-drug_n-EF-2
-	-	HYPH	O	O	I-drug_n-EF-2
endorphin	endorphin	NN	B-NP	O	E-drug_n-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naloxone	naloxone	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
40	40	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
completely	completely	RB	B-ADVP	O	O
blocked	block	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
flick	flick	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
intraventricular	intraventricular	JJ	B-NP	B-protein	O
beta	beta	SYM	I-NP	I-protein	B-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
endorphin	endorphin	NN	I-NP	O	E-drug_n-EF-2
(	(	(	O	O	O
16	16	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
naloxone	naloxone	NN	I-NP	O	S-drug-EF-1
(	(	(	O	O	O
12	12	CD	B-NP	O	O
-	-	HYPH	O	O	O
120	120	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
only	only	RB	B-NP	O	O
a	a	DT	I-NP	O	O
very	very	RB	I-NP	O	O
weak	weak	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
flick	flick	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
intraventricular	intraventricular	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug-EF-2
(	(	(	O	O	O
40	40	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Intraventricular	Intraventricular	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naloxone	naloxone	NN	B-NP	O	S-drug-EF-1
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
1.2	1.2	CD	B-NP	O	O
to	to	TO	I-NP	O	O
12	12	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
equally	equally	RB	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
flick	flick	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
intraventricular	intraventricular	JJ	B-NP	B-protein	O
beta	beta	SYM	I-NP	I-protein	B-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
endorphin	endorphin	NN	I-NP	O	E-drug_n-EF-2
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
naloxone	naloxone	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
endorphinergic	endorphinergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
production	production	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	O	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
endorphin	endorphin	NN	B-NP	O	E-drug_n
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
morphine	morphine	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
tail	tail	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
flick	flick	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
intraventricular	intraventricular	JJ	B-NP	B-protein	O
beta	beta	SYM	I-NP	I-protein	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
endorphin	endorphin	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
elicit	elicit	VBP	B-VP	O	O
their	their	PRP$	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
activation	activation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
descending	descend	VBG	I-NP	O	O
pain	pain	NN	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
systems	system	NNS	I-NP	O	O
;	;	:	O	O	O

descending	descend	VBG	B-VP	O	O
epsilon	epsilon	NN	B-NP	O	O
and	and	CC	I-NP	O	O
mu	mu	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
endorphin	endorphin	NN	I-NP	O	E-drug_n
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
proposed	propose	VBN	I-VP	O	O
.	.	.	O	O	O

Neurochemical	Neurochemical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
functional	functional	JJ	I-NP	O	O
consequences	consequence	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
1	1	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,5,6	1,2,5,6	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
MPTP	MPTP	NN	B-NP	B-protein	S-drug_n
)	)	)	O	O	O
and	and	CC	O	O	O
methamphetamine	methamphetamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
neurochemical	neurochemical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
functional	functional	JJ	I-NP	O	O
consequences	consequence	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
MPTP	MPTP	NN	B-NP	O	S-drug_n
administration	administration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
and	and	CC	O	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
similar	similar	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
MPTP	MPTP	NN	B-NP	B-protein	S-drug_n-EF-1
induced	induce	VBD	B-VP	O	O
long	long	JJ	B-NP	O	O
lasting	lasting	JJ	I-NP	O	O
depletions	depletion	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
striatal	striatal	JJ	B-NP	O	O
dopamine	dopamine	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prevented	prevent	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pargyline	pargyline	NN	B-NP	O	S-drug-EF-2
pretreatment	pretreatment	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
MPTP	MPTP	NN	I-NP	B-protein	S-drug-EF-1
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
neuronal	neuronal	JJ	I-NP	O	O
damage	damage	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
disruptive	disruptive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
supersensitivity	supersensitivity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
disruptive	disruptive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
apomorphine	apomorphine	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
responding	respond	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
schedule	schedule	NN	I-NP	O	O
controlled	controlled	JJ	I-NP	O	O
paradigm	paradigm	NN	I-NP	O	O
.	.	.	O	O	O

Methamphetamine	Methamphetamine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
like	like	IN	B-PP	O	O
MPTP	MPTP	NN	B-NP	B-protein	S-drug_n
,	,	,	O	O	O
produced	produce	VBD	B-VP	O	O
depletions	depletion	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
striatal	striatal	JJ	B-NP	O	O
dopamine	dopamine	NN	I-NP	O	O
but	but	CC	O	O	O
these	these	DT	B-NP	O	O
actions	action	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pargyline	pargyline	NN	B-NP	O	S-drug-EF-2
pretreatment	pretreatment	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
observations	observation	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
reference	reference	NN	B-NP	O	O
to	to	TO	B-PP	O	O
possible	possible	JJ	B-NP	O	O
deleterious	deleterious	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pargyline	pargyline	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
Disease	Disease	NN	I-NP	O	O
.	.	.	O	O	O

Jacalin	Jacalin	NN	B-NP	O	S-drug_n
:	:	:	O	O	O
an	an	DT	B-NP	O	O
IgA	IgA	NN	I-NP	B-protein	O
-	-	HYPH	O	I-protein	O
binding	bind	VBG	B-VP	I-protein	O
lectin	lectin	NN	B-NP	I-protein	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
previously	previously	RB	B-ADVP	O	O
reported	report	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
seeds	seed	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Artocarpus	Artocarpus	NN	B-NP	O	O
integrifolia	integrifolia	NN	I-NP	O	O
(	(	(	O	O	O
jackfruit	jackfruit	NN	B-NP	O	O
)	)	)	O	O	O
contain	contain	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
lectin	lectin	NN	I-NP	B-protein	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
we	we	PRP	B-NP	O	O
call	call	VBP	B-VP	O	O
jacalin	jacalin	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
both	both	CC	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
T	T	NN	I-NP	B-protein	O
cell	cell	NN	I-NP	I-protein	O
mitogen	mitogen	NN	I-NP	I-protein	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
apparently	apparently	RB	I-NP	O	O
T	T	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
independent	independent	JJ	I-NP	O	O
activator	activator	NN	I-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
B	B	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
immunoglobulins	immunoglobulin	NNS	B-NP	B-protein	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
above	above	JJ	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
we	we	PRP	B-NP	O	O
noted	note	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
massive	massive	JJ	I-NP	O	O
precipitation	precipitation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cell	cell	NN	B-NP	B-cell_line	O
cultures	culture	NNS	I-NP	I-cell_line	O
stimulated	stimulate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
or	or	CC	O	O	O
equal	equal	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
100	100	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lectin	lectin	NN	B-NP	B-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
precipitate	precipitate	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
formed	form	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
jacalin	jacalin	NN	B-NP	B-protein	S-drug_n
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
added	add	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
culture	culture	NN	I-NP	O	O
medium	medium	NN	I-NP	O	O
.	.	.	O	O	O

More	More	RBR	B-ADVP	O	O
importantly	importantly	RB	I-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
IgA	IgA	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
probably	probably	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
constituent	constituent	NN	I-NP	O	O
precipitated	precipitate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lectin	lectin	NN	I-NP	B-protein	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
IgG	IgG	NN	I-NP	B-protein	O
or	or	CC	I-NP	O	O
IgM	IgM	NN	I-NP	B-protein	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
precipitates	precipitate	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
secretions	secretion	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
colostrum	colostrum	NN	B-NP	O	O
,	,	,	O	O	O
IgA	IgA	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
only	only	JJ	I-NP	O	O
protein	protein	NN	I-NP	O	O
precipitated	precipitate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
jacalin	jacalin	NN	B-NP	O	S-drug_n
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
specificity	specificity	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
simple	simple	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
reliable	reliable	JJ	I-NP	O	O
affinity	affinity	NN	I-NP	O	O
chromatography	chromatography	NN	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
purification	purification	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	B-NP	O	O
human	human	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
colostrum	colostrum	NN	I-NP	O	O
IgA	IgA	NN	I-NP	O	O
.	.	.	O	O	O

Jacalin	Jacalin	NN	B-NP	B-protein	S-drug_n
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
D	D	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Gal	Gal	JJ	I-NP	B-protein	O
binding	binding	NN	I-NP	I-protein	O
lectin	lectin	NN	I-NP	I-protein	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
useful	useful	JJ	I-NP	O	O
tool	tool	NN	I-NP	O	O
for	for	IN	B-PP	O	O
studying	study	VBG	B-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	O	O	O
secretory	secretory	JJ	B-NP	O	O
IgA	IgA	NN	I-NP	B-protein	O
.	.	.	O	O	O

Cancer	Cancer	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
:	:	:	O	O	O
basic	basic	JJ	B-NP	O	O
science	science	NN	I-NP	O	O
and	and	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
aspects	aspect	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	O
increases	increase	VBZ	B-VP	O	O
progressively	progressively	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
age	age	NN	B-NP	O	O
.	.	.	O	O	O

Rearrangements	Rearrangement	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
genomes	genome	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
accompany	accompany	VB	I-VP	O	O
cellular	cellular	JJ	B-NP	O	O
aging	aging	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
factors	factor	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
concert	concert	NN	B-NP	O	O
with	with	IN	B-PP	O	O
age	age	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
immune	immune	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
host	host	NN	B-NP	O	O
defense	defense	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
help	help	VB	I-VP	O	O
to	to	TO	I-VP	O	O
explain	explain	VB	I-VP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
malignant	malignant	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
aged	aged	JJ	B-NP	O	O
persons	person	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
presentation	presentation	NN	I-NP	O	O
and	and	CC	O	O	O
natural	natural	JJ	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neoplasia	neoplasia	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
aging	aging	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
conference	conference	NN	I-NP	O	O
reviews	review	VBZ	B-VP	O	O
recent	recent	JJ	B-NP	O	O
developments	development	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
areas	area	NNS	I-NP	O	O
,	,	,	O	O	O
examines	examine	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
and	and	CC	O	O	O
implications	implication	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
management	management	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
discusses	discuss	VBZ	B-VP	O	O
current	current	JJ	B-NP	O	O
information	information	NN	I-NP	O	O
on	on	IN	B-PP	O	O
how	how	WRB	B-ADVP	O	O
age	age	NN	B-NP	O	O
may	may	MD	B-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
response	response	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	O
to	to	TO	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

Dexamethasone	Dexamethasone	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
retinyl	retinyl	NN	I-NP	O	B-drug-EF-1
acetate	acetate	NN	I-NP	O	E-drug-EF-1
similarly	similarly	RB	B-ADVP	O	O
inhibit	inhibit	VBP	B-VP	O	O
and	and	CC	I-VP	O	O
stimulate	stimulate	VBP	I-VP	O	O
EGF	EGF	NN	B-NP	B-protein	S-drug_n-EF-2
-	-	HYPH	B-NP	O	O
or	or	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug-EF-2
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostatic	prostatic	JJ	B-NP	O	O
epithelium	epithelium	NN	I-NP	O	O
.	.	.	O	O	O

Prostatic	Prostatic	JJ	B-NP	O	O
epithelium	epithelium	NN	I-NP	O	O
proliferates	proliferate	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
defined	define	VBN	I-NP	O	O
medium	medium	NN	I-NP	O	O
consisting	consist	VBG	B-VP	O	O
of	of	IN	B-PP	O	O
basal	basal	JJ	B-NP	O	O
medium	medium	NN	I-NP	O	O
RPMI1640	RPMI1640	NN	I-NP	O	O
containing	contain	VBG	B-VP	O	O
transferrin	transferrin	NN	B-NP	B-protein	S-drug_n
(	(	(	O	O	O
1	1	CD	B-NP	O	O
microgram	microgram	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
EGF	EGF	NN	B-NP	B-protein	S-drug_n
(	(	(	O	O	O
10	10	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
(	(	(	O	O	O
3.7	3.7	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
or	or	CC	O	O	O
0.1	0.1	CD	B-NP	O	O
IU	IU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
neither	neither	CC	O	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-EF-1
nor	nor	CC	O	O	O
retinyl	retinyl	NN	B-NP	O	B-drug-EF-1
acetate	acetate	NN	I-NP	O	E-drug-EF-1
affected	affect	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostatic	prostatic	JJ	B-NP	O	O
epithelium	epithelium	NN	I-NP	O	O
in	in	IN	B-PP	O	O
RPMI1640	RPMI1640	NN	B-NP	B-cell_line	O
containing	contain	VBG	B-VP	O	O
transferrin	transferrin	NN	B-NP	B-protein	S-drug_n
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
modify	modify	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
mitogenic	mitogenic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EGF	EGF	NN	B-NP	B-protein	S-drug_n-EF-2
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug-EF-2
.	.	.	O	O	O

Dexamethasone	Dexamethasone	NN	B-NP	O	S-drug-EF-1
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
10	10	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
or	or	CC	I-NP	O	O
retinyl	retinyl	NN	I-NP	O	B-drug-EF-1
acetate	acetate	NN	I-NP	O	E-drug-EF-1
at	at	IN	B-PP	O	O
about	about	IN	B-NP	O	O
3	3	CD	I-NP	O	O
X	X	SYM	I-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
9	9	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
proliferation	proliferation	NN	B-NP	O	O
stimulated	stimulate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
EGF	EGF	NN	B-NP	B-protein	S-drug_n-EF-2
.	.	.	O	O	O

Higher	High	JJR	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
8	8	CD	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
6	6	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
retinyl	retinyl	NN	B-NP	O	B-drug-EF-1
acetate	acetate	NN	I-NP	O	E-drug-EF-1
(	(	(	O	O	O
3	3	CD	B-NP	O	O
X	X	SYM	O	O	O
10	10	CD	O	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
8	8	CD	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
7	7	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
)	)	)	O	O	O
enhance	enhance	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
mitogenic	mitogenic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EGF	EGF	NN	B-NP	B-protein	S-drug_n-EF-2
.	.	.	O	O	O

Dexamethasone	Dexamethasone	NN	B-NP	O	S-drug
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
retinyl	retinyl	NN	B-NP	O	B-drug-EF-1
acetate	acetate	NN	I-NP	O	E-drug-EF-1
stimulated	stimulate	VBN	B-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
,	,	,	O	O	O
proliferation	proliferation	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug-EF-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
both	both	CC	O	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
retinyl	retinyl	NN	B-NP	O	B-drug-EF-1
acetate	acetate	NN	I-NP	O	E-drug-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
possibly	possibly	RB	B-NP	O	O
other	other	JJ	I-NP	O	O
glucocorticoids	glucocorticoid	NNS	I-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
retinoids	retinoid	NNS	I-NP	O	S-group-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
regulate	regulate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostate	prostate	NN	B-NP	O	O
epithelium	epithelium	NN	I-NP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
modification	modification	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug-EF-2
and	and	CC	I-NP	O	O
EGF	EGF	NN	I-NP	B-protein	S-drug_n-EF-2
.	.	.	O	O	O

Pharmacokinetics	Pharmacokinetic	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
entry	entry	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
.	.	.	O	O	O

Effective	Effective	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
depends	depend	VBZ	B-VP	O	O
not	not	RB	B-CONJP	O	O
only	only	RB	I-CONJP	O	O
on	on	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
acumen	acuman	NNS	I-NP	O	O
but	but	CC	B-CONJP	O	O
also	also	RB	I-CONJP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
availability	availability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
relevant	relevant	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
information	information	NN	I-NP	O	O
assists	assist	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
development	development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
safe	safe	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
,	,	,	O	O	O
prediction	prediction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	O
handling	handling	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
states	state	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
disease	disease	NN	B-NP	O	O
and	and	CC	O	O	O
disorder	disorder	NN	B-NP	O	O
and	and	CC	I-NP	O	O
anticipation	anticipation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
the	the	DT	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
entry	entry	NN	I-NP	O	I-group
blocking	block	VBG	B-VP	O	I-group
agents	agent	NNS	B-NP	O	E-group
now	now	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
States	States	NNP	I-NP	O	O
(	(	(	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
well	well	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
patterns	pattern	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
use	use	NN	B-NP	O	O
evolved	evolve	VBN	B-VP	O	O
.	.	.	O	O	O

Nonetheless	Nonetheless	RB	B-ADVP	O	O
,	,	,	O	O	O
their	their	PRP$	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
continues	continue	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dependence	dependence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
on	on	IN	B-PP	O	O
intact	intact	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
and	and	CC	I-NP	O	O
function	function	NN	I-NP	O	O
for	for	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
rates	rate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
elimination	elimination	NN	B-NP	O	O
;	;	:	O	O	O

by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nonlinear	nonlinear	JJ	I-NP	O	O
kinetic	kinetic	JJ	I-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	O	S-drug
(	(	(	O	O	O
and	and	CC	O	O	O
probably	probably	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
as	as	RB	B-ADVP	O	O
well	well	RB	I-ADVP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
derivative	derivative	JJ	I-NP	O	O
implications	implication	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
requirements	requirement	NNS	I-NP	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
by	by	IN	B-PP	O	O
observations	observation	NNS	B-NP	O	O
now	now	RB	B-VP	O	O
appearing	appear	VBG	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
relation	relation	NN	I-NP	O	O
between	between	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
drug	drug	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
both	both	DT	B-ADJP	O	O
therapeutic	therapeutic	JJ	I-ADJP	O	O
and	and	CC	I-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
herein	herein	RB	B-ADVP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
emphasis	emphasis	NN	B-NP	O	O
on	on	IN	B-PP	O	O
those	those	DT	B-NP	O	O
aspects	aspect	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
impact	impact	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
calcium	calcium	NN	I-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
entry	entry	NN	I-NP	O	I-group
antagonists	antagonist	NNS	I-NP	O	E-group
.	.	.	O	O	O

Selective	Selective	JJ	B-NP	O	O
survival	survival	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pentazocine	pentazocine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
tripelennamine	tripelennamine	NN	I-NP	O	S-drug
of	of	IN	B-PP	O	O
Pseudomonas	Pseudomonas	NNP	B-NP	O	O
aeruginosa	aeruginosa	NN	I-NP	O	O
serotype	serotype	NN	I-NP	O	O
O11	O11	NN	I-NP	O	O
from	from	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
addicts	addict	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
growth	growth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Pseudomonas	Pseudomonas	NNP	B-NP	O	O
aeruginosa	aeruginosa	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-NP	O	O
serotype	serotype	NN	I-NP	O	O
O11	O11	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
pentazocine	pentazocine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
tripelennamine	tripelennamine	NN	I-NP	O	S-drug

was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
explanation	explanation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
association	association	NN	I-NP	O	O
of	of	IN	B-PP	O	O
deep	deep	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
seated	seat	VBN	I-NP	O	O
infection	infection	NN	I-NP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
organism	organism	NN	I-NP	O	O
and	and	CC	I-NP	O	O
abuse	abuse	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
growth	growth	NN	B-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
1,000	1,000	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
for	for	IN	B-PP	O	O
49	49	CD	B-NP	O	O
Pseudomonas	Pseudomonas	NNP	I-NP	O	O
strains	strain	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
for	for	IN	B-PP	O	O
32	32	CD	B-NP	O	O
strains	strain	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
addicts	addict	NNS	I-NP	O	O
(	(	(	O	O	O
4.2	4.2	CD	B-NP	O	O
vs.	vs.	IN	B-PP	O	O
1.3	1.3	CD	B-NP	O	O
logs	log	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
reduction	reduction	NN	B-NP	O	O
at	at	IN	B-PP	O	O
2	2	CD	B-NP	O	O
hr	hr	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
.0005	.0005	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
phenotypic	phenotypic	JJ	I-NP	O	O
subset	subset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serotype	serotype	NN	I-NP	O	O
O11	O11	NN	I-NP	O	O
strains	strain	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
addicts	addict	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
especially	especially	RB	B-ADJP	O	O
resistant	resistant	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Twelve	Twelve	CD	B-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Staphylococcus	Staphylococcus	FW	B-NP	O	O
aureus	aureus	FW	I-NP	O	O
(	(	(	O	O	O
a	a	DT	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
infection	infection	NN	B-NP	O	O
in	in	IN	B-PP	O	O
heroin	heroin	NN	B-NP	O	S-drug_n
,	,	,	B-PP	O	O
but	but	CC	I-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
pentazocine	pentazocine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
tripelennamine	tripelennamine	NN	I-NP	O	S-drug-EF-2
,	,	,	O	O	O
addicts	addict	NNS	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
completely	completely	RB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
response	response	NN	I-NP	O	O
curves	curve	NNS	I-NP	O	O
(	(	(	O	O	O
derived	derive	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
pure	pure	JJ	B-NP	O	O
powders	powder	NNS	I-NP	O	O
)	)	)	O	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
tripelennamine	tripelennamine	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
partially	partially	RB	I-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pentazocine	pentazocine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
P	P	NN	I-NP	O	O
.	.	.	O	O	O

aeruginosa	aeruginosa	NN	B-NP	O	O
serotype	serotype	NN	I-NP	O	O
O11	O11	NN	I-NP	O	O
strains	strain	NNS	I-NP	O	O
,	,	,	B-NP	O	O
but	but	CC	I-NP	O	O
not	not	RB	I-NP	O	O
S	S	NN	B-NP	O	O
.	.	.	O	O	O

aureus	aureus	RB	B-ADVP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
survive	survive	VB	I-VP	O	O
in	in	IN	B-PP	O	O
pentazocine	pentazocine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
tripelennamine	tripelennamine	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
explain	explain	VB	I-VP	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
a	a	DT	B-NP	O	O
shift	shift	NN	I-NP	O	O
from	from	IN	B-PP	O	O
S	S	NN	B-NP	O	O
.	.	.	O	O	O

aureus	aureus	NN	B-NP	O	O
to	to	TO	B-PP	O	O
P	P	NN	B-NP	O	O
.	.	.	O	O	O

aeruginosa	aeruginosa	NN	B-NP	O	O
as	as	IN	B-PP	O	O
common	common	JJ	B-NP	O	O
pathogens	pathogen	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
addicts	addict	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
areas	area	NNS	B-NP	O	O
where	where	WRB	B-ADVP	O	O
abuse	abuse	NN	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
has	have	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
raise	raise	VB	I-VP	O	O
serum	serum	NN	B-NP	B-protein	O
digoxin	digoxin	NN	I-NP	I-protein	S-drug-ME-2
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
designed	design	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
10	10	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
variables	variable	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1.0	1.0	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
subject	subject	NN	I-NP	O	O
,	,	,	O	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	O	S-drug
,	,	,	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-ME-1
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
systemic	systemic	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
234	234	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
72	72	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	B-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
standard	standard	JJ	B-NP	O	O
deviation	deviation	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
172	172	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
33	33	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
reductions	reduction	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
105	105	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
39	39	CD	B-NP	O	O
to	to	TO	B-PP	O	O
84	84	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
15	15	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
nonrenal	nonrenal	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
130	130	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
38	38	CD	B-NP	O	O
to	to	TO	B-PP	O	O
88	88	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
20	20	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
elimination	elimination	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
34	34	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
13	13	CD	B-NP	O	O
to	to	TO	B-PP	O	O
40	40	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
16	16	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
distribution	distribution	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
changed	change	VBN	I-VP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	O	S-drug
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
three	three	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
to	to	TO	B-PP	O	O
fivefold	fivefold	JJ	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
reverse	reverse	JJ	I-NP	O	O
triiodothyronine	triiodothyronine	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
thyroid	thyroid	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
quantitatively	quantitatively	RB	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	O	S-drug-ME-2
explain	explain	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
level	level	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
combination	combination	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
clinically	clinically	RB	B-ADVP	O	O
.	.	.	O	O	O

Misonidazole	Misonidazole	NN	B-NP	O	S-drug_n-EF-1
protects	protect	VBZ	B-VP	O	O
mouse	mouse	NN	B-NP	O	O
tumour	tumour	NN	I-NP	O	O
and	and	CC	O	O	O
normal	normal	JJ	B-NP	O	O
tissues	tissue	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
CCNU	CCNU	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
nitrosourea	nitrosourea	NN	I-NP	O	S-group
CCNU	CCNU	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
exclusively	exclusively	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
studies	study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antitumour	antitumour	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
acute	acute	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
and	and	CC	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
CCNU	CCNU	NN	I-NP	O	S-drug
,	,	,	O	O	O
either	either	CC	O	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
chemosensitizer	chemosensitizer	NN	I-NP	O	O
misonidazole	misonidazole	NN	I-NP	O	S-drug_n
.	.	.	O	O	O

In	In	IN	B-PP	O	O
both	both	CC	O	O	O
plasma	plasma	NN	B-NP	O	O
and	and	CC	I-NP	O	O
KHT	KHT	NN	I-NP	O	O
tumour	tumour	NN	I-NP	O	O
the	the	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	O	O	O
``	``	``	O	O	O
early	early	JJ	B-ADVP	O	O
``	``	``	O	O	O

AUC	AUC	NN	B-NP	O	O
for	for	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
nitrosoureas	nitrosourea	NNS	I-NP	O	S-group
were	be	VBD	B-VP	O	O
about	about	RB	B-NP	O	O
1.4	1.4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
1.5	1.5	CD	I-NP	O	O
fold	fold	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
i.p	i.p	NN	I-NP	O	O
.	.	.	O	O	O

route	route	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reflected	reflect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
roughly	roughly	RB	I-NP	O	O
twofold	twofold	RB	I-NP	O	O
greater	great	JJR	I-NP	O	O
antitumour	antitumour	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
acute	acute	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
CCNU	CCNU	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
1.45	1.45	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
less	less	RBR	B-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
limiting	limit	VBG	B-VP	O	O
organ	organ	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
different	different	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
routes	route	NNS	I-NP	O	O
.	.	.	O	O	O

Misonidazole	Misonidazole	NN	B-NP	O	S-drug_n-EF-1
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
antitumour	antitumour	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
CCNU	CCNU	NN	I-NP	O	S-drug-EF-2
by	by	IN	B-PP	O	O
dose	dose	NN	B-NP	B-protein	O
modifying	modifying	NN	I-NP	I-protein	O
factors	factor	NNS	I-NP	I-protein	O
(	(	(	O	O	O
DMF	DMF	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
0.58	0.58	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.71	0.71	CD	I-NP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
diminished	diminish	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
DMF	DMF	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.74	0.74	CD	B-NP	O	O
.	.	.	O	O	O

Misonidazole	Misonidazole	NN	B-NP	O	S-drug_n-ME-1
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
complex	complex	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
CCNU	CCNU	NN	I-NP	O	S-drug-ME-2
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tumour	tumour	NN	I-NP	O	O
total	total	VBP	B-VP	O	O
nitrosourea	nitrosourea	NN	B-NP	O	S-group
peak	peak	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
1.5	1.5	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1.7	1.7	CD	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
respectively	respectively	RB	I-ADVP	O	O
.	.	.	O	O	O

Misonidazole	Misonidazole	NN	B-NP	O	S-drug_n
also	also	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
``	``	``	I-NP	O	O
early	early	JJ	I-NP	O	O
``	``	``	O	O	O

nitrosourea	nitrosourea	NN	B-NP	O	S-group
AUC	AUC	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
depending	depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
minimum	minimum	JJ	I-NP	O	O
effective	effective	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
(	(	(	O	O	O
MEC	MEC	NN	B-NP	O	O
)	)	)	O	O	O
chosen	chosen	NN	B-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
example	example	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
nitrosourea	nitrosourea	NN	I-NP	O	S-group
AUC	AUC	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
factors	factor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
1.05	1.05	CD	B-NP	O	O
and	and	CC	I-NP	O	O
9.6	9.6	CD	I-NP	O	O
for	for	IN	B-PP	O	O
MEC	MEC	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
2	2	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
ml	ml	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
propose	propose	VBP	B-VP	O	O
these	these	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
underlying	underlie	VBG	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
CCNU	CCNU	NN	I-NP	O	S-drug-ME-1
cytotoxicity	cytotoxicity	NN	I-NP	O	O
by	by	IN	B-PP	O	O
misonidazole	misonidazole	NN	B-NP	O	S-drug_n-ME-2
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
detailed	detailed	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
.	.	.	O	O	O

Enhanced	Enhance	VBN	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-ME-1
clearance	clearance	NN	I-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
report	report	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
two	two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-1
clearance	clearance	NN	I-NP	O	O
accelerated	accelerate	VBD	B-VP	O	O
markedly	markedly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-2
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Maximum	Maximum	JJ	B-NP	O	O
calculated	calculate	VBN	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
ranged	range	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
2	2	CD	B-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
2	2	CD	B-NP	O	O
to	to	TO	B-PP	O	O
3	3	CD	B-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
baseline	baseline	NN	I-NP	O	O
.	.	.	O	O	O

Onset	Onset	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
began	begin	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
five	five	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
beginning	begin	VBG	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
use	use	NN	I-NP	O	O
,	,	,	O	O	O
clinicians	clinician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
added	add	VBN	I-VP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
reexacerbation	reexacerbation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pulmonary	pulmonary	JJ	B-NP	O	O
symptomatology	symptomatology	NN	I-NP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
lowered	lower	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-EF-2
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Stereoselective	Stereoselective	JJ	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
N	N	NN	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
allylnormetazocine	allylnormetazocine	NN	I-NP	O	E-drug_n
in	in	IN	B-PP	O	O
pigeons	pigeon	NNS	B-NP	O	O
and	and	CC	O	O	O
squirrel	squirrel	NN	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stereoisomers	stereoisomer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
N	N	NN	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
allylnormetazocine	allylnormetazocine	NN	B-NP	O	E-drug_n
(	(	(	O	O	O
NANM	NANM	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
phencyclidine	phencyclidine	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
PCP	PCP	NN	B-NP	B-DNA	S-drug_n
)	)	)	O	O	O
in	in	IN	B-PP	O	O
pigeons	pigeon	NNS	B-NP	O	O
and	and	CC	O	O	O
squirrel	squirrel	NN	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
responding	respond	VBG	B-VP	O	O
under	under	IN	B-PP	O	O
a	a	DT	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
fixed	fix	VBN	I-NP	O	O
-	-	HYPH	I-NP	O	O
interval	interval	NN	I-NP	O	O
fixed	fix	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
(	(	(	O	O	O
FI	FI	NN	B-NP	O	O
FR	FR	NN	I-NP	O	O
)	)	)	O	O	O
schedule	schedule	NN	B-NP	O	O
of	of	IN	B-PP	O	O
food	food	NN	B-NP	O	O
presentation	presentation	NN	I-NP	O	O
.	.	.	O	O	O

Intermediate	Intermediate	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	O	B-drug_n
+	+	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
or	or	CC	I-NP	O	O
PCP	PCP	NN	I-NP	B-protein	S-drug_n
produced	produce	VBD	B-VP	O	O
transient	transient	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
FI	FI	NN	B-NP	O	O
responding	respond	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
monkeys	monkey	NNS	B-NP	O	O
and	and	CC	O	O	O
sustained	sustained	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
FI	FI	NN	B-NP	O	O
responding	respond	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
pigeons	pigeon	NNS	B-NP	O	O
;	;	:	O	O	O

higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
FI	FI	NN	B-NP	O	O
and	and	CC	I-NP	O	O
FR	FR	NN	I-NP	O	O
responding	respond	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
species	specie	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
enantiomer	enantiomer	NN	I-NP	O	O
,	,	,	O	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
FI	FI	NN	B-NP	O	O
responding	respond	VBG	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
either	either	CC	O	O	O
species	specie	NNS	B-NP	O	O
;	;	:	O	O	O

at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
decreased	decrease	VBD	B-VP	O	O
FI	FI	NN	B-NP	O	O
and	and	CC	I-NP	O	O
FR	FR	NN	I-NP	O	O
responding	responding	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
monkeys	monkey	NNS	B-NP	O	O
,	,	,	O	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
was	be	VBD	B-VP	O	O
about	about	RB	B-NP	O	O
10	10	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
more	more	RBR	B-ADJP	O	O
potent	potent	JJ	I-ADJP	O	O
than	than	IN	B-SBAR	O	O
(	(	(	O	O	B-drug_n
+	+	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
in	in	IN	B-PP	O	O
decreasing	decrease	VBG	B-VP	O	O
responding	respond	VBG	B-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
in	in	IN	B-PP	O	O
pigeons	pigeon	NNS	B-NP	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	B-NP	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
was	be	VBD	B-VP	O	O
about	about	RB	B-ADJP	O	O
equipotent	equipotent	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
(	(	(	O	O	B-drug_n
+	+	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
.	.	.	O	O	O

In	In	IN	B-PP	O	O
both	both	DT	B-NP	O	O
species	specie	NNS	I-NP	O	O
,	,	,	O	O	O
(	(	(	O	O	B-drug_n-EF-1
-	-	SYM	O	O	I-drug_n-EF-1
)	)	)	O	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
NANM	NANM	NN	I-NP	B-protein	E-drug_n-EF-1
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
(	(	(	O	O	B-drug_n
+	+	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
,	,	,	O	O	O
antagonized	antagonize	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
-	-	HYPH	O	O	O
decreasing	decrease	VBG	B-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
on	on	IN	B-PP	O	O
FI	FI	NN	B-NP	O	O
and	and	CC	I-NP	O	O
FR	FR	NN	I-NP	O	O
responding	responding	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
monkeys	monkey	NNS	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	O	B-drug_n-EF-1
-	-	SYM	O	O	I-drug_n-EF-1
)	)	)	O	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
NANM	NANM	NN	I-NP	B-protein	E-drug_n-EF-1
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
(	(	(	O	O	B-drug_n
+	+	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
or	or	CC	I-NP	O	O
PCP	PCP	NN	I-NP	B-protein	S-drug_n
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
naloxone	naloxone	NN	B-NP	O	S-drug-EF-2
;	;	:	O	O	O

the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
naloxone	naloxone	NN	B-NP	O	S-drug-EF-1
required	require	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	O	B-drug_n-EF-2
-	-	SYM	O	O	I-drug_n-EF-2
)	)	)	O	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
NANM	NANM	NN	I-NP	B-protein	E-drug_n-EF-2
were	be	VBD	B-VP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
100	100	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
required	require	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
pigeons	pigeon	NNS	B-NP	O	O
,	,	,	O	O	O
naloxone	naloxone	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	O	B-drug_n
-	-	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
,	,	,	O	O	O
(	(	(	O	O	B-drug_n
+	+	SYM	O	O	I-drug_n
)	)	)	O	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
NANM	NANM	NN	I-NP	B-protein	E-drug_n
or	or	CC	I-NP	O	O
PCP	PCP	NN	I-NP	B-protein	S-drug_n
.	.	.	O	O	O

Haloperidol	Haloperidol	NN	B-NP	O	S-drug-EF-1
reduced	reduce	VBD	B-VP	O	O
or	or	CC	I-VP	O	O
eliminated	eliminate	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
FI	FI	NN	B-NP	O	O
responding	respond	VBG	B-VP	O	O
produced	produce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
intermediate	intermediate	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
(	(	(	O	O	B-drug_n-EF-2
+	+	SYM	O	O	I-drug_n-EF-2
)	)	)	O	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
NANM	NANM	NN	I-NP	B-protein	E-drug_n-EF-2
or	or	CC	I-NP	O	O
PCP	PCP	NN	I-NP	B-protein	S-drug_n-EF-2
in	in	IN	B-PP	O	O
pigeons	pigeon	NNS	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
FI	FI	NN	B-NP	O	O
or	or	CC	I-NP	O	O
FR	FR	NN	I-NP	O	O
responding	respond	VBG	B-VP	O	O
produced	produce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PCP	PCP	NN	B-NP	O	O
or	or	CC	O	O	O
either	either	CC	O	O	O
stereoisomer	stereoisomer	NN	B-NP	O	O
of	of	IN	B-PP	O	O
NANM	NANM	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stereoselectivity	stereoselectivity	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NANM	NANM	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

The	The	DT	B-NP	O	O
levorotatory	levorotatory	JJ	I-NP	O	O
isomer	isomer	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
opioid	opioid	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
and	and	CC	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
opioid	opioid	JJ	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
pigeons	pigeon	NNS	B-NP	O	O
and	and	CC	O	O	O
mixed	mixed	JJ	B-NP	O	O
opioid	opioid	JJ	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
monkeys	monkey	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dextrorotatory	dextrorotatory	JJ	I-NP	O	O
isomer	isomer	NN	I-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
had	have	VBD	B-VP	O	O
effects	effect	NNS	B-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
PCP	PCP	NN	B-NP	B-protein	S-drug_n
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
species	specie	NNS	I-NP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
hepatotoxicity	hepatotoxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-EF-1
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
frequently	frequently	RB	B-ADVP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
interest	interest	NN	I-NP	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hepatotoxicity	hepatotoxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
Sprague	Sprague	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
fasted	fast	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
18	18	CD	B-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p	i.p	NN	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

as	as	IN	B-SBAR	O	O
judged	judge	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
activities	activity	NNS	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
necrosis	necrosis	NN	I-NP	O	O
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
observations	observation	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
hepatotoxicity	hepatotoxicity	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug-EF-2
thiosulfate	thiosulfate	NN	I-NP	O	E-drug-EF-2
protection	protection	NN	I-NP	O	O
.	.	.	O	O	O

Nephrotoxicity	Nephrotoxicity	NN	B-NP	O	O
frequently	frequently	RB	B-ADVP	O	O
limits	limit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
per	per	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
.	.	.	O	O	O

Sodium	Sodium	NN	B-NP	O	B-drug-EF-1
thiosulfate	thiosulfate	NN	I-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
neutralizing	neutralize	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug-EF-2
that	that	WDT	B-NP	O	O
protects	protect	VBZ	B-VP	O	O
against	against	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
thiosulfate	thiosulfate	NN	B-NP	O	S-drug
would	would	MD	B-VP	O	O
permit	permit	VB	I-VP	O	O
larger	large	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
fixed	fix	VBN	I-NP	O	O
9.9	9.9	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
m2	m2	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thiosulfate	thiosulfate	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
over	over	IN	B-PP	O	O
three	three	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
escalating	escalate	VBG	B-VP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cisplatin	Cisplatin	NN	B-NP	B-protein	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
two	two	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
thiosulfate	thiosulfate	NN	I-NP	O	S-drug
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

Using	Use	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
technique	technique	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
escalate	escalate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cisplatin	cisplatin	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
to	to	TO	B-PP	O	O
225	225	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
before	before	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	O	O	O
limiting	limit	VBG	B-NP	O	O
toxicities	toxicity	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
encountered	encounter	VBN	I-VP	O	O
.	.	.	O	O	O

Comparison	Comparison	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
202.5	202.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
m2	m2	NN	B-NP	O	O
plus	plus	CC	O	O	O
thiosulfate	thiosulfate	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
without	without	IN	B-PP	O	O
thiosulfate	thiosulfate	NN	B-NP	O	S-drug
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
constant	constant	NN	I-NP	O	O
,	,	,	O	O	O
volume	volume	NN	B-NP	O	O
of	of	IN	B-PP	O	O
distribution	distribution	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
total	total	JJ	B-NP	O	O
body	body	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
approximately	approximately	RB	B-ADVP	O	O
twofold	twofold	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
demonstrates	demonstrate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thiosulfate	thiosulfate	NN	B-NP	O	S-drug-ME-1
permits	permit	NNS	I-NP	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
a	a	DT	B-NP	O	O
twofold	twofold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
and	and	CC	O	O	O
total	total	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Interferon	Interferon	NN	B-NP	B-protein	O
induction	induction	NN	I-NP	O	O
:	:	:	O	O	O
tool	tool	NN	B-NP	O	O
for	for	IN	B-PP	O	O
establishing	establish	VBG	B-VP	O	O
interactions	interaction	NNS	B-NP	O	O
among	among	IN	B-PP	O	O
homopolyribonucleotides	homopolyribonucleotide	NNS	B-NP	O	O
.	.	.	O	O	O

Hitherto	Hitherto	RB	B-NP	O	O
unrecognized	unrecognized	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
homopolyribonucleotides	homopolyribonucleotide	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
complexes	complex	NNS	I-NP	O	O
thereof	thereof	RB	B-ADVP	O	O
are	be	VBP	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
interferon	interferon	NN	B-NP	B-protein	O
induction	induction	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
highly	highly	RB	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
assay	assay	NN	I-NP	O	O
system	system	NN	I-NP	O	O
of	of	IN	B-PP	O	O
primary	primary	JJ	B-NP	B-cell_line	O
rabbit	rabbit	NN	I-NP	I-cell_line	O
kidney	kidney	NN	I-NP	I-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
cultures	culture	NNS	I-NP	I-cell_line	O
superinduced	superinduce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
.	.	.	O	O	O

Repeated	Repeat	VBN	B-NP	O	O
oral	oral	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumaphos	coumapho	NNS	B-NP	O	S-drug_n
in	in	IN	B-PP	O	O
sheep	sheep	NNS	B-NP	O	O
:	:	:	O	O	O
interactions	interaction	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
coumaphos	coumapho	NNS	B-NP	O	S-drug_n
with	with	IN	B-PP	O	O
bishydroxycoumarin	bishydroxycoumarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
trichlorfon	trichlorfon	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
and	and	CC	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
treatments	treatment	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coumaphos	coumapho	NNS	B-NP	O	S-drug_n
,	,	,	O	O	O
bishydroxycoumarin	bishydroxycoumarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
an	an	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group
)	)	)	O	O	O
,	,	,	O	O	O
trichlorfon	trichlorfon	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
an	an	DT	B-NP	O	O
organophosphorous	organophosphorous	JJ	I-NP	O	B-group
compound	compound	NN	I-NP	O	E-group
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
(	(	(	O	O	O
an	an	DT	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
microsomal	microsomal	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
sheep	sheep	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumaphos	coumaphos	NN	B-NP	O	S-drug_n
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
antiprothrombinemic	antiprothrombinemic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bishydroxy	bishydroxy	NN	B-NP	B-protein	B-drug
-	-	HYPH	I-NP	I-protein	I-drug
coumarin	coumarin	NN	I-NP	I-protein	E-drug
in	in	IN	B-PP	O	O
wethers	wether	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ewes	ewe	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
(	(	(	O	O	O
IV	IV	CD	O	O	O
)	)	)	O	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
trichlorfon	trichlorfon	NN	B-NP	O	S-drug_n-EF-1
,	,	,	O	O	O
insufficient	insufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
produce	produce	VB	I-VP	O	O
significant	significant	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythrocyte	erythrocyte	NN	B-NP	B-protein	O
acetylcholinesterase	acetylcholinesterase	NN	I-NP	I-protein	O
(	(	(	O	O	O
AChE	AChE	NN	B-NP	O	O
)	)	)	O	O	O
activity	activity	NN	B-NP	O	O
,	,	,	O	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumaphos	coumaphos	NN	B-NP	O	S-drug_n-EF-2
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
ewes	ewe	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	B-drug-EF-1
sodium	sodium	NN	I-NP	O	E-drug-EF-1
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
(	(	(	O	O	O
IP	IP	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
anticholinesterase	anticholinesterase	NN	I-NP	B-protein	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumaphos	coumaphos	NN	B-NP	O	S-drug_n-EF-2
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
and	and	CC	O	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
present	present	JJ	B-ADJP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumaphos	coumaphos	NN	B-NP	O	S-drug_n
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
modify	modify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinesterase	anticholinesterase	NN	I-NP	B-protein	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2nd	2nd	JJ	I-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatments	treatment	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
6	6	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

Diagnostic	Diagnostic	JJ	B-NP	O	O
,	,	,	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
and	and	CC	O	O	O
aftercare	aftercare	VB	B-VP	O	O
approaches	approach	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
abuse	abuse	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
public	public	JJ	I-NP	O	O
feels	feel	NNS	I-NP	O	O
that	that	IN	B-SBAR	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
particularly	particularly	RB	B-ADJP	O	O
dangerous	dangerous	JJ	I-ADJP	O	O
because	because	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
well	well	RB	I-NP	O	O
defined	define	VBN	I-NP	O	O
physical	physical	JJ	I-NP	O	O
dependency	dependency	NN	I-NP	O	O
and	and	CC	I-NP	O	O
abstinence	abstinence	NN	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
addiction	addiction	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
defined	define	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
compulsion	compulsion	NN	B-NP	O	O
,	,	,	O	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
and	and	CC	O	O	O
continued	continue	VBN	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
spite	spite	NN	B-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
consequences	consequence	NNS	I-NP	O	O
,	,	,	O	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
drug	drug	NN	I-NP	O	O
hunger	hunger	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
seen	see	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
addictive	addictive	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Withdrawal	Withdrawal	NN	B-NP	O	O
from	from	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
dependence	dependence	NN	I-NP	O	O
usually	usually	RB	B-ADVP	O	O
involves	involve	VBZ	B-VP	O	O
depression	depression	NN	B-NP	O	O
,	,	,	I-NP	O	O
anxiety	anxiety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
lethargy	lethargy	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
usually	usually	RB	I-NP	O	O
clear	clear	JJ	B-ADJP	O	O
within	within	IN	B-PP	O	O
a	a	DT	B-NP	O	O
week	week	NN	I-NP	O	O
,	,	,	O	O	O
leaving	leave	VBG	B-VP	O	O
only	only	RB	B-NP	O	O
the	the	DT	I-NP	O	O
``	``	``	I-NP	O	O
drug	drug	NN	I-NP	O	O
hunger	hunger	NN	I-NP	O	O
``	``	``	O	O	O

to	to	TO	B-VP	O	O
contend	contend	VB	I-VP	O	O
with	with	IN	B-PP	O	O
.	.	.	O	O	O

Medication	Medication	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
rarely	rarely	RB	I-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
addiction	addiction	NN	I-NP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
effective	effective	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
group	group	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
recovering	recover	VBG	I-NP	O	O
cocaine	cocaine	NN	I-NP	O	O
abusers	abuser	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
incorporate	incorporate	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
principles	principle	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
and	and	CC	O	O	O
define	define	VB	B-VP	O	O
positive	positive	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
constructive	constructive	JJ	I-NP	O	O
alternatives	alternative	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
dealing	deal	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	O	O
hunger	hunger	NN	I-NP	O	O
.	.	.	O	O	O

Recovery	Recovery	NN	B-NP	O	O
programs	program	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
flexible	flexible	JJ	B-ADJP	O	O
and	and	CC	O	O	O
involve	involve	VBP	B-VP	O	O
individual	individual	NN	B-NP	O	O
and	and	CC	I-NP	O	O
family	family	NN	I-NP	O	O
education	education	NN	I-NP	O	O
on	on	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
nature	nature	NN	I-NP	O	O
of	of	IN	B-PP	O	O
addictive	addictive	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Exercise	Exercise	NN	B-NP	O	O
that	that	WDT	B-NP	O	O
produces	produce	VBZ	B-VP	O	O
cardiopulmonary	cardiopulmonary	JJ	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
helpful	helpful	JJ	I-NP	O	O
means	mean	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
reducing	reduce	VBG	B-VP	O	O
drug	drug	NN	B-NP	O	O
hunger	hunger	NN	I-NP	O	O
and	and	CC	O	O	O
anxiety	anxiety	NN	B-NP	O	O
during	during	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Failure	Failure	NN	B-NP	O	O
of	of	IN	B-PP	O	O
neomycin	neomycin	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
modify	modify	VB	I-VP	O	O
ACTH	ACTH	NN	B-NP	B-protein	S-group
induced	induced	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
in	in	IN	B-PP	O	O
sheep	sheep	NN	B-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
neomycin	neomycin	NN	B-NP	O	S-drug-EF-1
administration	administration	NN	I-NP	O	O
attenuates	attenuate	VBZ	B-VP	O	O
certain	certain	JJ	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adrenocortical	adrenocortical	JJ	B-NP	O	B-group
steroid	steroid	NN	I-NP	O	E-group
dependent	dependent	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
ACTH	ACTH	NN	B-NP	O	S-drug-EF-2
hypertension	hypertension	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
neomycin	neomycin	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
ACTH	ACTH	NN	B-NP	B-protein	S-group
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
conscious	conscious	JJ	B-NP	O	O
sheep	sheep	NNS	I-NP	O	O
.	.	.	O	O	O

Neomycin	Neomycin	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
or	or	CC	O	O	O
metabolic	metabolic	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
ACTH	ACTH	NN	B-NP	O	S-group
in	in	IN	B-PP	O	O
sheep	sheep	NN	B-NP	O	O
.	.	.	O	O	O

Changes	Change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
homocysteine	homocysteine	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
synthetic	synthetic	JJ	B-NP	O	B-group
steroidal	steroidal	JJ	I-NP	O	I-group
estrogen	estrogen	NN	I-NP	O	E-group
and	and	CC	O	O	O
progestogen	progestogen	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
work	work	NN	I-NP	O	O
involved	involve	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
ethynyl	ethynyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	O	O	O
levonorgestrel	levonorgestrel	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
groups	group	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
determination	determination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
homocysteine	homocysteine	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
excreted	excrete	VBN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
homocysteine	homocysteine	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
control	control	NN	B-NP	O	O
and	and	CC	I-NP	O	O
levonorgestrel	levonorgestrel	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
shown	show	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ethynyl	ethynyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
implications	implication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
observations	observation	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
homocysteine	homocysteine	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
precipitating	precipitating	JJ	I-NP	B-protein	O
factor	factor	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thrombosis	thrombosis	NN	B-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
included	include	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
confirms	confirm	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
identity	identity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
HPLC	HPLC	NN	I-NP	O	O
peak	peak	NN	I-NP	O	O
as	as	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
homocysteine	homocysteine	NN	B-NP	O	O
by	by	IN	B-PP	O	O
forming	form	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
radioactive	radioactive	JJ	I-NP	O	O
derivative	derivative	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
particular	particular	JJ	I-NP	O	O
sulphydryl	sulphydryl	NN	I-NP	O	O
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
amino	amino	NN	B-NP	O	O
acid	acid	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	B-ADVP	O	O
analysing	analyse	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
resulting	result	VBG	I-NP	O	O
mixture	mixture	NN	I-NP	O	O
by	by	IN	B-PP	O	O
TLC	TLC	NN	B-NP	B-protein	O
.	.	.	O	O	O

Altered	Alter	VBN	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
after	after	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
organic	organic	JJ	B-NP	O	O
lead	lead	NN	I-NP	O	O
.	.	.	O	O	O

Ethyl	Ethyl	NN	B-NP	O	B-drug
alcohol	alcohol	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
effect	effect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
functional	functional	JJ	I-NP	O	O
integrity	integrity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
limbic	limbic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
alter	alter	VB	I-VP	O	O
behaviors	behavior	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
thought	think	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
limbic	limbic	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Organometals	Organometal	NNS	B-NP	O	O
also	also	RB	B-ADVP	O	O
compromise	compromise	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
limbic	limbic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
and	and	CC	O	O	O
result	result	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
deficits	deficit	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
learning	learning	NN	B-NP	O	O
and	and	CC	I-NP	O	O
memory	memory	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
both	both	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
organoleads	organolead	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
environment	environment	NN	I-NP	O	O
and	and	CC	O	O	O
seem	seem	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
influence	influence	VB	I-VP	O	O
limbic	limbic	JJ	B-NP	O	O
integration	integration	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
compounds	compound	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
experiment	experiment	NN	I-NP	O	O
.	.	.	O	O	O

Thirty	Thirty	CD	B-NP	O	O
male	male	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Fischer	Fischer	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
344	344	CD	I-NP	O	O
strain	strain	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
three	three	CD	B-NP	O	O
equal	equal	JJ	I-NP	O	O
groups	group	NNS	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
injections	injection	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
trimethyl	trimethyl	NN	B-NP	O	B-drug_n
lead	lead	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
TML	TML	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
(	(	(	O	O	O
8.0	8.0	CD	B-NP	O	O
or	or	CC	I-NP	O	O
17.0	17.0	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
ml	ml	NN	I-NP	O	O
SC	SC	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
saline	saline	NN	I-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
.	.	.	O	O	O

Fourteen	Fourteen	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
challenged	challenge	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
hypnotic	hypnotic	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
(	(	(	O	O	O
3.5	3.5	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
IP	IP	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
v	v	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
v	v	NN	I-NP	O	O
solution	solution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
prepared	prepare	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
water	water	NN	B-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
stock	stock	NN	I-NP	O	O
solution	solution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
latency	latency	NN	I-NP	O	O
to	to	TO	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
righting	righting	JJ	I-NP	O	O
reflex	reflex	NN	I-NP	O	O
and	and	CC	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sleep	sleep	NN	B-NP	O	O
time	time	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
kept	keep	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
sound	sound	NN	B-NP	O	O
-	-	HYPH	O	O	O
attenuating	attenuate	VBG	B-VP	O	O
chambers	chamber	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TML	TML	NN	B-NP	O	S-drug_n
manifested	manifest	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
longer	long	JJR	I-NP	O	O
latencies	latency	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
lose	lose	VB	I-VP	O	O
the	the	DT	B-NP	O	O
righting	righting	NN	I-NP	O	O
reflex	reflex	NN	I-NP	O	O
and	and	CC	O	O	O
shorter	short	JJR	B-NP	O	O
durations	duration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sleep	sleep	NN	B-NP	O	O
than	than	IN	B-SBAR	O	O
did	do	VBD	O	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
environmental	environmental	JJ	B-NP	O	O
lead	lead	NN	I-NP	O	S-drug_n-EF-1
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
biological	biological	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
animal	animal	NN	I-NP	O	O
to	to	TO	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Cholinergic	Cholinergic	JJ	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
's	's	POS	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
evoked	evoke	VBN	B-NP	O	O
potentials	potential	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
visual	visual	JJ	B-NP	O	O
cortex	cortex	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
albino	albino	JJ	I-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Photic	Photic	JJ	B-NP	O	O
evoked	evoked	JJ	I-NP	O	O
potentials	potential	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
visual	visual	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronically	chronically	RB	B-NP	O	O
implanted	implant	VBN	I-NP	O	O
albino	albino	NN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
photic	photic	JJ	B-NP	B-protein	O
evoked	evoke	VBN	I-NP	I-protein	O
potential	potential	JJ	I-NP	I-protein	O
components	component	NNS	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
representations	representation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
neural	neural	JJ	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
activated	activate	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
photic	photic	JJ	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
,	,	,	O	O	O
study	study	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
these	these	DT	B-NP	O	O
components	component	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
help	help	VB	I-VP	O	O
to	to	TO	I-VP	O	O
trace	trace	VB	I-VP	O	O
pathways	pathway	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
evoked	evoke	VBD	B-VP	O	O
potentials	potential	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
5	5	CD	B-NP	O	O
,	,	,	I-NP	O	O
20	20	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
40	40	CD	B-NP	O	O
min	min	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
IP	IP	NN	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
saline	saline	NN	B-NP	O	O
,	,	,	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
(	(	(	O	O	O
2.0	2.0	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
physostigmine	physostigmine	NN	B-NP	O	S-drug
(	(	(	O	O	O
0.6	0.6	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
atropine	atropine	NN	B-NP	O	S-drug
(	(	(	O	O	O
15.0	15.0	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
separate	separate	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Ethanol	Ethanol	NN	B-NP	O	S-drug
depressed	depress	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
amplitudes	amplitude	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
evoked	evoke	VBN	I-NP	O	O
potential	potential	JJ	I-NP	O	O
components	component	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
to	to	TO	B-PP	O	O
saline	saline	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Component	Component	NN	B-NP	O	O
P2	P2	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
amplitude	amplitude	NN	B-NP	O	O
.	.	.	O	O	O

Physostigmine	Physostigmine	NN	B-NP	O	S-drug
briefly	briefly	NN	I-NP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
amplitude	amplitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
components	component	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
P2	P2	NN	B-NP	B-DNA	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
atropine	atropine	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
amplitudes	amplitude	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
components	component	NNS	B-NP	O	O
P1	P1	NN	I-NP	B-DNA	O
and	and	CC	I-NP	O	O
P2	P2	NN	I-NP	B-DNA	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
decreasing	decrease	VBG	B-VP	O	O
components	component	NNS	B-NP	O	O
N1	N1	NN	I-NP	B-protein	O
,	,	,	O	O	O
N2	N2	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
N3	N3	NN	I-NP	B-protein	O
for	for	IN	B-PP	O	O
varying	vary	VBG	B-NP	O	O
durations	duration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
time	time	NN	B-NP	O	O
.	.	.	O	O	O

Physostigmine	Physostigmine	NN	B-NP	O	S-drug-EF-1
pretreatment	pretreatment	NN	I-NP	O	O
augmented	augment	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
depressant	depressant	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
components	component	NNS	I-NP	O	O
P1	P1	NN	I-NP	B-DNA	O
and	and	CC	I-NP	O	O
N1	N1	NN	I-NP	B-protein	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
attenuating	attenuate	VBG	B-VP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
's	's	POS	B-NP	O	O
influence	influence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
components	component	NNS	B-NP	O	O
P2	P2	NN	I-NP	B-DNA	O
and	and	CC	I-NP	O	O
P3	P3	NN	I-NP	B-DNA	O
.	.	.	O	O	O

Pretreatment	Pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
atropine	atropine	NN	B-NP	O	S-drug
likewise	likewise	RB	B-ADVP	O	O
further	further	RB	I-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
amplitudes	amplitude	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
components	component	NNS	B-NP	O	O
P1	P1	NN	I-NP	B-DNA	O
and	and	CC	I-NP	O	O
N1	N1	NN	I-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
component	component	NN	B-NP	O	O
N3	N3	NN	I-NP	O	O
.	.	.	O	O	O

Atropine	Atropine	NN	B-NP	O	S-drug
,	,	,	O	O	O
either	either	CC	O	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
produced	produce	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
the	the	DT	I-NP	O	O
same	same	JJ	I-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enhancement	enhancement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
component	component	NN	B-NP	O	O
P2	P2	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
to	to	TO	B-PP	O	O
saline	saline	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
three	three	CD	I-NP	O	O
agents	agent	NNS	I-NP	O	O
produced	produce	VBD	B-VP	O	O
reliable	reliable	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
peak	peak	JJ	B-NP	O	O
latency	latency	NN	I-NP	O	O
for	for	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
components	component	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
only	only	RB	B-NP	O	O
N3	N3	NN	I-NP	B-protein	O
showing	show	VBG	B-VP	O	O
no	no	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
amplitude	amplitude	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
's	's	POS	B-NP	O	O
augmentation	augmentation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
component	component	NN	B-NP	O	O
P2	P2	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
,	,	,	O	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
cholinergic	cholinergic	JJ	B-NP	O	O
functions	function	NNS	I-NP	O	O
.	.	.	O	O	O

Hypothermia	Hypothermia	NN	B-NP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
index	index	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
disulfiram	disulfiram	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug
reaction	reaction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Decreased	Decrease	VBN	B-NP	O	O
core	core	NN	I-NP	O	O
temperature	temperature	NN	I-NP	O	O
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
one	one	CD	B-NP	O	O
possible	possible	JJ	I-NP	O	O
index	index	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
disulfiram	disulfiram	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
reaction	reaction	NN	I-NP	O	O
(	(	(	O	O	O
DER	DER	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Core	Core	NN	B-NP	O	O
temperature	temperature	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
disulfiram	disulfiram	NN	B-NP	O	S-drug-EF-2
8	8	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug
challenge	challenge	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
temperature	temperature	NN	B-NP	O	O
began	begin	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
20	20	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-SBAR	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
reaching	reach	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
maximal	maximal	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
between	between	IN	B-PP	O	O
60	60	CD	B-NP	O	O
and	and	CC	I-NP	O	O
120	120	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
post	post	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
core	core	NN	I-NP	O	O
temperature	temperature	NN	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
300	300	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
carotid	carotid	NN	B-NP	O	O
cannulation	cannulation	NN	I-NP	O	O
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
along	along	IN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
core	core	NN	I-NP	O	O
temperature	temperature	NN	I-NP	O	O
.	.	.	O	O	O

Maximal	Maximal	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
120	120	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
post	post	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
300	300	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Heart	Heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
initially	initially	RB	B-ADVP	O	O
and	and	CC	O	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
40	40	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
challenge	challenge	NN	I-NP	O	O
.	.	.	O	O	O

Excretion	Excretion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
thioethers	thioether	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
after	after	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
electrophilic	electrophilic	JJ	B-NP	O	O
chemicals	chemical	NNS	I-NP	O	O
.	.	.	O	O	O

Electrophilic	Electrophilic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
-	-	SYM	O	O	O
-	-	HYPH	O	O	O
a	a	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chemicals	chemical	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
includes	include	VBZ	B-VP	O	O
most	most	RBS	B-NP	O	O
genotoxic	genotoxic	JJ	I-NP	O	O
compounds	compound	NNS	I-NP	O	O
-	-	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
inactivated	inactivate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
reaction	reaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
glutathione	glutathione	NN	B-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
SH	SH	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
bearing	bear	VBG	B-VP	I-protein	O
molecules	molecule	NNS	B-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
conjugates	conjugate	NNS	I-NP	O	O
so	so	RB	B-VP	O	O
formed	form	VBN	I-VP	O	O
often	often	RB	B-ADVP	O	O
appear	appear	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
as	as	IN	B-PP	O	O
mercapturic	mercapturic	JJ	B-NP	O	O
acids	acid	NNS	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
thioether	thioether	NN	I-NP	B-protein	O
products	product	NNS	I-NP	I-protein	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
critically	critically	RB	B-ADVP	O	O
reviews	review	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
suitability	suitability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
thioether	thioether	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
method	method	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
detection	detection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
electrophilic	electrophilic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
or	or	CC	O	O	O
their	their	PRP$	B-NP	O	O
precursors	precursor	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
practice	practice	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
greatest	great	JJS	I-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
thioether	thioether	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
lie	lie	VB	I-VP	O	O
in	in	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
signal	signal	NN	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
cigarette	cigarette	NN	B-NP	O	O
smokers	smoker	NNS	I-NP	O	O
and	and	CC	O	O	O
industrial	industrial	JJ	B-NP	O	O
workers	worker	NNS	I-NP	O	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
chemical	chemical	JJ	B-NP	O	O
waste	waste	NN	I-NP	O	O
incineration	incineration	NN	I-NP	O	O
.	.	.	O	O	O

Whenever	Whenever	WRB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
thioether	thioether	NN	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
suspect	suspect	JJ	I-NP	O	O
compounds	compound	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
thioether	thioether	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
ranges	range	VBZ	B-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
limits	limit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
,	,	,	O	O	O
one	one	PRP	B-NP	O	O
must	must	MD	B-VP	O	O
not	not	RB	I-VP	O	O
conclude	conclude	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
negligible	negligible	JJ	B-NP	O	O
,	,	,	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

More	More	RBR	B-NP	O	O
specific	specific	JJ	I-NP	O	O
applications	application	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
assay	assay	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thio	thio	NN	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
allow	allow	VBP	B-VP	O	O
development	development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
selective	selective	JJ	B-NP	O	O
methods	method	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
biological	biological	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antinociceptive	antinociceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
between	between	IN	B-PP	O	O
neurotensin	neurotensin	NN	B-NP	B-protein	S-drug_n-EF-1
and	and	CC	I-NP	O	O
enkephalins	enkephalin	NNS	I-NP	O	S-drug_n-EF-2
or	or	CC	I-NP	O	O
tuftsin	tuftsin	NN	I-NP	O	S-drug_n-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
neurotensin	neurotensin	NN	B-NP	B-protein	S-drug_n
and	and	CC	O	O	O
both	both	DT	B-NP	O	O
enkephalins	enkephalin	NNS	I-NP	O	S-drug_n
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
synthetic	synthetic	JJ	I-NP	O	O
analogue	analogue	NN	I-NP	O	O
D	D	NN	I-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
Ala2	Ala2	NN	I-NP	B-protein	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
metenkephalinamide	metenkephalinamide	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
or	or	CC	O	O	O
tuftsin	tuftsin	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antinonciceptive	antinonciceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
peptides	peptide	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
after	after	IN	B-PP	O	O
intracisternal	intracisternal	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

Antinociception	Antinociception	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hot	hot	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
plate	plate	NN	I-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
neurotensin	neurotensin	NN	B-NP	B-protein	S-drug_n-EF-1
antagonized	antagonize	VBD	B-VP	O	O
evidently	evidently	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
antinociceptive	antinociceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enkephalins	enkephalin	NNS	B-NP	O	S-drug_n-EF-2
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
analogue	analogue	NN	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contrary	contrary	NN	I-NP	O	O
,	,	,	I-NP	O	O
neurotensin	neurotensin	NN	I-NP	B-protein	S-drug_n-EF-1
and	and	CC	I-NP	O	O
tuftsin	tuftsin	NN	I-NP	O	S-drug_n-EF-2
were	be	VBD	B-VP	O	O
agonists	agonist	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
analgesia	analgesia	NN	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
neurotensin	neurotensin	NN	B-NP	O	S-drug_n-EF-1
modulates	modulate	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
opposite	opposite	JJ	I-NP	O	O
way	way	NN	I-NP	O	O
the	the	DT	B-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enkephalinergic	enkephalinergic	JJ	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tuftsin	tuftsin	NN	B-NP	O	S-drug_n-EF-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
lab	lab	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
:	:	:	O	O	O
implications	implication	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
nutrition	nutrition	NN	B-NP	O	O
support	support	NN	I-NP	O	O
.	.	.	O	O	O

Acetylcysteine	Acetylcysteine	NN	B-NP	O	S-drug
interference	interference	NN	I-NP	O	O
with	with	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
ketone	ketone	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
important	important	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
health	health	NN	B-NP	O	O
care	care	NN	I-NP	O	O
professionals	professional	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Medications	Medication	NNS	B-NP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
effects	effect	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
or	or	CC	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
analyte	analyte	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
altered	alter	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
assay	assay	NN	I-NP	O	O
result	result	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
true	true	JJ	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
accurate	accurate	JJ	I-ADJP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
effect	effect	NN	I-NP	O	O
occurs	occur	VBZ	B-VP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
assay	assay	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
result	result	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
erroneous	erroneous	JJ	B-ADJP	O	O
and	and	CC	O	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
interpreted	interpret	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
report	report	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
recently	recently	RB	I-NP	O	O
identified	identify	VBN	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interference	interference	NN	B-NP	O	O
of	of	IN	B-PP	O	O
acetylcysteine	acetylcysteine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ketones	ketone	NNS	B-NP	O	O
and	and	CC	O	O	O
demonstrates	demonstrate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
importance	importance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
thorough	thorough	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
review	review	NN	I-NP	O	O
in	in	IN	B-PP	O	O
evaluating	evaluate	VBG	B-VP	O	O
abnormal	abnormal	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
2	2	CD	B-NP	O	O
epidemics	epidemic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
arsenical	arsenical	JJ	B-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
trypanosomiasis	trypanosomiasis	NN	B-NP	O	O
,	,	,	O	O	O
Uganda	Uganda	NNP	B-NP	O	O
,	,	,	O	O	O
1992	1992	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1993	1993	CD	I-NP	O	O
]	]	)	O	O	O
Since	Since	IN	B-PP	O	O
1988	1988	CD	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
french	french	JJ	I-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
governmental	governmental	JJ	I-NP	O	O
organisation	organisation	NN	I-NP	O	O
M	M	NN	I-NP	O	O
decins	decin	VBZ	B-VP	O	O
Sans	Sans	NNP	B-NP	O	O
Fronti	Fronti	NNP	I-NP	O	O
res	re	VBZ	B-VP	O	O
is	be	VBZ	B-VP	O	O
running	run	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
control	control	NN	I-NP	O	O
program	program	NN	I-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
african	african	JJ	I-NP	O	O
trypanosomiasis	trypanosomiasis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
district	district	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Moyo	Moyo	NNP	B-NP	O	O
,	,	,	O	O	O
North	North	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Uganda	Uganda	NNP	I-NP	O	O
.	.	.	O	O	O

Between	Between	IN	B-PP	O	O
1988	1988	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1993	1993	CD	I-NP	O	O
,	,	,	O	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
7,000	7,000	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
and	and	CC	O	O	O
treated	treat	VBN	B-VP	O	O
.	.	.	O	O	O

Since	Since	IN	B-PP	O	O
1988	1988	CD	B-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
noted	note	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
incidence	incidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
melarsoprol	melarsoprol	NN	B-NP	O	S-drug
reaction	reaction	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
systematically	systematically	RB	B-ADVP	O	O
between	between	IN	B-PP	O	O
June	June	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
October	October	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
year	year	NN	I-NP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
strong	strong	JJ	B-NP	O	O
seasonal	seasonal	JJ	I-NP	O	O
variation	variation	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
1992	1992	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1993	1993	CD	I-NP	O	O
,	,	,	O	O	O
two	two	CD	B-NP	O	O
outbreaks	outbreak	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
arsenical	arsenical	JJ	B-NP	O	O
reactive	reactive	JJ	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	O
(	(	(	O	O	O
ARE	ARE	NN	B-NP	B-DNA	O
)	)	)	O	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sleeping	sleep	VBG	I-NP	O	O
sickness	sickness	NN	I-NP	O	O
center	center	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Adjumani	Adjumani	NNP	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ARE	ARE	NN	B-NP	B-DNA	O
suddenly	suddenly	RB	B-ADVP	O	O
exceeded	exceed	VBD	B-VP	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
melarsoprol	melarsoprol	NN	B-NP	O	S-drug
during	during	IN	B-PP	O	O
August	August	NNP	B-NP	O	O
1992	1992	CD	I-NP	O	O
and	and	CC	O	O	O
September	September	NNP	B-NP	O	O
1993	1993	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
80	80	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
those	those	DT	B-NP	O	O
``	``	``	I-NP	O	O
epidemic	epidemic	JJ	I-NP	O	O
``	``	``	O	O	O

cases	case	NNS	B-NP	O	O
,	,	,	O	O	O
occurred	occur	VBD	B-VP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
5th	5th	JJ	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
11th	11th	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
1992	1992	CD	B-NP	O	O
(	(	(	O	O	O
75	75	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
1993	1993	CD	B-NP	O	O
(	(	(	O	O	O
51	51	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
studied	study	VBN	B-VP	O	O
,	,	,	O	O	O
two	two	CD	B-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ARE	ARE	NN	B-NP	B-DNA	O
:	:	:	O	O	O
the	the	DT	B-NP	O	O
prescription	prescription	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thiabendazole	thiabendazole	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
strongyloidiasis	strongyloidiasis	NN	B-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
melarsoprol	melarsoprol	NN	I-NP	O	S-drug-EF-2
cure	cure	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
bad	bad	JJ	I-NP	O	O
general	general	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
observations	observation	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
exogenous	exogenous	JJ	B-NP	B-protein	O
co	co	AFX	I-NP	I-protein	O
-	-	HYPH	I-NP	I-protein	O
factors	factor	NNS	B-NP	I-protein	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ARE	ARE	NN	B-NP	B-DNA	O
.	.	.	O	O	O

Recommendations	Recommendation	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
avoid	avoid	VB	I-VP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diffusible	diffusible	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
helminthic	helminthic	JJ	I-NP	O	E-group
treatment	treatment	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cure	cure	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
improve	improve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cure	cure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
melarsoprol	melarsoprol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cobalt	cobalt	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
iron	iron	NN	I-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
and	and	CC	I-NP	O	O
retention	retention	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
supplementary	supplementary	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
cobalt	cobalt	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
iron	iron	NN	I-NP	O	S-drug
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
both	both	DT	B-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	B-DNA	O
site	site	NN	I-NP	I-DNA	O
,	,	,	O	O	O
fecal	fecal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
urinary	urinary	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
retention	retention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
trace	trace	NN	I-NP	B-DNA	O
elements	element	NNS	I-NP	I-DNA	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
four	four	CD	B-NP	O	O
diets	diet	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
either	either	CC	O	O	O
9	9	CD	B-NP	O	O
or	or	CC	I-NP	O	O
63	63	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Co	Co	NNP	B-NP	O	S-drug
and	and	CC	O	O	O
48	48	CD	B-NP	O	O
or	or	CC	I-NP	O	O
446	446	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Fe	Fe	NN	B-NP	O	S-drug
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
19	19	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
24	24	CD	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Retention	Retention	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
balance	balance	NN	I-NP	O	O
technique	technique	NN	I-NP	O	O
and	and	CC	B-PP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
comparative	comparative	JJ	I-NP	O	O
slaughter	slaughter	NN	I-NP	O	O
technique	technique	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
one	one	CD	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
fecal	fecal	JJ	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
elements	element	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
already	already	RB	I-VP	O	O
responded	respond	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
dietary	dietary	JJ	I-NP	O	O
treatments	treatment	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
constant	constant	JJ	B-NP	O	O
values	value	NNS	I-NP	O	O
being	be	VBG	B-VP	O	O
reached	reach	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
three	three	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Cobalt	Cobalt	NN	B-NP	O	S-drug
excretion	excretion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
supplementary	supplementary	JJ	B-NP	O	O
cobalt	cobalt	NN	I-NP	O	S-drug
;	;	:	O	O	O

fecal	fecal	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
,	,	,	O	O	O
too	too	RB	B-ADVP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
supplementary	supplementary	JJ	B-NP	O	O
iron	iron	NN	I-NP	O	S-drug
;	;	:	O	O	O

whereas	whereas	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
iron	iron	NN	I-NP	O	S-drug-ME-1
significantly	significantly	RB	B-ADVP	O	O
inhibited	inhibit	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cobalt	cobalt	NN	B-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
dietary	dietary	JJ	I-NP	O	O
cobalt	cobalt	NN	I-NP	O	S-drug-ME-2
treatments	treatment	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
446	446	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Fe	Fe	NNP	B-NP	O	S-drug-ME-1
instead	instead	RB	B-PP	O	O
of	of	IN	I-PP	O	O
48	48	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Fe	Fe	NN	B-NP	O	S-drug
per	per	IN	B-PP	O	O
kg	kg	NN	B-NP	O	O
diet	diet	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cobalt	cobalt	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
iron	iron	NN	B-NP	O	S-drug-ME-1
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
retention	retention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cobalt	cobalt	NN	B-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
on	on	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
interactions	interaction	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
elements	element	NNS	I-NP	O	O
only	only	RB	B-ADVP	O	O
take	take	VBP	B-VP	O	O
place	place	NN	B-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
site	site	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
dietary	dietary	JJ	I-NP	O	O
cobalt	cobalt	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
iron	iron	NN	I-NP	O	S-drug
contents	content	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diets	diet	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cobalt	cobalt	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
iron	iron	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
and	and	CC	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
.	.	.	O	O	O

Differences	Difference	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
iron	iron	NN	B-NP	O	S-drug
balance	balance	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
only	only	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
both	both	DT	B-NP	O	O
dietary	dietary	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
showing	show	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
absolute	absolute	NN	I-NP	O	O
but	but	CC	O	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
relative	relative	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
retention	retention	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
fed	feed	VBN	B-VP	O	O
further	further	RBR	B-NP	O	O
Fe	Fe	NNP	I-NP	O	S-drug
.	.	.	O	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
250	250	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
estradiol	estradiol	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
endotoxin	endotoxin	NN	B-NP	B-protein	S-drug_n
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
steroid	steroid	NN	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
lethality	lethality	NN	B-NP	O	O
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
exogenous	exogenous	JJ	B-NP	O	O
estradiol	estradiol	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
steroid	steroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonlethal	nonlethal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Escherichia	Escherichia	FW	B-NP	B-protein	O
coli	coli	FW	I-NP	I-protein	O
endotoxin	endotoxin	NN	I-NP	I-protein	S-drug_n
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
deaths	death	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
nonlethal	nonlethal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
lethal	lethal	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
endotoxin	endotoxin	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

Injection	Injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
estradiol	estradiol	NN	B-NP	O	S-drug-EF-1
5	5	CD	I-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonlethal	nonlethal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
endotoxin	endotoxin	NN	B-NP	B-protein	S-drug_n-EF-2
changed	change	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
sex	sex	NN	I-NP	O	O
steroid	steroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
response	response	NN	I-NP	O	O
of	of	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
endotoxin	endotoxin	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

The	The	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
estrogen	estrogen	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
estradiol	estradiol	NN	B-NP	O	S-drug-ME-1
+	+	SYM	B-NP	O	O
endotoxin	endotoxin	NN	I-NP	B-protein	S-drug_n-ME-2
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
endotoxin	endotoxin	NN	I-NP	B-protein	S-drug_n
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
androgen	androgen	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
estradiol	estradiol	NN	B-NP	O	S-drug
+	+	SYM	B-NP	O	O
endotoxin	endotoxin	NN	I-NP	B-protein	S-drug_n
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
endotoxin	endotoxin	NN	B-NP	B-protein	S-drug_n
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
dropped	drop	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
30	30	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O

0.001	0.001	CD	B-NP	O	O
.	.	.	O	O	O

Exogenous	Exogenous	JJ	B-NP	O	O
estradiol	estradiol	NN	I-NP	O	S-drug-EF-1
also	also	RB	B-ADVP	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
percentage	percentage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
endotoxin	endotoxin	NN	B-NP	B-protein	S-drug_n-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
deaths	death	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
deaths	death	NNS	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
nonlethal	nonlethal	JJ	O	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
endotoxin	endotoxin	NN	B-NP	B-protein	S-drug_n
but	but	CC	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
deaths	death	NNS	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
highly	highly	RB	I-NP	O	O
lethal	lethal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
,	,	,	O	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
relationships	relationship	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	O	S-group
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
immune	immune	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
,	,	,	O	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
affect	affect	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
septic	septic	JJ	B-NP	O	O
shock	shock	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
complex	complex	JJ	I-NP	O	O
fashion	fashion	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
either	either	CC	O	O	O
protective	protective	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
deleterious	deleterious	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Analysis	Analysis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
16,16	16,16	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
dimethylprostaglandin	dimethylprostaglandin	NN	I-NP	O	I-drug_n
E2	E2	NN	I-NP	O	E-drug_n
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
16,16	16,16	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
dimethylprostaglandin	dimethylprostaglandin	NN	I-NP	O	I-drug_n
E2	E2	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
dmPGE2	dmPGE2	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
prepared	prepare	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
resecting	resecte	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
cecum	cecum	NN	I-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
vasculature	vasculature	NN	I-NP	O	O
without	without	IN	B-PP	O	O
disturbing	disturb	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
ileocecal	ileocecal	JJ	I-NP	O	O
junction	junction	NN	I-NP	O	O
.	.	.	O	O	O

dmPGE2	dmPGE2	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.0	1.0	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
p.o	p.o	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

dose	dose	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependently	dependently	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
defecation	defecation	NN	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
and	and	CC	O	O	O
induced	induce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
soft	soft	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
watery	watery	NN	I-NP	O	O
stool	stool	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
0.3	0.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
-	-	HYPH	O	O	O
inducing	induce	VBG	B-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
dmPGE2	dmPGE2	NN	B-NP	O	S-drug_n
were	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-VP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
i.p	i.p	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
dmPGE2	dmPGE2	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
0.3	0.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
induced	induce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
watery	watery	NN	I-NP	O	O
stool	stool	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
control	control	NN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
short	short	JJ	B-ADJP	O	O
-	-	HYPH	O	O	O
lasting	last	VBG	B-VP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Castor	Castor	NN	B-NP	O	B-drug
oil	oil	NN	I-NP	O	E-drug
(	(	(	O	O	O
4	4	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
p.o	p.o	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

also	also	RB	B-NP	O	O
induced	induce	VBN	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
watery	watery	NN	I-NP	O	O
stool	stool	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
control	control	NN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
basal	basal	JJ	B-NP	O	O
small	small	JJ	I-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
transits	transit	NNS	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
dmPGE2	dmPGE2	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
0.3	0.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
p.o	p.o	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
enhancements	enhancement	NNS	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
basal	basal	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
dmPGE2	dmPGE2	NN	I-NP	O	S-drug_n
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
jejunal	jejunal	JJ	I-NP	O	O
net	net	JJ	I-NP	O	O
fluid	fluid	NN	I-NP	O	O
transfers	transfer	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-VP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
enhanced	enhance	VBN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
colonic	colonic	JJ	B-NP	O	O
fluid	fluid	NN	I-NP	O	O
by	by	IN	B-PP	O	O
dmPGE2	dmPGE2	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
given	give	VBN	B-VP	O	O
intraluminally	intraluminally	RB	B-ADVP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
only	only	RB	B-NP	O	O
half	half	NN	I-NP	O	O
of	of	IN	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
colonic	colonic	JJ	I-NP	O	O
transit	transit	NN	I-NP	O	O
-	-	HYPH	O	O	O
enhancing	enhance	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dmPGE2	dmPGE2	NN	B-NP	O	S-drug_n
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
15	15	CD	B-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
at	at	IN	I-PP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
basal	basal	JJ	I-NP	O	O
colonic	colonic	JJ	I-NP	O	O
fluid	fluid	NN	I-NP	O	O
contents	content	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
transits	transit	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-VP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Loperamide	Loperamide	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1.0	1.0	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
s.c	s.c	NN	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Loperamide	Loperamide	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug-EF-1
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1.0	1.0	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
s.c.	s.c.	JJ	B-ADJP	O	O
)	)	)	O	O	O
inhibited	inhibit	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
dmPGE2	dmPGE2	NN	I-NP	O	S-drug_n-EF-2
(	(	(	O	O	O
0.3	0.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
p.o	p.o	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

N	N	NN	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
methyllevallorphan	methyllevallorphan	NN	B-NP	O	E-drug_n
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
s.c	s.c	NN	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

N	N	NN	B-NP	O	B-drug_n-EF-1
-	-	HYPH	O	O	I-drug_n-EF-1
methyllevallorphan	methyllevallorphan	NN	B-NP	O	E-drug_n-EF-1
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
s.c.	s.c.	JJ	B-ADJP	O	O
)	)	)	O	O	O
completely	completely	RB	B-ADVP	O	O
antagonized	antagonize	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
loperamide	loperamide	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
partly	partly	RB	B-VP	O	O
antagonized	antagonize	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dmPGE2	dmPGE2	NN	B-NP	O	S-drug_n
induces	induce	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
pronounced	pronounced	JJ	I-NP	O	O
secretory	secretory	JJ	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cecectomized	cecectomize	VBN	B-VP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
probably	probably	RB	B-ADVP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reservoir	reservoir	NN	I-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cecum	cecum	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
operated	operate	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
secretory	secretory	JJ	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	O
model	model	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
suitable	suitable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
evaluating	evaluate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
antidiarrheal	antidiarrheal	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

Therapeutic	Therapeutic	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
can	can	MD	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
iatrogenic	iatrogenic	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
99mTc	99mTc	NN	B-NP	O	B-drug-EF-1
-	-	HYPH	O	O	I-drug-EF-1
methylene	methylene	NN	B-NP	O	I-drug-EF-1
diphosphonate	diphosphonate	NN	I-NP	O	E-drug-EF-1
(	(	(	O	O	O
MDP	MDP	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
gentamicin	gentamicin	NN	I-NP	O	S-drug-EF-2
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Gentamicin	Gentamicin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
aminoglycoside	aminoglycoside	NN	I-NP	O	B-group
antibiotic	antibiotic	NN	I-NP	O	E-group
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
a	a	DT	B-NP	O	O
wide	wide	JJ	I-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
infections	infection	NNS	B-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
gram	gram	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
negative	negative	JJ	I-NP	O	O
organisms	organism	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
potentially	potentially	RB	B-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
its	its	PRP$	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
,	,	,	O	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
abnormal	abnormal	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
seen	see	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
99mTc	99mTc	NN	B-NP	O	B-drug-ME-2
-	-	HYPH	I-NP	O	I-drug-ME-2
MDP	MDP	NN	I-NP	O	E-drug-ME-2
bone	bone	NN	I-NP	O	O
scintigraphy	scintigraphy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
radiopharmaceutical	radiopharmaceutical	NN	I-NP	O	S-group
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
,	,	,	O	O	O
along	along	IN	B-ADVP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
retention	retention	NN	I-NP	O	O
,	,	,	O	O	O
tend	tend	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
scintigraphic	scintigraphic	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
falsely	falsely	RB	B-ADVP	O	O
identify	identify	VBP	B-VP	O	O
characteristics	characteristic	NNS	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
diseases	disease	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
renal	renal	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
tract	tract	NN	I-NP	O	O
obstruction	obstruction	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
even	even	RB	B-NP	O	O
renal	renal	JJ	I-NP	O	O
cancer	cancer	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
altered	alter	VBN	I-NP	O	O
biodistribution	biodistribution	NN	I-NP	O	O
may	may	MD	B-VP	O	O
provide	provide	VB	I-VP	O	O
misleading	misleading	JJ	B-NP	O	O
information	information	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
either	either	CC	I-VP	O	O
mask	mask	VB	I-VP	O	O
or	or	CC	I-VP	O	O
mimic	mimic	VB	I-VP	O	O
certain	certain	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
method	method	NN	I-NP	O	O
to	to	TO	B-VP	O	O
maximize	maximize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
benefit	benefit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug
while	while	IN	B-SBAR	O	O
minimizing	minimize	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
hot	hot	JJ	I-NP	O	O
kidney	kidney	NN	I-NP	O	O
on	on	IN	B-PP	O	O
scintigraphy	scintigraphy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
desirable	desirable	JJ	B-ADJP	O	O
.	.	.	O	O	O

Serial	Serial	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
proposed	propose	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
method	method	NN	I-NP	O	O
to	to	TO	B-VP	O	O
accomplish	accomplish	VB	I-VP	O	O
this	this	DT	B-NP	O	O
goal	goal	NN	I-NP	O	O
.	.	.	O	O	O

Therapeutic	Therapeutic	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
(	(	(	O	O	O
TDM	TDM	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
bone	bone	NN	B-NP	O	O
scintigraphy	scintigraphy	NN	I-NP	O	O
employing	employ	VBG	B-VP	O	O
99mTc	99mTc	NN	B-NP	O	B-drug
-	-	HYPH	O	O	I-drug
MDP	MDP	NN	B-NP	O	E-drug
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
radiopharmaceutical	radiopharmaceutical	NN	I-NP	O	S-group
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
in	in	IN	B-PP	O	O
22	22	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
presented	present	VBN	B-VP	O	O
here	here	RB	B-ADVP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
with	with	IN	B-PP	O	O
serial	serial	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug
,	,	,	O	O	O
the	the	DT	B-NP	O	O
iatrogenic	iatrogenic	JJ	I-NP	O	O
alteration	alteration	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Immunosuppressive	Immunosuppressive	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
complications	complication	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
suppress	suppress	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
immune	immune	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
widely	widely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
part	part	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
organ	organ	NN	B-NP	O	O
transplants	transplant	NNS	I-NP	O	O
,	,	,	O	O	O
malignancy	malignancy	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
increasingly	increasingly	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
conditions	condition	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
psoriasis	psoriasis	NN	B-NP	O	O
,	,	,	O	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
liver	liver	NN	B-NP	O	O
and	and	CC	I-NP	O	O
bowel	bowel	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
inflammation	inflammation	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
aetiological	aetiological	JJ	I-NP	B-protein	O
factor	factor	NN	I-NP	I-protein	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
broadening	broaden	VBG	I-NP	O	O
indications	indication	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
immunosuppressive	immunosuppressive	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
prolonged	prolong	VBN	I-NP	O	O
survival	survival	NN	I-NP	O	O
in	in	IN	B-PP	O	O
conditions	condition	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
being	be	VBG	I-VP	O	O
used	use	VBN	I-VP	O	O
,	,	,	O	O	O
many	many	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
immunosuppression	immunosuppression	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
now	now	RB	I-VP	O	O
cared	care	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
community	community	NN	I-NP	O	O
or	or	CC	O	O	O
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
specialist	specialist	NN	I-NP	O	O
hospitals	hospital	NNS	I-NP	O	O
,	,	,	O	O	O
usually	usually	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
close	close	JJ	B-NP	O	O
collaboration	collaboration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
specialist	specialist	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
article	article	NN	I-NP	O	O
looks	look	VBZ	B-VP	O	O
at	at	IN	B-PP	O	O
five	five	CD	B-NP	O	O
commonly	commonly	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
immunosuppressive	immunosuppressive	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
in	in	IN	B-PP	O	O
turn	turn	NN	B-NP	O	O
(	(	(	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group
,	,	,	O	O	O
cyclosporin	cyclosporin	NN	B-NP	O	S-drug
,	,	,	O	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
,	,	,	O	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
discussing	discuss	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
,	,	,	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	B-NP	O	O
infection	infection	NN	I-NP	O	O
,	,	,	O	O	O
unwanted	unwanted	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
ways	way	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
avoid	avoid	VB	I-VP	O	O
them	them	PRP	B-NP	O	O
and	and	CC	O	O	O
what	what	WP	B-NP	O	O
to	to	TO	B-VP	O	O
do	do	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
problems	problem	NNS	B-NP	O	O
arise	arise	VBP	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
infection	infection	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
dealt	deal	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
separate	separate	JJ	I-NP	O	O
section	section	NN	I-NP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
constituents	constituent	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcoholic	alcoholic	JJ	B-NP	O	O
beverages	beverage	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
promotion	promotion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

Little	Little	JJ	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
congeners	congener	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
acetaldehyde	acetaldehyde	NN	I-NP	O	S-drug_n
,	,	,	O	O	O
coexisting	coexist	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contents	content	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcoholic	alcoholic	JJ	B-NP	O	O
beverages	beverage	NNS	I-NP	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
four	four	CD	I-NP	O	O
male	male	JJ	I-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
four	four	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
SH	SH	NN	B-NP	O	O
/	/	SYM	O	O	O
DA	DA	NN	B-NP	O	O
;	;	:	O	O	O
SH	SH	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
FA	FA	NN	I-NP	B-protein	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
submitted	submit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
daily	daily	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
synthetic	synthetic	JJ	B-NP	O	O
hydroalcoholic	hydroalcoholic	JJ	I-NP	O	O
solutions	solution	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
,	,	,	O	O	O
methanol	methanol	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
alcohols	alcohol	NNS	I-NP	O	S-drug_n
and	and	CC	I-NP	O	O
acetaldehyde	acetaldehyde	NN	I-NP	O	S-drug_n
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
proportions	proportion	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
those	those	DT	B-NP	O	O
found	find	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
common	common	JJ	I-NP	O	O
distilled	distil	VBN	I-NP	O	O
and	and	CC	I-NP	O	O
fermented	ferment	VBN	I-NP	O	O
alcoholic	alcoholic	JJ	I-NP	O	O
beverages	beverage	NNS	I-NP	O	O
;	;	:	O	O	O

the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
SH	SH	NN	B-NP	B-protein	O
/	/	SYM	B-NP	I-protein	O
EA	EA	NN	I-NP	I-protein	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
hydroalcoholic	hydroalcoholic	JJ	I-NP	O	O
solution	solution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
;	;	:	O	O	O

the	the	DT	B-NP	O	O
fourth	fourth	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
served	serve	VBD	B-VP	O	O
as	as	IN	B-PP	O	O
control	control	NN	B-NP	O	O
and	and	CC	O	O	O
received	receive	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
equivalent	equivalent	JJ	I-NP	O	O
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
isocaloric	isocaloric	JJ	I-NP	O	O
solution	solution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dextrose	dextrose	NN	B-NP	O	S-drug
.	.	.	O	O	O

All	All	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
animals	animal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
killed	kill	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
9th	9th	JJ	I-NP	O	O
week	week	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
experiment	experiment	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
and	and	CC	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
lower	low	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
histology	histology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
altered	alter	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
three	three	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
submitted	submit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hydroalcoholic	hydroalcoholic	JJ	I-NP	O	O
solutions	solution	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
quantitative	quantitative	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
qualitative	qualitative	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
hepatoxicity	hepatoxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug-EF-1
in	in	IN	B-PP	O	O
alcoholic	alcoholic	JJ	B-NP	O	O
beverages	beverage	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
congeners	congener	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
acetaldehyde	acetaldehyde	NN	I-NP	O	S-drug_n-EF-2
;	;	:	O	O	O

they	they	PRP	B-NP	O	O
also	also	RB	B-ADVP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
alcoholic	alcoholic	JJ	B-NP	O	O
beverages	beverage	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
equivalent	equivalent	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
liver	liver	NN	B-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

Induction	Induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
breast	breast	NN	B-NP	B-cell_type	O
cancer	cancer	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
in	in	IN	B-PP	O	O
response	response	NN	I-PP	O	O
to	to	TO	I-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
and	and	CC	O	O	O
antiestrogens	antiestrogen	NNS	B-NP	O	S-group
.	.	.	O	O	O

1,25	1,25	CD	B-NP	O	O
-	-	HYPH	I-NP	O	I-drug
Dihydroxycholecalciferol	Dihydroxycholecalciferol	NN	I-NP	O	I-drug
D3	D3	NN	I-NP	O	E-drug
(	(	(	O	O	O
1,25	1,25	CD	B-NP	O	B-drug
(	(	(	O	O	I-drug
OH	OH	NN	B-NP	O	I-drug
)	)	)	O	O	I-drug
2D3	2D3	NN	B-NP	O	E-drug
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
growth	growth	NN	I-NP	O	O
both	both	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
MCF	MCF	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
7	7	CD	I-NP	O	O
cells	cell	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
100	100	CD	B-NP	O	O
nM	nM	NN	I-NP	O	O
1,25	1,25	CD	I-NP	O	B-drug
(	(	(	O	O	I-drug
OH	OH	NN	B-NP	O	I-drug
)	)	)	O	O	I-drug
2D3	2D3	NN	B-NP	O	E-drug
exhibit	exhibit	VBP	B-VP	O	O
characteristic	characteristic	JJ	B-NP	O	O
apoptotic	apoptotic	JJ	I-NP	O	O
morphology	morphology	NN	I-NP	O	O
(	(	(	O	O	O
pyknotic	pyknotic	JJ	B-NP	O	O
nuclei	nucleus	NNS	I-NP	O	O
,	,	,	O	O	O
chromatin	chromatin	NN	B-NP	B-DNA	O
and	and	CC	O	O	O
cytoplasmic	cytoplasmic	JJ	B-NP	O	O
condensation	condensation	NN	I-NP	O	O
,	,	,	O	O	O
nuclear	nuclear	JJ	B-NP	O	O
matrix	matrix	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
reorganization	reorganization	NN	I-NP	O	O
)	)	)	O	O	O
within	within	IN	B-PP	O	O
48	48	CD	B-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
experiments	experiment	NNS	I-NP	O	O
reported	report	VBN	B-VP	O	O
here	here	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
1,25	1,25	CD	B-NP	O	B-drug
(	(	(	O	O	I-drug
OH	OH	NN	B-NP	O	I-drug
)	)	)	O	O	I-drug
2D3	2D3	NN	B-NP	O	E-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
antiestrogen	antiestrogen	NN	I-NP	B-protein	S-group
4	4	CD	I-NP	I-protein	B-drug_n
-	-	HYPH	O	O	I-drug_n
hydroxytamoxifen	hydroxytamoxifen	NN	B-NP	O	E-drug_n
(	(	(	O	O	O
TAM	TAM	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
also	also	RB	B-ADVP	O	O
induces	induce	VBZ	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
MCF	MCF	NN	B-NP	B-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
7	7	CD	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
TAM	TAM	NN	B-NP	B-protein	S-drug_n-EF-1
significantly	significantly	RB	B-ADVP	O	O
potentiates	potentiate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cell	cell	NN	B-NP	O	O
number	number	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
1,25	1,25	CD	B-NP	O	B-drug-EF-2
(	(	(	O	O	I-drug-EF-2
OH	OH	NN	B-NP	O	I-drug-EF-2
)	)	)	O	O	I-drug-EF-2
2D3	2D3	NN	B-NP	O	E-drug-EF-2
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Combined	Combine	VBN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
1,25	1,25	CD	B-NP	O	B-drug-EF-1
(	(	(	O	O	I-drug-EF-1
OH	OH	NN	B-NP	O	I-drug-EF-1
)	)	)	O	O	I-drug-EF-1
2D3	2D3	NN	B-NP	O	E-drug-EF-1
and	and	CC	I-NP	O	O
TAM	TAM	NN	I-NP	B-protein	S-drug_n-EF-2
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
assessed	assess	VBN	B-VP	O	O
using	use	VBG	B-VP	O	O
morphological	morphological	JJ	B-NP	O	O
markers	marker	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
identify	identify	VBP	B-VP	O	O
chromatin	chromatin	NN	B-NP	B-DNA	O
and	and	CC	O	O	O
nuclear	nuclear	JJ	B-NP	O	O
matrix	matrix	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
condensation	condensation	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
selected	select	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
subclone	subclone	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MCF	MCF	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
7	7	CD	I-NP	O	O
cells	cell	NNS	I-NP	O	O
resistant	resistant	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
1,25	1,25	CD	B-NP	O	B-drug
(	(	(	O	O	I-drug
OH	OH	NN	B-NP	O	I-drug
)	)	)	O	O	I-drug
2D3	2D3	NN	B-NP	O	E-drug
(	(	(	O	O	O
MCF	MCF	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
7D3Res	7D3Re	NNS	I-NP	B-DNA	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
cells	cell	NNS	I-NP	O	O
express	express	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
vitamin	vitamin	NN	I-NP	B-protein	O
D	D	NN	I-NP	I-protein	O
receptor	receptor	NN	I-NP	I-protein	O
and	and	CC	O	O	O
exhibit	exhibit	VBP	B-VP	O	O
doubling	double	VBG	I-VP	O	O
times	time	NNS	B-NP	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
parental	parental	JJ	I-NP	B-cell_line	O
MCF	MCF	NN	I-NP	I-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
7	7	CD	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
,	,	,	O	O	O
even	even	RB	B-ADVP	O	O
when	when	WRB	I-ADVP	O	O
grown	grow	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mM	mM	NN	I-NP	O	O
1,25	1,25	CD	I-NP	O	B-drug
(	(	(	O	O	I-drug
OH	OH	NN	B-NP	O	I-drug
)	)	)	O	O	I-drug
2D3	2D3	NN	B-NP	O	E-drug
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	B-NP	O	O
parental	parental	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
resistant	resistant	JJ	I-NP	O	O
MCF	MCF	NN	I-NP	B-protein	O
-	-	HYPH	O	O	O
7	7	CD	B-NP	O	O
cells	cell	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
TAM	TAM	NN	B-NP	O	S-drug_n
induces	induce	VBZ	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
and	and	CC	I-NP	O	O
clusterin	clusterin	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
emphasize	emphasize	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
apoptosis	apoptosis	NN	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
induced	induce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
MCF	MCF	NN	B-NP	B-cell_line	O
-	-	HYPH	O	I-cell_line	O
7	7	CD	B-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
either	either	CC	B-PP	O	O
by	by	IN	B-PP	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
D	D	NN	I-NP	O	E-group
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
signalling	signalling	NN	I-NP	O	O
or	or	CC	I-NP	O	O
disruption	disruption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	O	S-group
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
signalling	signalling	NN	I-NP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
etodolac	etodolac	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
special	special	JJ	B-NP	B-cell_type	O
populations	population	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
etodolac	etodolac	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
normal	normal	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
extensively	extensively	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
well	well	RB	I-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

Etodolac	Etodolac	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
characterised	characterise	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
,	,	,	O	O	O
low	low	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
distribution	distribution	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
7	7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
essentially	essentially	RB	I-VP	O	O
completely	completely	RB	I-VP	O	O
metabolised	metabolise	VBN	I-VP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
little	little	JJ	B-NP	O	O
is	be	VBZ	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

Etodolac	Etodolac	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-ADVP	O	O
protein	protein	NN	B-NP	O	O
bound	bind	VBD	B-VP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
disease	disease	NN	B-NP	O	O
states	state	NNS	I-NP	O	O
or	or	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
etodolac	etodolac	NN	B-NP	O	S-drug
,	,	,	O	O	O
additional	additional	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
in	in	IN	B-PP	O	O
special	special	JJ	B-NP	B-cell_type	O
populations	population	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
etodolac	etodolac	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
defined	define	VBN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
,	,	,	O	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
relevant	relevant	JJ	I-ADJP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
date	date	NN	B-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
disease	disease	NN	B-NP	O	O
states	state	NNS	I-NP	O	O
,	,	,	O	O	O
underlying	underlying	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
concomitantly	concomitantly	RB	B-VP	O	O
administered	administer	VBN	I-VP	B-protein	O
highly	highly	RB	B-NP	I-protein	O
protein	protein	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
essentially	essentially	RB	B-NP	O	O
no	no	DT	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
etodolac	etodolac	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
etodolac	etodolac	NN	B-NP	O	S-drug
can	can	MD	B-VP	O	O
generally	generally	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
without	without	IN	B-PP	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
modifications	modification	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
special	special	JJ	B-NP	O	O
populations	population	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
uncompromised	uncompromised	JJ	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
impairment	impairment	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
xanthine	xanthine	NN	B-NP	O	B-group
derivatives	derivative	NNS	I-NP	O	E-group
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
light	light	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
dark	dark	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
contribution	contribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	B-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
,	,	,	O	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
8	8	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyltheophylline	phenyltheophylline	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
and	and	CC	O	O	O
8	8	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
cyclopentyl	cyclopentyl	NN	I-NP	B-protein	I-drug_n
-	-	HYPH	B-NP	I-protein	I-drug_n
1,3	1,3	CD	I-NP	I-protein	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
dipropylxanthine	dipropylxanthine	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
DPCPX	DPCPX	NN	B-NP	B-protein	S-drug_n
)	)	)	O	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
light	light	JJ	I-NP	O	O
/	/	SYM	I-NP	O	O
dark	dark	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
spent	spend	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
light	light	JJ	I-NP	O	O
zone	zone	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
suggested	suggest	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
anxiogenic	anxiogenic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
anxiogenic	anxiogenic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-EF-1
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
CGS	CGS	NN	B-NP	O	B-drug_n-EF-2
21680	21680	CD	I-NP	O	E-drug_n-EF-2
,	,	,	O	O	O
an	an	DT	B-NP	O	O
A2	A2	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
selective	selective	JJ	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
,	,	,	B-PP	O	O
but	but	CC	I-PP	O	O
not	not	RB	I-PP	O	O
by	by	IN	B-PP	O	O
N6	N6	NN	B-NP	B-protein	B-drug_n
-	-	HYPH	O	O	I-drug_n
cyclopentyladenosine	cyclopentyladenosine	NN	B-NP	O	E-drug_n
(	(	(	O	O	O
CPA	CPA	NN	B-NP	B-protein	S-drug_n
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
A1	A1	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
selective	selective	JJ	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
antagonism	antagonism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-EF-1
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
anxiogenic	anxiogenic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
CGS21680	CGS21680	NN	B-NP	O	S-drug_n-EF-2
was	be	VBD	B-VP	O	O
only	only	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
spent	spend	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
light	light	JJ	I-NP	O	O
zone	zone	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
DPCPX	DPCPX	NN	B-NP	B-protein	S-drug_n
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
anxiogenic	anxiogenic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
neither	neither	DT	B-NP	O	O
reversed	reverse	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CGS	CGS	NN	B-NP	O	B-drug
21680	21680	CD	I-NP	O	E-drug
nor	nor	CC	B-PP	O	O
by	by	IN	B-PP	O	O
CPA	CPA	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

Finally	Finally	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
notable	notable	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
xanthine	xanthine	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
derived	derive	VBN	B-NP	O	O
adenosine	adenosine	NN	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
tested	test	VBN	B-VP	O	O
here	here	RB	B-ADVP	O	O
commonly	commonly	RB	B-ADVP	O	O
showed	show	VBD	B-VP	O	O
anxiogenic	anxiogenic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
light	light	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dark	dark	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
minor	minor	JJ	I-NP	O	O
contribution	contribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	B-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
to	to	TO	B-PP	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
anxiogenic	anxiogenic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
A2	A2	NN	I-NP	B-protein	O
receptor	receptor	NN	I-NP	I-protein	O
agonist	agonist	NN	I-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sandimmune	sandimmune	JJ	B-NP	O	S-brand
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mixed	mix	VBN	B-NP	B-protein	O
-	-	HYPH	I-NP	I-protein	O
function	function	NN	I-NP	I-protein	O
mono	mono	AFX	B-NP	I-protein	O
-	-	HYPH	I-NP	I-protein	O
oxidases	oxidas	NNS	B-NP	I-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
microsomes	microsome	NNS	I-NP	O	O
]	]	)	O	O	O
The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
immunodepressant	immunodepressant	NN	I-NP	O	S-group
-	-	HYPH	O	O	O
-	-	HYPH	O	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
sandimmune	sandimmune	JJ	I-NP	O	S-brand
-	-	HYPH	B-VP	O	O
-	-	HYPH	B-NP	O	O
on	on	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
microsomal	microsomal	JJ	I-NP	I-protein	O
monooxygenase	monooxygenase	NN	I-NP	I-protein	O
activities	activity	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
some	some	DT	B-NP	O	O
inhibiting	inhibit	VBG	I-NP	O	O
activity	activity	NN	I-NP	O	O
against	against	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
microsomal	microsomal	JJ	I-NP	I-protein	O
7	7	CD	I-NP	I-protein	O
-	-	HYPH	I-NP	I-protein	O
ethoxycoumarine	ethoxycoumarine	NN	I-NP	I-protein	O
deethylase	deethylase	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
sandimmune	sandimmune	NN	B-NP	O	S-brand
produced	produce	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hexanal	hexanal	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
sleep	sleep	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
slight	slight	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tested	test	VBN	I-NP	O	O
activities	activity	NNS	I-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
verografin	verografin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
iodamide	iodamide	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
]	]	)	O	O	O
The	The	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
enhanced	enhance	VBD	B-VP	O	O
verografine	verografine	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
iodamide	iodamide	NN	I-NP	O	S-drug-ME-2
excretion	excretion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
canine	canine	JJ	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
verografine	verografine	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
iodamide	iodamide	NN	I-NP	O	S-drug
excretion	excretion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
their	their	PRP$	B-NP	O	O
increased	increase	VBN	I-NP	O	O
renal	renal	JJ	I-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
unchanged	unchange	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiotrast	cardiotrast	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
test	test	NN	I-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
anionic	anionic	JJ	B-NP	O	O
transport	transport	NN	I-NP	O	O
.	.	.	O	O	O

Possible	Possible	JJ	B-NP	O	O
extrarenal	extrarenal	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
verografine	verografine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
iodamide	iodamide	NN	I-NP	O	S-drug
transport	transport	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
examined	examine	VBN	I-VP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Hippocampus	Hippocampus	NN	B-NP	O	O
as	as	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
sites	site	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	O
memory	memory	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
]	]	)	O	O	O
Most	Most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
theories	theory	NNS	I-NP	O	O
assume	assume	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
multiple	multiple	JJ	B-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
memory	memory	NN	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
supported	support	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
separate	separate	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
different	different	JJ	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
studies	study	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
various	various	JJ	I-NP	O	O
dual	dual	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
memory	memory	NN	I-NP	O	O
theories	theory	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
mainly	mainly	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
system	system	NN	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Specifically	Specifically	RB	B-ADVP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
focused	focus	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
aspects	aspect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
learning	learning	NN	B-NP	O	O
and	and	CC	I-NP	O	O
memory	memory	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
impaired	impaired	JJ	B-ADJP	O	O
(	(	(	O	O	O
vs.	vs.	FW	B-VP	O	O
spared	spar	VBN	I-VP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
lesions	lesion	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
formation	formation	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
several	several	JJ	B-NP	O	O
instances	instance	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
animal	animal	NN	I-NP	O	O
literature	literature	NN	I-NP	O	O
showing	show	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
lesions	lesion	NNS	I-NP	O	O
actually	actually	RB	B-ADVP	O	O
produced	produce	VBD	B-VP	O	O
enhanced	enhance	VBN	B-NP	O	O
learning	learning	NN	I-NP	O	O
and	and	CC	I-NP	O	O
memory	memory	NN	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
acquisition	acquisition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tasks	task	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
facilitated	facilitate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
lesions	lesion	NNS	I-NP	O	O
(	(	(	O	O	O
or	or	CC	O	O	O
dysfunction	dysfunction	NN	B-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
nevertheless	nevertheless	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
intact	intact	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
specific	specific	JJ	B-NP	O	O
neurobiological	neurobiological	JJ	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
problem	problem	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
analysed	analyse	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
two	two	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
tasks	task	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
bar	bar	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
press	press	NN	I-NP	O	O
conditioning	conditioning	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
spatial	spatial	JJ	I-NP	B-protein	O
discrimination	discrimination	NN	I-NP	I-protein	O
task	task	NN	I-NP	I-protein	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
depending	depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
task	task	NN	I-NP	O	O
considered	consider	VBN	B-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
either	either	CC	O	O	O
a	a	DT	B-NP	O	O
facilitation	facilitation	NN	I-NP	O	O
or	or	CC	O	O	O
an	an	DT	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acquisition	acquisition	NN	B-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
each	each	DT	B-NP	O	O
task	task	NN	I-NP	O	O
induced	induce	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
hippocampal	hippocampal	JJ	B-NP	B-protein	O
adenylate	adenylate	NN	I-NP	I-protein	O
cyclase	cyclase	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
but	but	CC	B-PP	O	O
in	in	IN	B-PP	O	O
opposite	opposite	JJ	B-NP	O	O
directions	direction	NNS	I-NP	O	O
.	.	.	O	O	O

Together	Together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
the	the	DT	I-NP	O	O
so	so	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
called	call	VBN	B-VP	O	O
``	``	``	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dependent	dependent	JJ	I-NP	O	O
``	``	``	O	O	O

``	``	``	O	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
independent	independent	JJ	I-NP	O	O
``	``	``	O	O	O

forms	form	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
memory	memory	NN	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
postulated	postulate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
observed	observe	VBN	I-NP	O	O
training	training	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
neurobiological	neurobiological	JJ	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
might	might	MD	B-VP	O	O
reflect	reflect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
two	two	CD	B-NP	O	O
(	(	(	O	O	O
or	or	CC	O	O	O
more	more	JJR	B-ADJP	O	O
)	)	)	O	O	O
competing	compete	VBG	B-NP	O	O
memory	memory	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
level	level	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
proposed	propose	VBN	I-NP	O	O
specific	specific	JJ	I-NP	O	O
information	information	NN	I-NP	O	O
processing	processing	NN	I-NP	O	O
functions	function	NNS	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
relational	relational	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
would	would	MD	B-VP	O	O
play	play	VB	I-VP	O	O
a	a	DT	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
addressing	address	VBG	B-VP	O	O
information	information	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
memory	memory	NN	I-NP	O	O
system	system	NN	I-NP	O	O
that	that	IN	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
given	give	VBN	I-NP	O	O
situation	situation	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
best	good	JJS	I-NP	O	O
adaptive	adaptive	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
.	.	.	O	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
250	250	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Magnesium	Magnesium	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
therapeutics	therapeutic	NNS	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
:	:	:	O	O	O
physiological	physiological	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
supplementation	supplementation	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
totally	totally	RB	B-ADJP	O	O
atoxic	atoxic	JJ	I-ADJP	O	O
since	since	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
palliates	palliate	VBZ	B-VP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
deficiencies	deficiency	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
simply	simply	RB	B-ADVP	O	O
normalizing	normalize	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
intake	intake	NN	I-NP	O	O
and	and	CC	O	O	O
pharmacological	pharmacological	JJ	B-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
since	since	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
creates	create	VBZ	B-VP	O	O
iatrogenic	iatrogenic	JJ	B-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
overload	overload	NN	I-NP	O	O
.	.	.	O	O	O

Primary	Primary	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
secondary	secondary	JJ	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
deficiencies	deficiency	NNS	I-NP	O	O
constitute	constitute	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
sole	sole	JJ	I-NP	O	O
indication	indication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
physiological	physiological	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
therefore	therefore	RB	B-ADVP	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
well	well	RB	I-VP	O	O
acquainted	acquaint	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
paraclinical	paraclinical	JJ	I-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
deficit	deficit	NN	I-NP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
discriminate	discriminate	VB	I-VP	O	O
between	between	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
deficiency	deficiency	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
insufficient	insufficient	JJ	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
intake	intake	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
only	only	RB	B-ADVP	O	O
requires	require	VBZ	B-VP	O	O
oral	oral	JJ	B-NP	O	O
physiological	physiological	JJ	I-NP	O	O
supplementation	supplementation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
depletion	depletion	NN	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
dysregulation	dysregulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
status	status	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
requires	require	VBZ	B-VP	O	O
more	more	RBR	B-ADVP	O	O
or	or	CC	I-ADVP	O	O
less	less	RBR	B-NP	O	O
specific	specific	JJ	I-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
causal	causal	JJ	I-NP	O	O
dysregulation	dysregulation	NN	I-NP	O	O
.	.	.	O	O	O

Physiological	Physiological	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
load	load	NN	I-NP	O	O
constitutes	constitute	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
best	good	JJS	I-NP	O	O
tool	tool	NN	I-NP	O	O
for	for	IN	B-PP	O	O
diagnosis	diagnosis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
deficiency	deficiency	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
step	step	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Physiological	Physiological	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
supplementation	supplementation	NN	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
easy	easy	JJ	B-ADJP	O	O
and	and	CC	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diet	diet	NN	I-NP	O	O
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	B-drug
salts	salt	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
practically	practically	RB	B-NP	O	O
only	only	RB	I-NP	O	O
one	one	CD	I-NP	O	O
contra	contra	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
indication	indication	NN	I-NP	O	O
:	:	:	O	O	O
overt	overt	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
.	.	.	O	O	O

Specific	Specific	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
aspecific	aspecific	JJ	I-NP	O	O
treatments	treatment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
depletion	depletion	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
tricky	tricky	JJ	B-PP	O	O
using	use	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
example	example	NN	B-NP	O	O
magnesium	magnesium	NN	I-NP	O	B-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
,	,	,	O	O	O
pharmacological	pharmacological	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-drug
B6	B6	NN	I-NP	O	E-drug
,	,	,	O	O	O
physiological	physiological	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	B-group
D	D	NN	I-NP	O	E-group
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
selenium	selenium	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
use	use	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
induced	induce	VBN	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
hypermagnesaemia	hypermagnesaemia	NN	I-NP	O	O
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
(	(	(	O	O	O
>	>	JJR	B-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
indications	indication	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
parenteral	parenteral	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
suitable	suitable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
indications	indication	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
3	3	CD	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indications	indication	NNS	B-NP	O	O
:	:	:	O	O	O
specific	specific	JJ	B-ADJP	O	O
(	(	(	O	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
deficit	deficit	NN	I-NP	O	O
i.e	i.e	NN	I-NP	O	O
.	.	.	O	O	O
acute	acute	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
pharmacological	pharmacological	JJ	O	O	O
(	(	(	O	O	O
i.e	i.e	JJ	O	O	O
.	.	.	O	O	O
without	without	IN	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
status	status	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
mixed	mix	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
-	-	HYPH	I-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
aetiopathogenic	aetiopathogenic	JJ	I-NP	O	O
-	-	HYPH	O	O	O
-	-	HYPH	O	O	O
(	(	(	O	O	O
for	for	IN	B-PP	O	O
example	example	NN	B-NP	O	O
complications	complication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
alcoholism	alcoholism	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Today	Today	NN	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
mainly	mainly	RB	B-ADVP	O	O
concerns	concern	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
obstetrical	obstetrical	JJ	I-NP	O	O
,	,	,	I-NP	O	O
cardiological	cardiological	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
anaesthesiological	anaesthesiological	JJ	I-NP	O	O
fields	field	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
indications	indication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
eclampsia	eclampsia	NN	B-NP	O	O
,	,	,	O	O	O
some	some	DT	B-NP	O	O
dysrhythmias	dysrhythmia	NNS	I-NP	O	O
(	(	(	O	O	O
torsades	torsade	NNS	B-NP	O	O
de	de	IN	B-PP	O	O
pointe	pointe	NN	B-NP	O	O
particularly	particularly	RB	B-ADVP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
myocardial	myocardial	JJ	B-NP	O	O
ischaemias	ischaemia	NNS	I-NP	O	O
.	.	.	O	O	O

But	But	CC	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
now	now	RB	B-ADVP	O	O
difficult	difficult	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
situate	situate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
exact	exact	JJ	I-NP	O	O
place	place	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
indications	indication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
.	.	.	O	O	O

Magnesium	Magnesium	NN	B-NP	O	S-drug
infusions	infusion	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
only	only	RB	I-VP	O	O
be	be	VB	I-VP	O	O
envisaged	envisage	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
intensive	intensive	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
units	unit	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pulse	pulse	NN	B-NP	O	O
,	,	,	O	O	O
arterial	arterial	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
deep	deep	JJ	B-NP	O	O
tendon	tendon	NN	I-NP	O	O
reflexes	reflex	NNS	I-NP	O	O
,	,	,	O	O	O
hourly	hourly	JJ	B-NP	O	O
diuresis	diuresis	NN	I-NP	O	O
,	,	,	O	O	O
electrocardiogram	electrocardiogram	NN	B-NP	O	O
and	and	CC	O	O	O
respiratory	respiratory	JJ	B-NP	O	O
recordings	recording	NNS	I-NP	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
besides	besides	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
laxative	laxative	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
may	may	MD	B-VP	O	O
bring	bring	VB	I-VP	O	O
latent	latent	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
lifespan	lifespan	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
may	may	MD	B-VP	O	O
remain	remain	VB	I-VP	O	O
some	some	DT	B-NP	O	O
indications	indication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
laxative	laxative	NN	I-NP	O	O
and	and	CC	I-NP	O	O
antacid	antacid	NN	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
non	non	JJ	B-NP	O	O
soluble	soluble	JJ	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
intermittent	intermittent	JJ	B-NP	O	O
haemodialysis	haemodialysis	NN	I-NP	O	O
.	.	.	O	O	O

Lastly	Lastly	RB	B-NP	O	O
local	local	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mucocutaneous	mucocutaneous	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
cytoprotective	cytoprotective	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
still	still	RB	B-ADVP	O	O
valid	valid	JJ	B-ADJP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
cardioplegic	cardioplegic	JJ	B-NP	O	B-drug
solutions	solution	NNS	I-NP	O	E-drug
and	and	CC	B-PP	O	O
for	for	IN	B-PP	O	O
preservation	preservation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
transplants	transplant	NNS	B-NP	O	O
particularly	particularly	RB	B-ADVP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
glycine	glycine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
glutamate	glutamate	NN	I-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
in	in	IN	B-PP	O	O
chick	chick	NN	B-NP	O	O
embryos	embryo	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
also	also	RB	B-NP	O	O
glycine	glycine	NN	I-NP	O	S-drug
fulfils	fulfil	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
function	function	NN	I-NP	O	O
as	as	IN	B-PP	O	O
co	co	AFX	B-NP	B-protein	O
-	-	HYPH	I-NP	I-protein	O
activator	activator	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
glutamatergic	glutamatergic	JJ	B-NP	O	O
activation	activation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NMDA	NMDA	NN	B-NP	B-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neuronal	neuronal	JJ	I-NP	O	O
apparatus	apparatus	NN	I-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
in	in	IN	B-PP	O	O
chick	chick	NN	B-NP	O	O
embryos	embryo	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
successive	successive	JJ	I-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glycine	glycine	NN	B-NP	O	S-drug
(	(	(	O	O	O
5	5	CD	B-NP	O	O
or	or	CC	I-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
egg	egg	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
(	(	(	O	O	O
e.w	e.w	JJ	O	O	O
.	.	.	O	O	O
)	)	)	O	O	O

and	and	CC	O	O	O
glutamate	glutamate	NN	B-NP	O	S-drug
(	(	(	O	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
e.w	e.w	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

The	The	DT	B-NP	O	O
successive	successive	JJ	I-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glycine	glycine	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
5	5	CD	B-NP	O	O
or	or	CC	I-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
egg	egg	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
(	(	(	O	O	O
e.w	e.w	JJ	O	O	O
.	.	.	O	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
glutamate	glutamate	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
e.w	e.w	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
min	min	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
activation	activation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
17	17	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
chick	chick	NN	I-NP	O	O
embryos	embryo	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glutamate	glutamate	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
depend	depend	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
order	order	NN	I-NP	O	O
of	of	IN	B-PP	O	O
application	application	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
13	13	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
day	day	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
embryos	embryo	NNS	I-NP	O	O
,	,	,	O	O	O
glycine	glycine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
ineffective	ineffective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
modulatory	modulatory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glycine	glycine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
evidently	evidently	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
later	later	RB	I-NP	O	O
developmental	developmental	JJ	I-NP	O	O
acquisition	acquisition	NN	I-NP	O	O
(	(	(	O	O	O
after	after	IN	B-PP	O	O
day	day	NN	B-NP	O	O
15	15	CD	I-NP	O	O
of	of	IN	B-PP	O	O
incubation	incubation	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
embryogenesis	embryogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NMDA	NMDA	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
ergic	ergic	JJ	I-NP	O	O
activation	activation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
in	in	IN	B-PP	O	O
chick	chick	NN	B-NP	O	O
embryos	embryo	NNS	I-NP	O	O
similarly	similarly	RB	B-ADVP	O	O
as	as	IN	B-PP	O	O
glycinergic	glycinergic	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
.	.	.	O	O	O

Evidence	Evidence	NN	B-NP	O	O
for	for	IN	B-PP	O	O
reduction	reduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	B-DNA	S-drug
uptake	uptake	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
failing	fail	VBG	I-NP	O	O
human	human	JJ	I-NP	O	O
heart	heart	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuronal	neuronal	JJ	B-NP	O	O
uptake	uptake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
(	(	(	O	O	O
uptake	uptake	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
failure	failure	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
local	local	JJ	I-NP	B-protein	O
factor	factor	NN	I-NP	I-protein	O
for	for	IN	B-PP	O	O
altering	alter	VBG	B-VP	O	O
concentrations	concentration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
myocyte	myocyte	NN	I-NP	O	O
membranes	membrane	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
neuroeffector	neuroeffector	NN	I-NP	O	O
defects	defect	NNS	I-NP	O	O
occur	occur	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
.	.	.	O	O	O

Whether	Whether	IN	B-PP	O	O
an	an	DT	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
uptake	uptake	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
occurs	occur	VBZ	B-VP	O	O
is	be	VBZ	B-VP	O	O
still	still	RB	B-ADVP	O	O
unresolved	unresolved	JJ	B-ADJP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
uptake	uptake	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
electrically	electrically	RB	B-NP	O	O
stimulated	stimulate	VBN	I-NP	O	O
(	(	(	I-NP	O	O
1	1	CD	I-NP	O	O
Hz	Hz	NN	I-NP	O	O
,	,	,	O	O	O
37	37	CD	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
C	C	JJ	B-ADJP	O	O
)	)	)	O	O	O
human	human	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
and	and	CC	O	O	O
isolated	isolate	VBN	B-VP	O	O
myocardial	myocardial	JJ	B-NP	O	O
membranes	membrane	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
force	force	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contraction	contraction	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
relation	relation	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potency	potency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
failing	fail	VBG	B-VP	O	O
hearts	heart	NNS	B-NP	O	O
(	(	(	O	O	O
New	New	NNP	B-NP	O	O
York	York	NNP	I-NP	O	O
Heart	Heart	NNP	I-NP	O	O
Association	Association	NNP	I-NP	O	O
functional	functional	JJ	I-NP	O	O
class	class	NN	I-NP	O	O
IV	IV	CD	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
relation	relation	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
producing	produce	VBG	B-VP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
maximal	maximal	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
(	(	(	O	O	O
EC50	EC50	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
EC50	EC50	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	O	S-drug
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
uptake	uptake	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
myocardium	myocardium	NN	B-NP	O	O
in	in	IN	B-PP	O	O
functional	functional	JJ	B-NP	O	O
classes	class	NNS	I-NP	O	O
II	II	CD	B-NP	O	O
to	to	TO	B-PP	O	O
III	III	CD	B-NP	O	O
and	and	CC	I-NP	O	O
IV	IV	CD	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
nonfailing	nonfailing	JJ	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
uptake	uptake	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
cocaine	cocaine	NN	I-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
desipramine	desipramine	NN	I-NP	O	S-drug-EF-1
(	(	(	O	O	O
3	3	CD	B-NP	O	O
mumol	mumol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
liter	liter	NN	I-NP	O	O
)	)	)	O	O	O
potentiated	potentiate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
inotropic	inotropic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
nonfailing	nonfailing	JJ	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.05	0.05	CD	I-NP	O	O
)	)	)	O	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
functional	functional	JJ	B-NP	O	O
class	class	NN	I-NP	O	O
IV	IV	CD	I-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
.	.	.	O	O	O

Radioligand	Radioligand	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
uptake	uptake	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
hydrogen	hydrogen	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
mazindol	mazindol	NN	I-NP	O	S-drug
revealed	reveal	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
uptake	uptake	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
carrier	carrier	NN	I-NP	O	O
density	density	NN	I-NP	O	O
in	in	IN	B-PP	O	O
functional	functional	JJ	B-NP	O	O
classes	class	NNS	I-NP	O	O
II	II	CD	B-NP	O	O
to	to	TO	B-PP	O	O
III	III	CD	B-NP	O	O
and	and	CC	I-NP	O	O
IV	IV	CD	I-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
versus	versus	IN	B-PP	O	O
nonfailing	nonfailing	JJ	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
failure	failure	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
presynaptic	presynaptic	JJ	I-NP	O	O
defect	defect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
uptake	uptake	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
defect	defect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
failing	fail	VBG	I-NP	O	O
heart	heart	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
mimicked	mimic	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
uptake	uptake	NN	B-NP	O	O
blocking	block	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
desipramine	desipramine	NN	I-NP	O	S-drug
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nonfailing	nonfailing	JJ	I-NP	O	O
heart	heart	NN	I-NP	O	O
only	only	RB	B-ADVP	O	O
.	.	.	O	O	O

Compromised	Compromise	VBN	B-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	S-drug
uptake	uptake	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
in	in	IN	B-PP	O	O
functional	functional	JJ	B-NP	O	O
class	class	NN	I-NP	O	O
IV	IV	CD	I-NP	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
further	further	RBR	I-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
desipramine	desipramine	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pathophysiologic	pathophysiologic	JJ	I-NP	O	O
consequences	consequence	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug
predisposing	predispose	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
adenylyl	adenylyl	NN	B-NP	B-protein	O
cyclase	cyclase	NN	I-NP	I-protein	O
desensitization	desensitization	NN	I-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
A	A	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B-protein	S-drug_n
on	on	IN	B-PP	O	O
stimulated	stimulate	VBN	B-NP	O	O
gastric	gastric	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
]	]	)	I-NP	O	O
Chronic	Chronic	NNP	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
gastric	gastric	JJ	B-NP	O	O
fistulas	fistula	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B-protein	B-drug_n
1	1	CD	I-NP	I-protein	E-drug_n
and	and	CC	O	O	O
angiotensin	angiotensin	NN	B-NP	B-protein	B-drug_n
2	2	CD	I-NP	I-protein	E-drug_n
on	on	IN	B-PP	O	O
pentagastrin	pentagastrin	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
histamine	histamine	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
gastric	gastric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
established	establish	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
both	both	DT	B-NP	O	O
angiotensins	angiotensin	NNS	I-NP	O	O
inhibited	inhibit	VBD	B-VP	O	O
gastric	gastric	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
stimulated	stimulate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pentagastrin	pentagastrin	NN	B-NP	O	S-drug
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
by	by	IN	I-PP	O	O
histamine	histamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Comparative	Comparative	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
stimulation	stimulation	NN	B-NP	O	O
and	and	CC	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cholino	cholino	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	O	O	O
adrenoreceptors	adrenoreceptor	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
this	this	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensins	angiotensin	NNS	B-NP	O	S-drug_n
suggested	suggest	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
mediation	mediation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	O	S-drug_n
influence	influence	NN	I-NP	O	O
through	through	IN	B-PP	O	O
the	the	DT	B-NP	O	O
modulation	modulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cholinergic	cholinergic	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
parietal	parietal	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stomach	stomach	NN	I-NP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
gentamycin	gentamycin	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
atracurium	atracurium	NN	I-NP	O	S-drug-IN-2
in	in	IN	B-PP	O	O
anaesthetised	anaesthetise	VBN	B-NP	O	O
horses	horse	NNS	I-NP	O	O
.	.	.	O	O	O

Evoked	Evoke	VBN	B-NP	O	O
hind	hind	NN	I-NP	O	O
limb	limb	NN	I-NP	O	O
digital	digital	JJ	I-NP	O	O
extensor	extensor	NN	I-NP	O	O
tension	tension	NN	I-NP	O	O
(	(	(	O	O	O
hoof	hoof	NN	B-NP	O	O
twitch	twitch	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
for	for	IN	B-PP	O	O
1	1	CD	B-NP	O	O
h	h	NN	I-NP	O	O
by	by	IN	B-PP	O	O
atracurium	atracurium	NN	B-NP	O	S-drug
infusion	infusion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
7	7	CD	B-NP	O	O
horses	horse	NNS	I-NP	O	O
anaesthetised	anaesthetise	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug
.	.	.	O	O	O

After	After	IN	B-PP	O	O
1	1	CD	B-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
atracurium	atracurium	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
and	and	CC	O	O	O
hoof	hoof	NN	B-NP	O	O
twitch	twitch	NN	I-NP	O	O
allowed	allow	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
recover	recover	VB	I-VP	O	O
to	to	TO	B-PP	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Atracurium	Atracurium	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
again	again	RB	I-VP	O	O
given	give	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
infusion	infusion	NN	B-NP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
twitch	twitch	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
hour	hour	NN	I-NP	O	O
,	,	,	O	O	O
then	then	RB	O	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
gentamycin	gentamycin	NN	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
bwt	bwt	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
i.v	i.v	JJ	B-ADJP	O	O
.	.	.	O	O	O

Atracurium	Atracurium	NN	B-NP	O	S-drug
infusion	infusion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
continued	continue	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
hour	hour	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	O	O	O
hoof	hoof	NN	B-NP	O	O
twitch	twitch	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
again	again	RB	I-VP	O	O
allowed	allow	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
recover	recover	VB	I-VP	O	O
spontaneously	spontaneously	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Gentamycin	Gentamycin	NN	B-NP	O	S-drug
reduced	reduce	VBD	B-VP	O	O
twitch	twitch	JJ	B-NP	O	O
strength	strength	NN	I-NP	O	O
from	from	IN	B-PP	O	O
40	40	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
sem	sem	NN	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
29	29	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
within	within	IN	B-PP	O	O
7.0	7.0	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.5	1.5	CD	B-NP	O	O
min	min	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.02	0.02	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Twitch	Twitch	NN	B-NP	O	O
gradually	gradually	RB	B-ADVP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
pre	pre	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
gentamycin	gentamycin	NN	I-NP	O	S-drug
strength	strength	NN	I-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
next	next	JJ	I-NP	O	O
hour	hour	NN	I-NP	O	O
.	.	.	O	O	O

Recovery	Recovery	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hoof	hoof	NN	B-NP	O	O
twitch	twitch	NN	I-NP	O	O
from	from	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
took	take	VBD	B-VP	O	O
7.7	7.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.7	0.7	CD	B-NP	O	O
min	min	NN	I-NP	O	O
for	for	IN	B-PP	O	O
atracurium	atracurium	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
11.5	11.5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.7	2.7	CD	B-NP	O	O
min	min	NN	I-NP	O	O
for	for	IN	B-PP	O	O
atracurium	atracurium	NN	B-NP	O	S-drug-EF-1
plus	plus	CC	O	O	O
gentamycin	gentamycin	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.03	0.03	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Recovery	Recovery	NN	B-NP	O	O
from	from	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
twitch	twitch	NN	I-NP	O	O
to	to	TO	B-PP	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
fade	fade	NN	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
took	take	VBD	B-VP	O	O
13.8	13.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.8	0.8	CD	B-NP	O	O
min	min	NN	I-NP	O	O
for	for	IN	B-PP	O	O
atracurium	atracurium	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
13.7	13.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.2	1.2	CD	B-NP	O	O
min	min	NN	I-NP	O	O
for	for	IN	B-PP	O	O
atracurium	atracurium	NN	B-NP	O	S-drug-EF-1
plus	plus	CC	I-NP	O	O
gentamycin	gentamycin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

At	At	IN	B-PP	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fade	fade	NN	B-NP	O	O
,	,	,	O	O	O
hoof	hoof	NN	B-NP	O	O
twitch	twitch	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
87	87	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
for	for	IN	B-PP	O	O
atracurium	atracurium	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
82	82	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
for	for	IN	B-PP	O	O
atracurium	atracurium	NN	B-NP	O	S-drug-EF-1
plus	plus	CC	I-NP	O	O
gentamycin	gentamycin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Reversal	Reversal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
block	block	NN	I-NP	O	O
with	with	IN	B-PP	O	O
edrophonium	edrophonium	NN	B-NP	O	S-drug
and	and	CC	O	O	O
subsequent	subsequent	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
horses	horse	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
anaesthesia	anaesthesia	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
uneventful	uneventful	JJ	B-ADJP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
gentamycin	gentamycin	NN	B-NP	O	S-drug-EF-1
did	do	VBD	B-VP	O	O
augment	augment	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atracurium	atracurium	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
minimal	minimal	JJ	B-ADJP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
plans	plan	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group
can	can	MD	B-VP	O	O
become	become	VB	I-VP	O	O
complicated	complicate	VBN	I-VP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
predispose	predispose	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
to	to	TO	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
problems	problem	NNS	B-NP	O	O
.	.	.	O	O	O

Many	Many	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
dentistry	dentistry	NN	B-NP	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
prophylaxis	prophylaxis	NN	I-NP	O	O
.	.	.	O	O	O

Successful	Successful	JJ	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
manic	manic	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
depressive	depressive	JJ	I-NP	O	O
disorder	disorder	NN	I-NP	O	O
requires	require	VBZ	B-VP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prescription	prescription	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	B-drug
carbonate	carbonate	NN	I-NP	O	E-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administrative	administrative	JJ	I-NP	O	O
arrangements	arrangement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
area	area	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Scotland	Scotland	NNP	B-NP	O	O
were	be	VBD	B-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
300	300	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
admissions	admission	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
mania	mania	NN	B-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
area	area	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
West	West	NNP	I-NP	O	O
Midlands	Midlands	NNP	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Multiple	Multiple	JJ	B-NP	O	O
occupational	occupational	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
solvents	solvent	NNS	B-NP	O	O
]	]	)	O	O	O
This	This	DT	B-NP	O	O
article	article	NN	I-NP	O	O
review	review	NN	I-NP	O	O
papers	paper	NNS	I-NP	O	O
published	publish	VBN	B-VP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
20	20	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
occupational	occupational	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
solvents	solvent	NNS	B-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
the	the	DT	B-NP	O	O
toxicokinetic	toxicokinetic	JJ	I-NP	O	O
interferences	interference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
solvents	solvent	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
generally	generally	RB	I-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
and	and	CC	O	O	O
presumably	presumably	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
limit	limit	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
.	.	.	O	O	O

Conversely	Conversely	RB	B-ADVP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
close	close	RB	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
``	``	``	I-NP	O	O
limit	limit	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
``	``	``	O	O	O

metabolic	metabolic	JJ	B-NP	O	O
interference	interference	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
sometimes	sometimes	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
behaviour	behaviour	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
biological	biological	JJ	I-NP	O	O
indicators	indicator	NNS	I-NP	O	O
differs	differ	VBZ	B-VP	O	O
from	from	IN	B-PP	O	O
what	what	WP	B-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

Toxicodynamic	Toxicodynamic	JJ	B-NP	O	O
interference	interference	NN	I-NP	O	O
between	between	IN	B-PP	O	O
solvents	solvent	NNS	B-NP	O	O
can	can	MD	B-VP	O	O
give	give	VB	I-VP	O	O
rise	rise	NN	B-NP	O	O
to	to	TO	B-PP	O	O
additive	additive	JJ	B-NP	O	O
,	,	,	I-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
,	,	,	O	O	O
synergistic	synergistic	JJ	B-NP	O	O
,	,	,	I-NP	O	O
antagonistic	antagonistic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
the	the	DT	B-NP	O	O
identification	identification	NN	I-NP	O	O
of	of	IN	B-PP	O	O
``	``	``	B-NP	O	O
limit	limit	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
``	``	``	O	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
generally	generally	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
deriving	derive	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
be	be	VB	B-VP	O	O
considered	consider	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
additive	additive	JJ	B-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
numerous	numerous	JJ	B-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
frequently	frequently	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
substances	substance	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
widespread	widespread	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
lists	list	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
substances	substance	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
interferences	interference	NNS	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
behaviour	behaviour	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
biological	biological	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
drawn	draw	VBN	I-VP	O	O
up	up	RP	B-PRT	O	O
and	and	CC	O	O	O
proposed	propose	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tool	tool	NN	I-NP	O	O
for	for	IN	B-PP	O	O
easy	easy	JJ	B-NP	O	O
consultation	consultation	NN	I-NP	O	O
.	.	.	O	O	O

Determinants	Determinant	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cellular	cellular	JJ	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
topoisomerase	topoisomerase	NN	B-NP	B-protein	B-group
-	-	HYPH	O	O	I-group
targeting	target	VBG	B-VP	O	I-group
antitumor	antitumor	JJ	B-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
now	now	RB	B-ADVP	O	O
clear	clear	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
topoisomerase	topoisomerase	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
level	level	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
determinant	determinant	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sensitivity	sensitivity	NN	B-NP	O	O
to	to	TO	B-VP	O	O
topo	topo	VB	I-VP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
topoisomerases	topoisomeras	NNS	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
doubt	doubt	NN	I-NP	O	O
complex	complex	NN	I-NP	O	O
and	and	CC	O	O	O
multifaceted	multifacete	VBN	B-VP	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
probably	probably	RB	I-VP	O	O
accomplished	accomplish	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
redundancy	redundancy	NN	B-NP	O	O
at	at	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
control	control	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
(	(	(	I-NP	O	O
s	s	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
altered	alter	VBN	B-NP	O	O
topo	topo	NN	I-NP	O	O
I	I	CD	I-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
tumor	tumor	NN	I-NP	O	O
types	type	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
importance	importance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
topoisomerases	topoisomeras	NNS	B-NP	B-protein	O
in	in	IN	B-PP	O	O
proliferating	proliferate	VBG	B-VP	O	O
cell	cell	NN	B-NP	O	O
functions	function	NNS	I-NP	O	O
(	(	(	O	O	O
transcription	transcription	NN	B-NP	O	O
,	,	,	O	O	O
replication	replication	NN	B-NP	O	O
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
aberrant	aberrant	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
activation	activation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
functions	function	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
specific	specific	JJ	B-NP	O	O
tumorigenic	tumorigenic	JJ	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
.	.	.	O	O	O

Small	Small	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
sensitivity	sensitivity	NN	B-NP	O	O
to	to	TO	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
can	can	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
dramatic	dramatic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
cure	cure	NN	B-NP	O	O
rates	rate	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
subtle	subtle	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
type	type	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
important	important	JJ	B-NP	O	O
determinants	determinant	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
.	.	.	O	O	O

Whether	Whether	IN	B-SBAR	O	O
abnormal	abnormal	JJ	B-NP	O	O
topoisomerase	topoisomerase	NN	I-NP	O	O
quantity	quantity	NN	I-NP	O	O
and	and	CC	O	O	O
specific	specific	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
resistance	resistance	NN	B-NP	O	O
or	or	CC	I-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
topoisomerase	topoisomerase	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
targeted	target	VBN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinic	clinic	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
now	now	RB	I-VP	O	O
being	be	VBG	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Determinants	Determinant	NNS	B-NP	O	O
downstream	downstream	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
cleavable	cleavable	JJ	B-NP	O	O
complex	complex	NN	I-NP	O	O
formation	formation	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
affect	affect	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tumor	tumor	NN	B-NP	B-cell_type	O
versus	versus	IN	B-PP	I-cell_type	O
normal	normal	JJ	B-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
to	to	TO	B-VP	O	O
topo	topo	VB	I-VP	O	O
drugs	drug	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
DNA	DNA	NN	I-NP	O	O
-	-	HYPH	O	O	O
damaging	damage	VBG	B-VP	O	O
agents	agent	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
are	be	VBP	B-VP	O	O
little	little	JJ	B-ADJP	O	O
known	know	VBN	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
goal	goal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enhancing	enhance	VBG	B-VP	O	O
selective	selective	JJ	B-NP	O	O
tumor	tumor	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
killing	killing	NN	I-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
dose	dose	NN	B-NP	O	O
limiting	limit	VBG	B-VP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
achieved	achieve	VBN	I-VP	O	O
either	either	CC	O	O	O
by	by	IN	B-PP	O	O
overcoming	overcome	VBG	B-VP	O	O
tumor	tumor	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
or	or	CC	B-PP	O	O
by	by	IN	B-PP	O	O
protecting	protect	VBG	B-VP	O	O
normal	normal	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
strategies	strategy	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
become	become	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
feasible	feasible	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
specific	specific	JJ	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	O
and	and	CC	O	O	O
normal	normal	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
are	be	VBP	B-VP	O	O
being	be	VBG	I-VP	O	O
rapidly	rapidly	RB	I-VP	O	O
identified	identify	VBN	I-VP	O	O
and	and	CC	O	O	O
new	new	JJ	B-NP	O	O
combination	combination	NN	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
take	take	VBP	B-VP	O	O
advantage	advantage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
being	be	VBG	I-VP	O	O
designed	design	VBN	I-VP	O	O
and	and	CC	I-VP	O	O
tested	test	VBN	I-VP	O	O
.	.	.	O	O	O

Acid	Acid	NN	B-NP	O	O
-	-	HYPH	B-PP	O	O
catalyzed	catalyze	VBN	B-NP	O	O
ethanolysis	ethanolysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
temazepam	temazepam	NN	B-NP	O	S-drug-ME-1
in	in	IN	B-PP	O	O
anhydrous	anhydrous	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
aqueous	aqueous	JJ	I-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug-ME-2
solutions	solution	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
benzodiazepines	benzodiazepine	NNS	I-NP	O	S-group
are	be	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
family	family	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anxiolytic	anxiolytic	JJ	B-NP	O	S-group
and	and	CC	I-NP	O	O
hypnotic	hypnotic	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
,	,	,	O	O	O
potentiating	potentiate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
depression	depression	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
report	report	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
chemical	chemical	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
temazepam	temazepam	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
a	a	DT	B-NP	O	O
benzodiazepine	benzodiazepine	NN	I-NP	O	S-group
)	)	)	O	O	O
and	and	CC	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug-ME-2
under	under	IN	B-PP	O	O
acidic	acidic	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
found	find	VBN	B-VP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
ethoxylated	ethoxylate	VBN	I-NP	O	O
product	product	NN	I-NP	O	O
.	.	.	O	O	O

Optimal	Optimal	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
,	,	,	O	O	O
kinetics	kinetic	NNS	B-NP	O	O
,	,	,	O	O	O
equilibrium	equilibrium	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
acid	acid	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
catalyzed	catalyze	VBN	B-NP	O	O
ethanolysis	ethanolysis	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
raise	raise	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
ethanolysis	ethanolysis	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stomach	stomach	NN	I-NP	O	O
of	of	IN	B-PP	O	O
people	people	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
consume	consume	VBP	B-VP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
3	3	CD	B-NP	O	B-group-ME-2
-	-	HYPH	I-NP	O	I-group-ME-2
hydroxy	hydroxy	NN	I-NP	O	I-group-ME-2
-	-	HYPH	B-NP	O	I-group-ME-2
1,4	1,4	CD	I-NP	O	I-group-ME-2
-	-	HYPH	I-NP	O	I-group-ME-2
benzodiazepine	benzodiazepine	NN	I-NP	O	E-group-ME-2
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
regular	regular	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
acid	acid	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
catalyzed	catalyze	VBN	B-NP	O	O
ethanol	ethanol	NN	I-NP	O	S-drug
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
relatively	relatively	RB	I-NP	O	O
unexplored	unexplored	JJ	I-NP	O	O
area	area	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

